0000950170-24-12329610-Q MANNKIND CORP 20241107202411071606561606561606560656 0 0000950170-24-123296 10-Q 114 20240930 20241107 20241107 MANNKIND CORP 0000899460 2834 133607736 DE 1231 10-Q 34 000-50865 241435591 1 CASPER STREET DANBURY CT 06810 818-661-5000 1 CASPER STREET DANBURY CT 06810 10-Q 1 mnkd-20240930.htm 10-Q 10-Q --12-31Q3false0000899460P2YP3YP4YP2YP3YP4YP2YP3YP4Yhttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#FinanceLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent2024 2025 20262025 20263793660000899460us-gaap:ServiceMember2024-01-012024-09-300000899460us-gaap:InProcessResearchAndDevelopmentMember2024-09-300000899460us-gaap:LicenseAndServiceMember2024-09-300000899460mnkd:SagardHealthcarePartnersFundingBorrowerSPE2LPMembermnkd:RemainderOfYearMember2023-12-012023-12-310000899460us-gaap:ProductMember2024-09-300000899460mnkd:StevenBBinderMember2024-09-300000899460us-gaap:CommonStockMember2023-07-012023-09-300000899460us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Membermnkd:EstimatedFairValueMember2023-12-310000899460us-gaap:LicenseAndServiceMembermnkd:CommercialSupplyAgreementMembermnkd:UnitedTherapeuticsCorporationMember2024-07-012024-09-300000899460us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembermnkd:MidCapCreditFacilityMember2024-09-300000899460mnkd:InsulinMember2023-12-310000899460us-gaap:RetainedEarningsMember2023-03-3100008994602024-04-012024-06-300000899460mnkd:CommonStockOptionsAndPerformanceBasedStockOptionAwardsMember2024-01-012024-09-300000899460us-gaap:CommonStockMembermnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMember2023-07-012023-09-300000899460mnkd:ConvertibleNotePrincipalAndInterestMembermnkd:TheMannGroupLLCMember2024-04-012024-06-300000899460us-gaap:FairValueInputsLevel3Membermnkd:MilestoneRightsLiabilityMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000899460mnkd:LicenseAgreementMemberus-gaap:LicenseAndServiceMembermnkd:UnitedTherapeuticsCorporationMember2023-01-012023-09-3000008994602023-01-012023-03-310000899460mnkd:RoyaltiesArrangementMembermnkd:UnitedTherapeuticsCorporationMember2024-07-012024-09-3000008994602023-03-3100008994602023-01-012023-09-300000899460us-gaap:CommonStockMembermnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMember2023-04-012023-06-300000899460mnkd:EmployeeStockPurchasePlanMember2024-01-012024-09-300000899460us-gaap:ProductMember2024-01-012024-09-300000899460us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-01-012024-03-310000899460mnkd:CollaborationAndLicenseAgreementMembermnkd:UnitedTherapeuticsCorporationMember2023-12-012023-12-310000899460mnkd:PulmatrixIncMember2024-07-310000899460us-gaap:RetainedEarningsMember2023-09-300000899460us-gaap:AdditionalPaidInCapitalMember2023-12-310000899460mnkd:MilestoneRightsLiabilityMemberus-gaap:MeasurementInputExpectedTermMember2024-09-300000899460mnkd:MarlboroughLeaseMemberus-gaap:BuildingMember2022-06-012022-06-300000899460mnkd:CiplaLtdMembermnkd:LicenseAndDistributionAgreementMember2024-09-300000899460mnkd:ProductRevenueMember2024-07-012024-09-300000899460mnkd:ConvertiblePromissoryNoteMembermnkd:TheMannGroupLLCMember2024-01-012024-09-300000899460mnkd:MarketRestrictedStockUnitsMembermnkd:EmployeeMember2024-04-012024-06-300000899460mnkd:StevenBBinderMember2024-07-012024-09-300000899460us-gaap:CommonStockMember2024-01-012024-03-310000899460mnkd:RestrictedStockUnitsAndOptionsMember2023-07-012023-09-300000899460us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000899460us-gaap:EquipmentMember2024-01-012024-09-300000899460mnkd:ContingentMilestoneLiabilityMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2024-09-300000899460us-gaap:BuildingMember2023-12-310000899460us-gaap:CarryingReportedAmountFairValueDisclosureMembermnkd:MannGroupConvertibleNoteMember2023-12-310000899460mnkd:ThironaBioIncMembermnkd:ConvertiblePromissoryNoteMember2023-01-012023-09-300000899460mnkd:ManufacturingServicesAndProductSalesMembermnkd:CollaborationAndLicenseAgreementMembermnkd:UnitedTherapeuticsCorporationMember2022-12-012022-12-310000899460us-gaap:CommonStockMember2024-03-310000899460us-gaap:MeasurementInputPriceVolatilityMemberus-gaap:SeniorNotesMember2024-09-300000899460us-gaap:SeniorNotesMember2023-12-3100008994602022-12-310000899460us-gaap:RetainedEarningsMember2024-04-012024-06-300000899460us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-07-012024-09-300000899460srt:MinimumMemberus-gaap:ProductMember2024-01-012024-09-300000899460mnkd:CollaborationAndLicenseAgreementMembermnkd:UnitedTherapeuticsCorporationMember2022-12-310000899460us-gaap:CommonStockMember2024-04-012024-06-300000899460mnkd:MilestoneRightsLiabilityMembermnkd:DeerfieldManagementCompanyLpMember2024-09-300000899460mnkd:SupplyAndDistributionAgreementMembermnkd:BiommSAMemberus-gaap:ProductMember2023-01-012023-12-310000899460us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember2023-12-310000899460us-gaap:CaliforniaFranchiseTaxBoardMembermnkd:SenateBills167Member2024-06-300000899460us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-3000008994602024-07-082024-07-0800008994600us-gaap:RetainedEarningsMember2024-03-310000899460mnkd:ThironaBioIncMembermnkd:ConvertiblePromissoryNoteMember2021-06-300000899460us-gaap:CommonStockMember2024-09-300000899460mnkd:CommercialSupplyMembermnkd:UnitedTherapeuticsCorporationMember2024-07-012024-09-300000899460mnkd:ManufacturingServicesAndProductSalesMemberus-gaap:TransferredAtPointInTimeMembermnkd:CollaborationAndLicenseAgreementMembermnkd:UnitedTherapeuticsCorporationMember2022-12-012022-12-310000899460us-gaap:EmployeeStockMember2024-09-300000899460us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300000899460us-gaap:CommonStockMembermnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMember2023-01-012023-03-310000899460us-gaap:CommonStockMember2023-01-012023-03-310000899460mnkd:PreLaunchInventoryMember2024-09-300000899460us-gaap:AdditionalPaidInCapitalMember2023-09-300000899460mnkd:MidCapCreditFacilityMembersrt:MaximumMember2023-12-310000899460us-gaap:MeasurementInputPriceVolatilityMembermnkd:MilestoneRightsLiabilityMember2024-09-300000899460mnkd:TrancheOneMember2019-08-012019-08-310000899460mnkd:SupplyAndDistributionAgreementMembermnkd:BiommSAMemberus-gaap:ProductMember2024-01-012024-03-310000899460mnkd:MilestoneRightsLiabilityMembersrt:MaximumMembermnkd:DeerfieldManagementCompanyLpMember2013-07-010000899460us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMembermnkd:EmployeeMember2024-01-012024-03-3100008994602019-08-012019-08-310000899460us-gaap:ConstructionInProgressMember2024-09-300000899460mnkd:FinancingLiabilityMember2024-01-012024-09-300000899460mnkd:RestrictedStockUnitsAndOptionsMember2024-07-012024-09-300000899460mnkd:ConvertiblePromissoryNoteMembermnkd:TheMannGroupLLCMember2024-09-300000899460mnkd:TrancheTwoMember2020-12-012020-12-310000899460us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Membermnkd:GrossUnrealizedHoldingGainsMember2024-09-300000899460us-gaap:CarryingReportedAmountFairValueDisclosureMembermnkd:ContingentMilestoneLiabilityMember2023-12-310000899460us-gaap:RestrictedStockUnitsRSUMembermnkd:EmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-07-012024-09-300000899460mnkd:TrancheTwoMembermnkd:MidCapCreditFacilityMember2020-01-012020-12-310000899460mnkd:ThironaBioIncMembermnkd:ConvertiblePromissoryNoteMember2023-12-310000899460us-gaap:ProductMember2024-07-012024-09-300000899460us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMembermnkd:GrossUnrealizedHoldingGainsMember2023-12-310000899460mnkd:ComputerEquipmentAndSoftwareMember2023-12-310000899460mnkd:TrancheTwoMember2020-12-310000899460mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMember2024-01-012024-03-310000899460mnkd:CollaborationAndLicenseAgreementMembermnkd:UnitedTherapeuticsCorporationMember2024-01-012024-09-300000899460mnkd:AmortizedCostMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2023-12-310000899460us-gaap:EquipmentMembermnkd:VGoMember2022-06-012022-06-3000008994602023-12-310000899460us-gaap:RestrictedStockUnitsRSUMember2024-09-300000899460mnkd:GrossUnrealizedHoldingGainsMember2024-09-300000899460us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Membermnkd:GrossUnrealizedHoldingLossesMember2024-09-300000899460mnkd:EmployeeMemberus-gaap:EmployeeStockMember2024-01-012024-09-300000899460mnkd:ManufacturingServicesAndProductSalesMemberus-gaap:TransferredAtPointInTimeMembermnkd:CollaborationAndLicenseAgreementMembermnkd:UnitedTherapeuticsCorporationMember2022-12-310000899460mnkd:TransactionPriceForThePerformanceObligationsMembermnkd:CollaborationAndLicenseAgreementMembermnkd:NextGenResearchAndDevelopmentServicesMembermnkd:U12-310000899460mnkd:SeniorConvertibleNotesMember2024-01-012024-09-300000899460mnkd:AmortizedCostMember2024-09-300000899460us-gaap:ServiceMember2024-07-012024-09-300000899460mnkd:ProductRevenueMember2023-07-012023-09-300000899460mnkd:ContingentMilestoneLiabilityMemberus-gaap:MeasurementInputExpectedTermMember2024-09-300000899460mnkd:LoanArrangementMembermnkd:PrivatelyNegotiatedExchangeAgreementMembermnkd:ConvertiblePromissoryNoteMembermnkd:TheMannGroupLLCMember2019-08-3100008994602024-07-012024-09-300000899460mnkd:LicenseAgreementMembermnkd:UnitedTherapeuticsCorporationMember2023-07-012023-09-300000899460us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000899460us-gaap:CommonStockMember2023-09-300000899460us-gaap:RestrictedStockUnitsRSUMembermnkd:EmployeeMember2024-07-012024-09-300000899460mnkd:ConvertiblePromissoryNoteMembermnkd:TheMannGroupLLCMember2023-01-012023-09-300000899460mnkd:RestrictedStockUnitsAndOptionsMember2024-01-012024-09-300000899460mnkd:RoyaltyLiabilityMember2023-12-310000899460us-gaap:CaliforniaFranchiseTaxBoardMembermnkd:SenateBills167Member2024-06-012024-06-300000899460us-gaap:FairValueInputsLevel3Membermnkd:MidCapCreditFacilityMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000899460mnkd:ProductRevenueMember2023-01-012023-09-3000008994602023-04-012023-06-300000899460srt:MaximumMember2024-01-012024-09-300000899460us-gaap:FairValueInputsLevel3Membermnkd:FinancingLiabilityMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000899460us-gaap:FairValueInputsLevel3Membermnkd:ContingentMilestoneLiabilityMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000899460mnkd:EmployeeStockPurchasePlanMember2024-07-012024-09-300000899460us-gaap:RoyaltyMember2024-07-012024-09-300000899460mnkd:AudioVisualEquipmentMember2024-01-012024-09-300000899460srt:MinimumMembermnkd:LiabilityForSaleOfFutureRoyaltiesMember2024-09-300000899460us-gaap:SeniorNotesMember2024-09-300000899460mnkd:TyvasoDPIMember2023-12-012023-12-310000899460mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMember2023-01-012023-03-310000899460mnkd:MidCapCreditFacilityMember2024-04-012024-04-010000899460mnkd:MilestoneRightsLiabilityMemberus-gaap:MeasurementInputEntityCreditRiskMember2024-09-300000899460mnkd:RestrictedStockUnitsAndMarketRestrictedStockUnitsMember2024-01-012024-09-300000899460us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembermnkd:TrancheTwoMember2020-12-012020-12-310000899460mnkd:FinancingLiabilityMember2023-12-310000899460mnkd:MilestoneRightsLiabilityMembermnkd:DeerfieldManagementCompanyLpMember2023-01-012023-09-300000899460us-gaap:SeniorNotesMembersrt:MinimumMember2024-09-300000899460mnkd:ThironaBioIncMembermnkd:ConvertiblePromissoryNoteMember2021-06-012021-06-3000008994602024-03-310000899460mnkd:ComputerEquipmentAndSoftwareMember2024-09-300000899460mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMemberus-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000899460us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310000899460mnkd:ThironaBioIncMembermnkd:ConvertiblePromissoryNoteMember2024-09-300000899460us-gaap:SeniorNotesMember2021-03-040000899460us-gaap:FairValueInputsLevel3Membermnkd:MilestoneRightsLiabilityMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000899460mnkd:UtManufacturingFacilityMember2024-09-300000899460mnkd:InsulinMember2024-09-300000899460us-gaap:CommonStockMembermnkd:ConvertibleNotePrincipalAndInterestMembermnkd:TheMannGroupLLCMember2024-04-012024-06-300000899460mnkd:SagardHealthcarePartnersFundingBorrowerSPE2LPMember2023-01-012023-12-310000899460us-gaap:BuildingMembersrt:MaximumMember2024-09-300000899460mnkd:RoyaltyLiabilityMember2024-01-012024-09-300000899460mnkd:PulmatrixIncMember2024-07-080000899460mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000899460us-gaap:CommonStockMembermnkd:CantorFitzgeraldMembermnkd:AtMarketIssuanceSalesAgreementMember2024-01-012024-09-300000899460us-gaap:CommonStockMembermnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMember2024-01-012024-03-310000899460us-gaap:RetainedEarningsMember2024-07-012024-09-300000899460us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-300000899460us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000899460mnkd:CiplaLtdMembermnkd:LicenseAndDistributionAgreementMember2018-05-012018-05-310000899460mnkd:MarketRestrictedStockUnitsMembermnkd:EmployeeMember2024-01-012024-09-300000899460us-gaap:LicenseAndServiceMembermnkd:CommercialSupplyAgreementMembermnkd:UnitedTherapeuticsCorporationMember2023-01-012023-09-300000899460us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-04-012024-06-300000899460us-gaap:LandMember2024-09-300000899460mnkd:MilestoneRightsLiabilityMembermnkd:DeerfieldManagementCompanyLpMember2013-07-010000899460us-gaap:LicenseAndServiceMembermnkd:CiplaLtdMembermnkd:LicenseAndDistributionAgreementMember2023-01-012023-09-3000008994602023-09-300000899460us-gaap:RetainedEarningsMember2024-09-300000899460mnkd:ManufacturingServicesAndProductSalesMembermnkd:TransactionPriceForTheContractualObligationsMembermnkd:CollaborationAndLicenseAgreementMembermnkd:Unite12-310000899460mnkd:OfficeMembermnkd:RussellRanchRoadIILLCMember2023-02-012023-02-280000899460mnkd:RoyaltyLiabilityMember2024-09-300000899460mnkd:SagardHealthcarePartnersFundingBorrowerSPE2LPMember2024-01-012024-09-300000899460us-gaap:SeniorNotesMember2024-01-012024-09-300000899460mnkd:MarketRestrictedStockUnitsMembermnkd:ShareBasedCompensationAwardsTrancheFiveMembermnkd:EmployeeMember2024-04-012024-06-300000899460mnkd:RestrictedStockUnitsAndOptionsMember2023-01-012023-09-3000008994602024-01-012024-03-310000899460mnkd:UnitedTherapeuticsCorporationMember2024-07-012024-09-300000899460us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember2024-09-300000899460us-gaap:SeniorNotesMember2024-09-300000899460us-gaap:FairValueInputsLevel3Membermnkd:LiabilityForSaleOfFutureRoyaltiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000899460mnkd:AccruedInterestMembermnkd:ConvertiblePromissoryNoteMembermnkd:TheMannGroupLLCMember2023-01-012023-09-300000899460mnkd:UnitedTherapeuticsCorporationMember2023-07-012023-09-300000899460mnkd:MannGroupConvertibleNoteMember2023-01-012023-09-300000899460us-gaap:DevelopedTechnologyRightsMember2024-09-300000899460us-gaap:MoneyMarketFundsMembermnkd:AmortizedCostMemberus-gaap:FairValueInputsLevel1Member2024-09-300000899460us-gaap:RetainedEarningsMember2023-12-310000899460us-gaap:SeniorNotesMembersrt:MaximumMember2023-12-310000899460mnkd:TheMannGroupLLCMember2023-01-

012023-09-300000899460mnkd:SupplyAndDistributionAgreementMembermnkd:BiommSAMemberus-gaap:ProductMember2024-07-012024-09-300000899460us-gaap:AdditionalPaidInCapitalMember2023-03-310000899460mnkd:OfficeMembermnkd:RussellRanchRoadIILLCMembersrt:MaximumMember2023-02-012023-02-280000899460mnkd:NewLoanArrangementMembermnkd:ConvertiblePromissoryNoteMembermnkd:TheMannGroupLLCMember2019-08-012019-08-310000899460mnkd:ContingentMilestoneLiabilityMemberus-gaap:MeasurementInputEntityCreditRiskMember2024-09-300000899460mnkd:DueInOneYearOrLessMember2023-12-310000899460mnkd:EstimatedFairValueMember2024-09-300000899460mnkd:MarketRestrictedStockUnitsMembermnkd:EmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-04-012024-06-300000899460mnkd:SagardHealthcarePartnersFundingBorrowerSPE2LPMembermnkd:TyvasoDPIMembermnkd:NetSalesThresholdsAAndBMember2023-12-012023-12-310000899460us-gaap:MeasurementInputExpectedDividendRateMembermnkd:ContingentMilestoneLiabilityMember2023-12-310000899460mnkd:CantorFitzgeraldMemberus-gaap:CommonStockMembermnkd:ContolledEquityOfferingSalesAgreementMembersrt:MaximumMember2018-02-012018-02-280000899460mnkd:FurnitureFixturesAndOfficeEquipmentMember2023-12-310000899460us-gaap:MeasurementInputRiskFreeInterestRateMembermnkd:MilestoneRightsLiabilityMember2023-12-310000899460mnkd:ThironaBioIncMembermnkd:ConvertiblePromissoryNoteMember2024-01-012024-09-300000899460us-gaap:AdditionalPaidInCapitalMember2022-12-310000899460srt:MinimumMembermnkd:MidCapCreditFacilityMember2023-12-310000899460mnkd:ContingentMilestoneLiabilityMemberus-gaap:MeasurementInputEntityCreditRiskMember2023-12-310000899460mnkd:EmployeeMember2024-01-012024-09-300000899460mnkd:MidCapCreditFacilityMember2021-04-012021-04-300000899460mnkd:MidCapCreditFacilityMember2024-01-012024-09-300000899460mnkd:MarketRestrictedStockUnitsMember2024-04-012024-06-300000899460us-gaap:RestrictedStockUnitsRSUMembermnkd:EmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-04-012024-06-300000899460us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembermnkd:TrancheOneMember2019-08-012019-08-310000899460us-gaap:SeniorNotesMembersrt:MaximumMember2024-09-300000899460us-gaap:RetainedEarningsMember2024-01-012024-03-310000899460mnkd:MidCapCreditFacilityMember2023-12-310000899460mnkd:LicenseAgreementMembermnkd:UnitedTherapeuticsCorporationMember2023-01-012023-09-300000899460mnkd:MarketRestrictedStockUnitsMembermnkd:ShareBasedCompensationAwardsTrancheFourMembermnkd:EmployeeMember2024-04-012024-06-300000899460mnkd:FurnitureFixturesAndOfficeEquipmentMembersrt:MaximumMember2024-09-300000899460us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-07-012024-09-300000899460us-gaap:SeniorNotesMember2023-01-012023-12-310000899460mnkd:SagardHealthcarePartnersFundingBorrowerSPE2LPMembermnkd:NetSalesThresholdAMembermnkd:TyvasoDPIMember2023-12-012023-12-310000899460us-gaap:MeasurementInputExpectedDividendRateMembermnkd:ContingentMilestoneLiabilityMember2024-09-300000899460us-gaap:CommonStockMember2023-06-300000899460srt:MaximumMemberus-gaap:ProductMember2024-01-012024-09-300000899460mnkd:PreLaunchInventoryMember2023-12-310000899460mnkd:DueInOneYearOrLessMember2024-09-300000899460mnkd:ThironaBioIncMembermnkd:ConvertiblePromissoryNoteMember2023-07-012023-09-300000899460mnkd:CommonStockOptionsAndPerformanceBasedStockOptionAwardsMember2023-07-012023-09-300000899460mnkd:LicenseAgreementMemberus-gaap:LicenseAndServiceMembermnkd:UnitedTherapeuticsCorporationMember2023-07-012023-09-300000899460us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Membermnkd:EstimatedFairValueMember2024-09-300000899460us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000899460us-gaap:BuildingImprovementsMember2023-12-310000899460us-gaap:BuildingImprovementsMembersrt:MinimumMember2024-09-300000899460mnkd:ConvertiblePromissoryNoteMembermnkd:TheMannGroupLLCMember2023-12-310000899460mnkd:MidCapCreditFacilityMember2024-01-012024-03-310000899460us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000899460mnkd:UnitedTherapeuticsCorporationMember2023-01-012023-09-300000899460us-gaap:RestrictedStockUnitsRSUMembermnkd:EmployeeMember2024-01-012024-03-310000899460us-gaap:FairValueInputsLevel3Membermnkd:ContingentMilestoneLiabilityMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000899460us-gaap:LicenseAndServiceMembermnkd:CommercialSupplyAgreementMembermnkd:UnitedTherapeuticsCorporationMember2023-07-012023-09-300000899460mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMember2023-04-012023-06-300000899460mnkd:EmployeeStockPurchasePlanMember2023-07-012023-09-300000899460mnkd:MilestoneRightsLiabilityMembermnkd:DeerfieldManagementCompanyLpMember2024-01-012024-09-300000899460mnkd:SagardHealthcarePartnersFundingBorrowerSPE2LPMembermnkd:NetSalesThresholdBMembermnkd:TyvasoDPIMember2023-12-012023-12-310000899460mnkd:CasperLLCMembersrt:MinimumMember2021-11-300000899460us-gaap:RoyaltyMember2023-01-012023-09-300000899460us-gaap:FairValueInputsLevel3Memberus-gaap:SeniorNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000899460mnkd:LoanArrangementMembermnkd:PrivatelyNegotiatedExchangeAgreementMembermnkd:TheMannGroupLLCMember2019-08-310000899460us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000899460mnkd:MidCapCreditFacilityMember2023-01-012023-12-310000899460mnkd:MilestoneRightsLiabilityMembermnkd:DeerfieldManagementCompanyLpMember2024-06-300000899460us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Membermnkd:GrossUnrealizedHoldingLossesMember2023-12-310000899460us-gaap:RestrictedStockUnitsRSUMembermnkd:EmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-04-012024-06-300000899460mnkd:FinancingLiabilityMember2024-09-300000899460us-gaap:RestrictedStockUnitsRSUMembermnkd:NonEmployeeDirectorMember2024-04-012024-06-300000899460mnkd:ConvertibleNotePrincipalAndInterestMembermnkd:TheMannGroupLLCMemberus-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000899460mnkd:TheMannGroupLLCMember2024-04-022024-04-020000899460us-gaap:AdditionalPaidInCapitalMember2024-06-300000899460mnkd:CasperLLCMember2021-11-012021-11-300000899460us-gaap:MeasurementInputPriceVolatilityMembermnkd:MannGroupConvertibleNoteMember2023-12-310000899460mnkd:TrancheOneMember2019-08-310000899460mnkd:TheMannGroupLLCMember2024-04-020000899460us-gaap:RestrictedStockUnitsRSUMembermnkd:EmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-01-012024-03-310000899460mnkd:SagardHealthcarePartnersFundingBorrowerSPE2LPMembermnkd:RoyaltyLiabilityMember2023-12-012023-12-310000899460mnkd:RoyaltiesArrangementMembermnkd:UnitedTherapeuticsCorporationMember2023-07-012023-09-300000899460us-gaap:RoyaltyMember2023-07-012023-09-300000899460us-gaap:ProductMember2023-12-310000899460us-gaap:ServiceMember2023-07-012023-09-300000899460us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMembermnkd:GrossUnrealizedHoldingGainsMember2024-09-3000008994602023-01-012023-12-310000899460us-gaap:MeasurementInputPriceVolatilityMemberus-gaap:SeniorNotesMember2023-12-310000899460us-gaap:TransferredOverTimeMembermnkd:CollaborationAndLicenseAgreementMembermnkd:NextGenResearchAndDevelopmentServicesMembermnkd:UnitedTherapeuticsCorporationMember2023-12-310000899460mnkd:CommercializationAndContinuousImprovementActivitiesMembermnkd:UnitedTherapeuticsCorporationMember2022-12-012022-12-310000899460mnkd:GrossUnrealizedHoldingLossesMember2023-12-310000899460us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-07-012024-09-3000008994602024-09-300000899460mnkd:ThironaBioIncMembermnkd:ConvertiblePromissoryNoteMember2024-07-012024-09-300000899460mnkd:AccruedInterestMembermnkd:ConvertiblePromissoryNoteMembermnkd:TheMannGroupLLCMember2024-01-012024-09-300000899460us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310000899460us-gaap:CommonStockMember2024-06-300000899460mnkd:LicenseAgreementMemberus-gaap:LicenseAndServiceMembermnkd:UnitedTherapeuticsCorporationMember2024-01-012024-09-300000899460mnkd:CommercialSupplyMembermnkd:UnitedTherapeuticsCorporationMember2023-07-012023-09-300000899460mnkd:GrossUnrealizedHoldingLossesMember2024-09-300000899460mnkd:SagardHealthcarePartnersFundingBorrowerSPE2LPMembermnkd:TyvasoDPIMember2023-12-012023-12-310000899460mnkd:UnitedTherapeuticsCorporationMember2024-01-012024-09-300000899460mnkd:MidCapCreditFacilityMembermnkd:TrancheOneMember2024-04-012024-04-010000899460us-gaap:FairValueInputsLevel3Membermnkd:MannGroupConvertibleNoteMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000899460us-gaap:MeasurementInputRiskFreeInterestRateMembermnkd:MilestoneRightsLiabilityMember2024-09-300000899460us-gaap:CarryingReportedAmountFairValueDisclosureMembermnkd:FinancingLiabilityMember2023-12-310000899460mnkd:AmortizedCostMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2024-09-300000899460mnkd:RestrictedStockUnitsAndMarketRestrictedStockUnitsMember2024-07-012024-09-300000899460us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Membermnkd:GrossUnrealizedHoldingGainsMember2023-12-310000899460us-gaap:SeniorNotesMember2024-01-012024-09-300000899460srt:MinimumMembermnkd:MannGroupConvertibleNoteMember2023-12-310000899460us-gaap:CommonStockMember2023-03-310000899460us-gaap:ConstructionInProgressMember2023-12-310000899460us-gaap:MeasurementInputExpectedDividendRateMembermnkd:MilestoneRightsLiabilityMember2023-12-310000899460mnkd:ContingentMilestoneLiabilityMemberus-gaap:MeasurementInputExpectedTermMember2023-12-310000899460us-gaap:RestrictedStockUnitsRSUMembermnkd:EmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-07-012024-09-300000899460us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-04-012024-06-300000899460mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMemberus-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000899460us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMembermnkd:GrossUnrealizedHoldingLossesMember2024-09-300000899460us-gaap:AdditionalPaidInCapitalMember2024-09-300000899460mnkd:ThironaBioIncMember2024-01-012024-09-300000899460mnkd:ManufacturingServicesMembermnkd:UnitedTherapeuticsCorporationMember2022-12-012022-12-310000899460mnkd:CasperLLCMember2021-11-300000899460mnkd:ManufacturingServicesMembermnkd:CollaborationAndLicenseAgreementMembermnkd:UnitedTherapeuticsCorporationMember2022-12-310000899460us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembermnkd:MidCapCreditFacilityMember2024-01-012024-09-300000899460mnkd:ProductRevenueMember2024-01-012024-09-300000899460us-gaap:SeniorNotesMember2021-03-042021-03-040000899460mnkd:MarketRestrictedStockUnitsMember2024-09-300000899460us-gaap:AdditionalPaidInCapitalMember2023-06-300000899460us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000899460us-gaap:CarryingReportedAmountFairValueDisclosureMembermnkd:FinancingLiabilityMember2024-09-300000899460mnkd:UnitedTherapeuticsCorporationMember2023-01-012023-12-310000899460us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMembermnkd:EstimatedFairValueMember2024-09-300000899460us-gaap:CommonStockMember2024-07-012024-09-300000899460mnkd:FurnitureFixturesAndOfficeEquipmentMember2024-09-300000899460mnkd:CommercialSupplyMembermnkd:UnitedTherapeuticsCorporationMember2023-01-012023-09-300000899460us-gaap:FairValueInputsLevel3Memberus-gaap:SeniorNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000899460mnkd:MannGroupConvertibleNoteMembersrt:MaximumMember2023-12-310000899460mnkd:ContingentMilestoneLiabilityMemberus-gaap:MeasurementInputPriceVolatilityMember2023-12-310000899460us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2024-09-300000899460us-gaap:LicenseAndServiceMember2023-01-012023-09-300000899460mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMemberus-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000899460mnkd:RestrictedStockUnitsAndMarketRestrictedStockUnitsMember2023-01-012023-09-300000899460us-gaap:LicenseAndServiceMember2024-04-012024-09-300000899460us-gaap:MoneyMarketFundsMembermnkd:AmortizedCostMemberus-gaap:FairValueInputsLevel1Member2023-12-310000899460mnkd:PulmatrixIncMember2024-07-012024-07-310000899460mnkd:OfficeMembermnkd:RussellRanchRoadIILLCMember2024-01-012024-09-300000899460us-gaap:LicenseAndServiceMember2024-01-012024-09-300000899460us-gaap:RestrictedStockUnitsRSUMembermnkd:ShareBasedCompensationAwardsTrancheFourMember2024-04-012024-06-300000899460us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMembermnkd:EmployeeMember2024-04-012024-06-300000899460mnkd:TheMannGroupLLCMember2024-01-012024-09-300000899460mnkd:MidCapCreditFacilityMember2024-04-010000899460srt:MaximumMembermnkd:LiabilityForSaleOfFutureRoyaltiesMember2024-09-300000899460us-gaap:RestrictedStockUnitsRSUMembermnkd:NonEmployeeDirectorMember2024-01-012024-09-300000899460us-gaap:RetainedEarningsMember2023-06-300000899460us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Membermnkd:EstimatedFairValueMember2024-09-300000899460mnkd:SagardHealthcarePartnersFundingBorrowerSPE2LPMember2023-12-012023-12-310000899460mnkd:OfficeAndVehicleMember2024-09-300000899460mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMember2023-07-012023-09-300000899460mnkd:ThironaBioIncMembermnkd:ConvertiblePromissoryNoteMember2024-06-272024-06-270000899460us-gaap:MeasurementInputPriceVolatilityMembermnkd:MilestoneRightsLiabilityMember2023-12-310000899460us-gaap:BuildingImprovementsMembersrt:MaximumMember2024-09-300000899460mnkd:EmployeeStockPurchasePlanMember2023-01-012023-09-300000899460us-gaap:CarryingReportedAmountFairValueDisclosureMembermnkd:MidCapCreditFacilityMember2023-12-3100000899460246020240-07-080000899460us-gaap:LicenseAndServiceMember2023-07-012023-09-3000008994602018-06-01mnkd:CiplaLtdMembermnkd:LicenseAndDistributionAgreementMember2018-05-310000899460mnkd:ZealandPharmaUsMember2023-12-310000899460us-gaap:RestrictedStockUnitsRSUMember2024-04-012024-06-300000899460mnkd:RoyaltiesArrangementMembermnkd:UnitedTherapeuticsCorporationMember2023-01-012023-09-300000899460mnkd:SeniorConvertibleNotesMember2023-01-012023-09-300000899460mnkd:LicenseAgreementMembermnkd:UnitedTherapeuticsCorporationMember2024-01-012024-09-300000899460us-gaap:BuildingImprovementsMember2024-09-300000899460mnkd:CiplaLtdMembermnkd:LicenseAndDistributionAgreementMember2023-12-310000899460mnkd:FurnitureFixturesAndOfficeEquipmentMembersrt:MinimumMember2024-09-300000899460us-gaap:CommonStockMember2022-12-310000899460srt:WeightedAverageMemberus-gaap:CommonStockMembermnkd:CantorFitzgeraldMembermnkd:AtMarketIssuanceSalesAgreementMember2024-09-300000899460us-gaap:ServiceMember2023-01-012023-09-3000008994602023-07-012023-09-300000899460us-gaap:TransferredOverTimeMembermnkd:ResearchAndDevelopmentServicesAndLicenseMembermnkd:CollaborationAndLicenseAgreementMembermnkd:UnitedTherapeuticsCorporationMember2012-012022-12-310000899460mnkd:RoyaltiesArrangementMembermnkd:UnitedTherapeuticsCorporationMember2024-01-012024-09-300000899460mnkd:FinancingLiabilityMembersrt:MaximumMember2024-09-300000899460mnkd:MannGroupConvertibleNoteMember2023-12-310000899460mnkd:CollaborationAndLicenseAgreementMembermnkd:UnitedTherapeuticsCorporationMember2018-10-312018-10-310000899460us-gaap:LicenseAndServiceMembermnkd:CiplaLtdMembermnkd:LicenseAndDistributionAgreementMember2024-07-012024-09-300000899460mnkd:CommonStockOptionsAndPerformanceBasedStockOptionAwardsMember2023-01-012023-09-300000899460mnkd:EstimatedFairValueMember2023-12-310000899460mnkd:PromissoryNotesMembermnkd:NewLoanArrangementMembermnkd:TheMannGroupLLCMember2019-08-012019-08-

310000899460mnkd:AtTheMarketIssuanceMember2023-01-012023-09-300000899460us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Membermnkd:EstimatedFairValueMember2023-12-310000899460mnkd:MarketRestrictedStockUnitsMembermnkd:EmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-04-012024-06-300000899460mnkd:GrossUnrealizedHoldingGainsMember2023-12-310000899460us-gaap:RestrictedStockUnitsRSUMembermnkd:EmployeeMember2024-01-012024-09-300000899460mnkd:ThironaBioIncMember2023-02-280000899460mnkd:CollaborationAndLicenseAgreementMembermnkd:UnitedTherapeuticsCorporationMember2023-12-310000899460us-gaap:LicenseAndServiceMember2023-12-310000899460us-gaap:FairValueInputsLevel3Membermnkd:FinancingLiabilityMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000899460mnkd:AudioVisualEquipmentMember2024-09-300000899460us-gaap:VehiclesMembermnkd:MasterLeaseAgreementWithEnterpriseMember2024-01-012024-09-300000899460us-gaap:EquipmentMember2024-07-012024-09-300000899460us-gaap:ProductMember2023-07-012023-09-300000899460us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-01-012024-03-310000899460us-gaap:CommercialPaperMembermnkd:AmortizedCostMemberus-gaap:FairValueInputsLevel2Member2024-09-300000899460us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000899460us-gaap:SeniorNotesMembersrt:MinimumMember2023-12-3100008994602024-10-250000899460us-gaap:SeniorNotesMembersrt:MinimumMember2021-03-040000899460mnkd:MilestoneRightsLiabilityMemberus-gaap:MeasurementInputExpectedTermMember2023-12-310000899460mnkd:MidCapCreditFacilityMembermnkd:TrancheOneMember2019-08-012019-08-310000899460mnkd:CiplaLtdMemberus-gaap:LicenseAndServiceMembermnkd:LicenseAndDistributionAgreementMember2023-07-012023-09-300000899460mnkd:ThironaBioIncMembermnkd:ConvertiblePromissoryNoteMember2022-01-012022-01-310000899460us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000899460us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310000899460us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2024-09-300000899460mnkd:CommercialSupplyMembermnkd:UnitedTherapeuticsCorporationMember2024-01-012024-09-300000899460mnkd:PulmatrixIncMember2024-07-080000899460us-gaap:BuildingMember2024-09-300000899460us-gaap:CarryingReportedAmountFairValueDisclosureMembermnkd:MilestoneRightsLiabilityMember2023-12-310000899460us-gaap:LandMember2023-12-310000899460us-gaap:MeasurementInputExpectedDividendRateMembermnkd:MilestoneRightsLiabilityMember2024-09-300000899460us-gaap:CommercialPaperMembermnkd:AmortizedCostMemberus-gaap:FairValueInputsLevel2Member2023-12-310000899460us-gaap:CaliforniaFranchiseTaxBoardMembermnkd:SenateBills175Member2024-06-012024-06-300000899460mnkd:MarketRestrictedStockUnitsMember2024-01-012024-09-300000899460us-gaap:ShareBasedCompensationAwardTrancheTwoMembermnkd:MarketRestrictedStockUnitsMembermnkd:EmployeeMember2024-04-012024-06-300000899460mnkd:PulmatrixIncMember2024-07-082024-07-080000899460us-gaap:CarryingReportedAmountFairValueDisclosureMembermnkd:LiabilityForSaleOfFutureRoyaltiesMember2024-09-300000899460us-gaap:RetainedEarningsMember2022-12-310000899460us-gaap:CommonStockMember2023-12-310000899460us-gaap:ProductMember2023-01-012023-09-300000899460us-gaap:RetainedEarningsMember2024-06-300000899460us-gaap:LicenseAndServiceMembermnkd:CommercialSupplyAgreementMembermnkd:UnitedTherapeuticsCorporationMember2024-01-012024-09-300000899460mnkd:CollaborationAndLicenseAgreementMembermnkd:UnitedTherapeuticsCorporationMember2024-09-300000899460us-gaap:MeasurementInputPriceVolatilityMembermnkd:ContingentMilestoneLiabilityMember2024-09-300000899460us-gaap:RetainedEarningsMember2023-07-012023-09-300000899460us-gaap:DevelopedTechnologyRightsMember2023-12-3100008994602023-04-01us-gaap:LicenseAndServiceMember2024-09-3000008994602024-06-012024-06-300000899460us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-03-310000899460mnkd:LiabilityForSaleOfFutureRoyaltiesMember2024-09-300000899460us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-3000008994602023-06-300000899460mnkd:SeniorConvertibleNotesMember2024-07-012024-09-300000899460mnkd:CiplaLtdMemberus-gaap:LicenseAndServiceMembermnkd:LicenseAndDistributionAgreementMember2024-01-012024-09-300000899460us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310000899460us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMembermnkd:EstimatedFairValueMember2023-12-310000899460srt:MinimumMemberus-gaap:BuildingMember2024-09-300000899460us-gaap:RestrictedStockUnitsRSUMembermnkd:EmployeeMember2024-04-012024-06-300000899460us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000899460us-gaap:LicenseAndServiceMember2024-07-012024-09-300000899460mnkd:CommonStockOptionsAndPerformanceBasedStockOptionAwardsMember2024-07-012024-09-300000899460us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-04-012024-06-300000899460us-gaap:CarryingReportedAmountFairValueDisclosureMembermnkd:ContingentMilestoneLiabilityMember2024-09-300000899460mnkd:LiabilityForSaleOfFutureRoyaltiesMember2024-01-012024-09-300000899460mnkd:MilestoneRightsLiabilityMemberus-gaap:MeasurementInputEntityCreditRiskMember2023-12-310000899460mnkd:PromissoryNotesMembermnkd:NewLoanArrangementMembermnkd:TheMannGroupLLCMember2019-08-310000899460mnkd:DavidThomsonMember2024-07-012024-09-300000899460srt:MinimumMembermnkd:FinancingLiabilityMember2024-09-300000899460us-gaap:AdditionalPaidInCapitalMember2024-03-310000899460us-gaap:RelatedPartyMember2023-12-310000899460us-gaap:SeniorNotesMemberus-gaap:PrivatePlacementMember2021-03-310000899460mnkd:MannGroupConvertibleNoteMember2023-01-012023-12-310000899460srt:MinimumMember2024-01-012024-09-300000899460mnkd:ThironaBioIncMembermnkd:ConvertiblePromissoryNoteMember2024-06-300000899460us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310000899460mnkd:DavidThomsonMember2024-09-300000899460us-gaap:SeniorNotesMember2023-12-310000899460us-gaap:MachineryAndEquipmentMember2023-12-310000899460us-gaap:CarryingReportedAmountFairValueDisclosureMembermnkd:MilestoneRightsLiabilityMember2024-09-300000899460us-gaap:MachineryAndEquipmentMember2024-09-300000899460mnkd:TyvasoDPIMember2024-01-012024-09-300000899460mnkd:PulmatrixIncMember2024-05-282024-05-280000899460us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMembermnkd:EmployeeMember2024-07-012024-09-3000008994602024-06-300000899460us-gaap:RetainedEarningsMember2023-01-012023-03-310000899460mnkd:RestrictedStockUnitsAndMarketRestrictedStockUnitsMember2023-07-012023-09-300000899460mnkd:NewLoanArrangementMembermnkd:ConvertiblePromissoryNoteMembermnkd:TheMannGroupLLCMember2019-08-310000899460mnkd:MilestoneRightsLiabilityMembermnkd:DeerfieldManagementCompanyLpMember2023-12-310000899460us-gaap:RoyaltyMember2024-01-012024-09-300000899460us-gaap:RestrictedStockUnitsRSUMembermnkd:EmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-03-310000899460us-gaap:CommonStockMember2023-04-012023-06-300000899460mnkd:ContingentMilestoneLiabilityMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-12-310000899460mnkd:AmortizedCostMember2023-12-310000899460us-gaap:TransferredOverTimeMembermnkd:CollaborationAndLicenseAgreementMembermnkd:UnitedTherapeuticsCorporationMembermnkd:NextGenResearchAndDevelopmentServicesMember2022-12-012022-12-310000899460us-gaap:RetainedEarningsMember2023-04-012023-06-30iso4217:EURxbrli:puremnkd:Employeesxbrli:sharesmnkd:Distributorutr:Dmnkd:ConsecutiveMonthmnkd:Notemnkd:Segmentiso4217:USDiso4217:USDxbrli:sharesmnkd:Installment Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Â â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 13-3607736 (State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification No.) Â Â 1 Casper Street Danbury, Connecticut 06810 (Address of principal executive offices) (Zip Code) (818) 661-5000 (Registrantâ€™s telephone number, including area code) N/A (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Â TradingSymbol(s) Â Name of each exchange on which registered Common Stock, par value $0.01 per share Â MNKD Â The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Large accelerated filer â˜’ Accelerated filer â˜ Â Â Non-accelerated filer â˜ Smaller reporting company â˜ Â Â Â Â Â Emerging growth company â˜ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ As of October 25, 2024, there were 275,777,693 shares of the registrantâ€™s common stock, $0.01 par value per share, outstanding. Â Â Â MANNKIND CORPORATION Form 10-Q For the Quarterly Period Ended September 30, 2024 TABLE OF CONTENTS Â Page PART I: FINANCIAL INFORMATION 2 Â Â Item 1. Financial Statements (Unaudited) 2 Condensed Consolidated Statements of Operations: Three and nine months ended September 30, 2024 and 2023 2 Condensed Consolidated Statements of Comprehensive Income (Loss): Three and nine months ended September 30, 2024 and 2023 3 Condensed Consolidated Balance Sheets: September 30, 2024 and December 31, 2023 4 Condensed Consolidated Statements of Stockholdersâ€™ Deficit: Three and nine months ended September 30, 2024 and 2023 5 Condensed Consolidated Statements of Cash Flows: Nine months ended September 30, 2024 and 2023 7 Notes to Condensed Consolidated Financial Statements 9 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 39 Item 3. Quantitative and Qualitative Disclosures About Market Risk 48 Item 4. Controls and Procedures 48 Â Â PART II: OTHER INFORMATION 49 Â Â Item 1. Legal Proceedings 49 Item 1A. Risk Factors 49 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 77 Item 3. Defaults Upon Senior Securities 77 Item 4. Mine Safety Disclosures 77 Item 5. Other Information 77 Item 6. Exhibits 79 Â Â SIGNATURES 81 Â Â Â 1 Â PART 1: FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS MANNKIND CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (In thousands except per share data) Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Net revenue â€“ commercial product sales Â $ 19,728 Â Â $ 17,927 Â Â $ 59,272 Â Â $ 53,834 Â Revenue â€“ collaborations and services Â Â 23,268 Â Â Â 13,108 Â Â Â 74,130 Â Â Â 35,705 Â Royalties â€“ collaboration Â Â 27,083 Â Â Â 20,218 Â Â Â 75,326 Â Â Â 50,951 Â Total revenues Â Â 70,079 Â Â Â 51,253 Â Â Â 208,728 Â Â Â 140,490 Â Expenses: Â Â Â Â Â Â Â Â Â Â Â Â Cost of goods sold Â Â 3,197 Â Â Â 3,995 Â Â Â 12,621 Â Â Â 14,749 Â Cost of revenue â€“ collaborations and services Â Â 14,826 Â Â Â 10,259 Â Â Â 44,377 Â Â Â 29,955 Â Research and development Â Â 12,926 Â Â Â 9,989 Â Â Â 34,755 Â Â Â 22,047 Â Selling Â Â 13,093 Â Â Â 13,440 Â Â Â 36,189 Â Â Â 40,752 Â General and administrative Â Â 10,823 Â Â Â 10,538 Â Â Â 34,168 Â Â Â 33,027 Â Loss (gain) on foreign currency transaction Â Â 2,454 Â Â Â (2,065) Â Â 526 Â Â Â (860) Total expenses Â Â 57,319 Â Â Â 46,156 Â Â Â 162,636 Â Â Â 139,670 Â Income from operations Â Â 12,760 Â Â Â 5,097 Â Â Â 46,092 Â Â Â 820 Â Other income (expense): Â Â Â Â Â Â Â Â Â Â Â Â Interest income, net Â Â 3,179 Â Â Â 1,580 Â Â Â 9,790 Â Â Â 4,429 Â Interest expense on liability for sale of future royalties Â Â (4,089) Â Â â€“ Â Â Â (12,720) Â Â â€“ Â Interest expense on financing liability Â Â (2,470) Â Â (2,459) Â Â (7,361) Â Â (7,332) Interest expense Â Â (1,801) Â Â (2,815) Â Â (10,419) Â Â (12,474) Gain on bargain purchase Â Â 5,259 Â Â Â â€“ Â Â Â 5,259 Â Â Â â€“ Â Other income Â Â 32 Â Â Â 318 Â Â Â 32 Â Â Â 286 Â Loss on extinguishment of debt Â Â â€“ Â Â Â â€“ Â Â Â (7,050) Â Â â€“ Â (Loss) gain on available-for-sale securities Â Â â€“ Â Â Â â€“ Â Â Â (1,550) Â Â 932 Â Total other expense Â Â 110 Â Â Â (3,376) Â Â (24,019) Â Â (14,159) Income (loss) before income tax expense Â Â 12,870 Â Â Â 1,721 Â Â Â 22,073 Â Â Â (13,339) Income tax expense Â Â 1,320 Â Â Â â€“ Â Â Â 1,907 Â Â Â â€“ Â Net income (loss) Â $ 11,550 Â Â $ 1,721 Â Â $ 20,166 Â Â $ (13,339) Net income (loss) per share â€“ basic Â $ 0.04 Â Â $ 0.01 Â Â $ 0.07 Â Â $ (0.05) Weighted average shares used to compute net income (loss) Â Â Â per share â€“ basic Â Â 274,998 Â Â Â 268,732 Â Â Â 272,811 Â Â Â 266,126 Â Net income (loss) per share â€“ diluted Â $ 0.04 Â Â $ 0.01 Â Â $ 0.07 Â Â $ (0.05) Weighted average shares used to compute net income (loss) Â Â Â per share â€“ diluted Â Â 284,693 Â Â Â 323,770 Â Â Â 281,407 Â Â Â 266,126 Â Â See notes to condensed consolidated financial statements. 2 Â MANNKIND CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (In thousands) Â Net income (loss) Â $ 11,550 Â Â $ 1,721 Â Â $ 20,166 Â Â $ (13,339) Other comprehensive income: Â Â Â Â Â Â Â Â Â Â Â Â Unrealized gain on available-for-sale securities Â Â 588 Â Â Â â€“ Â Â Â 588 Â Â Â 443 Â Comprehensive income (loss) Â $ 12,138 Â Â $ 1,721 Â Â $ 20,754 Â Â $ (12,896) Â See notes to condensed consolidated financial statements. 3 Â MANNKIND CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Â Â Â Â Â Â Â Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â (In thousands except share and per share data) Â ASSETS Â Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Â Cash and cash equivalents Â $ 62,373 Â Â $ 238,480 Â Short-term investments Â Â 189,215 Â Â Â 56,619 Â Accounts receivable, net Â Â 18,184 Â Â Â 14,901 Â Inventory Â Â 26,663 Â Â Â 28,545 Â Prepaid expenses and other current assets Â Â 31,229 Â Â Â 34,848 Â Total current assets Â Â 327,664 Â Â Â 373,393 Â Restricted cash Â Â 735 Â Â Â â€“ Â Long-term investments Â Â 16,796 Â Â Â 7,155 Â Property and equipment, net Â Â 85,339 Â Â Â 84,220 Â Goodwill Â Â 1,931 Â Â Â 1,931 Â Other intangible assets Â Â 5,313 Â Â Â 1,073 Â Other assets Â Â 26,422 Â Â Â 7,426 Â Total assets Â $ 464,200 Â Â $ 475,198 Â Â Â Â Â Â Â Â LIABILITIES AND STOCKHOLDERS' DEFICIT Â Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Â Accounts payable Â $ 6,444 Â Â $ 9,580 Â Accrued expenses and other current liabilities Â Â 37,386 Â Â Â 42,036 Â Liability for sale of future royalties â€“ current Â Â 11,755 Â Â Â 9,756 Â Financing liability â€“ current Â Â 9,998 Â Â Â 9,809 Â Deferred revenue â€“ current Â Â 6,518 Â Â Â 9,085 Â Recognized loss on purchase commitments â€“ current Â Â â€“ Â Â Â 3,859 Â Midcap credit facility â€“ current Â Â â€“ Â Â Â 20,000 Â Total current liabilities Â Â 72,101 Â Â Â 104,125 Â Senior convertible notes Â Â 227,941 Â Â Â 226,851 Â Liability for sale of future royalties â€“ long term Â Â 137,140 Â Â Â 136,054 Â Financing liability â€“ long term Â Â 94,005 Â Â Â 94,319 Â Deferred revenue â€“ long term Â Â 65,150 Â Â Â 69,794 Â Recognized loss on purchase commitments â€“ long term Â Â 62,638 Â Â Â 60,942 Â Operating lease liability Â Â 12,167 Â Â Â 3,925 Â Milestone liabilities Â Â 2,813 Â Â Â 3,452 Â Financing lease liability Â Â 171 Â Â Â â€“ Â Midcap credit facility â€“ long term Â Â â€“ Â Â Â 13,019 Â Mann Group convertible note Â Â â€“ Â Â Â 8,829 Â Accrued interest â€“ Mann Group convertible note Â Â â€“ Â Â Â 56 Â Total liabilities Â Â 674,126 Â Â Â 721,366 Â Commitments and contingenciesÂ (Note 15) Â Â Â Â Â Â Â Stockholders' deficit: Â Â Â Â Â Â Â Undesignated preferred stock, $0.01Â par value â€“ 10,000,000Â shares authorized; Â Â Â noÂ shares issued or outstanding as of September 30, 2024 or December 31, 2023 Â Â â€“ Â Â Â â€“ Â Common stock, $0.01Â par value â€“ 800,000,000Â shares authorized;Â Â Â 275,775,038Â and 270,034,495Â shares issued and outstanding as ofÂ Â Â September 30, 2024 and December 31, 2023, respectively Â Â 2,753 Â Â Â 2,700 Â Additional paid-in capital Â Â 2,995,974 Â Â Â 2,980,539 Â Accumulated other comprehensive income Â Â 588 Â Â Â â€“ Â Accumulated deficit Â Â (3,209,241) Â Â (3,229,407) Total stockholders' deficit Â Â (209,926) Â Â (246,168) Total liabilities and stockholders' deficit Â $ 464,200 Â Â $ 475,198 Â Â See notes to condensed consolidated financial statements. 4 Â MANNKIND CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ DEFICIT (Unaudited) Â Â Common Stock Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shares Â Â Amount Â Â AdditionalPaid-in Capital Â Â Accumulated Other Comprehensive Income Â Â Accumulated Deficit Â Â Total Â Â Â (In thousands) Â BALANCE, JANUARY 1, 2023 Â Â 263,793 Â Â $ 2,638 Â Â $ 2,964,293 Â Â $ â€“ Â Â $ (3,217,469) Â $ (250,538) Issuance of common stock associatedÂ Â Â with at-the-market offering Â Â 269 Â Â Â 3 Â Â Â 1,196 Â Â Â â€“ Â Â Â â€“ Â Â Â 1,199 Â Issuance costs associated with at-the-marketÂ Â Â offering Â Â â€“ Â Â Â â€“ Â Â Â (24) Â Â Â â€“ Â Â Â â€“ Â Â Â (24) Net issuance of common stock associatedÂ Â Â with stock options and restricted stock units Â 206 Â Â Â 2 Â Â Â 50 Â Â Â â€“ Â Â Â â€“ Â Â Â 52 Â Issuance of common stock pursuant to Â Â Â conversion of the Mann GroupÂ Â Â convertible note interest Â Â 11 Â Â Â â€“ Â

Â Â 55 Â Â Â â€” Â Â Â â€” Â Â Â 55 Â Stock-based compensation expense Â â€” Â Â Â â€” Â Â Â 3,655 Â Â Â â€” Â Â Â â€” Â Â Â 3,655 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (9,795) Â Â (9,795) BALANCE, MARCH 31, 2023 Â Â 264,279 Â Â $ 2,643 Â Â $ 2,969,225 Â Â $ â€” Â Â $ (3,227,264) Â $ (255,396) Issuance of common stock associatedÂ Â Â with at-the-market offering Â Â 362 Â Â Â 4 Â Â Â 1,579 Â Â Â â€” Â Â Â â€” Â Â Â 1,583 Â Issuance costs associated with at-the-marketÂ Â Â offering Â Â â€” Â Â Â â€” Â Â Â (17) Â Â â€” Â Â Â â€” Â Â Â (17) Issuance of common stock pursuant to Â Â Â conversion of the Mann GroupÂ Â Â convertible note interest Â Â 13 Â Â Â â€” Â Â Â 54 Â Â Â â€” Â Â Â â€” Â Â Â 54 Â Net issuance of common stock associatedÂ Â Â with stock options and restricted stockÂ Â Â units Â Â 3,279 Â Â Â 32 Â Â Â (8,576) Â Â â€” Â Â Â â€” Â Â Â (8,544) Issuance of common stock under Â Â Â employee stock purchase plan Â Â 266 Â Â Â 3 Â Â Â 920 Â Â Â â€” Â Â Â â€” Â Â Â 923 Â Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 5,580 Â Â Â â€” Â Â Â â€” Â Â Â 5,580 Â Issuance of common stock from marketÂ Â Â price stock purchase plan Â Â 36 Â Â Â â€” Â Â Â 152 Â Â Â â€” Â Â Â â€” Â Â Â 152 Â Cumulative gain on available-for-saleÂ Â Â securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 443 Â Â Â â€” Â Â Â 443 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (5,265) Â Â (5,265) BALANCE, JUNE 30, 2023 Â Â 268,235 Â Â $ 2,682 Â Â $ 2,968,917 Â Â $ 443 Â Â $ (3,232,529) Â $ (260,487) Issuance of common stock associatedÂ Â Â with at-the-market offering Â Â 847 Â Â Â 8 Â Â Â 4,097 Â Â Â â€” Â Â Â â€” Â Â Â 4,105 Â Issuance costs associated with at-the-marketÂ Â Â offering Â Â â€” Â Â Â â€” Â Â Â (67) Â Â â€” Â Â Â â€” Â Â Â (67) Issuance of common stock pursuant to Â Â Â conversion of the Mann GroupÂ Â Â convertible note interest Â Â 13 Â Â Â 1 Â Â Â 55 Â Â Â â€” Â Â Â 56 Â Net issuance of common stock associatedÂ Â Â with stock options and restricted stockÂ Â Â units Â Â 448 Â Â Â 4 Â Â Â (1,712) Â Â â€” Â Â Â â€” Â Â Â (1,708) Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 4,601 Â Â Â â€” Â Â Â â€” Â Â Â 4,601 Â Net income Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 1,721 Â Â Â 1,721 Â BALANCE, SEPTEMBER 30, 2023 Â Â 269,543 Â Â $ 2,695 Â Â $ 2,975,891 Â Â $ 443 Â Â $ (3,230,808) Â $ (251,779) Â 5 Â Â Â Common Stock Â Â Â

reserve are made when changes in the Company's assumptions result in revised estimates.Provider Chargebacks and Discounts â€” Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase products from the Company. Customers charge the Company for the difference between what they pay for products and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is recorded in accrued expenses and other current liabilities. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by Customers, and the Company generally issues credits for such amounts within a few weeks of the Customerâ€™s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold to qualified healthcare providers, and chargebacks that Customers have claimed, but for which the Company has not yet issued a credit.Government Rebates â€” The Company is subject to discount obligations under Medicare and state Medicaid programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses and other current liabilities. Estimates around Medicaid have historically required significant judgment due to timing lags in receiving invoices for claims from states. For Afrezza, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Companyâ€™s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for products that have been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. The Companyâ€™s estimates include consideration of historical claims experience, payer channel mix, current contract prices, unbilled claims, claim submission time lags and inventory in the distribution channel.Payer Rebates â€” The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates, including estimates for product that has been recognized as revenue, but which remains in the distribution channel, and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities. The Companyâ€™s estimates include consideration of historical claims experience, payer channel mix, current contract prices, unbilled claims, claim submission time lags and inventory in the distribution channel.Other Incentives â€” Other incentives which the Company offers include voluntary patient support programs, such as the Company's co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with co-payments required by payers. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with the products that have been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses and other current liabilities. 11 Â Revenue Recognition â€” Revenue â€” Collaborations and Services â€” The Company enters into licensing, research or other agreements under which the Company licenses certain rights to its product candidates to third parties, conducts research or provides other services to third parties. The terms of these arrangements may include but are not limited to payment to the Company of one or more of the following: up-front license fees; development, regulatory, and commercial milestone payments; payments for commercial manufacturing and clinical supply services the Company provides; and royalties on net sales of licensed products and sublicenses of the rights. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment such as determining the performance obligation in the contract and determining the stand-alone selling price for each performance obligation identified in the contract. With respect to the Company's significant collaboration and service agreement with UT that includes a long-term commercial supply agreement (as amended, the â€œCSAâ€), the Company has identified three distinct performance obligations: (1) the license, supply of product to be used in clinical development, and continued development and approval support for Tyvaso DPI (â€œR&D Services and Licenseâ€); (2) development activities for the next generation of the product (â€œNext-Gen R&D Servicesâ€); and (3) a material right associated with current and future manufacturing and supply of product (â€œManufacturing Services and Product Salesâ€). Pre-production activities under the CSA, such as facility expansion services and other administrative services, were considered bundled services under the Manufacturing Services and Product Sales performance obligation as required by ASC 606. Following the FDAâ€™s approval of Tyvaso DPI, UT began issuing purchase orders for the supply of product, which represents distinct contracts and performance obligations under ASC 606. Revenue is recognized for the supply of product at a point in time, once control is transferred to UT. See Note 10 â€” Collaboration, Licensing and Other Arrangements. If an arrangement has multiple performance obligations, the allocation of the transaction price is determined from observable market inputs, and the Company uses key assumptions to determine the stand-alone selling price, which may include development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success. Revenue is recognized based on the measurement of progress as the performance obligation is satisfied and consideration received that does not meet the requirements to satisfy the revenue recognition criteria is recorded as deferred revenue. Current deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. For further information, see Note 10 â€” Collaboration, Licensing and Other Arrangements.The Company recognizes upfront license payments as revenue upon delivery of the license only if the license is determined to be a separate unit of accounting from the other undelivered performance obligations. The undelivered performance obligations typically include manufacturing or development services or research and/or steering committee services. If the license is not considered as a distinct performance obligation, then the license and other undelivered performance obligations would be evaluated to determine if such should be accounted for as a single unit of accounting. If concluded to be a single performance obligation, the transaction price for the single performance obligation is recognized as revenue over the estimated period of when the performance obligation is satisfied. If the license is considered to be a distinct performance obligation, then the estimated revenue is included in the transaction price for the contract, which is then allocated to each performance obligation based on the respective standalone selling prices.Whenever the Company determines that an arrangement should be accounted for over time, the Company determines the period over which the performance obligations will be performed, and revenue will be recognized over the period the Company is expected to complete its performance obligations. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. The Companyâ€™s collaboration agreements typically entitle the Company to additional payments upon the achievement of development, regulatory and sales milestones. If the achievement of a milestone is considered probable at the inception of the collaboration, the related milestone payment is included with other collaboration consideration, such as upfront fees and research funding, in the Companyâ€™s revenue calculation. If these milestones are not considered probable at the inception of the collaboration, the milestones will typically be recognized in one of two ways depending on the timing of when the milestone is achieved. If the milestone is improbable at inception and subsequently deemed probable of achievement, such will be added to the transaction price, resulting in a cumulative adjustment to revenue. If the milestone is achieved after the performance period has been completed and all performance obligations have been delivered, the Company will recognize the milestone payment as revenue in its entirety in the period the milestone was achieved. The Companyâ€™s collaboration agreements, for accounting purposes, represent contracts with customers and therefore are not subject to accounting literature on collaboration agreements. The Company grants licenses to its intellectual property, supplies raw materials, semi-finished goods or finished goods, provides research and development services and offers sales support for the co-promotion of products, all of which are outputs of the Companyâ€™s ongoing activities, in exchange for consideration. Accordingly, the Company concluded that its collaboration agreements must generally be accounted for pursuant to ASC 606.For collaboration agreements that allow collaboration partners to select additional optioned products or services, the Company evaluates whether such options contain material rights (i.e., have exercise prices that are discounted compared to what the Company 12 Â would charge for a similar product or service to a new collaboration partner). The exercise price of these options includes a combination of licensing fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, the Company concludes the option does not contain a material right, and therefore is not included in the transaction price at contract inception. The Company assessed the long-term commercial supply agreement with UT (as amended, the "CSA") and determined that a material right existed for the manufacturing services performance obligation. The transaction price is allocated to the material right as well as the remaining performance obligations in accordance with ASC 606. The Company also evaluates grants of additional licensing rights upon option exercises to determine whether such should be accounted for as separate contracts.Revenue Recognition â€” Royalties â€” The Company recognizes royalty revenue for a sales-based or usage-based royalty if it is promised in exchange for an intellectual property license. The royalty revenue is recognized as the latter of the subsequent sale of the product occurs or if the performance obligation to which the royalty has been allocated has been satisfied or partially satisfied. The Companyâ€™s UT License Agreement (as defined in Note 10 â€” Collaboration, Licensing and Other Arrangements) entitles it to receive a 10% royalty on net sales of Tyvaso DPI for the license of the Companyâ€™s IP that was considered to be interdependent with the development activities that supported the approval of Tyvaso DPI. Although the Company recognizes a 10% royalty on net revenue from the sale of Tyvaso DPI as revenue, it only collects 9% due to its sale in December 2023 of 1% of future royalties as detailed in Note 15 â€” Commitments and Contingencies.The Companyâ€™s net revenue and cost of revenue and goods sold as shown on the condensed consolidated statement of operations is comprised of revenue generated from product sales, services and royalties as shown below (in thousands): Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net revenue: Â Â Â Â Â Â Â Â Â Â Â Â Product revenue (1) Â $ 42,959 Â Â $ 30,727 Â Â $ 132,945 Â Â $ 88,731 Â Services (2) Â Â 37 Â Â Â 308 Â Â Â 457 Â Â Â 808 Â Royalties (3) Â Â 27,083 Â Â Â 20,218 Â Â Â 75,326 Â Â Â 50,951 Â Total net revenue Â $ 70,079 Â Â $ 51,253 Â Â $ 208,728 Â Â $ 140,490 Â _____(1)Amounts represent the revenue from Afrezza and V-Go sales to wholesalers and specialty pharmacies and Tyvaso DPI to UT.(2)Amounts represent revenue generated from the Company's collaboration arrangements, including Next-Gen R&D Services (as defined in Note 10) for UT as well as arrangements with other collaboration partners. See Note 10 â€” Collaboration, Licensing and Other Arrangements. (3)Amounts represent royalties on UTâ€™s net revenue from Tyvaso DPI sales. Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of goods sold and cost of revenue: Â Â Â Â Â Â Â Â Â Â Â Â Product revenue Â $ 18,023 Â Â $ 13,983 Â Â $ 56,651 Â Â $ 44,006 Â Services Â Â Â â€” Â Â Â 271 Â Â Â 347 Â Â Â 698 Â Total cost of goods sold and cost of revenue Â $ 18,023 Â Â $ 14,254 Â Â $ 56,998 Â Â $ 44,704 Â The Company follows accounting guidance in measuring revenue and certain judgments affect the application of its revenue policy. For example, in connection with its existing collaboration agreements, the Company has recorded short-term and long-term deferred revenue on its condensed consolidated balance sheets based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. However, this estimate is based on the Companyâ€™s current project development plan and, if the development plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period.Milestone Payments â€” At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the customer, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as, or when, the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its 13 Â estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration, other revenue, and earnings in the period of adjustment.Cost of Goods Sold â€” Cost of goods sold includes material, labor costs and manufacturing overhead. Cost of goods sold also includes a component of current period manufacturing costs in excess of costs capitalized into inventory (â€œexcess capacity costsâ€). These costs, in addition to the impact of the revaluation of inventory for standard costing, and write-offs of inventory are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. Cost of goods sold excludes the cost of insulin purchased under the Companyâ€™s Insulin Supply Agreement (the â€œInsulin Supply Agreementâ€) with Amphastar Pharmaceuticals, Inc. (â€œAmphastarâ€). All insulin inventory on hand was written off and the full purchase commitment contract to purchase future insulin was accrued as a recognized loss on purchase commitments as of the end of 2016.Cost of Revenues â€” Collaborations and Services â€” Cost of revenues for collaborations and services includes material, labor costs, manufacturing overhead, and excess capacity costs. These costs, in addition to the write-offs of inventory are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. Cost of revenues for collaborations and services also includes the cost of product development.Research and Development ("R&D") â€” Clinical trial expenses result from obligations under contracts with vendors, consultants and clinical site agreements in addition to internal costs associated with conducting clinical trials. R&D costs are expensed as incurred. Clinical study and certain research costs are recognized over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Nonrefundable advance payments for services to be received in the future for use in R&D activities are recorded as prepaid assets and expensed in the period when the services are performed. Cash, Cash Equivalents and Restricted Cash â€” The Company considers all highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase that are readily convertible into cash to be cash equivalents. As of September 30, 2024 and December 31, 2023, cash equivalents were comprised of money market funds, U.S. Treasury securities, corporate bonds and commercial paper with original maturities less than 90 days from the date of purchase. The Company records restricted cash when cash and cash equivalents are restricted as to withdrawal or usage. Restricted cash under a letter of credit issued in connection with a facility lease assumed by the Company that will not be available for use in the Companyâ€™s operations within 12 months of the reporting date is presented in non-current assets. See Note 2 â€” Pulmatrix Transaction. Held-to-Maturity Investments â€” The Companyâ€™s investments generally consist of commercial paper, corporate notes or bonds and U.S. Treasury securities. As of September 30, 2024 and December 31, 2023, the Company held short-term and long-term investments of debt securities, including commercial paper and bonds. The Company intends to hold its investments until maturity; therefore, these investments are stated at amortized cost. The investments with maturities less than 12 months are included in short-term investments and investments with maturities in excess of twelve months are included in long-term investments in the condensed consolidated balance sheets. The amortization or accretion of the Companyâ€™s investments is recognized as interest income in the condensed consolidated statements of operations.Available-for-Sale Investment â€” In June 2021, the Company purchased a $3.0 million convertible promissory note issued by Thirona Bio, Inc. (â€œThironaâ€). In January 2022, the Company purchased an additional $5.0 million convertible promissory note issued by Thirona (the â€œThirona convertible notesâ€). The Thirona convertible notes are general unsecured obligations of Thirona and initially accrued interest at a rate of 6% per annum. Unless earlier converted into conversion shares pursuant to the note purchase agreement, the aggregate principal of $8.0 million and accrued interest shall be due and payable by Thirona on demand by the Company at any time after the maturity date. The Thirona convertible notes were amended in February 2023 to extend the maturity date from December 31, 2022 to June 30, 2024, and again on June 27, 2024 to extend the maturity date to June 30, 2026 and increase the interest rate to 10% per annum. The Thirona convertible notes are classified as available-for-sale securities and included in other assets as of September 30, 2024 and prepaid expense and other current assets as of December 31, 2023 in the condensed consolidated balance sheets. The Company periodically assesses whether it has any intention to sell the investment, determines the fair value of its available-for-sale investment using level 3 inputs and assesses whether there were other-than-temporary impairments associated with the investment. Unrealized holding gains and losses are excluded from earnings and reported in other comprehensive income until realized, while unrealized losses related to credit risk are reported through earnings in the period incurred.Concentration of Credit Risk â€” Financial instruments that potentially subject the Company to concentration of credit risk consisted of cash and cash equivalents and investments. Cash and cash equivalents are held in high credit quality institutions. Cash equivalents consisted of interest-bearing money market funds and U.S. Treasury securities with original or remaining maturities of 90 days or less 14 Â at the time of purchase. Investments

generally consisted of commercial paper, corporate notes or bonds and U.S. Treasury securities. The cash equivalents and investments are regularly monitored by management.Accounts Receivable and Allowance for Credit Losses â€“ Accounts receivable are recorded at the invoiced amount and are not interest bearing. Accounts receivable are presented net of an allowance for credit losses if there are estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for credit losses. The allowance for expected credit losses is based primarily on past collections experience relative to the length of time receivables are past due. However, when available evidence reasonably supports an assumption that future economic conditions will differ from current and historical payment collections, an adjustment is reflected in the allowance for expected credit losses. Accounts receivable are also presented net of an allowance for product returns and trade discounts and allowances because the Companyâ€™s customers have the right of setoff for these amounts against the related accounts receivable.Pre-Launch Inventory â€“ An improvement to the manufacturing process for the Companyâ€™s primary excipient, fumaryl diketopiperazine (â€œFDKPâ€) was demonstrated to be viable and management expects to realize an economic benefit in the future as a result of such process improvement. Accordingly, the Company is required to assess whether to capitalize inventory costs related to such excipient prior to validation of the improved manufacturing process and adoption of the new supplier. In doing so, management must consider a number of factors in order to determine the amount of inventory to be capitalized, including the historical experience of modifying the Companyâ€™s manufacturing processes, feedback from technical experts and regulatory agencies on the changes being effected and the amount of inventory that is likely to be used in commercial production. The shelf life of the excipient will be determined as part of the validation process; in the interim, the Company must assess the available stability data to determine whether there is likely to be adequate shelf life to support anticipated future sales occurring beyond the expected adoption date of the new raw material. If management is aware of any specific material risks or contingencies other than the normal regulatory reporting process, or if the criteria for capitalizing inventory produced prior to regulatory approval are otherwise not met, the Company would not capitalize such inventory costs, choosing instead to recognize such costs as R&D expense in the period incurred. See Note 5 â€“ Inventories.Inventories â€“ Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. The Company capitalizes inventory costs associated with the Companyâ€™s products based on managementâ€™s judgment that future economic benefits are expected to be realized; otherwise, such costs are expensed as incurred as cost of goods sold. The Company uses a contract manufacturing organization outside of the U.S. for certain stages of V-Go inventory.The Company periodically analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value and writes down such inventories, as appropriate. In addition, the Companyâ€™s products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or may become obsolete or are forecasted to become obsolete due to expiration, the Company will record a charge to write down such unmarketable inventory to its estimated net realizable value. The Company analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company performs an assessment of projected sales and evaluates the lower of cost or net realizable value and the potential excess inventory on hand at the end of each reporting period.Property and Equipment â€“ Property and equipment is recorded at historical cost, net of accumulated depreciation. Depreciation expense is recorded over the assetsâ€™ useful lives on a straight-line basis and included in cost of goods sold, research and development, and general and administrative expense in the condensed consolidated statements of operations. See Note 6 â€“ Property and Equipment.Impairment of Long-Lived Assets â€“ Long-lived assets include property and equipment, operating lease right-of-use assets and other intangible assets. The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Assets are considered to be impaired if the carrying value is considered to be unrecoverable.If the Company believes an asset to be impaired, the impairment recognized is the amount by which the carrying value of the asset exceeds the fair value of the asset. Fair value is determined using the market, income or cost approaches as appropriate for the asset. Any write-downs are treated as permanent reductions in the carrying amount of the asset and recognized as an operating loss.Acquisitions â€“ The Company first determines whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, the Company accounts for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process R&D (â€œIPR&Dâ€), and liabilities assumed are recorded at their respective fair values as of the acquisition date in the Companyâ€™s condensed consolidated financial statements. Leases are recorded at the net present value of the remaining lease payments. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. A gain on bargain purchase is recorded if the fair value of the net assets acquired exceeds the fair value of the 15 Â consideration transferred. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquireeâ€™s liability arising from an acquisition it consummated prior to the Companyâ€™s acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&D projects with no alternative future use are recorded in R&D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. Goodwill and Other Intangible Assets â€“ The fair value of acquired intangible assets is determined using either a cost approach or an income approach. The cost approach establishes fair value based on the cost of reproducing or replacing the asset, less depreciation for functional or economic obsolescence. The income approach, referred to as the excess earnings method, utilizes Level 3 fair value inputs to determine the present value of future economic benefits to be derived from ownership of the intangible asset. Market participant valuations assume a global view considering all potential jurisdictions and indications based on discounted after-tax cash flow projections, risk adjusted for estimated probability of technical and regulatory success. The Company tests for impairment annually on a reporting unit basis, at the beginning of the Companyâ€™s fourth fiscal quarter and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying amount. To the extent the carrying amount of a reporting unit is less than its estimated fair value, an impairment charge will be recorded.Finite-lived intangible assets are amortized on a straight-line basis over the estimated useful life. Estimated useful lives are determined considering the period assets are expected to contribute to future cash flows. Finite-lived intangible assets are tested for impairment when facts or circumstances suggest that the carrying value of the asset may not be recoverable. If the carrying value exceeds the projected undiscounted pretax cash flows of the intangible asset, an impairment loss equal to the excess of the carrying value over the estimated fair value (discounted after-tax cash flows) is recognized.IPR&D acquired in a business combination is considered an indefinite-lived intangible asset until the completion or abandonment of the associated R&D efforts. During the R&D period, the asset is not amortized but rather is tested for impairment when facts or circumstances suggest that the carrying value of the asset may not be recoverable. Once the R&D efforts are completed, the Company accounts for the resulting asset as a finite-lived intangible asset. If the R&D efforts are abandoned, the asset balance is written off to R&D expense.Recognized Loss on Purchase Commitments â€“ The Company reviews the terms of the long-term supply agreements and assesses the need for any accrual for estimated losses, such as lower of cost or net realizable value, that will not be recovered by future product sales. The recognized loss on purchase commitments is reduced as inventory items are received or as the liability is extinguished. See Note 15 â€“ Commitments and Contingencies. Milestone Rights Liability â€“ In July 2013, in conjunction with the execution of a (now repaid) loan agreement with Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively, â€œDeerfieldâ€), the Company entered into a Milestone Rights Purchase Agreement (the â€œMilestone Rights Agreementâ€) pursuant to which the Company issued certain milestone rights to Deerfield Private Design Fund II, L.P. and Horizon SantÂ© FLML SÃ€RL (the â€œOriginal Milestone Purchasersâ€). The foregoing milestone rights provided the Original Milestone Purchasers certain rights to receive payments of up to $90.0 million upon the occurrence of specified strategic and Afrezza sales milestones, $50.0 million of which remains payable as of September 30, 2024 upon achievement of such milestones (collectively, the â€œMilestone Rightsâ€). In December 2021, the Milestone Rights were purchased by Barings Global Special Situations Credit Fund 4 (Delaware), L.P. and Barings Global Special Situations Credit 4 (LUX) S.ar.l. (together, the â€œMilestone Purchasersâ€). As a result, the Milestone Purchasers have assumed the obligations of the Original Milestone Purchasers and are now entitled to all rights under the Milestone Rights Agreement. The Milestone Rights liability is reported at fair value at the date of the agreement which is periodically offset against payments. See Note 11 â€“ Fair Value of Financial Instruments.The initial fair value estimate of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones and discounted to present value using a selected market discount rate. The expected timing and probability of achieving the milestones was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. The Milestone Rights liability is remeasured as the specified milestone events are achieved. Specifically, as each milestone event is achieved, the portion of the initially recorded Milestone Rights liability that pertains to the milestone event being achieved, is remeasured to the amount of the specified related milestone payment. The resulting change in the balance of the Milestone Rights liability due to remeasurement is recorded in the 16 Â Companyâ€™s condensed consolidated statements of operations as interest expense. Furthermore, the Milestone Rights liability is reduced upon the settlement of each milestone payment. As a result, each milestone payment is effectively allocated between a reduction of the recorded Milestone Rights liability and an expense representing a return on a portion of the Milestone Rights liability paid to the investor for the achievement of the related milestone event. See Note 8 â€“ Accrued Expenses and Other Current Liabilities and Note 15 â€“ Commitments and Contingencies.Fair Value of Financial Instruments â€“ The Company applies various valuation approaches in determining the fair value of its financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Companyâ€™s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 â€“ Quoted prices for identical instruments in active markets.Level 2 â€“ Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.Level 3 â€“ Significant inputs to the valuation model are unobservable.Income Taxes â€“ The provisions for federal, foreign, state and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized.For uncertain tax positions, the Company determines whether it is â€œmore likely than notâ€ that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit can be recorded in the financial statements. For those tax positions where it is â€œnot more likely than notâ€ that a tax benefit will be sustained, no tax benefit is recognized. Penalties, if probable and reasonably estimable, are recognized as a component of income tax expense. The Company has reduced its deferred tax assets for uncertain tax positions but has not recorded liabilities for income tax expense, penalties, or interest. Contingencies â€“ The Company records a loss contingency for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These accruals represent managementâ€™s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may revise its estimates.Stock-Based Compensation â€“ Share-based payments to employees, including grants of restricted stock units (â€œRSUsâ€), performance-based non-qualified stock options awards (â€œPNQsâ€), restricted stock units with market conditions (â€œMarket RSUsâ€), options and the compensatory elements of employee stock purchase plans, are recognized in the condensed consolidated statements of operations based upon the fair value of the awards at the grant date. RSUs are valued based on the market price on the grant date. Market RSUs are valued using a Monte Carlo valuation model and RSUs with performance conditions are evaluated for the probability that the performance conditions will be met and estimates the date at which the performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period. The Company uses the Black-Scholes option valuation model to estimate the grant date fair value of employee stock options and the compensatory elements of employee stock purchase plans. Net Income (Loss) Per Share of Common Stock â€“ Basic net income or loss per share ("EPS") is calculated by dividing net income by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the effect of potential common stock issuances resulting from assumed stock option exercises and vesting of restricted stock units, unless the effect is anti-dilutive, when applying the treasury stock method, as well as potential dilution under the if-converted method for convertible debt securities. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted EPS as they would be anti-dilutive. 17 Â Recently Issued Accounting Standards â€“ In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). This ASU requires disaggregated information about a public entityâ€™s effective tax rate reconciliation as well as additional information on income taxes paid. This ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact of the guidance on its condensed consolidated financial statement disclosures.From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Companyâ€™s condensed consolidated financial position or results of operations upon adoption. 2. Pulmatrix Transaction On May 28, 2024, the Company executed a bill of sale and assignment agreement with Pulmatrix, Inc. ("Pulmatrix") whereby the Company acquired from Pulmatrix certain lab assets and assumed certain liabilities, including the lease for an R&D facility in Bedford, Massachusetts. Concurrently, the Company and Pulmatrix entered into an intellectual property cross-license agreement (the "Cross License Agreement") for the Company's out-licensing of its CricketÂ® Device to Pulmatrix and in-licensing of Pulmatrix's iSPERSEâ„¢ technology, and a master service agreement. The parties and landlord also entered into an amendment to lease and consent to assignment of the lease. Each of these agreements became effective upon the closing of the collective transaction (the "Pulmatrix Transaction") on July 8, 2024 (the "Effective Date"). The Company also entered into employment agreements with 13 Pulmatrix R&D employees who began employment with the Company on the Effective Date.Pursuant to the Cross License Agreement, the Company granted to Pulmatrix certain exclusive and non-exclusive rights to develop, use, manufacture, market, offer and sell its single-use disposable dry powder inhaler (the "Cricket Device") for the inhaled delivery of dihydroergotamine in any formulation whatsoever (including Pulmatrix'sâ€™s PUR3100 treatment of acute migraine), and the inhaled delivery of one or more active pharmaceutical ingredients formulated with iSPERSE for the treatment of neurological disease in humans (collectively, the â€œCricket Licenseâ€).In return, Pulmatrix granted to the Company certain exclusive and non-exclusive rights to develop, use, manufacture, market, offer and sell iSPERSE formulations of clofazimine and insulin, and formulations of iSPERSE with one or more active pharmaceutical ingredients for the treatment of nontuberculous mycobacteria lung disease in humans, endocrine disease in humans, and interstitial lung diseases in humans (collectively, the â€œiSPERSE Licenseâ€).The Company may also provide certain development services to Pulmatrix under the Master Services Agreement, including but not limited to, activities to develop a dry powder formulation of the active pharmaceutical ingredient that Pulmatrix provides to the Company for oral inhalation using iSPERSE.Â Accounting TreatmentÂ The Pulmatrix Transaction was accounted for as a business combination using the acquisition method of accounting, which requires, among other things, the assets acquired and liabilities assumed to be recognized at their respective fair values as of the Effective Date. The excess of the fair value of the net assets acquired over the purchase price in this non-cash transaction was recorded as a gain on bargain purchase. 18 Â The fair values of identifiable assets acquired and liabilities assumed by the Company from Pulmatrix as of the Effective Date are

reflected below (in thousands): Â Â Amount Â Assets: Â Â Â iSPERSE License â€“ IPR&D Â $ 4,300 Â Right-of-use asset â€“ Bedford R&D facility Â Â 10,057 Â Property and equipment Â Â 959 Â Total assets Â Â 15,316 Â Liabilities: Â Â Â Operating lease liability â€“ Bedford R&D facility Â Â 10,057 Â Total liabilities Â Â 10,057 Â Net assets acquired â€“ Gain on bargain purchase Â $ 5,259 Â The fair value of the Cricket License transferred to Pulmatrix was determined to be immaterial based on the current market availability of numerous third party single-dose dry powder inhalers and the significant time, cost, and risk required to potentially commercialize the Cricket Device. The transfer of the Cricket License was within the scope of ASC 606 as a sale of functional intellectual property, however, since no value was attributed to the Cricket License, no revenue was recognized by the Company.The fair value of the iSPERSE License was determined by applying a cost approach, which assesses current replacement cost to acquire or construct a substitute asset of comparable utility as of the Effective Date. The iSPERSE License was deemed to have a fair value of $4.3 million based on the estimate of internal and external costs to recreate the underlying technology, which are inputs not observable in the market and therefore considered Level 3 measurements. The iSPERSE technology will be utilized in the Company's continuing R&D efforts and accounted for as IPR&D.The fair values of the right-of-use asset and lease liability for the assumed R&D facility operating lease were assessed in accordance with ASC 842, Leases, based on discounted cash flows from future lease payments, utilizing the Companyâ€™s incremental borrowing rate of 7.25%. In June 2024, in anticipation of the facility lease assumption on the Effective Date, the Company transferred $0.7 million to a depository account at a financial institution to collateralize a conditional stand-by letter of credit as required under the lease. This amount is reflected as long-term restricted cash as of September 30, 2024. The lease term extends from the Effective Date through November 30, 2033 with monthly payments of $0.1 million increasing 3% annually starting on December 1, 2024. See Note 15 â€“ Commitments and Contingencies.Property and equipment were assessed for monetary benefit, remaining economic life, and relative risk based on the Company's industry knowledge and analysis of sales of comparable equipment to arrive at fair value.Transaction costs totaling $0.1 million were expensed as incurred and reflected in the condensed consolidated statements of operations for the three and nine months ended September 30, 2024.Pro forma results of operation for the Transaction have not been presented, as the effects of the Transaction were not material to the condensed consolidated financial statements. 19 Â 3. Investments Cash Equivalents â€“ Cash equivalents consist of highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase that are readily convertible into cash. Available-for-Sale Investment â€“ The Company's investment in Thirona is comprised of two notes with aggregate face value of $8.0 million and stated interest rate of 10%. The Thirona convertible notes are classified as available-for-sale securities and are included in other assets as of September 30, 2024 and prepaid expenses and other current assets as of December 31, 2023 in the condensed consolidated balance sheets. Available-for-sale investments are measured at fair value with realized gains and losses reported in other income (expense) in the condensed consolidated statements of operations. Unrealized holding gains and losses are excluded from earnings and reported in other comprehensive income (loss) until realized. The Company determines the fair value of its available-for-sale investments using level 3 inputs and evaluates the fair value of its investment in Thirona by applying a scenario based method with a hypothetical yield of 28.0% and 35.0%, and volatility of 70.0% and 90.0% at September 30, 2024 and December 31, 2023, respectively. As of September 30, 2024 and December 31, 2023, the fair value of the Company's investment in Thirona was $5.9 million and $6.9 million, respectively. For the three and nine months ended September 30, 2024, the Company recorded an unrealized holding gain of $0.6 million. Additionally, for the nine months ended September 30, 2024, the Company recognized a loss of $1.6 million on its investment in Thirona as a result of modification of the Thirona convertible notes. For the three and nine months ended September 30, 2023, the Company recognized a gain of $0.9 million on its investment in Thirona as a result of the recovery of a temporary impairment and an unrealized holding gain of $0.4 million. For the three and nine months ended September 30, 2024, the Company recognized no interest income on investment and $0.1 million and $0.4 million for the three and nine months ended September 30, 2023, respectively.Held-to-Maturity Investments â€“ Investments consist of highly liquid investments that are intended to facilitate liquidity and capital preservation. The amortization or accretion of the Companyâ€™s investments is recognized in the condensed consolidated statements of operations as interest income. For the three and nine months ended September 30, 2024, the Company recognized $3.2 million and $9.8 million, respectively, of interest income on investments, of which $2.1 million and $6.0 million, respectively, was net accretion on certain investments. For the three and nine months ended September 30, 2023, the Company recognized $1.5 million and $4.0 million, respectively, of interest income on investments, of which $0.5 million and $0.9 million, respectively, was net accretion on certain investments. No allowance for credit losses on held-to-maturity securities was required as of September 30, 2024 or December 31, 2023.The contractual maturities of the Companyâ€™s held-to-maturity investments are summarized below (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â AmortizedCost Basis Â Â AggregateFair Value Â Â AmortizedCost Basis Â Â AggregateFair Value Â Due in one year or less(1) Â $ 230,797 Â Â $ 231,555 Â Â $ 115,263 Â Â $ 115,374 Â Due after one year through five years Â Â 16,796 Â Â Â 16,992 Â Â Â 7,155 Â Â Â 7,197 Â Total Â $ 247,593 Â Â $ 248,547 Â Â $ 122,418 Â Â $ 122,571 Â _____(1)The investments due in one year or less include cash equivalents of $41.6 million as of September 30, 2024 and $58.6 million as of December 31, 2023. The fair value of the cash equivalents, long-term and short-term investments are disclosed below (dollars in thousands).Â Â Â September 30, 2024 Â Â Â Investment Level Â Amortized Cost(Carrying Value) Â Â Gross Unrealized HoldingGains Â Â Gross UnrealizedHoldingLosses Â Â EstimatedFair Value Â Money market funds and other Â Level 1 Â $ 31,298 Â Â $ â€“ Â Â $ â€“ Â Â $ 31,298 Â Commercial bonds and paper Â Level 2 Â Â 57,477 Â Â Â 268 Â Â Â (12) Â Â 57,733 Â U.S. Treasury Securities Â Level 2 Â Â 158,818 Â Â Â 700 Â Â Â (2) Â Â 159,516 Â Total cash equivalents and investments Â Â Â Â 247,593 Â Â Â 968 Â Â Â (14) Â Â 248,547 Â Less: cash equivalents Â Â Â Â (41,582) Â Â â€“ Â Â Â â€“ Â Â Â (41,582) Total Investments Â Â Â $ 206,011 Â Â $ 968 Â Â $ (14) Â $ 206,965 Â Â 20 Â Â Â December 31, 2023 Â Â Â Investment Level Â Amortized Cost(Carrying Value) Â Â Gross Unrealized HoldingGains Â Â Gross UnrealizedHoldingLosses Â Â EstimatedFair Value Â Money market funds Â Level 1 Â $ 69,611 Â Â $ â€“ Â Â $ â€“ Â Â $ 69,611 Â Commercial bonds and paper Â Level 2 Â Â 43,251 Â Â Â 135 Â Â Â (38) Â Â 43,348 Â U.S. Treasury Securities Â Level 2 Â Â 9,556 Â Â Â 56 Â Â Â â€“ Â Â Â 9,612 Â Total cash equivalents and investments Â Â Â Â 122,418 Â Â Â 191 Â Â Â (38) Â Â 122,571 Â Less: cash equivalents Â Â Â Â (58,644) Â Â â€“ Â Â Â â€“ Â Â Â (58,644) Total Investments Â Â Â $ 63,774 Â Â $ 191 Â Â $ (38) Â $ 63,927 Â As of September 30, 2024 and December 31, 2023, there was $1.1 million and $0.5 million, respectively, of accrued interest receivable on investments which is included in prepaid expense and other current assets in our condensed consolidated balance sheets. 4. Accounts Receivable Accounts receivable, net consists of the following (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Accounts receivable â€“ commercial Â Â Â Â Â Â Accounts receivable, gross Â $ 18,359 Â Â $ 20,199 Â Wholesaler distribution fees and prompt pay discounts Â Â (2,363) Â Â (2,469) Reserve for returns Â Â (7,817) Â Â (6,215) Allowance for credit losses Â Â â€“ Â Â Â (157) Total accounts receivable â€“ commercial, net Â Â 8,179 Â Â Â 11,358 Â Accounts receivable â€“ collaborations and services Â Â 10,005 Â Â Â 3,543 Â Total accounts receivable, net Â $ 18,184 Â Â $ 14,901 Â As of December 31, 2023, the allowance for credit losses and doubtful accounts for commercial accounts receivable of $0.2 million was related to accounts receivable for Zealand Pharma US, Inc. As of September 30, 2024, the Company had three wholesale distributors representing approximately 87% of commercial accounts receivable and 77% and 73% of gross sales during the three and nine months ended September 30, 2024, respectively.As of September 30, 2024 and December 31, 2023, there was no allowance for credit losses for accounts receivable for collaborations and services. The Company had one collaboration partner, UT, that comprised 100% of the collaboration and services net accounts receivable as of September 30, 2024 and December 31, 2023 and approximately 100% of gross revenue from collaborations and services for the three and nine months ended September 30, 2024. 5. InventoriesInventories consist of the following (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Raw materials Â $ 6,437 Â Â $ 6,262 Â Work-in-process Â Â 9,074 Â Â Â 13,646 Â Finished goods Â Â 11,152 Â Â Â 8,637 Â Total inventory Â $ 26,663 Â Â $ 28,545 Â Work-in-process and finished goods as of September 30, 2024 and December 31, 2023 include conversion costs and exclude the cost of insulin. All insulin inventory on hand was written off and the projected loss on the purchase commitment contract to purchase future insulin was accrued as of the end of 2016. Raw materials inventory included $0.8 million of pre-launch inventory as of September 30, 2024 and December 31, 2023. 21 Â The Company analyzed its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company also performed an assessment of projected sales and evaluated the lower of cost or net realizable value and the potential excess inventory on hand as of September 30, 2024 and December 31, 2023. Inventory that did not meet acceptable standards or was forecasted to become obsolete due to expiration is reserved for inventory obsolescence in the condensed consolidated balance sheets and recorded in costs of goods sold in the condensed consolidated statements of operations. As a result of these assessments there were inventory write-offs of $0.3 million and $1.9 million for the three and nine months ended September 30, 2024, respectively, and $0.3 million and $3.7 million for the three and nine months ended September 30, 2023, respectively. 6. Property and Equipment Property and equipment consisted of the following (dollars in thousands): Â Â Estimated Useful Â Â Â Â Â Â Life (Years) Â Â September 30, 2024 Â Â December 31, 2023 Â Land Â Â â€“ Â Â $ 875 Â Â $ 875 Â Buildings Â 39-40 Â Â Â 17,389 Â Â Â 17,389 Â Building improvements(1) Â 5-40 Â Â Â 90,573 Â Â Â 46,357 Â Machinery and equipment Â 3-15 Â Â Â 65,733 Â Â Â 60,410 Â Furniture, fixtures and office equipment Â 5-10 Â Â Â 3,350 Â Â Â 3,070 Â Computer equipment and software Â Â 3 Â Â Â 8,811 Â Â Â 8,658 Â Construction in progress(1) Â Â â€“ Â Â Â 5,242 Â Â Â 48,997 Â Total property and equipment Â Â Â Â Â 191,973 Â Â Â 185,756 Â Less accumulated depreciation Â Â Â Â Â (106,634) Â Â (101,536) Total property and equipment, net Â Â Â Â Â $ 85,339 Â Â $ 84,220 Â _____(1)During the nine months ended September 30, 2024, the Company transferred $43.5 million from construction in progress to building improvements for assets placed in service related to the expansion of the Company's manufacturing facility.Depreciation expense related to property and equipment was as follows (in thousands): Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Depreciation Expense Â $ 2,099 Â Â $ 1,117 Â Â $ 5,151 Â Â $ 3,250 Â During each of the three and nine months ended September 30, 2024, the Company retired $0.1 million of manufacturing equipment as it was no longer in service. The net book value for the disposed assets was de minimis. There were no asset retirements during the three and nine months ended September 30, 2023. 7. Goodwill and Other Intangible AssetsGoodwill â€“ Goodwill represents the excess of the purchase price over the identifiable tangible and intangible assets acquired plus liabilities assumed arising from business combinations. The balance of goodwill was $1.9 million as of September 30, 2024 and December 31, 2023 as a result of the Company's acquisition of V-Go in May 2022. Goodwill is tested at least annually for impairment by assessing qualitative factors in determining whether it is more likely than not that the fair value of net assets is below their carrying amounts. See Note 1 â€“ Description of Business and Significant Accounting Policies.Other Intangible Assets â€“ Other intangible assets consisted of the following (dollars in thousands): Â Â Estimated Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â UsefulLife (Years) Â Â Cost Â Â AccumulatedAmortization Â Â Net Book Value Â Â Cost Â Â AccumulatedAmortization Â Â Net Book Value Â Developed technology Â Â 15 Â Â Â $ 1,200 Â Â Â $ (187) Â Â $ 1,013 Â Â Â $ 1,200 Â Â Â $ (127) Â Â $ 1,073 Â iSPERSE License â€“ IPR&D Â Â Â â€“ Â Â Â Â 4,300 Â Â Â Â â€“ Â Â Â Â 4,300 Â Â Â Â â€“ Â Â Â Â â€“ Â Â Â Â â€“ Â Total Â Â Â Â Â Â $ 5,500 Â Â Â $ (187) Â Â $ 5,313 Â Â Â $ 1,200 Â Â Â $ (127) Â Â $ 1,073 Â Amortization expense related to the developed technology was de minimis for the three and nine months ended September 30, 2024 and 2023. The estimated annual amortization expense for the developed technology for the years ended December 31, 2024 through 2028 is approximately $0.1 million per year and $0.6 million, thereafter. 22 Â The iSPERSE License â€“ IPR&D is an indefinite-lived intangible asset, and as such is not amortized but rather is tested for impairment when facts or circumstances indicate the carrying value of the asset may not be recoverable. Upon completion of the underlying R&D efforts, the intangible asset will be accounted for as a finite-lived intangible asset. If the R&D efforts are abandoned, the IPR&D asset balance will be written off to R&D expense. The Company evaluates its other intangible assets for potential impairment annually and when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. See Note 1 â€“ Description of Business and Significant Accounting Policies. 8. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities were comprised of the following (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Salary and related expenses Â $ 16,239 Â Â $ 19,506 Â Discounts and allowances for commercial product sales Â Â 9,869 Â Â Â 9,541 Â Accrued interest Â Â 479 Â Â Â 2,153 Â Deferred lease liability Â Â 2,483 Â Â Â 1,423 Â Current portion of milestone rights liability(1) Â Â 639 Â Â Â 752 Â Returns reserve for acquired product(2) Â Â 1,468 Â Â Â 601 Â Professional fees Â Â 563 Â Â Â 979 Â State income tax liability Â Â 1,507 Â Â Â 1,561 Â Other Â Â 4,139 Â Â Â 5,520 Â Accrued expenses and other current liabilities Â $ 37,386 Â Â $ 42,036 Â _____(1)See Note 15 â€“ Commitments and Contingencies under Contingencies â€“ Milestone Rights.(2)See Note 15 â€“ Commitments and Contingencies under Loss Contingencies â€“ Returns Reserve for Acquired Product. 9. Borrowings Carrying amount of the Company's borrowings consisted of the following (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Senior convertible notes Â $ 227,941 Â Â $ 226,851 Â MidCap credit facility Â Â â€“ Â Â Â 33,019 Â Mann Group convertible note Â Â â€“ Â Â Â 8,829 Â Total debt â€“ net carrying amount Â $ 227,941 Â Â $ 268,699 Â The following table provides a summary of the Companyâ€™s principal balance of debt and key terms: Â Â Amount Due Â Terms Â Â September 30, 2024 Â Â December 31, 2023 Â Annual InterestÂ Â Â Rate Â Maturity Date Â Conversion Price Senior convertible notes Â $230.0Â million Â Â $230.0Â million Â 2.50% Â March 2026 Â $5.21Â per share MidCap credit facility(1) Â $ â€“ Â Â Â $33.3Â million Â one-monthSOFR(1% floor)plus 6.25%;cap of 8.25% Â August 2025 Â N/A Mann Group convertible note(2) Â $ â€“ Â Â Â $8.8Â million Â 2.50% Â December 2025 Â $2.50per share _____(1)Repaid on April 1, 2024.(2)Repaid on April 2, 2024. 23 Â The maturities of the Companyâ€™s borrowings as of September 30, 2024 are as follows (in thousands): Â Â Amounts Â Remainder of 2024 Â $ â€“ Â Â â€“ Â 2025 Â Â â€“ Â 2026 Â Â 230,000 Â Total principal payments Â Â 230,000 Â Debt issuance costs Â Â (2,059) Total debt Â $ 227,941 Â Senior convertible notes â€“ In March 2021, the Company issued $230.0 million aggregate principal amount of Senior convertible notes in a private offering. The Senior convertible notes were issued pursuant to an indenture, dated March 4, 2021 (the â€œIndentureâ€), between the Company and U.S. Bank National Association, as trustee.The Senior convertible notes are general unsecured obligations of the Company and will mature on March 1, 2026, unless earlier converted, redeemed or repurchased by the Company. The Senior convertible notes will bear cash interest from March 4, 2021 at an annual rate of 2.50% payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2021. The Senior convertible notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding December 1, 2025, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021 (and only during such calendar quarter), if the last reported sale price of the Companyâ€™s common stock, par value $0.01 per share, for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the Senior convertible notes on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Senior convertible notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on each such trading day; (3) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Senior convertible notes called (or deemed called) for redemption; or (4) upon the occurrence of specified corporate events as set forth in the Indenture. On or after December 1, 2025 until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at the Companyâ€™s election, in the manner and subject to the terms and conditions provided in the Indenture.The initial conversion rate is 191.8281 shares of common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.21 per share of common stock). The initial conversion price of the Senior convertible notes represents a premium of approximately 30% to the last reported sale price of the common stock on the Nasdaq Global Market on March 1, 2021. The conversion rate for the Senior convertible notes is subject to adjustment under certain circumstances in accordance with the terms of the Indenture, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date of the Senior convertible notes or if the Company delivers a notice of redemption in respect of the Senior convertible notes, the Company will, in certain circumstances, increase the conversion rate of the Senior convertible notes for a holder who elects to convert its Senior convertible notes in connection with such a corporate event or convert its Notes called for redemption during the related redemption period (as defined in the Indenture), as the case may be.The Company may redeem for cash all or any portion of the Senior convertible notes, at its option, on or after March 6, 2024 and prior to the 36th scheduled trading day immediately preceding the maturity date, if the last reported sale price of common stock has been at least 130% of the conversion price for the Senior convertible notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding

the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Senior convertible notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company elects to redeem less than all of the outstanding Senior convertible notes, at least $75.0 million aggregate principal amount of Senior convertible notes must be outstanding and not subject to redemption as of the relevant redemption notice date. No sinking fund is provided for the Senior convertible notes.If the Company undergoes a fundamental change (as defined in the Indenture), then, subject to certain conditions and except as described in the Indenture, holders may require the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Senior convertible notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. 24 Â The Indenture includes customary covenants and sets forth certain events of default after which the Senior convertible notes may be declared immediately due and payable. If certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries) occur, 100% of the principal of and accrued and unpaid interest on the Senior convertible notes will automatically become due and payable. If an event of default with respect to the Senior convertible notes, other than certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries), occurs and is continuing, the trustee, by notice to the Company, or the holders of at least 25% in principal amount of the outstanding Senior convertible notes by notice to the Company and the trustee, may, and the trustee at the request of such holders shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the Senior convertible notes to be due and payable. Notwithstanding the foregoing, the Indenture provides that, to the extent the Company so elects, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture will, for the first 365 days after the occurrence of such an event of default consist exclusively of the right to receive additional interest on the Senior convertible notes as set forth in the Indenture.The Indenture provides that the Company shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of the consolidated properties and assets of the Company and its subsidiaries, taken as a whole, to, another person (other than any such sale, conveyance, transfer or lease to one or more of the Companyâ€™s direct or indirect wholly owned subsidiaries), unless: (i) the resulting, surviving or transferee person (if not the Company) is a corporation organized and existing under the laws of the United States of America, any State thereof or the District of Columbia, and such corporation (if not the Company) expressly assumes by supplemental indenture all of the Companyâ€™s obligations under the Senior convertible notes and the Indenture; and (ii) immediately after giving effect to such transaction, no default or event of default has occurred and is continuing under the Indenture.The Companyâ€™s net proceeds from the March 2021 offering were approximately $222.7 million, after deducting the initial purchasersâ€™ discounts and commissions and the estimated offering expenses payable by the Company. As of September 30, 2024 and December 31, 2023, the unamortized debt issuance cost was $2.1 million and $3.1 million, respectively.MidCap credit facility â€” In August 2019, the Company entered into the MidCap credit facility and borrowed the first advance of $40.0 million (â€œTranche 1â€) in August 2019 and the second advance of $10.0 million (â€œTranche 2â€) in December 2020. In April 2021, $10.0 million was prepaid. Tranche 1 and Tranche 2 accrued interest at an annual rate equal to the lesser of (i) 8.25% and (ii) the one-month Secured Overnight Financing Rate ("SOFR") (subject to a one-month SOFR floor of 1.00%) plus 6.25%. Interest on each term loan advance was due and payable monthly in arrears. Principal on each term loan advance under Tranche 1 and Tranche 2 was payable in 24 equal monthly installments that began September 1, 2023. During the three months ended March 31, 2024, the Company made $5.0 million in principal payments on the MidCap credit facility. On April 1, 2024, the Company exercised its option to prepay in full all outstanding indebtedness, consisting of $28.3 million in principal and $0.2 million in accrued interest, and terminated all commitments and obligations under the MidCap credit facility that would have matured on August 1, 2025 in exchange for a payment of $31.6 million, including an exit fee of $2.8 million which is 7.00% of the initial Tranche 1 balance of $40.0 million, and a prepayment fee of $0.3 million which is 1.00% of principal prepaid. Additionally, unamortized debt discount and capitalized prepayment fees totaling $0.2 million were written off, resulting in a loss on extinguishment of debt of $3.3 million recognized in the condensed consolidated statements of operations. In connection with the repayment of outstanding indebtedness by the Company, all liens, mortgages and security interests in any assets or property securing the obligations under the MidCap credit facility were automatically terminated and released and the Company was automatically released from all guarantees. Mann Group convertible note â€” In August 2019, the Company issued a $35.0 million note that was convertible into shares of the Companyâ€™s common stock at $2.50 per share (the â€œMann Group convertible noteâ€) as part of a restructuring of its then existing indebtedness to Mann Group. The Mann Group convertible note accrued interest at the rate of 2.5% per year on the principal amount, payable quarterly in arrears on the first day of each calendar quarter, with a maturity date of December 31, 2025. The principal and any accrued and unpaid interest under the Mann Group convertible note was convertible, at the option of Mann Group, at any time on or prior to the close of business on the business day immediately preceding the stated maturity date, into shares of the Companyâ€™s common stock at a conversion rate of 400 shares per $1,000 of principal and/or accrued and unpaid interest, which is equal to a conversion price of $2.50 per share. Interest on the convertible note was payable in kind by adding the amount thereof to the principal amount; provided that with respect to interest accruing from and after January 1, 2021, the Company had the option to pay any such interest on any interest payment date, if certain conditions were met, in shares of the Companyâ€™s common stock at a price per share equal to the last reported sale price on the trading day immediately prior to the payment date. 25 Â During the nine months ended September 30, 2024, Mann Group converted $0.1 million of interest into 15,285 shares of common stock. During the nine months ended September 30, 2023, Mann Group converted $0.2 million of interest into 37,122 shares of common stock. On April 2, 2024, the Company and Mann Group agreed to discharge and terminate the Mann Group convertible note. As of April 2, 2024, the outstanding principal balance of the Mann Group convertible note plus accrued interest was $8.9 million and was convertible at Mann Groupâ€™s option into 3,554,198 shares of common stock of the Company. The Company and Mann Group agreed to terminate all outstanding indebtedness, rights and obligations under the Mann Group convertible note in exchange for (i) the Companyâ€™s issuance to Mann Group of 1,500,000 shares of the Companyâ€™s common stock converted at the contractual rate of $2.50 per share and (ii) the Companyâ€™s payment to Mann Group of $8.9 million, which represented the market value of 2,054,198 shares of common stock of the Company on April 2, 2024 to settle the remaining principal and interest of $5.1 million, after the conversion noted in (i) above. Termination of the Mann Group convertible note resulted in a loss on extinguishment of debt of $3.7 million recognized in the condensed consolidated statements of operations. Amortization of the premium and accretion of debt issuance costs related to all borrowings were as follows (in thousands): Â Three MonthsEnded September 30, Â Nine MonthsEnded September 30, Â 2024 Â 2023 Â 2024 Â 2023 Â Amortization of debt discount and prepayment fee Â $ â€” Â $ 109 Â $ 85 Â $ 323 Â Amortization of debt issuance cost Â 363 Â 363 Â 1,175 Â 1,090 Â 10. Collaboration, Licensing and Other ArrangementsRevenue from collaborations and services were as follows (in thousands): Â Three MonthsEnded September 30, Â Nine MonthsEnded September 30, Â 2024 Â 2023 Â 2024 Â 2023 Â UT CSA(1) Â $ 23,231 Â $ 12,800 Â $ 73,673 Â $ 34,897 Â UT License AgreementÂ (2) Â â€” Â 271 Â 347 Â 698 Â Cipla License and Distribution Agreement Â 37 Â 37 Â 110 Â 110 Â Total revenue from collaborations and services Â $ 23,268 Â $ 13,108 Â $ 74,130 Â $ 35,705 Â _____(1)Amounts consist of revenue recognized for Manufacturing Services and Product Sales to UT for the periods presented.(2)Amounts consist of revenue recognized for Next-Gen R&D Services and R&D Services and License for the periods presented.United Therapeutics License Agreement â€” In September 2018, the Company and UT entered into an exclusive global license and collaboration agreement (the â€œUT License Agreementâ€), pursuant to which UT is responsible for global development, regulatory and commercial activities with respect to Tyvaso DPI. Pursuant to the UT License Agreement, the Company receives a 10% royalty on net sales of Tyvaso DPI. In December 2023, the Company sold a 1% royalty on future net sales of Tyvaso DPI to a royalty purchaser, with the Company retaining a 9% royalty. In August 2021, the Company and UT entered into the CSA, pursuant to which the Company is responsible for manufacturing and supplying to UT, and UT is responsible for purchasing from the Company on a cost-plus basis. In addition, UT is responsible for supplying treprostinil at its expense in quantities necessary to enable the Company to manufacture Tyvaso DPI as required by the CSA.Total revenue from UT was as follows (in thousands): Â Three MonthsEnded September 30, Â Nine MonthsEnded September 30, Â 2024 Â 2023 Â 2024 Â 2023 Â UT Revenue Â UT CSA Â $ 23,231 Â $ 12,800 Â $ 73,673 Â $ 34,897 Â UT License Agreement Â â€” Â 271 Â 347 Â 698 Â Royalties â€” Collaboration (1) Â 27,083 Â 20,218 Â 75,326 Â 50,951 Â Total revenue from UT Â $ 50,314 Â $ 33,289 Â $ 149,346 Â $ 86,546 Â _____(1)Amounts consist of royalties associated with the UT License Agreement. The contract assets related to the royalties is included in prepaid expense and other current assets in the condensed consolidated balance sheets. 26 Â The activities and deliverables under the CSA and UT License Agreement resulted in distinct performance obligations which include the: (1) R&D Services and License, (2) Next-Gen R&D Services, and (3) Manufacturing Services and Product Sales. There have been various amendments to the UT License Agreement and the CSA since inception. As amended, the term of the CSA continues until December 31, 2031 (unless earlier terminated) and is thereafter renewed automatically for additional, successive two-year terms unless (i) UT provides notice to the Company at least 24 months in advance of such renewal that UT does not wish to renew the CSA or (ii) the Company provides notice to UT at least 48 months in advance of such renewal that the Company does not wish to renew the CSA. The Company and UT each have normal and customary termination rights, including termination for material breach that is not cured within a specific timeframe or in the event of liquidation, bankruptcy or insolvency of the other party. The Company accounted for the contract modification as if it were part of the existing contract since the amendment modified the scope and price of the CSA by extending the term and increasing the occupancy rate. The effect of the modification on the transaction price and on the measure of progress is recognized as an adjustment to revenue as of the date of modification. The modification did not result in a change in the activities and deliverables under the CSA.In December 2022, the Company and UT agreed to fund an additional $39.5 million to support capital and continuous improvement activities and $2.3 million in the development of alternative manufacturing processes. The Company determined that the capital and continuous improvements should be combined with the manufacturing services performance obligation and the alternative manufacturing processes should be combined with the Next-Gen R&D Services. The total revised anticipated cash flows of $722.3 million from the transaction was allocated to the three distinct performance obligations as follows (dollars in millions): Â Anticipated Â Cash Flow Â Revenue Allocation Â Recognition Method Â Progress Measure Â RevenueRecognition Â Total anticipated cash flow(1) Â $ 722.3 Â Distinct Performance Obligation Â R&D Services and License Â $ â€” Â Over time Â Ratably Â Aug 2021 - Oct 2021 Â Next-Gen R&D Services Â $ 10.0 Â Over time Â Input Â % of completion of costs Â Manufacturing Services andÂ Product Sales(2) Â $ 712.3 Â Point in time Â Transfer of control Â _____(1)The total anticipated cash flow includes a transaction price of $120.0 million for the contractual obligations under the CSA for the Manufacturing Services and Product Sales and the Next-Gen R&D Services performance obligations and $602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA.(2)The Manufacturing Services and Product Sales performance obligation will be recognized as control of manufactured products is transferred to UT. The modification did not result in a cumulative catch-up adjustment as a result of the revenue being deferred for the performance obligations that were affected by the modification. The allocation of the transaction price for the Manufacturing Services and Product Sales includes a material right related to the Companyâ€™s estimated production of product in the amount of $220.8 million. The Company will sell product to UT under individual purchase orders, which represent distinct performance obligations. The ultimate cash flows may vary as manufacturing purchase orders are received.In February 2024, the Company entered into an additional agreement for a separate performance obligation which was accounted for separately as it was distinct from Manufacturing Services and Product Sales and offered at a standalone selling price. Revenue is recognized at a point in time as services are rendered.As of September 30, 2024, deferred revenue from UT consisted of $70.5 million, of which $6.4 million was classified as current and $64.1 million was classified as long-term on the condensed consolidated balance sheet. As of December 31, 2023, deferred revenue consisted of $77.5 million, of which $8.9 million was classified as current and $68.6 million was classified as long-term on the condensed consolidated balance sheet. The Company determined that the revenue recognition associated with the capital improvements should be combined with the Manufacturing Services and Product Sales performance obligation.Thirona Collaboration Agreement â€” In June 2021, the Company and Thirona entered into a collaboration agreement to evaluate the therapeutic potential of Thironaâ€™s compound for the treatment of fibrotic pulmonary diseases. If initial studies are promising, the Company can exercise certain rights to seek a full license to the compound for clinical development and commercialization. The parties will perform their respective obligations and provide reasonable support for research, clinical development and regulatory strategy. The collaboration agreement was accounted for under ASC 808, Collaborative Agreements; however, no consideration was exchanged between the parties. The costs incurred by the Company were expensed as R&D in the condensed consolidated statements of operations. On February 28, 2023, the collaboration agreement was amended to extend the term through June 2024. In accordance 27 Â with the amendment, the Company agreed to fund a minimum of $1.1 million to be expended on a revised development plan prepared by Thirona, of which $1.1 million has been funded through September 30, 2024. Biomm Supply and Distribution Agreement â€” In May 2017, the Company and Biomm S.A. ("Biomm") entered into a supply and distribution agreement for the commercialization of Afrezza in Brazil. Under this agreement, Biomm was responsible for pursuing regulatory approvals of Afrezza in Brazil, including from the AgÃªncia Nacional de VigilÃ¢ncia SanitÃ¡ria (â€œANVISAâ€) and, with respect to pricing matters, from the Camara de RegulaÃ§Ã£o de Mercado de Medicamentos (â€œCMEDâ€), both of which were received. Biomm commenced product sales in January 2020. No shipments of product were made to Biomm in 2023 or the first three quarters of 2024.Cipla License and Distribution Agreement â€” In May 2018, the Company and Cipla Ltd. (â€œCiplaâ€) entered into an exclusive agreement for the marketing and distribution of Afrezza in India and the Company received a $2.2 million nonrefundable license fee. Under the terms of the agreement, Cipla is responsible for obtaining regulatory approvals to distribute Afrezza in India and for all marketing and sales activities of Afrezza in India. The Company is responsible for supplying Afrezza to Cipla. The Company has the potential to receive an additional regulatory milestone payment, minimum purchase commitment revenue and royalties on Afrezza sales in India once cumulative gross sales have reached a specified threshold. Cipla is currently seeking regulatory approval with the India authorities.The nonrefundable licensing fee was recorded in deferred revenue and is being recognized in net revenue â€” collaborations over 15 years, representing the estimated period to satisfy the performance obligation. The additional milestone payment represents variable consideration for which the Company has not recognized any revenue because Cipla has not yet obtained all of the required marketing approvals.As of September 30, 2024, the deferred revenue balance for Cipla was $1.2 million, of which $0.1 million was classified as current and $1.1 million was classified as long term in the condensed consolidated balance sheets. As of December 31, 2023, the deferred revenue balance was $1.4 million, of which $0.2 million was classified as current and $1.2 million was classified as long term in the condensed consolidated balance sheets. 11. Fair Value of Financial InstrumentsThe availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement. The Company uses the exit price method for estimating the fair value of loans for disclosure purposes. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy, as follows:Level 1 â€” Quoted prices for identical instruments in active markets.Level 2 â€” Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.Level 3 â€” Significant inputs to the valuation model are unobservable.The carrying amounts reported in the condensed consolidated financial statements for cash, accounts receivable, accounts payable, and accrued expenses and other current liabilities (excluding the Milestone Rights liability) approximate their fair value due to their relatively short maturities. The fair value of the Senior convertible notes, MidCap credit facility, Mann Group convertible note, Milestone Rights liability, Contingent milestone liability, Financing liability and Liability for sale of future royalties are disclosed below. 28 Â Financial Liabilities â€” The following tables set forth the fair value of the Companyâ€™s financial instruments (Level 3 in the fair value hierarchy) (in millions): Â September 30, 2024 Â Fair Value Â Carrying Value Â SignificantUnobservableInputs (Level 3) Â Financial liabilities: Â Senior convertible notes(1) Â $ 227.9 Â $ 284.7 Â Milestone rights(2) Â 3.2 Â 11.3 Â Contingent milestone liability(3) Â 0.3 Â 0.3 Â Financing liability(4) Â 104.0 Â 106.5 Â Liability for sale of future royalties(5) Â 147.5 Â 137.4 Â _____(1)Fair value was determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 11.0%, volatility of 52.0% and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or â€” 2% would result in a fair value of $279.6 million and $290.0 million, respectively.(2)Fair value was determined by applying a Monte Carlo simulation method for the calculation of the

potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.7%, dividend yield of 0.0%, volatility of 50.0%, period of 7.3 years and credit risk of 15.0%.(3)Fair value was determined by using the Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.9%, dividend yield of 0.0%, volatility of 43.0%, period of 13.3 years and credit risk of 15.0%. (4)Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 9.5%. A change in yield of + or â€“ 2% would result in a fair value of $94.1 million and $121.8 million, respectively.(5)At September 30, 2024, fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 11.0%. A change in yield of + or â€“ 2% would result in a fair value of $121.9 million and $156.4 million, respectively. At December 31, 2023, the carrying value approximated the fair value. Â Â December 31, 2023 Â Â Â Â Â Â Fair Value Â Â Â Carrying Value Â Â SignificantUnobservableInputs (Level 3) Â Financial liabilities: Â Â Â Â Â Â Senior convertible notes(1) Â $ 226.9 Â Â $ 231.3 Â MidCap credit facility(2) Â Â 33.0 Â Â Â 35.5 Â Mann Group convertible note(3) Â Â 8.8 Â Â Â 14.4 Â Milestone rights(4) Â Â 3.9 Â Â Â 11.9 Â Contingent milestone liability(5) Â Â 0.3 Â Â Â 0.3 Â Financing liability(6) Â Â 104.1 Â Â Â 106.8 Â _____(1)Fair value was determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 11.0%, volatility of 62.7% and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or â€“ 2% would result in a fair value of $224.1 million and $238.9 million, respectively.(2)Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 12.0%. A change in yield of + or â€“ 2% would result in a fair value of $35.0 million and $36.0 million, respectively.(3)Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 13.0% and volatility of 62.7% to the straight note and a binomial option pricing model for the value of the conversion feature. A change in yield of + or â€“ 2% would result in a fair value of $14.2 million and $14.7 million, respectively.(4)Fair value was determined by applying a Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.9%, dividend yield of 0.0%, volatility of 50.0%, period of 8 years and credit risk of 17.0%.(5)Fair value was determined by using the Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market-based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 4.0%, dividend yield of 0.0%, volatility of 43.0%, period of 15 years and credit risk of 17.0%. (6)Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 9.5%. Milestone Rights Liability â€” The fair value measurement of the Milestone Rights liability is sensitive to the discount rate and the timing of achievement of milestones. The Company utilized a Monte-Carlo Simulation Method to simulate the Afrezza net sales under 29 Â a neutral framework to estimate the potential payments and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. The Company then discounted the future expected payments at cost of debt with a term equal to the simulated time to payout based on cumulative sales. See Note 15 â€“ Commitments and Contingencies.Contingent Milestone Liability â€” The acquisition of V-Go in May 2022 resulted in a contingent milestone liability which could result in obligations to the seller if certain revenue thresholds are met. The initial fair value of the contingent milestone liability was recorded as an adjustment to the purchase price. Subsequent changes in the fair value are reported in general and administrative expenses.Financing Liability â€” The Sale-Leaseback Transaction in November 2021 resulted in a financing liability. See Note 15 â€“ Commitments and Contingencies.Liability for Sale of Future Royalties â€” The sale of a portion of our royalty rights in December 2023 resulted in a liability for sale of future royalties. See Note 15 â€“ Commitments and Contingencies. 12. Common and Preferred StockThe Company is authorized to issue 800,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of undesignated preferred stock, par value $0.01 per share, issuable in one or more series as designated by the Companyâ€™s board of directors. No other class of capital stock is authorized. As of September 30, 2024 and December 31, 2023, 275,775,038 and 270,034,495 shares of common stock, respectively, were issued and outstanding and no shares of preferred stock were outstanding. In February 2018, the Company entered into a controlled equity offering sales agreement (the â€œCF Sales Agreementâ€) with Cantor Fitzgerald & Co. (â€œCantor Fitzgeraldâ€), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor Fitzgerald, shares of the Companyâ€™s common stock having an aggregate offering price of up to $50.0 million or such other amount as may be permitted by the Sales Agreement. Under the Sales Agreement, Cantor Fitzgerald may sell shares by any method deemed to be an â€œat-the-market offeringâ€ as defined in Rule 415 under the Securities Act of 1933, as amended. There were no sales under the CF Sales Agreement during the nine months ended September 30, 2024. During the nine months ended September 30, 2023, the Company sold 1,478,090 shares of common stock at a weighted average purchase price of $4.66 per share for gross proceeds of approximately $6.9 million pursuant to the CF Sales Agreement. During the nine months ended September 30, 2024, the Company received $1.4 million from the market price stock purchase plan ("MPSPP") for 416,099 shares of common stock. During the nine months ended September 30, 2023, the Company received $0.2 million from the MPSPP for 36,004 shares.For shares of common stock issued pursuant to the Company's 2004 employee stock purchase plan ("ESPP"), see Note 14 â€“ Stock-Based Compensation Expense. 13. Earnings per Common ShareThe following tables summarize the components of the basic and diluted EPS computations (in thousands, except per share amounts): Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â EPS â€“ basic: Â Â Â Â Â Â Â Â Â Â Â Net income (loss) (numerator) Â $ 11,550 Â Â $ 1,721 Â $ 20,166 Â Â $ (13,339) Weighted average common shares (denominator) Â Â 274,998 Â Â Â 268,732 Â Â 272,811 Â Â Â 266,126 Â Net income (loss) per share Â $ 0.04 Â Â $ 0.01 Â $ 0.07 Â Â $ (0.05) EPS â€“ diluted: Â Â Â Â Â Â Â Â Â Â Â Adjusted net income (loss) (numerator) Â $ 11,550 Â Â $ 3,578 Â $ 20,166 Â Â $ (13,339) Weighted average common shares Â Â 274,998 Â Â Â 268,732 Â Â Â 272,811 Â Â Â 266,126 Â Effect of dilutive securities â€“ common shares issuable Â Â 9,695 Â Â Â 55,038 Â Â 8,596 Â Â Â â€“ Â Adjusted weighted average common shares (denominator) Â Â 284,693 Â Â Â 323,770 Â Â 281,407 Â Â Â 266,126 Â Net income (loss) per share Â $ 0.04 Â Â $ 0.01 Â $ 0.07 Â Â $ (0.05) For the three months ended September 30, 2024, diluted net income per share excluded the weighted average effect of 10.4 million shares of RSUs and Market RSUs, 0.4 million options and PNQs and 44.1 million common shares issuable upon conversion of our Senior convertible notes, as they were antidilutive. For the nine months ended September 30, 2024, diluted net income per share 30 Â excluded the weighted average effect of 9.1 million RSUs and Market RSUs, 0.7 million options and PNQs and 44.1 million common shares issuable upon conversion of our Senior convertible notes, as they were antidilutive.For the three months ended September 30, 2023, diluted net income per share excluded the weighted average effect of 9.4 million shares of RSUs and Market RSUs and 2.0 million options and PNQs as they were antidilutive.Common shares issuable represents incremental shares of common stock which consist of RSUs, stock options, warrants, and shares that could be issued upon conversion of the Senior convertible notes and the Mann Group convertible notes. Potentially dilutive securities outstanding which were considered antidilutive due to the net losses incurred for the nine months ended September 30, 2023 are summarized as follows (in shares): Â September 30, Â Â 2023 Â Senior convertible notes Â 44,120,463 Â RSUs and Market RSUs(1) Â 21,151,454 Â Common stock options and PNQs Â 8,447,339 Â Mann Group convertible notes Â 3,370,000 Â Total shares Â 77,089,256 Â _____(1)Market RSUs issued in 2021, 2022 and 2023 are included at the share delivery of 0%, 205% and 219%, respectively, in accordance with a valuation assessment obtained as of September 30, 2023. 31 Â 14. Stock-Based Compensation Expense The Company granted the following awards (in shares): Â Â Three Months Ended March 31, Â Â Three Months Ended June 30, Â Â Three Months EndedÂ September 30, Â Â Nine Months EndedSeptember 30, Â Â Â 2024 Â Â 2024 Â Â 2024 Â Â 2024 Â Employee awards: Â Â Â Â Â Â Â Â Â Â RSUs Â Â 267,990 Â Â (1) Â 3,205,910 Â Â (2) Â 241,253 Â Â (5) Â 3,715,153 Â Market RSUs Â Â â€“ Â Â Â 2,144,000 Â Â (3) Â â€“ Â Â Â 2,144,000 Â Non-employee director RSUs Â Â â€“ Â Â Â 280,376 Â Â (4) Â â€“ Â Â Â 280,376 Â Total awards issued Â Â 267,990 Â Â Â 5,630,286 Â Â Â 241,253 Â Â Â 6,139,529 Â _____(1)RSUs had a weighted average grant date fair value of $3.28 per share, of which 211,895 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, 53,720 RSUs had a cliff vesting period of three years, and 2,375 RSUs had a vesting period of 25% annually over four years. (2)RSUs had a weighted average grant date fair value of $4.45 per share, of which 3,033,680 RSUs had a vesting period of 25% annually over four years, 145,980 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, and 26,250 RSUs had a cliff vesting period of two years.(3)Market RSUs had a grant date fair value of $10.30 per share and will vest on July 15, 2027. The number of shares delivered on the vesting date is determined by the percentile ranking of MannKind total shareholder return ("TSR") over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.(4)RSUs had a weighted average grant date fair value of $4.45 per share and vested immediately upon the grant date; however, the underlying shares of common stock will not be delivered until there is a separation of service such as resignation, retirement or death.(5)RSUs had a weighted average grant date fair value of $5.34 per share, of which 219,285 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, and 21,968 RSUs had a vesting period of 40% on the first anniversary and 60% on the second anniversary of the vesting determination date.As of September 30, 2024, there was $26.2 million and $27.4 million of unrecognized stock-based compensation expense related to RSUs and Market RSUs, respectively, which is expected to be recognized over a weighted average period of approximately 2.84 and 1.98 years, respectively. Total stock-based compensation expense recognized in the condensed consolidated statements of operations as cost of goods sold, cost of revenue â€“ collaborations and services, R&D and selling, general and administrative expense was as follows (in thousands): Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â RSUs and options Â $ 5,047 Â Â $ 4,442 Â Â $ 14,994 Â Â $ 13,324 Â Employee stock purchase plan Â Â 180 Â Â Â 159 Â Â Â 546 Â Â Â 512 Â Total Â $ 5,227 Â Â $ 4,601 Â Â $ 15,540 Â Â $ 13,836 Â Employee Stock Purchase PlanThe Company provides all employees, including executive officers, the ability to purchase common stock at a discount under the ESPP. The ESPP is designed to comply with Section 423 of the Internal Revenue Code and provides all employees with the opportunity to purchase up to $25,000 worth of common stock (based on the undiscounted fair market value at the commencement of the offering period) each year at a purchase price that is the lower of 85% of the fair market value of the common stock on either the date of purchase or the commencement of the offering period. An employee may not purchase more than 5,000 shares of common stock on any purchase date. The executivesâ€™ rights under the ESPP are the same as those of all other employees.There were approximately 2.6 million shares of common stock available for issuance under the ESPP as of September 30, 2024. 32 Â 15. Commitments and Contingencies Guarantees and Indemnifications â€” In the ordinary course of its business, the Company makes certain indemnities, commitments and guarantees under which it may be required to make payments in relation to certain transactions. The Company, as permitted under Delaware law and in accordance with its Bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Companyâ€™s request in such capacity. The term of the indemnification period is for the officerâ€™s or directorâ€™s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal and therefore has not recorded any liability for these indemnities in the condensed consolidated balance sheets. The Company accrues for losses for any known contingent liability, including those that may arise from indemnification provisions, when future payment is probable and the amount can be reasonably estimated. No such losses have been recorded to date. Litigation â€” The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. The Company does not anticipate the final disposition of any matters will have a material adverse effect on the results of operations, financial position, or cash flows of the Company. The Company maintains liability insurance coverage to protect the Companyâ€™s assets from losses arising out of or involving activities associated with ongoing and normal business operations. The Company records a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Companyâ€™s policy is to accrue for legal expenses in connection with legal proceedings and claims as they are incurred. Contingencies â€” Milestone Rights â€” In July 2013, the Company entered into the Milestone Rights Agreement with the Original Milestone Purchasers, pursuant to which the Company granted the Milestone Rights to receive payments up to $90.0 million upon the occurrence of specified strategic and sales milestones, $50.0 million of which remains payable to the Milestone Purchasers as of September 30, 2024. The Milestone Rights Agreement includes customary representations and warranties and covenants by the Company, including restrictions on transfers of intellectual property related to Afrezza. The Milestone Rights are subject to acceleration in the event the Company transfers its intellectual property related to Afrezza in violation of the terms of such agreement.During each of the nine months ended September 30, 2024 and 2023, the Company made milestone payments of $5.0 million to the Milestone Purchasers. As of September 30, 2024 and December 31, 2023, the remaining Milestone Rights liability balance was $3.2 million and $3.9 million, respectively, and consisted of $0.7 million and $0.8 million, respectively, of current liability, which was presented as accrued expenses and other current liabilities, and $2.5 million and $3.1 million, respectively, of long-term liability, which was presented as milestone liabilities in the condensed consolidated balance sheets. The value of the Milestone Rights liability was based on initial fair value estimates calculated using the income approach and is reduced by milestone achievement payments made. Loss Contingencies â€” Returns Reserve for Acquired Product â€” During the nine months ended September 30, 2024, the Company reassessed its previously-determined estimate for product returns associated with sales of V-Go that pre-date the Company's acquisition of the product and recorded an additional $1.4 million, which is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets as of September 30, 2024 and being reduced as product returns are received. Losses on estimated returns of acquired product were recorded in general and administrative expenses in the condensed consolidated statements of operations.Liability for Sale of Future Royalties â€” In December 2023, the Company executed a Purchase and Sale Agreement (the â€œPSAâ€) with Sagard Healthcare Partners Funding Borrower SPE 2, LP (â€œSagardâ€). Pursuant to the PSA, Sagard paid the Company $150.0 million (the â€œUpfront Proceedsâ€), net of $0.4 million in reimbursements of Sagardâ€™s fees and expenses (the â€œReimbursementsâ€), for the purchase of a 1% royalty on future net sales of Tyvaso DPI by UT under the terms of the UT License Agreement (the â€œSagard Royaltyâ€). Sagard will also pay the Company a milestone of $50.0 million if net sales of Tyvaso DPI meet or exceed $1.9 billion for any twelve consecutive months on or prior to December 31, 2026 (â€œNet Sales Threshold Aâ€), or a milestone of $45.0 million if net Sales Threshold A is not met and net sales of Tyvaso DPI meet or exceed $2.3 billion for any twelve consecutive months on or prior to September 30, 2027 (â€œNet Sales Threshold Bâ€), resulting in a purchase price not to exceed $200.0 million (the â€œPurchase Priceâ€). If Net Sales Thresholds A and B are not met and net sales of Tyvaso DPI meet or exceed $3.5 billion for any calendar year after September 30, 2027, no royalties will be payable to Sagard for the remainder of that year. The PSA applies to net sales of Tyvaso DPI generated during October 1, 2023 through December 31, 2042 (the â€œTermination Dateâ€) and will automatically terminate upon payment of the final royalty owed to Sagard thereafter. Upon the Termination Date, ownership of the Sagard Royalty will revert to the Company. 33 Â Given the Companyâ€™s continuing involvement with the generation of Tyvaso DPI revenue under the UT License Agreement and CSA, which includes the Companyâ€™s supply and manufacture of Tyvaso DPI, and the Companyâ€™s retention and associated defense and maintenance obligations of the intellectual property required in the manufacture of Tyvaso DPI, the Upfront Proceeds were recorded as a liability for sale of future royalties (the â€œRoyalty Liabilityâ€) on the condensed consolidated balance sheets, and any proceeds from future milestones will be added to the Royalty Liability balance upon receipt. Although the Company is not obligated to repay any portion of the Purchase Price to Sagard, the Royalty Liability under the PSA is secured by a security interest granted to Sagard in the underlying 1% royalty rights and any proceeds therefrom. As a result of the PSA, transaction costs totaling $4.4 million (including the Reimbursements) are reported net of the Royalty Liability balance and amortized to interest expense in the condensed consolidated statements of operations over the life of the PSA using the effective interest method. Unamortized transaction costs totaled $4.2 million and $4.4 million at September 30, 2024 and December 31, 2023, respectively.The Company will continue to recognize the full 10% of future royalty revenues in its condensed consolidated statements of operations, with the Sagard Royalty being non-cash revenue for the Company. As royalty payments are earned by and remitted to Sagard, the balance of the Royalty Liability will be effectively repaid as it is amortized over the life of the PSA. To amortize the Royalty Liability, the Company estimated the total amount of future royalty payments to be made to Sagard over the life of the PSA. The excess of those future estimated royalty payments over the Purchase Price proceeds received is recognized in the condensed consolidated statements of operations as non-cash interest expense over the life of the PSA utilizing an imputed effective interest rate. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate may vary during the term of the agreement depending on a number of factors, including the

amount and timing of forecasted royalty payments which affects the timing and ultimate amount of reductions to the liability. The Company will evaluate the effective interest rate periodically based on its forecasted royalty payments utilizing the prospective method.The Company periodically assesses the forecasted royalty payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments, or the timing of such payments, are materially different than original estimates, the Company will prospectively adjust the effective interest rate and amortization of the Royalty Liability. The following table shows the activity within the Royalty Liability account during the nine months ended September 30, 2024 as well as the effective interest rate (dollars in thousands): Balance, January 1, 2024 $ 145,810 Â Amortization of deferred transaction costs Â 172 Â Non-cash interest expense on liability for sale of future royalties Â 12,548 Â Royalty revenue earned by or payable to Sagard Â (9,635) Balance, September 30, 2024 $ 148,895 Â Â Â Â Effective interest rate 8.8% â€“ 11.5% Â Sale-Leaseback Transactionâ€” In November 2021, the Company sold certain land, building and improvements located in Danbury, CT (the "Property") to an affiliate of Creative Manufacturing Properties (the "Purchaser") for a sales price of $102.3 million, subject to terms and the conditions contained in a purchase and sale agreement. Effective with the closing of the Sale-Leaseback Transaction, the Company and the Purchaser entered into a lease agreement (the â€œLeaseâ€), pursuant to which the Company leased the Property from the Purchaser for an initial term of 20 years, with four renewal options of five years each. The total annual rent under the Lease starts at approximately $9.5 million per year, subject to a 50% rent abatement during the first year of the Lease, and will increase annually by (i) 2.5% in the second through fifth year of the Lease and (ii) 3% in the sixth and each subsequent year of the Lease, including any renewal term, utilizing a weighted average discount rate of 9.0%. The Company is responsible for payment of operating expenses, property taxes and insurance for the Property. The Purchaser will hold a security deposit of $2.0 million during the Lease term. Pursuant to the terms of the Lease, the Company has four options to repurchase the Property, in 2026, 2031, 2036 and 2041, for the greater of (i) $102.3 million and (ii) the fair market value of the Property.Effective with the closing of the Sale-Leaseback Transaction, the Company and the Purchaser also entered into a right of first refusal agreement (the â€œROFRâ€), pursuant to which the Company has a right to re-purchase the Property from the Purchaser in accordance with terms and conditions set forth in the ROFR. Specifically, if the Purchaser receives, and is willing to accept, a bona fide purchase offer for the Property from a third-party purchaser, the Company has certain rights of first refusal to purchase the Property on the same material terms as proposed in such bona fide purchase offer. 34 Â As of September 30, 2024, the related financing liability was $104.0 million, which was recognized in the condensed consolidated balance sheet and of which $94.0 million was long-term and $10.0 million was current. As of December 31, 2023, the related financing liability was $104.1 million, of which $94.3 million was long-term and $9.8 million was current. Financing liability information was as follows (dollars in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Weighted average remaining lease term (in years) Â Â 17.1 Â Â Â 17.8 Â Â Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Interest expense on financing liability Â $ 2,470 Â Â $ 2,459 Â Â $ 7,361 Â Â $ 7,332 Â The Company's remaining financing liability payments were as follows (in thousands): Â Â September 30, 2024 Â Remainder of 2024 Â $ 2,532 Â 2025 Â Â 10,269 Â 2026 Â Â 10,533 Â 2027 Â Â 10,849 Â 2028 Â Â 11,174 Â Thereafter Â Â 177,278 Â Total Â Â 222,635 Â Interest payments Â Â (116,113) Debt issuance costs Â Â (2,519) Total financing liability Â $ 104,003 Â Financing Lease â€“ In May 2024, the Company acquired audio-visual equipment via a financing lease with de minimis monthly principal and interest payments and a termination date in May 2029. Financing lease information was as follows (dollars in thousands): Â Â September 30, 2024 Â Financing lease right-of-use asset(1) Â $ 219 Â Â Â Â Financing lease liability-current(2) Â $ 52 Â Financing lease liability-long-term Â Â 171 Â Total Â $ 223 Â Â Â Â Weighted average remaining lease term (in years) Â Â 4.7 Â Weighted average discount rate Â Â 7.25 % _____(1)Financing right-of-use asset is included in other assets in the condensed consolidated balance sheets.(2)Financing lease liability â€“ current is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets.The Company's remaining financing lease payments were as follows (in thousands): Â Â September 30, 2024 Â Remainder of 2024 Â $ 27 Â 2025 Â Â 54 Â 2026 Â Â 54 Â 2027 Â Â 54 Â 2028 Â Â 54 Â Thereafter Â Â 23 Â Total Â Â 266 Â Interest payments Â Â (43) Total financing liability Â $ 223 Â Â 35 Â Commitments â€“ In July 2014, the Company entered into the Insulin Supply Agreement pursuant to which Amphastar manufactures for and supplies to the Company certain quantities of recombinant human insulin for use in Afrezza. Under the terms of the Insulin Supply Agreement, Amphastar is responsible for manufacturing the insulin in accordance with the Companyâ€™s specifications and agreed-upon quality standards. In December 2023, the Company and Amphastar amended the Insulin Supply Agreement to extend the term, restructure the annual purchase commitments and include a capacity fee for certain future periods. The Company's remaining purchase commitments and estimated capacity fee liability as of September 30, 2024 were as follows (â‚¬ in millions): Â September 30, 2024 Â Â Remaining Purchase Commitments Â Â Estimated Capacity Fees Â 2025 Â â€” Â Â Â 1.5 Â 2026(1) Â 4.2 Â Â Â 2.0 Â 2027 Â 6.0 Â Â Â 1.0 Â 2028 Â 6.0 Â Â Â 1.0 Â 2029 Â 6.0 Â Â Â 1.0 Â 2030 Â 6.0 Â Â Â 1.0 Â 2031 Â 8.0 Â Â Â 0.5 Â 2032 Â 8.0 Â Â Â 0.5 Â 2033 Â 8.0 Â Â Â 0.5 Â 2034 Â 4.4 Â Â Â 0.5 Â Total Â 56.6 Â Â Â 9.5 Â _____(1)If there is a delay in the availability of insulin with FDA approved inclusion bodies and supply does not begin in 2026 as currently expected, the Company will incur a capacity fee of â‚¬750,000 per quarter that the product is not available for purchase. Pursuant to the amendment, the term of the Insulin Supply Agreement expires on the later of December 31, 2034 or until the completion of the total remaining purchase commitment quantities, unless terminated earlier, and can be renewed for additional, successive two-year terms upon 12 monthsâ€™ written notice given prior to the end of the initial term or any additional two-year term. The Company and Amphastar each have normal and customary termination rights, including termination for a material breach that is not cured within a specific time frame or in the event of liquidation, bankruptcy or insolvency of the other party. In addition, the Company may terminate the Insulin Supply Agreement upon two yearsâ€™ prior written notice to Amphastar without cause or upon 30 daysâ€™ prior written notice to Amphastar if a controlling regulatory authority withdraws approval for Afrezza, provided, however, in the event of a termination pursuant to either of the latter two scenarios, the provisions of the Insulin Supply Agreement require the Company to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination. The Company periodically reviews the terms of the long-term Insulin Supply Agreement and assesses the need for any accrual for estimated losses, such as lower-of-cost or net-realizable-value that will not be recovered by future product sales. The recognized loss on purchase commitments of $62.6 million and $64.8 million is included in our condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023, respectively, and is reduced as inventory items are received or such liability is extinguished. As a result of the increase in future cash flows for the excess capacity fees and extended term included in the amendment of the Insulin Supply Agreement, the Company analyzed the need for additional estimated losses and concluded that an increase in the recognized loss on purchase commitments was not required as the net realizable value of inventory resulting from the purchase commitment was in excess of the carrying value. Increases in costs associated with the amendment will be recognized through inventory as incurred.Vehicle Leases â€“ During the second quarter of 2018, the Company entered into a master lease agreement with Enterprise Fleet Management Inc. The monthly payment inclusive of maintenance fees, insurance and taxes is approximately $0.1 million. The lease expense is included in selling expenses in the condensed consolidated statements of operations.Office Leases â€“ In May 2017, the Company executed an office lease with Russell Ranch Road II LLC for the Companyâ€™s corporate offices in Westlake Village, California, which was renewed in April 2022. Pursuant to the renewal, the monthly lease payments of $79,543 began in February 2023 and are subject to 3% annual increases, plus the estimated cost of maintaining the property and common areas by the landlord, and are further subject to a six-month base rent concession beginning February 2023. The Company is also entitled to a one-time allowance up to $0.9 million as reimbursement for tenant improvements or the purchase of furniture, 36 Â fixtures or equipment. Of the $0.9 million allowance, an amount up to $0.7 million may be applied as an additional base rent concession. The Company has no further right to extend the lease term beyond July 31, 2028. In May 2022, the Company assumed certain leased real property (the â€œMarlborough Leaseâ€) in connection with the V-Go acquisition. The Marlborough Lease pertains to certain premises in a building located in Marlborough, Massachusetts. The monthly payments of $28,895 began in June 2022, subject to approximately 3% annual increases through February 28, 2026.The Company also acquired rights to a manufacturing service agreement where V-Go is manufactured using Company-owned equipment located at the manufacturing facility. The Company determined that this arrangement results in an embedded lease which granted the Company exclusive use of space within the manufacturing facility. The Company assessed the embedded lease cost to be $14,370 per month through February 28, 2026.In July 2024, the Company assumed certain leased real property (the "Bedford Lease") in connection with the Pulmatrix Transaction. The Bedford Lease pertains to certain premises in a building located in Bedford, Massachusetts. The monthly base rent payments of $101,282 are subject to 3% annual increases, plus the estimated cost of maintaining the property and common areas by the landlord. The Company also assumed from Pulmatrix a $0.7 million obligation to repay landlord-funded tenant improvements at a rate of $6,000 per month through the end of the lease term in November 2033. The Company has the right to extend the lease term for an additional five-year term.Lease information was as follows (dollars in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Operating lease right-of-use assets(1) Â $ 13,637 Â Â $ 4,685 Â Â Â Â Â Â Â Â Operating lease liability-current(2) Â $ 2,431 Â Â $ 1,423 Â Operating lease liability-long-term Â Â 12,167 Â Â Â 3,925 Â Total Â $ 14,598 Â Â $ 5,348 Â Â Â Â Â Â Â Â Weighted average remaining lease term (in years) Â Â 7.3 Â Â Â 3.7 Â Weighted average discount rate Â Â 7.25 % Â Â 7.25 % _____(1)Operating right-of-use assets related to vehicles, offices and the manufacturing facility for V-Go are included in other assets in the condensed consolidated balance sheets.(2)Operating lease liability â€“ current is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease costs Â $ 719 Â Â $ 422 Â Â $ 1,417 Â Â $ 1,253 Â Variable lease costs Â Â 104 Â Â Â 48 Â Â Â 122 Â Â Â 97 Â Cash paid Â Â 860 Â Â Â 268 Â Â Â 1,407 Â Â Â 825 Â The Company's future minimum office and vehicle lease payments were as follows (in thousands): Â Â September 30, 2024 Â Remainder of 2024 Â $ 784 Â 2025 Â Â 3,157 Â 2026 Â Â 2,579 Â 2027 Â Â 2,540 Â 2028 Â Â 2,087 Â Thereafter Â Â 7,721 Â Total Â Â 18,868 Â Interest expense Â Â (4,270) Total operating lease liability Â $ 14,598 Â Â 37 Â 16. Income TaxesDuring the three and nine months ended September 30, 2024, the Company recorded income tax expense of $1.3 million and $1.9 million, respectively, related to state taxes, which was calculated using the discrete year-to-date method. The income tax provision for the three and nine months ended September 30, 2023 resulted in no tax expense. The effective tax rate differs from the statutory tax rate of 21% primarily due to the existence of valuation allowances against net deferred tax assets and current liabilities resulting from the estimated state income tax liabilities.Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and concluded, in accordance with the applicable accounting standards, that net deferred tax assets should be fully reserved.The Company has assessed its position with regards to uncertainty in tax positions and has not recognized a liability for unrecognized tax benefits. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. The Company recognizes interest and penalties accrued related to unrecognized tax benefits in income tax expense. During the nine months ended September 30, 2024, the Company did not recognize any interest or penalties. The Companyâ€™s tax years since 2019 remain subject to examination by tax authorities.In June 2024, California enacted Senate Bills 167 and 175 ("SB 167" and "SB 175"). SB 167 suspends the use of net operating losses ("NOLs") and limits the use of business credits to $5.0 million for the 2024-2026 tax years. Under SB 175, the NOL suspension and credit limitations will not apply for the 2025 and 2026 tax years if certain budget goals are met. Although the Company does not expect this legislation to have a material effect on its results of operations or cash flows, management continues to evaluate any potential impact. 38 Â ITEM 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Statements in this report that are not strictly historical in nature are â€œforward-looking statementsâ€ within the meaning of the federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as â€œanticipate,â€ â€œbelieve,â€ â€œcould,â€ â€œestimate,â€ â€œexpect,â€ â€œgoal,â€ â€œintend,â€ â€œmay,â€ â€œplan,â€ â€œpotential,â€ â€œpredict,â€ â€œproject,â€ â€œshould,â€ â€œwill,â€ â€œwould,â€ and similar expressions intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below in Part II, Item 1A Risk Factors and elsewhere in this Quarterly Report on Form 10-Q. The preceding interim condensed consolidated financial statements and this Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and related notes for the year ended December 31, 2023 and Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations contained in the Annual Report. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made. OVERVIEW We are a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Our signature technologiesâ€”Technosphere dry-powder formulations and Dreamboat inhalation devicesâ€”offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. In our endocrine business unit, we currently commercialize two products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Afrezza was developed by us and received approval from the FDA in June 2014. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. V-Go received 510(k) clearance by the FDA in 2010 and has been available commercially since 2012. In May 2022, we acquired V-Go from Zealand Pharma A/S and Zealand Pharma US, Inc. (together, â€œZealandâ€) and began integrating the product into our endocrine business unit. V-Go is a mechanical basal-bolus insulin delivery system that is worn like a patch and can eliminate the need for taking multiple daily injections. We are conducting a Phase 3 clinical study, known as INHALE-1, evaluating the efficacy and safety of Afrezza in combination with basal insulin versus multiple daily injections of insulin in children and adolescents aged 4-17 who are living with type 1 or type 2 diabetes. A primary endpoint analysis for INHALE-1 is expected in the fourth quarter of 2024, with full results expected in the first half of 2025 and a planned FDA submission for a label expansion in 2025. The first product to come out of our orphan lung disease pipeline, Tyvaso DPI (treprostinil) inhalation powder, received FDA approval in May 2022 for the treatment of PAH and PH-ILD. Our development and marketing partner, United Therapeutics, began commercializing Tyvaso DPI in June 2022 and is obligated to pay us a royalty on net sales of the product. We also receive a margin on supplies of Tyvaso DPI that we manufacture for UT. The lead program in our pipeline of potential treatments for orphan lung diseases is MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial (NTM) lung disease. We believe an orally inhaled formulation of clofazimine could potentially provide several clinical advantages over the current solid oral dosage form, including directly targeting the site of the infection while lowering the systemic exposure of patients to the drug. The FDA has granted MNKD-101 status as an orphan drug and as a qualified infectious disease product for the treatment of pulmonary NTM infections. It has also granted Fast Track designation to our development program. In June 2024, we initiated a Phase 3 clinical study to investigate the potential of MNKD-101 to treat NTM lung disease. We began enrolling patients into this study in the third quarter of 2024. The next most advanced program in our pipeline is MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis ("IPF"). An oral dosage form of nintedanib was approved for IPF by the FDA in 2014. However, a fairly large oral dose is required in order to achieve sufficient drug levels in lung tissue. Our goal with an inhaled formulation is to deliver a therapeutic amount of nintedanib to the lungs while avoiding high levels of the drug in other tissues, where it is associated with undesirable side effects. Earlier this year, we conducted a first-in-human Phase 1 study of MNKD-201 for pulmonary fibrotic diseases, including IPF. A data readout is expected in the fourth quarter of 2024. Our business is subject to significant risks, including but not limited to our ability to manufacture sufficient quantities of our products and Tyvaso DPI. Other significant risks also include the risk that our products may only achieve a limited degree of commercial 39 Â success and the risks inherent in drug development, clinical trials and the regulatory approval process for our product candidates, which in some cases depends upon the efforts of our partners. As of September 30, 2024, we had an accumulated deficit of $3.2 billion and a stockholdersâ€™ deficit of $209.9 million. We had net income of $11.6 million and $20.2 million for the three and nine months ended September 30, 2024, respectively. To date, we have funded our operations primarily through the sale of our equity and convertible debt securities, from the receipt of upfront and milestone payments from collaborations, from borrowings, from sales of Afrezza and V-Go, from royalties and manufacturing revenue from UT as well as from proceeds of the sale-leaseback of our manufacturing facility in Danbury, CT and from the sale of a portion of future royalties that we receive from UT. CRITICAL ACCOUNTING POLICIES AND ESTIMATES Our critical accounting policies and estimates can be found in Item 7. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report. See Note 1 â€“ Description of Business and Significant Accounting Policies in

the condensed consolidated financial statements included in Part I â€“ Financial Statements (Unaudited) for descriptions of the new accounting policies and impact of adoption. RESULTS OF OPERATIONS Trends and Uncertainties Our collaboration agreement with UT entitles us to receive a 10% royalty on net sales of Tyvaso DPI, subject to the sale by us in December 2023 of a 1% royalty on future net sales to a royalty purchaser (leaving us with a 9% royalty). Our royalty revenue reflects the upward trend in demand for Tyvaso DPI in the marketplace. See Note 15 â€“ Commitments and Contingencies in the condensed consolidated financial statements. Our future success is dependent on our, and our current and future collaboration partnersâ€™, ability to effectively commercialize approved products. Our future success is also dependent on our pipeline of new products. There is a high rate of failure inherent in the R&D process for new drugs. As a result, there is a high risk that the funds we invest in research programs will not generate sufficient financial returns. Products may appear promising in development but fail to reach market within the expected or optimal timeframe, or at all. Three and nine months ended September 30, 2024 and 2023 Revenues The following table provides a comparison of the revenue categories for the three and nine months ended September 30, 2024 and 2023 (dollars in thousands): Â Â Three Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â $ Change Â Â % Change Â Net revenue â€“ commercial product sales: Â Â Â Â Â Â Â Â Â Â Â Â Gross revenue from product sales Â $ 32,232 Â Â $ 32,094 Â Â $ 138 Â Â Â 0 % Less: Wholesaler distribution fees, rebates andÂ Â Â chargebacks, product returns and otherÂ Â Â discounts Â Â 12,504 Â Â Â 14,167 Â Â $ (1,663) Â Â (12 %) Net revenue â€“ commercial product sales Â $ 19,728 Â Â $ 17,927 Â Â $ 1,801 Â Â Â 10 % Gross-to-net revenue adjustment percentage Â Â 39 % Â Â 44 % Â Â Â Â Â Â Revenue â€“ collaborations and services Â Â 23,268 Â Â Â 13,108 Â Â $ 10,160 Â Â Â 78 % Royalties â€“ collaboration Â Â 27,083 Â Â Â 20,218 Â Â $ 6,865 Â Â Â 34 % Total revenues Â $ 70,079 Â Â $ 51,253 Â Â $ 18,826 Â Â Â 37 % Â 40 Â Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â $ Change Â Â % Change Â Net revenue â€“ commercial product sales: Â Â Â Â Â Â Â Â Â Â Â Â Gross revenue from product sales Â $ 97,953 Â Â $ 95,722 Â Â $ 2,231 Â Â Â 2 % Less: Wholesaler distribution fees, rebates andÂ Â Â chargebacks, product returns and otherÂ Â Â discounts Â Â 38,681 Â Â Â 41,888 Â Â $ (3,207) Â Â (8 %) Net revenue â€“ commercial product sales Â $ 59,272 Â Â $ 53,834 Â Â $ 5,438 Â Â Â 10 % Gross-to-net revenue adjustment percentage Â Â 39 % Â Â 44 % Â Â Â Â Â Â Revenue â€“ collaborations and services Â Â 74,130 Â Â Â 35,705 Â Â $ 38,425 Â Â Â 108 % Royalties â€“ collaboration Â Â 75,326 Â Â Â 50,951 Â Â $ 24,375 Â Â Â 48 % Total revenues Â $ 208,728 Â Â $ 140,490 Â Â $ 68,238 Â Â Â 49 % Afrezza â€“ Gross revenue from sales of Afrezza increased by $1.7 million, or 8%, for the three months ended September 30, 2024 compared to the same period in the prior year. The increase was driven by higher demand. The gross-to-net adjustment was 36% of gross revenue, or $8.3 million, for the three months ended September 30, 2024 compared to 38% of gross revenue, or $8.1 million, for the same period in the prior year. The improved gross-to-net percentage was primarily attributable to a decrease in anticipated product returns (as a percentage of gross sales). As a result, net revenue from sales of Afrezza increased by $1.6 million, or 12%, for the three months ended September 30, 2024 compared to the same period in the prior year. Â Gross revenue from sales of Afrezza increased by $6.4 million, or 10%, for the nine months ended September 30, 2024 compared to the same period in the prior year. The increase was driven by higher demand and price. The gross-to-net adjustment was 35% of gross revenue, or $24.4 million, for the nine months ended September 30, 2024 compared to 38% of gross revenue, or $24.3 million, for the same period in the prior year. The improved gross-to-net percentage was primarily attributable to a decrease in anticipated product returns (as a percentage of gross sales). As a result, net revenue from sales of Afrezza increased by $6.3 million, or 16%, for the nine months ended September 30, 2024 compared to the same period in the prior year. Â V-Go â€“ Gross revenue from sales of V-Go decreased by $1.6 million, or 15%, for the three months ended September 30, 2024 compared to the same period in the prior year and was primarily a result of lower demand partially offset by increased price. The gross-to-net adjustment was 47% of gross revenue, or $4.2 million, for the three months ended September 30, 2024 compared to 58% of gross revenue, or $6.1 million, for the same period in the prior year. The improved gross-to-net percentage was primarily attributable to a decrease in rebates. As a result, net revenue from sales of V-Go increased by $0.2 million, or 5%, for the three months ended September 30, 2024 compared to the same period in the prior year. Gross revenue from sales of V-Go decreased by $4.2 million, or 13%, for the nine months ended September 30, 2024 compared to the same period in the prior year and was primarily a result of lower demand partially offset by increased price. The gross-to-net adjustment was 51% of gross revenue, or $14.3 million, for the nine months ended September 30, 2024 compared to 55% of gross revenue, or $17.6 million, for the same period in the prior year. The improved gross-to-net percentage was primarily attributable to a decrease in rebates. As a result, net revenue from sales of V-Go decreased by $0.9 million, or 6%, for the nine months ended September 30, 2024 compared to the same period in the prior year. Collaborations and Services â€“ Net revenue from collaborations and services increased by $10.2 million, or 78%, for the three months ended September 30, 2024 compared to the same period in the prior year. The increase in revenue was primarily attributable to increased manufacturing volume for product sold to UT. Royalty revenue from UT increased by $6.9 million, or 34%, for the three months ended September 30, 2024 due to UT's increase in net revenue from sales of Tyvaso DPI. See Note 10 â€“ Collaboration, Licensing and Other Arrangements. Net revenue from collaborations and services increased by $38.4 million, or 108%, for the nine months ended September 30, 2024 compared to the same period in the prior year. The increase in revenue was primarily attributable to increased manufacturing volume 41 Â for product sold to UT. Royalty revenue from UT increased by $24.4 million, or 48%, for the nine months ended September 30, 2024 due to UT's increase in net revenue from sales of Tyvaso DPI. See Note 10 â€“ Collaboration, Licensing and Other Arrangements. Commercial product gross profit The following table provides a comparison of the commercial product gross profit categories for the three and nine months ended September 30, 2024 and 2023 (dollars in thousands): Â Â Three MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â $ Change Â Â % Change Â Commercial product gross profit: Â Â Â Â Â Â Â Â Â Â Â Â Net revenue â€“ commercial product sales Â $ 19,728 Â Â $ 17,927 Â Â $ 1,801 Â Â Â 10 % Less: Cost of goods sold Â Â 3,197 Â Â Â 3,995 Â Â $ (798) Â Â (20 %) Commercial product gross profit: Â $ 16,531 Â Â $ 13,932 Â Â $ 2,599 Â Â Â 19 % Gross margin Â Â 84 % Â Â 78 % Â Â Â Â Â Â Â Â Â Â Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â $ Change Â Â % Change Â Commercial product gross profit: Â Â Â Â Â Â Â Â Â Â Â Â Net revenue â€“ commercial product sales Â $ 59,272 Â Â $ 53,834 Â Â $ 5,438 Â Â Â 10 % Less: Cost of goods sold Â Â 12,621 Â Â Â 14,749 Â Â $ (2,128) Â Â (14 %) Commercial product gross profit: Â $ 46,651 Â Â $ 39,085 Â Â $ 7,566 Â Â Â 19 % Gross margin Â Â 79 % Â Â 73 % Â Â Â Â Â Â Â Â Commercial product gross profit increased by $2.6 million, or 19%, for the three months ended September 30, 2024 compared to the same period in the prior year and $7.6 million, or 19%, for the nine months ended September 30, 2024 compared to the same period in the prior year. The increase in gross profit and gross margin was primarily attributable to an increase in Afrezza net revenue and improved gross-to-net adjustments related to V-Go rebates. Expenses The following table provides a comparison of the expense categories for the three and nine months ended September 30, 2024 and 2023 (dollars in thousands): Â Â Three MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â $ Change Â Â % Change Â Expenses: Â Â Â Â Â Â Â Â Â Â Â Â Cost of goods sold Â $ 3,197 Â Â $ 3,995 Â Â $ (798) Â Â (20 %) Â Cost of revenue â€“ collaborations and services Â Â 14,826 Â Â Â 10,259 Â Â $ 4,567 Â Â Â 45 % Â Research and development Â Â 12,926 Â Â Â 9,989 Â Â $ 2,937 Â Â Â 29 % Â Selling Â Â 13,093 Â Â Â 13,440 Â Â $ (347) Â Â (3 %) Â General and administrative Â Â 10,823 Â Â Â 10,538 Â Â $ 285 Â Â Â 3 % Â Loss (gain) on foreign currency transaction Â Â 2,454 Â Â Â (2,065) Â $ 4,519 Â Â * Â Total expenses Â $ 57,319 Â Â $ 46,156 Â Â $ 11,163 Â Â Â 24 % Â 42 Â Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â $ Change Â Â % Change Â Expenses: Â Â Â Â Â Â Â Â Â Â Â Â Cost of goods sold Â $ 12,621 Â Â $ 14,749 Â Â $ (2,128) Â Â (14 %) Â Cost of revenue â€“ collaborations and services Â Â 44,377 Â Â Â 29,955 Â Â $ 14,422 Â Â Â 48 % Â Research and development Â Â 34,755 Â Â Â 22,047 Â Â $ 12,708 Â Â Â Â 58 % Â Selling Â Â 36,189 Â Â Â 40,752 Â Â $ (4,563) Â Â (11 %) Â General and administrative Â Â 34,168 Â Â Â 33,027 Â Â $ 1,141 Â Â Â 3 % Â Loss (gain) on foreign currency transaction Â Â 526 Â Â Â (860) Â $ 1,386 Â Â * Â Total expenses Â $ 162,636 Â Â $ 139,670 Â Â $ 22,966 Â Â Â 16 % _____ * Not meaningful Â Cost of revenue â€“ collaborations and services increased by $4.6 million, or 45%, for the three months ended September 30, 2024 compared to the same period in the prior year and $14.4 million, or 48%, for the nine months ended September 30, 2024 compared to the same period in the prior year. The increases were primarily attributable to increased manufacturing volume for Tyvaso DPI. R&D expenses increased by $2.9 million, or 29%, for the three months ended September 30, 2024 and $12.7 million, or 58%, for the nine months ended September 30, 2024 compared to the same periods in the prior year. The increases were primarily attributable to increased expenditures for development activities and a Phase 3 clinical study of clofazimine inhaled suspension (MNKD-101), a Phase 1 clinical study of a dry-powder formulation of nintedanib (MNKD-201) for treatment of pulmonary fibrotic diseases, and personnel costs due to increased headcount as a result of the Pulmatrix Transaction. Selling expenses decreased by $0.3 million, or 3%, for the three months ended September 30, 2024 compared to the same period in the prior year. The decrease was primarily attributable to reduced personnel related to sales force restructuring activities completed during the first quarter of 2024, partially offset by an increase in promotional activities. Selling expenses decreased by $4.6 million, or 11%, for the nine months ended September 30, 2024 compared to the same period in the prior year. The decrease was primarily attributable to reduced personnel expenses related to sales force restructuring activities completed during the first quarter of 2024. General and administrative expenses increased by $0.3 million, or 3%, for the three months ended September 30, 2024 compared to the same period in the prior year. The increase was primarily attributable to increases in personnel costs, partially offset by reduced consulting fees. General and administrative expenses increased by $1.1 million, or 3%, for the nine months ended September 30, 2024 compared to the same period in the prior year. The increase was primarily attributable to a loss of $1.4 million for estimated returns associated with sales of V-Go that pre-date our acquisition of the product and increases in personnel costs, partially offset by reduced consulting fees. 43 Â Under the Insulin Supply Agreement, payment obligations are denominated in Euros. We are required to record the foreign currency transaction impact of the U.S. dollar to Euro exchange rate associated with the recognized gain or loss on purchase commitments. The foreign currency transaction loss was $2.5 million for the three months ended September 30, 2024 compared to a gain of $2.1 million for the same period in the prior year and a loss of $0.5 million for the nine months ended September 30, 2024 compared to a gain of $0.9 million for the same period in the prior year due to the conversion of Euro to U.S. dollar exchange rates. Other Income (Expense) The following table provides a comparison of the other income (expense) categories for the three and nine months ended September 30, 2024 and 2023 (dollars in thousands): Â Â Three MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â $ Change Â Â % Change Â Interest income, net Â $ 3,179 Â Â $ 1,580 Â Â $ 1,599 Â Â Â 101 % Interest expense on liability for sale of future royalties Â Â (4,089) Â Â â€” Â Â $ (4,089) Â * Â Interest expense on financing liability Â Â (2,470) Â Â (2,459) Â $ 11 Â Â Â 0 % Interest expense Â Â (1,801) Â Â (2,815) Â $ (1,014) Â Â (36 %) Gain on bargain purchase Â Â 5,259 Â Â Â â€” Â Â $ 5,259 Â Â * Â Other income Â Â 32 Â Â Â 318 Â Â $ (286) Â Â (90 %) Total other income (expense) Â $ 110 Â Â $ (3,376) Â $ 3,486 Â Â Â 103 % Â Â Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â $ Change Â Â % Change Â Interest income, net Â $ 9,790 Â Â $ 4,429 Â Â $ 5,361 Â Â Â 121 % Interest expense on liability for sale of future royalties Â Â (12,720) Â Â â€” Â Â $ (12,720) Â * Â Interest expense on financing liability Â Â (7,361) Â Â (7,332) Â $ 29 Â Â Â 0 % Interest expense Â Â (10,419) Â Â (12,474) Â $ (2,055) Â Â (16 %) Gain on bargain purchase Â Â 5,259 Â Â Â â€” Â Â $ 5,259 Â Â * Â Other income Â Â 32 Â Â Â 286 Â Â $ (254) Â Â (89 %) Loss on extinguishment of debt Â Â (7,050) Â Â â€” Â Â $ (7,050) Â * Â (Loss) gain on available-for-sale securities Â Â (1,550) Â Â 932 Â Â Â $ (2,482) Â * Â Total other expense Â $ (24,019) Â $ (14,159) Â $ 9,860 Â Â Â 70 % _____ * Not meaningful Â Interest income, net, consisting of interest and accretion on investments net of amortization, increased by $1.6 million for the three months ended September 30, 2024 and $5.4 million for the nine months ended September 30, 2024 compared to the same periods in the prior year primarily due to an increase in the underlying investments from the proceeds of the sale of 1% of our Tyvaso DPI royalties in December 2023 and higher yields on our securities portfolio. Interest expense on liability for sale of future royalties was $4.1 million and $12.7 million for the three and nine months ended September 30, 2024, respectively, and was attributable to imputed interest and amortization of debt issuance costs on the liability recorded in connection with the sale of 1% of our Tyvaso DPI royalties in December 2023. See Note 15 â€“ Commitments and Contingencies. Interest expense on financing liability was $2.5 million for each of the three months ended September 30, 2024 and 2023, and $7.4 million and $7.3 million for the nine months ended September 30, 2024 and 2023, respectively, and represented interest incurred on the sale lease-back transaction for our manufacturing facility in Danbury, CT. Interest expense decreased by $1.0 million for the three months ended September 30, 2024 and $2.1 million for the nine months ended September 30, 2024 compared to the same periods in the prior year. The decrease was primarily due to repayment of the MidCap credit facility and Mann Group convertible note in April 2024. See Note 9 â€“ Borrowings. Gain on bargain purchase of $5.3 million for the three and nine months ended September 30, 2024 was the result of the excess of net assets acquired over consideration paid in the Pulmatrix Transaction. See Note 2 â€“ Pulmatrix Transaction. 44 Â Other income for the three and nine months ended September 30, 2023 consisted primarily of gains associated with foreign currency hedging transactions which were entered into to mitigate our exposure to foreign currency exchange risks associated with our insulin purchase obligation under the Insulin Supply Agreement. Loss on extinguishment of debt of $7.1 million for the nine months ended September 30, 2024 was incurred in connection with the repayment of the MidCap credit facility and Mann Group convertible note in April 2024. See Note 9 â€“ Borrowings. Loss on available-for-sale securities for the nine months ended September 30, 2024 was $1.6 million as a result of modification of the Thirona investment. The gain on available-for-sale securities for the nine months ended September 30, 2023 was $0.9 million as a result of the change in fair value of the investment. See Note 3 â€“ Investments. Non-GAAP MeasuresTo supplement our condensed consolidated financial statements presented under GAAP, we are presenting non-GAAP net income (loss) and non-GAAP net income (loss) per share â€“ diluted, which are non-GAAP financial measures. We are providing these non-GAAP financial measures to disclose additional information to facilitate the comparison of past and present operations, and they are among the indicators management uses as a basis for evaluating our financial performance. We believe that these non-GAAP financial measures, when considered together with our GAAP financial results, provide management and investors with an additional understanding of our business operating results, including underlying trends. These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that we may exclude for purposes of our non-GAAP financial measures; and we may in the future cease to exclude items that we have historically excluded for purposes of our non-GAAP financial measures. Likewise, we may determine to modify the nature of its adjustments to arrive at our non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by us in this Quarterly Report on Form 10-Q have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.The following table reconciles our financial measures for net income (loss) and net income (loss) per share ("EPS") for diluted weighted average shares as reported in our condensed consolidated statements of operations to a non-GAAP presentation. Â Three Months Â Â Nine Months Â Â Ended September 30, Â Â Ended September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Net Income Â Â Basic EPS Â Â Net Income Â Â Basic EPS Â Â Net Income Â Â Basic EPS Â Â Net Loss Â Â Basic EPS Â Â (In thousands except per share data) Â GAAP reported net income (loss) $ 11,550 Â Â $ 0.04 Â Â $ 1,721 Â Â $ 0.01 Â Â $ 20,166 Â Â $ 0.07 Â Â $ (13,339) Â $ (0.05) Non-GAAP adjustments: Â Sold portion of royalty revenue (1) Â (2,708) Â Â (0.01) Â Â â€” Â Â Â â€” Â Â Â (7,533) Â Â (0.03) Â Â â€” Â Â Â â€” Â Interest expense on liability for sale of future royalties Â 4,089 Â Â 0.02 Â Â Â â€” Â Â Â â€” Â Â 12,720 Â Â 0.04 Â Â Â â€” Â Â Â â€” Â Stock compensation Â 5,227 Â Â 0.02 Â Â Â 4,601 Â Â 0.02 Â Â Â 15,540 Â Â Â 0.06 Â Â Â 13,836 Â Â Â 0.05 Â Loss (gain) on foreign currency transaction Â 2,454 Â Â Â 0.01 Â Â (2,065) Â Â (0.01) Â Â 526 Â Â Â â€” Â Â (860) Â Â â€” Â Gain on bargain purchase Â (5,259) Â Â (0.02) Â Â â€” Â Â Â â€” Â Â (5,259) Â Â (0.02) Â Â â€” Â Â Â â€” Â Loss on extinguishment of debt Â â€” Â Â Â â€” Â Â Â 7,050 Â Â Â 0.03 Â Â Â â€” Â Â Â â€” Â Loss (gain) on available-for-sale securities Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 1,550 Â Â Â 0.01 Â Â (932) Â Â â€” Â Non-GAAP adjusted net income (loss) $ 15,353 Â Â $ 0.06 Â Â $ 4,257 Â Â $ 0.02 Â Â $ 44,760 Â Â $ 0.16 Â Â $ (1,295) Â $ (0.00) Weighted average shares used to compute net income (loss) Â Â Â Â per share â€“ basic Â 274,998 Â Â Â Â Â Â 268,732 Â Â Â Â Â Â 272,811 Â Â Â Â Â Â 266,126 Â Â Â Â _____ (1)Represents the non-cash portion of the 1% royalty on net sales of Tyvaso DPI earned during the three and nine months ended September 30, 2024 which is remitted to the royalty purchaser by UT and recognized as royalties â€“ collaboration in our condensed consolidated statements of operations. Our royalties â€“ collaboration during the three and nine months ended September 30, 2024 totaled $27.1 million and $75.3 million, respectively, of which $2.7 million and $7.5 million, respectively, was non-cash revenue attributed to the royalty purchaser. LIQUIDITY AND CAPITAL RESOURCES Our principal sources of liquidity are our cash, cash equivalents, and investments. Our primary uses of cash include the development of our product pipeline, the manufacturing and marketing of Afrezza and V-Go, manufacturing Tyvaso DPI, the funding of general and administrative expenses, and principal and interest payments on our financing liability and debt. 45 Â Historically,

we have funded our operations primarily through the sale of equity and convertible debt securities, from the receipt of upfront and milestone payments from collaborations, from borrowings, from proceeds from the sale of certain assets and the sale of a portion of our future royalties that we receive from UT. More recently, sales of Afrezza and V-Go, and royalties and manufacturing revenue from UT, have become a more significant source of funding for our operations, In combination with our cash, cash equivalents and investments on hand, we believe that these sources of revenue, as well as the potential financing sources currently available to us, will allow us to meet our liquidity needs over the next twelve months and in the longer term. As of September 30, 2024, we had $62.6 million in insulin purchase commitments and $230.0 million principal amount of outstanding Senior convertible notes bearing interest at 2.50% and maturing on March 1, 2026, unless earlier converted, redeemed or repurchased by us. The Senior convertible notes are convertible at an initial conversion price of approximately $5.21 per share of common stock. The conversion rate is subject to adjustment under certain circumstances in accordance with the terms of the Indenture. With the repayment of the MidCap credit facility and the Mann Group convertible note in April 2024, our Senior convertible notes are our only remaining notes outstanding. In July 2013, we issued the Milestone Rights pursuant to the Milestone Rights Agreement to the Original Milestone Purchasers. The Milestone Rights were subsequently assigned the Milestone Purchasers. The Milestone Rights provide the Milestone Purchasers certain rights to receive payments of up to $90.0 million upon the occurrence of specified strategic and sales milestones, $50.0 million of which remain payable as of September 30, 2024. See Note 15 â€“ Commitments and Contingencies for further information related to the Milestone Rights. During the nine months ended September 30, 2024, we generated $19.9 million of cash from our operating activities, which consisted primarily of $189.3 million in cash receipts from customers (net primarily of $11.5 million of non-cash revenue that was previously deferred and $7.5 million of non-cash revenue for the 1% sold portion of our royalties), partially offset by $59.8 million of cost of goods sold, $35.5 million of selling expenses, $34.3 million of costs for research and development, $29.4 million of general and administrative expenses, and $9.0 million of net cash paid for interest. During the nine months ended September 30, 2023, we generated $12.4 million of cash from our operating activities, which consisted primarily of $167.3 million of revenue, partially offset by $60.4 million of cost of goods sold, $35.7 million of selling expenses, $25.4 million of general and administrative expenses, $20.8 million of R&D costs and $13.0 million of cash paid for interest. Cash used in investing activities of $144.9 million for the nine months ended September 30, 2024 was primarily due to the purchase of $273.8 million of debt securities and $6.8 million of property and equipment, partially offset by the maturity of $135.3 million of debt securities. Cash provided by investing activities of $5.9 million for the nine months ended September 30, 2023 was primarily due to $92.6 million of proceeds received from the sales of debt securities, partially offset by the purchase of debt securities of $50.5 million and by $36.6 million for the purchase of property and equipment which was substantially paid for by UT as part of our facility expansion project to increase manufacturing capacity. Cash used in financing activities of $50.4 million for the nine months ended September 30, 2024 was primarily due to principal and early extinguishment payments on the MidCap credit facility of $36.6 million and Mann Group convertible note of $8.9 million, and $6.2 million of payments to taxing authorities from equity withheld upon vesting of RSUs and stock options, partially offset by $2.3 million in proceeds from the MPSPP and ESPP. Cash used in financing activities of $5.1 million for the nine months ended September 30, 2023 was primarily due to $10.2 million of payments to taxing authorities from equity withheld upon vesting of RSUs and stock options, and payments of $1.7 million on MidCap credit facility, partially offset by $6.9 million in proceeds from at-the-market offerings and $1.1 million in proceeds from market price and ESPP. Future Liquidity Needs Although we have not generated net income or cash flows from operating activities on a consistent basis, we believe we will be able to meet our near-term liquidity needs based on our cash, cash equivalents and investments on hand, sales of Afrezza and V-Go, and royalties and manufacturing revenue from the production and sale of Tyvaso DPI as well as through debt or equity financing, if necessary, for our long-term liquidity needs. We expect to continue to incur expenditures for the foreseeable future in support of our manufacturing operations, sales and marketing costs for our products and development costs for other product candidates in our pipeline. As of September 30, 2024, we had capital resources comprised of cash, cash equivalents, short-term investments and long-term investments totaling $268.4 million, and total principal amount of outstanding borrowings of $230.0 million. 46 Â We believe our resources will be sufficient to fund our operations for the next twelve months from the date of issuance of our condensed consolidated financial statements included in Part I â€“ Financial Statements (Unaudited). Contractual Obligations See Note 9 â€“ Borrowings and Note 15 â€“ Commitments and Contingencies for a discussion of material changes outside of the ordinary course of business in our contractual obligations from those disclosed within â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations,â€ as contained in the Annual Report. 47 Â ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Interest Rate Risk The Senior convertible notes have a fixed interest rate of 2.50%, and therefore the interest expense associated with such debt is not exposed to changes in market interest rates. See Note 9 â€“ Borrowings for information about the principal amount of outstanding debt. Foreign Currency Exchange Risk We incur and will continue to incur significant expenditures for insulin supply obligations under our Insulin Supply Agreement. Such obligations are denominated in Euros. At the end of each reporting period, the recognized gain or loss on purchase commitment is converted to U.S. dollars at the then-applicable foreign exchange rate. As a result, our business is affected by fluctuations in exchange rates between the U.S. dollar and the Euro. For the nine months ended September 30, 2024, we realized a $0.5 million currency loss, which was reflected as loss on foreign currency transaction in the accompanying condensed consolidated statements of operations. Exchange rate fluctuations may adversely affect our expenses, results of operations, financial position and cash flows. If a change in the U.S. dollar to Euro exchange rate equal to 10% of the U.S. dollar to Euro exchange rate on September 30, 2024 were to have occurred, this change would have resulted in a foreign currency impact to our pre-tax income of approximately $6.3 million. ITEM 4. CONTROLS AND PROCEDURES Disclosure Controls and Procedures Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), as of September 30, 2024. The term â€œdisclosure controls and procedures,â€ as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the companyâ€™s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2024, our Chief Executive Officer and our Chief Financial Officer have concluded, as of such date, that our disclosure controls and procedures were effective. Changes in Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rule 13a-15(f) of the Exchange Act. An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. 48 Â PART II. OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS We are subject to legal proceedings and claims that arise in the ordinary course of our business. As of the date hereof, we believe that the final disposition of such matters will not have a material adverse effect on our financial position, results of operations or cash flows. We maintain liability insurance coverage to protect our assets from losses arising out of or involving activities associated with ongoing and normal business operations. See Note 15 â€“ Commitments and Contingencies in the condensed consolidated financial statements. Item 1A. Risk Factors Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found under the heading â€œRisk Factorsâ€ and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q and our other filings with the SEC before making investment decisions regarding our common stock. Summary Risk Factors We face risks and uncertainties related to our business, many of which are beyond our control. In particular, risks associated with our business include: RISKS RELATED TO OUR BUSINESS â€¢The products that we or our collaboration partner are commercializing may only achieve a limited degree of commercial success. â€¢Manufacturing risks may adversely affect our ability to manufacture our products and Tyvaso DPI, which could reduce our gross margin and profitability. â€¢If our suppliers fail to deliver materials and services needed for commercial manufacturing in a timely and sufficient manner or fail to comply with applicable regulations, and if we fail to timely identify and qualify alternative suppliers, our business, financial condition and results of operations would be harmed and the market price of our common stock and other securities could decline. â€¢If third-party payers do not cover our approved products, such products might not be prescribed, used or purchased, which would adversely affect our revenues. â€¢We may need to raise additional capital to fund our operations. â€¢If our information technology systems, or those of third parties with whom we work, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences. â€¢We expect that our results of operations will fluctuate for the foreseeable future, which may make it difficult to predict our future performance from period to period. â€¢We may incur losses and may not generate positive cash flow from operations in the future. â€¢We may not be able to generate sufficient cash to service all of our indebtedness and commitments â€¢Continued testing of our products and product candidates may not yield successful results, and even if it does, we may still be unable to successfully commercialize our current or future products. â€¢If we do not achieve our projected development goals in the timeframes we expect, our business, financial condition and results of operations will be harmed and the market price of our common stock and other securities could decline. â€¢The long-term safety and efficacy of approved products may differ from clinical studies, which could negatively impact sales and could lead to reputational harm or other negative effects. â€¢Our products and product candidates may be rendered obsolete by rapid technological change. â€¢We may undertake internal restructuring activities in the future that could result in disruptions to our business or otherwise materially harm our results of operations or financial condition. 49 Â RISKS RELATED TO GOVERNMENT REGULATION â€¢Our product candidates must undergo costly and time-consuming rigorous nonclinical and clinical testing and we must obtain regulatory approval prior to the sale and marketing of any product in each jurisdiction. The results of this testing or issues that develop in the review and approval by a regulatory agency may subject us to unanticipated delays or prevent us from marketing any products. â€¢If we do not comply with regulatory requirements at any stage, whether before or after marketing approval is obtained, we may be fined or forced to remove a product from the market, subject to criminal prosecution, or experience other adverse consequences, including restrictions or delays in obtaining regulatory marketing approval. â€¢We are subject to stringent, ongoing government regulation. â€¢If we or any future partner fails to comply with federal and state healthcare laws, including fraud and abuse and health information laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected. â€¢We are subject to stringent and changing U.S. and foreign laws, regulations and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences. RISKS RELATED TO OUR COMMON STOCK â€¢Our stock price is volatile. â€¢Future sales of shares of our common stock in the public market, or the perception that such sales may occur, may depress our stock price and adversely impact the market price of our common stock and other securities. GENERAL RISK FACTORS â€¢Unstable market, economic and geopolitical conditions may have serious adverse consequences on our business, financial condition and stock price. You should consider carefully the following information about the risks described below, together with the other information contained in this Quarterly Report on Form 10-Q before you decide to buy or maintain an investment in our common stock. We believe the risks described below are the risks that are material to us as of the date of this Quarterly Report. Additional risks and uncertainties that we are unaware of may also become important factors that affect us. The risk factors set forth below marked with an asterisk (*) did not appear as separate risk factors in, or contains changes to the similarly titled risk factors included in, Item 1A of the Annual Report. If any of the following risks actually occur, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock could decline, and you may lose all or part of the money you paid to buy our common stock. Risk Factors RISKS RELATED TO OUR BUSINESS The products that we or our collaboration partner are commercializing may only achieve a limited degree of commercial success.* Successful commercialization of therapeutic products is subject to many risks, including some that are outside our control. There are numerous examples of failures to fully exploit the market potential of therapeutic products, including by biopharmaceutical and device companies with more experience and resources than us. Products that we commercialize ourselves (including any products that we may develop or acquire in the future) and the product that is commercialized by our current collaboration partner (including future products that may be commercialized by a collaboration partner) may not gain market acceptance among physicians, patients, third-party payers and the healthcare community. The degree of market acceptance of our or a collaboration partnerâ€™s products depends on many factors, including the following: â€¢approved labeling claims; â€¢effectiveness of efforts by us and/or any current or future collaboration or marketing partner to support and educate patients and physicians about the benefits and proper administration of our products, and the perceived advantages of our products and the disadvantages of competitive products; 50 Â â€¢willingness of the healthcare community and patients to adopt new technologies; â€¢ability to manufacture the product in sufficient quantities with acceptable quality and cost; â€¢perception of patients and the healthcare community, including third-party payers, regarding the safety, efficacy and benefits compared to competing products or therapies; â€¢convenience and ease of administration relative to existing treatment methods; â€¢coverage and reimbursement, as well as pricing relative to other treatment therapeutics and methods; and â€¢marketing and distribution support. Because of these and other factors, the products described above may not gain market acceptance or otherwise be commercially successful. Failure to achieve market acceptance would limit our ability to generate revenue and would adversely affect our results of operations. We and our current or any future collaboration partner may need to enhance our/their commercialization capabilities in order to successfully commercialize such products in the United States or any other jurisdiction in which such product is approved for commercial sale, and we or the collaboration partner may not have sufficient resources to do so. In order to increase adoption and sales of our products, we need to continue to develop our commercial organization, including maintaining and growing a highly experienced and skilled workforce with qualified sales representatives.* We have built a sales force that promotes Afrezza and V-Go to endocrinologists and selected primary care physicians. In order to successfully commercialize any approved products, we must continue to build our sales, marketing, distribution, managerial and other commercial capabilities. The market for skilled commercial personnel is highly competitive, and we may not be able to hire all of the personnel we need on a timely basis or retain them for a sufficient period. Factors that may hinder our ability to successfully market and commercially distribute our products include: â€¢inability to recruit, retain and effectively manage adequate numbers of effective sales personnel; â€¢lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies that have more extensive product lines; and â€¢unforeseen delays, costs and expenses associated with maintaining our sales organization. If we are unable to maintain an effective sales force for our products, including potential future products, we may not be able to generate sufficient product revenue in the United States. We are required to expend significant time and resources to train our sales force to educate physicians about our products. In addition, we must continually train our sales force and equip them with effective marketing materials to ensure that a consistent and appropriate message about our products is being delivered to our potential customers. We currently have limited resources compared to some of our competitors, and the continued development of our own commercial organization to market our products and any additional products we may develop or acquire will be expensive and time-consuming. We also cannot be certain that we will be able to continue to successfully develop this capability. Similarly, if UT does not effectively engage or maintain its sales force for Tyvaso DPI, our ability to recognize royalties and manufacturing revenue from this collaboration will be adversely affected. Manufacturing risks may adversely affect our ability to manufacture our products and Tyvaso DPI, which could reduce our gross margin and profitability.* We use our Danbury, Connecticut facility to assemble the inhalers from their individual molded parts, formulate both the Afrezza and Tyvaso DPI inhalation powders, fill plastic cartridges with the powders, package the cartridges into secondary packaging and assemble final kits for certain stock-keeping units. Other semi-finished goods are assembled into

the final kits for commercial sale by a contract packager. The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products often encounter difficulties in production, especially in scaling up production to commercial batch sizes. These problems include difficulties with production costs, capacity utilization and yields. We may also experience shortages of qualified personnel, which could impact our ability to meet manufacturing requirements. In addition, there is a need to comply with strictly enforced federal, state and foreign regulations, including inspections. Our facility is inspected on a regular basis by the FDA. If the FDA makes any major observations during future inspections, the corrective actions required could be onerous and time-consuming. Any of these factors could cause us to delay or suspend production, could entail higher costs and may result in our being unable to obtain sufficient quantities for the commercialization of drug products at the costs that we currently anticipate. Furthermore, if we or a third-party manufacturer fail to deliver the required commercial quantities of the product or any raw material on a timely basis, and at 51 Â commercially reasonable prices, sustainable compliance and acceptable quality, and we were unable to promptly find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volume and quality on a timely basis, we would likely be unable to meet demand for such drug products and we would lose potential revenues. As demand for our products increases, we may have to invest additional resources to purchase components, hire and train employees, and enhance our manufacturing processes. If we fail to increase our production capacity efficiently, our sales may not increase in line with our forecasts and our operating margins could fluctuate or decline. In addition, we may be unable to support commercialization of Tyvaso DPI. In addition, we rely on our contract manufacturers in Southern China to manufacture V-Go. Our contract manufacturer uses MannKind-owned custom-designed, semi-automated manufacturing equipment and production lines to meet our quality requirements. Separate contract manufacturers in China perform release testing, sterilization, inspection and packaging functions. As a result, our business is subject to risks associated with doing business in China, including: â€¢adverse political and economic conditions, particularly those potentially negatively affecting the trade relationship between the United States and China; â€¢trade protection measures, such as tariff increases, and import and export licensing and control requirements; â€¢potentially negative consequences from changes in tax laws; â€¢difficulties associated with the Chinese legal system, including increased costs and uncertainties associated with enforcing contractual obligations in China; â€¢historically lower protection of intellectual property rights; â€¢unexpected or unfavorable changes in regulatory requirements; â€¢changes and volatility in currency exchange rates; â€¢possible patient or physician preferences for more established pharmaceutical products and medical devices manufactured in the United States; and â€¢difficulties in managing foreign relationships and operations generally. These risks are likely to be exacerbated by our limited experience with V-Go and its manufacturing processes. If our suppliers fail to deliver materials and services needed for commercial manufacturing in a timely and sufficient manner or fail to comply with applicable regulations, and if we fail to timely identify and qualify alternative suppliers, our business, financial condition and results of operations would be harmed and the market price of our common stock and other securities could decline. For the commercial manufacture of inhaled drug products, we need access to sufficient, reliable and affordable supplies of FDKP, the inhaler, the related cartridges and other materials. For Afrezza, we also require a supply of insulin. Currently, the only source of insulin that we have qualified for Afrezza is manufactured by Amphastar. We must rely on all of our suppliers to comply with relevant regulatory and other legal requirements, including the production of insulin and FDKP in accordance with current good manufacturing practice (â€œcGMPâ€) for drug products, and the molding of the inhaler and cartridges components in accordance with quality system regulations for medical devices (â€œQSRsâ€). For V-Go, we obtain parts from a small number of suppliers, including some parts and components that are purchased from single-source vendors. Depending on a limited number of suppliers exposes us to risks, including limited control over pricing, availability, quality and delivery schedules. In addition, we do not have long-term supply agreements with most of our suppliers and, in many cases, we make our purchases on a purchase order basis. Under many of our supply agreements, we have no obligation to buy any given quantity of components, and our suppliers have no obligation to manufacture for us or sell to us any given quantity of components. Because we do not have long-standing relationships with all of our suppliers, we may not be able to convince them to continue to make components available to us unless there is demand for such components from their other customers. If any one or more of our suppliers cease to provide us with sufficient quantities of components in a timely manner or on terms acceptable to us, we would have to seek alternative sources of supply. Because of factors such as the proprietary nature of our product, our quality control standards and regulatory requirements, we cannot quickly engage additional or replacement suppliers for some of our critical components. Â We may also have difficulty obtaining similar components from other suppliers that meet the requirements of the FDA or other regulatory agencies. Although we conduct our own inspections and review and/or approve investigations of each supplier, there can be 52 Â no assurance that the FDA, upon inspection, would find that the supplier substantially complies with the QSR or cGMP requirements, where applicable. If a supplier fails to comply with these requirements or the comparable requirements in foreign countries, regulatory authorities may subject us to regulatory action, including criminal prosecutions, fines and suspension of the manufacture of our products. If we are required to find a new or additional supplier, we will need to evaluate that supplierâ€™s ability to provide material that meets regulatory requirements, including cGMP or QSR requirements, as well as our specifications and quality requirements, which would require significant time and expense and could delay production. As a result, our ability to purchase adequate quantities of the components for our products may be limited. Additionally, our suppliers may encounter problems that limit their ability to manufacture components for us, including financial difficulties or damage to their manufacturing equipment or facilities. In general, if any of our suppliers is unwilling or unable to meet its supply obligations or if we encounter delays or difficulties in our relationships with manufacturers or suppliers, and we are unable to secure an alternative supply source in a timely manner and on favorable terms, our business, financial condition, and results of operations may be harmed and the market price of our common stock and other securities may decline. If third-party payers do not cover our approved products, such products might not be prescribed, used or purchased, which would adversely affect our revenues. In the United States and elsewhere, sales of prescription pharmaceuticals depend in large part on the availability of coverage and adequate reimbursement to the consumer from third-party payers, such as government health administration authorities and private insurance plans. Third-party payers are increasingly challenging the prices charged for medical products and services. The market for our approved products depends significantly on access to third-party payersâ€™ formularies, which are the lists of medications and devices for which third-party payers provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical and device companies. Also, third-party payers may refuse to include a particular branded product in their formularies or otherwise restrict patient access to a branded product when a less costly generic equivalent or other alternative is available. Even if favorable coverage and reimbursement status is attained for our products, less favorable coverage policies and reimbursement rates may be implemented in the future. In addition, because each third-party payer individually approves coverage and reimbursement levels, obtaining coverage and adequate reimbursement is a time-consuming and costly process. We may be required to provide scientific and clinical support for the use of any product to each third-party payer separately with no assurance that approval would be obtained. This process could delay the market acceptance of any product and could have a negative effect on our future revenues and operating results. Even if we succeed in bringing more products to market, we cannot be certain that any such products would be considered cost-effective or that coverage and adequate reimbursement to the consumer would be available. Patients will be unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Our future revenues and ability to generate positive cash flow from operations may be affected by the continuing efforts of government and other third-party payers to contain or reduce the costs of healthcare through various means. In the United States, there have been several congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, the Inflation Reduction Act (the â€œIRAâ€) limited insulin copays to $35 per month for Medicare Part D beneficiaries starting in 2023. In certain foreign markets, the pricing of prescription pharmaceuticals is subject to direct governmental control. The European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. If we or any collaboration or marketing partner is unable to obtain and maintain coverage of, and adequate third-party reimbursement for, our approved products, physicians may limit how much or under what circumstances they will prescribe or administer them and patients may decline to purchase them. This in turn could affect our or any collaboration or marketing partnerâ€™s ability to successfully commercialize such products and would impact our profitability, results of operations, financial condition, and prospects. We may need to raise additional capital to fund our operations.* We may need to raise additional capital, whether through the sale of equity or debt securities, additional strategic business collaborations, the establishment of other funding facilities, licensing arrangements, asset sales or other means, in order to support our ongoing activities, including the commercialization of our products and the development of our product candidates. It may be difficult for us to raise additional funds on favorable terms, or at all. The extent of our additional funding requirements will depend on a number of factors, including: â€¢the degree to which we are able to generate revenue from products that we or a collaboration partner commercialize; â€¢the costs of developing Afrezza and of commercializing Afrezza and V-Go on our own in the United States; 53 Â â€¢the demand by any or all of the holders of our Senior convertible notes to require us to repay or repurchase such debt securities if and when required; â€¢our ability to repay or refinance existing indebtedness, and the extent to which our Senior convertible notes or any other convertible debt securities we may issue are converted into or exchanged for shares of our common stock; â€¢the rate of progress and costs of our clinical studies and R&D activities; â€¢the costs of procuring raw materials and operating our manufacturing facility; â€¢our success in establishing additional strategic business collaborations or other sales or licensing of assets, and the timing and amount of any payments we might receive from any such transactions; â€¢actions taken by the FDA and other regulatory authorities affecting Afrezza, V-Go, Tyvaso DPI, our product candidates or competitive products; â€¢the emergence of competing technologies and products and other market developments; â€¢the costs of preparing, filing, prosecuting, maintaining and enforcing patent claims and other intellectual property rights or defending against claims of infringement by others; â€¢the level of our legal and litigation expenses; and â€¢the costs of discontinuing projects and technologies, and/or decommissioning existing facilities, if we undertake any such activities. We have raised capital in the past through the sale of equity and debt securities and the sale of certain assets. In the future, we may pursue the sale of additional equity, debt securities and/or assets, or the establishment of other funding facilities including asset-based borrowings. There can be no assurances, however, that we will be able to raise additional capital in the future on acceptable terms, or at all. Volatility and disruptions of the global supply chain and financial markets, if sustained or recurrent, could prevent us or make it more difficult for us to access capital. Â Issuances of additional debt or equity securities or the issuance of common stock upon conversion of outstanding convertible debt securities for shares of our common stock could impact the rights of the holders of our common stock and will dilute their ownership percentage. Moreover, the establishment of other funding facilities may impose restrictions on our operations. These restrictions could include limitations on additional borrowing and specific restrictions on the use of our assets, as well as prohibitions on our ability to create liens, pay dividends, redeem our stock or make investments. We may also raise additional capital by pursuing opportunities for the licensing or sale of certain intellectual property and other assets. We cannot offer assurances, however, that any strategic collaboration, sales of securities or sales or licenses of assets will be available to us on a timely basis or on acceptable terms, if at all. We may be required to enter into relationships with third parties to develop or commercialize products or technologies that we otherwise would have sought to develop independently, and any such relationships may not be on terms as commercially favorable to us as might otherwise be the case. Â In the event that sufficient additional funds are not obtained through strategic collaboration opportunities, sales of securities, funding facilities, licensing arrangements, borrowing arrangements and/or asset sales on a timely basis, we may be required to reduce expenses through the delay, reduction or curtailment of our projects, or further reduction of costs for facilities and administration. Â We cannot provide assurances that changed or unexpected circumstances will not result in the depletion of our capital resources more rapidly than we currently anticipate. There can be no assurances that we will be able to raise additional capital in sufficient amounts or on favorable terms, or at all. If we are unable to raise adequate additional capital when required or in sufficient amounts or on terms acceptable to us, we may have to delay, scale back or discontinue one or more product development programs, curtail our commercialization activities, significantly reduce expenses, sell assets (potentially at a loss), enter into relationships with third parties to develop or commercialize products or technologies that we otherwise would have sought to develop or commercialize independently, cease operations altogether, pursue an acquisition of our company at a price that may result in up to a total loss on investment for our stockholders, file for bankruptcy or seek other protection from creditors, or liquidate all of our assets. If our information technology systems, or those of third parties with whom we work, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.* We, and third parties with whom we work, employ and are increasingly dependent upon information technology systems, infrastructure, applications, websites and other resources. Our business requires collecting, receiving, manipulating, analyzing, storing, processing, generating, using, disclosing, protecting, securing, transmitting, sharing, disposing of, and making accessible (collectively 54 Â â€œprocessâ€) large amounts of data, including proprietary, confidential and sensitive data (such as personal or health-related data), intellectual property, and trade secrets (collectively, â€œsensitive informationâ€). As a result, we and the third parties with whom we work face a variety of evolving threats that could cause security incidents. Cyber-attacks, malicious internet-based activity, online and offline fraud and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems, and those of the third parties with whom we work. Such threats are prevalent and continue to increase, are increasingly difficult to detect, and come from a variety of sources, including traditional computer â€œhackers,â€ threat actors â€œhacktivists,â€ organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation-states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors, for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties with whom we work may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services. We and the third parties with whom we work may be subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), credentials harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, attached enhanced or facilitated by AI, telecommunications failures, earthquakes, fires, floods, attacks enhanced or facilitated by artificial intelligence, and other similar threats. Ransomware attacks, including by organized criminal threat actors, nation-states, and nation-state-supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, loss of data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Some of our workforce works remotely, which also poses increased risks to our information technology systems and data, as employees working from home, in transit or in public locations, utilize network connections, computers and devices outside our premises or network. Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entitiesâ€™ systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program. We rely on third parties and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, and other functions. We also rely on third-party service providers to provide other products or services, or otherwise to operate our business. For example, we rely on an enterprise software system to operate and manage our business. Our business, including our ability to manufacture drug products and conduct clinical trials, therefore depends on the continuous, effective, reliable and secure operation of our information technology resources and those of third parties with whom we work, including computer hardware, software, networks, Internet servers and related infrastructure. Our ability to monitor these third partiesâ€™ information security practices is limited, and these third parties may not have adequate information security

measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. In particular, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partnersâ€™ supply chains have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems (including our products) or the third-party information technology systems that support us and our services. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate and remediate vulnerabilities in our information technology systems (such as our hardware and/or software, including that of third parties with whom we work), but we may not be able to detect, mitigate, and remediate all such vulnerabilities including on a timely basis. It may also be difficult and/or costly to detect, investigate, mitigate, contain, and remediate a security incident. Further, we may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities, which could be exploited and result in a security incident. Actions taken by us or the third parties with whom we work to detect, investigate, mitigate, contain, and remediate a security incident could result in outages, data losses, and disruptions of our business. Threat actors may also gain access to other networks and systems after a compromise of our networks and systems. We have in the past experienced security incidents. For example, like many companies, we use SolarWinds to help manage our information technology systems. A cyber-attack on SolarWinds was discovered in December 2020 and widely exploited by threat actors. Upon learning of this vulnerability, we applied the software patch provided by SolarWinds and remediated the incident. The incident did not appear to have any negative impact on our operations or the sensitive information we may process. In addition, a ransomware attack on Ultimate Kronos Groupâ€™s (â€œUKGâ€) Kronos Private Cloud service was discovered in December 2021. At the time, we used UKG Pro, a product offered through UKG that is not in the Kronos Private Cloud, for human capital management. UKG is not aware of an impact on UKG Pro and the incident did not appear to have any negative impact on our 55 Â operations or the sensitive information we may process. These incidents illustrate that despite our efforts to identify and remediate vulnerabilities, if any, in our information technology systems, our efforts may not be successful. Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information or our information technology systems, or those of the third parties with whom we work. A security incident or other interruption could disrupt our ability (and that of third parties with whom we work) to provide our products. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures, industry-standards or reasonable security measures to protect our information technology systems and sensitive information. Applicable data privacy and security obligations may require us, or we may voluntarily choose, to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents, or to take other actions, such as providing credit monitoring and identity theft protection services. Such disclosures and related actions can be costly, and the disclosures or the failure to comply with such applicable requirements could lead to adverse consequences. If we (or a third party with whom we work) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause customers to stop using our products, deter new customers from using our products, and negatively impact our ability to grow and operate our business. Additionally, our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our cybersecurity insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Sensitive information of the Company or our customers could also be leaked, disclosed, or revealed as a result of or in connection with our employeesâ€™, personnelâ€™s, or vendorsâ€™ use of generative artificial intelligence (â€œAIâ€) technologies. We expect that our results of operations will fluctuate for the foreseeable future, which may make it difficult to predict our future performance from period to period. Our operating results have fluctuated in the past and are likely to do so in future periods. Some of the factors that could cause our operating results to fluctuate from period to period include the factors that will affect our funding requirements described above under â€œRisk Factors â€” We may need to raise additional capital to fund our operations.â€ In addition, the current inflationary environment related to increased aggregate demand and supply chain constraints has the potential to adversely affect our operating expenses. We believe that comparisons from period to period of our financial results are not necessarily meaningful and should not be relied upon as indications of our future performance. We may incur losses and may not generate positive cash flow from operations in the future.* Our ability to achieve and sustain positive cash flow from operations and profitability depends heavily upon successfully commercializing our products, and although we had positive cash flows from operations during the nine months ended September 30, 2024 and the year ended December 31, 2023, we may not generate positive cash flow from operations or be profitable in the future. Our losses have had, and may in the future have, an adverse impact on our working capital, total assets and stockholdersâ€™ equity. As of September 30, 2024, we had an accumulated deficit of $3.2 billion. The accumulated deficit has resulted principally from costs incurred in our R&D programs, the write-off of assets (including goodwill, inventory and property, plant and equipment) and general operating expenses. We expect to make substantial expenditures and may incur operating losses in the future in order to continue commercializing our products and to advance development of product candidates in our pipeline. We may not be able to generate sufficient cash to service all of our indebtedness and commitments.* Our ability to make scheduled payments on our insulin purchase commitments and debt obligations will depend on our financial and operating performance, which is subject to the commercial success of our products and the commercial success of the product(s) of our collaboration partners, the extent to which we are able to successfully develop and commercialize additional products, the extent 56 Â to which we enter into additional collaboration or licensing arrangements, prevailing economic and competitive conditions, and certain financial, business and other factors beyond our control. We cannot assure you that we will maintain a level of cash flows from operating activities sufficient to permit us to pay the principal, premium, if any, and interest on our indebtedness. If we fail to pay interest on, or repay, our borrowings under the Senior convertible notes when required, we will be in default under the instrument for such debt securities, and may also suffer an event of default under the terms of other borrowing arrangements that we may enter into from time to time. If our cash flows and capital resources are insufficient to fund our obligations, we may be forced to reduce or delay capital expenditures, sell assets or operations, seek additional capital or restructure or refinance our lease obligations. We cannot assure you that we would be able to take any of these actions, that these actions would be successful and permit us to meet our scheduled obligations or that these actions would be permitted under the terms of our future debt agreements. In the absence of sufficient operating results and resources, we could face substantial liquidity problems and might be required to dispose of material assets or operations to meet our debt service and other obligations. We may not be able to consummate those dispositions or obtain sufficient proceeds from those dispositions to meet our debt service and other obligations when due. Any of these events could have a material adverse effect on our business, results of operations and financial condition, up to and including the noteholders initiating bankruptcy proceedings or causing us to cease operations altogether. In addition, we may from time to time seek to retire or purchase our outstanding debt, including the Senior convertible notes, through cash purchases and/or exchanges for equity securities, in open market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions, and other factors. The amounts involved in any such transactions, individually or in the aggregate, may be material. Further, any such purchases or exchanges may result in us acquiring and retiring a substantial amount of such indebtedness, which could impact the trading liquidity of such indebtedness. Our business, product sales, results of operations and ability to access capital could be adversely affected by the effects of health pandemics or epidemics, in regions where we or third parties distribute our products or where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations. Our business could be adversely affected by the effects of health pandemics or epidemics in regions where we have business operations, and we could experience significant disruptions in the operations of third-party manufacturers and distributors upon whom we rely. For example, sales and demand for Afrezza were adversely affected by the global COVID-19 pandemic, and future pandemics or epidemics could adversely affect the demand for and sales of our products in the future. Quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to infectious diseases, could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. In addition, our contract manufacturers in China could be impacted by that countryâ€™s recent policy of strict lockdowns in order to reduce the spread of disease. Disruptions in sales and demand for our products would be expected to occur: â€¢if patients are physically quarantined or are unable or unwilling to visit healthcare providers, â€¢if physicians restrict access to their facilities for a material period of time, â€¢if healthcare providers prioritize treatment of acute or communicable illnesses over chronic disease management, â€¢if pharmacies are closed or suffering supply chain disruptions, â€¢if patients lose access to employer-sponsored health insurance due to periods of high unemployment, or â€¢as a result of general disruptions in the operations of payers, distributors, logistics providers and other third parties that are necessary for our products to be prescribed and reimbursed. Clinical trials of our products were delayed as a result of the COVID-19 pandemic and may be affected by a future health pandemic or epidemic. Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the health pandemic or epidemic. Some patients may not be able or willing to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff would adversely impact our clinical trial operations. A pandemic or epidemic also has the potential for disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could negatively affect our liquidity. In addition, a recession or market correction as a result of a health pandemic or epidemic could materially affect our business and the value of our common stock. If we do not obtain regulatory approval of our products in foreign jurisdictions, we will not be able to market in such jurisdictions, which could limit our commercial revenues. We may not be able to establish additional regional partnerships or other arrangements with third parties for the commercialization of our products outside of the United States. 57 Â Although Afrezza has been approved in the United States by the FDA and in Brazil by ANVISA, we have not yet obtained approval in any other jurisdiction. Similarly, V-Go has received 510(k) clearance from the FDA, but has not received a comparable approval in any other country. In order to market our products in a foreign jurisdiction, we must obtain regulatory approval in each such foreign jurisdiction, and we may never be able to obtain such approvals. The research, testing, manufacturing, labeling, sale, import, export, marketing, and distribution of therapeutic products outside the United States are subject to extensive regulation by foreign regulatory authorities, whose regulations differ from country to country. We will be required to comply with the different regulations and policies of the jurisdictions where we seek approval for our products, and we have not yet identified all of the requirements that we will need to satisfy to submit our products for approval for other jurisdictions. This will require additional time, expertise and expense, including the potential need to conduct additional studies or development work for other jurisdictions beyond the work that we have conducted to support the approval of our products in the United States. Our current strategy for the future commercialization of our products outside of the United States, subject to receipt of the necessary regulatory approvals, is to seek, establish and maintain regional partnerships in foreign jurisdictions where there are commercial opportunities. It may be difficult to find or maintain collaboration partners that are able and willing to devote the time and resources necessary to successfully commercialize our products. Collaborations with third parties may require us to relinquish material rights, including revenue from commercialization, agree to unfavorable terms or assume material ongoing development obligations that we would have to fund. These collaboration arrangements are complex and time-consuming to negotiate, and if we are unable to reach agreements with third-party collaborators, we may fail to meet our business objectives and our financial condition may be adversely affected. We may also face significant competition in seeking collaboration partners, and may not be able to find a suitable collaboration partner in a timely manner on acceptable terms, or at all. Any of these factors could cause delay or prevent the successful commercialization of our products in foreign jurisdictions and could have a material and adverse impact on our business, financial condition and results of operations and the market price of our common stock and other securities could decline. Continued testing of our products and product candidates may not yield successful results, and even if it does, we may still be unable to successfully commercialize our current or future products. We have generally sought to develop product candidates through our internal research programs. All such product candidates will require additional research and development and, in some cases, significant preclinical, clinical and other testing prior to seeking regulatory approval to market them. Accordingly, these product candidates will not be commercially available for a number of years, if at all. Further research and development on these programs will require significant financial resources. Given our limited financial resources, we may not be able to advance these programs into clinical development unless we are able to obtain specific funding for these programs or enter into collaborations with third parties. Our research and development programs are designed to test the safety and efficacy of our product candidates through extensive nonclinical and clinical testing. We may experience numerous unforeseen events during, or as a result of, the testing process that could delay or impact commercialization of any of our product candidates, including the following: â€¢safety and efficacy results obtained in our nonclinical and early clinical testing may be inconclusive or may not be predictive of results that we may obtain in our future clinical studies or following long-term use, and we may as a result be forced to stop developing a product candidate or alter the marketing of an approved product; â€¢the analysis of data collected from clinical studies of our product candidates may not reach the statistical significance necessary, or otherwise be sufficient to support FDA or other regulatory approval for the claimed indications; â€¢after reviewing clinical data, we or any collaborators may abandon projects that we previously believed were promising; â€¢our product candidates may not produce the desired effects or may result in adverse health effects or other characteristics that preclude regulatory approval or limit their commercial use once approved; and â€¢disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions. As a result of any of these events, we, any collaborator, the FDA, or any other regulatory authorities may suspend or terminate clinical studies or marketing of any of our products or product candidates at any time. Any suspension or termination of our clinical studies or marketing activities may harm our business, financial condition and results of operations and the market price of our common stock and other securities may decline. If we do not achieve our projected development goals in the timeframes we expect, our business, financial condition and results of operations will be harmed and the market price of our common stock and other securities could decline.* For planning purposes, we estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical studies and the submission of regulatory filings. From time to time, we publicly announce the expected timing of some of these milestones. All of these milestones are based on a variety of assumptions. The actual timing of the 58 Â achievement of these milestones can vary dramatically from our estimates, in many cases for reasons beyond our control, depending on numerous factors, including: â€¢the rate of progress, costs and results of our clinical studies and preclinical research and development activities; â€¢our ability to identify and enroll patients who meet clinical study eligibility criteria; â€¢our ability to access sufficient, reliable and affordable supplies of components used in the manufacture of our product candidates or to source clinical supplies from contract manufacturers; â€¢the costs of expanding and maintaining manufacturing operations, as necessary; â€¢the extent to which our clinical studies compete for clinical sites and eligible subjects with clinical studies sponsored by other companies; â€¢actions by regulators; and â€¢disruptions caused by geopolitical conflicts, man-made or natural disasters or public health pandemics or epidemics or other business interruptions. If we fail to commence or complete, or experience delays in or are forced to curtail, our proposed development programs or otherwise fail to adhere to our projected development goals in the timeframes we expect (or within the timeframes expected by analysts or investors), our business, financial condition and results of operations may be harmed and the market price of our common stock and other securities may decline. In addition, we may be delayed or prevented from generating revenues from milestone or other payments that depend on our ability to achieve any milestone obligations specified in an

out-licensing arrangement. The long-term safety and efficacy of approved products may differ from clinical studies, which could negatively impact sales and could lead to reputational harm or other negative effects. The effects of approved therapeutic products over terms longer than the clinical studies or in much larger populations may not be consistent with earlier clinical results. If long-term use of an approved therapeutic product results in adverse health effects or reduced efficacy or both, the FDA or other regulatory agencies may terminate our or any marketing or collaboration partnerâ€™s ability to market and sell the product, may narrow the approved indications for use or otherwise require restrictive product labeling or marketing, or may require further clinical studies, which may be time-consuming and expensive and may not produce favorable results. Â V-Go received pre-market clearance in 2010 under Section 510(k) of the U.S. Federal Food, Drug, and Cosmetic Act (â€œFDCAâ€). This process typically requires the submission of less supporting documentation than other FDA approval processes and does not always require long-term clinical studies. As a result, we currently lack significant published long-term clinical data supporting the safety and efficacy of V-Go and the benefits it offers that might have been generated in connection with other approval processes. For these reasons, adults who require insulin and their healthcare providers may be slower to adopt or recommend V-Go, we may not have comparative data that our competitors have or are generating, and third-party payers may not be willing to provide coverage or reimbursement for V-Go. Further, future studies or clinical experience may indicate that treatment with V-Go is not superior to treatment with competitive products. Such results could slow the adoption of V-Go and significantly reduce our sales, which could prevent us from achieving our forecasted sales targets or achieving or sustaining profitability. Moreover, if future results and experience indicate that V-Go causes unexpected or serious complications or other unforeseen negative effects, we could be subject to mandatory product recalls, suspension or withdrawal of FDA clearance or approval, significant legal liability or harm to our business reputation. We may not realize the anticipated benefits of any future acquisition or strategic transaction; we may be unable to successfully integrate new products or businesses we may acquire. We periodically evaluate and pursue acquisition of therapeutic products. The integration of any acquired business, product or other assets into our company may be complex and time-consuming and, if such businesses, products or assets are not successfully integrated, we may not achieve the anticipated benefits, cost-savings or growth opportunities. Potential difficulties that may be encountered in the integration process include the following: â€¢unanticipated liabilities related to acquired assets, companies or joint ventures; â€¢integrating personnel, operations and systems, while maintaining focus on producing and delivering consistent, high quality products; â€¢coordinating geographically dispersed organizations; â€¢diversion of management time and focus from operating our business to management of strategic alliances or joint ventures or acquisition integration challenges; 59 Â â€¢retention of key employees; â€¢increases in our expenses and reductions in our cash available for operations and other uses; â€¢retaining existing customers and attracting new customers; â€¢managing inefficiencies associated with integrating the operations of our company; and â€¢possible write-offs or impairment charges relating to acquired assets, businesses or joint ventures. Furthermore, these acquisitions and other arrangements, even if successfully integrated, may fail to further our business strategy as anticipated, expose us to increased competition or challenges with respect to our products or geographic markets, and expose us to additional liabilities associated with an acquired business, product, technology or other asset or arrangement. Any one of these challenges or risks could impair our ability to realize any benefit from our acquisitions or arrangements after we have expended resources on them. Future acquisitions or dispositions could also result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. Our products and product candidates may be rendered obsolete by rapid technological change. The rapid rate of scientific discoveries and technological changes could result in our approved products or one or more of our product candidates becoming obsolete or noncompetitive. Our competitors may develop or introduce new products that render our technology or products less competitive, uneconomical or obsolete. Our future success may depend not only on our ability to develop our product candidates, but also our ability to improve them in order to keep pace with emerging industry developments. We cannot assure you that we will be able to do so. We also expect to face competition from universities and other non-profit research organizations. These institutions carry out a significant amount of research and development in various areas of unmet medical need. These institutions are becoming increasingly aware of the commercial value of their findings and are more active in seeking patent and other proprietary rights as well as licensing revenues. Reports of side effects or safety concerns in related technology fields or in other companiesâ€™ clinical studies could delay or prevent us from obtaining regulatory approval for our product candidates or negatively impact public perception of our approved products. There are a number of clinical studies being conducted by other pharmaceutical companies involving compounds similar to, or potentially competitive with, our product candidates. Adverse results reported by these other companies in their clinical studies or by companies that use our proprietary formulation and inhaler technologies could delay or prevent us from obtaining regulatory approval, may subject our products to class warnings in their labels or negatively impact public perception of our product candidates, which could harm our business, financial condition and results of operations and cause the market price of our common stock and other securities to decline. If product liability claims are brought against us, we may incur significant liabilities and suffer damage to our reputation. The testing, manufacturing, marketing and sales of our products and any clinical testing of our product candidates expose us to potential product liability claims. A product liability claim may result in substantial judgments as well as consume significant financial and management resources and result in adverse publicity, decreased demand for a product, injury to our reputation, withdrawal of clinical studies volunteers and loss of revenues. We currently carry worldwide product liability insurance in the amount of $10.0 million as well as an errors and omissions policy in the amount of $1.0 million. Our insurance coverage may not be adequate to satisfy any liability that may arise, and because insurance coverage in our industry can be very expensive and difficult to obtain, we cannot assure you that we will seek to obtain, or be able to obtain if desired, sufficient additional coverage. If losses from such claims exceed our liability insurance coverage, we may incur substantial liabilities that we may not have the resources to pay. If we are required to pay a product liability claim our business, financial condition and results of operations would be harmed and the market price of our common stock and other securities may decline. If we lose any key employees or scientific advisors, our operations and our ability to execute our business strategy could be materially harmed. We face intense competition for qualified employees among companies in the biotechnology and biopharmaceutical industries. Our success depends upon our ability to attract, retain and motivate highly skilled employees. We may be unable to attract and retain these individuals on acceptable terms, if at all. In addition, we may be required to expand our workforce. These activities will require the addition of new personnel, including management, and the development of additional expertise by existing personnel, and we cannot assure you that we will be able to attract or retain any such new personnel on acceptable terms, if at all. 60 Â The loss of the services of any principal member of our management, commercial and scientific staff could significantly delay or prevent the achievement of our scientific and business objectives. All of our employees are â€œat willâ€ and we currently do not have employment agreements with any of the principal members of our management, commercial or scientific staff, and we do not have key person life insurance to cover the loss of any of these individuals. Replacing key employees may be difficult and time-consuming because of the limited number of individuals in our industry with the skills and experience required to develop, gain regulatory approval of and commercialize products successfully. We have relationships with scientific advisors at academic and other institutions to conduct research or assist us in formulating our research, development or clinical strategy. These scientific advisors are not our employees and may have commitments to, and other obligations with, other entities that may limit their availability to us. We have limited control over the activities of these scientific advisors and can generally expect these individuals to devote only limited time to our activities. Failure of any of these persons to devote sufficient time and resources to our programs could harm our business. In addition, these advisors are not prohibited from, and may have arrangements with, other companies to assist those companies in developing technologies that may compete with our products. If our internal controls over financial reporting are not considered effective, our business, financial condition and market price of our common stock and other securities could be adversely affected. Section 404 of the Sarbanes-Oxley Act of 2002 requires us to evaluate the effectiveness of our internal controls over financial reporting as of the end of each fiscal year, and to include a management report assessing the effectiveness of our internal controls over financial reporting in our annual report on Form 10-K for that fiscal year. Our management, including our Chief Executive Officer and our Chief Financial Officer, does not expect that our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control systemâ€™s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud involving a company have been, or will be, detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and we cannot assure you that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. A material weakness in our internal controls has been identified in the past, and we cannot assure you that we or our independent registered public accounting firm will not identify a material weakness in our internal controls in the future. A material weakness in our internal controls over financial reporting would require management and our independent registered public accounting firm to evaluate our internal controls as ineffective. If our internal controls over financial reporting are not considered effective, we may experience a loss of public confidence, which could have an adverse effect on our business, financial condition and the market price of our common stock and other securities. Changes or modifications in financial accounting standards may harm our results of operations. From time to time, the Financial Accounting Standards Board (â€œFASBâ€), either alone or jointly with other organizations, promulgates new accounting principles that could have an adverse impact on our financial position, results of operations and presentation or classification of cash flows. New pronouncements and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future and as a result we may be required to make changes in our accounting policies. Any difficulties in adopting or implementing new accounting standards, and updating or modifying our internal controls as needed on a timely basis, could result in our failure to meet our financial reporting obligations, which could result in regulatory discipline and harm investorsâ€™ confidence in us. Finally, if we were to change our critical accounting estimates, including those related to the recognition of collaboration revenue and other revenue sources, our operating results could be significantly affected. Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations. New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Cuts and Jobs Act of 2017 (the "Tax Act"), the Coronavirus Aid, Relief, and Economic Security Act and the IRA enacted many significant changes to the U.S. tax laws. Further guidance from the Internal Revenue Service and other tax authorities with respect to such legislation may affect us, and certain aspects of such legislation could be repealed or modified in future legislation. In addition, it is uncertain if and to what extent various states will conform to federal tax laws. Future tax reform legislation could have a material impact on the value of our deferred tax assets and could increase our future U.S. tax expense. 61 Â Effective January 1, 2022, the Tax Act eliminated the option to deduct research and development expenses for tax purposes in the year incurred and requires taxpayers to capitalize and subsequently amortize such expenses over five years for research activities conducted in the United States and over 15 years for research activities conducted outside the United States. Unless the United States Department of the Treasury issues regulations that narrow the application of this provision to a smaller subset of our research and development expenses or the provision is deferred, modified, or repealed by Congress, it could harm our future operating results by effectively increasing our future tax obligations. The actual impact of this provision will depend on multiple factors, including the amount of research and development expenses we will incur, whether we achieve sufficient income to fully utilize such deductions and whether we conduct our research and development activities inside or outside the United States. Our ability to use net operating loss carryforwards to offset future taxable income may be subject to limitations.* As of December 31, 2023, the Company had federal and state net operating loss carryforwards of approximately $2.0 billion and $1.3 billion available, respectively, to reduce future taxable income. $494.0 million of the federal net operating loss carryforwards do not expire and the remaining federal net operating loss carryforwards have started expiring, beginning in the current year through various future dates. Pursuant to Internal Revenue Code Sections 382 and 383, annual use of the Companyâ€™s federal and California net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. As a result of the Company's initial public offering, an ownership change within the meaning of Section 382 occurred in August 2004. As a result, federal net operating loss and credit carryforwards of approximately $105.8 million are subject to an annual use limitation of approximately $13.0 million. The annual limitation is cumulative and therefore, if not fully utilized in a year can be utilized in future years in addition to the Section 382 limitation for those years. We have completed a Section 382 analysis beginning from the date of our initial public offering through December 31, 2023, to determine whether additional limitations apply to the net operating loss carryforwards and other tax attributes, and no additional changes in ownership that met Section 382 study ownership change threshold have been identified through December 31, 2023. There is a risk that changes in ownership may occur in tax years after December 31, 2023. If a change in ownership were to occur, our net operating loss carryforwards and other tax attributes could be further limited or restricted. If limited, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, related to the Companyâ€™s operations in the U.S. will not impact the Companyâ€™s effective tax rate. In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California imposed limits on the usability of California state net operating losses to offset taxable income in tax years 2024 through 2026. As a result, if we earn net taxable income, we may be unable to use all or a material portion of our net operating loss carryforwards and other tax attributes, which could potentially result in increased future tax liability to us and adversely affect our future cash flows. Tax authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or non-realization of expected benefits. A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, the U.S. Internal Revenue Service or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable nexus, often referred to as a â€œpermanent establishmentâ€ under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. A tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, in which case, we expect that we might contest such assessment. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable. We may undertake internal restructuring activities in the future that could result in disruptions to our business or otherwise materially harm our results of operations or financial condition. From time to time, we may undertake internal restructuring activities as we continue to evaluate and attempt to optimize our cost and operating structure in light of developments in our business strategy and long-term operating plans. These activities may result in write-offs or other restructuring charges. There can be no assurance that any restructuring activities that we undertake will achieve the cost savings, operating efficiencies or other benefits that we may initially expect. Restructuring activities may also result in a loss of continuity, accumulated knowledge and inefficiency during transitional periods and thereafter. In addition, internal restructurings can require a significant amount of time and focus from management and other employees, which may divert attention from commercial operations. If we undertake any internal restructuring activities and fail to achieve some or all of the expected benefits therefrom, our business, results of operations and financial condition could be materially and adversely affected. 62 Â Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event. At least for the foreseeable future, we expect that our manufacturing facility in Connecticut will be the sole location for the manufacturing of Afrezza and Tyvaso DPI. Similarly, our contract manufacturer in Southern China is the only location for the assembly of V-Go. Additional contract manufacturers in China perform release testing, sterilization, inspection and packaging functions. These facilities and the specialized manufacturing equipment we use at them would be costly to replace and could require substantial lead-time to repair or replace. We depend on our facilities and on collaborators, contractors and vendors for the continued operation of our business. Natural disasters, such as interruptions in the supply of natural resources, public health pandemics or epidemics, earthquakes and extreme weather conditions, including, but not limited to, hurricanes, floods, tornados, wildfires, and winter storms, or other catastrophic events, including political and governmental changes, conflicts (including the current Russia-Ukraine war, the state of war between Israel and Hamas and attacks on commercial marine vessels in the Red Sea by Houthi

rebels), explosions, actions of animal rights activists, terrorist attacks and wars, could disrupt our operations or those of our collaborators, contractors and vendors. Such conditions may be further exacerbated by the effects of climate change. We might suffer losses as a result of business interruptions that exceed the coverage available under our and our contractorsâ€™ insurance policies or for which we or our contractors do not have coverage. For example, we are not insured against a terrorist attack. Any natural disaster or catastrophic event could have a significant negative impact on our operations and financial results. Moreover, any such event could delay our research and development programs or cause interruptions in our commercialization of our products. We deal with hazardous materials and must comply with environmental laws and regulations, which can be expensive and restrict how we do business. Our research and development work involves the controlled storage and use of hazardous materials, including chemical and biological materials. Our operations also produce hazardous waste products. We are subject to federal, state and local laws and regulations (i) governing how we use, manufacture, store, handle and dispose of these materials (ii) imposing liability for costs of cleaning up, and damages to natural resources from past spills, waste disposals on and off-site, or other releases of hazardous materials or regulated substances, and (iii) regulating workplace safety. Moreover, the risk of accidental contamination or injury from hazardous materials cannot be completely eliminated, and in the event of an accident, we could be held liable for any damages that may result, and any liability could fall outside the coverage or exceed the limits of our insurance. Currently, our general liability policy provides coverage up to $1.0 million per occurrence and $2.0 million in the aggregate and is supplemented by an umbrella policy that provides a further $20.0 million of coverage; however, our insurance policy excludes pollution liability coverage and we do not carry a separate hazardous materials policy. In addition, we could be required to incur significant costs to comply with environmental laws and regulations in the future. Finally, current or future environmental laws and regulations may impair our research, development or production efforts or have an adverse impact on our business, results of operations and financial condition. When we purchased our facility in Connecticut in 2001, a soil and groundwater investigation and remediation was being conducted by a former site operator (a â€œresponsible partyâ€) under the oversight of the Connecticut Department of Energy & Environmental Protection (formerly the Connecticut Department of Environmental Protection), which investigation and remediation is ongoing. The former site operator and responsible party will make further filings necessary to achieve closure for the environmental investigation and remediation it has conducted at the site, and has agreed to indemnify us for any future costs and expenses we may incur that are directly related to its prior operations at the facility. If we are unable to collect these future costs and expenses, if any, from the responsible party, our business, financial condition and results of operations may be harmed. When we sold a portion of the property upon which our facility is located to the entity that is now our landlord, we became an additional responsible party for any environmental investigation and remediation on that portion of the property, including with respect to investigation or remediation that may be required as a result of our activities since 2001. To date, we have not identified any material environmental investigation or remediation activities that we are required to perform. Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.* The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last decade, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future 63 Â government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations.* Adverse developments that affect financial institutions, such as events involving liquidity that are rumored or actual, have in the past and may in the future lead to bank failures and market-wide liquidity problems. For example, in March 2023, Silicon Valley Bank (â€œSVBâ€) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (â€œFDICâ€) as receiver. Similarly, days later, Signature Bank and Silvergate Capital Corp. were each swept into receivership. In addition, in May 2023, the FDIC seized First Republic Bank and sold its assets to JPMorgan Chase & Co. While the U.S. Department of Treasury, FDIC and Federal Reserve Board have implemented a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediate liquidity may exceed the capacity of such program, there is no guarantee that such programs will be sufficient. Additionally, it is uncertain whether the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion. Although we assess our banking relationships as we believe necessary or appropriate, our access to cash in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect the financial institutions with which we have banking relationships. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could also include factors involving financial markets or the financial services industry generally. The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets; or termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements. In addition, widespread investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations. We maintain our cash at financial institutions, often in balances that exceed federally insured limits. We maintain the majority of our cash and cash equivalents in accounts at banking institutions in the United States that we believe are of high quality. Cash held in these accounts often exceed the FDIC insurance limits. If such banking institutions were to fail, we could lose all or a portion of amounts held in excess of such insurance limitations. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position. RISKS RELATED TO GOVERNMENT REGULATION Our product candidates must undergo costly and time-consuming rigorous nonclinical and clinical testing and we must obtain regulatory approval prior to the sale and marketing of any product in each jurisdiction. The results of this testing or issues that develop in the review and approval by a regulatory agency may subject us to unanticipated delays or prevent us from marketing any products. Our research and development activities for product candidates, as well as the manufacturing and marketing of approved products, are subject to regulation, including regulation for safety, efficacy and quality, by the FDA in the United States and comparable authorities in other countries. FDA regulations and the regulations of comparable foreign regulatory authorities are wide-ranging and govern, among other things: â€¢product design, development, manufacture and testing; 64 Â â€¢product labeling; â€¢product storage and shipping; â€¢pre-market clearance or approval; â€¢advertising and promotion; and â€¢product sales and distribution. The requirements governing the conduct of clinical studies as well as the manufacturing and marketing of drug products outside the United States vary widely from country to country. Foreign approvals may take longer to obtain than FDA approvals and can require, among other things, additional testing and different clinical study designs. Foreign regulatory approval processes include essentially all of the risks associated with the FDA approval processes. Some of those agencies also must approve prices of the products. Approval of a product by the FDA does not ensure approval of the same product by the health authorities of other countries. In addition, changes in regulatory policy in the United States or in foreign countries for product approval during the period of product development and regulatory agency review of each submitted new application may cause delays or rejections. Clinical testing can be costly and take many years, and the outcome is uncertain and susceptible to varying interpretations. We cannot be certain if or when regulatory agencies might request additional studies, under what conditions such studies might be requested, or what the size or length of any such studies might be. The clinical studies of our product candidates may not be completed on schedule, regulatory agencies may order us to stop or modify our research, or these agencies may not ultimately approve any of our product candidates for commercial sale. The data collected from our clinical studies may not be sufficient to support regulatory approval of our product candidates. Even if we believe the data collected from our clinical studies are sufficient, regulatory agencies have substantial discretion in the approval process and may disagree with our interpretation of the data. Our failure to adequately demonstrate the safety and efficacy of any of our product candidates would delay or prevent regulatory approval of our product candidates, which could prevent us from achieving profitability. Questions that have been raised about the safety of marketed drugs generally, including pertaining to the lack of adequate labeling, may result in increased cautiousness by regulatory agencies in reviewing new drugs based on safety, efficacy, or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Such regulatory considerations may also result in the imposition of more restrictive drug labeling or marketing requirements as conditions of approval, which may significantly affect the marketability of our drug products. If we do not comply with regulatory requirements at any stage, whether before or after marketing approval is obtained, we may be fined or forced to remove a product from the market, subject to criminal prosecution, or experience other adverse consequences, including restrictions or delays in obtaining regulatory marketing approval. Even if we comply with regulatory requirements, we may not be able to obtain the labeling claims necessary or desirable for product promotion. We may also be required to undertake post-marketing studies. In addition, if we or other parties identify adverse effects after any of our products are on the market, or if manufacturing problems occur, regulatory approval may be withdrawn and a reformulation of our products, additional clinical studies, changes in labeling of, or indications of use for, our products and/or additional marketing applications may be required. If we encounter any of the foregoing problems, our business, financial condition and results of operations will be harmed and the market price of our common stock and other securities may decline. We are subject to stringent, ongoing government regulation.* The FDA and comparable foreign regulatory authorities subject any approved therapeutic product to extensive and ongoing regulatory requirements concerning the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and good clinical practice guidelines for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: â€¢restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls; â€¢revisions to the approved labeling to add new safety information; â€¢fines, warning letters or holds on clinical trials; 65 Â â€¢refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals; â€¢product seizure or detention, or refusal to permit the import or export of our product candidates; and â€¢injunctions or the imposition of civil or criminal penalties. We also are required to register our establishments and list our products with the FDA and certain state agencies. We and any third-party manufacturers or suppliers must continually adhere to federal regulations setting forth cGMP (for drugs) and QSR (for medical devices), and their foreign equivalents, which are enforced by the FDA and other national regulatory bodies through their facilities inspection programs. In complying with cGMP and foreign regulatory requirements, we and any of our third-party manufacturers or suppliers will be obligated to expend time, money and effort in production, record-keeping and quality control to ensure that our products meet applicable specifications and other requirements. QSR requirements also impose extensive testing, control and documentation requirements. State regulatory agencies and the regulatory agencies of other countries have similar requirements. In addition, we will be required to comply with regulatory requirements of the FDA, state regulatory agencies and the regulatory agencies of other countries concerning the reporting of adverse events and device malfunctions, corrections and removals (e.g., recalls), promotion and advertising and general prohibitions against the manufacture and distribution of adulterated and misbranded devices. Failure to comply with these regulatory requirements could result in significant civil fines, product seizures, injunctions and/or criminal prosecution of responsible individuals and us. Any such actions would have a material adverse effect on our business, financial condition and results of operations. As part of the approval of Afrezza, the FDA required us to conduct certain additional clinical studies of Afrezza. One of these studies, a Phase 3 clinical trial to evaluate the safety and efficacy of Afrezza in 4-17 year-old children and adolescents, is nearing completion. The other required study is a long-term safety study that was originally intended to compare the incidence of pulmonary malignancy observed with Afrezza to that observed in a standard of care control group. We have an ongoing dialogue with the FDA regarding the agencyâ€™s current interest in the long-term safety of Afrezza and an appropriate study design or registry to address any concerns. To date, we have not commenced a long-term safety study or budgeted any amount for it, but such a study in its original design would be anticipated to require substantial capital resources that we may not be able to obtain. The FDA and other regulatory authorities impose significant restrictions on approved products through regulations on advertising, promotional and distribution activities. This oversight encompasses, but is not limited to, direct-to-consumer advertising, healthcare provider-directed advertising and promotion, sales representative communications to healthcare professionals, promotional programming and promotional activities involving the Internet. Regulatory authorities may also review industry-sponsored scientific and educational activities that make representations regarding product safety or efficacy in a promotional context. Prescription drugs may be promoted only for the approved indications in accordance with the approved label. The FDA and other regulatory authorities may take enforcement action against a company for promoting unapproved uses of a product or for other violations of its advertising and labeling laws and regulations. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments, but the FDA does restrict manufacturerâ€™s communications on the subject of off-label use of their products. Enforcement action may include product seizures, injunctions, significant civil or criminal penalties or regulatory letters, which may require corrective advertising or other corrective communications to healthcare professionals. Failure to comply with such regulations also can result in adverse publicity or increased scrutiny of company activities by the U.S. Congress or other legislators. Certain states have also adopted regulations and reporting requirements surrounding the promotion of pharmaceuticals. Failure to comply with state requirements may affect our ability to promote or sell our products in certain states. The FDAâ€™s and other regulatory authoritiesâ€™ policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates, delay the submission or review of an application or require additional expenditures by us. In addition, interested parties (such as individuals, advocacy groups and competing pharmaceutical companies) can file a citizen petition with the FDA to request policy change or some form of administrative action on the FDAâ€™s part, including with respect to a New Drug Application (â€œNDAâ€). For example, in July 2021, a third party submitted a citizen petition to the FDA requesting that the FDA refuse to approve Tyvaso DPI, and/or impose additional requirements in order to approve the product. This prompted the FDA to request additional information concerning Tyvaso DPI prior to granting approval in May 2022. If successful, a citizen petition can significantly delay, or even prevent, the approval of a drug product. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. We also cannot be sure that actions by foreign regulatory bodies pertaining to the safety of drugs or medical devices will not adversely affect our operations. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be denied marketing approval or lose any marketing approval

that we have already obtained. There can be no assurance that we will be able to obtain necessary regulatory clearances or approvals on a timely basis, if at all, for any of our product candidates under development, and delays in receipt or failure to receive such clearances or approvals, the loss of previously received clearances or 66 Â approvals, or failure to comply with existing or future regulatory requirements could have a material adverse effect on our business and results of operations. Healthcare legislation may make it more difficult to receive revenues.* In both the United States and certain foreign jurisdictions, there has been a number of legislative and regulatory proposals in recent years to change the healthcare system in ways that could impact our ability to sell our products profitably. The most recent significant healthcare legislation was the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the â€œPPACAâ€) enacted in March 2010, which substantially changed the way healthcare is financed by both governmental and private insurers and continues to significantly affect the healthcare industry. There have been executive, judicial and congressional challenges to certain provisions of the PPACA, although the constitutionality of the PPACA appears to now be settled. In addition, there have been proposed and enacted health reform initiatives affecting the PPACA. For example, on August 16, 2022, President Biden signed the IRA into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in PPACA marketplaces through plan year 2025, eliminates the â€œdonut holeâ€ under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program, and capped the out-of-pocket cost of insulin (including Afrezza) at $35 per month for Medicare recipients beginning in 2023. It is possible that the PPACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges, other litigation, and the healthcare reform measures of the current administration will impact the PPACA. Recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. Specifically, there have been several recent U.S. Presidential executive orders, Congressional inquiries and proposed and enacted legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. These new laws and initiatives may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and accordingly, our financial operations. Our future revenues and ability to generate positive cash flow from operations may be affected by the continuing efforts of government and other third-party payers to contain or reduce the costs of healthcare through various means. In the United States, there have been several congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, in July 2021, the Biden administration released an executive order, â€œPromoting Competition in the American Economy,â€ with multiple provisions aimed at prescription drugs. In response to Bidenâ€™s executive order, on September 9, 2021, the U.S. Department of Health and Human Services (â€œHHSâ€) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions began to take effect progressively starting in fiscal year 2023. On August 15, 2025, HHS announced the agreed-upon reimbursement price of the first ten drugs that were subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. HHS will select up to fifteen additional drugs covered under Part D for negotiation in 2025. Further, in response to the Biden administration's October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Centers for Medicare & Medicaid Services ("CMS") Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. On December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Floridaâ€™s Section 804 Importation Program (â€œSIPâ€) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs. We expect that there will continue to be a number of federal and state proposals to implement similar and/or additional governmental controls. We cannot be certain what legislative proposals will be adopted or what actions federal, state or private third-party payers may take in response to any drug pricing and reimbursement reform proposals or legislation. Further, to the extent that such reforms 67 Â have a material adverse effect on our ability to commercialize our products and product candidates under development, our business, financial condition and profitability may be adversely affected. We expect that the IRA, as well as other healthcare reform measures that may be adopted in the future, are likely to have a significant effect on the pharmaceutical industry, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private third-party payers. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. If we or any future partner fails to comply with federal and state healthcare laws, including fraud and abuse and health information laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected. As a biopharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payers, certain federal and state healthcare laws and regulations, including those pertaining to fraud and abuse and patientsâ€™ rights, are and will be applicable to our business. The number and scope of these laws, regulations and industry standards are changing, subject to differing applications and interpretations, and may be inconsistent between jurisdictions or in conflict with each other, making compliance difficult. The key laws that may affect our ability to operate include, among others: â€¢The federal Anti-Kickback Statute (as amended by PPACA, which modified the intent requirement of the federal Anti-Kickback Statute so that a person or entity no longer needs to have actual knowledge of the Statute or specific intent to violate it to have committed a violation), which constrains our business activities, including our marketing practices, educational programs, pricing policies, and relationships with healthcare providers or other entities by prohibiting, among other things, knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual or the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; â€¢Federal civil and criminal false claims laws, including without limitation the False Claims Act, and civil monetary penalties laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other federal healthcare programs that are false or fraudulent, and knowingly making, or causing to be made, a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government, and under PPACA, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal false claims laws; â€¢The federal Physician Payments Sunshine Act under PPACA, which requires certain manufacturers of drugs, devices, biologics, and medical supplies to report annually to CMS information related to payments and other transfers of value to physicians (defined to include defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members. â€¢The federal Health Insurance Portability and Accountability Act of 1996 (â€œHIPAAâ€), which created new federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program or falsifying, concealing, or covering up a material fact in connection with the delivery of or payment for health care benefits. â€¢HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (â€œHITECHâ€), and their respective implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on entities subject to the law, such as certain healthcare providers, health plans, and healthcare clearinghouses and their respective business associates that perform services for them that involve the creation, use, maintenance or disclosure of, individually identifiable health information as well as their covered subcontractors. â€¢Other state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state and foreign laws governing the privacy and security and other processing of personal data (including health information) in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; state laws that require pharmaceutical companies to comply with the industryâ€™s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government that otherwise restricts certain payments that may be made to healthcare providers and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state laws that require drug manufacturers to report 68 Â information related to payments and other transfer of value to physicians and other healthcare providers and entities, marketing expenditures or drug pricing. Because of the breadth of these laws and the narrowness of available statutory exceptions and regulatory safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. With Afrezza approved in Brazil and as our partners pursue additional international approvals, we will be subject to similar foreign laws and regulations. If we or our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, or any contractual obligations related to the same, we may be subject to governmental enforcement actions, investigations, litigation (including class action lawsuits) and other penalties, including significant civil, criminal and administrative penalties, damages, fines, imprisonment, disgorgement, defense costs, exclusion from U.S. federal or state healthcare programs, additional reporting requirements and/or oversight (including if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws), bans or restrictions on our processing of personal data, indemnity obligations and the curtailment or restructuring of our operations. Any such event or consequence, including penalties, damages, fines, and curtailment or restructuring of our operations, could materially adversely affect our ability to operate our business, including our ability to run clinical trials, and our financial results and harm our reputation. Although compliance programs can help mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our managementâ€™s attention from the operation of our business. Moreover, achieving and sustaining compliance with applicable federal and state fraud laws may prove costly. We are subject to stringent and changing U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.* In the ordinary course of business, we process sensitive information (as those terms are defined above). Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security. In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. In the past few years, numerous U.S. statesâ€”including California, Virginia, Colorado, Connecticut, and Utahâ€”have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018 (â€œCCPAâ€) applies to personal data of consumers, business representatives, and employees who are California residents, and requires businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA provides for fines (up to $7,500 per intentional violation) and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA (like other U.S. comprehensive privacy laws) exempts some data processed in the context of clinical trials, the CCPA may increase compliance costs and potential liability with respect to other personal data we maintain about California residents. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. These developments may further complicate compliance efforts and increase legal risk and compliance costs for us and the third parties with whom we work. Outside the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the European Union's General Data Protection Regulation (â€œEU GDPRâ€), the United Kingdomâ€™s GDPR (â€œUK GDPRâ€) (EU GDPR and UK GDPR, collectively â€œGDPRâ€), Brazilâ€™s General Data Protection Law (Lei Geral de ProteÃ§Ã£o de Dados Pessoais, or â€œLGPDâ€) (Law No. 13,709/2018), and Australiaâ€™s Privacy Act impose strict requirements for processing personal data. For example, under the GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to the processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. We may also be subject to new and emerging data privacy regimes in Asia, including Japanâ€™s Act on the Protection of Personal Information. 69 Â Our employees and personnel use generative AI technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating generative AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages. In the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the United States or other countries. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (â€œEEAâ€) and the United Kingdom (â€œUKâ€) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA standard contractual clauses, the UKâ€™s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework)these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Some European regulators have prevented companies from transferring personal data out

of Europe for allegedly violating the GDPRâ€™s cross-border data transfer limitations. Regulators in the United States are also increasingly scrutinizing certain personal data transfers and may impose data localization requirements, particularly if we transfer personal data to, or process personal data of residents of, high risk or sanctioned jurisdictions, such as the Biden Administrationâ€™s executive order Preventing Access to Americansâ€™ Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern. We are also bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. We publish privacy policies, marketing materials and other statements, such as compliance with certain certifications or self-regulatory principles, regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences. In addition, privacy advocates and industry groups have proposed, and may propose, standards with which we are legally or contractually bound to comply, or may become subject to in the future. Our obligations related to data privacy and security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Moreover, despite our efforts, our personnel or third parties with whom we work may fail to comply with such obligations, which could negatively impact our business operations and compliance posture. If we or the third parties with whom we work fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-related claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans or restrictions on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations. If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the United States, we could be subject to additional reimbursement requirements, fines, sanctions and exposure under other laws which could have a material adverse effect on our business, results of operations and financial condition.* We participate in the Medicaid Drug Rebate Program, as administered by CMS, and other federal and state government pricing programs in the United States, and we may participate in additional government pricing programs in the future. These programs generally require us to pay rebates or otherwise provide discounts to government payers in connection with drugs that are dispensed to 70 Â beneficiaries/recipients of these programs. In some cases, such as with the Medicaid Drug Rebate Program, the rebates are based on pricing that we report on a monthly and quarterly basis to the government agencies that administer the programs. Pricing requirements and rebate/discount calculations are complex, vary among products and programs, and are often subject to interpretation by governmental or regulatory agencies and the courts. The requirements of these programs, including, by way of example, their respective terms and scope, change frequently. For example, in March 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminated the statutory Medicaid drug rebate cap, previously set at 100% of a drugâ€™s average manufacturer's price (â€œAMPâ€), for single source and innovator multiple source drugs effective January 1, 2024. Responding to current and future changes may increase our costs, and the complexity of compliance will be time consuming. Invoicing for rebates is provided in arrears, and there is frequently a time lag of up to several months between the sales to which rebate notices relate and our receipt of those notices, which further complicates our ability to accurately estimate and accrue for rebates related to the Medicaid program as implemented by individual states. Thus, there can be no assurance that we will be able to identify all factors that may cause our discount and rebate payment obligations to vary from period to period, and our actual results may differ significantly from our estimated allowances for discounts and rebates. Changes in estimates and assumptions may have a material adverse effect on our business, results of operations and financial condition. In addition, the Office of Inspector General of the HHS and other Congressional, enforcement and administrative bodies have recently increased their focus on pricing requirements for products, including, but not limited to the methodologies used by manufacturers to calculate AMP and best price (â€œBPâ€) for compliance with reporting requirements under the Medicaid Drug Rebate Program. We are liable for errors associated with our submission of pricing data and for any overcharging of government payers. For example, failure to submit monthly/quarterly AMP and BP data on a timely basis could result in a civil monetary penalty. Failure to make necessary disclosures and/or to identify overpayments could result in allegations against us under the False Claims Act and other laws and regulations. Any required refunds to the U.S. government or responding to a government investigation or enforcement action would be expensive and time consuming and could have a material adverse effect on our business, results of operations and financial condition. In addition, in the event that the CMS were to terminate our rebate agreement, no federal payments would be available under Medicaid or Medicare for our covered outpatient drugs. Our business could be negatively impacted by environmental, social and corporate governance (â€œESGâ€) matters or our reporting of such matters.* There is an increasing focus from certain investors, employees, partners, and other stakeholders concerning ESG matters. We may be, or be perceived to be, not acting responsibly in connection with these matters, which could negatively impact us. For example, we have not previously reported our environmental emissions and such lack of reporting may have resulted in certain investors declining to invest in our common stock. However, the SEC recently finalized rules designed to enhance and standardize climate-related disclosures. These climate disclosure rules have been challenged in court and the SEC has issued an order staying their implementation pending the outcome of judicial review. These new climate-related disclosures, if required, may significantly increase our compliance and reporting costs and may also result in disclosures that certain investors or other stakeholders deem to impact our reputation negatively and/or that harm our stock price. Our portfolio of investment securities may require us to register with the SEC as an â€œinvestment companyâ€ in accordance with the Investment Company Act of 1940 (â€œâ€˜40 Actâ€). The rules and interpretations of the SEC and the courts relating to the definition of "investment company" are very complex. Although we are a biopharmaceutical company and we do not hold ourselves out as an investment company, the value of our investment securities relative to our total assets (exclusive of government securities and cash items) has in the past exceeded safe harbor limits prescribed in the â€˜40 Act. If our asset mix does not continue to qualify for one of the safe harbor limits prescribed in the â€˜40 Act, it is possible that the SEC would take the position that we would be required to register under the â€˜40 Act and comply with the â€˜40 Actâ€™s registration and reporting requirements, capital structure requirements, affiliate transaction restrictions, conflict of interest rules, requirements for disinterested directors, and other substantive provisions. If we were required to register as an â€œinvestment companyâ€ and be subject to the restrictions of the â€˜40 Act, those restrictions likely would require significant changes in the way we do business and add significant administrative costs and burdens to our operations. RISKS RELATED TO INTELLECTUAL PROPERTY If we are unable to protect our proprietary rights, we may not be able to compete effectively, or operate profitably. Our commercial success depends, in large part, on our ability to obtain and maintain intellectual property protection for our technology. Our ability to do so will depend on, among other things, complex legal and factual questions, and it should be noted that the standards regarding intellectual property rights in our fields are still evolving. We attempt to protect our proprietary technology through a combination of patents, trade secrets and confidentiality agreements. We own a number of domestic and international patents, have a number of domestic and international patent applications pending and have licenses to additional patents. We cannot assure you that our patents and licenses will successfully preclude others from using our technologies, and we could incur substantial 71 Â costs in seeking enforcement of our proprietary rights against infringement. Even if issued, the patents may not give us an advantage over competitors with alternative technologies. For example, the coverage claimed in a patent application can be significantly reduced before a patent is issued, either in the United States or abroad. Statutory differences in patentable subject matter may limit the protection we can obtain on some of our inventions outside of the United States. For example, methods of treating patients are not patentable in many countries outside of the United States. These and other issues may limit the patent protection we are able to secure internationally. Consequently, we do not know whether any of our pending or future patent applications will result in the issuance of patents or, to the extent patents have been issued or will be issued, whether these patents will be subjected to further proceedings limiting their scope, will provide significant proprietary protection or competitive advantage, or will be circumvented or invalidated. Furthermore, patents already issued to us or our pending applications may become subject to disputes that could be resolved against us. In the United States and certain other countries, applications are generally published 18 months after the applicationâ€™s priority date. Because publication of discoveries in scientific or patent literature often trails behind actual discoveries, we cannot be certain that we were the first inventor of the subject matter covered by our pending patent applications or that we were the first to file patent applications on such inventions. Assuming the other requirements for patentability are met, in the United States prior to March 15, 2013, the first to make the claimed invention is entitled to the patent, while outside the United States, the first to file a patent application is entitled to the patent. After March 15, 2013, under the Leahy-Smith America Invents Act (â€œAIAâ€), the United States moved to a first inventor to file system. In general, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. Moreover, the term of a patent is limited and, as a result, the patents protecting our products expire at various dates. As and when these different patents expire, our products could become subject to increased competition. As a consequence, we may not be able to recover our development costs. An issued patent is presumed valid unless it is declared otherwise by a court of competent jurisdiction. However, the issuance of a patent is not conclusive as to its validity or enforceability and it is uncertain how much protection, if any, will be afforded by our patents. A third party may challenge the validity or enforceability of a patent after its issuance by various proceedings such as oppositions in foreign jurisdictions, or post grant proceedings, including, oppositions, re-examinations or other review in the United States. In some instances, we may seek re-examination or reissuance of our own patents. If we attempt to enforce our patents, they may be challenged in court where they could be held invalid, unenforceable, or have their breadth narrowed to an extent that would destroy their value. We also rely on unpatented technology, trade secrets, know-how and confidentiality agreements. We require our officers, employees, consultants and advisors to execute proprietary information and invention and assignment agreements upon commencement of their relationships with us. These agreements provide that all inventions developed by the individual on behalf of us must be assigned to us and that the individual will cooperate with us in connection with securing patent protection on the invention if we wish to pursue such protection. We also execute confidentiality agreements with outside collaborators. However, disputes may arise as to the ownership of proprietary rights to the extent that outside collaborators apply technological information to our projects that are developed independently by them or others, or apply our technology to outside projects, and there can be no assurance that any such disputes would be resolved in our favor. In addition, any of these parties may breach the agreements and disclose our confidential information or our competitors might learn of the information in some other way. Thus, there can be no assurance, however, that our inventions and assignment agreements and our confidentiality agreements will provide meaningful protection for our inventions, trade secrets, know-how or other proprietary information in the event of unauthorized use or disclosure of such information. If any trade secret, know-how or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, our business, results of operations and financial condition could be adversely affected. If we become involved in lawsuits to protect or enforce our patents or the patents of our collaborators or licensors, we would be required to devote substantial time and resources to prosecute or defend such proceedings. Competitors may infringe our patents or the patents of our collaborators or licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover its technology. A court may also decide to award us a royalty from an infringing party instead of issuing an injunction against the infringing activity. An adverse determination of any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. Interference proceedings brought by the United States Patent and Trademark Office (â€œUSPTOâ€), may be necessary to determine the priority of inventions with respect to our pre-AIA patent applications or those of our collaborators or licensors. Additionally, the AIA 72 Â has greatly expanded the options for post-grant review of patents that can be brought by third parties. In particular, Inter Partes Review (â€œIPRâ€), available against any issued United States patent (pre-and post-AIA), has resulted in a higher rate of claim invalidation, due in part to the much reduced opportunity to repair claims by amendment as compared to re-examination, as well as the lower standard of proof used at the USPTO as compared to the federal courts. With the passage of time an increasing number of patents related to successful pharmaceutical products are being subjected to IPR. Moreover, the filing of IPR petitions has been used by short-sellers as a tool to help drive down stock prices. We may not prevail in any litigation, post-grant review, or interference proceedings in which we are involved and, even if we are successful, these proceedings may result in substantial costs and be a distraction to our management. Further, we may not be able, alone or with our collaborators and licensors, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, the market price of our common stock and other securities may decline. If our technologies conflict with the proprietary rights of others, we may incur substantial costs as a result of litigation or other proceedings and we could face substantial monetary damages and be precluded from commercializing our products, which would materially harm our business and financial condition. Biotechnology patents are numerous and may, at times, conflict with one another. As a result, it is not always clear to industry participants, including us, which patents cover the multitude of biotechnology product types. Ultimately, the courts must determine the scope of coverage afforded by a patent and the courts do not always arrive at uniform conclusions. A patent owner may claim that we are making, using, selling or offering for sale an invention covered by the ownerâ€™s patents and may go to court to stop us from engaging in such activities. Such litigation is not uncommon in our industry. Patent lawsuits can be expensive and would consume time and other resources. There is a risk that a court would decide that we are infringing a third partyâ€™s patents and would order us to stop the activities covered by the patents, including the commercialization of our products. In addition, there is a risk that we would have to pay the other party damages for having violated the other partyâ€™s patents (which damages may be increased, as well as attorneysâ€™ fees ordered paid, if infringement is found to be willful), or that we will be required to obtain a license from the other party in order to continue to commercialize the affected products, or to design our products in a manner that does not infringe a valid patent. We may not prevail in any legal action, and a required license under the patent may not be available on acceptable terms or at all, requiring cessation of activities that were found to infringe a valid patent. We also may not be able to develop a non-infringing product design on commercially reasonable terms, or at all. Moreover, certain components of our products may be manufactured outside the United States and imported into the United States. As such, third parties could file complaints under 19 U.S.C. Section 337(a)(1)(B) (a â€œ337 actionâ€) with the International Trade Commission (the â€œITCâ€). A 337 action can be expensive and would consume time and other resources. There is a risk that the ITC would decide that we are infringing a third partyâ€™s patents and either enjoin us from importing the infringing products or parts thereof into the United States or set a bond in an amount that the ITC considers would offset our competitive advantage from the continued importation during the statutory review period. The bond could be up to 100% of the value of the patented products. We may not prevail in any legal action, and a required license under the patent may not be available on acceptable terms, or at all, resulting in a permanent injunction preventing any further importation of the infringing products or parts thereof into the United States. We also may not be able to develop a non-infringing product design on commercially reasonable terms, or at all. Although we do not believe that our products or product candidates infringe any third-party patents, if a plaintiff was to allege infringement of their patent rights, we would have to establish with the court that their patents are invalid or unenforceable in order to avoid legal liability for infringement of these patents. However, proving patent invalidity or unenforceability can be difficult because issued patents are presumed valid. Therefore, in the event that we are unable to prevail in a non-infringement or invalidity action we will

have to either acquire the third-party patents outright or seek a royalty-bearing license. Royalty-bearing licenses effectively increase production costs and therefore may materially affect product profitability. Furthermore, should the patent holder refuse to either assign or license us the infringed patents, it may be necessary to cease manufacturing the product entirely and/or design around the patents, if possible. In either event, our business, financial condition and results of operations would be harmed and our profitability could be materially and adversely impacted. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, the market price of our common stock and other securities may decline. 73 Â In addition, patent litigation may divert the attention of key personnel and we may not have sufficient resources to bring these actions to a successful conclusion. At the same time, some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. An adverse determination in a judicial or administrative proceeding or failure to obtain necessary licenses could prevent us from manufacturing and selling our products or result in substantial monetary damages, which would adversely affect our business, financial condition and results of operations and cause the market price of our common stock and other securities to decline. We may not obtain trademark registrations for our potential trade names. We have not selected trade names for some of our product candidates in our pipeline; therefore, we have not filed trademark registrations for such potential trade names for our product candidates, nor can we assure that we will be granted registration of any potential trade names for which we do file. No assurance can be given that any of our trademarks will be registered in the United States or elsewhere, or once registered that, prior to our being able to enter a particular market, they will not be cancelled for non-use. Nor can we give assurances, that the use of any of our trademarks will confer a competitive advantage in the marketplace. Furthermore, even if we are successful in our trademark registrations, the FDA has its own process for drug nomenclature and its own views concerning appropriate proprietary names. It also has the power, even after granting market approval, to request a company to reconsider the name for a product because of evidence of confusion in the marketplace. We cannot assure you that the FDA or any other regulatory authority will approve of any of our trademarks or will not request reconsideration of one of our trademarks at some time in the future. RISKS RELATED TO OUR COMMON STOCK Our stock price is volatile. The trading price of our common stock has been and is likely to continue to be volatile. The volatility of pharmaceutical and biotechnology stocks often does not relate to the operating performance of the companies represented by the stock. Our business and the market price of our common stock may be influenced by a large variety of factors, including: â€¢our ability to obtain marketing approval for our products outside of the United States and to find collaboration partners for the commercialization of our products in foreign jurisdictions; â€¢future estimates of product sales, royalties, prescriptions or other operating metrics; â€¢our ability to successfully commercialize other products based on our Technosphere drug delivery platform; â€¢the progress and results of preclinical and clinical studies of our product candidates and of post-approval studies of approved products that are required by the FDA; â€¢general economic, political or stock market conditions, especially for emerging growth and pharmaceutical market sectors; â€¢geopolitical events, such as the current Russia-Ukraine and Israel-Hamas conflicts and Houthis rebel attacks on commercial marine vessels in the Red Sea; â€¢legislative developments; â€¢disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions; â€¢changes in the structure of the healthcare payment systems; â€¢announcements by us, our collaborators, or our competitors concerning clinical study results, acquisitions, strategic alliances, technological innovations, newly approved commercial products, product discontinuations, or other developments; â€¢the availability of critical materials used in developing and manufacturing our products and product candidates; â€¢developments or disputes concerning our relationship with any of our current or future collaborators or third party manufacturers; â€¢developments or disputes concerning our patents or proprietary rights; â€¢the expense and time associated with, and the extent of our ultimate success in, securing regulatory approvals; â€¢announcements by us concerning our financial condition or operating performance; â€¢changes in securities analystsâ€™ estimates of our financial condition or operating performance; 74 Â â€¢sales of large blocks of our common stock, including sales by our executive officers, directors and significant stockholders; â€¢the trades of short sellers; â€¢our ability, or the perception of investors of our ability, to continue to meet all applicable requirements for continued listing of our common stock on The Nasdaq Global Market, and the possible delisting of our common stock if we are unable to do so; â€¢the status of any legal proceedings or regulatory matters against or involving us or any of our executive officers and directors; and â€¢discussion of our products, competitorsâ€™ products, or our stock price by the financial and scientific press, the healthcare community and online investor communities such as chat rooms. In particular, it may be difficult to verify statements about us that appear on interactive websites that permit users to generate content anonymously or under a pseudonym. Statements attributed to company officials may, in fact, have originated elsewhere. Any of these risks, as well as other factors, could cause the market value of our common stock and other securities to decline. If we fail to continue to meet all applicable listing requirements, our common stock may be delisted from the Nasdaq Global Market, which could have an adverse impact on the liquidity and market price of our common stock. Our common stock is currently listed on The Nasdaq Global Market, which has qualitative and quantitative listing criteria. If we are unable to meet any of the Nasdaq listing requirements in the future, such as the corporate governance requirements, the minimum closing bid price requirement, or the minimum market value of listed securities requirement, Nasdaq could determine to delist our common stock. A delisting of our common stock could adversely affect the market liquidity of our common stock, decrease the market price of our common stock, adversely affect our ability to obtain financing for the continuation of our operations and result in the loss of confidence in our company. Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. We are incorporated in Delaware. Certain anti-takeover provisions under Delaware law and in our certificate of incorporation and amended and restated bylaws, as currently in effect, may make a change of control of our company more difficult, even if a change in control would be beneficial to our stockholders or the holders of our other securities. Our anti-takeover provisions include provisions such as a prohibition on stockholder actions by written consent, the authority of our board of directors to issue preferred stock without stockholder approval, and supermajority voting requirements for specified actions. In addition, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which generally prohibits stockholders owning 15% or more of our outstanding voting stock from merging or combining with us in certain circumstances. These provisions may delay or prevent an acquisition of us, even if the acquisition may be considered beneficial by some of our stockholders. In addition, they may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America are the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholdersâ€™ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. Our amended and restated bylaws provide that, to the fullest extent permitted by law and subject to the courtâ€™s having personal jurisdiction over the indispensable parties named as defendants, the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: â€¢any derivative action or proceeding brought on our behalf; â€¢any action or proceeding asserting a breach of fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; â€¢any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees arising out of or pursuant to any provision of the Delaware General Corporation Law, our amended and certificate of incorporation or amended and restated bylaws; â€¢any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws; 75 Â â€¢any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and â€¢any action asserting a claim against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine. This provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act of 1933, as amended (the "Securities Act"), creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated bylaws further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. These exclusive forum provisions may limit a stockholderâ€™s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business. Because we do not expect to pay dividends in the foreseeable future, you must rely on stock appreciation for any return on any investment in our common stock.* We have paid no cash dividends on any of our capital stock to date, and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. As a result, we do not expect to pay any cash dividends in the foreseeable future, and payment of cash dividends, if any, will also depend on our financial condition, results of operations, capital requirements and other factors and will be at the discretion of our board of directors. There is no guarantee that our common stock will appreciate or maintain its current price. You could lose the entire value of any investment in our common stock. Future sales of shares of our common stock in the public market, or the perception that such sales may occur, may depress our stock price and adversely impact the market price of our common stock and other securities.* We may need to raise substantial additional capital in the future to fund our operations. If we raise additional funds by issuing equity securities or additional convertible debt, the market price of our common stock and other securities may decline. Similarly, if our existing stockholders sell substantial amounts of our common stock in the public market, the market price of our common stock and other securities could decrease. The perception in the public market that we or our existing stockholders might sell shares of common stock could also depress the market price of our common stock and the market price of our other securities. Likewise, the issuance of additional shares of our common stock upon the exchange or conversion of the Senior convertible notes could adversely affect the market price of our common stock and other securities. Moreover, the existence of these notes may encourage short selling of our common stock by market participants, which could adversely affect the market price of our common stock and other securities. In addition, a substantial number of shares of our common stock is reserved for issuance upon the exercise of stock options, the vesting of restricted stock unit awards and purchases under our ESPP. The issuance or sale of substantial amounts of common stock, or the perception that such issuances or sales may occur, could adversely affect the market price of our common stock and other securities. If other biotechnology and biopharmaceutical companies or the securities markets in general encounter problems, the market price of our common stock and other securities could be adversely affected. Public companies in general, including companies listed on The Nasdaq Stock Market, have experienced price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. There has been particular volatility in the market prices of securities of biotechnology and other life sciences companies, and the market prices of these companies have often fluctuated because of problems or successes in a given market segment or because investor interest has shifted to other segments. These broad market and industry factors may cause the market price of our common stock and other securities to decline, regardless of our operating performance. We have no control over this volatility and can only focus our efforts on our own operations, and even these may be affected due to the state of the capital markets. 76 Â In the past, following periods of large price declines in the public market price of a companyâ€™s securities, securities class action litigation has often been initiated against that company. Litigation of this type could result in substantial costs and diversion of managementâ€™s attention and resources, which would hurt our business. Any adverse determination in litigation could also subject us to significant liabilities. GENERAL RISK FACTORS Unstable market, economic and geopolitical conditions may have serious adverse consequences on our business, financial condition and stock price.* The global credit and financial markets have experienced extreme volatility and disruptions in the past. These disruptions can result in severely diminished liquidity and credit availability, increase in inflation, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment, actual or anticipated bank failures, higher inflation, or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Our portfolio of corporate and government bonds could also be adversely impacted. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our operations, growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn or rising inflation, which could directly affect our ability to attain our operating goals on schedule and on budget. Other international and geopolitical events could also have a serious adverse impact on our business. For instance, in February 2022, Russia initiated military action against Ukraine and the two countries are now at war. In response, the United States and certain other countries imposed significant sanctions and trade actions against Russia and could impose further sanctions, trade restrictions, and other retaliatory actions. Additionally, in October 2023, Hamas initiated an attack against Israel, provoking a state of war and subsequently a larger regional conflict. Furthermore, following Hamasâ€™ attack on Israel, the Houthi movement, which controls parts of Yemen, launched a number of attacks on commercial marine vessels in the Red Sea. The Red Sea is an important maritime route for international trade and as such disruptions to these trade routes can have an impact on global supply chains. As a result of such disruptions, we may experience in the future extended lead times, delays in supplier deliveries, and increased freight costs. While we cannot predict the broader consequences, these conflicts and retaliatory and counter-retaliatory actions could materially adversely affect global trade, currency exchange rates, inflation, regional economies, and the global economy, which in turn may increase our costs, disrupt our supply chain, impair our ability to raise or access additional capital when needed on acceptable terms, if at all, or otherwise adversely affect our business, financial condition, and results of operations. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS None. ITEM 3. DEFAULTS UPON SENIOR SECURITIES None. ITEM 4. MINE SAFETY DISCLOSURES Not applicable. ITEM 5. OTHER INFORMATIONÂ During the three months ended September 30, 2024, two of our officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted written trading plans for the orderly disposition of the Companyâ€™s securities as set forth in the table below:Â 77 Â Â Â Â Â Â Â Â Â Type of Trading Arrangement Â Â Â Â Â Â Â Name and Position Â Action Â AdoptionDate Â Rule 10b5-1(1) Â Non-Rule 10b5-1(2) Â Â Total Shares of Common Stock to be Sold (3) Â Â Expiration Date Steven B. BinderDirector Â Adoption Â August 16, 2024 Â X Â Â Â â€” Â Â Â 297,075 Â Â August 29, 2025 David ThomsonEVP, General Counsel Â Adoption Â August 19, 2024 Â X Â Â Â â€” Â Â Â 188,780 Â Â August 19, 2025 _____(1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.(2) "Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.(3) These trading plans include the potential exercise and sale by Steven Binder and David Thomson of short-dated options exercisable for up to 135,075 and 147,780 shares of common stock, respectively. The remainder of each plan is designed to sell a specified percentage of the net shares delivered after tax withholding upon the vesting of restricted stock unit awards held by each individual. The actual number of shares to be sold will depend on state and federal tax rates applicable on the relevant vesting dates (currently assumed to be a combined 34%) as well as the payout, if any, of market RSU awards that will deliver a number of shares determined by the percentile ranking of MannKind total shareholder return ("TSR") over a three-year measurement period relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period (currently assumed to be 100% of target). Based on these assumptions, the number of shares of common stock to be sold by Steven Binder and David Thomson after tax withholdings approximate 162,000 and 41,000, respectively, for total estimated shares of common stock to be sold of up to 297,075 and 188,780, respectively. Â 78 Â ITEM 6. EXHIBITS Â ExhibitNumber Â Description of Document Â Â Â Â Â Â Â Â 3.1 Â Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to MannKindâ€™s Quarterly Report on Form 10-Q (File No. 000-50865), filed with the SEC on August 9, 2016). Â Â Â Â Â Â Â Â 3.2 Â Certificate of Amendment of Amended and Restated Certificate of Incorporation of MannKind Corporation

(incorporated by reference to Exhibit 3.1 to MannKindâ€™s Current Report on Form 8-K (File No. 000-50865), filed with the SEC on March 2, 2017). Â Â Â Â Â Â Â 3.3 Â Certificate of Amendment of Amended and Restated Certificate of Incorporation of MannKind Corporation (incorporated by reference to Exhibit 3.1 to MannKindâ€™s Current Report on Form 8-K (File No. 000-50865), filed with the SEC on December 13, 2017). Â Â Â Â Â Â Â 3.4 Â Certificate of Amendment of Amended and Restated Certificate of Incorporation of MannKind Corporation (incorporated by reference to Exhibit 3.1 to MannKindâ€™s Current Report on Form 8-K (File No. 000-50865), filed with the SEC on May 27, 2020). Â Â Â Â Â Â Â 3.5 Â Certificate of Amendment of Amended and Restated Certificate of Incorporation of MannKind Corporation (incorporated by reference to Exhibit 3.1 to MannKindâ€™s Current Report on Form 8-K (File No. 000-50865), filed with the SEC on May 30, 2023). Â Â Â Â Â Â Â 3.6 Â Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to MannKindâ€™s Current Report on Form 8-K (File No. 000-50865), filed with the SEC on May 27, 2020). Â Â Â Â Â Â Â 4.1 Â Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4, 3.5Â and 3.6. Â Â Â Â Â Â Â 4.2 Â Form of common stock certificate (incorporated by reference to Exhibit 4.2 to MannKindâ€™s Annual Report on Form 10-K (File No. 000-50865), filed with the SEC on March 16, 2017). Â Â Â Â Â Â Â 4.3 Â Milestone Rights Purchase Agreement, dated as of July 1, 2013, by and among MannKind, Deerfield Private Design Fund II, L.P. and Horizon SantÃ© FLML SÃRL (incorporated by reference to Exhibit 99.3 to MannKindâ€™s Current Report on Form 8-K (File No. 000-50865), filed with the SEC on July 1, 2013). Â Â Â Â Â Â Â 4.4 Â Form of Warrant to Purchase Stock issued to MidCap Financial Trust on August 6, 2019 (incorporated by reference to Exhibit 4.1 to MannKindâ€™s Current Report on Form 8-K (File No. 000-50865), filed with the SEC on August 7, 2019). Â Â Â Â Â Â Â 4.5 Â Indenture, dated as of March 4, 2021, by and between MannKind Corporation and U.S. Bank National Association, as Trustee (incorporated by reference to Exhibit 4.1 to MannKindâ€™s Current Report on Form 8-K (File No. 000-50865), filed with the SEC on March 5, 2021). Â Â Â Â Â Â Â 4.6 Â Form of Global Note, representing MannKind Corporationâ€™s 2.50% Convertible Senior Notes due 2026 (included as Exhibit A to the Indenture filed as Exhibit 4.15) (incorporated by reference to Exhibit 4.2 to MannKindâ€™s Current Report on Form 8-K (File No. 000-50865), filed with the SEC on March 5, 2021). Â Â Â Â Â Â Â 10.1*** Â Second Amendment to Supply Agreement, dated November 9, 2016, by and between MannKind and Amphastar Pharmaceuticals, Inc. Â Â Â Â Â Â Â 10.2*** Â Third Amendment to Supply Agreement, dated April 11, 2018, by and between MannKind and Amphastar Pharmaceuticals, Inc. Â Â Â Â Â Â Â 10.3*** Â Research Agreement, dated September 3, 2018 by and between MannKind and United Therapeutics Corporation. Â Â Â Â Â Â Â 31.1 Â Certification of the Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended. Â Â Â Â Â Â Â 31.2 Â Certification of the Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended. Â Â Â Â Â Â Â 32.1 Â Certification of the Chief Executive Officer pursuant to Rules 13a-14(b) and 15d-14(b) of the Securities Exchange Act of 1934, as amended and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Â§1350). Â Â Â Â Â Â Â 32.2 Â Certification of the Chief Financial Officer pursuant to Rules 13a-14(b) and 15d-14(b) of the Securities Exchange Act of 1934, as amended and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Â§1350). Â Â Â 79 Â ExhibitNumber Â Description of Document Â Â Â Â 101 Â Inline Interactive Data Files pursuant to Rule 405 of Regulation S-T. Â Â Â Â Â Â Â 104 Â The cover page has been formatted in Inline XBRL. *** Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. 80 Â SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Dated: November 7, 2024 MANNKIND CORPORATION Â Â Â Â By: /s/ MICHAEL E. CASTAGNA Â Â Michael E. Castagna Â Â Chief Executive Officer(on behalf of the registrant and as the registrantâ€™s Principal Executive Officer) Â Â Â Â By: /s/ CHRISTOPHER B. PRENTISS Â Â Christopher B. Prentiss Â Â Chief Financial Officer Â Â (Principal Financial and Accounting Officer) Â 81 EX-10.1 2 mnkd-ex10_1.htm EX-10.1 EX-10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. Exhibit 10.1 SECOND AMENDMENT TO SUPPLY AGREEMENT This second amendment (â€œSecond Amendmentâ€) to the Supply Agreement by and between MannKind Corporation (â€œMannKindâ€) and Amphastar Pharmaceuticals, Inc. (â€œAmphastarâ€), originally dated July 31, 2014 and as previously amended on October 31, 2014 (collectively, the â€œAgreementâ€), is hereby made as of the 9th day of November, 2016, by and between MannKind on the one hand, and on the other hand, Amphastar. RECITALS: WHEREAS, MannKind and Amphastar entered into the Agreement pursuant to which Amphastar is to manufacture and supply the Product to MannKind, and MannKind is to purchase certain minimum quantities of the Product; WHEREAS, MannKind and Amphastar are concurrently entering into a first amendment to the Insulin Purchase Option Agreement originally dated January 1, 2015 (the â€œOption Amendmentâ€) and WHEREAS MannKind and Amphastar have determined it to be mutually beneficial to amend the Agreement as set forth herein. NOW, THEREFORE, for good and valuable consideration, MannKind and Amphastar, hereby agree to amend the Agreement as follows: 1. Definitions. Unless otherwise defined herein, each of the capitalized terms used in this Second Amendment shall have the definition and meaning ascribed to it in the Agreement. 2. Amendments to the Agreement. 2.1 The following sentence in Section 5.1 of the Agreement: â€œUpon delivery to MannKind, AFP shall ensure Product will have a remaining expiry date of not less than four (4) years.â€ Is amended and replaced in its entirety with the following: â€œIn calendar year 2017 and 2018, upon delivery to MannKind, Amphastar shall ensure that Product will have a remaining expiry date of not less than two (2) years. In calendar year 2019 and the remainder of the term of the Agreement, Amphastar shall ensure Product will have a remaining expiry date of not less than three (3) years.â€ 2.2 The following sentence in Section 6.1 of the Agreement: â€œPurchase Commitment and Purchase Price. MannKind shall purchase from AFP the minimum quantities of Product (the â€œPurchase Commitment Quantitiesâ€) at the purchase price per gram (the â€œPurchase Priceâ€) in each calendar year as provided in the table set forth below. In the event that MannKind fails to meet the Purchase Commitment Quantities in any given calendar year, MannKind shall pay AFP for the difference in the amount of the Purchase Commitment Quantities and the actual amount purchased for the corresponding calendar year (such difference, the â€œPurchase Commitment Differenceâ€). AFP shall issue an invoice and MannKind shall pay the Purchase Commitment Difference no later than thirty (30) days after the close of the corresponding calendar year.â€ is amended and replaced in its entirety with the following: Â Â Purchase Commitment and Purchase Price. MannKind shall purchase from Amphastar the minimum quantities of Product (the â€œPurchase Commitment Quantitiesâ€) at the purchase price per gram (the â€œPurchase Priceâ€) in each calendar year as provided in the table set forth below. This annual Purchase Commitment Quantities will be divided into four (4) equal quarterly commitments (the â€œQuarterly Commitmentâ€). In the event that MannKind fails to meet the Quarterly Commitment in any given calendar quarter, MannKind shall pay Amphastar for the difference in the amount of the Quarterly Commitment and the actual amount purchased for the corresponding calendar quarter (such difference, the â€œPayment Commitment Differenceâ€). Amphastar shall issue an invoice and MannKind shall pay the Payment Commitment Difference no later than thirty (30) days after the close of the corresponding calendar quarter. Notwithstanding the foregoing, the parties hereby agree that the Purchase Commitment Quantities for 2017 shall not be divided into four (4) equal quarterly payments but rather MannKind shall take receipt of the entire [***] Kgs of Product in the fourth (4th) quarter of 2017 but no later than November 15, 2017. 2.3 The table in Section 6.1 of the Agreement is amended and replaced in its entirety with the following: Â Â Â Â Â Â Â CalendarYear Purchase CommitmentQuantities (kg) Purchase Price(per gram) Delivery and Payment Â Â Â Â 2014 [***] EUR [***] Â Â Â Â Â 2015 [***] EUR [***] Â Â Â Â Â Â 2016 [***] EUR [***] Â Â Â Â Â Â 2017 [***] EUR [***] 100% of the Purchase Commitment Quantities Payment shall be paid no later than November 5, 2017 Â Â Â Â 2018 [***] EUR [***] 25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis Â Â Â Â 2019 [***] EUR [***] 25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis Â Â Â Â 2020 [***] EUR [***] 25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis Â Â Â Â 2021 [***] EUR [***] 25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis Â Â Â Â 2022 [***] EUR [***] 25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis Â Â Â Â 2023 [***] EUR [***] 25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis - 2 - Â Â 2.4 Section 6.2 of the Agreement shall be amended and replaced in its entirety with the following: 6.2 Payment. In calendar year 2017 and 2018, MannKind shall pre-pay Amphastar for the Product at least ten (10) days prior to the estimated delivery date. For the avoidance of doubt, Amphastar shall not ship the Product to MannKind until such payment is received. Beginning in 2019 and for the remainder of the term of the Agreement, MannKind shall pay Amphastar for the Product within forty-five (45) days from shipment date of the Product. Amphastar shall submit an invoice electronically to MannKind, Attention: Account Payable, valenciaap@mannkindcorp.com. If any portion of an invoice is disputed then MannKind shall pay the undisputed amount and the Parties shall use good faith efforts to reconcile the disputed amount as soon as practicable. 2.5 A new Section 6.5 shall be added to the Agreement as follows: 6.5 Right of First Refusal in China. In consideration of the amendments contained in this Second Amendment and in the Option Amendment, MannKind hereby grants Amphastar the right of first refusal to participate in the development and commercialization of Afrezza in China through a collaborative arrangement. Specifically, Amphastar and MannKind agree that MannKind will not commence the process of obtaining approval of Afrezza in China without first providing Amphastar with (i) at least ninety (90) days prior written notice of MannKindâ€™s intention to commence the process of obtaining approval of Afrezza in China, and (ii) if Amphastar confirms its interest in collaborating in the development or commercialization of Afrezza in China in writing within thirty (30) days of receipt of MannKindâ€™s notice, then the Parties shall reserve sixty (60) days to negotiate in good faith the terms of such a collaborative arrangement for Afrezza in China. In the event that the Parties are unable to agree on commercial terms for a collaborative agreement after the sixty (60) day negotiation period, then MannKind shall have the right to negotiate a collaborative agreement with another party (â€œCompeting Termsâ€). MannKind shall present the Competing Terms to Amphastar in writing, and within sixty (60) days of receipt of the Competing Terms, Amphastar shall have the option to either (i) decline to match the Competing Terms, or (ii) agree to match the same Competing Terms and enter into a collaborative agreement with MannKind in China. 2.6 Section 10.1 of the Agreement shall be extended until December 31, 2023. All other terms and conditions in paragraph 10.1 shall remain in full force and effect. 3. Final Agreement. From and after the execution of this Second Amendment, all references in the Agreement (or in the Second Amendment) to â€œthis Agreement,â€ â€œhereof,â€ â€œherein,â€ â€œhereto,â€ and similar words or phrases shall mean and refer to the Agreement as amended by this Second Amendment. The Agreement as amended by this Second Amendment constitutes the entire agreement by and between the Parties as to the subject matter hereof. Except as expressly modified by this Second Amendment, all other terms and conditions of the Agreement shall remain in full force and effect. Â Â Â Â Â - 3 - Â Â IN WITNESS WHEREOF, each of MannKind and Amphastar has caused this Second Amendment to be executed by their duly authorized officers. Â Â Â MannKind Corporation Â Â By: /s/ Matthew Pfeffer Name: Matthew Pfeffer Title: CEO Â Amphastar Pharmaceuticals, Inc. Â Â By: /s/ Jason Shandell Name: Jason Shandell Title: President - 4 - Â EX-10.2 3 mnkd-ex10_2.htm EX-10.2 EX-10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. Exhibit 10.2 THIRD AMENDMENT TO SUPPLY AGREEMENT This third amendment (â€œThird Amendmentâ€) to the Supply Agreement by and between MannKind Corporation (â€œMannKindâ€) and Amphastar Pharmaceuticals, Inc. (â€œAmphastarâ€), originally dated July 31, 2014 and as previously amended on October 31, 2014 and November 9, 2016 (collectively, the â€œAgreementâ€), is hereby made as of the 11th day of April, 2018, by and between MannKind on the one hand, and on the other hand, Amphastar. RECITALS: WHEREAS, MannKind and Amphastar entered into the Agreement pursuant to which Amphastar is to manufacture and supply the Product to MannKind, and MannKind is to purchase certain minimum quantities of the Product; WHEREAS, any distribution or sales by MannKind of the Product or the MannKind Product made using the Product shall be limited to the Territory; and WHEREAS MannKind and Amphastar have determined it to be mutually beneficial to amend the Agreement as set forth herein. NOW, THEREFORE, for good and valuable consideration, MannKind and Amphastar, hereby agree to amend the Agreement as follows: 1.Definitions. Unless otherwise defined herein, each of the capitalized terms used in this Third Amendment shall have the definition and meaning ascribed to it in the Agreement. 2.Amendments to the Agreement. 2.1Section 1.4 of the Agreement is amended and replaced in its entirety with the following: â€œâ€˜Excluded Countriesâ€™ means [***]â€ 3.Final Agreement. From and after the execution of this Third Amendment, all references in the Agreement (or in the Third Amendment) to â€œthis Agreement,â€ â€œhereof,â€ â€œherein,â€ â€œhereto,â€ and similar words or phrases shall mean and refer to the Agreement as amended by this Third Amendment. The Agreement as amended by this Third Amendment constitutes the entire agreement by and between the Parties as to the subject matter hereof. Except as expressly modified by this Third Amendment, all other terms and conditions of the Agreement shall remain in full force and effect. Â Â Â IN WITNESS WHEREOF, each of MannKind and Amphastar has caused this Third Amendment to be executed by their duly authorized officers. MannKind Corporation By:/s/ Michael Castagna _____ Name: Michael Castagna Title: Chief Executive Officer Amphastar Pharmaceuticals, Inc. By:/s/ Jason Shandell _____ Name: Jason Shandell Title: President Â EX-10.3 4 mnkd-ex10_3.htm EX-10.3 EX-10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. Exhibit 10.3 Â Research Agreement This Research Agreement (the â€œAgreementâ€) is entered into as of September 3, 2018 (the â€œEffective Dateâ€) between MannKind Corporation, a Delaware corporation (â€œMannKindâ€), having a principal place of business at 30930 Russell Ranch Road, Suite 301, Westlake Village, California 91362, and United Therapeutics Corporation, a Delaware corporation (â€œUnited Therapeuticsâ€), having a principal place of business at 1040 Spring Street, Silver Spring, Maryland 20910 (each of MannKind and United Therapeutics, a â€œPartyâ€ and together, the â€œPartiesâ€). RECITALS Whereas, MannKind possesses (i) certain proprietary technology focused on the pulmonary delivery of certain pharmaceuticals, and (ii) experience and expertise with Bluetooth and WiFi components of devices; Whereas, United Therapeutics is engaged in the development and commercialization of pharmaceutical products; Whereas, the Parties have entered into a License and Collaboration Agreement dated September 3, 2018 (the â€œLCAâ€) pursuant to which MannKind has granted to United Therapeutics certain exclusive rights and licenses to develop a specified pharmaceutical product in collaboration with MannKind and to commercialize that product; and Whereas, MannKind and United Therapeutics desire to enter into this Agreement to provide the terms and conditions upon which (i) the Parties will evaluate the feasibility of formulating a Prototype Formulation (as defined below), which may have the potential for further development and commercialization under the framework established by the LCA, and (ii) MannKind will assist United Therapeutics and its collaborators in developing the hardware, software and firmware for a Bluetooth and WiFi component for United Therapeutics product. AGREEMENT Now Therefore, in consideration for the covenants set forth below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as set forth below. 1. Â 1.Certain Definitions. Certain capitalized terms not otherwise defined in this Agreement shall have the meaning given to such terms in the LCA. 1.1 â€œAccessory Apparatusâ€ shall mean an interactive apparatus that contains one or more sensors for real-time profiling of the ([***], etc.) through a Device, such as the BluhaleÂ® apparatus. 1.2 â€œCompoundâ€ shall mean any active pharmaceutical ingredient that is a [***]. 1.3 â€œDeveloped Technologyâ€ shall mean all data, results, information, materials, ideas, inventions, techniques and other technology, whether or not patentable, that are generated, developed or discovered by or on behalf of a Party in the course of performance of the Work Plans or in the assistance of the performance of such Work Plans. 1.4 â€œDeviceâ€ shall mean any device Controlled by MannKind through which a Formulation may be administered by inhalation, such as the DreamboatÂ® inhaler and CricketÂ® inhaler. 1.5 â€œFormulationâ€ shall mean a formulation of an active pharmaceutical ingredient suitable for pulmonary administration based upon or incorporating the drug delivery technology Controlled by MannKind involving diketopiperazine as a carrier. 1.6 â€œIntellectual Property Rightsâ€ shall mean any and all rights in and to discoveries, concepts, ideas, technical information, developments, specifications, methods, drawings, designs, flow charts, diagrams, models, formulae, procedures, processes, schematics, specifications, algorithms, apparatus, inventions, ideas, knowâ€‘how, materials, techniques, methodologies, modifications, improvements, works of authorship and data (whether or not protectable under patent, copyright, trade secrecy or similar laws), including patents, utility models, and registered and unregistered designs, including mask works, copyrights, trade secrets designated in writing at the time of disclosure, design history, manufacturing documentation, and any other form of protection afforded by law to inventions, models, designs, works of authorship, databases or technical information and applications and registrations with respect thereto. 1.7 â€œProductâ€ shall mean a product in a form suitable for human applications consisting of (a) a Formulation that contains Compound for use in an inhalation device or a Device, (b) a Device, but only to the extent that it is sold (or intended to be sold) for use with such a Formulation described in clause (a), (c) both a Device and such a Formulation described in clause (a) for use together, or (d) an Accessory Apparatus for use with the Product configuration described in (c), in each case, including all improvements incorporated therein. 1.8 â€œOption Deadlineâ€ shall mean the date that is [***] years after the Effective Date of this Agreement. 2. Â Â 1.9 â€œPrototype Formulationâ€ shall mean a Formulation of a Compound prepared in accordance with a Work Plan to evaluate a dosage form comprising a cartridge containing a dry powder Formulation of a Compound, which cartridge would be inserted into, or contained within, a pulmonary delivery device (including a Device) for administration in vivo. Â 1.10 â€œWork Planâ€ means any written work plan(s) mutually agreed by MannKind to United Therapeutics in writing as of the Effective Date or during the term of this Agreement, which

set(s) forth the activities to be conducted under this Agreement, as may be amended in accordance with Section 2.4, including the work plans set forth as exhibits attached to a separate letter delivered by MannKind to United Therapeutics and agreed to in writing by United Therapeutics as of the Effective Date. 2. Study Obligations 2.1 Feasibility Activities. 2.1.1 Performance. MannKind agrees to use commercially reasonable efforts to (i) undertake the responsibilities assigned to it in the Work Plans, (ii) perform its obligations under the Work Plans in good faith in a commercially reasonable and workmanlike manner; (iii) as appropriate, make available to United Therapeutics those resources set forth in the Work Plans; and (iv) carry out all work done in the course of the Work Plans in material compliance with all Applicable Laws. 2.1.2 Records. MannKind shall keep complete and accurate records of the results of the Work Plans under this Agreement. These records, including any electronic files where such information may also be contained, shall fully and properly reflect all work done and results achieved in the performance of the Work Plans in sufficient detail and in good scientific manner appropriate for patent, compliance and regulatory purposes. During the term of this Agreement, United Therapeutics shall have the right to review and copy such records maintained by MannKind at reasonable times and upon reasonable notice. (a) Report. Within 30 days of the completion of the Work Plans, MannKind shall submit to United Therapeutics a comprehensive written report of MannKindâ€™s activities thereunder. 2.2 Project Liaison. 2.2.1 Formation; Composition. The Parties shall designate one individual (â€œProject Liaisonâ€) to serve as the primary point of contact between the Parties with regard to activities contemplated by this Agreement. The United Therapeutics Project Liaison shall have the requisite skills in the discipline(s) necessary to provide such reasonable assistance to MannKind as may be required for MannKind to conduct the Work Plans. The MannKind Project Liaison shall provide the United Therapeutics Project Liaison with regular updates as necessary. 2.2.2 Meetings. The Project Liaisons shall meet at such times and locations, either in person or through video or telephone communications, as are necessary to accomplish the Work Plans. As necessary written minutes shall be kept of all material decisions made at such meetings. 3. Â Â 2.3 Regular Communication. Each Party shall be available for a reasonable number of telephone and written consultations regarding activities contemplated by this Agreement on a schedule to be determined by mutual arrangement between the Parties. 2.4 Decision-Making. The Project Liaisons shall discuss in good faith any issues that arise with regard to activities conducted during the course of this Agreement. Any changes to a Work Plan shall require the mutual written approval of the Partiesâ€™ Project Liaisons. In the event of a dispute on any matter within the responsibilities of the Project Liaisons, then the matter shall be referred to the Partiesâ€™ Senior Executives as provided in Section 11.8. 3. Ownership Rights 3.1 Ownership Rights. This Agreement does not convey any ownership or other rights in any Prototype Formulation or MannKind Intellectual Property Rights embodied therein by implication, estoppel or otherwise except for the rights expressly granted in Article 4. MannKind shall retain ownership and control of the Prototype Formulation and all of MannKindâ€™s Intellectual Property Rights therein that were in existence as of the Effective Date or are later generated by MannKind whether inside or outside of scope of the performance by MannKind of its obligations under this Agreement. Similarly, this Agreement does not convey any ownership or other rights in any Intellectual Property Rights of United Therapeutics by implication, estoppel or otherwise. United Therapeutics shall retain ownership and control of United Therapeuticsâ€™ Intellectual Property Rights that were in existence as of the Effective Date or are later generated by United Therapeutics whether inside or outside of scope of the performance by United Therapeutics of its obligations under this Agreement. 3.2 Results of Work Plans. All Developed Technology and all associated Intellectual Property Rights, that are generated, developed or discovered by or on behalf of MannKind shall be deemed MannKind Intellectual Property Rights. All Developed Technology and all associated Intellectual Property Rights, that are generated, developed or discovered by or on behalf of United Therapeutics shall be deemed United Therapeutics Intellectual Property Rights. 3.3 Developed [***]. 3.3.1 Notwithstanding the foregoing provisions of this Article 3, as between the parties, United Therapeutics owns all right, title, and interest in any and all Developed Technology that MannKind develops in the course of performing under this Agreement that constitutes or relates [***] for United Therapeuticsâ€™ products, and all Intellectual Property Rights therein (collectively, [***]), but excluding Developed IP of General Application. MannKind hereby assigns, and shall continue to assign to United Therapeutics, all of its right, title and interest in any [***] that is not Developed IP of General Application. 3.3.2 â€œDeveloped IP of General Applicationâ€ means Developed Technology that MannKind develops in the course of performing under this Agreement that (i) consists of subject matter of general applicability; and (ii) is reasonably necessary or useful for MannKindâ€™s use in its products, and all Intellectual Property Rights therein. 4. Â Â 3.3.3 MannKind hereby grants to United Therapeutics a non-exclusive, fully paid-up, irrevocable license, with the right to grant and authorize sublicenses, under all [***] that is Developed IP of General Application, to make, have made, use, sell, have sold, offer for sale, import and distribute any and all products, components and services for any and all applications. Â 3.4 Reservation of Rights. Except for the rights expressly provided in this Agreement or any other written agreement of the Parties, no other rights are granted by either Party to the other Party. Notwithstanding anything to the contrary, no rights or licenses are granted under this Agreement by either Party to the other for the use of any trade names, trademarks, and service marks. 4. Research Agreement Option 4.1 Option. Subject to the terms and conditions of this Agreement, including payment of the amount set forth in Article 5, MannKind hereby grants to United Therapeutics an exclusive option (the â€œResearch Agreement Optionâ€) to obtain from MannKind exclusive rights and licenses to develop Products in collaboration with MannKind and to commercialize Products, all on terms substantially the same as those provided in the LCA. 4.2 Option Exercise. In order to exercise the Research Agreement Option, United Therapeutics must deliver to MannKind a written exercise notice no later than 5:00 p.m. (Pacific Time) on the Option Deadline. In its notice to MannKind, United Therapeutics shall specify the particular Compound for which it wishes to exercise the Research Agreement Option (the â€œSpecified Compoundâ€). In the event that the Research Agreement Option is not timely exercised, this Agreement shall terminate and United Therapeutics shall have no further rights under this Article 4 with respect to the Compounds. 4.3 Effect of Option Exercise. As soon as practicable (and in any event within 30 days) of the timely exercise of the Research Agreement Option in accordance with Section 4.2, United Therapeutics and MannKind shall use best efforts to agree upon and execute a new royalty-bearing license and collaboration agreement (additional to and separate from the existing LCA) (â€œSecond LCAâ€) on substantially the same terms and the existing LCA (including, for clarity the additional option to add additional Products as provided in Section 2.6 of the LCA), except that: 4.3.1 As used in the Second LCA, the following terms shall have the following meanings and not the meanings provided in the LCA: (a) â€œAPIâ€ shall mean the Specified Compound (as defined above in Section 4.2 of this Agreement). (b) â€œFieldâ€ shall mean the administration of Compounds to human beings for the prevention or treatment of Pulmonary Hypertension. 5. Â (c) â€œMilestonesâ€ and â€œMilestone Paymentsâ€ shall refer to the following: Â Â Milestone Event Milestone Payment (A)Â Â Â Â Â Â [***] $15,000,000 (B) [***] $15,000,000 (C)Â Â Â Â Â Â [***] $15,000,000 (D) [***] $15,000,000 Â (d) â€œOptioned Agentâ€ shall mean any Compound (as defined above in Section 1.1 of this Agreement), other than API. (e) â€œOther Agentâ€ shall be deleted. 4.3.2 All provisions of the LCA that are specific to the Initial Device, Initial Development Plan and Initial Product (as defined in the LCA) shall be deleted or amended as appropriate to effect the intent of the Research Agreement Option with respect to Product based on the Specified Compound for which the Research Agreement Option is exercised. 4.3.3 Corresponding changes from the LCA shall be made in the Second LCA, mutatis mutandis, as appropriate to effect the intent of the Research Agreement Option. For clarity, no Option Exercise Fee shall be payable pursuant to this Agreement, the LCA or the Second LCA in order to exercise the Research Agreement Option or effect the Second LCA or the rights of United Therapeutics with respect to Product based on the Specified Compound for which the Research Agreement Option is exercised. In addition, the Parties shall discuss and agree on a Development Plan for such Product, allocating operational and financial responsibilities to each Party as appropriate for the different indications and therapeutic areas being pursued by each Party for such Product. 4.4 If the Parties are unable to agree on the terms of the Second LCA (a â€œNegotiation Disputeâ€) either Party may submit the matter for resolution by a transactional lawyer (the â€œNeutral Lawyerâ€) with at least fifteen years of experience and a background in biotechnology or agreements of the development, licensing and commercialization of pharmaceuticals. The Neutral Lawyer shall be selected by mutual agreement of the Parties; provided, however, that if the Parties cannot agree on a Neutral Lawyer within five days of a partyâ€™s request for a Neutral Lawyer under this provision, the Neutral Lawyer shall be selected by the American Arbitration Association in Washington, D.C. Each Party shall submit its position as to the Negotiation Dispute to the Neutral Lawyer, who shall resolve the dispute by agreeing to one of the submitted positions of the Parties without any changes to such position. The Parties agree that the position agreed to by the Neutral Lawyer shall be reflected in the Second LCA. The costs of the Neutral Lawyer shall be shared equally by the Parties. The decision of the Neutral Lawyer shall be final and binding on the Parties. The Parties shall cooperate in all respects to resolve any Negotiation Dispute promptly. 6. Â Â 5. Financial Obligations Â As consideration for the activities to be performed by MannKind under the Work Plans and for other rights granted to United Therapeutics under this Agreement, United Therapeutics shall pay to MannKind a one-time, non-refundable fee of $10,000,000 within five business days of the Effective Date via wire transfer as instructed by MannKind. Except as otherwise set forth herein, each Party shall bear its own costs and expenses in connection with performance of this Agreement and the Work Plans. 6. Representations And Warranties; Covenants Â 6.1 General Representations and Warranties. Each Party represents and warrants: Â 6.1.1 Corporate Power and Authorization. It is duly organized and validly existing under the laws of the state of its incorporation, and has full corporate power and authority to execute and deliver this Agreement and to perform all of its obligations hereunder; and Â 6.1.2 Binding Agreement. This Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms; and Â 6.1.3 No Conflict. The execution, delivery and performance of this Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a Party or by which it may be bound, nor violate any law or regulation of any court, governmental body, or administrative or other agency having jurisdiction over it; and Â 6.1.4 Resources. It has adequate resources, both financial and otherwise, to perform its duties hereunder. Â 6.2 Warranty. MannKind represents and warrants to United Therapeutics that it has and shall at all times throughout the term of this Agreement maintain, whether by ownership, by license or otherwise, the Intellectual Property Rights that are required to use, manufacture, market, offer to sell, sell, import and export the Prototype Formulation. 6.3 Disclaimer. Except as expressly set forth in this Agreement, MannKind makes no representations nor extends any warranties of any kind, either express or implied, and expressly disclaims all implied warranties of merchantability and of fitness for a particular purpose or use, non-infringement, validity and enforceability of patents, or the prospects or likelihood of development or commercial success of the Prototype Formulation. Except as expressly stated in this Agreement, all representations and warranties, whether arising by operation of law or otherwise, are expressly excluded. 7. Indemnification Â Each Party (the â€œIndemnifying Partyâ€) shall indemnify and hold harmless the other Party and its Affiliates, and their respective directors, employees, consultants and agents (the â€œIndemnified Partiesâ€) from and against any and all Losses from any Third Party Claims incurred by the Indemnified Parties arising from, or occurring as a result of any breach of any representation, warranty, covenant, or obligation of the Indemnifying Party under this Agreement or any intentional misconduct or negligence by the Indemnifying Party or any of its employees, agents, or subcontractors, except, in each case, to the extent such Losses result from the intentional misconduct or negligence of any of the Indemnified Parties. 7. Â Â 8. Insurance Protection Each Party shall obtain and maintain during the term of this Agreement insurance to support its obligations under this Agreement, which may include self-insurance. 9. Term; Termination 9.1 Term. This Agreement shall begin on the Effective Date and, unless terminated sooner as provided in Section 9.2, shall terminate (a) at 5:00 p.m. (Pacific Time) on the Option Deadline if the Research Agreement Option is not exercised prior to that time in accordance with Section 4.2, or (b) if the Research Agreement Option is timely exercised in accordance with Section 4.2, upon execution by the Parties of the Second LCA as contemplated by Section 4.3. 9.2 Termination Events (a) Without Cause. United Therapeutics shall have the right to terminate this Agreement without cause upon 30 daysâ€™ written notice to MannKind. (b) Business Circumstances. A Party shall have the right to terminate this Agreement in the event of the other Partyâ€™s liquidation, bankruptcy or state of insolvency. 9.3 Effects of Termination. Upon the expiration or earlier termination of this Agreement, each Party shall return to the other Party, upon the other Partyâ€™s request, all tangible items of the other Party in its possession or under its control evidencing the Confidential Information of the other Party unless the Research Option is timely exercised in accordance with Section 4.2, in which case the terms of the Second LCA shall apply to such information. The expiration or earlier termination of this Agreement shall not affect any rights or claims of a Party hereunder that accrued prior to the date of such expiration or earlier termination. 9.4 Survival. Sections 3, 6.3, 7, 9.3, 9.4, 10 and 11 shall survive the expiration or termination of this Agreement. 10. Confidential Information All confidential or proprietary information of a Party disclosed to the other Party or generated in the course of this Agreement, including the identity of Compound, shall be deemed to be Confidential Information as such term is used in the LCA and shall be subject to the secrecy and non-use terms for such information set forth in the LCA. 8. Â Â 11. Miscellaneous 11.1 Assignment. Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld); provided, however, that either Party may assign this Agreement and its rights and obligations hereunder (including, for clarity, with respect to the Research Agreement Option) without the other Partyâ€™s consent (a) in connection with the transfer or sale of all or substantially all of the business of such Party to which this Agreement relates to a Third Party, whether by merger, sale of stock, sale of assets or otherwise, or (b) to any Affiliate. Notwithstanding the foregoing, any such assignment to an Affiliate shall not relieve the assigning Party of its responsibilities for performance of its obligations under this Agreement. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties. Any assignment not in accordance with this Agreement shall be void. 11.2 Relationship of the Parties. It is expressly agreed that United Therapeutics and MannKind shall be independent contractors and that the relationship between the Parties shall not constitute a partnership, joint venture or agency of any kind. Neither Party shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party. 11.3 Amendment. Unless otherwise provided herein, this Agreement may not be changed, waived, discharged, or terminated orally, but instead only by a written document that is signed by the duly authorized representatives of both Parties. 11.4 Waiver. No failure or delay by either Party in exercising any right, power, or privilege under this Agreement shall operate as a waiver thereof, nor shall any single or partial waiver thereof include any other or further exercise thereof or the exercise of any other right, power, or privilege. 11.5 Severability. Whenever possible, each provision of the Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any term or provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of the Agreement and this Agreement shall be interpreted and construed as if such provision had never been contained herein. 9. Â Â 11.6 Notices. Any notice or communication required or permitted under this Agreement shall be in writing in the English language, delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by internationally-recognized courier or sent by registered or certified mail, postage prepaid to the following addresses of the Parties (or such other address for a Party as may be at any time thereafter specified by like notice): To MannKind:MannKind Corporation30930 Russell Ranch Road, Suite 301Westlake Village, California 91362Telephone: (818) 661-5000Facsimile: (818) 661-5098Attention: General Counsel with a copy to:Cooley LLP4401 Eastgate MallSan Diego, CA 92121Telephone: (858) 550-6000Facsimile: (858) 550-6420Attention: L. Kay Chandler, Esq.Â To United Therapeutics:United Therapeutics Corporation1040 Spring Street, Silver Spring, Maryland 20910Attention: General Counsel with a copy to:Wilson Sonsini Goodrich & Rosati1700 K Street, NW, Suite 500Washington, DC 20006Telephone: (202) 973-8830Facsimile: (202) 973-8899Attention: James G. Clessuras, Esq. Â Any such notice shall be deemed to have been given: (a) when delivered if personally delivered; (b) on the next Business Day after dispatch if sent by confirmed facsimile or by internationally-recognized overnight courier; and/or (c) on the third Business Day following the date of mailing if sent by mail or nationally recognized courier. Â 11.7 Dispute Resolution. If a dispute arises under this Agreement, including a dispute between the Project Liaisons, then the Parties shall use reasonable efforts to attempt to resolve such dispute, including escalation of discussions to the appropriate level of management, as provided in Section 11.8, prior to exercising any remedies that may exist by commencing an action against the other Party. Â 11.8 Escalation. Prior to taking action as provided in Section 11.9 below, and at the request of any Party if there is a dispute, the Parties shall first submit such dispute to their respective chief executive officers, or the representative designated by such individual (provided that such representative is a senior executive officer of such Party with authority to settle the applicable issue or dispute submitted for resolution under this Section 11.8) (â€œSenior Executivesâ€) for good faith discussion and attempted resolution. The Senior Executives to whom any dispute is submitted shall attempt to resolve the dispute through good faith negotiations over a reasonable period, not to exceed 10 Business Days, unless the Senior Executives mutually agree in writing to extend such period of negotiation. Such 10 Business Day period shall be deemed to commence on the date the dispute was submitted by a Party to the Senior Executives. The Senior Executives shall, if mutually agreed by the Senior Executives, submit the dispute to voluntary mediation at such place and following such procedures as the Parties shall reasonably agree. All negotiations and discussions pursuant to this Section 11.8 shall be confidential, and the Parties agree that all information concerning or disclosed as part of such negotiations and discussions are and such shall be treated as compromise and settlement negotiations for purposes of applicable rules of evidence. Â 10. Â Â 11.9 Court Actions. If the Senior Executives of the Parties are unable to resolve a given dispute within the time limits set forth in Section 11.8, either

Party may file suit to resolve such matter (including bringing an action for injunctive relief (or any other provisional remedy) as described below. Unless otherwise agreed, by the Parties, all actions and proceedings relating to this Agreement shall be heard and determined in any New York State or federal court sitting in the City of New York, County of Manhattan, and the Parties hereby irrevocably submit to exclusive jurisdiction of such courts in any such action or proceeding and irrevocably waive any defense of inconvenient forum to the maintenance of any such action or proceeding and waive any right to request transfer venue outside any New York State or federal court sitting in the City of New York, County of Manhattan. 11.10 Governing Law. This Agreement, and all questions regarding the existence, validity, interpretation, breach or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, United States, without reference to its conflicts of law principles with the exception of sections 5-1401 and 5-1402 of New York General Obligations Law. 11.11 Entire Agreement. This Agreement includes all exhibits attached hereto and any specifications that are executed by authorized representatives of the Parties, and constitutes the entire Agreement by and between the Parties with respect to the formulation prototyping activities described in the Work Plans. 11.12 Counterparts; Electronic or Facsimile Signatures. This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. This Agreement may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party. 11.13 Limitation of Liability. EXCEPT FOR LIABILITY FOR BREACH OF ARTICLE 10, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE OR RIGHT GRANTED HEREUNDER; provided, however, that this Section 11.13 shall not be construed to limit either Partyâ€™s indemnification obligations with respect to Third Party Claims under Article 7. 11.14 Separate Agreements. For the avoidance of any doubt, this Agreement and the Second LCA (if executed) are entirely separate from, and its effectiveness is not conditioned in any way on the effectiveness of, the LCA. [Signature Page Follows] 11. Â Â In Witness Whereof, the Parties hereto have this day caused this Agreement to be executed by their duly authorized officers. MANNKIND CORPORATION UNITED THERAPEUTICS CORPORATION Â Â Â Â Â By: /s/ Michael Castagna Â By: /s/ Martine Rothblatt Name: Michael Castagna Â Name: Martine Rothblatt Title: Chief Executive Officer Title: Chief Executive Officer EX-31.1 5 mnkd-ex31_1.htm EX-31.1 EX-31.1 Â Exhibit 31.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED I, Michael E. Castagna, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 of MannKind Corporation; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Â /s/ Michael E. Castagna Michael E. CastagnaChief Executive Officer and Director Â Date: November 7, 2024 Â Â EX-31.2 6 mnkd-ex31_2.htm EX-31.2 EX-31.2 Â Exhibit 31.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED I, Christopher B. Prentiss, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 of MannKind Corporation; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Â /s/ Christopher B. Prentiss Christopher B. PrentissChief Financial Officer Â Date: November 7, 2024 Â Â EX-32.1 7 mnkd-ex32_1.htm EX-32.1 EX-32.1 Â Exhibit 32.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(b) OR 15d-14(b) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND SECTION 1350 OF CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE (18 U.S.C. Â§ 1350)1 In connection with the filing of the quarterly report of MannKind Corporation (the â€œCompanyâ€) on Form 10-Q for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission on or about the date hereof, to which this certification is attached as Exhibit 32.1 (the â€œReportâ€) and pursuant to the requirement set forth in Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Â§1350), Michael E. Castagna, Chief Executive Officer of MannKind Corporation (the â€œCompanyâ€), hereby certifies that, to the best of his knowledge: 1. The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. In Witness Whereof, the undersigned has set his hand hereto as of the 7th day of November, 2024. Â Â /s/ Michael E. Castagna Michael E. Castagna Chief Executive Officer Â 1 This certification is being furnished solely to accompany this quarterly report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not deemed filed for purposes of Section 18 of the Exchange Act or the Securities Act of 1933, as amended, and is not incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language contained in such filing. Â Â EX-32.2 8 mnkd-ex32_2.htm EX-32.2 EX-32.2 Â Exhibit 32.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13a-14(b) OR 15d-14(b) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND SECTION 1350 OF CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE (18 U.S.C. Â§ 1350)1 In connection with the filing of the quarterly report of MannKind Corporation (the â€œCompanyâ€) on Form 10-Q for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission on or about the date hereof, to which this certification is attached as Exhibit 32.2 (the â€œReportâ€) and pursuant to the requirement set forth in Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Â§1350), Christopher B. Prentiss, Chief Financial Officer of MannKind Corporation (the â€œCompanyâ€), hereby certifies that, to the best of his knowledge: 1. The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. In Witness Whereof, the undersigned has set his hand hereto as of the 7th day of November, 2024. Â Â /s/ Christopher B. Prentiss Christopher B. Prentiss Chief Financial Officer Â 1 This certification is being furnished solely to accompany this quarterly report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not deemed filed for purposes of Section 18 of the Exchange Act or the Securities Act of 1933, as amended, and is not incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language contained in such filing. Â Â EX-101.SCH 9 mnkd-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Commitment and contingencies - Schedule of Remaining Financing Lease Payments (Detail) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Disclosure - Commitments and Contingencies - Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements (Detail) 2 link:presentationLink link:calculationLink link:definitionLink 100040 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Office And Vehicle Lease Payments (Detail) 2 link:presentationLink link:calculationLink link:definitionLink 100050 - Disclosure - Commitments and Contingencies - Schedule of Remaining Financing Liability Payments (Detail) 2 link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100090 - Statement - Condensed Consolidated Statements of Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 100100 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Description of Business and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Pulmatrix Transaction link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Accounts Receivable link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Borrowings link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Collaboration, Licensing and Other Arrangements link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Common and Preferred Stock link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Earnings Per Common Share link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Stock-Based Compensation Expense link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Description of Business and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Description of Business and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Pulmatrix Transaction (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Accounts Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Collaboration, Licensing and Other Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Earnings Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Stock-Based Compensation Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Description of Business and Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Description of Business and Significant Accounting Policies - Additional Information (Detail 1) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Description of Business and Significant Accounting Policies - Additional Information (Detail 1) [Default] link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Description of Business and Significant Accounting Policies - Summary of Revenue and Cost of Revenue and Goods Sold Generated From Product Sales, Services and Royalties (Detail) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Pulmatrix Transaction - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Pulmatrix Transaction - Schedule of Preliminary Purchase Consideration (Detail) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Pulmatrix Transaction - Schedule of Fair Value of Identifiable Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Pulmatrix Transaction - Summary of Supplemental Pro Forma Information (Unaudited) (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Investments - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Investments - Schedule of Contractual Maturities of Held to Maturity Investments (Detail) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Investments - Schedule of Contractual Maturities of Held to Maturity Investments (Parenthetical) (Detail) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Investments - Schedule of Fair Value of Cash Equivalents, Long and Short Term Investments (Detail) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Schedule of Accounts Receivable, Net (Detail) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Accounts Receivable - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Inventories - Components of Inventory (Detail) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Inventories - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Property and Equipment, Net (Detail) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Property and Equipment, Net (Parenthetical) (Detail) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Depreciation Expense Related to Property and Equipment (Detail) link:presentationLink link:calculationLink

link:definitionLink 995955 - Disclosure - Property and Equipment - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - Goodwill and Other Intangible Assets - Summary of Other Intangible Asset (Detail) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - Accrued Expenses and Other Current Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 995995 - Disclosure - Accrued Expenses and Other Current Liabilities (Parenthetical) (Detail) link:presentationLink link:calculationLink link:definitionLink 996005 - Disclosure - Borrowings - Summary of Carrying Amount of Borrowings (Detail) link:presentationLink link:calculationLink link:definitionLink 996015 - Disclosure - Borrowings - Schedule of Line of Credit Facility Debt and Key Terms (Detail) link:presentationLink link:calculationLink link:definitionLink 996025 - Disclosure - Borrowings - Schedule of Maturities of Company's Borrowings (Detail) link:presentationLink link:calculationLink link:definitionLink 996035 - Disclosure - Borrowings - Senior Convertible Notes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 996045 - Disclosure - Borrowings - MidCap Credit Facility - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 996055 - Disclosure - Borrowings - Mann Group Promissory Notes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 996065 - Disclosure - Borrowings - Schedule of Amortization of Premium and Accretion of Debt Issuance Costs (Detail) link:presentationLink link:calculationLink link:definitionLink 996075 - Disclosure - Collaboration, Licensing and Other Arrangements - Schedule of Revenue from Collaborations and Services (Details) link:presentationLink link:calculationLink link:definitionLink 996085 - Disclosure - Collaboration, Licensing and Other Arrangements - Summary of UT Revenue (Detail) link:presentationLink link:calculationLink link:definitionLink 996095 - Disclosure - Collaboration, Licensing and Other Arrangements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 996105 - Disclosure - Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Detail) link:presentationLink link:calculationLink link:definitionLink 996115 - Disclosure - Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 996125 - Disclosure - Collaboration, Licensing and Other Arrangements - Additional Information (Detail 1) link:presentationLink link:calculationLink link:definitionLink 996125 - Disclosure - Collaboration, Licensing and Other Arrangements - Additional Information (Detail 1) [Default] link:presentationLink link:calculationLink link:definitionLink 996135 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 996145 - Disclosure - Fair Value of Financial Instruments - Fair Value of Financial Instruments (Detail) link:presentationLink link:calculationLink link:definitionLink 996155 - Disclosure - Fair Value of Financial Instruments - Fair Value of Financial Instruments (Parenthetical) (Detail) link:presentationLink link:calculationLink link:definitionLink 996165 - Disclosure - Common and Preferred Stock - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 996175 - Disclosure - Earnings Per Common Share - Components of Basic and Diluted EPS Computations (Detail) link:presentationLink link:calculationLink link:definitionLink 996185 - Disclosure - Earnings Per Common Share - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Detail) link:presentationLink link:calculationLink link:definitionLink 996195 - Disclosure - Earnings Per Common Share - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Parenthetical) (Detail) link:presentationLink link:calculationLink link:definitionLink 996205 - Disclosure - Stock-Based Compensation Expense - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 996215 - Disclosure - Stock-Based Compensation Expense - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Details) link:presentationLink link:calculationLink link:definitionLink 996225 - Disclosure - Stock-Based Compensation Expense - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 996235 - Disclosure - Stock-Based Compensation Expense - Stock Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations (Detail) link:presentationLink link:calculationLink link:definitionLink 996245 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 996255 - Disclosure - Commitments and Contingencies - Schedule Of Royalty Liability Account Roll Forward (Details) link:presentationLink link:calculationLink link:definitionLink 996265 - Disclosure - Commitments and Contingencies - Schedule of Financing Liability Lease Term and Discount Rate (Detail) link:presentationLink link:calculationLink link:definitionLink 996275 - Disclosure - Commitments and Contingencies - Summary of Financing Liability Costs (Detail) link:presentationLink link:calculationLink link:definitionLink 996285 - Disclosure - Commitments and Contingencies - Schedule of Remaining Financing Liability Payments (Detail) link:presentationLink link:calculationLink link:definitionLink 996295 - Disclosure - Commitments and Contingencies - Summary of Finance Lease Information (Detail) link:presentationLink link:calculationLink link:definitionLink 996305 - Disclosure - Commitment and contingencies - Schedule of Remaining Financing Lease Payments (Detail) link:presentationLink link:calculationLink link:definitionLink 996315 - Disclosure - Commitments and Contingencies - Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements (Detail) link:presentationLink link:calculationLink link:definitionLink 996325 - Disclosure - Commitments and Contingencies - Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 996335 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate (Detail) link:presentationLink link:calculationLink link:definitionLink 996345 - Disclosure - Commitments and Contingencies - Summary of Lease Information (Detail) link:presentationLink link:calculationLink link:definitionLink 996355 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Office And Vehicle Lease Payments (Detail) link:presentationLink link:calculationLink link:definitionLink 996365 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 996375 - Disclosure - Subsequent Events (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items] Statement [Line Items] Right-of-use asset - Bedford R&D facility Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right Of Use Assets Business combination recognized identifiable assets acquired and liabilities assumed operating lease right-of-use assets. Furniture, fixtures and office equipment Furniture Fixtures And Office Equipment [Member] Furniture, fixtures and office equipment. Inventory Current [Table] Inventory Current [Table] Number of wholesale distributors Number Of Wholesale Distributors Number of wholesale distributors. Land Land [Member] Principal and early extinguishment payments on MidCap credit facility. Principal and early extinguishment payments on MidCap credit facility Principal and early extinguishment payments on MidCap credit facility Principal and early extinguishment payments on MidCap credit facility Debt Instrument Debt Instrument [Axis] Market value of common stock Market Value Of Common Stock Market value of common stock. Capacity fee Capacity Fee Capacity fee. Accounts receivable, net Increase Decrease In Accounts Receivable Estimated Capacity Fees, Total Estimated Capacity Fees Estimated capacity fees. Sale Leaseback Transaction, Net Book Value, Total Lease repurchase, amount Sale Leaseback Transaction Net Book Value Senior Convertible Notes Senior Convertible Notes [Member] Senior convertible notes. Deerfield Management Company Lp [Member] Deerfield Management Company L.P. Deerfield Entity Address, Postal Zip Code Entity Address Postal Zip Code Loss on estimated returns of acquired product Loss on Estimated Returns of Acquired Product Loss on estimated returns of acquired product. Percentage of Future Royalty Revenues Percentage of Future Royalty Revenues Percentage of future royalty revenues. Acquisitions Business Combinations Policy Sinking fund Debt Instrument Sinking Fund Payment Revenue Remaining Performance Obligation Anticipated Revenue Allocation Anticipated revenue allocation Weighted average common shares Weighted Average Number of Shares Outstanding, Diluted, Adjustment Weighted Average Number of Shares Outstanding, Diluted, Adjustment, Total Amount receivable on matured investment Amount Receivable On Matured Investment Amount receivable on matured investment. Entity Incorporation, State or Country Code Entity Incorporation State Country Code Discounts and allowances for commercial product sales Customer Discounts And Allowances Customer Discounts And Allowances Expenses: Costs And Expenses [Abstract] Revenues: Revenues [Abstract] Interest paid in cash Interest Paid Net Index Target 90th Percentile or Higher Share Based Compensation Awards Tranche Five [Member] Share based compensation awards tranche five. Senior Convertible Notes Senior Notes [Member] Unrecognized compensation expense related to non-option Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options Number of operating segment Number Of Operating Segments Share-Based Payment Arrangement, Tranche One Share Based Compensation Award Tranche One [Member] Estimated Capacity Fees, 2027 Estimated Capacity Fees Due In Third Year Estimated capacity fees due in third year. Pulmatrix Transaction Business Combination Disclosure [Text Block] Finite-Lived Intangible Asset, Expected Amortization, Year Four 2027 Organization Consolidation And Presentation Of Financial Statements Disclosure [Table] Organization Consolidation And Presentation Of Financial Statements Disclosure [Table] Initial conversion price of premium percentage Debt Instrument Initial Conversion Price Of Premium Percentage Debt Instrument initial conversion price of premium percentage. Income Tax Authority, Name [Domain] Line of credit facility principal payment start date Line Of Credit Facility Principal Payment Start Date Line of credit facility principal payment start date. Beginning Balance (in shares) Ending Balance (in shares) Shares Outstanding Other Noncash Income (Expense), Total Other Noncash Income (Expense) Other, net Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Master Lease Agreement with Enterprise Master Lease Agreement With Enterprise [Member] Master lease agreement with enterprise. Schedule of Fair Value of Identifiable Assets Acquired and Liabilities Assumed Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed Table [Text Block] Fair Value, Inputs, Level 2 Fair Value Inputs Level2 [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Fair Value Measurement Fair Value Disclosure Item Amounts [Domain] Long-Term Debt, Type Longterm Debt Type [Domain] Open Tax Year Tax years Non-cash acquisition of intangible asset Non-cash Acquisition Of Intangible Asset Non-cash acquisition of intangible asset. Credit Risk Dividend Yield Measurement Input Entity Credit Risk [Member] Remainder of 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Aggregate fair value, due in one year or less Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Maximum value of additional investment limit Maximum Value Of Additional Investment Limit Maximum value of additional investment limit. Product and Service Product Or Service [Axis] Business Business Policy [Text Block] Business. Asset acquisition, effective date of acquisition Asset Acquisition Effective Date Of Acquisition Finite-Lived Intangible Assets by Major Class Finite Lived Intangible Assets By Major Class [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] NON-CASH INVESTING AND FINANCING ACTIVITIES: Noncash Investing And Financing Items [Abstract] Payments to Acquire Productive Assets, Total Cash consideration Asset acquisition, up-front consideration Payments To Acquire Productive Assets ESPP Employee Stock [Member] Effect of dilutive securities - common shares issuable Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Thereafter Finance Lease Liability Discounted Payments Due After Year Four Finance lease liability discounted payments due after year four. Interest expense Interest Expense, Nonoperating Interest Expense, Nonoperating, Total Common and Preferred Stock Stockholders Equity Note Disclosure [Text Block] Deferred lease liability Direct Financing Lease Deferred Selling Profit Title of Individual Title Of Individual [Axis] convertible note plus accrued interest Increase Decrease In Accrued Interest On Convertible Notes Increase decrease in accrued interest on convertible notes. Sale of Stock Sale Of Stock Name Of Transaction [Domain] Cash and Cash Equivalents Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member] Remainder of Year Remainder of Year[Member] Remainder of year. Work-in-process Inventory Work In Process Net Of Reserves Total principal payments Debt Instrument Carrying Amount Other Other Agreement [Member] Other agreement. Amount available under credit facility Line Of Credit Facility Remaining Borrowing Capacity Principal payments on mid cap credit facility. Principal payments on mid cap credit facility Principal payments on MidCap credit facility Unrealized gain (loss) on available-for-sale securities Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax Unrealized gain on available-for-sale securities Estimated Useful Life (Years) Finite Lived Intangible Asset Useful Life Inventories Inventory Policy [Text Block] Entity Central Index Key Entity Central Index Key Less: cash equivalents Cash Equivalents, at Carrying Value, Total Cash Equivalents At Carrying Value Less cash equivalents Common Stock Options and PNQs Common Stock Options And Performance Based Stock Option Awards [Member] Common stock options and performance based stock option awards. 2027 Finance Lease Liability Discounted Payments Due Year Three Finance lease liability discounted payments due year three. Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Loss (gain) on available-for-sale securities Debt Securities, Available-for-Sale, Gain (Loss) Debt Securities, Available-for-Sale, Gain (Loss), Total (Loss) gain on available-for-sale securities Common stock, shares issued Common Stock Shares Issued Proceeds from offering after deducting initial purchasers discounts and commissions and estimated offering expenses payable Proceeds from the Senior convertible notes Proceeds From Convertible Debt Dividend Yield Measurement Input Expected Dividend Rate [Member] Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Senior Notes, Total Senior convertible notes Senior Notes Principal payments on financing liability. Principal payments on financing liability Principal payments on financing liability Income Statement [Abstract] Accounts Receivable Financing Receivables [Text Block] Entity Address, State or Province Entity Address State Or Province Description of Business and Significant Accounting Policies Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block] Funding for capital improvements Payments For Capital Improvements Stock Issued During Period Value Employee Stock Purchase Plan Issuance of common stock under the employee stock purchase plan Assets: Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets [Abstract] Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income (loss) before income tax expense Debt Securities, Held-to-Maturity, Maturity, Allocated and Single Maturity Date, Fair Value Aggregate fair value, total Discount on purchase price percentage of fair market value Discount On Purchase Price Percentage Of Fair Market Value Discount on purchase price percentage of fair market value. Debt default, description Default Longterm Debt Description Of Violation Or Event Of Default Mann Group convertible note Convertible Notes Non Current Convertible notes non current. Collaboration and License Agreement Collaboration And License Agreement [Member] Collaboration and license agreement. Portion at Fair Value Measurement [Member] [Default] Fair Value Disclosure Item Amounts [Default] Portion At Fair Value Fair Value Disclosure [Member] Financing liability noncurrent. Financing Liability Noncurrent Financing liability - long term Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Lease repurchase description Lease Repurchase Description Lease repurchase description. Schedule Of Investments [Table] Schedule Of Investments [Table] Unamortized transaction costs. Unamortized Transaction Costs Unamortized transaction costs On or Prior to April 22, 2022 Debt Instrument Redemption Period One [Member] Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total Unrecognized income tax interest and penalties Unrecognized Tax Benefits Income Tax Penalties And Interest Expense Deferred transaction costs Deferred Transaction Costs Deferred transaction costs. Finite-Lived Intangible Asset, Expected Amortization, Year Three 2026 Debt instrument extended interest-only date Debt Instrument Extended Interest Only Date Debt instrument extended interest-only date. Principal amount per share Principal Amount Per Share Principal amount per share. Reclassification Of Investments From Long Term To Current Reclassification of investments from long-term to current. Reclassification of investments from long-term to current Convertible Note Interest Convertible Note Interest [Member] Convertible note interest. Promissory Notes Promissory Notes [Member] Promissory notes. Raw materials inventory Inventory Raw Materials Interest payments Finance Lease Liability Discounted Excess Amount Finance lease liability discounted excess amount. Interest payments Amortization of Debt Issuance Costs Amortization of debt issuance cost Net issuance of common stock associated with stock options and restricted stock units Stock Issued During Period Value Stock Options And Restricted Stock Units Net Of Forfeitures Stock issued during period value stock options and restricted stock units net of forfeitures. Note payable, percentage of hypothetical yield Debt Instrument Measurement Input After Change Debt instrument measurement input after change. Hypothetical yield percentage Cover [Abstract] Subsequent Event [Line Items] Net income (loss) per share, Basic Earnings Per Share, Basic, Total Earnings Per Share Basic Net income (loss) per share - basic Consecutive trading days Consecutive Trading Days Consecutive trading days. Description of right to extension of lease term Lessee Operating Lease Option To Extend Timing of Transfer of Good or Service Timing Of Transfer Of Good Or Service [Axis] Finance Lease, Principal Payments Principal payments on financing lease liability Milestone Rights Milestone Rights Liability Milestone Rights Liability [Member] Milestone Rights Liability Deferred revenue - current Deferred revenue â€" current Contract With Customer Liability Current Asset Acquisition [Axis] Debt instrument remaining principal and interest after conversion. Debt instrument remaining principal and interest after conversion Royalty percentage Royalty Net Sales Percentage Royalty net sales percentage. Fair Value Of Financial Instruments [Table] Fair Value Of Financial Instruments [Table] Fair Value of Financial Instruments [Table] Reclassification Of Convertible Notes And Interest Receivable Reclassification of convertible notes and interest

receivable. Reclassification of Thirona convertible notes and interest receivable from current to long-term Recognition Period Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation Allocated Share Based Compensation Expense Total Remaining Purchase Commitments, 2028 Purchase Obligation Due In Fourth Year Russell Ranch Road II LLC Russell Ranch Road I I L L C [Member] Russell Ranch Road II LLC. Non-Convertible Note Non Convertible Note [Member] Non convertible note. Total debt â€" net carrying amount Long Term Debt Payment of credit facility exit fee Payment Of Credit Facility Exit Fee Payment of credit facility exit fee. Zealand Pharma US Zealand Pharma US [Member] Zealand Pharma US [Member] Retained Earnings (Accumulated Deficit), Total Accumulated deficit Retained Earnings Accumulated Deficit Percentage of royalty on net sales Percentage of Royalty on Net Sales Percentage of royalty on net sales. Current assets: Assets Current [Abstract] Common stock available for issuance Common Stock Capital Shares Reserved For Future Issuance Estimated Capacity Fees, 2033 Estimated Capacity Fees Due In Ninth Year Estimated capacity fees due in ninth year. Transaction Price For The Contractual Obligations Transaction Price For The Contractual Obligations [Member] Transaction price for the contractual obligations. Commercial Supply Agreement Commercial Supply Agreement [Member] commercial supply agreement. Net cash provided by operating activities Net Cash Provided By Used In Operating Activities Net assets acquired - Gain on bargain purchase Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net Royalties Royalty Expense Product and Service Products And Services [Domain] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income Loss Net Of Tax Lease initial term Lessee Operating Lease Term Of Contract Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total Property and equipment Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment Operating Loss Carryforwards Net operating losses Total property and equipment, net Property and equipment, net Property Plant And Equipment Net Year 4 Lessee Operating Lease Liability Payments Due Year Four Deferred revenue - non-current Deferred revenue â€" long term Contract With Customer Liability Noncurrent CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided By Used In Operating Activities [Abstract] Sale price Proceeds From Sale Of Real Estate Reimbursements Fees and Expenses Fees and expenses. Gross Unrealized Holding Losses Gross Unrealized Holding Losses [Member] Gross unrealized holding losses. Fair Value of Financial Instruments Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Vesting Vesting [Axis] Common stock, par value Common Stock Par Or Stated Value Per Share Commercialization and Continuous Improvement Activities Commercialization And Continuous Improvement Activities [Member] Commercialization and continuous improvement activities. Recognized loss on purchase commitments â€" long term Purchase Obligation Noncurrent Purchase obligation noncurrent. Repayments of Notes Payable Principal and early extinguishment payments on Mann Group convertible note Tranche 2 Tranche Two [Member] Tranche 2 Remaining Purchase Commitments, 2026 Purchase Obligation Due In Second Year Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Debt instrument, prepayment penalty percentage Payments of Debt Issuance Costs Percentage Payments of debt issuance costs percentage. Measurement Input Type Measurement Input Type [Domain] Estimated Capacity Fees, 2029 Estimated Capacity Fees Due In Fifth Year Estimated capacity fees due in fifth year. Contract with Customer, Liability, Total Deferred revenue Contract With Customer Liability Business Acquisition Pro Forma Information [Abstract] Net loss per share - diluted Business Acquisition Pro Forma Earnings Per Share Diluted Returns reserve for acquired product Returns Reserve For Acquired Product Returns reserve for acquired product. Timing of Transfer of Good or Service Timing Of Transfer Of Good Or Service [Domain] Statement Of Cash Flows [Abstract] Counterparty Name Counterparty Name [Axis] Held-to-Maturity Investments Held To Maturity Securities Purchased Options Price Policy Antidilutive Securities, Name Antidilutive Securities Name [Domain] Office Lease Office [Member] Office. Recognized loss on purchase commitments â€" current Purchase Obligation Current Purchase obligation current. Accounts Receivable [Line Items] Accounts Notes And Loans Receivable [Line Items] Entity Entity [Domain] Additional Paid-in Capital Statement Equity Components [Axis] Entity Address, Address Line One Entity Address Address Line1 Senate Bills 167. Senate Bills 167 [Member] Senate Bills 167 Components of Basic and Diluted EPS Computations Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Employee-related Liabilities, Current, Total Salary and related expenses Employee Related Liabilities Current Granted awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Schedule Of Finite Lived Intangible Assets [Table] Schedule Of Finite Lived Intangible Assets [Table] Loss on purchase commitments, number of new contracts recognized Loss On Purchase Commitments Number Of Contracts Recognized Loss on purchase commitments number of contracts recognized. Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Subsequent Event Type [Axis] Redemption price percentage Debt Instrument Redemption Price Percentage Of Principal Amount Redeemed Sagard Sagard Healthcare Partners Funding Borrower S P E 2, L P [Member] Sagard Healthcare Partners Funding Borrower S P E 2, LP. Total other expense Nonoperating Income Expense Potential Dilutive Securities Outstanding that are Considered Antidilutive Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Payments to Acquire Held-to-Maturity Securities Purchase of held-to-maturity debt securities Milestone Rights Liability to be Paid Milestone Rights Liability to be Paid Milestone rights liability to be paid UT Manufacturing facility. UT Manufacturing Facility [Member] UT Manufacturing Facility Remaining Purchase Commitments, 2029 Purchase Obligation Due In Fifth Year Unamortized debt issuance cost Unamortized Debt Issuance Expense Investments Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Finite-Lived Intangible Asset, Expected Amortization, Year Two 2025 Amendment Flag Amendment Flag Operating Loss Carryforwards [Table] Fair value of contingent consideration Asset Acquisition Consideration Transferred Contingent Consideration Cipla Ltd Cipla Ltd [Member] Cipla Ltd. Operating lease liability Operating Lease Liability Noncurrent Schedule Of Amortization Of Debt Issuance Cost And Debt Discount Table [Text Block] Schedule of amortization of debt issuance cost and debt discount. Schedule of Amortization of Premium and Accretion of Debt Issuance Costs Total financing liability Total financing liability Finance Lease Liability Discounted Finance lease liability discounted. Common stock issued to pay interest Common Stock Issued To Pay Interest Common stock issued to pay interest. Finished goods Inventory Finished Goods Net Of Reserves Debt Instrument, Name Debt Instrument Name [Domain] Additional paid-in capital Additional Paid In Capital Common Stock Purchase of available-for-sale securities Purchase of available-for-sale securities Purchase of available-for-sale investment Purchase Of Available For Sale Securities Purchase of available-for-sale securities. Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] SOFR Secured Overnight Financing Rate Sofr Overnight Index Swap Rate [Member] Receivables [Abstract] Receivable [Policy Text Block] Accounts Receivable and Allowance for Credit Losses Net income (loss) Net income (loss) Financing liability current. Financing Liability Current Financing liability - current Variable Rate Variable Rate [Domain] Product Sales Product Sales [Member] Product sales. Net revenue Business Acquisitions Pro Forma Revenue Schedule Of Debt Table [Text Block] Summary of Carrying Amount of Borrowings Landlord-funded tenant improvements payable Landlord Funded Tenant Improvements Payable Landlord funded tenant improvements payable. Thereafter Lessee Operating Lease Liability Payments Due After Year Four Lessee operating lease liability payments due after year four. Equity Component Equity Component [Domain] Statistical Measurement Range [Member] 2026 Finance Lease Liability Discounted Payments Due Year Two Finance lease liability discounted payments due year two. General and Administrative Expense, Total General and Administrative Expense General and administrative Interest rate Investment Interest Rate Interest Expense Debt Interest Expense, Debt, Total Interest expense on notes Interest Expense Debt Royalties Arrangement [Member] Royalties. Royalties Arrangement Other income Other Nonoperating Income (Expense), Total Other Nonoperating Income Expense Disaggregation Of Revenue [Table] Disaggregation Of Revenue [Table] Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Profit Loss Undesignated preferred stock, shares issued Preferred Stock Shares Issued Payments for taxes related to net issuance of common stock associated with restricted stock units and stock options Payments For Taxes Related To Net Issuance Of Common Stock Associated With Restricted Stock Units And Stock Options Payments for taxes related to net issuance of common stock associated with restricted stock units and stock options. Transaction costs Payments for Merger Related Costs Cash paid Operating Lease Payments Unamortized discount and prepayment fee Debt Instrument, Unamortized Discount, Total Unamortized debt discount Debt Instrument Unamortized Discount Debt instrument advance available date Debt Instrument Advance Available Date Debt instrument advance available date. Payables And Accruals [Abstract] Royalty retaining percentage Royalty Retaining Percentage Royalty retaining percentage. Stock Issued During Period Shares Employee Stock Purchase Plans Issuance of common stock under the employee stock purchase plan (in shares) Short-Term Investments, Total Short-term investments Short Term Investments Non-cash revenue recognized Non Cash Revenue Recognized Non-cash revenue recognized. Cantor Fitzgerald Cantor Fitzgerald [Member] Cantor fitzgerald. Operating lease rent expenses Operating Lease Expense Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Over Time Transferred Over Time [Member] Contingent liability remain payable Contingent Liability Remaining Payable Amount Contingent liability remaining payable amount. Accrued Expenses And Other Current Liabilities Accrued Expenses And Other Current Liabilities [Member] Accrued expenses and other current liabilities. Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Percentage of revenue from major customers collaborations and services Percentage Of Revenue From Major Customers Collaborations And Services Percentage of revenue from major customers collaborations and services. Collaboration, Licensing and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Summary of Other Intangible Assets Schedule Of Finite Lived Intangible Assets Table [Text Block] Comprehensive Income Net Of Tax Comprehensive income (loss) Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common stock, shares outstanding Common Stock Shares Outstanding Finite-Lived Intangible Assets, Major Class Name Finite Lived Intangible Assets Major Class Name [Domain] Purchase Commitment, Remaining Minimum Amount Committed Minimum amount to expended Undesignated preferred stock, par value Preferred Stock Par Or Stated Value Per Share Payments of principal and interest through common stock issuances. Payments of principal and interest through common stock issuances Payments of Mann Group principal and interest through common stock issuances Weighted Average Weighted Average [Member] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Cost of Revenues Cost Of Revenues Policy [Text Block] Cost of revenues. Amount of divestiture of long-lived Property, Plant and Equipment, Disposals Finite Lived Intangible Assets [Line Items] Finite Lived Intangible Assets [Line Items] Royalty Revenue Royalty revenue. Royalty revenue earned by or payable to Sagard Schedule of Revenue from Collaboration and Services Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions Table [Text Block] Entity Interactive Data Current Entity Interactive Data Current AFREZZA product sales Commercial product sales Product [Member] Net sales Revenue Recognition, Milestone Method, Revenue Recognized Liabilities: Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities [Abstract] Principal payment on mid cap credit facility. Principal Payment On Mid Cap Credit Facility Principal payment on MidCap credit facility Payments Of Debt Extinguishment Costs Debt instrument, prepayment penalty 2024 Convertible Notes Two Thousand Twenty Four Convertible Notes [Member] Two thousand twenty four convertible notes. Percentage of repurchase price Debt Instrument Redemption Price Percentage Document Quarterly Report Document Quarterly Report Early termination fees, percentage Early Termination Fees Percentage Early termination fees percentage. Related Party Transaction Related Party Transaction [Domain] Balance Sheet Location Statement of Financial Position Location, Balance [Axis] Thereafter Long Term Debt Maturities Repayments Of Principal After Year Three Long term debt maturities repayments of principal after year three. Statistical Measurement Range [Axis] 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Five Selling Expense Selling Contingencies Commitments And Contingencies Policy [Text Block] Cost of Goods and Services Sold, Total Cost of goods sold Cost Of Goods And Services Sold Operating lease costs Operating Lease Cost Share-Based Payment Arrangement, Tranche Three Index Target 50th Percentile Share Based Compensation Award Tranche Three [Member] Related Party Related and Nonrelated Parties [Domain] Lease, Cost, Total Embedded lease cost per month Lease Cost Summary of Revenue and Cost of Revenue and Goods Sold Generated From Product Sales, Services and Royalties Disaggregation Of Revenue Table [Text Block] Schedule of Future Minimum Office And Vehicle Lease Payments Lessee Operating Lease Liability Maturity Table [Text Block] On or After April 23, 2023 Through Maturity Date Debt Instrument Redemption Period Three [Member] Cash paid for interest on financing liability Finance Lease, Interest Payment on Liability Commercial Bonds and Paper Commercial Paper [Member] Finite-Lived Intangible Assets, Gross, Total Cost Finite Lived Intangible Assets Gross Restricted stock units weighted average grant date fair value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value Unrecognized compensation expense, weighted average period for recognition Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Remainder of Remaining Purchase Commitments, 2024 Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year Loss Contingency, Nature Loss Contingency Nature [Domain] Machinery And Equipment [Member] Machinery and Equipment Remaining Purchase Commitments, 2025 Purchase Obligation Due In Next Twelve Months Percentage of gross sales from major wholesale distributors Percentage Of Sales From Major Customers Percentage of sales from major customers. Research and Development Research and Development Expense, Policy [Policy Text Block] Measurement Basis Fair Value By Measurement Basis [Axis] Accrued expenses and other current liabilities. Accrued Expenses and Other Current Liabilities [Line Items] Income Statement Location Statement of Income Location, Balance [Axis] Cash and Cash Equivalents Cash And Cash Equivalents [Axis] Total assets Assets Debt Instrument [Table] Debt Instrument [Table] Note payable, fair value key inputs Debt Instrument Measurement Input Volatility percentage Business Acquisition [Line Items] Business Acquisition [Line Items] Marlborough Lease Marlborough Lease [Member] Marlborough lease. Entity Address, City or Town Entity Address City Or Town Thirona Bio, Inc. Thirona Bio Inc [Member] Thirona Bio, Inc. AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income Equity [Abstract] Reclassification of operating lease liability from long-term to current. Reclassification of operating lease liability from long-term to current Reclassification of operating lease liability from long-term to current Sold portion of royalty revenue. Sold Portion of Royalty Revenue Sold portion of royalty revenue Sold portion of royalty revenue Investment Building and Building Improvements Amount transferred from construction in progress to building improvements Payments Of Stock Issuance Costs Issuance costs associated with at-the-market offering Schedule Of Maturities Of Long Term Debt Table [Text Block] Schedule of Maturities of Company's Borrowings Amortization of debt discount and prepayment fee Amortization of debt discount and prepayment fee Amortization of debt discount and prepayment fee. V-Go V Go [Member] V-Go. Number of pulmatrix employees which began employment. Number of pulmatrix employees which began employment Fair value of consideration: Asset Acquisition Consideration Transferred [Abstract] Senate Bills 175. Senate Bills 175 [Member] Senate Bills 175 Amortization of transaction costs Amortization Of Transaction Costs Amortization of transaction costs. Reserve for allowance for credit losses Contract With Customer Receivable Allowance For Credit Loss Principal amount Debt Instrument Face Amount Amount Due Depreciation, Total Depreciation Expense Depreciation Common stock price per share Share Price Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Organization, consolidation and presentation of financial statements disclosure. Options and PNQs Employee Stock Options And Performance Based Options [Member] Employee stock options and performance based options. Loan Arrangement Loan Arrangement [Member] Loan arrangement. Remaining Purchase Commitments, 2032 Purchase Obligation Due In Eighth Year Purchase obligation due in eighth year. Private Placement Private Placement [Member] Amortization of deferred transaction costs Amortization of Deferred Transaction Costs Amortization of deferred transaction costs. Upfront payment received Upfront Payment Received Upfront payment received. Stock-Based Compensation Expense Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Construction In Progress [Member] Construction in Progress Stock issued during period shares market price stock purchase plan. Stock Issued During Period Shares Market Price Stock Purchase Plan Issuance of common stock under Market Price Stock Purchase Plan (in shares) Revenue Recognition - Net Revenue - Commercial Product Sales Revenue From Contract With Customer From Commercial Product Sales Policy [Text Block] Revenue from contract with customer from commercial product sales. Operating lease weighted average discount rate Incremental borrowing rate Operating Lease Weighted Average Discount Rate Percent Fair Value Disclosures [Abstract] Estimated Capacity Fees, 2028 Estimated Capacity Fees Due In Fourth Year Estimated capacity fees due in fourth year. Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and Contingencies [Line Items] Maturity date Investment Maturity Period Investment maturity period. VGo assets. V Go Assets [Member] V-Go Allocated Transaction Price Allocated transaction price. Allocated transaction price Summary of Supplemental Pro Forma Information (Unaudited) Business Acquisition Pro Forma Information [Text Block] Proceeds from held-to-maturity debt securities Proceeds from Sale and Maturity of Held-to-Maturity Securities, Total Proceeds From Sale And Maturity Of Held To Maturity Securities Stock Issued During Period Value New Issues Issuance of common stock associated with at-the-market offering State income tax liability Deferred State And Local Income Tax Expense Deferred State And Local Income Tax Expense Fair Value Of Financial Instruments [Line Items] Fair Value Of Financial Instruments [Line Items] Fair value of financial instruments. Current liabilities: Liabilities Current [Abstract] Outstanding principal amount redeemed Debt Instrument Outstanding Principal Amount

Redeemed Debt instrument outstanding principal amount redeemed. Non-cash interest expense Non cash Interest Expense Non-cash interest expense. Controlled Equity Offering Sales Agreement Contolled Equity Offering Sales Agreement [Member] Contolled equity offering sales agreement. Income Taxes Paid, Net, Total Income Taxes Paid, Net Income taxes paid in cash Document Type Document Type Interest rate floor Debt Instrument Floor Rate Debt instrument floor rate. United Therapeutics Corporation United Therapeutics Corporation [Member] United Therapeutics Corporation. Percentage of royalty on future net sales Percentage of Royalty on Future Net Sales Percentage of royalty on future net sales. Market RSU's Market Restricted Stock Units [Member] Market restricted stock units. Market RSUs Percentage of collaborations and services net accounts receivables Percentage Of Collaborations And Services Net Accounts Receivables Percentage of collaborations and services net accounts receivables. Title of 12(b) Security Security12b Title Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Balance Sheet Location Statement of Financial Position Location, Balance [Domain] Share delivery percentage in accordance with valuation assessment obtained Share Delivery Percentage Share delivery percentage. Summary of Lease Information Lease Cost Table [Text Block] Debt Instrument, Redemption, Period Debt Instrument Redemption Period [Axis] Statement Of Stockholders Equity [Abstract] Inventory [Line Items] Inventory [Line Items] Document Fiscal Period Focus Document Fiscal Period Focus Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Finite-Lived Intangible Asset, Expected Amortization, after Year Four Thereafter 2027 Indefinite-Lived Intangible Assets [Axis] Steven B. Binder Steven B. Binder [Member] Steven B. Binder. Effective interest rate Effective Interest Rate Effective interest rate. Total property and equipment Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Total Property Plant And Equipment Gross Principles of Consolidation Consolidation Policy [Text Block] On or After April 23, 2022 Through and Including April 22, 2023 Debt Instrument Redemption Period Two [Member] Subsequent Event Type [Domain] Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total Finance Lease, Right-of-Use Asset, after Accumulated Amortization Financing lease right-of-use asset Basis of Presentation Basis Of Presentation Policy [Text Block] Basis of Presentation. Period Measurement Input Expected Term [Member] Estimate of Fair Value Measurement Estimate Of Fair Value Fair Value Disclosure [Member] Pulmatrix, Inc. Pulmatrix, Inc [Member] Pulmatrix, Inc Payments for (Proceeds from) Tenant Allowance Reimbursement for tenant improvements Repayments of debt Repayments Of Related Party Debt Amortization of liability for sale of future royalties Amortization Of Liability For Sale Of Future Royalties Amortization Of Liability For Sale Of Future Royalties Number of notes Number Of Notes Number of notes. Payments for Rent Lease monthly payments Financial Instruments [Domain] Milestone rights payment. Milestone Rights Payment Milestone Rights Payment Proceeds From Market Price Stock Purchase Plan And From Employee Stock Purchase Plan Proceeds from market price stock purchase plan and from employee stock purchase plan. Proceeds from market price stock purchase plan and employee stock purchase plan Proceeds from insurance claim Proceeds from Insurance Settlement, Investing Activities Inventory Public Utilities Inventory [Axis] Remaining performance obligation, Expected timing of satisfaction, period Deferred revenue recognition period Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 Sale of Stock Subsidiary Sale Of Stock [Axis] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided By Used In Investing Activities [Abstract] Estimated Capacity Fees, 2034 Estimated Capacity Fees Due In Tenth Year Estimated capacity fees due in tenth year. Estimated Capacity Fees, 2024 Estimated Capacity Fees Remainder Of Fiscal Year Estimated capacity fees remainder of fiscal year. Supply and Distribution Agreement Supply And Distribution Agreement [Member] Supply and distribution agreement. Debt Instrument, Repaid, Principal Operating lease liabilities Increase Decrease In Operating Lease Liabilities Increase decrease in operating lease liabilities. Total revenue from UT Total revenues Total revenue from collaborations and services Total net revenue Manufacturing Equipment, Computer Hardware and Software, Computer Equipment, Lab Equipment, and Building Improvements Manufacturing Equipment, Computer Hardware and Software, Computer Equipment, Lab Equipment, and Building Improvements. Manufacturing Equipment Computer Hardware And Software Computer Equipment Lab Equipment And Building Improvements [Member] Manufacturing Equipment, Computer Hardware and Software, Computer Equipment, Lab Equipment, and Building Improvements Statement Of Income And Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Gross Unrealized Holding Gains Gross Unrealized Holding Gains [Member] Gross unrealized holding gains. Sale leaseback transaction, date Sale Leaseback Transaction Date Income Taxes Income Tax Disclosure [Text Block] Lessee, Finance Lease, Renewal Term Remaining Purchase Commitments, 2034 Purchase Obligation Due In Tenth Year Purchase obligation due in tenth year. Royalty future net sales percentage Royalty Future Net Sales Percentage Royalty future net sales percentage. Debt instrument minimum unrestricted cash and short-term investments Debt Instrument Minimum Unrestricted Cash And Short Term Investments Debt instrument minimum unrestricted cash and short-term investments. Non-cash acquisition of property and equipment Non-cash Acquisition Of Property And Equipment Non-cash acquisition of property and equipment. Vehicle Leases Vehicles [Member] Business Combination And Asset Acquisition [Abstract] Short-Term Debt, Type [Axis] Credit Facility Credit Facility [Domain] Transaction Price For The Performance Obligations Transaction Price For The Performance Obligations [Member] Transaction price for the performance obligations. Percentage of annual increment on lease. Percentage of annual increment on lease Debt Securities, Held-to-Maturity [Table] Finite-Lived Intangible Assets, Net, Ending Balance Finite-Lived Intangible Assets, Net, Beginning Balance Net Book Value Finite Lived Intangible Assets Net Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation and amortization Depreciation And Amortization Short-Term Debt, Type [Domain] Debt instrument payment term description Debt Instrument Frequency Of Periodic Payment Other Other Accrued Liabilities Current Increase (Decrease) in Accounts Payable, Total Accounts payable Increase Decrease In Accounts Payable Entity Address, Address Line Two Entity Address Address Line2 LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities And Stockholders Equity [Abstract] Debt instrument fair value in excess of face amount Debt Instrument Fair Value In Excess Of Face Amount Debt instrument fair value in excess of face amount. Document Period End Date Document Period End Date Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year One Amortized cost basis, due in one year or less Net Cash Provided By Used In Financing Activities Net cash used in financing activities Effective tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, Percent, Total Number of consecutive months Debt Instrument, Convertible, Threshold Trading Days Anti-dilutive securities excluded from computation of earnings per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Carrying Reported Amount Fair Value Disclosure [Member] Carrying Amount Remaining milestone rights liability Milestone Rights Liabilities Current And Noncurrent Milestone rights liabilities current and noncurrent. Remaining Purchase Commitments, 2027 Purchase Obligation Due In Third Year APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Stock-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Debt issuance amount Debt Conversion Converted Instrument Amount1 Accrued expenses and other current liabilities Accrued expenses and other current liabilities Accrued Liabilities Current Income tax expense Income tax expense Income Tax Expense (Benefit), Total Income Tax Expense Benefit Royalty Liability Royalty Liability [Member] Royalty liability. Lease term exsention period. Lease term extension period Income Tax Authority, Name [Axis] Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Ending Balance Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Beginning Balance Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Total Allowance for credit losses Debt Securities Held To Maturity Allowance For Credit Loss Liability for sale of future royalties - current Liability for sale of future royalties current Liability Sale For Future Royalties Current Trading Symbol Trading Symbol Business Combinations [Abstract] Debt premium recognized in additional paid-in capital Debt Premium Recognized In Additional Paid In Capital Debt premium recognized in additional paid-in capital. Variable Rate Variable Rate [Axis] Total stockholders' deficit Beginning Balance Ending Balance Stockholders Equity Mann Group Convertible Notes Mann Group Convertible Note [Member] Mann group convertible note. Schedule Of Investments [Abstract] Next-Gen R&D Services Next Gen Research And Development Services [Member] Next-gen research and development services. Schedule of Effect of Modification on Transaction Price Schedule Of Effect Of Modification On Transaction Price Table [Text Block] Schedule of effect of modification on transaction price. Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Conversion price Conversion price Debt Instrument Convertible Conversion Price1 RSUs RSU Restricted Stock Units R S U [Member] Convertible Note Convertible Notes [Member] Convertible notes. Related Party Transactions [Abstract] Product Revenue Product Revenue [Member] Product revenue member. Variable lease costs Variable Lease Cost Tranche 1 Tranche One [Member] Tranche one. Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Goodwill, Ending Balance Goodwill, Beginning Balance Goodwill, Total Goodwill Goodwill Pre Launch Inventory Pre Launch Inventory Policy [Text Block] Pre-launch inventory. Estimated Capacity Fees, 2031 Estimated Capacity Fees Due In Seventh Year Estimated capacity fees due in seventh year. Zealand Zealand [Member] Zealand. Stock Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Accrued Liabilities [Member] Accrued interest Schedule of Accounts Receivable, Net Schedule Of Accounts Notes Loans And Financing Receivable [Text Block] Security deposit Security Deposit Measurement Input Type Measurement Input Type [Axis] Recognized loss on purchase commitments Increase Decrease In Recognized Loss On Purchase Commitments Increase decrease in recognized loss on purchase commitments. Privately Negotiated Exchange Agreement Privately Negotiated Exchange Agreement [Member] Privately-negotiated exchange agreement. Unrecognized compensation expense related to options Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options 2025 Finance Lease Liability Discounted Payments Due Next Twelve Months Finance lease liability discounted payments due next twelve months. Net issuance of common stock associated with stock options and restricted stock units (in shares) Stock Issued During Period Shares Stock Options And Restricted Stock Units Net Of Forfeitures Stock issued during period shares stock options and restricted stock units net of forfeitures. Manufacturing Equipment Equipment Equipment [Member] Financial Statement Estimates Use Of Estimates RSUs and Market RSUs Restricted Stock Units And Market Restricted Stock Units [Member] Restricted stock units and market restricted stock units. Supply Agreement renewal period Longterm Purchase Commitment Renewal Time Period Long-term purchase commitment, renewal time period. New Loan Arrangement New Loan Arrangement [Member] New loan arrangement. Issuance of common stock pursuant to conversion notes Stock Issued During Period Value Conversion Of Convertible Securities Related Party Related Party [Member] Liability for sale of future royalties - long term Liability Sale Of Future Royalties Non current Liability Sale Of Future Royalties Non current Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Class of Stock [Line Items] Class Of Stock [Line Items] Supply Agreement expiration period Long Term Purchase Commitment Expiration Date Long Term Purchase Commitment, Expiration Date Volatility Measurement Input Price Volatility [Member] Debt instrument redemption description Debt Instrument Redemption Description Schedule Of Business Acquisitions By Acquisition [Table] Schedule Of Business Acquisitions By Acquisition [Table] Scenario [Axis] Recently Issued Accounting Standards Recently Issued Accounting Standards Policy [Text Block] Recently issued accounting standards. Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Summary of Remaining Financing Liability Payments Security Exchange Name Security Exchange Name Addition of right-of-use-asset and financing lease liability. Addition of right-of-use-asset and financing lease liability Addition of right-of-use-asset and financing lease liability Accrued Interest Deposit Liabilities, Accrued Interest Counterparty Name Repurchase Agreement Counterparty Name [Domain] Operating Loss Carryforwards [Line Items] Business Acquisition, Acquiree [Domain] Note payable, percentage of interest rate increases (decreases) Note Payable Percentage Of Interest Rate Change Note payable, percentage of interest rate change. Operating Expenses, Total Operating Expenses Total cost of goods sold and cost of revenue Risk-Free Rate Measurement Input Risk Free Interest Rate [Member] Non-employee Directors Awards Non Employee Director [Member] Non-employee director. Percentage of annual increase in lease payment Operating Leases Annual Increase In Rent Expense Operating leases annual increase in rent expense. Funding for development of alternative manufacturing processes Payments To Acquire Other Productive Assets Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Loss Contingency Nature Loss Contingencies By Nature Of Contingency [Axis] Manufacturing Services Manufacturing Services [Member] Manufacturing services. 2028 Finance Lease Liability Discounted Payments Due Year Four Finance lease liability discounted payments due year four. Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Less accumulated depreciation Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Legal Entity Legal Entity [Axis] Net Sales Threshold B Net Sales Threshold B [Member] Net Sales Threshold B. Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Year 3 Lessee Operating Lease Liability Payments Due Year Three Commercial Supply Commercial Supply [Member] Commercial Supply [Member| Amortized Cost [Member] Amortized cost. Amortized Cost Credit risk recognized Gain Loss Related To Credit Risk Recognized Gain loss related to credit risk recognized. Investment securities Interest Receivable Current David Thomson David Thomson [Member] David Thomson. Subsequent Event Subsequent Event Subsequent Event [Member] Conversion of notes accrued interest to common shares, value Debt Conversion Converted Instrument Accrued Interest Of Notes Value Debt conversion converted instrument accrued interest of notes value. Maximum Maximum [Member] Total liabilities and stockholders' deficit Liabilities And Stockholders Equity Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt, Total Loss on extinguishment of debt Gains Losses On Extinguishment Of Debt Schedule of Fair Value of Cash Equivalents, Long and Short Term Investments Schedule Of Fair Value Of Cash Equivalents Long And Short Term Investments Table [Text Block] Schedule of fair value of cash equivalents long and short term investments. Operating Lease Right Of Use Asset Operating lease, right-of-use asset SUPPLEMENTAL CASH FLOWS DISCLOSURES: Supplemental Cash Flow Information [Abstract] Financial Liabilities Fair Value Disclosure, Total Financial Liabilities Fair Value Disclosure Total financial liabilities fair value Financial liabilities fair value Net income (loss) per share, diluted Earnings Per Share, Diluted, Total Earnings Per Share Diluted Net income (loss) per share - diluted Total liabilities Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities Credit facility current. Credit Facility Current Midcap credit facility - current Balance, end of period Balance, beginning of period Total liabilities Liabilities Computer Equipment And Software [Member] Computer equipment and software. Computer Equipment and Software Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Total current assets Assets Current Net cash (used in) provided by investing activities Net Cash Provided By Used In Investing Activities Forcast Forecast [Member] Number of shares sold during the period Stock Issued During Period Shares New Issues Issuance of common stock associated with at-the-market offering (in shares) Vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Restricted stock units grant date fair value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Grants In Period Share based compensation arrangement by share based payment award equity instruments other than options vested grants in period. Debt Conversion Description [Axis] Entity Filer Category Entity Filer Category Conversion of notes to common shares, shares Capitalized interest into common stock Conversion of debt shares issued Goodwill and Other Intangible Assets Goodwill And Intangible Assets Disclosure [Text Block] Estimated Fair Value Estimated Fair Value [Member] Estimated fair value. Property Plant And Equipment [Abstract] Revenue Recognition- Net Revenue - Collaborations and Services Revenue From Contract With Customer From Collaborations And Services Policy [Text Block] Revenue from contract with customer from collaborations and services. Asset Acquisition [Domain] Debt Instrument, Redemption, Period Debt Instrument Redemption Period [Domain] Financing liability. Financing liability [Member] Financing Liability Remaining Purchase Commitments, 2031 Purchase Obligation Due In Seventh Year Purchase obligation due in seventh year. Debt Instrument unamortized prepayment penalty. Debt Instrument Unamortized Prepayment Penalty Debt Instrument unamortized prepayment penalty. Liability for Sale of Future Royalties Liability for Sale of Future Royalties [Member] Liability for sale of future royalties. Other income (expense): Nonoperating Income Expense [Abstract] Losses on estimated returns of acquired product. Losses On Estimated Returns Of Acquired Product Losses on estimated returns of acquired product Tyvaso DPI Tyvaso D P I [Member] Tyvaso DPI. Cumulative gain loss on available for sale securities. Cumulative Gain Loss On Available For Sale Securities Cumulative gain on available-for-sale securities Current Fiscal Year End Date Current Fiscal Year End Date Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and Contingencies [Table] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Interest expense Prepaid of borrowing Prepayment Of Secured Lines Of Credit Prepayment of secured lines of credit. Issuance of common stock from market price stock purchase plan Stock Issued During Period Value Market Price Stock Purchase Plan Stock issued during period value market price stock purchase plan. Stock-based compensation Share-Based Payment Arrangement, Noncash Expense, Total Share Based Compensation Building Improvements [Member] Building Improvements Related Party Transaction Related Party Transaction [Axis] Related Party Related Party Transactions By Related Party [Axis] Reserve for returns Reserve For Returns Reserve for returns. Convertible

Promissory Note Convertible Promissory Note [Member] Convertible promissory note. Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis] Schedule of Lease Term and Discount Rate Schedule Of Lease Term And Discount Rate Table [Text Block] Schedule of Lease Term and Discount Rate. Entity Registrant Name Entity Registrant Name Lessee,option to extend [true false] Lessee Operating Sublease Existence Of Option To Extend Anticipated Cash Flow Revenue Remaining Performance Obligation Anticipated Cash Flow Revenue remaining performance obligation anticipated cash flow. Total anticipated cash flows Net Sales Thresholds A and B Net Sales Thresholds A and B [Member] Net Sales Thresholds A and B. Milestone rights liability, current Milestone Rights Liability Current Milestone rights liability current. Weighted average remaining lease term (in years) Finance Lease Weighted Average Remaining Lease Term1 Indefinite-Lived Intangible Assets, Major Class Name [Domain] Percentage of accounts receivable from major wholesale distributors Percentage Of Accounts Receivable From Major Customers Percentage of accounts receivable from major customers. Fair value of iSPERSE license iSPERSE License - IPR&D Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, In-Process Research and Development Business combination, recognized identifiable assets acquired and liabilities assumed, in-process research and development. Cost of Revenue, Total Cost of revenue Cost Of Revenue Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Employee Awards and Non-employee Director Award Plan Activity Schedule Of Share Based Compensation Employee Stock Purchase Plan And Non Employee Director Stock Award Plan Activity Table [Text Block] Schedule of share based compensation employee stock purchase plan and non employee director stock award plan activity. Earnings Per Common Share Earnings Per Share [Text Block] Maturity date Debt Instrument Maturity Date Entity Emerging Growth Company Entity Emerging Growth Company Estimated Capacity Fees, 2030 Estimated Capacity Fees Due In Sixth Year Estimated capacity fees due in sixth year. Progress Measure Revenue Performance Obligation Satisfied Over Time Method Used Description Milestone Payment Received Milestone Payment Received Milestone payment received. Money Market Funds Money Market Funds [Member] Total Finance Lease Liability Discounted Payments Due Finance lease liability discounted payments due. Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number Of Shares Outstanding Basic Weighted average common shares (denominator), Basic Weighted average shares used to compute net income (loss) per share - basic Vesting Vesting [Domain] Transaction costs Transaction Costs Transaction costs. Financing liability, long term Financing lease liability-long-term Financing lease liability Operating Lease Liabilities Payments Due [Abstract] Schedule of Line of Credit Facility Debt and Key Terms Schedule Of Line Of Credit Facilities [Text Block] Common stock, shares authorized Common Stock Shares Authorized Accrued interest Interest Payable Current Estimated Useful Life (Years) Property Plant And Equipment Useful Life Royalties Royalty [Member] Royalties collaborations Amount of net proceeds from issuance of securities Proceeds From Issuance Of Common Stock 2024 Convertible Note Interest Two Thousand Twenty Four Convertible Note Interest [Member] Two thousand twenty four convertible note interest. Interest expense on liability for sale of future royalties Non-cash interest expense on liability for sale of future royalties Liability for Future Policy Benefit, Interest Expense Fair Value, Inputs, Level 1 Fair Value Inputs Level1 [Member] Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year One through Five Amortized cost basis due after one year through five years Debt Disclosure [Abstract] Vesting date Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Date Share-based compensation arrangement by share-based payment award, award vesting date. Financial Instrument [Axis] Net Income (Loss) Per Share of Common Stock Earnings Per Share Policy [Text Block] Amendment description Agreement Amendment Description Agreement amendment description. Milestone Payments Debt Policy [Text Block] General and Administrative Expense [Member] General and Administrative Expense Revenue Recognition Revenue Recognition Policy [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] SIFMA Municipal Swap Rate [Member] Impairment of Long-Lived Assets Impairment Or Disposal Of Long Lived Assets Policy [Text Block] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Audio visual equipment. Audio Visual Equipment [Member] Audio Visual Equipment Co-Promotion Agreement Co Promotion Agreement [Member] Co-promotion agreement. Net loss Business Acquisitions Pro Forma Net Income Loss Weighted average remaining lease term Weighted Average Remaining Lease Term Weighted average remaining lease term (in years) Tranche 3 Tranche Three Tranche Three [Member] Tranche 3. Debt Securities, Available-for-Sale, Total Investment securities Available For Sale Securities Debt Securities Accounting Policies [Abstract] License And Distribution Agreement Member License and Distribution Agreement License And Distribution Agreement [Member] Reclassification of milestone from long-term to current. Reclassification of milestone from long-term to current Insulin Insulin [Member] Insulin. Long-Term Line of Credit, Total Credit Facility Line Of Credit Income Tax Disclosure [Abstract] Funded amount Long-Term Purchase Commitment, Amount Raw materials Inventory Raw Materials Net Of Reserves Stockholders' deficit: Stockholders Equity [Abstract] Schedule Of Investments [Line Items] Schedule Of Investments [Line Items] Purchase Obligation Fiscal Year Maturity [Abstract] Debt instrument minimum cash covenant. Debt Instrument Minimum Cash Covenant Minimum cash covenant Litigation settlement amount Litigation Settlement, Fee Expense Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy Cash, Cash Equivalents and Restricted Cash Statement [Table] Statement [Table] Segment Information Segment Reporting Policy Policy [Text Block] Property and Equipment, Net Property Plant And Equipment [Text Block] At-the-market Placement At The Market Offering [Member] At-the-market offering. Vertice Pharma LLC Vertice Pharma L L C [Member] Vertice Pharma LLC. Royalty rights Royalty Rights Royalty rights. Gain on bargain purchase Gain on bargain purchase Business Combination, Bargain Purchase, Gain Recognized, Amount MidCap Credit Facility Mid Cap Credit Facility [Member] MidCap Credit Facility. Subsequent Event [Table] Debt payable number of equal monthly installments Debt Instrument Payment Number Of Equal Monthly Installments Debt instrument payment number of equal monthly installments. Accrued interest â€" promissory note Accrued Interest Noncurrent Accrued interest noncurrent. Accrued interest - Mann Group convertible note EPS - diluted: Earnings Per Share, Diluted [Abstract] Undesignated preferred stock, shares authorized Preferred Stock Shares Authorized Interest on available for sale investment Interest And Dividend Income Debt Securities Available For Sale Interest and dividend income debt securities available for sale. Lease, description Sale Leaseback Transaction Lease Terms Entity File Number Entity File Number Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH Revenue From Contract With Customer [Abstract] Earnings Per Share [Abstract] Point In Time Transferred At Point In Time [Member] After 2028 Finite-Lived Intangible Asset, Expected Amortization, after Year Five Remainder of 2024 Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year Inventory Disclosure [Abstract] Statement Of Financial Position [Abstract] Collaborations and services License And Service [Member] License Agreement Income from operations Operating Income Loss Adjusted net income (loss) (numerator) Undistributed Earnings, Diluted Undistributed Earnings, Diluted, Total 2025 Long Term Debt Maturities Repayments Of Principal In Next Twelve Months Exchange price per share Shares Issued Price Per Share Net accretion of investments Net accretion of investments Net Accretion Of Investments Net accretion of investments. At The Market Issuance At The Market Issuance [Member] At-the-market issuance. Entity Shell Company Entity Shell Company Professional fees Accrued Professional Fees Current Remaining Purchase Commitments, Total Loss on purchase commitments Purchase Obligation Annual interest rate Debt Instrument Interest Rate Effective Percentage Entity Tax Identification Number Entity Tax Identification Number ASSETS Assets [Abstract] Fair Value of Financial Instruments Fair Value Of Financial Instruments Policy Cash Collateral for Borrowed Securities Letters of credit secured by cash held in restricted depository account Percentage of royalty on net revenue Percentage of Royalty on Net Revenue Percentage of royalty on net revenue. Entity Current Reporting Status Entity Current Reporting Status Accrued interest receivable Accrued Interest Receivable Accrued interest receivable. Debt Securities, Available-for-Sale, Realized Gain (Loss), Total Debt Securities, Available-for-Sale, Realized Gain (Loss) Recognized gain (loss) Property and Equipment Property Plant And Equipment Disclosure [Text Block] Long-Term Debt, Type Longterm Debt Type [Axis] Subsequent Events [Abstract] Employees Awards Employee [Member] Employee [Member] Inventories Inventory Disclosure [Text Block] Royalty commencement date Royalty Commencement Date Royalty commencement date. Deferred revenue Increase Decrease In Contract With Customer Liability Casper L L C [Member] 1 Casper, LLC. Casper L L C Total assets Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets Amortization on investments Amortization On Investments Amortization on investments. Document Fiscal Year Focus Document Fiscal Year Focus Financing liability. Financing Liability Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements Long Term Purchase Commitment [Text Block] Due in One Year or Less Due In One Year Or Less [Member] Due in one year or less. Share-Based Payment Arrangement, Tranche Two Share Based Compensation Award Tranche Two [Member] Marketing and distribution agreement date Date Of Agreement Initiation For Marketing And Distribution Date of agreement initiation for marketing and distribution. Undesignated preferred stock, $0.01 par value -- 10,000,000 shares authorized; no shares issued or outstanding as of September 30, 2024 or December 31, 2023 Preferred Stock Value At Market Issuance Sales Agreement At Market Issuance Sales Agreement [Member] At market issuance sales agreement. Capital Expenditures Incurred But Not Yet Paid Non-cash construction in progress, property and equipment Accumulated Amortization Finite Lived Intangible Assets Accumulated Amortization Conversion price percentage Debt Instrument Convertible Conversion Price Percentage Debt instrument convertible conversion price percentage. California Franchise Tax Board [Member] California Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD Long-Term Investments, Total Long-term investments Long Term Investments Proceeds from at-the-market offering Proceeds From Issuance Initial Public Offering License agreement description License Agreement Description License agreement description. Manufacturing Services and Product Sales Manufacturing Services And Product Sales [Member] Manufacturing services and product sales. Cost of Goods Sold Cost Of Sales Policy [Text Block] Business Acquisition [Axis] Operating lease liability - Bedford R&D facility Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Liability Business combination recognized identifiable assets acquired and liabilities assumed operating lease liability. City Area Code City Area Code Reclassification, Comparability Adjustment [Policy Text Block] Reclassifications Total current liabilities Liabilities Current Accrued interest. Accrued Interest [Member] Accrued Interest Total inventory Inventory Inventory Net Biomm Biomm S A [Member] Biomm S.A. Sales return right following product expiration in months Sales return right following product expiration in months Sales Return Period Sales return period. Issuance of common stock Issuance of common stock pursuant to conversion notes (in shares) Stock Issued During Period Shares Conversion Of Convertible Securities Goodwill and Other Intangible Assets Goodwill And Intangible Assets Policy [Text Block] Organization Consolidation And Presentation Of Financial Statements [Abstract] Local Phone Number Local Phone Number Depreciation Expense Related to Property and Equipment Depreciation Expense Related To Property And Equipment Table [Text Block] Depreciation expense related to property and equipment. Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred stock, shares outstanding Undesignated preferred stock, shares outstanding Preferred Stock Shares Outstanding Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] License Agreement License Agreement [Member] License agreement. Income Tax Jurisdiction [Axis] Income Taxes Income Tax Policy [Text Block] Interest on loans increased, percentage Debt Instrument Interest Rate Increase Decrease Increased interest rate Commitments And Contingencies Disclosure [Abstract] Debt Securities, Held-to-Maturity, Maturity [Abstract] Schedule of Held-to-Maturity Securities [Line Items] Midcap credit facility - long term Credit Facility Noncurrent Credit facility noncurrent. Interest expense on financing liability Interest expense on financing liability Interest Expense On Financing Liability Interest expense on financing liability. Fair Value By Balance Sheet Grouping [Table] Fair Value By Balance Sheet Grouping [Table] Reclassification of financing liability from long-term to current. Reclassification of financing liability from long-term to current Reclassification of financing liability from long-term to current Financial liabilities: Financial Liabilities Fair Value Disclosure [Abstract] Debt Issuance Costs, Net, Total Debt issuance costs Deferred Finance Costs Net Schedule of Preliminary Purchase Consideration Asset Acquisition Table [Text Block] Lessee, Finance Leases [Text Block] Summary of Financing Lease Information Operating Lease, Liability, Current Operating lease liability-current Developed Technology Developed Technology Rights [Member] iSPERSE License - IPR&D In Process Research and Development [Member] Income Tax Jurisdiction [Domain] Stated interest rate Annual interest rate Senior notes, effective interest rate Accumulated Deficit Retained Earnings [Member] Amortization of Debt Issuance Costs and Discounts, Total Amortization of debt issuance cost Amortization Of Financing Costs And Discounts Amortization of debt discount and issuance costs EPS - basic: Earnings Per Share, Basic [Abstract] R&D Services and License Research And Development Services And License [Member] Research and development services and license. Inventory Public Utilities Inventory Type [Domain] Prepaid Expenses and Other Current Assets Prepaid Expenses And Other Current Assets [Member] Payments to Acquire Property, Plant, and Equipment, Total Purchase of property and equipment Payments To Acquire Property Plant And Equipment Document Transition Report Document Transition Report Cumulative loss on available-for-sale securities Cumulative loss on available-for-sale securities Cumulative Loss On Available For Sale Securities Cumulative loss on available-for-sale securities Debt instrument, date of first required interest payment Debt Instrument Date Of First Required Payment1 Increase (Decrease) in Other Operating Assets, Total Other assets Increase Decrease In Other Operating Assets The Mann Group L L C [Member] The mann group llc. The Mann Group L L C Payment On Mid Cap Credit Facility Payment on mid cap credit facility. Payment On Mid Cap Credit Facility Year 2 Lessee Operating Lease Liability Payments Due Year Two Clinical Trial Expense Policy [Text Block] Clinical Trial Expense Clinical Trial Expenses Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Debt issuance costs Debt issuance costs Finance Lease Liability Discounted Debt Issuance Costs Finance lease liability discounted debt issuance costs. Proceeds from market price stock purchase plan Proceeds From Stock Plans Measurement period percentage Measurement Period Percentage Measurement period percentage. Concentration of Credit Risk Concentration Risk Credit Risk Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year 2023 Minimum Minimum [Member] Common Stock Common Stock [Member] Restricted Cash, Total Restricted Cash Restricted cash 2026 Long Term Debt Maturities Repayments Of Principal In Year Two Accrued Expenses and Other Current Liabilities Accounts Payable And Accrued Liabilities Disclosure [Text Block] Estimated Capacity Fees, 2032 Estimated Capacity Fees Due In Eighth Year Estimated capacity fees due in eighth year. Number of trading days Number Of Trading Days Number of trading days. Amortization of right-of-use assets Operating Lease Right Of Use Asset Amortization Expense Additional Paid-in Capital Additional Paid In Capital [Member] Goodwill adjustment for a net reduction in liabilities Goodwill Adjustment For A Net Reduction In Liabilities Goodwill adjustment for a net reduction in liabilities. Net loss per share - basic Business Acquisition Pro Forma Earnings Per Share Basic Schedule Of Royalty Liability Account Roll Forward Schedule of Royalty Liability Account Roll Forward [TableText Block] Schedule of royalty liability account roll forward. Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Additional option exercise and development milestone payments to be receive Additional Option Exercise And Development Milestone Payments To Be Received Additional option exercise and development milestone payments to be received. Supplier Finance Program [Table] Lease renewal options Lessee Operating Sublease Option To Extend Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Other comprehensive income: Income Statement Location Statement of Income Location, Balance [Domain] Lessee Operating Lease Liability Payments Due Next Twelve Months Year 1 Accounts receivable Accounts receivable, gross Accounts Receivable Gross Current Other assets Other Assets Noncurrent Recognized Loss on Purchase Commitments Loss On Purchase Commitments Policy Policy [Text Block] Loss on purchase commitments. Remainder of 2024 Finance Lease Liability Discounted Payments Due Remainder Of Fiscal Year Finance lease liability discounted payments due remainder of fiscal year. Components of Inventory Schedule Of Inventory Current Table [Text Block] Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Total Unrealized holding gain Goodwill And Intangible Assets Disclosure [Abstract] Loss (gain) on foreign currency transaction Foreign Currency Transaction Gain Loss Realized Loss (gain) on foreign currency transaction Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding No of convertible shares Debt Instrument Convertible Conversion Ratio1 Accrued expenses and other current liabilities Increase Decrease In Accrued Liabilities And Other Operating Liabilities Disaggregation Of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Schedule Of Accounts Notes Loans And Financing Receivable [Table] Schedule Of Accounts Notes Loans And Financing Receivable [Table] Milestone Rights Liability Milestone Rights Liability Policy [Text Block] Milestone rights liability. Finite-Lived Intangible Asset, Expected Amortization, Year One 2024 Available-for-Sale Investment Available For Sale Securities Purchased Options Price Policy Scenario [Domain] Title of Individual Title Of Individual With Relationship To Entity [Domain] Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Issuance costs associated with at-the- market offering Available-for-Sale Investment, credit losses Debt Securities, Available-for-Sale, Allowance for Credit

Loss Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total Financing liability, short term Financing liability â€" current Financing lease liability-current Payment of credit facility prepayment fee Payment Of Credit Facility Prepayment Fee Payment of credit facility prepayment fee. Common stock, $0.01 par value -- 800,000,000 shares authorized; 275,775,038 and 270,034,495 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Common Stock Value Asset acquisition, date of acquisition agreement Asset Acquisition Date Of Acquisition Agreement Royalty termination date Royalty Termination Date Royalty termination date. Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Milestone payments Milestone payment Milestone payments. Milestone Payments Milestone payment Purchase price Payments for Royalties Interest income, net Investment Income Interest Current portion of milestone rights liability Current Portion Of Milestone Right Liability Current portion of milestone right liability. Short term milestone right liability. Short Term Milestone Right Liability Short Term Milestone Right Liability Employee Stock Purchase Plan Employee Stock Purchase Plan [Member] Employee stock purchase plan. Landlord-funded tenant improvements payable per month Landlord Funded Tenant Improvements Payable Per Month Landlord funded tenant improvements payable per month. Market price stock purchase plan Market Price Stock Purchase Plan Market price stock purchase plan. Remaining Purchase Commitments, 2030 Purchase Obligation Due In Sixth Year Purchase obligation due in sixth year. Interest on liability for sale of future royalties Interest On Liability For Sale Of Future Royalties Interest on liability for sale of future royalties. Long Term Debt Maturities Repayments Of Principal In Year Three 2026 Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date Amortized cost basis, total Operating Lease, Liability Total Operating lease, liability Interest And Dividend Income Securities Held To Maturity Interest on held to maturity investments Reclassification of credit facility from long-term to current. Reclassification Of Credit Facility From Long-term To Current Reclassification of Midcap credit facility from long-term to current Debt Conversion, Name [Domain] Accrued Expenses and Other Current Liabilities Schedule Of Accrued Liabilities Table [Text Block] Commitments and contingencies (Note 15) Commitments And Contingencies Sale leaseback transaction, lease agreement period. Sale Leaseback Transaction Lease Agreement Periods Sale leaseback transaction, lease agreement periods. Net Sales Threshold A Net Sales Threshold A [Member] Net Sales Threshold A. Finance lease liability weighted average discount rate percent. Finance Lease Liability Weighted Average Discount Rate Percent Weighted average discount rate Index Target 75th Percentile Share Based Compensation Awards Tranche Four [Member] Share based compensation awards tranche four. Share-Based Payment Arrangement, Tranche Four Estimated Capacity Fees, 2026 Estimated Capacity Fees Due In Second Year Estimated capacity fees due in second year. Adjusted weighted average common shares (denominator) Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number Of Diluted Shares Outstanding Weighted average shares used to compute net income (loss) per share - diluted Research and development Research And Development Expense Excluding Acquired In Process Cost Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Total accounts receivable, net Accounts receivable, net Accounts Receivable Net Current Accounts receivable Lease renewal option Lessee Operating Lease Renewal Term Total Lessee Operating Lease Liability Payments Due Increase (Decrease) in Inventories, Total Inventory Increase Decrease In Inventories Milestone liabilities remeasurement amount. Milestone Liabilities Remeasurement Amount Milestone liabilities remeasurement amount Maturity date Debt Instrument Maturity Month And Year Debt instrument maturity month and year. Financing liability Finance Lease Liability Total Total Pre-launch Inventory Pre Launch Inventory [Member] pre-launch inventory. Entity Small Business Entity Small Business Debt Securities, Held-to-Maturity [Table Text Block] Schedule of Contractual Maturities of Held to Maturity Investments Advance of borrowing Proceeds From Secured Lines Of Credit Interest rate (LIBOR) Debt Instrument Basis Spread On Variable Rate1 Accrued interest paid-in-kind Accrued Paid In Kind Interest Accrued paid in kind interest. Convertible shares of common stock Convertible Shares Of Common Stock Convertible shares of common stock. Remaining Purchase Commitments, 2033 Purchase Obligation Due In Nineth Year Purchase obligation due in nineth year. RSUs and Options RSUs and Options Restricted Stock Units And Options [Member] Restricted stock units and options. Borrowings Debt Disclosure [Text Block] Production Related Impairments or Charges, Total Inventory write-offs Write-off of inventory Production Related Impairments Or Charges Repayment of debt Repayments of Debt Wholesaler distribution fees and prompt pay discounts Wholesaler Distribution Fees And Prompt Pay Discounts Wholesaler distribution fees and prompt pay discounts. Interest and dividend income net accretion of investments held-to-maturity. Interest And Dividend Income Net Accretion Of Investments Held-to-Maturity Net accretion on investments held to maturity U.S. Treasury Securities U S Treasury Securities [Member] Milestone liabilities Milestone Liabilities Noncurrent Milestone liabilities non-current. Total cash equivalents and investments Cash Equivalents And Investments Cash equivalents and investments. Total cash equivalents and investments Credit Facility Credit Facility [Axis] Upfront proceeds Proceeds from Royalties Received Services Service [Member] Net accretion of investments Accretion or amortization Accretion (Amortization) of Discounts and Premiums, Investments Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Aggregate fair value, due after one year through five years Stock-Based Compensation Compensation Related Costs Policy [Text Block] Total Asset Acquisition Consideration Transferred Redemption period start date Debt Instrument Redemption Period Start Date CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided By Used In Financing Activities [Abstract] Additional Base Rent Concession Additional Base Rent Concession Additional base rent concession Estimated Capacity Fees, 2025 Estimated Capacity Fees Due In Next Twelve Months Estimated capacity fees due in next twelve months. Mann Group convertible note Senior convertible notes Convertible Long Term Notes Payable Proceeds from repayment of debt Proceeds from (Repayments of) Debt Proceeds from (Repayments of) Debt, Total Interest on Mann Group convertible note Interest On Convertible Note Interest on convertible note. Other intangible assets Intangible Assets, Net (Excluding Goodwill), Total Intangible Assets Net Excluding Goodwill Right-of-use asset modification Right Of Use Assets Modification Right-of-use assets modification. Assumption of right-of-use-asset and operating lease liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability office and vehicle Office And Vehicle [Member] Office and vehicle. Interest rate cap Debt Instrument Cap Interest Rate Debt instrument cap interest rate. Percentage of future royalties Percentage of Future Royalties Percentage of future royalties. Contingent liability for milestone payments Contingent Liability Contingent Liability Fair Value, Inputs, Level 3 Fair Value Inputs Level3 [Member] Weighted average remaining lease term (in years) Operating Lease Weighted Average Remaining Lease Term1 Subsequent Events Subsequent Events [Text Block] Accounts Payable, Current, Total Accounts payable Accounts Payable Current Principal prepayment against outstanding term loans Repayments Of Long Term Lines Of Credit Total Investments Total Investments Net Investments Net investments. Total expenses Costs And Expenses Contingent Milestone Liability Contingent Milestone Liability [Member] Contingent milestone liability. Buildings Building [Member] Allowance for credit losses and doubtful accounts Allowance For Doubtful Accounts Receivable Current Allowance for credit losses Convertible note principal and interest. Convertible Note Principal And Interest [Member] Convertible Note Principal and Interest XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Oct. 25, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Trading Symbol MNKD Â Entity Registrant Name MannKind Corporation Â Entity Central Index Key 0000899460 Â Entity Current Reporting Status Yes Â Current Fiscal Year End Date --12-31 Â Entity Filer Category Large Accelerated Filer Â Entity Shell Company false Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity File Number 000-50865 Â Entity Tax Identification Number 13-3607736 Â Entity Address, Address Line One 1 Casper Street Â Entity Address, City or Town Danbury Â Entity Address, State or Province CT Â Entity Address, Postal Zip Code 06810 Â City Area Code 818 Â Local Phone Number 661-5000 Â Entity Common Stock, Shares Outstanding Â 275,777,693 Document Quarterly Report true Â Document Transition Report false Â Entity Incorporation, State or Country Code DE Â Title of 12(b) Security Common Stock, par value $0.01 per share Â Security Exchange Name NASDAQ Â Entity Interactive Data Current Yes Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenues: Â Â Â Â Total revenues $ 70,079 $ 51,253 $ 208,728 $ 140,490 Expenses: Â Â Â Â Cost of goods sold 3,197 3,995 12,621 14,749 Research and development 12,926 9,989 34,755 22,047 Selling 13,093 13,440 36,189 40,752 General and administrative 10,823 10,538 34,168 33,027 Loss (gain) on foreign currency transaction 2,454 (2,065) 526 (860) Total expenses 57,319 46,156 162,636 139,670 Income from operations 12,760 5,097 46,092 820 Other income (expense): Â Â Â Â Interest

income, net 3,179 1,580 9,790 4,429 Interest expense on liability for sale of future royalties (4,089) Â (12,720) Â Interest expense on financing liability (2,470) (2,459) (7,361) (7,332) Interest expense (1,801) (2,815) (10,419) (12,474) Gain on bargain purchase 5,259 Â 5,259 Â Other income 32 318 32 286 Loss on extinguishment of debt Â Â (7,050) Â (Loss) gain on available-for-sale securities Â Â (1,550) 932 Total other expense 110 (3,376) (24,019) (14,159) Income (loss) before income tax expense 12,870 1,721 22,073 (13,339) Income tax expense 1,320 Â 1,907 Â Net income (loss) $ 11,550 $ 1,721 $ 20,166 $ (13,339) Net income (loss) per share - basic $ 0.04 $ 0.01 $ 0.07 $ (0.05) Weighted average shares used to compute net income (loss) per share - basic 274,998 268,732 272,811 266,126 Net income (loss) per share - diluted $ 0.04 $ 0.01 $ 0.07 $ (0.05) Weighted average shares used to compute net income (loss) per share - diluted 284,693 323,770 281,407 266,126 Commercial product sales Â Â Â Â Revenues: Â Â Â Â Total revenues $ 19,728 $ 17,927 $ 59,272 $ 53,834 Collaborations and services Â Â Â Â Revenues: Â Â Â Â Total revenues 23,268 13,108 74,130 35,705 Expenses: Â Â Â Â Cost of revenue 14,826 10,259 44,377 29,955 Royalties Â Â Â Â Revenues: Â Â Â Â Total revenues $ 27,083 $ 20,218 $ 75,326 $ 50,951 X - DefinitionInterest expense on financing liability. + ReferencesNo definition available. + Details Name: mnkd_InterestExpenseOnFinancingLiability Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIn a business combination in which the amount of net identifiable assets acquired and liabilities assumed exceeds the aggregate consideration transferred or to be transferred (as defined), this element represents the amount of gain recognized by the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-5Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details Name: us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax, of realized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -

Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossRealized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest expense recognized for liability for future policy benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 29E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29E + Details Name: us-gaap_LiabilityForFuturePolicyBenefitInterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal

operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpenses recognized in the period that are directly related to the selling and distribution of products or services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement Of Income And Comprehensive Income [Abstract] Â Â Â Â Net income (loss) $ 11,550 $ 1,721 $ 20,166 $ (13,339) Other comprehensive income: Â Â Â Â Unrealized gain on available-for-sale securities 588 Â 588 443 Comprehensive income (loss) $ 12,138 $ 1,721 $ 20,754 $ (12,896) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic

205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-12 + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 62,373 $ 238,480 Short-term investments 189,215 56,619 Accounts receivable, net 18,184 14,901 Inventory 26,663 28,545 Prepaid expenses and other current assets 31,229 34,848 Total current assets 327,664 373,393 Restricted cash 735 Â Long-term investments 16,796 7,155 Property and equipment, net 85,339 84,220 Goodwill 1,931 1,931 Other intangible assets 5,313 1,073 Other assets 26,422 7,426 Total assets 464,200 475,198 Current liabilities: Â Â Accounts payable 6,444 9,580 Accrued expenses and other current liabilities 37,386 42,036 Liability for sale of future royalties - current 11,755 9,756 Financing liability - current 9,998 9,809 Deferred revenue â€” current 6,518 9,085 Recognized loss on purchase commitments â€” current Â 3,859 Midcap credit facility - current Â 20,000 Total current liabilities 72,101 104,125 Senior convertible notes 227,941 226,851 Liability for sale of future royalties - long term 137,140 136,054 Financing liability - long term 94,005 94,319 Deferred revenue â€” long term 65,150 69,794 Recognized loss on purchase commitments â€” long term 62,638 60,942 Operating lease liability 12,167 3,925 Milestone liabilities 2,813 3,452 Financing lease liability 171 Â Mann Group convertible note Â 8,829 Accrued interest - Mann Group convertible note Â 56 Midcap credit facility - long term Â 13,019 Total liabilities 674,126 721,366 Commitments and contingencies (Note 15) Stockholders' deficit: Â Â Undesignated preferred stock, $0.01 par value -- 10,000,000 shares authorized; no shares issued or outstanding as of September 30, 2024 or December 31, 2023 Common stock, $0.01 par value -- 800,000,000 shares authorized; 275,775,038 and 270,034,495 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 2,753 2,700 Additional paid-in capital 2,995,974 2,980,539 Accumulated other comprehensive income 588 Â Accumulated deficit (3,209,241) (3,229,407) Total stockholders' deficit (209,926) (246,168) Total liabilities and stockholders' deficit $ 464,200 $ 475,198 X - DefinitionAccrued interest noncurrent. + ReferencesNo definition available. + Details Name: mnkd_AccruedInterestNoncurrent Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionConvertible notes non current. + ReferencesNo definition available. + Details Name: mnkd_ConvertibleNotesNonCurrent Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCredit facility current. + ReferencesNo definition available. + Details Name: mnkd_CreditFacilityCurrent Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCredit facility noncurrent. + ReferencesNo definition available. + Details Name: mnkd_CreditFacilityNoncurrent Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinancing liability current. + ReferencesNo definition available. + Details Name: mnkd_FinancingLiabilityCurrent Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinancing liability noncurrent. + ReferencesNo definition available. + Details Name: mnkd_FinancingLiabilityNoncurrent Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLiability Sale For Future Royalties Current + ReferencesNo definition available. + Details Name: mnkd_LiabilitySaleForFutureRoyaltiesCurrent Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLiability Sale Of Future Royalties Non current + ReferencesNo definition available. + Details Name: mnkd_LiabilitySaleOfFutureRoyaltiesNonCurrent Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMilestone liabilities non-current. + ReferencesNo definition available. + Details Name: mnkd_MilestoneLiabilitiesNoncurrent Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPurchase obligation current. + ReferencesNo definition available. + Details Name: mnkd_PurchaseObligationCurrent Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPurchase obligation noncurrent. + ReferencesNo definition available. + Details Name: mnkd_PurchaseObligationNoncurrent Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:

debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleLongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -

Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Statement Of Financial Position [Abstract] Â Â Undesignated preferred stock, par value $ 0.01 $ 0.01 Undesignated preferred stock, shares authorized 10,000,000 10,000,000 Undesignated preferred stock, shares issued 0 0 Undesignated preferred stock, shares outstanding 0 0 Common stock, par value $ 0.01 $ 0.01 Common stock, shares authorized 800,000,000 800,000,000 Common stock, shares issued 275,775,038 270,034,495 Common stock, shares outstanding 275,775,038 270,034,495 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands Total Convertible Note Interest The Mann Group L L C Convertible Note Principal and Interest The Mann Group L L C Common Stock Common Stock Convertible Note Interest The Mann Group L L C Common Stock Convertible Note Principal and Interest The Mann Group L L C Additional Paid-in Capital Additional Paid-in Capital Convertible Note Interest The Mann Group L L C Additional Paid-in Capital Convertible Note Principal and Interest The Mann Group L L C Accumulated Other Comprehensive Income Accumulated Deficit Beginning Balance at Dec. 31, 2022 $ (250,538) Â Â $ 2,638 Â Â $ 2,964,293 Â Â Â $ (3,217,469) Beginning Balance (in shares) at Dec. 31, 2022 Â Â Â 263,793 Â Â Â Â Â Â Â Issuance of common stock associated with at-the-market offering 1,199 Â Â $ 3 Â Â 1,196 Â Â Â Â Issuance of common stock associated with at-the-market offering (in shares) Â Â Â 269 Â Â Â Â Â Â Â Issuance costs associated with at-the- market offering (24) Â Â Â Â Â (24) Â Â Â Â Net issuance of common stock associated with stock options and restricted stock units 52 Â Â $ 2 Â Â 50 Â Â Â Â Net issuance of common stock associated with stock options and restricted stock units (in shares) Â Â Â 206 Â Â Â Â Â Â Â Issuance of common stock pursuant to conversion notes Â $ 55 Â Â Â Â Â $ 55 Â Â Â Issuance of common stock pursuant to conversion notes (in shares) Â Â Â Â 11 Â Â Â Â Â Â Stock-based compensation expense 3,655 Â Â Â Â Â 3,655 Â Â Â Â Net Income (Loss) (9,795) Â Â Â Â Â Â Â Â (9,795) Ending Balance at Mar. 31, 2023 (255,396) Â Â $ 2,643 Â Â 2,969,225 Â Â Â (3,227,264) Ending Balance (in shares) at Mar. 31, 2023 Â Â Â 264,279 Â Â Â Â Â Â Â Beginning Balance at Dec. 31, 2022 (250,538) Â Â $ 2,638 Â Â 2,964,293 Â Â Â (3,217,469) Beginning Balance (in shares) at Dec. 31, 2022 Â Â Â 263,793 Â Â Â Â Â Â Â Net Income (Loss) (13,339) Â Â Â Â Â Â Â Â Ending Balance at Sep. 30, 2023 (251,779) Â Â $ 2,695 Â Â 2,975,891 Â Â $ 443 (3,230,808) Ending Balance (in shares) at Sep. 30, 2023 Â Â Â 269,543 Â Â Â Â Â Â Â Beginning Balance at Mar. 31, 2023 (255,396) Â Â $ 2,643 Â Â 2,969,225 Â Â Â (3,227,264) Beginning Balance (in shares) at Mar. 31, 2023 Â Â Â 264,279 Â Â Â Â Â Â Â Issuance of common stock associated with at-the-market offering 1,583 Â Â $ 4 Â Â 1,579 Â Â Â Â Issuance of common stock associated with at-the-market offering (in shares) Â Â Â 362 Â Â Â Â Â Â Â Issuance costs associated with at-the- market offering (17) Â Â Â Â Â (17) Â Â Â Â Issuance of common stock from market price stock purchase plan 152 Â Â Â Â Â 152 Â Â Â Â Issuance of common stock under Market Price Stock Purchase Plan (in shares) Â Â Â 36 Â Â Â Â Â Â Â Net issuance of common stock associated with stock options and restricted stock units (8,544) Â Â $ 32 Â Â (8,576) Â Â Â Â Net issuance of common stock associated with stock options and restricted stock units (in shares) Â Â Â 3,279 Â Â Â Â Â Â Â Issuance of common stock pursuant to conversion notes Â 54 Â Â Â Â Â 54 Â Â Â Issuance of common stock pursuant to conversion notes (in shares) Â Â Â Â 13 Â Â Â Â Â Â Stock-based compensation expense 5,580 Â Â Â Â Â 5,580 Â Â Â Â Issuance of common stock under the employee stock purchase plan 923 Â Â $ 3 Â Â 920 Â Â Â Issuance of common stock under the employee stock purchase plan (in shares) Â Â Â 266 Â Â Â Â Â Â Â Cumulative gain on available-for-sale securities 443 Â Â Â Â Â Â Â 443 Â Â Net Income (Loss) (5,265) Â Â Â Â Â Â Â Â (5,265) Ending Balance at Jun. 30, 2023 (260,487) Â Â $ 2,682 Â Â 2,968,917 Â Â 443 (3,232,529) Ending Balance (in shares) at Jun. 30, 2023 Â Â Â 268,235 Â Â Â Â Â Â Â Issuance of common stock associated with at-the-market offering 4,105 Â Â $ 8 Â Â 4,097 Â Â Â Â Issuance of common stock associated with at-the-market offering (in shares) Â Â Â 847 Â Â Â Â Â Â Â Issuance costs associated with at-the- market offering (67) Â Â Â Â Â (67) Â Â Â Â Net issuance of common stock associated with stock options and restricted stock units (1,708) Â Â $ 4 Â Â (1,712) Â Â Â Â Net issuance of common stock associated with stock options and restricted stock units (in shares) Â Â Â 448 Â Â Â Â Â Â Â Issuance of common stock pursuant to conversion notes Â 56 Â Â $ 1 Â Â 55 Â Â Â Issuance of common stock pursuant to conversion notes (in shares) Â Â Â 13 Â Â Â Â Â Â Stock-based compensation expense 4,601 Â Â Â Â Â 4,601 Â Â Â Â Net Income (Loss) 1,721 Â Â Â Â Â Â Â Â 1,721 Ending Balance at Sep. 30, 2023 (251,779) Â Â $ 2,695 Â Â 2,975,891 Â Â 443 (3,230,808) Ending Balance (in shares) at Sep. 30, 2023 Â Â Â 269,543 Â Â Â Â Â Â Â Beginning Balance at Dec. 31, 2023 (246,168) Â Â $ 2,700 Â Â 2,980,539 Â Â Â (3,229,407) Beginning Balance (in shares) at Dec. 31, 2023 Â Â Â 270,034 Â Â Â Â Â Â Â Issuance of common stock associated with at-the-market offering 1,361 Â Â Â Â Â 1,361 Â Â Â Â Issuance of common stock associated with at-the-market offering (in shares) Â Â Â 416 Â Â Â Â Â Â Â Net issuance of common stock associated with stock options and restricted stock units 266 Â Â $ 3 Â Â 263 Â Â Â Â Net issuance of common stock associated with stock options and restricted stock units (in shares) Â Â Â 337 Â Â Â Â Â Â Â Issuance of common stock pursuant to conversion notes Â $ 56 Â Â Â Â Â $ 56 Â Â Â Issuance of common stock pursuant to conversion notes (in shares) Â Â Â 15 Â Â Â Â Â Â Stock-based compensation expense 3,885 Â Â Â Â Â 3,885 Â Â Â Â Net Income (Loss) 10,630 Â Â Â Â Â Â Â Â 10,630 Ending Balance at Mar. 31, 2024 (229,970) Â Â $ 2,703 Â Â 2,986,104 Â Â Â (3,218,777) Ending Balance (in shares) at Mar. 31, 2024 Â Â Â 270,802 Â Â Â Â Â Â Â Beginning Balance at Dec. 31, 2023 (246,168) Â Â $ 2,700 Â Â 2,980,539 Â Â Â (3,229,407) Beginning Balance (in shares) at Dec. 31, 2023 Â Â Â 270,034 Â Â Â Â Â Â Â Net Income (Loss) 20,166 Â Â Â Â Â Â Â Â Ending Balance at Sep. 30, 2024 (209,926) Â Â $ 2,753 Â Â 2,995,974 Â Â 588 (3,209,241) Ending Balance (in shares) at Sep. 30, 2024 Â Â Â 275,775 Â Â Â Â Â Â Â Beginning Balance at Mar. 31, 2024 (229,970) Â Â $ 2,703 Â Â 2,986,104 Â Â Â (3,218,777) Beginning Balance (in shares) at Mar. 31, 2024 Â Â Â 270,802 Â Â Â Â Â Â Â Net issuance of common stock associated with stock options and restricted stock units (4,933) Â Â $ 19 Â Â (4,952) Â Â Â Â Net issuance of common stock associated with stock options and restricted stock units (in shares) Â Â Â 1,855 Â Â Â Â Â Â Â Issuance of common stock pursuant to conversion notes Â Â $ 3,750 Â Â $ 15 Â Â $ 3,735 Â Â Issuance of common stock pursuant to conversion notes (in shares) Â Â Â Â Â 1,500 Â Â Â Â Â Stock-based compensation expense 6,428 Â Â Â Â Â 6,428 Â Â Â Â Issuance of common stock under the employee stock purchase plan 959 Â Â $ 3 Â Â 956 Â Â Â Â Issuance of common stock under the employee stock purchase plan (in shares) Â Â Â 310 Â Â Â Â Â Â Â Net Income (Loss) (2,014) Â Â Â Â Â Â Â Â (2,014) Ending Balance at Jun. 30, 2024 (225,780) Â Â $ 2,740 Â Â 2,992,271 Â Â Â (3,220,791) Ending Balance (in shares) at Jun. 30, 2024 Â Â Â 274,467 Â Â Â Â Â Â Â Net issuance of common stock associated with stock options and restricted stock units (1,511) Â Â $ 13 Â Â (1,524) Â Â Â Â Net issuance of common stock associated with stock options and restricted stock units (in shares) Â Â Â 1,308 Â Â Â Â Â Â Â Stock-based compensation expense 5,227 Â Â Â Â Â 5,227 Â Â Â Â Cumulative gain on available-for-sale securities 588 Â Â Â Â Â Â Â 588 Â Net Income (Loss) 11,550 Â Â Â Â Â Â Â Â 11,550 Ending Balance at Sep. 30, 2024 $ (209,926) Â Â $ 2,753 Â Â $ 2,995,974 Â Â $ 588 $ (3,209,241) Ending Balance (in shares) at Sep. 30, 2024 Â Â Â 275,775 Â Â Â Â Â Â Â X - DefinitionCumulative gain loss on available for sale securities. + ReferencesNo definition available. + Details Name: mnkd_CumulativeGainLossOnAvailableForSaleSecurities Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period shares market price stock purchase plan. +

ReferencesNo definition available. + Details Name: mnkd_StockIssuedDuringPeriodSharesMarketPriceStockPurchasePlan Namespace Prefix: mnkd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period shares stock options and restricted stock units net of forfeitures. + ReferencesNo definition available. + Details Name: mnkd_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsNetOfForfeitures Namespace Prefix: mnkd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period value market price stock purchase plan. + ReferencesNo definition available. + Details Name: mnkd_StockIssuedDuringPeriodValueMarketPriceStockPurchasePlan Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period value stock options and restricted stock units net of forfeitures. + ReferencesNo definition available. + Details Name: mnkd_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsNetOfForfeitures Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-

gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Net income (loss) $ 20,166 $ (13,339) Adjustments to reconcile net income (loss) to net cash provided by operating activities: Â Â Stock-based compensation 15,540 13,836 Interest on liability for sale of future royalties 12,720 Â Loss on extinguishment of debt 7,050 Â Depreciation and amortization 5,211 3,310 Write-off of inventory 1,909 3,659 Loss (gain) on available-for-sale securities 1,550 (932) Loss on estimated returns of acquired product 1,444 Â Amortization of debt discount and issuance costs 1,333 1,570 Amortization of right-of-use assets 1,140 978 Loss (gain) on foreign currency transaction 526 (860) Other, net 49 13 Sold portion of royalty revenue (7,533) Â Gain on bargain purchase (5,259) Â Net accretion of investments (3,765) (420) Changes in operating assets and liabilities: Â Â Accounts receivable, net (3,728) (5,021) Inventory (27) (9,004) Prepaid expenses and other current assets (6,442) (8,516) Other assets (2,821) (35) Accounts payable (3,136) 5,702 Accrued expenses and other current liabilities (4,809) (3,824) Deferred revenue (7,211) 33,722 Recognized loss on purchase commitments (2,689) (6,810) Operating lease liabilities (1,407) (1,778) Net cash provided by operating activities 19,867 12,416 CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Purchase of held-to-maturity debt securities (273,789) (50,516) Proceeds from held-to-maturity debt securities 135,317 92,608 Purchase of property and equipment (6,797) (36,567) Proceeds from insurance claim 396 382 Net cash (used in) provided by investing activities (144,873) 5,907 CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Principal and early extinguishment payments on MidCap credit facility (36,617) (1,667) Principal and early extinguishment payments on Mann Group convertible note (8,854) Â Payments for taxes related to net issuance of common stock associated with restricted stock units and stock options (6,178) (10,200) Proceeds from market price stock purchase plan and employee stock purchase plan 2,320 1,075 Milestone payment (752) (924) Principal payments on financing liability (282) (137) Principal payments on financing lease liability (3) Â Net cash used in financing activities (50,366) (5,074) NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH (175,372) 13,249 CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD 238,480 69,767 CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD 63,108 83,016 SUPPLEMENTAL CASH FLOWS DISCLOSURES: Â Â Interest paid in cash 13,616 7,978 Income taxes paid in cash 1,961 Â NON-CASH INVESTING AND FINANCING ACTIVITIES: Â Â Assumption of right-of-use-asset and operating lease liability 10,057 Â Non-cash acquisition of intangible asset 4,300 Â Amortization of liability for sale of future royalties 2,912 Â Non-cash construction in progress, property and equipment 1,486 2,490 Non-cash acquisition of property and equipment 959 Â Addition of right-of-use-asset and financing lease liability 226 Â Right-of-use asset modification 0 728 Goodwill adjustment for a net reduction in liabilities Â 497 The Mann Group L L C Â Â Adjustments to reconcile net income (loss) to net cash provided by operating activities: Â Â Interest on Mann Group convertible note 56 165 NON-CASH INVESTING AND FINANCING ACTIVITIES: Â Â Payments of Mann Group principal and interest through common stock issuances $ 3,806 165 At The Market Issuance Â Â CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Proceeds from at-the-market offering Â 6,887 Issuance costs associated with at-the-market offering Â $ (108) X - DefinitionAddition of right-of-use-asset and financing lease liability. + ReferencesNo definition available. + Details Name: mnkd_AdditionOfRightOfUseAssetAndFinancingLeaseLiability Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmortization Of Liability For Sale Of Future Royalties + ReferencesNo definition available. + Details Name: mnkd_AmortizationOfLiabilityForSaleOfFutureRoyalties Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGoodwill adjustment for a net reduction in liabilities. + ReferencesNo definition available. + Details Name: mnkd_GoodwillAdjustmentForANetReductionInLiabilities Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease decrease in operating lease liabilities. + ReferencesNo definition available. + Details Name: mnkd_IncreaseDecreaseInOperatingLeaseLiabilities Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease decrease in recognized loss on purchase commitments. + ReferencesNo definition available. + Details Name: mnkd_IncreaseDecreaseInRecognizedLossOnPurchaseCommitments Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInterest on convertible note. + ReferencesNo definition available. + Details Name: mnkd_InterestOnConvertibleNote Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInterest on liability for sale of future royalties. + ReferencesNo definition available. + Details Name: mnkd_InterestOnLiabilityForSaleOfFutureRoyalties Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLoss on estimated returns of acquired product. + ReferencesNo definition available. + Details Name: mnkd_LossOnEstimatedReturnsOfAcquiredProduct Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMilestone payments. + ReferencesNo definition available. + Details Name: mnkd_MilestonePayments Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNet accretion of investments. + ReferencesNo definition available. + Details Name: mnkd_NetAccretionOfInvestments Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNon-cash acquisition of intangible asset. + ReferencesNo definition available. + Details Name: mnkd_NonCashAcquisitionOfIntangibleAsset Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNon-cash acquisition of property and equipment. + ReferencesNo definition available. + Details Name: mnkd_NonCashAcquisitionOfPropertyAndEquipment Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayments for taxes related to net issuance of common stock associated with restricted stock units and stock options. + ReferencesNo definition available. + Details Name: mnkd_PaymentsForTaxesRelatedToNetIssuanceOfCommonStockAssociatedWithRestrictedStockUnitsAndStockOptions Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayments of principal and interest through common stock issuances. + ReferencesNo definition available. + Details Name: mnkd_PaymentsOfPrincipalAndInterestThroughCommonStockIssuances Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPrincipal and early extinguishment payments on MidCap credit facility. + ReferencesNo definition available. + Details Name: mnkd_PrincipalAndEarlyExtinguishmentPaymentsOnMidcapCreditFacility Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPrincipal payments on financing liability. + ReferencesNo definition available. + Details Name: mnkd_PrincipalPaymentsOnFinancingLiability Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds from market price stock purchase plan and from employee stock purchase plan. + ReferencesNo definition available. + Details Name: mnkd_ProceedsFromMarketPriceStockPurchasePlanAndFromEmployeeStockPurchasePlan Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRight-of-use assets modification. + ReferencesNo definition available. + Details Name: mnkd_RightOfUseAssetsModification Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionSold portion of royalty revenue. + ReferencesNo definition available. + Details Name: mnkd_SoldPortionOfRoyaltyRevenue Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIn a business combination in which the amount of net identifiable assets acquired and liabilities assumed exceeds the aggregate consideration transferred or to be transferred (as defined), this element represents the amount of gain recognized by the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-5Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details Name: us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-

45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of realized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossRealized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow through purchase of long-term held-to-maturity securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireHeldToMaturitySecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 21B -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21B + Details Name: us-gaap_ProceedsFromInsuranceSettlementInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from the sale or maturity of long-term held-to-maturity securities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProductionRelatedImpairmentsOrCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_TheMannGroupLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=mnkd_AtTheMarketIssuanceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Â Net Income (Loss) $ 11,550 $ (2,014) $ 10,630 $ 1,721 $ (5,265) $ (9,795) $ 20,166 $ (13,339) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 shares Trading Arrangements, by Individual Â Material Terms of Trading Arrangement During the three months ended September 30, 2024, two of our officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted written trading plans for the orderly disposition of the Companyâ€™s securities as set forth in the table below:Â Â Â Â Â Â Â Type of Trading Arrangement Â Â Â Â Â Â Name and Position Â Action Â AdoptionDate Â Rule 10b5-1(1) Â Non-Rule 10b5-1(2) Â Â Total Shares of Common Stock to be Sold (3) Â Â Expiration Date Steven B. BinderDirector Â Adoption Â August 16, 2024 Â X Â Â â€” Â Â Â 297,075 Â Â August 29, 2025 David ThomsonEVP, General Counsel Â Adoption Â August 19, 2024 Â X Â Â â€” Â Â Â 188,780 Â Â August 19, 2025 _____(1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.(2) "Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.(3) These trading plans include the potential exercise and sale by Steven Binder and David Thomson of short-dated options exercisable for up to 135,075 and 147,780 shares of common stock, respectively. The remainder of each plan is designed to sell a specified percentage of the net shares delivered after tax withholding upon the vesting of restricted stock unit awards held by each individual. The actual number of shares to be sold will depend on state and federal tax rates applicable on the relevant vesting dates (currently assumed to be a combined 34%) as well as the payout, if any, of market RSU awards that will deliver a number of shares determined by the percentile ranking of MannKind total shareholder return ("TSR") over a three-year measurement period relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period (currently assumed to be 100% of target). Based on these assumptions, the number of shares of common stock to be sold by Steven Binder and David Thomson after tax withholdings approximate 162,000 and 41,000, respectively, for total estimated shares of common stock to be sold of up to 297,075 and 188,780, respectively. Steven B. Binder Â Trading Arrangements, by Individual Â Name Steven B. Binder Title Director Rule 10b5-1 Arrangement Adopted true Non-Rule 10b5-1 Arrangement Adopted false Adoption Date August 16, 2024 Expiration Date August 29, 2025 Arrangement Duration 379 days Aggregate Available 297,075 David Thomson Â Trading Arrangements, by Individual Â Name David Thomson Title EVP, General Counsel Rule 10b5-1 Arrangement Adopted true Non-Rule 10b5-1 Arrangement Adopted false Adoption Date August 19, 2024 Expiration Date August 19, 2025 Arrangement Duration 366 days Aggregate Available 188,780 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrAdoptionDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph C + Details Name: ecd_TrdArrDuration Namespace Prefix: ecd_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph C + Details Name: ecd_TrdArrExpirationDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndName Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndTitle Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details Name: ecd_TrdArrSecuritiesAggAvailAmt Namespace Prefix: ecd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: ecd_IndividualAxis=mnkd_StevenBBinderMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=mnkd_DavidThomsonMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Description of Business and Significant Accounting Policies 1. Description of Business and Significant Accounting Policies The unaudited condensed consolidated financial statements of MannKind Corporation and its subsidiaries (â€œMannKind,â€ the â€œCompany,â€ â€œweâ€ or â€œusâ€), have been prepared in accordance with generally accepted accounting principles in the United States of America (â€œGAAPâ€) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the â€œSECâ€). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Companyâ€™s annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 27, 2024 (the â€œAnnual Reportâ€). In the opinion of management, all adjustments, consisting only of normal, recurring adjustments, considered necessary for a fair presentation of the results of these interim periods have been included. The results of operations for the three and nine months ended September 30, 2024 may not be indicative of the results that may be expected for the full year. Financial Statement Estimates â€” The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and notes. Actual results could differ from those estimates or assumptions. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. These effects could have a material impact on the estimates and assumptions used in the preparation of the condensed consolidated financial statements. The more significant estimates include revenue recognition, including gross-to-net adjustments, stand-alone selling price considerations for recognition of collaboration revenue, assessing long-lived assets for impairment, clinical trial expenses, inventory costing, stock-based compensation, the determination of the provision for income taxes and corresponding deferred tax assets and liabilities, the valuation allowance recorded against net deferred tax assets, and expected cash flows from royalties received in connection with United Therapeutics' ("UT's") net revenue for the sale of Tyvaso DPI.Business â€” MannKind is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The Companyâ€™s signature technologiesâ€”Technosphere dry-powder formulations and Dreamboat inhalation devicesâ€”offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. The Company is currently commercializing Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. The first product to come out of the orphan lung disease pipeline, Tyvaso DPI (treprostinil) inhalation powder, received approval from the U.S. Food and Drug Administration (â€œFDAâ€) in May 2022 for the treatment of pulmonary arterial hypertension (â€œPAHâ€) and for the treatment of pulmonary hypertension associated with interstitial lung disease (â€œPH-ILDâ€). The Company's development and marketing partner, UT, began commercializing Tyvaso DPI in June 2022 and is obligated to pay a 10% royalty on net sales of the product, of which 9% is allocated to the Company and 1% to another party as detailed in Note 15 â€” Commitments and Contingencies. The Company also receives a margin on supplies of Tyvaso DPI that it manufactures for UT.Basis of Presentation â€” The condensed consolidated financial statements have been prepared in accordance with GAAP. Principles of Consolidation â€” The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.Reclassifications â€” Certain amounts reported in the prior period have been reclassified to conform with current period presentation. The Company has separated non-cash accretion income on investments from other, net, and presented it as net accretion of investments in the condensed consolidated statements of cash flows. The Company has also presented non-cash interest accretion on financing liability in other, net. Additionally, the Company has combined accruals for the Danbury facility buildout with other in Note 8 â€” Accrued Expenses and Other Current Liabilities.Segment Information â€” Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and manages its business as one segment operating in the United States of America ("U.S.").Revenue Recognition â€” The Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Accounting Standards Codification (â€œASCâ€) Topic 606, Revenue from Contracts with Customers (â€œASC 606â€), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC 606, including when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company has two types of contracts with customers: (i) contracts for commercial product sales with wholesale distributors, specialty and retail pharmacies, and durable medical equipment suppliers ("DMEs") and (ii) collaboration arrangements.Revenue Recognition â€” Net Revenue â€” Commercial Product Sales â€” The Company sells its products to a limited number of wholesale distributors, specialty and retail pharmacies, and DMEs in the U.S. (collectively, its â€œCustomersâ€). Wholesale distributors subsequently resell the Companyâ€™s products to retail pharmacies and certain medical centers or hospitals. Specialty and retail pharmacies sell directly to patients. In addition to distribution agreements with Customers, the Company enters into arrangements with payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Companyâ€™s products.The Company transfers control and recognizes revenue upon delivery of product to wholesale distributors and specialty pharmacies. The Company transfers control and recognizes revenue on product sales to a retail pharmacy as the product is dispensed to patients. Product revenues are recorded net of applicable reserves, including discounts, allowances, rebates, returns and other incentives. See Reserves for Variable Consideration below.Reserves for Variable Consideration â€” Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its Customers, payers, and other indirect customers relating to the Companyâ€™s sale of its products. These reserves, as further detailed below, are based on the amounts earned, or to be claimed on the related sales, and result in a reduction of accounts receivable or establishment of a current liability. Significant judgment is required in estimating gross-to-net adjustments, including historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, claim submission time lags and inventory levels in the distribution channel.Where appropriate, these estimates take into consideration a range of possible outcomes, which are probability-weighted in accordance with the expected value method in ASC 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reduce recognized revenue to the Companyâ€™s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Companyâ€™s analysis also contemplates application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the current period estimates of gross-to-net adjustments and, therefore, the transaction price was not reduced further during the current period. Actual amounts of consideration ultimately received may differ from the Companyâ€™s estimates. If actual results in the future vary from the Companyâ€™s estimates, the Company will adjust these estimates, which would affect net revenue from commercial product sales and earnings in the period such variances become known.Trade Discounts and Allowances â€” The Company generally provides Customers with discounts which include incentives, such as prompt pay discounts, that are explicitly stated in the Companyâ€™s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its Customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Companyâ€™s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of revenue and as a reduction to accounts receivable, net. Product Returns â€” Consistent with industry practice, the Company generally offers Customers a right of return for unopened product that has been purchased from the Company for a period beginning six months prior to and ending 12 months after its expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as reductions to accounts receivable, net. The Company currently estimates product returns using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Companyâ€™s current return reserve percentage is estimated to be in the single digits. Adjustments to the returns reserve are made when changes in the Company's assumptions result in revised estimates.Provider Chargebacks and Discounts â€” Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase products from the Company. Customers charge the Company for the difference between what they pay for products and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is recorded in accrued expenses and other current liabilities. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by Customers, and the Company generally issues credits for such amounts within a few weeks of the Customerâ€™s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold to qualified healthcare providers, and chargebacks that Customers have claimed, but for which the Company has not yet issued a credit.Government Rebates â€” The Company is subject to discount obligations under Medicare and state Medicaid programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses and other current liabilities. Estimates around Medicaid have historically required significant judgment due to timing lags in receiving invoices for claims from states. For Afrezza, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Companyâ€™s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for products that have been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. The Companyâ€™s estimates include consideration of historical claims experience, payer channel mix, current contract prices, unbilled claims, claim submission time lags and inventory in the distribution channel.Payer Rebates â€” The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to

utilization of its products. The Company estimates these rebates, including estimates for product that has been recognized as revenue, but which remains in the distribution channel, and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities. The Companyâ€™s estimates include consideration of historical claims experience, payer channel mix, current contract prices, unbilled claims, claim submission time lags and inventory in the distribution channel.Other Incentives â€” Other incentives which the Company offers include voluntary patient support programs, such as the Company's co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with co-payments required by payers. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with the products that have been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses and other current liabilities.Revenue Recognition â€” Revenue â€” Collaborations and Services â€ The Company enters into licensing, research or other agreements under which the Company licenses certain rights to its product candidates to third parties, conducts research or provides other services to third parties. The terms of these arrangements may include but are not limited to payment to the Company of one or more of the following: up-front license fees; development, regulatory, and commercial milestone payments; payments for commercial manufacturing and clinical supply services the Company provides; and royalties on net sales of licensed products and sublicenses of the rights. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment such as determining the performance obligation in the contract and determining the stand-alone selling price for each performance obligation identified in the contract. With respect to the Company's significant collaboration and service agreement with UT that includes a long-term commercial supply agreement (as amended, the â€œCSAâ€), the Company has identified three distinct performance obligations: (1) the license, supply of product to be used in clinical development, and continued development and approval support for Tyvaso DPI (â€œR&D Services and Licenseâ€); (2) development activities for the next generation of the product (â€œNext-Gen R&D Servicesâ€); and (3) a material right associated with current and future manufacturing and supply of product (â€œManufacturing Services and Product Salesâ€). Pre-production activities under the CSA, such as facility expansion services and other administrative services, were considered bundled services under the Manufacturing Services and Product Sales performance obligation as required by ASC 606. Following the FDAâ€™s approval of Tyvaso DPI, UT began issuing purchase orders for the supply of product, which represents distinct contracts and performance obligations under ASC 606. Revenue is recognized for the supply of product at a point in time, once control is transferred to UT. See Note 10 â€ Collaboration, Licensing and Other Arrangements. If an arrangement has multiple performance obligations, the allocation of the transaction price is determined from observable market inputs, and the Company uses key assumptions to determine the stand-alone selling price, which may include development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success. Revenue is recognized based on the measurement of progress as the performance obligation is satisfied and consideration received that does not meet the requirements to satisfy the revenue recognition criteria is recorded as deferred revenue. Current deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. For further information, see Note 10 â€ Collaboration, Licensing and Other Arrangements.The Company recognizes upfront license payments as revenue upon delivery of the license only if the license is determined to be a separate unit of accounting from the other undelivered performance obligations. The undelivered performance obligations typically include manufacturing or development services or research and/or steering committee services. If the license is not considered as a distinct performance obligation, then the license and other undelivered performance obligations would be evaluated to determine if such should be accounted for as a single unit of accounting. If concluded to be a single performance obligation, the transaction price for the single performance obligation is recognized as revenue over the estimated period of when the performance obligation is satisfied. If the license is considered to be a distinct performance obligation, then the estimated revenue is included in the transaction price for the contract, which is then allocated to each performance obligation based on the respective standalone selling prices.Whenever the Company determines that an arrangement should be accounted for over time, the Company determines the period over which the performance obligations will be performed, and revenue will be recognized over the period the Company is expected to complete its performance obligations. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. The Companyâ€™s collaboration agreements typically entitle the Company to additional payments upon the achievement of development, regulatory and sales milestones. If the achievement of a milestone is considered probable at the inception of the collaboration, the related milestone payment is included with other collaboration consideration, such as upfront fees and research funding, in the Companyâ€™s revenue calculation. If these milestones are not considered probable at the inception of the collaboration, the milestones will typically be recognized in one of two ways depending on the timing of when the milestone is achieved. If the milestone is improbable at inception and subsequently deemed probable of achievement, such will be added to the transaction price, resulting in a cumulative adjustment to revenue. If the milestone is achieved after the performance period has been completed and all performance obligations have been delivered, the Company will recognize the milestone payment as revenue in its entirety in the period the milestone was achieved. The Companyâ€™s collaboration agreements, for accounting purposes, represent contracts with customers and therefore are not subject to accounting literature on collaboration agreements. The Company grants licenses to its intellectual property, supplies raw materials, semi-finished goods or finished goods, provides research and development services and offers sales support for the co-promotion of products, all of which are outputs of the Companyâ€™s ongoing activities, in exchange for consideration. Accordingly, the Company concluded that its collaboration agreements must generally be accounted for pursuant to ASC 606.For collaboration agreements that allow collaboration partners to select additional optioned products or services, the Company evaluates whether such options contain material rights (i.e., have exercise prices that are discounted compared to what the Company would charge for a similar product or service to a new collaboration partner). The exercise price of these options includes a combination of licensing fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, the Company concludes the option does not contain a material right, and therefore is not included in the transaction price at contract inception. The Company assessed the long-term commercial supply agreement with UT (as amended, the "CSA") and determined that a material right existed for the manufacturing services performance obligation. The transaction price is allocated to the material right as well as the remaining performance obligations in accordance with ASC 606. The Company also evaluates grants of additional licensing rights upon option exercises to determine whether such should be accounted for as separate contracts.Revenue Recognition â€” Royalties â€ The Company recognizes royalty revenue for a sales-based or usage-based royalty if it is promised in exchange for an intellectual property license. The royalty revenue is recognized as the latter of the subsequent sale of the product occurs or if the performance obligation to which the royalty has been allocated has been satisfied or partially satisfied. The Companyâ€™s UT License Agreement (as defined in Note 10 â€ Collaboration, Licensing and Other Arrangements) entitles it to receive a 10% royalty on net sales of Tyvaso DPI for the license of the Companyâ€™s IP that was considered to be interdependent with the development activities that supported the approval of Tyvaso DPI. Although the Company recognizes a 10% royalty on net revenue from the sale of Tyvaso DPI as revenue, it only collects 9% due to its sale in December 2023 of 1% of future royalties as detailed in Note 15 â€ Commitments and Contingencies.The Companyâ€™s net revenue and cost of revenue and goods sold as shown on the condensed consolidated statement of operations is comprised of revenue generated from product sales, services and royalties as shown below (in thousands): Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net revenue: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Product revenue (1) Â $ 42,959 Â Â $ 30,727 Â Â $ 132,945 Â Â $ 88,731 Â Services (2) Â Â 37 Â Â Â 308 Â Â Â 457 Â Â Â 808 Â Royalties (3) Â Â 27,083 Â Â Â 20,218 Â Â Â 75,326 Â Â Â 50,951 Â Total net revenue Â $ 70,079 Â Â $ 51,253 Â Â $ 208,728 Â Â $ 140,490 Â _____(1)Amounts represent the revenue from Afrezza and V-Go sales to wholesalers and specialty pharmacies and Tyvaso DPI to UT.(2)Amounts represent revenue generated from the Company's collaboration arrangements, including Next-Gen R&D Services (as defined in Note 10) for UT as well as arrangements with other collaboration partners. See Note 10 â€ Collaboration, Licensing and Other Arrangements. (3)Amounts represent royalties on UTâ€™s net revenue from Tyvaso DPI sales. Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of goods sold and cost of revenue: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Product revenue Â $ 18,023 Â Â $ 13,983 Â Â $ 56,651 Â Â $ 44,006 Â Services Â Â â€” Â Â Â 271 Â Â Â 347 Â Â Â 698 Â Total cost of goods sold and cost of revenue Â $ 18,023 Â Â $ 14,254 Â Â $ 56,998 Â Â $ 44,704 Â The Company follows accounting guidance in measuring revenue and certain judgments affect the application of its revenue policy. For example, in connection with its existing collaboration agreements, the Company has recorded short-term and long-term deferred revenue on its condensed consolidated balance sheets based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. However, this estimate is based on the Companyâ€™s current project development plan and, if the development plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period.Milestone Payments â€ At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the customer, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as, or when, the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration, other revenue, and earnings in the period of adjustment.Cost of Goods Sold â€ Cost of goods sold includes material, labor costs and manufacturing overhead. Cost of goods sold also includes a component of current period manufacturing costs in excess of costs capitalized into inventory (â€œexcess capacity costsâ€). These costs, in addition to the impact of the revaluation of inventory for standard costing, and write-offs of inventory are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. Cost of goods sold excludes the cost of insulin purchased under the Companyâ€™s Insulin Supply Agreement (the â€œInsulin Supply Agreementâ€) with Amphastar Pharmaceuticals, Inc. (â€œAmphastarâ€). All insulin inventory on hand was written off and the full purchase commitment contract to purchase future insulin was accrued as a recognized loss on purchase commitments as of the end of 2016.Cost of Revenues â€ Collaborations and Services â€ Cost of revenues for collaborations and services includes material, labor costs, manufacturing overhead, and excess capacity costs. These costs, in addition to the write-offs of inventory are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. Cost of revenues for collaborations and services also includes the cost of product development.Research and Development ("R&D") â€ Clinical trial expenses result from obligations under contracts with vendors, consultants and clinical site agreements in addition to internal costs associated with conducting clinical trials. R&D costs are expensed as incurred. Clinical study and certain research costs are recognized over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Nonrefundable advance payments for services to be received in the future for use in R&D activities are recorded as prepaid assets and expensed in the period when the services are performed. Cash, Cash Equivalents and Restricted Cash â€ The Company considers all highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase that are readily convertible into cash to be cash equivalents. As of September 30, 2024 and December 31, 2023, cash equivalents were comprised of money market funds, U.S. Treasury securities, corporate bonds and commercial paper with original maturities less than 90 days from the date of purchase. The Company records restricted cash when cash and cash equivalents are restricted as to withdrawal or usage. Restricted cash under a letter of credit issued in connection with a facility lease assumed by the Company that will not be available for use in the Companyâ€™s operations within 12 months of the reporting date is presented in non-current assets. See Note 2 â€ Pulmatrix Transaction. Held-to-Maturity Investments â€ The Companyâ€™s investments generally consist of commercial paper, corporate notes or bonds and U.S. Treasury securities. As of September 30, 2024 and December 31, 2023, the Company held short-term and long-term investments of debt securities, including commercial paper and bonds. The Company intends to hold its investments until maturity; therefore, these investments are stated at amortized cost. The investments with maturities less than 12 months are included in short-term investments and investments with maturities in excess of twelve months are included in long-term investments in the condensed consolidated balance sheets. The amortization or accretion of the Companyâ€™s investments is recognized as interest income in the condensed consolidated statements of operations.Available-for-Sale Investment â€ In June 2021, the Company purchased a $3.0 million convertible promissory note issued by Thirona Bio, Inc. (â€œThironaâ€). In January 2022, the Company purchased an additional $5.0 million convertible promissory note issued by Thirona (the â€œThirona convertible notesâ€). The Thirona convertible notes are general unsecured obligations of Thirona and initially accrued interest at a rate of 6% per annum. Unless earlier converted into conversion shares pursuant to the note purchase agreement, the aggregate principal of $8.0 million and accrued interest shall be due and payable by Thirona on demand by the Company at any time after the maturity date. The Thirona convertible notes were amended in February 2023 to extend the maturity date from December 31, 2022 to June 30, 2024, and again on June 27, 2024 to extend the maturity date to June 30, 2026 and increase the interest rate to 10% per annum. The Thirona convertible notes are classified as available-for-sale securities and included in other assets as of September 30, 2024 and prepaid expense and other current assets as of December 31, 2023 in the condensed consolidated balance sheets. The Company periodically assesses whether it has any intention to sell the investment, determines the fair value of its available-for-sale investment using level 3 inputs and assesses whether there were other-than-temporary impairments associated with the investment. Unrealized holding gains and losses are excluded from earnings and reported in other comprehensive income until realized, while unrealized losses related to credit risk are reported through earnings in the period incurred.Concentration of Credit Risk â€ Financial instruments that potentially subject the Company to concentration of credit risk consisted of cash and cash equivalents and investments. Cash and cash equivalents are held in high credit quality institutions. Cash equivalents consisted of interest-bearing money market funds and U.S. Treasury securities with original or remaining maturities of 90 days or less at the time of purchase. Investments generally consisted of commercial paper, corporate notes or bonds and U.S. Treasury securities. The cash equivalents and investments are regularly monitored by management.Accounts Receivable and Allowance for Credit Losses â€ Accounts receivable are recorded at the invoiced amount and are not interest bearing. Accounts receivable are presented net of an allowance for credit losses if there are estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for credit losses. The allowance for expected credit losses is based primarily on past collections experience relative to the length of time receivables are past due. However, when available evidence reasonably supports an assumption that future economic conditions will differ from current and historical payment collections, an adjustment is reflected in the allowance for expected credit losses. Accounts receivable are also presented net of an allowance for product returns and trade discounts and allowances because the Companyâ€™s customers have the right of setoff for these amounts against the related accounts receivable.Pre-Launch Inventory â€ An improvement to the manufacturing process for the Companyâ€™s primary excipient, fumaryl diketopiperazine (â€œFDKPâ€) was demonstrated to be viable and management expects to realize an economic benefit in the future as a result of such process improvement. Accordingly, the Company is required to assess whether to capitalize inventory costs related to such excipient prior to validation of the improved manufacturing process and adoption of the new supplier. In doing so, management must consider a number of factors in order to determine the amount of inventory to be capitalized, including the historical experience of modifying the Companyâ€™s manufacturing processes, feedback from technical experts and regulatory agencies on the changes being effected and the amount of inventory that is likely to be used in commercial production. The shelf life of the excipient will be determined as part of the validation process; in the interim, the Company must assess the available stability data to determine whether there is likely to be adequate shelf life to support anticipated future sales occurring beyond the expected adoption date of the new raw material. If management is aware of any specific material risks or contingencies other than the normal regulatory reporting process, or if the criteria for capitalizing inventory produced prior to regulatory approval are otherwise not met, the Company would not capitalize such inventory costs, choosing instead to recognize such costs as R&D expense in the period incurred. See Note 5 â€ Inventories.Inventories â€ Inventories are stated at the

lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. The Company capitalizes inventory costs associated with the Companyâ€™s products based on managementâ€™s judgment that future economic benefits are expected to be realized; otherwise, such costs are expensed as incurred as cost of goods sold. The Company uses a contract manufacturing organization outside of the U.S. for certain stages of V-Go inventory.The Company periodically analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value and writes down such inventories, as appropriate. In addition, the Companyâ€™s products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or may become obsolete or are forecasted to become obsolete due to expiration, the Company will record a charge to write down such unmarketable inventory to its estimated net realizable value. The Company analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company performs an assessment of projected sales and evaluates the lower of cost or net realizable value and the potential excess inventory on hand at the end of each reporting period.Property and Equipment â€” Property and equipment is recorded at historical cost, net of accumulated depreciation. Depreciation expense is recorded over the assetsâ€™ useful lives on a straight-line basis and included in cost of goods sold, research and development, and general and administrative expense in the condensed consolidated statements of operations. See Note 6 â€” Property and Equipment.Impairment of Long-Lived Assets â€” Long-lived assets include property and equipment, operating lease right-of-use assets and other intangible assets. The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Assets are considered to be impaired if the carrying value is considered to be unrecoverable.If the Company believes an asset to be impaired, the impairment recognized is the amount by which the carrying value of the asset exceeds the fair value of the asset. Fair value is determined using the market, income or cost approaches as appropriate for the asset. Any write-downs are treated as permanent reductions in the carrying amount of the asset and recognized as an operating loss.Acquisitions â€” The Company first determines whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, the Company accounts for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process R&D (â€œIPR&Dâ€), and liabilities assumed are recorded at their respective fair values as of the acquisition date in the Companyâ€™s condensed consolidated financial statements. Leases are recorded at the net present value of the remaining lease payments. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. A gain on bargain purchase is recorded if the fair value of the net assets acquired exceeds the fair value of the consideration transferred. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquireeâ€™s liability arising from an acquisition it consummated prior to the Companyâ€™s acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&D projects with no alternative future use are recorded in R&D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. Goodwill and Other Intangible Assets â€” The fair value of acquired intangible assets is determined using either a cost approach or an income approach. The cost approach establishes fair value based on the cost of reproducing or replacing the asset, less depreciation for functional or economic obsolescence. The income approach, referred to as the excess earnings method, utilizes Level 3 fair value inputs to determine the present value of future economic benefits to be derived from ownership of the intangible asset. Market participant valuations assume a global view considering all potential jurisdictions and indications based on discounted after-tax cash flow projections, risk adjusted for estimated probability of technical and regulatory success. The Company tests for impairment annually on a reporting unit basis, at the beginning of the Companyâ€™s fourth fiscal quarter and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying amount. To the extent the carrying amount of a reporting unit is less than its estimated fair value, an impairment charge will be recorded.Finite-lived intangible assets are amortized on a straight-line basis over the estimated useful life. Estimated useful lives are determined considering the period assets are expected to contribute to future cash flows. Finite-lived intangible assets are tested for impairment when facts or circumstances suggest that the carrying value of the asset may not be recoverable. If the carrying value exceeds the projected undiscounted pretax cash flows of the intangible asset, an impairment loss equal to the excess of the carrying value over the estimated fair value (discounted after-tax cash flows) is recognized.IPR&D acquired in a business combination is considered an indefinite-lived intangible asset until the completion or abandonment of the associated R&D efforts. During the R&D period, the asset is not amortized but rather is tested for impairment when facts or circumstances suggest that the carrying value of the asset may not be recoverable. Once the R&D efforts are completed, the Company accounts for the resulting asset as a finite-lived intangible asset. If the R&D efforts are abandoned, the asset balance is written off to R&D expense.Recognized Loss on Purchase Commitments â€” The Company reviews the terms of the long-term supply agreements and assesses the need for any accrual for estimated losses, such as lower of cost or net realizable value, that will not be recovered by future product sales. The recognized loss on purchase commitments is reduced as inventory items are received or as the liability is extinguished. See Note 15 â€” Commitments and Contingencies. Milestone Rights Liability â€” In July 2013, in conjunction with the execution of a (now repaid) loan agreement with Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively, â€œDeerfieldâ€), the Company entered into a Milestone Rights Purchase Agreement (the â€œMilestone Rights Agreementâ€) pursuant to which the Company issued certain milestone rights to Deerfield Private Design Fund II, L.P. and Horizon SantÃ© FLML SÃ€RL (the â€œOriginal Milestone Purchasersâ€). The foregoing milestone rights provided the Original Milestone Purchasers certain rights to receive payments of up to $90.0 million upon the occurrence of specified strategic and Afrezza sales milestones, $50.0 million of which remains payable as of September 30, 2024 upon achievement of such milestones (collectively, the â€œMilestone Rightsâ€). In December 2021, the Milestone Rights were purchased by Barings Global Special Situations Credit Fund 4 (Delaware), L.P. and Barings Global Special Situations Credit 4 (LUX) S.ar.l. (together, the â€œMilestone Purchasersâ€). As a result, the Milestone Purchasers have assumed the obligations of the Original Milestone Purchasers and are now entitled to all rights under the Milestone Rights Agreement. The Milestone Rights liability is reported at fair value at the date of the agreement which is periodically offset against payments. See Note 11 â€” Fair Value of Financial Instruments.The initial fair value estimate of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones and discounted to present value using a selected market discount rate. The expected timing and probability of achieving the milestones was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. The Milestone Rights liability is remeasured as the specified milestone events are achieved. Specifically, as each milestone event is achieved, the portion of the initially recorded Milestone Rights liability that pertains to the milestone event being achieved, is remeasured to the amount of the specified related milestone payment. The resulting change in the balance of the Milestone Rights liability due to remeasurement is recorded in the Companyâ€™s condensed consolidated statements of operations as interest expense. Furthermore, the Milestone Rights liability is reduced upon the settlement of each milestone payment. As a result, each milestone payment is effectively allocated between a reduction of the recorded Milestone Rights liability and an expense representing a return on a portion of the Milestone Rights liability paid to the investor for the achievement of the related milestone event. See Note 8 â€” Accrued Expenses and Other Current Liabilities and Note 15 â€” Commitments and Contingencies.Fair Value of Financial Instruments â€” The Company applies various valuation approaches in determining the fair value of its financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Companyâ€™s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 â€” Quoted prices for identical instruments in active markets.Level 2 â€” Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.Level 3 â€” Significant inputs to the valuation model are unobservable.Income Taxes â€” The provisions for federal, foreign, state and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized.For uncertain tax positions, the Company determines whether it is â€œmore likely than notâ€ that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit can be recorded in the financial statements. For those tax positions where it is â€œnot more likely than notâ€ that a tax benefit will be sustained, no tax benefit is recognized. Penalties, if probable and reasonably estimable, are recognized as a component of income tax expense. The Company has reduced its deferred tax assets for uncertain tax positions but has not recorded liabilities for income tax expense, penalties, or interest. Contingencies â€” The Company records a loss contingency for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These accruals represent managementâ€™s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may revise its estimates.Stock-Based Compensation â€” Share-based payments to employees, including grants of restricted stock units (â€œRSUsâ€), performance-based non-qualified stock options awards (â€œPNQsâ€), restricted stock units with market conditions (â€œMarket RSUsâ€), options and the compensatory elements of employee stock purchase plans, are recognized in the condensed consolidated statements of operations based upon the fair value of the awards at the grant date. RSUs are valued based on the market price on the grant date. Market RSUs are valued using a Monte Carlo valuation model and RSUs with performance conditions are evaluated for the probability that the performance conditions will be met and estimates the date at which the performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period. The Company uses the Black-Scholes option valuation model to estimate the grant date fair value of employee stock options and the compensatory elements of employee stock purchase plans. Net Income (Loss) Per Share of Common Stock â€” Basic net income or loss per share ("EPS") is calculated by dividing net income by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the effect of potential common stock issuances resulting from assumed stock option exercises and vesting of restricted stock units, unless the effect is anti-dilutive, when applying the treasury stock method, as well as potential dilution under the if-converted method for convertible debt securities. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted EPS as they would be anti-dilutive.Recently Issued Accounting Standards â€” In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). This ASU requires disaggregated information about a public entityâ€™s effective tax rate reconciliation as well as additional information on income taxes paid. This ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact of the guidance on its condensed consolidated financial statement disclosures.From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Companyâ€™s condensed consolidated financial position or results of operations upon adoption. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Pulmatrix Transaction 9 Months Ended Sep. 30, 2024 Business Combination And Asset Acquisition [Abstract] Â Pulmatrix Transaction 2. Pulmatrix Transaction On May 28, 2024, the Company executed a bill of sale and assignment agreement with Pulmatrix, Inc. ("Pulmatrix") whereby the Company acquired from Pulmatrix certain lab assets and assumed certain liabilities, including the lease for an R&D facility in Bedford, Massachusetts. Concurrently, the Company and Pulmatrix entered into an intellectual property cross-license agreement (the "Cross License Agreement") for the Company's out-licensing of its CricketÂ® Device to Pulmatrix and in-licensing of Pulmatrix's iSPERSEâ„¢ technology, and a master service agreement. The parties and landlord also entered into an amendment to lease and consent to assignment of the lease. Each of these agreements became effective upon the closing of the collective transaction (the "Pulmatrix Transaction") on July 8, 2024 (the "Effective Date"). The Company also entered into employment agreements with 13 Pulmatrix R&D employees who began employment with the Company on the Effective Date.Pursuant to the Cross License Agreement, the Company granted to Pulmatrix certain exclusive and non-exclusive rights to develop, use, manufacture, market, offer and sell its single-use disposable dry powder inhaler (the "Cricket Device") for the inhaled delivery of dihydroergotamine in any formulation whatsoever (including Pulmatrix'sâ€™s PUR3100 treatment of acute migraine), and the inhaled delivery of one or more active pharmaceutical ingredients formulated with iSPERSE for the treatment of neurological disease in humans (collectively, the â€œCricket Licenseâ€).In return, Pulmatrix granted to the Company certain exclusive and non-exclusive rights to develop, use, manufacture, market, offer and sell iSPERSE formulations of clofazimine and insulin, and formulations of iSPERSE with one or more active pharmaceutical ingredients for the treatment of nontuberculous mycobacteria lung disease in humans, endocrine disease in humans, and interstitial lung diseases in humans (collectively, the â€œiSPERSE Licenseâ€).The Company may also provide certain development services to Pulmatrix under the Master Services Agreement, including but not limited to, activities to develop a dry powder formulation of the active pharmaceutical ingredient that Pulmatrix provides to the Company for oral inhalation using iSPERSE.Â Accounting TreatmentÂ The Pulmatrix Transaction was accounted for as a business combination using the acquisition method of accounting, which requires, among other things, the assets acquired and liabilities assumed to be recognized at their respective fair values as of the Effective Date. The excess of the fair value of the net assets acquired over the purchase price in this non-cash transaction was recorded as a gain on bargain purchase.The fair values of identifiable assets acquired and liabilities assumed by the Company from Pulmatrix as of the Effective Date are reflected below (in thousands): Â Â Amount Â Assets: Â Â Â iSPERSE License â€“ IPR&D Â $ 4,300 Â Right-of-use asset â€“ Bedford R&D facility Â Â 10,057 Â Property and equipment Â Â 959 Â Total assets Â Â 15,316 Â Liabilities: Â Â Â Operating lease liability â€“ Bedford R&D facility Â Â 10,057 Â Total liabilities Â Â 10,057 Â Net assets acquired â€“ Gain on bargain purchase Â $ 5,259 Â The fair value of the Cricket License transferred to Pulmatrix was determined to be immaterial based on the current market availability of numerous

third party single-dose dry powder inhalers and the significant time, cost, and risk required to potentially commercialize the Cricket Device. The transfer of the Cricket License was within the scope of ASC 606 as a sale of functional intellectual property, however, since no value was attributed to the Cricket License, no revenue was recognized by the Company.The fair value of the iSPERSE License was determined by applying a cost approach, which assesses current replacement cost to acquire or construct a substitute asset of comparable utility as of the Effective Date. The iSPERSE License was deemed to have a fair value of $4.3 million based on the estimate of internal and external costs to recreate the underlying technology, which are inputs not observable in the market and therefore considered Level 3 measurements. The iSPERSE technology will be utilized in the Company's continuing R&D efforts and accounted for as IPR&D.The fair values of the right-of-use asset and lease liability for the assumed R&D facility operating lease were assessed in accordance with ASC 842, Leases, based on discounted cash flows from future lease payments, utilizing the Companyâ€™s incremental borrowing rate of 7.25%. In June 2024, in anticipation of the facility lease assumption on the Effective Date, the Company transferred $0.7 million to a depository account at a financial institution to collateralize a conditional stand-by letter of credit as required under the lease. This amount is reflected as long-term restricted cash as of September 30, 2024. The lease term extends from the Effective Date through November 30, 2033 with monthly payments of $0.1 million increasing 3% annually starting on December 1, 2024. See Note 15 â€“ Commitments and Contingencies.Property and equipment were assessed for monetary benefit, remaining economic life, and relative risk based on the Company's industry knowledge and analysis of sales of comparable equipment to arrive at fair value.Transaction costs totaling $0.1 million were expensed as incurred and reflected in the condensed consolidated statements of operations for the three and nine months ended September 30, 2024.Pro forma results of operation for the Transaction have not been presented, as the effects of the Transaction were not material to the condensed consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/805/tableOfContent + Details Name: us-gaap_BusinessCombinationDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Investments 9 Months Ended Sep. 30, 2024 Schedule Of Investments [Abstract] Â Investments 3. Investments Cash Equivalents â€” Cash equivalents consist of highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase that are readily convertible into cash. Available-for-Sale Investment â€” The Company's investment in Thirona is comprised of two notes with aggregate face value of $8.0 million and stated interest rate of 10%. The Thirona convertible notes are classified as available-for-sale securities and are included in other assets as of September 30, 2024 and prepaid expenses and other current assets as of December 31, 2023 in the condensed consolidated balance sheets. Available-for-sale investments are measured at fair value with realized gains and losses reported in other income (expense) in the condensed consolidated statements of operations. Unrealized holding gains and losses are excluded from earnings and reported in other comprehensive income (loss) until realized. The Company determines the fair value of its available-for-sale investments using level 3 inputs and evaluates the fair value of its investment in Thirona by applying a scenario based method with a hypothetical yield of 28.0% and 35.0%, and volatility of 70.0% and 90.0% at September 30, 2024 and December 31, 2023, respectively. As of September 30, 2024 and December 31, 2023, the fair value of the Company's investment in Thirona was $5.9 million and $6.9 million, respectively. For the three and nine months ended September 30, 2024, the Company recorded an unrealized holding gain of $0.6 million. Additionally, for the nine months ended September 30, 2024, the Company recognized a loss of $1.6 million on its investment in Thirona as a result of modification of the Thirona convertible notes. For the three and nine months ended September 30, 2023, the Company recognized a gain of $0.9 million on its investment in Thirona as a result of the recovery of a temporary impairment and an unrealized holding gain of $0.4 million. For the three and nine months ended September 30, 2024, the Company recognized no interest income on investment and $0.1 million and $0.4 million for the three and nine months ended September 30, 2023, respectively.Held-to-Maturity Investments â€” Investments consist of highly liquid investments that are intended to facilitate liquidity and capital preservation. The amortization or accretion of the Companyâ€™s investments is recognized in the condensed consolidated statements of operations as interest income. For the three and nine months ended September 30, 2024, the Company recognized $3.2 million and $9.8 million, respectively, of interest income on investments, of which $2.1 million and $6.0 million, respectively, was net accretion on certain investments. For the three and nine months ended September 30, 2023, the Company recognized $1.5 million and $4.0 million, respectively, of interest income on investments, of which $0.5 million and $0.9 million, respectively, was net accretion on certain investments. No allowance for credit losses on held-to-maturity securities was required as of September 30, 2024 or December 31, 2023.The contractual maturities of the Companyâ€™s held-to-maturity investments are summarized below (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â AmortizedCost Basis Â Â AggregateFair Value Â Â AmortizedCost Basis Â Â AggregateFair Value Â Due in one year or less(1) Â $ 230,797 Â Â $ 231,555 Â Â $ 115,263 Â Â $ 115,374 Â Due after one year through five years Â Â 16,796 Â Â Â 16,992 Â Â Â Â 7,155 Â Â Â Â 7,197 Â Total Â $ 247,593 Â Â $ 248,547 Â Â $ 122,418 Â Â $ 122,571 Â _____(1)The investments due in one year or less include cash equivalents of $41.6 million as of September 30, 2024 and $58.6 million as of December 31, 2023. The fair value of the cash equivalents, long-term and short-term investments are disclosed below (dollars in thousands).Â Â Â September 30, 2024 Â Â Â Investment Level Â Amortized Cost(Carrying Value) Â Â Gross Unrealized HoldingGains Â Â Gross UnrealizedHoldingLosses Â Â EstimatedFair Value Â Money market funds and other Â Level 1 Â $ 31,298 Â Â $ â€” Â Â $ â€” Â Â $ 31,298 Â Commercial bonds and paper Â Level 2 Â Â Â 57,477 Â Â Â Â 268 Â Â Â Â (12) Â Â 57,733 Â U.S. Treasury Securities Â Level 2 Â Â Â 158,818 Â Â Â Â 700 Â Â Â Â (2) Â Â 159,516 Â Total cash equivalents and investments Â Â Â Â Â 247,593 Â Â Â Â 968 Â Â Â Â (14) Â Â 248,547 Â Less: cash equivalents Â Â Â Â Â (41,582) Â Â Â â€” Â Â Â â€” Â Â Â (41,582) Total Investments Â Â Â Â $ 206,011 Â Â $ 968 Â Â $ (14) Â $ 206,965 Â Â Â Â December 31, 2023 Â Â Â Investment Level Â Amortized Cost(Carrying Value) Â Â Gross Unrealized HoldingGains Â Â Gross UnrealizedHoldingLosses Â Â EstimatedFair Value Â Money market funds Â Level 1 Â $ 69,611 Â Â $ â€” Â Â $ â€” Â Â $ 69,611 Â Commercial bonds and paper Â Level 2 Â Â 43,251 Â Â Â 135 Â Â (38) Â Â 43,348 Â U.S. Treasury Securities Â Level 2 Â Â 9,556 Â Â Â 56 Â Â Â â€” Â Â Â 9,612 Â Total cash equivalents and investments Â Â Â Â 122,418 Â Â Â 191 Â Â Â (38) Â Â 122,571 Â Less: cash equivalents Â Â Â Â (58,644) Â Â Â â€” Â Â Â â€” Â Â Â (58,644) Total Investments Â Â Â $ 63,774 Â Â $ 191 Â Â $ (38) Â $ 63,927 Â As of September 30, 2024 and December 31, 2023, there was $1.1 million and $0.5 million, respectively, of accrued interest receivable on investments which is included in prepaid expense and other current assets in our condensed consolidated balance sheets. X - DefinitionThe entire disclosure for investments in certain debt and equity securities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-320/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph b -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/942-320/tableOfContent + Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfInvestmentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Accounts Receivable 9 Months Ended Sep. 30, 2024 Receivables [Abstract] Â Accounts Receivable 4. Accounts Receivable Accounts receivable, net consists of the following (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Accounts receivable â€“ commercial Â Â Â Â Â Â Accounts receivable, gross Â $ 18,359 Â Â $ 20,199 Â Wholesaler distribution fees and prompt pay discounts Â Â (2,363) Â Â (2,469) Reserve for returns Â Â (7,817) Â Â (6,215) Allowance for credit losses Â Â Â â€” Â Â Â (157) Total accounts receivable â€“ commercial, net Â Â 8,179 Â Â Â 11,358 Â Accounts receivable â€“ collaborations and services Â Â 10,005 Â Â Â 3,543 Â Total accounts receivable, net Â $ 18,184 Â Â $ 14,901 Â As of December 31, 2023, the allowance for credit losses and doubtful accounts for commercial accounts receivable of $0.2 million was related to accounts receivable for Zealand Pharma US, Inc. As of September 30, 2024, the Company had three wholesale distributors representing approximately 87% of commercial accounts receivable and 77% and 73% of gross sales during the three and nine months ended September 30, 2024, respectively.As of September 30, 2024 and December 31, 2023, there was no allowance for credit losses for accounts receivable for collaborations and services. The Company had one collaboration partner, UT, that comprised 100% of the collaboration and services net accounts receivable as of September 30, 2024 and December 31, 2023 and approximately 100% of gross revenue from collaborations and services for the three and nine months ended September 30, 2024. X - DefinitionThe entire disclosure for financing receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 12A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481933/310-10-55-12AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-42Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 44 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-44Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/310-10/tableOfContentReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/310-20/tableOfContent + Details Name: us-gaap_FinancingReceivablesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ReceivablesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] Â Inventories 5. InventoriesInventories consist of the following (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Raw materials Â $ 6,437 Â Â $ 6,262 Â Work-in-process Â Â 9,074 Â Â Â 13,646 Â Finished goods Â Â Â 11,152 Â Â Â Â 8,637 Â Total inventory Â $ 26,663 Â Â $ 28,545 Â Work-in-process and finished goods as of September 30, 2024 and December 31, 2023 include conversion costs and exclude the cost of insulin. All insulin inventory on hand was written off and the projected loss on the purchase commitment contract to purchase future insulin was accrued as of the end of 2016. Raw materials inventory included $0.8 million of pre-launch inventory as of September 30, 2024 and December 31, 2023. The Company analyzed its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company also performed an assessment of projected sales and evaluated the lower of cost or net realizable value and the potential excess inventory on hand as of September 30, 2024 and December 31, 2023. Inventory that did not meet acceptable standards or was forecasted to become obsolete due to expiration is reserved for inventory obsolescence in the condensed consolidated balance sheets and recorded in costs of goods sold in the condensed consolidated statements of operations. As a result of these assessments there were inventory write-offs of $0.3 million and $1.9 million for the three and nine months ended September 30, 2024, respectively, and $0.3 million and $3.7 million for the three and nine months ended September 30, 2023, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment 9 Months Ended Sep. 30, 2024 Property Plant And Equipment [Abstract] Â Property and Equipment 6. Property and Equipment Property and equipment consisted of the following (dollars in thousands): Â Â Estimated Useful Â Â Â Â Â Â Life (Years) Â Â September 30, 2024 Â Â December 31, 2023 Â Land Â Â â€” Â Â $ 875 Â Â $ 875 Â Buildings Â 39-40 Â Â Â 17,389 Â Â Â 17,389 Â Building improvements(1) Â Â 5-40 Â Â Â 90,573 Â Â Â 46,357 Â Machinery and equipment Â 3-15 Â Â Â 65,733 Â Â Â 60,410 Â Furniture, fixtures and office equipment Â 5-10 Â Â Â 3,350 Â Â Â 3,070 Â Computer equipment and software Â Â 3 Â Â Â 8,811 Â Â Â 8,658 Â Construction in progress(1) Â Â Â â€” Â Â Â 5,242 Â Â Â 48,997 Â Total property and equipment Â Â Â Â Â 191,973 Â Â Â 185,756 Â Less accumulated depreciation Â Â Â Â Â (106,634) Â Â (101,536) Total property and equipment, net Â Â Â Â Â $ 85,339 Â Â $ 84,220 Â _____(1)During the nine months ended September 30, 2024, the Company transferred $43.5 million from construction in progress to building improvements for assets placed in service related to the expansion of the Company's manufacturing facility.Depreciation expense related to property and equipment was as follows (in thousands): Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Depreciation Expense Â $ 2,099 Â Â $ 1,117 Â Â $ 5,151 Â Â $ 3,250 Â During each of the three and nine months ended September 30, 2024, the Company retired $0.1 million of manufacturing equipment as it was no longer in service. The net book value for the disposed assets was de minimis. There were no asset retirements during the three and nine months ended September 30, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7 + Details Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Other Intangible Assets 9 Months Ended Sep. 30, 2024 Goodwill And Intangible Assets Disclosure [Abstract] Â Goodwill and Other Intangible Assets 7. Goodwill and Other Intangible AssetsGoodwill â€“ Goodwill represents the excess of the purchase price over the identifiable tangible and intangible assets acquired plus liabilities assumed arising from business combinations. The balance of goodwill was $1.9 million as of September 30, 2024 and December 31, 2023 as a result of the Company's acquisition of V-Go in May 2022. Goodwill is tested at least annually for impairment by assessing qualitative factors in determining whether it is more likely than not that the fair value of net assets is below their carrying amounts. See Note 1 â€“ Description of Business and Significant Accounting Policies.Other Intangible Assets â€“ Other intangible assets consisted of the following (dollars in thousands): Â Â Estimated Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â UsefulLife (Years) Â Â Cost Â Â AccumulatedAmortization Â Â Net Book Value Â Â Cost Â Â AccumulatedAmortization Â Â Net Book Value Â Developed technology Â Â 15 Â Â $ 1,200 Â Â $ (187) Â $ 1,013 Â Â $ 1,200 Â Â $ (127) Â $ 1,073 Â iSPERSE License â€“ IPR&D Â Â â€” Â Â Â 4,300 Â Â Â Â â€” Â Â Â 4,300 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Total Â Â Â Â $ 5,500 Â Â $ (187) Â $ 5,313 Â Â $ 1,200 Â Â $ (127) Â $ 1,073 Â Amortization expense related to the developed technology was de minimis for the three and nine months ended September 30, 2024 and 2023. The estimated annual amortization expense for the developed technology for the years ended December 31, 2024 through 2028 is approximately $0.1 million per year and $0.6 million, thereafter.The iSPERSE License â€“ IPR&D is an indefinite-lived intangible asset, and as such is not amortized but rather is tested for impairment when facts or circumstances indicate

the carrying value of the asset may not be recoverable. Upon completion of the underlying R&D efforts, the intangible asset will be accounted for as a finite-lived intangible asset. If the R&D efforts are abandoned, the IPR&D asset balance will be written off to R&D expense. The Company evaluates its other intangible assets for potential impairment annually and when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. See Note 1 â€“ Description of Business and Significant Accounting Policies. X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Current Liabilities 9 Months Ended Sep. 30, 2024 Payables And Accruals [Abstract] Â Accrued Expenses and Other Current Liabilities 8. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities were comprised of the following (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Salary and related expenses Â $ 16,239 Â Â $ 19,506 Â Discounts and allowances for commercial product sales Â Â 9,869 Â Â Â 9,541 Â Accrued interest Â Â 479 Â Â Â 2,153 Â Deferred lease liability Â Â 2,483 Â Â Â 1,423 Â Current portion of milestone rights liability(1) Â Â 639 Â Â Â 752 Â Returns reserve for acquired product(2) Â Â 1,468 Â Â Â 601 Â Professional fees Â Â 563 Â Â Â 979 Â State income tax liability Â Â 1,507 Â Â Â 1,561 Â Other Â Â 4,139 Â Â Â 5,520 Â Accrued expenses and other current liabilities Â $ 37,386 Â Â $ 42,036 Â _____(1)See Note 15 â€“ Commitments and Contingencies under Contingencies â€“ Milestone Rights.(2)See Note 15 â€“ Commitments and Contingencies under Loss Contingencies â€“ Returns Reserve for Acquired Product. X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Borrowings 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Borrowings 9. Borrowings Carrying amount of the Company's borrowings consisted of the following (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Senior convertible notes Â $ 227,941 Â Â $ 226,851 Â MidCap credit facility Â Â â€“ Â Â Â 33,019 Â Mann Group convertible note Â Â â€“ Â Â Â 8,829 Â Total debt â€“ net carrying amount Â $ 227,941 Â Â $ 268,699 Â The following table provides a summary of the Companyâ€™s principal balance of debt and key terms: Â Â Amount Due Â Terms Â Â September 30, 2024 Â Â December 31, 2023 Â Annual InterestÂ Â Â Rate Â Maturity Date Â Conversion Price Senior convertible notes Â $230.0Â million Â Â $230.0Â million Â 2.50% Â March 2026 Â $5.21Â per share MidCap credit facility(1) Â $ â€“ Â Â $33.3Â million Â one-monthSOFR(1% floor)plus 6.25%;cap of 8.25% Â August 2025 Â N/A Mann Group convertible note(2) Â $ â€“ Â Â $8.8Â million Â 2.50% Â December 2025 Â $2.50per share _____(1)Repaid on April 1, 2024.(2)Repaid on April 2, 2024.The maturities of the Companyâ€™s borrowings as of September 30, 2024 are as follows (in thousands): Â Â Amounts Â Remainder of 2024 Â $ â€“ Â 2025 Â Â â€“ Â 2026 Â Â 230,000 Â Total principal payments Â Â 230,000 Â Debt issuance costs Â Â (2,059) Total debt Â $ 227,941 Â Senior convertible notes â€“ In March 2021, the Company issued $230.0 million aggregate principal amount of Senior convertible notes in a private offering. The Senior convertible notes were issued pursuant to an indenture, dated March 4, 2021 (the â€œIndentureâ€), between the Company and U.S. Bank National Association, as trustee.The Senior convertible notes are general unsecured obligations of the Company and will mature on March 1, 2026, unless earlier converted, redeemed or repurchased by the Company. The Senior convertible notes will bear cash interest from March 4, 2021 at an annual rate of 2.50% payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2021. The Senior convertible notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding December 1, 2025, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021 (and only during such calendar quarter), if the last reported sale price of the Companyâ€™s common stock, par value $0.01 per share, for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the Senior convertible notes on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Senior convertible notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on each such trading day; (3) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Senior convertible notes called (or deemed called) for redemption; or (4) upon the occurrence of specified corporate events as set forth in the Indenture. On or after December 1, 2025 until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at the Companyâ€™s election, in the manner and subject to the terms and conditions provided in the Indenture.The initial conversion rate is 191.8281 shares of common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.21 per share of common stock). The initial conversion price of the Senior convertible notes represents a premium of approximately 30% to the last reported sale price of the common stock on the Nasdaq Global Market on March 1, 2021. The conversion rate for the Senior convertible notes is subject to adjustment under certain circumstances in accordance with the terms of the Indenture, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date of the Senior convertible notes or if the Company delivers a notice of redemption in respect of the Senior convertible notes, the Company will, in certain circumstances, increase the conversion rate of the Senior convertible notes for a holder who elects to convert its Senior convertible notes in connection with such a corporate event or convert its Notes called for redemption during the related redemption period (as defined in the Indenture), as the case may be.The Company may redeem for cash all or any portion of the Senior convertible notes, at its option, on or after March 6, 2024 and prior to the 36th scheduled trading day immediately preceding the maturity date, if the last reported sale price of common stock has been at least 130% of the conversion price for the Senior convertible notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Senior convertible notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company elects to redeem less than all of the outstanding Senior convertible notes, at least $75.0 million aggregate principal amount of Senior convertible notes must be outstanding and not subject to redemption as of the relevant redemption notice date. No sinking fund is provided for the Senior convertible notes.If the Company undergoes a fundamental change (as defined in the Indenture), then, subject to certain conditions and except as described in the Indenture, holders may require the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Senior convertible notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.The Indenture includes customary covenants and sets forth certain events of default after which the Senior convertible notes may be declared immediately due and payable. If certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries) occur, 100% of the principal of and accrued and unpaid interest on the Senior convertible notes will automatically become due and payable. If an event of default with respect to the Senior convertible notes, other than certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries), occurs and is continuing, the trustee, by notice to the Company, or the holders of at least 25% in principal amount of the outstanding Senior convertible notes by notice to the Company and the trustee, may, and the trustee at the request of such holders shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the Senior convertible notes to be due and payable. Notwithstanding the foregoing, the Indenture provides that, to the extent the Company so elects, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture will, for the first 365 days after the occurrence of such an event of default consist exclusively of the right to receive additional interest on the Senior convertible notes as set forth in the Indenture.The Indenture provides that the Company shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of the consolidated properties and assets of the Company and its subsidiaries, taken as a whole, to, another person (other than any such sale, conveyance, transfer or lease to one or more of the Companyâ€™s direct or indirect wholly owned subsidiaries), unless: (i) the resulting, surviving or transferee person (if not the Company) is a corporation organized and existing under the laws of the United States of America, any State thereof or the District of Columbia, and such corporation (if not the Company) expressly assumes by supplemental indenture all of the Companyâ€™s obligations under the Senior convertible notes and the Indenture; and (ii) immediately after giving effect to such transaction, no default or event of default has occurred and is continuing under the Indenture.The Companyâ€™s net proceeds from the March 2021 offering were approximately $222.7 million, after deducting the initial purchasersâ€™ discounts and commissions and the estimated offering expenses payable by the Company. As of September 30, 2024 and December 31, 2023, the unamortized debt issuance cost was $2.1 million and $3.1 million, respectively.MidCap credit facility â€“ In August 2019, the Company entered into the MidCap credit facility and borrowed the first advance of $40.0 million (â€œTranche 1â€) in August 2019 and the second advance of $10.0 million (â€œTranche 2â€) in December 2020. In April 2021, $10.0 million was prepaid. Tranche 1 and Tranche 2 accrued interest at an annual rate equal to the lesser of (i) 8.25% and (ii) the one-month Secured Overnight Financing Rate ("SOFR") (subject to a one-month SOFR floor of 1.00%) plus 6.25%. Interest on each term loan advance was due and payable monthly in arrears. Principal on each term loan advance under Tranche 1 and Tranche 2 was payable in 24 equal monthly installments that began September 1, 2023. During the three months ended March 31, 2024, the Company made $5.0 million in principal payments on the MidCap credit facility. On April 1, 2024, the Company exercised its option to prepay in full all outstanding indebtedness, consisting of $28.3 million in principal and $0.2 million in accrued interest, and terminated all commitments and obligations under the MidCap credit facility that would have matured on August 1, 2025 in exchange for a payment of $31.6 million, including an exit fee of $2.8 million which is 7.00% of the initial Tranche 1 balance of $40.0 million, and a prepayment fee of $0.3 million which is 1.00% of principal prepaid. Additionally, unamortized debt discount and capitalized prepayment fees totaling $0.2 million were written off, resulting in a loss on extinguishment of debt of $3.3 million recognized in the condensed consolidated statements of operations. In connection with the repayment of outstanding indebtedness by the Company, all liens, mortgages and security interests in any assets or property securing the obligations under the MidCap credit facility were automatically terminated and released and the Company was automatically released from all guarantees. Mann Group convertible note â€“ In August 2019, the Company issued a $35.0 million note that was convertible into shares of the Companyâ€™s common stock at $2.50 per share (the â€œMann Group convertible noteâ€) as part of a restructuring of its then existing indebtedness to Mann Group. The Mann Group convertible note accrued interest at the rate of 2.5% per year on the principal amount, payable quarterly in arrears on the first day of each calendar quarter, with a maturity date of December 31, 2025. The principal and any accrued and unpaid interest under the Mann Group convertible note was convertible, at the option of Mann Group, at any time on or prior to the close of business on the business day immediately preceding the stated maturity date, into shares of the Companyâ€™s common stock at a conversion rate of 400 shares per $1,000 of principal and/or accrued and unpaid interest, which is equal to a conversion price of $2.50 per share. Interest on the convertible note was payable in kind by adding the amount thereof to the principal amount; provided that with respect to interest accruing from and after January 1, 2021, the Company had the option to pay any such interest on any interest payment date, if certain conditions were met, in shares of the Companyâ€™s common stock at a price per share equal to the last reported sale price on the trading day immediately prior to the payment date.During the nine months ended September 30, 2024, Mann Group converted $0.1 million of interest into 15,285 shares of common stock. During the nine months ended September 30, 2023, Mann Group converted $0.2 million of interest into 37,122 shares of common stock. On April 2, 2024, the Company and Mann Group agreed to discharge and terminate the Mann Group convertible note. As of April 2, 2024, the outstanding principal balance of the Mann Group convertible note plus accrued interest was $8.9 million and was convertible at Mann Groupâ€™s option into 3,554,198 shares of common stock of the Company. The Company and Mann Group agreed to terminate all outstanding indebtedness, rights and obligations under the Mann Group convertible note in exchange for (i) the Companyâ€™s issuance to Mann Group of 1,500,000 shares of the Companyâ€™s common stock converted at the contractual rate of $2.50 per share and (ii) the Companyâ€™s payment to Mann Group of $8.9 million, which represented the market value of 2,054,198 shares of common stock of the Company on April 2, 2024 to settle the remaining principal and interest of $5.1 million, after the conversion noted in (i) above. Termination of the Mann Group convertible note resulted in a loss on extinguishment of debt of $3.7 million recognized in the condensed consolidated statements of operations. Amortization of the premium and accretion of debt issuance costs related to all borrowings were as follows (in thousands): Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Amortization of debt discount and prepayment fee Â $ â€“ Â Â $ 109 Â Â $ 85 Â Â $ 323 Â Amortization of debt issuance cost Â Â 363 Â Â Â 363 Â Â Â 1,175 Â Â Â 1,090 Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -

Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration, Licensing and Other Arrangements 9 Months Ended Sep. 30, 2024 Organization Consolidation And Presentation Of Financial Statements [Abstract] Â Collaboration, Licensing and Other Arrangements 10. Collaboration, Licensing and Other ArrangementsRevenue from collaborations and services were as follows (in thousands): Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â UT CSA(1) Â $ 23,231 Â Â $ 12,800 Â Â $ 73,673 Â Â $ 34,897 Â UT License AgreementÂ (2) Â Â â€” Â Â Â 271 Â Â Â 347 Â Â Â 698 Â Cipla License and Distribution Agreement Â Â 37 Â Â Â 37 Â Â Â 110 Â Â Â 110 Â Total revenue from collaborations and services Â $ 23,268 Â Â $ 13,108 Â Â $ 74,130 Â Â $ 35,705 Â _____(1)Amounts consist of revenue recognized for Manufacturing Services and Product Sales to UT for the periods presented.(2)Amounts consist of revenue recognized for Next-Gen R&D Services and R&D Services and License for the periods presented.United Therapeutics License Agreement â€” In September 2018, the Company and UT entered into an exclusive global license and collaboration agreement (the â€œUT License Agreementâ€), pursuant to which UT is responsible for global development, regulatory and commercial activities with respect to Tyvaso DPI. Pursuant to the UT License Agreement, the Company receives a 10% royalty on net sales of Tyvaso DPI. In December 2023, the Company sold a 1% royalty on future net sales of Tyvaso DPI to a royalty purchaser, with the Company retaining a 9% royalty. In August 2021, the Company and UT entered into the CSA, pursuant to which the Company is responsible for manufacturing and supplying to UT, and UT is responsible for purchasing from the Company on a cost-plus basis. In addition, UT is responsible for supplying treprostinil at its expense in quantities necessary to enable the Company to manufacture Tyvaso DPI as required by the CSA.Total revenue from UT was as follows (in thousands): Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â UT Revenue Â Â Â Â Â Â Â Â Â Â Â Â UT CSA Â $ 23,231 Â Â $ 12,800 Â Â $ 73,673 Â Â $ 34,897 Â UT License Agreement Â Â â€” Â Â Â 271 Â Â Â 347 Â Â Â 698 Â Royalties â€” Collaboration (1) Â Â 27,083 Â Â Â 20,218 Â Â Â 75,326 Â Â Â 50,951 Â Total revenue from UT Â $ 50,314 Â Â $ 33,289 Â Â $ 149,346 Â Â $ 86,546 Â _____(1)Amounts consist of royalties associated with the UT License Agreement. The contract assets related to the royalties is included in prepaid expense and other current assets in the condensed consolidated balance sheets.The activities and deliverables under the CSA and UT License Agreement resulted in distinct performance obligations which include the: (1) R&D Services and License, (2) Next-Gen R&D Services, and (3) Manufacturing Services and Product Sales. There have been various amendments to the UT License Agreement and the CSA since inception. As amended, the term of the CSA continues until December 31, 2031 (unless earlier terminated) and is thereafter renewed automatically for additional, successive two-year terms unless (i) UT provides notice to the Company at least 24 months in advance of such renewal that UT does not wish to renew the CSA or (ii) the Company provides notice to UT at least 48 months in advance of such renewal that the Company does not wish to renew the CSA. The Company and UT each have normal and customary termination rights, including termination for material breach that is not cured within a specific timeframe or in the event of liquidation, bankruptcy or insolvency of the other party. The Company accounted for the contract modification as if it were part of the existing contract since the amendment modified the scope and price of the CSA by extending the term and increasing the occupancy rate. The effect of the modification on the transaction price and on the measure of progress is recognized as an adjustment to revenue as of the date of modification. The modification did not result in a change in the activities and deliverables under the CSA.In December 2022, the Company and UT agreed to fund an additional $39.5 million to support capital and continuous improvement activities and $2.3 million in the development of alternative manufacturing processes. The Company determined that the capital and continuous improvements should be combined with the manufacturing services performance obligation and the alternative manufacturing processes should be combined with the Next-Gen R&D Services. The total revised anticipated cash flows of $722.3 million from the transaction was allocated to the three distinct performance obligations as follows (dollars in millions): Â Â Anticipated Â Â Â Â Â Â Â Â Â Â Â Â Cash Flow Â Â Revenue Allocation Â Â Recognition Method Â Progress Measure Â RevenueRecognition Â Total anticipated cash flow(1) Â $ 722.3 Â Â Â Â Â Â Â Â Â Â Â Â Distinct Performance Obligation Â Â Â Â Â Â Â Â Â Â Â Â R&D Services and License Â Â Â Â Â $ â€” Â Â Over time Â Ratably Â Aug 2021 - Oct 2021 Â Next-Gen R&D Services Â Â Â Â Â $ 10.0 Â Â Over time Â Input Â % of completion of costs Â Manufacturing Services andÂ Â Â Product Sales(2) Â Â Â Â Â $ 712.3 Â Â Point in time Â Â Â Transfer of control Â _____(1)The total anticipated cash flow includes a transaction price of $120.0 million for the contractual obligations under the CSA for the Manufacturing Services and Product Sales and the Next-Gen R&D Services performance obligations and $602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA.(2)The Manufacturing Services and Product Sales performance obligation will be recognized as control of manufactured products is transferred to UT. The modification did not result in a cumulative catch-up adjustment as a result of the revenue being deferred for the performance obligations that were affected by the modification. The allocation of the transaction price for the Manufacturing Services and Product Sales includes a material right related to the Companyâ€™s estimated production of product in the amount of $220.8 million. The Company will sell product to UT under individual purchase orders, which represent distinct performance obligations. The ultimate cash flows may vary as manufacturing purchase orders are received.In February 2024, the Company entered into an additional agreement for a separate performance obligation which was accounted for separately as it was distinct from Manufacturing Services and Product Sales and offered at a standalone selling price. Revenue is recognized at a point in time as services are rendered.As of September 30, 2024, deferred revenue from UT consisted of $70.5 million, of which $6.4 million was classified as current and $64.1 million was classified as long-term on the condensed consolidated balance sheet. As of December 31, 2023, deferred revenue consisted of $77.5 million, of which $8.9 million was classified as current and $68.6 million was classified as long-term on the condensed consolidated balance sheet. The Company determined that the revenue recognition associated with the capital improvements should be combined with the Manufacturing Services and Product Sales performance obligation.Thirona Collaboration Agreement â€” In June 2021, the Company and Thirona entered into a collaboration agreement to evaluate the therapeutic potential of Thironaâ€™s compound for the treatment of fibrotic pulmonary diseases. If initial studies are promising, the Company can exercise certain rights to seek a full license to the compound for clinical development and commercialization. The parties will perform their respective obligations and provide reasonable support for research, clinical development and regulatory strategy. The collaboration agreement was accounted for under ASC 808, Collaborative Agreements; however, no consideration was exchanged between the parties. The costs incurred by the Company were expensed as R&D in the condensed consolidated statements of operations. On February 28, 2023, the collaboration agreement was amended to extend the term through June 2024. In accordance with the amendment, the Company agreed to fund a minimum of $1.1 million to be expended on a revised development plan prepared by Thirona, of which $1.1 million has been funded through September 30, 2024. Biomm Supply and Distribution Agreement â€” In May 2017, the Company and Biomm S.A. ("Biomm") entered into a supply and distribution agreement for the commercialization of Afrezza in Brazil. Under this agreement, Biomm was responsible for pursuing regulatory approvals of Afrezza in Brazil, including from the AgÃªncia Nacional de VigilÃ¢ncia SanitÃ¡ria (â€œANVISAâ€) and, with respect to pricing matters, from the Camara de RegulaÃ§Ã£o de Mercado de Medicamentos (â€œCMEDâ€), both of which were received. Biomm commenced product sales in January 2020. No shipments of product were made to Biomm in 2023 or the first three quarters of 2024.Cipla License and Distribution Agreement â€” In May 2018, the Company and Cipla Ltd. (â€œCiplaâ€) entered into an exclusive agreement for the marketing and distribution of Afrezza in India and the Company received a $2.2 million nonrefundable license fee. Under the terms of the agreement, Cipla is responsible for obtaining regulatory approvals to distribute Afrezza in India and for all marketing and sales activities of Afrezza in India. The Company is responsible for supplying Afrezza to Cipla. The Company has the potential to receive an additional regulatory milestone payment, minimum purchase commitment revenue and royalties on Afrezza sales in India once cumulative gross sales have reached a specified threshold. Cipla is currently seeking regulatory approval with the India authorities.The nonrefundable licensing fee was recorded in deferred revenue and is being recognized in net revenue â€” collaborations over 15 years, representing the estimated period to satisfy the performance obligation. The additional milestone payment represents variable consideration for which the Company has not recognized any revenue because Cipla has not yet obtained all of the required marketing approvals.As of September 30, 2024, the deferred revenue balance for Cipla was $1.2 million, of which $0.1 million was classified as current and $1.1 million was classified as long term in the condensed consolidated balance sheets. As of December 31, 2023, the deferred revenue balance was $1.4 million, of which $0.2 million was classified as current and $1.2 million was classified as long term in the condensed consolidated balance sheets. X - DefinitionThe entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 808 -Publisher FASB -URI https://asc.fasb.org/808/tableOfContent + Details Name: us-gaap_CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value of Financial Instruments 11. Fair Value of Financial InstrumentsThe availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement. The Company uses the exit price method for estimating the fair value of loans for disclosure purposes. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy, as follows:Level 1 â€” Quoted prices for identical instruments in active markets.Level 2 â€” Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.Level 3 â€” Significant inputs to the valuation model are unobservable.The carrying amounts reported in the condensed consolidated financial statements for cash, accounts receivable, accounts payable, and accrued expenses and other current liabilities (excluding the Milestone Rights liability) approximate their fair value due to their relatively short maturities. The fair value of the Senior convertible notes, MidCap credit facility, Mann Group convertible note, Milestone Rights liability, Contingent milestone liability, Financing liability and Liability for sale of future royalties are disclosed below. Financial Liabilities â€” The following tables set forth the fair value of the Companyâ€™s financial instruments (Level 3 in the fair value hierarchy) (in millions): Â Â September 30, 2024 Â Â Â Â Â Â Â Fair Value Â Â Â Carrying Value Â Â SignificantUnobservableInputs (Level 3) Â Financial liabilities: Â Â Â Â Â Â Senior convertible notes(1) Â $ 227.9 Â Â $ 284.7 Â Milestone rights(2) Â Â 3.2 Â Â Â 11.3 Â Contingent milestone liability(3) Â Â 0.3 Â Â Â 0.3 Â Financing liability(4) Â Â 104.0 Â Â Â 106.5 Â Liability for sale of future royalties(5) Â Â 147.5 Â Â Â 137.4 Â _____(1)Fair value was determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 11.0%, volatility of 52.0% and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or â€” 2% would result in a fair value of $279.6 million and $290.0 million, respectively.(2)Fair value was determined by applying a Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.7%, dividend yield of 0.0%, volatility of 50.0%, period of 7.3 years and credit risk of 15.0%.(3)Fair value was determined by using the Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.9%, dividend yield of 0.0%, volatility of 43.0%, period of 13.3 years and credit risk of 15.0%. (4)Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 9.5%. A change in yield of + or â€” 2% would result in a fair value of $94.1 million and $121.8 million, respectively.(5)At September 30, 2024, fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 11.0%. A change in yield of + or â€” 2% would result in a fair value of $121.9 million and $156.4 million, respectively. At December 31, 2023, the carrying value approximated the fair value. Â Â December 31, 2023 Â Â Â Â Â Â Fair Value Â Â Â Carrying Value Â Â SignificantUnobservableInputs (Level 3) Â Financial liabilities: Â Â Â Â Â Â Senior convertible notes(1) Â $ 226.9 Â Â $ 231.3 Â MidCap credit facility(2) Â Â 33.0 Â Â Â 35.5 Â Mann Group convertible note(3) Â Â 8.8 Â Â Â 14.4 Â Milestone rights(4) Â Â 3.9 Â Â Â 11.9 Â Contingent milestone liability(5) Â Â 0.3 Â Â Â 0.3 Â Financing liability(6) Â Â 104.1 Â Â Â 106.8 Â _____(1)Fair value was determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 11.0%, volatility of 62.7% and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or â€” 2% would result in a fair value of $224.1 million and $238.9 million, respectively.(2)Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 12.0%. A change in yield of + or â€” 2% would result in a fair value of $35.0 million and $36.0 million, respectively.(3)Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 13.0% and volatility of 62.7% to the straight note and a binomial option pricing model for the value of the conversion feature. A change in yield of + or â€” 2% would result in a fair value of $14.2 million and $14.7 million, respectively.(4)Fair value was determined by applying a Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.9%, dividend yield of 0.0%, volatility of 50.0%, period of 8 years and credit risk of 17.0%.(5)Fair value was determined by using the Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market-based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 4.0%, dividend yield of 0.0%, volatility of 43.0%, period of 15 years and credit risk of 17.0%. (6)Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 9.5%. Milestone Rights Liability â€” The fair value measurement of the Milestone Rights liability is sensitive to the discount rate and the timing of achievement of milestones. The Company utilized a Monte-Carlo Simulation Method to simulate the Afrezza net sales under a neutral framework to estimate the potential payments and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. The Company then discounted the future expected payments at cost of debt with a term equal to the

simulated time to payout based on cumulative sales. See Note 15 â€“ Commitments and Contingencies.Contingent Milestone Liability â€“ The acquisition of V-Go in May 2022 resulted in a contingent milestone liability which could result in obligations to the seller if certain revenue thresholds are met. The initial fair value of the contingent milestone liability was recorded as an adjustment to the purchase price. Subsequent changes in the fair value are reported in general and administrative expenses.Financing Liability â€“ The Sale-Leaseback Transaction in November 2021 resulted in a financing liability. See Note 15 â€“ Commitments and Contingencies.Liability for Sale of Future Royalties â€“ The sale of a portion of our royalty rights in December 2023 resulted in a liability for sale of future royalties. See Note 15 â€“ Commitments and Contingencies. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Common and Preferred Stock 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Common and Preferred Stock 12. Common and Preferred StockThe Company is authorized to issue 800,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of undesignated preferred stock, par value $0.01 per share, issuable in one or more series as designated by the Companyâ€™s board of directors. No other class of capital stock is authorized. As of September 30, 2024 and December 31, 2023, 275,775,038 and 270,034,495 shares of common stock, respectively, were issued and outstanding and no shares of preferred stock were outstanding. In February 2018, the Company entered into a controlled equity offering sales agreement (the â€œCF Sales Agreementâ€) with Cantor Fitzgerald & Co. (â€œCantor Fitzgeraldâ€), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor Fitzgerald, shares of the Companyâ€™s common stock having an aggregate offering price of up to $50.0 million or such other amount as may be permitted by the Sales Agreement. Under the Sales Agreement, Cantor Fitzgerald may sell shares by any method deemed to be an â€œat-the-market offeringâ€ as defined in Rule 415 under the Securities Act of 1933, as amended. There were no sales under the CF Sales Agreement during the nine months ended September 30, 2024. During the nine months ended September 30, 2023, the Company sold 1,478,090 shares of common stock at a weighted average purchase price of $4.66 per share for gross proceeds of approximately $6.9 million pursuant to the CF Sales Agreement. During the nine months ended September 30, 2024, the Company received $1.4 million from the market price stock purchase plan ("MPSPP") for 416,099 shares of common stock. During the nine months ended September 30, 2023, the Company received $0.2 million from the MPSPP for 36,004 shares.For shares of common stock issued pursuant to the Company's 2004 employee stock purchase plan ("ESPP"), see Note 14 â€“ Stock-Based Compensation Expense. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Earnings Per Common Share 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Earnings Per Common Share 13. Earnings per Common ShareThe following tables summarize the components of the basic and diluted EPS computations (in thousands, except per share amounts): Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â EPS â€” basic: Â Â Â Â Â Â Â Â Â Â Â Â Â Net income (loss) (numerator) Â $ 11,550 Â Â $ 1,721 Â $ 20,166 Â Â $ (13,339) Weighted average common shares (denominator) Â Â 274,998 Â Â Â 268,732 Â Â 272,811 Â Â Â 266,126 Â Net income (loss) per share Â $ 0.04 Â Â $ 0.01 Â $ 0.07 Â Â $ (0.05) EPS â€” diluted: Â Â Â Â Â Â Â Â Â Â Â Â Â Adjusted net income (loss) (numerator) Â $ 11,550 Â Â $ 3,578 Â $ 20,166 Â Â $ (13,339) Weighted average common shares Â Â 274,998 Â Â Â 268,732 Â Â Â 272,811 Â Â Â 266,126 Â Effect of dilutive securities â€” common shares issuable Â Â 9,695 Â Â Â 55,038 Â Â 8,596 Â Â Â â€” Â Adjusted weighted average common shares (denominator) Â Â 284,693 Â Â Â 323,770 Â Â 281,407 Â Â Â 266,126 Â Net income (loss) per share Â $ 0.04 Â Â $ 0.01 Â $ 0.07 Â Â $ (0.05) For the three months ended September 30, 2024, diluted net income per share excluded the weighted average effect of 10.4 million shares of RSUs and Market RSUs, 0.4 million options and PNQs and 44.1 million common shares issuable upon conversion of our Senior convertible notes, as they were antidilutive. For the nine months ended September 30, 2024, diluted net income per share excluded the weighted average effect of 9.1 million RSUs and Market RSUs, 0.7 million options and PNQs and 44.1 million common shares issuable upon conversion of our Senior convertible notes, as they were antidilutive.For the three months ended September 30, 2023, diluted net income per share excluded the weighted average effect of 9.4 million shares of RSUs and Market RSUs and 2.0 million options and PNQs as they were antidilutive.Common shares issuable represents incremental shares of common stock which consist of RSUs, stock options, warrants, and shares that could be issued upon conversion of the Senior convertible notes and the Mann Group convertible notes. Potentially dilutive securities outstanding which were considered antidilutive due to the net losses incurred for the nine months ended September 30, 2023 are summarized as follows (in shares): Â September 30, Â Â 2023 Â Senior convertible notes Â 44,120,463 Â RSUs and Market RSUs(1) Â 21,151,454 Â Common stock options and PNQs Â 8,447,339 Â Mann Group convertible notes Â 3,370,000 Â Total shares Â 77,089,256 Â _____(1)Market RSUs issued in 2021, 2022 and 2023 are included at the share delivery of 0%, 205% and 219%, respectively, in accordance with a valuation assessment obtained as of September 30, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation Expense 9 Months Ended Sep. 30, 2024 Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Â Stock-Based Compensation Expense 14. Stock-Based Compensation Expense The Company granted the following awards (in shares): Â Â Three Months Ended March 31, Â Â Three Months Ended June 30, Â Â Three Months EndedÂ September 30, Â Â Nine Months EndedSeptember 30, Â Â Â 2024 Â Â 2024 Â Â 2024 Â Â 2024 Â Employee awards: Â Â Â Â Â Â Â Â Â Â Â Â Â RSUs Â Â 267,990 Â Â (1) Â 3,205,910 Â Â (2) Â 241,253 Â Â (5) Â 3,715,153 Â Market RSUs Â Â Â â€” Â Â Â 2,144,000 Â Â (3) Â Â â€” Â Â Â 2,144,000 Â Non-employee director RSUs Â Â Â â€” Â Â Â 280,376 Â Â (4) Â Â â€” Â Â Â 280,376 Â Total awards issued Â Â 267,990 Â Â Â 5,630,286 Â Â Â Â 241,253 Â Â Â Â 6,139,529 Â _____(1)RSUs had a weighted average grant date fair value of $3.28 per share, of which 211,895 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, 53,720 RSUs had a cliff vesting period of three years, and 2,375 RSUs had a vesting period of 25% annually over four years. (2)RSUs had a weighted average grant date fair value of $4.45 per share, of which 3,033,680 RSUs had a vesting period of 25% annually over four years, 145,980 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, and 26,250 RSUs had a cliff vesting period of two years. (3)Market RSUs had a grant date fair value of $10.30 per share and will vest on July 15, 2027. The number of shares delivered on the vesting date is determined by the percentile ranking of MannKind total shareholder return ("TSR") over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.(4)RSUs had a weighted average grant date fair value of $4.45 per share and vested immediately upon the grant date; however, the underlying shares of common stock will not be delivered until there is a separation of service such as resignation, retirement or death.(5)RSUs had a weighted average grant date fair value of $5.34 per share, of which 219,285 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, and 21,968 RSUs had a vesting period of 40% on the first anniversary and 60% on the second anniversary of the vesting determination date.As of September 30, 2024, there was $26.2 million and $27.4 million of unrecognized stock-based compensation expense related to RSUs and Market RSUs, respectively, which is expected to be recognized over a weighted average period of approximately 2.84 and 1.98 years, respectively. Total stock-based compensation expense recognized in the condensed consolidated statements of operations as cost of goods sold, cost of revenue â€“ collaborations and services, R&D and selling, general and administrative expense was as follows (in thousands): Â Â Three MonthsEnded September 30, Â Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â Â 2023 Â Â Â 2024 Â Â Â 2023 Â RSUs and options Â $ 5,047 Â Â $ 4,442 Â Â $ 14,994 Â Â $ 13,324 Â Employee stock purchase plan Â Â 180 Â Â Â 159 Â Â Â 546 Â Â Â 512 Â Total Â $ 5,227 Â Â $ 4,601 Â Â $ 15,540 Â Â $ 13,836 Â Employee Stock Purchase PlanThe Company provides all employees, including executive officers, the ability to purchase common stock at a discount under the ESPP. The ESPP is designed to comply with Section 423 of the Internal Revenue Code and provides all employees with the opportunity to purchase up to $25,000 worth of common stock (based on the undiscounted fair market value at the commencement of the offering period) each year at a purchase price that is the lower of 85% of the fair market value of the common stock on either the date of purchase or the commencement of the offering period. An employee may not purchase more than 5,000 shares of common stock on any purchase date. The executivesâ€™ rights under the ESPP are the same as those of all other employees.There were approximately 2.6 million shares of common stock available for issuance under the ESPP as of September 30, 2024. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1:

http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments And Contingencies Disclosure [Abstract] Â Commitments and Contingencies 15. Commitments and Contingencies Guarantees and Indemnifications â€” In the ordinary course of its business, the Company makes certain indemnities, commitments and guarantees under which it may be required to make payments in relation to certain transactions. The Company, as permitted under Delaware law and in accordance with its Bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Companyâ€™s request in such capacity. The term of the indemnification period is for the officerâ€™s or directorâ€™s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal and therefore has not recorded any liability for these indemnities in the condensed consolidated balance sheets. The Company accrues for losses for any known contingent liability, including those that may arise from indemnification provisions, when future payment is probable and the amount can be reasonably estimated. No such losses have been recorded to date. Litigation â€” The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. The Company does not anticipate the final disposition of any matters will have a material adverse effect on the results of operations, financial position, or cash flows of the Company. The Company maintains liability insurance coverage to protect the Companyâ€™s assets from losses arising out of or involving activities associated with ongoing and normal business operations. The Company records a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Companyâ€™s policy is to accrue for legal expenses in connection with legal proceedings and claims as they are incurred. Contingencies â€” Milestone Rights â€” In July 2013, the Company entered into the Milestone Rights Agreement with the Original Milestone Purchasers, pursuant to which the Company granted the Milestone Rights to receive payments up to $90.0 million upon the occurrence of specified strategic and sales milestones, $50.0 million of which remains payable to the Milestone Purchasers as of September 30, 2024. The Milestone Rights Agreement includes customary representations and warranties and covenants by the Company, including restrictions on transfers of intellectual property related to Afrezza. The Milestone Rights are subject to acceleration in the event the Company transfers its intellectual property related to Afrezza in violation of the terms of such agreement.During each of the nine months ended September 30, 2024 and 2023, the Company made milestone payments of $5.0 million to the Milestone Purchasers. As of September 30, 2024 and December 31, 2023, the remaining Milestone Rights liability balance was $3.2 million and $3.9 million, respectively, and consisted of $0.7 million and $0.8 million, respectively, of current liability, which was presented as accrued expenses and other current liabilities, and $2.5 million and $3.1 million, respectively, of long-term liability, which was presented as milestone liabilities in the condensed consolidated balance sheets. The value of the Milestone Rights liability was based on initial fair value estimates calculated using the income approach and is reduced by milestone achievement payments made. Loss Contingencies â€” Returns Reserve for Acquired Product â€” During the nine months ended September 30, 2024, the Company reassessed its previously-determined estimate for product returns associated with sales of V-Go that pre-date the Company's acquisition of the product and recorded an additional $1.4 million, which is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets as of September 30, 2024 and being reduced as product returns are received. Losses on estimated returns of acquired product were recorded in general and administrative expenses in the condensed consolidated statements of operations.Liability for Sale of Future Royalties â€” In December 2023, the Company executed a Purchase and Sale Agreement (the â€œPSAâ€) with Sagard Healthcare Partners Funding Borrower SPE 2, LP (â€œSagardâ€). Pursuant to the PSA, Sagard paid the Company $150.0 million (the â€œUpfront Proceedsâ€), net of $0.4 million in reimbursements of Sagardâ€™s fees and expenses (the â€œReimbursementsâ€), for the purchase of a 1% royalty on future net sales of Tyvaso DPI by UT under the terms of the UT License Agreement (the â€œSagard Royaltyâ€). Sagard will also pay the Company a milestone of $50.0 million if net sales of Tyvaso DPI meet or exceed $1.9 billion for any twelve consecutive months on or prior to December 31, 2026 (â€œNet Sales Threshold Aâ€), or a milestone of $45.0 million if net Sales Threshold A is not met and net sales of Tyvaso DPI meet or exceed $2.3 billion for any twelve consecutive months on or prior to September 30, 2027 (â€œNet Sales Threshold Bâ€), resulting in a purchase price not to exceed $200.0 million (the â€œPurchase Priceâ€). If Net Sales Thresholds A and B are not met and net sales of Tyvaso DPI meet or exceed $3.5 billion for any calendar year after September 30, 2027, no royalties will be payable to Sagard for the remainder of that year. The PSA applies to net sales of Tyvaso DPI generated during October 1, 2023 through December 31, 2042 (the â€œTermination Dateâ€) and will automatically terminate upon payment of the final royalty owed to Sagard thereafter. Upon the Termination Date, ownership of the Sagard Royalty will revert to the Company. Given the Companyâ€™s continuing involvement with the generation of Tyvaso DPI revenue under the UT License Agreement and CSA, which includes the Companyâ€™s supply and manufacture of Tyvaso DPI, and the Companyâ€™s retention and associated defense and maintenance obligations of the intellectual property required in the manufacture of Tyvaso DPI, the Upfront Proceeds were recorded as a liability for sale of future royalties (the â€œRoyalty Liabilityâ€) on the condensed consolidated balance sheets, and any proceeds from future milestones will be added to the Royalty Liability balance upon receipt. Although the Company is not obligated to repay any portion of the Purchase Price to Sagard, the Royalty Liability under the PSA is secured by a security interest granted to Sagard in the underlying 1% royalty rights and any proceeds therefrom. As a result of the PSA, transaction costs totaling $4.4 million (including the Reimbursements) are reported net of the Royalty Liability balance and amortized to interest expense in the condensed consolidated statements of operations over the life of the PSA using the effective interest method. Unamortized transaction costs totaled $4.2 million and $4.4 million at September 30, 2024 and December 31, 2023, respectively.The Company will continue to recognize the full 10% of future royalty revenues in its condensed consolidated statements of operations, with the Sagard Royalty being non-cash revenue for the Company. As royalty payments are earned by and remitted to Sagard, the balance of the Royalty Liability will be effectively repaid as it is amortized over the life of the PSA. To amortize the Royalty Liability, the Company estimated the total amount of future royalty payments to be made to Sagard over the life of the PSA. The excess of those future estimated royalty payments over the Purchase Price proceeds received is recognized in the condensed consolidated statements of operations as non-cash interest expense over the life of the PSA utilizing an imputed effective interest rate. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate may vary during the term of the agreement depending on a number of factors, including the amount and timing of forecasted royalty payments which affects the timing and ultimate amount of reductions to the liability. The Company will evaluate the effective interest rate periodically based on its forecasted royalty payments utilizing the prospective method.The Company periodically assesses the forecasted royalty payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments, or the timing of such payments, are materially different than original estimates, the Company will prospectively adjust the effective interest rate and amortization of the Royalty Liability. The following table shows the activity within the Royalty Liability account during the nine months ended September 30, 2024 as well as the effective interest rate (dollars in thousands): Balance, January 1, 2024 $ 145,810 Â Amortization of deferred transaction costs Â 172 Â Non-cash interest expense on liability for sale of future royalties Â 12,548 Â Royalty revenue earned by or payable to Sagard Â (9,635) Balance, September 30, 2024 $ 148,895 Â Â Â Â Â Effective interest rate 8.8% â€” 11.5% Â Sale-Leaseback Transactionâ€” In November 2021, the Company sold certain land, building and improvements located in Danbury, CT (the "Property") to an affiliate of Creative Manufacturing Properties (the "Purchaser") for a sales price of $102.3 million, subject to terms and the conditions contained in a purchase and sale agreement. Effective with the closing of the Sale-Leaseback Transaction, the Company and the Purchaser entered into a lease agreement (the â€œLeaseâ€), pursuant to which the Company leased the Property from the Purchaser for an initial term of 20 years, with four renewal options of five years each. The total annual rent under the Lease starts at approximately $9.5 million per year, subject to a 50% rent abatement during the first year of the Lease, and will increase annually by (i) 2.5% in the second through fifth year of the Lease and (ii) 3% in the sixth and each subsequent year of the Lease, including any renewal term, utilizing a weighted average discount rate of 9.0%. The Company is responsible for payment of operating expenses, property taxes and insurance for the Property. The Purchaser will hold a security deposit of $2.0 million during the Lease term. Pursuant to the terms of the Lease, the Company has four options to repurchase the Property, in 2026, 2031, 2036 and 2041, for the greater of (i) $102.3 million and (ii) the fair market value of the Property.Effective with the closing of the Sale-Leaseback Transaction, the Company and the Purchaser also entered into a right of first refusal agreement (the â€œROFRâ€), pursuant to which the Company has a right to re-purchase the Property from the Purchaser in accordance with terms and conditions set forth in the ROFR. Specifically, if the Purchaser receives, and is willing to accept, a bona fide purchase offer for the Property from a third-party purchaser, the Company has certain rights of first refusal to purchase the Property on the same material terms as proposed in such bona fide purchase offer.As of September 30, 2024, the related financing liability was $104.0 million, which was recognized in the condensed consolidated balance sheet and of which $94.0 million was long-term and $10.0 million was current. As of December 31, 2023, the related financing liability was $104.1 million, of which $94.3 million was long-term and $9.8 million was current. Financing liability information was as follows (dollars in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Weighted average remaining lease term (in years) Â Â 17.1 Â Â Â 17.8 Â Â Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Interest expense on financing liability Â $ 2,470 Â Â $ 2,459 Â Â $ 7,361 Â Â $ 7,332 Â The Company's remaining financing liability payments were as follows (in thousands): Â Â September 30, 2024 Â Remainder of 2024 Â $ 2,532 Â 2025 Â Â 10,269 Â 2026 Â Â 10,533 Â 2027 Â Â 10,849 Â 2028 Â Â 11,174 Â Thereafter Â Â 177,278 Â Total Â Â 222,635 Â Interest payments Â Â (116,113) Debt issuance costs Â Â (2,519) Total financing liability Â $ 104,003 Â Financing Lease â€” In May 2024, the Company acquired audio-visual equipment via a financing lease with de minimis monthly principal and interest payments and a termination date in May 2029. Financing lease information was as follows (dollars in thousands): Â Â September 30, 2024 Â Financing lease right-of-use asset(1) Â $ 219 Â Â Â Â Â Financing lease liability-current(2) Â $ 52 Â Financing lease liability-long-term Â Â 171 Â Total Â $ 223 Â Â Â Â Â Weighted average remaining lease term (in years) Â Â 4.7 Â Weighted average discount rate Â Â 7.25 % _____(1)Financing right-of-use asset is included in other assets in the condensed consolidated balance sheets.(2)Financing lease liability â€“ current is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets.The Company's remaining financing lease payments were as follows (in thousands): Â Â September 30, 2024 Â Remainder of 2024 Â $ 27 Â 2025 Â Â 54 Â 2026 Â Â 54 Â 2027 Â Â 54 Â 2028 Â Â 54 Â Thereafter Â Â 23 Â Total Â Â 266 Â Interest payments Â Â (43) Total financing liability Â $ 223 Â Â Commitments â€” In July 2014, the Company entered into the Insulin Supply Agreement pursuant to which Amphastar manufactures for and supplies to the Company certain quantities of recombinant human insulin for use in Afrezza. Under the terms of the Insulin Supply Agreement, Amphastar is responsible for manufacturing the insulin in accordance with the Companyâ€™s specifications and agreed-upon quality standards. In December 2023, the Company and Amphastar amended the Insulin Supply Agreement to extend the term, restructure the annual purchase commitments and include a capacity fee for certain future periods. The Company's remaining purchase commitments and estimated capacity fee liability as of September 30, 2024 were as follows (â,¬ in millions): Â September 30, 2024 Â Â Remaining Purchase Commitments Â Â Estimated Capacity Fees Â 2025 Â â€” Â Â Â 1.5 Â 2026(1) Â 4.2 Â Â Â Â 2.0 Â 2027 Â 6.0 Â Â Â Â 1.0 Â 2028 Â 6.0 Â Â Â Â 1.0 Â 2029 Â 6.0 Â Â Â Â 1.0 Â 2030 Â 6.0 Â Â Â Â 1.0 Â 2031 Â 8.0 Â Â Â Â 0.5 Â 2032 Â 8.0 Â Â Â Â 0.5 Â 2033 Â 8.0 Â Â Â Â 0.5 Â 2034 Â 4.4 Â Â Â Â 0.5 Â Total Â 56.6 Â Â Â Â 9.5 Â _____(1)If there is a delay in the availability of insulin with FDA approved inclusion bodies and supply does not begin in 2026 as currently expected, the Company will incur a capacity fee of â,¬750,000 per quarter that the product is not available for purchase. Pursuant to the amendment, the term of the Insulin Supply Agreement expires on the later of December 31, 2034 or until the completion of the total remaining purchase commitment quantities, unless terminated earlier, and can be renewed for additional, successive two-year terms upon 12 monthsâ€™ written notice given prior to the end of the initial term or any additional two-year term. The Company and Amphastar each have normal and customary termination rights, including termination for a material breach that is not cured within a specific time frame or in the event of liquidation, bankruptcy or insolvency of the other party. In addition, the Company may terminate the Insulin Supply Agreement upon two yearsâ€™ prior written notice to Amphastar without cause or upon 30 daysâ€™ prior written notice to Amphastar if a controlling regulatory authority withdraws approval for Afrezza, provided, however, in the event of a termination pursuant to either of the latter two scenarios, the provisions of the Insulin Supply Agreement require the Company to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination. The Company periodically reviews the terms of the long-term Insulin Supply Agreement and assesses the need for any accrual for estimated losses, such as lower-of-cost or net-realizable-value that will not be recovered by future product sales. The recognized loss on purchase commitments of $62.6 million and $64.8 million is included in our condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023, respectively, and is reduced as inventory items are received or such liability is extinguished. As a result of the increase in future cash flows for the excess capacity fees and extended term included in the amendment of the Insulin Supply Agreement, the Company analyzed the need for additional estimated losses and concluded that an increase in the recognized loss on purchase commitments was not required as the net realizable value of inventory resulting from the purchase commitment was in excess of the carrying value. Increases in costs associated with the amendment will be recognized through inventory as incurred.Vehicle Leases â€” During the second quarter of 2018, the Company entered into a master lease agreement with Enterprise Fleet Management Inc. The monthly payment inclusive of maintenance fees, insurance and taxes is approximately $0.1 million. The lease expense is included in selling expenses in the condensed consolidated statements of operations.Office Leases â€” In May 2017, the Company executed an office lease with Russell Ranch Road II LLC for the Companyâ€™s corporate offices in Westlake Village, California, which was renewed in April 2022. Pursuant to the renewal, the monthly lease payments of $79,543 began in February 2023 and are subject to 3% annual increases, plus the estimated cost of maintaining the property and common areas by the landlord, and are further subject to a six-month base rent concession beginning February 2023. The Company is also entitled to a one-time allowance up to $0.9 million as reimbursement for tenant improvements or the purchase of furniture, fixtures or equipment. Of the $0.9 million allowance, an amount up to $0.7 million may be applied as an additional base rent concession. The Company has no further right to extend the lease term beyond July 31, 2028. In May 2022, the Company assumed certain leased real property (the â€œMarlborough Leaseâ€) in connection with the V-Go acquisition. The Marlborough Lease pertains to certain premises in a building located in Marlborough, Massachusetts. The monthly payments of $28,895 began in June 2022, subject to approximately 3% annual increases through February 28, 2026.The Company also acquired rights to a manufacturing service agreement where V-Go is manufactured using Company-owned equipment located at the manufacturing facility. The Company determined that this arrangement results in an embedded lease which granted the Company exclusive use of space within the manufacturing facility. The Company assessed the embedded lease cost to be $14,370 per month through February 28, 2026.In July 2024, the Company assumed certain leased real property (the "Bedford Lease") in connection with the Pulmatrix Transaction. The Bedford Lease pertains to certain premises in a building located in Bedford, Massachusetts. The monthly base rent payments of $101,282 are subject to 3% annual increases, plus the estimated cost of maintaining the property and common areas by the landlord. The Company also assumed from Pulmatrix a $0.7 million obligation to repay landlord-funded tenant improvements at a rate of $6,000 per month through the end of the lease term in November 2033. The Company has the right to extend the lease term for an additional five-year term.Lease information was as follows (dollars in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Operating lease right-of-use assets(1) Â $ 13,637 Â Â $ 4,685 Â Â Â Â Â Â Â Â Operating lease liability-current(2) Â $ 2,431 Â Â $ 1,423 Â Operating lease liability-long-term Â Â 12,167 Â Â Â 3,925 Â Total Â $ 14,598 Â Â $ 5,348 Â Â Â Â Â Â Â Â Weighted average remaining lease

term (in years) Â Â 7.3 Â Â Â 3.7 Â Weighted average discount rate Â Â 7.25 % Â Â 7.25 % _____(1)Operating right-of-use assets related to vehicles, offices and the manufacturing facility for V-Go are included in other assets in the condensed consolidated balance sheets.(2)Operating lease liability â€“ current is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease costs Â $ 719 Â Â $ 422 Â Â $ 1,417 Â Â $ 1,253 Â Variable lease costs Â Â 104 Â Â Â 48 Â Â Â 122 Â Â Â 97 Â Cash paid Â Â 860 Â Â Â 268 Â Â Â 1,407 Â Â Â 825 Â The Company's future minimum office and vehicle lease payments were as follows (in thousands): Â Â September 30, 2024 Â Remainder of 2024 Â $ 784 Â 2025 Â Â 3,157 Â 2026 Â Â 2,579 Â 2027 Â Â 2,540 Â 2028 Â Â 2,087 Â Thereafter Â Â 7,721 Â Total Â Â 18,868 Â Interest expense Â Â (4,270) Total operating lease liability Â $ 14,598 Â X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 9 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] Â Income Taxes 16. Income TaxesDuring the three and nine months ended September 30, 2024, the Company recorded income tax expense of $1.3 million and $1.9 million, respectively, related to state taxes, which was calculated using the discrete year-to-date method. The income tax provision for the three and nine months ended September 30, 2023 resulted in no tax expense. The effective tax rate differs from the statutory tax rate of 21% primarily due to the existence of valuation allowances against net deferred tax assets and current liabilities resulting from the estimated state income tax liabilities.Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and concluded, in accordance with the applicable accounting standards, that net deferred tax assets should be fully reserved.The Company has assessed its position with regards to uncertainty in tax positions and has not recognized a liability for unrecognized tax benefits. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. The Company recognizes interest and penalties accrued related to unrecognized tax benefits in income tax expense. During the nine months ended September 30, 2024, the Company did not recognize any interest or penalties. The Companyâ€™s tax years since 2019 remain subject to examination by tax authorities.In June 2024, California enacted Senate Bills 167 and 175 ("SB 167" and "SB 175"). SB 167 suspends the use of net operating losses ("NOLs") and limits the use of business credits to $5.0 million for the 2024-2026 tax years. Under SB 175, the NOL suspension and credit limitations will not apply for the 2025 and 2026 tax years if certain budget goals are met. Although the Company does not expect this legislation to have a material effect on its results of operations or cash flows, management continues to evaluate any potential impact. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Business Business â€“ MannKind is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The Companyâ€™s signature technologiesâ€”Technosphere dry-powder formulations and Dreamboat inhalation devicesâ€”offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. The Company is currently commercializing Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. The first product to come out of the orphan lung disease pipeline, Tyvaso DPI (treprostinil) inhalation powder, received approval from the U.S. Food and Drug Administration (â€œFDAâ€) in May 2022 for the treatment of pulmonary arterial hypertension (â€œPAHâ€) and for the treatment of pulmonary hypertension associated with interstitial lung disease (â€œPH-ILDâ€). The Company's development and marketing partner, UT, began commercializing Tyvaso DPI in June 2022 and is obligated to pay a 10% royalty on net sales of the product, of which 9% is allocated to the Company and 1% to another party as detailed in Note 15 â€“ Commitments and Contingencies. The Company also receives a margin on supplies of Tyvaso DPI that it manufactures for UT. Basis of Presentation Basis of Presentation â€“ The condensed consolidated financial statements have been prepared in accordance with GAAP. Principles of Consolidation Principles of Consolidation â€“ The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated. Reclassifications Reclassifications â€“ Certain amounts reported in the prior period have been reclassified to conform with current period presentation. The Company has separated non-cash accretion income on investments from other, net, and presented it as net accretion of investments in the condensed consolidated statements of cash flows. The Company has also presented non-cash interest accretion on financing liability in other, net. Additionally, the Company has combined accruals for the Danbury facility buildout with other in Note 8 â€“ Accrued Expenses and Other Current Liabilities. Segment Information Segment Information â€“ Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and manages its business as one segment operating in the United States of America ("U.S."). Revenue Recognition Revenue Recognition â€“ The Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Accounting Standards Codification (â€œASCâ€) Topic 606, Revenue from Contracts with Customers (â€œASC 606â€), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC 606, including when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company has two types of contracts with customers: (i) contracts for commercial product sales with wholesale distributors, specialty and retail pharmacies, and durable medical equipment suppliers ("DMEs") and (ii) collaboration arrangements. Revenue Recognition - Net Revenue - Commercial Product Sales Revenue Recognition â€“ Net Revenue â€“ Commercial Product Sales â€“ The Company sells its products to a limited number of wholesale distributors, specialty and retail pharmacies, and DMEs in the U.S. (collectively, its â€œCustomersâ€). Wholesale distributors subsequently resell the Companyâ€™s products to retail pharmacies and certain medical centers or hospitals. Specialty and retail pharmacies sell directly to patients. In addition to distribution agreements with Customers, the Company enters into arrangements with payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Companyâ€™s products.The Company transfers control and recognizes revenue upon delivery of product to wholesale distributors and specialty pharmacies. The Company transfers control and recognizes revenue on product sales to a retail pharmacy as the product is dispensed to patients. Product revenues are recorded net of applicable reserves, including discounts, allowances, rebates, returns and other incentives. See Reserves for Variable Consideration below.Reserves for Variable Consideration â€“ Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its Customers, payers, and other indirect customers relating to the Companyâ€™s sale of its products. These reserves, as further detailed below, are based on the amounts earned, or to be claimed on the related sales, and result in a reduction of accounts receivable or establishment of a current liability. Significant judgment is required in estimating gross-to-net adjustments, including historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, claim submission time lags and inventory levels in the distribution channel.Where appropriate, these estimates take into consideration a range of possible outcomes, which are probability-weighted in accordance with the expected value method in ASC 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reduce recognized revenue to the Companyâ€™s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Companyâ€™s analysis also contemplates application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the current period estimates of gross-to-net adjustments and, therefore, the transaction price was not reduced further during the current period. Actual amounts of consideration ultimately received may differ from the Companyâ€™s estimates. If actual results in the future vary from the Companyâ€™s estimates, the Company will adjust these estimates, which would affect net revenue from commercial product sales and earnings in the period such variances become known.Trade Discounts and Allowances â€“ The Company generally provides Customers with discounts which include incentives, such as prompt pay discounts, that are explicitly stated in the Companyâ€™s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its Customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Companyâ€™s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of revenue and as a reduction to accounts receivable, net. Product Returns â€“ Consistent with industry practice, the Company generally offers Customers a right of return for unopened product that has been purchased from the Company for a period beginning six months prior to and ending 12 months after its expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as reductions to accounts receivable, net. The Company currently estimates product returns using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Companyâ€™s current return reserve percentage is estimated to be in the single digits. Adjustments to the returns reserve are made when changes in the Company's assumptions result in revised estimates.Provider Chargebacks and Discounts â€“ Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase products from the Company. Customers charge the Company for the difference between what they pay for products and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is recorded in accrued expenses and other current liabilities. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by Customers, and the Company generally issues credits for such amounts within a few weeks of the Customerâ€™s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold to qualified healthcare providers, and chargebacks that Customers have claimed, but for which the Company has not yet issued a credit.Government Rebates â€“ The Company is subject to discount obligations under Medicare and state Medicaid programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses and other current liabilities. Estimates around Medicaid have historically required significant judgment due to timing lags in receiving invoices for claims from states. For Afrezza, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Companyâ€™s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for products that have been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. The Companyâ€™s estimates include consideration of historical claims experience, payer channel mix, current contract prices, unbilled claims, claim submission time lags and inventory in the distribution channel.Payer Rebates â€“ The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates, including estimates for product that has been recognized as revenue, but which remains in the distribution channel, and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities. The Companyâ€™s estimates include consideration of historical claims experience, payer channel mix, current contract prices, unbilled claims,

claim submission time lags and inventory in the distribution channel.Other Incentives â€” Other incentives which the Company offers include voluntary patient support programs, such as the Company's co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with co-payments required by payers. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with the products that have been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses and other current liabilities. Revenue Recognition- Net Revenue - Collaborations and Services Revenue Recognition â€” Revenue â€” Collaborations and Services â€” The Company enters into licensing, research or other agreements under which the Company licenses certain rights to its product candidates to third parties, conducts research or provides other services to third parties. The terms of these arrangements may include but are not limited to payment to the Company of one or more of the following: up-front license fees; development, regulatory, and commercial milestone payments; payments for commercial manufacturing and clinical supply services the Company provides; and royalties on net sales of licensed products and sublicenses of the rights. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment such as determining the performance obligation in the contract and determining the stand-alone selling price for each performance obligation identified in the contract. With respect to the Company's significant collaboration and service agreement with UT that includes a long-term commercial supply agreement (as amended, the â€œCSAâ€), the Company has identified three distinct performance obligations: (1) the license, supply of product to be used in clinical development, and continued development and approval support for Tyvaso DPI (â€œR&D Services and Licenseâ€); (2) development activities for the next generation of the product (â€œNext-Gen R&D Servicesâ€); and (3) a material right associated with current and future manufacturing and supply of product (â€œManufacturing Services and Product Salesâ€). Pre-production activities under the CSA, such as facility expansion services and other administrative services, were considered bundled services under the Manufacturing Services and Product Sales performance obligation as required by ASC 606. Following the FDAâ€™s approval of Tyvaso DPI, UT began issuing purchase orders for the supply of product, which represents distinct contracts and performance obligations under ASC 606. Revenue is recognized for the supply of product at a point in time, once control is transferred to UT. See Note 10 â€” Collaboration, Licensing and Other Arrangements. If an arrangement has multiple performance obligations, the allocation of the transaction price is determined from observable market inputs, and the Company uses key assumptions to determine the stand-alone selling price, which may include development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success. Revenue is recognized based on the measurement of progress as the performance obligation is satisfied and consideration received that does not meet the requirements to satisfy the revenue recognition criteria is recorded as deferred revenue. Current deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. For further information, see Note 10 â€” Collaboration, Licensing and Other Arrangements.The Company recognizes upfront license payments as revenue upon delivery of the license only if the license is determined to be a separate unit of accounting from the other undelivered performance obligations. The undelivered performance obligations typically include manufacturing or development services or research and/or steering committee services. If the license is not considered as a distinct performance obligation, then the license and other undelivered performance obligations would be evaluated to determine if such should be accounted for as a single unit of accounting. If concluded to be a single performance obligation, the transaction price for the single performance obligation is recognized as revenue over the estimated period of when the performance obligation is satisfied. If the license is considered to be a distinct performance obligation, then the estimated revenue is included in the transaction price for the contract, which is then allocated to each performance obligation based on the respective standalone selling prices.Whenever the Company determines that an arrangement should be accounted for over time, the Company determines the period over which the performance obligations will be performed, and revenue will be recognized over the period the Company is expected to complete its performance obligations. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. The Companyâ€™s collaboration agreements typically entitle the Company to additional payments upon the achievement of development, regulatory and sales milestones. If the achievement of a milestone is considered probable at the inception of the collaboration, the related milestone payment is included with other collaboration consideration, such as upfront fees and research funding, in the Companyâ€™s revenue calculation. If these milestones are not considered probable at the inception of the collaboration, the milestones will typically be recognized in one of two ways depending on the timing of when the milestone is achieved. If the milestone is improbable at inception and subsequently deemed probable of achievement, such will be added to the transaction price, resulting in a cumulative adjustment to revenue. If the milestone is achieved after the performance period has been completed and all performance obligations have been delivered, the Company will recognize the milestone payment as revenue in its entirety in the period the milestone was achieved. The Companyâ€™s collaboration agreements, for accounting purposes, represent contracts with customers and therefore are not subject to accounting literature on collaboration agreements. The Company grants licenses to its intellectual property, supplies raw materials, semi-finished goods or finished goods, provides research and development services and offers sales support for the co-promotion of products, all of which are outputs of the Companyâ€™s ongoing activities, in exchange for consideration. Accordingly, the Company concluded that its collaboration agreements must generally be accounted for pursuant to ASC 606.For collaboration agreements that allow collaboration partners to select additional optioned products or services, the Company evaluates whether such options contain material rights (i.e., have exercise prices that are discounted compared to what the Company would charge for a similar product or service to a new collaboration partner). The exercise price of these options includes a combination of licensing fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, the Company concludes the option does not contain a material right, and therefore is not included in the transaction price at contract inception. The Company assessed the long-term commercial supply agreement with UT (as amended, the "CSA") and determined that a material right existed for the manufacturing services performance obligation. The transaction price is allocated to the material right as well as the remaining performance obligations in accordance with ASC 606. The Company also evaluates grants of additional licensing rights upon option exercises to determine whether such should be accounted for as separate contracts.Revenue Recognition â€” Royalties â€” The Company recognizes royalty revenue for a sales-based or usage-based royalty if it is promised in exchange for an intellectual property license. The royalty revenue is recognized as the latter of the subsequent sale of the product occurs or if the performance obligation to which the royalty has been allocated has been satisfied or partially satisfied. The Companyâ€™s UT License Agreement (as defined in Note 10 â€“ Collaboration, Licensing and Other Arrangements) entitles it to receive a 10% royalty on net sales of Tyvaso DPI for the license of the Companyâ€™s IP that was considered to be interdependent with the development activities that supported the approval of Tyvaso DPI. Although the Company recognizes a 10% royalty on net revenue from the sale of Tyvaso DPI as revenue, it only collects 9% due to its sale in December 2023 of 1% of future royalties as detailed in Note 15 â€” Commitments and Contingencies.The Companyâ€™s net revenue and cost of revenue and goods sold as shown on the condensed consolidated statement of operations is comprised of revenue generated from product sales, services and royalties as shown below (in thousands): Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net revenue: Â Â Â Â Â Â Â Â Â Â Â Â Product revenue (1) Â $ 42,959 Â Â $ 30,727 Â Â $ 132,945 Â Â $ 88,731 Â Services (2) Â Â 37 Â Â Â 308 Â Â Â 457 Â Â Â 808 Â Royalties (3) Â Â 27,083 Â Â Â 20,218 Â Â Â 75,326 Â Â Â 50,951 Â Total net revenue Â $ 70,079 Â Â $ 51,253 Â Â $ 208,728 Â Â $ 140,490 Â _____(1)Amounts represent the revenue from Afrezza and V-Go sales to wholesalers and specialty pharmacies and Tyvaso DPI to UT.(2)Amounts represent revenue generated from the Company's collaboration arrangements, including Next-Gen R&D Services (as defined in Note 10) for UT as well as arrangements with other collaboration partners. See Note 10 â€” Collaboration, Licensing and Other Arrangements. (3)Amounts represent royalties on UTâ€™s net revenue from Tyvaso DPI sales. Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of goods sold and cost of revenue: Â Â Â Â Â Â Â Â Â Â Â Â Product revenue Â $ 18,023 Â Â $ 13,983 Â Â $ 56,651 Â Â $ 44,006 Â Services Â Â â€” Â Â Â 271 Â Â Â 347 Â Â Â 698 Â Total cost of goods sold and cost of revenue Â $ 18,023 Â Â $ 14,254 Â Â $ 56,998 Â Â $ 44,704 Â The Company follows accounting guidance in measuring revenue and certain judgments affect the application of its revenue policy. For example, in connection with its existing collaboration agreements, the Company has recorded short-term and long-term deferred revenue on its condensed consolidated balance sheets based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. However, this estimate is based on the Companyâ€™s current project development plan and, if the development plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period. Milestone Payments Milestone Payments â€” At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the customer, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as, or when, the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration, other revenue, and earnings in the period of adjustment. Cost of Goods Sold Cost of Goods Sold â€” Cost of goods sold includes material, labor costs and manufacturing overhead. Cost of goods sold also includes a component of current period manufacturing costs in excess of costs capitalized into inventory (â€œexcess capacity costsâ€). These costs, in addition to the impact of the revaluation of inventory for standard costing, and write-offs of inventory are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. Cost of goods sold excludes the cost of insulin purchased under the Companyâ€™s Insulin Supply Agreement (the â€œInsulin Supply Agreementâ€) with Amphastar Pharmaceuticals, Inc. (â€œAmphastarâ€). All insulin inventory on hand was written off and the full purchase commitment contract to purchase future insulin was accrued as a recognized loss on purchase commitments as of the end of 2016. Cost of Revenues Cost of Revenues â€” Collaborations and Services â€” Cost of revenues for collaborations and services includes material, labor costs, manufacturing overhead, and excess capacity costs. These costs, in addition to the write-offs of inventory are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. Cost of revenues for collaborations and services also includes the cost of product development. Research and Development Research and Development ("R&D") â€” Clinical trial expenses result from obligations under contracts with vendors, consultants and clinical site agreements in addition to internal costs associated with conducting clinical trials. R&D costs are expensed as incurred. Clinical study and certain research costs are recognized over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Nonrefundable advance payments for services to be received in the future for use in R&D activities are recorded as prepaid assets and expensed in the period when the services are performed. Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents and Restricted Cash â€” The Company considers all highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase that are readily convertible into cash to be cash equivalents. As of September 30, 2024 and December 31, 2023, cash equivalents were comprised of money market funds, U.S. Treasury securities, corporate bonds and commercial paper with original maturities less than 90 days from the date of purchase. The Company records restricted cash when cash and cash equivalents are restricted as to withdrawal or usage. Restricted cash under a letter of credit issued in connection with a facility lease assumed by the Company that will not be available for use in the Companyâ€™s operations within 12 months of the reporting date is presented in non-current assets. See Note 2 â€” Pulmatrix Transaction. Held-to-Maturity Investments Held-to-Maturity Investments â€” The Companyâ€™s investments generally consist of commercial paper, corporate notes or bonds and U.S. Treasury securities. As of September 30, 2024 and December 31, 2023, the Company held short-term and long-term investments of debt securities, including commercial paper and bonds. The Company intends to hold its investments until maturity; therefore, these investments are stated at amortized cost. The investments with maturities less than 12 months are included in short-term investments and investments with maturities in excess of twelve months are included in long-term investments in the condensed consolidated balance sheets. The amortization or accretion of the Companyâ€™s investments is recognized as interest income in the condensed consolidated statements of operations. Available-for-Sale Investment Available-for-Sale Investment â€” In June 2021, the Company purchased a $3.0 million convertible promissory note issued by Thirona Bio, Inc. (â€œThironaâ€). In January 2022, the Company purchased an additional $5.0 million convertible promissory note issued by Thirona (the â€œThirona convertible notesâ€). The Thirona convertible notes are general unsecured obligations of Thirona and initially accrued interest at a rate of 6% per annum. Unless earlier converted into conversion shares pursuant to the note purchase agreement, the aggregate principal of $8.0 million and accrued interest shall be due and payable by Thirona on demand by the Company at any time after the maturity date. The Thirona convertible notes were amended in February 2023 to extend the maturity date from December 31, 2022 to June 30, 2024, and again on June 27, 2024 to extend the maturity date to June 30, 2026 and increase the interest rate to 10% per annum. The Thirona convertible notes are classified as available-for-sale securities and included in other assets as of September 30, 2024 and prepaid expense and other current assets as of December 31, 2023 in the condensed consolidated balance sheets. The Company periodically assesses whether it has any intention to sell the investment, determines the fair value of its available-for-sale investment using level 3 inputs and assesses whether there were other-than-temporary impairments associated with the investment. Unrealized holding gains and losses are excluded from earnings and reported in other comprehensive income until realized, while unrealized losses related to credit risk are reported through earnings in the period incurred. Concentration of Credit Risk Concentration of Credit Risk â€” Financial instruments that potentially subject the Company to concentration of credit risk consisted of cash and cash equivalents and investments. Cash and cash equivalents are held in high credit quality institutions. Cash equivalents consisted of interest-bearing money market funds and U.S. Treasury securities with original or remaining maturities of 90 days or less at the time of purchase. Investments generally consisted of commercial paper, corporate notes or bonds and U.S. Treasury securities. The cash equivalents and investments are regularly monitored by management. Accounts Receivable and Allowance for Credit Losses Accounts Receivable and Allowance for Credit Losses â€” Accounts receivable are recorded at the invoiced amount and are not interest bearing. Accounts receivable are presented net of an allowance for credit losses if there are estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for credit losses. The allowance for expected credit losses is based primarily on past collections experience relative to the length of time receivables are past due. However, when available evidence reasonably supports an assumption that future economic conditions will differ from current and historical payment collections, an adjustment is reflected in the allowance for expected credit losses. Accounts receivable are also presented net of an allowance for product returns and trade discounts and allowances because the Companyâ€™s customers have the right of setoff for these amounts against the related accounts receivable. Pre Launch Inventory Pre-Launch Inventory â€” An improvement to the manufacturing process for the Companyâ€™s primary excipient, fumaryl diketopiperazine (â€œFDKPâ€) was demonstrated to be viable and management expects to realize an economic benefit in the future as a result of such process improvement. Accordingly, the Company is required to assess whether to capitalize inventory costs related to such excipient prior to validation of the improved manufacturing process and adoption of the new supplier. In doing so, management must consider a number of factors in order to determine the amount of inventory to be capitalized, including the historical experience of modifying the Companyâ€™s manufacturing processes, feedback from technical experts and regulatory agencies on the changes being effected and the amount of inventory that is likely to be used in commercial production. The shelf life of the excipient will be determined as part of the validation process; in the interim, the Company must assess the available stability data to determine whether there is likely to be adequate shelf life to support anticipated future sales occurring beyond the expected adoption date of the new raw material. If management is aware of any specific material risks or contingencies other than the normal regulatory reporting process, or if the criteria for capitalizing inventory produced prior to regulatory approval are otherwise not met, the Company would not capitalize such inventory costs, choosing instead to recognize such costs as R&D expense in the period incurred. See Note 5 â€” Inventories. Inventories Inventories â€” Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. The Company capitalizes inventory costs associated with the Companyâ€™s products based on managementâ€™s judgment that future economic benefits are expected to be realized;

otherwise, such costs are expensed as incurred as cost of goods sold. The Company uses a contract manufacturing organization outside of the U.S. for certain stages of V-Go inventory.The Company periodically analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value and writes down such inventories, as appropriate. In addition, the Companyâ€™s products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or may become obsolete or are forecasted to become obsolete due to expiration, the Company will record a charge to write down such unmarketable inventory to its estimated net realizable value. The Company analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company performs an assessment of projected sales and evaluates the lower of cost or net realizable value and the potential excess inventory on hand at the end of each reporting period. Property and Equipment Property and Equipment â€” Property and equipment is recorded at historical cost, net of accumulated depreciation. Depreciation expense is recorded over the assetsâ€™ useful lives on a straight-line basis and included in cost of goods sold, research and development, and general and administrative expense in the condensed consolidated statements of operations. See Note 6 â€” Property and Equipment. Impairment of Long-Lived Assets Impairment of Long-Lived Assets â€” Long-lived assets include property and equipment, operating lease right-of-use assets and other intangible assets. The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Assets are considered to be impaired if the carrying value is considered to be unrecoverable.If the Company believes an asset to be impaired, the impairment recognized is the amount by which the carrying value of the asset exceeds the fair value of the asset. Fair value is determined using the market, income or cost approaches as appropriate for the asset. Any write-downs are treated as permanent reductions in the carrying amount of the asset and recognized as an operating loss. Acquisitions Acquisitions â€” The Company first determines whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, the Company accounts for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process R&D (â€œIPR&Dâ€), and liabilities assumed are recorded at their respective fair values as of the acquisition date in the Companyâ€™s condensed consolidated financial statements. Leases are recorded at the net present value of the remaining lease payments. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. A gain on bargain purchase is recorded if the fair value of the net assets acquired exceeds the fair value of the consideration transferred. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquireeâ€™s liability arising from an acquisition it consummated prior to the Companyâ€™s acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&D projects with no alternative future use are recorded in R&D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets â€” The fair value of acquired intangible assets is determined using either a cost approach or an income approach. The cost approach establishes fair value based on the cost of reproducing or replacing the asset, less depreciation for functional or economic obsolescence. The income approach, referred to as the excess earnings method, utilizes Level 3 fair value inputs to determine the present value of future economic benefits to be derived from ownership of the intangible asset. Market participant valuations assume a global view considering all potential jurisdictions and indications based on discounted after-tax cash flow projections, risk adjusted for estimated probability of technical and regulatory success. The Company tests for impairment annually on a reporting unit basis, at the beginning of the Companyâ€™s fourth fiscal quarter and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying amount. To the extent the carrying amount of a reporting unit is less than its estimated fair value, an impairment charge will be recorded.Finite-lived intangible assets are amortized on a straight-line basis over the estimated useful life. Estimated useful lives are determined considering the period assets are expected to contribute to future cash flows. Finite-lived intangible assets are tested for impairment when facts or circumstances suggest that the carrying value of the asset may not be recoverable. If the carrying value exceeds the projected undiscounted pretax cash flows of the intangible asset, an impairment loss equal to the excess of the carrying value over the estimated fair value (discounted after-tax cash flows) is recognized.IPR&D acquired in a business combination is considered an indefinite-lived intangible asset until the completion or abandonment of the associated R&D efforts. During the R&D period, the asset is not amortized but rather is tested for impairment when facts or circumstances suggest that the carrying value of the asset may not be recoverable. Once the R&D efforts are completed, the Company accounts for the resulting asset as a finite-lived intangible asset. If the R&D efforts are abandoned, the asset balance is written off to R&D expense. Recognized Loss on Purchase Commitments Recognized Loss on Purchase Commitments â€” The Company reviews the terms of the long-term supply agreements and assesses the need for any accrual for estimated losses, such as lower of cost or net realizable value, that will not be recovered by future product sales. The recognized loss on purchase commitments is reduced as inventory items are received or as the liability is extinguished. See Note 15 â€” Commitments and Contingencies. Milestone Rights Liability Milestone Rights Liability â€” In July 2013, in conjunction with the execution of a (now repaid) loan agreement with Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively, â€œDeerfieldâ€), the Company entered into a Milestone Rights Purchase Agreement (the â€œMilestone Rights Agreementâ€) pursuant to which the Company issued certain milestone rights to Deerfield Private Design Fund II, L.P. and Horizon SantÂ© FLML SÃ€RL (the â€œOriginal Milestone Purchasersâ€). The foregoing milestone rights provided the Original Milestone Purchasers certain rights to receive payments of up to $90.0 million upon the occurrence of specified strategic and Afrezza sales milestones, $50.0 million of which remains payable as of September 30, 2024 upon achievement of such milestones (collectively, the â€œMilestone Rightsâ€). In December 2021, the Milestone Rights were purchased by Barings Global Special Situations Credit Fund 4 (Delaware), L.P. and Barings Global Special Situations Credit 4 (LUX) S.ar.l. (together, the â€œMilestone Purchasersâ€). As a result, the Milestone Purchasers have assumed the obligations of the Original Milestone Purchasers and are now entitled to all rights under the Milestone Rights Agreement. The Milestone Rights liability is reported at fair value at the date of the agreement which is periodically offset against payments. See Note 11 â€” Fair Value of Financial Instruments.The initial fair value estimate of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones and discounted to present value using a selected market discount rate. The expected timing and probability of achieving the milestones was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. The Milestone Rights liability is remeasured as the specified milestone events are achieved. Specifically, as each milestone event is achieved, the portion of the initially recorded Milestone Rights liability that pertains to the milestone event being achieved, is remeasured to the amount of the specified related milestone payment. The resulting change in the balance of the Milestone Rights liability due to remeasurement is recorded in the Companyâ€™s condensed consolidated statements of operations as interest expense. Furthermore, the Milestone Rights liability is reduced upon the settlement of each milestone payment. As a result, each milestone payment is effectively allocated between a reduction of the recorded Milestone Rights liability and an expense representing a return on a portion of the Milestone Rights liability paid to the investor for the achievement of the related milestone event. See Note 8 â€” Accrued Expenses and Other Current Liabilities and Note 15 â€” Commitments and Contingencies. Fair Value of Financial Instruments Fair Value of Financial Instruments â€” The Company applies various valuation approaches in determining the fair value of its financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Companyâ€™s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 â€” Quoted prices for identical instruments in active markets.Level 2 â€” Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.Level 3 â€” Significant inputs to the valuation model are unobservable. Income Taxes Income Taxes â€” The provisions for federal, foreign, state and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized.For uncertain tax positions, the Company determines whether it is â€œmore likely than notâ€ that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit can be recorded in the financial statements. For those tax positions where it is â€œnot more likely than notâ€ that a tax benefit will be sustained, no tax benefit is recognized. Penalties, if probable and reasonably estimable, are recognized as a component of income tax expense. The Company has reduced its deferred tax assets for uncertain tax positions but has not recorded liabilities for income tax expense, penalties, or interest. Contingencies Contingencies â€” The Company records a loss contingency for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These accruals represent managementâ€™s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may revise its estimates. Stock-Based Compensation Stock-Based Compensation â€” Share-based payments to employees, including grants of restricted stock units (â€œRSUsâ€), performance-based non-qualified stock options awards (â€œPNQsâ€), restricted stock units with market conditions (â€œMarket RSUsâ€), options and the compensatory elements of employee stock purchase plans, are recognized in the condensed consolidated statements of operations based upon the fair value of the awards at the grant date. RSUs are valued based on the market price on the grant date. Market RSUs are valued using a Monte Carlo valuation model and RSUs with performance conditions are evaluated for the probability that the performance conditions will be met and estimates the date at which the performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period. The Company uses the Black-Scholes option valuation model to estimate the grant date fair value of employee stock options and the compensatory elements of employee stock purchase plans. Net Income (Loss) Per Share of Common Stock Net Income (Loss) Per Share of Common Stock â€” Basic net income or loss per share ("EPS") is calculated by dividing net income by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the effect of potential common stock issuances resulting from assumed stock option exercises and vesting of restricted stock units, unless the effect is anti-dilutive, when applying the treasury stock method, as well as potential dilution under the if-converted method for convertible debt securities. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted EPS as they would be anti-dilutive. Recently Issued Accounting Standards Recently Issued Accounting Standards â€” In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). This ASU requires disaggregated information about a public entityâ€™s effective tax rate reconciliation as well as additional information on income taxes paid. This ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact of the guidance on its condensed consolidated financial statement disclosures.From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Companyâ€™s condensed consolidated financial position or results of operations upon adoption. X - DefinitionBasis of Presentation. + ReferencesNo definition available. + Details Name: mnkd_BasisOfPresentationPolicyTextBlock Namespace Prefix: mnkd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionBusiness. + ReferencesNo definition available. + Details Name: mnkd_BusinessPolicyTextBlock Namespace Prefix: mnkd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionCost of revenues. + ReferencesNo definition available. + Details Name: mnkd_CostOfRevenuesPolicyTextBlock Namespace Prefix: mnkd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLoss on purchase commitments. + ReferencesNo definition available. + Details Name: mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock Namespace Prefix: mnkd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionMilestone rights liability. + ReferencesNo definition available. + Details Name: mnkd_MilestoneRightsLiabilityPolicyTextBlock Namespace Prefix: mnkd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionPre-launch inventory. + ReferencesNo definition available. + Details Name: mnkd_PreLaunchInventoryPolicyTextBlock Namespace Prefix: mnkd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionRecently issued accounting standards. + ReferencesNo definition available. + Details Name: mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock Namespace Prefix: mnkd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionRevenue from contract with customer from collaborations and services. + ReferencesNo definition available. + Details Name: mnkd_RevenueFromContractWithCustomerFromCollaborationsAndServicesPolicyTextBlock Namespace Prefix: mnkd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionRevenue from contract with customer from commercial product sales. + ReferencesNo definition available. + Details Name: mnkd_RevenueFromContractWithCustomerFromCommercialProductSalesPolicyTextBlock Namespace Prefix: mnkd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-9 + Details Name: us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4 + Details Name: us-gaap_BusinessCombinationsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time

deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 450 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_CommitmentsAndContingenciesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_CompensationRelatedCostsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cost of product sold and service rendered. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 705 -Publisher FASB -URI https://asc.fasb.org/705/tableOfContent + Details Name: us-gaap_CostOfSalesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_DebtPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1 + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for premium paid to acquire option for investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-9 + Details Name: us-gaap_HeldToMaturitySecuritiesPurchasedOptionsPricePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4 + Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContentReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6 + Details Name: us-gaap_InventoryPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1 + Details Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2 + Details Name: us-gaap_ReceivablesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4 + Details Name: us-gaap_RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10

-Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Summary of Revenue and Cost of Revenue and Goods Sold Generated From Product Sales, Services and Royalties The Companyâ€™s net revenue and cost of revenue and goods sold as shown on the condensed consolidated statement of operations is comprised of revenue generated from product sales, services and royalties as shown below (in thousands): Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net revenue: Â Â Â Â Â Â Â Â Â Â Â Â Â Product revenue (1) Â $ 42,959 Â Â $ 30,727 Â Â $ 132,945 Â Â $ 88,731 Â Services (2) Â Â 37 Â Â Â 308 Â Â Â 457 Â Â Â 808 Â Royalties (3) Â Â 27,083 Â Â Â 20,218 Â Â Â 75,326 Â Â Â 50,951 Â Total net revenue Â $ 70,079 Â Â $ 51,253 Â Â $ 208,728 Â Â $ 140,490 Â _____(1)Amounts represent the revenue from Afrezza and V-Go sales to wholesalers and specialty pharmacies and Tyvaso DPI to UT.(2)Amounts represent revenue generated from the Company's collaboration arrangements, including Next-Gen R&D Services (as defined in Note 10) for UT as well as arrangements with other collaboration partners. See Note 10 â€“ Collaboration, Licensing and Other Arrangements. (3)Amounts represent royalties on UTâ€™s net revenue from Tyvaso DPI sales. Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of goods sold and cost of revenue: Â Â Â Â Â Â Â Â Â Â Â Â Â Product revenue Â $ 18,023 Â Â $ 13,983 Â Â $ 56,651 Â Â $ 44,006 Â Services Â Â â€” Â Â Â 271 Â Â Â 347 Â Â Â 698 Â Total cost of goods sold and cost of revenue Â $ 18,023 Â Â $ 14,254 Â Â $ 56,998 Â Â $ 44,704 Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Pulmatrix Transaction (Tables) 9 Months Ended Sep. 30, 2024 Business Acquisition [Line Items] Â Schedule of Fair Value of Identifiable Assets Acquired and Liabilities Assumed The fair values of identifiable assets acquired and liabilities assumed by the Company from Pulmatrix as of the Effective Date are reflected below (in thousands): Â Â Amount Â Assets: Â Â Â iSPERSE License â€“ IPR&D Â $ 4,300 Â Right-of-use asset â€“ Bedford R&D facility Â Â 10,057 Â Property and equipment Â Â 959 Â Total assets Â Â 15,316 Â Liabilities: Â Â Â Operating lease liability â€“ Bedford R&D facility Â Â 10,057 Â Total liabilities Â Â 10,057 Â Net assets acquired â€“ Gain on bargain purchase Â $ 5,259 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Paragraph 1 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Investments (Tables) 9 Months Ended Sep. 30, 2024 Schedule Of Investments [Abstract] Â Schedule of Contractual Maturities of Held to Maturity Investments The contractual maturities of the Companyâ€™s held-to-maturity investments are summarized below (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â AmortizedCost Basis Â Â AggregateFair Value Â Â AmortizedCost Basis Â Â AggregateFair Value Â Due in one year or less(1) Â $ 230,797 Â Â $ 231,555 Â Â $ 115,263 Â Â $ 115,374 Â Due after one year through five years Â Â 16,796 Â Â Â 16,992 Â Â Â 7,155 Â Â Â 7,197 Â Total Â $ 247,593 Â Â $ 248,547 Â Â $ 122,418 Â Â $ 122,571 Â _____(1)The investments due in one year or less include cash equivalents of $41.6 million as of September 30, 2024 and $58.6 million as of December 31, 2023. Schedule of Fair Value of Cash Equivalents, Long and Short Term Investments The fair value of the cash equivalents, long-term and short-term investments are disclosed below (dollars in thousands).Â Â Â September 30, 2024 Â Â Â Investment Level Â Amortized Cost(Carrying Value) Â Â Gross Unrealized HoldingGains Â Â Gross UnrealizedHoldingLosses Â Â EstimatedFair Value Â Money market funds and other Â Level 1 Â $ 31,298 Â Â $ â€” Â Â $ â€” Â Â $ 31,298 Â Commercial bonds and paper Â Level 2 Â Â 57,477 Â Â Â 268 Â Â Â (12) Â Â 57,733 Â U.S. Treasury Securities Â Level 2 Â Â 158,818 Â Â Â 700 Â Â Â (2) Â Â 159,516 Â Total cash equivalents and investments Â Â Â Â 247,593 Â Â Â 968 Â Â Â (14) Â Â 248,547 Â Less: cash equivalents Â Â Â Â (41,582) Â Â â€” Â Â Â â€” Â Â Â (41,582) Total Investments Â Â Â Â $ 206,011 Â Â $ 968 Â Â $ (14) Â $ 206,965 Â Â Â Â December 31, 2023 Â Â Â Investment Level Â Amortized Cost(Carrying Value) Â Â Gross Unrealized HoldingGains Â Â Gross UnrealizedHoldingLosses Â Â EstimatedFair Value Â Money market funds Â Level 1 Â $ 69,611 Â Â $ â€” Â Â $ â€” Â Â $ 69,611 Â Commercial bonds and paper Â Level 2 Â Â 43,251 Â Â Â 135 Â Â Â (38) Â Â 43,348 Â U.S. Treasury Securities Â Level 2 Â Â 9,556 Â Â Â 56 Â Â Â â€” Â Â Â 9,612 Â Total cash equivalents and investments Â Â Â Â 122,418 Â Â Â 191 Â Â Â (38) Â Â 122,571 Â Less: cash equivalents Â Â Â Â (58,644) Â Â â€” Â Â Â â€” Â Â Â (58,644) Total Investments Â Â Â $ 63,774 Â Â $ 191 Â Â $ (38) Â $ 63,927 Â X - DefinitionSchedule of fair value of cash equivalents long and short term investments. + ReferencesNo definition available. + Details Name: mnkd_ScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsTableTextBlock Namespace Prefix: mnkd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 15: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B + Details Name: us-gaap_HeldToMaturitySecuritiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfInvestmentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Accounts Receivable (Tables) 9 Months Ended Sep. 30, 2024 Receivables [Abstract] Â Schedule of Accounts Receivable, Net Accounts receivable, net consists of the following (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Accounts receivable â€“ commercial Â Â Â Â Â Â Accounts receivable, gross Â $ 18,359 Â Â $ 20,199 Â Wholesaler distribution fees and prompt pay discounts Â Â (2,363) Â Â (2,469) Reserve for returns Â Â (7,817) Â Â (6,215) Allowance for credit losses Â Â â€” Â Â Â (157) Total accounts receivable â€“ commercial, net Â Â 8,179 Â Â Â 11,358 Â Accounts receivable â€“ collaborations and services Â Â 10,005 Â Â Â 3,543 Â Total accounts receivable, net Â $ 18,184 Â Â $ 14,901 Â X - ReferencesNo definition available. + Details Name: us-gaap_ReceivablesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories (Tables) 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] Â Components of Inventory Inventories consist of the following (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Raw materials Â $ 6,437 Â Â $ 6,262 Â Work-in-process Â Â 9,074 Â Â Â 13,646 Â Finished goods Â Â 11,152 Â Â Â 8,637 Â Total inventory Â $ 26,663 Â Â $ 28,545 Â X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment (Tables) 9 Months Ended Sep. 30, 2024 Property Plant And Equipment [Abstract] Â Property and Equipment, Net Property and equipment consisted of the following (dollars in thousands): Â Â Estimated Useful Â Â Â Â Â Â Life (Years) Â Â September 30, 2024 Â Â December 31, 2023 Â Land Â Â â€” Â Â $ 875 Â Â $ 875 Â Buildings Â 39-40 Â Â Â 17,389 Â Â Â 17,389 Â Building improvements(1) Â 5-40 Â Â Â 90,573 Â Â Â 46,357 Â Machinery and equipment Â 3-15 Â Â Â 65,733 Â Â Â 60,410 Â Furniture, fixtures and office equipment Â 5-10 Â Â Â 3,350 Â Â Â 3,070 Â Computer equipment and software Â Â 3 Â Â Â 8,811 Â Â Â 8,658 Â Construction in progress(1) Â Â â€” Â Â Â 5,242 Â Â Â 48,997 Â Total property and equipment Â Â Â Â Â 191,973 Â Â Â 185,756 Â Less accumulated depreciation Â Â Â Â Â (106,634) Â Â (101,536) Total property and equipment, net Â Â Â Â $ 85,339 Â Â $ 84,220 Â _____(1)During the nine months ended September 30, 2024, the Company transferred $43.5 million from construction in progress to building improvements for assets placed in service related to the expansion of the Company's manufacturing facility. Depreciation Expense Related to Property and Equipment Depreciation expense related to property and equipment was as follows (in thousands): Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â 2024 Â Â 2023 Â Depreciation Expense Â $ 2,099 Â Â $ 1,117 Â Â $ 5,151 Â Â $ 3,250 Â X - DefinitionDepreciation expense related to property and equipment. + ReferencesNo definition available. + Details Name: mnkd_DepreciationExpenseRelatedToPropertyAndEquipmentTableTextBlock Namespace Prefix: mnkd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Other Intangible Assets (Tables) 9 Months Ended Sep. 30, 2024 Goodwill And Intangible Assets Disclosure [Abstract] Â Summary of Other Intangible Assets Other Intangible Assets â€“ Other intangible assets consisted of the following (dollars in thousands): Â Â Estimated Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â UsefulLife (Years) Â Â Cost Â Â AccumulatedAmortization Â Â Net Book Value Â Â Cost Â Â AccumulatedAmortization Â Â Net Book Value Â Developed technology Â Â 15 Â Â $ 1,200 Â Â $ (187) Â $ 1,013 Â Â $ 1,200 Â Â $ (127) Â $ 1,073 Â iSPERSE License â€“ IPR&D Â Â â€” Â Â Â 4,300 Â Â Â â€” Â Â Â 4,300 Â Â Â â€” Â Â Â â€” Â Total Â Â Â Â $ 5,500 Â Â $ (187) Â $ 5,313 Â Â $ 1,200 Â Â $ (127) Â $ 1,073 Â X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Current Liabilities (Tables) 9 Months Ended Sep. 30, 2024 Payables And Accruals [Abstract] Â Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities were comprised of the following (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Salary and related expenses Â $ 16,239 Â Â $ 19,506 Â Discounts and allowances for commercial product sales Â Â 9,869 Â Â Â 9,541 Â Accrued interest Â Â 479 Â Â Â 2,153 Â Deferred lease liability Â Â 2,483 Â Â Â 1,423 Â Current portion of milestone rights liability(1) Â Â 639 Â Â Â 752 Â Returns reserve for acquired product(2) Â Â 1,468 Â Â Â 601 Â Professional fees Â Â 563 Â Â Â 979 Â State income tax liability Â Â 1,507 Â Â Â 1,561 Â Other Â Â 4,139 Â Â Â 5,520 Â Accrued expenses and other current liabilities Â $ 37,386 Â Â $ 42,036 Â _____(1)See Note 15 â€“ Commitments and Contingencies under Contingencies â€“ Milestone Rights.(2)See Note 15 â€“ Commitments and Contingencies under Loss Contingencies â€“ Returns Reserve for Acquired Product. X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Borrowings (Tables) 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Summary of Carrying Amount of Borrowings Carrying amount of the Company's borrowings consisted of the following (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Senior convertible notes Â $ 227,941 Â Â $ 226,851 Â MidCap credit facility Â Â â€” Â Â Â 33,019 Â Mann Group convertible note Â Â â€” Â Â Â 8,829 Â Total debt â€“ net carrying amount Â $ 227,941 Â Â $ 268,699 Â Schedule of Line of Credit Facility Debt and Key Terms The following table provides a summary of the Companyâ€™s principal balance of debt and key terms: Â Â Amount Due Â Terms Â Â September 30, 2024 Â Â December 31, 2023 Â Annual InterestÂ Â Rate Â Maturity Date Â Conversion Price Senior convertible notes Â $230.0Â million Â Â $230.0Â million Â 2.50% Â March 2026 Â $5.21Â per share MidCap credit facility(1) Â $ â€” Â Â $33.3Â million Â one-monthSOFR(1% floor)plus 6.25%;cap of 8.25% Â August 2025 Â N/A Mann Group convertible note(2) Â $ â€” Â Â $8.8Â million Â 2.50% Â December 2025 Â $2.50per share _____(1)Repaid on April 1, 2024.(2)Repaid on April 2, 2024. Schedule of Maturities of Company's Borrowings The maturities of the Companyâ€™s borrowings as of September 30, 2024 are as follows (in thousands): Â Â Amounts Â Remainder of 2024 Â $ â€” Â 2025 Â Â â€” Â 2026 Â Â 230,000 Â Total principal payments Â Â 230,000 Â Debt issuance costs Â Â (2,059) Total debt Â $ 227,941 Â Schedule of Amortization of Premium and Accretion of Debt Issuance Costs Amortization of the premium and accretion of debt issuance costs related to all borrowings were as follows (in thousands): Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Amortization of debt discount and prepayment fee Â $ â€” Â Â $ 109 Â Â $ 85 Â Â $ 323 Â Amortization of debt issuance cost Â Â 363 Â Â Â 363 Â Â Â 1,175 Â Â Â 1,090 Â X - DefinitionSchedule of amortization of debt issuance cost and debt discount. + ReferencesNo definition available. + Details Name: mnkd_ScheduleOfAmortizationOfDebtIssuanceCostAndDebtDiscountTableTextBlock Namespace Prefix: mnkd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity and sinking fund requirement for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration, Licensing and Other Arrangements (Tables) 9 Months Ended Sep. 30, 2024 Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Schedule of Revenue from Collaboration and Services Revenue from collaborations and services were as follows (in thousands): Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â UT CSA(1) Â $ 23,231 Â Â $ 12,800 Â Â $ 73,673 Â Â $ 34,897 Â UT License AgreementÂ (2) Â Â â€” Â Â Â 271 Â Â Â 347 Â Â Â 698 Â Cipla License and Distribution Agreement Â Â 37 Â Â Â 37 Â Â Â 110 Â Â Â 110 Â Total revenue from collaborations and services Â $ 23,268 Â Â $ 13,108 Â Â $ 74,130 Â Â $ 35,705 Â _____(1)Amounts consist of revenue recognized for Manufacturing Services and Product Sales to UT for the periods presented.(2)Amounts consist of revenue recognized for Next-Gen R&D Services and R&D Services and License for the periods presented. Schedule of Effect of Modification on Transaction Price The Company determined that the capital and continuous improvements should be combined with the manufacturing services performance obligation and the alternative manufacturing processes should be combined with the Next-Gen R&D Services. The total revised anticipated cash flows of $722.3 million from the transaction was allocated to the three distinct performance obligations as follows (dollars in millions): Â Â Anticipated Â Â Â Â Â Â Â Â Â Â Â Â Cash Flow Â Â Revenue Allocation Â Â Recognition Method Â Progress Measure Â RevenueRecognition Â Total anticipated cash flow(1) Â $ 722.3 Â Â Â Â Â Â Â Â Â Â Â Â Distinct Performance Obligation Â Â Â Â Â Â Â Â Â Â Â Â Â Â R&D Services and License Â Â Â Â $ â€” Â Â Over time Â Ratably Â Aug 2021 - Oct 2021 Â Next-Gen R&D Services Â Â Â Â $ 10.0 Â Â Over time Â Input Â % of completion of costs Â Manufacturing Services andÂ Â Â Product Sales(2) Â Â Â Â $ 712.3 Â Â Point in time Â Â Â Transfer of control Â _____(1)The total anticipated cash flow includes a transaction price of $120.0 million for the contractual obligations under the CSA for the Manufacturing Services and Product Sales and the Next-Gen R&D Services performance obligations and $602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA.(2)The Manufacturing Services and Product Sales performance obligation will be recognized as control of manufactured products is transferred to UT. The modification did not result in a cumulative catch-up adjustment as a result of the revenue being deferred for the performance obligations that were affected by the modification. The allocation of the transaction price for the Manufacturing Services and Product Sales includes a material right related to the Companyâ€™s estimated production of product in the amount of $220.8 million. The Company will sell product to UT under individual purchase orders, which represent distinct performance obligations. The ultimate cash flows may vary as manufacturing purchase orders are received. United Therapeutics Corporation Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Schedule of Revenue from Collaboration and Services Total revenue from UT was as follows (in thousands): Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â UT Revenue Â Â Â Â Â Â Â Â Â Â Â Â UT CSA Â $ 23,231 Â Â $ 12,800 Â Â $ 73,673 Â Â $ 34,897 Â UT License Agreement Â Â â€” Â Â Â 271 Â Â Â 347 Â Â Â 698 Â Royalties â€“ Collaboration (1) Â Â 27,083 Â Â Â 20,218 Â Â Â 75,326 Â Â Â 50,951 Â Total revenue from UT Â $ 50,314 Â Â $ 33,289 Â Â $ 149,346 Â Â $ 86,546 Â _____(1)Amounts consist of royalties associated with the UT License Agreement. The contract assets related to the royalties is included in prepaid expense and other current assets in the condensed consolidated balance sheets. X - DefinitionSchedule of effect of modification on transaction price. + ReferencesNo definition available. + Details Name: mnkd_ScheduleOfEffectOfModificationOnTransactionPriceTableTextBlock Namespace Prefix: mnkd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_UnitedTherapeuticsCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value of Financial Instruments The following tables set forth the fair value of the Companyâ€™s financial instruments (Level 3 in the fair value hierarchy) (in millions): Â Â September 30, 2024 Â Â Â Â Â Â Fair Value Â Â Â Carrying Value Â Â SignificantUnobservableInputs (Level 3) Â Financial liabilities: Â Â Â Â Â Â Senior convertible notes(1) Â $ 227.9 Â Â $ 284.7 Â Milestone rights(2) Â Â 3.2 Â Â Â Â 11.3 Â Contingent milestone liability(3) Â Â 0.3 Â Â Â 0.3 Â Financing liability(4) Â Â 104.0 Â Â Â 106.5 Â Liability for sale of future royalties(5) Â Â 147.5 Â Â Â 137.4 Â _____(1)Fair value was determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 11.0%, volatility of 52.0% and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or â€“ 2% would result in a fair value of $279.6 million and $290.0 million, respectively.(2)Fair value was determined by applying a Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.7%, dividend yield of 0.0%, volatility of 50.0%, period of 7.3 years and credit risk of 15.0%.(3)Fair value was determined by using the Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.9%, dividend yield of 0.0%, volatility of 43.0%, period of 13.3 years and credit risk of 15.0%. (4)Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 9.5%. A change in yield of + or â€“ 2% would result in a fair value of $94.1 million and $121.8 million, respectively.(5)At September 30, 2024, fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 11.0%. A change in yield of + or â€“ 2% would result in a fair value of $121.9 million and $156.4 million, respectively. At December 31, 2023, the carrying value approximated the fair value. Â Â December 31, 2023 Â Â Â Â Â Â Fair Value Â Â Â Carrying Value Â Â SignificantUnobservableInputs (Level 3) Â Financial liabilities: Â Â Â Â Â Â Senior convertible notes(1) Â $ 226.9 Â Â $ 231.3 Â MidCap credit facility(2) Â Â 33.0 Â Â Â 35.5 Â Mann Group convertible note(3) Â Â 8.8 Â Â Â 14.4 Â Milestone rights(4) Â Â 3.9 Â Â Â 11.9 Â Contingent milestone liability(5) Â Â 0.3 Â Â Â 0.3 Â Financing liability(6) Â Â 104.1 Â Â Â 106.8 Â _____(1)Fair value was determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 11.0%, volatility of 62.7% and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or â€“ 2% would result in a fair value of $224.1 million and $238.9 million, respectively.(2)Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 12.0%. A change in yield of + or â€“ 2% would result in a fair value of $35.0 million and $36.0 million, respectively.(3)Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 13.0% and volatility of 62.7% to the straight note and a binomial option pricing model for the value of the conversion feature. A change in yield of + or â€“ 2% would result in a fair value of $14.2 million and $14.7 million, respectively.(4)Fair value was determined by applying a Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.9%, dividend yield of 0.0%, volatility of 50.0%, period of 8 years and credit risk of 17.0%.(5)Fair value was determined by using the Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market-based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 4.0%, dividend yield of 0.0%, volatility of 43.0%, period of 15 years and credit risk of 17.0%. (6)Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 9.5%. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Earnings Per Common Share (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Components of Basic and Diluted EPS Computations The following tables summarize the components of the basic and diluted EPS computations (in thousands, except per share amounts): Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â EPS â€“ basic: Â Â Â Â Â Â Â Â Â Â Â Â Net income (loss) (numerator) Â $ 11,550 Â Â $ 1,721 Â $ 20,166 Â Â $ (13,339) Weighted average common shares (denominator) Â Â 274,998 Â Â Â 268,732 Â Â 272,811 Â Â Â 266,126 Â Net income (loss) per share Â $ 0.04 Â Â $ 0.01 Â $ 0.07 Â Â $ (0.05) EPS â€“ diluted: Â Â Â Â Â Â Â Â Â Â Â Â Adjusted net income (loss) (numerator) Â $ 11,550 Â Â $ 3,578 Â $ 20,166 Â Â $ (13,339) Weighted average common shares Â Â 274,998 Â Â Â 268,732 Â Â 272,811 Â Â Â 266,126 Â Effect of dilutive securities â€“ common shares issuable Â Â 9,695 Â Â Â 55,038 Â Â 8,596 Â Â Â Â â€” Â Adjusted weighted average common shares (denominator) Â Â 284,693 Â Â Â 323,770 Â Â 281,407 Â Â Â 266,126 Â Net income (loss) per share Â $ 0.04 Â Â $ 0.01 Â $ 0.07 Â Â $ (0.05) For the three months ended September 30, 2024, diluted net income per share excluded the weighted average effect of 10.4 million shares of RSUs and Market RSUs, 0.4 million options and PNQs and 44.1 million common shares issuable upon conversion of our Senior convertible notes, as they were antidilutive. For the nine months ended September 30, 2024, diluted net income per share excluded the weighted average effect of 9.1 million RSUs and Market RSUs, 0.7 million options and PNQs and 44.1 million common shares issuable upon conversion of our Senior convertible notes, as they were antidilutive.For the three months ended September 30, 2023, diluted net income per share excluded the weighted average effect of 9.4 million shares of RSUs and Market RSUs and 2.0 million options and PNQs as they were antidilutive. Potential Dilutive Securities Outstanding that are Considered Antidilutive Potentially dilutive securities outstanding which were considered antidilutive due to the net losses incurred for the nine months ended September 30, 2023 are summarized as follows (in shares): Â September 30, Â Â 2023 Â Senior convertible notes Â 44,120,463 Â RSUs and Market RSUs(1) Â 21,151,454 Â Common stock options and PNQs Â 8,447,339 Â Mann Group convertible notes Â 3,370,000 Â Total shares Â 77,089,256 Â _____(1)Market RSUs issued in 2021, 2022 and 2023 are included at the share

delivery of 0%, 205% and 219%, respectively, in accordance with a valuation assessment obtained as of September 30, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation Expense (Tables) 9 Months Ended Sep. 30, 2024 Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Â Schedule of Employee Awards and Non-employee Director Award Plan Activity The Company granted the following awards (in shares): Â Â Three Months Ended March 31, Â Â Three Months Ended June 30, Â Â Three Months EndedÂ September 30, Â Â Nine Months EndedSeptember 30, Â Â Â 2024 Â Â 2024 Â Â 2024 Â Â 2024 Â Employee awards: Â Â Â Â Â Â Â Â Â Â Â RSUs Â Â 267,990 Â Â (1) Â 3,205,910 Â Â (2) Â 241,253 Â Â (5) Â 3,715,153 Â Market RSUs Â Â â€” Â Â Â 2,144,000 Â Â (3) Â â€” Â Â Â 2,144,000 Â Non-employee director RSUs Â Â â€” Â Â Â 280,376 Â Â (4) Â â€” Â Â Â 280,376 Â Total awards issued Â Â 267,990 Â Â Â 5,630,286 Â Â Â 241,253 Â Â Â 6,139,529 Â _____(1)RSUs had a weighted average grant date fair value of $3.28 per share, of which 211,895 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, 53,720 RSUs had a cliff vesting period of three years, and 2,375 RSUs had a vesting period of 25% annually over four years. (2)RSUs had a weighted average grant date fair value of $4.45 per share, of which 3,033,680 RSUs had a vesting period of 25% annually over four years, 145,980 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, and 26,250 RSUs had a cliff vesting period of two years.(3)Market RSUs had a grant date fair value of $10.30 per share and will vest on July 15, 2027. The number of shares delivered on the vesting date is determined by the percentile ranking of MannKind total shareholder return ("TSR") over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.(4)RSUs had a weighted average grant date fair value of $4.45 per share and vested immediately upon the grant date; however, the underlying shares of common stock will not be delivered until there is a separation of service such as resignation, retirement or death.(5)RSUs had a weighted average grant date fair value of $5.34 per share, of which 219,285 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, and 21,968 RSUs had a vesting period of 40% on the first anniversary and 60% on the second anniversary of the vesting determination date. Stock Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations Total stock-based compensation expense recognized in the condensed consolidated statements of operations as cost of goods sold, cost of revenue â€” collaborations and services, R&D and selling, general and administrative expense was as follows (in thousands): Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â RSUs and options Â $ 5,047 Â Â $ 4,442 Â Â $ 14,994 Â Â $ 13,324 Â Employee stock purchase plan Â Â 180 Â Â Â 159 Â Â Â 546 Â Â Â 512 Â Total Â $ 5,227 Â Â $ 4,601 Â Â $ 15,540 Â Â $ 13,836 Â X - DefinitionSchedule of share based compensation employee stock purchase plan and non employee director stock award plan activity. + ReferencesNo definition available. + Details Name: mnkd_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanAndNonEmployeeDirectorStockAwardPlanActivityTableTextBlock Namespace Prefix: mnkd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Tables) 9 Months Ended Sep. 30, 2024 Commitments And Contingencies [Line Items] Â Schedule Of Royalty Liability Account Roll Forward The following table shows the activity within the Royalty Liability account during the nine months ended September 30, 2024 as well as the effective interest rate (dollars in thousands): Balance, January 1, 2024 $ 145,810 Â Amortization of deferred transaction costs Â 172 Â Non-cash interest expense on liability for sale of future royalties Â 12,548 Â Royalty revenue earned by or payable to Sagard Â (9,635) Balance, September 30, 2024 $ 148,895 Â Â Â Â Effective interest rate 8.8% â€“ 11.5% Â Schedule of Lease Term and Discount Rate Financing liability information was as follows (dollars in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Weighted average remaining lease term (in years) Â Â 17.1 Â Â Â 17.8 Â Lease information was as follows (dollars in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Operating lease right-of-use assets(1) Â $ 13,637 Â Â $ 4,685 Â Â Â Â Â Â Â Â Operating lease liability-current(2) Â $ 2,431 Â Â $ 1,423 Â Operating lease liability-long-term Â Â 12,167 Â Â Â 3,925 Â Total Â $ 14,598 Â Â $ 5,348 Â Â Â Â Â Â Â Â Weighted average remaining lease term (in years) Â Â 7.3 Â Â Â 3.7 Â Weighted average discount rate Â Â 7.25 % Â Â 7.25 % _____(1)Operating right-of-use assets related to vehicles, offices and the manufacturing facility for V-Go are included in other assets in the condensed consolidated balance sheets.(2)Operating lease liability â€“ current is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. Summary of Lease Information Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Interest expense on financing liability Â $ 2,470 Â Â $ 2,459 Â Â $ 7,361 Â Â $ 7,332 Â Â Â Three MonthsEnded September 30, Â Â Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease costs Â $ 719 Â Â $ 422 Â Â $ 1,417 Â Â $ 1,253 Â Variable lease costs Â Â 104 Â Â Â 48 Â Â Â 122 Â Â Â 97 Â Cash paid Â Â 860 Â Â Â 268 Â Â Â 1,407 Â Â Â 825 Â Summary of Remaining Financing Liability Payments The Company's remaining financing liability payments were as follows (in thousands): Â Â September 30, 2024 Â Remainder of 2024 Â $ 2,532 Â 2025 Â Â 10,269 Â 2026 Â Â 10,533 Â 2027 Â Â 10,849 Â 2028 Â Â 11,174 Â Thereafter Â Â 177,278 Â Total Â Â 222,635 Â Interest payments Â Â (116,113) Debt issuance costs Â Â (2,519) Total financing liability Â $ 104,003 Â Summary of Financing Lease Information Financing lease information was as follows (dollars in thousands): Â Â September 30, 2024 Â Financing lease right-of-use asset(1) Â $ 219 Â Â Â Â Â Financing lease liability-current(2) Â $ 52 Â Financing lease liability-long-term Â Â 171 Â Total Â $ 223 Â Â Â Â Â Weighted average remaining lease term (in years) Â Â 4.7 Â Weighted average discount rate Â Â 7.25 % _____(1)Financing right-of-use asset is included in other assets in the condensed consolidated balance sheets.(2)Financing lease liability â€“ current is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements The Company's remaining purchase commitments and estimated capacity fee liability as of September 30, 2024 were as follows (â‚¬ in millions): Â September 30, 2024 Â Â Remaining Purchase Commitments Â Â Estimated Capacity Fees Â 2025 Â â€“ Â Â Â 1.5 Â 2026(1) Â 4.2 Â Â Â 2.0 Â 2027 Â 6.0 Â Â Â 1.0 Â 2028 Â 6.0 Â Â Â 1.0 Â 2029 Â 6.0 Â Â Â 1.0 Â 2030 Â 6.0 Â Â Â 1.0 Â 2031 Â 8.0 Â Â Â 0.5 Â 2032 Â 8.0 Â Â Â 0.5 Â 2033 Â 8.0 Â Â Â 0.5 Â 2034 Â 4.4 Â Â Â 0.5 Â Total Â 56.6 Â Â Â 9.5 Â _____If there is a delay in the availability of insulin with FDA approved inclusion bodies and supply does not begin in 2026 as currently expected, the Company will incur a capacity fee of â‚¬750,000 per quarter that the product is not available for purchase. Schedule of Future Minimum Office And Vehicle Lease Payments The Company's future minimum office and vehicle lease payments were as follows (in thousands): Â Â September 30, 2024 Â Remainder of 2024 Â $ 784 Â 2025 Â Â 3,157 Â 2026 Â Â 2,579 Â 2027 Â Â 2,540 Â 2028 Â Â 2,087 Â Thereafter Â Â 7,721 Â Total Â Â 18,868 Â Interest expense Â Â (4,270) Total operating lease liability Â $ 14,598 Â Audio Visual Equipment Â Commitments And Contingencies [Line Items] Â Summary of Remaining Financing Liability Payments The Company's remaining financing lease payments were as follows (in thousands): Â Â September 30, 2024 Â Remainder of 2024 Â $ 27 Â 2025 Â Â 54 Â 2026 Â Â 54 Â 2027 Â Â 54 Â 2028 Â Â 54 Â Thereafter Â Â 23 Â Total Â Â 266 Â Interest payments Â Â (43) Total financing liability Â $ 223 Â Â X - DefinitionCommitments and Contingencies [Line Items] + ReferencesNo definition available. + Details Name: mnkd_CommitmentsAndContingenciesLineItems Namespace Prefix: mnkd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSchedule of Lease Term and Discount Rate. + ReferencesNo definition available. + Details Name: mnkd_ScheduleOfLeaseTermAndDiscountRateTableTextBlock Namespace Prefix: mnkd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSchedule of royalty liability account roll forward. + ReferencesNo definition available. + Details Name: mnkd_ScheduleOfRoyaltyLiabilityAccountRollForwardTabletextBlock Namespace Prefix: mnkd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeFinanceLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount. + ReferencesNo definition available. + Details Name: us-gaap_LongTermPurchaseCommitmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=mnkd_AudioVisualEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Significant Accounting Policies - Additional Information (Detail) â‚¬ in Millions, $ in Millions 1 Months Ended 9 Months Ended Jun. 27, 2024 Dec. 31, 2023 USD ($) Jan. 31, 2022 USD ($) Jun. 30, 2021 USD ($) Sep. 30, 2024 USD ($) Segment Sep. 30, 2024 EUR (â‚¬) Jun. 30, 2024 USD ($) Jul. 01, 2013 USD ($) Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Percentage of future royalties Â Â Â Â 1.00% Â Â Â Â Number of operating segment | Segment Â Â Â Â Â 1 Â Â Â Â Loss on purchase commitments | â‚¬ Â Â Â Â Â Â Â Â â‚¬ 56.6 Â Â Â Sagard Â Â Â Â Â Â Â Â Â Â Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Â Â Â Â Â Â Â Â Â Â Percentage of royalty on net sales Â Â Â Â Â 1.00% Â Â Â Â Percentage of royalty on future net sales Â 1.00% Â Â Â Â Â Â Â Â Insulin Â Â Â Â Â Â Â Â Â Â Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Â Â Â Â Â Â Â Â Â Â Loss on purchase commitments Â $ 64.8 Â Â $ 62.6 Â Â Â Â Tyvaso DPI Â Â Â Â Â Â Â Â Â Â Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Â Â Â Â Â Â Â Â Â Â Percentage of royalty on net sales Â Â Â Â Â 10.00% Â Â Â Â Percentage of royalty on future net sales Â Â Â Â Â 9.00% Â Â Â Â Percentage of royalty on net revenue Â Â Â Â 10.00% Â Â Â Â Percentage of future royalties Â Â Â Â 9.00% Â Â Â Â Maximum | AFREZZA product sales Â Â Â Â Â Â Â Â Â Â Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Â Â Â Â Â Â Â Â Â Â Sales return right following product expiration in months Â Â Â Â 12 months Â Â Â Â Minimum | AFREZZA product sales Â Â Â Â Â Â Â Â Â Â Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Â Â Â Â Â Â Â Â Â Â Sales return right following product expiration in months Â Â Â Â 6 months Â Â Â Convertible Promissory Note | Thirona Bio, Inc. Â Â Â Â Â Â Â Â Â Â Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Â Â Â Â Â Â Â Â Â Â Increased interest rate 10.00% Â Â Â Â Â Â Â Â Principal amount Â Â Â Â $ 8.0 Â $ 8.0 Â Purchase of available-for-sale securities Â Â $ 5.0 $ 3.0 Â Â Â Â Â Interest rate Â Â Â 6.00% Â Â Â Â Â MidCap Credit Facility Â Â Â Â Â Â Â Â Â Â Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Â Â Â Â Â Â Â Â Principal amount Â $ 33.3 Â Â Â Â Â Â Milestone Rights Liability | Deerfield Â Â Â Â Â Â Â Â Â Â Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Â Â Â Â Â Â Â Â Contingent liability remain payable Â Â Â Â Â Â Â Â $ 50.0 Milestone Rights Liability | Maximum | Deerfield Â Â Â Â Â Â Â Â Â Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Â Â Â Â Â Â Â Â Contingent liability for milestone payments Â Â Â Â Â Â Â Â $ 90.0 X - DefinitionContingent Liability + ReferencesNo definition available. + Details Name: mnkd_ContingentLiability Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContingent liability remaining payable amount. + ReferencesNo definition available. + Details Name: mnkd_ContingentLiabilityRemainingPayableAmount Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionOrganization, consolidation and presentation of financial statements disclosure. + ReferencesNo definition available. + Details Name: mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems Namespace Prefix: mnkd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage of future royalties. + ReferencesNo definition available. + Details Name: mnkd_PercentageOfFutureRoyalties Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of royalty on future net sales. + ReferencesNo definition available. + Details Name: mnkd_PercentageOfRoyaltyOnFutureNetSales Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of royalty on net revenue. + ReferencesNo definition available. + Details Name: mnkd_PercentageOfRoyaltyOnNetRevenue Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of royalty on net sales. + ReferencesNo definition available. + Details Name: mnkd_PercentageOfRoyaltyOnNetSales Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPurchase of available-for-sale securities. + ReferencesNo definition available. + Details Name: mnkd_PurchaseOfAvailableForSaleSecurities Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSales return period. + ReferencesNo definition available. + Details Name: mnkd_SalesReturnPeriod Namespace Prefix: mnkd_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -

SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncremental percentage increase (decrease) in the stated rate on a debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentInterestRateIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRate of interest on investment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_InvestmentInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionMinimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: dei_LegalEntityAxis=mnkd_SagardHealthcarePartnersFundingBorrowerSPE2LPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mnkd_InsulinMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mnkd_TyvasoDPIMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mnkd_ConvertiblePromissoryNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_ThironaBioIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=mnkd_MidCapCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=mnkd_MilestoneRightsLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Significant Accounting Policies - Additional Information (Detail 1) - Collaborations and services Sep. 30, 2024 Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-04-01 Â Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Â Remaining performance obligation, Expected timing of satisfaction, period 12 months Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-04-01 Â Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Â Remaining performance obligation, Expected timing of satisfaction, period 12 months X - DefinitionOrganization, consolidation and presentation of financial statements disclosure. + ReferencesNo definition available. + Details Name: mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems Namespace Prefix: mnkd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-04-01 Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Significant Accounting Policies - Summary of Revenue and Cost of Revenue and Goods Sold Generated From Product Sales, Services and Royalties (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Disaggregation Of Revenue [Line Items] Â Â Â Â Â Total net revenue $ 70,079 $ 51,253 $ 208,728 $ 140,490 Total cost of goods sold and cost of revenue 18,023 14,254 56,998 44,704 Product Revenue Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Total net revenue 42,959 30,727 132,945 88,731 Total cost of goods sold and cost of revenue 18,023 13,983 56,651 44,006 Services Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Total net revenue 37 308 457 808 Total cost of goods sold and cost of revenue 0 271 347 698 Royalties Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Total net revenue $ 27,083 $ 20,218 $ 75,326 $ 50,951 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=mnkd_ProductRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Pulmatrix Transaction - Additional Information (Detail) 1 Months Ended 3 Months Ended Jul. 08, 2024 USD ($) Employees May 28, 2024 Jul. 31, 2024 USD ($) Jun. 30, 2024 USD ($) Sep. 30, 2024 USD ($) Dec. 31, 2023 Business Acquisition [Line Items] Â Â Â Â Â Â Number of pulmatrix employees which began employment | Employees 13 Â Â Â Â Â Incremental borrowing rate 7.25% Â Â Â 7.25% 7.25% Letters of credit secured by cash held in restricted depository account Â Â Â $ 700,000 Â Â Lease term extension period Â Â Â Effective Date through November 30, 2033 Â Â Lease monthly payments Â Â Â $ 100,000 Â Â Percentage of annual increment on lease Â Â Â 3.00% Â Â Transaction costs Â Â Â Â $ 100,000 Â Pulmatrix, Inc Â Â Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Â Asset acquisition, date of acquisition agreement Â May 28, 2024 Â Â Â Â Asset acquisition, effective date of acquisition Jul. 08, 2024 Â Â Â Â Â Fair value of iSPERSE license $ 4,300,000 Â Â Â Â Â Lease monthly payments Â Â $ 101,282 Â Â Â Percentage of annual increment on lease Â Â 3.00% Â Â Â X - DefinitionBusiness combination, recognized identifiable assets acquired and liabilities assumed, in-process research and development. + ReferencesNo definition available. + Details Name: mnkd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLease term exsention period. + ReferencesNo definition available. + Details Name: mnkd_LeaseTermExtensionPeriod Namespace Prefix: mnkd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of pulmatrix employees which began employment. + ReferencesNo definition available. + Details Name: mnkd_NumberOfPulmatrixEmployeesWhichBeganEmployment Namespace Prefix: mnkd_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionPercentage of annual increment on lease. + ReferencesNo definition available. + Details Name: mnkd_PercentageOfAnnualIncrementOnLease Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDate when asset acquisition agreement is executed, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionDateOfAcquisitionAgreement Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionDate when acquirer obtains control of acquired asset, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1 + Details Name: us-gaap_AssetAcquisitionEffectiveDateOfAcquisition Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose

reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount as of the balance sheet date of cash collateral held for borrowed securities, for which the cash is restricted as to withdrawal or usage. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CashCollateralForBorrowedSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe amount of cash paid during the reporting period for charges associated with the mergers. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForMergerRelatedCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash payments to lessor's for use of assets under operating leases. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForRent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_AssetAcquisitionAxis=mnkd_PulmatrixIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Pulmatrix Transaction - Schedule of Fair Value of Identifiable Assets Acquired and Liabilities Assumed (Details) - Pulmatrix, Inc $ in Thousands Jul. 08, 2024 USD ($) Assets: Â iSPERSE License - IPR&D $ 4,300 Right-of-use asset - Bedford R&D facility 10,057 Property and equipment 959 Total assets 15,316 Liabilities: Â Operating lease liability - Bedford R&D facility 10,057 Total liabilities 10,057 Net assets acquired - Gain on bargain purchase $ 5,259 X - DefinitionBusiness combination, recognized identifiable assets acquired and liabilities assumed, in-process research and development. + ReferencesNo definition available. + Details Name: mnkd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionBusiness combination recognized identifiable assets acquired and liabilities assumed operating lease liability. + ReferencesNo definition available. + Details Name: mnkd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionBusiness combination recognized identifiable assets acquired and liabilities assumed operating lease right-of-use assets. + ReferencesNo definition available. + Details Name: mnkd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of assets acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liabilities assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of property, plant, and equipment recognized as of the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=mnkd_PulmatrixIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Investments - Additional Information (Detail) 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Note Sep. 30, 2023 USD ($) Jun. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Schedule Of Investments [Line Items] Â Â Â Â Â Â Interest on held to maturity investments $ 3,200,000 $ 1,500,000 $ 9,800,000 $ 4,000,000 Â Â Net accretion on investments held to maturity 2,100,000 500,000 6,000,000 900,000 Â Â Allowance for credit losses 0 Â 0 Â Â $ 0 Prepaid Expenses and Other Current Assets Â Â Â Â Â Â Schedule Of Investments [Line Items] Â Â Â Â Â Â Accrued interest receivable $ 1,100,000 Â $ 1,100,000 Â Â $ 500,000 Convertible Promissory Note | Thirona Bio, Inc. Â Â Â Â Â Â Â Schedule Of Investments [Line Items] Â Â Â Â Â Â Â Hypothetical yield percentage 28 Â 28 Â Â 35 Volatility percentage 70 Â 70 Â Â 90 Interest on available for sale investment $ 0 100,000 $ 0 400,000 Â Â Number of notes | Note Â Â 2 Â Â Â Amount Due $ 8,000,000 Â $ 8,000,000 Â $ 8,000,000 Â Stated interest rate 10.00% Â 10.00% Â Â Â Investment securities $ 5,900,000 Â $ 5,900,000 Â Â $ 6,900,000 Recognized gain (loss) Â 900,000 1,600,000 900,000 Â Â Unrealized holding gain Â $ 400,000 $ 600,000 $ 400,000 Â Â X - DefinitionAccrued interest receivable. + ReferencesNo definition available. + Details Name: mnkd_AccruedInterestReceivable Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDebt instrument measurement input after change. + ReferencesNo definition available. + Details Name: mnkd_DebtInstrumentMeasurementInputAfterChange Namespace Prefix: mnkd_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionInterest and dividend income debt securities available for sale. + ReferencesNo definition available. + Details Name: mnkd_InterestAndDividendIncomeDebtSecuritiesAvailableForSale Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionInterest and dividend income net accretion of investments held-to-maturity. + ReferencesNo definition available. + Details Name: mnkd_InterestAndDividendIncomeNetAccretionOfInvestmentsHeldToMaturity Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of notes. + ReferencesNo definition available. + Details Name: mnkd_NumberOfNotes Namespace Prefix: mnkd_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionValue of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_DebtInstrumentMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionAmount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of allowance for credit loss for debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of operating interest income, including amortization and accretion of premiums and discounts, on held-to-maturity securities. + ReferencesNo definition available. + Details Name: us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting

Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column D)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)(Footnote 10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 43: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 44: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 45: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 46: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 47: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 48: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 50: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 51: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 52: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 53: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 54: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 55: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 56: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 57: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 58: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 59: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 60: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 61: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 62: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 63: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 64: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19Reference 65: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 + Details Name: us-gaap_ScheduleOfInvestmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mnkd_ConvertiblePromissoryNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_ThironaBioIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Investments - Schedule of Contractual Maturities of Held to Maturity Investments (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Debt Securities, Held-to-Maturity, Maturity [Abstract] Â Â Amortized cost basis, due in one year or less [1] $ 230,797 $ 115,263 Amortized cost basis due after one year through five years 16,796 7,155 Amortized cost basis, total 247,593 122,418 Aggregate fair value, due in one year or less [1] 231,555 115,374 Aggregate fair value, due after one year through five years 16,992 7,197 Aggregate fair value, total $ 248,547 $ 122,571 [1] The investments due in one year or less include cash equivalents of $41.6 million as of September 30, 2024 and $58.6 million as of December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A + Details Name: us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3 + Details Name: us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single

maturity date. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3 + Details Name: us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A + Details Name: us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A + Details Name: us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3 + Details Name: us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Investments - Schedule of Contractual Maturities of Held to Maturity Investments (Parenthetical) (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Schedule of Held-to-Maturity Securities [Line Items] Â Â Cash and cash equivalents $ 62,373 $ 238,480 Due in One Year or Less Â Â Schedule of Held-to-Maturity Securities [Line Items] Â Â Cash and cash equivalents $ 41,600 $ 58,600 X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5 + Details Name: us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ShortTermDebtTypeAxis=mnkd_DueInOneYearOrLessMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Investments - Schedule of Fair Value of Cash Equivalents, Long and Short Term Investments (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Amortized Cost Â Â Schedule Of Investments [Line Items] Â Â Total cash equivalents and investments $ 247,593 $ 122,418 Less: cash equivalents (41,582) (58,644) Total Investments 206,011 63,774 Amortized Cost | Money Market Funds | Fair Value, Inputs, Level 1 Â Â Schedule Of Investments [Line Items] Â Â Total cash equivalents and investments 31,298 69,611 Amortized Cost | Commercial Bonds and Paper | Fair Value, Inputs, Level 2 Â Â Schedule Of Investments [Line Items] Â Â Total cash equivalents and investments 57,477 43,251 Amortized Cost | U.S. Treasury Securities | Fair Value, Inputs, Level 2 Â Â Schedule Of Investments [Line Items] Â Â Total cash equivalents and investments 158,818 9,556 Gross Unrealized Holding Gains Â Â Schedule Of Investments [Line Items] Â Â Total cash equivalents and investments 968 191 Total Investments 968 191 Gross Unrealized Holding Gains | Commercial Bonds and Paper | Fair Value, Inputs, Level 2 Â Â Schedule Of Investments [Line Items] Â Â Total cash equivalents and investments 268 135 Gross Unrealized Holding Gains | U.S. Treasury Securities | Fair Value, Inputs, Level 2 Â Â Schedule Of Investments [Line Items] Â Â Total cash equivalents and investments 700 56 Gross Unrealized Holding Losses Â Â Schedule Of Investments [Line Items] Â Â Total cash equivalents and investments (14) (38) Total Investments (14) (38) Gross Unrealized Holding Losses | Commercial Bonds and Paper | Fair Value, Inputs, Level 2 Â Â Schedule Of Investments [Line Items] Â Â Total cash equivalents and investments (12) (38) Gross Unrealized Holding Losses | U.S. Treasury Securities | Fair Value, Inputs, Level 2 Â Â Schedule Of Investments [Line Items] Â Â Total cash equivalents and investments (2) Â Estimated Fair Value Â Â Schedule Of Investments [Line Items] Â Â Total cash equivalents and investments 248,547 122,571 Less: cash equivalents (41,582) (58,644) Total Investments 206,965 63,927 Estimated Fair Value | Money Market Funds | Fair Value, Inputs, Level 1 Â Â Schedule Of Investments [Line Items] Â Â Total cash equivalents and investments 31,298 69,611 Estimated Fair Value | Commercial Bonds and Paper | Fair Value, Inputs, Level 2 Â Â Schedule Of Investments [Line Items] Â Â Total cash equivalents and investments 57,733 43,348 Estimated Fair Value | U.S. Treasury Securities | Fair Value, Inputs, Level 2 Â Â Schedule Of Investments [Line Items] Â Â Total cash equivalents and investments $ 159,516 $ 9,612 X - DefinitionCash equivalents and investments. + ReferencesNo definition available. + Details Name: mnkd_CashEquivalentsAndInvestments Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNet investments. + ReferencesNo definition available. + Details Name: mnkd_NetInvestments Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section

S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column D)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)(Footnote 10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 43: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 44: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 45: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 46: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 47: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 48: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 50: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 51: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 52: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 53: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 54: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 55: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 56: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 57: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 58: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 59: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 60: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 61: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 62: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 63: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 64: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19Reference 65: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 + Details Name: us-gaap_ScheduleOfInvestmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=mnkd_AmortizedCostMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=mnkd_GrossUnrealizedHoldingGainsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=mnkd_GrossUnrealizedHoldingLossesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=mnkd_EstimatedFairValueMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Accounts Receivable, Net (Detail) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Accounts Receivable [Line Items] Â Â Allowance for credit losses $ 0 $ 0 Total accounts receivable, net 18,184,000 14,901,000 Commercial product sales Â Â Accounts Receivable [Line Items] Â Â Accounts receivable, gross 18,359,000 20,199,000 Wholesaler distribution fees and prompt pay discounts (2,363,000) (2,469,000) Reserve for returns (7,817,000) (6,215,000) Allowance for credit losses 0 (157,000) Total accounts receivable, net 8,179,000 11,358,000 Collaborations and services Â Â Accounts Receivable [Line Items] Â Â Total accounts receivable, net $ 10,005,000 $ 3,543,000 X - DefinitionReserve for returns. + ReferencesNo definition available. + Details Name: mnkd_ReserveForReturns Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionWholesaler distribution fees and prompt pay discounts. + ReferencesNo definition available. + Details Name: mnkd_WholesalerDistributionFeesAndPromptPayDiscounts Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsNotesAndLoansReceivableLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1 + Details Name: us-gaap_AccountsReceivableGrossCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Accounts Receivable - Additional Information (Detail) 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2024 USD ($) Distributor Dec. 31, 2023 USD ($) Distributor Accounts Receivable [Line Items] Â Â Â Number of wholesale distributors | Distributor Â 3 3 Percentage of gross sales from major wholesale distributors 77.00% 73.00% Â Allowance for credit losses and doubtful accounts $ 0 $ 0 $ 0 Percentage of revenue from major customers collaborations and services 100.00% 100.00% Â Zealand Pharma US Â Â Â Accounts Receivable [Line Items] Â Â Â Allowance for credit losses and doubtful accounts Â Â $ 200,000 United Therapeutics Corporation Â Â Â Accounts Receivable [Line Items] Â Â Â Percentage of collaborations and services net accounts receivables Â 100.00% 100.00% Commercial product sales Â Â Â Accounts Receivable [Line Items] Â Â Â Percentage of accounts receivable from major wholesale distributors 87.00% 87.00% Â Allowance for credit losses and doubtful accounts $ 0 $ 0 $ 157,000 Accounts receivable $ 18,359,000 $ 18,359,000 $ 20,199,000 X - DefinitionNumber of wholesale distributors. + ReferencesNo definition available. + Details Name: mnkd_NumberOfWholesaleDistributors Namespace Prefix: mnkd_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionPercentage of accounts receivable from major customers. + ReferencesNo definition available. + Details Name: mnkd_PercentageOfAccountsReceivableFromMajorCustomers Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage of collaborations and services net accounts receivables. + ReferencesNo definition available. + Details Name: mnkd_PercentageOfCollaborationsAndServicesNetAccountsReceivables Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of revenue from major customers collaborations and services. + ReferencesNo definition available. + Details Name: mnkd_PercentageOfRevenueFromMajorCustomersCollaborationsAndServices Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of sales from major customers. + ReferencesNo definition available. + Details Name: mnkd_PercentageOfSalesFromMajorCustomers Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -

Name Accounting Standards Codification -Section 40 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsNotesAndLoansReceivableLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1 + Details Name: us-gaap_AccountsReceivableGrossCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_ZealandPharmaUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_UnitedTherapeuticsCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories - Components of Inventory (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Â Â Raw materials $ 6,437 $ 6,262 Work-in-process 9,074 13,646 Finished goods 11,152 8,637 Total inventory $ 26,663 $ 28,545 X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoodsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcessNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 63 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories - Additional Information (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Inventory [Line Items] Â Â Â Â Â Â Inventory write-offs $ 300 $ 300 $ 1,909 $ 3,659 Â Pre-launch Inventory Â Â Â Â Â Â Inventory [Line Items] Â Â Â Â Â Â Raw materials inventory $ 800 Â $ 800 Â $ 800 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_InventoryLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterials Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProductionRelatedImpairmentsOrCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_PublicUtilitiesInventoryAxis=mnkd_PreLaunchInventoryMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Net (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Property Plant And Equipment [Line Items] Â Â Total property and equipment $ 191,973 $ 185,756 Less accumulated depreciation (106,634) (101,536) Total property and equipment, net 85,339 84,220 Land Â Â Property Plant And Equipment [Line Items] Â Â Total property and equipment 875 875 Buildings Â Â Property Plant And Equipment [Line Items] Â Â Total property and equipment $ 17,389 17,389 Buildings | Minimum Â Â Property Plant And Equipment [Line Items] Â Â Estimated Useful Life (Years) 39 years Â Buildings | Maximum Â Â Property Plant And Equipment [Line Items] Â Â Estimated Useful Life (Years) 40 years Â Building Improvements Â Â Property Plant And Equipment [Line Items] Â Â Total property and equipment $ 90,573 46,357 Building Improvements | Minimum Â Â Property Plant And Equipment [Line Items] Â Â Estimated Useful Life (Years) 5 years Â Building Improvements | Maximum Â Â Property Plant And Equipment [Line Items] Â Â Estimated Useful Life (Years) 40 years Â Machinery and Equipment Â Â Property Plant And Equipment [Line Items] Â Â Total property and equipment $ 65,733 60,410 Machinery and Equipment | Minimum Â Â Property Plant And Equipment [Line Items] Â Â Estimated Useful Life (Years) 3 years Â Machinery and Equipment | Maximum Â Â Property Plant And Equipment [Line Items] Â Â Estimated Useful Life (Years) 15 years Â Furniture, fixtures and office equipment Â Â Property Plant And Equipment [Line Items] Â Â Total property and equipment $ 3,350 3,070 Furniture, fixtures and office equipment | Minimum Â Â Property Plant And Equipment [Line Items] Â Â Estimated Useful Life (Years) 5 years Â Furniture, fixtures and office equipment | Maximum Â Â Property Plant And Equipment [Line Items] Â Â Estimated Useful Life (Years) 10 years Â Computer Equipment and Software Â Â Property Plant And Equipment [Line Items] Â Â Total property and equipment $ 8,811 8,658 Estimated Useful Life (Years) 3 years Â Construction in Progress Â Â Property Plant And Equipment [Line Items] Â Â Total property and equipment $ 5,242 $ 48,997 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_FurnitureFixturesAndOfficeEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_ComputerEquipmentAndSoftwareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Net (Parenthetical) (Detail) $ in Millions Sep. 30, 2024 USD ($) UT Manufacturing Facility Â Property Plant And Equipment [Line Items] Â Amount transferred from construction in progress to building improvements $ 43.5 X - DefinitionAggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_InvestmentBuildingAndBuildingImprovements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_UtManufacturingFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Depreciation Expense Related to Property and Equipment (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Property Plant And Equipment [Abstract] Â Â Â Â Depreciation Expense $ 2,099 $ 1,117 $ 5,151 $ 3,250 X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type:

xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 67 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment - Additional Information (Detail) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Property Plant And Equipment [Line Items] Â Â Â Â Amount of divestiture of long-lived Â $ 0 Â $ 0 Manufacturing Equipment Â Â Â Â Property Plant And Equipment [Line Items] Â Â Â Â Amount of divestiture of long-lived $ 100,000 Â $ 100,000 Â X - DefinitionAmount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentDisposals Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Finite Lived Intangible Assets [Line Items] Â Â Goodwill $ 1,931 $ 1,931 Developed Technology Â Â Finite Lived Intangible Assets [Line Items] Â Â 2024 100 Â 2025 100 Â 2026 100 Â 2027 100 Â 2028 100 Â After 2028 $ 600 Â X - DefinitionAmount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Other Intangible Assets - Summary of Other Intangible Asset (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Finite Lived Intangible Assets [Line Items] Â Â Cost $ 5,500 $ 1,200 Accumulated Amortization (187) (127) Net Book Value 5,313 1,073 iSPERSE License - IPR&D Â Â Finite Lived Intangible Assets [Line Items] Â Â Cost 4,300 Â Net Book Value $ 4,300 Â Developed Technology Â Â Finite Lived Intangible Assets [Line Items] Â Â Estimated Useful Life (Years) 15 years Â Cost $ 1,200 1,200 Accumulated Amortization (187) (127) Net Book Value $ 1,013 $ 1,073 X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Payables And Accruals [Abstract] Â Â Salary and

related expenses $ 16,239 $ 19,506 Discounts and allowances for commercial product sales 9,869 9,541 Accrued interest 479 2,153 Deferred lease liability 2,483 1,423 Current portion of milestone rights liability 639 752 Returns reserve for acquired product [1] 1,468 601 Professional fees 563 979 State income tax liability 1,507 1,561 Other 4,139 5,520 Accrued expenses and other current liabilities $ 37,386 $ 42,036 [1] See Note 15 â€“ Commitments and Contingencies under Loss Contingencies â€“ Returns Reserve for Acquired Product. X - DefinitionCurrent portion of milestone right liability. + ReferencesNo definition available. + Details Name: mnkd_CurrentPortionOfMilestoneRightLiability Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCustomer Discounts And Allowances + ReferencesNo definition available. + Details Name: mnkd_CustomerDiscountsAndAllowances Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDeferred State And Local Income Tax Expense + ReferencesNo definition available. + Details Name: mnkd_DeferredStateAndLocalIncomeTaxExpense Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionReturns reserve for acquired product. + ReferencesNo definition available. + Details Name: mnkd_ReturnsReserveForAcquiredProduct Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred selling profit from direct financing lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-6 + Details Name: us-gaap_DirectFinancingLeaseDeferredSellingProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 71 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Borrowings - Summary of Carrying Amount of Borrowings (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Senior convertible notes $ 227,941 $ 226,851 Mann Group convertible note 227,941 226,851 Total debt â€“ net carrying amount $ 227,941 268,699 MidCap Credit Facility Â Â Debt Instrument [Line Items] Â Â Credit Facility Â 33,019 Related Party Â Â Debt Instrument [Line Items] Â Â Mann Group convertible note Â $ 8,829 X - DefinitionCarrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleLongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncluding the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_SeniorNotes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_CreditFacilityAxis=mnkd_MidCapCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Borrowings - Schedule of Line of Credit Facility Debt and Key Terms (Detail) - USD ($) $ / shares in Units, $ in Millions 9 Months Ended Sep. 30, 2024 Apr. 02, 2024 Dec. 31, 2023 Mar. 04, 2021 Senior Convertible Notes Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Amount Due $ 230.0 Â $ 230.0 Â Annual interest rate 2.50% Â Â Â Maturity date 2026-03 Â Â Â Conversion price $ 5.21 Â Â $ 5.21 MidCap Credit Facility Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Amount Due Â Â 33.3 Â Maturity date 2025-08 Â Â Â SOFR | MidCap Credit Facility Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Annual interest rate 6.25% Â Â Â Interest rate floor 1.00% Â Â Â Interest rate cap 8.25% Â Â Â The Mann Group L L C Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Conversion price Â $ 2.5 Â Â The Mann Group L L C | Convertible Promissory Note Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Amount Due Â Â $ 8.8 Â Annual interest rate 2.50% Â Â Â Maturity date 2025-12 Â Â Â Conversion price $ 2.5 Â Â Â Â X - DefinitionDebt instrument cap interest rate. + ReferencesNo definition available. + Details Name: mnkd_DebtInstrumentCapInterestRate Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDebt instrument floor rate. + ReferencesNo definition available. + Details Name: mnkd_DebtInstrumentFloorRate Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDebt instrument maturity month and year. + ReferencesNo definition available. + Details Name: mnkd_DebtInstrumentMaturityMonthAndYear Namespace Prefix: mnkd_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. +

ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=mnkd_MidCapCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_TheMannGroupLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mnkd_ConvertiblePromissoryNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Borrowings - Schedule of Maturities of Company's Borrowings (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Debt Disclosure [Abstract] Â Â Remainder of 2024 $ 0 Â 2025 0 Â 2026 230,000 Â Total principal payments 230,000 Â Debt issuance costs (2,059) Â Total debt â€” net carrying amount $ 227,941 $ 268,699 X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 74 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Borrowings - Senior Convertible Notes - Additional Information (Detail) 1 Months Ended 9 Months Ended Mar. 04, 2021 USD ($) d $ / shares Aug. 31, 2019 Sep. 30, 2024 USD ($) d $ / shares Dec. 31, 2023 USD ($) $ / shares Mar. 31, 2021 USD ($) Debt Instrument [Line Items] Â Â Â Â Â Maturity date Â Dec. 31, 2025 Â Â Â Common stock, par value | $ / shares Â Â $ 0.01 $ 0.01 Â Senior Convertible Notes Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Principal amount Â Â $ 230,000,000 $ 230,000,000 Â Maturity date Â Â Mar. 01, 2026 Â Â Annual interest rate Â Â 2.50% Â Â Common stock, par value | $ / shares Â Â $ 0.01 Â Â Number of trading days | d 20 Â 20 Â Â Consecutive trading days | d 30 Â 30 Â Â Conversion price percentage 130.00% Â 130.00% Â Â Principal amount per share | $ / shares $ 1,000 Â $ 1,000 Â Â Measurement period percentage Â Â 98.00% Â Â Conversion price | $ / shares $ 5.21 Â $ 5.21 Â Â Initial conversion price of premium percentage 30.00% Â Â Â Â Â No of convertible shares 191.8281 Â Â Â Â Redemption period start date Mar. 06, 2024 Â Â Â Â Redemption price percentage 100.00% Â Â Â Â Sinking fund $ 0 Â Â Â Â Debt instrument redemption description Â Â The Company may redeem for cash all or any portion of the Senior convertible notes, at its option, on or after March 6, 2024 and prior to the 36th scheduled trading day immediately preceding the maturity date, if the last reported sale price of common stock has been at least 130% of the conversion price for the Senior convertible notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Senior convertible notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company elects to redeem less than all of the outstanding Senior convertible notes, at least $75.0 million aggregate principal amount of Senior convertible notes must be outstanding and not subject to redemption as of the relevant redemption notice date. No sinking fund is provided for the Senior convertible notes. Â Â Percentage of repurchase price 100.00% Â Â Â Â Debt default, description Â Â If certain bankruptcy and insolvency-related

events of default involving the Company (and not just any of its significant subsidiaries) occur, 100% of the principal of and accrued and unpaid interest on the Senior convertible notes will automatically become due and payable. If an event of default with respect to the Senior convertible notes, other than certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries), occurs and is continuing, the trustee, by notice to the Company, or the holders of at least 25% in principal amount of the outstanding Senior convertible notes by notice to the Company and the trustee, may, and the trustee at the request of such holders shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the Senior convertible notes to be due and payable. Notwithstanding the foregoing, the Indenture provides that, to the extent the Company so elects, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture will, for the first 365 days after the occurrence of such an event of default consist exclusively of the right to receive additional interest on the Senior convertible notes as set forth in the Indenture Â Â Proceeds from offering after deducting initial purchasers discounts and commissions and estimated offering expenses payable $ 222,700,000 Â Â Â Â Unamortized debt issuance cost Â Â $ 2,100,000 $ 3,100,000 Â Senior Convertible Notes | Minimum Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Outstanding principal amount redeemed $ 75,000,000.0 Â Â Â Â Senior Convertible Notes | Private Placement Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Principal amount Â Â Â Â $ 230,000,000.0 X - DefinitionConsecutive trading days. + ReferencesNo definition available. + Details Name: mnkd_ConsecutiveTradingDays Namespace Prefix: mnkd_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionDebt instrument convertible conversion price percentage. + ReferencesNo definition available. + Details Name: mnkd_DebtInstrumentConvertibleConversionPricePercentage Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDebt Instrument initial conversion price of premium percentage. + ReferencesNo definition available. + Details Name: mnkd_DebtInstrumentInitialConversionPriceOfPremiumPercentage Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDebt instrument outstanding principal amount redeemed. + ReferencesNo definition available. + Details Name: mnkd_DebtInstrumentOutstandingPrincipalAmountRedeemed Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMeasurement period percentage. + ReferencesNo definition available. + Details Name: mnkd_MeasurementPeriodPercentage Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of trading days. + ReferencesNo definition available. + Details Name: mnkd_NumberOfTradingDays Namespace Prefix: mnkd_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionPrincipal amount per share. + ReferencesNo definition available. + Details Name: mnkd_PrincipalAmountPerShare Namespace Prefix: mnkd_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionRatio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6 + Details Name: us-gaap_DebtInstrumentConvertibleConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionDescription of debt redemption features under terms of the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentRedemptionDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionStart date of debt instrument redemption period, in YYYY-MM-DD format. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentRedemptionPeriodStartDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionPercentage price of original principal amount of debt at which debt can be redeemed by the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentRedemptionPricePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of principal amount of debt redeemed. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount paid into a fund, which is used to retire the debt instrument. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_DebtInstrumentSinkingFundPayment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDiscussion of the facts and amounts pertaining to each failure to comply with an affirmative or negative covenant of a long-term debt instrument, including violating payment terms or an inability to meet certain minimum financial requirements or achieve or maintain certain financial ratios. The discussion would generally be expected to also include whether or not the failure can and will be overcome and a description of the terms of any waivers, including the amount of the waiver and the period of time covered by the waiver, and if reclassification of long-term debt to current has been made in the current balance sheet. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-5 + Details Name: us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset. + ReferencesNo definition available. + Details Name: us-gaap_UnamortizedDebtIssuanceExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType

Balance Type: debit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R65.htm IDEA: XBRL DOCUMENT v3.24.3 Borrowings - MidCap Credit Facility - Additional Information (Detail) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Apr. 01, 2024 USD ($) Apr. 30, 2021 USD ($) Dec. 31, 2020 Installment Aug. 31, 2019 USD ($) Installment Mar. 31, 2024 USD ($) Sep. 30, 2024 USD ($) Dec. 31, 2020 USD ($) Debt Instrument [Line Items] Â Â Â Â Â Â Â Maturity date Â Â Â Dec. 31, 2025 Â Â Â Debt instrument payment term description Â Â Â Â Â Principal on each term loan advance under Tranche 1 and Tranche 2 was payable in 24 equal monthly installments that began September 1, 2023. Â Loss on extinguishment of debt Â Â Â Â Â $ (7,050) Â MidCap Credit Facility Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Prepaid of borrowing Â $ 10,000 Â Â Â Â Â Â Debt Instrument unamortized prepayment penalty. $ 200 Â Â Â Â Â Â Â Debt Instrument, Repaid, Principal 28,300 Â Â Â Â Â Â Â Accrued Interest 200 Â Â Â Â Â Â Â Principal payment on MidCap credit facility Â Â Â Â $ 5,000 Â Â Â Payment of credit facility exit fee 2,800 Â Â Â Â Â Â Â Payment of credit facility prepayment fee 300 Â Â Â Â Â Â Â Loss on extinguishment of debt 3,300 Â Â Â Â Â Â Â Repayment of debt $ 31,600 Â Â Â Â Â Â Â Early termination fees, percentage 1.00% Â Â Â Â Â Â Â MidCap Credit Facility | SOFR Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Interest rate floor Â Â Â Â Â 1.00% Â Tranche 1 Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Annual interest rate Â Â Â 8.25% Â Â Â Debt payable number of equal monthly installments | Installment Â Â Â 24 Â Â Â Line of credit facility principal payment start date Â Â Â Sep. 01, 2023 Â Â Â Tranche 1 | SOFR Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Interest rate (LIBOR) Â Â Â 6.25% Â Â Â Interest rate floor Â Â Â 1.00% Â Â Â Tranche 1 | MidCap Credit Facility Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Advance of borrowing Â Â Â $ 40,000 Â Â Â Debt instrument, prepayment penalty percentage 7.00% Â Â Â Â Â Â Â Debt instrument, prepayment penalty $ 40,000 Â Â Â Â Â Â Â Tranche 2 Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Annual interest rate Â Â Â 8.25% Â Â Â 8.25% Debt payable number of equal monthly installments | Installment Â Â 24 Â Â Â Â Line of credit facility principal payment start date Â Â Sep. 01, 2023 Â Â Â Tranche 2 | SOFR Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Interest rate (LIBOR) Â Â 6.25% Â Â Â Â Interest rate floor Â Â 1.00% Â Â Â Â Tranche 2 | MidCap Credit Facility Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Advance of borrowing Â Â Â Â Â Â $ 10,000 X - DefinitionDebt instrument floor rate. + ReferencesNo definition available. + Details Name: mnkd_DebtInstrumentFloorRate Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDebt instrument payment number of equal monthly installments. + ReferencesNo definition available. + Details Name: mnkd_DebtInstrumentPaymentNumberOfEqualMonthlyInstallments Namespace Prefix: mnkd_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionDebt Instrument unamortized prepayment penalty. + ReferencesNo definition available. + Details Name: mnkd_DebtInstrumentUnamortizedPrepaymentPenalty Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEarly termination fees percentage. + ReferencesNo definition available. + Details Name: mnkd_EarlyTerminationFeesPercentage Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine of credit facility principal payment start date. + ReferencesNo definition available. + Details Name: mnkd_LineOfCreditFacilityPrincipalPaymentStartDate Namespace Prefix: mnkd_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionPayment of credit facility exit fee. + ReferencesNo definition available. + Details Name: mnkd_PaymentOfCreditFacilityExitFee Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayment of credit facility prepayment fee. + ReferencesNo definition available. + Details Name: mnkd_PaymentOfCreditFacilityPrepaymentFee Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayments of debt issuance costs percentage. + ReferencesNo definition available. + Details Name: mnkd_PaymentsOfDebtIssuanceCostsPercentage Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPrepayment of secured lines of credit. + ReferencesNo definition available. + Details Name: mnkd_PrepaymentOfSecuredLinesOfCredit Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPrincipal payment on mid cap credit facility. + ReferencesNo definition available. + Details Name: mnkd_PrincipalPaymentOnMidCapCreditFacility Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDescription of the frequency of periodic payments (monthly, quarterly, annual). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentFrequencyOfPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionAmount of principal of debt repaid. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_DebtInstrumentRepaidPrincipal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accrued but unpaid interest on deposit liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_DepositLiabilitiesAccruedInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtExtinguishmentCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromSecuredLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_CreditFacilityAxis=mnkd_MidCapCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mnkd_TrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mnkd_TrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R66.htm IDEA: XBRL DOCUMENT v3.24.3 Borrowings - Mann Group Promissory Notes - Additional Information (Detail) $ / shares in Units, $ in Thousands 1 Months Ended 9 Months Ended Apr. 02, 2024 USD ($) $ / shares shares Aug. 31, 2019 USD ($) $ / shares Sep. 30, 2024 USD ($) $ / shares shares Sep. 30, 2023 USD ($) shares Dec. 31, 2023 USD ($) Debt Instrument [Line Items] Â Â Â Â Â Â Debt instrument payment term description Â Â Principal on each term loan advance under Tranche 1 and Tranche 2 was payable in 24 equal monthly installments that began September 1, 2023. Â

Â Maturity date Â Dec. 31, 2025 Â Â Â Loss on extinguishment of debt Â Â $ (7,050) Â Â The Mann Group L L C Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Loss on extinguishment of debt $ 3,700 Â Â Â Â Debt instrument remaining principal and interest after conversion $ 5,100 Â Â Â Â Conversion price | $ / shares $ 2.5 Â Â Â Â Debt issuance amount $ 8,900 Â Â Â Â Conversion of notes to common shares, shares | shares 1,500,000 Â Â Â Â convertible note plus accrued interest $ 8,900 Â Â Â Â Convertible shares of common stock | shares 3,554,198 Â Â Â Â Market value of common stock | shares 2,054,198 Â Â Â Â The Mann Group L L C | Convertible Promissory Note Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Principal amount Â Â Â Â Â $ 8,800 Senior notes, effective interest rate Â Â 2.50% Â Â Conversion price | $ / shares Â Â $ 2.5 Â Â Conversion of notes to common shares, shares | shares Â Â 15,285 37,122 Â The Mann Group L L C | Convertible Promissory Note | Accrued Interest Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt issuance amount Â Â $ 100 $ 200 Â The Mann Group L L C | New Loan Arrangement | Convertible Promissory Note Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â No of convertible shares Â 400 Â Â Â Principal amount per share | $ / shares Â $ 1,000 Â Â Â Conversion price | $ / shares Â $ 2.50 Â Â Â The Mann Group L L C | New Loan Arrangement | Promissory Notes Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Senior notes, effective interest rate Â 2.50% Â Â Â Debt instrument payment term description Â quarterly Â Â Â The Mann Group L L C | Privately Negotiated Exchange Agreement | Loan Arrangement Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Common stock price per share | $ / shares Â $ 2.50 Â Â Â The Mann Group L L C | Privately Negotiated Exchange Agreement | Loan Arrangement | Convertible Promissory Note Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Principal amount Â $ 35,000 Â Â Â X - DefinitionConvertible shares of common stock. + ReferencesNo definition available. + Details Name: mnkd_ConvertibleSharesOfCommonStock Namespace Prefix: mnkd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionDebt instrument remaining principal and interest after conversion. + ReferencesNo definition available. + Details Name: mnkd_DebtInstrumentRemainingPrincipalAndInterestAfterConversion Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncrease decrease in accrued interest on convertible notes. + ReferencesNo definition available. + Details Name: mnkd_IncreaseDecreaseInAccruedInterestOnConvertibleNotes Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMarket value of common stock. + ReferencesNo definition available. + Details Name: mnkd_MarketValueOfCommonStock Namespace Prefix: mnkd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPrincipal amount per share. + ReferencesNo definition available. + Details Name: mnkd_PrincipalAmountPerShare Namespace Prefix: mnkd_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionRatio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6 + Details Name: us-gaap_DebtInstrumentConvertibleConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDescription of the frequency of periodic payments (monthly, quarterly, annual). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentFrequencyOfPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_TheMannGroupLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mnkd_ConvertiblePromissoryNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtConversionByUniqueDescriptionAxis=mnkd_AccruedInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=mnkd_NewLoanArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mnkd_PromissoryNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_PrivatelyNegotiatedExchangeAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=mnkd_LoanArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R67.htm IDEA: XBRL DOCUMENT v3.24.3 Borrowings - Schedule of Amortization of Premium and Accretion of Debt Issuance Costs (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Debt Disclosure [Abstract] Â Â Â Â Amortization of debt discount and prepayment fee Â $ 109 $ 85 $ 323 Amortization of debt issuance cost $ 363 $ 363 $ 1,175 $ 1,090 X - DefinitionAmortization of debt discount and prepayment fee. + ReferencesNo definition available. + Details Name: mnkd_AmortizationOfDebtDiscountAndPrepaymentFee Namespace

Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 78 R68.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration, Licensing and Other Arrangements - Schedule of Revenue from Collaborations and Services (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Total revenue from collaborations and services $ 70,079 $ 51,253 $ 208,728 $ 140,490 United Therapeutics Corporation Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Total revenue from collaborations and services 50,314 33,289 149,346 86,546 United Therapeutics Corporation | Commercial Supply Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Total revenue from collaborations and services 23,231 12,800 73,673 34,897 United Therapeutics Corporation | License Agreement Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Total revenue from collaborations and services Â 271 347 698 United Therapeutics Corporation | Royalties Arrangement Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Total revenue from collaborations and services 27,083 20,218 75,326 50,951 Collaborations and services Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Total revenue from collaborations and services 23,268 13,108 74,130 35,705 Collaborations and services | License and Distribution Agreement | Cipla Ltd Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Total revenue from collaborations and services 37 37 110 110 Collaborations and services | United Therapeutics Corporation | Commercial Supply Agreement Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Total revenue from collaborations and services $ 23,231 12,800 73,673 34,897 Collaborations and services | United Therapeutics Corporation | License Agreement Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Total revenue from collaborations and services Â $ 271 $ 347 $ 698 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_UnitedTherapeuticsCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_CommercialSupplyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_LicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_RoyaltiesArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_LicenseAndDistributionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mnkd_CiplaLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_CommercialSupplyAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 79 R69.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration, Licensing and Other Arrangements - Summary of UT Revenue (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Total revenue from UT $ 70,079 $ 51,253 $ 208,728 $ 140,490 United Therapeutics Corporation Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Total revenue from UT 50,314 33,289 149,346 86,546 United Therapeutics Corporation | Commercial Supply Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Total revenue from UT 23,231 12,800 73,673 34,897 United Therapeutics Corporation | License Agreement Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Total revenue from UT Â 271 347 698 United Therapeutics Corporation | Royalties Arrangement Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Total revenue from UT $ 27,083 $ 20,218 $ 75,326 $ 50,951 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_UnitedTherapeuticsCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_CommercialSupplyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_LicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_RoyaltiesArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 80 R70.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration, Licensing and Other Arrangements - Additional Information (Detail) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Oct. 31, 2018 Dec. 31, 2023 Dec. 31, 2022 May 31, 2018 Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Feb. 28, 2023 Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Deferred revenue - current Â $ 9,085,000 Â Â $ 6,518,000 Â Â $ 6,518,000 Â $ 9,085,000 Â Deferred revenue - non-current Â 69,794,000 Â Â 65,150,000 Â Â 65,150,000 Â 69,794,000 Â Total revenue from UT Â Â Â Â 70,079,000 Â $ 51,253,000 208,728,000 $ 140,490,000 Â Â Collaborations and services Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Total revenue from UT Â Â Â Â 23,268,000 Â 13,108,000 74,130,000 35,705,000 Â Â AFREZZA product sales Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Total revenue from UT Â Â Â Â 19,728,000 Â 17,927,000 59,272,000 53,834,000 Â Â United Therapeutics Corporation Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Total revenue from UT Â Â Â Â 50,314,000 Â 33,289,000 149,346,000 86,546,000 Â Â United Therapeutics Corporation | Manufacturing Services Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Funding for development of alternative manufacturing processes Â Â $ 2,300,000 Â Â Â Â Â Â Â Â Â Â United Therapeutics Corporation | Commercialization and Continuous Improvement Activities Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Funding for capital improvements Â Â 39,500,000 Â Â Â Â Â Â Â Â Â Â Thirona Bio, Inc. Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Minimum amount to expended Â Â Â Â Â Â Â Â Â Â $ 1,100,000 Funded amount Â Â Â Â Â Â Â Â 1,100,000 Â Â Â Collaboration and License Agreement | United Therapeutics Corporation Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Total anticipated cash flows [1] Â Â 722,300,000 Â Â Â Â Â Â Â Â Â Â Deferred revenue Â 77,500,000 Â Â 70,500,000 Â Â 70,500,000 Â 77,500,000 Â Deferred revenue - current Â 8,900,000 Â Â 6,400,000 Â Â 6,400,000 Â 8,900,000 Â Deferred revenue - non-current Â $ 68,600,000 Â Â 64,100,000 Â Â $ 64,100,000 Â 68,600,000 Â Royalty percentage 10.00% Â Â Â Â Â Â Â Â Â Â Royalty future net sales percentage Â 1.00% Â Â Â Â Â Â Â Â Â Â Royalty retaining percentage Â 9.00% Â Â Â Â Â Â Â Â Â Â License agreement description Â Â Â Â Â Â Â Â There have been various amendments to the UT License Agreement and the CSA since inception. As amended, the term of the CSA continues until December 31, 2031 (unless earlier terminated) and is thereafter renewed automatically for additional, successive two-year terms unless (i) UT provides notice to the Company at least 24 months in advance of such renewal that UT does not wish to renew the CSA or (ii) the Company provides notice to UT at least 48 months in advance of such renewal that the Company does not wish to renew the CSA Â Â Â Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Total anticipated cash flows Â Â 722,300,000 Â Â Â Â Â Â Â Â Â Â Collaboration and License Agreement | United Therapeutics Corporation | Next-Gen R&D Services | Transaction Price For The Performance Obligations Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Total anticipated cash flows Â Â $ 602,300,000 Â Â Â Â Â Â Â Â Â Â Commercial Supply Agreement | United Therapeutics Corporation | Collaborations and services Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Total revenue from UT Â Â Â Â 23,231,000 Â 12,800,000 $ 73,673,000 34,897,000 Â Â Supply and Distribution Agreement | AFREZZA product sales | Biomm Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Total revenue from UT Â Â Â Â 0 $ 0 Â Â Â Â 0 Â License and Distribution Agreement | Cipla Ltd Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Deferred revenue Â $ 1,400,000 Â Â 1,200,000 Â Â 1,200,000 Â 1,400,000 Â Deferred revenue - current Â 200,000 Â Â 100,000 Â Â 100,000 Â 200,000 Â Deferred revenue - non-current Â $ 1,200,000 Â Â 1,100,000 Â Â $ 1,200,000 Â Marketing and distribution agreement date Â Â Â 2018-05 Â Â Â Â Â Â Â Â Â Â License and Distribution Agreement | Collaborations and services | Cipla Ltd Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â

Total revenue from UT Â Â Â Â $ 37,000 Â $ 37,000 $ 110,000 $ 110,000 Â Â [1] The total anticipated cash flow includes a transaction price of $120.0 million for the contractual obligations under the CSA for the Manufacturing Services and Product Sales and the Next-Gen R&D Services performance obligations and $602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA. X - DefinitionDate of agreement initiation for marketing and distribution. + ReferencesNo definition available. + Details Name: mnkd_DateOfAgreementInitiationForMarketingAndDistribution Namespace Prefix: mnkd_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionLicense agreement description. + ReferencesNo definition available. + Details Name: mnkd_LicenseAgreementDescription Namespace Prefix: mnkd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRevenue remaining performance obligation anticipated cash flow. + ReferencesNo definition available. + Details Name: mnkd_RevenueRemainingPerformanceObligationAnticipatedCashFlow Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRoyalty future net sales percentage. + ReferencesNo definition available. + Details Name: mnkd_RoyaltyFutureNetSalesPercentage Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalty net sales percentage. + ReferencesNo definition available. + Details Name: mnkd_RoyaltyNetSalesPercentage Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalty retaining percentage. + ReferencesNo definition available. + Details Name: mnkd_RoyaltyRetainingPercentage Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe minimum amount the entity agreed to spend under the long-term purchase commitment. + ReferencesNo definition available. + Details Name: us-gaap_LongTermPurchaseCommitmentAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsForCapitalImprovements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireOtherProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMinimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_UnitedTherapeuticsCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mnkd_ManufacturingServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mnkd_CommercializationAndContinuousImprovementActivitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_ThironaBioIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mnkd_NextGenResearchAndDevelopmentServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=mnkd_TransactionPriceForThePerformanceObligationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_CommercialSupplyAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_SupplyAndDistributionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mnkd_BiommSAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_LicenseAndDistributionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mnkd_CiplaLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R71.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Detail) - Collaboration and License Agreement - United Therapeutics Corporation $ in Millions 1 Months Ended Dec. 31, 2022 USD ($) Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Total anticipated cash flows $ 722.3 [1] R&D Services and License | Over Time Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Progress Measure Ratably Recognition Period Aug 2021 - Oct 2021 Next-Gen R&D Services | Over Time Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Anticipated Revenue Allocation $ 10.0 Progress Measure Input Recognition Period % of completion of costs Manufacturing Services and Product Sales | Point In Time Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Anticipated Revenue Allocation $ 712.3 [2] Recognition Period Transfer of control [2] [1] The total anticipated cash flow includes a transaction price of $120.0 million for the contractual obligations under the CSA for the Manufacturing Services and Product Sales and the Next-Gen R&D Services performance obligations and $602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA. [2] The Manufacturing Services and Product Sales performance obligation will be recognized as control of manufactured products is transferred to UT. The modification did not result in a cumulative catch-up adjustment as a result of the revenue being deferred for the performance obligations that were affected by the modification. The allocation of the transaction price for the Manufacturing Services and Product Sales includes a material right related to the Companyâ€™s estimated production of product in the amount of $220.8 million. The Company will sell product to UT under individual purchase orders, which represent distinct performance obligations. The ultimate cash flows may vary as manufacturing purchase orders are received. X - DefinitionRevenue remaining performance obligation anticipated cash flow. + ReferencesNo definition available. + Details Name: mnkd_RevenueRemainingPerformanceObligationAnticipatedCashFlow Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDescription of method used to recognize revenue for performance obligation that is satisfied over time. Includes, but not is limited to, output or input method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18 + Details Name: us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDescription of when remaining performance obligation is expected to be recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_UnitedTherapeuticsCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mnkd_ResearchAndDevelopmentServicesAndLicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mnkd_NextGenResearchAndDevelopmentServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mnkd_ManufacturingServicesAndProductSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 82 R72.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Parenthetical) (Details) - United Therapeutics Corporation - Collaboration and License Agreement $ in Millions 1 Months Ended Dec. 31, 2022 USD ($) Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Total anticipated cash flows $ 722.3 [1] Manufacturing Services Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Total anticipated cash flows 722.3 Manufacturing Services and Product Sales Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Allocated transaction price 220.8 Manufacturing Services and Product Sales | Transaction Price For The Contractual Obligations Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Total anticipated cash flows 120.0 Next-Gen R&D Services | Transaction Price For The Performance Obligations Â Collaborative Arrangements And

Noncollaborative Arrangement Transactions [Line Items] Â Total anticipated cash flows $ 602.3 [1] The total anticipated cash flow includes a transaction price of $120.0 million for the contractual obligations under the CSA for the Manufacturing Services and Product Sales and the Next-Gen R&D Services performance obligations and $602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA. X - DefinitionAllocated transaction price. + ReferencesNo definition available. + Details Name: mnkd_AllocatedTransactionPrice Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRevenue remaining performance obligation anticipated cash flow. + ReferencesNo definition available. + Details Name: mnkd_RevenueRemainingPerformanceObligationAnticipatedCashFlow Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_UnitedTherapeuticsCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mnkd_ManufacturingServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mnkd_ManufacturingServicesAndProductSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=mnkd_TransactionPriceForTheContractualObligationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mnkd_NextGenResearchAndDevelopmentServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=mnkd_TransactionPriceForThePerformanceObligationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 83 R73.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration, Licensing and Other Arrangements - Additional Information (Detail 1) - License and Distribution Agreement - Cipla Ltd - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2018-06-01 $ in Millions May 31, 2018 USD ($) Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Anticipated revenue allocation $ 2.2 Deferred revenue recognition period 15 years X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPeriod in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_LicenseAndDistributionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mnkd_CiplaLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2018-06-01 Namespace Prefix: Data Type: na Balance Type: Period Type: XML 84 R74.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments - Fair Value of Financial Instruments (Detail) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Carrying Amount | MidCap Credit Facility Â Â Financial liabilities: Â Â Total financial liabilities fair value Â $ 33.0 Carrying Amount | Senior Convertible Notes Â Â Financial liabilities: Â Â Total financial liabilities fair value $ 227.9 226.9 Carrying Amount | Mann Group Convertible Note Â Â Financial liabilities: Â Â Total financial liabilities fair value Â 8.8 Carrying Amount | Milestone Rights Â Â Financial liabilities: Â Â Total financial liabilities fair value 3.2 3.9 Carrying Amount | Contingent Milestone Liability Â Â Financial liabilities: Â Â Total financial liabilities fair value 0.3 0.3 Carrying Amount | Financing Liability Â Â Financial liabilities: Â Â Total financial liabilities fair value 104.0 104.1 Carrying Amount | Liability for Sale of Future Royalties Â Â Financial liabilities: Â Â Total financial liabilities fair value 147.5 Â Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3 | MidCap Credit Facility Â Â Financial liabilities: Â Â Total financial liabilities fair value Â 35.5 Estimate of Fair Value Measurement | Senior Convertible Notes | Fair Value, Inputs, Level 3 Â Â Financial liabilities: Â Â Total financial liabilities fair value 284.7 231.3 Estimate of Fair Value Measurement | Mann Group Convertible Note | Fair Value, Inputs, Level 3 Â Â Financial liabilities: Â Â Total financial liabilities fair value Â 14.4 Estimate of Fair Value Measurement | Milestone Rights | Fair Value, Inputs, Level 3 Â Â Financial liabilities: Â Â Total financial liabilities fair value 11.3 11.9 Estimate of Fair Value Measurement | Contingent Milestone Liability | Fair Value, Inputs, Level 3 Â Â Financial liabilities: Â Â Total financial liabilities fair value 0.3 0.3 Estimate of Fair Value Measurement | Financing Liability | Fair Value, Inputs, Level 3 Â Â Financial liabilities: Â Â Total financial liabilities fair value 106.5 $ 106.8 Estimate of Fair Value Measurement | Liability for Sale of Future Royalties | Fair Value, Inputs, Level 3 Â Â Financial liabilities: Â Â Total financial liabilities fair value $ 137.4 Â X - DefinitionFair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FinancialLiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=mnkd_MidCapCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=us-gaap_SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mnkd_MannGroupConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mnkd_MilestoneRightsLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mnkd_ContingentMilestoneLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mnkd_FinancingLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mnkd_LiabilityForSaleOfFutureRoyaltiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 85 R75.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments - Fair Value of Financial Instruments (Parenthetical) (Detail) $ in Millions 9 Months Ended 12 Months Ended Sep. 30, 2024 USD ($) Dec. 31, 2023 USD ($) MidCap Credit Facility Â Â Fair Value Of Financial Instruments [Line Items] Â Â Note payable, percentage of hypothetical yield Â 12 Note payable, percentage of interest rate increases (decreases) Â 2.00% MidCap Credit Facility | Minimum Â Â Fair Value Of Financial Instruments [Line Items] Â Â Financial liabilities fair value Â $ 35.0 MidCap Credit Facility | Maximum Â Â Fair Value Of Financial Instruments [Line Items] Â Â Financial liabilities fair value Â $ 36.0 Mann Group Convertible Notes Â Â Fair Value Of Financial Instruments [Line Items] Â Â Note payable, percentage of hypothetical yield Â 13.0 Note payable, percentage of interest rate increases (decreases) Â 2.00% Mann Group Convertible Notes | Volatility Â Â Fair Value Of Financial Instruments [Line Items] Â Â Note payable, fair value key inputs Â 62.7 Mann Group Convertible Notes | Minimum Â Â Fair Value Of Financial Instruments [Line Items] Â Â Financial liabilities fair value Â $ 14.2 Mann Group Convertible Notes | Maximum Â Â Fair Value Of Financial Instruments [Line Items] Â Â Financial liabilities fair value Â $ 14.7 Senior Convertible Notes Â Â Fair Value Of Financial Instruments [Line Items] Â Â Note payable, percentage of hypothetical yield 11 11 Note payable, percentage of interest rate increases (decreases) 2.00% 2.00% Senior Convertible Notes | Volatility Â Â Fair Value Of Financial Instruments [Line Items] Â Â Note payable, fair value key inputs 52 62.7 Senior Convertible Notes | Minimum Â Â Fair Value Of Financial Instruments [Line Items] Â Â Financial liabilities fair value $ 279.6 $ 224.1 Senior Convertible Notes | Maximum Â Â Fair Value Of Financial Instruments [Line Items] Â Â Financial liabilities fair value $ 290.0 $ 238.9 Financing Liability Â Â Fair Value Of Financial Instruments [Line Items] Â Â Note payable, percentage of hypothetical yield 9.5 9.5 Note payable, percentage of interest rate increases (decreases) 2.00% Â Financing Liability | Minimum Â Â Fair Value Of Financial Instruments [Line Items] Â Â Financial liabilities fair value $ 94.1 Â Financing Liability | Maximum Â Â Fair Value Of Financial Instruments [Line Items] Â Â Financial liabilities fair value $ 121.8 Â Milestone Rights | Risk-Free Rate Â Â Fair Value Of Financial Instruments [Line Items] Â Â Note payable, fair value key inputs 3.7 3.9 Milestone Rights | Dividend Yield Â Â Fair Value Of Financial Instruments [Line Items] Â Â Note payable, fair value key inputs 0 0 Milestone Rights | Volatility Â Â Fair Value Of Financial Instruments [Line Items] Â Â Note payable, fair value key inputs 50 50 Milestone Rights | Period Â Â Fair Value Of Financial Instruments [Line Items] Â Â Note payable, fair value key inputs 7.3 8 Milestone Rights | Credit Risk Â Â Fair Value Of Financial Instruments [Line Items] Â Â Note payable, fair value key inputs 15 17 Contingent Milestone Liability | Risk-Free Rate Â Â Fair Value Of Financial Instruments [Line Items] Â Â Note payable, fair value key inputs 3.9 4 Contingent Milestone Liability | Dividend Yield Â Â Fair Value Of Financial Instruments [Line Items] Â Â Note payable, fair value key inputs 0 0 Contingent Milestone Liability | Volatility Â Â Fair Value Of Financial Instruments [Line Items] Â Â Note payable, fair value key inputs 43 43 Contingent Milestone Liability | Period Â Â Fair Value Of Financial Instruments [Line Items] Â Â Note payable, fair value key inputs 13.3 15 Contingent Milestone Liability | Credit Risk Â Â Fair Value Of Financial Instruments [Line Items] Â Â Note payable, fair value key inputs 15 17 Liability for Sale of Future Royalties Â Â Fair Value Of Financial Instruments [Line Items] Â Â Note payable, percentage of hypothetical yield 11 Â Note payable, percentage of interest rate increases (decreases) 2.00% Â Liability for Sale of Future Royalties | Minimum Â Â Fair Value Of Financial Instruments [Line Items] Â Â Financial liabilities fair value $ 121.9 Â Liability for Sale of Future Royalties | Maximum Â Â Fair Value Of Financial Instruments [Line Items] Â Â Financial liabilities fair value $ 156.4 Â X - DefinitionDebt instrument measurement input after change. + ReferencesNo definition available. + Details Name: mnkd_DebtInstrumentMeasurementInputAfterChange Namespace Prefix: mnkd_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionFair value of financial instruments. + ReferencesNo definition available. + Details Name: mnkd_FairValueOfFinancialInstrumentsLineItems Namespace Prefix: mnkd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNote payable, percentage of interest rate change. + ReferencesNo definition available. + Details Name: mnkd_NotePayablePercentageOfInterestRateChange Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionValue of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_DebtInstrumentMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionFair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FinancialLiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_CreditFacilityAxis=mnkd_MidCapCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=mnkd_MannGroupConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=us-gaap_SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mnkd_FinancingLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mnkd_MilestoneRightsLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputEntityCreditRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mnkd_ContingentMilestoneLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mnkd_LiabilityForSaleOfFutureRoyaltiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 86 R76.htm IDEA: XBRL DOCUMENT v3.24.3 Common and Preferred Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions 1 Months Ended 3 Months Ended 9 Months Ended Feb. 28, 2018 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Common stock, shares authorized Â Â Â Â Â Â 800,000,000 Â 800,000,000 Common stock, par value Â Â Â Â Â Â $ 0.01 Â $ 0.01 Undesignated preferred stock, shares authorized Â Â Â Â Â Â 10,000,000 Â 10,000,000 Undesignated preferred stock, par value Â Â Â Â Â Â $ 0.01 Â $ 0.01 Common stock, shares issued Â Â Â Â Â Â 275,775,038 Â 270,034,495 Common stock, shares outstanding Â Â Â Â Â Â 275,775,038 Â 270,034,495 Undesignated preferred stock, shares outstanding Â Â Â Â Â Â 0 Â 0 Proceeds from market price stock purchase plan Â Â Â Â Â Â $ 1.4 $ 0.2 Â Market price stock purchase plan Â Â Â Â Â Â 416,099 36,004 Â Common Stock Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Number of shares sold during the period Â 416,000 847,000 362,000 269,000 Â Â Â

Controlled Equity Offering Sales Agreement | Cantor Fitzgerald | Common Stock | Maximum Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Amount of net proceeds from issuance of securities $ 50.0 Â Â Â Â Â Â Â Â Â Â At Market Issuance Sales Agreement | Cantor Fitzgerald | Common Stock Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Amount of net proceeds from issuance of securities Â Â Â Â Â Â $ 6.9 Â Â Â Number of shares sold during the period Â Â Â Â Â Â 1,478,090 Â Â Â At Market Issuance Sales Agreement | Cantor Fitzgerald | Common Stock | Weighted Average Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Exchange price per share Â Â Â Â Â Â $ 4.66 Â Â Â X - DefinitionMarket price stock purchase plan. + ReferencesNo definition available. + Details Name: mnkd_MarketPriceStockPurchasePlan Namespace Prefix: mnkd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_ContolledEquityOfferingSalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=mnkd_CantorFitzgeraldMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_AtMarketIssuanceSalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_WeightedAverageMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 87 R77.htm IDEA: XBRL DOCUMENT v3.24.3 Earnings Per Common Share - Components of Basic and Diluted EPS Computations (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 EPS - basic: Â Â Â Â Â Â Â Â Â Â Net Income (Loss) $ 11,550 $ (2,014) $ 10,630 $ 1,721 $ (5,265) $ (9,795) $ 20,166 $ (13,339) Weighted average common shares (denominator), Basic 274,998 Â Â 268,732 Â Â 272,811 266,126 Net income (loss) per share - basic $ 0.04 Â Â $ 0.01 Â Â $ 0.07 $ (0.05) EPS - diluted: Â Â Â Â Â Â Â Â Â Â Adjusted net income (loss) (numerator) $ 11,550 Â Â $ 3,578 Â Â $ 20,166 $ (13,339) Weighted average common shares 274,998 Â Â 268,732 Â Â 272,811 266,126 Effect of dilutive securities - common shares issuable 9,695 Â Â 55,038 Â Â 8,596 Â Adjusted weighted average common shares (denominator) 284,693 Â Â 323,770 Â Â 281,407 266,126 Net income (loss) per share - diluted $ 0.04 Â Â $ 0.01 Â Â $ 0.07 $ (0.05) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareDilutedAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-42Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed. Includes the adjustments resulting from the assumption that dilutive securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions. + ReferencesNo definition available. + Details Name: us-gaap_UndistributedEarningsDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 88 R78.htm IDEA: XBRL DOCUMENT v3.24.3 Earnings Per Common Share - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Detail) - shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive securities excluded from computation of earnings per share Â Â Â 77,089,256 Senior Convertible Notes Â Â Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive securities excluded from computation of earnings per share 44,100,000 Â 44,100,000 44,120,463 RSUs and Market RSUs Â Â Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive securities excluded from computation of earnings per share 10,400,000 9,400,000 9,100,000 21,151,454 Common Stock Options and

PNQs Â Â Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive securities excluded from computation of earnings per share 400,000 2,000,000 700,000 8,447,339 Mann Group Convertible Notes Â Â Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive securities excluded from computation of earnings per share Â Â Â 3,370,000 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnkd_SeniorConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnkd_RestrictedStockUnitsAndMarketRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnkd_CommonStockOptionsAndPerformanceBasedStockOptionAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnkd_MannGroupConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 89 R79.htm IDEA: XBRL DOCUMENT v3.24.3 Earnings Per Common Share - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Parenthetical) (Detail) 12 Months Ended Dec. 31, 2023 Dec. 31, 2022 Dec. 31, 2021 RSU Â Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Â Share delivery percentage in accordance with valuation assessment obtained 219.00% 205.00% 0.00% X - DefinitionShare delivery percentage. + ReferencesNo definition available. + Details Name: mnkd_ShareDeliveryPercentage Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 90 R80.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation Expense - Additional Information (Detail) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Sep. 30, 2024 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Issuance of common stock under the employee stock purchase plan Â $ 959,000 Â $ 923,000 Â Common Stock Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Issuance of common stock under the employee stock purchase plan Â $ 3,000 Â $ 3,000 Â Issuance of common stock under the employee stock purchase plan (in shares) Â 310,000 Â 266,000 Â ESPP Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Common stock available for issuance 2,600,000 Â Â Â 2,600,000 Employees Awards Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Issuance of common stock under the employee stock purchase plan Â Â Â Â Â $ 25,000 Issuance of common stock under the employee stock purchase plan (in shares) Â Â Â Â Â 5,000 Employees Awards | ESPP Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Discount on purchase price percentage of fair market value Â Â Â Â 85.00% RSUs Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Restricted stock units weighted average grant date fair value $ 5.3 $ 4.45 $ 3.28 Â Â Restricted stock units grant date fair value 219,285 3,033,680 211,895 Â Â Unrecognized compensation expense, weighted average period for recognition Â Â Â Â 2 years 10 months 2 days Unrecognized compensation expense related to non-option $ 26,200,000 Â Â Â $ 26,200,000 RSUs | Share-Based Payment Arrangement, Tranche One Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Vesting period Â 4 years 3 years Â Â Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 33.30% 25.00% 33.30% Â Â RSUs | Share-Based Payment Arrangement, Tranche Two Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Vesting period Â 2 years 4 years Â Â Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 33.30% 33.30% 33.30% Â Â RSUs | Share-Based Payment Arrangement, Tranche Three Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 33.30% 33.30% 33.30% Â Â RSUs | Employees Awards | Share-Based Payment Arrangement, Tranche One Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Vesting period 2 years 2 years 2 years Â Â Restricted stock units grant date fair value 21,968 145,980 53,720 Â Â Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 40.00% Â Â Â Â RSUs | Employees Awards | Share-Based Payment Arrangement, Tranche Two Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Vesting period 3 years 3 years 3 years Â Â Restricted stock units grant date fair value Â 26,250 2,375 Â Â Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 60.00% Â 25.00% Â Â RSUs | Employees Awards | Share-Based Payment Arrangement, Tranche Three Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Vesting period 4 years 4 years 4 years Â Â Market RSU's Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Restricted stock units weighted average grant date fair value Â $ 10.3 Â Â Â Unrecognized compensation expense, weighted average period for recognition Â Â Â Â 1 year 11 months 23 days Unrecognized compensation expense related to non-option $ 27,400,000 Â Â Â $ 27,400,000 Market RSU's | Employees Awards | Share-Based Payment Arrangement, Tranche One Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Â 0.00% Â Â Â Market RSU's | Employees Awards | Share-Based Payment Arrangement, Tranche Two Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Â 50.00% Â Â Â Market RSU's | Employees Awards | Share-Based Payment Arrangement, Tranche Three Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Â 100.00% Â Â Â X - DefinitionDiscount on purchase price percentage of fair market value. + ReferencesNo definition available. + Details Name: mnkd_DiscountOnPurchasePricePercentageOfFairMarketValue Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionShare based compensation arrangement by share based payment award equity instruments other than options vested grants in period. + ReferencesNo definition available. + Details Name: mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedGrantsInPeriod Namespace Prefix: mnkd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=mnkd_EmployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=mnkd_MarketRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 91 R81.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation Expense - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Details) - shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2024 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Granted awards 241,253 5,630,286 267,990 6,139,529 Employees Awards | RSUs Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Granted awards 241,253 3,205,910 267,990 3,715,153 Employees Awards | Market RSUs Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Granted awards Â 2,144,000 Â 2,144,000 Non-employee Directors Awards | RSUs Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Granted awards Â 280,376 Â 280,376 X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_TitleOfIndividualAxis=mnkd_EmployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=mnkd_MarketRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=mnkd_NonEmployeeDirectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 92 R82.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation Expense - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Parenthetical) (Details) - $ / shares 3 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 RSUs Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Restricted stock units weighted average grant date fair value $ 5.3 $ 4.45 $ 3.28 Restricted stock units grant date fair value 219,285 3,033,680 211,895 RSUs | Share-Based Payment Arrangement, Tranche One Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 33.30% 25.00% 33.30% Vesting period Â 4 years 3 years RSUs | Share-Based Payment Arrangement, Tranche Two Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 33.30% 33.30% 33.30% Vesting period Â 2 years 4 years RSUs | Share-Based Payment Arrangement, Tranche Three Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 33.30% 33.30% 33.30% RSUs | Share-Based Payment Arrangement, Tranche Four Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Â 33.30% Â Market RSUs Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Restricted stock units weighted average grant date fair value Â $ 10.3 Â Employees Awards | RSUs | Share-Based Payment Arrangement, Tranche One Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Restricted stock units grant date fair value 21,968 145,980 53,720 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 40.00% Â Â Vesting period 2 years 2 years 2 years Employees Awards | RSUs | Share-Based Payment Arrangement, Tranche Two Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Restricted stock units grant date fair value Â 26,250 2,375 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 60.00% Â 25.00% Vesting period 3 years 3 years 3 years Employees Awards | RSUs | Share-Based Payment Arrangement, Tranche Three Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Vesting period 4 years 4 years 4 years Employees Awards | Market RSUs Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Vesting date Â Jul. 15, 2027 Â Employees Awards | Market RSUs | Share-Based Payment Arrangement, Tranche One Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Â 0.00% Â Employees Awards | Market RSUs | Share-Based Payment Arrangement, Tranche Two Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Â 50.00% Â Employees Awards | Market RSUs | Share-Based Payment Arrangement, Tranche Three Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Â 100.00% Â Employees Awards | Market RSUs | Share-Based Payment Arrangement, Tranche Four Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Â 200.00% Â Employees Awards | Market RSUs | Index Target 90th Percentile or Higher Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Â 300.00% Â Non-employee Directors Awards | RSUs Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Restricted stock units weighted average grant date fair value Â $ 4.45 Â X - DefinitionShare-based compensation arrangement by share-based payment award, award vesting date. + ReferencesNo definition available. + Details Name: mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate Namespace Prefix: mnkd_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionShare based compensation arrangement by share based payment award equity instruments other than options vested grants in period. + ReferencesNo definition available. + Details Name: mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedGrantsInPeriod Namespace Prefix: mnkd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10

-Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=mnkd_ShareBasedCompensationAwardsTrancheFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=mnkd_MarketRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=mnkd_EmployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=mnkd_ShareBasedCompensationAwardsTrancheFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=mnkd_NonEmployeeDirectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 93 R83.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation Expense - Stock Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Total $ 5,227 $ 4,601 $ 15,540 $ 13,836 RSUs and Options Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Total 5,047 4,442 14,994 13,324 Employee Stock Purchase Plan Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Total $ 180 $ 159 $ 546 $ 512 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=mnkd_RestrictedStockUnitsAndOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=mnkd_EmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 94 R84.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Detail) â¬ in Millions 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Jul. 31, 2024 USD ($) Jun. 30, 2024 USD ($) Dec. 31, 2023 USD ($) ConsecutiveMonth Feb. 28, 2023 USD ($) Jun. 30, 2022 USD ($) Nov. 30, 2021 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Sep. 30, 2024 EUR (â¬) Jul. 08, 2024 Jul. 01, 2013 USD ($) Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating lease costs Â Â Â Â Â Â Â $ 719,000 $ 422,000 $ 1,417,000 $ 1,253,000 Â Â Â Â Operating lease weighted average discount rate Â Â 7.25% Â Â Â 7.25% Â 7.25% Â 7.25% 7.25% 7.25% Â Financing Liability Â Â $ 104,100,000 Â Â Â $ 104,000,000 Â $ 104,000,000 Â $ 104,100,000 Â Â Â Financing liability - long term Â Â 94,319,000 Â Â Â Â 94,005,000 Â 94,005,000 Â 94,319,000 Â Â Â Financing liability - current Â Â 9,809,000 Â Â Â 9,998,000 Â $ 9,998,000 Â 9,809,000 Â Â Â Supply Agreement expiration period Â Â Â Â Â Â Â Dec. 31, 2034 Â Â Â Â Â Supply Agreement renewal period Â Â Â Â Â Â Â Â 2 years Â Â Â Â Â Lease monthly payments Â $ 100,000 Â Â Â Â Â Â Â Â Â Â Â Percentage of annual increment on lease Â 3.00% Â Â Â Â Â Â Â Â Â Â Â Milestone liabilities Â Â 3,452,000 Â Â Â 2,813,000 Â $ 2,813,000 Â 3,452,000 Â Â Â Returns reserve for acquired product [1] Â Â 601,000 Â Â Â 1,468,000 Â 1,468,000 Â 601,000 Â Â Â Losses on estimated returns of acquired product Â Â Â Â Â Â Â Â 1,400,000 Â Â Â Â Â Milestone payments Â Â Â Â Â Â Â Â 752,000 924,000 Â Â Â Â Loss on purchase commitments | â¬ Â Â Â Â Â Â Â Â Â Â Â â¬ 56.6 Â Â Insulin Â Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Loss on purchase commitments Â Â $ 64,800,000 Â Â Â 62,600,000 Â 62,600,000 Â 64,800,000 Â Â Â Tyvaso DPI Â Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Royalty commencement date Â Â Oct. 01, 2023 Â Â Â Â Â Â Â Â Â Royalty termination date Â Â Dec. 31, 2042 Â Â Â Â Â Â Â Â Â Â Pulmatrix, Inc Â Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Lease renewal option 5 years Â Â Â Â Â Â Â Â Â Â Â Landlord-funded tenant improvements payable $ 700,000 Â Â Â Â Â Â Â Â Â Â Â Landlord-funded tenant improvements payable per month 6,000,000,000 Â Â Â Â Â Â Â Â Â Â Â Lease monthly payments $ 101,282 Â Â Â Â Â Â Â Â Â Â Â Percentage of annual increment on lease 3.00% Â Â Â Â Â Â Â Â Â Â Â Vehicle Leases | Master Lease Agreement with Enterprise Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Operating lease rent expenses Â Â Â Â Â Â Â Â $ 100,000 Â Â Â Â Buildings | Marlborough Lease Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Operating lease rent expenses Â Â Â Â $ 28,895 Â Â Â Â Â Â Â Percentage of annual increase in lease payment Â Â Â 3.00% Â Â Â Â Â Â Â Â Â Equipment | V-Go Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Lease Cost Â Â Â Â $ 14,370 Â Â Â Â Â Â Â Â Â Casper L L C Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Sale price Â Â Â Â $ 102,300,000 Â Â Â Â Â Â Â Â Â Lease initial term Â Â Â Â Â 20 years Â Â Â Â Â Â Â Lease renewal options Â Â Â renewal options of five years Â Â Â Â Â Â Lessee,option to extend [true false] Â Â Â Â true Â Â Â Â Â Â Â Operating lease costs Â Â Â Â $ 9,500,000 Â Â Â Â Â Â Operating lease weighted average discount rate Â Â Â Â 9.00% Â Â Â Â Â Â Â Lease, description Â Â Â Â The total annual rent under the Lease starts at approximately $9.5 million per year, subject to a 50% rent abatement during the first year of the Lease, and will increase annually by (i) 2.5% in the second through fifth year of the Lease and (ii) 3% in the sixth and each subsequent year of the Lease,

including any renewal term, utilizing a weighted average discount rate of 9.0%. Â Â Â Â Â Â Â Â Security deposit Â Â Â Â Â $ 2,000,000.0 Â Â Â Â Â Â Â Â Lease repurchase description Â Â Â Â Â the Company has four options to repurchase the Property, in 2026, 2031, 2036 and 2041, for the greater of (i) $102.3 million and (ii) the fair market value of the Property. Â Â Â Â Â Â Â Â Maximum Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Effective interest rate Â Â Â Â Â Â Â Â Â Â Â 11.50% Â Â Â Â Â Â Â Â Minimum Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Effective interest rate Â Â Â Â Â Â Â Â 8.80% Â Â Â Â Â Â Minimum | Casper L L C Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Lease repurchase, amount Â Â Â Â Â $ 102,300,000 Â Â Â Â Â Â Â Â Deerfield | Milestone Rights Liability Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent liability remain payable Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 50,000,000 Remaining milestone rights liability Â $ 3,200,000 $ 3,900,000 Â Â Â Â Â Â Â Â 3,900,000 Â Â Â Milestone rights liability, current Â Â 800,000 Â Â Â 700,000 Â $ 700,000 Â 800,000 Â Â Â Milestone liabilities Â Â 3,100,000 Â Â Â $ 2,500,000 Â 2,500,000 Â 3,100,000 Â Â Â Milestone payments Â Â Â Â Â Â Â $ 5,000,000 $ 5,000,000 Â Â Â Â Deerfield | Milestone Rights Liability | Maximum Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent liability for milestone payments Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 90,000,000 Russell Ranch Road II LLC | Office Lease Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating lease rent expenses Â Â Â $ 79,543 Â Â Â Â Â Â Â Â Â Percentage of annual increase in lease payment Â Â Â 3.00% Â Â Â Â Â Â Â Â Â Description of right to extension of lease term Â Â Â Â Â Â Â Â Â The Company has no further right to extend the lease term beyond July 31, 2028. Â Â Â Â Â Russell Ranch Road II LLC | Maximum | Office Lease Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Reimbursement for tenant improvements Â Â Â $ 900,000 Â Â Â Â Â Â Â Â Â Additional base rent concession Â Â Â $ 700,000 Â Â Â Â Â Â Â Â Â Â Â Sagard Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Upfront proceeds Â Â 150,000,000 Â Â Â Â Â Â Â Â Â Â Â Reimbursements Â Â $ 400,000 Â Â Â Â Â Â Â Â Â Percentage of royalty on future net sales Â Â 1.00% Â Â Â Â Â Â Â Â Â Unamortized transaction costs Â Â Â Â Â Â Â Â $ 4,200,000 Â $ 4,400,000 Â Â Â Sagard | Tyvaso DPI Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Purchase price Â Â Â $ 200,000,000 Â Â Â Â Â Â Â Â Â Sagard | Net Sales Threshold A | Tyvaso DPI Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Milestone payments Â Â 50,000,000 Â Â Â Â Â Â Â Â Â Net sales Â Â 1,900,000,000 Â Â Â Â Â Â Â Â Â Sagard | Net Sales Threshold B | Tyvaso DPI Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Milestone payments Â Â 45,000,000 Â Â Â Â Â Â Â Â Â Net sales Â Â $ 2,300,000,000 Â Â Â Â Â Â Â Â Â Number of consecutive months | ConsecutiveMonth Â Â 12 Â Â Â Â Â Â Â Â Â Sagard | Net Sales Thresholds A and B | Tyvaso DPI Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net sales Â Â $ 3,500,000,000 Â Â Â Â Â Â Â Â Â Sagard | Remainder of Year Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Royalties Â Â $ 0 Â Â Â Â Â Â Â Â Â Sagard | Royalty Liability Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Royalty rights Â Â 1.00% Â Â Â Â Â Â Â Â Â Transaction costs Â Â $ 4,400,000 Â Â Â Â Â Â Â Â Â Percentage of Future Royalty Revenues Â Â 10.00% Â Â Â Â Â Â Â Â Â [1] See Note 15 â€” Commitments and Contingencies under Loss Contingencies â€” Returns Reserve for Acquired Product. X - DefinitionAdditional Base Rent Concession + ReferencesNo definition available. + Details Name: mnkd_AdditionalBaseRentConcession Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCommitments and Contingencies [Line Items] + ReferencesNo definition available. + Details Name: mnkd_CommitmentsAndContingenciesLineItems Namespace Prefix: mnkd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionContingent Liability + ReferencesNo definition available. + Details Name: mnkd_ContingentLiability Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContingent liability remaining payable amount. + ReferencesNo definition available. + Details Name: mnkd_ContingentLiabilityRemainingPayableAmount Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEffective interest rate. + ReferencesNo definition available. + Details Name: mnkd_EffectiveInterestRate Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFees and expenses. + ReferencesNo definition available. + Details Name: mnkd_FeesAndExpenses Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFinancing liability. + ReferencesNo definition available. + Details Name: mnkd_FinancingLiability Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinancing liability current. + ReferencesNo definition available. + Details Name: mnkd_FinancingLiabilityCurrent Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinancing liability noncurrent. + ReferencesNo definition available. + Details Name: mnkd_FinancingLiabilityNoncurrent Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLandlord funded tenant improvements payable. + ReferencesNo definition available. + Details Name: mnkd_LandlordFundedTenantImprovementsPayable Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLandlord funded tenant improvements payable per month. + ReferencesNo definition available. + Details Name: mnkd_LandlordFundedTenantImprovementsPayablePerMonth Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLease repurchase description. + ReferencesNo definition available. + Details Name: mnkd_LeaseRepurchaseDescription Namespace Prefix: mnkd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLong Term Purchase Commitment, Expiration Date + ReferencesNo definition available. + Details Name: mnkd_LongTermPurchaseCommitmentExpirationDate Namespace Prefix: mnkd_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionLong-term purchase commitment, renewal time period. + ReferencesNo definition available. + Details Name: mnkd_LongtermPurchaseCommitmentRenewalTimePeriod Namespace Prefix: mnkd_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLosses on estimated returns of acquired product. + ReferencesNo definition available. + Details Name: mnkd_LossesOnEstimatedReturnsOfAcquiredProduct Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMilestone liabilities non-current. + ReferencesNo definition available. + Details Name: mnkd_MilestoneLiabilitiesNoncurrent Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMilestone payments. + ReferencesNo definition available. + Details Name: mnkd_MilestonePayments Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMilestone rights liabilities current and noncurrent. + ReferencesNo definition available. + Details Name: mnkd_MilestoneRightsLiabilitiesCurrentAndNoncurrent Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMilestone rights liability current. + ReferencesNo definition available. + Details Name: mnkd_MilestoneRightsLiabilityCurrent Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionOperating leases annual increase in rent expense. + ReferencesNo definition available. + Details Name: mnkd_OperatingLeasesAnnualIncreaseInRentExpense Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of annual increment on lease. + ReferencesNo definition available. + Details Name: mnkd_PercentageOfAnnualIncrementOnLease Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of future royalty revenues. + ReferencesNo definition available. + Details Name: mnkd_PercentageOfFutureRoyaltyRevenues Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of royalty on future net sales. + ReferencesNo definition available. + Details Name: mnkd_PercentageOfRoyaltyOnFutureNetSales Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionReturns reserve for acquired product. + ReferencesNo definition available. + Details Name: mnkd_ReturnsReserveForAcquiredProduct Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRoyalty commencement date. + ReferencesNo definition available. + Details Name: mnkd_RoyaltyCommencementDate Namespace Prefix: mnkd_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionRoyalty rights. + ReferencesNo definition available. + Details Name: mnkd_RoyaltyRights Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalty termination date. + ReferencesNo definition available. + Details Name: mnkd_RoyaltyTerminationDate Namespace Prefix: mnkd_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionTransaction costs. + ReferencesNo definition available. + Details Name: mnkd_TransactionCosts Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUnamortized transaction costs. + ReferencesNo definition available. + Details Name: mnkd_UnamortizedTransactionCosts Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThreshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdTradingDays Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDescription of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionIndicates (true false) whether sublessee has option to extend operating sublease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionDescription of terms and conditions of option to extend operating sublease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingSubleaseOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionNet cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_PaymentsForProceedsFromTenantAllowance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash payments to lessor's for use of assets under operating leases. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForRent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of cash paid for royalties during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForRoyalties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash received for royalties during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_ProceedsFromRoyaltiesReceived Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received for the sale of real estate that is not part of an investing activity during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfRealEstate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMinimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of consideration recognized during the period for the milestone or milestones. + ReferencesNo definition available. + Details Name: us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X -

DefinitionAmount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RoyaltyExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA description of the terms of the lease(s) related to the assets being leased-back in connection with the transaction involving the sale of property to another party and the lease of the property back to the seller. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481295/840-40-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -SubTopic 40 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479741/842-40-50-2 + Details Name: us-gaap_SaleLeasebackTransactionLeaseTerms Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net book value of the asset(s) sold in connection with the sale of the property to another party and lease back to the seller. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481266/840-40-55-50Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481266/840-40-55-52Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 51 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481266/840-40-55-51Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479741/842-40-50-2 + Details Name: us-gaap_SaleLeasebackTransactionNetBookValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_SecurityDeposit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_ProductOrServiceAxis=mnkd_InsulinMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_TyvasoDPIMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AssetAcquisitionAxis=mnkd_PulmatrixIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_MasterLeaseAgreementWithEnterpriseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mnkd_MarlboroughLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AssetAcquisitionAxis=mnkd_VGoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mnkd_CasperLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=mnkd_MilestoneRightsLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=mnkd_RussellRanchRoadIILLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_OfficeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=mnkd_SagardHealthcarePartnersFundingBorrowerSPE2LPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=mnkd_NetSalesThresholdAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=mnkd_NetSalesThresholdBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=mnkd_NetSalesThresholdsAAndBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=mnkd_RemainderOfYearMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=mnkd_RoyaltyLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 95 R85.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Schedule Of Royalty Liability Account Roll Forward (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Commitments And Contingencies [Line Items] Â Â Balance, beginning of period Â $ 721,366 Non-cash interest expense on liability for sale of future royalties $ 4,089 12,720 Balance, end of period 674,126 $ 674,126 Minimum Â Â Commitments And Contingencies [Line Items] Â Â Effective interest rate Â 8.80% Maximum Â Â Commitments And Contingencies [Line Items] Â Â Effective interest rate Â 11.50% Royalty Liability Â Â Commitments And Contingencies [Line Items] Â Â Balance, beginning of period Â $ 145,810 Amortization of deferred transaction costs Â 172 Non-cash interest expense on liability for sale of future royalties Â 12,548 Royalty revenue earned by or payable to Sagard Â (9,635) Balance, end of period $ 148,895 $ 148,895 X - DefinitionAmortization of deferred transaction costs. + ReferencesNo definition available. + Details Name: mnkd_AmortizationOfDeferredTransactionCosts Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCommitments and Contingencies [Line Items] + ReferencesNo definition available. + Details Name: mnkd_CommitmentsAndContingenciesLineItems Namespace Prefix: mnkd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEffective interest rate. + ReferencesNo definition available. + Details Name: mnkd_EffectiveInterestRate Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalty revenue. + ReferencesNo definition available. + Details Name: mnkd_RoyaltyRevenue Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of interest expense recognized for liability for future policy benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 29E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29E + Details Name: us-gaap_LiabilityForFuturePolicyBenefitInterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=mnkd_RoyaltyLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 96 R86.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Schedule of Financing Liability Lease Term and Discount Rate (Detail) Sep. 30, 2024 Dec. 31, 2023 Commitments And Contingencies Disclosure [Abstract] Â Â Weighted average remaining lease term (in years) 17 years 1 month 6 days 17 years 9 months 18 days X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 97 R87.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Summary of Financing Liability Costs (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Commitments And Contingencies Disclosure [Abstract] Â Â Â Â Interest expense on financing liability $ 2,470 $ 2,459 $ 7,361 $ 7,332 X - DefinitionInterest expense on financing liability. + ReferencesNo definition available. + Details Name: mnkd_InterestExpenseOnFinancingLiability Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 98 R88.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Schedule of Remaining Financing Liability Payments (Detail) $ in Thousands Sep. 30, 2024 USD ($) Operating Lease Liabilities Payments Due [Abstract] Â Remainder of 2024 $ 2,532 2025 10,269 2026 10,533 2027 10,849 2028 11,174 Thereafter 177,278 Total 222,635 Interest payments (116,113) Debt issuance costs (2,519) Total financing liability $ 104,003 X - DefinitionFinance lease liability discounted. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscounted Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinance lease liability discounted debt issuance costs. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscountedDebtIssuanceCosts Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFinance lease liability discounted excess amount. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscountedExcessAmount Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinance lease liability discounted payments due. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscountedPaymentsDue Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinance lease liability discounted payments due after year four. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueAfterYearFour Namespace Prefix: mnkd_

Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinance lease liability discounted payments due next twelve months. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueNextTwelveMonths Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinance lease liability discounted payments due remainder of fiscal year. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueRemainderOfFiscalYear Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinance lease liability discounted payments due year four. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueYearFour Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinance lease liability discounted payments due year three. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueYearThree Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinance lease liability discounted payments due year two. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueYearTwo Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 99 R89.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Summary of Finance Lease Information (Detail) $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Commitments And Contingencies Disclosure [Abstract] Â Financing lease right-of-use asset $ 219 Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other Assets Noncurrent Financing lease liability-current $ 52 Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Accrued Liabilities Current Financing lease liability-long-term $ 171 Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Financing lease liability-long-term Total $ 223 Weighted average remaining lease term (in years) 4 years 8 months 12 days Weighted average discount rate 7.25% X - DefinitionFinance lease liability weighted average discount rate percent. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityWeightedAverageDiscountRatePercent Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term + ReferencesNo definition available. + Details Name: mnkd_WeightedAverageRemainingLeaseTerm Namespace Prefix: mnkd_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes current finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes noncurrent finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionAmount, after accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes finance lease right-of-use asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant XML 100 R90.htm IDEA: XBRL DOCUMENT v3.24.3 Commitment and contingencies - Schedule of Remaining Financing Lease Payments (Detail) $ in Thousands Sep. 30, 2024 USD ($) Commitments And Contingencies [Line Items] Â Remainder of 2024 $ 2,532 2025 10,269 2026 10,533 2027 10,849 2028 11,174 Thereafter 177,278 Total 222,635 Interest payments (116,113) Total financing liability 104,003 Audio Visual Equipment Â Commitments And Contingencies [Line Items] Â Remainder of 2024 27 2025 54 2026 54 2027 54 2028 54 Thereafter 23 Total 266 Interest payments (43) Total financing liability $ 223 X - DefinitionCommitments and Contingencies [Line Items] + ReferencesNo definition available. + Details Name: mnkd_CommitmentsAndContingenciesLineItems Namespace Prefix: mnkd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFinance lease liability discounted. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscounted Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinance lease liability discounted excess amount. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscountedExcessAmount Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinance lease liability discounted payments due. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscountedPaymentsDue Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinance lease liability discounted payments due after year four. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueAfterYearFour Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinance lease liability discounted payments due next twelve months. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueNextTwelveMonths Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinance lease liability discounted payments due remainder of fiscal year. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueRemainderOfFiscalYear Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinance lease liability discounted payments due year four. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueYearFour Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinance lease liability discounted payments due year three. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueYearThree Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFinance lease liability discounted payments due year two. + ReferencesNo definition available. + Details Name: mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueYearTwo Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=mnkd_AudioVisualEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 101 R91.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements (Detail) â¬ in Millions Sep. 30, 2024 EUR (â¬) Purchase Obligation Fiscal Year Maturity [Abstract] Â Remaining Purchase Commitments, 2026 â¬ 4.2 Remaining Purchase Commitments, 2027 6.0 Remaining Purchase Commitments, 2028 6.0 Remaining Purchase Commitments, 2029 6.0 Remaining Purchase Commitments, 2030 6.0 Remaining Purchase Commitments, 2031 8.0 Remaining Purchase Commitments, 2032 8.0 Remaining Purchase Commitments, 2033 8.0 Remaining Purchase Commitments, 2034 4.4 Remaining Purchase Commitments, Total 56.6 Estimated Capacity Fees, 2025 1.5 Estimated Capacity Fees, 2026 2.0 Estimated Capacity Fees, 2027 1.0 Estimated Capacity Fees, 2028 1.0 Estimated Capacity Fees, 2029 1.0 Estimated Capacity Fees, 2030 1.0 Estimated Capacity Fees, 2031 0.5 Estimated Capacity Fees, 2032 0.5 Estimated Capacity Fees, 2033 0.5 Estimated Capacity Fees, 2034 0.5 Estimated Capacity Fees, Total â¬ 9.5 X - DefinitionEstimated capacity fees. + ReferencesNo definition available. + Details Name: mnkd_EstimatedCapacityFees Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEstimated capacity fees due in eighth year. + ReferencesNo definition available. + Details Name: mnkd_EstimatedCapacityFeesDueInEighthYear Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEstimated capacity fees due in fifth year. + ReferencesNo definition available. + Details Name: mnkd_EstimatedCapacityFeesDueInFifthYear Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEstimated capacity fees due in fourth year. + ReferencesNo definition available. + Details Name: mnkd_EstimatedCapacityFeesDueInFourthYear Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEstimated capacity fees due in next twelve months. + ReferencesNo definition available. + Details Name: mnkd_EstimatedCapacityFeesDueInNextTwelveMonths Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEstimated capacity fees due in ninth year. + ReferencesNo definition available. + Details Name: mnkd_EstimatedCapacityFeesDueInNinthYear Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEstimated capacity fees due in second year. + ReferencesNo definition available. + Details Name: mnkd_EstimatedCapacityFeesDueInSecondYear Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEstimated capacity fees due in seventh year. + ReferencesNo definition available. + Details Name: mnkd_EstimatedCapacityFeesDueInSeventhYear Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEstimated capacity fees due in sixth year. + ReferencesNo definition available. + Details Name: mnkd_EstimatedCapacityFeesDueInSixthYear Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEstimated capacity fees due in tenth year. + ReferencesNo definition available. + Details Name: mnkd_EstimatedCapacityFeesDueInTenthYear Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEstimated capacity fees due in third year. + ReferencesNo definition available. + Details Name: mnkd_EstimatedCapacityFeesDueInThirdYear Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPurchase obligation due in eighth year. + ReferencesNo definition available. + Details Name: mnkd_PurchaseObligationDueInEighthYear Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPurchase obligation due in nineth year. + ReferencesNo definition available. + Details Name: mnkd_PurchaseObligationDueInNinethYear Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPurchase obligation due in seventh year. + ReferencesNo definition available. + Details Name: mnkd_PurchaseObligationDueInSeventhYear Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPurchase obligation due in sixth year. + ReferencesNo definition available. + Details Name: mnkd_PurchaseObligationDueInSixthYear Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPurchase obligation due in tenth year. + ReferencesNo definition available. + Details Name: mnkd_PurchaseObligationDueInTenthYear Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMinimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligationDueInFifthYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligationDueInFourthYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligationDueInSecondYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligationDueInThirdYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligationFiscalYearMaturityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 102 R92.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements (Parenthetical) (Details) Sep. 30, 2024 EUR (â¬) Purchase Obligation Fiscal Year Maturity [Abstract] Â Capacity fee â¬ 750,000 X - DefinitionCapacity fee. + ReferencesNo definition available. + Details Name: mnkd_CapacityFee Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligationFiscalYearMaturityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 103 R93.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Schedule of Lease Term and Discount Rate (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Jul. 08, 2024 Dec. 31, 2023 Commitments And Contingencies Disclosure [Abstract] Â Â Â Operating lease, right-of-use asset $ 13,637 Â $ 4,685 Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other assets Â Other assets Operating lease liability-current $ 2,431 Â $ 1,423 Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Accrued expenses and other current liabilities Â Accrued expenses and other current liabilities Operating lease liability $ 12,167 Â $ 3,925 Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating lease liability Â Operating lease liability Total $ 14,598 Â $ 5,348 Weighted average remaining lease term (in years) 7 years 3 months 18 days Â 3 years 8 months 12 days Incremental borrowing rate 7.25% 7.25% 7.25% X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted

obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes current operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes noncurrent operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes operating lease right-of-use asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 104 R94.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Summary of Lease Information (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Commitments And Contingencies Disclosure [Abstract] Â Â Â Â Operating lease costs $ 719 $ 422 $ 1,417 $ 1,253 Variable lease costs 104 48 122 97 Cash paid $ 860 $ 268 $ 1,407 $ 825 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 105 R95.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Schedule of Future Minimum Office And Vehicle Lease Payments (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Commitments And Contingencies [Line Items] Â Â Operating lease, liability $ 14,598 $ 5,348 office and vehicle Â Â Commitments And Contingencies [Line Items] Â Â Remainder of 2024 784 Â Year 1 3,157 Â Year 2 2,579 Â Year 3 2,540 Â Year 4 2,087 Â Thereafter 7,721 Â Total 18,868 Â Interest expense (4,270) Â Operating lease, liability $ 14,598 Â X - DefinitionCommitments and Contingencies [Line Items] + ReferencesNo definition available. + Details Name: mnkd_CommitmentsAndContingenciesLineItems Namespace Prefix: mnkd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLessee operating lease liability payments due after year four. + ReferencesNo definition available. + Details Name: mnkd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour Namespace Prefix: mnkd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnkd_OfficeAndVehicleMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 106 R96.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes - Additional Information (Detail) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended Jun. 30, 2024 Sep. 30, 2024 Sep. 30, 2024 Operating Loss Carryforwards [Line Items] Â Â Â Income tax expense Â $ 1,320,000 $ 1,907,000 Effective tax rate (as a percent) Â Â 21.00% Unrecognized income tax interest and penalties Â Â $ 0 California | Senate Bills 167 Â Â Â Operating Loss Carryforwards [Line Items] Â Â Â Net operating losses $ 5,000,000 Â Â Tax years 2024 2025 2026 Â Â California | Senate Bills 175 Â Â Â Operating Loss Carryforwards [Line Items] Â Â Â Tax years 2025 2026 Â Â X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTax year that remains open to examination under enacted tax laws, in YYYY format. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15 + Details Name: us-gaap_OpenTaxYear Namespace Prefix: us-gaap_ Data Type: dtr-types:gYearListItemType Balance Type: na Period Type: duration X - DefinitionAmount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3 + Details Name: us-gaap_OperatingLossCarryforwards Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3 + Details Name: us-gaap_OperatingLossCarryforwardsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15 + Details Name: us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_IncomeTaxAuthorityAxis=mnkd_SenateBills167Member Namespace Prefix: Data Type: na Balance Type: xbrli:stringItemType Balance Type: duration X - Details Name: us-gaap_IncomeTaxAuthorityAxis=mnkd_SenateBills175Member Namespace Prefix: Data Type: na Balance Type: xbrli:stringItemType Balance Type: duration XML 107 R97.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events (Additional Information) (Details) $ in Millions 1 Months Ended Jul. 08, 2024 Employees Jun. 30, 2024 USD ($) Subsequent Event [Line Items] Â Â Letters of credit secured by cash held in restricted depository account Â $ 0.7 Number of pulmatrix employees which began employment | Employees 13 Â Lease term extension period Â Effective Date through November 30, 2033 Lease monthly payments Â $ 0.1 Percentage of annual increment on lease Â 3.00% X - DefinitionLease term exsention period. + ReferencesNo definition available. + Details Name: mnkd_LeaseTermExtensionPeriod Namespace Prefix: mnkd_ Data Type: xbrli:stringItemType Balance Type: duration X - DefinitionNumber of pulmatrix employees which began employment. + ReferencesNo definition available. + Details Name: mnkd_NumberOfPulmatrixEmployeesWhichBeganEmployment Namespace Prefix: mnkd_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionPercentage of annual increment on lease. + ReferencesNo definition available. + Details Name: mnkd_PercentageOfAnnualIncrementOnLease Namespace Prefix: mnkd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: durationCarrying amount as of the balance sheet date of cash collateral held for borrowed securities, for which the cash is restricted as to withdrawal or usage. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CashCollateralForBorrowedSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCash payments to lessor's for use of assets under requirements leases. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForRent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further supplemented with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration EXCEL 108 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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}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{7\IAOL#Z!@ MP$[%]5.VQ"E;ZHIM.':]0,5VA?JYE%SQRFY8/GHE!^?1CF!M' R="J"P'^G3 M#(("*PQCI,6BB&",CT@'W,A5;55AOLD/E(5O+-=,B0/F7.[? =T=0 "G:J40 P/_A5Z%/>'"%-L5*>3I55YF MY4))F=[GH%M-W3@E+#1R'@CS=>$&P4*E;'1W@3 Z(FQPKU:Q7:[J?@ --F7C M%$<(ZP8#,!)A8R:'V!#3)\L4Q"D_LQ&3>[F* [7KU)R5HFN%^R:I&VWB[O9+K MV8CIII[TB3Z&$6.[)#Z?+D'' 9J4Z&X#,%A7P!<0 MI0"&1 $<)Z27O^0"^:OBA+]+E1/V>;UIZK@F^2[Y"$@/V0FO%09.V1(":.,0 M^7I:=M7IT.>]U"9VJ7W3./V#M^X>T>PURXOLI>!3-?=-V[FOYJK^R,>F/#O] MU2/@DBTAIER?8M\< 1,6C^5YTDMZ8I?TAQI&M$^M)=430,]C?68#0%-*0[V, M@6"$(2/10SC,L#^BID@OZ8E5GA[+F)NBC:D7WA2P1X4OLW>K'RA0UT3&'_! M0GV=*0%0A*"0ZGXP85-,*1WS0R^CR;=D]$4F_*8ZK)M;N_JZD<"Z#-&H>X8 M1WT.W=>+L\W%Z[-AWL.P8" ,5$$X4"O P&8-6!Z<4SL MXMBPV-NIM-%NT7G39B#/B%]P0=&&2X 42$; --%,M!HJEKY M(_[H13*QB^3O2\C%9N)XSL.%:[[,M+G@QN.* M+6$. ^J::29RYK4O*"R@5%R61L@X%] [YU*-&8".^<=BHK3$QJ=P*<6IT/!5E MB@\%4H(C)7*>,HV32Y:S,@$R-\:*O)TQ":7.0/.$Y>_(>_*:N$1E>%6-78T< MQLU-FC4OZS7]6O.H>J1@)X1G_K]#OGTL/P*$I1[5A[LREW,OBV!WY; MW!! M/AR-*6-G:O)U03[R$A/G+"?7:G6WOUN;_,2GJN*)3!Q M\"U3(-?@Q&]>>0/ZH2OQ_V2V4X:@+4-PR#V^P490?%G:YX_^"Y 21]B!R=T9 MJ9@D:Y:OH*L&M7%DCJ-W?5V;D>"=IC[+7/_!SU N$6ED? KSR/^$P)W<@C;',*7Y\"56G7SAT^P'H,?BM@A'K3$@Y<3XY:A M^M37BZ[L =\L0]%[&!'+79T$'LJB@)?YU,:.CJEH8\$[3 .6\;A,QA/:N#A MDSH-:7<'GQ*Y0SUJJ4?/I][?LJ,G"X41E%(@^$CXJY(2H-^? Q1V$WOTW[Y MG\]I&D;RU/(.T.[T=VMW=L2E(CDL4$M[$9K(^C123[2H[(9^*S0> M#^PPPQ,<2!. JQ="Z(>).2.T9\+X+U!+ P04 " #5@&=991YI7^44 !Q M*@$ & 'AL+W=OWNWK\9F;8UE26M1"?MM[^4K)@A $.B?9)V.M/X MC>[S;8JKP\;W2^O_.$POKHO%ZN+=V\./WN_??=F_5 O%ZOJ M_7:P>[B_+[>__5@MUY_>7G@7GW_PC\7M7;W_P=6[- YORMOJYJO^U>;]MOKMZ MHEPO[JO5;K%>#;;5S=N+OWD_J%&XW^#P%_]>5)]V7WP]V! *A_7ZE_TW^?; MB^%^CZIE-:_W8++YYV,UJ9;+/:G9C_\&8#_[B!KVT0)L]L$!PW"+0-8N^9# <+C!N&Y MNQ0=-XCT"L\==\S<(-8V2,)G-DB.&R3:!OYS!STZ;C ZM\+XN,%8V^#YAAM^ M;KFAMDDP?FZ3I\;66]M_MLKGYO8.[7WU>&(=SLII69?OWFS7GP;;_=\WO/T7 MAU/[L'US,BY6^Q3^7&^;WRZ:[>IWD_7JNLE4=3UHOMJMEXOKLFZ^^;EN_FG" M5N\&ZYOFN_7\E[OU\KK:[OY[_*UN%O-%/;@<_.OGZ>"[/_UEL+LKM]5NL%@- M_GFW? MB5J^O=7P=_ZGS_YJNJG9?\VI^W+,?^_?,?V;/_KFNRZ5ELXE[L^8P M/E;;>O%A60W^OJZK0;ZJJV;OZF9?JL%Y6HUR+;KA\U -?]-+/QI3_[[[6(U M7VS*Y: YSM[5TE/5[N^;]ZI# UBVGIV_]>#5+TSVFF*O>Y6$N_3?KJ\7^_?T MAOZ^7%Q?-B?>I-PL[.=/_E+6ZU_!@BO]NM=3GMB1^?SA_F%Y>"?XW_JNVC;U M]M_.F[?^W[<'_=\?5]9N.I[O%=I NY:MZ]GM["_*>W,/] #9^A_EC=+E:K MQ>IV\&.Y+%?S:E#6#7[^_2#P_CKPA[YO>_-Y9,8'YOY2Y>.[2S\:1L'HS=7' M+]]MG+7WUT@_[#;EO'I[T;P^NVK[L;IX]^?_\N+A_]C>6DA8:AZ!'^N[/R,K M9B1,6'9_'(? ^..@>04X6+4B8)&'*$\?CI]>BD(WA*1] S'=\U[RN/ M/?9?SD]*D]_S,"-H=+I[*W6X]7QQZR4^+^]X)Z673"5\VGY)_:3Z6 MXWJ]NJ;SO[5%-33.8<\;C[4>S;E7?2-(PM+0>_ 4TT>6RTB8L+[TL=:7D14+ M$B9)F()@G51%3ZF*OF:JONP=;0ES%N_;&9*P*0E+(TMGJ+V/S,B"&0D3)"PG M804)DR1,0;!.9N.GS,;G97:^WM6[YY(Z.*,#C(WS]M(/M?[/N2]]4T?"4A(V M(V$9"1-G- %).%BQ(F"1A"H)U4I<\I2YQIN[O3986Y_:6CS]=;_;C4[O#F--^ MO&F[.__XO&7#ZM%;1WG38SVCGPMD\X][9M)$I8FYC"%U@^2Y3(2)BPO_%#+ M&5FO(&&2A"D(ULG9Z"EGHV^? LU/7J10^U#UXPLF)$P M^TO1>R$E:0,$G"% 3K)'G\E.3QRSY;;AZV^] 4@WK=_&) J^9@*:S6=67M$9UE M^J9S;/104=2-P)2LEY*P&0G+2)@@8?GI-BK(>I*$*0C6B9PW; 6%(1^Z4VU MNV;?!**T*4I+4=KL2.L.-)#+ MO1]WO4_MIEKMRH-V5_VZ_]HF#_QX1'YY<@6Q_CXY<1?N'3:2EJ*T&4K+4)HX MJZURM&:\TH2E&?QQ/!H; M0BI:MD!ITG(0ED[(T+AB1+46 ME)8&YLPD^K2#:,$,I0E; PS'1L^%NBHH3:(T1=&Z$6M=E>"%K@KS.**[>)N M$IV'!J6E@>ELC,)$#RJL* T@=)RE%:@-(G2%$7KKOW>RB[AF;++JQ]'#"W3 M?\3Z)SOWWO2- ($I+4=H,I64H39S35#E:LD!I$J4IBM:-8&NNA&YSY9L]0Q&: M"L6EEPSU>;/=N]L[HZCO,95D7M&:&TH2E&>S+NJ!E M"Y0F+0=A6F>V$\ZYK$O8&BUAKU6- ^B[KXJ,W_K2%6BXH+0TMBPC9EG5!JV8H M3:"T*45*$VB-$71NAEME9C0K<2<7-76'DW3_[CTP]B+C;MSJ,2"TM[TB=(41>L&L95@8K<$XWY^ MUOZ1SQ0[+OWA>.P;P43M%)26'FG=Z\I('R9!:V8H35B:P1^/HW&B#Y.@90N4 M)BT'$8VTSR?*=L(%S1GGA\\\AZWLDCLED7.?W[6'@54$4%I4Y26QN:T(DU> MDD1_XARMFJ$T@=)RE%:@-(G2%$7K9K052F*W4&(=_3@],&E;6\@VF.^NWCMU MJ P26]86,@?ST9H92A.69K /YJ-E"Y0F49JRG9GNP?S6XHC=%L?)T8_3L4'7 M(4)I4Y26QI;Y1ZSC^:C5@= ($2LM16H'2)$I3%*T;T];^B$_;']_D@9_8O+E^ M&8X#?<%8]^[VCBEJD,3F\D3>6(\HZH6@-&%O@DB?X1TM6J TB=(41>MFK_5* M8K<7\KL\]>/>]Z]*JJ?H+0T-DT%;Z3/JCQ#:V8H3:"T'*45*$VB- $71.KE. M6H\E.7/=HM<^]N.NTS>K*&UZI'6>?TTB[1-MBM:4HK4!I$J6IDR=Y-V&M M*I.X51G3YBP>5FZ%+;%Z,E$RTCT9=^G>B4,]F<3FR81&EX9Z,BA-6)K!'X]] M/]&GU47+%BA-

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Ô6.]Y7M=ZJQ5'QKPKZ8)KQ>++82O(-\L7):R(^1K6LU@&K"C6 M41932+M%J9\FHDFEA'0=U4CY?=-2D&COVN&^ZT N@LC=ZZH"@]"FJPV5.M M<16,T$@-^J'!9(G_KA4IN\L"%@/0_@QX=Y[3+'Y!91X!NL6FO--HWTT\7>JB M$>]%@6FT)0][=AB^+1HUS$"UJM\W@!)$CK MD0JQ/0I_[R@2\!A[%,>329JX$?#5T6.N5BJ]T@_\KE<:,0\; MXAU+H,6.O9Q:1-F<%J+H;"N*]M4R7'#\4S\&UMQ_ "?BIMNX,AX1S;X7P8 M5ZA0B)*%b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ÔWUV9_XK$##^Q'?Q];HN[F]Z55! MU^JSP()Y=0GCGVB'O!F,M]AO]R6YV?LMP.'7:YTF]6]JJ]>]X0-K4 M8ON: M'H;C^~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ÉZ MZE" (8]I4FFKUJQ,?F[3D>',:1W(M%;.A!9WR9\P5, MP'S-[Q3>=2J42*20:2$SIF!^U9KX[ZZ#'@G8%=\$K/3.-2-39E(^TLUM=-7R MB!D!J"X/BSA!M($D)"'O^5H*U*)PGN7F_0_[#&HS$SKN%&)G^+R,17K5&+ M13#G16+NY>HO*WJUXHVW_92NWMHN+PT(;F9;"R" 5F?OE3Z4C=@1&WC," M02D06-Y.D67Y@1L^OE1RQ12M1C2ZL*9::20G,HK*U"A*U#.C& 1OQ$HJ]!X M)+(%FRC%LP6@WXV^[!C40.LZ88EV[=""9]"Z[+/,3*S9QRR':%^~@\PJ>L&& MWG70"#B%_)QUO38+O*#'=,P5Z ;8;F5UU\)VGX&ML[;-9FMVFT5B*:*")W7&M.]!>/2C5SSN=\Q"N6E@@&M026N.WK_V!]Z!7MW(-.?9^NWK4> /WVNF(41K MC #-.-T9 C$Q,;+V\1G2FE%W>O?J89W#,YY]]86GP'@6L;N-PHGK*Q-B3!?6 MP!/_E'V1V9F["4[9@S08M*G-7,)&?NA--C4R?1&+HFHVE4G$3KJGZ(I<*&[! ML)CAU=3 $GUP?O&?!Q;#M#?N; M%<&%7=%_}8%C@K.'6*8:Y3}^NVNS/R$#A2OQ9)%AP_P~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|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

?5@48CX'N M.&*#)(-"><?'3V]GTS9D3MW]\F4\G$^21DCXFJR2X1-.& W' JU [3REDH +T MK8Q5'54132'!.U+5>IT"/W
V\D=SID0M(81CWQ5L; *6'K5J+94O2X$GNR:S8YBQ[M$H3O3L^0W!^)D"%^=3)(B4&>#-/G_YXI&]-C MX!Q9C6+/Y7?-L0UXYUITPA"%W<51"#OS?P[%'I>##;4+9=.V-*T3U3HU"XA2
M5DM1MDBB1V%(!"922VIN^=AL "G$=K@PI#*>Z'HAEM?!3-(515LH,K=*M[MG:D^?%U@\, .]MTV)+0UU20=^#ETA[NX; LFS):M!YN\NC7E0YIDP1O<^L> MY +:S:#FA_79X?
A_BQ$623]0M#/-[68J1=)8WHKZ#$>TW# ZUXW!$U/3UI[N M?>WC3?[;3ZA6$DTP;%%9(!Z.Z%,DH^F C(:3@CT;,EHI7Y@LH$D\.@$P:30 _MJY@H4794AMH:-E, L,2%R$>:%!D5-^0-/^JYDZ>>
GFI6=;Z.RTDIREM<<\U M70O)):[O9=GRQNC\W19#SD!ADW7=BLV^>*<&INRJ9NZ[Y&E:FQ:4_8TE:J&I MDVG'@)%*5VRU:O(O:6TSTIEG!U<51?B 1Q)W>K!3L%S'T^F9 M^'@;:
<'/XCB93R8'/$L?FIQ[)1O2+^XH[6.Z.YTDDY,W![>1E9*]E%"AQ-^= MO#OXBM981K],3Y+Y]/7!IXU'3@]^QT[)Q1"H6W37^H=/#T<,W=P]^&U/BD2A M?WLBQG#'23([>;
<3ZAB0G6X6$@FMQ.YR&\JJ3 'lJ'?$XM 5GA)^E_P6((L4 MJYL+NNXDY+W49?0"-0+DC*46@"2&'X@9KR.QR8S;1V=1'Z2AZF"I M2Y$IM/;J[D:\GKP.!<2F=D&=FPAAJ$]B**2P9?!!S^*,
M>1Y7]YN@.@0O)'&K'8]*$0YS4A(U()BQRCPT%V03=PE MX6SJ=B&5N,\'1VTFPJ'YEB"[;;WCYFX6Q!78Q"Z+8IV$% 9\>7!;G/N ML75OPR#9]C'6(2 9@<\5\]JF&)L".EF,TFUPK24RN[M\2R!
MBYCS)9MP@@=&.[A'YN@N+K2FO"7VW)W12)X7P0Z"QR+CZ/S5CS,HT.!Z0CMC MK5G12MLERYOQ[$3\PE/ KRWH*LW!29B?0+UTLT7.>GN[Z9[]"?V(]'/5=5N(&Q.*!URD,J\S
MW:&6\PCCX8(4)3Z 8DH$DOK0!F@W)+=[#?&5R(GDQBVT&[1X["K!R@X)88A& M >#2/D"ASN]4XU6%,:%_TRE"V@5?\4XJ1K"#$,P]O,(7:"_+0OP& C40-9^' MI*GHM2PZ0HQ\P(3)>-
I[DF,MF7S.Q2^(8=UR#X$_+*M+W940-5#X<0R5QP[6W5 B%0@T_P32V\S[GP0L$42*H"U6K7*/A(1G1 MZ$D9H'YM*IVBTG+5=4)%7)VG2+3$+8C;X("NLQ8A6(MOM5EA]EYV[RT1^;73
M+K[,=#NXO%&3$LY:'E_J'+6&WP_ B;JAI3==C0;JAX:@FY.#M$\3E!=%3%Q M.@RCW Q+"1U-J3,>]Q$6K_I0=B!"4VP_AQ88ML*,3;-D%=[+*WHOOR?A."P\
M5$E*TK;]Z";L2<@H[BRZFE#>&C_>]2C\:? ,!]UGREQ["?Q1F^!S2W^T_)EV%;RB;Y>%+U&?P2@ ' MJC#'5J#.R2B@?KSPIN$O*@OCO:GX9Z$D@($6X'EN4!G=!1W0?V*[_]02P,$ M% @
U8!G63UZJ4P/" -Q@ !D !X;"]W;W)K&ULO5GK;]LX$O_NOX+P9O<20+'U]"-- J1I[[K =K?8;,\^' X'6J(M MHI2H):FXWK_^9DA)EI]-B^*"(*9)SOLWPR%SNY;JD\X9,^1S(4I]-\R-J6[&
M8YWFK*!Z)"M6PLI2JH(:^!68UTI1C-+5(AQZ/N3<4%Y.;R_M7,?U/VMK(W@ M)?N@B*Z+@K:;R;D^FX8#-N)W_D]-S@QOK^MZ(H],?.Q^J#@V[CCDO&"E9K+ MDBBVO!L^!#>O8]QO-
_R3L[7NC0E:LI#R$W[Y.;L;^]@0$RPUR(""QS-[9$(@ M(U#CSX;GL!.)A/UQR_WOUG:P94$U>Y3B7SPS^=UP-B096])):F-_E^AUK[$F0 M7RJ%MG_)VNV-
DB%):VUDT1"#!@4OW2?]W/BA1S#S3Q"$#4%H]7:"K)9OJ*'W MMTJNB<+=P T'UE1+#()X3M[+TN2:O"TSENW2CT&13INPU>9U>);A$ZM&)/(]$OIA?(9?U%D767[1 M*7Z X:P6C/RV)#U+R;\?
%MHH0,1_CAGM>,;'>6*6W.B*INQN"&F@F7IFP_N? M?@@F_JLS&L>=QO$Y[E^*QWGB:+1CY2/5.7G[9\V?J; 3/_TP"X/PE5M@0854 M0I9I0^22Y !CL2&"PW)&>(_=FIN<2,57O*0"!I"3F/6\7
$@3:VXX4PCB[E/ M,K1N$4PK0DUQ.2,&$AF7*YJE>:02#)*U0Q@M6$@U!0XYDIPQ<0,5X:25)0 M=$0>GBD7%":OH0A=/X./3,[H X $8^RJ&BY^9ON*0Y#6.-*EI1P-+6H%-AURQ[!B =-M
EE*P&A%(9+L,]1QW;!SY"!!H8-VV+QA:<,E ML%PB%(?A T,RY)!9M$C!,^N"!16T!&?9$]3W@V5MZ8,(#2D8U;5"TPTXFJO& MT38$ 7!_X*U%4#+*2ND1KW!#JE,WWQPB 1(73:F77U!4QLSIP78"
<<:! WB M"3I_+#NQN109(OI /"K./C<16"I9$$85@M_M.M3. HWE>'X]LTY7Y'9%ZM@P MT=DZZF,7CA3 %%1ZD(G&]!P$6G-S%"U]#]<:]1?LF0F"P:MXU1DR(6:DWR/
MI\QB0VA5B0TRI42GK*2*2WL29A!)D\NL21Z2;RHTW? 4ZL.&,V%S+,3<^=%J M$"4X].SX60IPO^!F@YNF?K=IW@S-*40?(-0#3^J*V?-=; ""Y_+A*/6A.\P+
M:LD:\N6")*/Y3F&X()/MS+YBT$>X2I@KQNQV !#D@SM$&1ZBQ]3V^OH RU0J MW$E+P-%1X+J:Y8\FK2+@DRSCB'8JQ,8CRT:1;Q2_*JU(:G/#"0NVP@C\GL83 MECMT"W1-2%G(#,I@:C.Q]?
S)TOF-'HS.F=#WU_R;3$#6R)TM5BF!,1#-8 > MEW"0R)5E8,OX%T,6;T/VW=#2V%K*[7G5E*,TZ#WYU{4H'3]!)II-8$6 DYRK#)X/CL2%=(ZI[2* M:4&:)LXBT%5B6D IYW\UF(1C-DT5ZP.T<:Y5=/I*
[RC!== GWW8B(<+V0O7] MX7!!HE&X%^GY:'\=GGVD#B''FVWK'>YL H/ #19-M![;/&2EE" ;/GYY*D MD/F8%ST)WS_]L6XE>XK&IQ7].A X!ZS]4T?#U_C@5TF@B,NU[;HP'8$ 0-WV M*4"6-
]E5M-G5\R91CL+67[G6_A!"5P/SDF7&X!?>W&J(7-VN_YCB7&@R7XK MZ-X";"P6^$! +FW&R%J#Q_35S>"(<@>:#1Y%,SVY\!9#;0 MO747E,O@"C$+$];SJ1T%7I(D"(\@\<))U(RB:6QYT"6
8,L&T"CK54Z6V.CA MC";!!%A-\&,^#\G4"X ;)U/!W](+#H@(YYZR3RRHYF7Q"@W"$,O#F;-*)D& MŸ+^G?ZS6&)*^3[,3%C9W!WNAVKGQV6,G(I_>9V\3T/#,#O8>7AD<$*'4/_
M'J"V7%UCP^NN53D$S7W=1TK&=0H0WP(EDT*@JW< ,SH"F$'OLOB+;8NWV'B4 MD,K_4-C&]"X![YJ#^6#AK89++);NP7MP\08R0'V"I%W6(+MWL7)2 BRQ@1?. M,:#MH=8?
N<4!)$W!5,H!%@O9,JIHU3$*23+UXNF4A),9N01LD"N$DP:(!X H7W?=_B=.YDQ\"A M >S@%T#6S2&'2\"3E\Q05FMK^[E=:L3WSWC(!'_B^0'Z#:5=M/+S+$87H)1,"OZU8 ME!F^-
)QMB0GF02NXJ36GPPD0FL3QT7"V2T?#.8FV\Z33&:C8/;#2M.#\L _#Z=? M>4USAS0@4 G?O"HYTJ\\HIU]1 ML/K6ZH6O>,>]QUQ TMVL]VL-^(]ZE-X3- & M8$L@]4?
39$B4>Z9V7XRL[-/P0AHC"SO,&&ULE5;;;MM&$'WW5PR8-(@!0N)%LB1;$B [+9]' (8O#="B#RMR M)!)9[K*[2\O^^\XL9=IN*25YD9:[,V?.F9F]S'?:?+,%HH/'2BJ[" KGZO/A MT&8%5L(.=
(V*5C;:5,+1I]D.;6U0Y-ZIDL,DBLZ&E2A5L)S[N6NSG.O&R5+A MM0';5)4P3Y>VD92TL7FGYM2X$8UT-WKW.^[UC!DOT]+Z7]BU MMDD:0-98IZN],S&H2M7^B\=]'EXY3*,##LG>(?&\VT">Y2?
AQ')N] X,6Q,: M#[Q4[TWD2L5%N76&5DOR<\M5ENE&.0LWF&'Y(-82YT-'P+P\S/8@ERU(<@!D M!E^T+SV]R+. MPE^KM76&NN'O/]$MSJ@?AW?(N:U%AHN MH!%\X#!\L.[^"RZ.,)RU+$'<'4/_
MT5HG)35LS$FDHLFN,8KM).(TGWNXL3.(QV:TX!T)EK65F,"\=2&)' M ;V:Y(*LXS%YG=QI)R2=+C^BNTWY-(PG,XAC4CG]3L*D%&MM!,MMI3+ _,B.: M<11&T1C2<#Q*#W-H _J4QM,1#T;A+
(IAY>5Q0)`IZ'M ')/)'+=K-VF>171 MVW4R>[-!\=Y#-$CH%).2R[<3O"Z%PQR<[O5AV#]12 YZ70@ZA>'^-H3/*AOL M)?0T9:OAB#QEU"]"83N 7 M#Ö(=91S\T>+2&%L37ZFTL^ M'=',@
>J:=!G6NFC9>690Q4XTH8#N/M/KC6I>N- V](XA2:$^SLF)/C,J6I3 M6I(<1U&;+L[-6[@K9?!!U0-R:83Y>CVX[S\?#UA MT'=-#%]=W)1G6_]{+>5MC=Y-]N]@U;M]?]BWCZBO@BS+8FKQ VY1H/).
#3 M/DS:#Z=K_QA8:T=/"S\LZ"V'A@UH?:.U>_[@ -WK&PO=V]R:W-H965TM[MAKN2Y4ML!'V1R%G.F3,W5=-LKTG8S M30;)3G"KEF5@06\V6F'VT:S)!.L4^4DO
)#%O;Q5OFJ4T^\HGXM/UH32B >FH.*Q?@$]FS2 M'9NK]%7 .UIU1=;OB+2?#E_!R ;>91$O>\.[K7BG?*ZMKQV)OR[G/CB4P]\O M>=P
#E\&Y!:Y\"N9TS1!#WAR:TIF/ \T&/= _>X7N<$]W^!KZ6\EX25?EE:J.N M. !]M,XM.LL'81FL+_>G&$I 2JYN3VF1'O*&\E
M@RC)CF[E!F49R"FIO3@6X\XP.XW_Z3@]^H+./%'F9.5LX3MZ+\T[_="@&66<\ M'!]]4$:A@ NQM+;P8C#H#$:I..N,L].CSS9(+=0^C< M0H.T6#Q&E)Z=?,$-/OO,%5C+=5T0!VA-+MX^N?6A@:;
[YB.'C*6,K(ROD8VN MN-1ZMSG@#/V253?@L7$]!#+06D0XA@'S?W!'@2X*U//Q**U=7N*Z@96J4@'W M8&!&L7!%L _?%W7@JM[992LRSUT-O,9Q1B/8PC+M#\9=\3A7#T1;QPL$M]\] MPVVC-
3L//134B9:UR6X>XPMDF#[B:%4-QAK@.." _)A\4^UK@!9%:?9-S M36(M=4U/"&F/F)+C9XXCA_?">^#$N,<([)+DI::V%A@G8G.(T3UP%T>;LG#"
MX$E]:O0AZ3:P@RCNEN_S>OG!LGWH]#94A2]$L0@9O^TH"0!%(CX 0#HT!DAR MNT@]*OF<3,X5V78) M'@?C<99O'*M5$4,VEUKRJ?AT-?$$"^NX_M2NX^!_T\+0*]X A%L(%(A$-4PM
M#5N/MN0B 6,\U&T_H&T>TNM9@GK:4&RCG2_SJ)KWD?A]?"F5'>:UHCB:Z&VG!7YN*NN>_C]3V1-37?'2 M>]4[&"Q[I7]N*N&N&:3;"K.);,;<"0$Y&PO=V]R:W-H965TD M9,4I'
^=/@GZNZYE^>,Y'PKU5>]033P5)5"+[R-,?7Y;*2S#59,#V6-@KX4 M4E7,T*M:CW2MD.7.J"I'41",1Q7CPEO.W=]=6LYE8THN\$Z!;JJ*J>=++.5V
MX87>;N$S7V^,71@MYS5;XSV:+_6=HK=1CY+S"H7F4H#"8N%=A.>7B=5W"K]S MW.H]&6PF*RF_VI=?\X47V("PQ,Q8!$9_C_@1R](*41C?.DRO=VD-]^4=^B>7 M.^6R8AH_RO((GIO-
PIMZD&/!FM)\EMM?L,LGM7B9++5[PK;530(/LD8;677& M%$'%1?O/GKHZ!E,WS*(.H/(Q=TZ,<.6JL*3@N+"GW M1M%73G9F>:>(7V6>@8DZR'$ <^'1$&4',&+^T1CAQ?_5Z)W)1,&+O;3A;\N
M5MHHZI" #V7> B>'@>W4G.N:9;CP:"PTJD?TEN_?A>/@PY&PDS[LY!CZ# !S M'&<\A,-0KY>Q7\XD#9XVF(,LP&P0"EG2!".QAM.<1*8T<$%?9*/)4I^=#ZZU MX30G9/)%8]&4@QM>
()S^B:1[!D2HP6J%JF<5KC#K5D*W$@]N;!#OWTVC,/H M)S"=I.US<-GP,B?G&N(9_Q) .'$CZ>S[J__#KRJE7Q$FX.&T_ ,TE9]%OCI M)9D[,?I9'#+L@U52'V?
=4S*80KCU)_$,8P#/PF#P:=&"6X:A3X4 ,D*VIG) MM9 9[EE;5V$;,FPSV 2##[*]FX,I?BB94VU+,R6*22'4W\:AO0{[55M,)IZ!1E7H I4BY1-(<A*% M6V-9VD80*)2O7NP?+:"2L#C8*G6[
M$82ZY)F.;=F=I8MP0K:,I&UC0*?* AW M*'63T87UDZ:-630%;2-M=B3QDIOG(37Z7IW)GZU5[!O\+=E1)?N)H^:X+MY M>]@HQ-V^^YLM8RL/7,GL/$$O#5Z%<-V%< *1'\PL;Z$?
AA/Z3_TP#>D_]B/J MX8XFI&G9)6N<4QOG_R!.H>$M:<$P[#DCY->%VYL5VF3:.@@)I11KPGYA9@@/ MMH&H ^VQ#X^L;-!1:7WF7-=2D[..5PN2HSU#*><4U.%L:P*U]$+C3Z@)L>R)_ MZ=$?
2CJ&X:&-?[1W2%>HUNXJHJE7&V':\[I?[6\[%^TA_Z+>7I5NF5ISH:'$ M@DR#X23U0+77C_;%R-H=^2MIZ +AQ>Y=V%!9!?I>2&EV+]9!?P=<_@M02P,$ M% @ U8!G63N@%R>$!0 :@'T !D
!X;"]W;W)K&ULK5==3QPW%'WG5UB;*$VD[7Y"(20(- 4J4D1).E#U0?OS)T=*QY[M8GM8MK^^Y]HS X&%5%5?=F?L^WGNO<>>@Y5U7WU)%,1-I8T_')0AU/OCL<]* MJJ0?
V9H,=@KK*AGPZI9C7SN2>52J]'@VF;P>5U*9P=%!7+MP1P>V"5H9NG#" M-U4EW?J$M%T=#J:#;N%2+1:[,!R)K?+!5JXP(*F72O[QI<;BCL#=Y1&'6*LQBW,E1C/)4!GETX.Q*.):& M-7Z(J49M!*
<,%^4J..PJZ(6C]];F*Z6UD"87OX>2G#@W09JE6F@2Q]Y3\ ?C M $\L^Y:JR?)ZNP1JV_$!VM*Z<69R2G_7G^,"/LP9UV8)[,G#5Y1/1+5R5#, M)K/M)^S-^[3GT=[\1VD?(^T"'8M3Y3-M?>-(_'F\\,&A>?
[:!$/RLKW9"P_4 MOJ]E1H<#3(PG=TV#HQ?/IJ\G;Y,(8;O/8?LIZ_^Y=$];W1V)?V/X5NC%L[W9 M=/;V=L%13-9 "+J";C+R7M@BOM6-RTI,D:B=RDC8:QCG=95#015*LHO>%P>@
M;EW+Y%IFWQKE*!>U;KS0T%%:!46>!9H*&(IK\Q2%,Y68M'@F4/(;+501C(; M^)'X!*\+J:7A, JQ[,)?22^>B^GH#<9-Z\@<,7JT8*]J@7B[/HSAG5+6KD[C MZIS%)4#PX(4NZW>VJJ59_]3&
[E5D)&Q^^?F]18;B@URS\NP.^ KPD0^<31": MI _P9QJI]5J C(6"2>7 CTLUA:W/^!A$5)).=*-"WUGGVD%,@!P)AD55) ML:HJL)?*HLVU^DHP'$IIA+&!'T(,O8 3<2UU$U$R."";:*D!!SP9S.4A#)I'-K
M-BXKVZ#V(P!&X],-)*:I1Z9O 9;/G*][[$^ZRC"05VIIT "91$+'6<9&V-R% MU2KCVHX>;<6N]/^PW[)4&\5D6S+45B-P-GZRQR/,B$42MMX1.)?[6^=^:! M^5#94/8')=_Z[*EH-,KL8^Q-
U>BH_!%PG>!$$E\B@#_8WSJE:R!:8R-05AJK M[7(MICO?JM!SW/HL&TI'B2#0TMA.YPWQ>?/8J'*ITMQ3 M7]XT4MRT#Z/K7&T,]]M<$[=/\GN_ ;8Y2MLL2W[9XXF1=>3WL32-?:7LN)J-I M3S,U%-
E:C)6W7G=;0 ;$*U>!$4X);*SN[&YUV9E!6^.& N0" :Q!" _9=!B] M 6+?9"4K\?"W:$!\T03A9)JKGH_NL0_8Q$2F 4V"!Y1#?_O O,ICE6.B TH8W>HKHZ8178QBXTJRCZP4W1<;'
I\$(_&Y!C(@[EI3QQJLU" OIZ.Q+FJ%?P MPW2?)XSPV.&$@L)XUE">GM^ GG]WITOE> M.14"<0X%=WQO,;5;*FQ[4@ABC <(&1<'VVSJ&Q8(JT<1W:M*?%%S=6"#T ML&DK!(Y?
QMH\7JR6_.^ 1,J,O39M=A(\?EFCQ^M$"_M^CP*:+T_C. ;K<+ _:?T@&ULK59MC^(V$/[.KQCE M3J===*2*O!-@%)):]4RO=MFA1VP]559ED M8E<*]6 MR#+K5!9>Z/N)5S)>..N%/=O*U4(TNN
5;B6HIBR9?'W 0IR63N"<#Y[YX:C- M@;=:U.R .]2_U%M).Z]'R7B)E>*B HGYTED'=P^QL;<&OW(\J<$:C)*]$% , MYL=LZ?B&$!:8:H/ Z.L;;K H#!#^-IA.GU(XSAVD9<\4;D3Q&_T
M<>G,',@P9TVAG\7!!^ST3 Q>*@IEGW!J;>.I VFCM"@[9V)0\]K]9B]='@8. M, _^"0]@YA)9W&\BR?&2:K192G$ ::T(S"RO5>A,Y7IFB[+2DMYS\]&J=IK+! M##Z^4)D5*F!5!C_K(TK8-
%)BI>$S9WM><,U1+3Q-,8VGEW;X#RU^> %_#D^B MTD<%'LZL_W_Z>\2Ü)QR>"3^$5P%W6(\A\ET(_3"^@A?U"8@L7G0!;\M>V;X@ MX6L2;K/!"@"6_K_=*2[HR?[PEN46,WT8T/Z,
[5;,4EP[]3A3*;^BL/KP+$O_^ M"M^XYQM?0 \?"G8=?S:&[PO1F^/07%CSM#,O!N8GE BI*&O)%7F)',@4B402C;N]&5'"-Y9[0SE6'1TR[D\">1*,=*ZBEV,@2"Z:'=-Y# MD+AA-
#>+N3OQD]$C5ZEH*MU2928RJU(RI29GJ)4H4\X*J*7(FE2#8N:"S-U9 M,J?G) Y&9\V\TB1':8BGNFO]#J>11"X,?$]Y[$6 MTC8GRD+)*8@6%8(TG40-/&^"6TA(P'02CIY1-{)2T-
TL2YFE7QMN0IX)WX2W M)E R@\0/1ELI&PO=V]R:W-H965T"T^]'6F(]+-GKH2'L&=B>W0]!$%23 MU=V,^.AAD9)Z7_V>>^O!(KO9DC*S0((D5I/UN'4?YYY;57SS4%9W>JU4+1[S MK-
!OC]=UO7E]=J;CM#-LJQR6>-GM3K3FTK)A#OEV=ET/+XXRV5: M'+][P\"J=Z]*9LZ2POU2R5TD^>RVKY76?GP]GAR[!'\35?KFAZ3U^_/J3TW^.]4>C@;T=$K693E'?WX ME+P]'I- *E-Q32-
(_'.O/J@LHX$@QF]VS&,_)74,_W:C_\1KQUH64JL/9?8_ M:5*OWQY?'8M$+663U5_+A_]2=CUS&B\N,\W _+QY,V^GEL8@;79>Y[0P)\K0P M_\I'JX>@P]5XH,/4=IBRW&8BEO*CK.6[-
U7Y("IJC='H#UXJ]X9P:4%&^597 M>)NB7_WN?5FA1UJL])NS&N/1T[/8]GUO^DX'^EZ+SV51K[7XSR}12;?_&4;U MPDR=,_^G!P?\IC8C,1M'8C]>GA\8;^87-^/Q9@/C?52+6GQ,=9R5NJF4^-OM
M0M<5'.'O^Q9KQCX?/Q8%QVN]D;%Z>PSOUZJZ5\?O_ORGR<7XYH"DYU[2\T.C M/V&&@WWW2W8]$NV8XH.LJBW^$C(OFZ(6Y5+4:R4^E/E&%MO_T&+1MHU+1)RN M5>):+B-FLV@\N3[Z+
(M"_*4JF\W.L+[I570UO3[Z7M8R0Y3"#_C%Y$840+JX MIX^.*!=7T<7UM?C>67HM:89-5=ZG"627#L5ZJN1)+F\T6J9%G&XP^4)FLH@5 M-60YH#MQI[:B5E6N7Q_=&@D^-
DI\IR?/4JJX+8H&8W\J,(K2M?@LZZ8B30$$ M2!A2"N/F+U4:JX,VF(U'8R!+EE'S_N_I:#X6/V#X*E[3S!=H,1]-!PUU,CE% M"V>#5S#8:.8'*POU8TZ((288SV MH*E/IMW)6O?7<&]YGC
5^;Q/X;^P^)_51N9POD+<0LC9L*H_'S$T_5?3MU+ M\I;<&"&%7@>\(@SR8WV&%L"J/#2N)[>B3GC+_KHJZ*4FZ GAN&.7A5'O-C@ MQP59-1J/QS8>6N?>I;+I4+GE;'-8)\' M!)
38]-4M/!:U"7"5)!Z"YA412*1!(AF%>=LJ(DXH870&J?CFT^N*?^>W)Q& M8J'J!Z6*SG(I\G\=?0,VR^.)?)%$3+"T6ZW+..5?$=F^KA #2CTA.3G*2A6J MP@A-H56,Z>&:BRQ=\5!]+^39'Z!AXZB*O-
BLR+CXA8@P3J:T%DI66:K\[*J) M0, 2I7*:H,+?T%2\!AE*Q&(;SO&4LFGV!48' NLU%&SA:UF5>4^[DI 2_V6< MJXQ!753#:QF.M[(TA2HZ1,P@G\527YFM*24VUJDN8^'"7I,"G8<7P7P1TJ<2\S9-!7
M B@R$1N(IM>2 A=E"ZD^4Y*S"D)+LLC0*8#M8:TP?$4^#9,R]4$849W0:H=& M2TMF0[-QV*0[EE=%Q"X'U,H:>A*U"PS:NX7M-^N.GE,M (C2V %A 7G5;Q08 M*)C$+"CA>WF=\HD-
92'W)BM:1XD)M-EL8<5H&<-YSUK"K8H6CA'<^TZC%> MPBX.T!M0DVN,4'U8IYB5AG3OC< GP#]451B?FU$##ZZG;-E7\:DJKVIX>!2 M21>\UCV&R.$@F(&2H1/R
9(P&K+*KZ]:+8,&)DWL)WS*>T-O9>?H6$@F39-O_BE$4+G&YM$7HPV5.XG388%A-K9[Y_4OIV-DR.@ MM*E-R#^D8'B)0T*;S?MH$UH)9CS!"]M?C%/3GM+NB&?/SD_%%9N8/V(_$K
M*:WUN"X'XZ2\H5 @&V0(V7+X_7TBES'[\.[V;")GKAQ)GM$%0S6+?P:.Q544O\#R4(HP[[%EVBZ F(2> M%F@\'V.B'(%!VS%BI#IU)O\$66;<-K0G1FM41MT08'(8 QH2KFL8 MHEKWL0OYU/)]
C..'Z(%"V5GP?*7-D Q6$4E WE>4W!1Z-CLB H>F1AGC$(* MYB3K(Q023&WPK O6'#P5M+& Y2EWV0:@+ :96>F2J+9S?@.902#EA*FN64E@$J4 M07SXS7?A=AK@NQU_FUV0LEY(!')
[1F,O@,8J"*A"5!&S])_JZ'%2_9LA?H_ MKO^ J#8'B#^WO:>_R??9"T_STB7+A>9I/+&]LJ;1S);/N3?LB45TW)<5 MVQ84XW%(=5](LC' 0OG= A1G6:,/H24Z&+A5CQT5]/@E0+6+;2TJV)AIJ3H'
MC6E=-C6A$JOL8,08_W@E+N>_?QLJIQW,17=R6CEY6)"Y0HOX' 1T4?>T!16\ MM48T:OA2"O#-.QISV9#G!'3GJ=C842)GS%7)&]HTFJ0\2JP":EP]48NQF>"^
MP8K!.>I&*T;EE6;6O!@.J[2Q9[ANHRX(@)5J8ZLK#&W[_0,A.R0YGVK"T;[M?XD OT?VKP?!8:F-0WP/U6B!A/(8GQW2"45<(MM))GS$GU6M;2WDS&59"!]0 M\'&FS18MK@R[.NRN*N:31UO+?
SI,H,4 M\?9EUYWA4J+>S1RX.?;VYVTJ-N(']N@^-?]C,F448=):L^ G1T' M P:2,WF==/8)RHBK(M[R!*I+(*4<]UES)!GK2CI:;$>! *@YI3HHWO'/EV# MD,JY#EMF*9-
*#UA[FS9'EVU\0KN00TXI4Q4+!R4 Z"[TT9#CC\LWF5@INN_M M-V#U ;L*IJ)*HMS0VI2)>ZDYT^PY@F+L"/ ",\L[Q21(4L&7J8CSH2P,KF%4 M#36>!"C'*R:346'A5D#%Y[Y5P$)EH5@-935XI)"
;\2U48_]FV0APW>?VJQ0,-.*1T4JVG#*/D@U8[*3R0>OW5^+E"SPK9:UV;.ZA<$!S!$KBA]3NTKAE8V+CQ@0 M3=C7/Y19DR]2&=D--CJ"4397!ZI&TD3?Z@=9.,$-;-9I,IRU?\Z6GH,7VM
MAZ>5[=J&H\4"L8^(&WYTDL(*(?4P8;XR5K"%(-S [:T76MK]Q:+TD4Z'_WH MI^+4 D6RF\T"B7L[C/UETIT3Q$>L5*+-82=U:@_% 6&U.8[N[PA.I]/1I:M* M(KLZ$/XFKAVDN_U
1PXK;2>'8^N8KPS87=(\3[7VW)SQ';Z52W/CQXH!\RK4 MNJH?M?:/>6\'KR]@T-W[*B9-- 5R-0Q*;IWL7#3@ Q>ZHC%I*["'[@;,VB>1 M(T6,Q"/QQ'VA3T5[H61RW=W$4@S1G&U-
FAL8BV0P]S94$J04F=R[:SXOQ'EX M>>'$W@GX#D>+T7[B[@000A?B>/UK1053=\3)H1&GX8CA%9DO@DMGL6[TLEAB(@;F'0FAH+_+XN.1DZV_^?+/7 M%'Y&9!><0'J*DGXJ3<),W'
&OS>4AFG$R(G9U:BHL M>UL2*Y9EK<[P0L%[-^YC3 #&_C8;D/6:\HIN;F_J>@"IL43&W/G76 _/ M9:+X;*'UA0Z)]A>!+&'9"PQ\6M:Y%M6+J4=5Q2E="VEW(,E^["K\V&5#11$E MA("G4ZI8
'_H&"URE(L3*(7"]"JX0]9E_@P/X]$T?-WW7DO?834ZF2(S\MCL[U2_T!JOO6I03XD.5 MUG2M /DI:JF6N>^5E>8L%E4*GC6I7N<^BR^E+LBF6U>.=&]M8XL-+_)FPS@ZFQ5AL!0)
[TGR72^7L/PY$%V3D_P£$D. M+6W52'@JF;H[3GW=@^E;'M-3Ÿ)%0R3C 4Q42MT9FI-[>VM'Z(CX)V;?4[I)H M>P ,WO,L *?DQGO*W8'FV8'SP9/,\.Q.R=!.$Y?<<{(&X[AR&3&[2V+U6S M*
[87YNB^'-9"]JT6WO[DT9[I9RWT'J M.7#9#A/>3.@ -11Y1JGGT#Z31WKZSK3^9.{?FQTJ59[7M>S1D! [M*"[XS2 M7HE5D=V_J;\&H2[P'#UF+ M)XX1 PVE]!AF 7\NTLP]Y1[T9Y05(:5M64*L3L
MD!#382%FE]%D.AT4XN?>'?^NPY!?!9/*%=AX0BHEOH,15ZI+.Y]"+5=1[YDR M9!)[/RMY"A [IT]>!Z;:OAI==ZKM?@*5=3!TNVWC[H^0&J/Y_#R:7%\-W@SK
M^'KWSL.@&EO%'2X6>!V((<_H@^/'7>;>?VP]-L4G>S,Y6=MNL MGP0W8PY8W-0.9I3GE@Z7?VS1<&NJHX[[A:>.PY2[N7N'IGVUX\H1]/*\N.'T7 M18;(#W\Y]O)UW#.PGFU\(5\W?1VPR!E+_ UU%?
SMU:KE<]AA]B3<;7Y'CTP=5L M:*SNUM_L8L;_FT23RSFQF.NQV/=9Y5GPI2L?:M#WO!1>D,I\],J?^D^&;|V7 MLFUS\[WQ9X!T6M 5[R6ZCD>?\V.#)NY'76[XN]E%6:/$X3_72@)7J '>+TMX
ME/U!$ @/J=_]'U!+ P04 " #5@&=9SUDKIP$/ #4+ &0 'AL+W=O MY?@?%N,\Z,(NME6XZ3S"C. MILU.|Y@XV7[H=#H0"4EH2((!23O*K^^Y%P ?,J4X[>[LKB4*N" _'X<' _5Z4]*#
MTQ?/'XM8K625E! -W=^4U^>,Z$4F*?C_XLZMO;@\%E%5E";UFR%! MJC/W5W[S=FAMF(_V;)CX#1.6VS%B*5_)4KYX9LV=L+0:U.@#]J[((9S.Z%!N M2HM?:?:5+Z!-(I?
&2K+10/Q=1V3P;"UD%HOWY499L;!69FN%DRB+9Z.D83/8PN!1O359N"O%;%JNXN_\4PM823X+$+R<'"=ZH?"BFHX&8C":S M _2FM06F3&^ZA]Y[NY:9_LX&$- C,]'5P>T
MF]7:SOU]_S/.IS"#!6@H?I*)^*AN558IL;(F%5%[<|%;R B@48@[9960A5AA MC;DKQ(G.1+DQ58%5Q>.G1Y[V5JG@8.]J=F?]\1+Y!#C(5]:>CSY_$]BT>_ MS"'CR9687(RQJD*
<7\Z/KG6>R'HJZ?!*PR/TLG*.5!.87M"_X &(_COZ9$HX MDGVH.9S8YW,2>SH8C^C#Q6PPGI+\T[/!Q>A, 'O?/ZSX(C45G4 $VA!0F%7- MW:K{K!$(*H:YK7@KLVH%CZXL'>1-
$$%R2)BXBDIQ(Q,|*8V J6@+#EKDRFH3 M%R)W8:/B(=OLX7S?J6_ED[^J3'Q)-/\ZE67=>_ #8/8#,GS.-/Z*3W!%F2L< M2E3TGaXXV3<9&.0([B4|=S(:SP=,,]]JDN=Q -/XZO%
Y)4M*HDMX':WT=&&9- % M[%?D9-5EXBS@F<:@DV7&Z;&@DE, M/FUO96'$]PJOAN)#BSE)W"=]UT@X5@5;X(0$G/TOPIJM3,JM@/89L$;'O@,W M:'.!W5]AFS<[?
+U#$8DY)FI=8JL*+JKVT21Y9;T<)HPV*.%VX)3MREL"PG#2 M$I<-"Q9J4:U1B4FD\8\]@7^_6?0=6'MKS\FEG9#CR*_R/-G2-XZR06#8LJGK M1FLYC[1YD-HJI)5I(ŝ^%I,N5R&PPY%#U9$N+>
M8?F?6!I\30I5XG^N$'W5X2/[$AF'?QU?=2LF9^;)Q6 T)YD&D_%<7)P-II-S M<38:7)Z-^\H$>/]*/T_',Q((LLXO2=;9Y6 Z.\>G^?G@#!]^OAS4LLJB,,@1 ME#?K:.E3>4AIE4@P J)MJJ233'BKCXB&+-
Q,9\B4,0<,)>ENUKM0MRKQS1?LI&/E2S!EP=]J8\ M%_ GT\L <}{U&'E@HT;R6J(:)>0J'8X:\#29PI!K,@FT04WA&*(30< MBH4GHV*7!Y'V4G*:L(&<0,-'R:XE$D6=S:=CPNL(IY,J@Y3('=(FFDX %("H
M8>+'S!K>08>OY[_P/R9NH/U984^%:.9))L.3.%S"63 ;)41"F'*F]Y9YYL M09OIDA3,[$0_)F61P&YU3"G*@)0*9JB3>2D2)2G/ST3]\H:F%'6GI%?#9. M)$1CN<%Z$(V-(X@8*39$DA?
4%H&H)QKLVXQZY "AFOUL_E#V;:(_D,-%Q&[= MDJ#(GI*1/R<."#3R?G;GPWWW]3=PA^==W-%:/WJJA>>$*186J;+$FHG$T+9 M9QQ%221#$T"L=B1+]_Q[BJ7,OM@J+Z.M6XK(QSKZ
MYKS/I8Q<6BK9'56CB'*<1Y=E.U.E)B8I/"2#N5(C*Y2V6YU>[TPD&@L"':L8MM&&*(73^+8+DB/#=15$$#](@]WD!G:K4B<.;)=>0WSGH0,%HZWFQ&XWIQ0W8IR%-
Q7[X($*^*%S5KQ$XU51R MNO_ "5@M=B17=V01&%/*I<]M 9R '9%BI'4Z?9=$V9L%, K:P'#6&\[0][#A MI!>(,:[FFK/"=J=*R!-4)B^'9R+524+281'!&X.#CVI2QNR^#^+H51QM0I1:I/ MBUU)
0^&TYJ4UZ8%NB%:AY MI@(T7I)KITO>7Q?L+N.ZD^PO877R?X#H![GN+6A.X3+@&4UUG)!CI',NXY%$ M\EHQH(,%;DF;3O7P+;MY8P#@0&C-MPH&?W]L&*W\6-,D,QRTO7\"$8N&N&.
MKDFXUUA=#S 6CB^)|=$%$7]^JX!$N3"{&'OKXRY@3(?G>O7VXPG6^^A

S:+BI=N2_'M3L@D_P2P^>Q&/T;\ VJ4D5!M^ M"DZ%JA'<=,OXRI#<5Z5>,6]I>&. ["#+TQ7!C>2A8B<*>KQ)9QA-;CZ,,O,: MI!\I?'@1#G2@CO^V.C"R7>5NDU1 ^=YE;YZAE'.W2CWPY\(/]Q+C-JTS_!T@ M4]75P,%%,I-V4N)1X-8:TB!<3=L:!W@1X6B6(RD,,NL[=C6.&)SM1&P'>3+=P MQ_BGE;>ZX3'0,P209O-"0! *'/`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{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{0HRN0NA9]CXTR"-2D'T[T A"Z M;1-T<'I8-'UB)([J[AJ0#\,6K'XP^2>8A;9!+E!DDH 2HD'\0J MII34H(LLU5/M2LSNNH,[AV#D&F,+C0BYM9I@WM5\DI6W0'1@1RKZ8$0" @ M* LE$-$OP%N [A6^G@\29KL@Z#(OZ"9H=(4NTHCI!CH3B^$.]EQ$I&CR^)5$ MGT!O *%E08?R_(BE=OCN_VY=. M9%|+E-RGUJFC:,P"3BDK0 D?05PWY{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{[X?,Q.V# MF9!;]NN1!&2UA]_79$@("(AAR#S=!]E/&:TWP[T7%T<40]V\AHJC1D)"_ M:J*,DP^7R,>H6ZP3?>"ASU5E; ?)!=E[?B$/ /IX#?Q2'21UFWR2A%G7%T) M"XAD(LQB5!;6T$BF8A5;+WT8L.!5,9F/W(D)'%X34PYHXWEE5&T7+2UTXHC.U M4.A#B]CWH9_LN4GDNTSV0;D0WX&\1'M2/D)]4R1EPY:JB21.J=3'QYA5:+ % MV=ZL"[C/]SA3),.#C++ \4L* %##/O: ^P&K&22Z'_3)?^1_QB,_JRA>TA3DN MV<_%D%BUA&_E#%6]34NIEJ*X$P"FSE&LEDU7D\..LZ(UY.Ü#EBN0P!O.R =* MOPFA.*3>9!+XO+]^Z!<.$]5H]0,XXR9'S$5=^PP2C,,<=:56/YF>1D!VZDOP4?:W$X(CI&;X,*368&]'6V M_KR,7QTD+,M7#Q>HJ7H^;,,YZ9*^U3\ H)N/TZ1E<(X$*:,XO*X:\H7+AC"[L#'.G@KWGW>?YWQV<98 ML5[*)HZAGU09(!*5 ^MLU]X^+$}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|HL5\L?FVIYPZX60E&*DVR(G-L*!,KGB*H2B+WL4$W< M%S/U'B1,0D6AD-TPBR6N8N'ZVQ4B$E=2+<+997NZ[=L0=WZ^ ^^@.L>BI>]52 MRC+4X&?DCOSS5SB/@%$@'M?_KJYP"&K[_JM9&AD/-?DT>GB^>/G\,/9)+IZ=/ MX8>3,_C5H\?PT[-GBZ=G)U_YP"%&?,^>PI//DD>/GR;/CI]]%5@H1F=/GRZ. MG^$&%]GZ<_)^I_]$!SD- 6U,9%:&T=I-',%,'=J^3QW<#FFD!M1'^P3:DYO(>@&'Y[XN+C!(;IEF,VPW4R)C[!%1](9VPKW8>MG\I8**JG_RDQ M2Z!'1(01T-BLF0_O1RF5@&5@31>U_#R4?RF4;JE[R "&U (]VR!2R$!+)X_MPQ|>/UD\>7R"1/)H<5\Y*M!0MCITY/D[-'3Y,GS9X+?ZSM]/OK:(T#]1_RU M\Y\?|=>>'C^*=!%.EVJLX:VM%!+J18;12<8XH:YB>9).IS[31"GV1(;0)0]X& M%\4>YY "+ZV3$^$@ELKFY9U\;MM3D?KJ%$T6;6C;%E:=RM,S\"T6=%XTX:E?1RW9+C2Y#%BE7?[:F MR'N(.!J64, <$60TC7SF:9_N0M[@NQN$=353]W$<]DSD=\R12/ MLA&,.+O-0GGH$+C-N]+S2J=QOI'U^JX<\QS8C?A21\OO5> ^]S5;GVG3Z//++ M(O^(S5!D$>ZT1.[?NW7/X6P(:2#3ZQHC*3(A=RQ B?LZW26NQ^&Cl;/"? M;QG*-#VE+?1]"99V*M8 AHW-B+K?+&9C#OX^0#,<)06VN<0FL7X1356G3),9M+|+G!4&YYSSQ_UT7N@*!V,L)NI$1UHII@TU9$.NO9@-68[T/,*#&K/S?)C7 M;VSD?HK_J)?_2(E%36EM&]8+@> _Z2)''5%ZJ"=!.?85&B>QGPN84A:USO0I M)3Q3'(0[KU111OXS[MDUAISGY4&P::.I.H>H%7."FUU='W5YO::2YC\]/[46R M6+'T-N),9QJR!^F&9CEP&*%V,COS[#O5^7XDI>L2E*Y1#ORYBYC:@(%2YUFM M^M86"8&#,]&T\[Y->X&+NG(I=9$AH[X^%Z[PO"B2,%I,CPU@N"+X MHZE88UX5PF7CLR V'09-4W- T)G!6K/?3OXL[1SW#,DHN+I$..5U2+JB'S M;V1MGDFQL1SZ]/CDR2Q_"$,+3^9G#^H%:Z_94>[P>4M\5MW0R]CZT<4P8NA M2?TL=UE,L!9AnV-4?3LU_2L1XYUA%?-2Z_J;S-"]>:?PN"PD_9]&8A6P\}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{PD_ORO MA.2-D4%@8V/MI(5KIMD.Q%DEV.)%I2#=I@*6868'>)]YE|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{Y9_4U1W^$'=^->5S)+86&MN2Q'%6)E*2R[%]X=TY\@DL'>*$ M 3YV7B@VVJ"PU=)&2"R3[TV]?C'D3KB//N[U^HZC(H&Z M-S"81#-*5J!\IZ:H*IY4.[:[J8 -,\ ),RU#0YFV]U3< TMLV]&LW3&*Q-8M MUO5I0C0BZWCG;F209%KGC0^\Z:.'5#EOLJM)%V9U,XTAF7GOP01"6RSV/6-[M*,Q\6WK>3[Q[6T&MKT8.T9+8-6=G>0$]^.KD$(8TRD5$>[W96YIV008S.QA0 MNQ[PK@DN)1/2162J+NY3P,)8A5V5X6@Y95. N/2;1>0HZL-SK#];'Y,G.!*< M1[F76FF24 6=5I0 0XS)O;QD/;7@M1K0:+=H3,'Z&($5$1[X7BFV.% M_"T6D/&H5O0;JQV)SK)2G%(: /7&[FQ:^6DH03F=+'T+'XJ'PB3Z6W3S)BC+,XK M'U\V4BAB[A6X:5]Q'}7_7"XZ1Z3R)=[JCA1"_ :UD=$0/AG'FC=U(U (DM+-A MGX[T]8=_%NG:\#O402E[Q9JQ/.F^*]?:*;0.WDCVX#1KC II=G>T8[1 PZ 5 M:7PGLLRG6ZF*P!-'X1QO)6W-G$Q^XZUW9,OF)4X6H,1Y&2^13JC81I49WK4II\XCV>#++<:$EW" G[/9M/*-0OBAX7_<\.#V M02I6.P:+EM+>>DS6;2HI1!820*D2+&Y=V3.-@Q%U^[IF8K/?$25L&'B+K].V(}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

*M[^40_P]@L !D !X;"]W;W)K&ULK59=;]HP M%/TK5E95K;0U7Q!""T@M[%NE54*EW1ZF/9CD E83;[_=;/_]:"=-882L2'DA MMG//R3G7U^8,.HP_BQ6 1"]I0L706DF97=JVB%:08G'!,J#]S8+O%$LUY4M;.M9!QP;$!I8GN.$]@!)M0:#&;@Y6A$D$$E.@=5C#6-($LVD=/PI2:WJFQIX/7YCOS7FE9DY%C!FR4\2 MR]70"BT4PP+GB7O@FV!0&NIJOH@EPORB31GK6"C*A61!"58*4D*+)WXI$!$% M<#L' %X\)#X*\$N ;XP6RHRM"99X .!L@!B.5FQZ8')CT,H-H7H;0Y*KMT3A-MY.B& <84@="G0%S0K]A*0!1!GSE_5,KI.64ZE7MH*/9N Q^0Y5YBGV02=G9RC M$T0H>ERQ7& .BX$ME3C]"3L]A=P40KP#0F;072#?`>8P\Q~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{K*Q,W)0"DM<4G7/-U^AYAD8OX13 M:? 1IF[K.2@IL>)Y+=8)2LQ2&;,E*1S0= MN4D=9U+%\?2$F4 O@0+O, .(IO]kBW;+9Y!H>< *e]I=R5Z=N1L=0I\>W?L% MOX5",R(3RF4I{A)\64@E]*?WJPVM\NJW>YGI>"4+G,#8T?-.@EB#$Y\<]4+O MN@WT/YF]P@X. [*#+/;X'_]3$.;5[WD3D\HBM!9FK5C'7N2N=Q$Z.SD0H=\@ M]/&L1=.I!6^I*.>A(W>E[8.I!DWPKP1]A6^K!N]1^X.G?F^B=Y@=&#YOH86?T M!ZXP184@+'"&%*>&M7NO5ZQH0?@RGL\,# <88-SK 3O\]V(F6)60(HX,*=9/B. MY SW!I=O0#][I.A!DU(",/O!>4H-S_XU8OIPD& AMGH51SCG)5-M,*`W M$|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}AY+/0S%$Z&,? <M+]-R% 6&K0QC/^20RO59DGL4L[I&? MN>5O'/(CF%*M"7^KBO22^? B)R@LROAP2?^O[Y.O+C+Q_]X'$Y!T9$;6FDIF^ M2;HQ/Q:K"O)X!M.[Z9NC6_R%Y2 ^MD.Z/^5(E$#$]07(58 M*]Y!2%",9F!Q@X.C76@P-]5E ;Y.DW_\&1]0)\U2]<^>43Z4:)?]\,9# _Z)R M&K&[,A@Q>0K&IS_\0_>=/RG/EXQP6:88'-.L!)K./O9E48(Y(T<8@YF#DF6(@&$M>UP4G.X<>KM4.0IA $(4]&W M(U1'IRHYU*+ "38KP.XLF$G+7N_%V/O=O3:YN^41B'2L#]\ M3&M>)ID%>#D7R/BZ<2.=R@0DVPP2;8X%?&& =;]]t;]0X^(5)K>88# ,L#DF M6(=@M0S'WNN;WVKEVGR7/(IY#IDU3462ZCU.GPK6+8H+ .2K!RS7ZP;C\M^ $ M3VX9(@VPP\9 S<,-.? Y>E..7/I0(3;'9L8I"VDW&5\TS[EA3F;$(DL Z)WKC9 MYHZ=L,V8906L*)Y!O^.R -LNF'.I1.5,5:A>5XWI$#Y:F=AH?8:8]%UB6O5 M)[S_28:IACV;2$RT685V),E$[3/$0NO2Z#&G:#PZ. [P;$[.]SA'[3'$0NL2TA17/.?>'M95IEA4F+KN-M:90$>PH*]BA!K9J01(SF3$63X=-4?.MJD]TZY9^O(M@EQ+.4L/LE"[G]%V&6&A=3IKZAN+^.BZ02UXH*+- M*K3K3F9P<[W+'VHM PNMRU]3S2"HE8J3^IRC M|AEBH75Y:.H0GKL,9!0S<'O1:0 X";.\2(MM.L>8!X+4*C5!U2T.2I: MB(76Y;.I8WCN_2YG89B+6A5AOO(KHL:R@'4=NO(MK_WIXG.&6+%#+1V]AH(19: M!W2ZJ6#X[@K&%O;S -+>G[E684Y!*?; N=02N*O),R_+/9>_9-FKU.A5MCHH6 M8]%U[6U]'+Z[OM&F]H3$OT+K9.$[!]+=X=G48;+ 4-%"++0N=4U=PW27-5YX M|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z*3Z@ M>[,>>RE%O5D9%6VB9C9!10NOT+JT-X= -@8]J0/.T!'5+09*MH<%NO2 MW!H.W7V$=L#H66ZI(LZG%??P<]5Y2O0 -E0W ?0@_U4? >\IL)*W4>LM%RF3*_L^$E/V M-DK*%U[4O\;O//EHW_0Q:IJ7+TSY1.6PRXV84L0'5],QDR:!G!]*<"]5U],!_6;8,[_#5!+ P04 " #5@&=9*2" M1P,* #<= &0 'AL+W=O>VDYN/)/TC6TJ9DQ^K*,YN!\L\7W\=#K/94J2"(#)9 MRUB]LTC259"KS?1MF*U3&TKO;I)`H6Q?$!) MMEFM@O3S04,)Q^W `FQ?> (?EGQOPO#N9AV\R1>9_[Y^2M76L*',PY6,LS") M22H7MX-[^ZOP)D5 ^8E_AO(CVWE.B]_RFB1_%!N:\N]5=1(1G*6%XA /,$+ M8]RRB@]3]\6<`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|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

>&PO=V]R:W-H965T3GC36DCBSG1;^ >PDI+?,0,6^M'"B\ IY-M3XYC>[2D[#=/ 01ZR+.*CXU4B/+$'F<0H[Y,2VAD$\2RG(L9)/-35XRP+,Z
M*],Q((&9HY)842C^MXUBT:T$ADIX)HA7N4Y9H]GD-'EV!+"]QLW9)X*=<,. M1B6>PQ3$77G-9,OL5&8DAX(36B-&R=@XM4\FMJ<"ZA{?""$YVC525NXL -T:-M%[.Q82DBR" 62@+!+OP5,
(,N4DN3XTXH:W9@!>FCI9N2*%>XU0P^93(M.!% :)X3(=^+!X @7,S2AA2#%'(J8 $=':"KK9E9E@&B'/E>B8H"N2$'R*D=? MDX3$@$YEU#=(22P[78+,*+K&CXW@X3D(3+
(/4N=N>HX.#SZ@ T0*=)O2BLO1 M^.@4TH,B,>.6]ZSA=?!.X7R&+G61^18CM<3/M&'GT.LP^TZW-T,-V7FNOO1 M?2[<6LJ!0?I.=!+WU)V1Q<'G'GTM@6%E'&6] CZBC.!|DA'QV&>
[T1K46NHSLXAL MSQ^&(W.Q[F>WE^]Z|TX;G%[*Z6DY;5.R]M-73E\EJ1UF3QO-! M9R+0FO@!F"%{GSS8(7=M/]A"UXKOB1YVZ,'SZ$X?>KB#[OC!< M=*[XG^K!#
M'SZ/[O;A#WO0/6L+72N^)([IMK99VZWGXWF)O S?HK7"[9O3R^^^*O[4QL+?YM M"G)CF@A@O1;LW0D,./V!>T0^UI8[0YL[.H;W5*!LUYZ9X?>#L/!]AJHE]\7 M?
[6]V_IE_:*0R0VZ'HA_SM9[.M4V\.D%=838G!9? B92WC@.98M8<2I[&H&6]K[^G0IX2ZLM4 M'N2 J0[R>4*!>&]HHTW-(S^ E!+ P04 " #5@&=0RFKL"*L# ?$@ M&0
'AL+W=O2K)L{0!3%^R-)4!\7^H\.M)(!)3G="?E0; $WV><;5S-MH75SYODHVD%-U*0K@^&8E9&XU%N7:5X4$FI;B M//.C(!GZ.67!6'/2.H:_S%8*=.[HD)Y4&(CZ9P
MF\Z\P'P19)!H8T'Q\@@+R#+CA-_Q7VWJ-6T:X>G]P2V7,G@,YH$J6(CL;Y;J-MSR2%%=UF^H/8_0IU0./CEXA,E;]D5]4=C#R2;)46>2W&+\@9KZYT7X,X
M$;!/MR"]!=&?"GIUH/>E@GXMZ)=DJE!*#C'5=#Z58D>D]8UNJY;$6:HQ2.9 MOR^UQ+<,=7I^RQ.1 _F3[D&1G\AUFC+3'S0CM[P.5;9W+F+0E&5OL,;]B87 MW[^9^AL-
QY^4K=T4[44O=!22-X+KC>*O.4II!WZA5W?>TT?V_43B]V';@VZ-MZ(#^N)K(-_K.EEZ07_$BB(.IWQ6.7+Z&PRN.OEK>BZ34#H5?Z]5[P^Z, B9W-_MU^2=4(HL)1/. !V5*.* /,.Y-
;#;GZMZOC*^M^M[5)75>]H-G,/.Q-"N0C M>/,?O@N'P<]=V%R:O8[,6DC[#=*^S?TPMS3=$]ACHE;0Q<[]<2Z[RFQ8FIF4 M_S@/> @7$ 13__$42T>]23-ZK=>*>-|$/+!& :U@C*1ET'C>
)R016A! =7 M EQWI@VKY;D-7)K%E=GXA%)P&87=B(8-HJ$5T3V7D(@U9_]#2MAQA#"N 3]) M$\I3Q(496# 07;RL_N:?R/5[1F M.6 6-/S_^O<)%H-SB7ERIV-ZF3Q'7YM?
AL..O%9_V*!TNWV)5;F^MQ7O!;U\BO3&>[UCZ3G2[T7;E5E/R3'74,3"B2 MB"W7U>.Z>=[W[_6+TZ,GE/Y9IQ13)8H32X'.&J4E:G$55!BZ+&ULK5;..N,V$/V5@;HH M$["
(9,F)C=06D%O1%)M%L.&V#T4?:&EL$6+L/9H\H5NG. *'PW81DIF]M^]Z9O2B/%.MS3;XA.Y3_6AH%OH+_<*#*Z7*=7D\E;NSX<#OW/"$KK3-[R7VY MC!)O$-@6]OB#0KA@.!"T+!=
MQ([L\&AQT>F\.76FK^BG6SAY=SIB8-9[.0NXV7=Z&?Y\3R?@WJ&T M?PV8>=W"38?A?&5?VIH5N(RH=*V:+4;YCS],+I*?ASC_3V OF$[IYM,Q\/P] M.H?&@EY#89
2"RP6#8U@M8>"V0H]%*7/)+M#"\<,958:\N=-GL|\T(WR@WY M.%3O6WW4@DV2@..OOFV>G.T6\7:_^WG/_7R4^X=&KM!XZG4CI(H,?P8\)"?L M*EY4L
(-4]V1]>GQIVC^7K<;SX_.G&2]E2Y54;/^8[#O>LH7WP@W7:E $9> MSZZ[[<7)=#:&;!WAK"<+!)#W$:.!W\]M!9N_H)9D7W&+C]@1++,)KP,+X0)L.V* YC[MKD+?C?
\]WKY>'IC9<&6)W9I$Z2:@HC+MBZ"=.%V'IKK2CEIT&%;TB$+C#]#^ M6FMWF'@% ,.L P=02P,$% @ U8!G6:[1=@)L.P "!8 T !X,"]S
M='EL97,N>&ULW5C=;MHP%'Z5*%VG5IH.0D8@*R!M2)4F;5.E]F)WE2$.6')^ MY[@.>KGGV5/M2>9CAR10'T1[L9.!VMCG\ G,=XY/$K?#4]XYO5E0*IU5RK-R
MY"ZD+#YX7CE.T)24%WE!.X4DN4B)5%.Q\|"4!*7X)RK|OIA%Y*6...A)DR MO4IEZUM22U&._M41CYX*!TlV2+$4>69%5MFQOA@CCW.U;GEBOFZ-NC=M[^'72'^MV#2KVGT)K8
M]]IW/$SRK.GBP#4&%9FDU+DC?.1."&=3P< K(2GC:V/N@F&6\UPX4MT^2HH/ MEO+!P+Z0P9U5\:0LRX6.;2*8W]-]^0ZPF8% OGDML.L.PWA8$"FIR*[41" 6 MQD>04XUOUX52.!=D[7=
[;N.@+RK(-!E2B23<^@4>BUHPE9ZODJ[1B[C[.3HN#KCYS-LY2.Y \. M.!Z2C9^SR 5[4-&@56;*0(7KW%,AV:QM^2E(<4M7,2Y95LP6+
M8$YH].AD]>DFFZL -+7ZU/]8)67)Y6X,CMQE !3%,IE&|ZAH*4;UIQE\@/3^L MS_T]%LMBNJ+QI])I*^50/'3504:L/,.PB5 IC1S ?@]D1P+ XF +,QWAALOL$ >PJ|@V[@W$DBC $>M'>HV&
(5"'>$KWU_L+LD"*+(C@!F M5Q $&)W(XY@"D #A@2!?@ NO(^\S7O*: [W_.X+t4$L#!!0 (-6 9UF7 MBKL.8?20$3;8T.P6BP^0"X09K>]9!:G6QM3W+6.\0>3ZZY;O9E.?
76M6NG MBMEPIZE=.WL MPD=W.?4KIV3MKY7]VF:.[. GTU9J.WGW]O%<9VY*/]A.59VV)FP<.GS7ZM8 M[O\"BAOMJ:5N='= .,!G?.VHB6FUT]W^K^F"R/Q''^VM[^8YW^;4TGF /*V.8Y
MF.S6.[XUW^GJ/YO/\@+>>G'+9V\ "8#R,$DWP]G7&KGN &(\?PR-ZH/% MF7+CUX?I\$3[JK& ^=XH@E@"QY$4\.5[7RHD+)^O04XM#YZ2Y&OJ>SA/"!2!< M\!*>*%)YO1JV"
[L41[W71GD -=NOG^HKVX_NH{!]GOM9]$[{D]-T02N-E]:=D MH&68-7-[;I3O_KRH_^24&;.4#JO*]H%'2%.5TC=R ./5G-&22&;.*AFB9+N1. M*HH6\L:.61PA&UR%7.U^GYK=QWZD].0
M;9JK@4.<4DRDC!FS.\(MY_H@B?=WJT$=GN >]\Y13"2.&;.UC]QS]C9TQM'= MAQPO8Y;$<1@M.FDPC4R3.ICBV.1M<.L3NS*FE M[I"]=B&N*MR6D5H2I);$62VGIK*M$A?
R+F0"0DF8A0)SOFB.F$@KS5F >&V.BLMZ>+ZNE .))@YLV@TAA'$[FE MSNP.F#2*5[20C723.NL&YSZT.)LB\Z3.YL&8&<5$YDF9S8.QAW/7/>V04F2AE.E" . JB|$9^ ?A?!0362AE
MME", ^1##T4A#UT3+9BFR4.IL(8@9=>\ILE#Z@L.<&'.T/<5$%D]9+43!<*D^ M0Q:*F"VT.6!&FA+.%1!:*7F# ^Y7%LMC4:=GR$(9LX6VE! >;U.*B2R4.5L(EQ!H23!#%LJ8+80Q:?:>
(0ME 4W M44.F(E](@"^7.%B*5C]#TOFVENQ\3# ^G]H2\^1A7)F"\68RF@[%# ^"05VGXPPI1Q.*7ZX*MR<<^Z 18 MKL2Q4Z'#
EG%44362AGME",*8T1X>)1$;K]5GLZ.97#56?.%MIZ.QZUD46 MRI&%HDL5#):%.*F#2*5[20C723.NL&YSZT.)LB\Z3.YL&8&<5$YDF9S8.QAW/7/>V04F2AE.E" . JB|$9^ ?A?!0362AE
0MLQHY:..+%2R/X*#.*.6CBQ4LH^%$&.4TN%S..QC M(809M71DH?+%5B>.E%7.)&%%NRK$Y!7A6^8#.28 MR$(+9@N=)Y=> >.['#NG]S7KQ.$6EF.A"B]%"T %@ ^YMK9:.]/!+ ^ D?ME>R
MJ=%GV37.&PO7W)E;'.O=V]R:V)O;VLN>&UL+G)E;'/ MVKUNHT 81N%;L;B X/F?6<6IMDF[R@U8SMB.8AL+6&URJVLYA7W0%MM$O!4.
M$!^G>H1@'G 5PWI\ZT[# NT\+#Z.A].P;O;C>/(1ML-F?X_KX:$[U]/ERK,K MC^QOLNQW[.7F]>5 O:FN7R]CV]S..I\?IF8N7SW/JGXG==ONVJ3^[S>]C/8W M&-S^Z?
KW85_KV"O>UOVNCINF 3C<3@ M]6 >+1..O?/KINF?7TW3SAUD$63G M#W((03Y^8,"@L+\01%!1D!O2[VM M@.Z6>EL!O>WD95M ,TN!K8#>EGL .TM].8">EOI.07TMM3,"NAM[.<5T-
M2 M;RN@MZ/>3D!O1[V=@-Z >CL!O=WD8XF WHYZ.P&]"25V GH[ZNT$']4VPGH M[.BW$]#.46\GH+>GWEY .T']O8#>GCI[.T!]?8">OO)OVX!O3WU@>IZ>^KM M!?3VU-L+Z.VIMQ?
0VU-O+Z!WH.Y!0.] O8. WH%Z!P&] 4. GH'ZAT$] Z3 MGY4">@?J'03T#M0[".@=]'<0T#M0[R"@=Z3>44#O2+VC@-Z1>DBWDE [T2]DX#>B7HG M.;T3]4X">B?JG03T3M0["B=]'<2T#M-
@L*Z)VH=Q+0.U'O)*!WIMY90.], MQ;. WIEZ9P&], 7. GIGZIT%[.[4.POHG:EW%M [4^\LH'>>>,/86T#M3[RR@ M=Z'>14#O0KV+@-Z%>A^OM\=?EU]D).U>DO4$L#!!0 (-6 9UF, MQ2:?3@(
"'VI23;.>XLIW<4JWLZWN;R>MK MG3723&.P8UN%@[/<62W]4.25I\A6223>.F<;.WR>KC:>.Q:Y/4\]OW31WB M>O8XMK^3?GAKV=
WW>ROXH8D>S/AN/+G@.=S7Q^MU"U_I(>[* M#GWFPU-O?7]^Q!LJ3MMMU]AV:AZ&>"3ULI-UZW?6AJ%/3T6OSB>'>,A\]\E?MG+ ^4.1<8=]ZY:?9O8LZ^/^YE),?3ZSD6LBYTYU_Q-
3&6OOC]["::K6W .CM> M[X_]\9=Y^&QY7'['O\[XM?X[^Q"0/B2D#P7[HX#TH2%]E) ^#*2/"M)'?DUI MA"]J3B$UIYB;4U# *:KF%%9SB]LY!=:.<([N@R"HHL@]*K((B]Z#(*BBR"HJL
M@B*KH,@]*+)*BJR2(JNDR"HILD]*K)(BJZ3(*BFR2HILDB*KHLBJ*+(JB]R* M(JNBR*HHLBJ*K(HBJZ+(JBBR%A19"XJL!476@BJK09&UH,A:4&0M*+(6%%D+ MBJR:(JNFR*HILF]*K)HBJZ;
(JBFR:HJLFB*KILA:4F0M*;*6%%E+BJPE1=;2 M(FM)D;6DR%I29"TILAJ*K(8BJZ'(;BBR&HJLAB*KH;.X K @ $0 M @ &O 9&JC4'}O<';O8V]R92YX;6Q02P$"% ,4 " #5@&=9 MF5R<(O & "<)P
$P @ ', 0 >&PO=&AE;64O=&AE;64Q M+GAM;%!+ 0(4 Q0 (-6 9UEFL<^.S@4 -T> 8 " M@0T(!X,"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ U8!G6&PO=V]R:W-H965T&UL4$L! A0#
M% @ U8!G664>.5 F% <2H! !@ ("!M"4 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ U8!G6?O@^5PO M!P @1@ !@ ("!Y$D 'AL+W=O&UL4$L! A0#% @ U8!G M69AI P:V"@ ;AL !D
("!F7D 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ U8!G68V_+;F(! LPH M !D ("!^9 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ U8!G63R8_6_P + @ !D M ("!#;
'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ U8!G6<^Z?>3,"0 'B, !D ("!Y<4 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ U8!G692$ MQ4 X!P TA0 !D ("!F H
'AL+W=O&PO=V]R:W-H965T!R":3P4 #$, 9 " @3G^ !X,"]W;W)K&UL4$L! A0#% @ U8!G65;;A A,/@ =.. !D M ("!OP,! 'AL+W=O&PO M=V]R:W-H965T[+ , M -L 6 9 "@>O&
0!X,"]W;W)K&UL4$L! A0#% @ U8!G61K83Z.N! PL !D ("! M3TH! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ U8!G62)D^DD?! B@D !D ("!.54! 'AL+W=O&PO=V]R:W-H965TQP@4
%P6 9 " @8QL 0!X,"]W;W)K&UL4$L! A0#% @ U8!G65;O% \>!0 .0X !D M ("!A7(! 'AL+W=O&PO=V]R M.W-H965T&UL M4$L! A0#% @ U8!G60M,> +.@"0 P'$!D ("!O88! M
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MU8!G6>C0 DY[!0 TB4 !D ("!2I@! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ U8!G69XO Q>= P M$@L !D ("!7Z&PO=V]R:W-
H965TN 0!X,"]W;W)K&UL4$L! A0#% @ U8!G6>L&9M5W P WPT !D M ("!GK0! 'AL+W=O&PO=V]R:W-H M965T]\ 0!X,"]W;W)K&UL4$L! M A0#% @ U8!G64@A\483 P X0T !D ("!N;\! 'AL
M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ U8!G M60P&PAJB @ Z@< !D ("! \P! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ U8!G6< &JO^ P M@X M !D ("!)-4!
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ U8!G60@,#]YE!0 9B@ !D M ("!=N ! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ U8!G62D@@$<#"@ W'0 !D ("!.?0! 'AL+W=O
M&PO=V]R:W-H965T&UL4$L! A0#% @ U8!G60$O M,!K2!0 1"T !D ("!(0H" 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ U8!G60*!2,K$!0 410 !D M ("!8B4" 'AL+W=O&PO M=V]R:W-
H965T&UL4$L! A0#% @ U8!G6<[.("B]!0 #BP !D ("! MVS(" 'AL+W=OFDA0) &A5@ &0 @('((>&PO=V]R:W-H965T&UL4$L! A0#% M @ U8!G60@ V=T8!0 4!X !D ("!>DD"
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ U8!G62(^.)W M"@ .G@ !D ("!>58" 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ U8!G66P1W\? P L! !D M ("!?6T" 'AL+W=O \P$ &0
@(%3<0(>&PO=V]R M:W-H965T&UL M4$L! A0#% @ U8!G63!#@5YB @ J04 !D ("!.90" M 'AL+W=O&PO=V]R:W-H965T 0((<(9 M " @<29 @!X,"]W;W)K&UL4$L! A0#% @
MU8!G65LC\IR P G@H !D ("!^P" 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ U8!G638FE2=U P)@X !D M ("!";(" 'AL+W=O&PO=V]R:W-H 9965TY @!X,"]W;W)K&UL4$L! M A0#%
@ U8!G6;[1=@)L P "!8 T (!#[T" 'AL M+W T-5QE&PO=V]R:V)O;VLN>&UL4$L! A0# M% @ U8!G6;0I?LS" @ "CD !H (!DL@" 'AL+U]R M96QS+W=O XML 109 Show.js IDEA: XBRL
DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their
employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={}; Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var
e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function()
{Show.LastAR.style.display='none';Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var
d,p ;if(e.style.display=='none'){d='block';p='';}else{d='none';p='+';} e.style.display=d;if(a.textContent)
{a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}} } XML 110 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /*
DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-
weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report
table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-
size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font:
normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-
align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top;
white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl
div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report
.rc { background-color: #f0f0f0; } /* Even rows... */ .report .ro, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro,
.report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for
footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left:
2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em;
} .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .more { display: none; } .report sup { font-style: italic

falsefalseR25.htm995605 - Disclosure - Income TaxesSheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesIncome_TaxesNotes25 falsefalseR26.htm995625 - Disclosure - Description of Business and Significant Accounting Policies (Policies)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPoliciesDescription of Business and Significant Accounting Policies (Policies)Policieshttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPolicies26 falsefalseR27.htm995635 - Disclosure - Description of Business and Significant Accounting Policies (Tables)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesTablesDescription of Business and Significant Accounting Policies (Tables)Tableshttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPolicies27 falsefalseR28.htm995645 - Disclosure - Pulmatrix Transaction (Tables)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionTablesPulmatrix Transaction (Tables)Tableshttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransaction28 falsefalseR29.htm995655 - Disclosure - Investments (Tables)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsTablesInvestments (Tables)Tableshttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestments29 falsefalseR30.htm995665 - Disclosure - Accounts Receivable (Tables)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableTablesAccounts Receivable (Tables)Tableshttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivable30 falsefalseR31.htm995675 - Disclosure - Inventories (Tables)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesTablesInventories (Tables)Tableshttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventories31 falsefalseR32.htm995685 - Disclosure - Property and Equipment (Tables)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentTablesProperty and Equipment (Tables)Tableshttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipment32 falsefalseR33.htm995695 - Disclosure - Goodwill and Other Intangible Assets (Tables)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsTablesGoodwill and Other Intangible Assets (Tables)Tableshttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssets133 falsefalseR34.htm995705 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTablesAccrued Expenses and Other Current Liabilities (Tables)Tableshttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities34 falsefalseR35.htm995715 - Disclosure - Borrowings (Tables)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsTablesBorrowings (Tables)Tableshttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowings35 falsefalseR36.htm995725 - Disclosure - Collaboration, Licensing and Other Arrangements (Tables)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsTablesCollaboration, Licensing and Other Arrangements (Tables)Tableshttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangements36 falsefalseR37.htm995735 - Disclosure - Fair Value of Financial Instruments (Tables)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTablesFair Value of Financial Instruments (Tables)Tableshttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments37 falsefalseR38.htm995745 - Disclosure - Earnings Per Common Share (Tables)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShareTablesEarnings Per Common Share (Tables)Tableshttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShare138 falsefalseR39.htm995755 - Disclosure - Stock-Based Compensation Expense (Tables)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTablesStock-Based Compensation Expense (Tables)Tableshttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpense39 falsefalseR40.htm995765 - Disclosure - Commitments and Contingencies (Tables)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTablesCommitments and Contingencies (Tables)Tableshttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies40 falsefalseR41.htm995775 - Disclosure - Description of Business and Significant Accounting Policies - Additional Information (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetailDescription of Business and Significant Accounting Policies - Additional Information (Detail)Details41 falsefalseR42.htm995785 - Disclosure - Description of Business and Significant Accounting Policies - Additional Information (Detail 1)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail1Description of Business and Significant Accounting Policies - Additional Information (Detail 1)Details42 falsefalseR43.htm995795 - Disclosure - Description of Business and Significant Accounting Policies - Summary of Revenue and Cost of Revenue and Goods Sold Generated From Product Sales, Services and Royalties (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesSummaryOfRevenueAndCostOfRevenueAndGoo of Business and Significant Accounting Policies - Summary of Revenue and Cost of Revenue and Goods Sold Generated From Product Sales, Services and Royalties (Detail)Details43 falsefalseR44.htm995805 - Disclosure - Pulmatrix Transaction - Additional Information (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetailPulmatrix Transaction - Additional Information (Detail)Details44 falsefalseR45.htm995825 - Disclosure - Pulmatrix Transaction - Schedule of Fair Value of Identifiable Assets Acquired and Liabilities Assumed (Details)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetailsPulma Transaction - Schedule of Fair Value of Identifiable Assets Acquired and Liabilities Assumed (Details)Details45 falsefalseR46.htm995845 - Disclosure - Investments - Additional Information (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetailInvestments - Additional Information (Detail)Details46 falsefalseR47.htm995855 - Disclosure - Investments - Schedule of Contractual Maturities of Held to Maturity Investments (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfHeldToMaturityInvestmentsDetailInvestments - Schedule of Contractual Maturities of Held to Maturity Investments (Detail)Details47 falsefalseR48.htm995865 - Disclosure - Investments - Schedule of Contractual Maturities of Held to Maturity Investments (Parenthetical) (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfHeldToMaturityInvestmentsParentheticalDetailInvestments - Schedule of Contractual Maturities of Held to Maturity Investments (Parenthetical) (Detail)Details48 falsefalseR49.htm995875 - Disclosure - Investments - Schedule of Fair Value of Cash Equivalents, Long and Short Term Investments (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetailInvestments - Schedule of Fair Value of Cash Equivalents, Long and Short Term Investments (Detail)Details49 falsefalseR50.htm995885 - Disclosure - Schedule of Accounts Receivable, Net (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureScheduleOfAccountsReceivableNetDetailSchedule of Accounts Receivable, Net (Detail)Details50 falsefalseR51.htm995895 - Disclosure - Accounts Receivable - Additional Information (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetailAccounts Receivable - Additional Information (Detail)Details51 falsefalseR52.htm995905 - Disclosure - Inventories - Components of Inventory (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesComponentsOfInventoryDetailInventories - Components of Inventory (Detail)Details52 falsefalseR53.htm995915 - Disclosure - Inventories - Additional Information (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetailInventories - Additional Information (Detail)Details53 falsefalseR54.htm995925 - Disclosure - Property and Equipment, Net (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetailProperty and Equipment, Net (Detail)Detailshttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables54 falsefalseR55.htm995935 - Disclosure - Property and Equipment, Net (Parenthetical) (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetParentheticalDetailProperty and Equipment, Net (Parenthetical) (Detail)Detailshttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables55 falsefalseR56.htm995945 - Disclosure - Depreciation Expense Related to Property and Equipment (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDepreciationExpenseRelatedToPropertyAndEquipmentDetailDepreciation Expense Related to Property and Equipment (Detail)Details56 falsefalseR57.htm995955 - Disclosure - Property and Equipment - Additional Information (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetailProperty and Equipment - Additional Information (Detail)Details57 falsefalseR58.htm995965 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetailGoodwill and Other Intangible Assets - Additional Information (Detail)Details58 falsefalseR59.htm995975 - Disclosure - Goodwill and Other Intangible Assets - Summary of Other Intangible Asset (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsSummaryOfOtherIntangibleAssetDetailGoodwill and Other Intangible Assets - Summary of Other Intangible Asset (Detail)Details59 falsefalseR60.htm995985 - Disclosure - Accrued Expenses and Other Current Liabilities (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetailAccrued Expenses and Other Current Liabilities (Detail)Detailshttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables60 falsefalseR61.htm996005 - Disclosure - Borrowings - Summary of Carrying Amount of Borrowings (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsSummaryOfCarryingAmountOfBorrowingsDetailBorrowings - Summary of Carrying Amount of Borrowings (Detail)Details61 falsefalseR62.htm996015 - Disclosure - Borrowings - Schedule of Line of Credit Facility Debt and Key Terms (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetailBorrowings - Schedule of Line of Credit Facility Debt and Key Terms (Detail)Details62 falsefalseR63.htm996025 - Disclosure - Borrowings - Schedule of Maturities of Company's Borrowings (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsScheduleOfMaturitiesOfCompanysBorrowingsDetailBorrowings - Schedule of Maturities of Company's Borrowings (Detail)Details63 falsefalseR64.htm996035 - Disclosure - Borrowings - Senior Convertible Notes - Additional Information (Detail)Noteshttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetailBorrowings - Senior Convertible Notes - Additional Information (Detail)Details64 falsefalseR65.htm996045 - Disclosure - Borrowings - MidCap Credit Facility - Additional Information (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetailBorrowings - MidCap Credit Facility - Additional Information (Detail)Details65 falsefalseR66.htm996055 - Disclosure - Borrowings - Mann Group Promissory Notes - Additional Information (Detail)Noteshttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetailBorrowings - Mann Group Promissory Notes - Additional Information (Detail)Details66 falsefalseR67.htm996065 - Disclosure - Borrowings - Schedule of Amortization of Premium and Accretion of Debt Issuance Costs (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsScheduleOfAmortizationOfPremiumAndAccretionOfDebtIssuanceCostsDetailBorrowings - Schedule of Amortization of Premium and Accretion of Debt Issuance Costs (Detail)Details67 falsefalseR68.htm996075 - Disclosure - Collaboration, Licensing and Other Arrangements - Schedule of Revenue from Collaborations and Services (Details)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetailsC Licensing and Other Arrangements - Schedule of Revenue from Collaborations and Services (Details)Details68 falsefalseR69.htm996085 - Disclosure - Collaboration, Licensing and Other Arrangements - Summary of UT Revenue (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsSummaryOfUtRevenueDetailCollaboration, Licensing and Other Arrangements - Summary of UT Revenue (Detail)Details69 falsefalseR70.htm996095 - Disclosure - Collaboration, Licensing and Other Arrangements - Additional Information (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetailCollaboration, Licensing and Other Arrangements - Additional Information (Detail)Details70 falsefalseR71.htm996105 - Disclosure - Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAl Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Detail)Details71 falsefalseR72.htm996115 - Disclosure - Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Parenthetical) (Details)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsA Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Parenthetical) (Details)Details72 falsefalseR73.htm996125 - Disclosure - Collaboration, Licensing and Other Arrangements - Additional Information (Detail 1)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail1Collaboration, Licensing and Other Arrangements - Additional Information (Detail 1)Details73 falsefalseR74.htm996145 - Disclosure - Fair Value of Financial Instruments - Fair Value of Financial Instruments (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetailFair Value of Financial Instruments - Fair Value of Financial Instruments (Detail)Details74 falsefalseR75.htm996155 - Disclosure - Fair Value of Financial Instruments - Fair Value of Financial Instruments (Parenthetical) (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetailFair Value of Financial Instruments - Fair Value of Financial Instruments (Parenthetical) (Detail)Details75 falsefalseR76.htm996165 - Disclosure - Common and Preferred Stock - Additional Information (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetailCommon and Preferred Stock - Additional Information (Detail)Details76 falsefalseR77.htm996175 - Disclosure - Earnings Per Common Share - Components of Basic and Diluted EPS Computations (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShareComponentsOfBasicAndDilutedEpsComputationsDetailEarnings Per Common

Share - Components of Basic and Diluted EPS Computations (Detail)Details77 falsefalseR78.htm996185 - Disclosure - Earnings Per Common Share - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveDetailEarnin Per Common Share - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Detail)Details78 falsefalseR79.htm996195 - Disclosure - Earnings Per Common Share - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Parenthetical) (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveParenthetic Per Common Share - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Parenthetical) (Detail)Details79 falsefalseR80.htm996205 - Disclosure - Stock-Based Compensation Expense - Additional Information (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetailStock-Based Compensation Expense - Additional Information (Detail)Details80 falsefalseR81.htm996215 - Disclosure - Stock-Based Compensation Expense - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Details)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityI Based Compensation Expense - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Details)Details81 falsefalseR82.htm996225 - Disclosure - Stock-Based Compensation Expense - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Parenthetical) (Details)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityI Based Compensation Expense - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Parenthetical) (Details)Details82 falsefalseR83.htm996235 - Disclosure - Stock-Based Compensation Expense - Stock Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseStockBasedCompensationExpenseRecognizedInCondensedConsolidat Based Compensation Expense - Stock Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations (Detail)Details83 falsefalseR84.htm996245 - Disclosure - Commitments and Contingencies - Additional Information (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetailCommitments and Contingencies - Additional Information (Detail)Details84 falsefalseR85.htm996255 - Disclosure - Commitments and Contingencies - Schedule Of Royalty Liability Account Roll Forward (Details)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRoyaltyLiabilityAccountRollForwardDetailsCommitments and Contingencies - Schedule Of Royalty Liability Account Roll Forward (Details)Details85 falsefalseR86.htm996265 - Disclosure - Commitments and Contingencies - Schedule of Financing Liability Lease Term and Discount Rate (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFinancingLiabilityLeaseTermAndDiscountRateDetailCommit and Contingencies - Schedule of Financing Liability Lease Term and Discount Rate (Detail)Details86 falsefalseR87.htm996275 - Disclosure - Commitments and Contingencies - Summary of Financing Liability Costs (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFinancingLiabilityCostsDetailCommitments and Contingencies - Summary of Financing Liability Costs (Detail)Details87 falsefalseR88.htm996285 - Disclosure - Commitments and Contingencies - Schedule of Remaining Financing Liability Payments (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRemainingFinancingLiabilityPaymentsDetailCommitments and Contingencies - Schedule of Remaining Financing Liability Payments (Detail)Details88 falsefalseR89.htm996295 - Disclosure - Commitments and Contingencies - Summary of Finance Lease Information (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFinanceLeaseInformationDetailCommitments and Contingencies - Summary of Finance Lease Information (Detail)Details89 falsefalseR90.htm996305 - Disclosure - Commitment and contingencies - Schedule of Remaining Financing Lease Payments (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfRemainingFinancingLeasePaymentsDetailCommitment and contingencies - Schedule of Remaining Financing Lease Payments (Detail)Details90 falsefalseR91.htm996315 - Disclosure - Commitments and Contingencies - Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirer and Contingencies - Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements (Detail)Details91 falsefalseR92.htm996325 - Disclosure - Commitments and Contingencies - Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements (Parenthetical) (Details)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirc and Contingencies - Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements (Parenthetical) (Details)Details92 falsefalseR93.htm996335 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetailCommitments and Contingencies - Schedule of Lease Term and Discount Rate (Detail)Details93 falsefalseR94.htm996345 - Disclosure - Commitments and Contingencies - Summary of Lease Information (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseInformationDetailCommitments and Contingencies - Summary of Lease Information (Detail)Details94 falsefalseR95.htm996355 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Office And Vehicle Lease Payments (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumOfficeAndVehicleLeasePaymentsDetailCom and Contingencies - Schedule of Future Minimum Office And Vehicle Lease Payments (Detail)Details95 falsefalseR96.htm996365 - Disclosure - Income Taxes - Additional Information (Detail)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetailIncome Taxes - Additional Information (Detail)Details96 falsefalseR97.htm996375 - Disclosure - Subsequent Events (Additional Information) (Details)Sheethttp://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsSubsequent Events (Additional Information) (Details)Details97 falsefalseAll ReportsBookAll Reports mnkd-20240930.htmmnkd-20240930.xsd http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024falsefalse JSON 115 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mnkd-20240930.htm": { "nsprefix": "mnkd", "nsuri": "http://www.mannkindcorp.com/20240930", "dts": { "inline": { "local": ["mnkd-20240930.htm"] }, "schema": { "local": ["mnkd-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 363, "keyCustom": 172, "axisStandard": 38, "axisCustom": 0, "memberStandard": 47, "memberCustom": 82, "hidden": { "total": 30, "http://xbrl.sec.gov/dei/2024": 4, "http://xbrl.sec.gov/ecd/2024": 2, "http://fasb.org/us-gaap/2024": 24 }, "contextCount": 468, "entityCount": 1, "segmentCount": 135, "elementCount": 1030, "unitCount": 12, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 999, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 19 }, "report": { "R1": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"] }, "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"] }, "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations", "longName": "100010 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefe-a5042321184d", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefe-a5042321184d", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R3": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "longName": "100060 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefe-a5042321184d", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefe-a5042321184d", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R4": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "longName": "100070 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:ShortTermInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R5": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "100080 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R6": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit", "longName": "100090 - Statement - Condensed Consolidated Statements of Stockholders' Deficit", "shortName": "Condensed Consolidated Statements of Stockholders' Deficit", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_9e4fc6ba-85a0-4151-8ac8-d489c9ba4f44", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_8a11df8e-11f2-4597-b188-3ce08e2a32ef", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "U_USD", "xsiNil": "false", "lang", null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R7": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "100100 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefe-a5042321184d", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefe-a5042321184d", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefe-a5042321184d", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPolicies", "longName": "995455 - Disclosure - Description of Business and Significant Accounting Policies", "shortName": "Description of Business and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType":

```
"", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } } }, "R11": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransaction", "longName": "995465 - Disclosure - Pulmatrix Transaction", "shortName": "Pulmatrix Transaction", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestments", "longName": "995475 - Disclosure - Investments", "shortName": "Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } } }, "R13": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivable", "longName": "995485 - Disclosure - Accounts Receivable", "shortName": "Accounts Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:FinancingReceivablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:FinancingReceivablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } } }, "R14": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventories", "longName": "995495 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } } }, "R15": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipment", "longName": "995505 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } } }, "R16": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssets1", "longName": "995515 - Disclosure - Goodwill and Other Intangible Assets", "shortName": "Goodwill and Other Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } } }, "R17": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities", "longName": "995525 - Disclosure - Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } } }, "R18": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowings", "longName": "995535 - Disclosure - Borrowings", "shortName": "Borrowings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangements", "longName": "995545 - Disclosure - Collaboration, Licensing and Other Arrangements", "shortName": "Collaboration, Licensing and Other Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } } }, "R20": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments", "longName": "995555 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } } }, "R21": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStock", "longName": "995565 - Disclosure - Common and Preferred Stock", "shortName": "Common and Preferred Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } } }, "R22": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShare1", "longName": "995575 - Disclosure - Earnings Per Common Share", "shortName": "Earnings Per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } } }, "R23": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpense", "longName": "995585 - Disclosure - Stock-Based Compensation Expense", "shortName": "Stock-Based Compensation Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } } }, "R24": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "995595 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } } }, "R25": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxes", "longName": "995605 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } } }, "R26": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies", "longName": "995625 - Disclosure - Description of Business and Significant Accounting Policies (Policies)", "shortName": "Description of Business and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "mnkd:BusinessPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "mnkd:BusinessPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } } }, "R27": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesTables", "longName": "995635 - Disclosure - Description of Business and Significant Accounting Policies (Tables)", "shortName": "Description of Business and Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionTables", "longName": "995645 - Disclosure - Pulmatrix Transaction (Tables)", "shortName": "Pulmatrix Transaction (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } } }, "R29": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsTables", "longName": "995655 - Disclosure - Investments (Tables)", "shortName": "Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:HeldToMaturitySecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:HeldToMaturitySecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableTables", "longName": "995665 - Disclosure - Accounts Receivable (Tables)", "shortName": "Accounts Receivable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_0a07854c-
```

078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:FinancingReceivablesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:FinancingReceivablesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesTables", "longName": "995675 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables", "longName": "995685 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsTables", "longName": "995695 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "shortName": "Goodwill and Other Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "longName": "995705 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsTables", "longName": "995715 - Disclosure - Borrowings (Tables)", "shortName": "Borrowings (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsTables", "longName": "995725 - Disclosure - Collaboration, Licensing and Other Arrangements (Tables)", "shortName": "Collaboration, Licensing and Other Arrangements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables", "longName": "995735 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShareTables", "longName": "995745 - Disclosure - Earnings Per Common Share (Tables)", "shortName": "Earnings Per Common Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables", "longName": "995755 - Disclosure - Stock-Based Compensation Expense (Tables)", "shortName": "Stock-Based Compensation Expense (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "mnkd:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanAndNonEmployeeDirectorStockAwardPlanActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "mnkd:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanAndNonEmployeeDirectorStockAwardPlanActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "longName": "995765 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "mnkd:ScheduleOfRoyaltyLiabilityAccountRollForwardTabletextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "mnkd:ScheduleOfRoyaltyLiabilityAccountRollForwardTabletextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail", "longName": "995775 - Disclosure - Description of Business and Significant Accounting Policies - Additional Information (Detail)", "shortName": "Description of Business and Significant Accounting Policies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "mnkd:PercentageOfFutureRoyalties", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "mnkd:PercentageOfFutureRoyalties", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail1", "longName": "995785 - Disclosure - Description of Business and Significant Accounting Policies - Additional Information (Detail 1)", "shortName": "Description of Business and Significant Accounting Policies - Additional Information (Detail 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_63a82e97-5549-47a9-9670-27d0fa76d875", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_63a82e97-5549-47a9-9670-27d0fa76d875", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesSummaryOfRevenueAndCostOfRevenueAndGoodsSoldGene "longName": "995795 - Disclosure - Description of Business and Significant Accounting Policies - Summary of Revenue and Cost of Revenue and Goods Sold Generated From Product Sales, Services and Royalties (Detail)", "shortName": "Description of Business and Significant Accounting Policies - Summary of Revenue and Cost of Revenue and Goods Sold Generated From Product Sales, Services and Royalties (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefe-a5042321184d", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefe-a5042321184d", "name": "us-gaap:OperatingExpenses", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R44": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail", "longName": "995805 - Disclosure - Pulmatrix Transaction - Additional Information (Detail)", "shortName": "Pulmatrix Transaction - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_a4905dd7-d406-4f7d-91a7-ab74c78f14b7", "name": "mnkd:NumberOfPulmatrixEmployeesWhichBeganEmployment", "unitRef": "U_Employees", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefe-a5042321184d", "name": "us-gaap:PaymentsForMergerRelatedCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R45": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails", "longName": "995825 - Disclosure - Pulmatrix Transaction - Schedule of Fair Value of Identifiable Assets Acquired and Liabilities Assumed (Details)", "shortName": "Pulmatrix Transaction - Schedule of Fair Value of Identifiable Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_5acbf653-ce6f-4587-96f0-8546e82aa6f7", "name": "mnkd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_5acbf653-ce6f-4587-96f0-8546e82aa6f7", "name": "mnkd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail", "longName": "995845 - Disclosure - Investments - Additional Information (Detail)", "shortName": "Investments - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefe-a5042321184d", "name": "us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefe-a5042321184d", "name": "us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R47": { "role":

"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfHeldToMaturityInvestmentsDetail", "longName": "995855 - Disclosure - Investments - Schedule of Contractual Maturities of Held to Maturity Investments (Detail)", "shortName": "Investments - Schedule of Contractual Maturities of Held to Maturity Investments (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:HeldToMaturitySecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfHeldToMaturityInvestmentsParentheticalDetail", "longName": "995865 - Disclosure - Investments - Schedule of Contractual Maturities of Held to Maturity Investments (Parenthetical) (Detail)", "shortName": "Investments - Schedule of Contractual Maturities of Held to Maturity Investments (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true } }, "uniqueAnchor": { "contextRef": "C_04148de2-811b-42f4-a10f-d6a0ce830fec", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "link:footnote", "div", "div", "us-gaap:HeldToMaturitySecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R49": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail", "longName": "995875 - Disclosure - Investments - Schedule of Fair Value of Cash Equivalents, Long and Short Term Investments (Detail)", "shortName": "Investments - Schedule of Fair Value of Cash Equivalents, Long and Short Term Investments (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_bf731737-19b0-40ea-a6a9-99b9631acc14", "name": "mnkd:CashEquivalentsAndInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "mnkd:ScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bf731737-19b0-40ea-a6a9-99b9631acc14", "name": "mnkd:CashEquivalentsAndInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "mnkd:ScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureScheduleOfAccountsReceivableNetDetail", "longName": "995885 - Disclosure - Schedule of Accounts Receivable, Net (Detail)", "shortName": "Schedule of Accounts Receivable, Net (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:FinancingReceivablesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_828a447a-c7d0-4189-a2dd-5e40bb409d3b", "name": "mnkd:WholesalerDistributionFeesAndPromptPayDiscounts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "div", "us-gaap:FinancingReceivablesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R51": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail", "longName": "995895 - Disclosure - Accounts Receivable - Additional Information (Detail)", "shortName": "Accounts Receivable - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "mnkd:NumberOfWholesaleDistributors", "unitRef": "U_Distributor", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:FinancingReceivablesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "mnkd:NumberOfWholesaleDistributors", "unitRef": "U_Distributor", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:FinancingReceivablesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesComponentsOfInventoryDetail", "longName": "995905 - Disclosure - Inventories - Components of Inventory (Detail)", "shortName": "Inventories - Components of Inventory (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail", "longName": "995915 - Disclosure - Inventories - Additional Information (Detail)", "shortName": "Inventories - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefc-a5042321184d", "name": "us-gaap:ProductionRelatedImpairmentsOrCharges", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_02bb2682-f873-4812-81e1-62e210ac7e24", "name": "us-gaap:InventoryRawMaterials", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["us-gaap:InventoryRawMaterials", "span", "p", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R54": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail", "longName": "995925 - Disclosure - Property and Equipment, Net (Detail)", "shortName": "Property and Equipment, Net (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetParentheticalDetail", "longName": "995935 - Disclosure - Property and Equipment, Net (Parenthetical) (Detail)", "shortName": "Property and Equipment, Net (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_d79d4210-1c14-4c21-9a4d-d6be816a62ff", "name": "us-gaap:InvestmentBuildingAndBuildingImprovements", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d79d4210-1c14-4c21-9a4d-d6be816a62ff", "name": "us-gaap:InvestmentBuildingAndBuildingImprovements", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDepreciationExpenseRelatedToPropertyAndEquipmentDetail", "longName": "995945 - Disclosure - Depreciation Expense Related to Property and Equipment (Detail)", "shortName": "Depreciation Expense Related to Property and Equipment (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefc-a5042321184d", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "mnkd:DepreciationExpenseRelatedToPropertyAndEquipmentTableTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefc-a5042321184d", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "mnkd:DepreciationExpenseRelatedToPropertyAndEquipmentTableTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail", "longName": "995955 - Disclosure - Property and Equipment - Additional Information (Detail)", "shortName": "Property and Equipment - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_4bb4c8a5-fdf5-4bbe-a28b-a60d99588871", "name": "us-gaap:PropertyPlantAndEquipmentDisposals", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4bb4c8a5-fdf5-4bbe-a28b-a60d99588871", "name": "us-gaap:PropertyPlantAndEquipmentDisposals", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetail", "longName": "995965 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Detail)", "shortName": "Goodwill and Other Intangible Assets - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:Goodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f19f3408-1d71-46e8-a053-2f9d158bdc03", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R59": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsSummaryOfOtherIntangibleAssetDetail", "longName": "995975 - Disclosure - Goodwill and Other Intangible Assets - Summary of Other Intangible Asset (Detail)", "shortName": "Goodwill and Other Intangible Assets - Summary of Other Intangible Asset (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetail", "longName": "995985 - Disclosure - Accrued Expenses and Other Current Liabilities (Detail)", "shortName": "Accrued Expenses and Other Current Liabilities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsSummaryOfCarryingAmountOfBorrowingsDetail", "longName": "996005 - Disclosure - Borrowings - Summary of Carrying Amount of Borrowings (Detail)", "shortName": "Borrowings - Summary of Carrying Amount of Borrowings (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:SeniorNotes", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:SeniorNotes", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail", "longName": "996015 - Disclosure - Borrowings - Schedule of Line of Credit Facility Debt and Key Terms (Detail)", "shortName": "Borrowings - Schedule of Line of Credit Facility Debt and Key Terms (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_ce849c41-b594-4d97-aa37-fee26219bb3d", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "td", "tr", "table", "us-

gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_27b96a55-fdaf-48f4-84c1-4db8149cd52c", "name": "mnkd:DebtInstrumentMaturityMonthAndYear", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R63": { "role":
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsScheduleOfMaturitiesOfCompanysBorrowingsDetail", "longName": "996025 - Disclosure - Borrowings - Schedule of Maturities of Company's Borrowings (Detail)", "shortName": "Borrowings - Schedule of Maturities of Company's Borrowings (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757302c5ac", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757302c5ac", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R64": { "role":
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail", "longName": "996035 - Disclosure - Borrowings - Senior Convertible Notes - Additional Information (Detail)", "shortName": "Borrowings - Senior Convertible Notes - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_b0ab97fc-30bc-40e1-92c5-f3d44159ac48", "name": "us-gaap:DebtInstrumentMaturityDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_27b96a55-fdaf-48f4-84c1-4db8149cd52c", "name": "us-gaap:DebtInstrumentMaturityDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R65": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail", "longName": "996045 - Disclosure - Borrowings - MidCap Credit Facility - Additional Information (Detail)", "shortName": "Borrowings - MidCap Credit Facility - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "C_b0ab97fc-30bc-40e1-92c5-f3d44159ac48", "name": "us-gaap:DebtInstrumentMaturityDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_fc5ba581-cc0c-444d-9c94-1be98ff83127", "name": "mnkd:PrepaymentOfSecuredLinesOfCredit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R66": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail", "longName": "996055 - Disclosure - Borrowings - Mann Group Promissory Notes - Additional Information (Detail)", "shortName": "Borrowings - Mann Group Promissory Notes - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:DebtInstrumentFrequencyOfPeriodicPayment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_135ee29d-4b78-4121-93c6-2199f46eb994", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R67": { "role",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsScheduleOfAmortizationOfPremiumAndAccretionOfDebtIssuanceCostsDetail", "longName": "996065 - Disclosure - Borrowings - Schedule of Amortization of Premium and Accretion of Debt Issuance Costs (Detail)", "shortName": "Borrowings - Schedule of Amortization of Premium and Accretion of Debt Issuance Costs (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "C_4bb4c8a5-fdf5-4bbe-a28b-a60d09588871", "name": "mnkd:AmortizationOfDebtDiscountAndPrepaymentFee", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "mnkd:ScheduleOfAmortizationOfDebtIssuanceCostAndDebtDiscountTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4bb4c8a5-fdf5-4bbe-a28b-a60d09588871", "name": "mnkd:AmortizationOfDebtDiscountAndPrepaymentFee", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "mnkd:ScheduleOfAmortizationOfDebtIssuanceCostAndDebtDiscountTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R68": { "role":
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails", "longName": "996075 - Disclosure - Collaboration, Licensing and Other Arrangements - Schedule of Revenue from Collaborations and Services (Details)", "shortName": "Collaboration, Licensing and Other Arrangements - Schedule of Revenue from Collaborations and Services (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "C_e242faa7-2879-4b62-aefe-a5042321184d", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_06c70fed-be8d-45ba-8dfd-e2841d85018f", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R69": { "role":
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsSummaryOfUtRevenueDetail", "longName": "996085 - Disclosure - Collaboration, Licensing and Other Arrangements - Summary of UT Revenue (Detail)", "shortName": "Collaboration, Licensing and Other Arrangements - Summary of UT Revenue (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "C_e242faa7-2879-4b62-aefe-a5042321184d", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": null }, "R70": { "role",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail", "longName": "996095 - Disclosure - Collaboration, Licensing and Other Arrangements - Additional Information (Detail)", "shortName": "Collaboration, Licensing and Other Arrangements - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "C_bb71325a-27e8-40c6-bcbc-bf37c6aa2265", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2e7ba47c-1ee9-4335-b140-6501e7051515", "name": "us-gaap:PaymentsToAcquireOtherProductiveAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R71": { "role",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo "longName": "996105 - Disclosure - Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Detail)", "shortName": "Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "C_a0927df9-c2dd-40b7-8de5-4c2ec74c510b", "name": "mnkd:RevenueRemainingPerformanceObligationAnticipatedCashFlow", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_4c261b9c-8e78-421c-aac2-05189700f0b6", "name": "us-gaap:RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R72": { "role",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo "longName": "996115 - Disclosure - Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Parenthetical) (Details)", "shortName": "Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Parenthetical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "C_a0927df9-c2dd-40b7-8de5-4c2ec74c510b", "name": "mnkd:RevenueRemainingPerformanceObligationAnticipatedCashFlow", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9b57ea63-46d0-499c-a994-01afbe51ac81", "name": "mnkd:AllocatedTransactionPrice", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "link:footnote", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R73": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail1", "longName": "996125 - Disclosure - Collaboration, Licensing and Other Arrangements - Additional Information (Detail 1)", "shortName": "Collaboration, Licensing and Other Arrangements - Additional Information (Detail 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "C_4604994f-995a-4320-ba69-53a8e061ef52", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4604994f-995a-4320-ba69-53a8e061ef52", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R74": { "role",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail", "longName": "996145 - Disclosure - Fair Value of Financial Instruments - Fair Value of Financial Instruments (Detail)", "shortName": "Fair Value of Financial Instruments - Fair Value of Financial Instruments (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "C_437f4dd8-3081-4aac-9239-28024bb1d5b4", "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_437f4dd8-3081-4aac-9239-28024bb1d5b4", "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R75": { "role",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail", "longName": "996155 - Disclosure - Fair Value of Financial Instruments - Fair Value of Financial Instruments (Parenthetical) (Detail)", "shortName": "Fair Value of Financial Instruments - Fair Value of Financial Instruments (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "C_ff458533-046e-4a08-8772-00cd88d9036f", "name": "mnkd:DebtInstrumentMeasurementInputAfterChange", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C_ff458533-046e-4a08-8772-00cd88d9036f", "name": "mnkd:DebtInstrumentMeasurementInputAfterChange", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail", "longName": "996165 - Disclosure - Common and Preferred Stock - Additional Information (Detail)", "shortName": "Common and Preferred Stock - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757302c5ac", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:ProceedsFromStockPlans", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R77": { "role":
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShareComponentsOfBasicAndDilutedEpsComputationsDetail", "longName": "996175 - Disclosure - Earnings Per Common Share - Components of Basic and Diluted EPS Computations (Detail)", "shortName": "Earnings Per Common Share - Components of Basic and Diluted EPS Computations (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "C_e242faa7-2879-4b62-aefe-a5042321184d", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e242faa7-2879-4b62-aefe-a5042321184d", "name": "us-gaap:UndistributedEarningsDiluted", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R78": { "role":
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveDetail", "longName": "996185 - Disclosure - Earnings Per Common Share - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Detail)", "shortName": "Earnings Per Common Share - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "C_8d2582ac-13cb-43bb-8a78-aead7b18bfd4", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8d2582ac-13cb-43bb-8a78-aead7b18bfd4", "name": "us-

gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }], "R79": { "role", "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsiderecdAntidilutiveParentheticalDetail", "longName": "996195 - Disclosure - Earnings Per Common Share - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Parenthetical) (Detail)", "shortName": "Earnings Per Common Share - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "C_70ed6f32-dc56-4a20-b4d2-acfdc182719a", "name": "mnkd:ShareDeliveryPercentage", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "div", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_70ed6f32-dc56-4a20-b4d2-acfdc182719a", "name": "mnkd:ShareDeliveryPercentage", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R80": { "role", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail", "longName": "996205 - Disclosure - Stock-Based Compensation Expense - Additional Information (Detail)", "shortName": "Stock-Based Compensation Expense - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "C_8631bdd9-4b77-4b76-9c5a-682b6ac99b0e", "name": "us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_fc2804b8-0455-4f26-9081-3c6c9f2ade37", "name": "us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R81": { "role",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityDetails", "longName": "996215 - Disclosure - Stock-Based Compensation Expense - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Details)", "shortName": "Stock-Based Compensation Expense - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefc-a5042321184d", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table",
"mnkd:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanAndNonEmployeeDirectorStockAwardPlanActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefc-a5042321184d", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table",
"mnkd:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanAndNonEmployeeDirectorStockAwardPlanActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R82": { "role",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall "longName": "996225 - Disclosure - Stock-Based Compensation Expense - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Parenthetical) (Details)", "shortName": "Stock-Based Compensation Expense - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Parenthetical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "C_a7f7aa43-8d52-4371-b471-79bd9589f2c4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": ["span", "div", "div",
"mnkd:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanAndNonEmployeeDirectorStockAwardPlanActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3b1fa1f2-1dd7-49ac-b706-f512c7450cbe", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "span", "div", "div",
"mnkd:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanAndNonEmployeeDirectorStockAwardPlanActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R83": { "role",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseStockBasedCompensationExpenseRecognizedInCondensedConsolidatedStatemen "longName": "996235 - Disclosure - Stock-Based Compensation Expense - Stock Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations (Detail)", "shortName": "Stock-Based Compensation Expense - Stock Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefc-a5042321184d", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefc-a5042321184d", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } },
"R84": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "longName": "996245 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType", "details", "menuCat": "Details", "order", "84", "firstAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefc-a5042321184d", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "mnkd:LongTermPurchaseCommitmentExpirationDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R85": { "role",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRoyaltyLiabilityAccountRollForwardDetails", "longName": "996255 - Disclosure - Commitments and Contingencies - Schedule Of Royalty Liability Account Roll Forward (Details)", "shortName": "Commitments and Contingencies - Schedule Of Royalty Liability Account Roll Forward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "C_bb71325a-27e8-40e6-bcbc-bf37c6aa2265", "name": "us-gaap:Liabilities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c70e2438-6d40-4bf3-a594-624db8ae8c0c", "name": "us-gaap:Liabilities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table",
"mnkd:ScheduleOfRoyaltyLiabilityAccountRollForwardTabletextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R86": { "role",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFinancingLiabilityLeaseTermAndDiscountRateDetail", "longName": "996265 - Disclosure - Commitments and Contingencies - Schedule of Financing Liability Lease Term and Discount Rate (Detail)", "shortName": "Commitments and Contingencies - Schedule of Financing Liability Lease Term and Discount Rate (Detail)", "isDefault", "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "mnkd:ScheduleOfLeaseTermAndDiscountRateTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "mnkd:ScheduleOfLeaseTermAndDiscountRateTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R87": { "role", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFinancingLiabilityCostsDetail", "longName", "996275 - Disclosure - Commitments and Contingencies - Summary of Financing Liability Costs (Detail)", "shortName": "Commitments and Contingencies - Summary of Financing Liability Costs (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "C_c242faa7-2879-4b62-aefc-a5042321184d", "name": "mnkd:InterestExpenseOnFinancingLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": null }, "R88": { "role",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRemainingFinancingLiabilityPaymentsDetail", "longName": "996285 - Disclosure - Commitments and Contingencies - Schedule of Remaining Financing Liability Payments (Detail)", "shortName": "Commitments and Contingencies - Schedule of Remaining Financing Liability Payments (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "mnkd:FinanceLeaseLiabilityDiscountedPaymentsDueRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "mnkd:FinanceLeaseLiabilityDiscountedDebtIssuanceCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R89": { "role",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFinanceLeaseInformationDetail", "longName": "996295 - Disclosure - Commitments and Contingencies - Summary of Finance Lease Information (Detail)", "shortName", "Commitments and Contingencies - Summary of Finance Lease Information (Detail)", "isDefault", "false", "groupType", "disclosure", "subGroupType", "details", "menuCat", "Details", "order", "89", "firstAnchor", { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeFinanceLeasesTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeFinanceLeasesTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R90": { "role",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfRemainingFinancingLeasePaymentsDetail", "longName": "996305 - Disclosure - Commitment and contingencies - Schedule of Remaining Financing Lease Payments (Detail)", "shortName": "Commitment and contingencies - Schedule of Remaining Financing Lease Payments (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "mnkd:FinanceLeaseLiabilityDiscountedPaymentsDueRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_53977960-42cc-44af-a902-b019a5e6fe56", "name":
"mnkd:FinanceLeaseLiabilityDiscountedPaymentsDueRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R91": { "role",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail" "longName": "996315 - Disclosure - Commitments and Contingencies - Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements (Detail)", "shortName": "Commitments and Contingencies - Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:PurchaseObligationDueInSecondYear", "unitRef": "U_EUR", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392c5ac", "name": "us-gaap:PurchaseObligationDueInSecondYear", "unitRef": "U_EUR", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R92": { "role":
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsParent "longName": "996325 - Disclosure - Commitments and Contingencies - Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements (Parenthetical) (Details)",

```
"shortName": "Commitments and Contingencies - Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements (Parenthetical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392e5ac", "name": "mnkd:CapacityFee", "unitRef": "U_EUR", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "ix:continuation", "span", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392e5ac", "name": "mnkd:CapacityFee", "unitRef": "U_EUR", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "ix:continuation", "span", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R93": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetail", "longName": "996335 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate (Detail)", "shortName": "Commitments and Contingencies - Schedule of Lease Term and Discount Rate (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392e5ac", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392e5ac", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true } }, "R94": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseInformationDetail", "longName": "996345 - Disclosure - Commitments and Contingencies - Summary of Lease Information (Detail)", "shortName": "Commitments and Contingencies - Summary of Lease Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "C_e242faa7-2879-4b62-acfe-a5042321184d", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e242faa7-2879-4b62-acfe-a5042321184d", "name": "us-gaap:VariableLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R95": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumOfficeAndVehicleLeasePaymentsDetail", "longName": "996355 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Office And Vehicle Lease Payments (Detail)", "shortName": "Commitments and Contingencies - Schedule of Future Minimum Office And Vehicle Lease Payments (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "C_1bf0ddf8-6e4d-4028-ab4e-0e757392e5ac", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_410d7fc3-127c-4609-bbdf-aeb77f15052b", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R96": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "longName": "996365 - Disclosure - Income Taxes - Additional Information (Detail)", "shortName": "Income Taxes - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "C_c242faa7-2879-4b62-acfe-a5042321184d", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0a07854c-078b-4863-a21c-3787931e61a5", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "unique": true } }, "R97": { "role": "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "longName": "996375 - Disclosure - Subsequent Events (Additional Information) (Details)", "shortName": "Subsequent Events (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "C_76b4fb24-6436-4fcc-a4c8-9aede2d739dd", "name": "us-gaap:CashCollateralForBorrowedSecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mnkd-20240930.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureScheduleOfAccountsReceivableNetDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable [Line Items]", "label": "Accounts Notes And Loans Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth_ref": [ "r297", "r1084" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses and Other Current Liabilities", "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r71", "r74", "r80", "r1176" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable, Current, Total", "terseLabel": "Accounts payable", "label": "Accounts Payable Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r71", "r927" ] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureScheduleOfAccountsReceivableNetDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts receivable", "terseLabel": "Accounts receivable, gross", "label": "Accounts Receivable Gross Current", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r210", "r297", "r865" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureScheduleOfAccountsReceivableNetDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total accounts receivable, net", "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable Net Current", "verboseLabel": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1082" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Net accretion of investments", "verboseLabel": "Accretion or amortization", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r117" ] }, "mnkd_AccruedExpensesAndOtherCurrentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AccruedExpensesAndOtherCurrentLiabilitiesLineItems", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesParentheticalDetail" ], "lang": { "en-us": { "role": { "documentation": "Accrued expenses and other current liabilities.", "label": "Accrued Expenses and Other Current Liabilities [Line Items]" } } }, "auth_ref": [] }, "mnkd_AccruedExpensesAndOtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AccruedExpensesAndOtherCurrentLiabilitiesMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses And Other Current Liabilities", "label": "Accrued Expenses And Other Current Liabilities [Member]", "documentation": "Accrued expenses and other current liabilities." } } }, "auth_ref": [] }, "mnkd_AccruedInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AccruedInterestMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Accrued interest.", "label": "Accrued Interest [Member]", "terseLabel": "Accrued Interest" } } }, "auth_ref": [] }, "mnkd_AccruedInterestNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AccruedInterestNoncurrent", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest \u2014 promissory note", "label": "Accrued Interest Noncurrent", "documentation": "Accrued interest noncurrent.", "verboseLabel": "Accrued interest - Mann Group convertible note" } } }, "auth_ref": [] }, "mnkd_AccruedInterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AccruedInterestReceivable", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest receivable", "label": "Accrued Interest Receivable", "documentation": "Accrued interest receivable." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Accrued expenses and other current liabilities", "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Liabilities Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r74" ] }, "us-gaap_AccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities [Member]", "terseLabel": "Accrued interest", "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered." } } }, "auth_ref": [ "r74" ] }, "mnkd_AccruedPaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AccruedPaidInKindInterest", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest paid-in-kind", "label": "Accrued Paid In Kind Interest", "documentation": "Accrued paid in kind interest." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Professional fees", "label": "Accrued Professional Fees Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r74" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": { "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "negatedLabel": "Less accumulated depreciation", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r37", "r201", "r690" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r17", "r18", "r97", "r211", "r685", "r718", "r719" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [
```

```
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r13", "r18", "r555", "r558", "r622", "r714", "r715", "r1054", "r1055", "r1056", "r1069", "r1070", "r1071", "r1073" ] }, "mnkd_AdditionOfRightOfUseAssetAndFinancingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AdditionOfRightOfUseAssetAndFinancingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Addition of right-of-use-asset and financing lease liability.", "label": "Addition of right-of-use-asset and financing lease liability", "terseLabel": "Addition of right-of-use-asset and financing lease liability" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r982" ] }, "mnkd_AdditionalBaseRentConcession": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AdditionalBaseRentConcession", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Additional Base Rent Concession", "label": "Additional Base Rent Concession", "terseLabel": "Additional base rent concession" } } }, "auth_ref": [] }, "mnkd_AdditionalOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AdditionalOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Additional option exercise and development milestone payments to be receive", "label": "Additional Option Exercise And Development Milestone Payments To Be Received", "documentation": "Additional option exercise and development milestone payments to be received." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid In Capital Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r86" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid In Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r730", "r1069", "r1070", "r1071", "r1073", "r1185", "r1260" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r995" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r995" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r995" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r995" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total", "terseLabel": "Stock-based compensation expense", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r40", "r50", "r472" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs", "negatedLabel": "Issuance costs associated with at the- market offering", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": [ "r14", "r135" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:", "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForApplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForApplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1028" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r954", "r964", "r974", "r1006" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r957", "r967", "r977", "r1009" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1029" ] }, "mnkd_AgreementAmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AgreementAmendmentDescription", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment description", "label": "Agreement Amendment Description", "documentation": "Agreement amendment description." } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r995" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r1002" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r958", "r968", "r978", "r1002", "r1010", "r1014", "r1022" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r1020" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseStockBasedCompensationExpenseRecognizedInCondensedConsolidatedStatemen ], "lang": { "en-us": { "role": { "label": "Allocated Share Based Compensation Expense", "terseLabel": "Total", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r501", "r506" ] }, "mnkd_AllocatedTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AllocatedTransactionPrice", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Allocated Transaction Price", "documentation": "Allocated transaction price.", "terseLabel": "Allocated transaction price" } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureScheduleOfAccountsReceivableNetDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit losses and doubtful accounts", "label": "Allowance For Doubtful Accounts Receivable Current", "negatedLabel": "Allowance for credit losses", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r212", "r301", "r342" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "mnkd_AmortizationOfDebtDiscountAndPrepaymentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AmortizationOfDebtDiscountAndPrepaymentFee", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsScheduleOfAmortizationOfPremiumAndAccretionOfDebtIssuanceCostsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt discount and prepayment fee", "label": "Amortization of debt discount and prepayment fee", "documentation": "Amortization of debt discount and prepayment fee." } } }, "auth_ref": [] }, "mnkd_AmortizationOfDeferredTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AmortizationOfDeferredTransactionCosts", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRoyaltyLiabilityAccountRollForwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred transaction costs", "label": "Amortization of Deferred Transaction Costs", "documentation": "Amortization of deferred transaction costs." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsScheduleOfAmortizationOfPremiumAndAccretionOfDebtIssuanceCostsDetail" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance cost", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r106", "r426", "r1063", "r1199" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total", "terseLabel": "Amortization of debt issuance cost", "label": "Amortization Of Financing Costs And Discounts", "verboseLabel": "Amortization of debt discount and issuance costs", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r426", "r892", "r893", "r1063", "r1199" ] }, "mnkd_AmortizationOfLiabilityForSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AmortizationOfLiabilityForSaleOfFutureRoyalties", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of liability for sale of future royalties", "label": "Amortization Of Liability For Sale Of Future Royalties", "documentation": "Amortization Of Liability For Sale Of Future Royalties" } } }, "auth_ref": [] }, "mnkd_AmortizationOfTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AmortizationOfTransactionCosts", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of transaction costs", "label": "Amortization Of Transaction Costs", "documentation": "Amortization of transaction costs." } } }, "auth_ref": [] }, "mnkd_AmortizationOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AmortizationOnInvestments", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization on investments", "label": "Amortization On Investments", "documentation": "Amortization on investments." } } }, "auth_ref": [] }, "mnkd_AmortizedCostMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AmortizedCostMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "label": "Amortized Cost [Member]", "documentation": "Amortized cost.", "terseLabel": "Amortized Cost" } } }, "auth_ref": [] }, "mnkd_AmountReceivableOnMaturedInvestment": {
```

```
"xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AmountReceivableOnMaturedInvestment", "crdr": "debit", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Amount receivable on
matured investment", "label": "Amount Receivable On Matured Investment", "documentation": "Amount receivable on matured investment." } } }, "auth_ref": [] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Anti-dilutive securities excluded from computation of earnings per share", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share
Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit
(EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for
the period presented." } } }, "auth_ref": [ "r267" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
"documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r31" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveParentheticalDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded From
Computation Of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities Name [Domain]", "documentation": "Incremental common shares attributable to securities that
were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r31"
] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ArrangementsAndNonarrangementTransactionsMember", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsSummaryOfUtRevenueDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail1",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Arrangements And Nonarrangement Transactions [Member]", "documentation": "Collaborative
arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r546" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfPreliminaryPurchaseConsiderationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionTables",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Asset
Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r362", "r363", "r364", "r365", "r366", "r1179" ] }, "us-
gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred",
"crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfPreliminaryPurchaseConsiderationDetail" ], "lang": {
"en-us": { "role": { "totalLabel": "Total", "label": "Asset Acquisition Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is
not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r911", "r1180", "r1181", "r1182" ] }, "us-
gaap_AssetAcquisitionConsiderationTransferredAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetAcquisitionConsiderationTransferredAbstract", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfPreliminaryPurchaseConsiderationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Fair value of consideration.", "label": "Asset Acquisition Consideration Transferred [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetAcquisitionConsiderationTransferredContingentConsideration", "crdr": "credit", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfPreliminaryPurchaseConsiderationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Fair value of contingent consideration", "label": "Asset Acquisition Consideration Transferred Contingent Consideration", "documentation": "Amount of contingent consideration
recognized as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r1180", "r1181", "r1182" ] }, "us-gaap_AssetAcquisitionDateOfAcquisitionAgreement": { "xbrltype":
"dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDateOfAcquisitionAgreement", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, date
of acquisition agreement", "label": "Asset Acquisition Date Of Acquisition Agreement", "documentation": "Date when asset acquisition agreement is executed, in YYYY-MM-DD format." } }
}, "auth_ref": [ "r1179" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfPreliminaryPurchaseConsiderationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionTables",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Asset
Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r362", "r363", "r364", "r365", "r366", "r1179" ] }, "us-gaap_AssetAcquisitionEffectiveDateOfAcquisition": {
"xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionEffectiveDateOfAcquisition", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition,
effective date of acquisition", "label": "Asset Acquisition Effective Date Of Acquisition", "documentation": "Date when acquirer obtains control of acquired asset, in YYYY-MM-DD format." }
} }, "auth_ref": [ "r1179", "r1180" ] }, "us-gaap_AssetAcquisitionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetAcquisitionTableTextBlock", "presentation":[ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionTables" ], "lang": { "en-us": { "role": {
"terseLabel": "Schedule of Preliminary Purchase Consideration", "label": "Asset Acquisition Table [Text Block]", "documentation": "Tabular disclosure of asset acquisition." } } }, "auth_ref":
[ "r1179" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label":
"Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r148", "r163", "r205", "r235", "r272", "r275", "r280", "r290", "r339",
"r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r548", "r552", "r589", "r680", "r754", "r881", "r882", "r927", "r945", "r1142", "r1143", "r1209" ] }, "us-
gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "ASSETS", "label": "Assets
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current
assets", "label": "Assets Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r195", "r215", "r235",
"r339", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r548", "r552", "r589", "r927", "r1142", "r1143", "r1209" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label":
"Assets Current [Abstract]" } } }, "auth_ref": [] }, "mnkd_AtMarketIssuanceSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930",
"localname": "AtMarketIssuanceSalesAgreementMember", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "At Market
Issuance Sales Agreement", "label": "At Market Issuance Sales Agreement [Member]", "documentation": "At market issuance sales agreement." } } }, "auth_ref": [] },
"mnkd_AtTheMarketIssuanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AtTheMarketIssuanceMember", "presentation":
["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "At The Market
Issuance", "label": "At The Market Issuance [Member]", "documentation": "At the market issuance." } } }, "auth_ref": [] }, "mnkd_AtTheMarketOfferingMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AtTheMarketOfferingMember", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "At-the-
market Placement", "label": "At The Market Offering [Member]", "documentation": "At-the-market offering." } } }, "auth_ref": [] }, "mnkd_AudioVisualEquipmentMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "AudioVisualEquipmentMember", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfRemainingFinancingLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "documentation": "Audio visual
equipment.", "label": "Audio Visual Equipment [Member]", "terseLabel": "Audio Visual Equipment" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Debt Securities, Available-
for-Sale, Total", "terseLabel": "Investment securities", "label": "Available For Sale Securities Debt Securities", "documentation": "Amount of investment in debt security measured at fair
value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r311", "r350", "r566", "r670", "r914", "r918", "r1085", "r1189", "r1190",
"r1191" ] }, "us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AvailableForSaleSecuritiesPurchasedOptionsPricePolicy", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
"Available-for-Sale Investment", "label": "Available For Sale Securities Purchased Options Price Policy", "documentation": "Disclosure of accounting policy for premium paid to acquire
option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r64" ] },
"ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation":[
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r1017" ] },
"ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation":[
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [
"r1018" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": {
"label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r1013" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation":[ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ],
"lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r1013" ] },
"ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation":[
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [
"r1013" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } },
"auth_ref": [ "r1013" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock",
```

```
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r1013" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r1013" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveParentheticalDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseStockBasedCompensationExpenseRecognizedInCondensedConsolidatedStatemen
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r1016" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1015" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r1014" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r1014" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r380", "r1227", "r1228" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r62", "r63", "r380", "r1227", "r1228" ] }, "mnkd_BasisOfPresentationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "BasisOfPresentationPolicyTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis Of Presentation Policy [Text Block]", "documentation": "Basis of Presentation." } } }, "auth_ref": [] }, "mnkd_BiommSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "BiommSAMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Biomm", "label": "Biomm S A [Member]", "documentation": "Biomm S.A." } } }, "auth_ref": [] }, "us-gaap_BuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingImprovementsMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": { "label": "Building Improvements [Member]", "terseLabel": "Building Improvements", "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r124" ] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r124" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfRemainingFinancingLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r362", "r363", "r364", "r365", "r366", "r542", "r905", "r906" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfRemainingFinancingLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r51", "r52", "r362", "r363", "r364", "r365", "r366", "r542", "r905", "r906" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfPreliminaryPurchaseConsiderationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionTables" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r542" ] }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionSummaryOfSupplementalProFormaInformationUnauditedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share - basic", "label": "Business Acquisition Pro Forma Earnings Per Share Basic", "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r1035", "r1036" ] }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionSummaryOfSupplementalProFormaInformationUnauditedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share - diluted", "label": "Business Acquisition Pro Forma Earnings Per Share Diluted", "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r1035", "r1036" ] }, "us-gaap_BusinessAcquisitionProFormaInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationAbstract", "lang": { "en-us": { "role": { "label": "Business Acquisition Pro Forma Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Supplemental Pro Forma Information (Unaudited)", "label": "Business Acquisition Pro Forma Information [Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": [ "r1035", "r1036" ] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionSummaryOfSupplementalProFormaInformationUnauditedDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss", "label": "Business Acquisitions Pro Forma Net Income Loss", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r540", "r541" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionSummaryOfSupplementalProFormaInformationUnauditedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net revenue", "label": "Business Acquisitions Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r540", "r541" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination And Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationBargainPurchaseGainRecognizedAmount", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain on bargain purchase", "terseLabel": "Gain on bargain purchase", "label": "Business Combination, Bargain Purchase, Gain Recognized, Amount", "documentation": "In a business combination in which the amount of net identifiable assets acquired and liabilities assumed exceeds the aggregate consideration transferred or to be transferred (as defined), this element represents the amount of gain recognized by the entity." } } }, "auth_ref": [ "r55", "r56", "r57", "r58", "r59", "r60" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransaction" ], "lang": { "en-us": { "role": { "terseLabel": "Pulmatrix Transaction", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r138", "r543" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": [ "r54" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets [Abstract]" } } }, "auth_ref": [] }, "mnkd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of iSPERSE license", "terseLabel": "iSPERSE License - IPR&D", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, In-Process Research and Development", "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, in-process research and development." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r54" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
```

```
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities [Abstract]" } } }, "auth_ref": [] }, "mnkd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability - Bedford R&D facility", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Liability", "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed operating lease liability." } } }, "auth_ref": [] }, "mnkd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset - Bedford R&D facility", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right Of Use Assets", "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed operating lease right of use assets." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total", "terseLabel": "Property and equipment", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r53", "r54" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net assets acquired - Gain on bargain purchase", "label": "Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r54" ] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Business Combinations Policy", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r139", "r140", "r141", "r142" ] }, "mnkd_BusinessPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "BusinessPolicyTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Business", "label": "Business Policy [Text Block]", "documentation": "Business." } } }, "auth_ref": [] }, "us-gaap_CaliforniaFranchiseTaxBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CaliforniaFranchiseTaxBoardMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "California Franchise Tax Board [Member]", "terseLabel": "California", "documentation": "Designated tax department of the government of the state of California." } } }, "auth_ref": [] }, "mnkd_CantorFitzgeraldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CantorFitzgeraldMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cantor Fitzgerald", "label": "Cantor Fitzgerald [Member]", "documentation": "Cantor fitzgerald." } } }, "auth_ref": [] }, "mnkd_CapacityFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CapacityFee", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsParent" ], "lang": { "en-us": { "role": { "terseLabel": "Capacity fee", "label": "Capacity Fee", "documentation": "Capacity fee." } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred But Not Yet Paid", "terseLabel": "Non-cash construction in progress, property and equipment", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r28", "r29", "r30" ] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Carrying Reported Amount Fair Value Disclosure [Member]", "terseLabel": "Carrying Amount", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r65", "r66" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfHeldToMaturityInvestmentsParentheticalDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "terseLabel": "Cash and cash equivalents", "label": "Cash And Cash Equivalents At Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r25", "r198", "r863" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash And Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r198" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy", "terseLabel": "Cash, Cash Equivalents and Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r26", "r146" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD", "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r25", "r113", "r232" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r113" ] }, "us-gaap_CashCollateralForBorrowedSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCollateralForBorrowedSecurities", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Cash Collateral for Borrowed Securities", "terseLabel": "Letters of credit secured by cash held in restricted depository account", "documentation": "Carrying amount as of the balance sheet date of cash collateral held for borrowed securities, for which the cash is restricted as to withdrawal or usage." } } }, "auth_ref": [ "r147", "r1225" ] }, "mnkd_CashEquivalentsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CashEquivalentsAndInvestments", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Total cash equivalents and investments", "label": "Cash Equivalents And Investments", "documentation": "Cash equivalents and investments.", "negatedLabel": "Total cash equivalents and investments" } } }, "auth_ref": [] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: cash equivalents", "totalLabel": "Cash Equivalents, at Carrying Value, Total", "label": "Cash Equivalents At Carrying Value", "terseLabel": "Less cash equivalents", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r1047", "r1225" ] }, "mnkd_CasperLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CasperLLCMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Casper L L C [Member]", "documentation": "1 Casper, LLC.", "terseLabel": "Casper L L C" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r993" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r990" ] },
"ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r988" ] }, "mnkd_CiplaLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CiplaLtdMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
```

```
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail1" ], "lang": { "en-us": { "role": { "terseLabel": "Cipla Ltd", "label": "Cipla Ltd [Member]", "documentation": "Cipla Ltd." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class Of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r207", "r208", "r209", "r274", "r436", "r437", "r438", "r440", "r443", "r448", "r450", "r723", "r724", "r725", "r726", "r894", "r1032", "r1065" ] }, "mnkd_ClinicalTrialExpensePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ClinicalTrialExpensePolicyTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Clinical Trial Expense Policy [Text Block]", "documentation": "Clinical Trial Expense", "terseLabel": "Clinical Trial Expenses" } } }, "auth_ref": [] }, "mnkd_CoPromotionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CoPromotionAgreementMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Co-Promotion Agreement", "label": "Co-Promotion Agreement [Member]", "documentation": "Co-promotion agreement." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PypDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r994" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PypDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r994" ] }, "mnkd_CollaborationAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CollaborationAndLicenseAgreementMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration and License Agreement", "label": "Collaboration And License Agreement [Member]", "documentation": "Collaboration and license agreement." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration, Licensing and Other Arrangements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r177", "r179", "r191" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsSummaryOfUtRevenueDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail1",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r546" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Bonds and Paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r128", "r394", "r939", "r940", "r941", "r942" ] }, "mnkd_CommercialSupplyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CommercialSupplyAgreementMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsSummaryOfUtRevenueDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Supply Agreement", "label": "Commercial Supply Agreement [Member]", "documentation": "commercial supply agreement." } } }, "auth_ref": [] }, "mnkd_CommercialSupplyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CommercialSupplyMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsSummaryOfUtRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Supply", "label": "Commercial Supply [Member]", "documentation": "Commercial Supply [ Member]" } } }, "auth_ref": [] }, "mnkd_CommercializationAndContinuousImprovementActivitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CommercializationAndContinuousImprovementActivitiesMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Commercialization and Continuous Improvement Activities", "label": "Commercialization And Continuous Improvement Activities [Member]", "documentation": "Commercialization and continuous improvement activities." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 15)", "label": "Commitments And Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r81", "r152", "r682", "r741" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments And Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r126", "r385", "r386", "r856", "r1129", "r1134" ] }, "mnkd_CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CommitmentsAndContingenciesLineItems", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfRemainingFinancingLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRoyaltyLiabilityAccountRollForwardDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumOfficeAndVehicleLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments And Contingencies [Line Items]", "label": "Commitments And Contingencies [Line Items]", "documentation": "Commitments and Contingencies [Line Items]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Contingencies", "label": "Commitments And Contingencies Policy [Text Block]", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r38", "r857" ] }, "mnkd_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CommitmentsAndContingenciesTable", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfRemainingFinancingLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRoyaltyLiabilityAccountRollForwardDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumOfficeAndVehicleLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments And Contingencies [Table]", "label": "Commitments And Contingencies [Table]", "documentation": "Commitments and Contingencies [Table]" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock available for issuance", "label": "Common Stock Capital Shares Reserved For Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r84" ] }, "mnkd_CommonStockIssuedToPayInterest": { "xbrltype": "sharesItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CommonStockIssuedToPayInterest", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued to pay interest", "label": "Common Stock Issued To Pay Interest", "documentation": "Common stock issued to pay interest." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r935", "r936", "r937", "r939", "r940", "r941", "r942", "r1069", "r1070", "r1073", "r1185", "r1258", "r1260" ] }, "mnkd_CommonStockOptionsAndPerformanceBasedStockOptionAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CommonStockOptionsAndPerformanceBasedStockOptionAwardsMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Options and PNQs", "label": "Common Stock Options And Performance Based Stock Option Awards [Member]", "documentation": "Common stock options and performance based stock option awards." } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value", "label": "Common Stock Par Or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r84" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r84", "r742" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued",
```

```
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "label": "Common Stock Shares Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r84" ] }, "us-gaap_CommonStockSharesOutstanding": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares outstanding", "label": "Common Stock Shares Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } },
"auth_ref": [ "r14", "r84", "r742", "r760", "r1260", "r1261" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockValue", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.01 par value - 800,000,000 shares authorized; 275,775,038 and 270,034,495 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively", "label": "Common Stock Value", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r84", "r684", "r927" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } } }, "auth_ref": [ "r999" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r998" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [
"r1000" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r997" ] }, "us-
gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationRelatedCostsPolicyTextBlock",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"terseLabel": "Stock-Based Compensation", "label": "Compensation Related Costs Policy [Text Block]", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r136", "r137" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label":
"Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive income (loss)", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r19", "r217", "r219", "r224", "r671", "r697", "r698" ] }, "mnkd_ComputerEquipmentAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "ComputerEquipmentAndSoftwareMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": { "label": "Computer Equipment And Software [Member]", "documentation": "Computer equipment and software.", "terseLabel": "Computer Equipment and Software" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
"Concentration of Credit Risk", "label": "Concentration Risk Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r69", "r181" ] },
"mnkd_ConsecutiveTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ConsecutiveTradingDays", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Consecutive trading days", "label": "Consecutive Trading Days", "documentation": "Consecutive trading days." } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
"Principles of Consolidation", "label": "Consolidation Policy [Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r61", "r872" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": { "label": "Construction In Progress [Member]",
"terseLabel": "Construction in Progress", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "mnkd_ContingentLiability": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "ContingentLiability", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role":
{ "verboseLabel": "Contingent liability for milestone payments", "label": "Contingent Liability", "documentation": "Contingent Liability" } } }, "auth_ref": [] },
"mnkd_ContingentLiabilityRemainingPayableAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"ContingentLiabilityRemainingPayableAmount", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role":
{ "verboseLabel": "Contingent liability remain payable", "label": "Contingent Liability Remaining Payable Amount", "documentation": "Contingent liability remaining payable amount." } } },
"auth_ref": [] }, "mnkd_ContingentMilestoneLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"ContingentMilestoneLiabilityMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Contingent Milestone Liability", "label": "Contingent Milestone Liability [Member]", "documentation": "Contingent milestone liability." } } }, "auth_ref": [] },
"mnkd_ContolledEquityOfferingSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"ContolledEquityOfferingSalesAgreementMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Controlled Equity Offering Sales Agreement", "label": "Contolled Equity Offering Sales Agreement [Member]", "documentation": "Contolled equity offering sales agreement." } } }, "auth_ref": [] },
"us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "totalLabel": "Contract with Customer, Liability, Total", "verboseLabel": "Deferred revenue", "label": "Contract With Customer Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r452", "r453", "r459" ] }, "us-
gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr":
"credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue - current", "terseLabel": "Deferred revenue \u2014 current", "label": "Contract With Customer Liability Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r452", "r453", "r459" ] }, "us-
gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent",
"crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue - non-current", "terseLabel": "Deferred revenue \u2014 long term", "label": "Contract With Customer Liability Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r452", "r453", "r459" ] }, "us-
gaap_ContractWithCustomerReceivableAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ContractWithCustomerReceivableAllowanceForCreditLoss", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Reserve for allowance for credit losses", "label": "Contract With Customer Receivable Allowance For Credit Loss", "documentation": "Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional." } } }, "auth_ref": [ "r342", "r454" ] }, "us-
gaap_ConvertibleLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleLongTermNotesPayable", "crdr": "credit",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsSummaryOfCarryingAmountOfBorrowingsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Mann Group convertible note", "terseLabel": "Senior convertible notes", "label": "Convertible Long Term Notes Payable", "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r15" ] },
"mnkd_ConvertibleNoteInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ConvertibleNoteInterestMember",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": {
"terseLabel": "Convertible Note Interest", "label": "Convertible Note Interest [Member]", "documentation": "Convertible note interest." } } }, "auth_ref": [] },
"mnkd_ConvertibleNotePrincipalAndInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"ConvertibleNotePrincipalAndInterestMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "documentation":
"Convertible note principal and interest.", "label": "Convertible Note Principal And Interest [Member]", "terseLabel": "Convertible Note Principal and Interest" } } }, "auth_ref": [] },
"mnkd_ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ConvertibleNotesMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel":
"Convertible Note", "label": "Convertible Notes [Member]", "documentation": "Convertible notes." } } }, "auth_ref": [] }, "mnkd_ConvertibleNotesNonCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ConvertibleNotesNonCurrent", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Mann Group convertible note", "label": "Convertible Notes Non Current", "documentation": "Convertible notes non current." } } }, "auth_ref": [] }, "mnkd_ConvertiblePromissoryNoteMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ConvertiblePromissoryNoteMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Promissory Note", "label": "Convertible Promissory Note [Member]", "documentation": "Convertible promissory note." } } }, "auth_ref": [] }, "mnkd_ConvertibleSharesOfCommonStock": { "xbrltype":
"sharesItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ConvertibleSharesOfCommonStock", "presentation": [
```

```
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible shares of common stock", "label": "Convertible Shares Of Common Stock", "documentation": "Convertible shares of common stock." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Cost of Goods and Services Sold, Total", "terseLabel": "Cost of goods sold", "label": "Cost Of Goods And Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r99", "r100", "r665" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Cost of Revenue, Total", "terseLabel": "Cost of revenue", "label": "Cost Of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r101", "r235", "r339", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r589", "r881", "r1142" ] }, "mnkd_CostOfRevenuesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CostOfRevenuesPolicyTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Revenues", "label": "Cost Of Revenues Policy [Text Block]", "documentation": "Cost of revenues." } } }, "auth_ref": [] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname", "CostOfSalesPolicyTextBlock", "presentation", [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang", { "en-us", { "role", { "terseLabel", "Cost of Goods Sold", "label": "Cost Of Sales Policy [Text Block]", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref", [ "r1039" ] ], "us-gaap_CostsAndExpenses", { "xbrltype", "monetaryItemType", "nsuri", "http://fasb.org/us-gaap/2024", "localname", "CostsAndExpenses", "crdr", "debit", "presentation", [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang", { "en-us", { "role", { "totalLabel", "Total expenses", "label", "Costs And Expenses", "documentation", "Total costs of sales and operating expenses for the period." } } }, "auth_ref", [ "r108" ] }, "us-gaap_CostsAndExpensesAbstract", { "xbrltype", "stringItemType", "nsuri", "http://fasb.org/us-gaap/2024", "localname", "CostsAndExpensesAbstract", "presentation", [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang", { "en-us", { "role", { "terseLabel", "Expenses:", "label", "Costs And Expenses [Abstract]" } } }, "auth_ref", [] }, "srt_CounterpartyNameAxis", { "xbrltype", "stringItemType", "nsuri", "http://fasb.org/srt/2024", "localname", "CounterpartyNameAxis", "presentation", [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail1",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail" ], "lang", { "en-us", { "role", { "terseLabel", "Counterparty Name", "label", "Counterparty Name [Axis]" } } }, "auth_ref", [ "r239", "r240", "r408", "r438", "r626", "r646", "r679", "r869", "r871" ] }, "dei_CoverAbstract", { "xbrltype", "stringItemType", "nsuri", "http://xbrl.sec.gov/dei/2024", "localname", "CoverAbstract", "lang", { "en-us", { "role", { "label", "Cover [Abstract]", "documentation", "Cover page." } } }, "auth_ref", [] }, "us-gaap_CreditFacilityAxis", { "xbrltype", "stringItemType", "nsuri", "http://fasb.org/us-gaap/2024", "localname", "CreditFacilityAxis", "presentation", [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsSummaryOfCarryingAmountOfBorrowingsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRoyaltyLiabilityAccountRollForwardDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r394", "r1140" ] }, "mnkd_CreditFacilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CreditFacilityCurrent", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Credit facility current.", "label": "Credit Facility Current", "terseLabel": "Midcap credit facility - current" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsSummaryOfCarryingAmountOfBorrowingsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRoyaltyLiabilityAccountRollForwardDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r394", "r1140", "r1141" ] }, "mnkd_CreditFacilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CreditFacilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Midcap credit facility - long term", "label": "Credit Facility Noncurrent", "documentation": "Credit facility noncurrent." } } }, "auth_ref": [] }, "mnkd_CumulativeGainLossOnAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CumulativeGainLossOnAvailableForSaleSecurities", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "documentation": "Cumulative gain loss on available for sale securities.", "label": "Cumulative Gain Loss On Available For Sale Securities", "terseLabel": "Cumulative gain on available-for-sale securities" } } }, "auth_ref": [] }, "mnkd_CumulativeLossOnAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CumulativeLossOnAvailableForSaleSecurities", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative loss on available-for-sale securities", "negatedLabel": "Cumulative loss on available-for-sale securities", "label": "Cumulative Loss On Available For Sale Securities", "documentation": "Cumulative loss on available-for-sale securities" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "mnkd_CurrentPortionOfMilestoneRightLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CurrentPortionOfMilestoneRightLiability", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of milestone rights liability", "label": "Current Portion Of Milestone Right Liability", "documentation": "Current portion of milestone right liability." } } }, "auth_ref": [] }, "mnkd_CustomerDiscountsAndAllowances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "CustomerDiscountsAndAllowances", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Discounts and allowances for commercial product sales", "label": "Customer Discounts And Allowances", "documentation": "Customer Discounts And Allowances" } } }, "auth_ref": [] }, "mnkd_DateOfAgreementInitiationForMarketingAndDistribution": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "DateOfAgreementInitiationForMarketingAndDistribution", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Marketing and distribution agreement date", "label": "Date Of Agreement Initiation For Marketing And Distribution", "documentation": "Date of agreement initiation for marketing and distribution." } } }, "auth_ref": [] }, "mnkd_DavidThomsonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "DavidThomsonMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "David Thomson", "label": "David Thomson [Member]", "documentation": "David Thomson." } } }, "auth_ref": [] }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionByUniqueDescriptionAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Conversion Description [Axis]", "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction." } } }, "auth_ref": [ "r28", "r30" ] }, "mnkd_DebtConversionConvertedInstrumentAccruedInterestOfNotesValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "DebtConversionConvertedInstrumentAccruedInterestOfNotesValue", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of notes accrued interest to common shares, value", "label": "Debt Conversion Converted Instrument Accrued Interest Of Notes Value", "documentation": "Debt conversion converted instrument accrued interest of notes value." } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance amount", "label": "Debt Conversion Converted Instrument Amount1", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r28", "r30" ] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Conversion of notes to common shares, shares", "verboseLabel": "Capitalized interest into common stock", "terseLabel": "Conversion of debt shares issued", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r28", "r30" ] }, "us-gaap_DebtConversionNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionNameDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Name [Domain]", "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r28", "r30" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowings" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r127", "r233", "r375", "r376", "r377", "r378", "r379", "r393", "r394", "r404", "r410", "r411", "r412", "r413", "r414", "r415", "r420", "r427", "r428", "r430", "r600" ] }, "mnkd_DebtInstrumentAdvanceAvailableDate": { "xbrltype": "dateItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "DebtInstrumentAdvanceAvailableDate", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument advance available date", "label": "Debt Instrument Advance Available Date", "documentation": "Debt instrument advance available date." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
```

```
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Debt
Instrument", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [
"r15", "r73", "r74", "r149", "r151", "r241", "r405", "r406", "r407", "r408", "r409", "r411", "r416", "r417", "r418", "r419", "r421", "r422", "r423", "r424", "r425", "r426", "r889", "r890",
"r891", "r892", "r893", "r925", "r1066", "r1130", "r1131", "r1132", "r1198", "r1200" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel":
"Interest rate (LIBOR)", "label": "Debt Instrument Basis Spread On Variable Rate1", "documentation": "Percentage points added to the reference rate to compute the variable rate on the
debt instrument." } } }, "auth_ref": [] }, "mnkd_DebtInstrumentCapInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"DebtInstrumentCapInterestRate", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Interest rate cap", "label": "Debt Instrument Cap Interest Rate", "documentation": "Debt instrument cap interest rate." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsScheduleOfMaturitiesOfCompanysBorrowingsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total
principal payments", "label": "Debt Instrument Carrying Amount", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes,
but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r15", "r151", "r431"
] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentConvertibleConversionPrice1", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel":
"Conversion price", "terseLabel": "Conversion price", "label": "Debt Instrument Convertible Conversion Price1", "documentation": "The price per share of the conversion feature embedded
in the debt instrument." } } }, "auth_ref": [ "r129", "r407" ] }, "mnkd_DebtInstrumentConvertibleConversionPricePercentage": { "xbrltype": "percentItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "DebtInstrumentConvertibleConversionPricePercentage", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Conversion price percentage", "label": "Debt Instrument Convertible Conversion Price Percentage", "documentation": "Debt instrument convertible conversion price percentage." } } },
"auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentConvertibleConversionRatio1", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "No
of convertible shares", "label": "Debt Instrument Convertible Conversion Ratio1", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares
divided by debt principal amount." } } }, "auth_ref": [ "r44", "r77", "r133", "r134", "r407" ] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype": "integerItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number
of consecutive months", "label": "Debt Instrument, Convertible, Threshold Trading Days", "documentation": "Threshold number of specified trading days that common stock price to
conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } } }, "auth_ref": [] }, "us-
gaap_DebtInstrumentDateOfFirstRequiredPayment1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentDateOfFirstRequiredPayment1",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Debt instrument, date of first required interest payment", "label": "Debt Instrument Date Of First Required Payment1", "documentation": "Date the debt agreement
requires the first payment to be made, in YYYY-MM-DD format." } } }, "auth_ref": [ "r15", "r68" ] }, "mnkd_DebtInstrumentExtendedInterestOnlyDate": { "xbrltype": "dateItemType",
"nsuri": "http://www.mannkindcorp.com/20240930", "localname": "DebtInstrumentExtendedInterestOnlyDate", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt
instrument extended interest only date", "label": "Debt Instrument Extended Interest Only Date", "documentation": "Debt instrument extended interest only date." } } }, "auth_ref": [] },
"us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Principal amount", "label":
"Debt Instrument Face Amount", "verboseLabel": "Amount Due", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r405", "r600", "r601",
"r890", "r891", "r925" ] }, "mnkd_DebtInstrumentFairValueInExcessOfFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"DebtInstrumentFairValueInExcessOfFaceAmount", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Debt instrument fair value in excess of face amount", "label": "Debt Instrument Fair Value In Excess Of Face Amount", "documentation": "Debt instrument fair value in excess of face
amount." } } }, "auth_ref": [] }, "mnkd_DebtInstrumentFloorRate": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"DebtInstrumentFloorRate", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Interest rate floor", "label": "Debt Instrument Floor Rate", "documentation": "Debt instrument floor rate." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt
instrument payment term description", "label": "Debt Instrument Frequency Of Periodic Payment", "documentation": "Description of the frequency of periodic payments (monthly,
quarterly, annual)." } } }, "auth_ref": [ "r15", "r68" ] }, "mnkd_DebtInstrumentInitialConversionPriceOfPremiumPercentage": { "xbrltype": "percentItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "DebtInstrumentInitialConversionPriceOfPremiumPercentage", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Initial conversion price of premium percentage", "label": "Debt Instrument Initial Conversion Price Of Premium Percentage", "documentation": "Debt Instrument initial conversion price of
premium percentage." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Annual
interest rate", "label": "Debt Instrument Interest Rate Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering
interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r76", "r433", "r600", "r601", "r925" ] }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateIncreaseDecrease", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role":
{ "terseLabel": "Interest on loans increased, percentage", "label": "Debt Instrument Interest Rate Increase Decrease", "verboseLabel": "Increased interest rate", "documentation":
"Incremental percentage increase (decrease) in the stated rate on a debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Stated interest rate",
"terseLabel": "Annual interest rate", "verboseLabel": "Senior notes, effective interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } }
}, "auth_ref": [ "r76", "r406" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsSummaryOfCarryingAmountOfBorrowingsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt
Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r241", "r405", "r406", "r407", "r408", "r409", "r411", "r416", "r417",
"r418", "r419", "r421", "r422", "r423", "r424", "r425", "r426", "r429", "r889", "r890", "r891", "r892", "r893", "r925", "r1066", "r1198", "r1200" ] }, "us-gaap_DebtInstrumentMaturityDate": {
"xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Maturity date", "label": "Debt Instrument Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [
"r206", "r889", "r1190", "r1191" ] }, "mnkd_DebtInstrumentMaturityMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.mannkindcorp.com/20240930",
"localname": "DebtInstrumentMaturityMonthAndYear", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Maturity date", "label": "Debt Instrument Maturity Month And Year", "documentation": "Debt instrument maturity month and year." } } }, "auth_ref": [] }, "us-
gaap_DebtInstrumentMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMeasurementInput", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Note payable, fair value key
inputs", "label": "Debt Instrument Measurement Input", "verboseLabel": "Volatility percentage", "documentation": "Value of input used to measure debt instrument, including, but not
limited to, convertible and non-convertible debt." } } }, "auth_ref": [ "r1189", "r1190", "r1191" ] }, "mnkd_DebtInstrumentMeasurementInputAfterChange": { "xbrltype":
"decimalItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "DebtInstrumentMeasurementInputAfterChange", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Note payable, percentage of
hypothetical yield", "label": "Debt Instrument Measurement Input After Change", "documentation": "Debt instrument measurement input after change.", "verboseLabel": "Hypothetical yield
percentage" } } }, "auth_ref": [] }, "mnkd_DebtInstrumentMinimumCashCovenant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"DebtInstrumentMinimumCashCovenant", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Debt instrument minimum cash covenant.", "label": "Debt Instrument Minimum Cash Covenant", "terseLabel": "Minimum cash covenant" } } }, "auth_ref": [] },
```

```
"mnkd_DebtInstrumentMinimumUnrestrictedCashAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "DebtInstrumentMinimumUnrestrictedCashAndShortTermInvestments", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument minimum unrestricted cash and short-term investments", "label": "Debt Instrument Minimum Unrestricted Cash And Short Term Investments", "documentation": "Debt instrument minimum unrestricted cash and short-term investments." } } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name", "label": "Debt Instrument Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r15", "r241", "r405", "r406", "r407", "r408", "r409", "r411", "r416", "r417", "r418", "r419", "r421", "r422", "r423", "r424", "r425", "r426", "r889", "r890", "r891", "r892", "r893", "r925", "r1066", "r1130", "r1131", "r1132", "r1198", "r1200" ] },
"mnkd_DebtInstrumentOutstandingPrincipalAmountRedeemed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "DebtInstrumentOutstandingPrincipalAmountRedeemed", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding principal amount redeemed", "label": "Debt Instrument Outstanding Principal Amount Redeemed", "documentation": "Debt instrument outstanding principal amount redeemed." } } }, "auth_ref": [] }, "mnkd_DebtInstrumentPaymentNumberOfEqualMonthlyInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "DebtInstrumentPaymentNumberOfEqualMonthlyInstallments", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt payable number of equal monthly installments", "label": "Debt Instrument Payment Number Of Equal Monthly Installments", "documentation": "Debt instrument payment number of equal monthly installments." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionDescription", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument redemption description", "label": "Debt Instrument Redemption Description", "documentation": "Description of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r159" ] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period", "label": "Debt Instrument Redemption Period [Axis]", "documentation": "Information by period of debt redemption feature under terms of debt agreement." } } }, "auth_ref": [ "r159" ] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period", "label": "Debt Instrument Redemption Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": [ "r159" ] }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodOneMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "On or Prior to April 22, 2022", "label": "Debt Instrument Redemption Period One [Member]", "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r159" ] }, "us-gaap_DebtInstrumentRedemptionPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodStartDate", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption period start date", "label": "Debt Instrument Redemption Period Start Date", "documentation": "Start date of debt instrument redemption period, in YYYY-MM-DD format." } } }, "auth_ref": [ "r159" ] }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodThreeMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "On or After April 23, 2023 Through Maturity Date", "label": "Debt Instrument Redemption Period Three [Member]", "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r159" ] }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodTwoMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "On or After April 23, 2022 Through and Including April 22, 2023", "label": "Debt Instrument Redemption Period Two [Member]", "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r159" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of repurchase price", "label": "Debt Instrument Redemption Price Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r159" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption price percentage", "label": "Debt Instrument Redemption Price Percentage Of Principal Amount Redeemed", "documentation": "Percentage of principal amount of debt redeemed." } } }, "auth_ref": [] }, "mnkd_DebtInstrumentRemainingPrincipalAndInterestAfterConversion": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "DebtInstrumentRemainingPrincipalAndInterestAfterConversion", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument remaining principal and interest after conversion.", "label": "Debt instrument remaining principal and interest after conversion" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRepaidPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRepaidPrincipal", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Repaid, Principal", "documentation": "Amount of principal of debt repaid." } } }, "auth_ref": [ "r726" ] }, "us-gaap_DebtInstrumentSinkingFundPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentSinkingFundPayment", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sinking fund", "label": "Debt Instrument Sinking Fund Payment", "documentation": "Amount paid into a fund, which is used to retire the debt instrument." } } }, "auth_ref": [ "r44", "r1139" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsSummaryOfCarryingAmountOfBorrowingsDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Table]", "label": "Debt Instrument [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r15", "r44", "r47", "r67", "r132", "r134", "r241", "r405", "r406", "r407", "r408", "r409", "r411", "r416", "r417", "r418", "r419", "r421", "r422", "r423", "r424", "r425", "r426", "r429", "r889", "r890", "r891", "r892", "r893", "r925", "r1066", "r1198", "r1200" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Unamortized discount and prepayment fee", "totalLabel": "Debt Instrument, Unamortized Discount, Total", "verboseLabel": "Unamortized debt discount", "label": "Debt Instrument Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r1145", "r1197", "r1198", "r1200" ] },
"mnkd_DebtInstrumentUnamortizedPrepaymentPenalty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "DebtInstrumentUnamortizedPrepaymentPenalty", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument unamortized prepayment penalty.", "label": "Debt Instrument Unamortized Prepayment Penalty", "documentation": "Debt Instrument unamortized prepayment penalty." } } }, "auth_ref": [] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtPolicyTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone Payments", "label": "Debt Policy [Text Block]", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": [ "r11" ] },
"mnkd_DebtPremiumRecognizedInAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "DebtPremiumRecognizedInAdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt premium recognized in additional paid-in capital", "label": "Debt Premium Recognized In Additional Paid In Capital", "documentation": "Debt premium recognized in additional paid-in capital." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-Sale Investment, credit losses", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance", "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance", "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r312", "r350", "r354", "r355" ] }, "us-gaap_DebtSecuritiesAvailableForSaleGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleGainLoss", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss (gain) on available-for-sale securities", "label": "Debt Securities, Available-for-Sale, Gain (Loss)", "totalLabel": "Debt Securities, Available-for-Sale, Gain (Loss), Total", "terseLabel": "(Loss) gain on available-for-sale securities", "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r1058", "r1059" ] }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Debt Securities, Available-for-Sale, Realized Gain (Loss), Total", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "terseLabel": "Recognized gain (loss)", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r1108" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)", "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Total", "terseLabel": "Unrealized holding gain", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r1088", "r1089" ] }, "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"DebtSecuritiesHeldToMaturityAllowanceForCreditLoss", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "periodEndLabel": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Ending Balance", "periodStartLabel": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Beginning Balance", "totalLabel": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Total", "terseLabel": "Allowance for credit losses", "label": "Debt Securities Held To Maturity Allowance For Credit Loss",
"documentation": "Amount of allowance for credit loss for debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r323", "r342", "r345", "r346" ] },
"mnkd_DecerfieldManagementCompanyLpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"DecerfieldManagementCompanyLpMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Decerfield Management Company Lp [Member]", "documentation": "Decerfield Management Company L.P.", "terseLabel": "Decerfield" } } }, "auth_ref": [] }, "us-
gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt default, description", "label": "Default Longterm Debt Description Of Violation Or Event Of Default", "documentation": "Discussion of the facts and amounts pertaining to each failure to comply with an affirmative or negative covenant of a long-term debt instrument, including violating payment terms or an inability to meet certain minimum financial requirements or achieve or maintain certain financial ratios. The discussion would generally be expected to also include whether or not the failure can and will be overcome and a description of the terms of any waivers, including the amount of the waiver and the period of time covered by the waiver, and if reclassification of long-term debt to current has been made in the current balance sheet." } } }, "auth_ref": [ "r39", "r119" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DeferredFinanceCostsNet", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsScheduleOfMaturitiesOfCompanysBorrowingsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Debt Issuance Costs, Net, Total", "negatedLabel": "Debt issuance costs", "label": "Deferred Finance Costs Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1145", "r1197", "r1198", "r1200" ] },
"mnkd_DeferredStateAndLocalIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"DeferredStateAndLocalIncomeTaxExpense", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "State income tax liability", "label": "Deferred State And Local Income Tax Expense", "documentation": "Deferred State And Local Income Tax Expense" } } }, "auth_ref": [] },
"mnkd_DeferredTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "DeferredTransactionCosts", "crdr": "debit",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRoyaltyLiabilityAccountRollForwardDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Deferred transaction costs", "label": "Deferred Transaction Costs", "documentation": "Deferred transaction costs." } } }, "auth_ref": [] }, "us-
gaap_DepositLiabilitiesAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositLiabilitiesAccruedInterest", "crdr": "credit",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Accrued Interest", "label", "Deposit Liabilities, Accrued Interest", "documentation": "Amount of accrued but unpaid interest on deposit liabilities." } } }, "auth_ref": [ "r150" ]
}, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDepreciationExpenseRelatedToPropertyAndEquipmentDetail" ], "lang": { "en-us": { "role": { "totalLabel":
"Depreciation, Total", "terseLabel": "Depreciation Expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r9", "r36" ] }, "us-
gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel",
"Depreciation, Depletion and Amortization, Nonproduction, Total", "terseLabel": "Depreciation and amortization", "label": "Depreciation And Amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r9", "r36" ] }, "mnkd_DepreciationExpenseRelatedToPropertyAndEquipmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "DepreciationExpenseRelatedToPropertyAndEquipmentTableTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation Expense Related to Property and Equipment", "label": "Depreciation Expense Related To Property And Equipment Table [Text Block]", "documentation": "Depreciation expense related to property and equipment." } } }, "auth_ref": [] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DevelopedTechnologyRightsMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsSummaryOfOtherIntangibleAssetDetail" ], "lang": { "en-us": { "role": { "terseLabel", "Developed Technology", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r144", "r1117", "r1118", "r1119", "r1120", "r1122", "r1124", "r1127", "r1128" ] }, "us-
gaap_DirectFinancingLeaseDeferredSellingProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DirectFinancingLeaseDeferredSellingProfit",
"crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "lang": { "en-us": { "role":
{ "terseLabel": "Deferred lease liability", "label": "Direct Financing Lease Deferred Selling Profit", "documentation": "Amount of deferred selling profit from direct financing lease." } } },
"auth_ref": [ "r621" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisaggregationOfRevenueLineItems", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesSummaryOfRevenueAndCostOfRevenueAndGoodsSoldGene
], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation Of Revenue [Line Items]", "label": "Disaggregation Of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [
"r458", "r895", "r896", "r897", "r898", "r899", "r900", "r901" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisaggregationOfRevenueTable", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesSummaryOfRevenueAndCostOfRevenueAndGoodsSoldGene
], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation Of Revenue [Table]", "label": "Disaggregation Of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r458",
"r895", "r896", "r897", "r898", "r899", "r900", "r901" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel":
"Summary of Revenue and Cost of Revenue and Goods Sold Generated From Product Sales, Services and Royalties", "label": "Disaggregation Of Revenue Table [Text Block]",
"documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1146" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpense" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation Expense", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } },
"auth_ref": [ "r470", "r474", "r502", "r503", "r505", "r908" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation
Related Costs Sharebased Payments [Abstract]" } } }, "auth_ref": [] }, "mnkd_DiscountOnPurchasePricePercentageOfFairMarketValue": { "xbrltype": "percentItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "DiscountOnPurchasePricePercentageOfFairMarketValue", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Discount on purchase price percentage of fair market value", "label": "Discount On Purchase Price Percentage Of Fair Market Value", "documentation": "Discount on purchase price percentage of fair market value." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentFiscalPeriodFocus", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype":
"gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus",
"label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label":
"Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] },
"dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report",
"label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r949" ] },
"dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report",
"label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r981" ] }, "dei_DocumentType": {
"xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Type", "label",
"Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "mnkd_DueInOneYearOrLessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930",
"localname": "DueInOneYearOrLessMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfHeldToMaturityInvestmentsParentheticalDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Due in One Year or Less", "label": "Due In One Year Or Less [Member]", "documentation": "Due in one year or less." } } }, "auth_ref": [] },
"ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r992" ] }, "mnkd_EarlyTerminationFeesPercentage": { "xbrltype": "percentItemType",
"nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EarlyTerminationFeesPercentage", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Early termination fees, percentage", "label": "Early Termination Fees Percentage", "documentation": "Early termination fees percentage." } } }, "auth_ref": [] }, "us-
gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label":
"Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EarningsPerShareBasic", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShareComponentsOfBasicAndDilutedEpsComputationsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income (loss) per share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "label": "Earnings Per Share Basic", "terseLabel": "Net income (loss) per share - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r225", "r247", "r248", "r249", "r250",
"r251", "r252", "r258", "r260", "r264", "r265", "r266", "r271", "r538", "r545", "r563", "r564", "r672", "r699", "r876" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [
```

```
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShareComponentsOfBasicAndDilutedEpsComputationsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "EPS - basic:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShareComponentsOfBasicAndDilutedEpsComputationsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income (loss) per share, diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "label": "Earnings Per Share Diluted", "terseLabel": "Net income (loss) per share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r225", "r247", "r248", "r249", "r250", "r251", "r252", "r260", "r264", "r265", "r266", "r271", "r538", "r545", "r563", "r564", "r672", "r699", "r876" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShareComponentsOfBasicAndDilutedEpsComputationsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "EPS - diluted:", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss) Per Share of Common Stock", "label": "Earnings Per Share Policy [Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r31", "r32", "r268" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShare1" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Common Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r257", "r267", "r269", "r270" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate (as a percent)", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r513", "r910" ] }, "mnkd_EffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EffectiveInterestRate", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRoyaltyLiabilityAccountRollForwardDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Effective Interest Rate", "documentation": "Effective interest rate." } } }, "auth_ref": [] }, "mnkd_EmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EmployeeMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Employees Awards", "label": "Employee [Member]", "documentation": "Employee [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Employee-related Liabilities, Current, Total", "terseLabel": "Salary and related expenses", "label": "Employee Related Liabilities Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r74" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense, weighted average period for recognition", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r504" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense related to non-option", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r1175" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense related to options", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r1175" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "ESPP", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "mnkd_EmployeeStockOptionsAndPerformanceBasedOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EmployeeStockOptionsAndPerformanceBasedOptionsMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options and PNQs", "label": "Employee Stock Options And Performance Based Options [Member]", "documentation": "Employee stock options and performance based options." } } }, "auth_ref": [] }, "mnkd_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EmployeeStockPurchasePlanMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseStockBasedCompensationExpenseRecognizedInCondensedConsolidatedStatemen ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Purchase Plan", "label": "Employee Stock Purchase Plan [Member]", "documentation": "Employee stock purchase plan." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address Address Line1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address Address Line2", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r947" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Entity", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r947" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r947" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
```

```
"EntityInteractiveDataCurrent", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1031" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r947" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r947" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r947" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r947" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r986" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r1027" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r1027" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1027" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Manufacturing Equipment", "terseLabel": "Equipment", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r193", "r221", "r222", "r223", "r242", "r243", "r244", "r246", "r251", "r253", "r255", "r273", "r340", "r341", "r373", "r451", "r528", "r529", "r535", "r536", "r537", "r539", "r544", "r545", "r554", "r555", "r556", "r557", "r558", "r559", "r562", "r593", "r594", "r595", "r596", "r597", "r598", "r602", "r604", "r622", "r695", "r714", "r715", "r716", "r730", "r781" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r996" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r954", "r964", "r974", "r1006" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r951", "r961", "r971", "r1003" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimate of Fair Value Measurement", "label": "Estimate Of Fair Value Fair Value Disclosure [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r418", "r588", "r890", "r891" ] }, "mnkd_EstimatedCapacityFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EstimatedCapacityFees", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Estimated Capacity Fees, Total", "label": "Estimated Capacity Fees", "documentation": "Estimated capacity fees." } } }, "auth_ref": [] }, "mnkd_EstimatedCapacityFeesDueInEighthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EstimatedCapacityFeesDueInEighthYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Capacity Fees, 2032", "label": "Estimated Capacity Fees Due In Eighth Year", "documentation": "Estimated capacity fees due in eighth year." } } }, "auth_ref": [] }, "mnkd_EstimatedCapacityFeesDueInFifthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EstimatedCapacityFeesDueInFifthYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Capacity Fees, 2029", "label": "Estimated Capacity Fees Due In Fifth Year", "documentation": "Estimated capacity fees due in fifth year." } } }, "auth_ref": [] }, "mnkd_EstimatedCapacityFeesDueInFourthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EstimatedCapacityFeesDueInFourthYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Capacity Fees, 2028", "label": "Estimated Capacity Fees Due In Fourth Year", "documentation": "Estimated capacity fees due in fourth year." } } }, "auth_ref": [] }, "mnkd_EstimatedCapacityFeesDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EstimatedCapacityFeesDueInNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Capacity Fees, 2025", "label": "Estimated Capacity Fees Due In Next Twelve Months", "documentation": "Estimated capacity fees due in next twelve months." } } }, "auth_ref": [] }, "mnkd_EstimatedCapacityFeesDueInNinthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EstimatedCapacityFeesDueInNinthYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Capacity Fees, 2033", "label": "Estimated Capacity Fees Due In Ninth Year", "documentation": "Estimated capacity fees due in ninth year." } } }, "auth_ref": [] }, "mnkd_EstimatedCapacityFeesDueInSecondYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EstimatedCapacityFeesDueInSecondYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Capacity Fees, 2026", "label": "Estimated Capacity Fees Due In Second Year", "documentation": "Estimated capacity fees due in second year." } } }, "auth_ref": [] }, "mnkd_EstimatedCapacityFeesDueInSeventhYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EstimatedCapacityFeesDueInSeventhYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Capacity Fees, 2031", "label": "Estimated Capacity Fees Due In Seventh Year", "documentation": "Estimated capacity fees due in seventh year." } } }, "auth_ref": [] }, "mnkd_EstimatedCapacityFeesDueInSixthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EstimatedCapacityFeesDueInSixthYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Capacity Fees, 2030", "label": "Estimated Capacity Fees Due In Sixth Year", "documentation": "Estimated capacity fees due in sixth year." } } }, "auth_ref": [] }, "mnkd_EstimatedCapacityFeesDueInTenthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EstimatedCapacityFeesDueInTenthYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Capacity Fees, 2034", "label": "Estimated Capacity Fees Due In Tenth Year", "documentation": "Estimated capacity fees due in tenth year." } } }, "auth_ref": [] }, "mnkd_EstimatedCapacityFeesDueInThirdYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EstimatedCapacityFeesDueInThirdYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Capacity Fees, 2027", "label": "Estimated Capacity Fees Due In Third Year", "documentation": "Estimated capacity fees due in third year." } } }, "auth_ref": [] }, "mnkd_EstimatedCapacityFeesRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EstimatedCapacityFeesRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Capacity Fees, 2024", "label": "Estimated Capacity Fees Remainder Of Fiscal Year", "documentation": "Estimated capacity fees remainder of fiscal year." } } }, "auth_ref": [] }, "mnkd_EstimatedFairValueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "EstimatedFairValueMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value", "label": "Estimated Fair Value [Member]", "documentation": "Estimated fair value." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r1002" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]", "label": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value By Balance Sheet Grouping [Table]", "label": "Fair Value By Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r65", "r66" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r418", "r461", "r462", "r463", "r464", "r465", "r466", "r565", "r567", "r568", "r569", "r570", "r576", "r577", "r579", "r633", "r634", "r635", "r890", "r891", "r902", "r903", "r904", "r914", "r918" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": [
```

```
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis", "label": "Fair Value By Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r418", "r890", "r891" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement", "label": "Fair Value Disclosure Item Amounts [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r418", "r890", "r891" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r572", "r574", "r575", "r576", "r579", "r580", "r581", "r582", "r583", "r668", "r914", "r919" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 1", "label": "Fair Value Inputs Level1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r418", "r461", "r466", "r567", "r577", "r633", "r902", "r903", "r904", "r914" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 2", "label": "Fair Value Inputs Level2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r418", "r461", "r466", "r567", "r568", "r577", "r634", "r890", "r891", "r902", "r903", "r904", "r914" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 3", "label": "Fair Value Inputs Level3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r418", "r461", "r462", "r463", "r464", "r465", "r466", "r567", "r568", "r569", "r570", "r577", "r635", "r890", "r891", "r902", "r903", "r904", "r914", "r918" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r418", "r461", "r462", "r463", "r464", "r465", "r466", "r565", "r567", "r568", "r569", "r570", "r576", "r577", "r579", "r633", "r634", "r635", "r890", "r891", "r902", "r903", "r904", "r914", "r918" ] }, "mnkd_FairValueOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "FairValueOfFinancialInstrumentsLineItems", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Of Financial Instruments [Line Items]", "label": "Fair Value Of Financial Instruments [Line Items]", "documentation": "Fair value of financial instruments." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value Of Financial Instruments Policy", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r12" ] }, "mnkd_FairValueOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "FairValueOfFinancialInstrumentsTable", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Of Financial Instruments [Table]", "label": "Fair Value Of Financial Instruments [Table]", "documentation": "Fair Value of Financial Instruments [Table]" } } }, "auth_ref": [] }, "mnkd_FeesAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "FeesAndExpenses", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Reimbursements", "label": "Fees and Expenses", "documentation": "Fees and expenses." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest on financing liability", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r609", "r615" ] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFinanceLeaseInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Financing liability", "label": "Finance Lease Liability", "verboseLabel": "Total", "totalLabel": "Total", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r606", "r619" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFinanceLeaseInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Financing liability, short term", "terseLabel": "Financing liability \u2014 current", "label": "Financing lease liability-current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r606" ] }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFinanceLeaseInformationDetail" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current finance lease liability." } } }, "auth_ref": [ "r607" ] }, "mnkd_FinanceLeaseLiabilityDiscounted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "FinanceLeaseLiabilityDiscounted", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfRemainingFinancingLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRemainingFinancingLiabilityPaymentsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total financing liability", "terseLabel": "Total financing liability", "label": "Finance Lease Liability Discounted", "documentation": "Finance lease liability discounted." } } }, "auth_ref": [] }, "mnkd_FinanceLeaseLiabilityDiscountedDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "FinanceLeaseLiabilityDiscountedDebtIssuanceCosts", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRemainingFinancingLiabilityPaymentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs", "negatedLabel": "Debt issuance costs", "label": "Finance Lease Liability Discounted Debt Issuance Costs", "documentation": "Finance lease liability discounted debt issuance costs." } } }, "auth_ref": [] }, "mnkd_FinanceLeaseLiabilityDiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "FinanceLeaseLiabilityDiscountedExcessAmount", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfRemainingFinancingLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRemainingFinancingLiabilityPaymentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payments", "label": "Finance Lease Liability Discounted Excess Amount", "documentation": "Finance lease liability discounted excess amount.", "negatedLabel": "Interest payments" } } }, "auth_ref": [] }, "mnkd_FinanceLeaseLiabilityDiscountedPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "FinanceLeaseLiabilityDiscountedPaymentsDue", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfRemainingFinancingLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRemainingFinancingLiabilityPaymentsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Finance Lease Liability Discounted Payments Due", "documentation": "Finance lease liability discounted payments due." } } }, "auth_ref": [] }, "mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "FinanceLeaseLiabilityDiscountedPaymentsDueAfterYearFour", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfRemainingFinancingLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRemainingFinancingLiabilityPaymentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finance Lease Liability Discounted Payments Due After Year Four", "documentation": "Finance lease liability discounted payments due after year four." } } }, "auth_ref": [] }, "mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "FinanceLeaseLiabilityDiscountedPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfRemainingFinancingLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRemainingFinancingLiabilityPaymentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease Liability Discounted Payments Due Next Twelve Months", "documentation": "Finance lease liability discounted payments due next twelve months." } } }, "auth_ref": [] }, "mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "FinanceLeaseLiabilityDiscountedPaymentsDueRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfRemainingFinancingLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRemainingFinancingLiabilityPaymentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2024", "label": "Finance Lease Liability Discounted Payments Due Remainder Of Fiscal Year", "documentation": "Finance lease liability discounted payments due remainder of fiscal year." } } }, "auth_ref": [] }, "mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "FinanceLeaseLiabilityDiscountedPaymentsDueYearFour", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfRemainingFinancingLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRemainingFinancingLiabilityPaymentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finance Lease Liability Discounted Payments Due Year Four", "documentation": "Finance lease liability discounted payments due year four." } } }, "auth_ref": [] }, "mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "FinanceLeaseLiabilityDiscountedPaymentsDueYearThree", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfRemainingFinancingLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRemainingFinancingLiabilityPaymentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease Liability Discounted Payments Due Year Three", "documentation": "Finance lease liability discounted payments due year three." } } }, "auth_ref": [] }, "mnkd_FinanceLeaseLiabilityDiscountedPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "FinanceLeaseLiabilityDiscountedPaymentsDueYearTwo", "crdr": "credit", "presentation": [
```

```
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfRemainingFinancingLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRemainingFinancingLiabilityPaymentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease Liability Discounted Payments Due Year Two", "documentation": "Finance lease liability discounted payments due year two." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ],
"lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Summary of Remaining Financing Liability Payments",
"documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1204" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFinanceLeaseInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Financing liability, long term", "label": "Financing lease liability-long-term", "terseLabel": "Financing lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r606" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype":
"enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFinanceLeaseInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability." } } }, "auth_ref": [ "r607" ] }, "mnkd_FinanceLeaseLiabilityWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "FinanceLeaseLiabilityWeightedAverageDiscountRatePercent", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFinanceLeaseInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Finance lease liability weighted average discount rate percent.", "label": "Finance Lease Liability Weighted Average Discount Rate Percent", "terseLabel": "Weighted average discount rate" } } }, "auth_ref": [] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Principal Payments", "negatedLabel": "Principal payments on financing lease liability", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r608",
"r615" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr":
"debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFinanceLeaseInformationDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Finance Lease, Right of Use Asset, after Accumulated Amortization, Total", "label": "Finance Lease, Right-of Use Asset, after Accumulated Amortization",
"terseLabel": "Financing lease right-of use asset", "documentation": "Amount, after accumulated amortization, of right-of use asset from finance lease." } } }, "auth_ref": [ "r605" ] }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFinanceLeaseInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Finance Lease, Right-of Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease right-of use asset." } } }, "auth_ref": [ "r607" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFinancingLiabilityLeaseTermAndDiscountRateDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (in years)", "label": "Finance Lease Weighted Average Remaining Lease Term1", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [
"r617", "r926" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319",
"r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r343", "r344", "r347", "r348", "r349",
"r351", "r352", "r353", "r429", "r448", "r560", "r584", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r647", "r648",
"r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r696", "r885", "r914", "r916", "r918", "r919", "r920", "r921", "r922", "r923", "r924",
"r928", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1108", "r1109", "r1110", "r1111", "r1186", "r1189", "r1190", "r1191", "r1192", "r1193" ] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr":
"credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail" ], "lang": { "en-us": {
"role": { "totalLabel": "Financial Liabilities Fair Value Disclosure, Total", "label": "Financial Liabilities Fair Value Disclosure", "verboseLabel": "Total financial liabilities fair value",
"terseLabel": "Financial liabilities fair value", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": [ "r1187", "r1188", "r1192" ] }, "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialLiabilitiesFairValueDisclosureAbstract", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Financial liabilities:", "label": "Financial Liabilities Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "mnkd_FinancingLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "FinancingLiability", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Financing liability.", "label": "Financing Liability" } } }, "auth_ref": [] }, "mnkd_FinancingLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "FinancingLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Financing liability current.", "label": "Financing Liability Current", "terseLabel": "Financing liability - current" } } }, "auth_ref": [] }, "mnkd_FinancingLiabilityMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.mannkindcorp.com/20240930", "localname": "FinancingLiabilityMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail" ], "lang": { "en-us": { "role": { "documentation": "Financing liability.", "label": "Financing liability [Member]", "terseLabel": "Financing Liability" } } }, "auth_ref": [] }, "mnkd_FinancingLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "FinancingLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Financing liability noncurrent.", "label": "Financing Liability Noncurrent", "terseLabel": "Financing liability - long term" } } }, "auth_ref": [] }, "us-gaap_FinancingReceivablesTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivablesTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivable" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Financing Receivables [Text Block]", "documentation": "The entire disclosure for financing receivable." } } }, "auth_ref": [ "r205", "r302", "r303", "r304", "r884" ] },
"mnkd_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "terseLabel": "Thereafter 2027" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsSummaryOfOtherIntangibleAssetDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Estimated Useful Life (Years)", "label": "Finite Lived Intangible Asset Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsSummaryOfOtherIntangibleAssetDetail" ], "lang": { "en-us": { "role": {
"negatedLabel": "Accumulated Amortization", "label": "Finite Lived Intangible Assets Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r203", "r359", "r367", "r887" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "After 2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1125", "r1262" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation":
[ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r368", "r860", "r887" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "2023", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [ "r1262" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r368", "r860", "r887" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r368", "r860", "r887" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r368", "r860", "r887" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived
```

```
Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r368", "r860", "r887" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsSummaryOfOtherIntangibleAssetDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finite Lived Intangible Assets by Major Class", "label": "Finite Lived Intangible Assets By Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r361", "r362", "r363", "r364", "r366", "r367", "r370", "r371", "r666", "r667", "r860" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsSummaryOfOtherIntangibleAssetDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Finite Lived Intangible Assets, Gross, Total", "terseLabel": "Cost", "label": "Finite Lived Intangible Assets Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r359", "r367", "r667", "r887" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsSummaryOfOtherIntangibleAssetDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finite Lived Intangible Assets [Line Items]", "label": "Finite Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r361", "r367", "r370", "r371", "r372", "r666", "r860", "r887" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsSummaryOfOtherIntangibleAssetDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finite Lived Intangible Assets, Major Class Name", "label": "Finite Lived Intangible Assets Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r361", "r362", "r363", "r364", "r366", "r367", "r370", "r371", "r860" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsSummaryOfOtherIntangibleAssetDetail" ], "lang": { "en-us": { "role": { "periodEndLabel": "Finite Lived Intangible Assets, Net, Ending Balance", "periodStartLabel": "Finite Lived Intangible Assets, Net, Beginning Balance", "totalLabel": "Net Book Value", "label": "Finite Lived Intangible Assets Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r666", "r1124" ] }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossRealized", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss (gain) on foreign currency transaction", "label": "Foreign Currency Transaction Gain Loss Realized", "negatedLabel": "Loss (gain) on foreign currency transaction", "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r762", "r943", "r1105", "r1106", "r1259" ] },
"ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r958", "r968", "r978", "r1010" ] },
"ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r958", "r968", "r978", "r1010" ] },
"ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r958", "r968", "r978", "r1010" ] },
"ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r958", "r968", "r978", "r1010" ] },
"ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r958", "r968", "r978", "r1010" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r991" ] },
"mnkd_FurnitureFixturesAndOfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "FurnitureFixturesAndOfficeEquipmentMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture, fixtures and office equipment", "label": "Furniture Fixtures And Office Equipment [Member]", "documentation": "Furniture, fixtures and office equipment." } } }, "auth_ref": [] }, "mnkd_GainLossRelatedToCreditRiskRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "GainLossRelatedToCreditRiskRecognized", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Credit risk recognized", "label": "Gain Loss Related To Credit Risk Recognized", "documentation": "Gain loss related to credit risk recognized." } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on extinguishment of debt", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total", "negatedLabel": "Loss on extinguishment of debt", "label": "Gains Losses On Extinguishment Of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r9", "r40", "r41" ] },
"us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "General and Administrative Expense, Total", "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r104", "r765" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expense", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r104" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "periodEndLabel": "Goodwill, Ending Balance", "periodStartLabel": "Goodwill, Beginning Balance", "totalLabel": "Goodwill, Total", "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r202", "r360", "r669", "r882", "r886", "r915", "r927", "r1114", "r1115" ] },
"mnkd_GoodwillAdjustmentForANetReductionInLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "GoodwillAdjustmentForANetReductionInLiabilities", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill adjustment for a net reduction in liabilities." } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill And Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssets1" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Intangible Assets", "label": "Goodwill And Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1113", "r1116" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Intangible Assets", "label": "Goodwill And Intangible Assets Policy [Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r1113", "r1116" ] },
"mnkd_GrossUnrealizedHoldingGainsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "GrossUnrealizedHoldingGainsMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Holding Gains", "label": "Gross Unrealized Holding Gains [Member]", "documentation": "Gross unrealized holding gains." } } }, "auth_ref": [] }, "mnkd_GrossUnrealizedHoldingLossesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "GrossUnrealizedHoldingLossesMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Holding Losses", "label": "Gross Unrealized Holding Losses [Member]", "documentation": "Gross unrealized holding losses." } } }, "auth_ref": [] }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesDebtMaturitiesAbstract", "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfHeldToMaturityInvestmentsDetail" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "Aggregate fair value, due after one year through five years", "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r166", "r173", "r336", "r677" ] }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfHeldToMaturityInvestmentsDetail" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year One through Five", "terseLabel": "Amortized cost basis due after one year through five years", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r328", "r675" ] }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfHeldToMaturityInvestmentsDetail" ], "lang": { "en-us": { "role": {
```

```
"label": "Debt Securities, Held-to Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date", "totalLabel": "Amortized cost basis, total", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date." } } }, "auth_ref": [ "r1095", "r1220" ] }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfHeldToMaturityInvestmentsDetail" ], "lang": { "en-us": { "role": {
"label": "Debt Securities, Held-to-Maturity, Maturity, Allocated and Single Maturity Date, Fair Value", "totalLabel": "Aggregate fair value, total", "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date." } } }, "auth_ref": [ "r164", "r171", "r1103", "r1221" ] }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfHeldToMaturityInvestmentsDetail" ], "lang": { "en-us": { "role": {
"label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Aggregate fair value, due in one year or less",
"documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r165", "r172", "r335", "r676" ] }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfHeldToMaturityInvestmentsDetail" ], "lang": { "en-us": { "role": {
"label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Amortized cost basis, due in one year or less", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r327", "r674" ] }, "us-gaap_HeldToMaturitySecuritiesPurchasedOptionsPricePolicy": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesPurchasedOptionsPricePolicy", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
"Held-to-Maturity Investments", "label": "Held To Maturity Securities Purchased Options Price Policy", "documentation": "Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r64" ] }, "us-gaap_HeldToMaturitySecuritiesTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsTables" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity [Table Text Block]", "terseLabel": "Schedule of Contractual Maturities of Held to Maturity Investments", "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
"Impairment of Long-Lived Assets", "label": "Impairment Or Disposal Of Long-Lived Assets Policy [Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } },
"auth_ref": [ "r0", "r125" ] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InProcessResearchAndDevelopmentMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsSummaryOfOtherIntangibleAssetDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"SPERSE License - IPR&D", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [ "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1124", "r1126", "r1127", "r1128" ] }, "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Income (loss) before income tax expense", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } } }, "auth_ref": [ "r98", "r156", "r162", "r673", "r692", "r878", "r881", "r1075", "r1077", "r1078", "r1079", "r1080" ] }, "us-gaap_IncomeStatementAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } },
"auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r374", "r380", "r384", "r571", "r573", "r578", "r709", "r713", "r766", "r860", "r917", "r1229" ] }, "us-
gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r380", "r384", "r571", "r573", "r578", "r709", "r713", "r766", "r860", "r917", "r1229" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]",
"documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r231", "r513", "r514", "r519", "r525", "r910", "r1178" ] }, "us-gaap_IncomeTaxAuthorityDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r231", "r513", "r514", "r519", "r525", "r910", "r1178" ] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r519", "r1178" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [ "r519", "r1178" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r236", "r509", "r513", "r515", "r516", "r517", "r520", "r523", "r530", "r532", "r533", "r534", "r728", "r910" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense", "negatedLabel": "Income tax expense", "totalLabel": "Income Tax Expense (Benefit), Total", "label": "Income Tax Expense Benefit", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r175", "r190", "r254", "r255", "r272", "r280", "r200", "r512", "r513", "r531", "r700", "r910" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxPolicyTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Policy [Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r220", "r510", "r511", "r520", "r521", "r522", "r527", "r722" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Income Taxes Paid, Net, Total", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes paid in cash", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r27", "r231", "r524", "r525" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "terseLabel": "Accounts payable", "label": "Increase Decrease In Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net", "label": "Increase Decrease In Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "mnkd_IncreaseDecreaseInAccruedInterestOnConvertibleNotes": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "IncreaseDecreaseInAccruedInterestOnConvertibleNotes", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"convertible note plus accrued interest", "label": "Increase Decrease In Accrued Interest On Convertible Notes", "documentation": "Increase decrease in accrued interest on convertible notes." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r1062" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase Decrease In Contract With Customer Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r663", "r1062" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Inventories, Total", "negatedLabel": "Inventory", "label": "Increase Decrease In Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel":
"Changes in operating assets and liabilities:", "label": "Increase Decrease In Operating Capital [Abstract]" } } }, "auth_ref": [] }, "mnkd_IncreaseDecreaseInOperatingLeaseLiabilities": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase Decrease In Operating Lease Liabilities", "documentation": "Increase decrease in operating lease liabilities." } } }, "auth_ref": [] }, "us-
gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets",
"crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"totalLabel": "Increase (Decrease) in Other Operating Assets, Total", "negatedLabel": "Other assets", "label": "Increase Decrease In Other Operating Assets", "documentation": "Amount of
```

increase (decrease) in operating assets classified as other." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r8"] }, "mnkd_IncreaseDecreaseInRecognizedLossOnPurchaseCommitments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "IncreaseDecreaseInRecognizedLossOnPurchaseCommitments", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Recognized loss on purchase commitments", "label": "Increase Decrease In Recognized Loss On Purchase Commitments", "documentation": "Increase decrease in recognized loss on purchase commitments." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShareComponentsOfBasicAndDilutedEpsComputationsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities - common shares issuable", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method." } } }, "auth_ref": ["r261", "r262", "r266"] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsSummaryOfOtherIntangibleAssetDetail"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r361", "r365", "r369", "r887"] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsSummaryOfOtherIntangibleAssetDetail"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": ["r361", "r365", "r369", "r887"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual." } } }, "auth_ref": ["r958", "r968", "r978", "r1002", "r1010", "r1014", "r1022"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r1020"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r950", "r1026"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r950", "r1026"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r950", "r1026"] }, "mnkd_InsulinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "InsulinMember", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Insulin", "label": "Insulin [Member]", "documentation": "Insulin." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets", "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total", "label": "Intangible Assets Net Excluding Goodwill", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r361", "r1124", "r1126"] }, "mnkd_InterestAndDividendIncomeDebtSecuritiesAvailableForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "InterestAndDividendIncomeDebtSecuritiesAvailableForSale", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Interest on available for sale investment", "label": "Interest And Dividend Income Debt Securities Available For Sale", "documentation": "Interest and dividend income debt securities available for sale." } } }, "auth_ref": [] }, "mnkd_InterestAndDividendIncomeNetAccretionOfInvestmentsHeldToMaturity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "InterestAndDividendIncomeNetAccretionOfInvestmentsHeldToMaturity", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Interest and dividend income net accretion of investments held-to-maturity.", "label": "Interest And Dividend Income Net Accretion Of Investments Held-to-Maturity", "terseLabel": "Net accretion on investments held to maturity" } } }, "auth_ref": [] }, "us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestAndDividendIncomeSecuritiesHeldToMaturity", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Interest And Dividend Income Securities Held To Maturity", "terseLabel": "Interest on held to maturity investments", "documentation": "Amount of operating interest income, including amortization and accretion of premiums and discounts, on held-to-maturity securities." } } }, "auth_ref": [] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Interest Expense Debt", "totalLabel": "Interest Expense, Debt, Total", "negatedLabel": "Interest expense on notes", "label": "Interest Expense Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r106", "r424", "r434", "r892", "r893"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "totalLabel": "Interest Expense, Nonoperating, Total", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r279", "r1060"] }, "mnkd_InterestExpenseOnFinancingLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "InterestExpenseOnFinancingLiability", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFinancingLiabilityCostsDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense on financing liability", "terseLabel": "Interest expense on financing liability", "label": "Interest Expense On Financing Liability", "documentation": "Interest expense on financing liability." } } }, "auth_ref": [] }, "mnkd_InterestOnConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "InterestOnConvertibleNote", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Interest on Mann Group convertible note", "label": "Interest On Convertible Note", "documentation": "Interest on convertible note." } } }, "auth_ref": [] }, "mnkd_InterestOnLiabilityForSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "InterestOnLiabilityForSaleOfFutureRoyalties", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Interest on liability for sale of future royalties", "label": "Interest On Liability For Sale Of Future Royalties", "documentation": "Interest on liability for sale of future royalties." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Interest paid in cash", "label": "Interest Paid Net", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r226", "r229", "r230"] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Interest Payable Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r74"] }, "us-gaap_InterestReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestReceivableCurrent", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Investment securities", "label": "Interest Receivable Current", "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r1049"] }, "us-gaap_InventoryCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryCurrentTable", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Inventory Current [Table]", "label": "Inventory Current [Table]", "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventories"], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r356"] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesComponentsOfInventoryDetail"], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory Finished Goods Net Of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": ["r122", "r866"] }, "us-gaap_InventoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryLineItems", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Line Items]", "label": "Inventory [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesComponentsOfInventoryDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total inventory", "terseLabel": "Inventory", "label": "Inventory Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r214", "r864", "r927"] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory Policy [Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": ["r176", "r197", "r213", "r356", "r357", "r359", "r664", "r873"] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Raw materials inventory", "label": "Inventory Raw Materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r1050"] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesComponentsOfInventoryDetail"], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory Raw Materials Net Of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": ["r122", "r868"] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri":

```
"http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesComponentsOfInventoryDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label":
"Inventory Work In Process Net Of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are
partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into
finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r122", "r867" ] }, "us-
gaap_InvestmentBuildingAndBuildingImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InvestmentBuildingAndBuildingImprovements", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Investment Building and
Building Improvements", "terseLabel": "Amount transferred from construction in progress to building improvements", "documentation": "Aggregate of the carrying amounts as of the
balance sheet date of investments in building and building improvements." } } }, "auth_ref": [ "r1222", "r1223" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income,
net", "label": "Investment Income Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } },
"auth_ref": [ "r272", "r278", "r290", "r881", "r1057" ] }, "us-gaap_InvestmentInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InvestmentInterestRate", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role":
{ "terseLabel": "Interest rate", "label": "Investment Interest Rate", "documentation": "Rate of interest on investment." } } }, "auth_ref": [ "r790", "r791", "r809", "r810", "r813", "r814",
"r844", "r845", "r937", "r1087", "r1090" ] }, "mnkd_InvestmentMaturityPeriod": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"InvestmentMaturityPeriod", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role":
{ "terseLabel": "Maturity date", "label": "Investment Maturity Period", "documentation": "Investment maturity period." } } }, "auth_ref": [] }, "us-
gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestments" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments In Debt And
Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } },
"auth_ref": [ "r158", "r192", "r306", "r308", "r585", "r586", "r1217" ] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LandMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Land", "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r1147" ] }, "mnkd_LandlordFundedTenantImprovementsPayable": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "LandlordFundedTenantImprovementsPayable", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Landlord-funded tenant improvements payable", "label": "Landlord Funded Tenant Improvements Payable", "documentation": "Landlord funded tenant improvements payable." } } },
"auth_ref": [] }, "mnkd_LandlordFundedTenantImprovementsPayablePerMonth": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"LandlordFundedTenantImprovementsPayablePerMonth", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Landlord-funded tenant improvements payable per month", "label": "Landlord Funded Tenant Improvements Payable Per Month", "documentation": "Landlord funded tenant improvements
payable per month." } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"totalLabel": "Lease, Cost, Total", "terseLabel": "Embedded lease cost per month", "label": "Lease Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." }
} }, "auth_ref": [ "r612", "r926" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LeaseCostTableTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role":
{ "terseLabel": "Summary of Lease Information", "label": "Lease Cost Table [Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest
expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [
"r1203" ] }, "mnkd_LeaseRepurchaseDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "LeaseRepurchaseDescription",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Lease repurchase description", "label": "Lease Repurchase Description", "documentation": "Lease repurchase description." } } }, "auth_ref": [] },
"mnkd_LeaseTermExtensionPeriod": { "xbrltype": "stringItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "LeaseTermExtensionPeriod", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease term exsention
period.", "label": "Lease term extension period" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"LegalEntityAxis", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role":
{ "terseLabel": "Legal Entity", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-
gaap_LesseeFinanceLeaseRenewalTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeaseRenewalTerm1", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lessee,
Finance Lease, Renewal Term", "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year,
five months, and thirteen days." } } }, "auth_ref": [ "r1202" ] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang":
{ "en-us": { "role": { "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Summary of Financing Lease Information", "documentation": "The entire disclosure for finance leases of
lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r603" ] }, "us-
gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Office And Vehicle Lease Payments", "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
"documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating
lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1204" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumOfficeAndVehicleLeasePaymentsDetail" ], "lang": {
"en-us": { "role": { "totalLabel": "Total", "label": "Lessee Operating Lease Liability Payments Due", "documentation": "Amount of lessee's undiscounted obligation for lease payment for
operating lease." } } }, "auth_ref": [ "r619" ] }, "mnkd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumOfficeAndVehicleLeasePaymentsDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "documentation": "Lessee operating lease liability payments due
after year four." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumOfficeAndVehicleLeasePaymentsDetail" ], "lang": {
"en-us": { "role": { "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "Year 1", "documentation": "Amount of lessee's undiscounted obligation for
lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement
of financial position date (rolling approach)." } } }, "auth_ref": [ "r619" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumOfficeAndVehicleLeasePaymentsDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Year 4", "label": "Lessee Operating Lease Liability Payments Due Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease
payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of
financial position date (rolling approach)." } } }, "auth_ref": [ "r619" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumOfficeAndVehicleLeasePaymentsDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Year 3", "label": "Lessee Operating Lease Liability Payments Due Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease
payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of
financial position date (rolling approach)." } } }, "auth_ref": [ "r619" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumOfficeAndVehicleLeasePaymentsDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Year 2", "label": "Lessee Operating Lease Liability Payments Due Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease
payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of
financial position date (rolling approach)." } } }, "auth_ref": [ "r619" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumOfficeAndVehicleLeasePaymentsDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Remainder of 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's
undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [
"r1204" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumOfficeAndVehicleLeasePaymentsDetail" ], "lang": {
"en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Interest expense", "documentation": "Amount of lessee's undiscounted
obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r619" ] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Description of right to extension of lease term", "label": "Lessee Operating Lease Option To Extend", "documentation": "Description of terms and conditions of option to extend lessee's
operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r611" ] }, "us-
gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Lease
renewal option", "label": "Lessee Operating Lease Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'
represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1202" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Lease
initial term", "label": "Lessee Operating Lease Term Of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents
reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1202" ] }, "us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingSubleaseExistenceOfOptionToExtend", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Lessee,option to extend [true false]", "label": "Lessee Operating Sublease Existence Of Option To Extend", "documentation": "Indicates (true false) whether sublessee has option to extend
operating sublease." } } }, "auth_ref": [ "r611" ] }, "us-gaap_LesseeOperatingSubleaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingSubleaseOptionToExtend", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Lease
renewal options", "label": "Lessee Operating Sublease Option To Extend", "documentation": "Description of terms and conditions of option to extend operating sublease." } } }, "auth_ref": [
```

```
"r611" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRoyaltyLiabilityAccountRollForwardDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance, end of period",
"periodStartLabel": "Balance, beginning of period", "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring
transfer or otherwise providing economic benefit to others." } } } }, "auth_ref": [ "r15", "r73", "r74", "r75", "r79", "r80", "r81", "r82", "r235", "r339", "r395", "r396", "r397", "r398", "r399",
"r400", "r401", "r402", "r403", "r549", "r552", "r553", "r589", "r740", "r877", "r945", "r1142", "r1209", "r1210" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and
stockholders' deficit", "label": "Liabilities And Stockholders Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling
interests, if any." } } }, "auth_ref": [ "r90", "r153", "r687", "r927", "r1067", "r1112", "r1194" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND
STOCKHOLDERS' DEFICIT", "label": "Liabilities And Stockholders Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities",
"label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one
business cycle, if longer." } } }, "auth_ref": [ "r75", "r196", "r235", "r339", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r549", "r552", "r553", "r589", "r927",
"r1142", "r1209", "r1210" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current
liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityForFuturePolicyBenefitInterestExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitInterestExpense", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRoyaltyLiabilityAccountRollForwardDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense
on liability for sale of future royalties", "terseLabel": "Non-cash interest expense on liability for sale of future royalties", "label": "Liability for Future Policy Benefit, Interest Expense",
"documentation": "Amount of interest expense recognized for liability for future policy benefit." } } }, "auth_ref": [ "r710", "r711", "r930" ] },
"mnkd_LiabilityForSaleOfFutureRoyaltiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"LiabilityForSaleOfFutureRoyaltiesMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Liability for Sale of Future Royalties", "label": "Liability for Sale of Future Royalties [Member]", "documentation": "Liability for sale of future royalties." } } },
"auth_ref": [] }, "mnkd_LiabilitySaleForFutureRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"LiabilitySaleForFutureRoyaltiesCurrent", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for sale of future
royalties - current", "label": "Liability for sale of future royalties current", "documentation": "Liability Sale For Future Royalties Current" } } }, "auth_ref": [] },
"mnkd_LiabilitySaleOfFutureRoyaltiesNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"LiabilitySaleOfFutureRoyaltiesNonCurrent", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for sale of future
royalties - long term", "label": "Liability Sale Of Future Royalties Non current", "documentation": "Liability Sale Of Future Royalties Non current" } } }, "auth_ref": [] },
"mnkd_LicenseAgreementDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "LicenseAgreementDescription", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "License agreement description", "label": "License Agreement Description", "documentation": "License agreement description." } } }, "auth_ref": [] },
"mnkd_LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "LicenseAgreementMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsSummaryOfUtRevenueDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "License Agreement", "label": "License Agreement [Member]", "documentation": "License agreement." } } }, "auth_ref": [] },
"mnkd_LicenseAndDistributionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"LicenseAndDistributionAgreementMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail1" ], "lang": { "en-us": { "role": {
"documentation": "License And Distribution Agreement Member", "terseLabel": "License and Distribution Agreement", "label": "License And Distribution Agreement [Member]" } } },
"auth_ref": [] }, "us-gaap_LicenseAndServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseAndServiceMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail1",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureScheduleOfAccountsReceivableNetDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborations and
services", "label": "License And Service [Member]", "verboseLabel": "License Agreement", "documentation": "Right to use intangible asset and performance of related service. Intangible
asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": [ "r1147" ] }, "us-gaap_LineOfCredit": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsSummaryOfCarryingAmountOfBorrowingsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Long-Term
Line of Credit, Total", "terseLabel": "Credit Facility", "label": "Line Of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of
long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this
element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time
conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short term obligations that would normally be classified as current liabilities
but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing
agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1
year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing
agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r15", "r151", "r1224" ] }, "mnkd_LineOfCreditFacilityPrincipalPaymentStartDate": {
"xbrltype": "dateItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "LineOfCreditFacilityPrincipalPaymentStartDate", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Line of
credit facility principal payment start date", "label": "Line Of Credit Facility Principal Payment Start Date", "documentation": "Line of credit facility principal payment start date." } } },
"auth_ref": [] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Amount
available under credit facility", "label": "Line Of Credit Facility Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit
facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r72", "r78", "r394" ] }, "us-gaap_LitigationSettlementExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementExpense", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Litigation settlement amount", "label": "Litigation Settlement, Fee Expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and
investigative fees." } } }, "auth_ref": [ "r1037" ] }, "mnkd_LoanArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"LoanArrangementMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Loan Arrangement", "label": "Loan Arrangement [Member]", "documentation": "Loan arrangement." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label":
"Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsScheduleOfMaturitiesOfCompanysBorrowingsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsSummaryOfCarryingAmountOfBorrowingsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt
\u2014 net carrying amount", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes
lease obligation." } } }, "auth_ref": [ "r15", "r151", "r417", "r432", "r890", "r891", "r925", "r1224" ] }, "mnkd_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearThree": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearThree", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsScheduleOfMaturitiesOfCompanysBorrowingsDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Thereafter", "label": "Long Term Debt Maturities Repayments Of Principal After Year Three", "documentation": "Long term debt maturities repayments of principal after year three." } } },
"auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsScheduleOfMaturitiesOfCompanysBorrowingsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2025",
"label": "Long Term Debt Maturities Repayments Of Principal In Next Twelve Months", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities
issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim
periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r241", "r422" ] }, "us-
gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsScheduleOfMaturitiesOfCompanysBorrowingsDetail" ], "lang": { "en-us": { "role": { "label": "Long Term
Debt Maturities Repayments Of Principal In Year Three", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued
that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods
are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r241", "r422" ] }, "us-
gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsScheduleOfMaturitiesOfCompanysBorrowingsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2026",
"label": "Long Term Debt Maturities Repayments Of Principal In Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that
are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods
are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r241", "r422" ] }, "us-
gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsScheduleOfMaturitiesOfCompanysBorrowingsDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Remainder of 2024", "label": "Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund
requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r1068" ]
}, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermInvestments", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Long-Term Investments,
```

Total", "terseLabel": "Long-term investments", "label": "Long Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": ["r199"] }, "us-gaap_LongTermPurchaseCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentAmount", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"terseLabel": "Funded amount", "label": "Long-Term Purchase Commitment, Amount", "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment." } } } }, "auth_ref": [] } }, "mnkd_LongTermPurchaseCommitmentExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "LongTermPurchaseCommitmentExpirationDate", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Supply Agreement expiration period", "label": "Long Term Purchase Commitment Expiration Date", "documentation": "Long Term Purchase Commitment, Expiration Date" } } }, "auth_ref": [] } }, "us-gaap_LongTermPurchaseCommitmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements", "label": "Long Term Purchase Commitment [Text Block]", "documentation": "Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type", "label": "Longterm Debt Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r15", "r1130", "r1131", "r1132"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type", "label": "Longterm Debt Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r15", "r39", "r1130", "r1131", "r1132"] }, "mnkd_LongtermPurchaseCommitmentRenewalTimePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "LongtermPurchaseCommitmentRenewalTimePeriod", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Supply Agreement renewal period", "label": "Longterm Purchase Commitment Renewal Time Period", "documentation": "Long-term purchase commitment, renewal time period." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"terseLabel": "Loss Contingency Nature", "label": "Loss Contingencies By Nature Of Contingency [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": ["r387", "r388", "r389", "r392", "r507", "r720", "r888", "r1135", "r1136"] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"terseLabel": "Loss Contingency, Nature", "label": "Loss Contingency Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": ["r387", "r388", "r389", "r392", "r507", "r720", "r888", "r1135", "r1136"] },
"mnkd_LossOnEstimatedReturnsOfAcquiredProduct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"LossOnEstimatedReturnsOfAcquiredProduct", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Loss on estimated returns of acquired product", "label": "Loss on Estimated Returns of Acquired Product", "documentation": "Loss on estimated returns of acquired product." } } }, "auth_ref": [] } },
"mnkd_LossOnPurchaseCommitmentsNumberOfContractsRecognized": { "xbrltype": "integerItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"LossOnPurchaseCommitmentsNumberOfContractsRecognized", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Loss on purchase commitments, number of new contracts recognized", "label": "Loss On Purchase Commitments Number Of Contracts Recognized", "documentation": "Loss on purchase commitments number of contracts recognized." } } }, "auth_ref": [] } }, "mnkd_LossOnPurchaseCommitmentsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "LossOnPurchaseCommitmentsPolicyPolicyTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel":
"Recognized Loss on Purchase Commitments", "label": "Loss On Purchase Commitments Policy Policy [Text Block]", "documentation": "Loss on purchase commitments." } } }, "auth_ref": [] } }, "mnkd_LossesOnEstimatedReturnsOfAcquiredProduct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"LossesOnEstimatedReturnsOfAcquiredProduct", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation":
"Losses on estimated returns of acquired product.", "label": "Losses On Estimated Returns Of Acquired Product", "terseLabel": "Losses on estimated returns of acquired product" } } },
"auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember",
"presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "label": "Machinery And Equipment [Member]", "terseLabel": "Machinery and Equipment", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "mnkd_MannGroupConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "MannGroupConvertibleNoteMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail"], "lang": { "en-us": {
"role": { "verboseLabel": "Mann Group Convertible Notes", "terseLabel": "Mann Group Convertible Note", "label": "Mann Group Convertible Note [Member]", "documentation": "Mann group convertible note." } } }, "auth_ref": [] } }, "mnkd_ManufacturingEquipmentComputerHardwareAndSoftwareComputerEquipmentLabEquipmentAndBuildingImprovementsMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"ManufacturingEquipmentComputerHardwareAndSoftwareComputerEquipmentLabEquipmentAndBuildingImprovementsMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel":
"Manufacturing Equipment, Computer Hardware and Software, Computer Equipment, Lab Equipment, and Building Improvements", "documentation": "Manufacturing Equipment, Computer Hardware and Software, Computer Equipment, Lab Equipment, and Building Improvements.", "label": "Manufacturing Equipment Computer Hardware And Software Computer Equipment Lab Equipment And Building Improvements [Member]", "terseLabel": "Manufacturing Equipment, Computer Hardware and Software, Computer Equipment, Lab Equipment, and Building Improvements" } } }, "auth_ref": [] }, "mnkd_ManufacturingServicesAndProductSalesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "ManufacturingServicesAndProductSalesMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing Services and Product Sales", "label": "Manufacturing Services And Product Sales [Member]", "documentation": "Manufacturing services and product sales." } } }, "auth_ref": [] }, "mnkd_ManufacturingServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930",
"localname": "ManufacturingServicesMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"terseLabel": "Manufacturing Services", "label": "Manufacturing Services [Member]", "documentation": "Manufacturing services." } } }, "auth_ref": [] },
"mnkd_MarketPriceStockPurchasePlan": { "xbrltype": "sharesItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MarketPriceStockPurchasePlan",
"presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"terseLabel": "Market price stock purchase plan", "label": "Market Price Stock Purchase Plan", "documentation": "Market price stock purchase plan." } } }, "auth_ref": [] },
"mnkd_MarketRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MarketRestrictedStockUnitsMember",
"presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel":
"Market RSU's", "label": "Market Restricted Stock Units [Member]", "documentation": "Market restricted stock units.", "terseLabel": "Market RSUs" } } }, "auth_ref": [] },
"mnkd_MarketValueOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MarketValueOfCommonStock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel":
"Market value of common stock", "label": "Market Value Of Common Stock", "documentation": "Market value of common stock." } } }, "auth_ref": [] }, "mnkd_MarlboroughLeaseMember":
{ "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MarlboroughLeaseMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel":
"Marlborough Lease", "label": "Marlborough Lease [Member]", "documentation": "Marlborough lease." } } }, "auth_ref": [] }, "mnkd_MasterLeaseAgreementWithEnterpriseMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MasterLeaseAgreementWithEnterpriseMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Master Lease Agreement with Enterprise", "label": "Master Lease Agreement With Enterprise [Member]", "documentation": "Master lease agreement with enterprise." } } }, "auth_ref": [] },
"srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRoyaltyLiabilityAccountRollForwardDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": ["r388", "r389", "r390", "r391", "r468", "r507", "r570", "r662", "r708", "r712", "r720", "r732", "r733", "r790", "r809", "r814", "r815", "r844", "r858", "r859",
"r884", "r894", "r907", "r918", "r919", "r923", "r924", "r931", "r1144", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216"] }, "mnkd_MaximumValueOfAdditionalInvestmentLimit": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MaximumValueOfAdditionalInvestmentLimit", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel":
"Maximum value of additional investment limit", "label": "Maximum Value Of Additional Investment Limit", "documentation": "Maximum value of additional investment limit." } } },
"auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r994"] }, "ecd_MeasureName": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r994"] }, "us-gaap_MeasurementInputEntityCreditRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputEntityCreditRiskMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail"], "lang": { "en-us": {

{"role": { "verboseLabel": "Credit Risk", "terseLabel": "Dividend Yield", "label": "Measurement Input Entity Credit Risk [Member]", "documentation": "Measurement input using risk of default, credit spread risk and downgrade risk." } } }, "auth_ref": ["r918", "r1189", "r1190", "r1191"] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail"], "lang": { "en-us": { "role": { "terseLabel": "Dividend Yield", "label": "Measurement Input Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": ["r1189", "r1190", "r1191"] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail"], "lang": { "en-us": { "role": { "terseLabel": "Period", "label": "Measurement Input Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": ["r1189", "r1190", "r1191"] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail"], "lang": { "en-us": { "role": { "terseLabel": "Volatility", "label": "Measurement Input Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": ["r918", "r1189", "r1190", "r1191"] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail"], "lang": { "en-us": { "role": { "terseLabel": "Risk Free Rate", "label": "Measurement Input Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": ["r1189", "r1190", "r1191"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r568", "r569", "r570", "r918"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r568", "r569", "r570", "r918"] }, "mnkd_MeasurementPeriodPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MeasurementPeriodPercentage", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Measurement period percentage", "label": "Measurement Period Percentage", "documentation": "Measurement period percentage." } } }, "auth_ref": [] }, "mnkd_MidCapCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MidCapCreditFacilityMember", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsSummaryOfCarryingAmountOfBorrowingsDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail"], "lang": { "en-us": { "role": { "terseLabel": "MidCap Credit Facility", "label": "Mid Cap Credit Facility [Member]", "documentation": "MidCap Credit Facility." } } }, "auth_ref": [] }, "mnkd_MilestoneLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MilestoneLiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Milestone liabilities", "label": "Milestone Liabilities Noncurrent", "documentation": "Milestone liabilities non-current." } } }, "auth_ref": [] }, "mnkd_MilestoneLiabilitiesRemeasurementAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MilestoneLiabilitiesRemeasurementAmount", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Milestone liabilities remeasurement amount.", "label": "Milestone Liabilities Remeasurement Amount", "terseLabel": "Milestone liabilities remeasurement amount" } } }, "auth_ref": [] }, "mnkd_MilestonePaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MilestonePaymentReceived", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Milestone Payment Received", "label": "Milestone Payment Received", "documentation": "Milestone payment received." } } }, "auth_ref": [] }, "mnkd_MilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MilestonePayments", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Milestone payments", "terseLabel": "Milestone payment", "documentation": "Milestone payments.", "label": "Milestone Payments", "negatedLabel": "Milestone payment" } } }, "auth_ref": [] }, "mnkd_MilestoneRightsLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MilestoneRightsLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Remaining milestone rights liability", "label": "Milestone Rights Liabilities Current And Noncurrent", "documentation": "Milestone rights liabilities current and noncurrent." } } }, "auth_ref": [] }, "mnkd_MilestoneRightsLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MilestoneRightsLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Milestone rights liability, current", "label": "Milestone Rights Liability Current", "documentation": "Milestone rights liability current." } } }, "auth_ref": [] }, "mnkd_MilestoneRightsLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MilestoneRightsLiabilityMember", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Milestone Rights", "terseLabel": "Milestone Rights Liability", "label": "Milestone Rights Liability [Member]", "documentation": "Milestone Rights Liability" } } }, "auth_ref": [] }, "mnkd_MilestoneRightsLiabilityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MilestoneRightsLiabilityPolicyTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Milestone Rights Liability", "label": "Milestone Rights Liability Policy [Text Block]", "documentation": "Milestone rights liability." } } }, "auth_ref": [] }, "mnkd_MilestoneRightsLiabilityToBePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MilestoneRightsLiabilityToBePaid", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesParentheticalDetail"], "lang": { "en-us": { "role": { "documentation": "Milestone Rights Liability to be Paid", "label": "Milestone Rights Liability to be Paid", "terseLabel": "Milestone rights liability to be paid" } } }, "auth_ref": [] }, "mnkd_MilestoneRightsPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "MilestoneRightsPayment", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesParentheticalDetail"], "lang": { "en-us": { "role": { "documentation": "Milestone rights payment.", "label": "Milestone Rights Payment", "terseLabel": "Milestone Rights Payment" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRoyaltyLiabilityAccountRollForwardDetails", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": ["r388", "r389", "r390", "r391", "r468", "r507", "r570", "r662", "r708", "r712", "r720", "r732", "r733", "r790", "r809", "r814", "r815", "r844", "r858", "r859", "r884", "r894", "r907", "r918", "r919", "r923", "r931", "r1144", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype", "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r1013"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestments", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r1148"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r1021"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r995"] }, "mnkd_NetAccretionOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "NetAccretionOfInvestments", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Net accretion of investments", "negatedLabel": "Net accretion of investments", "label": "Net Accretion Of Investments", "documentation": "Net accretion of investments." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash used in financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r228"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:", "label": "Net Cash Provided By Used In Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided By Used In Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring investments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r228"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:", "label": "Net Cash Provided By Used In Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": {

```
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided
by operating activities", "label": "Net Cash Provided By Used In Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued
operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r113", "r114", "r117" ]
}, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS
FROM OPERATING ACTIVITIES:", "label": "Net Cash Provided By Used In Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShareComponentsOfBasicAndDilutedEpsComputationsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit",
"http://www.mannkindcorp.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang":
{ "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)", "documentation": "The portion
of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r102", "r117", "r157", "r194", "r216", "r218", "r223", "r235", "r245", "r247",
"r248", "r249", "r250", "r251", "r254", "r255", "r263", "r339", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r538", "r545", "r564", "r589", "r604", "r763", "r779",
"r780", "r943", "r1142" ] }, "mnkd_NetInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "NetInvestments", "crdr": "debit",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ],
"lang": { "en-us": { "role": { "negatedTotalLabel": "Total Investments", "totalLabel": "Total Investments", "label": "Net Investments", "documentation": "Net investments." } } }, "auth_ref":
[] }, "mnkd_NetSalesThresholdAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "NetSalesThresholdAMember",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Net Sales Threshold A", "label": "Net Sales Threshold A [Member]", "documentation": "Net Sales Threshold A." } } }, "auth_ref": [] }, "mnkd_NetSalesThresholdBMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "NetSalesThresholdBMember", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net
Sales Threshold B", "label": "Net Sales Threshold B [Member]", "documentation": "Net Sales Threshold B." } } }, "auth_ref": [] }, "mnkd_NetSalesThresholdsAAndBMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "NetSalesThresholdsAAndBMember", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net
Sales Thresholds A and B", "label": "Net Sales Thresholds A and B [Member]", "documentation": "Net Sales Thresholds A and B." } } }, "auth_ref": [] },
"mnkd_NewLoanArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "NewLoanArrangementMember",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "New Loan Arrangement", "label": "New Loan Arrangement [Member]", "documentation": "New loan arrangement." } } }, "auth_ref": [] },
"mnkd_NextGenResearchAndDevelopmentServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"NextGenResearchAndDevelopmentServicesMember", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Next Gen R&D Services", "label": "Next Gen Research And Development Services [Member]", "documentation": "Next-gen research and development services." } } },
"auth_ref": [] }, "mnkd_NonCashAcquisitionOfIntangibleAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"NonCashAcquisitionOfIntangibleAsset", "crdr": "credit", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash
acquisition of intangible asset", "label": "Non-cash Acquisition Of Intangible Asset", "documentation": "Non-cash acquisition of intangible asset." } } }, "auth_ref": [] },
"mnkd_NonCashAcquisitionOfPropertyAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"NonCashAcquisitionOfPropertyAndEquipment", "crdr": "credit", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash
acquisition of property and equipment", "label": "Non-cash Acquisition Of Property And Equipment", "documentation": "Non-cash acquisition of property and equipment." } } }, "auth_ref":
[] }, "mnkd_NonCashInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "NonCashInterestExpense", "crdr": "debit",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Non-cash interest expense", "label": "Non-cash Interest Expense", "documentation": "Non-cash interest expense." } } }, "auth_ref": [] },
"mnkd_NonCashRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "NonCashRevenueRecognized", "crdr": "credit",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Non-cash revenue recognized", "label": "Non Cash Revenue Recognized", "documentation": "Non-cash revenue recognized." } } }, "auth_ref": [] },
"mnkd_NonConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "NonConvertibleNoteMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Non-Convertible Note", "label": "Non-Convertible Note [Member]", "documentation": "Non-convertible note." } } }, "auth_ref": [] }, "mnkd_NonEmployeeDirectorMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "NonEmployeeDirectorMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
], "lang": { "en-us": { "role": { "terseLabel": "Non-employee Directors Awards", "label": "Non-Employee Director [Member]", "documentation": "Non-employee director." } } }, "auth_ref": []
}, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure
Description" } } }, "auth_ref": [ "r994" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r958",
"r968", "r978", "r1002", "r1010" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually
Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r985" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us":
{ "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r984" ] },
"ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r1002" ] },
"ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1
Arrangement Adopted" } } }, "auth_ref": [ "r1021" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement
Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1021" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "NON-CASH
INVESTING AND FINANCING ACTIVITIES:", "label": "Noncash Investing And Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other
expense", "label": "Nonoperating Income Expense", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major
activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r105" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Other income
(expense):", "label": "Nonoperating Income Expense [Abstract]" } } }, "auth_ref": [] }, "mnkd_NotePayablePercentageOfInterestRateChange": { "xbrltype": "percentItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "NotePayablePercentageOfInterestRateChange", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Note payable, percentage of interest rate increases (decreases)", "label": "Note Payable Percentage Of Interest Rate Change", "documentation": "Note payable,
percentage of interest rate change." } } }, "auth_ref": [] }, "mnkd_NumberOfNotes": { "xbrltype": "integerItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"NumberOfNotes", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Number of notes", "label": "Number Of Notes", "documentation": "Number of notes." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype":
"integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role":
{ "terseLabel": "Number of operating segment", "label": "Number Of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an
enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of
the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the
segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn
revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r882", "r1076" ] },
"mnkd_NumberOfPulmatrixEmployeesWhichBeganEmployment": { "xbrltype": "integerItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"NumberOfPulmatrixEmployeesWhichBeganEmployment", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of pulmatrix
employees which began employment.", "label": "Number of pulmatrix employees which began employment" } } }, "auth_ref": [] }, "mnkd_NumberOfTradingDays": { "xbrltype":
"integerItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "NumberOfTradingDays", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Number of trading days", "label": "Number Of Trading Days", "documentation": "Number of trading days." } } }, "auth_ref": [] }, "mnkd_NumberOfWholesaleDistributors": { "xbrltype":
"integerItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "NumberOfWholesaleDistributors", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of
wholesale distributors", "label": "Number Of Wholesale Distributors", "documentation": "Number of wholesale distributors." } } }, "auth_ref": [] }, "mnkd_OfficeAndVehicleMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "OfficeAndVehicleMember", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumOfficeAndVehicleLeasePaymentsDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "office and vehicle", "label": "Office And Vehicle [Member]", "documentation": "Office and vehicle." } } }, "auth_ref": [] }, "mnkd_OfficeMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "OfficeMember", "presentation":[
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Office
Lease", "label": "Office [Member]", "documentation": "Office." } } }, "auth_ref": [] }, "us-gaap_OpenTaxYear": { "xbrltype": "gYearListItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OpenTaxYear", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "label": "Open Tax Year", "terseLabel": "Tax years", "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format." } } }, "auth_ref": [
"r519" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesSummaryOfRevenueAndCostOfRevenueAndGoodsSoldGene
], "lang": { "en-us": { "role": { "totalLabel": "Operating Expenses, Total", "label": "Operating Expenses", "terseLabel": "Total cost of goods sold and cost of revenue", "documentation":
"Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services.
```

Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Income from operations", "label": "Operating Income Loss", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r162", "r878", "r1075", "r1077", "r1078", "r1079", "r1080"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease costs", "label": "Operating Lease Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r613", "r926"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease rent expenses", "label": "Operating Lease Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r1201"] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "lang": { "en-us": { "role": { "label": "Operating Lease Liabilities Payments Due [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumOfficeAndVehicleLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetail"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Total", "terseLabel": "Operating lease, liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r606"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetail"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r606"] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetail"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": ["r607"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Operating Lease Liability Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r606"] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetail"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": ["r607"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid", "label": "Operating Lease Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r610", "r615"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetail"], "lang": { "en-us": { "role": { "label": "Operating Lease Right Of Use Asset", "terseLabel": "Operating lease, right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r605"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use assets", "label": "Operating Lease Right Of Use Asset Amortization Expense", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r1063"] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetail"], "lang": { "en-us": { "role": { "label": "Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List", "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": ["r607"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease weighted average discount rate", "terseLabel": "Incremental borrowing rate", "label": "Operating Lease Weighted Average Discount Rate Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r618", "r926"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (in years)", "label": "Operating Lease Weighted Average Remaining Lease Term1", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r617", "r926"] }, "mnkd_OperatingLeasesAnnualIncreaseInRentExpense": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "OperatingLeasesAnnualIncreaseInRentExpense", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of annual increase in lease payment", "label": "Operating Leases Annual Increase In Rent Expense", "documentation": "Operating leases annual increase in rent expense." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards", "terseLabel": "Net operating losses", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": ["r526"] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsLineItems", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r526"] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsTable", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization." } } }, "auth_ref": ["r526"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Description of Business and Significant Accounting Policies", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": ["r70", "r118", "r120", "r145"] }, "mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail1"], "lang": { "en-us": { "role": { "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]", "documentation": "Organization, consolidation and presentation of financial statements disclosure." } } }, "auth_ref": [] }, "mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail1"], "lang": { "en-us": { "role": { "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]", "documentation": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Table]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r74"] }, "mnkd_OtherAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "OtherAgreementMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Agreement [Member]", "documentation": "Other agreement." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r204"] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on available-for-sale securities", "label": "Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax", "verboseLabel": "Unrealized gain on available for sale securities", "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a

long-term investment nature." } } }, "auth_ref": ["r3", "r95", "r96", "r97", "r590", "r591", "r592"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]", "terseLabel": "Other comprehensive income:" } } }, "auth_ref": [] } }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Other Noncash Income (Expense), Total", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other, net", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": ["r117"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Other income", "totalLabel": "Other Nonoperating Income (Expense), Total", "label": "Other Nonoperating Income Expense", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r107"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r994"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r956", "r966", "r976", "r1008"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r959", "r969", "r979", "r1011"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r959", "r969", "r979", "r1011"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r983"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables And Accruals [Abstract]" } } }, "auth_ref": [] }, "mnkd_PaymentOfCreditFacilityExitFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PaymentOfCreditFacilityExitFee", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Payment of credit facility exit fee", "label": "Payment Of Credit Facility Exit Fee", "documentation": "Payment of credit facility exit fee." } } }, "auth_ref": [] }, "mnkd_PaymentOfCreditFacilityPrepaymentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PaymentOfCreditFacilityPrepaymentFee", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Payment of credit facility prepayment fee", "label": "Payment Of Credit Facility Prepayment Fee", "documentation": "Payment of credit facility prepayment fee." } } }, "auth_ref": [] }, "mnkd_PaymentOnMidCapCreditFacility": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PaymentOnMidCapCreditFacility", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Payment On Mid Cap Credit Facility", "documentation": "Payment on mid cap credit facility." , "terseLabel": "Payment On Mid Cap Credit Facility" } } }, "auth_ref": [] }, "us-gaap_PaymentsForCapitalImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForCapitalImprovements", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Funding for capital improvements", "label": "Payments For Capital Improvements", "documentation": "The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use." } } }, "auth_ref": ["r111"] }, "us-gaap_PaymentsForMergerRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForMergerRelatedCosts", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "label": "Payments for Merger Related Costs", "documentation": "The amount of cash paid during the reporting period for charges associated with the mergers." } } }, "auth_ref": ["r7"] }, "us-gaap_PaymentsForProceedsFromTenantAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromTenantAllowance", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Payments for (Proceeds from) Tenant Allowance", "terseLabel": "Reimbursement for tenant improvements", "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy." } } }, "auth_ref": ["r20", "r110"] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRent", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Payments for Rent", "terseLabel": "Lease monthly payments", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": ["r7"] }, "us-gaap_PaymentsForRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRoyalties", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Purchase price", "label": "Payments for Royalties", "documentation": "The amount of cash paid for royalties during the current period." } } }, "auth_ref": ["r7"] }, "mnkd_PaymentsForTaxesRelatedToNetIssuanceOfCommonStockAssociatedWithRestrictedStockUnitsAndStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PaymentsForTaxesRelatedToNetIssuanceOfCommonStockAssociatedWithRestrictedStockUnitsAndStockOptions", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Payments for taxes related to net issuance of common stock associated with restricted stock units and stock options", "label": "Payments For Taxes Related To Net Issuance Of Common Stock Associated With Restricted Stock Units And Stock Options", "documentation": "Payments for taxes related to net issuance of common stock associated with\n restricted stock units and stock options." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtExtinguishmentCosts", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Payments Of Debt Extinguishment Costs", "terseLabel": "Debt instrument, prepayment penalty", "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest." } } }, "auth_ref": ["r5"] }, "mnkd_PaymentsOfDebtIssuanceCostsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PaymentsOfDebtIssuanceCostsPercentage", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, prepayment penalty percentage", "label": "Payments of Debt Issuance Costs Percentage", "documentation": "Payments of debt issuance costs percentage." } } }, "auth_ref": [] }, "mnkd_PaymentsOfPrincipalAndInterestThroughCommonStockIssuances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PaymentsOfPrincipalAndInterestThroughCommonStockIssuances", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Payments of principal and interest through common stock issuances.", "label": "Payments of principal and interest through common stock issuances", "terseLabel": "Payments of Mann Group principal and interest through common stock issuances" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments Of Stock Issuance Costs", "negatedLabel": "Issuance costs associated with at-the-market offering", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r24"] }, "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireHeldToMaturitySecurities", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Held-to-Maturity Securities", "negatedLabel": "Purchase of held-to-maturity debt securities", "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities." } } }, "auth_ref": ["r22", "r307"] }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherProductiveAssets", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Funding for development of alternative manufacturing processes", "label": "Payments To Acquire Other Productive Assets", "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other." } } }, "auth_ref": ["r111"] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfPreliminaryPurchaseConsiderationDetail"], "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Productive Assets, Total", "verboseLabel": "Cash consideration", "terseLabel": "Asset acquisition, up front consideration", "label": "Payments To Acquire Productive Assets", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": ["r174", "r1180", "r1181", "r1182"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "negatedLabel": "Purchase of property and equipment", "label": "Payments To Acquire Property Plant And Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r111"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r993"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r993"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r985"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r1002"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r995"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r984"] }, "mnkd_PercentageOfAccountsReceivableFromMajorCustomers": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PercentageOfAccountsReceivableFromMajorCustomers", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of accounts receivable from major wholesale distributors", "label": "Percentage Of Accounts Receivable From Major Customers", "documentation": "Percentage of accounts receivable from major customers." } } }, "auth_ref": [] }, "mnkd_PercentageOfAnnualIncrementOnLease": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PercentageOfAnnualIncrementOnLease", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Percentage of annual increment on lease.", "label": "Percentage of annual increment on lease" } } }, "auth_ref": [] }, "mnkd_PercentageOfCollaborationsAndServicesNetAccountsReceivables": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PercentageOfCollaborationsAndServicesNetAccountsReceivables", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of collaborations and services net accounts receivables", "label": "Percentage Of Collaborations And Services Net Accounts Receivables", "documentation": "Percentage of collaborations and

services net accounts receivables." } } }, "auth_ref": [] }, "mnkd_PercentageOfFutureRoyalties": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PercentageOfFutureRoyalties", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of future royalties", "label": "Percentage of Future Royalties", "documentation": "Percentage of future royalties." } } }, "auth_ref": [] } }, "mnkd_PercentageOfFutureRoyaltyRevenues": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PercentageOfFutureRoyaltyRevenues", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of Future Royalty Revenues", "label": "Percentage of Future Royalty Revenues", "documentation": "Percentage of future royalty revenues." } } }, "auth_ref": [] } }, "mnkd_PercentageOfRevenueFromMajorCustomersCollaborationsAndServices": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PercentageOfRevenueFromMajorCustomersCollaborationsAndServices", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of revenue from major customers collaborations and services", "label": "Percentage Of Revenue From Major Customers Collaborations And Services", "documentation": "Percentage of revenue from major customers collaborations and services." } } }, "auth_ref": [] }, "mnkd_PercentageOfRoyaltyOnFutureNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PercentageOfRoyaltyOnFutureNetSales", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of royalty on future net sales", "label": "Percentage of Royalty on Future Net Sales", "documentation": "Percentage of royalty on future net sales." } } }, "auth_ref": [] }, "mnkd_PercentageOfRoyaltyOnNetRevenue": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PercentageOfRoyaltyOnNetRevenue", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of royalty on net revenue", "label": "Percentage of Royalty on Net Revenue", "documentation": "Percentage of royalty on net revenue." } } }, "auth_ref": [] }, "mnkd_PercentageOfRoyaltyOnNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PercentageOfRoyaltyOnNetSales", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of royalty on net sales", "label": "Percentage of Royalty on Net Sales", "documentation": "Percentage of royalty on net sales." } } }, "auth_ref": [] }, "mnkd_PercentageOfSalesFromMajorCustomers": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PercentageOfSalesFromMajorCustomers", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of gross sales from major wholesale distributors", "label": "Percentage Of Sales From Major Customers", "documentation": "Percentage of sales from major customers." } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r986"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r1030"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r985"] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail"], "lang": { "en-us": { "role": { "axisDefault": "Portion at Fair Value Measurement [Member] [Default]", "terseLabel": "Fair Value Disclosure Item Amounts [Default]", "label": "Portion At Fair Value Fair Value Disclosure [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": ["r587"] }, "mnkd_PreLaunchInventoryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PreLaunchInventoryMember", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Pre-launch Inventory", "label": "Pre Launch Inventory [Member]", "documentation": "pre-launch inventory." } } }, "auth_ref": [] }, "mnkd_PreLaunchInventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PreLaunchInventoryPolicyTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Pre Launch Inventory", "label": "Pre Launch Inventory Policy [Text Block]", "documentation": "Pre-launch inventory." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Undesignated preferred stock, par value", "label": "Preferred Stock Par Or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r83", "r436"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Undesignated preferred stock, shares authorized", "label": "Preferred Stock Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r83", "r742"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Undesignated preferred stock, shares issued", "label": "Preferred Stock Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r83", "r436"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "verboseLabel": "Preferred stock, shares outstanding", "terseLabel": "Undesignated preferred stock, shares outstanding", "label": "Preferred Stock Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r83", "r742", "r760", "r1260", "r1261"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Undesignated preferred stock, $0.01 par value -- 10,000,000 shares authorized; no shares issued or outstanding as of September 30, 2024 or December 31, 2023", "label": "Preferred Stock Value", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r83", "r683", "r927"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense And Other Assets Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r1053"] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Other Current Assets", "label": "Prepaid Expenses And Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "mnkd_PrepaymentOfSecuredLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PrepaymentOfSecuredLinesOfCredit", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid of borrowing", "label": "Prepayment Of Secured Lines Of Credit", "documentation": "Prepayment of secured lines of credit." } } }, "auth_ref": [] }, "mnkd_PrincipalAmountPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PrincipalAmountPerShare", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Principal amount per share", "label": "Principal Amount Per Share", "documentation": "Principal amount per share." } } }, "auth_ref": [] }, "mnkd_PrincipalAndEarlyExtinguishmentPaymentsOnMidcapCreditFacility": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PrincipalAndEarlyExtinguishmentPaymentsOnMidcapCreditFacility", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Principal and early extinguishment payments on MidCap credit facility.", "label": "Principal and early extinguishment payments on MidCap credit facility", "terseLabel": "Principal and early extinguishment payments on MidCap credit facility", "negatedLabel": "Principal and early extinguishment payments on MidCap credit facility" } } }, "auth_ref": [] }, "mnkd_PrincipalPaymentOnMidCapCreditFacility": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PrincipalPaymentOnMidCapCreditFacility", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Principal payment on mid cap credit facility.", "label": "Principal Payment On Mid Cap Credit Facility", "terseLabel": "Principal payment on MidCap credit facility" } } }, "auth_ref": [] }, "mnkd_PrincipalPaymentsOnFinancingLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PrincipalPaymentsOnFinancingLiability", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Principal payments on financing liability.", "label": "Principal payments on financing liability", "negatedLabel": "Principal payments on financing liability" } } }, "auth_ref": [] }, "mnkd_PrincipalPaymentsOnMidCapCreditFacility": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PrincipalPaymentsOnMidCapCreditFacility", "crdr": "credit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Principal payments on mid cap credit facility.", "label": "Principal payments on mid cap credit facility", "terseLabel": "Principal payments on MidCap credit facility" } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": ["r1046"] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Private Placement", "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "mnkd_PrivatelyNegotiatedExchangeAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PrivatelyNegotiatedExchangeAgreementMember", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Privately Negotiated Exchange Agreement", "label": "Privately Negotiated Exchange Agreement [Member]", "documentation": "Privately-negotiated exchange agreement." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from offering after deducting initial purchasers discounts and commissions and estimated offering expenses payable", "terseLabel": "Proceeds from the Senior convertible notes", "label": "Proceeds From Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r23"] }, "us-gaap_ProceedsFromInsuranceSettlementInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"ProceedsFromInsuranceSettlementInvestingActivities", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from insurance claim", "label": "Proceeds from Insurance Settlement, Investing Activities", "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities." } } }, "auth_ref": ["r6", "r20"] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from at-the-market offering", "label": "Proceeds From Issuance Initial Public Offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": ["r4"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Amount of net proceeds from issuance of securities", "label": "Proceeds From Issuance Of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r4"] }, "mnkd_ProceedsFromMarketPriceStockPurchasePlanAndFromEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "ProceedsFromMarketPriceStockPurchasePlanAndFromEmployeeStockPurchasePlan", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds From Market Price Stock Purchase Plan And From Employee Stock Purchase Plan", "documentation": "Proceeds from market price stock purchase plan and from employee stock purchase plan.",
"terseLabel": "Proceeds from market price stock purchase plan and employee stock purchase plan" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRepaymentsOfDebt": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfDebt", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel":
"Proceeds from repayment of debt", "label": "Proceeds from (Repayments of) Debt", "totalLabel": "Proceeds from (Repayments of) Debt, Total", "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRoyaltiesReceived": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRoyaltiesReceived", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Upfront proceeds", "label": "Proceeds from Royalties Received", "documentation": "Cash received for royalties during the current period." } } }, "auth_ref": ["r115", "r116"] }, "us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from held-to-maturity debt securities", "totalLabel": "Proceeds from Sale and Maturity of Held-to-Maturity Securities, Total", "label": "Proceeds From Sale And Maturity Of Held To Maturity Securities", "documentation": "Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities." } } }, "auth_ref": ["r21", "r1086"] }, "us-gaap_ProceedsFromSaleOfRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfRealEstate", "crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Sale price", "label": "Proceeds From Sale Of Real Estate", "documentation": "Cash received for the sale of real estate that is not part of an investing activity during the current period." } } }, "auth_ref": ["r109"] }, "us-gaap_ProceedsFromSecuredLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromSecuredLinesOfCredit", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel":
"Advance of borrowing", "label": "Proceeds From Secured Lines Of Credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets)." } } }, "auth_ref": ["r23"] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from market price stock purchase plan", "label": "Proceeds From Stock Plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": ["r4"] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureScheduleOfAccountsReceivableNetDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "verboseLabel": "AFREZZA product sales", "terseLabel": "Commercial product sales", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": ["r895"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail1",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesSummaryOfRevenueAndCostOfRevenueAndGoodsSoldGene
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureScheduleOfAccountsReceivableNetDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service" "label": "Product Or Service [Axis]" } } }, "auth_ref": ["r292", "r665", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r862", "r895", "r929", "r931", "r932", "r933", "r934", "r1137", "r1138", "r1146", "r1226", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257"] }, "mnkd_ProductRevenueMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "ProductRevenueMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesSummaryOfRevenueAndCostOfRevenueAndGoodsSoldGene
], "lang": { "en-us": { "role": { "terseLabel": "Product Revenue", "label": "Product Revenue [Member]", "documentation": "Product revenue member." } } }, "auth_ref": [] },
"mnkd_ProductSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ProductSalesMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesSummaryOfRevenueAndCostOfRevenueAndGoodsSoldGene
], "lang": { "en-us": { "role": { "terseLabel": "Product Sales", "label": "Product Sales [Member]", "documentation": "Product sales." } } }, "auth_ref": [] }, "us-gaap_ProductionRelatedImpairmentsOrCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductionRelatedImpairmentsOrCharges",
"crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail"
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Production Related Impairments or Charges, Total", "verboseLabel": "Inventory write-offs", "terseLabel": "Write-off of inventory", "label": "Production Related Impairments Or Charges", "documentation":
"Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold." } } },
"auth_ref": ["r99"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail1",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesSummaryOfRevenueAndCostOfRevenueAndGoodsSoldGene
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureScheduleOfAccountsReceivableNetDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Products And Services [Domain]" } } }, "auth_ref": ["r292", "r665", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r862", "r895", "r929", "r931", "r932", "r933", "r934", "r1137", "r1138", "r1146", "r1226", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "label": "Profit Loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r194", "r216", "r218", "r227", "r235", "r245", "r251", "r254", "r255", "r339", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r538", "r545", "r547", "r550", "r551", "r564", "r589", "r673", "r693", "r729", "r763", "r779", "r780", "r912", "r913", "r944", "r1056", "r1142"] }, "mnkd_PromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PromissoryNotesMember",
"presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail"], "lang": { "en-us": {
"role": { "terseLabel": "Promissory Notes", "label": "Promissory Notes [Member]", "documentation": "Promissory notes." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": {
"role": { "label": "Property Plant And Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetParentheticalDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumOfficeAndVehicleLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Property Plant And Equipment By Type [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r10", "r620"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipment"],
"lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property Plant And Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r123", "r182", "r188", "r189"] }, "us-gaap_PropertyPlantAndEquipmentDisposals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisposals", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Amount of divestiture of long-lived", "label": "Property, Plant and Equipment, Disposals", "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross",
"crdr": "debit", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "terseLabel":
"Total property and equipment", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "totalLabel": "Property, Plant and Equipment, Gross, Total", "label": "Property Plant And Equipment Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r124", "r200", "r691"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType",

"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetParentheticalDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "terseLabel": "Property Plant And Equipment [Line Items]", "label": "Property Plant And Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r620"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total property and equipment, net", "terseLabel": "Property and equipment, net", "label": "Property Plant And Equipment Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r10", "r620", "r678", "r691", "r927"] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r10", "r182", "r188", "r689"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables"], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, Net", "label": "Property Plant And Equipment [Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r10"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetParentheticalDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumOfficeAndVehicleLeasePaymentsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Property Plant And Equipment Type [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r124", "r620"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "terseLabel": "Estimated Useful Life (Years)", "label": "Property Plant And Equipment Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_PublicUtilitiesInventoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PublicUtilitiesInventoryAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Public Utilities Inventory [Axis]", "documentation": "Information by type of inventory held." } } }, "auth_ref": ["r1051"] }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PublicUtilitiesInventoryTypeDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Public Utilities Inventory Type [Domain]", "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale." } } }, "auth_ref": ["r1051"] }, "mnkd_PulmatrixIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PulmatrixIncMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Pulmatrix, Inc.", "label": "Pulmatrix, Inc [Member]", "terseLabel": "Pulmatrix, Inc" } } }, "auth_ref": [] }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Remaining Minimum Amount Committed", "terseLabel": "Minimum amount to expended", "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations." } } }, "auth_ref": ["r81", "r152"] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligation", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "totalLabel": "Remaining Purchase Commitments, Total", "terseLabel": "Loss on purchase commitments", "label": "Purchase Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "mnkd_PurchaseObligationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PurchaseObligationCurrent", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Recognized loss on purchase commitments \u2014 current", "label": "Purchase Obligation Current", "documentation": "Purchase obligation current." } } }, "auth_ref": [] }, "mnkd_PurchaseObligationDueInEighthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PurchaseObligationDueInEighthYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Remaining Purchase Commitments, 2032", "label": "Purchase Obligation Due In Eighth Year", "documentation": "Purchase obligation due in eighth year." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInFifthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligationDueInFifthYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Remaining Purchase Commitments, 2029", "label": "Purchase Obligation Due In Fifth Year", "documentation": "Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInFourthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligationDueInFourthYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Remaining Purchase Commitments, 2028", "label": "Purchase Obligation Due In Fourth Year", "documentation": "Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligationDueInNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Remaining Purchase Commitments, 2025", "label": "Purchase Obligation Due In Next Twelve Months", "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "mnkd_PurchaseObligationDueInNinethYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PurchaseObligationDueInNinethYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Remaining Purchase Commitments, 2033", "label": "Purchase Obligation Due In Nineth Year", "documentation": "Purchase obligation due in nineth year." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInSecondYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligationDueInSecondYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Remaining Purchase Commitments, 2026", "label": "Purchase Obligation Due In Second Year", "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "mnkd_PurchaseObligationDueInSeventhYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PurchaseObligationDueInSeventhYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Remaining Purchase Commitments, 2031", "label": "Purchase Obligation Due In Seventh Year", "documentation": "Purchase obligation due in seventh year." } } }, "auth_ref": [] }, "mnkd_PurchaseObligationDueInSixthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PurchaseObligationDueInSixthYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Remaining Purchase Commitments, 2030", "label": "Purchase Obligation Due In Sixth Year", "documentation": "Purchase obligation due in sixth year." } } }, "auth_ref": [] }, "mnkd_PurchaseObligationDueInTenthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PurchaseObligationDueInTenthYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Remaining Purchase Commitments, 2034", "label": "Purchase Obligation Due In Tenth Year", "documentation": "Purchase obligation due in tenth year." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInThirdYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligationDueInThirdYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Remaining Purchase Commitments, 2027", "label": "Purchase Obligation Due In Third Year", "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligationFiscalYearMaturityAbstract", "lang": { "en-us": { "role": { "label": "Purchase Obligation Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesRemainingPurchaseCommitmentsAndEstimatedCapacityFeeLiabilityRequirementsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Remainder of Remaining Purchase Commitments, 2024", "label": "Purchase Obligation, Future Minimum Payments, Remainder Of Fiscal Year", "documentation": "Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment." } } }, "auth_ref": [] }, "mnkd_PurchaseObligationNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "PurchaseObligationNoncurrent", "crdr": "credit", "presentation": [

```
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized loss on purchase commitments \u2014 long-term", "label": "Purchase Obligation Noncurrent", "documentation": "Purchase obligation noncurrent." } } }, "auth_ref": [] },
"mnkd_PurchaseOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"PurchaseOfAvailableForSaleSecurities", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role":
{ "terseLabel": "Purchase of available-for-sale securities", "negatedLabel": "Purchase of available-for-sale securities", "verboseLabel": "Purchase of available-for-sale investment", "label":
"Purchase Of Available For Sale Securities", "documentation": "Purchase of available-for-sale securities." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure
[Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r983" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]",
"terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r983" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RangeAxis", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRoyaltyLiabilityAccountRollForwardDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label":
"Range [Axis]" } } }, "auth_ref": [ "r388", "r389", "r390", "r391", "r460", "r468", "r497", "r498", "r499", "r507", "r570", "r636", "r645", "r662", "r708", "r712", "r720", "r732", "r733", "r790",
"r809", "r814", "r815", "r844", "r858", "r859", "r884", "r894", "r907", "r918", "r919", "r923", "r924", "r931", "r937", "r1133", "r1144", "r1190", "r1212", "r1213", "r1214", "r1215", "r1216" ]
}, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRoyaltyLiabilityAccountRollForwardDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label":
"Range [Member]" } } }, "auth_ref": [ "r388", "r389", "r390", "r391", "r460", "r468", "r497", "r498", "r499", "r507", "r570", "r636", "r645", "r662", "r708", "r712", "r720", "r732", "r733",
"r790", "r809", "r814", "r815", "r844", "r858", "r859", "r884", "r894", "r907", "r918", "r919", "r923", "r924", "r931", "r937", "r1133", "r1144", "r1190", "r1212", "r1213", "r1214", "r1215",
"r1216" ] }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "label":
"Receivables [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ReceivablesPolicyTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ],
"lang": { "en-us": { "role": { "label": "Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable and Allowance for Credit Losses", "documentation": "Disclosure of accounting
policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": [ "r298", "r299", "r300", "r305", "r1083" ] },
"mnkd_RecentlyIssuedAccountingStandardsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"RecentlyIssuedAccountingStandardsPolicyTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
"Recently Issued Accounting Standards", "label": "Recently Issued Accounting Standards Policy [Text Block]", "documentation": "Recently issued accounting standards." } } }, "auth_ref": [] },
"mnkd_ReclassificationOfConvertibleNotesAndInterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"ReclassificationOfConvertibleNotesAndInterestReceivable", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Reclassification Of
Convertible Notes And Interest Receivable", "documentation": "Reclassification of convertible notes and interest receivable.", "terseLabel": "Reclassification of Thirona convertible notes
and interest receivable from current to long-term" } } }, "auth_ref": [] }, "mnkd_ReclassificationOfCreditFacilityFromLongTermToCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "ReclassificationOfCreditFacilityFromLongTermToCurrent", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Reclassification
of credit facility from long-term to current.", "label": "Reclassification Of Credit Facility From Long-term To Current", "terseLabel": "Reclassification of Midcap credit facility from long-term
to current" } } }, "auth_ref": [] }, "mnkd_ReclassificationOfFinancingLiabilityFromLongTermToCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "ReclassificationOfFinancingLiabilityFromLongTermToCurrent", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Reclassification
of financing liability from long-term to current.", "label": "Reclassification of financing liability from long-term to current", "terseLabel": "Reclassification of financing liability from long-
term to current" } } }, "auth_ref": [] }, "mnkd_ReclassificationOfInvestmentsFromLongTermToCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "ReclassificationOfInvestmentsFromLongTermToCurrent", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Reclassification Of
Investments From Long Term To Current", "documentation": "Reclassification of investments from long-term to current.", "terseLabel": "Reclassification of investments from long-term to
current" } } }, "auth_ref": [] }, "mnkd_ReclassificationOfMilestoneFromLongTermToCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930",
"localname": "ReclassificationOfMilestoneFromLongTermToCurrent", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Reclassification
of milestone from long-term to current.", "label": "Reclassification of milestone from long-term to current" } } }, "auth_ref": [] },
"mnkd_ReclassificationOfOperatingLeaseLiabilityFromLongTermToCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"ReclassificationOfOperatingLeaseLiabilityFromLongTermToCurrent", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Reclassification
of operating lease liability from long-term to current.", "label": "Reclassification of operating lease liability from long-term to current", "terseLabel": "Reclassification of operating lease
liability from long-term to current" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel":
"Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r951", "r961", "r971", "r1003" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsSummaryOfCarryingAmountOfBorrowingsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsSummaryOfUtRevenueDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsTables",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Related
Party", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which
investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented
from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r296", "r467", "r623", "r624", "r681", "r688", "r735", "r736", "r737",
"r738", "r739", "r759", "r761", "r786" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember",
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsSummaryOfCarryingAmountOfBorrowingsDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is
accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r237", "r238", "r623", "r624",
"r625", "r626", "r681", "r688", "r735", "r736", "r737", "r738", "r739", "r759", "r761", "r786" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Related
Party Transaction", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r623", "r624", "r1208" ] }, "us-
gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Related
Party Transaction", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-
gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": {
"role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsSummaryOfCarryingAmountOfBorrowingsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsSummaryOfUtRevenueDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsTables",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail",
```

```
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party Transactions By Related Party [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r296", "r467", "r623", "r624", "r681", "r688", "r735", "r736", "r737", "r738", "r739", "r759", "r761", "r786", "r1208" ] }, "mnkd_RemainderOfYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "RemainderOfYearMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of Year", "label": "Remainder of Year[Member]", "documentation": "Remainder of year." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of debt", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r1061" ] }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Principal prepayment against outstanding term loans", "label": "Repayments Of Long Term Lines Of Credit", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r112" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Notes Payable", "negatedLabel": "Principal and early extinguishment payments on Mann Group convertible note", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r112" ] }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfRelatedPartyDebt", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of debt", "label": "Repayments Of Related Party Debt", "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party, including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": [ "r112" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail1",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name", "label": "Repurchase Agreement Counterparty Name [Domain]" } } }, "auth_ref": [ "r239", "r240", "r408", "r438", "r626", "r646", "r679", "r870", "r871" ] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research And Development Expense Excluding Acquired In Process Cost", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r1177" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r508" ] }, "mnkd_ResearchAndDevelopmentServicesAndLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ResearchAndDevelopmentServicesAndLicenseMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
], "lang": { "en-us": { "role": { "terseLabel": "R&D Services and License", "label": "Research And Development Services And License [Member]", "documentation": "Research and development services and license." } } }, "auth_ref": [] }, "mnkd_ReserveForReturns": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ReserveForReturns", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureScheduleOfAccountsReceivableNetDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Reserve for returns", "label": "Reserve For Returns", "documentation": "Reserve for returns." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r952", "r962", "r972", "r1004" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r953", "r963", "r973", "r1005" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r960", "r970", "r980", "r1012" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Restricted Cash, Total", "label": "Restricted Cash", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r1047", "r1064", "r1218", "r1225" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r198" ] }, "mnkd_RestrictedStockUnitsAndMarketRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "RestrictedStockUnitsAndMarketRestrictedStockUnitsMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveDetail" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs and Market RSUs", "label": "Restricted Stock Units And Market Restricted Stock Units [Member]", "documentation": "Restricted stock units and market restricted stock units." } } }, "auth_ref": [] }, "mnkd_RestrictedStockUnitsAndOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "RestrictedStockUnitsAndOptionsMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseStockBasedCompensationExpenseRecognizedInCondensedConsolidatedStatemen
], "lang": { "en-us": { "role": { "terseLabel": "RSUs and Options", "verboseLabel": "RSUs and Options", "label": "Restricted Stock Units And Options [Member]", "documentation": "Restricted stock units and options." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveParentheticalDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "RSUs", "terseLabel": "RSU", "label": "Restricted Stock Units R S U [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "terseLabel": "Accumulated deficit", "label": "Retained Earnings Accumulated Deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r87", "r135", "r686", "r717", "r719", "r727", "r743", "r927" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r193", "r242", "r243", "r244", "r246", "r251", "r253", "r255", "r340", "r341", "r373", "r528", "r529", "r535", "r536", "r537", "r539", "r544", "r545", "r554", "r556", "r557", "r559", "r562", "r602", "r604", "r714", "r716", "r730", "r1260" ] }, "mnkd_ReturnsReserveForAcquiredProduct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ReturnsReserveForAcquiredProduct", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Returns reserve for acquired product", "label": "Returns Reserve For Acquired Product", "documentation": "Returns reserve for acquired product." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue From Contract With Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsSummaryOfUtRevenueDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesSummaryOfRevenueAndCostOfRevenueAndGoodsSoldGene
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Total revenue from UT", "terseLabel": "Total revenues", "label": "Total revenue from collaborations and services", "netLabel": "Total net revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r160", "r161", "r272", "r276", "r277", "r288", "r290", "r292", "r293", "r294", "r457", "r458", "r665" ] },
"mnkd_RevenueFromContractWithCustomerFromCollaborationsAndServicesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "RevenueFromContractWithCustomerFromCollaborationsAndServicesPolicyTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition- Net Revenue - Collaborations and Services", "label": "Revenue From Contract With Customer From Collaborations And Services Policy [Text Block]", "documentation": "Revenue from contract with customer from collaborations and services." } } }, "auth_ref": [] },
"mnkd_RevenueFromContractWithCustomerFromCommercialProductSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "RevenueFromContractWithCustomerFromCommercialProductSalesPolicyTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
```

```
"Revenue Recognition - Net Revenue - Commercial Product Sales", "label": "Revenue From Contract With Customer From Commercial Product Sales Policy [Text Block]", "documentation": "Revenue from contract with customer from commercial product sales." } } }, "auth_ref": [] }, "us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo ], "lang": { "en-us": { "role": { "terseLabel": "Progress Measure", "label": "Revenue Performance Obligation Satisfied Over Time Method Used Description", "documentation": "Description of method used to recognize revenue for performance obligation that is satisfied over time. Includes, but not is limited to, output or input method." } } }, "auth_ref": [ "r456" ] }, "us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionMilestoneMethodRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "label": "Revenue Recognition, Milestone Method, Revenue Recognized", "documentation": "The amount of consideration recognized during the period for the milestone or milestones." } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue Recognition Policy [Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r764", "r861", "r874" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail1" ], "lang": { "en-us": { "role": { "label": "Revenue Remaining Performance Obligation", "verboseLabel": "Anticipated Revenue Allocation", "terseLabel": "Anticipated revenue allocation", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r185" ] }, "mnkd_RevenueRemainingPerformanceObligationAnticipatedCashFlow": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "RevenueRemainingPerformanceObligationAnticipatedCashFlow", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Anticipated Cash Flow", "label": "Revenue Remaining Performance Obligation Anticipated Cash Flow", "documentation": "Revenue remaining performance obligation anticipated cash flow." } } }, "verboseLabel": "Total anticipated cash flows" } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo ], "lang": { "en-us": { "role": { "terseLabel": "Recognition Period", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation", "documentation": "Description of when remaining performance obligation is expected to be recognized as revenue." } } }, "auth_ref": [ "r455" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail1", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail1" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r186" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Assumption of right-of-use asset and operating lease liability", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r616", "r926" ] }, "mnkd_RightOfUseAssetsModification": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "RightOfUseAssetsModification", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset modification", "label": "Right Of Use Assets Modification", "documentation": "Right-of-use assets modification." } } }, "auth_ref": [] }, "mnkd_RoyaltiesArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "RoyaltiesArrangementMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails" "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsSummaryOfUtRevenueDetail" ], "lang": { "en-us": { "role": { "label": "Royalties Arrangement [Member]", "documentation": "Royalties.", "terseLabel": "Royalties Arrangement" } } }, "auth_ref": [] }, "mnkd_RoyaltyCommencementDate": { "xbrltype": "dateItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "RoyaltyCommencementDate", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty commencement date", "label": "Royalty Commencement Date", "documentation": "Royalty commencement date." } } }, "auth_ref": [] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Royalties", "label": "Royalty Expense", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": [ "r103" ] }, "mnkd_RoyaltyFutureNetSalesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "RoyaltyFutureNetSalesPercentage", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty future net sales percentage", "label": "Royalty Future Net Sales Percentage", "documentation": "Royalty future net sales percentage." } } }, "auth_ref": [] }, "mnkd_RoyaltyLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "RoyaltyLiabilityMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRoyaltyLiabilityAccountRollForwardDetails", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty Liability", "label": "Royalty Liability [Member]", "documentation": "Royalty liability." } } }, "auth_ref": [] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesSummaryOfRevenueAndCostOfRevenueAndGoodsSoldGene "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Royalties", "label": "Royalty [Member]", "verboseLabel": "Royalties collaborations", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": [ "r1147" ] }, "mnkd_RoyaltyNetSalesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "RoyaltyNetSalesPercentage", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty percentage", "label": "Royalty Net Sales Percentage", "documentation": "Royalty net sales percentage." } } }, "auth_ref": [] }, "mnkd_RoyaltyRetainingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "RoyaltyRetainingPercentage", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty retaining percentage", "label": "Royalty Retaining Percentage", "documentation": "Royalty retaining percentage." } } }, "auth_ref": [] }, "mnkd_RoyaltyRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "RoyaltyRevenue", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRoyaltyLiabilityAccountRollForwardDetails" ], "lang": { "en-us": { "role": { "label": "Royalty Revenue", "documentation": "Royalty revenue.", "terseLabel": "Royalty revenue earned by or payable to Sagard" } } }, "auth_ref": [] }, "mnkd_RoyaltyRights": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "RoyaltyRights", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty rights", "label": "Royalty Rights", "documentation": "Royalty rights." } } }, "auth_ref": [] }, "mnkd_RoyaltyTerminationDate": { "xbrltype": "dateItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "RoyaltyTerminationDate", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty termination date", "label": "Royalty Termination Date", "documentation": "Royalty termination date." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1021" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1021" ] }, "mnkd_RussellRanchRoadIIILLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "RussellRanchRoadIIILLCMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Russell Ranch Road II LLC", "label": "Russell Ranch Road I I L L C [Member]", "documentation": "Russell Ranch Road II LLC." } } }, "auth_ref": [] }, "mnkd_SagardHealthcarePartnersFundingBorrowerSPE2LPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "SagardHealthcarePartnersFundingBorrowerSPE2LPMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sagard", "label": "Sagard Healthcare Partners Funding Borrower S P E 2, L P [Member]", "documentation": "Sagard Healthcare Partners Funding Borrower S P E 2, LP." } } }, "auth_ref": [] }, "us-gaap_SaleLeasebackTransactionDate": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleLeasebackTransactionDate", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sale leaseback transaction, date", "label": "Sale Leaseback Transaction Date", "documentation": "The date of the transaction involving the sale of the property to another party and the lease of the property back to the seller." } } }, "auth_ref": [ "r167", "r1205", "r1206" ] }, "mnkd_SaleLeasebackTransactionLeaseAgreementPeriods": { "xbrltype": "durationItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "SaleLeasebackTransactionLeaseAgreementPeriods", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sale leaseback transaction, lease agreement period.", "label": "Sale Leaseback Transaction Lease Agreement Periods", "documentation": "Sale leaseback transaction, lease agreement periods." } } }, "auth_ref": [] }, "us-gaap_SaleLeasebackTransactionLeaseTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleLeasebackTransactionLeaseTerms", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, description", "label": "Sale Leaseback Transaction Lease Terms", "documentation": "A description of the terms of the lease(s) related to the assets being leased back in connection with the transaction involving the sale of property to another party and the lease of the property back to the seller." } } }, "auth_ref": [ "r167", "r187" ] }, "us-gaap_SaleLeasebackTransactionNetBookValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleLeasebackTransactionNetBookValue", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Sale Leaseback Transaction, Net Book Value, Total", "terseLabel": "Lease repurchase, amount", "label": "Sale Leaseback Transaction Net Book Value", "documentation": "The net book value of the asset(s) sold in connection with the sale of the property to another party and lease back to the seller." } } }, "auth_ref": [ "r168", "r169", "r170", "r1206" ] }, "us-
```

gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale Of Stock Name Of Transaction [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "mnkd_SalesReturnPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "SalesReturnPeriod", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Sales return right following product expiration in months", "terseLabel": "Sales return right following product expiration in months", "label": "Sales Return Period", "documentation": "Sales return period." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": ["r469", "r1072"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": ["r256", "r469", "r1033", "r1072"] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureScheduleOfAccountsReceivableNetDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Accounts Notes Loans And Financing Receivable [Table]", "label": "Schedule Of Accounts Notes Loans And Financing Receivable [Table]", "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss." } } }, "auth_ref": ["r85", "r91", "r207", "r1084"] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts Receivable, Net", "label": "Schedule Of Accounts Notes Loans And Financing Receivable [Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": ["r85", "r91"] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses and Other Current Liabilities", "label": "Schedule Of Accrued Liabilities Table [Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "mnkd_ScheduleOfAmortizationOfDebtIssuanceCostAndDebtDiscountTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ScheduleOfAmortizationOfDebtIssuanceCostAndDebtDiscountTableTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsTables"], "lang": { "en-us": { "role": { "label": "Schedule Of Amortization Of Debt Issuance Cost And Debt Discount Table [Text Block]", "documentation": "Schedule of amortization of debt issuance cost and debt discount." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveParentheticalDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r31"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Potential Dilutive Securities Outstanding that are Considered Antidilutive", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r31"] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfPreliminaryPurchaseConsiderationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]", "label": "Schedule Of Business Acquisitions By Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": ["r51", "r52", "r542"] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails", "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsSummaryOfUtRevenueDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail1", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r546"] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue from Collaboration and Services", "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions Table [Text Block]", "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r1183"] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsTables"], "lang": { "en-us": { "role": { "label": "Schedule Of Debt Table [Text Block]", "terseLabel": "Summary of Carrying Amount of Borrowings", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Components of Basic and Diluted EPS Computations", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r1074"] }, "mnkd_ScheduleOfEffectOfModificationOnTransactionPriceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ScheduleOfEffectOfModificationOnTransactionPriceTableTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effect of Modification on Transaction Price", "label": "Schedule Of Effect Of Modification On Transaction Price Table [Text Block]", "documentation": "Schedule of effect of modification on transaction price." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"], "lang": { "en-us": { "role": { "terseLabel": "Stock Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r48"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r1187", "r1188"] }, "mnkd_ScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsTableTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Cash Equivalents, Long and Short Term Investments", "label": "Schedule Of Fair Value Of Cash Equivalents Long And Short Term Investments Table [Text Block]", "documentation": "Schedule of fair value of cash equivalents long and short term investments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsSummaryOfOtherIntangibleAssetDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]", "label": "Schedule Of Finite-Lived Intangible Assets [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": ["r361", "r367", "r370", "r371", "r372", "r666", "r860", "r887"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureGoodwillAndOtherIntangibleAssetsTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Other Intangible Assets", "label": "Schedule Of Finite Lived Intangible Assets Table [Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r887", "r1123"] }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfHeldToMaturitySecuritiesLineItems", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfHeldToMaturityInvestmentsParentheticalDetail"], "lang": { "en-us": { "role": { "label": "Schedule of Held-to-Maturity Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338"] }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfHeldToMaturitySecuritiesTable", "presentation": ["http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfHeldToMaturityInvestmentsParentheticalDetail"], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity [Table]", "documentation": "Disclosure of information about investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock",

```
"presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Inventory", "label": "Schedule Of Inventory Current Table [Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r16", "r92", "r93", "r94" ] }, "us-gaap_ScheduleOfInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentsLineItems", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Investments [Line Items]", "label": "Schedule Of Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853" ] }, "us-gaap_ScheduleOfInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentsTable", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Investments [Table]", "label": "Schedule Of Investments [Table]", "documentation": "Disclosure of information about investments owned by investment company." } } }, "auth_ref": [ "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853" ] }, "mnkd_ScheduleOfLeaseTermAndDiscountRateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ScheduleOfLeaseTermAndDiscountRateTableTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Term and Discount Rate", "label": "Schedule Of Lease Term And Discount Rate Table [Text Block]", "documentation": "Schedule of Lease Term and Discount Rate." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Line of Credit Facility Debt and Key Terms", "label": "Schedule Of Line Of Credit Facilities [Text Block]", "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r72", "r78" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Maturities Of Long Term Debt Table [Text Block]", "terseLabel": "Schedule of Maturities of Company's Borrowings", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetParentheticalDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Property Plant And Equipment [Table]", "label": "Schedule Of Property Plant And Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10", "r620" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Identifiable Assets Acquired and Liabilities Assumed", "label": "Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed Table [Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r143" ] }, "mnkd_ScheduleOfRoyaltyLiabilityAccountRollForwardTabletextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ScheduleOfRoyaltyLiabilityAccountRollForwardTabletextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Royalty Liability Account Roll Forward", "label": "Schedule of Royalty Liability Account Roll Forward [TableText Block]", "documentation": "Schedule of royalty liability account roll forward." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityDetails", "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseStockBasedCompensationExpenseRecognizedInCondensedConsolidatedStatemen ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r471", "r473", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500" ] }, "mnkd_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanAndNonEmployeeDirectorStockAwardPlanActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanAndNonEmployeeDirectorStockAwardPlanActivityTableTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee Awards and Non-employee Director Award Plan Activity", "label": "Schedule Of Share Based Compensation Employee Stock Purchase Plan And Non Employee Director Stock Award Plan Activity Table [Text Block]", "documentation": "Schedule of share based compensation employee stock purchase plan and non employee director stock award plan activity." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Stock By Class [Table]", "label": "Schedule Of Stock By Class [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r42", "r43", "r44", "r45", "r46", "r47", "r130", "r132", "r134", "r135", "r207", "r208", "r209", "r274", "r436", "r437", "r438", "r440", "r443", "r448", "r450", "r723", "r724", "r725", "r726", "r894", "r1032", "r1065" ] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "SOFR", "label": "Secured Overnight Financing Rate Sofr Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable rate leg." } } }, "auth_ref": [ "r1184" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Security12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r946" ] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Security deposit", "label": "Security Deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": [ "r1048" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r948" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting Policy Policy [Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r291", "r293", "r879", "r880", "r883" ] }, "us-gaap_SellingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingExpense", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling Expense", "terseLabel": "Selling", "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services." } } }, "auth_ref": [ "r104" ] }, "mnkd_SenateBills167Member": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "SenateBills167Member", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Senate Bills 167.", "label": "Senate Bills 167 [Member]", "terseLabel": "Senate Bills 167" } } }, "auth_ref": [] }, "mnkd_SenateBills175Member": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "SenateBills175Member", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Senate Bills 175.", "label": "Senate Bills 175 [Member]", "terseLabel": "Senate Bills 175" } } }, "auth_ref": [] }, "mnkd_SeniorConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "SeniorConvertibleNotesMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Convertible Notes", "label": "Senior Convertible Notes [Member]", "documentation": "Senior convertible notes." } } }, "auth_ref": [] }, "us-gaap_SeniorNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotes", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureBorrowingsSummaryOfCarryingAmountOfBorrowingsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Senior Notes, Total", "terseLabel": "Senior convertible notes", "label": "Senior Notes", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders." } } }, "auth_ref": [ "r151", "r1224" ] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFairValueOfFinancialInstrumentsParentheticalDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Convertible Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesSummaryOfRevenueAndCostOfRevenueAndGoodsSoldGene ], "lang": { "en-us": { "role": { "terseLabel": "Services", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r895" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total", "label": "Share-Based Compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate": { "xbrltype": "dateItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
```

```
], "lang": { "en-us": { "role": { "terseLabel": "Vesting date", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Date", "documentation": "Share-based compensation arrangement by share-based payment award, award vesting date." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r909" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted awards", "label": "Share Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r489" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units weighted average grant date fair value", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r489" ] }, "mnkd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedGrantsInPeriod", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units grant date fair value", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Grants In Period", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested grants in period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseStockBasedCompensationExpenseRecognizedInCondensedConsolidatedStatemen
], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r471", "r473", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveParentheticalDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseStockBasedCompensationExpenseRecognizedInCondensedConsolidatedStatemen
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche One", "label": "Share Based Compensation Award Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-Based Payment Arrangement, Tranche Three", "terseLabel": "Index Target 50th Percentile", "label": "Share Based Compensation Award Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche Two", "label": "Share Based Compensation Award Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "mnkd_ShareBasedCompensationAwardsTrancheFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ShareBasedCompensationAwardsTrancheFiveMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
], "lang": { "en-us": { "role": { "terseLabel": "Index Target 90th Percentile or Higher", "label": "Share Based Compensation Awards Tranche Five [Member]", "documentation": "Share based compensation awards tranche five." } } }, "auth_ref": [] }, "mnkd_ShareBasedCompensationAwardsTrancheFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ShareBasedCompensationAwardsTrancheFourMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
], "lang": { "en-us": { "role": { "terseLabel": "Index Target 75th Percentile", "label": "Share Based Compensation Awards Tranche Four [Member]", "documentation": "Share based compensation awards tranche four.", "verboseLabel": "Share-Based Payment Arrangement, Tranche Four" } } }, "auth_ref": [] }, "mnkd_ShareDeliveryPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ShareDeliveryPercentage", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonSharePotentialDilutiveSecuritiesOutstandingThatAreConsideredAntidilutiveParentheticalDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share delivery percentage in accordance with valuation assessment obtained", "label": "Share Delivery Percentage", "documentation": "Share delivery percentage." } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock price per share", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r1149" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange price per share", "label": "Shares Issued Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance (in shares)", "periodEndLabel": "Ending Balance (in shares)", "label": "Shares Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfHeldToMaturityInvestmentsParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r73", "r1130", "r1131", "r1132" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfHeldToMaturityInvestmentsParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r71", "r1130", "r1131", "r1132" ] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Short-Term Investments, Total", "terseLabel": "Short-term investments", "label": "Short Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r154", "r155", "r1052" ] }, "mnkd_ShortTermMilestoneRightLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ShortTermMilestoneRightLiability", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesParentheticalDetail" ], "lang": { "en-us": { "role": { "documentation": "Short term milestone right liability.", "label": "Short Term Milestone Right Liability", "terseLabel": "Short Term Milestone Right Liability" } } }, "auth_ref": [] }, "us-gaap_SifmaMunicipalSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SifmaMunicipalSwapRateMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail" ], "lang": { "en-us": { "role": { "label": "SIFMA Municipal Swap Rate [Member]", "documentation": "Fixed rate on US dollar, constant-notional interest rate swap with its variable-rate leg referenced to Securities Industry and Financial Markets Association (SIFMA) Municipal Swap Index with no additional spread over SIFMA Municipal Swap Index on its variable-rate leg." } } }, "auth_ref": [ "r1184" ] }, "mnkd_SoldPortionOfRoyaltyRevenue", { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "SoldPortionOfRoyaltyRevenue", "crdr": "credit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Sold portion of royalty revenue.", "label": "Sold Portion of Royalty Revenue", "terseLabel": "Sold portion of royalty revenue", "negatedLabel": "Sold portion of royalty revenue" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail",
```

```
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Statement Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r84", "r88", "r89", "r193", "r221", "r222", "r223", "r242", "r243", "r244", "r246", "r251", "r253", "r255", "r273", "r340", "r341", "r373", "r451", "r528", "r529", "r535", "r536", "r537", "r539", "r544", "r545", "r554", "r555", "r556", "r557", "r558", "r559", "r562", "r593", "r594", "r595", "r596", "r597", "r598", "r602", "r604", "r622", "r695", "r714", "r715", "r716", "r730", "r781" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r242", "r243", "r244", "r273", "r604", "r665", "r721", "r731", "r734", "r735", "r736", "r737", "r738", "r739", "r742", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r755", "r756", "r757", "r758", "r759", "r761", "r764", "r765", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r781", "r938" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement Of Income And Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r256", "r460", "r1033", "r1034", "r1072" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r242", "r243", "r244", "r273", "r296", "r604", "r665", "r721", "r731", "r734", "r735", "r736", "r737", "r738", "r739", "r742", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r755", "r756", "r757", "r758", "r759", "r761", "r764", "r765", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r781", "r938" ] }, "mnkd_StevenBBinderMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "StevenBBinderMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Steven B. Binder", "label": "Steven B. Binder [Member]", "documentation": "Steven B. Binder." } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r955", "r965", "r975", "r1007" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock", "terseLabel": "Issuance of common stock pursuant to conversion notes (in shares)", "label": "Stock Issued During Period Shares Conversion Of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r14", "r44", "r84", "r88", "r135", "r421" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Shares Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under the employee stock purchase plan (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r14", "r83", "r84", "r135" ] },
"mnkd_StockIssuedDuringPeriodSharesMarketPriceStockPurchasePlan": { "xbrltype": "sharesItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "StockIssuedDuringPeriodSharesMarketPriceStockPurchasePlan", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares market price stock purchase plan.", "label": "Stock Issued During Period Shares Market Price Stock Purchase Plan", "terseLabel": "Issuance of common stock under Market Price Stock Purchase Plan (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of shares sold during the period", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of common stock associated with at-the-market offering (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r14", "r83", "r84", "r135", "r723", "r781", "r854" ] },
"mnkd_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsNetOfForfeitures", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Net issuance of common stock associated with stock options and restricted stock units (in shares)", "label": "Stock Issued During Period Shares Stock Options And Restricted Stock Units Net Of Forfeitures", "documentation": "Stock issued during period shares stock options and restricted stock units net of forfeitures." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock pursuant to conversion notes", "label": "Stock Issued During Period Value Conversion Of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r14", "r84", "r88", "r89", "r135" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Value Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under the employee stock purchase plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r14", "r83", "r84", "r135" ] },
"mnkd_StockIssuedDuringPeriodValueMarketPriceStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "StockIssuedDuringPeriodValueMarketPriceStockPurchasePlan", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock from market price stock purchase plan", "label": "Stock Issued During Period Value Market Price Stock Purchase Plan", "documentation": "Stock issued during period value market price stock purchase plan." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of common stock associated with at-the-market offering", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r14", "r83", "r84", "r135", "r730", "r781", "r854", "r944" ] },
"mnkd_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsNetOfForfeitures", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Net issuance of common stock associated with stock options and restricted stock units", "label": "Stock Issued During Period Value Stock Options And Restricted Stock Units Net Of Forfeitures", "documentation": "Stock issued during period value stock options and restricted stock units net of forfeitures." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' deficit", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Stockholders Equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r84", "r88", "r89", "r121", "r744", "r760", "r782", "r783", "r927", "r945", "r1067", "r1112", "r1194", "r1260" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' deficit:", "label": "Stockholders Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStock" ], "lang": { "en-us": { "role": { "terseLabel": "Common and Preferred Stock", "label": "Stockholders Equity Note Disclosure [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r131", "r234", "r435", "r437", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r449", "r451", "r561", "r784", "r785", "r855" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r599", "r628" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Subsequent Event", "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r599", "r628" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r599", "r628" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r599", "r628" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent
```

```
Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r599", "r628" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } } }, "auth_ref": [ "r627", "r629" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Subsidiary Sale Of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL CASH FLOWS DISCLOSURES:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplierFinanceProgramTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramTable", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Supplier Finance Program [Table]", "documentation": "Disclosure of information about supplier finance program." } } }, "auth_ref": [ "r381", "r382", "r383" ] }, "mnkd_SupplyAndDistributionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "SupplyAndDistributionAgreementMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Supply and Distribution Agreement", "label": "Supply And Distribution Agreement [Member]", "documentation": "Supply and distribution agreement." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r1001" ] }, "mnkd_TheMannGroupLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "TheMannGroupLLCMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "The Mann Group L L C [Member]", "documentation": "The mann group llc.", "terseLabel": "The Mann Group L L C" } } }, "auth_ref": [] }, "mnkd_ThironaBioIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ThironaBioIncMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Thirona Bio, Inc.", "label": "Thirona Bio Inc [Member]", "documentation": "Thirona Bio, Inc." } } }, "auth_ref": [] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo ], "lang": { "en-us": { "role": { "terseLabel": "Timing of Transfer of Good or Service", "label": "Timing Of Transfer Of Good Or Service [Axis]", "documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": [ "r900", "r1146" ] }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TimingOfTransferOfGoodOrServiceDomain", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo ], "lang": { "en-us": { "role": { "terseLabel": "Timing of Transfer of Good or Service", "label": "Timing Of Transfer Of Good Or Service [Domain]", "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "auth_ref": [ "r900", "r1146" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityDetails", "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual", "label": "Title Of Individual [Axis]" } } }, "auth_ref": [ "r1081", "r1207" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityDetails", "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual", "label": "Title Of Individual With Relationship To Entity [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r993" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r1000" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r1020" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r1022" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "mnkd_TrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "TrancheOneMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche 1", "label": "Tranche One [Member]", "documentation": "Tranche one." } } }, "auth_ref": [] }, "mnkd_TrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "TrancheThreeMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail", "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Tranche 3", "terseLabel": "Tranche Three", "label": "Tranche Three [Member]", "documentation": "Tranche 3." } } }, "auth_ref": [] }, "mnkd_TrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "TrancheTwoMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche 2", "label": "Tranche Two [Member]", "documentation": "Tranche 2" } } }, "auth_ref": [] }, "mnkd_TransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "TransactionCosts", "crdr": "debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "label": "Transaction Costs", "documentation": "Transaction costs." } } }, "auth_ref": [] }, "mnkd_TransactionPriceForTheContractualObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "TransactionPriceForTheContractualObligationsMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction Price For The Contractual Obligations", "label": "Transaction Price For The Contractual Obligations [Member]", "documentation": "Transaction price for the contractual obligations." } } }, "auth_ref": [] }, "mnkd_TransactionPriceForThePerformanceObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "TransactionPriceForThePerformanceObligationsMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction Price For The Performance Obligations", "label": "Transaction Price For The Performance Obligations [Member]", "documentation": "Transaction price for the performance obligations." } } }, "auth_ref": [] }, "us-gaap_TransferredAtPointInTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransferredAtPointInTimeMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo ], "lang": { "en-us": { "role": { "terseLabel": "Point In Time", "label": "Transferred At Point In Time [Member]", "documentation": "Contract with customer in which good or service is transferred at point in time." } } }, "auth_ref": [ "r900" ] }, "us-gaap_TransferredOverTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransferredOverTimeMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo ], "lang": { "en-us": { "role": { "terseLabel": "Over Time", "label": "Transferred Over Time [Member]", "documentation": "Contract with customer in which good or service is transferred over time." } } }, "auth_ref": [ "r900" ] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r429", "r448", "r560", "r584", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r696", "r914", "r916", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r928", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1108", "r1109", "r1110", "r1111", "r1186", "r1189", "r1190", "r1191", "r1192", "r1193" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r1023" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r1024" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r1024" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1022" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r1022" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r1025" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination
```

```
Date" } } }, "auth_ref": [ "r1023" ] }, "mnkd_TwoThousandTwentyFourConvertibleNoteInterestMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.mannkindcorp.com/20240930", "localname": "TwoThousandTwentyFourConvertibleNoteInterestMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "2024
Convertible Note Interest", "label": "Two Thousand Twenty Four Convertible Note Interest [Member]", "documentation": "Two thousand twenty four convertible note interest." } } },
"auth_ref": [ ] }, "mnkd_TwoThousandTwentyFourConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"TwoThousandTwentyFourConvertibleNotesMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "2024
Convertible Notes", "label": "Two Thousand Twenty Four Convertible Notes [Member]", "documentation": "Two thousand twenty four convertible notes." } } }, "auth_ref": [ ] }, "us-
gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsSummaryOfUtRevenueDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMannGroupPromissoryNotesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail1",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Type Of Arrangement [Axis]", "documentation": "Information by collaborative arrangement and
arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r546" ] }, "mnkd_TyvasoDPIMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.mannkindcorp.com/20240930", "localname": "TyvasoDPIMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role":
{ "terseLabel": "Tyvaso DPI", "label": "Tyvaso D P I [Member]", "documentation": "Tyvaso DPI." } } }, "auth_ref": [ ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureInvestmentsScheduleOfFairValueOfCashEquivalentsLongAndShortTermInvestmentsDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "U.S. Treasury Securities", "label": "U S Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the
United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less),
treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r875", "r902", "r904", "r914", "r1219" ]
}, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnamortizedDebtIssuanceExpense", "crdr":
"debit", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsSeniorConvertibleNotesAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Unamortized debt issuance cost", "label": "Unamortized Debt Issuance Expense", "documentation": "The remaining balance of debt issuance expenses that were
capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or
asset." } } }, "auth_ref": [ ] }, "mnkd_UnamortizedTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"UnamortizedTransactionCosts", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Unamortized transaction costs.", "label": "Unamortized Transaction Costs", "terseLabel": "Unamortized transaction costs" } } }, "auth_ref": [ ] }, "us-gaap_UndistributedEarningsDiluted":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UndistributedEarningsDiluted", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShareComponentsOfBasicAndDilutedEpsComputationsDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Adjusted net income (loss) (numerator)", "label": "Undistributed Earnings, Diluted", "totalLabel": "Undistributed Earnings, Diluted, Total", "documentation": "The earnings
that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed. Includes
the adjustments resulting from the assumption that dilutive securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain
conditions." } } }, "auth_ref": [ ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price
Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r1019" ] }, "mnkd_UnitedTherapeuticsCorporationMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "UnitedTherapeuticsCorporationMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevenueFromCollaborationsAndServicesDetails",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsScheduleOfRevisedAnticipatedCashFlowsFromTransactionsAllocatedPerfo
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCollaborationLicensingAndOtherArrangementsSummaryOfUtRevenueDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "United
Therapeutics Corporation", "label": "United Therapeutics Corporation [Member]", "documentation": "United Therapeutics Corporation." } } }, "auth_ref": [ ] }, "us-
gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Unrecognized Tax Benefits,
Income Tax Penalties and Interest Expense, Total", "terseLabel": "Unrecognized income tax interest and penalties", "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest
Expense", "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax
return." } } }, "auth_ref": [ "r518", "r909" ] }, "mnkd_UpfrontPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"UpfrontPaymentReceived", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Upfront payment received", "label": "Upfront Payment Received", "documentation": "Upfront payment received." } } }, "auth_ref": [ ] }, "us-gaap_UseOfEstimates": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
"Financial Statement Estimates", "label": "Use Of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in
conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r33", "r34", "r35", "r178", "r180", "r183", "r184" ] }, "mnkd_UtManufacturingFacilityMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "UtManufacturingFacilityMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetParentheticalDetail" ], "lang": { "en-us": { "role": { "documentation": "UT Manufacturing
facility.", "label": "UT Manufacturing Facility [Member]", "terseLabel": "UT Manufacturing Facility" } } }, "auth_ref": [] }, "mnkd_VGoAssetsMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.mannkindcorp.com/20240930", "localname": "VGoAssetsMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionScheduleOfPreliminaryPurchaseConsiderationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosurePulmatrixTransactionTables" ], "lang": { "en-us": { "role": { "documentation": "VGo assets.", "label": "V Go Assets
[Member]", "terseLabel": "V Go" } } }, "auth_ref": [] }, "mnkd_VGoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname":
"VGoMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "V Go", "label": "V Go [Member]", "documentation": "V Go." } } }, "auth_ref": [] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Variable lease costs", "label": "Variable Lease Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for
finance and operating leases." } } }, "auth_ref": [ "r614", "r926" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"VariableRateAxis", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Variable Rate", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsMidcapCreditFacilityAdditionalInformationDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureBorrowingsScheduleOfLineOfCreditFacilityDebtAndKeyTermsDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Variable Rate", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref":
[ ] }, "us-gaap_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VehiclesMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vehicle
Leases", "label": "Vehicles [Member]", "documentation": "Equipment used primarily for road transportation." } } }, "auth_ref": [] }, "mnkd_VerticePharmaLLCMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "VerticePharmaLLCMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCollaborationLicensingAndOtherArrangementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Vertice Pharma LLC", "label": "Vertice Pharma L L C [Member]", "documentation": "Vertice Pharma LLC." } } }, "auth_ref": [ ] }, "us-gaap_VestingAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Vesting", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1149", "r1150", "r1151",
"r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172",
"r1173", "r1174" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfEmployeeAwardsAndNonemployeeDirectorAwardPlanActivityParentheticall
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Vesting", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1149", "r1150", "r1151", "r1152",
"r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173",
"r1174" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of
Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r989" ] },
"srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "WeightedAverageMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureCommonAndPreferredStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted
Average", "label": "Weighted Average [Member]" } } }, "auth_ref": [ "r570", "r645", "r858", "r859", "r918", "r1211", "r1213", "r1216" ] }, "us-
gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberDilutedSharesOutstandingAdjustment", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShareComponentsOfBasicAndDilutedEpsComputationsDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Weighted average common shares", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "totalLabel": "Weighted Average Number of Shares
Outstanding, Diluted, Adjustment, Total", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
} } }, "auth_ref": [ "r1074" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShareComponentsOfBasicAndDilutedEpsComputationsDetail",
```

```
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Adjusted weighted average common shares (denominator)", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "label": "Weighted Average Number Of Diluted Shares Outstanding", "terseLabel": "Weighted average shares used to compute net income (loss) per share - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r259", "r266" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureEarningsPerCommonShareComponentsOfBasicAndDilutedEpsComputationsDetail",
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "label": "Weighted Average Number Of Shares Outstanding Basic", "verboseLabel": "Weighted average common shares (denominator), Basic", "terseLabel": "Weighted average shares used to compute net income (loss) per share - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r258", "r266" ] }, "mnkd_WeightedAverageRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "WeightedAverageRemainingLeaseTerm", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFinanceLeaseInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term", "label": "Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (in years)" } } }, "auth_ref": [] }, "mnkd_WholesalerDistributionFeesAndPromptPayDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "WholesalerDistributionFeesAndPromptPayDiscounts", "crdr": "credit", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureScheduleOfAccountsReceivableNetDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Wholesaler distribution fees and prompt pay discounts", "label": "Wholesaler Distribution Fees And Prompt Pay Discounts", "documentation": "Wholesaler distribution fees and prompt pay discounts." } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEgtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEgtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r987" ] }, "mnkd_ZealandMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ZealandMember", "presentation": [ "http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Zealand", "label": "Zealand [Member]", "documentation": "Zealand." } } }, "auth_ref": [] }, "mnkd_ZealandPharmaUsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mannkindcorp.com/20240930", "localname": "ZealandPharmaUsMember", "presentation": [
"http://www.mannkindcorp.com/20240930/taxonomy/role/Role_DisclosureAccountsReceivableAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Zealand Pharma US", "label": "Zealand Pharma US [Member]", "documentation": "Zealand Pharma US [Member]" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21B", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21B" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-3" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-4" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "30", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-5" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "30", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-6" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r61": { "role":
```

"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-9" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805",

```
"Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481295/840-40-50-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481266/840-40-55-50" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "51", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481266/840-40-55-51" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481266/840-40-55-52" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477709/958-360-50-6" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
```

```
"Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r214": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r217": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-
1B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-
1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r223": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r225": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph":
"(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r228": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r230": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r232": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r234": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "
(SX 210.4-08(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" },
"r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r238": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-
1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r242": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r244": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-
50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r249": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r251": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r253": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r255": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r257": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" },
"r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r260": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r262": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "42", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r264": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph":
"(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r266": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "
(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
}, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-
2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r272": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r274": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r276": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-
22" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r281": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r283": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-
29" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r288": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-
30" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
```

"Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/310-10/tableOfContent" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481062/310-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "44", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-44" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/310-20/tableOfContent" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-

```
2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10",
```

```
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-4" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-
```

15" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-12" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-

20" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-6" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph", "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477706/946-210-45-4" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX

210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477068/946-235-50-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477068/946-235-50-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r912": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r916": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r917": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r918": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r919": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r920": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r921": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r922": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r923": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r924": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r925": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r926": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479580/842-20-55-53" }, "r927": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r928": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r929": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r930": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29E" }, "r931": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r932": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r933": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r934": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r935": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r936": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r937": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r938": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r939": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r941": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r942": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r943": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "930", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r944": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r945": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "I", "Paragraph": "a" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
```

```
"Section", "6", "Subsection", "F", "Paragraph", "1", "Subparagraph", "ii" ], "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 20-F",
"Section", "6", "Subsection", "F", "Paragraph", "1", "Subparagraph", "iii" ], "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
"Section": "6", "Subsection", "F", "Paragraph", "2" ], "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "a" ], "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" },
"r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" },
"r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" },
"r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" },
"r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" },
"r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" },
"r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r969": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r970": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r971": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r972": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r973": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r974": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r975": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r976": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r977": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r978": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r979": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r980": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r981": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r982": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r983": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r984": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii"
}, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name": "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "2",
"Subparagraph", "iii" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection",
"v", "Paragraph", "2", "Subparagraph", "iii", "Sentence", "B", "Clause", "1", "Subclause", "ii" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "2", "Subparagraph", "iii", "Sentence", "C", "Clause", "1", "Subclause", "i" }, "r988": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "2", "Subparagraph",
"iii", "Sentence", "C", "Clause", "1", "Subclause", "ii" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229",
"Section", "402", "Subsection", "v", "Paragraph", "2", "Subparagraph", "iii", "Sentence", "C", "Clause", "1", "Subclause", "iii" }, "r990": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "2", "Subparagraph",
"iii", "Sentence", "C", "Clause", "1", "Subclause", "iv" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229",
"Section", "402", "Subsection", "v", "Paragraph", "2", "Subparagraph", "iii", "Sentence", "C", "Clause", "1", "Subclause", "v" }, "r992": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "2", "Subparagraph",
"iii", "Sentence", "C", "Clause", "1", "Subclause", "vi" }, "r993": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name", "Regulation S-K", "Number": "229",
"Section", "402", "Subsection", "v", "Paragraph", "2", "Subparagraph", "iv" }, "r994": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-
K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "3", "Subparagraph", "vi" }, "r995", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC",
"Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "3" }, "r996", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC",
"Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "4" }, "r997", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC",
"Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "5", "Subparagraph", "i" }, "r998", { "role", "http://www.xbrl.org/2003/role/presentationRef",
"Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "5", "Subparagraph", "ii" }, "r999", { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "5", "Subparagraph",
"iii" }, "r1000", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph",
"5", "Subparagraph", "iv" }, "r1001", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402",
"Subsection", "v", "Paragraph", "6" }, "r1002", { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402",
"Subsection", "v", "Paragraph", "6", "Subparagraph", "i" }, "r1003", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number",
"229", "Section", "402", "Subsection", "w", "Paragraph", "1" }, "r1004", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number",
"229", "Section", "402", "Subsection", "w", "Paragraph", "1", "Subparagraph", "i" }, "r1005", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name",
"Regulation S-K", "Number", "229", "Section", "402", "Subsection", "w", "Paragraph", "1", "Subparagraph", "i", "Sentence", "A" }, "r1006", { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "w", "Paragraph", "1", "Subparagraph",
"i", "Sentence", "B" }, "r1007", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection",
"w", "Paragraph", "1", "Subparagraph", "i", "Sentence", "C" }, "r1008", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name", "Regulation S-K", "Number",
"229", "Section", "402", "Subsection", "w", "Paragraph", "1", "Subparagraph", "i", "Sentence", "D" }, "r1009", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC",
"Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "w", "Paragraph", "1", "Subparagraph", "i", "Sentence", "E" }, "r1010", { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "w", "Paragraph", "1", "Subparagraph",
"ii" }, "r1011", { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "w", "Paragraph",
"1", "Subparagraph", "iii" }, "r1012", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402",
"Subsection", "w", "Paragraph", "2" }, "r1013", { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402",
"Subsection", "x", "Paragraph", "1" }, "r1014", { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402",
"Subsection", "x", "Paragraph", "2" }, "r1015", { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402",
"Subsection", "x", "Paragraph", "2", "Subparagraph", "ii", "Sentence", "A" }, "r1016", { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-
K", "Number", "229", "Section", "402", "Subsection", "x", "Paragraph", "2", "Subparagraph", "ii", "Sentence", "C" }, "r1017", { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "x", "Paragraph", "2", "Subparagraph", "ii", "Sentence", "D" }, "r1018", { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "x", "Paragraph", "2", "Subparagraph",
"ii", "Sentence", "E" }, "r1019", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection",
"x", "Paragraph", "2", "Subparagraph", "ii", "Sentence", "F" }, "r1020", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number",
"229", "Section", "408", "Subsection", "a" }, "r1021", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section",
"408", "Subsection", "a", "Paragraph", "1" }, "r1022", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section",
"408", "Subsection", "a", "Paragraph", "2", "Subparagraph", "A" }, "r1023", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K",
"Number", "229", "Section", "408", "Subsection", "a", "Paragraph", "2", "Subparagraph", "B" }, "r1024", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC",
"Name", "Regulation S-K", "Number", "229", "Section", "408", "Subsection", "a", "Paragraph", "2", "Subparagraph", "C" }, "r1025", { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "408", "Subsection", "a", "Paragraph", "2", "Subparagraph": "D"
}, "r1026", { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "408", "Subsection", "b", "Paragraph", "1"
}, "r1027", { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Section", "402", "Number", "229", "Subsection", "v", "Paragraph", "2",
"Subparagraph", "iii", "Sentence", "C", "Clause", "1" }, "r1028", { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Section", "402",
"Subsection", "v", "Paragraph", "2", "Subparagraph", "iii", "Sentence", "A", "Number", "229" }, "r1029", { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC",
"Name", "Regulation S-K", "Section", "402", "Subsection", "v", "Paragraph", "2", "Subparagraph", "iii", "Sentence", "B", "Clause", "1", "Number", "229" }, "r1030", { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Section", "402", "Subsection", "v", "Paragraph", "2", "Subparagraph", "iii", "Sentence", "B",
"Clause", "1", "Subclause", "i", "Number", "229" }, "r1031", { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name": "Regulation S-T", "Number": "232",
"Section", "405" }, "r1032", { "role", "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic", "272", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section",
"45", "Paragraph", "3", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1033", { "role",
"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic", "450", "SubTopic", "20", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "10",
"Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1034", { "role", "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic", "855",
"SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "3", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483399/855-10-50-3" },
"r1035", { "role", "http://www.xbrl.org/2009/role/commonPracticeRef", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(h)(2)",
"SubTopic", "10", "Topic", "805", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1036", { "role",
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "3", "Subparagraph", "(h)(3)", "SubTopic", "10", "Topic",
"805", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1037", { "role", "http://www.xbrl.org/2009/role/commonPracticeRef", "Name", "Accounting
Standards Codification", "Section", "S99", "Paragraph", "2", "Subparagraph", "(SX 210.5-03(6))", "SubTopic", "10", "Topic", "220", "Publisher", "FASB", "URI",
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1038", { "role", "http://www.xbrl.org/2009/role/commonPracticeRef", "Name", "Accounting Standards Codification", "Topic",
"705", "Publisher", "FASB", "URI", "https://asc.fasb.org/705/tableOfContent" }, "r1039", { "role", "http://www.xbrl.org/2009/role/commonPracticeRef", "Name", "Regulation S-K (SK)",
"Number", "229", "Section", "1402", "Paragraph", "a", "Publisher", "SEC" }, "r1040", { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name", "Regulation S-K (SK)",
"Number", "229", "Section", "1402", "Paragraph", "b", "Subparagraph", "(1)", "Publisher", "SEC" }, "r1041", { "role", "http://www.xbrl.org/2009/role/commonPracticeRef", "Name",
"Regulation S-K (SK)", "Number", "229", "Section", "1402", "Paragraph", "b", "Subparagraph", "(2)", "Publisher", "SEC" }, "r1042", { "role",
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name", "Regulation S-K (SK)", "Number", "229", "Section", "1402", "Paragraph", "b", "Subparagraph", "(3)", "Publisher", "SEC" },
"r1043", { "role", "http://www.xbrl.org/2009/role/commonPracticeRef", "Name", "Regulation S-K (SK)", "Number", "229", "Section", "1402", "Paragraph", "c", "Subparagraph", "(2)(i)",
"Publisher", "SEC" }, "r1044", { "role", "http://www.xbrl.org/2009/role/commonPracticeRef", "Name", "Regulation S-K (SK)", "Number", "229", "Section", "1402", "Paragraph", "c",
"Subparagraph", "(2)(ii)", "Publisher", "SEC" }, "r1045", { "role", "http://www.xbrl.org/2009/role/commonPracticeRef", "Name", "Regulation S-K (SK)", "Number", "229", "Section", "1402",
"Paragraph", "c", "Subparagraph", "(2)(iii)", "Publisher", "SEC" }, "r1046", { "role", "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "205", "SubTopic", "10", "Name",
"Accounting Standards Codification", "Section", "50", "Paragraph", "1", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r1047", { "role",
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "-
(SX 210.5-02(1))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1048", { "role", "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic",
"210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(17))", "Publisher", "FASB", "URI",
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1049", { "role", "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting
Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(3)(a)(4))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
}, "r1050", { "role", "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1",
"Subparagraph", "(SX 210.5-02(6)(a)(4))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1051", { "role",
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "-
(SX 210.5-02(6)(a))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1052", { "role", "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(8))", "Publisher", "FASB", "URI",
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1053", { "role", "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting
Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(9))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" },
"r1054", { "role", "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "220", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "4",
"Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1055", { "role", "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "220", "SubTopic",
"10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "5", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1056", {
"role", "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "220", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "6", "Publisher",
"FASB", "URI", "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1057", { "role", "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "220", "SubTopic", "10", "Name",
```

"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147470536/321-10-50-3" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147470536/321-10-50-3" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "

{(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1204": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-1" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } }

ZIP 116 0000950170-24-123296-xbrl.zip !DEA: XBRL DOCUMENT begin 644 0000950170-24-123296-xbrl.zip M4$L#!!0 (-6 9UD#DR#K324$ *!\ P 1 ;6YK9"TR.#(T,#DS."YH M=&WLO5MW&T>6)OH^OT+C\] S:\ZVXGY1NSQ+DJ!]K9$MCF3{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{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j(% M.^M4?D86S\F.Z^#1.4FS:DH9A#1.RU1*!)..U]8C6;+GD=0R6&..0C.-FF^

MP,"8S0V.&\K@>%U$2S)%'URKG$1&4M:!EXZ1/SO)*!9>F?@Q7Z&,6OO>.Uj9 MF%42`>?W>;PL#&5GT\/&U\O%"BZ\K*=.?$"S=4G8\=47N
2)3MR[ETT)8YY%2W"\.EVPV[>@&48$1HMDNDVU("Y_9I[&RHZ 4.HW5[%3#3F\/2(6TZ2EE|()"R MJG6A=)(A@,XD.IGFB=?>/+V:O2D]5%(ZH?)5,R!G^$WYF"&4*D#%$(24Y&O& M?93W5]C'*`\M@^"OTD!W%'$>E5IS5":LF2 D B@I,OL%;1,OA2,N6P!S;Z[M.% 1[/YB!]ES&S61$@3T 9"P>.9#]6[?H|@3/=V4M,^5>;1IG]3.^D1A922< M?N@ M5UF7C +B)&G0T.+\U>O?
AU+,)^W1EY+OKYZ053N_GM>LJO<%oL-Y?:$ M1AN;3(;R4MDR$P05L9X,3K"8;@\G=!N<^7ZHS'F,Z<2L>3\K0,8^]\4"L= ME115H&6r;/2A&
(62UZ"3$FK;%!+URV+K9IK'F=&M>M6SG.$/%B.#Y%UU?OG MD[SMB*8?R!N!+*OFH1&:-A]%U$EI(@H722;!%(6%M|:!BN ."C*&"S5';$(DQ M5]'4I"2;-NL.0+'DBR!9C.X.?=V0-
(}+60D1C@]P5)Y/GN+1,(*C?:EFBI]D MU"PRNK10AK424&$"*1S5ZJP)MMMTP,Y21^?R1.N4V,>(f_(9/[\ HH; ?]/9 MX;YDBI+!H"T*2+%54QG/CF^,%K(I1FJA:=`=-
@%\#D7]@K,Q@ZC\LW;U6B! MH;B"G3]>O8OCYOL0x(TUO;'1GUR #&#%FQJT+;\Q@2+4XR&;@2 T7.HE6 MZHP1(4K+3K<3""%Z;5IYQ7Y"Z4RK-Z7XZ7;.(VE%#M[BX?
FHR=/1T1A? M+,I=5,1 2"S^<&J.8UI-]M4Y?>C/[PO(K@(18361.09EY6,0)$4*1>*-UU MTUY3]GQRZ%7KRMM<P'B9WHG5,MIY-]KNP[U]A]1(E)AZK-D$PF=.?$>1.X M.9/P<#?2
3V'!+8+^C43.=Q/):ZR$,K1^Z,38LLV*C%4$;$&\JARDW)M(^),65P7SAB@V^:UM#WA9K^P#/HW92Y6E=!M- NJ,37;5L=V#@0A"A10<9%2E
MC502@*0$5.6TK"'5S>YFEG3;WKVC^`C@=ZM\!A?),@G;>$6?.V!4[-,%H)7I MUK.[2C%?]9(9/9_T;GR51>TOU(4"-B;W 9>$%#4;O/V0DDE.5E"MR3L+;+6 M095>C#)EQ.
J*R!EU8UD%2B4H][0)B9TEWRWIOE"'T=2S,3.+L[A]!Q'55ZJ'G\)F=%8#M4'G>#^:1$03$ M%*R@C6.V0<^(M\U)92.K1'(H4NJV)K>3*.>6LB'H[S)&@21$,"E&'&WE@A"; M 9+(QO:+.;3?
N9WF*L]EQF\) ;9<'+>QYJ;6VVN6LPC(J;K& 6&7H(/S MC)Y 4 >F16,U8U)X=7;?3K/WF_M#"'7N(IER7S-U!9>%$#M@ 0 M ^4[. 9A#.9D-
)TUVI7=NJTA'92BI"4=]IBD]2V BMK";E9C<(O1E;= IL> M2#$DQB13LTL(H97B&&EEVOL.H)@0POGZ%EK$4$3E2XV0VWA)(U);D]@<. ,+9Z"#Z-KR(4LN9$%4 MDRF9W9(8GHAD_S+C\@A<.Z'&43@Y2G&T+RXIRBP% MRR^HTE(U!|D9"'"E!8]#\@^:.]M(&G QA [+.[XUPPV>]W)^.6(&\?ORU!H),. M!?,.'"W.BDBB.1A IMY$#RC G%@&6^= 6C)BV![%.*6?N5O)OC\,Z|\T'#*N;// M-
C 8Z)I:A;7'{63H=L2@</5BD= P >/EXNUT C]O1CF]POWA4!]+/M4-/1O4W!DRF]D-QO_>W<5Z-TH3E\EH)(Y+Y(=M-QO1LT(92LZ]#X8.*8B MA$ 9!/KBI,MS(/$2;4+S51V%(\%
(.I8*HO$"6R^D LE/I0I4E,#W-]M630G;/BFSI]ZJS=E?2S9$^3L,IA "=''' I2*#\SKI&NWZ]^;P.YV\H%H9:G9B);61%+0(EE %\W?2W,K)]T4M5 "&' .6ER#A]4CBRV MO41U7,
M1%&26]+1LMN\8 \AE"UYPBY1ZY4"]GQKF\49&$NF"!2R*H!$DR=A=]=''7,"[M5L*2"61,T%$UZ"PDIVOKR2 K0U42K4ZGT.W>)'Z,D@,73(' *RKKBKMJ7' M?Y].RR=B(:,/[**H3?
2>0^^59V:S;@16BUU5E9(0T5WQ^U]3#+UFI0^6"8^X =5L?2(YL]9 4P6'IEY%3R8 MT0=4O+:,LX [8!V3C?=4C>$;&]_^5'6N*M246B]W]+"A,<5XGQ
B00]B=8Y@N8;\=9%FZ.F9+MM>;SS.M(OAA,7 M7KF _E5Y.9C7K4Q6.VDNBL&J99QD]!!C&6),$TXKD02EV*WZVZ^>I[^F0 !X M' ,W=Z -D\ 4?6<+51=C(IV,S+=>\+$?B":UK0C!(%1CVD#;
MW%(T;95R*BS?VIOBNAWO=.,Y34 ^G*[RZBK\^G "?,K[9[TWW>E))^E#X<.T:BMY5HL7EIBABN."69 M;%)3Q;%] E.;%Q-L99KYHD0;.]IO$O(ISM^RPFW .,CS#L=79R#7A88'>'3M MV/;-
/.I<.]79M _@A\%92GO\@M(1^.)W9D:*A'/5V>B8:MESM0$+Z89+^W^ M8TTRG \^F1&.1 ^D\H_IN(WN_#N.MF&GMD5<*E7>4, ^,V:,4]QK!$98 V20".VE,/"
MFI3IMJU@OUKO;CL9N)N\4[+>YV!;DXXN;62S!/36@ X4+!. @X]IV6M-]MF&;.@ M(.G&3 >%X:"MIU-V!:N]BD77"%ZW&@7K R2.[55+<8YY;&[DNSA@-/F]G[
MM/OMT=K&+O20;.TW0.UUV|)*;>":;@BB84?A7+H0H(WMAO3+*20/7E]U=-%F5 MF$&V.ECC*H-X.2ODEYU$4C%@=^&5CG*5NU#[.7@3M0*.7H#)+18FT$ -Y%.5
M(:'7WBC610.TB2/X^>O29BOL??R;\G*VJCG\^AVP(24+"U/01$!5=17=04BI M,LNF;"LC;5?['&\48;DM#&1^9-F9V?PV;.'C=<=$H=\L 59M6[6K;S4Y)FV4- M23AV?I+QRD>3]N]VS7LG<;AS9!
#DB$[Y*4$"U[GB86#[$6!1.#TK%2\IG+_ M"MN^[4.1'67QDU9:9 6NDE)&LJUWEU$_KT&GB+78TBWIO^]0W2]+#09%D\X2 M,VNH4AP8HTK0W7.P$2*HB[2=QN!N!Y!/3Z]O@4$W
^D2385 M;R*4NG)NI8 @!$%IN[\8\BBZ#>5N98GBQI ^>#ZGQ>/,EYV/+HC%'W ?=DY3 MM?DTF[.,#S9* C&RTL]VC:D46M6,.W.!,Z2]?7,8.E"VWFZ .TG)-1E9.%0G M 1A9+.#! (E4<20P%.
%MB<.N^]WE+DDE6-73&!,# ^.<68TTKU#;. B25=3M M%V%N$[9^#:EELB8%9"T1!!.(,&5I<6QAM)%;!A_SIF?[?2F\[FL@<H+ B?
M^[.\B3FU,"ZQ(&-3[[LAHD5;4"D;.0L)Z;KCU+O.+>]^8$T/ AR52H%!A8VV M]4+Q/81("32K.E.D[NV[&X]R/^3K/H0R@+H=<*U(]H*!FVEQO$0 &"0(9#)0 MK S@0O-
)NZTY.X;MK(@KLZO_Y/A79.%A5OKPZ^ + ?83LJY:V)]-9TR^ YK5 MZ>P0)YE>IO'H#6Y2W+X7K'V-NOF5V>#O-&'?@Q]@:.3W!#.!.,5\[YI?]Y%Z , MB9?SL5,#WGEN@)#A2@"@;11&QN],+
[,VN;"/3(4R&O.K?TL>&= M+ + -;TYU?2 5& D6.(\?#F0V086!6F5ZB65E6"]6%1W'OTVEP0VH/<C =C.H. FA[NO[".K33?.]Q>N4@EDM3&KVG M4 D951
\]^%;IYA0@50*T#%&TDC*8K9M/Z0FEK)NBP?VLH=U3YU_6Z*AU$H8,&S3E-GY;T5RBIW+6]RE@MW6 MQ]W#Y$%FV@ &2]ZX50@"C;EMT(*"E C!%]PU:]-M#I;5>AS3M(.X>O:"5*OA
M=H7AF4E5LT<4#3C%ECP@A2RZC1I\LLG[U?08QXOCO9M"D7UK[V285A1;!A/8 M \4@+.0DDPZNDD .=9KGNUT% +, ^,%C2,X0[:8@J03U8F\1=+FZX\??2?
G^>+T2'SR.MZ]BK>>]REТP[.#C[MJH[,&&.I]]UC(.9K25#+EN3=[G?5?1=VD^C8A(6-O)!%>Y.U.#7$[NS]55[$ M.#:+$\]AKC>?05U+9Y.W;.'%YXVG.W;.^YXVG#K+<$E7+4, L-4LJW/=!B2%)P<1L)*06F#D#4'BJ1
MG?=M["E9H5M$./F% F!SV18'"5!B)(E ML,3=2549[W.WE2PWSV$>OV\Y!*>#YUN/7VV\ST /R&724G>R00AB+!)> HC% M1B"EL,58M>UW\?/T'+4'.]%#E4,585#K4EC+> TF>, .
,$=V:5"0:#/ZTAT:.M[C%0MMD\'O!U-M1#T.2HD+T;4&MSX75@#.@BV.TI:.3OMMRUZ$W/6 \P5_0 M4K%ZC6:;[>],D"#7T01EFH"[WR+W1<%,3L)6]F$-GEFE>Y0]]UUGCZB
M8N87G(UJBZL:)66>69'2)UXH@Y\K,Q%\V?4'A2@=Z6]P#7+4I3RK3064D4FAVL3LF/*4+5R M/]HJ37SE'<)Y);R77=X=5>4Q5H_E03)>@23R&,2R"ZF=@X94]+":,A,<5XGQ
MS6.VUW[<%P<'^P&'*B7&ALBD50P.LXYL\R4[@C8R+`;+1>1===(_W]DIW/;@NY M>=FF'*Y"]!AIJB0$T5;/&1G8R]"'V.M5R#RDC#);. HWEB(]E(FUSF.+'GS2
M38]HME7!Q6S]5]#%OBMMRK9=/"UM>]V]806!0E5ZB65E6"]6%1W'OTVEP0VH/<C =C.H. FA[NO[".K33?.]Q>N4@EDM3&KVG M4 D951
\]^%;IYA0@50*T#%&TDC*8K9M/Z0FEK)NBP?VLH=U3YU_6Z*AU$H8,&S3E-GY;T5RBIW+6]RE@MW6 MQ]W#Y$%FV@ &2]ZX50@"C;EMT(*"E C!%]PU:]-M[

8A0VV;9WT$$;(>X[;_YPB1Q8" U'$F6ZL89 M#AG!0;8,LTY+A@$ VT:;EF9%?G\.OW4]=UK@Y4O"M1.,(#O%; S >=)TXB$ M9#%7;7MB6]M-MK1U6I4)+HF2U@+7D"3 SF/9MHC<("HT=8)([KAN*]<|_6SK M_1"8Y[\&0.[EE"^\AKT$E9BY\],:^V,MB3U(BD24_+2YF$O!!F5&\(N+DMYV_],^ZWZ)-MX;.(G/PY)\Q/4G!.O?S=_F,P2-VSH^^H,AUCF$O'_&E_T!M\OIR<+]^+MR>9 M!05N%!*"9P/5&O#V%$94!9RLDD&K%26#C %IPX]4Z9?8OX@?XAF(%0C4C9DA M1Z[7_5QKR.O"ONE;YIZ[1R%CM#:.44MW.%).UZO&SE [K*^CQ([D$BRT)Y*EE(& ^![A=]0BS1 MY)*U7L,6]OW=_+,0*03]%%MD"07QEN"-N8R+*5%B4%9W%V<7 MM2\]*;6"ZX;Q-_M2YSDV"SE>`3ID1DAL91Y6E@(8,>9W4=L.W@&N#Y,4733AIGVK$- A=E%4[&0!22+*>?A1B0]19\#R.$,X8F[UM[QK?X$7N3CBK?C9%= M0A;2*J1 6BR#5M(%:6B9=(E%Q3'BR1ND&;&(>!ZL5HXKUCID6)<&.;MP M>6R(7F>W5QFP1G"RR++(D/.6J1" (J>V;&MZ*LX8VT,YA9;GDB D.B.U#0 [^ M0X%2I817$KM'H$5<\,S\,[F ?.Tt*]L)8S^(.1 MW.]0PQI6VO3E9025,BD9;63X#'D4B1Tf'9 .X$]ZUEF38=Y;4AX!ARK9.B M>>XU 9.? @)T!>PXZ!!.5&@C$MTZD8QW,B-<[.^E> .;${6IN*QD"MQ%)Y}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`MY>6FWP7<8+RN;.C';MJ]*9.BHC:A//PG%Z!8 MT,A1 ?BZ"G(,N>ME255)G(U'E1 ,[HW+H5,66R(Q@%%3?) *FV1<]8@G;1W MA"5L=6MM /M/5Q>4\1IB= _ &Q[^ 5&W(O+QSB$O?O V/IV@.9.6W \MWY MV@3=K'$*. ^4I -6,"*7/N3Z!Z IHC((TJG>0'R$T2UA<0RF]#@^'$(;(+ M)*5VB%.3D5/)H<0MIF! !\U.> [*PEH7.BW8H.[7.'5C&P>519[]>R.D21X9C MC[) $;3.CL26M/75IPP"3[TM9QO;&L>8*XY1G @P%B@@/&GSUY,%-M[F\,FIK MPYU16\U2,& ,K.'B @"',$.P=*1W"?&8 M&Y0+31\5;R6IV0&*2+?)PR)Z.OE[NJK T6?XCWU5+.VYN_M<]:\7.N?;!4AP>[=\&@W"]7=U$;@%1 ^ =P6>3^ZS\A#»]W>%PG> %NG2%XVW[U^NCWWP^.GP^. #@N5FELXGG/A M_VU!W? 8 CP?]3O5FY_5.1,'@9@&4F?<%[Z7,=(<'Z'OJA57=QIO/N .:*V1ON#?NVB M=GWM'K[]1*6.B06&L LXFX?@T7B;?P1KW7"KP,A/44VC5& AYO BMEAIP7TN M'P0/0(. [92F8P$QI91B)DECX3M_FX&'.5W05V[6I5XY@MV-#P17\^S4[W=]6 MOZP#?!>0>/%6U:~7/8O^>!?Q'<7 MVV;!!,,8.S?%V$NW]T=" (?2FPPKW 7 M[G(.?]!(_,X?A[$ZN- !=7QY!@+1UGYV1[8_0"$\0TW8=E@>!$L1%(OEQ8$YU-M-G&'E."4""T]\9I+/O[A1T"57N7D])\)*!S[^OQGU]T8<6CZ $$!CUG>[W!-MV V^/D<4GK8U] .,%45R^6@#H/<\0^O]:9)3] >/>AY/]# ^_^I_]P _[HPTGU M.N.'XX][AR25R5$%AO\)6/<58=71AX[(E^&GZNAM=?+7 >]&3W#M#^R]/LD? M$\.XBU8XAPWU(!"MB4L- E0U/HW5OZX$MYJ H?PT%>XDN MHQVBV&\';8P9T&DP((Z9.!#+.3V0CO1Y$O2%0#"#$[]>8H?NV M. *V]S^2PQ6 A-Z.V;'}.IUR>$?M\A'KX%9 .9&%&N+?$?#5M*W<=/T&= [^$XW3 M1T*_KPQ1EFD9.CPD=L&@CV F.9$!;$Y5[@QWSIG8]6'(\LW2!_OFX_RHL_M^]-W.?FP=WA\4%N:Q0C=.."B^,D+'U))Z987F]@[+9]YWK1>?HA^FF>Y>P&P M.NQU^[$1\GWK7YLX.SPH> _C.5]MIT:ML,5+D6[IN**?&5]G.BU7 .(OM'NPMR MCEQ.BD?!D!)$(&X(1E]%C:0+AD3A.!3IN9;*I&#U+2SFL%Y+. 89'H8$UE*L MDVM4C@/6Z,SPVZ/H0^!TCW1&)Z1P1(/Z$C[/"E#(L%@W,6 68!R# \UQ\X2\ M.>-=#V_[X$#Y15$(27/Q]_PM#?X&CF%UHW)D:.<(Z[UOM>K%R_VOUH|K$]HH& MJ1]>5/ZVCL3\5F. TRF%U=)F93BQQ:!W;9';QA M+\;#*PKFMP >R4O(EZ>O1QCN#N*YQ. M+MZF> 7WO% GY\ +#]Z= Z8ZZDXKAW;OO3R^"]\+UB7/L%$ ZVO>B OBT 7!.M5G]]}>+GN; SR\ CX?=O- 4W=K2E .)TW^@"4C-XSVG[OUGRC X@Y;?]2===L= M;WO3JX"=,D,L#V'OUM+2,ZR#\\B$W%LT8HUS%.#8348G\9A]8^+87<4NG4I=A,_ >\X85F&V6I M2^W>A*IZQ#R,<=QL MO.8Q'M2L22>C*.4DV\2H6 D\)5OO[Z,V!WSVNW>G$TPU(3W$ Is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|"2E>6\9_SWVIVGL3]THV# _4`?`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`\]4[IKW2ONW[KNWE^'5N )LO'HUM/]AA&%6YWU-WW%;R%[: MG^XW"LGZ^5D _<&3]=%][/6NQ*%Z"4Q>GV]/^KK_^/1XD]U3_0^\VE5]V8\2 M.IZ?PI.LL!(@HCD .@.[1J2IE\@]Z206DFK7T&R3X[PK=^'XY!@6WKLWFK?_MRO-(W-,IO]LB8GMUTL>]'P_RD%,].E6>QMG)PC&.U1_YCVW'N89H=`0QKM48Z+.7U46 .[G]QT]UA='H!6" M[YZ!+/WYQ<'AV]N"UK\X0V%0#^[*E[SX"U6BHX3]2..NV/XJH.O0^E2KO!Q M. MSQ4_]K4:3>]MIE=5UU=5UO56G&GS;K)W]I&EYDRK]*L@PN #[\)=]V2L%W>'$9LH9 M+Q=G_5>A.SKOV?.M9^\A8/7A-#GI]@>PFY-?U^2=A%Y[@B7MVMX?]G(T3>;Y2>DKVM5,7]/!!NUG M;-@LJ9;9"-1!*K6[95##?B#F M-D,5P>COZ]V!;8/(4=L/?[^HIVCU+]OWDP#"?AU8. ([GXY@;ME4,3RS;.;2), MK0W.2KF3O5 ?[> ?9S*^/#D_V#T^.VYOSZZS_Y^?AX*(?T'2S)OT]9O?E*=G! M1NR(.?)U^0[GRVN4 ,^OS0_S 9K] .+2W@7W-SYY7.GX^C1'>0^VY'8E4-G] M=)B=[3\!/HP 7.>0/W?$SP83^X=:U2X<`^NA=^OW/IQ4![O5VX/#0 M01K"\^$?[#"(X5OX)X35SWP#=S.#Y.IC, M1/^I-QBUA)$2>>PPGL)UN0U&!U!%/N7[^ 5:? RI_ W2F9UO.]+=@W=D>]/[/K M;70;XW%.CGO8_=?)BU3'}8OLWL>W;Z*?_I9TMIV)^?8R\3??W 3O^I3Y=_ #M#FP/*GIL3@P<>KZ[K26^T]\TX=CT;,%NU64U%/E6VRO?-]24K.\Z^WH M|%-]C8R_AM>IWO8&?X#>.BS, 2CF5EO*W/W!.(X^C0>?[N'R]UC0,IC[,+]+ MS[> ^A\OOB@MM,#WNC3^7#@8\C\L32>Y3L97NO'U_SZ M_OH5"D.VZ.B[]3@G.P6QV=_'7_0\F_F.#2HPV] M@6DH%386E,:Y [WXV28F%E/=YG^JR3?O\L,GMM:DX066M4I[&^?OO7C MP7(.929.N+=3NXW5\V\F#"P^N0/23Q?]L.V,OXUL+XX^Y9DEX\M/H\E(]&7& K_M *f>>)GJ.++],#M3MU^]SF^FK5!_/\]2A^E5N,&YATBUE4OX)IB4^OJ8(R\[^ MA7*7&;K{/1]4']>O<#.:7)AR2YE2K^ V4_.BV*F.ZA9-![\>7KAP2[E0?HI? M3[NNN\0"&+E3[4^? N7&E*=M".UP|CV*WP:5T9VN_2"VW.UO=)G2^+B'+;+14 M9)S&0;WU$6M0!Z\Z6)BUXKV4.V;W%37,U=5CFSAR<|/]>MWV8,%.+:+;WKCH^ MV8/7N|E+K 7OM0I>:L7" [^H;6>W!S\!.P[^%=?]L)50O[L_IE+';.'M7A\=OMD_/+I^1^_TV/GIW\&;O(S!4$A/?ZA@"YL^#+1^_T)VVT1F[6ZY^~=?8%: MU^WQ^3T5%945+7I%#W0U0=;+ZQ-" MRI..[-"S8MM] [FT8XAU7QOP0_[DSR_DBQ\O]-ZVKM65IES%5C39SG722./W M06XQ\(L;_OR7.]ID-]P2MYJ*(69KSTA%2K9#2NH^'$5(FCSC;4I:/U8AMZ$/ M]X9 SZ)3(^Z!ASX;>-I]2:!Z.; BN:1(@V]562DR,BS9>3.CIQ%1IZ3;]81 MBRU24S1+T2Q%1HIF*7[?^NWJUB /X0] 3QN(VB2PO#SH5^/3P<7(JL.HBE]] M\'RX'FA0;1178GE4D3#XC)?Y#_!+[%W&T^VP& M6F%)P$H,G,U>EGNTHN!^M A<7+B(++8Q=*%W@N9!ULY;[=(_D^EQ2.>C7D>N M\.K_]^CZ 1?E9O\1>%.;=|=3NXW5V\F#"P^N0/23Q?]L.V,OXUL+XX^Y9DEX\M/H\E(]&7& K_M *f>>)GJ.++],#M3MU^]SF^FK5!_/\]2A^E5N,&YATBUE4OX)IB4^OJ8(R\[^ MA7*7&;K{/1]4']>O<#.:7)AR2YE2K^ V4_.BV*F.ZA9-![\>7KAP2[E0?HI? M3[NNN\0"&+E3[4^? N7&E*=M".UP|CV*WP:5T9VN_2"VW.UO=)G2^+B'+;+14 M9)S&0;WU$6M0!Z\Z6)BUXKV4.V;W%37,U=5CFSAR<|/]>MWV8,%.+:+;WKCH^ MV8/7N|E+K 7OM0I>:L7" [^H;6>W!S\!.P[^%=?]L)50O[L_IE+';.'M7A\=OMD_/+I^1^_TV/GIW\&;O(S!4$A/?ZA@"YL^#+1^_T)VVT1F[6ZY^~=?8%: MU^WQ^3T5%945+7I%#W0U0=;+ZQ-" MRI..[-"S8MM] [FT8XAU7QOP0_[DSR_DBQ\O]-ZVKM65IES%5C39SG722./W M06XQ\(L;_OR7.]ID-]P2MYJ*(69KSTA%2K9#2NH^'$5(FCSC;4I:/U8AMZ$/ M]X9 SZ)3(^Z!ASX;>-I]2:!Z.; BN:1(@V]562DR,BS9>3.CIQ%1IZ3;]81 MBRU24S1+T2Q%1HIF*7[?^NWJUB /X0] 3QN(VB2PO#SH5^/3P<7(JL.HBE]] M\'RX'FA0;1178GE4D3#XC)?Y#_!+[%W&T^VP& M6F%)P$H,G,U>EGNTHN!^M A<7+B(++8Q=*%W@N9!UL\

*4Y!{W7!H{32W7 .#?F'SSZKXU<<, M#Z=V&*M?W/#GO\"OJW/ H,FQ@AW,,B1M_KYA#3MC L?]^>[QT?WSY! M*(;0]!3 E>46+MY4LF[47_!AS44F"W#A\+%*
M6TK6C5INZ0Z]'*UH1Z=5CC+X_(_XKXON%]O+Z=*EC&G>^HF5FT5ECMK\7;N4 MQ-QQC"CF7M--+"&L1$\C813H*-WY<+$9=P"$DC&?-X2$PUL@Z^C:,,2BAGJ MA?
4SY4(@;7O]D/ ;_R9S>^/7=CB\|/8__Y?M7<2&ZC0E[3"UP-93!0*S0%>! MKI5#5PC8;6(,2C'W(HK!(LTQ1BEI$H7A.E'\/70YIPBCPB*]HYH8AS%9&FSH*5FT32SE.*?1-6|@(1
M2LB.))=UMJT^VY#WLX'E7#Z"/X:JX7.U4_CHO.V&CI*CKCUL@7951@-M2J H@T%<6H*T@A\%=C0Z!NJ#$4SCF\>JO1*V#)=2BE'>O;2!#QIS;#M$*+|+FW
MR=Q=@&IC2+FA0)5"LD$QBA+68-P*2Y$67H/|K71RX-4RSYLP;I#X651%ALM3D59W%(65]M $N!$HAYQ3P+2U$ID6#*1 M."Q ?31AU5Y+%^B(IH[U9$?
*D!%0@&F[2;FAP&1Q9SXD-=-R>1XK=A' I#N"; O940G-+L5]?3^,Y[8;JOCU/#?+'-59N(,\ MS;+RMTI5BO*85]S*Z-FM'#UK2;(8M TH(66L>($;3"2D29!1,$#UWHFC#*/
M93R5X/V) ._U0SV+=]\6VF:C*8QT*%W@D>'&3(\MN%APL>#B/:C(9/26!H:4 MEC]/D?)(,TZ1L$QJZ8WDQ1$,X27B(N]HOK3Y16N,BTN1-,F;'JZCC;1R6!L
M>\5\WR9ON<3'-JH8S4@*BA'$/ 9U05F.1^.$N"68"@7;A[I&4BT6H4RHZDA9 MDBL*-&TW*3<4FE(,5'.?$sYTV+"T!9K3"#BG)>(E#|&%1I(K%@%-BG68V?83
MLX4'IN>Q6=MOE'Z(H_&PZ_-B^\;L(>_29CN2ZZ(=17;-N/(@LN;3LIUQZ7_N-/FA*Z9<1>>+AQ M.RVU=X,\|[4T(-@F4=E67+S;7E.6!XFI0UIZC5C+%1#,$R0,ETQXPZ,73=AK
M6=(6U'] =I21Q6XK^+35I-Q0?*(F6A*)0A;S!/ZD-<@R8Q SW$7'-<:LD0]M MQ>&3ZA"Q[6YE"23.F;$Z.(T^C1SAPB[B0!EFL:QPWBBG.G6ND".I*
MN)H*GW8,V_:V.06 3MIV&A60)#B?/3$P(:\X1-QJ,$W#EYB!H4PB&U5*/M"_3>VHXKT5.J$Z9(6F81M#]PB&U5*=4D0A10LF>-3(-TS29O0X85ZWU/QN^@&$N,$UY,!>?Z58]CU&]2"14 M
(0+S.S?&"!<:;@/9;6\V52SS)]6.]M I.=F%PD8/U*11(RQ^+_ IB-V%#E9+"E MV"N6NP1@4$Z,()/'WEHL C-@D%/;2*[$1"\UI(VXY!V*%Y@2]T.&6^^-5*"P
M0&&!PD<%OYT/D5(!.",90'"6R$B!D358]N2ET68F8C%_EZRFH%")#C%+ZP.[MUE X?QC\+N9ZK,6^]F'PZB%>VD@-.AN6/_GS"_#-?[C.=]#A I1G66[AXDTE MZT8M=_Z@4\-
Z[0[&7N2>?|+/COD!KUP?U>B@[U?#]X=G!SL'U=[MAV^]XY.CUW_[ZI/&[-_L?CO^S>K/_)N#UP4D!E]VI1M"T#EL+%6C5!NZ;F\
[[L;1;@&)K9&;+!0.)PL5;2M;-6FZ97[L4U;CG/>SA>%2= MVTOK>K&5:[MJB0[-TXGR;]DB5A30$T_K6_OI3 MU:0DBB E"@1 H#LG8FB*0 -=G?4\>:O,#(X9ZS=R=.
2;2\NP+!,9\3)FK!3-.MO2*]VDM1$E5MB*]T4\$I44!T'6$RYQ!-TI"R*,BSRUFL4-5;J?UM4I4?:T=M MP'8XS'70!N[\'/,(+^88+[]VMI.N'"ZMAH5(I_0."E5)
['L"&#=ZLL1<28R:&S%$U=S-"[*(3OVI;Q\.V_X>=S/M"),/AC'IE5YCC[3*9R42)6E>G(*8P;OG*U_IBNQA"@+O MP![^<3(-TS29O0X85ZWU/QN^@&$;*Y#/C-OD&AEKO.
(].9XO%J,+]['R>WH0%5LR\?3M9MB'6=-IA6. ; MJH;I=KD@81-N]V&YA-0[6H;&>)L8N%[_**8B5*O!@A8L,%=*3E[>.PSZXE); MGL2ZLM"^? @ M@M:<9Q^D6XE^K)/'WUK-
KQ5CSOC 0Q]$3T,795_I":F-E6X@2\5 154@A(@0 MD*5]SB;N&=M$VGYK],29&G-!.?HMAV;?1&#WWT1]A=/);-ZV=[>4-D1M.EN2 MA=ISM) *^&SF;(G9!6W!R5)
,9[\117!&U:X=SRR516PYDG3#RCI:39]_0D- MWSYO8+OLSKBI*(BP8Z_(7B6R&K8H>TI66(B,6]P2@K3ZUL]R_$[*.%KY(D86 MS732VA59E;'30R>KK<=C^VF\?
F.#K-.ZC4>5!]Z2ON@UFDA?7-47P>IL=$Y5 M073ZHB*$2OM@>;/HO&I1US-?3>XT190Q=E3RF+ M, ^.*819*Y 94\ $",_W]N)-)NAB*-9QMD6U4+RC)CIH<^V86BM!OO?
$56[3"@ M0RKBLW]B.LI04$ 1KE]HR!&NR.6 M&KHH>\I21BNC5!;@5>:@LI90+5@%)GPS)F _%XM 7;(4I)3\1<%:3?9TXH, MUV'@AE3"9^D['9T1,H+VN44TK(>0N
;/HI2:19!#O0S7.W6)V;B" 'K;-<5C MB;.&+N=K3;/67YIL/05D*2"[M@VY59.L. TZD-5[3&S:I$@[""Z'[!I9I%,$2),+09^*X/2]X'1+WYO-:PHQ M-
I+ZMA)++#5N4/66I$]1T7@9(,E:60A'!V P,8;-B/QPQ($_0:+]0)/CM4@%PD)RVD@ E4BAI"D+KE M{+B,AKA-E(:]A%M/S6P;2_"P<68&SMPC4!L-711]I2M-
(M)%^H$VW'.HU0Z]APT1 MU=!%>?!$-Q1RW,.,*CKP.0ST$%62L FW#[UH4D5O+F O3Z>B?].FVW3YJQ:P2_ M\1.9;NP$&7 4C5L#%D1<#-*LG)+X9LON4GL^NU2>&P_-:4-
6'#%OG4I .E]PK-L'YQ>W^DB?+4>+V>DDCVYZVE]$%>7G?%C)#1]U$+A< M\]%9;M_>'T55F9"1"(I1')2T!:*V$; XSKB4)H5-3WK?5.\,VV8H?[N: MNFW37-
WDQM!U,6#4986W+6@2F+@?<@N+!19.8] M7^D=?,]1]1OB5ROKEUD>-$-.^T > _]8#QLA/CS99B?8+3##Y$!Y,?%%9HP1KS_XE0^1.0OCK0876CL%B1F<$@&B
M#*K(A)IGI4&$'U_I$A]FN4/M9/H:I^F]WW+3?S86)VP[[&\ME3/B^N]?0V(O MM79]?.V5? M.?/?E=>Z'0MF"P4++I5W<5[':KGKAQ /5^UO0.N]6L]2;V]F
MI]7V6_Q_U6(MDS19/B:.& QN!D83M(L'*M9>+9=.0:VE['Z=9ES4SPU+S*/Z M[LO!.XNF \>COVS8@;PY1I690\F-!:Z4 R4,AUC=<#]!F$%6L-79G>ODP-X M\6%YG89_$>8G\U?
+MO#_"[?G^ +6KZ$;7X>OJJ_MO?7=RU.RM%,G%=_I_S [M/0WSQ>6/X6TGCW_\2LQK5MB=);APQ9@LW75"KV X'T"'"ZS5PD[<'4L2DZ,
MIN'7SQZOFWH>W!+AVVC4XBS.1^_;.C^>\|O)WD[*"<]D[<\@>%!&&'",.Q F MN&PY!BVWL+<{T2R.SI=O9O.V<>8SF2ZZ%S>R<4N.T?D(1B3;^G$D"/7^0'!M
M8F"98=Q(.]$M+XZS<95V^_\#[\W, M^=*Z3LZ7BV68Y1GT]7869YC-)O*Z.&ZK **O]@V 0A7HG&F"B#=]_W;CA8W MG=V%6QZ2?2;=#AW-Y]/9IV6/PF(T*Z-7>+;$MQ'G(\G&
(\&$;N_] =/E'WGW M1TFY_5X?23S(8[9?2>`Q9NE .6R0!*5=\C],C\2&-0:^,'35\\;? Y?V@7*M[=7:B! &2 @V^%RA;X$1%:N1F!BX5 HPSK244]ML,Q'"09UTIV?DKIT&F4UW
M&ZGCW.GHK01GVW1,;UGU!KR-+X@=U::M&J,KS>)QVUMS\)TT0O4/AI(H2T^ MAVHJQ-*6Q*.2,7 ?-N*)//#BAQ>CL!8AUXQ!-*8*B,=C7%5L8+'^:G6)K*R4
MPMJS5^\]0"?;IO6E{C?4H&S NC+!6WC , ^NQ/L'\X2V[!94YMG_AN8>,SDF? MG4)3+1(16)-IK#*U"#XK%GE C',3"R/$-,=0\G69<2*06OK3G659KU1 E!C
M,"9Z$\&NO&]UH_QG/#'!*KQ_7VQ^S&R<^]V*KM6.A.=]ANA*TE\"[F^%/M>XA,!7#5/"B^<-(OF.\RR27G=O#0?6-1!M.&^;> $MQ%"504@N,_U+T%$OYVE
M;0A@PE:RE&]L_$VCT78?46Q[N#WA!H,))>O1!K'H_H%9UC7\-Y/:0A"-MOQW$@PPS;(UYHU*A,J\%X4-E7NL4>!25;QB6H'VNZ%AIO'E/3=GY'AN;U64U
MS>HB;A]V*O*3@L3#),IJ,4SB;+<$H*H-=X(07PV7%'D3QW4H()HH4% M(H.@LH3$]XG)M0^6;61"UR>XO:AH>S8]OL#:%;VP,97@O1Y[]P:N%HBQAB[*
MGC*6$Q@5]IZ525/2@DF'@4-L6@FZA:&OP?MWR'IH*Q!MK26V1Z5CI:H9L2N=O MST^[>J#9\@W.Z]V_6Z]Z@I/%Y!V:]/W$&_LD(KX+,"DT3%A<-<289#5J M%0?O7
$3@\N>:Y'E1C*N5Z!WTI!W?!5XSSK<_31;+)[C\]J3\$0[<5*=5=U.R MDG8[$=>#+Y>(BSJX4ZARFQ>97+38L5U@=+#KIO45O/]_,O;;HY388Y&\4I4 MVI/P8?
LT_GY)KEM/WRUBR)Q+W$O<>]6#U07E5TI M$+,,5H+)?$'+,@((I$UE*-FPD OP@W"O\6#%+W'MWI]7!*SL1I71CQV)87D>6Q1'XI'HL$SS\|,Y/0'U(AW M0^=?MJ8;,WX0!Z\
<;U9F(=D4@0LH0BJD_HDP^IX0],I1OZ)598T?3 M?!_5]D6-IHP:BVW6 WUQJOS6A#$B22))(LD[-5<6VK#6,TNJUC/;.':"P6> MYUB*4YS[M.&!C%LE2:O'W. ,[#]HDOQ@[]?
AGKIW;;O.M/L/D] 5[(]B]^ MX5W7_3#+NP-@-[#85XBCZ6Q9W!N<-,!69VB!W43&SB7MSE.5R31,TZ3+/MZ4P-STD3)NO5:N>,N3B\5<^<7?;B?!\5R4MY_M^,+N4L!?
G(V6W3%*H_G>!I:CY4*PS_;(ZN?^?@C(O^\(^RX^-I3WD\A[\I M7&5Q^;,)ILU'C_WRYB?3T\FTWI4RS)>/P_ER!N3S%^!CO?AS)^^<+MSV4NK,' MX?2/\'[QY+M_?-
P1EY_\08B7HVRKP*YL@A5A;E9FV[>YMD$YG^2SO\3SQX70 M8E7&FW@&/Q\]?_Z?SY[,#H^>?GBY.71+\].GH^.ZK]?_?K]JV<-/#MZ^>SI
MJP=@Y<[CQG_KC9T<_^>_G_STP].7K[K#W_;)Z(>G/SX]?O;+ M=H7=D?F^@N%OOT[#>6]M4/^^1P(;79-(9_A1..@)\]=<"]"]V_7V CH=K>]#\|%@YB!4 MZ(]$M&A1..@)\]=<"]"]V_7V CH=K>]#\|%@YB!4
G)Q;=PQAZQOWZX(+6.KV<+?+S LS"O4/L@N,ZON?CI[ZZ'F]]- M%I/.37C_^,/U-YV#[[Y.FD?>R[]>52N7:[S0*_^XY3]^DTMLO3FWKS>WQB7M M8?M]O3E:SV/W2,D=
L;=`3.P(0IKW;DE,,V/?!2%U9W[MCRGL,A+MIA:WLT&TYBN#:,+_I?,6#27T=<^HKTPRZ..5Z6^,NYP/VX:D15KX- M*]\PM+G_,AW48FD#]T^F@UHL;>#^R710BZ4-
W#^9]FBQY(43+6R1%H;GA5 , MH2' FU!"*+D=]4=OJT!Y.JT H810.FB4?&QXW.WZ>G$Y%>'X;E,1*@V$C&C
MYTJ3OJX9[.BS;K"C9W=]PTPH(A01BBY0],/=2CP),@29(4.FJY8FD.Q']"U M:>T#.GM-/=M?W"?R^1K[*#]7_.W9=+1\,SM?A&E>?
+79I/X\@XSW1S\=/3]^.A[]Q]'S7X]>_M_1Y<3OK5>='XKMH; MZS71-+2 63(6$9+W M$K+4LC)>D.'+T""CQ.K$6:N5NLZ2'E5))@9P.C!07'-P(3G(ROGD8U"E7;/S
M"0R:C76_8E;,&;PY=,9.\Q6<'<%X0!(FJU|MEB?J.P6.S2!\V\ZFY_7W#[U9]_3)9O1E$)RS<(]7Y_PV7:]C(+S MR?0'UJ.R# 2BE'>C>]BT16EUT4A9,X]=V S MTO-->PVA.
M"6^F"1\|NU7>.AB_N&\(>Y%Q=TL7V2 Z]/I7EIL,O ;*\N= MPAK$7L1>]_&&7)*MQC!X;JHE77*HEK0L8+T.7"(38G7\RP;9Z[_"Z3G>3%[K MYU0HET*\-6!!#H'W7#92M B
R%@Y2$L.7I12R8O9:G(%[>4*;WE77,,""@$4E M4"@0G/%M0(O+,,4;?#L|LY\;LCWN)C[K"I/3O8$1-F.V)(FS M@Q$U8;8G@AR$CX &@XS5WN$NVD%*# M T C&8TD:L+L(1)F!V.J
FS/1'D?CAZ!WW.L6,X.N)4)E"P1O+,.6T$BG M%>,F.;Z)5--1;],]NUF[O\P^-6)M/5B?32\!L%YQ-3\8Z,?-/M]4-:+]DVM) MA.6)-LG4(5$39@,.LK.W5Q2A,;VB.B^5\!DEHB
M[>+%AHRO3N_.:.]UXCT<\.F#\#DQ);EF->=3!!=%:"+("JG)P4D$$5+R7&6T M>:7QQ;<4HKR=_I;_7$/7O7AR =6C:7[Y$:C="[\VF%9&."D_SN8%)\OS^4:K M[1B=_#X,MB-
/@$AN?5M=.O2:@61>5KN;90B1)6#2Y>QBL!IQ6R37'4>[+\]?= MPW8G>B-Z&ZX@!T%OJC@E(@8PI2A0 DUK1*9 *$S%&&F87PE%?$NF=(_I33/B M-
^*WX0f2DB^#$35AMB>"),P.1M2$V9X(^J M\U%=#%_NE=+<9S]BX'$2*NY[T Z@9^?S]LRM)S5QW9S8K-^3'U BP;7>OGR M#8Y^#M/IZ)5+&=?O&0YB:LU(K5A"Y)\[<&
(FC#;T.PQ")ECF?!4AI/2BG M(K@D/<0B;9:>F63,=4-$Q*RE<=40X=U9+1G Y39Z*%EN;.K.-[NK(=*YV!]F MA]S#N=9DA!"A#5>09(0,1M2$V9X(D€
[&%$39GLBR$$X#A*M<9N6H MWG -G'4[\6)88&Y9N3.<+D(-/RS_8X'K6]H2'_=_[9B0R)(PNQ@
M1$V8[8D@!^';.1E$;KF=%+*KOEVP$)-1U=5CF2$K!MW*Y(2MM;QLQTXZH_CX-MBDW\$G_GRS]0E_A_-TDX853^!+3[/6T^Y3./]S40,FQ&;H'2+0W;$&2]3(8 M41-F>R)
(PNQ@1$V8!8D@!^%>E&*]>Z$M%,4+*"8-!,L0LL@)%>=)^)>%?UMK M64GNO12@A&++73C_>N/]-ERMD@=3O+H@SP. 6QK MBOKKBR>#\\Y/[*)!SF2?-POQ W$#€<0-Q
W$#€<0-Q W$#€<0-Q W"# M3KF!ID?=&]HW2<XE[#YE[<]8Y&Q'!Q-OZ@*D"7A4-(6HAZN?]8%8]Z-9)@Q+W!A'W;KN4
M;]_Y_!X0^O[HIZ/GQT_'HY^/7A[_^TCR\4@P(4F],018XI%HR,]S\];B*VW89MTG*9L] :-2@(D]0=0Q"EBA,2((%]5?Z/SF?%5,.06SBM.':F/U?Y*MH#R.E6C6RJP:$P)0AG71O!M@"-;
X WL]/Z MU!=/?S^?+]O:OC>V"A)_$C\2/Q(_+B%VH=%\'QS*Z#M!*,W?BS$$@9Q)$D<21 ME.(GJB"[(*HX-'/JH+-.1F:=M1)M@+4+P!A=%!QS&JQH0DI"A>+Q;B2=:I?N"(+
ML)1Y-=;]%^Q8_0BI6\+)2L$YW;2Q=K?4DZPGFQT+HX9GM5?RGSB9.+DWG(PZ M%DQ:0TC9@_*\\FLV-9B6Z%CT)L25_*-+Z%Q #YAXO09="T6!DIR:',./F6S M>TX66H^F-
\3(VSP20,7/:R#OUIF78;&8I4E88KYE>N4?D^6;45C"\@U"O=_? M<%D_HV#K14T*ML=-":B%Q^T:*X.0@Q&^G5BKVB>*!%YD!T%RSL/,7'BQ(2H+=,)A=2L;)&]NN9!-
Y/7^CFL+49!>KS=B;=Z M(LA\!%.15OO$"U3+]X 224/@.H.P1H%MG-T[YXJZ>")(2X(.1-6&X)X(DS Y&U(39G@B#,M$#Y" MC)):Y@?V$=P6CO<.8C=!!'4E-
.Q=OLP$KG0"$KX+.,D#RSLG@=A=I{NE. M,WH^N9H?#/3C9!QRKNT?7(MJ32 :)-,'1(U8780@B3,#D;4A-F>")+9TL%[DG^^,>4)W<@[;)G9W/VRO+ MT7)6'!O-R;_Z,?
4!+1I.Z^7+-SCZ.4RGHW]6L9Q[\9+E!!5P3F=+'$T:(^)B M29KS8$],,VY9=TF(V]6(@=N6KM)# *]VN+/@@_>.(<:@PDHU>&L*;U,!914
M%7.]AF4#R(PQGEN!M!3NZVVIO<CDD_*3-2>(OL)4WI{<:++FC@_:>1VK % M22[\8$1-F.V)(=AB!3KDVP.LRU2@C*8P*5DH%BKLRB2VQMR@-8F(46!-MP& ME*TV2-3:@6-
(6-"A2B_Y2CIM]DAZWO9FNIGB=_&+$@R0@8C:L)L3P1)F!V, MJ FS/1'D(!P'.[,VV11(UFM0.4J(27 0AF5CI(PBK-2@,111.BW "ZM,#TP% M+@L)6)0Q7*?Z(Y+CL'\XH,*T763EGN-
R-+E?!\N+|\[.VA9=C,(TCUJ6;3Y) MK;RM>_&6JQM,%]3+>HQATF6WZS+#;&O\5D DVP):+$,!:'$^C\IF776W:=7 MW-OI; G+J;CNQ9,+W!Y-\\N/J.U>^+6AL]+#2?EQ-B\X69[/-
]H0<[NC-7N, M#]*YG@AR#$3G@M:21824A&TTQ\!%(T"CB<@Q>M0K!^HV17.=O7Y?EEO?@I?4 M[!?X;<"""W]-^.CCR"7*X%1 T,5]4$8P\-X72$YRI9P,+/+[5$L^+'O>;?2'
M&VN[Q<$?!W54F2AU+R6Z=Y1*F9F#%S5AMB>"),P.1M2$V9X(DER7^\>WM6Q9 MV00.:Y.&^MM_>]I#P0UT7U*HU+599[GL^]M MB6_/3F?O$4 &5;.*$(-CAL/
MG&L;@@]>NI7#1AL?1?CT$IG=FUY4&4[""]"]\1M8^T1G1V2]=29Y1 M\@7&9PG*EFI;.^=!BY*5L R#62FZVO1LPEO9;%,95^(QXK'A"G(0;,LMIH;
M!@&%!Q6"!I^M!!;=C$9RH^7*A.A-SRK<-H]YP8C)B,F&*TC*F0Q&U(39G@B2 M,#L841-F>R+!(@7@,,@DT"%KD JJY #Y6MR%R4U@)7@NAMCVYP\!C'U0N MNHOT8K=]
(=:]FUMZ\0RGB]A#?]LOR/IF]Y#C.Q'$C5A=A"'"),P.1M2$V9X(M?@%H(]"C*+OBBNC7,K/3A!=.X$M,L]?3[E,Z?W!338+&VE&]B&AOP((D4V4PHB;,]D20 MA-G'8)HPVQ-
!#L*]2&TTDD\!2K'5O2A%@T_"@%8V&9>$,(M;/P?N1=[@!8] M6WO0LK4RG[T=U?OX#9>WU*Z=S2L*1E2X1DJ,E-B%$A/(BG A V=9@7*1@TM< M 9>I9&6S]?
>K]/AZ9]&?.\"^.,C\\H&'^]40L(U(K,!"Y\Z,&(FC#;T. MP@#1V:/(R,#E:D>H,"PXDSSH$%SUJ;/1,.7 Y4.[5M[9_EC?-">:.NOL2DPU8 MD&1]#$;4A-F>")(P.QA1$V9[(LA:>
RF%&.0Q(&$JC4FTU@#8\?G;\L.PG+S#T>LPF8XJQL*I,#D-\12A,E!8U+Ul M2RYM\7&0)6FB'@.1K&s<2-6%V$((DS Y&U(39G@B2,#L841-F>R+(041H J2 M.2N V>Q >6D@^>))
6,V2+CY)7"E^Y$RK8+D!F]N):B*.,#J-3(%*5#$(CZ/MTGSR7_]9W=>?9HO%R?3H@P(XVS^]KJOKS$[ZJ1N*S2@U\/8YQ%_#%B39'(,1 M-
6&V)X(ZP!.1PLJY0*.H0.9F+%.&*_3RA26;\X,DJO+YXLQSL_ ML8M\-I-]WC#$#<0-Q W$#<0-Q W$#<0-Q W$#<0-Q W$#<0-.^6&[4:]['T . MUR1SRQ/\VX>']M\.8>K
F>L4+:.M<&&XC(,1@ '6.R8F4B58K#€)*Q*)T*.SO M !5])^]JMD?@<]! M/RGW\ZUPF]3_3MO+W%$O'S\=$_CU^=/1Y*.1X*U07>DW3:.*_%(-M-
&#EV7D\Q>'IMYN7OQ\:,MLZ2%MK"%,[7^>]3W+2$+Q"L-F[ZAI4_93D=1W$ M>$EJN 1!R (JQ0C12P?92&^X$$89L3(0L^ON>*^7"S#-$^FKS?7^U$8-Q9R M9SKHVF:AH
M1X_Z8'\ACMP\1SJ#0JDD0"6*F4RHZV,.3E5-L*1 MK=O$F]EI?>]+|[^?3Y;O-W2\4(R-VV+#">)'XD?BQ^'R8RX2/;<<1/0,5$D6 M/++&=4;'XI55826.(5DHV?.
(/H=8KU$2O'U8\0/XSQ:4Q:"C!Z:=K_Z[5A!Y=A=+A T*N5<="F)%7NT")^4<"!4JGPMN8789>F\]%EJ_S837+0W9)MK_6Y\A1.:@))<<="!9LM+EU^C*N]:.T"KG MRN-
>97"8"B0FN9,!0Q8KY\ZVS\G"L+%R-PP=[/(0!)5[KX&\6R=IAL5BEB9A-MB?F6YK]_3)9O1F$)RS<(;!MVV/4S"K9&V:1@>]R&@:J/?"&^PPHZF1E89@(H-M1
;>\ZJ.?)L(S:WA<64>M)-*2!<2E.QEO49I<-2<@P^1#0(V#]{R":QC3&E?B4JN MS.';(MU@S5N)[_U0!*.>(MX;]B"' 1O*:,-R=9##)*#DKKZ_%F&2F/5^#))
MQ(@K9Z^T92&VE!FRP]"RFX>0O8 LLO:H1.X2'Y*AVLLKF(NP8I2*KJ'XRH M",.]$21A=C"B)LS1V)*#\]%#R3$F]2&)(&)N'$#0$Q@089.)%&TIQ*SZ"BE$E M5[]91^.'H'?
215,2F28PH,.^56 M5AOPG",DZ9 +@T'+C;2:CO+_G"^6;^NM+'Z9'>4\.?<03E^$27XV0YGDV4X MO>)]?C#0CYM]OB'OTO0]_42E 42;9.]0J FS@Q D878PHB;,]D20Y)
[$ZN0>M$[N['S>7EF. MEK/ZV&Y.?M6/]0]HT7!;+U^^P=']83H=_:.*Y>R+ERPGK8!S.EOB:-(8$1=+ MTIP' ^]!:]7<\@&/^R92&[8@!T%] ME@*.\S&]RZ#LEE#**%
L4+KR(MT::4MY@9)K3N6]FV^DX MF&$[#E2TMXN,Y7-0" MMT?3_/(C:KL7?FWHK/1P4GZT1R Q;D($C.>UM)3BNP M1EE0T1B(R"OG2>&X'O1WT.6UI,A-! M&G JI]9I&
<$S*X'GJ}'+9.VIRDC?5CRO-M,%#ZV?(L#IP_]#*=1ZEY*=.\H ME=(R!R]IPFQ/!$F8'8RH",.]$22Y+O=V78+W61:C@5\3XGI@:@NK%W(8W6Y[
(/"'(_G.IMNWT2G6.Q@L*B0)5B(!T0$>1(N.& M*TPI:WS:3B=UMO#@%5/X)?Y^/EG4A;[""^;M)P@N7\26FV>M]IRF=]IBQT1N& M43TST=Z !4FFRF!$39CMB2)]X,1-
6&V)X(S.&I>2>[$'::*$BP9T5"4[3["UED-8%4ZS[""^,,0-Q W$#<0-Q W$#<0-Q W$#<0- MQ W$#<0-Q T[Y8:##I=[$9D-)@*6Q$"Y), 9CA"TLDDKH57DU\/E1B1=;,I0 MF F@/.?
@KDP[322V.=U"%QX>'D K^QQFRO^?4>@/G^MZ*>C\]=/QZ-73U_\\O3GI[^^^'$QV!@DF)*F\]GMCB&#:O"XE>(0@2:@;?M
MB\K5_N9)KS:L[EIQGIPO%\LPS9/IZ\TUZA3&CI7:XIC!+VZ6@\]) 1(T'2XUW MJVW_"W'DYCG2)C3>& RT/O7% MT]_/)\OW&[+/Q=CX+4[Y(GXD?B1^'"X_2K2HI+>
2E4;LC5%CE(6*%P8;ES) M'-EU?@S1F.R4!V9-QX*G&^.!#\:=E%KG&&Z>EK@=:?O16C^OW$T<21Q)'$D=N M@2-30>UT BT55AO29'!*1[#(T=AN1JQ?F2A;6$I<, ^"=C$CL2.
V7'@^?:U;*!'H32OOCA+;<;'@)A"!N-$9>7 T,.57H]> M1.M%?7MRH7)OUAHB4PD,MY)E9%H7LTGNO5O'I6DSHK-KLVIBL54MJZ3B MY-
YPLK6<,>X]9(6EVL.5CD,T'DSR605$?W*<0>4EB7K%"0O*X\7RR$X%P"% M"$D+[[/SN^=DH?G86D^,O$:WW?K74)?1_7H'_)CZSS47\!FG7R7<:|__Q2^|
M*S>W!>,)NU$Z#8NZN\[":X3I+..':^I]M9;G;Z=/\F1Q=AK>/VZO/CD+N254KYR/F5S79DHL_M(8!D_+^PQ=V MEP).\Y.SV:(K_'\\Q].PG+S#NN'^;.NOG_GXX][\XX4Q\6F9?1--
+>VQ/IG-MVI3*XSQ)G$IR.CZ=U+F]^.CV=3.M=+,.-\'=//G^A/M:+/W=ROCBS$TI=_MV^-P^D=XOWCRW3\^IHC+3_X@Q ZEG<"N;((586Y69MNW8;8!J4_RZ3CDFHBZ
M3@:=#"X?1[NC]G3]_MK;H<)G>A=FVA,/D3\Y.++ZP:Z1'[ZX<+ZKX[#6<+?:+S MLS /2_SP)#IE?/'9WUT_SO5NLIC$R6E5,X_7'_30:WNZZ1_D)3ZZU7172[W M0G;_N.4ZOI-+[".IJ;
[>W!]?FS?>TWIH/;2>=?E \&VL9^T&.3?IF;N>E/U]-MBZH/FFV+)O4W6*3W"P'T,;11\T)]Y=^^J'[B%9Y?Y3=4%#R;UN]]X?UP (U9_M]M8G=SQ[^]:ZV9WCN]
[6N,MY^WUX:H25;\.*^.16!B7302V6-G#_9#]HQ=(& M\H].!58VL#DVF/%DM>,-'"%FEA>%[X1;TC^=^$$D+)[2@Y>ZBMED)00B@A-ME'P!)1\'//R?:/_`_]^F/;!D.KJ<\T#H(?
00>KZ GI3.WYZ?AB7FT_M\1[WIF*BJ1O'V]!S]ODJ:SWEY$[(22[@0#2]V]4IDM9>"W'VM]C!8BQ?+3/00K?6@6$@0L2!@T$%$]7W!E0Z]:[`6]KJK M6<:
(L8BQ]DZ0Q%C;&65AN'0J:9#.5,.*F"!8K2'Q.*S4"U>Z77FI78>DX.L MT5262PJ<$@RR1IL9\]RDVF4_2,?&6FZQI0.Q%K%6[UAK^(,*":P$WMZ!EY15 MW6K0Y.'BE %,.\!8#9H2(?
+"(*$T/IO^GXQQ02Q2)M,"$*8!V!)HRZ[#9OVSML\7B/$P3 MCF;E8J1KX;%H&WU4YK.WHWH?O^&R._Y]0>ZW_3R;3Q)>7GEV/D]OP@)'9Z=A M2MKO8++!*6=]-JJ7(J8K*%
(@"6_=OC>"Y4E!UDG.8M8U\9#Z=+]7%4M+!2MN M^J2@*,)\[$5121+UGBC.,$L6Q]H6ARM%%6P6AVU]ZGD"K]6"H'DHV6IFHER9 M%RI-9$HQP))L=81SO3I)#BD&%I*-FN/-
\T96+8[_"]?G>+/!L7Y*E(^EV>)X MO!YO>>*NG@B2[(W!B)HPVQ-!$F8'(VK";$\$.0@?03$>BPT.##9[/RS&#R%6U M]XOA.1N)Q:65^5?)
(,])@\\'VYQM!R$S##ME8P2++#K(H@'^%!M.PV"Q77R95= M+UP\\39I M=;>X>+$!XJOM^_9:.]WC$8\&A5E24[>KJ5+UD5!*@"FE'"65]2_+L[?2W_.7.6??
BR054CZ;YY4>@=B_\VF!:&>&D_#B;%YPLS^>;.MS!+%V:N/*X]2K8MDNL\?MR MW/HFNR1Z/WH;KB '06^1.1Z,B)"4K39"'(0CD1P69E@_ZBL$53@!D)2";Q! M]%)
(]IVZ3\YRKQV)@1=;4!'@@Q8!GIW/VRO+T7)6'!O-JZ^7+ M-SCZ.4RGHW]6L9Q\\9+E))[B;#I;XFC2N*O"BG1BC]E6E!&%/ V_9 R,U8T<[X=*K[[M

>%OLT/6]Zf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|?_73T_/CI>/3STYA=1*E@7G M(@>S,K@I<25EM)"MKSI'8@#/?;7@04N9087$]EU>_M)*"7.BK$H.7*H.FU,+(5R;^9G=:GOGCZ^_ED^7Y3K=?'EFUQBA/Q(_$C|>-P M^3%C*,DY!\FDRH})%W#6,L01%:5[&)>"(;S!JS.E!2M3:54QE\JB29#>,1 MN47[_0[YT3LSYDPP11Q\'$D:?H"E^4<.,PE.5$%4052Q5^.;4;CBFI!N>7Q_:_#X M=FFL>6=|%!$,Y)P)4\1DB2@FYVETR&DRLY^:^O&6M#6YV014K7PJK&&$)0U&; ; M=LYF@[*$31HKB_KHZV!?K2T3W(VMM<.SVNZ&SK\3)QO.G$R?O/R>W*?)9LDJH MDE5^-4:#,SZ-82&@0R<#K@ZJ4%P57CUF5E]_6>X$>.D0F!+-|&R^44+A[3A;"-MC[W=V3F_7C R%0COK&#XMMF08;&8I4E88KYERN.?D^6;R_?.+H:GCL(TC^8?MQZ=>OMC0M""UV^-R?FI^<;L>||K%(+,%83*"LC& STJ#%L)YKYFQ>251%EAB M240),<766Z_JL5!4Y3KOI+12R\S<7:8;7QPPN.]XX_L-@AP[/?!F%T1SPQ;D M(&@N!,\5"@E9)@,JM7.Z6E3*RMG*Q'C@'+=%=@N3]+'?65RGER>E#A#Z+4O93HWE'J4-+_/18U8;8G@B3,#D;4A-F>m%5*281"=L:!M?7O43-F\$BY_

%M=:!>AP|@N^MW.]%=&=CV\H/Q3H^E=HNA#A0T5M'}@MB+_3_!O"S@[M1Q99D&629D0$&>IK:4*X+W.2\4A&*O)U'&3W0Q:VW\&VB>/}(EN/01NH-4U1 M^#;0,/ .&^C8.6J YV@641(JC2"1,\)YH C/HC!3DD9!NM9P3G$E Al2DB78 MI$[$IHF3(M)G20)$E%%?/0)({!0=H/HZ*U'+-<(&-A_ET8(75O_QCLN%\H+(MNK&"-P^@^-_<&C&G0XO>5_76;$IG:G;7Dj>[+>]84P6;%L]#;N'K3T$)/K-MY7P^+2PD#Z2XT=P*=#+/EN@;PWJS1CWYJ?/(H/Y19!BW<7E)-,,I#WF.'"#9%; 3SQ/!$)C(=2=HB"LF0G5*U5L+Y5 M3?YA9)%CKFZ_|<4)5:L!AHU7:0QK9>Z>E'3]_E"UPVB6K^?E=']DR]\S M>-HPM.7 ,_TG6^]9#A8]=IRT/HR*SVK>Q'GT#*VFA7&**_G0\@FT?*U8I$@]_M4=WG4I,\% E)B[-CE@KIK59 MTITT60YQ3@HCW.PII-G5$S/PMPU!_,*>U?\(- LSWD7SCIRZ5:\=3N3*7RK6W MJ5QMMD)S(L0'[K$;!N[?*MZ?OMBVV<-#3D/T(T1:$Q8Q1M(P8B36- WR+(_] M;"NMR$Z5B<2Q$;9M-L2ELW\ZGFL6'"%3^+HAY! [2U$QO)"1Hs;

*MM+IH--) B*7^_0R^1H@G!3Z5L7Y_;8N;-MHK:*Z4;!QNV!0U^469DS2EB>X8BOO"!&4DEXYJAEPMBB+/?3(#3%7M(4'OT=*
M=OICW#3^Z1HHBINL\!GTW]VFMKQWFLAWZ31'>)Q'$%0\W!+>CJ<@`S'K-&ZM-MFAK\X&(6)5N4@-?2_'>#==66"D1G;?58^YQ99^I2G29%;DA>!&K>7DH#?*
*8S\$^GM#!V]5;^TKC2@;Y!G8XM_3R!HT7^O,<#;V&!MB9[N M?&M7+3OUL0),)V2O[GO]@[AVF1-*Z#P!W("2!QJ]U'">]4M(P=3ML//BABQ M-9Y9K,(ZUW_ASH"S(UY9W?*S&C?!SU1MGU$L,D[E+36H&,+"S>]@S&0'9N"^HM6Q_7>+5Z8B,425>H8,=,7FZU*GE0^T<+)K03FV%=;>JZ6C2+ME%!O 1^=ECR!K =+JO8"*
<^X3>0$CBMUM[W7R$KW(KH+"Q-KRKK?:?QZY^LZYF M< O1Y[K L$85;[D]R.2;U3U40&73V3E(,(QPC9OBZ\FDAG--%]M&Z8#FSD#D M@\]BHZ"_K-OZVRV>I#["!GTEU7I%23]S.I1RDQ/=3<&QD_5Z,FI:6N<>MED' MG<#+=!XV5M5OCBS4/(70Q%8OZVS%)}9N0\5G^G/Z2$191]41>NI|C3%N!\|,
*{U7GAJ,IT!O%U@X9HDDB/6+9-&;*J=*#;& !T: MH^#W/^BEU-[]JH!71XT52OIX7!(,IU1>SS'H(JF&."=SVKDPEHRK,;1PZ[C MJ6E-[1N,D@=0#2H;|*
*<4X1]_#$G^"$N4OX)2+,59L@IOFVY*EMS_]WQ\ZR!*- MH*7G"0:Q -[^/&[U>6?AM4#<\))DZV(N2H)51!FS5@$TM*VVC-.I(([!9NT!F; M,?7VGT30"W2R>5]U524:K42@Z].8?*
0NB#[K@>>L]^[W@\]#QF]N#PJ,.Q:?! MZL7\0D]+UF<.TH_[%"(A:!N:A/]IE}_P#/EU4'(0K' M,EW&O N\ ]]E-H_O[^A-X\+:/$0?TG4%GZ#IFVNQ@_H%ZOA03WWTM&%L@P,-
*M<]E\;)VLMNX;R]^#]PZGW-86B++GT^[EBR:-T &H@OMB8U2MSN\M$F/.]ADOU M$8*LQJ_=N<6(KULUF+1IQ\NJ;9KJW*"D@;*;)QH2U9F?!'@J^!:GIKWZ!O*^*
M/>#4L:3Q2CR;W]:JNR#!;?^/S-71VO-B;,,.6D.A:@TF>)]>O=;5/-#Z MD%[_6D.A:UM9)0M@#+@T!9C+)?! ZQ9#3-15<+9C1=&=2+1W5V@4@-M-0ND[UU];.(
(]MNC6UB;_H+F0-3]ETUGNVT?B 'DZ'0FKZ^]]PYE(U4"S<_Q MPQV%\-!?TSE'U-D:+=\B_@>\/AF++#97CASOZ2/>>;,'$SUL ?*,I$!?R95PE M(_[<+];09EN@XIXXB3)C3:;
*KWTVFU5I&>"0:Y>^M<'FC\\T. 5M]WR3C-V1 MX.KZYO*C!)MK%"<[9@,ISD3.945)81HGPE!(EJ,(_*2:45V49]N'F#Z;3 ME==^!%FWWFK6^H.B3P>NVKQ!U$,I@LY*LE.B)*
*(XI_%7G=RW3WR"-O3? ;.' M\;S"^>DG]9]FRT4456_?O7U_TF*DKS3=MV*DVC!+MF7S-VV[]-%ZXT=X+Q9$5V[4!*P3]O3F5?W2]RJG$1;P"Z-6RH M^2<|;=N9E@NTAAI-*
*%".54=S7V"MPQY]26NX_R#]ZL(BG+Z;D:'N%RU1/+B-E M+?K4%;M.HH&.X0E,P*V,4CA'!YUC IQGHIBTG5&C-C5[K8XX:B-0]VS4@<*
*M"2[$L,MT55G&;DE\.ZI@T,VQWO)=U_5P]6 MU5A%37'!/!ZV\;%]9F. 3?PBGKI..#K>ZJKEQI4/8<5K+ _"%B](.Q]6@XJ;_MA-=W'J0;/Q]OHW<9RVE*C]=1N9[,L'JUUTO*
(Z"WC7]O=+,IV 9O:/#_ZT%, MV+L8[>$((=3.VKBQIFB]DK:LHEGD<ZGWIQPL#[6X+&M)L-,H874)/A2&S<9C1=&_9A%S<9"Y80(.R9NI0V"5@@6C31_?^*I]
[?.|^F|M<5, M2Y6HM?O'NR$L)^#]?DXQ SV*TSD^G2T(UCG4,F.],G;3&CGI(-OPPSVPQ51R MWW1%I4@.'-,XAK\P0;##FI]VV*[KSXXJC]...C10?6RRJ8$S)E2#:%!XGS^5$
MEEE),D&SS)M2";;1=G G9[(MW7T__VE<7"<[2@=\|^(VKFD2UU17W=>B"^V4+<+WI)$FL88< MVWEBYHO, EE6O@^GF&)KX^E"35_%/H,&@JEO)G6&SV1C(>AF=27F,
*<.)N"BD!W/0=HC,GP" T9'9%$#O$5!]>2S&$]N^<5KPRR9@+VQG3CA M-O-P]1VMCSFK9Y;%=7G7A@)77S^N-A_.]O3N[3>O&-]2%O5R6&T68ZU.2S-^*
*M@B.VJNY25Z_II!TQ4!-3#W)DO#*2SESVW+1-HFEM@FAL>[>M!:/]S.GH;?>+ M<=6/Y__E"KI-[,@WFO'^[-J,]*ZHZ1J1WD4]3XO&6)*
M4IX4!M24&)S4NJE9&&JKU,1OD!SQK\(J 5,YXF.V@K+,I&W\,-%O@\N.PV M556@']Z,N3PW09]51+CGOV0;9. ^TEB3$25^+=:!MG:Q%$1WK^W%@L:G))"&E*
MI["F.5%]J8O,+(2-7_I.TH*L9F.H>A^PXW:^MI"}_9>4D>';Y>]*T-_5VZL[;? MV(6]:E+13?:IR~)+_^U#_I$GP)W]G,DY]R!@XKW$DMU2|C;$g]-8T1/JA&Y_*
MVD=_K0D4]DD\2,5U'.S6[=T4^\@.M9I;\5/KJ+_B9$YT!FCIJ?;@-C1O2$T M\,,MZUNUY==]0^'"I6A1V7_/2KYT*/R8GM4RKOU],@'Z%%Y,6;BKFO>]:!P M-$U=;K-*
84VM|F>QIV77L]?-I&X' M>G>5Q:MU3K%,V7@?9X7,)NV |ZYDOQ=*63&L^OO"9%C=."#^_=3QT@&-,ER=@ M0F/#[M]AX:>H0IW :-,?*
+8!1FMD>K7BP8R:=B0|&7_S)R4J9R3JY[C]O5L>_;.MW)T=UCRX1XWEW^0_ZX;GZ0Q>&H?G),^58C$4.(:Z;U7]J49--WZ3NKf!_<5 M.%OJR1GHPKC,7V%M*6O?*
*5E)FCF6(23ZLCPKQ>U8*1GHC6F$@\(1W=UA. M;0!WWBGU038E<*KFI+:],&-[CB*RO&7'(=-'HC-!TTM>0V!)F&!KF]C-$L%-*
M2PW_T!M/C02T4=B_$=W86<678NX@<6,6)XU>^S+U\^JL?-'V+]Q=V>GHUX20-M@>7ML6"_]HFDA45'"%S>IPF(VLDHSAEK)'O4=CA=MBV!^>\E6'=N;+NAAW4J
M/Z]O;*FZPLU%OIX9*&_IC[C,)E]:514:F%+]$#-,+38!-;6 "7YWS8<=@T'M:XT&U=+&"]XC$?9/7LC=)!Z\\-5F$A&1YF*!8]S>Z.QHK*%KQM#7D3WC87\Q M@+<#Q3LEG.P&.*
*(88?BPRF?:,,8L~,47-+:,3M]4K&85-](D5DM0);L,G=&CNZW9LT*TH M=GSV5KNN_6LZ6AH;ZF54QIV9;%=2GT4A-0!$3O+B=[@:W?>,!U2)WP*
M\^://]>>6T\5]D5FK\&CMY1^_75T/<9FF;Y:X'?RL?]=\2#K2'5UP)S+8L? MN\E2 G^%"ZKEIT^^ZE'Z5?G775G[=UL3\OWH=%> N9SV%_'<_(H6]':IK'4:
MCW/(L1=]TGA%]I'\]5ULWF>/H[^[6C55WZ\,S'@9C-0YCSW3;U=H:+7V(IIX M#NR3^BU%SY!1,&);P>9&!#5LVE3OU,37],9T3JD<4BV'>,#ES7CGK$4X3!*
<\QI[+OL+KS=55[_$0VG***8F++MH4NU!8[;T MRI-OV77;!2;\;GI\>,K\'8A*/"[@<@D\&VVP/CK<4'TGCNUR5//29<$)8E6!4$7 M$AF^DA0^QVG65%!]KS;PV$>/,"7OI\U@*
KB(\W"'P$EN[>#N1U!!5[?9DUSE)..0M7=ZI:N5%/LKH[LSZ)>P6Y-Z=FF7&%:CTH MU;3JN"1;V-B;U;.099]O= M1!M0]MJ5]6]QL9X.VV!T&OZ_=(0WRV+I6^PU.>1-+PY,
[0G.TI'.VK/]<BD=!S3-<'9"BP[]?,& M_UV'[+H>6?_5VV6;AAQ]-YU]&26T\^]\&%]H1';Z9F?O\^,2+0?IB//V, MX"=?P,V,WI)K.GKWIF3TR^F'TWILY(Z/QID!R?
*8%,=|^\UV#P_39(V!)78#5 MOJ4KP.J;=+&:HYFL)PXU38IG M#?OFZ7WPT"V.]-IG_$_X2X^:ER SF\+7H]>__/K+Z,/_^7\PQ5___LO*XM\W MT+O=+IKMSM=F&F%S9 (DVU@A*
CJ,G4^M>5>^LMUEM|=:N;6U8DA%RXM=XS$>MAP..;M*-SPH=2IL1*W-*!$(M@<@"+.T")F1C/*-23?:@W%>6!#PN5+P'UL2 MF5%&RKQ0N569-*
*[E=D?)=W4(KA/8TX4;1XQQO$].I2+0)GZ4!XJF;AF-/&2(P M?0)M&V$4P|S_|Y^Z[F%MV0!,RH%4NR&)-@-*U9845A9@7-B.8=@XC]2L(SK!U!(GQ1(>H(^=U-*
7J%LEN9L=@.+>G&>FXH MQSA8HQNY"[4#Q&OLQK!(<6Z/B+OX?_'BR8=5N.51ETG1M_]Y"<1^.C!GM:I M4U0@^5_^_'^^^WTU?/3"5@.BBQ6&_ 8YO:M.&;#CUM?9<]31?
*+CYK"[BAC M5H?\7:|K.WS3+VBDC!>3.M^)0 /L.)=MO?IN,R2![XW?KWB0[? /!"SI K-U M<*T/2]4SVB+AC:M5$(Q9"#$,5@_;=A7@G5O*CM(MC6U+_]%$#[N1#MV@JF-P*
M3H]UR#ME^N.\RSX5-A&DWNK5)CVW0/YT1T$#F M+#O UV8073]##F?9.$1-4FE\'@/##6C%;N(\">&V);X3O[$]OLN(+&9KY0A-
MQ5OE:U39>MY&\TR<+|>T7&PNY;,+2#"4L4N_.9?5ZK)/H!_BQ;X\W%RR281-M4Z\+LL&W@<2H$+_0Q<1:6P"ZBA#2XLJUL)(QF-75<%I3O2\/V%]%A$ T=C*
*M$L#ZBEK$P>;&8-W|==;6RU!HV=|]5DUF-59#PGC/XU@#<35-YZK]-=>RB6 M-=:/G-2 *0.5M,UVZD5?. 7C%BM.DF^3952UHZMI7)GS)IEM7MJF45]2V87?;, M;BI\NY?*
6C+BH+=I@&H2)|L$1[>%&MRG7=$&YD9ZXU"'"(>>GB?:TU,,/3TO MMJ='WJVG1^Y_I^?EA.>OR$5=I%]V%|!02M_5.?KUO;Z&MG2OPTOH.GJO5__1 MF.LPI: <.)JKR4I-
=E.J]5JS.JYX9QR66AL%R05;X_EM:#]YLX[JA3 0P!-M;PLB++%=$.9<3ZP17W)E2[P=D$:,E,5SR/K3!DEZL9"O:R#/0'7L-!W!Q(M^_M)8Z.LQ*JT6<|'\^65=>2T$?F*
4>H;%M<9@WIC%WD!(<*Q^CORK=M:,KL+33!5_"M_UD7]6|+"\I84_EY,\:H'=V,"|CXZ'*Z^6%$67OS:,WP+5L^_M4P\P6!=#ZQ/+QZYM?*UXO96CJG'KEPFR\)-XU*
*3KJ?WZJO#ML8MI[2VU'H.T?;.WMZ4*6T:3-Y];K0) M9W5UA(2CJ.:SO_PTH>[&O/[B M;.Y] XV[\KWI#HUC/'@3*3JU9&X^Q=K+B!*N5?B-,_^R;]>_JR='BV,6*
*MH[OVG7JT6%N"\K^7L[HI'1D@5@A'4&.[-FP994F"R$ED6FV/F+^4 ^17'& 7 MO+SB^%Z/_N>*D]_]EOKQ)#&.X7SIU:IK.'#G)Z3IE^LUO7TYFU4KDJLGS^#[MTJ^QZ"5&-*
*]M@N,,7S==?>-FWG[6W_[%W7EVOX[]3K?\&XGGUU>>5CNB. MWGE-.El8(L &)=*YDO#2,.^J8X*@#PAL3 GIH;,>KG;0)LMI'L&1FQNXZ2A'*
M<)9',8GDCY1B^SRNHCR)_<4>DU63DUB\!L=WDF(WR1J=)1T2]H# /;2^CRZ/ M& =-^=B+5'^L-1R:<9#XNXG^TH>_3J9^C4!X-4QY-);;>I!CN"S\P@#6X\:*
*M10&W3",T_67Z]:V:|N>X>'MIC4B?=/]Z[&4K7;:WG2Z,HOE!H+P$7E^ M5_#VQO+I !VA<5Q'4_B)%))D$-, (+? 6*86W+HJ9]MEU54Y]8VNO+UMP*V6 M5>U-*
Q:"J_PKKK_OFS&7R5GI0L_"'&>+A< D.FB=SP#I0?D7_[^:Y8HMTLE MJG 'K.+,&,-$5E\Y"=SQW*_N-XY$NIF>FZ5L./D$P6;ZGUCMI!QJ '.?+.)@ MF"!HH%U2*_\:*
<@O\XJ1%A>E!Y,9>N=G4-V,"6\9K8^#[(..&VF"W!@JV";2 MPFZ2B:V# ^ X\G?;(^S(MFJH;BS@9771,C9](@?J.O3>#H
M($P;B^/9#9&2QV)BGVDFE!)F'U96+QK[9N168K%#OUXO9GT4,>H=77G(6LC= ML7FM@U:[3(4YO M1O:V>XM>Z_6/KVZ_.[+4P+^;AVLM7.Q?
*AD_7$!R3RP);8W&VO;42E=*R;G.(M?4\:SJ5:)4&M*E*$T=Q SG2X#<1JZG3%MVQ'WO7G-N/$KJ8FKM'M;?U5QBP M@+8+5#^PJHC!^KYY3$07*N/]!-Z(X<7D7+2EA'XI"$A M5&R-*
?9^P4JZ)2M97A\/J4_ZUG](6O8KN@31&K.H>7+^BE3;6[L@[KNDM'J,_MLSJH'W%6XJ!F6OG^<0$'0'Z(M-T_KB/(/GT\ [8C MB>W:TEH.?5=?K
M5T^E0\>Q_B8@5A('!-8]/OB&69/[^*)1[360°#;_^Z]:L?WQMK8.CV"-2.U MI=]\HP;]6EU5^WYU[+/-Q6#KMY[T]27-4=3?V+:.07TPT.E!K]OC=1F35@]^M
*M.=DRVR,=2RWSXDW$2M[3N*VXBOCYM:1.DS/"('+SL_[#0;/UOZ.IJX0Z/5S^OQ(*U [3HC MJ*(7][C!:_KSY-/ H;K.MIY5'=DU";/MLVM38-.'Z41-6^%X28S:XA'7[>V@&-*
LK_PV8L0YB?X> M=^/X)"23D)*12<6.ZF13H_ .P,%#0SC0*D&9L4?05@^E$5%_W=-S]_^/A- MA,OJQ;$-QE[!G4&9VGN\CGU]B;6]Z(HA.-(G/YHN8Q-?QS_ #0#??<6IT N=*
M[,]6DM;RYI?Q9(GO@]O[@QJ4,XV^MU9MLUK(_]C]WO"=.]*^.!.*>=TZUQ//8(ZGF@\,;#?5"SA+ M"CR-R_I=W?P7."W$CNV!1NDlV$S<|N*-_]X?'&>L2$R#9N+\|/3#Z/HY;O8@*
MML%5K/V&!A,Q]D$ _MNPEELI8DN+EY5O$>_)-N)9/+4;.GWHOK4'L]F;/. M-'3QO%RTW!CKW5_J.+FL:SMP'%#_N&[@1PQ]"$^T#Z$<^A!>;|_"?1L*-NP; MZ]TTP@>22W#*
[199S8]3DQ:;2Y4$ZZTIV;V'BWSTRS.3R7<10>=-.\OJ(B@H] MEL';8FG;.M1.JQ1=UJC|KB.P.Q9 Q+(4KCL\!GC|%#JZO+4ZVM>@=STC5L419QCA-.WD8RN2
*(79ZY&W_TQNP!6*07]_H#%Z> G@CF$YUD';2M1_MEM6?/LW]IV@ZKD0^8U6H!H_-P $D1(*N?K3M+&D+!Z)+.[7@9K?QW.9ZVA$] MG4U7ZS&P"-2WQG[_2MU/,I^UH_$2<'!"*
*(P(U(TQU6%:1_7341?+$R;&Z0A\ M)&R(<;65F3 -SA%IT_7?N"VCFP(($>P!,Y*7"-<9,QR)5N'AV/CK(V M>E<==;3:4UW)!'T2W':RPT=LFQ_YM!R[U-A:HUW?>+!?;(;NB?!E@*
]C2;O M^#SV]^+_3\IX_M;~HA4-)UAON"!,>N;Z]VD:+P@6M+TYVK6EC&(A5]WLRP MU[PK*HETU#W=5M>WL!]=-7V-'SRD>]F=R5^(??<$8/E[7LJK686G;V;]M^*HC*
MD'DCX^M-,M=*\I$2NV^OL6W3+_EF[_:,OQ)^]X[3H1LBS'B8 AT\-9#CPF0 MIF:]>WL7VVT13IDUK,Q)D-P3H:DDLF2"2/BC$H5Q2FI[9^UH[&XG|&]::GB3 MQ1YJ[68**H*
5/G'I%&^.OJPG !-SL=?1WIT(V+OHSKWO,3;SIJX77EQO,>C M$*\OMZ>-[N\O>*MYR!DCF<)X;$8S(]7)B"B\XU8+H1$#,)5'22%\+HPB)<|S M(AV1!N1$U7X4C'X38.CM%=Y-,
[XZ8UT_@DDUOO^T$+G+2*"8;2C9S#U[y_A M^XC3EP2K'<'//<@[*HO1UPF Z9?PK0B, |E6*X!;$; T!BV,G%06(@(>DV! M~=]S&E.R"A/;.OP)VM'GH^^^:?,7UH6FKBK!^P
D7Z^4X@WZZ]M=\YI^ M,@QYQSN_57#^.>FX'$P_;TI:%/4Y$;K,"7AE@3BC,B\%2P7]\Q5[39WUG-M-5+@PT1/%_"}GQM\L"<-IW+UL:KM)HF-)\-Q!_'?^#Y4(^^*O"/V:
*(=T3DH MOD'Q#8KO;HH/|%I9.!YPK HG@@M.M+&6N*QPN2ZXDO>+3#Z$XMNO'Y>?9*P8 M%-TC^7!|SLVOZ[7C45PW3LSWZ'O(SM\R.W] 27RH_/SSV/*0[7A4:[F-B-9P*
M)]V$GB'I,=C6@WI0D39K5F!2=Y#"I9+8D6FA*GM2P+K7,OPQ$G3IK?7SZA MG,E@=:=\W]_+20T]GI\T7U/L8EA4'Z#\KM. ^.5$>,F]R0RCS@@CI6&5(U16T
M5K3T7O/2'5M@J?>30><|)9UW!\?P+BKN>'38C:-+OVV!+&A\OG_LP!P8I-Y^.M69?L ML!N E8^H!/AQFSD\N5U#)5X.)D*# M7+ &FIB =8*/@^M7H-809:<9S-ZB!8W/VP$A*_-*
^:[#S9NYO/?4F!4D1BP]/ M'5'X%F?CN8M@TY<-?};,5=M0,[N)LOV)!6F.BYU5BX3'-Q|7?W6#YW&N,F\[M4LZ,Q+&1N+N8$/S^'YZ?U$SW>+G0+_G[$|SD&_5VOC4V@K-*
*}XJ[2.CX-MJ_E,V!,&X0L-3ORW9:JYOYCH-*4H/8$8ZTD(<-]*#O2L[_91LGW>*:,;W!CML=N M\IL(!312R- +14Q)>.(SB/XW0LM^8 X:P;.\%/V*4C<[CA."$|*
[[+MV7ME/?(L_],V+%KPWBJ-&M<+$M M4'B [VQFE*SC!|;=P,%U!|;9W;BY#$]'6EX"?'-'1R%%--!YS>>=*Q+DZL]VDV(C:&R>Q+ ME1"TPA+AH^N#OM 1^!YG=$?N:*
*PUT?.@9&2V QMS=E\/ON"GYS7@N'8ABMH MF4E9T(P85B@B9(DN!4XH"HKA: A#DI8U3?HT0:9.6*XTD28'(G6Y\)FAI"PQ+..$!(-) &SLH]F:PL\HV!;841P7!!*
M"'I^A'!@#"TL/NB=YZL E'/KI/XC2)$?s8@M<A?>O)W-?XA2P+N/|9#[/5E% M]'1WDN'QR:NUBM#,AVU$2-9[+(Q"A'G5_=&;8ZGR>2O'!MD:']^.HSF,H M:AP)2@P2Y6*1'$^+
*.88Y>[&HR0VQ4<&\0 M-1B<2-LJ@.1D'.X@WG,W=T4*6'=\ MJFAEQFE=D\O62MJC<[T_#;D-5 MC0;X4!\"R/[?]^<#TU-VC-(^VKLZXL$?VWVS,B^"H8YXKN\"G4)#M1*$9YJ[*
M/+-6T0WC]M92I#98P8Q']I$%N>OO&@_@_32*F)O:LOP: CBF@6'?UC/F>4C M;'F<=3CMS:IO1M5_]-MUQ,,L\[<9R%*6M\GO8W'*P6@^'R_J&>Y3A[-?\1@\]M6$>WGW7_-
*(=!;8J!S'"0_-3#.T[:CO7XRF2G8?WS<[!=)B, M@Z_3*S6(?.J68/E=COZ:SKY,O/M43_@%@_.R&E?-V-]J+1;= .M+1/MW/D\CJ5:|$(^+^/]^1-#FK@FTCM5D!D6?_U*
*A,OT;\:IT'2KN,'QO,]\KHW*6/8]@:RI;BT#U0)0O?VH|U MJ|/GK#5ATO5G<<'MQ!M #,^Z^2H_W0"79Z.AW&?=6I?*N-LPM M=75QF(/?N_N)L6XD=W:HL5U.-LJ>N?\|2@NR?*
>6%.L8JE@-= :D-[D$'P]^ MC69D2S?UX-WY& X==/ULWG,-P5*H^1A?H>C(@4#'CTQPXE^:&QAK_#7[2B_M.\(UC40"EH\%>=-8@)K*+C!7 0L]/:#5_,"U%$=+!LF]2>>>;$$S
MR4>L(.P$ MR &OHZ'?/|;B"\W2T.OYXVP\GTTUYJ$PF# ?QYC$\14$6!FHRQTE.0ZL$S)8 M<'E!;96,%]JT(5:,N|!XHR22|*=/<_|) MDSD!OF;O-8=*
*[O)@/"^\A=N6G@A;4|)RGQ$KN+9YH,'QC<2XR[T2!9A.>)]- M)RD$(C&NXTHSP|>247RR? MKUHW)46N8ZTHSI!/@;8T8KGI XPFT&:D*CX)6[O08]<$\-+KTN--,??*:]HT M3Y;R/-*
*DU<3XC)I$@L3KS'LM/WVSNI6_1X4;]>E6W&EM/DA7!LLE2>B@V.:;'@ MC;&Z81^S^:*_?3B0&=AWW15;^_Z.$*FG@N/-'5*
*>NPC&UV,_>0HI;\\RPI*E2+.9B""F=!$8K5"GDE'-0TY2.C!B.!H?ZW* MWU^]TO!W2 EO,/KUXYF>;A6_MY&Y_+AT\K>1Q(_MQI7.F%=91@JIX<;\X"+*.M>FLD.9C#-M-*
^8TFU(6WH-ZA]L'DZV(&-;$_A1(:5BBOK#W'B6']>-IWSP MYOE&7INNOF.C !TLRQDX6K!"F#-B7865UZ0D8X0U5)F&_W"]|>ZUFG@GA=? MTN.Z^-*
D=9W/+UICJU7LVPSS+ %\K[QAEO0 >J1[^("M24/IC0V$..N(\!9D5XEU=CG+,T?S(,5&.<9=Y%WK9;R=S3%8V5UD#_V7HV?MG^Z&.SAP_'X0DXR2"D+
*SK.41!JQA&P;4'&.5G8@OI2L8W*S+L(PD(H M26!=|+Q|8L4TAVP3{'E0%HQGBFVXE+<)Z?>MCE[F?(WUNO@)(E#],JOV5Q&W&\C_<$P'&MXU_4N3 MRY,C|&!*
[.IQ6HW3H&^P|2L8&,,R@#U"%=@CPC/02 4+!"RXH3ZWNBPWS/G|M.I;O#\-[4"C9"LNX=\N-^K*$RJ4K"& +#9&!E*QMA97AEEROC&\X6@H1 8J2$-P $-$2 M3.'<5T-*
R1EGPCA9'L>6Z59;^VD+K @4 MP$DBE&*O4(6/YB-L?.ES$PVW@> M7Y#;5)Z4#9J!VJ.6%43RP@$I4@*,+-$<6V8TYX5>H,4]\]J#V:#;M^T"*#. MJ8.U&X:(*
*Q)L;A4H*7@1J2B=M&XCG;Y__GM PUL\0Y_F#7 ;UB9G!X9U[@,5E_@^:.1FW?GG&$U+ MU8CZ?#9?C/|9OJ?F"/0U]_U@VR8V8K>(\0H6\QW|PF.C^8HZ[JS]}V]S'YW> MR'->T*
4 6N9@DF@!-$Y!HEFAE6R(;#=OS+C@*.U5'IS:0)?^8-0RY)Z61 MQ?)C5!I':4.H4+|"LA)\"@^.B'4!BSC H>K&!JH,V&W=MW#T(!ZE4=(*
M"ZOZ^*2%FM|ECE3Q(PE^NA(2*A@:= H3M +SW,-H@$<>9?+++#/4T|RQ^XB3 M]\W0W_SB3:.OWH>>#GT0W)CNBBSHE"62I(!!W?L4]Z5SP*W&Y[#;*
*<3),.EW.HB6FIL## WXS,.7.APK@<^7^A94DHUX4(?<4 MS/[(B);CHHOC+Q2_C=EW;+14Z>$!9/!!\%(E@F!F3D)3 !ND^>.%P&L-Z\WN\LR3(.'CE9P(;0HP*0N@X4QC48-F-FPF*
*MI^\025PEV(Z0=R'X/?\Q9?@WY"2;-!T>N0'=?R"8;?5CC@3E& MW6LSFQ9@;U1?>]_J. #3F@&[$>YQ#2L4KR.!@=:XG+@4A.FDK^/'R41?SI8+ M>/M7!UZG;V*4GM)OFP?*
*B%)N+RK^]/ ^&+WQ# .''^6WKW-]M&W?\>5^, T^Y5 M\X[7.V;8QZ\5]%0H_FT?2[3>;P(3_=L5S[+'?8O_*E@94^G0V>BN*Q]PAF M!NW^>>>0C?M;[!0_^]LN$&D88@4V-*
MG]]FL^64T=JD9GFF\\7F6A#)2CC5PG0 M&'^P0YQL'ZU^+&#$=YND_B+V!W2 OXVNYY5[;3&F&\SQB\4HUE:,&KVI9>5; M3D?
NZ7#NAQW>!R&^_0BUVU/%;>76)!F1W%^1\ ^^]K@P#T'Y9X-WV](GEM0 MUQ$J\V=VPB]*//%!/*VC@*>J4^_^;N9_^S>&GAHT$,##PT\-.BA)\)#UWB<,:BYZ7)..(@;^5=*
M;EWST<17[U%\3M/21TS^]1]=>CUO)D1=GI#$3!\Q6DC5_P=#]K!49G%;PHSX|KR^5GQ&|OD2%W MX.T5VA@I-&642*P.%2.(B/"*
*<,.E=2&PC*E_LE^L'47<$ M6QY$W3{1"G/&PD MSW??R3]5?AA$W"#B!A%W18U^\$)+QHBD',055V#->4Y)Q@H-EIP->;Y1HW^7 MLO4CLN9*

```
MJ[6@Y7/;VX*6MT,W831WQ"+"<40\)0"I%##"T9,4C4W"ZP.CVUZM5E6LUMGD M=@JYF:??[CGDYEC XDX,4W_X_<<_/OQ8_5+[W )Y4<#RY]__^"][/G[[0Y$>
M+X;;7JK0F%5Y+)M>^/BZ+;TY&/BY;_J=PJ&?)A9L5B")3YY;S%#@6N=#78FT M5 1%'Y-QT7J/U_JB:T*EM"P@;@5&G'F&7%0<1<)#HMAH9N4C^0SY"3NTS_V M\=_/G5T*1A;,?
(X8>0AJ]>!%P8N"%\|3+S;K5"$Q&CWQ2*NL)/&$D%+PH>%'PHN!%P8N"%X]? MNZ,;?3W,W7+?T/S478IYS);D;Q+7/63YJ?AJX[LCC#KX.)K80<'N6]0E>G+G M\
\@S\HZO!2&N)],HJ.4 ON6@$HL6:2(9 MXL)%9!SAB&FO2.(F2A7VT?3\@<[KQ8EX6,_R%6)Y>OI<@6,CXMY1I*E4"/OHG!721;P6<[]G"'[B=3".%I)+WE'!YH+-#ZG.BF"%
M"Q(EH17BS 509PU#3LJ ]??$V+5":WO&TOV%2H@3=NBJ&T>+G/?'CF?D/RSH M6M#U&-"5*V$E91P1"'GB"@?DDE= MAQN9\M):2]5XO@5!GC&^%C]S0=&"HL?
@/Y#)LR0)DIZ_NH51NC4'JQPIZ!TAN5!'@EQ"'+&$4I,$F= M4B'@M1.R/O]X)_AL81K_O=Z^(]2?;S4A0N'?#QM9=&4PU[Y\ MRPHMR_0]?
AUW]4^:V,G[:C*]F<1B"']*5'UQ;;5CCK0'8;=7YJ?_*:>P%KY MK1,)L8*?ZO.Z/?RHMHTA,VBW8I.S)L;*#D,UK(' MZ&>O);/7PBA'TT]G^1^ZJMO*CL?-Z&OW[L'%
VSNC1)N^=5W>.[^*Q]89TWP M"?'D*>+6:Z0CM\@)YK$)20MVZ(+/RWSZ8T\"O\'+/GZ)@\_QUXZ^MLH1N2)' MQ UR9/,2Z"B2)S8A%J0%40D"T.8_M(LYLB1Q+=#01#%CY\
M&^IV/+ 7;_*O;\Z'/\OWZ+_XUQ34T70Q?V%W*P*-\NUXU-;= MLSMK ;8-S,.O>9'@F6\6EN+76YJ#][&>[M<0^'[;2NG*'G;&XF+GSA8I-+/1 MU\,!V -@T-AF\L9.)Z.WJS_NO9?
=QO=Y]%TE/+&#K[8B_;MJ[\L2&+VY/DN M=C9UMV-+5+"VF_O=M,.?A.]AAS;X )8YZ^Z0W"-K?D$-YMD2M#HI+*@,%C%) M-.+"&*0I Y7!:A:$I]QB^D]R>'YX/&]"-
E\W%E.E2\54.U.3U@R(-'5" @VR ME( OYF*BLEE.G'2BV]95,_5G^;,A:#*WA>%R-YU4CA\/(@=$F67T!P9 ?;KT?38?S6<"\;77M^IQ6/_=OO/*:RC9PA8/%&PUC MZ%]ZN?
C].YT=Y%58O/M+4T]@#V$.*7MI%D_LI?/I(XK-9<9]UGSS/5"2'5Y4 M,9,@T"50:";;GL"O;'W;D"B8YZ._N-G^+YG@#-X2D?Z MVWG!3E89 A@.B#(3-
RQ*3SP==>8/.1%TO)4_/L18_09#K,BBH/(Q.0Q_B*UO MZO&<=;^;MB"!V[9;MP] #G6")8&9O^O9,J_%[R-X8!T?T<.XIC$NBZ$]2;;U M5MZ TSPQFI DP8#Z#T:Q48HA9Y15)H
5$/U5DP%;K+3@'L%?#G$M&;*4>,24 M5H:1*(E=.R:9K73[N[W(%/1N&.";9AK#+[5U]0 4E]C^4+=^,&]G3?P(+_MN
M,/)_OJI@)^TXQP7"Q<Z97[R)03"6GOL\?.8F2HQ(A%F@3Q#">SYK';A5X_^+,8 MIH/X/JW3Z<=,P?#-_QI8*#/UKI3Q5])ME$W VW=X&_,LUMY+=[]SQ-GIJ M'OB-SVV*-]3WT-?
V"=G$57>I^7%C/-(#:UP0? MJ3["DH*/=KN[Z+];%N]];/]W0GE-I6%CF']CH![GE2"3F&?:RSRU0@55KCG M&*MW[9)L]R@1M'=:W ]V8)O>:S8/?YM,,"6'^PDV@BJ](_<8-*
2L8QQC*2S M!"E##*8210E"XP1; 3=2RFA'\_'@]%%C'_T'+CD3YGYLO85*RU/*#.E?V2! ML6/?T@)C>X0Q')@4E"L4OB M&;\<]BJ29+69>I0X@%105*B<%&"0Q@$C;J1+VB?
#W%I&R%T4XO/AG^'-]],6 MIA>;!6OF$_$%8^Y)AI@3+8LF7&"K;.D+@"WN";>&@/:JP)@'91;L>.W K(=/ M7).HF+Z7 OR0L"7XIMR5ETCCQ?-
[+U:9!ZS4F<]C.RG2X<5P3I$.R]+!,L^L M3119$B/BFBJDI:8H"]T3,0]4V[74L%V\O#_/&&T6Y[E?GPA719LM>%6V] 7@
M%:784<=T]M\ZQ+V5R##CD!14*2(H=5KNPYU[4+RB)T09P761&07$RI:^ ! S M ?1@A8<&,7+";0&QXL'= ^/,$UW'N39$ MG\X-
(P*+;32,5<>E[;HVO/W=>6]G(TIMEO\3V_J,7*Z//%5PT7J-E:U%Q$GI M#_5RF+R(M66QQK#%5G&&E!4>\1 =TEHF% T()V><,W0?$10=,/S>X\+[].L< M%?[(\]%NS/GR1UD6
%N,]6/G_@DCAQ':1!A"L'P"4X)A63S$*")SSB(K M+N@6.ZUCU%,MR776ZNGOYD&&K'3;]3_?CG)%TD M(Y)C)1 ESO21Q8: ;HPCP\)827U8B\W;Q?G;<>IZYZ<]E[,X(8>.*KY-K?SG
MSBP%(0M"OAR$Q-$+1WA"2>]4HY<5<@(;!'IW4-Y%R^X7O?R@""E.!,4%(8_/ M&=V-/G=Y'LZ>NHO"/EN2K]E>]Y#EI^*K??V.4)^_6SO$(M;VRZOTE&9F#:-I
M;M3XB(+M<>KXWV8QGJF,<]QXJP-'@DB&N*4$F>@U\LD(H9/RBN_%"CBT>&/J MA.D#U_B_EDR>GH0K8%G LH#EG2KI&(.SF8%; /S? W)?CMV,#[G]O^N]]W@]L"]0&@SA'
M@[J=H#B(Y_";,B#CV"P:=X:Z'0_LQ9LTB%]7U^9?TW92IXOYVILK4#NQS>1M MMPHH/[Q]XVP;!_4PK]W7Y1S8*6/LF[TNH+KU LY>OF3U_1GC&,8Q>#N?>SW,
M$T#=$EPSZY5B)WF1YVPW[W_^S94GWFN&9D<2^1!C]=MH$BLB%NW>=Q[$SIWF M_^M_:4K(VWL/X*95Z*_,#WY33X"V_-815=^/SL_K26:"WH#]'GZJAY_BT"\9 MK0^^72
TPN5AV7<]*Z5-U&TK?5(G&_ZC+WV],%X@ GS/\LR',PY*%W1AY0 M(-)H-!EF+.A4I-\^_M-31TA4"?$8.>**4F0(8Z#U,&;]"X)]4)*^G@_>#.SP MT_]]%8?
H[Q\*BAT5=Q84N\TZ_3)]VRU0-B_N\,=2<8=Y6F3U^VV+.SS85"Z1 M=HFC5W%W9BS\-CV/3>VO_1;4Y+]VOZ[\.+.AA'2:,(&1P)X@;I0 > @"*6.T M),8Z9]=L*&RQTH)
[!'\YQ+5DR%+B$5-:&4:B)':]3F-TD]Q:9S!]ITW\"_[ M;C#R?[ZJ(IA,X^QW!Q.K?U$]!&/KW>2VH_LGN9W50NA-E'Y [7]G/#*G]Z'+ MY?[U>QA,]=VH:49?
@+_NA3O['M552V@S*5SWZ%>;F8-@0Q21"2EI#>(R.>1H MPL@Q')-*FJ3UB+]=F..#/XMA.HCO4V:3CIF:W<8AMR+U&VW-%4KO&.,HB/U[ MVS070%V5/<\MN')%S,E9S
(0AG+Q?]K*+>@OKWH+NB;@]^RJ-,K=NO+=K^LA M?#.:MB MVV_?/)XRL4R9@YHVFH!_6 M7V-XNU !3T$)G-T \QG8<1O?M"%L&SM9:,B=)ZY_]JM-YZ>?Z[;NLU+>S)^Q
M+7"Q>ZV4IXKFUW[-:Y/'.)LN4-/7MZ_^K3=WT7/V6[UCB?QW,6F8OBDHICRW0GE-@$_Q[!^1\ ]3^]M+#/ M-2XP,]QIQRA0R)@4DK
V*!B^57RMTMTL86]^!^=1@7QVZ*54GIO3H+HAU M_%M:$&N/B$5P8BY$B@PU@#X2.V2#%\BK$*.7TM(8]Q%+=@C$DB=:%,2ZCTI; MBA;-%O?
7.GQOQY5O8J@G5;*^%"QZ6?SS4J7"+%*@;'KAXY>\I4^>C]>4[]%. M\$@8(@ETNMP%"6GI. +%3@:F-15QK:5R2EQHP1C"7$;$+89[E*((8Q^T#@8S MF:YJ=[_4P_@^?
=])SWUE4K$33$]DRN*PW(=V9X?#ZF^P-N,UIV41#:4R1:E, M\2AJXK.JTU#PHN!%P8L;U%&;9(J.$X2-E(@K87.MKX2"E11+#TJGT%?549D( MMI$Y)%4
=919BJQ("44AF!5$&1SL577T^TLA_\MH^.EC;,XIS^/O]B*%>Y) M0]4GFI9B7T?HHBRE;/)S/HXF=@#T[";5++FG&L9)Y5=CC8L\*U492E6&?0@W M%IW!V@H4E4LY
4(B1R5#Q K./&&>]IV<_<\E6DZ9>$]'_|^L$D,!R *0!2#O M I">>&9RAS=%L4-<2HRL30P%]I737%NGU[I@[!)]< B E/I$F@=5]I\\0&XL M5;,Y?7>OR8O>4$RL2@BG1!"/!F2J-
1X)2S@0'1^'H/= MXNS #GW,%W8F3"X \&>\J -S]N2VKC/U$9.3S'6#YN^M]MM!@;ZP'F&.]Z& M3S5_X)'B4Z8?/$/5G$IYO"\]PBS.IY_4^,RGMT@Z$R7I[&IQ[+XZP0_36YV:
M[]NC78CH61!1MLRV9HH5P"Z 7;*$2Y+]<:0)OP3N*1SSF'GUA7Z>&?V\&PZG M=E#]G-\3V\E?7?.7V2HN__F'O5W@:2&L0EB+$.;)M*DG%]4/A78*[=R-=OIP MN#:?
Q/W>U'XK^=PORV#/YM?3RS*X3UF4XYC\PYMF>:*W8]>]37QG?KLQ1."P MX44X2D*$1BX%BSB3"FE#*6+".)&P#,+PJ]>:/FIN/"?(P8^Y<[M"UC*%4HQ4 M4F*<8V%3P>*?
A^VDF>;*VS_!B'NWW]:3=+ERDBYN.DEG^'1[_\<]K6!/FD 8 M WCXCNQW%%3Y,(+QF:#-D>_ET2.,E]9AQ2RR,6G$B:0(OB HN8A9C-@]LI8L
MJ@AV426&L%01<8,%TE**'$>!%>$QJ%00IK#HSG%"6:I: MX3U*B3&+'2?>]?T+X;DW(;L-/DS@C_![;/*,[:?57);QM(D+KD%TF6WX35QS M*@[.--
\\95IZ(:RS..8N.AF\Q1PE[')=NV21D\Z@R(VU,;;=QK6& %0Y(ZT0 M"/35'_^?.-(\=[,(3A/@B"#H(K;]?/AGN$+T^+/L!);+;4E6HA>?WOZ^,')^,LH7=IABG3RB(%] MD>(4.:
(\DMH)'J1,+*TI7_>7+$N)DI=.HLY'1%:U,?@80R=[VO?I74?^]H<< M7-BT'\[LDM3!RT*'WB!TQ"G=GG2R5TVM<\2/8U.U>;2/GJ'X3,ML7%M$;?M+
M\AP0/Y7:+/\GMB5N7BZ$/,TMZL:CMLZ4\Z:) SNI/\>M UQJ:GG?=([GI<#? MG*-P%-1X\"2=*_+]:6;?[+56QR/M^\/DY#U?)KXE@1>%;*M"QI4@3BF,J E@ MZF,=D#66(F,']3WIT
M'UX_"L*+B6U."$L(T7ES=L7QND'V*#'EX(/,DPZB.YK Q&+$/@T>V^R]203D@PD@9B*3 MB'N#D0:F0#8X$I-C 8>UR%VCI*0>A(M+/H&L C^=D@!1<4%#B>@+.BL,A2XY
,AKDD@P]ZK4;G_<75(T<[/H0D MNWNPB#.T:!N)R@.8J:9;B"P MH(L$UE"WXX&]>),&\>OJVOQKVD[]=#%_>W<%:B>VF;SM5@'EA[=OG&WCH![& MM?6ZG_[98Q]L]
<%5+=>P-G+EQRN?\8XAG$,WL[G7@_S!%"W!-?,>B7@2/.+9UJ ";WHV;>E#UA5_XZ8)"NA+%EX6*"Z4@VE;"YTO?%; .)EPAJ#\82&HQ#G;WZULB3_Z7K0?'V#V-MN 4/=Q$Z4
MY&*_T_/AVQ6R&]L0ZN&GI6H7=3^_V:%+_\7&G8G#L,'OOU1T=5%(X^LMM9P[ M%K7>8Y6,^]5\OE(%ZG*7\]Z=+S0!CU^B;,Z)31?7_^G M=CE>3#I-F,!(X)R79I1
AH")]($1DACKG W_)+T>"K?&\&YRZ]OHJSV7M5>< M.Y6H1\0Y!\8H)\B$F) "*]1&(1Q+&YRE]REK/[-?ZZP$+_=4^)CUQ9=;W?Y\ ML2S;JM@#CS5=_?NVLNT] K;V,.#U"I 5V
5Y6'V1_K9Z70]A$J-I:X>A_?;- M$@\]D_+V&M[*=RLT3D\?NBZ^.-6'?.,QU=<]KT,8Q*.10GO/?7T^\[NYC--L MKB^OM%I_D+A+B:^;E^RYEM4M<6#WG>_3= M?
ZC6'I$+W9"+12K&&>S'3 MRI%PD1S/FE6*P%@).TPZ!.H8PHI$Q(7P2',KD=4YL5LSZ[U[8('Q\_W>-?' M+W'P.7;A(FV1%L<@+8K1<2DM9)$6+X-5BK18EA826^:
(SK5P24Y"]QQ9%@R2 M1'A,#':.K@4.'EQ:9'OBXY?1OKI;,WP"JU4DQ!0ZLN>.?'_?N./F7 M*=LB,3XI$&;8,8VXC@+9P!+\077B@8I@Q#YDV]4R'TUS40\_W9"$]7 R;!N= M+
Y@GA^;%'/HGHD5;E+5;3NU0Q^!0=K;R:LC7HS'MHYN/CI^,KRUH_UTI\/S MIRF%']8,'/-2>*,YBJ[+]TH8@62+R*J0N/742K562GLWJ99BT]3P4SW,,/!] M1H'?XMX$V@D6YK
FV>[- (_@='1KF9%BOSV"_19 (!:+[1$E)CVEF7W#:)]# M-1]19CY.;,-M%N/)B\\M1IP4TD4E$3:4(,ZC0UT&Y M+QE'U8GAVTN>'IY/'E/.W=]R6^1N;LXV.G!*SN'#\/M+\Y/?
U"!E:G_GW]N/ M&'K?G;^2M]7/P^K7>25U+8N(>6Y!@Z:@ M/$?BOVB2++F4.8"TD<@%$,=N^%>?;;[&\/ MFU[-:O14]M.G)GZRD[CDVK;=Y'+8YE9RK>'.?,?
G?.+D2XS#%9*UPU#]_?3#:?6='?Y9_=:E4\'4WK7MR-?=OTYR=@EL M:3N)\709Q9X\"%V7%;1U=W*ZS:Z#,;_(1;]\R&,]KU)/%X*(3;4T#!-5F2)MQ5X=VETF*)%-.M/!+YOPL
M@0#MAR "\RU+E_6$=P,%9^1=_A;(-)/_;-Q1Q0QUST8#L [:GH:!/V"26?[" M T&"Y@O\8-1V!.VF;3W,'#?])>+BWP!457T._;R+\)$83%]S/G:U:+^4C]@ M<0+WP@73+GLC/Z-
/PLR7^KKQT_-VDCV)[9OJ-?FV"M,L_+MA9;(8!N#%?T\M M\'B>+;QPZ+O?<^YX/]2K5\&_9FOW_TZ'<9X""G(_KWHWE-D[VBDL^=7;00.H
M^T4:6&!\0))1QI>]A>OR&OFX+0$VCVZ4R6[D_SP!GZ)]DN PF M(&^(0SS1A(RG%E%'M8 -LU2LA8+N @K?=POR(:_'[[9YW_10\(^\*(_'LYI" M^ZA ]-
^@#N^MA<@^].%%+:*3#&*9S08Q4]/148*FC@GED=(.3![81>28P4CP MJ*C27IGUBE1WH82N/ARH#2XGA7QL;&;,'^S%:ISO#\N;^?-O/^6XRV/:S$D_M[HQX;?
7ZRUD$YF^RE@& F]YX,0E=N7]KT?A&!4"GD*B5#.$#?:(6\&1 MD4(BP;0+@7".W5]WH#OO^/>7BW+[36='M>E+^[I* OI#P
D9E_6*+!M]5KNL"F3O_*1+VBR,WPJE>]HTP#K>QP/QBT&QA*>"M M^9'SW_L!O[;PV)C@^=UE^8*%H^7;3C@>G4X4 J/$>XJPR@4:$]"U)D"H&+L8
MDZ'6T;5.77>FYD4L<^_PVU4)NB1B?%-?M6NCPQY#,=K@%KR6M#/M=[2] 53/ M0:<"BLK(,"?*+T!YG8.@@\]C(S*>L FYEQME$A1O!<+788X1$!+EUOM$Z%HS
MI3L3V:^7]_)]MR@[8:/96W7W?4+CN!F%]5]0S4T6VK)%UDGK*_#:>VUFX-E9 M@ZNPR;Z=VX)S-R6LU]#M+_UM09_9\W0^GGF![VQ1M[/24V&%Q#."D-
VN_U),S^+D=1S^9OW8K8^69P#M?PX\SOUG_S;=7IO0V*R&O^;?5 M=#P;\,CI:=/$8;_.^6UUJO/]HP9V(B]I_)QCV;-'O(V3_+S)V9H<.*W>=_I- M+W.N^@R 4"?UX-
ZNB,EEY:J+V6K-71_G<--L52]8>#<4V+A,2Y>.DKJ9;?/2 MMF9/XR?;A YF9H0&4XR?1FL>C=/]WG1+BEN]2"L]0=F]VOG0.^=E)OC-]YS,O4)771AQT%=5
M/)EO%W#EL%,)X%%3]Z\EPH)=.V^['V!ZH>Z=^L"?G^NP0>]_G".1&A"V!OEV M%6;JS:>RCRF.P.X#%3Y29'!2B%.ID?/4H^ $)MQ1H=V:'XAAX@G!N0*? 1'F
M54":)8<(]T1+$CM9-RA'O4?F73)=OF$5UW#_TT,.05#XZBI9W>_B[.WP/33S&2 AS4Y"BGKPM-A5RQ] M'C=PFN/@.OBFN[VZ[M7E[=T3?ULVD5?MX65':E=]'*Y8^G7F MA[K6
[K)R'ML_^G^@54!"^8:R @"VA558K]75WC^PZH_% MTO\06]_4W<=',_[F7)'WM(]'ZJBG-\>W.1FNX33;D^-HYEP:+7E,#A,=)T4, M@@38"RE9+BLHD#8@3"ES7M)
I&5KFWA_D_!R$WN/Y8?<1>"A,K)D]5RL<2 M*M>)HQ41PF3&OSMZ&Z]XSVX1&K.B YP!TKD<37NT(1"$6*%HCGX08 0#^.22 M:*(#HXB!ZJFA:R$0]]07RS'F9G$-
/W:*2$PIZR%"3FC"?&"2X.2"$ "3F!D M':&(D)A,2LRE]2(2=S%Y7VCDS/ (#4KAL?3*(N=R#TUB,>P:Y;E]7_[M#7$VMQ->87:^=QFG,%?09@<5[69C M*)_VK"CU'7X=;22.8\)0' B*-
H((XXHBHT4$S=OPH)4)SH6#*FVKHFNI9EOO M^/UC%IE_6YEVLP^.')6;=^EX^H[1#4!,+BXR%TZ]\6#:7N=/@!MZAT3\NL(. M5\Z$3ZN?5ZW_2[MY9I50S64_VFQ-
_S8Z)D)L^VE6:9H5@:4H@YLLBM,;K/)G'8QP M101T'O%/HQS+TBVDS>22CX5_"'RZ(62S$S*@B"VQ[:4#>Q'\D9D;Y%(<3ZKN
M8=D=YS8\;C4&I\D'H4U<&6L'"_,OEMXT%;"=#;-;NEI1Z[+)>HMP5XCIHU" MH,]!7>FM1<)B(R(7D1I2=+ECUN46F:>[]W/74W G 5<*95QI]%DZ[#Z1#KNK
M3:Q*A]V7U&&7[M9AEQV>)1XW?G*A)LQ9]FMWQ6-KZG(:='?]93,<3?S'S?+:C 0S07Z!YO,$Z ME=?#SW#1W.\YUZ-?S^WM+(@[O1ENR0?*+6QOG6J?
36Q0ZML:"+VI8_MM'WIR M@\KD%G=DW:X3SLYI*"[Y*\-\Y[,':U4?).- MZ&T6R6WV9S&-A,=AX=>C!)
ME98^(6:41#Q[APUS/G>SB31@0CWF!3T.AAY=V$A/Y/UYPRWLZ#78^&TTR1"Q MH/25M*N350_3Y?%>#]<\F9,\;&X7;K]$_>T\IK!_D!&)G)0_"YFX9WK0-5;
M/WD$EUZP9.O!M.G9[(HC"T!P/,_-FU_>1\YT<: +A?:]EVP663EW<::Z ;YC M4O2'Z9?E;ZYDXW7AC1M&G4]GZW;F:6C!>!LLTFB[@]V]S\W'?'H[#UB%S;VU M
+@VU^_H@],>.]KR,PU[]>GR7T 0HTY8 MM3&39T<(P-B3Q@[;U =W#+IXWYFS-HM)8-D<'P\4MW38N/2]'*X4DLSWL^&_)W/ X T[]/2(+[-^L9E0'/G%&\^V2%0
M3IBYY('O\Q,O"W -]?%ZO;9,56?'I._G"7(G'0+U7V=KVLB_#3#HA_@@7!) MAR_?9^>@]^W)+$O.,&DS?30MM/S'C;;Z7@\B#.GYZ*"YS+% M7%WUY6]2EW/;CE
SE6;!$6^[KU[7L O+MGX/K9_Z79B%H@$9S-/#AZV=I<@. M1PMTS44*KB)N#GV<@7-8UPN71OP"DV2O;N401 =@@(\QM'VMQ;PPEP6$%T5A M^[*O1YX.QP5UGC&/<*
(<\:Q$.FD)"DH)HK$-SJVUXMA%W?Q]MF(_P8(MQ91> M6ZI\O98PI:?]B#3,>=C!R8P10\P5'^8:WSR9;7X8TK0S&@(,;GVVBN8YZ>?G M==LNSB4[]0]@\+P3-PMJ
B2*PQ;&-2_>>+58Z+MV6Q&OAUF-R^]/LS*&O)O. MHEP"Z_.GV&.69,T+-@7*S"IM%CIAK4U45Y;EZ-B4FN@X-API'Q7B6E&DL3.( M"]X4#\KH]82570!]&-
F#!:>QY96DIR402[]!)#6*](N,$":2D%PDIC17@,*CW. MQK.CW/B3N2NOLS2?EV+37WJ;_@R_UN%I.ZX\:( UV,;6UX-Z3M%9QS0\H#%'1&8VD,]EWJ!URR3"4)%$L*.\# M5]_Y%)%
[]/WW2+>7COC1]KHX?6L?\)',(@\[#V9]T_(O]\ETEHH M7VW,D6+'31U8>!8Y!=D>8I^T80C&R$AI(@$E01I]E3JGS#H=YR:XL?.^<@:+B[=+?86I$]$N&40U0%F%7&#^U@ M?
M)1@U,B7]Y75786#)8\=2E<[D3E&7)8DMS<3E%EN$M4/]2L]"D5&_#G: #I MFTNG;W=Z-IQ5%*AFL%N]_QR;87XS6ZBO"S5ZU6 MGP
_5VDP&C7'6/@=;%1"2)K1!^=:@QR+H,QZ%9/3*2]ZYI1,D5EKHT 1Z G8 M!8=,6 :,SR0,!P7'$WM-2W^Z,HXW),KHM(R>@]*NP/]C!O+D;6&(D5, M--99U65I7.,X2(AHGV"KND7'.
96:2!TE(6S0L>Y FYM![SO;UNT'&+(-[X?_ML$V=/O72D$"81X'S[%H$ C3"2R2M)TE[]4-I+Z-3^WE6X&-LU.^7$4);MZD_!-VFKW8VPVSSZB.LYJZ$L9I:1"+/ MJIH U H^(>4-
MD(" )%U?P$GA"=C D(B&+FLALY1]2!1K!FE+B4KA%*L_V< MUP7Y,6OKO_9DG2^R@T'^>;5NQ-(/:\%E6^H):.%<" Y% 5HDEPDC9S%&R8$1
M2ZP&O5M=G9CUH&0FP&SK%"P&#C;/R:'@I2,Z6:>C>L")Y=2:X\6PF9EU"4B7 M,^RCM=RPC>AE^I!\N*UU.SG(46D?$70NL15/E60 "7SU# M.K?A"/L>\LA=XKD%*I$6D(]$,#-
-\->&\E#($)M4,N,L,E8)+*?B$>=31,0 MB H;K9-)UC.QN>CY#!3>#_OSLU7HV-/A[Y%6#%E)5I@YMA=M.S8?)W;M0/]# M@(T4%;_&QM>YG^]E0)(?<).9D'07?A ME4=X
.6)DS8HB[S-)BTF*@LE,!V=R45]4F)I3>\*F%O&0D#8]%SI1G%DNR-- M_/^S]Z;-;5S7NO#W^RM0OL>G[']YZ3T/4FZ]%#E.^51D^UK*N1]3>Q1Q# (( M&I#$_/IWK6Z,;'
42#3)9E(R"?2PA[6>->PU>"[!YO0FL9O2%-IOR;0\6C MV%/1>=+L9'2*+"4R'B6) ;,"Q@8P3I%8D[4)< P7=I=.8#*M;"F.MXX)RMJ=EA#\B!PURI:
(%C=0'AOU/$5,1*U,O]YLABEP9G_M*RFB@&(ZT/R5;\C MS%W^LJSUT)2]7N)F)Y%*!*94,IDHBOY85M#Y1CEQI7BN="2M!]9W0>I?E\= MBU:8G7N'L-
8;8J;8]>X@39YLJAS6.3Q?D)1R-X,EA ;+03A.>$0_EU29A" 3 MB4FIH(-SWK4]\G>@@$:76IV)]RI/?X6%^2D?+G*R2ZWN-@?F=<6"#G:-RCH) M)G@BC@KLE.D+Z--
@;GO'BU2Q&,5;;B_.A&?%"U(R-CYDR@*U@.;MF4@R9@&J M>-FW\TNV7T5.OIU4\^H^QY+74X#9?VQSO"/*5=/@9;#[QC\:_*BSX5-2R!2% M!T30>'13#-"%=(:8Y)AC%
A%M)M;WH$NUN%3.Z3QUR^HSB^&U5E36;NZY"2\ M/RYT-/2N45+\TO"I-82NR@C'A&"(Z>T];84;@XS>@AG8.4P1S2@DPC N6ZI4),06=3;<8SOX22DGFU3EVGX>C"9-.]Z\
(X6;+-C0 M3=/5H2*$0$#,B26AH;?L+I_F#A5$99VK$F]S%=_^:'X^KOL#ZY^G6\]Z4< MUI;MIE":Y3CYV"2A+ZM!8/P_YCVEW=3_"C/,SU>%>;_,0.- MX&)Y\?),Y$Z>H"9O>:=
TK:C:9S]FM=8-G2=,K%NL8;%#7;N7%]:ITKCU#XN M/!@)\[Q5\[@_%7NT-"\_'@_^-ILLIJVR QW/]<(L7:2X[L&T Z',%$"NT#$!
MY";:I%!DQS38$)8KVSK4CUQ$C5[)P!3HFPDLC\":]L:%@7G*O;^AFQQ8#[FI M?V9'/0(&;=_0RZX%G^:&NIG+EEN[-#*IUK667UJYQOXL>.U$R4K3,
MV+0>W<]@X#E:=%9W#Y+IF;] M=,^:?H !'8* ;VL,P)"T58C&Y4]3)^LPW(<)200G8C7VZH7O]ME?C&N7ADGEQLE(>ED%ZP/&;NT^:G..+ MP1P&O>QGO=.D.(XF58T285$-
:TUQB3CKOZ]O^5B[DU*K;?'=+1Z_KUM]U_0@ M *FB+%A!2=;MNJW#=#%#K$]%48-5C]N)<]+0#&A(P%Q&9Z9TQ!L--I0]EF4! MT&?VQ(K=V+_X=_2$[4LTV^@^%
]5.V7]+$D"]9_.6;C11&]]E$2$2(D43H-Z M"YIKXD8+7Z3PO'72<9>]W8U6;KP>H [V;K;>WS#0=H)[18)]!RD 0C^
M@,%WU]6R7A^WKFLE[$#%N@]ZYPB**0/ZLG!82P"T'8V5C#+U1.M(E301OFRU M%C,.$\-](8 J0$;&>6(5X(U@-$<>M97RAH()>\&B=]BPY^Y1VM_58)W*28O6VBO-TT1&Y??
I6X*&\,>2;MNIE@? M': 24)?9_"\_7F"G48[9+MNXC.?MB4ZAMW[BTTAY>TBX;57>?7WZ]!F*83+ MOJZ!]<'(><8B\>,[B^B&V38NK-WR)=@[H2FUCN=,0#LKYAS?T$-
Z2Q_9GD+? M=.TY-%U3.[O8-UU[8DW7[NTQV&;6NS1]>YB.:_7EG3 +M[+\QD#2NTE^[?K# MQZPTW+9")2PH*"G1+)F6,U$6>*IT20HRG+Q!=2OUM$E2S11EP7)'AN< M,<:
(*]P2;KV-SA1MXUYOYD:E>KM:D(WJU>CT[& Q2ETL-%L?-:WTC=K,[QPY M4"T+*-]D4&F)]%@R.JI E!?<2PJZN&]E2CBC-8\,K/D2D1R*(\Y8$##)\V Y M#]*&.Y-
#K457/]='_KM$T:A==S+CU FW73K$V%(=M]7$T\$6O!UO=+< UJ.6 M<'\BP"HI%DXR1"C!L12G!_[@6/*!.V5X '!MG?GG$G40V$7;,X7' H4_&:2
M7+0IQ<15V%M5Z5&!M9/!GYT'5DFS-P44MR +;"W6]@FI:,(BC]$4)A5O)9Q$ ME9S, 82Q50Z U6L"FAXE/*=8DE(Y^;V'P(\&K,*<,-XI>K@"6)_M:4UW-/-U M102^KR("^FZV<-
M_G&7T_DSJ*'_8LX]Y-YWYIG.<5;.3/:_)ZVDM%N M.B*]]PZV@DPZV17$%E-DD1Q@!,^1M8DD9%L(+=%(T,69S+]EO0N5,W>)R&! MQ6,',N2)U#@Z38;?
<[C^/XPPC>'_,S7]_'E_*O?]UA3.XAK]@_ZH# M"1M[ZKH$+MM]0BZ'*?KY%DUMNGXU/LA.2B3AE#8!6PMDK!6NM2?>>DE<9*!Y M2.Y9:JGZ=Z:=+<)H!,^OY6T-
S.\1E[]6_)PH)4^8ZU1*]'X)=,E+?#KXP+N?>S6-( M+5(1F3"*9]3*2A*4HD3G*$7DV>8][C&E.8^ZD(A5@F74E(0(A]"G.CA*02S[ M8Q]#WE1DHJ-
GE+OET"^3V^KTJX5/G:,JG63PB@=B0P8*H06DKL:&/:J49 4U MK+0.MQ\$H [K&^BFNK8*@IAE;.2*AWG-^3 84G_D^>"3'RTZ&2ZEF2O<>$-B
```

*MP+XLW^MB+8LD)QU4X4&S=H&U.^MG[^I%^&]<@T-J9OR$/E'-K*YVM6U4UNUT-M\WP^RLN$SG,_',_;EG6_W^5800?QAFN?&3H2G9>@[X>$NI 10!O)8(1,E]QM M)MY!BNW)0_]]M4Z,H*WQVF!\@X?.&V Z6'W)+I[YK%K#;B)]JE7"6YUMC;JV M#Y-/&6R"36&(V_@IFO3VYBE/,KN=60?R3A9"&:=@ABH@4%DBH38X35.0DL=# MB,"RV[O8F_B V2W=\1]^C4!%;T4#!H8DIW%P"%-O0\2\=P9P[QQ@O/DFL1 MWUW;'M28^#Z>Y,08953.ZZH<|8*VZX0!-N)'/RY+GGS $+LA-Z_C&I9G($< MI_!,P-;\S ;\MM=I!8+P_/A8AD &.,LK[YL-V^N!G7H4>,^0:=)"3-Y3 MO.K9V0Q="%>F=;13_5H%;S7?;L=@+=>Y"<+ZX9I;MV:FXYXWWN\V=,LL?|8W]#/L9=FV&? _IA/MO^,L@2PN8&GS\XR/H@^-$EH!<-MZI_](@/P9$*<)]'S5A'OB!U=@1]U<@MJS%-&-9-@G%/:('WN@R,W]L;9W4C7W M!&3.TQTF_+ 3O'5HZE=,#^@"OZVUUVNGNH[(745H3^>#6ALZD}A]L.?_]],;[H_Z5RSG@V34M&)%7U4?G],$^XY M[,K5^P6#!WL&.QB]=4DE@)5Z!N+Q14A_WF/3Y6RJK8R0'GQZ? NGYY49^$3V_M]-IPST&IQ.D,!_42YWGS2RlQ#F@>UL=P;?LPPE*&"=3<.^8;VT?/FAJ_U?$ M)5P^;6PWGMAM-G$;VKS-2EV+98]?!^'KL7K[L>~)WE|#+_M:|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|^UR4L)'1KU0A'LLL<*M)H#9@1B=HDN>E"K["TD;> M,'$ _U*/TCU*]RC=H_3145]$[+RW=@E@L?R5M!116@+C)2EV=,3S(EL=#:*B\ M0(@S@GHV$U)WE4!S77 YGFV;KH=!!6TY& >%5&^7E|!]KF?S5_7]T#PX=6KX*L\&HYS:[TV- 5/$DZ+?9)"WB M?/ >$*X:S">#?WRH;YF?Y0%0SW"2]@&,N4+1DT[7Q-=TL*[_[8GPP8B0/R4X9?:D MWN6WDW,8TT5- 8!&M=(+TQF. 9U@K!E5MFKX*0\^CB;!CP:CK02? G;/N@5l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|_"OQ1"7,ERL%O+TLOU_=XY,,\Y2 M0UZ=;H>07&*!%*Q)*F4!J6LC)\%IE].+I\")>)8N% M!9CU]`MX8GJ RfH!QC07T.3^,EO|[\4?7^,T1Z ME^|K*! M_Q=8N\GG:O =4.^,\;+*H@%6]fUH%=<,*BU8|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`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

*FN>"82YZ7=*NJ1!: TO0#L(:S?TI< 84PR(SR MD8 !< CB*C 0=);$B,U#.MW5X^!VK8!P[%^4F%?2>Y:C_>=7/V5+/R_X,,(AS,AI6B#3/%MG;>]T8-A9F[V-%NI. ;_K52#X\.H5]l;"7@&M]=K,09P*(;X]-MZ *:6R_@\N5;IMH?.4]A'*-U]XEELX-Z":Z9]4[.ZU8]|?5EZF\O/?&K9NCN M22(_;8ROCH;E-'D\\"/_>BB&JY[M]53SF4>0KK./ZWYL<.? 9Q11;Q#0-F2Z&>92N:A)^]D&9-L&_6S99*63!+W@/]!,N)B"D1]%94-5DN[=CZ?C_](KW[, M8;IP?ANTR:NKK_S!AMEO#WSXX^]H#^MI< &ZW_^Y;>; R.Q=CD_.H5]>5+X M-$&;>=6#1G:;STH*(FKL=IPTVBR6!"\%2=0+GD6R/+)6K_D8I309P<141KQ=6Z_ED MP5P14A%F5*9.:1MYO"SPK[_]K|QRO3NUY4VWJ,$[_&3PUL\&$^S#MA@U/0'0 MD;-]I;7N@M 4+ZCJ[S.V=;JG@S>#6/,#]CQ8(\?_AUW6ZF8)|'77;(DF[U6@ MFM"]]JG($2D!((2P3 I]*6EU4,[!\F%-IYDC_:O3Y)X;+QAN$LR,&-]2CLP M\@N ZV]-6ZI?\@QU;_\Q_UI^1AT\5_/? _3Q?"2-+Y9'PNY'7 [1*OC]M?9XL M@!)@JHO1O&X(>*FGQ@T-M!\?8%3D@CI&1(F12*L\V DN$9V\%PX)7C+*9*X M,#Z , D**$,&;# *T1$OM/,,2 \P=>1,6>.,=7?(8MU ^O8MU!^= 8GU.,4? M 6:\QYA2H !M&"@.T87L8Y+%7Z: DC'1+"7"@$]{-.$$5&(2-(@!$#*6:9YZ. M3 &.=DGHK"C@!*%AFF/3)'#3'G+3VMZPP>1[.Y.'/Q^1-I2('(^UE_[--]^A: M82*CN-*HECH4&%IP]92G/]+NMG 6*<^:19GE3WF\ ,WL7=T^=]DI>M4+=]T,=+1N M555_\3ECS]9E6_'5^-]9>*M'8N^L/_+%3AORX1@;B&;4)6?#Z@]29AGNP(%U MSXX0VEG*M2.9:[C!*HG 92(HU*ZLR5*I=!GG.]1#$8INLXD1(/_S6+1(&Z M$$!|3$&Z1[4CQ#75+XYA.0*(8#?GU%G'072L6(,ZNS>HO1M-7(B)%&-*X"H M%=EJL*=B\%1GP%/*"]@#$=2!H!-QOC@:2K**M:+6'G37.R7'N^XO"-'"IG)~ MHLR!2">C9*PP1DRTP.<*3 #'-24A4A<,X(5SC[OC MJFM;#AK7<-)%!O>1@ZJM&,G6P78+5P#6,R=9&YECA$UU!N4>$IDQH101*0;< M;D; 8 N$ ==>7HA78@*TC[3MO\]GH!;SV[8=G--.8--YL7C*:P7V<\;M6'9@!ME M? =)H% GB\ZPG46@M2|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f'@F %9"=JO2-K*=F5YG4R!6ABM4?5 M6 H2P"HCQF:A$P,S+'H^X>$)Z\W4,Z884T2)Q$:U 'QG,[(@WAEF!,FPN/E!!3'R0(TSN&7G%ZOENO3L!HV%,)>K9YQ14VMYK5:GOJ.K_V"RX|C M7"XI*/A?7G_SPS6WLOO?>~<_;^*E[Y#<^MRG>4+'-7ENP;1_CWJ6*VXV54U:V MXI[R$_9 U2]!JN?!9HA7M<>M&X|';E6.JOJ>>< MGG/NP#GOX37# BLQGO\IS'[X\S_&DU#EV2=TFM8?_-PD?'WW]R9K[%:UY?OF MNIW@OZ&_VH$E/RS5%>MY[$JS-S1+\Z-UL[1AKEX=&LF>5!7P^UC:1RR/?2Q; M^Z5,N:?H9[V\SV[*W>Y? =%E"/OGF1>_S>#B9+6O:SH=X;HZEL3O5KHCU[8]> M8N^#77*Y:J[_<>"]H08@'C1!C&LF@XZ$AZ"(Q&(%CH9 O"C;Z6 T*ZY5TJXLS M3ZP?PA&*]-^FX(9XF2A3E4I7H? 9!'[CW*N;XF8NVI$G[?MZC'LA[+KDE:4DPE M[34IV;.FE87W!5#->9,BCPRPJ15[*7FRN23B$ 2E"1A]ZRS1V3*EE2N)'AO+ M!+NF,.-3)?QC>+5Z)?Z.,/9NF-[ZZ;H(1_&Q#C;MD@K/>Q7^Y?|_+ ^VV15VV MT@7';.V(6ZR_S(F3F1+*N$TF9R54]]*8%*;(E"P1U(*$]#X2QX4CW(+]'@)+ M*AQ9VHGK"E#UY-XC6$>FW'/8(8K<14V45"1]+!8=":4VHE@4R[0FT/@>6T4& MHG5":5.1(PC@&<4]:2&7%A7369-/]/_:(";ZELFIS_THZRH?CP=_@6$< MMOSN7=+9;Q?)T4N\9P$!O<3;J:11JDL.Z[$L]<4U>FIO0>PCDRY![''O!S %>K;1 M(A)/L>HQ T3R $0D6]5-#$E&|/R\"V"<&2N]LR11E;$PMB:!%M#M .P$5K6$ M7XY4]W@99% [!V%_9_[*%?SR3@/;OIM5'B.I/7TE\WO9C:\;TS[XRD MBM!D&)&%@\[M#&KL7LB@K,F^5?]411V9+)]PQ"F1RF<2DF(D9$U9=ISJ=M^K M1_9.]3$Q/B#U6_H2 $SGH 26X8V*@9Y.N2$V!D.85BX%SK ,8:MQGW$L*V%) M,1KN\8X29PTV\W8M<1*7HY=B.ZZ.G0OBI[QfU_JCZNEOX;?A^"/\@;,7GEBK[M*C6L4Q$QJM?:7PX*I$)O1^@54[A*E 2E!;4%R2$) GU-.00&,BU5O75($LN M*@>BI-78QHL2KP(C+%L9&@^]2W][HM?0D 9A)GC+E$PPA4[,# M:.T2C_]XD]0Z5]>=8I=-_ @D8J {7U1$;|%(E8G%Z,+/%#7 U@WJ+UWKA^C MB,/X8SP-.M0RK'|ZXQ>UV"LI_<>PCHRY1["OA[*A* N9^J) M$T83*3(C3@F'W>Z(%,7;Q%H=6F.T15@1 <(20ABSQ"O/"#.!JA*.CN7(S@9& M=1_;MT=;A]^Q+MVQ$\1O4D'OV4_EGU?]\-)UH0/L\6W*S[_00KE.3GE030 IZ!\A>D1(*Q3-23* $Z.?>|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|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|,SW" //'JR/F^OJ DG/J48.TW<Q=O!KBIL%4'<4'S-%U1 MO#',/N.2P#- ?!9#2>0Z/_GS'$D;W9&MZ=:6L_6\B=Q=V\1SC<.>,.-T5+5Z-? M*2B-&O+*+Q>SUQ>,@'5M/VXVNJU+/I9G BIV,%^<[M_ULU=$CCO,=VNX]%6T=;7/Q$PN5/BF*F^5?;"E=Y\KB6F5[OHU!+O/Q?Y;C M5KH@T_R3_&V&L?&_^+.*4|Y7X?+-V17P49S=U".F@H'&8[CH8IS]+,#6-(A[M74TM3R9Y7HU+%?+\X>&B%>O#MW#€\6R2@(3GJ_N6C08@U6'T',Q9'-5XW'C ME, *!PA"(0G:)S)&Y1.J1XW^NAH/&(KQ&!B_R2D!_'FW##7 !5[1)HO4.)'% M1>7;-\=]H/Y:GE@"!D1M,E62;#H8\QB:0 $@6I: X8\+2OTV6PZKU3^]M7 M*G\R)7[;7GH'Z$[^#I9ZQL+TU?NYGJ9K#|<4]^LFP#$"NS +K%#Z59?'Z3$ M("7NM1WG @$C(9 6$=A^:A6 MK5K\(G?\ "KUFF_$);Z97)€S^J'K'(KUG =6V@4KW>*BZ/(9N_36__P>UB#, MQ_\YJ@$829WGXW+N#/YU>9)1[U^%#T1&N2Q@/-FHB+0F@2T5*;&!/?QX[UD/5@(MY-)5AM_;>2YY/@<<;BCHGB+GUMK3SREQ;E+RUZ;T&&]JN3B>S1M7+,B^X[H& M1?,F Z5;W|S[ZEI8C+5X1T3&>(,B,O$L Q*D$30:BI%(G<3Z4&AS5[VS;+K! M6N*#S(1FHXOP/*IN$%)++& TEO#L&;;Y^LUF<\|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|_MD5AUCF;BBN4D)1>X &I5W?CNG4QM9V0-VI"0(^FN"L3K#UE?9TAM5Y$9M:EB MC9&=VGRR_WO)6/D8"PH1Z F28!Z68 (L{P8L3%[QZ70)NP$%*_2[A _&Z3. M$2D)@XSK/+T6|8W5(GE'4D@:,WP]\4)$8@ $6=4)5'T(;SSQY*:S V&, M2^9"RPQ;'- '}^2+.&RZ;I8_3ZN?*K^Y$].7\,HC]IOUL^X?,WZ$2,T$=9OAT>/* > M3(KVX+Z--MB>THE?C;H!5PPR&%5E/CO9Q/C@O[@*\|GRPQ5C&VU1[U6VR#;4 M5\]? ^8POC,#:8^XU9$T<06- G^)[>V<>6QL50%<@229 >P[@YABHP-IP M:G5TFJ;.!E2,E@#OGJ2OK4K@@3,%"Q2:UIB!KNFD]WI=CZ+.,?Z}|@%U!#\ M-.;? RL:RL*.BJT#S9T7XD">@58?$W": M1Y*HB-8SEZ3OM"N5066MP/3W-GBLJ SWY&R(R-)*'S(\L9/0O&WEOL75>*AO M=R7?Z#8M\5OK6&C=)R+:^'B;)X/\UE= XFTHKZ)#SJ%OSXW;=Z3L_[13 0" MT*IXHJ.5@:IE*$B>E)X;2)$$-LKS;&N8A.+,O|4<_1>'QRL_V\KZU0)^, &? M>);WTTYD7[23>8YY_#'?6I) [_]#!A<$"&)+XA$?9,=O9%[>)34]PHI0PMN-? M?4B$VS9TM$>++$S^M=U6"^TCV$2];4QW(8&6+M$I'JY^<:R*P#M4W7_WR|MW; MMU_]N9$_?:,1K5B*AH*4\|%^%)^PB13H&*"1R.0HM]T&J/>AD28COBU9UF@B M+7VL%@CIY-&:JV0:]-9>"96K]=8+]E>O345Q-<(]?LQWBM=]DCC-QZU9[Z!= M,>|+H0]A63:R)Y3OC- ++4V^]DL)W#;INX0FV1.!$#UA,.Q\4B^)OW M9[_<[E>ZKH]2%LFY!N8R SN'9R=.^(VZ/!7KK^&%7*TBS-+0RD.X9^T_++SKTO,^2]M=`I\- &4RKJSG]##= MWLB1=H/^VR" U\Z PVH.:#FEX.:IF2J45&G EO@15N(TZ$0D;.-)3L= M6.?\D-+FH_R^>[8ZSL@Z!>+H-%%GF),A"&,2H?% M_K&@3"(Z<%YYL-AV]\R$.XV? 3,_G(LB<^$1L0=-_!|3\DE!3&!-EL(P8:058 MZS81[Z,BG!4K&=7,Z(|>^1 ?\|/IG7K$^!,?Q;THU!SB;I_JG93*W00;,OE M37[$D3G3;(EE5]1N#W/N>M=%N.%RCFP!)B.+)- ,111XMF =!$,)V8D4Z:PJ_M]M-D]2%>Z2N+-,^C+1T]N]*=P.STN$)N@%#!PP=,/0^&,I2$IH&2+BFDBG M+7&E"+ 5 J>]<6#8TW86/^CDQ=*\,&@%#!R?U@*=? +)Z&DJUDTI+@#""LOE!P?M;@!&,W2UU[%:-M89*=D,5 MFV%^AS"_@5:'^1W*_ 9:'>9W*/,,,/5%S&^()-FWQ_Y-^N]EC;F>TZ&DW>"$ M&YQP3QY##"6(5S80[,3Q0M$01"> (]"'!-?^8IG&]F(\#^@?6 M'K15^_,#JJ376[_8<&@QX.6 ET^/EYDES8H(`;9$DF=)L%E2:C(F"I/"U5A M%X$T>\|+,5)FK\GP USVR<&_IV)^ W .P-EDR1M&M?*)F"PSD2: ,9RY(%G& M+&U@QI6=1,SL 3CW42-P0.Y!T1SP\HO R_U$QTBE4[9!DI"L!OR5E+A,,^&! M%F]$5B\U%>`1,?L!G_[4Z"PMT \E#$\,-?VS64,\!EY@*5$]ZH,';R@NUHP M6:1+E- X34.]!R/"DB0W1$I QC-NDG??^BH.K@13IY9!>PQU N,^L/*#+Y7) M!EQ[<5OZ0G&-4Y>L,I$HR2.1K"3BF&6$1RM]*;Z"]:95])MHKT->,R,0ZQTFA+$6NC+!R)X[U?93M>^E, M,.#:B]O2%XIK7L=2)3%$1[]!5ZH)U7&OK4L<.W5DYO?WJ:WLHK'*

7BF,|\V(Z'HF'>%I_GL9Y1IGE)|\W M7-R*M3>+|E@0^?C||/O9%+:GAM'|5G{(8?%N P&[DW1NI-U>$^4/O(#L@*(# MB@XH>@N*1L^T<- :1P#0@8M*"'])LDB9;)0KUVU,9=^'5[@Z)*C:@8NF;]1\CM M:YCP *A?$*"]8))/BA)&702UM###B*59P\C' *S3HF3OI_M(;0+4CY8;^|B\1 M3P>U]+DW_0M T96';,"'+ (;2U+\K@IFK#IZ%5]Y K\HR_T)31*YI\U]4)8Q M0IU!?ZZEQ 55B*",,Y&USU(^8;ONZ\XL=WA2;>5(,_&%)G@,RO* G@-Z/AEZ M,B^U^UC$(<=*]&:>.'X5B2:48#PO(3U=?,X^T%-P,3D*(CS,M%S<-WV9_N_M *?#-27WG5+,%T.42A2KX3 2E'D$X-#.I:S-5#UAX^Y],*!L)/?;">7 G2^' M@Z"#_OG\V_X%ZY]>Y]0V,!,X"]@%)&8!NVYS83;D&V6TNG0:5]8=&IIX]T+4#2@ZH.B HO>*/-8Q*T8C,3(#(EH.*!H2)SDF%T-T*]5. MK?9=- /'>+XH.;;Q?)HKVU6$]X.F7BJRXRR0ZJHG$FA8^"@O(&AVC0GI7 M.AG?NVCBO5|\'=IXOTP\';32 45?8J%BGR+CAAI2@A6(Q8)891710CB3M>^O?#'\CLD[=YH#X_#W? K7:2X.Y)~77+,-LWFU,,[P_S$G MZ@0^/ZZK/$TY5>_RZ2+CD4XEZ*CBE,L'E 6Y:@+W&-WNHQPDJPIBG. Q;HRZYPV M)R!@E8'-,#= WREQXJD'F1' >/-9YT9+W70-U_51 #\/4%;!E&?:,:Z|* *(" M>?2,:>G3| M,=M@ZM[2*,53*S-EA%)AD&8B<0+0QL3H31"6!<4OTTPHVC@ *"*4". D;"&. MVDR8#!I-6:)R(5 M ^W%2D6XR\X{]J55G=H8QH02I6-$F\@P(SP0GQDG"=!$]*09W-MW4'|]+G> M|++O15AB ;25DA,)%]NK.%-(<#81(6F23@:;G.!E-V+G>;R7DB>[Z\6X;,_ M+ZGADAIA?ET* (SD78_KO9IQ1ZLO5YLOJC|C'1S6'4] M[,OJ48MCOX [9E-4A=R\=T3&%>H#BI3KU(?F>7C!+WXZK?XVGRU/UQ<|'S&> M#^_HL7"U09V59W9]+ (SD78_KO9IQ1ZLO5YLOJC|C'1S6'4] M[,OJ48MCOX [9E-4A=R\=T3&%>H#BI3KU(?F>7C!+WXZK?XVGRU/UQ<|'S&> M#^_HL7"U09V59W9]+ MCOHMQ$L.UN9-<4:9V4@OU73S.:3G) MOY5'PL][&,=W$Z")KZH,>'.*J87SY3 MLRL[DLS.DV-77-% 3L,:"7Y+%]"G2DO0^6;M>0K(-\PIS W'+>=X;;G[68NH M4 .KER<- -###A\|79I/\|%-=?3-;>,_B:7VWPIK*Q_QP&=^Q/O.MNK@-TFOB< MJU&&[?TRD,,,XL.8|#?\7(R\6>P]+!9GW-ZW6XU"Y$NDW3M:EU MJN$,.ZZ5LK!4,[FP-O MJIE(:"9Z;UVV1=).NL?3N=GN-M=^8S8IR.I'[BHL8'PPQ[*WC4IV2^1[#550[UVUUD, BCX#=MO]3UQ0".E\& M,$SAHF[$U[5)8^S>A?Y?!F4/,+|- \78Z+17E)#IL\B2@FC@V1+X5#MA%3QNCX?\|SI#82.FV$BJ)RX)=##,,"C0 MC^*%[[=/9BZ?A'V9%#7 ZT4M.F;!HB&BF$2DP71#2C-1,>94O!+%==*%9/;. M,)=(" <5BB(0@P8#ZK245S%I>M M -4LH[$LDY@\|C5K05RTF00FO+5&&A$[=8(*3=%:@&%-,7^W8&^F$ATQ)E+M M% (V6IS$2_C[@*D;"T!$LW0"N^U5='U22^3+;'GP]YO>S\Z"DNQ#RS04.3H6OV:Q925842H8HAT'L-"F2,BJL)9M,EUPXD?4I2H M'R+ F!&U;L35PXKW7T=QF]/ PZ]>]'A1@PBA,R&<++DB=-9&HSDM,\WQS.7|@ROJ X5R;3-JG0KYME(/CP^E7P=<9\MZ,Z"G4]"' DAOM|"HH[K^#]Y5LJPO\Y6]Y(X)IL,^U5"=[,$-|SZ@M=|*_1O M$T3W!:4G/F]&|H$*TLIT L H2'D\QH|$UT8^\<7!MPB#"TU4BBE\T\9-M>D|"-M'07H.*MFI0=E&/J2NH!>",.<;K$OR3 E+E(X:-E@GXD+R) @3I9&RA-*M*&4T M\SH!%62--6X3)\'+1$0.O-!@,,?]X?O;8'Y#ZL$1\4CYP+K1QG60 0W/217"2,(5:>DY)D+#5/I84F>6&:,_776;7 M.VF?@Y%!%S[%ZC4?\^1LA/+&QP@"UT]CKCZ-%\>5KS[ZR2K8W6/H? HW:2#4+ M"P^'LHG!?I,QS\I3I(X^=#3G>5;G]6FNS;>ZYO.A$E'?@&QH1+1(5.Y!$(%F,!%W#:A!$G!-N.:,LX#F73EWFLZ0_3"NXV16@\CYK:'S(T_K M!C%^QQW-Z? M9O6AK+W\!EQZZ\0G^OK\M!Z76!@.S9[!Y3 Y%'U#D,$2+,T MU?;J53[^QM\?5;QNQ\.M+KL"=D;J0@3I+!5$>TS^-Q$,,@K;,B^24Y9E49(^ MAE1;Q6F30GE.C=LK_N/)Z61VEG.S(V^7\W@,5fR=^,F;,?KU_,L?&ADVFS>7 MO?GDYZFY!E64\>+L/?](D7,MWIP>IK$_!YL?%O./SVK/F".\;H&19L B,F8 M'A? KFDS(TY>2>BC5D97V@9F 1Y0^-/_P@;>!%*8/\>V#)RF'20Z3(.4DJY3* M=Y_4O2O _9 SL|[,">\|P=[$/R//+7,;W3;FM7V9-884?F\(*?PGS;.&T(1Y7 M@GSU

*MNZQP.J.U9J;3;.:&Z1(CKJ#?,T3NC)2,47>P"BS>MY^G4U)7B>XI56YZ\$1}T1R MZ_9\W8-AU0>2P;TRE@|3}CV%"GN7Q.673CH#@@P(\F4@R-7;ZY[_P+@(MKPKFM*CI0 M!8J9"D0J08F709&DE LJT5!LIQ^:R%[3PC1)'A1 &;DC/F5!2M'.2FJ4CF90 MZ[X8F'V6@$6^([I&=;W,.?!V/+58Y$<OP0L5C3%8J9W0I#C'B+2,@I"4G' KA&.OZJQ3Y[P0/F4I@CA-/!.9G 71 M2!E)VG .:$ZR,,.5C?O(M;.^1X Y/. [AI0/:#FA[!{2E+C@E%*:'X@IO)+%6 M&1)L?'>@ IL$'0U M)SZ73+RBD@O.F)7I8/%V+WG\ ]H..#N@[9>'MJ" -&B-+ (4&E3*22$355# ;!%_M"T"K4A2=Z GJ[;%X)?PB3D-EEWC.{A=(4&*9)-RDD_W+1)>L2$&RGN!KQ]H"L= M?OS$$=`B*!WNH3FSDNX>OG6FS+\"D#@/(^3[^)5 ME? PB5\6/Y1}'/UGF:E;J_[6>UO9P[SZ6W>?G"D5=,))@9BV1/%KB64D$"V8E MFIF2N:.(LQ1L++D053(HXEC-M4EE*867E!0ST3];?N[_6>W$FW8CFB]_@&WX M"7;AG[@)%V3'/^#7G-XMX(+ZM_+F!!X1_0^SR<3/ZV8XP+^ ZC /NBU@^&U% M98ZXO5:R[)U:*\"AJ!&2(Z1 >$L\KGI&A@J4#.>X(9D7($,6,@GH57~>)Z O MXWSNG';2@JJS2!D;&2=VCT9~=+Y073T:!2\A;0? M8:7"TP\(TI=&2,\IWJ4M I>@:YZLCE\$)@7>W?_!,L/1UY:?3)>BW M9\4.UCI*A,(CT>B2&DOJ'.GX,SD>IY2GKWI'ZEY ^*ZL4209^2%&@-C;[NI^"#IMPFI);1 @Q)(&!KLVI$M1D M S#042@?K&L_A#IM:9VZ]F%O45$>Y66<_29U7GZ/#)CGG-UEOW\O.K!A,4 M;!&RTD3[X2WI]T)X"AF M0RS5H@G,#"X<+ASQD3!/X*?0!1KUWEL "B-8?<61:$"-D5H4X@Q"4G'2*R- MI?XQU-0+N^\V=RGO%?51&{1R\525(!Y3\&,8P+[&F002OIZX).(G32 MGA[L"'FA<@M5[*Z*K:/S3NEI_'"]R1 M #R$TT(?M==)1J*%!_,^8XT7 TJ4<-PDZEBPL>,2N \9'IX.+D94B)&V/?4* M]%X/IQSHP "P6:L*4 >+tQ+-<0$$35B5E2A*=|Q<=>9 T8^J'#B'+#BS!=U1FH,#H[*"'|UH/%|2 A8[!0S3>&R$S9~%$!8SC&*2&DGZN#!NS{HX0=V M#+1[3|85UG#-P' +0#\N@_9D4B^%6T!N,/"2[X3AEJ1#],'B"9,D4bD(P;<,) MUYQY#F*PA'*X8HM)-7*#'THT)3+1GGI"MX_,5$)HX91HRT{AJ"'V,=-P(/ MKH3 %2DL4ZRX8HDKPA%KLC!%%6F$[V70>E@\A>7.>T8EX=SB07DTQ.D422Y% M,Q\ILENWVG;TWDB $!3}14()B- 7HS: (M2^(,M0G$GW&RXW(4@17/"B=]W-T@0&8LQ9><,Y5T.HR7U#37IXONNI MXR9J29+$$[D"X.<0_$IR)@GKHV$=)5T$HT,"H6@&* ,G0H2LBD M+=U=)YWK$54[U]+V&F_C$2Y;K&^_4'?! M^'0;L :'=[+_AW9;O9E7@';,P1W5)4"\X- _!"7HB4-A*OM" :C+SB MM4Z>=_)02@*%WPH!V]8&,X}:L)HS:#J9@]:?M:;T"S^]8_1(]$D2;LJ[&DW] MTW@R:61A!53P)!(P>R=+T9%D'T "}E" ?7:)F=+*S>@^(,U!^ O@#; M6IT1^&2"RGU.2%\75'N$PW&J4?'ABG#67":;>F[&DUS!JOV!%/S?@$SX?\9 M \4NFE*RS>./9Y,$;YOGQ7(^K;IYZOV[WI_Z\IFS8Z7:E?GLI&K7KEDZ"4P/ M3X>/IKD2]./RGC=#C!%)X:]?_]YY)O9RX4=QA!B%*119 UD6,P?:4G3C6.D& ML\03N# 6I&)&Z\["5;8T+7CIE?/S-BG6(PGV=4.DH.5FD;COM6.X M=8IG04#B <4HJHD7/A(:;&#&\|-5)_);92f%M:!"%>F)%#*3((H@PFF3G X^_M>790M-,G1\ %XE&TU\0C@$8\TD!R@8+FY"6HU@+^M%H+R@5S5Y5]:B.BSY!$ M03'>H 1B)2!6"A%H#DBHE,,"'G9#L]?G11{3;^AAQL*.&4>TL][B+V M5+-Y=0R+D.=|HR,=I"TA2B(__4G8YD!]$L6D&N: 8W1;L1 #M$KR3A1&!H% MQ"9P(+)@3.@06H#Y_2@Z$CTBXY._?QR?+DJ{OU"T7K4>L:HWY &85EB$\ MG8%VCU957GS*>7]-:557/H#;/G@R]^WJE/WW9+Z(_,JI9$)8Q*_@R+ 35P MQXF07(CHN%2Y$[K2YRZ@O?!HC7]H"%I?FR.,ZOQR4E.8YCXY*Q:GJZ\3^=D M^[HZGGW*L(BCYHOE-.7YY R=32O/%=!RG)V5.NC$A\)AB6AY &9AW-%%-UJ(\44S$4<8V' M35H?O(\Z\8Y/Y3YD>("A.LR-N.V3.#^D>'KAM79&H[,6.XL:ATE@H#F*;)+V M*MJ4NNIED)H#NJEQ8+|}2.CN6 DI2RD]TE$>UA%^*ZK4V$51C@1SC)HWB{F MXCE,.#+%5 Q9>-|Y-Z'425A(B^Y+K$\H0<((+XDPH>0$HE=&G]B!* MS2RI",R)6,4M0C2O2&9X8B5EB!3DNB=4)5?HT(E2=PI;O M2S/$T|\60!S!4LU8Z4,*;M#U%HGS@I*L3=9%:X!M.L33/W4\O02\%AX+PS$\ MRS5,$U>|1P^'#R+*%/CS9#5\:?TQD?'18'E%PYT-PFHZ5CB|*?Q*1:,L'V> MQ(8VGK[JR58\9L0(360-&13.. MR<&")QM."]}3|<&@KJ-2)GN OBYCL:#@HZ@*.FD:#2_QL.(P=!_)IU5#[Y= M=]6'O1-$VWQZAS95C-\VAR?L5/7@D- ,WS>G&NWRZR$VX[BH(5CY?$.QH=83R MR=>W>;YO?OO[M[V?UXM?9XQ_+,)(X^S"%)4OG3VIONJRP7'15Q_MA@Q%Z&R*(NC7I[XCW]?<, M7#W!?42TCNB2C%Z]80GAMDFU,]!5&DK"L4H@K2N=*2*H'XYZPQ11H%4\<(2 M#[^2I(6&9QG%64>J'#Q1F2/9IZ(" %U.VYO5: ^)22,;\=QXLW15_HR_YZ]) MML^8O] JSTB56[EB>!Q.%NN),\%P1 M]Z>G\|EG6$@\!7\D!UR7X"I8*IC+V;*@7J+(2':0*SV2D0NG>U&QWM)N2I> MDV(04*7SQ- J,9S(F:0;&/)4=+^^3T7%KG_TTFZ\^PNNN3H'%5(9GD=<5/[(; MX;SKA)^'C^IV7?VA1,6934(H2ICS$2M8%1*2=B19EE2Q+J74#9M/*T"O=P(MK%%#+04- W2=@29FM=KP8I2FRJB43%3MRMNH=435YWA>Q&\@.92?QRI]:=4;&N MWA=OL3>R ?TP@0X0$F6$Y60I+\S2&';27CD>Y[2WB_B-;IZW M%BK:I_@5WC"M9Y-Q:G2 &@- !&M\A2ND9"SF036&B.49)N.6ZL-LENH*[DFC MS6?S_#%/E[GZTW]8SMAK^'PR\6&VN1L >15Q!CST>Y.H!\/]4]!:IA|&U8<\ MA9=- F@]|@OF.Z\6\S0)[;9BJS90VWU']^M<41Z[;.35?G]8:L MMA#WZI5?+F;KAM:X*3 "-('QB646EEUE9BZ0B#: MT]TTN4?G;IY?EH7W\DK\Z3^8IJ^W]9MO%^D>$W[:"5XEZG<|/: +_+9QSU 6H_S2)TN]D:65VN]HP^?U=-J'47P-PFZ7!IVGP]00\ OX2E =&G[B!* MS2RI",R)6,4M0C2O2&9X8B5EB!3DNB=4)5?HT(E2=PI;O M2S/$T|\60!S!4LU8Z4,*;M#U%HGS@I*L3=9%:X!M.L33/W4\O02\%AX+PS$\ MRS5,$U>|1P^'#R+*%/CS9#5\:?TQD?'18'E%PYT-PFHZ5CB|*?Q*1:,L'V> MQ(8VGK[JR58\9L0(360-&13.. MR<&")QM."]}3|<&@KJ-2)GN OBYCL:#@HZ@*.FD:#2_QL.(P=!_)IU5#[Y= M=]6'O1-$VWQZAS95C-\VAR?L5/7@D- ,WS>G&NWRZR$VX[BH(5CY?$.QH=83R MR=>W>;YO?OO[M[V?UXM?9XQ_+,)(X^S"%)4OG3VIONJRP7'15Q_MA@Q%Z&R*(NC7I[XCW]?<, M7#W!?42TCNB2C%Z]80GAMDFU,]!5&DK"L4H@K2N=*2*H'XYZPQ11H%4\<(2 M#[^2I(6&9QG%64>J'#Q1F2/9IZ(" %U.VYO5: ^)22,;\=QXLW15_HR_YZ]) MML^8O] JSTB56[EB>!Q.%NN),\%P1 M]Z>G\|EG6$@\!7\D!UR7X"I8*IC+V;*@7J+(2':0*SV2D0NG>U&QWM)N2I> MDV(04*7SQ- J,9S(F:0;&/)4=+^^3T7%KG_TTFZ\^PNNN3H'%5(9GD=<5/[(; MX;SKA)^'C^IV7?VA1,6934(H2ICS$2M8%1*2=B19EE2Q+J74#9M/*T"O=P(MK%%#+04- W2=@29FM=KP8I2FRJB43%3MRMNH=435YWA>Q&\@.92?QRI]:=4;&N MWA=OL3>R ?TP@0X0$F6$Y60I+\S2&';27CD>Y[2WB_B-;IZW M%BK:I_@5WC"M9Y-Q:G2 &@- !&M\A2ND9"SF036&B.49)N.6ZL-LENH*[DFC MS6?S_#%/E[GZTW]8SMAK^'PR\6&VN1L >15Q!CST>Y.H!\/]4]!:IA|&U8<\ MA9=- F@]|@OF.Z\6\S0)[;9BJS90VWU']^M<41Z[;.35?G]8:L MMA#WZI5?+F;KAM:X*3 "-('QB646EEUE9BZ0B#: MT]TTN4?G;IY?EH7W\DK\Z3^8IJ^W]9MO%^D>$W[:"5XEZG<|/: +_+9QSU 6H_S2)TN]D:65VN]HP^?U=-J'47P-PFZ7!IVGP]00\ OX2E =&G[B!* MS2RI",R)6,4M0C2O2&9X8B5EB!3DNB=4)5?HT(E2=PI;O M2S/$T|\60!S!4LU8Z4,*;M#U%HGS@I*L3=9%:X!M.L33/W4\O02\%AX+PS$\ MRS5,$U>|1P^'#R+*%/CS9#5\:?TQD?'18'E%PYT-PFHZ5CB|*?Q*1:,L'V> MQ(8VGK[JR58\9L0(360-&13.. MR<&")QM."]}3|<&@KJ-2)GN OBYCL:#@HZ@*.FD:#2_QL.(P=!_)IU5#[Y= M=]6'O1-$VWQZAS95C-\VAR?L5/7@D- ,WS>G&NWRZR$VX[BH(5CY?$.QH=83R MR=>W>;YO?OO[M[V?UXM?9XQ_+,)(X^S"%)4OG3VIONJRP7'15Q_MA@Q%Z&R*(NC7I[XCW]?<, M7#W!?42TCNB2C%Z]80GAMDFU,]!5&DK"L4H@K2N=*2*H'XYZPQ11H%4\<(2 M#[^2I(6&9QG%64>J'#Q1F2/9IZ(" %U.VYO5: ^)22,;\=QXLW15_HR_YZ]) MML^8O] JSTB56[EB>!Q.%NN),\%P1 M]Z>G\|EG6$@\!7\D!UR7X"I8*IC+V;*@7J+(2':0*SV2D0NG>U&QWM)N2I> MDV(04*7SQ- J,9S(F:0;&/)4=+^^3T7%KG_TTFZ\^PNNN3H'%5(9GD=<5/[(; MX;SKA)^'C^IV7?VA1,6934(H2ICS$2M8%1*2=B19EE2Q+J74#9M/*T"O=P(MK%%#+04- W2=@29FM=KP8I2FRJB43%3MRMNH=435YWA>Q&\@.92?QRI]:=4;&N MWA=OL3>R ?TP@0X0$F6$Y60I+\S2&';27CD>Y[2WB_B-;IZW M%BK:I_@5WC"M9Y-Q:G2 &@- !&M\A2ND9"SF036&B.49)N.6ZL-LENH*[DFC MS6?S_#%/E[GZTW]8SMAK^'PR\6&VN1L >15Q!CST>Y.H!\/]4]!:IA|&U8<\ MA9=- F@]|@OF.Z\6\S0)[;9BJS90VWU'\^M<41Z[;.35?G]8:L MMA#WZI5?+F;KAM:X*3 "-(^

*<8P8OWFRQAF2QR4@:-M1E1(II,P7(!V^7&;VRO.D1F'L1";ZV:!7E5S9&:@2FJ01 -OK?!]!@WPHS'">/L*K,[!BQ ?P] M/\^KI]OKX!Q^/!M?!M,RA\V:PC[*B0GR5?*

^O_U0&\"E,)#V6&CFS\,7VC+*C M)UQ%G]6W6F],Z<@QK11A"4@)+!PB(IHID491IGFHJN$ZWT^:\JJSMRXSJ9188 M>[_"M?FDEG](<1>R6BHC9K*

65UD%5Y<3>UHR"]9/5DELZ%ZV?.TXPYV?4/] MLJ%^V0NH7 ,;X#+N\KZ2RFN3?R5ENC)V\>O]!*&S",LE \S)@LW-!B3"9)%!`MTB6QSA+'M^AL6%5=O"PFA2/S"LN?*

5G;6'>/27YM?COM%^%$BUV_\::TQ<5N M)T%/*<>3) DMWS%-OTY-CU-FLBS)"<MCA:4]+,FH5L3s7!G*)\,9 MVZ&:W@78B9Z7)?OQG_3RO;48V& P'&X^ZU#K^7;*OI-*

Q%O.,I)&CA%L6FC M2Z@00C*6&*/7VN4^5-'O4@G>U&"U)4T_'@HY/T14[RA[,>]&=<9=:,*,$I=D M0+U&<2(-Y42 ?:L2G9E$Q(\BJL?%Y)1@-/IJ 3G(1.U8Y$-V^$%FAV]H79 J*

MKE.015*E">$NI"23-B34*AY5F5G.']2ZX%IQ]K&8Z*U*-)KNN.'HGF9O[[F% MVB^5L-$LN1F-^YD4\2%78#BD_=HOV38$:%Y](@,8PJM,P3 D#?16T6!L1P2DC M0ILHXPGGL7U0*

8AK!=W6ORT.2=^:$YIY3MT8#WQY!PG,'$(JT9W",H>PX+T*:MRCR_>XL_]H>ES!@*^4]II!U\:],IX5L^75;L5$"YX.3]49QDEN/K^!TVY M26AF2:JCB/ XE$0:$Y(X8<8Z"G^Y-1?*

_7>Y_^*N"+2L=UYSTI64DKSB> !LM MZ8+HE'UEYB6RU?;8F1\M>F6L7H5[B32\5W& Y .IKGY&N!ME4$60!@^>I:R*

M8&>>!PFBP60B(PFS"19,B8G(I";,)5R'D4TE=;NY>;XB8]J+Z%^ &S_;4J_Z MW;?STG:>"<+ZK@E^@V34C=FSQJK&?R-26G?4-DF,ZEI>OW-A^7]Z,?\RK6>XNV[?[M,Y!]}LO9:*

[\+! >O7BG@@W$^L6O[M5A#=!1%T8];W<#TUAO8O+RG-/QA[13F M,7[=KCV?X *(WX)K5KUTD:-W#[]!OOKCRH@/6F'VX"N^ZS=D@ARO\^KQW%B\ MA1X4LS-

;UK]]OEB'3B,6U062343'W&3]&DH.?9EX]HS"U_N;J!^A5]/_>`M[OQ=ZT,D/?:<2&\EH23P12?HZZ >0]_2H=2ZG,./IOL42;^NAU 39_M$,U9N MMT"15Y];QGJW5+ MNA(<%*

[;T2_4/K]YL!0?>,KB ^'BOUV^_MD4(GA.H9\#7]Y0AF H0S"$TO;0 M65H[_(%H@L+=FO@&_^BS=!$-5VMNEXNL,Y?0,"%IK#CABH8DHV!WI%;SA(4V MB>-PU3B)HRQ-

LP1L&:8UX5PZ(K.0$1723,8V<39.[MFCI^/03^Y]CEY1[!BW MK4RN]."\I4/([6G:6,>#X'@QW#+(BZ4VUG'"=$ACDAIG"<^T)=(H1VP<&D9=

M8KA2CR@O/L);3B\]>OJ%5YY%MJV>]/'0RGHP.+8C*I)!+P8;AE$15]4B-"E MW,6*),9%A(>Q)AD'R6&9#:DQF:\A6O7 -8H*M^1.+H!0NR#A!B,B86$2 <) M\6*X99 0?*

0FA3&0CY3*B;)R A$@B(I(X(TXXKD(IK92/Z7SR$N*LM-OJ%#W(MB,&*V)*,$(,,>#'<,LB()2O"9$Y(ITC$1(J94)K(4(=$)HQ&D8LCH]>RIW8L M(IX7\VW%)

81,9@16RES!IJ^8C"YA@9>LL2YW'+F0S5NNY>KA\QU4\\)HI,<,+&N M08 =A-(W6#I+U;)X&MDXXR36AA$>PQ^9D0D)!1.$%)KS;*U:U@Z%S[;D39(,

M)LV@XCR<:3Y,5FKE#H]0BL'0&2^=&NNE:6^Q4>#&+I1^F'--7&1C G7/"8BY(9* M-&$<_J,_#$:^]=26 MU >)-U0F'BH3,T-<;6ZD-%]2B'L#V0(G<\.>

MK$30KFH=7+'T*PMETAA_>M_B M)UNT+E)B\M)[^L.K_'SR>]FRRU0:]*LI^OD]3H:K:#^X,K*)W9BKNB8 MUKN\WY'H]UO2X1V+66SQEO3#SC=:OGFT*&2")W?6*5K-

]N2,KYP3%TN8OD7 ML*_UQ_Z@:VW+!Q%?R?&%O*R:0@C],V]/T7,$/[$>%:R=YG8/!;ER8(^5O#<G]M,U[;X4S&$3S6C_'=L\3N MB[O47\617^6@'>=ZXP&*

<[^UE=R>6>IN\8&$ PREX"R:[_\S'EP$+*1_Y M6D5-*9K HX@O>C0K_"\^3*HYL&7P=3Z=PA/!ZZ7U!;,"Z;RLYA)^@"_"?/59 M<'P^/9/(U@:,8>Y ZL!+BP5K2E\OJ<(1L#Q2,W+

[2@WR7<(_HFCU064"A< M.!?G"G6567 VAP%A2O5,<#RL& 8_'KO2_OFG/ I^_?G<52L.^T'N&[RH]Y< M$0+F@!M>8*EOZYE "!C6!=\L.,[$5+2K)Q[PO>?R@D@ZAAY19]A-2?=

M@P%)95-D+)"!EEB("8C"V9H(6[9PEHUS4F),>EIZ.T]>KW*S7% ,$BQ+ ^&G$.QAXC>O5*BVVN M#/Z0TG17*!ZWI(M[D1/KG',/O4!:0H^B4#QNE;/D*(W3QWWE4<0?

>XUQMLLU M/OJ;< .*Z=E<5-TN&^F9#?;-'K&\V\.WCW"[_-XT2=E:U3KH^0&WGV$RIX# M*QT&*]WKK+(WK57VWM]!-A 8RW_PP$>N24VGM,*)+7VHF=>-F'PY[2/MYR4?Z

M#/GXZBP=FLHDXMB""*PPCO(YGB!34D93&QFCTHHNUN]]W[N+5Z2VMVH):R]NY M_3"YMKC@N]^^= D]R5+ *3GQ#P@X].KRV7<.-B">N+KAY2)PQX4>)R/K_Q9ON

MG"Z6G1QA?ZU%(Z-B>;TSKV'#X,,!|:>ND,=QVF6\9385 >H)[$B BB5R\'#P MVAG!LRQ["&BW,=`68?>)P>)\2,N#]E>+:S.#6RHL?'ZI'Y$1O@>M WAR,]?.A*

M0ZZ,2!RQUF#YAS@F6N4GH8 MA#, 9!\@79)Q$3)+@##$$X8)F1% A2"2TX5(KP?5:P&<)8!"J251FAIHM=602ME;9:XNJW;:1BP[(-?@0 MGZJV&$0SH"/?

7S,9&82QU.2.@/X:$5&E-5X*I]$W(DP=>L7HK>HV6&!P]G9 MH-KM#Y[/MW!'>F!0I>-%1-:\323!,,JAS)4L8)3OES]H'%0F(7N047]#:K=U MZ!ITN\%KMRW=+GN9A#,

Y)+MF]I(IA% 7 0XQU.NB0K3A%B1*NG _'61W:5N ME[M!M=LG,A]4NX,[T@-%+AUGQF9@AKHT2PA764B$MI*P)-/P"A]f5.Q2M=LR M<@V:W>"UVY)F%X4ODW &?

%SJQJXBI]}4DC +L20A=R0#,9,PFL6%. MA8+O3*VSWV!JVX1',<#CH-@-1_H2@"L5FNO0A23BL2"<*0Z8!>;I-HQ;9UED MV8/N?

MUX@6+;V14.=W4'ClV65#OV,@EG0,BE6&SBJ.."I2ISV'A$2)+)3&*G M1Y';D"]HKE4,WI9]]PY7,&AV>T3D@V9W<$=ZH+B59@ES3!EB0QL#!@E*E +P M"H5)J4Z2S+@'Y0?!H-

EM';H&Q6[PV6U+L8M<)N$, +D4TY LL2]B4Z5)CRQ M >]!R @#1K&Q0!%FFZ:X4NX_YQ Z*W3X1^:#8'=R1'BANQ=3%.G81432F:) - M(IA2A'(J;1RR,-

%KC9NW66,O'QQV^Z37#0Z[A5YW]]X-MR:KC (\O%AZ3V"DK !XC$<6$8S-$&=&8"!O**{]$3=3#8R+7U&9Y M;C'C@T+(P?WX((XZ*69RO$/]8D<,R'X(/.BH S0.T'@+

M:)0NBV,1.L"::N-.BI/(U(+ R G.%@<V.\HNW%+!)]KF;Z!)&QKYO"S]B4 M>B^5P\[5,DGMV+/]]TW]+6J/20AP^,?FWNB6Y'LL*2! F=TI[\W%K#0E>CAS=FRQAZ;? MX-267;M$DU?

3L;Q\Y<;V>W/<-,_F /QN\MV7OXI]D)K)<_&'M%.8O?MVN/I_@ HC?A&M6O=14 MI=?YO6N&_N/*B.T*!3NG3UDF(]4N."%\S.;&F#O HD@!JL*<@G^%D@O\E! M+,M^[4'AX,-

J#HL-+O+96?#^[7$ %%86WZR!W^CQO,+EJL+D\%XY 1",3Z?C M2X A^/>DF 7*M'@V-@_)Y!5H.=E"9.]CO4ZL!>T?^O6^*<]B%2WC/>(Q# MSTN8F6Z;6SIK<3+'_]B\B2G@'(?

U[N_VF:_C(OATE&2T"C%DC\QD38"4<6L MRZSCAFZADT%0]T+](58"F^02FDNQ@N9>RVGFY-'Z_K/6T@OFRYZ MX0X%V;U7"W9E-9<3.+.B!@^00@8E45M3X,Y9(*

(6[GL=OG'''JQ_GY[,.=9=9&=DD5)3P#,L7LI@3I2QP;A)K MKB,CDVBM?&$H0^Q^IPG\I0@7240DNDVC5,!PU"94QDNL^DLQ.3V!I,=6]Z/+)

M]3M<;QTN@F4NLZ[!3\@YO/D,AR)&7I)+*TMB)T]RM,%;]^VY@K.(Z"A8"M N M,>Q3\AI@P1RX?NP)1X, &5L/RPW)S=!=%Y1=U_$6-_"K58$@\L (,Q!?(QAK

M:*0*4VT>\HAY6/1'}SBX*SS+[1ZBXHU4PGP)M4A9X)f\-IWT=7!!4PM25I(.19#D1=(RL0(&A,"R(.VAWPOS!*3GIZ M%5+P\?D4SA2472!L?1:

<2:#5"9[AN"9PT(UA'>5EQP+(3-[_]RW94"E=E@"CK$Y1$(FFY' MEC7+<[E8F+U>)OF3@LT,<#.]DZH/9>6\X(P6VXJK+..P9CFO_++\0%$8)K? M89CX+5%(6XS'N>&E/YR

8"S@:.8=7E*@3X\M,*2^]1B6'[-AL,[;J&>Q(I>U$P@]J4:NH M?'SPD9N#XB_/BWDS-?C7?#*5N;D*MZO S&&# MOWF=<84M&E)++P@#=-A,#&XK;W\]/.@=F!\(T2ES\%)#

[K+\11_N@/DX/6&WL MX]+4RQ+T;@&QE/9;;H&@6^6O.[0QB"7B3W2&"R:JR^#__S,2V4AKA3^MR MWG"(;U^,"Q^>U13 !BG8V"4DA0.YEK-D'\G=D8

TL.YGVA$."QN.W1S=NI MM84+Tl9(BC" @-E-U/@=$ZRR8"FBPJJ$0OW8Z@9VK?QS4++=.VK#FIZ/ ?WV@ M\G(':>WIY01NMZS!*=9R4]DALP0#NH\TVI&

(13(U=DJW7K_(B$@[%QN\$ 6 M.=Z=$@X4?A:Z*$N8CK2R=XR1_?:UI7UKK;%K8F1/ #'P[3%N+5+,.0&>++W&R3 M:ZBL9,*/H"??#:-AV.EQW("RE!U9BW@ MH'QB*/QJI/&:[

1!&;<\\R*8E_R.)O^2FIIV@\,J0/.$P_4Z2Y_\E]QD M-^G,RP:,!!/O$K6'9>UF8?ZM*C:U55>T;_=ZBYPLK6UV!fWD0M867:/(>\JN MIX*?M4I24"M)/G304GV]MVC)N+

(XKPV'*YPQ%YV5VEUM]D;+LK5$1_VX:_-5_ML_=?13T-@:([=.X7[L,4RWOL-36UM,S9I6G,3\]Z,_1O]K&)!,L=!,W77\61 M7^4S>*G>R 5_LV>YAO/I!=

[=IP,=;RBS*Z,\3{4W3[@;;^>E=[H 35>^9W47 M+0$&82$5RR#A4T \U(!MC9Z9"K\Z]OPN.V/)L\D[_.]TS.$W[\<@<8-? 6%. MZR\ E]5&BW=6 2:!F>Y_T43]OGD.1\\J3-,+;

<2^D0\7EO[?B#TS^1WYM/%0 M?/?@!&,]5/?;>@1/""">S. Y)*/."$\$448EA$4FI5PGDHNUL$ <:2S'P$@8 M*@-V"7-$2!N1A*,"F3@$;3!9U?T^@;4K$0<|CfWI/D4E:$OJ7WA$]U#

[JXFH M9C];KW<5+;(0L[>1]?EVU8FF#DEC-X*_.4"[f'84OO%38_N0<.A\KU'[" V]0 M&_YOO\U+1+9T!9F^6%SW$Y08H?&3KNG"@I&7>86$$'P\\(_%-(=($'SX$O_SR MIE.VFG$;-

RIH744Y+C><+Y.^A 8_F'#?X&[=@-@K>P.[!$)-B$M%-:S;@#14^'> 1K-0LHD-X2] M&#TG"COP1HQH8;6B+DUELI8]9U;.L1@L7HG9"!P,6Y+A#646IR[A3&F7R'L"

MVAWR$(J1S*-] C)E3[W.'+RW]IQC= 1MOMK=""%9!-5?_ .,/"6;?B$#"B856 M4Q)'D25<:I1]U1 LMD92+71$UZIDW(4(?,!PF0*]X\ED+L>MCOYA\]6.>[^-1 M!:C_MA-

TA/5)A/WPG_M$ #_"4>,..K,)MQ)%>FH!S$R"\! M'9I=-K;8^3EZWG <|!77L96)@76844=2#GLMN'C^\O5-RR/2+W

MSFWW=%/PXCD_5R"+:V/$:P!^\X/W&S\\GKY<2 M?:?H$IJ<]NXLYO5DFVM^]0=79L+:B7D]+2KO4'I5VK%$G^9K57S'+8$Q7W5) MY\]OF5G^$#5[<9_A\0\Q2I9.<9'-

AR=WUMV<;&;?!'C(1.)7=20R+ X5YUG*I.|\]_SP=!YR M!Y)K7CZI5Q #]_^QVG:@[M[E#>Z]["N&R6$;&.:]#QN]<(XHF&,$9B&GBPDRLWV>[M"V%X8^RXBP7|%?

0AM+W>=":]F@AW4=:P.P^9=1/;|KT)2<]&-C5UE-5P96 M'YZHJQ(:)S3-B,!F,CQC*G>8#I8H#C?^;CRS:Z+I9N>>Q'.\N1>9HWWA%K,;B,K82A]P]. MP 3:ENCH[_/^

CPPMOQ$SZ!KEH6OOY5EF-007W$U1.I_YR^_KF.X$XFM2VS MB-W^C?Q7$4@-TKY6:FLOQMHPF#N(,ZB0H-K9P!::&TRB,8A/%.W?P,C$2V>:,T4_IX/V?^<0V M]-

YWO2V%+O>-#F0LK:,@:H9X,X0S&QO\U@B1H&@F<* V76]Q<1*D^WBY% M9.%.%5X>)8<59[Q-BK;W&7LXQL2"^CY(T&073.8.3]I.4:AL^0VC>KTT W_) MV.-

Y7O6^#04I+B9XW;fU[SJX;JZ#+K\'?O)Y>UB)0= MWC*X[>R:S/4ZZ)5W^]_!{*?:0WO6N$PS2CF1"69?*V&(C%1.E$MI8A!E8K6* M+TK%Rf!?WCB!U=EI2$086F),;

!B;"K#:%V7]9?-JME#9 OEHRC=P=WF^\L6 MO-Q<1VU>).Y\F-1/6;1WE>=_,&OUL#YFU[K/^V&C^OAY/@8:?)OP0GP3;RAFPWKVKF>'L*U+1NR=F[W7

ML.@;1UN.ZH/E&CD3.[!E\79QK 11U#"BTSBT8<2NF+LK[K]9. '6399^<6\ ]"L?G[5.Y>V9J,OV;B2%X, +JO-? MFAP47 &FI(!9ZF_4C^5E,9_!I+Y;\

[JKM'<4_M@^H/'UT[^]D"R%/5]RE?M&)N*E?O7)LE1RM,?^WDSS3;5B3-_N>99>I0R>L]' M[_D8.\K"Y'%?>7B+O*$>OKBV:]-5"F7&OF'7NGY8-<'=("]:,]M6N]4Y.1

M=N97[(!8TN8+,_RHF8*58S-';[,WYJ2;M-Y8Q_V;V"?@7VVQ#YKI24&[GFN MW6?>GU^7]Q6-2Y)_)V>]Y;7,RZOWOL78)8RXD,4_!FC4R(R)*4EMR-,,,!Y

M?/5PU@:1428C,)5($AD8),Y23&_-2)HF-,QL!';TV6)K@,Z.;EP&7N?'^EP8 MBL60ZJR|\7KE7YNG@;M.^%$BUV_P"0W%GT_PMKDZ^GVFY;0]RD^]*Y9M'/ ML1?(,DG=6.EJ;

KR4%>PRV(="]9@@I83#EA$I%(A>N2$=)&@D7M0_^2KL]Z^ MX-H^N=\J>XR0L]'W&RWY?J., IG1*(DVAQ&&%B$#8 Z .0#FPP"312K2,;_= M99CJR5)*9)(E1 I-

E8E3$XNUV*M2O@:.)"5%8CBA38C22A/EHE0G4C*6W) F MO!O Y*$#"V5MF$0#3]-P2E5Z?2,?@#EHQO"USR0-$';P'M^3]N?J?:?P

MKK\HHS2)8Y*Y##0ZRD,B7>I(GAE;612$8D;77_;:":Q4GN48N-XQU,B>(07 MW9,XB7B<YO7?\L<'0]V'"%_78J/N:R~NO>]"MC(C!T*"8 M^YMJ2X3&!$X'2,*4I#I>NV#P<(?

=+RU6O*FA8DL&*!OQ:'-U>=*[X,K;H"P M_<*N23\7*:,\XB26#EOH\8QDW$@BF>2OELKRQ&S?A;8C"*,CSC9?H'FN]#ZD M"VS?9C JX2:FEF1296 SF(Q(PQ5ARH

8#K450MYH,ZC412'>]8@G7.B9* M6NRI8Q7153HCPD6R&KG_8M5;#(.3NR_0WIVH]&UCH2I#IAF2U0Y*/UH8F+=0E M8:P9O0QsH^-!3&B*S=?B2(,I@[J?WR

?/Q83O5T1R48T>=2X_-7)>8?:, _-*.M#BCY7%9MAP]6+AX_CQ[&3%YX4,SF^#3D>TG[M MEWP;LLY>:M99&L4.9%I(M!4A-I%)B8HR2ES"HSB)0IF;M:)A6S0)MF4(!%&<

M;>ZH.R2<#< Z .L K(!)K(FRU.HH(X+A_0>1'1$\8P"2,K;.&F4ROD,K8DO M&H!B/N#]:A)YV_#$8R;R;NN"Z)[F\3ZGY=TGZ?$0KO[>*>7Q92QX(;,#/=L# M6_!>9>_"5CV]+GVGS?

V[WR:LE@Y+B=2=8>/B\]3+.!J[3W4SX)L-;,-.2EOIP< MEV>9RK6A&B--56)3L'RJ@CGAA,E(TZ$<#P%>T@:M!95Z>%.I9;WCFO6^M>R

MEO\E5G2D5Y9T1$;,'H.G1XM",=79QRH>N^I>L"NEW#*5V,7TRH-J;$DS00C MW#! L=2&)+4T#DT6A3I9PZZ'^VWV KLB++)4]8-=^9IT>@*YK\DK[OI]8&W;0

M;%\ 'SU+Z;"SP_"-- @8#M(AY GAF.2"<&5_(620'NTZV^C)87!CCY&#Y(!YP;X .*WX)I5+Y5]];4.Z9I2_+@RXH-6F-V31!97W*ZHA1OXHA38Y*D(MOMFS7(^Q(5GA7*YA<-

ETW[FZ7:GOQ%,WWBZQ(8@>STW=[[#PG=N;-S0M3V%" M!OOI[!NXI.R_7N5'\N)MD%U9N'+B^8ML)WMGWM!OK[_RB%2,'M.%+QR2=:W MBZ?T=##

<5,"6P7TZE%]7<^P27+>:.K@FZ)L[VB7:LW&Z!4O^RTC:H3\%7"Y_K MMN.'36V(XH11)PPGJ0K!=,,Z&8II3F0<24%=]IBQV(:H0-KLQ/#6>W?9B1ZU M_4QV1 5fY!8[PPJ'%>

[7"H<>27N2NO6LUM?E;B5#DY?5]VEGI;6!;R-._85>,"@0>+L#P<-$N>P^660.$->\Z/E-.]&1751]7K;#NG.

MFQ?]/+.=AN+KMZLD!1,7)5E*HDB&A';JB1(BAC]BE2@:4BK7RB9JQIF3,B5_.MI!GA*F%$6F>)C$/.(D:IX.,Z?+!WP'Q;JG62TNS@\OE>8"+K@&,#CCT$QR0W M

H$')H@5]8QS1$81X!@5(K)1+&3F5G&,*6UD#%QQL6 8PH@C E%9!*:+(N% M$*E]-!SCC TX|OP)>]"Q <<>5(N#C.&V8E.QEB S@AG;4)E3?

AMRAG^B+#%XJ%OUT,\C4.UL&9S_R;+W%\A&!R-++Y%[!L'0%PP1%2S, M:$I@RP3A-HY(EFI'E&49BY-,Q6RM/^U]_(LMTVU=+H1\D K/GZX'[*ID)[QU M]%(ZBEBH+,E<8@D/I2-

2;E_ZA?,XU)Q'=!M>Q5VAUZZKP]D/8#7<,I["EY9 M*K(XC2S1,I6$IS(D(K$9B42F5>HL"]=5K_NX$G>F>@T1D<%*'(]T)4 5C=#*

M8YPD@F(;\R@EBBM.8A5E5B:*\EANPWVX*ZC*AHC'0UR'0Y)BL[EO9'463&5N M!DGP8EAFD 1+@23)>&1#185,.%C\=0CC4AJ I)"8F (?

MQ#I#H4BI+,&@T09AU1H=;$)5]I+$EY MEJY!Y,.S$+<,870$ZN, 8H/=.!SIX2-6YE1B .A()&U(N.0IR8R,B$FLB;(T M<'MP+6_ZX0F(V!8;#[V_>_GO5>#FL"$V@"_GY_/SIN*Z

MKT_=E&%ODBVG#4,&%[;$HNW ;^-Q<5'YYJRSLV)>P3/5SZ]Z=`<@99\%O)7? MKTHM.PK%XU;PC8_$+H M_X;,KI/:=:)@> ^O*%4R\;=6ZKK&0R%CIYS3'1?[EO= M:7_KQJI -

R#X;TU_^]T;+]#,'2[<;=`>=2P+7<3 +1$_>$K!Y CCE,0LX0+, MC21*U^L=T-"DSD;$LE03GH094%.WJ+@7#S(C1?#+8.X6$]P#!/#>.QQ%D(XL(Y(JT M(5D%H9>4D&,HH?

C1Q\79N/!)K3B[L^)NMNPAL25A$(QH/(9\l-#N>I;A(!G'Q M8KAE$!=]<1'&"8QD!_^4X0SGA*!I2,\2Y6C,LP2O5;.8Y?B NV)DXMB6[E- MHS@=BD;NH5&Q+[Z)NPJ*=!

4+X9A!D&Q9%=P;TV:&B(2;<"N2^A1]3&$.BH2 M&B9W+2?>%_-M!2G8*!2#WVD/+8KG)R9.SBPLW 'G#\+B

MH!3QSQ[ZG9*5%@G#I"D+.5082QDH&ADD(AHE@$2.*6FFRC*M8KA6_ MN8O .9)&KXM;8Z1G;#0/ME?7R+!U=)\]5,C@>A]&(4 MN<&"64]XBC0--<\(8S8FW$;"9%'&"

(^$U2YAFC+[F!;,MBY)BI$8KGH/ILLV M&.<#XUX1U&D M1(E(**>Q4FBV<_GUV\3DE0;PG%GS[KN&KQZ?X[^V5>YXQ-(=1VOVU":Z76[] MS_",'I^@L];1D&QTF%XW%+](>WRW71B"';F6*.W:?4!(^S8V6VVS&LQ>* M&[J)))+1S%B;83=BD, 'LHT43PRCE*9AF;!'O\]A-@&\;4MFXN/XFS'-M>U M1/*\O7=+]2 6]1O;;A ;JD3

P_L!FUNHG:"V5[@XK(*AQ{(""!S*4TLFA;'M M,S\L%^O2/3;C>UW0#]2>A+$2@/S\\EK4-*F8WGY"G_[>BI- 4[M]3QY/;-&;@_^,>\FN7NLGVA?

Y38B7D]+:K%:R=YG8/[7GRU.)\MEM?AAD#MI@D3J (MBU1"9 +2266I5"S+M'1K?L3[U)?Y,-"%N3V1W]^"Q34NJGGXL($RR9/5D>F7 M*-

C"0=/D**@W)X#=L4NM^;:^#]NP.K:PYK?S$NV2V9F% Y>VKIPS 2@>S@N\ M?A4 HE@3K!=Z&/EGFCH\ 8@)Y'T3Y/7^S>3WUM>'- /OZ"K66%WN?,M8=E[^KC^&O

M=F)AMAL5U61)48UO4E2/-K=$??Q##N#;8]QB)-Z!UA:1*1EF4<@=T$TD"*= M9DJEC% G6)PFAE*[1FL/DB@[HK7-5W*>CM9&@'G5%++7C;W9\B?\"?0@ -<%; M?.

GA$!;C0*8ASX++F05P-KUO/!2O&!%[V>I86O7U9@A@A!I]M[$PAP% M6.JLAZC3LL#B7W"^L&^.\;?;AS\MB^@)SPN.:3Z>>=$43(J^9*KWUSI7GZ+_

M%19B@T.!S\HJ<&5QIK<93Q2TZO)R\9T-4NT.,I[^E8M,9!F3DH#6B)E-,2B0 M6@E"N0EYK-.(9VH;|/ZNW;&.[[_CKRI+6L@[,9'4DR6+V]/0=']((P/@9\ M^/C^ICS.S1E-

CT]3/P(GPK1*>"8P7;2<_AT,NN P2. M$&VD1J483SZXR8=G?C@YG8YS[0M*XJ_G$W^]<(03(TM3H58M-]-'=5;.QP8F M&;CY>(OJ=V7+;];L^)CWLO:G/UO<%_B?\:?

2^B;JW2[A,&%'D3GG< 3E4%@/-M3A"K?:(H,;Y,GQL.-2EFWHPYG<,32 7411HO;>>3WB]O!%4K.54M1=]F<+6 M0Z&,T3,_KXV/XMSTF9R<@H2!?4->)\U^5?=H!4L MJLFOP,6

;)-C#QM 86#%F[IYNLGDNL#'KQMM1T#.0:V.6/ATH+QND)K_:$GA* M^9P:&X54Q81+@06$.<8H:$1L9E.=I40LQ7Y_%OOC$$X-IXU4GKSRV'\$]_MFYG3:.

[K*OMF(4T]JU%08U"WLL;"_G-2\)&,]C%S@ 31L0CP@ {\0$!1._@I&4Q70)/4(1=,X^.F'KW_% M#W[PG_A_I/$//Q\%]<=>PT6!=31"_X83FM1L)Q6(OEEX@^,- 'S_]4OWPLQ[G MG)]

[7%\H]#6 AD1(@)EE&LQ]]*&~=61 GY ,G29QG(#F+B5H][.0F.5:"-;C M,.1KKE\9)7%D>$@<$3#N\Q>3(,I(;3:),R+'_AN^Y03&<]) M0+5^-/F?9/%?Z#IS^6Z.^_Z3"(D_TI.

<@/*XZOWOZLT8KT>"TB]#?$!,L MI(@F),V.D@+6BUCX-GH>_DJ7"14M_/<'1=""[%/SF"[C6'%!+<>#H!@"]UJU7-MLV_-X+5Q*6K>>.QU+52J+Q_KD%T:

<|>$(U9C!QP6@Q1/,_2QA2*..!CA8?9D MAQS[O=K/@PYR%S1Z.*"R.04P/RT 5@)9>H_747 \QD+\IV?+FMR*1CT[RZM@ M;$_S:ES+7@#T,XD&78#V<)G+<+>/3"1!?

9ZWU?*$T*#K7!.H&[NJ.NP",OG M.QNRR1&P7E:TUJ-7{@8%K@K?D,/DI&Q)R%^9=##$W_<]_BZ&^/NSC;.O?HE>.M08-UG?_,.BZ\ 1/4[^KXVJX

*^=/8779J.'B*V10G;--@7!8LSUX M!N51O6O=Q&(;_O3'SX$>XS;ZE*7+_O1@9F&7TZ*LA?WX)L'PP1$?) /TT\6V MF3=;?Y67J(&R3V52^VTS]:O]J/X_"Y0#PW[VR!X<_^6K?\O*QH]!'>$5BJ/@ MIUEQ:A&O1ZU%UGRS,KZ%*V:CO'SXCJ&:'8F1Q/GW&(B MC<=X)2LY!N8>>Q)9(;$:W6KB@ ?!%@,,S_] L05&%1K>"+0(D1AI\K'K.@\' MCPG%AO0:[#FFXTW'|:!%B$F ^^4?MIZ\&!'Q,70,MQGF-6!))$"1Z!)R1UX10 MS>;F_O"-@:C5!G9;@+*#:-EQJR|A-(9^M.OY:]O=UW MKMI<#X]MGL@Z\@J MBH@MXUDL0)1^BP?@YI2&VK2>8;-Z=I|/ 4ZXX2F@(&% M7V)?0YE=3FU 45S[GUB'L :%34K@)3++M.B]1M488B4BWI=]1Z&N>5'S(=@,/IC M,/H :YN|I:0YPM^2PA@RC5/U?%'B9;B!U'!"7 [/.\ZM+6 M90!@9,=W$)2Z(1]OA XG5\$ MAI*S-HGW_%_>U+Z_-_DPR]O:\5[U5R +?[#>B:> N5.\&V_@5B =YTL# 70 M/FHIT]>7\)G>*A92':.#(Z-GI78IU!K/5-8*0E6EW*,Z##QR4B ;;S6C3[M>10@.(VK3F3[P#02 SY5S3$!N'ZH-P,OCR{0D5"9HV\,K0O;AGBPA\1RXUP%UEK^$Y_OKQ_[XE- 30EW!D:C|VF:\K MBID>%T[^B0(?R/M*>]PL]FH W&4!Pf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f[VSZ6):W&%55%;IF M2C[3C#M4>>W J!!9:U\;H,((60)DES7W8)"G=MC4)HKG:.]W$4S[\8Z FL5I MPVDM\\(Y^!-:.7!<N;QL0F@-#\INNL:>XCU=U\,Z_7=_[*PA M,W*?,R.S(3/RD#,CGRN25W:-)6&{H$*-E:_^6&^\Y(T%T%,Y1PLM>H8Y5^]9 M>XJZ!M#[LWP3\)\G^T%+ZPO+'57AT$S*,K9 OYK M)T5U#Z'|/"^\"?NE7U4ZZ *3[C"HB5=4Y^=-50QC479ZE>Y?HR,6J%Y5%PE3 M+_0?9\48TU.:O)BE)UB8'67MC1]OY. KT$O37&O%++U%ZE"Q5BX''X$VK]X3N M6@JI7PH$+-;")XHTR_R&[7]DJSZMDC%6=00@-=UUQ{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|WFS5&>9,O@=# MONQS6)MJ.7UD3^DCA^EQH H5V-%):+D>A(?#-=6X:QDC(8C5?1Z885;HN,PP MUTYQOZ@SG+=@F$R[%84IT^ZZL.[6NC2%:7?[RO3:8?N>>1G? 1,!(\ 1W0$'MVC?2'+[/!=GM6=I4P)#(^-8?<)RJ5CK5D3&1+2B@W7';IQO^LF9(/&;I, M%7FIKP293,@O@*AR7 ^T,A,Q<@'[=@<[T>S#TRV]W75B?U5KDAT8"ZYAI]5KG4^A%KG&H2/:-]=`>2QUSI7 Q^88S#'V!_';+KMUN[T MLV/G&$>F4#RI7LENDS6 ?NJ>G_;I#'.FWX,AWR/3W:9)MSW6E#Y>N/$D7I;K M*!6!*63@W(T=J;SM1AMU7B_*^H%\3B/IZ?6D=2ZB]ESYK.DVSW97"/'@G;'% MQ-R"N46=N46OY;9[^_+',K&YQ%)R@[E3>.G?/VZ=U!CK3[\'0+SM8UG:P MU+KET@X<+-/!? :H#_5@)]IQY]X.O6O?-\'7">?^L, I$D?W\Q$3?R)(P\;9Z! M?>`>EM_D@?G_O*DU8QF(U+.^5H.#=X_EA5U5,)0+ M+8PN$N17 GILG5B[/COG(:YR.5+,*;!C7M!Z,/6)>LGP!^B#.CE7!5]FEL-%^9!RB= M,9+(RT1.1"Q2:>ZZ 1)Q:^\6L"_S63_R^`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{(14T1NQO_?BMIE+]WX,1[%@B3.#KQI.1RS2+]?2Q*!W) M>,G#\,8! #)E#PAW .8.P$O*X,_=T_/=:6_<9C9 [.'PV$/W99!EP/X;ZS)>=]QV\PBZX;QA0JX13-F3LS;]!.L_M87$RT(=]Y!PSCSSX&@B+ ME1^[^^%VSZKM2^FWR.FWXY{7N]9*4R_3+!'3+!NMU-K^X7?)V#(EUT. M;_>\;!89SE7.'CE,CP.5J,".3D++]2 \[FT]AF\X$QDC(8C5C1Z885;HN,PP MUTZSV-W0L&>G_$8=K M&:R9D@\9NMMXL'KN6;/'L&8!7('CAV83>ZA=I5KG0^AUOFLYW;:IUSK?%"BESD&-T]AA>*PU''VF]A]\KINYXS|)DR_53CND2EOVR3ML=N$AVI1T//)#3E(Y]LO8Z31=I]UL=[%1YD3$\%D: MT5.)&$OL7^%''KR+_C2!7^+]W\[Z$'M&4$VEB!O.-=R* 81S)Q+'BWT &H)D M!%P)I\-(6,53W[RQNX5874+PP<[I*X3NC0UY@N3+\]T:G .WF,.V<++W]!;_X% M#/YUP3^>Q-MW')ND7C%X(N7!TP07B:(U(U+ @9+()% (9H_(%K%B$(§7\B M4EAO=BK0:UA'V OGT"3>*;AO,.OQ#++)@M1U(XTZW&0TQ(';,69A3P!#CW? MZQU++!5A3TNI?_]Z)$)U1:)_C<$\#PL?K":>-,IG*FQ:5AWI{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|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|L4PIV16N2S-^GQU=V>&=65@S91\R-#=CD)G5K7?|/+ MX6#(EET.CX^)GMVM'+S&H*X,]\FO#QFZ M6[6M/3+_H=-&C:T:IV6S1Z(C<__7@B'Y'R+'WW $Z MAQ|ZL)'+-JZXSDW/CI_3EX-$HA:Q5!7W6FD/P'64BL"1>D8=LZ69 ^L1C[35 M!?,PUQ9 Y5&1[48:U_*BK|_(?+'Z*B:/N*456+/,/56#S6U!<[TSM[-:N5EV MJ?EHT=T@7[XL';BL==1R!SD?!%\|]@/I6 FJG'GW@Z|%\WQ<)Y_ZPP"D21_ M;?S$1-_(DC#QIGH%%x<=Z6W^2_ ^G\]I5-0SD_8GGQY*(-9EAOK-O>.7YR200 MTTO\|<HB/.\/;_)#-W^VIEVMJD__)XEJ3^+3VK$,J#(%M%+Q|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|8OKMNF==;K[!%N%XS+|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|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`(%8I+(RT1.1"Q2::Z B%"M_6+6;W?K)[[J^7EI-MGE^4HT2OZ\';3O%U]W@GN#=]3KCD^ZL7;Y<\UFIT-GCH\8[<-%KG3_(B/A ? MR!RHO8?W/.!?/W\PXW 1"UO?YWZ(D\D/^&AYNG<KRU/?9ZINBQ]*YS/\.DK^ MUH_?_N-CZ$G/^2$GJ!SW9>QTFBX/9%#T2K$APH5H_OL M*"YA5J9MK-JLK MFY8P+SHF>MKE;3I.J%,.1Q[<%#ZSJ:P+N/";:MW/CQG4S#Y'B_Y=MUNFIO<,/E6X;A, MOH\FWY[,..WU$ HFWX,A7\YE7#N7L5UKFN696L\]4PNI7^`9RK88508V$_#A$3# [%!Y/R6VWV>L=/M"9 MD.L$4Y,$ZTOB6G=(K_2.J\/T,?PL_! 3&/KP1OQQDL6#D6!?0ZWHAAGD^H67 M[5ZM/0T<-V&J/3]JY:H#IMQ]')?]"BQVF7RYU(!++#?99:L 9 +#.5VN6-#,9 MEA=5Y1+,'C'6L=2XRZP5,LD=`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v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{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{<"'R'&/_]6.1AWW1;0"?3"^8B)NY$B>=)\'6@"/J; [^Y/R6^XO3SI7PT#>GWB +

M@D"DJU_X3SD069(K1OC=CYX{1[RE5&-3N'6(%98"D))/&&GM92SU$]"?P -QD#HU5?)6C$=.&*1SS 7RRN@CBIUG;-&YZSS-MRG:;ZC,JK^G;)<^U'0](MW'>N7B2-SW-(WP>/L]3/M)KM_J/ R?;I^GV!CH M[>,\#W1;.'^P_>,B2;YN!X;*5$OLI9]}]_OBX8,NV-2"@Y_OZ-S;A:]MW]92 MYQ!%_CZ3^W95[4QU;V0/!6"<=CC1?PO:*(SWK,@>29Z>E3GQX.@N(_5P<'-_M*&^=+!5N#R62DQ%3$4502R6<3NGSE,FSMGYSI MAJF&J89E#5,-4PW+F@H@$MM+>VR6S]2HG? R=3Y1:A33)$LRIHW'T,X_1>(/MG(_?.DPZ;#88=IAVF&QU4T,L8M)ATF&OP[3#M,-BATF'2><9Q YV'&'*M89K4TUU*E6;^[>K4NQX>MUF]YO=Z^!XCM$^3///)OGT>KWL0_IMTJT6ZST5R9#%EA@#/E,N4>*>6VW+-V M]\809]}ETCU2T@6ARY3+E/OLIV7*?2SEMIMNZ_2TQB!GVF7;/5+:!:E[5F.M,^4RY1XIY;YN==Q.Y^+@8?ZHL E3<0T@RE1L43${X-[!0WPA#3\ZROS4-<$5 MC3) ,_1WWK;$/E]LG9!T$;^2CU>IH;R-G)=C\6OPY/<!}IM,|[RRZON(1NX_0^OC6)$AK\>QE+G&M]*Q^(1-;YN.G)4@@]-MH3%M$ZIJNV?-\OI#FN\-AQ9O9M!]1)BYSMG53+I,ND=*NG_Y^\[:K3:#7GFY MV4_+-,LTRS3+@#Q(FGU]YO8Z*Z>Y5!C2K",S[1XK{8)YRZ3+I%N=TS+IL]K, M]C(#DFGV0$"[<;421[H?@5F?D!DDCKR?B+#1#11Z 2^Z/N!GTZ=8017+P*)M,?!AEF:QU*%P7Z[L1WY0R'BD?*?K-L_K7//\P)K"7M/Y&:.3UIUVPT-L,YRJ2 M+BOY3+"LY#/-,B"99AG43PI}\N/#A>TV7:S;!EF;9T?4!=),Q8<+6YXB<1QP M9AH^7-BR0GTTH&8R/ES8,AES:7;E@E<_TFCPAS.(QABN%E@O?51(=J3\I.>V M\]PVGSWCSWY:IE@./S/!,B /CV"[[FFM.Q8PQ3+%'A?%LHBM$9R9A@\7MMM$ MGGMNK\N1Y}IFJGX<&&[G23F<:QU@3/3\,'"=AM)W"/,TS%=8$T4_'APG8[M25SGZ8Y<)EW-J/.O49(XKV^$'{I|"NEA%,.5A\X@BV,9#J9.&HLP$0.,1Q\' MEVF[W1ZGFK*Q -E/RQ2[OE[P2TFV&<_+1/LFH^7W?;,W56Y;G%(-/NL=)N MS:7MTY-N)2#.U.S4O"CWNLU>\;] F4GX<&'+Y5A' VHFX\.%[39Z]?EIG5/% M6*UF8CXPV+),YA+IR@6K?Q9~B%']/KP1?YQD\6D$GE4]'.D7.5USVWWZMRR MF|WFK!$<*^W6O*"+29=)}TA)|QB5>,;9XP8DTRR#FOUH#-OGUIK9XJTER)F<MF9S9"#X4B#,U,S6SCEU[4#,9'RYLF8RYL+IRL6HJK(Y"U[@AS>9GXS&\'_MF_9D(5TJA#/>P]!FU_E1))I[FA_S31{((!DFCT:4#/-'@@@F6;/!M1,LP<" MR+K3{)G;[-6Y2HLIEBGVN"BVV6AV&,Y,L,]}6B985HN99AF03+,' FHN=WZ& MWMSB5OB!Z 2R9!C%)XD(I)/(01;[J2^3G:%?'R BX_QXC=XD=9(H\#W'G*$.M"+HA+U]>.96:]^82AMI=@X988Y+"V'>P+R!>0/S!N8-S!N8-S!O8-[O(%Y M_,&Y@W,&Y9<67W1VUR>C MFHR!&THRAV.P0Z'YI+X,K^,#O2O2>_/SNW3='>+|G22HI}Y2X6>)#:"R= MUT4<}W(_'S:CC:CI15D_D,_(RM837R_WQM,6WT/=N5JKYW9ZN\O7?O#*M:L766.5A3L&83QPDG^BZ[=X9,PIF%,PHF%&L4"CVY7)E M/L%\@OG$@?");M<]V^&D7N84S"F84QPDIV@V6NRB8#[!?(+YQ,/)'BVW?=$[-M>$[!"1_,,IAE{(AE-!O-P[=!MN8^^[.46DNM 5B_9?N2'],@,.(&^DD(Q'# M7K(${_I9&SB ;3[)45J=[.'_KQV\U2YO_]T3&:B6'\I9:5TY?)/[@]!K&'&EO MH/99U[VX.&=05Y%3[%)? 1S!3_[^HOVBKFB^9_6-K^"P*8!96;5P>1NI=7KN MGNVM?0.15UOFMU.:M7[!U;'>HSOOL3*IVLNCLI9WMI=L?`!@fK>-,M6U"%0.DLMEEJ'@LM:65&Q,09W[&MS6K895S)TPM.R0+T9/_HT$U83;N4PGRL/B;9ETY$5VQO/=1[.XMRNHL$\)D.9G>)4KEHTI#A M%L;!L<@#H\!P8L31[\)1# @$/&CWSK0(9WB!YVG7"G&;?M9:W7TUL!Z/?AVR=WUOP%NR,"UO8G<+UH:K5>*Q)35,A)L4W=H).*46QW9HZ^M#S18.]R:Q/4=AY_+MTJEOE0'OPP8(]7$:"S/CN(Q=C^3#ER :A)@NPX+>*EE M=40@NO,H7V:(M 3:<()%;-@-8,?:I&Y/Y14XR\TVXGC^0_$D<%E\$1H C%;$T MG"PV^L;Q%>>G&E(SW3'^075#T0@LDJ[<^074?G\ $'Q#>7W7WF+%_,L3LI&K<-M]2:*O(34),.D#]V,Y5,SBY:#{Z:^3+6X,\>(-V 5CPL;5@721 MNA+@B$>EM.9=*]PRT62$C2IT&4@11)ES?2@VK%LUS7)T*=,Y(5NTWYZQ!U(]ML6(HQ4_LIHQ4CIKT@=T=VW=N]75C5OMOI-6QTD;3?R0ND*H2"[V4\MYH9^8 M#XT_7BT1.X=\7S54^>G#. ^IJH7^F(=D)]=1C\3O:=WT<\ZK;4GCJR-JBL|[M M:N4^CK4)HYM%%D99WLTU"E5)\0*-^UCDV:N\@PC0@&E"HBY(I2.HP0/DSZ\N ME5E"YJO-?^KKZ-IS PK?4#3(.#X0_XMY2=2&1*K)0$P5/:QA<;KR,(^+R@!_MJ^+,2NX4[?YF8E=:.YS9C,3JAX?R4Q4@1Z!$DJ5CW-2ZEGUKL5?4WUA>!MJH> MY9 C5,Y9K)V;B)1V'.CL@%C<%:URYF}3RCH5:75"|5QW5N6ZLQ;7G=6VfNQ@ M94HI|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f!12 6)"Q/YP;&M: MB'NJ^ZF)=<$3? U#WPJ\3$#;03N"10&%495;I M28QWC'>;XUTI,C2K;j@\6C&_ O0 D#)PDBGHO.-RI$1Q3L]RDY<[GL^NJL(R MU(LO6CC7*]=K&;49M3='1!%@112C-AM@2_4[&=NJ0(1"/Y4!UB9E*EJ+461L M[7LS8FG.]+==|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{(@LR2F4ZU.CR7O|S/>;]W >)T1," MSJE[@RK=C-J#!O+&3W0?8M.+!DX"5BK8ES?*

Copyright © 2026 Google LLC. All rights reserved.

*MT=>'>=^)QM<;IL!T>7]"KHHVT^^?G#Y;7%BC(EWH]X]/GZ9?&%=M82$3K$PA-M/&(BN3HWE:>+WW_RIT]<"Z3;9WOB-SZG0G3)8%2:%97,V<:D3^YZ(40V< K#M2BZ';MP+"H&:1O$M 0(-EE.U]T56]%CK*7ON/H/V(#[LPQ?L@8:!^/_B") M>LD9H*I-"R.$$ZP1$8_+I%9'[_M_^4RI!U;Rf"00E7Q3W=;?12]"VJ*H6RT M]HO0:3S&L=YSL;+AD4\N31HTI&>]^WI T$ZG/#-K4+CQH]>OI%;F'N,KO_M-9LTS]@AM\AWW3?(K?#S8SN=B0K K+P; JRLU\@%K)9M2/9_T7W MJ_B>5YBO[(P^VY)6V+?,^0DFI.8FEHP?YE4 M2&:70;0S<1.^%[-[>]6T86<90:V^VZZD+2D *SR+]J M78TI+E?:!-M_%PD_U^NJ9YP_17K:68QA",@P. E<(:OEC85?]:RX9SSY-P M(IK1EWD7MLJ9*[\ <&MF^UNE!Q>3.LLO'LV4#S024S-)$@I!.)UA++-RN+G\I M](R38I&P?]ZDK.(&+$-I?4WR<(M^>45G$RZ[;D,EY MQ(2HD,!E[JL)=H2D)]WEHSFTLX2R8AW%-;SYY"P4AJBGI)QAC+^",9+B!W1% M#^\WKOZJ5X7AE2QL{(2;[@]!36<5E>4RU&&8'7&"TJM(0B+FC>5A:=XXC+[A M#9+5+9R[0N@[:'CN_%909!@A^DYA[1ZTf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š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}($M<4$9,<97&DN M,,9DPGRR*BI_N<{\B*U)X^Q)-(%ZW4%<*EM\TPD+*T$SKDNKT($EV8S|\J59YBP*5O#(QY)R5X"T? @=MK&C[!Q6^AC*IH(Q.",<$6&M. M.C/^*+C*.QP;'W=DO#>9G_\R0L9H:)8K#G#N>$A&]EWE9BV:4:WW-2=0JB M13TE ;3^.&K/? BREH_9'H7"RMC:S9_@'XZ^N*;A72A25^$/5VOSZS/^?E< P M1)=%0:7X;WRP+"BL$;#A.=|..0FY!EA4[&XRGRZ>1\2;_Y>Z?84/YNG=1C\M- MH]7N?GN>]U_3$?R%-O#0+OWNQ:N_OUI\]^7_G'W_Y?/%]I\NOO[V7U!^]X]O MOOS'[_3;K_|)OW_O[3_>'S_Y/T+TH SW@^K"OH$TNN'4/^R]6QNO-+YV_T MA&!77;8=YP$:IOZLFMA>%G\PWCCM+ <%UM63HD2I V@#[Q.![JA40A.YIJ!0K@ M8G-@3\SFA?/=GF5O$AY#D<;>@[U_D?7!3M>RB=G?"0*/'@DHNS&J1C*E%I<-.MFECTE'0:W\&_$:N6J(_L;=RKO$=NRV_8|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|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

*MLYZHZX+)RG3/+F4T1/R"N4QL6>049?Q?R#$I,__MO/CTT2/(-TC[H80*J<-05BQ/8Q_I(B2H05;-L75G>T_,,(.:PU1E]8*T'#1S MY-*
(J.WOL!\P+HH<0#/)A@_F01V.S915I3N+Y_9\H1U2U"BM@G >\-U7I)!TR-M+I\@C.&(PQ*I<65[>2Q(:ZE5Q_"0YE4!2'+OR6+-+:;3Q2M_W@JJ5'(;0HXI M[V-*
\XZWCNLNX61X0=9?;0PJ2ARU^_<9$9S*5G<,/V+$ MUD@EE BV1@:;@fM$"SK&DC5"ADRH4T9#SFMV2-G,1-#+NQOC3GMS@R("\X7+|_X2*/M!!DE,^^'_^OR=/*
M'S^C_W_R^3,&|&=/W5FV_>$GFIRTK*0OI:?_GZY?/TI/RI?I1GBX>/RT^?_2G M4/)QIK[W&<\)\+;)$!NJ/OLP#N/7\'WEFV:PE?ED;)-D82\$7LN,,\EISC@_MC]W!3LQ@UU\T(FG%*
*<,&]>,<4;LELV@IRNGSY-&"UGS- QMH\7B*8IW&8O'X M\]-/XZ>V7-$CPT1.3PT ?_R\3O6B%?9L1%!,Z5HL/OF#U/NXT6EQ6;<72#LH MRQ"0',,-*
=N(0W+65YE_^+>2UD1)BLMM"W]YES8 #IT^-L9'+-E]QI+]Z8@E M>V^Q9!^PF].Y$S*(&QHFE"#K5V)X_B4.7M!IY5VPZ3(#]YT78B?9/TRZ;B,,_M< 7RY';.K'3VF%(VB-*
D>LY=:A.2,M:LJM;8IWV)?+A$9?.C31LB6%R^'<@M?W@,%')5_%_G17R*"">C_ E-/559G3_^-'&?:TPBU%YVB"$_V!K ?=+>O4O= M"QS=AD+#,MQ0J_1(JN-
*V1\Y2IAS4A>+!^QH^~ZJ3I9ME5W# 2Y5/T1;!CB8OA8 MS ?.]"76Q.%1E/EKQ!C?;/J?I-W<0R]>OBWK%Y,[)=G%F+.#JG:*0[&R7H1[1H6 M'JY?!P69QL1@S<)N9>3%T"861-2!Y3*
W]3C__/WE(B9GJNFL MNRTQ6P')^+W94 J3V5L;B$:)@5+;&]IY').(N/0=$$-N6@)$&\/_)(.0<$UO.MWPEFK/?=E74^Q+K>"(Z-_MS@RU,9@)fF"@2+DL[5H1:\3/,fC'UPS?*
V$2LGQB!_ M'I;3W#E)/(<8X\C]XIFC_C3]*J?CUNU5$=]BO0.H4:.7O%&Q-#R;QUNO8-GR M+#2"SV"$(V%, .]%P]!>M"#W1=M#<|\AV"W/(-LVJA(G(9|S]OTLSEY24Z.&9
*MADOW/87JAGP"6E M\+"#P,)6A'\&5+T%,>OZRU5{1QI!1AA;7# F%WG$FI[F/1779'B&-X';5EN&K MRIS*25?=E2Z>W*
*MWG@".6^.0AO*D$]_\/1+=Z(8,NI!Y\X9IM1#$;5X>!=15BPJ;_/E,*Y6MGX4 M(NU&5?,'B(2C@8UW4&662U-/S0(%9VAB2_S4I\KR+XU:IWG%EF;:?]-P2D5<*
*M@<;QCB2Y[&%P@EN+++80,>EE)^&B1\.W+G1?%8N-+.?F0M+GIX<855S9F^D,M ML,%BXZS*DETSX58HLAF* I&- 0$EM\,(X2+&M>2IF_@Q N:(D#^MCN+T.2/ MD%*
7CUE9F13E^R8$YY;8H4QQ3N)%3.9$+%#P=RVP6DLD;>%A'5Q;OM!DI17/ M:C - BC/P HN:'WQJIT?B MFK!A5E]"!FYF"#W7L,L .G ZC5S-?Q5!F]P/54:%&23*
*MO$G)YUTO^7.Q,II?9=95:M#X:IS-S;-.S-M:*I=>/UFBANWA^XL[$;.M;U-M?8>~958K@'.8&F16-]I5_/5.YDYK;'Z.)%)IR)-B;S%0K%"[%P&_"XV MS*Y=`G2-GN_)6Q@E*%G-*
*C%X;D=[0-^\Z<6C[CKS=A@-Z8:@ZXU3LYTX#2=5 MGJ15$YW<'8!C6#R"[],,:'8*N1;V.>)/E4O"TU$V*S9XJA(I3%ZC#(]LU-, M7FRP/VEQ\(=QZ MV><>\BG-!QI%=/MYIQV4?*
*P.Y <<]<&V*C3!21V+P87S#3 M.Q+]PU&_V+#&_>4"0N@0I_@*Z4^*)0N@0I_@*4%MG#HL#(L,2)M-5 MYIKW]QXK-)Q=0@66RL/'74BE"P*.*5\Q._D:2[,VV.KB?/Z<R2R!|O=&< ML^-*
CE"OL&W+?UTO$8/V?0.E$]_7V,DT1GJ0''@0V_Z/< H>=0:^4R;2&FF!1 MG0IE$:@E27UP+6(M&6;'K GOD&L_Z]WUH?0"O?]]"F.DU8U_M8:!KQY("%Z!
MO1_"\U"U0RNWCYNJ!j_?@/0POZ)KJ'&9 AZS-;D1Y;J(CT-4\F)"?YDV%OX38 M)Z?A@8#\=!;6LIR.E1;N7XL<=3A9L55F\B!8'>]L_'RLS11L)WB!Z8&R44X%>@,,:]=3K*
M%##7X%R)?LW8-^ (/MBPT@W0/K3I;^"A;S*/LBY)(/&ZR>$)OA+7@11!MJ++.N"&%,/& M4KZBT,5B-])2O9A>?.OZN6XC>B?K.VPJGH5S$4B)4YP=L)(%%;ABJYU1N+@A*
M,$:9H&BA;1/D@0?,$RL/#'MWY&283LYX/^(Q)_0[DY0Z5P_761S6A$VQM2^QCA(PS"D)"O=>>9-4-8$(?]J5D!FN!6QF%-,DE'^M@'1+9F;BW(N0L[OUM_XN
M#!0U@A9GN!H5'FW65,<]G1W#[A-!Q1NZ4'9[0E>.Y18#RB,$"L;]2+292IP MKK6GL4^R]'<1 BLBTME#YP.G 5QH9,.BL5&9$26-9OM>RY %P+=(GT$;G$H> M
*^YXA;JI[HS1#5GDC/S 8+YRV:ZI"BF%5AX86D1[AE4;3JG[P@>9I^&++_Z=/^WLFWW4_>UZ,O7_>/3OZG M]GZ*V,$B10B38&G,1_)5*1=+=):F[8 ;T_2WB*
W$:53AQB*-0R5R>_7IAQ[J ML#TA^>5"Z/5+7P,@,,;:A(H^TU"C5T]M4=.K.(3225&,.Q8"=H.2?16B+Z$ MYIC3#QRZ4J'$1UR N5 M9S$S6<.$]N[OLB@6V3FFT2K'X-
9NWE,#J.Y#@@HH$<'E;"@&;L,4,)) =.O/PR MB778=O(94I'A+&%\5VFJ?(R;3FR+ ^MW*-4YKK7) ZIGB#FA8E#E 5)S[%@ M86'[@8IYU7-.K6=[*'+,33@!?X.O%7NS=)B-*
[++1P+?4GFO)21-/R#?$Y>4P- MUHJE=Y&L:&=H2EAND"GF2B@7A3DTZE 0430*!Z>75IF>[5-LJ6+'E{(X)S& MMN5OCUVLD8S;C&3LU$C&&LFX,0:=''}D?
9;8@>Z69$U3>=ECLO.[XA|[?^C`M+6^?AWY1FK7!87=N)Q!9[Y NR422+7")^_5 #.^YBTPTYR.OYY\LXTNLJR"1GDC36%Q*9Q+U-F;\3>D)>N<50UCNHZ.*INC:.J<53;IL^A*
*MT0B'/ -[TD]U^7X!)N!(F[@DY&]ND''YG81WD!17*R04K& &'_'V-M1O-B#(+ M*5B'(]JF-@0'!A!RRRVA?0MP$[@.4"K!DG) #@U@K1UF]]B1G+#:(4HU33?$(0J*
MOS@D)\FNPC3EN-FH[%T=2YA[#-(9HGY]3H2E/P*)F$J3<:>8WF%8QE^;I8 M!F:6#LT<]P_=#0734A&R9DBBW5YUBX+6V^]095D LE?JL+-L>$#QAYY6 2RC*
MMM=;4!UZCF3!;@ >KH:EN$6(4I"T_UD*C)0T@W0=.33 <*:)$%BY9F<+[T@ MQ6FGD+9W.GEM5[QN10^RL2[3#>,85KDWZ@I%B2XFR,7BHV0 (?_1*
*M+IB>_N%>BN({#6ARHU2GFPG*Q`'V,4W=G)\ZRD*C%&4U4VA.(SN\>&?;B4 M8S0PQF!DC)F*!]' .N,+B'(3<,%A3< MH$YW\8P;\ZLF/P:*2,6-$9]>)T<84%*?ABY?+/&:]N:ER-*
Q\F-J%G7G-/P" M5/BJ2X!6724S'HI/VFTF<@0,3KY)2D1'/O|{$]GE-"F5W*@X6 M6G?%_"*CW(@E+-!,"S^]=TIDZF9"4@CTI@PIBTSZVUI*|S^SV(7//%>/'2M*
*MfYDE(LMM,+8)UW0&5Q1G8-VY-,+J=*U?1JMQ"S0IBE,AN6ZDI"#0P-HG$1: M=C4\H.5OVIS"9@_QID 40:RZ"S8.0\)YC1_,(273P GNBY8DC>1XF37#/I MHA1GG."*
*(5TU2TC##G!HE"0+#*F+<:0;Q:-A19) A%(0I9U"I&H(\3 Y0XP?`M%Z@0O9791_U0E,DCKW.NO*05P;K)XAN0$*!>59KIVYSX-W5V@AD7L&);3)X@ M1IF , S-=S$F%AA2I&*
[@)",_G4C!5/K!)Q@, D&$//P4T&V1Z1,5@GKOX3! MP6A"(U41,"I^8&89<[P-F-XX9^A[H@>_(>VPF$M-11&S?37@6%-CM@A@IV<0 M[GN:4/OOBB(63#5K"BH9GPH|"(]
*/&8[<,LI!OME#B4I1)3O*E5IMQ2|F M;SEO:;I8E94&K4KQ4:I"VT]112UQOOD@&NI.E2PT:R&.+#2;0L&ET^,Q5*01T M%>*((FH<4VPXJ[*79,K F8|SJEV;4PX$T/"4/+=*']*4Z*
*C61,,ZRM4/;?M" M@C_!]"<*9V*L)]=>VN>Q*XO8:-Y08GM0@*NAHG>: MJ54H"P$3MC/Z%,KQ*EAYTRA T1FEY]:L=+ ^X[N6U;\S=-X\TH1<>6\O%4ISX MA-O'16?'[!-*
*JFHC*BD!4O#$/5\)-'(0O!](@GN&BE >"7!,W4;S[50(T #1Z_ MJ7XIBQ1G9>@&I":%DR#5DEO2!Q(OT ,0!>%(FA&%ADQGF:T+,>/+:<7=>;27*
MO1&6NBH0M7]VEE!_@(RJ+7.Q.=6+&CL!@8UH H9[F8=OV= ,2K19G/,<&(5 M^2F7R*D&'TDX^@P-P>,^Q@\'@!C(&X(Z "Z;E+&-1&,<&H_6NH%"-1 F#_ M-*
*7MP9X)\OWO*SG%8W.N-7HLWKSMO7K]_X[T6FAE'_9H%W7!&.WQ@+B$ 5K& M&$P3.K_.F14'$!@G>X8)S-OU[%4?P'[@HYWLV89/\X#9*&^)S6=.;+NP M?*
EPR:B7",=KPC$1V5+%[-+(@:C)Z?Q %7X3F;47@;G&F+%'|LT<(0ONC@_4IT_M&6V4+ ^TX^OAZ713H[MF%AIWV^VN=?!#A1P. ^1V'9+Z< M1_),.K@0=[-X297Z"1
$D3EF4\]3;I)+8KU!f_ 0TU6]R)+&>-O4+T(K[2P8[XK=TTX-Z8KLPZ'GB!(?>9WUSG9*]B?K IQ3XD!4#E/*DRK-G]C9L5)H8LI0=@17+2^V6"3<=-*
*(0W9B_)*X,D4W\6Z,4[_(#XHJ-+4 M(9IEW252\E(+059HB!$@@-(?]PQ;/8M0U2I *H,8*R'L!@J3^]3&E-8%?1 M6C=WV:EI@2*
&MFEW^CQ:C3NNY2UUWNH^Y2PZ^V&7!5]^%?-?QIVTO/00=;-@Z= MAZ=A;-A_+N2XSZD +_;IL!2XCM@IM#WX6M5GDOU&
M:.%)R>:)1,5+%OP(GQ,J62!#NZY/WIL87R9]7;@D?H>I' M'!J>)6V7L9N67|^89O59!+5R8;P>;H4)MY"!_%EF%K15"='Z,I/*42K!@25R\/%6F^Y)>E.WB,QD/,*W](V8EC_*
M&)"$>Z.H>'! @,I8N')#@>]2+/3!O?,LG9WZ,&NE@=NX>G>=@2TH] .'-D ME&0SD-"N U5)'>U3F=[@OT1++":*X8\/-XIP:2!8'EVX'!8)5!82=&K;7[P]"= M%%76N=1,&^5*$>(.
*<2]=0T;/+3";[V< B_'U1+6\0[$QCOY:LE?-,(I*/^*/A+LZWX!X-RWR$V@80X[ ]\'V8Y5AF|HUO*4>#;X=:,&31ESO':)ZT(4X[W].7P)Q2"WXTX5GVH-IP6"J@^?MBEP15@7(:-*
\QHQL,-8'IFG -] MP9R8QC2;$WP2$O&%,5<6@51$:Y$R] YRRBO/&#|],@T/SYQF>)HQ%2:,GP M@F?O15@T Z3&(09$<(T.U1UP$O"G6@DISGC3FI 0C\VDX> ;*&G5"5&E[^*
*MZR738S^YWF.G@5-S9,IGA-[@$'D'7+(%P+_V&|]5"3^6%5_6>0W_6N$N77!]X4-*ZPP0'&"EGHDK>-)=A M2"'QU(.]B-$*!#OE3&5HX%^*
M\.!U359"GC\\K4PQKADX%5!RE]Z4,++U6V&#P.>$<-M.<\8;4BS%X!O2M(f\GAT!Y/T;G.R#68F->?&C4E\0+BKJKW>E7*ZH!XO.NW*
M!MWQ;\4,6\EMKDRE82YH!^6LB5.:WODB(P^S+)%62-3->]/?GDI$^ZW1H-L9 MC8?]2,:)\4.3]W&R7'1C M)F7KOHTO()ZB@>)]?$SE%M0]N0"T8W4;Z M-
*)L**R8K;\O)*?]JR6=*;9AHLJ!P+C2.+,",@0D'!E(Q\LCW9:ELHRU&O+6]+ MH[UJE:QE\OZT<6&P31*R:OIH2$7ZR)[*!+<MH;6F-/4/Z+((%%D@-N7]/D|\Y7=_YD9UG=/0I&TI-*
M]\+=L\;7G\@L3+DOK@-MU ?G;AH9F6LS,RD5"2]+?&E.,FT!9$'@)?#8-&))2^9G-&W"=)V'&SP-GK'. MSL8. /CL)!BN4,OPML@PX!)6Q)9=:H%LN& *G1,I$-TGI?YR[H.P:1)TAI'K
M"MQA[&=C5@H'+@2:FN;U82\&KH6Q..OD#1H.(I=&"D2;)8'V%HJ4(M%:Q2 M]F%8RN0K@+RUJ5.7[YWD.^2L>R:<9+_"< M8XT>A]U $ZIZE@;1XR1I=*
*ID6>HKA@*FM>?X,S$?Q!U9EDDI,I%DE/W("M,D M"%/G&M6) &0+R-@*E MGCAM 5)H_&NEWB8GQ@*PLLOI9R03_0N_H)$ A82\L6L^.4F.->'ZEE7"4Z3# M*36<).DR0=5\"GS*
*L2"%+?R4!E$<,18+3R@YH7+^S"G!$7"^:R)B/ZGRR]$ M%E1%X5O\RM,>1*$F?;5L)"ORYZW>T4T.ZWF&73TFY7VRL264F;$ WX==!&-M-:/A.G\#FWT>FN6,?2@0+)3(#2W#*
(IY2%1@%+$MD-3+ 9@Y,WY?BG'XAYY58_0IHD;U#K:\/9XU)#;)0\66"QHQ M@TNKOHYI^C.5%Q5C=SYJ<2G7?HEX'!;^CT64NEKD@4M0T>7@ 2Y5&9
*MEQ5*GB9SEQT75Q$18BS3GOD]\4*32XD!T:.!$%384,&@8_:FGW2+1<5.+JUN MB?6>W0*WR\]2-GOW.?]9X23Y_$N58GW&8]OS KF96V M\!PQ*9W!;*
[";'1Z&UK0V1"S,?=<4MOH17@41JRO4C68V5Y0J MQ0@7TB.DLI+K$9O]7%P0:)#55ZG"U!*+F^O\F56FYAF$5;1B"W/<';96]!W7 MQP=>X+7"=$7=$<5'NK@WK4I]*
<#]P0%)>5N5ALOG""[GPG8.V+M!ZV[&7.%O" MBH"]B2R2RV42Q6:(5NE2%2]_=CN>F.[P$I-`)T@/6H/]W,,Q1FHW]V9PU%(3 M5V
*>!GXP*D,7%$(92&Z_!&JE7,_8K20<4[_<56=>63!46 2R1(+V,Y0O=<:9 ML=CE1(?(V("%?F?_4@C5A>=VK<$'<>>00'[_!F=FEOWR(4*S\^4 @1Q-\3] M^%S$_]H?*
0JLH3NDY)\=6N)%78CE/+N2M>^?(7GD3<2MH1D<@38)*%X9;$LY M0^9IU.Z/$H=_8L"6V&%;9O ?CUJE&0)]NUSR.<\,GXYBV#P99[BW>MPBL.,&*
MX",$RG#'@3"1(@T.0I15R;$)Z<)D/D_,46'"<&L|"93YR=S"1\GWLQ/^$A-? MJC_5!))UT>(V8&)PD-+HC+--4PW%=&9$^"D,X\LU/YDO9V(>UO7>6NSN)G:5 MLJ8$1]
(L5N'!;BB++#72Y4;12)4A<&A;P@XCIG8MWJ[K4D7R8G)MTU?SQ75\--;IN!HF\08UPW2H9"0)2M51+1WX+DJ@A#$;GO!LDT3POPOA>" MICP!AET;5IFQ1,B&TC0*
J(]7!I.#R3/5'!2(_7FD9EBC|->S3+O_^0J^NXT M;WF%D7:F>MLUV7BIW:GJ\ZDUX/R_S:57T-GWM5_."K-PV^++=$)?Y=F]DC\%A>,%L'4LY\7KV@%/^0Q60+OZ M<0:(-(K $;R
*=#.K.6;E<1A[!}0 ?(">6*WQ(H&X&T)/83)=MAY EZL@(6VK MKH9DMOIVVU*;GH2Y]0P!LX2I80(T @XN5@N;% 6''@FH=0OG%[@HL2YO+>\? MLV@NB];3W5 3A=& 3=*
[&6<@.7HZIX0/WP\%D]CT-; 4HL.DU2@K#3>A:C3I U@ .Q=SE=[XT5"4I @Q$1+@'1HL4 M>F@U'@$/&0RL+G'<.")!*)FI'BA-2U9Y:E(SFS5VY[4:\?5>0$LDOSF/1T/Q*
MH(6'S:BXU8M!BA&"Y1(1@)VEZG7A$)BJfU.IKA#_4NV:S?J&N\1fFYIV MR65P$8?
*(V*FDXA2!.V0('8l$E^NK?!';16!KY(!XUD)S+FER.8XJDQ%HE(U;5T#40L85=YE0'KKXX-023/90&VJJX>$)H-O4-D M&>(9<0*9L6#;)O;6(L0D7+'+Y[/XF5YU(L&P>ECY.T"8)1*
]HV-(H1^5/%] M+I$EY()EBF^ UA:^.:)^6QB/#/.A +F5L!H55D"@UW%E.MD&@8=:Q ^&URI7; MO&A=V4:S]0;EK=;4:3Q8!P8B\]I(@+VI#3U<"Yf^S"[#6=6'&/>.!0?VZ +\3
*MM@U,@*FM>?X,GK,VDJXTP+!;(%-I.T>N<;OJ-G&GHN.1,5Q;OME/(9EIFK MV,-$LLM#$Q;,HJV,-DJO:QP0A<[%==ZW)%9+HB>$VLVO-U:J M+K0:=*N7_8'AIUNEWRDBHX;*
*<5$29=(&;!?^(U5*A\L7+,YR*%U$:D MB0>X_:P N@:RF>*2+))5G-_D$-[^B74#'76NT01NYRQ7W8X.^+G4.A#U6RW@ M!/&[&9U2U6_'I@QUPK7?8l_'U!3*
*+XLPWYXC_BGZ(<_5*20QA&.GQZL[I^P2 MN[).)B;+PIU%*9]*%Y1R+./(_(&.JW*YC A?UK=Y0|/A?5;N&20P&_Q8F/@S M$^,S?6,XI>KW',Q.YJA-#:,8BD$/A-0*T9*@Q&*
*[P=H ^O\5+DK]!9Pf;-%Y! M%\E5?@TVL,@49HU L&8DV!%,F#'[*F4]F45]R*XUI/&E:BB&! $E9T]P%'!L> MY#T#GO:P2I609U(#N>%H]H'-.?B7-*
:P]/BLX3WK#;,A1[B2_SPO1%,WW5@DOV-MS,3N.?G6RD/AR6%18L;=4+)7_:8T:I1Z}]DJ008DUZV C<#HT2 QF\RE7P J0U("J01-M&)#* "77. +&EG-*
PYS/OBSGT\L\1)$T*/J8\M3#*%B>>!.E(=-DZ6R-&!6SV^<*$T6'CA,=5H@U"=8\"B7Q M$TU1MOC>C4K/+;-6U2ZMLP9Z@;#5TM2?M-"C2B.F?=HQX9U&T+NYT)-X3Q=< ML]/?-
A1(6'Z&IB)8C&P6A24P:I$\'?M/TD?H(@S#"75;:|"!>6'2):!4URAQ M;G@0+24.)&!.E=G &E:1Y'&XRRU/Y]#BQ#9D4T>3,FW.KB)05T *$B<;3U<4 MA,M072K/<="
*(I.8\+R2*L3<&2TB9Q!ZQ6#UZP,D*8:20+MEJQ,,>Z:XL<1IO MN,MKO.+P1F*Y/=[! 2="1*;,NNW6!,N>! !Q->E!UN%9=?[$ MV 2A&3-,P=:;:@J;!/P-U!>OO#&2!?*
*X+E2&"%RD1'Y,)R*W3?RVV R\&(9D!,J8*M:QM5^"1,P0!5FL MI0!6C=G%-!Y$Z.R3\[).ODBW^]I08KKE58V:NC+W,Y1^6&> `S)0VO3FO^\? M[A_M?O*.#H[_]#*
[N!U\.3JN=T:],M\ 1@3)+9W;E>IORO&IT(4BKG?0!+XF.8UBMZ +6'^MZP$7HXSZ+/,":{JNF#S-I"3-4#Q@,_P_\O:&:\]B8,?+0Q1E\8C# E1**V190<).8-,*
*[MPX3$>P[5)0=8Q_0,T6XPZE$*7B M5W%&:XH 5#9,RB>#]SQ&$B>TX[IS1=G+3.[=36CA$2S"#O"3$<#UK59 M(>2&KW&#C,[VP57]T*!NNJ3"RRZ;%K2'PU>@O%X;,4"TK*

*M6!{&8),_3*GW+,>!8K@K!#YS-K&!>QRE90M$\"(PPC3-MP*M=#Z3,>*;J!8$ M'USFUIT@Y"82MUMD_#F!EBKXGR^-S1H.MW,)U'D+LW>7%#*%9/B*I_U>_<[ME*E.H2*F).TI5!F_D[OXG?-8VY%\.#C9_^QU6]ZWPZ/!WP^.3_;/]C]XQ[N? M]H^]+Q^]_?_Z=O $N,&-$>G_>,;?[>]^.#DX.U//M'G[POAWOPW-^/?]RM[__ MX7B+GO46^;R;Y8*WQ/,Z3&XUKN(^#UOO>R!# 3K@.T!4U $##9-1WFR_>HJ/6 M:WD?!C_N?OMTOK;\"_?Y/YWZ'U5 MYC^4RE!"<\4\R2 AM$4GN+|-VI,%B_'YX'!?>0H?]H? HF92#\,\@_3E^-O M1{7Z>A+UE3OCF+,AI#R-(AM\5PV(%&.2($^4!=>)?@VW0E2U8C"\G?^P?;=`S M> >"[\|X=5]4[&N;_R9#852_6Y/%9^3?]^&^=YX "/4X,_EAE>]> M?>"-D=Y"_6D&I< TY,+`*=@>+UV]*^_08FP36P4S,21$B6+O",H; MG:%H=EZ';QR6%9<"Z(TG@F2)] $\F@8R; A.@MJ0H9A',!H6E3.-6M-8S;V- M*^1,F$J<%)+/=-*2LEN^G" <%GOE?&>%6.(TU=^P'+ U:O7@XTUU>).5.H313QGL M&#[5OLW_04E]7.QS.2[3"X%5#OT-J0H!7AM?@+\U"$8^@:Z&*A+O|!7,Q]3G M@B(%8;?=ZDVZO{FRP^M-PO-VXS<[K?;X5M_KMC]3P2]^QTYK=,LI/MZ7V]WN M8+CESWC+%0C^YHL|L%3^]6V>KIIR-@6HX7PQ_7&:)KL?:I*E#/&_:DOL)N2 M58)?5&H(;)R>BCEK>M+^6V-/;F D\]! ^N_KMZK>KW^[AWDYI7OC;WU|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`"CFH+6UO8VL+6%O:F M%K;W4H_$3>1_&VUL;SCN=2=O@T&G,^B.:AOl,#;\eYQ*Q#YV>D]M9W_5D_>K MOE=M45^F1>UO;VBW10=@^TRJTNZ#GO?D>O>1M,>L/.L%,^;UC+%R\(=UC<%R^\|+_T2RZ4V$G^X^#]PQG_;@NE.#H*Y(X9^_M;:LOF0*U-HEFW!I?/<Z9^$Y_JV46O?RCD>HZI4ZSW$8PW$71=VD)P>]*E M#89FO

M(I.CA,"RMP+\UlC;>U2WJ=;665X9R;96-_'!5H(V=!%BN_55\PL1KR09G-W-M2]R=+!\3N+?I0">?AG//+I9]F&OWB_7XY!7I\C<-G=PZG;CT(QH1B-94\^)R-M>%S*FK5-7X*$VK37:2D-MA-I$BM0P_%N:^*'TK!O!ZNY?R'F@T*IR$Y>RM?5Y">4VR.6Y(AJ4V7G4L.<[-MR0-2T_';\O+SE*0=.?7K/A1&L2N*'A=I@-M>7,_QCX%F4"!X.*
*CN%>RW=4UGTFXP",*T)8<,!?Y3< O77L[6]!7."TEP-HM;RA^\B-I_\-MZ[GXF?$C0YA>K>VT?O;K=P@-E$;?]>[N+]E)N$!+LV_\(GMK.G6Q#5"I,50/V9^>'2=)_+F M7";X'E288-M_=Z>8U"OFFC1#*7-W:6!^"\&G&7_)+_PL7"EF+V|K_\G$W%/%MBAP64P&AZ\K?RR&2Y2QU!59!KX1O8D4V54RPN:.S12W#+9CC:2K%&L++V?TBP*
M4J=)E._3T[&7FY7::\83:+W;W1MNNF_$4Y36^-N;,_MJ,Z#P'Q#IGN^T<'"%F?O9_E0+_%)$T2/@13\F?G![>W=WJYF>;:"IY$$=>&M66X0U^L*/ZI>5LVM& P4;V%420-TU57-MWQIK-'@_$11N ! I2F95I M'&1M8C[021 =.LXD;NK.X/11M3ZV&U)Z5^$0#!]1OH<*V.TT%U&G& M=@ERS_@5?WT$NV"=I"3+7[$?I@XNLYCE^ZI^!K5=9G7YM##?
&72!ILQ8;S+S M]+@HX[3[CX"'=4$/-N:T"PP!2C.W2/RZS1M2.)W6QI0Y!2"SS*_5\-)8 MGL$/:XZ(2I7C^_1^3&) G.?ZB+;.O2:0=![Z31BSVM&63!.L$"GE#\;0*.*
*MF)^%6<]*3C;&<+95#)$F M2MY,Q@9METE=)VQ45<0LF= MGPBK2 %<-N$KJ]9JK#!O[&8,T'V[0INE 7(7_SZZ1J=)"54W=N0*)&6%>?3L M7>+#=%X9-*
R9^O/[N\O6EH'_*9)3"FU18D?1\7((?L/W#$ MGY1,+6MK,_<2Q7AK+L(HRC[]HG?J6T#:;;@:F56E>&_Z4F)37TY#:CY]|Q#^& MX?>(2/R 8.S5Y^2@^]D[T4.KU=.O6DC#(-$4RXT?,UG@!TP"X#UHQ[^*!:8: M?@:?C 9IHQLLCY& ;0RD),LJ@#FA"/1] ==0%4^258$(LCOL(#KS\^&;I(H. M'>>2]#(# >0<1>9()2>I.%W^@!*=?L97/%R M'?+Z?145*
0HH7.MV5W @Z;8TUU@LC;0P>B64H>@_;R'G M.3LY05JBR&"W.1WRQ)W?[H#$(:IFB'%.@7-U&LV8!L _A,&#"2> M>XE2Q(*"?@!:\"NPQ4S$"LLJ"#!?_T0Z)^WH-P1 M8*
7@'HIHZ^=I^,Y-C=F?-^%J_)C^:JNX-'M2F'TM!L.;UIN,[5=!$?Z MN]]T*UM:MAOU4Q-BW6277Y<>#IUBM/XAH$AQ.U>%?GP>11FHD.>,.OY-@(QN8.%X!%8X*
4]=+J35QZ^LC$<(Z9QMM8/D[7:3X#F9? M'=Q7210&U#!%WK0,[+WTBRS1YTL,EE"O26O8LSZ&[9AD$;&(.2%A:BA=_P0S_M_B)0XW]1?VO'D3'>LRL'W?"RY0W"*L>1-*
*V_<0TN75F-N(Z=':91X:LZ!S2K ME7!H#8U'EFFIB-'_P57VM#$?K[MUBI]!IN?0UT^.?*5HZ3)>C=U$!&>R=)Z+ MP(NMD(>L0R3;(*HNY2)X[FGW,8/:?*
("UCY#$)"FBVUA6(=11RL3D@>U!5,G ME9@/)";'RF8!N2OI5;&&GM>@|+&TLID140 R$HH.C'[B$&A*K9^O M<>|=KFX14]*GMHMMP2K+PRVYQ?R=OP+C*%,];,??1$C5$D"G?M8A(93I#EKA
MME,_RW.M3)\\ IC>1[+Y=O:MU$Q7"&=I:K6Q+8D%)'6-1%&IE09&L_)3$% RF'+I8|ZTW?A"MN:'ODFOY'KV1 MO_3$WFWTM8XWS<&F\"<#^?*
*^X;T2]C4O_79X0UZ.C[0HJ_(D3# I"O+'V.N_< MUUW\9Q4(Q;R+AA=?TV%46'(!1J]*K24F0 M<@3(VB2*$(N;7ZSQ!X5W@PC>YUA_.IAY^G1W$U'RCI I=)[I*XZTVHX,9 "-M8,Y*
*(EYJ?QFUJ!23#@-32-K5MPX&DF6"YP0K1#A5YN.HNDW3'P&K5O-BE MVYCHO33PB.#'SD*_.%.FLZF8_"NQG2+)HERG1QH/^XRXFTJ XGOP@1(5*
*M.1.*A)!VN2^YB3Y()BWN/WU^7H9Y*W93VF1NT;SY19^F>WSIZI*YNO6=%4*) M-N=%T\&VH1&,@%H:-#Y; I_M^$WN\TT2!2C-.D55=NOK-.0/:H?*
*L52J8IN'$/E%7YZQ<.P0<@YY)T!K=;,VQ,[",]=FX?2C8MTI!3Z6BPN23JH)T)(T MLVV:QXH@P2?55"G5-)P?XK$NR]_0R:D+M0R&Z8K*I.DRTX=X^28/7^W;V|V3*
*M7#QGZ|\%9(6^,B52*WRJV\\"M^01')|+]=>,WGHJ7z&FA^7+B"2F @!?%0O6 MP5_=H9>[[/9&\AM_6'".79_D;N[H+K&'N647ZJ)*3U4#06A:[-*
M%I.T%TC++#I24BT M9]5MBIEV@8[KV]NV_;#8[2+/\.Z$M91G@MBH#5'@73J-QOK$12V+J-I.MJ_MZGVIQ|NN4C"#7'"ZW]M8#OZ@T /Z=':?]UJBB_VD9/[A&L@P@B0-
U7=A#%D/-MHH@+>+*-(@&1H[.7E!U'ZHY\&;WX*\8A/R3J"'_F?RK9W_G/YLP)70A>7,=WP M<_!3TK Ls0[>0}/I[K'L1,4RHQ 'P-<8?Y818)[^F)!M_@'?Y)KC-7=R=RA8*
MK"%WRK._^EFL,-/V[G3]XCXDL'MU<6T7QU#P-6,ZBM&;'X%%5R69&SI-DZ6K M=&J.?6PGOM$HO'H,GC[:QM1EU#!-AB$,MP2/SF,A5D^:),WA"O,"G4,(C>
*M.$'10DX)^%VH4U7TIVK"I,U]G7VB/Z%-N(H4A>L4C9QG"0E%&_$N-]%G^E=^ MU!%Q"(S!>)M@0^&!=+]]M*T[WWZMMJ36W"MM:ALKL9'F=I.DRPV26GQT!1S[*
M4QDQ!/D\C@N2343]!8N8O)2F2&-%KQE@JZD2U72HL5U[NPP\4$5;]?.\#)UF M@2@$%Z;@X%/:=0]YG.MZJ-9%*UG8B^Z24FHS6J/Q0IBCPY7S]Q3+,G1R]% M.2G (;QC^*:]1?*
*8@.;.!0BA(#R4'.ICNL.(#-MXK?]M!#IZ M1KCV13)N>)8$^R%.II-XI4;Z[7G/892/W *"=.@5]&WC1=WGV;P]X+9.Y<)*
MEAV)#0[.X;X4;CT=V'N1^1#>6Z6]WM$U&;'BP!2R4&HVZ?+_!U]6*?7.KV(M,XH\"UR&2G;NC_B\R+?)"#IW_M;G25?T\'I75+) M-'7%I1<&_*
*&$;',39U9PB.*1&FD(FB(X'7M.I$\S>?HOWU.FF%BI;_/R6%G M"N74=AG!SO*0HFU8;*O:O[>Q0A!0F5IZ4'#GYO73$.R&H'I],]6,JGKUJ3C[Z/?3Q(\3K5W 2*E@ZWMLK8%3YH,9?*
*%-E0C05.ZLR-J(5F2'QT]JTI?Y(C5:D^DWWJ]*VQYN1 M8==4%%K>? 8\P(-VB @"1<<@C*1T<5>0KMU/N3]%=]O L&&OT"I)E%;M9JO9*
MH!89=!5E\|'3+ZOO%@RDBY@[)81B++(+\C!"UI]&4A8NVM^CER0/X6IQ?L>#_MQB^H0R9OC[N8D;Z7,/W'3&EH.#\S4^#,)GD?B3^':YB_(7_!?"M^1F)A155 MX2:3C&T?WI-
*,]"IMI+S05%7T[0HJ?+SGRS<4O:(O"18SY"4L#]=F'>Y24S:M 4253ID3?HWRQODG2-0K!T2!=K?4QW'TV7&%70(Z@U6CF;[M<,)"XF"*L^QT8C MVWY:R7F2TC_]H?0/67;-Y?*
$+SE*M^UWB"> AENDQ=0(V0HGO)I#0W$P6W0&6O%!I[+,Y@KNP3 #C9E!-=P;<>'G;$>[HI?22 MO7[?A32861+:WZ_O;'1 XI#Y<&?NCH4JE_?F;BO*ISI*Y2MTG"GS>(S[YR!*
*MK452^S&[V-O_ZF;+|DC&[H*S-!<6B_]5+13_?0]_0NH6YG7>Z$ M;.)H3QW9H^"4",H50<;9:=]RSUIS (ZO'Q#+BT]4Q:(SVMS>@?IZHZ?2A.*
M%%G'#9+R;ZV0\BXS#('+ADG-(R>4E,4.D.5 ;@%FG>>;^^,Q#?DRPC63_K)"7V M1).4V]6G\W!5&0<&?L2GH"^X9NQG'9,H1RP37(3W$,O47))K26]!Z-S9/7^Q M7 8 <1M[:5 ;
C81[CBKH,KS+,KW$]COU(VMCRKN@? M"= US'L5ZPH4]^CM'/Q_F;#;@L!8L-BJ\)6!QJB");MUGE\8J!%SI4M/=X@2 M\&R1!.X7A 4GA)7#>Y!721E7_FL=VGH/ F,"PY[#]77-G?*
*D #:7]^E)O&>32 M; MB0Q91DO#/$9+)2D_"750C!WR$RE==^C%CQA^3/O3D;6P[L&4S)DE8,&% MSH.C:.M.$6IGV!LCQ_1]'$/&*HSWCA(8#D!ET>M/OWJL C;+!>O0CR@*
O2Y6 M7=K2MC&!?N^(O/FI)R-K9AMW&C_@\ HR'|HRH>F>(,]6(2>RN77KZ##7EPGJ M912>/B-=W=YVFJ/_&@;+3;+-DEA]\I)63FN;"$4DM7]3O.T(F:)Z/(2ZM8D5 M%I-
A3PRG-ZDEZXO_#N#+TB-H_WVV2&^]9\+4S5WR D#]PVV'L@58_/$C5H39 MAKH$-'4'S?U&RWPL10JLROC9!G;P%0M^^$%UZ\"KKM/(]2- =S;M'K4H=7W*
*M<7@]8SF%6*K\" !B)DK>;F."@]P!@+MK;|=^+2R/";>#1%S6>D1^=W%6C:P MQZX MJPE<9E:.S2?T P 1 O1"@-DJ7),T/VH!8J-\.XF6?92B9%7]C,.W;*
M'LVVME=>$ALD;SN'9-K_0(ZAH]$" X$ZK+Y\<00R:I M;J-'Y.]'PYT%C7QO!LRO6INY@:5V+T#;@\"T@4DLSN@F2=*5Y@5- WG%O), M$R?
*NT1OY4|_8YF9GAPCWTM3/*N#!8E\U8:8PD@Q$_N\GRE+ZZJE6A|"MCQPZ M-ZKQ"46DB4=MN?%CED7S$\F;^@&$3RK-;#0S=Q#.8"<8DOI7B\|!8Q*WB0C5N*
ML&YI)T6YOPDCE{Z.7]H]-0-5}GLO.2#1ZXA>4P>C?-:). =RP))6LR1.M]O)Y/8F.];<@B%7QT#*?0NU2.G4=);(!#'AF/%UE6]M)^'(4<-/L2X=> MHU9!^1K[W#7YD*
*(=E9H>L%H1R:.>>_0>*W,/:SO2!#PU"W3MZDZ53>*$VZ0I M5#&+HC,\!.9^UA/5F >$OZ6/"&]DG &$"C71L5 YZ3%T[FP;0&S_ZF?)U<.M M!C^LT<2V38SVOB'O;%_'YJQ]&8.-*
*D7*G,_CV$PD0B/C,"W6()SX_@ME+7 M(%(VG9_XI1=9>G+6G&)11@38=9 $((_*P;PY;NQ]R6D5WLQ;_T M7Y6,@'V<&ZQ @^# A#"Y7MYL-!R,'Y-*
*MV&6)>E>#P)OZN*0&8@1XQ&!PDNO MP78)O#/ ?1G&6ZA4-WZ":]V6l-3?\KQ85_I*PE8'FZ7F6R9 R Q;-G%S*M M^H0E=:0QJ3'!$;Y&%H GVG%N2*!6=IL+L+54X%W#F_J-3[[' *
*'/K*D'9)F0Y"=5 ML$IO,N.8'_5<#Z4"5^&.0NC2\">-K;$_K;%3(()SS.=-|\B-J'6PG-*"\]J!1N73Z4G$8;1\@-;J4O=?_ +\G*8$T4N;* M#Z%D6Y42\[@Y1&\5U@]N*
*3H+YB>0RC"|:5A>@\U(MUM(*0/-55Z*1;;*8=W MA^>50"@_N]D5[%OO,P-D)6,X0Z:*9^@&N324_FBRH7QB)$;/R8O>#-_2).W M? ,LYL?*
J\!=YZ^EJ4X3O!U6F+NYUKJE4CS5>T,4++"@!C"U7U"^20*(\C3C M\UD@/)9,SNYJ*L7(#)[*D]^*;([W-4M'8&3Z".JZ@4V]GF]|0 M5.X+V$;V]&6+(L|*
*&1!?._@9#%>*L^A*PIE26?2K5]6IM[*M9*[LMZ3FB]3+ MW&PS"Z58@N+;00N6I9D%]"@N@B?I2&6HA>)&>@/=UBOX_Y!EG@4FO$!NO=W*
*MJ,UMMY"HQL@EPRKV=V&+^C2PSEN_<.$ZP9;T&@\O\(+...LB^@N7*OD[RX|MW4F+).#+@$%?:^/R!%8(!1E8J,"[3B30M<#IZOTW!+/|KTERTU29%@*6+[A*
*M<[X#!%2C4"AG;TW\57\JSK,K]V6]>AKQS9?R(HF"9<'- %2@'Y@+V6S!TKO&N+V*TW*1)\;*YP2H3]+<9*
MR11,TSTD!>H"D&R/XM3L4]5O&"0G1>.Y)")R7&](@KVB+N'5Q@#0;M2!!*K6 ML|%5=HO!-/6RC?,%D;/\?\%\((:D-2A@1//N]L&RUJZ2UC#;V/J0ZK9>;_-M8Q)B*
*1'1D'4ODK=^K]V8S+?',F?Z70^YG[NF*Q\$HC\6=ZJ++2-&$#(1_LL M7*JFTNT#B;K3V\/UUO]2Q"2L)'IZ\W=&Y&IM%W=]f7:'Y3L2]HSBP|@EF1\M MU@*
*41<($J!NY&^|>1&H&EAC@IA(0F1'0SU!W5M':.PB362<*SO $7%%@:(X7)/\H@<[V[M]K>|+<.8*-D)F#N-8*/"7Q=!M78(MJMW&45*U.\0#(S%HSLW-TE9#E"/]1* IH/UC-*
*,5R:4DX<<=Y&CX7'6^3;AVM!\FN(!HO7(^[U#1!?P756<7Q-D MJ;K##,1\>SVSE!^R!#)G1.IA2Y1U15|S*I4);Z8/B5&5A*KY@V7!;,,"%AXS+!-M7X$O?\/.G1P^&SF/($-*
*Y3L%Z35XB=0|W#G]\F9!%7L>*KBK:R_]."7F5!W\(M28<7'JLFJE7GZXW<31:]T$C '2"V,.EYW\U2TZWO_*(5#H9P&,^#D"\W+"U^.ML5XCR)?76$Z4C2W/ZB?*
PLJ_0P\9/M_[=W:5Z2HJ6MG49&H-|,\FDBD]M@?-5 MC9!=<^&G+WX8\V<3P%]]A!NMM'H@,>M1QA#G7<>SUE054[>>2Y43[=TL:SJJ M$,,|$CR%E\X?O0EB?--1 !*_2@BLJ-*
*9L.E*R/;52^@HHP8-32>C9N9X>X; MA&\3+3^KW?*3K_;ZB(B!EHE>DLC7X MIZ^QH*]\1R>>A.MH#A6@K&>&UZ=[[-H|HSI?3 o+(C4K?P/\(0FA-CC-X!&/$ M8Q@ZN;ST5*
*-8C5:C@P*P.>D4B_NH+[]#J,HW$=0C[5]Y,!ZV6+]@!5H$DM# M'R,;Y'$U^A9>8H9EKKU]5*W= M]P9@U)D+9U-F\" 4]\"OC+I*_5INUR#/?=;?RW/O/E&XI>$;$1**N"#:,+I*
M%M"3U=,@8-FWL/3?.7(7#=,R6&94[=V62C'&^=4;N4^ %(1(H9:8UJW= MK:],FQ $D>>0&G.3I!=)FB9O*##&E7;L.2(8('/_+;_,DLMAWSIUF?2K95=Y MZ4,'Y:1HJ^Q^;CNG*
*H8L8.[1VCL!*97&_X?D1^!2X-?S-|<|3VG"_H'KVU3-MMEXDG'HS-#EG@<31ZKM.E<7_^F)TI'9W#;P&T.MU-3&[]>8D\W*F$6FZS). M7-K$%0/N-?*
EP%!GEJJ8N0\$.CA.9B8CO#R_P_;6-4&HVF5-P MT,'0NI1)\"AH0/9%C,$K\$B-MA!U(TGDM>NDA61SRLC_@W^C4Q44[4DZ[]+3=H060-4L8@+"LDBAV('Z=E&V=6O\;$.7$"!G
*MELCXEN@3S7M0L+WU^$ERR%T9A*U10P$ MG4*U;$OKUN"Z=9<4F>B0Y-BIGT/3QBL,8BX[(.0X+6R6QH&%P4^7V2_P7E M#WZH!!3LVGV67O_5BA.+)#"'Y5MZ@+-?*
*06C4"%D!]*TJHLZ]-":[:%4'')G M%*Z3- [\&W+!AAED7%XD^,;5WM3F?L<97U8&<7$8D!_2I-CQND^0[%V@=@+F1 MDU:M,B=3<"Y:J;5H79)QC\X:F@ M)PW%!:QI-*
2MK00OW^AD#1:&)}9LI3+,;W/U-M=M4;%;9A:>#5KNE_"Z;0;N16\R-=O5M&N%6:3Z)56L&4LD1E_)6H=2]'8_>0[XN:JFL\PX+89+]]VK9%P$QO@GLB*
MP4QR26R"+R@&!,K.&5;]:,.R]6H9^K3V)S #Q335CTW7>AX+M@)@:|{H>CD/9 M=B3$!R:_+.)N\0M=NKF/ K_87_@1\7=N$,])DPP#/4 '7\@KBK#Z'"S1:A,G4?+"P..T_G93 M+X<:
*_&'9N#@1GZZ M"#T(N%LD-[U8)BP,09D\IUID=P(39S80**N01E] ?JDFM:'5 MU+8!@T:8AJ\$V%81JRO62$T.W7O/1!Z@D>IIW80II)M#2ZA?')IT[B@*\[_C'++ MR.=*
<@:,!*8.G2WS4$UB6-BA='FD\D.VDYNIT>XB&6 RK)9Z3LXG5X52B"_M#Z*DCZS?$NT^G:!W*X,B%58E1@%-KAY@V7!;,,"%AXS+!-M7X$O?\/.G1P^&SF/(&-*
*M%AV[=D9|Z8QBWAKXET'H4-U!2L:VXY7QKM6L1=3 ,*_M]-D=NN8.G8 QS(%F 3R&V<_TYH6?E"X_=8]99@-^U$3{IX&?:H&QW6{(T%[8$ M_ZO:#OR/O{$*05(!H/UWH|(G)"8?*
*ISY%]-7.H8U(S+51VH9JC9RGU72"/C2(M+X>0<@E71ZQ56*XB@?=QP.*1!:=7=S2.0ZG91CS)\G!+"H+[.RP4YW1 TR.Y MV]=@O]|(+K#N_6R#1+(2'EC3)OEG_EX.#REI-A/?4*
*,,7W+/=_(6=2#C[BL) M F(&)2-(^[V-68*P]B6L]',167H+0I0R51N?SDOJ,_5% MO=0]YF(8>BK98_MEQS(,B%58E1@%-WZNI,%B.Y2M(%2-Z^H^]1(96*(*
*M5);6:C%EHPPG[#B*H4R.N4MHZ%R'4 95G[FPKM(:VQ5C_E!RSC6D"0*TAQ2S MH'.061?)[=**[3*:&%]6!LY)\1QUX;[RKH4J#Y%R1F98&CNYC1K)"<@9>A M##%=@#-\IJ+-*
*S]YGB#7^-4QN(PQ(R&42-B5F=NPTDU@***E* MBE):=JR1=7?F8>;_O*3HA3F+&?K_G2$IR|AM:[}D%Q+ODQQE=PF^+_.1E &E ME>C8T>G>BYIMYRXW'|^-4JB-*
\MO7;L>B;>THQXTD@[;4@98LL0!5(E7M|VTBDOPYS*T $4R2|\"9 M"8H$[.0FW"T3^L8K%|*7PCP,R 1_BX!FHXOOI4)RIHK)>10E;5!+_&\;?G*P MNJA+OOSD$H^C0fUO-9I-*
ARO# M!8Q%#F2BNA6Z$QBGY@@$E##1/)D69+AUP2X>DE*8G//T]3],[.H2_ GJCX MLZ W&Y$?K XQED3,[75:V;=LY#S?!5_LE)/4RJ2T]5/ OOIB4P*SYA4:L**
*MYM8S6\B+\@"R/"B@=35'"X71M;OM@(0-'A"NCQY3-?;Q'=G%*E?1,&6F)4"X MLKFXE;J+,8>&'P=1D@8W11Q YC@6-O+,[2Y-7NG5Q$+C'E!*5#FI1Z,G">O*
*MTE#8@=;AJQ2^JZ/ZC'U& L!9Q!4^"I6>%^N:,]D)M]*I8WMV/*%X6#ZP2% \D-G-\K*8,M4#:W& F<2(MF@K+C8KF?9A40;|"DM$/$6'@O2(U&N5IU$!)*6TI3.Z%E1=IQR*
*]6%D%.3 M2.76N?>W^GQ[9?-Y^ D:KIJ>_G0C@3FB*FJL'JH>(Z"!D_OHV5_]+'B-Y'>E MQD[CT'1/>3\"MA,+$*WB 8]EMDFB0 .JKFPI1;3,GQ&HH*@XQQ^?_X)XI L@ MWK":E-*
7S,E8^[R8I4O76]R,P6;+,$\1(! T3981^SBZ5!A?P MU)DKR$A&05=TZKY47";;2;!PF,>0)EV3^'4%U'B?X&,]%CZ$(KS<@54@8ME M8*V 7O^04.LMB;',P -*
[%RHWQ1[]&86RXHN_;R"KT&560&%,]IZ@F'N+9)V1)[#.6M5Z0D1_QYUQB$NI ++(EV[6B\^ M(<:R<>V1& 3/U0]WAU[SNL#[7,;6C8TINO,++(&5\M'T4\ ML5$9W%EO-
*3LSFDFO-?;,;'^P*3 R4,KS+W%:B MTSA7[C$KIO:N*)WL@X^-Z3.O5U]%Y?7BC8=Z7.WAEFF>W O$FPG.E'*,4'-MCQGN8 =*
[L+K=]fW>58U%>|%QI$8B2_,,L5<@^Q55C(IUX%H5ZUUL-BAZ8S MMOKZM$R)CB|(,%H|$4V""90A?6T90P_;[VB]=CM)+%-50^_0P9WSH^8_TU0L MDS2Z]?'G8;-
PX=]OKM[&I>6.WF5U]/GRKJ85.K=ALLPG>ALJT^^&GB)K$J4KK&74,W59VGXF,_8@"M"4Z"2N[G/M1+HGY[MO; MV?+- 7R !5BHS$SMC.!U ;#2$I@OJ.L@)O&L&(2-
*2RX*N_62N7$-&8M_>+1%W-MN3&$QQF17%<6#]N\W_2]YB%(==,QM5U&BV{5=A!V3A^SVF5L,H"OEE6+,X_2 M<\I%A*=0Q>^:NMJU:=?1+*
[$L2E)%Y4EN6KKT[6TE|5HMG6OGI-L;[MX'TFYLD M[1<8.H2BY2-;K/$&VS>3V@3KB)-=2)%RU$](@/CB%FN%F9U_S0ZVC!HS;.C"D31SYQOE:L9MO"OR[
*ZB*A5;]7>9!SB5SYGZ|\%1$^]DIQR4\RNLKWSH"$F,'4+%VHTGH7QGHM_=QT\ MLN9^]J-U#4,,1@N'8C@M=,BKMRGE]D:ST6[QEO%9$Z,1H9=#7.LP A%3>ZTW*
*M&KF[%00@B*NB>,]71=2.%31<%%NC:>,!T6ES#]K_S_6G;JV%DV:R+D#O6\C M_%/\]=O4'SV\>F;VD[P@ 3 I'[E2A!8GGV^M^BYU*>,29.(T1/&;_TGTI3.Z%E1=IQR*
*]6%D%.3 M2.76N?>W^GQ[9?-Y^ D:KIJ>_G0C@3FB*FJL'JH>(Z"!D_OHV5_]+'B-Y'>E MQD[CT'1/>3\"MA,+$*WB 8]EMDFB0 .JKFPI1;3,GQ&HH*@XQQ^?_X)XI L@ MWK":E-*
7S,E8^[R8I4O76]R,P6;+,$\1(! T3981^SBZ5!A?P MU)DKR$A&05=TZKY47";;2;!PF,>0)EV3^'4%U'B?X&,]%CZ$(KS<@54@8ME M8*V 7O^04.LMB;',P -*
[%RHWQ1[]&86RXHN_;R"KT&560&%,]IZ@F'N+9)V1)[#.6M5Z0D1_QYUQB$NI ++(EV[6B\^ M(<:R<>V1& 3/U0]WAU[SNL#[7,;6C8TINO,++(&5\M'T4\ ML5$9W%EO-
*3LSFDFO-?;,;'^P*3 R4,KS+W%:B MTSA7[C$KIO:N*)WL@X^-Z3.O5U]%Y?7BC8=Z7.WAEFF>W O$FPG.E'*,4'-MCQGN8 =*
[L+K=]fW>58U%>|%QI$8B2_,,L5<@^Q55C(IUX%H5ZUUL-BAZ8S MMOKZM$R)CB|(,%H|$4V""90A?6T90P_;[VB]=CM)+%-50^_0P9WSH^8_TU0L MDS2Z]?'G8;-
PX=]OKM[&I>6.WF5U]/GRKJ85.K=ALLPG>ALJT^^&GB)K$J4KK&74,W59VGXF,_8@"M"4Z"2N[G/M1+HGY[MO; MV?+- 7R !5BHS$SMC.!U ;#2$I@OJ.L@)O&L&(2-
*2RX*N_62N7$-&8M_>+1%W-MN3&$QQF17%<6#]N\W_2]YB%(==,QM5U&BV{5=A!V3A^SVF5L,H"OEE6+,X_2 M<\I%A*=0Q>^:NMJU:=?1+*
[$L2E)%Y4EN6KKT[6TE|5HMG6OGI-L;[MX'TFYLD M[1<8.H2BY2-;K/$&VS>3V@3KB)-=2)%RU$](@/CB%FN%F9U_S0ZVC!HS;.C"D31SYQOE:L9MO"OR[
*ZB*A5;]7>9!SB5SYGZ|\%1$^]DIQR4\RNLKWSH"$F,'4+%VHTGH7QGHM_=QT\ MLN9^]J-U#4,,1@N'8C@M=,BKMRGE]D:ST6[QEO%9$Z,1H9=#7.LP A%3>ZTW*
*M&KF[%00@B*NB>,]71=2.%31<%%NC(*"SZMFP>>!'%6. M3=X7!*-[]#:\QXUA'A,;,:EI;T6F4.H/X\I2DVX/.WPKV_++V17QXSUM#=V:-M/|"MB0%E'-7'L#GRJ"&*
(!W"#'#-]C-2_*1=-[>7X'6N!<]!4LCCKE:++L^0 M!:C/?]3;80|S=_'1X20%0AJ=EV+O'Z8'ECA'\X,5H\-? ZLJ:-M2CXEZ7';^+'PRG56Y$=E.8CNVZ0>9O[+ ^#\('RG56Y$=E.8CNVZ0>9O[+ ^#\('RG56Y$=E.8CNVZ0>9O[+ ^#\('R

"O$ZL%N9DG7L\CHMH#DGM|D$11T6$EY|&[V^^{G}NBW&I%)"[^(N_|%0;P MR BC"l,W81SFZ Y|M3211L<4"(LQ,!:P+!L2WS MF|N7S&/[ZE%LM_@^"D'7!?,,U!5Y2+'.N5BS DY5/.#H:! M+=G1@;Q=.=(O8?7LZV[&lO&-J ;TR(CP:,;$QO8=?U$:TDGO[&Q+VXHPILMR3 M+:X9WL^+?)-/.|[?XNN$@BH.SP")/T,$VO)/K! [+>7RGA<3_W.RP'OB9'3K49<^61L&B M&J&+YL-X%8@/-V10D;RKHUYT,R'E@!,?WWG1# 3LN\A=5?B,@EC$KA\ MX4$^"+\Y<4 M$47OSV&^N880%?P\9A8\)W0,A@U? CN\K&6:\IRC7&:D?>&?ZRNM\\"CE#^PY M^'Q0S'IVT=?4%}{RRF[L;-^;,*V3N+COK!0<4GK1|PF #""'V*V, + MB^.]TD)%D^]5=(S;5'XEE3DON$G<8?EI \0R*)GI $^O"F.IQK"*J%I#S^9/I M3W8,"_RE+_WW 3$N0(%8K,>,8[$P79%C8+H0CC)R98XDOO2SC0 %LE@W'/F# M8A>3^(P83OO] !!UPRJ0@92>.K8U1HWE";1:1FW&.1S;\IHE5C]>XNAJG/#0 M$3F1)I!2Y\!CF/U\F!!:A[Q@G@\@=YS+]>>@OD*QN,#[RY@@?>.NAQM/*N)4 M2?!8^K!P8)/I"W<(\SNJ%P$JZ^:R8AH4MR2 .H;+-#XT= GH20('Q!45'Q?\S\3!RZ+%YP@(GW*?:LA?KrI.0#XJUACUI'K'0WP3K^U0?)A MA!EP_,3H[3:D5[@MMJS2S7D0$- G6 MCRJ8FKL0\|C"#@U7@3C'.-.H_HRRV)%U0_"Z}\W=ZS+,/FU MNI_J;&I1EN9_8U"\BY1E5PYUIS-Z5%;@).<^_:@~J"T5:9II.X!GGB2D4>=3* MJ\U)'L.\H_J4&0#K)*^MS64H"K";M @UAG! V_?/QKCH2%RP;YU%;[LA/01L)V& MW>0>:,EF2O=RP]T4I@DZ^3T65ZO?"%G"%F!R+I,(#TY -?&E*^X/2);BOVF$ M;0XP';5.1[X9_"D21B$6BOHX8H+V=' \943Q*^5$/"^6R1>_D.@(&SAW]XO[ML\OSIQ^]V_N?KI^6M_<_>.?W5]|-[?WY_27YU^7R]J?;Y>WUT^A0>*,MN'($ MLOAP-@ YZG((&G(R+0 =M\TO$Q81QY0C_%G1YW%(G#\G#9WF3\M2^L+;39@*X5!7^~,_Y1. @IO_^3TBD"Q.UNG"Z(CGN548,UEQK6G R@^'^R9 MPU_2ZZ>'AR.8,CN:"NV+6'.G>M%(96*BP4>L7CG)J3K/AS1\+G(2A)Q4V<"+ M-7B<*Q_3H/,AJB6HT &Y0.?925A[ZQ>8L$+LZP8LT2RHPUAIR^.6E:KI^L6 M:X.'XXKO5;5]0A(Y_E?#WSFJ%8D^U*CNW^:@SZ52 7A$YVM\|#9@3)98Z$4^ M4/LEK*Q2R4D.)LUP*$)L!$Y8X$U8[L M-^(Z .YIP!/5&K_'H$P $4(QAEE: (Y=@9'1RP,H!A(0KX94,R@R<2 M/:+UB+!*[?E%3%1XT6"31%:S*ZQD);0 8UVA-B""K5FC5)<(R(C'^WRN!*% MH. 1 0B&\PKG\5%/!VR^U0;T!!)RXT(^$;$<>O0H9I6DSW&=X<_^65L M&0!*+=:"=7QX#A90)X7N)A$"K"\E$E911LL1W"W\+X'Z9'E9CYA/TG!%0'NS M#<4XXO^ //**IX@5&OEO+;B62"H"!'O"#P+I7]*"Y6E70]+5GDN6K?G+)% 2 M0@(.,W##[@6U3\Z]+25Z4>*F1_/ 31>B=I*)H"%!M]9G"?I_L])^O-MC 7> M%Y0#]D2&TM=AP@Y0/0OCEO>X2K*0491MD#TB#%,.)0(HHH9#ZHZM& M-<3-2S]-I^:\;);G.0VP4M.1'"W3OJ-;#M;L&/"@3ANH54UR3HP$ MZ,U^QI$P60%C:9)[V;,\FX#,9!TE<-+HE_"=!&ZSK+]^D:1!\H9_X$4.!OFB M:0%?_]4/(^(4*LAKT\#>/.[U,F:\4X"JE@-YY4AE$8Y1&;4)II)HMXB\AE-ZH M;\1 WGUHW>"D1G-(*G T#WHTSAY$P>Q|>RWT&-=93Q"1+9:.,O772VY"",1, MT0;%6?B**$CF39*B\"6^+-(4Q:N]H!QC+8G*R(\^@/^.,Z2+#M/PPQ_?%=% M"N9<@B]++)+6E_SZT@)P? $;BR%SR2|ZL(C_5KV*[RUCM;)>?E%8@;^\?>M M|FK7IL8A5]6P#@#ZIFI4#=%\A@ALT(;I>FR:'IVD1V?)!64\T7_!O:Y'N#5Y MU#5SJO,&OF9H741WX7I00'Q5!HK2\X"@]RO0F\<'C!YC<>S3T69#B&N=3/&U MF!'';4[?I.FWU+6)\R,"U#X-X:]@@=/(?=-U=W7,NJ 1R" 7(J3B2Z#@MK!3<8*^\+];)0BH66+ <3< M$0!0X<^T*K"-S"8:UTK);VQD&F9T_[] ,2N.-(LEA=2]81G4]MB&EV">Q.PV MY;8T3!QL>S*R|$3@A9VP/3014&SC^60*X]H\N@>\|@O"[W*1HT 4P>EW&"=93 MR=*]PIA) #,9|-@W8&T#,HE;SF'@*X2]=)F2LRX2W\78A'!1@[CY0022-3_" M$*T0"!\ZB"F!\)AW&\%9>ZH@M"]D+B8X-,F,583TDVYX:)FR2%(!AN M&ADH0H.5Z%@=^G!OF+,\7@- ^X'EMJ3#"!VHX^Q6,,KHM9)S%BMI$WQ5I%], MM'#AUJ++F8<]3Q#..";8;985*+ @@!.!ZH.85S=^.11+]Y$)URQ/[G:2=9"(M$11D-VFR%<)+@36'F9,Y86^-*7O)>HV(W9VF-06(),+B?_,RJ3L\QPU^:=*L ME"GHPPI)D_A(2WD:E6;,DB9++,I ')DBH]+BGC4 UX0=RS<(7UEQF*3M\-LC M6F#46!N0K 56 I'}X;@OPT D)0?%?L3\=/00V],6Q(Y, K/- AO#*E<(@TV9V MU\3>AQ3M_##@*3(LDPWK_#3^IA]^@%0H9"-45PQ<00EQ3JZ(QRYG2L"1++[Z# M_, ^WHDQ(8B,2(Q"+LHD*^BM>%C.BR 4LLN5T)DJW7' S,7T!4?/PH#I1 ^T] MGSK\|IXQ*:(>6]>|QO0H5(/MFB)\QC MY.4=,LB!D)F2VM0#TB#%,.\QEV=60@#.5TP[@?U5IJF4"_E<1G3@H MX#P(<)N,L,H6R5ACM>ZI@[;%1LK1O6IXCX__K[Z-C-O$;7]U>5)/ MJS\3B%HLYUI=\+5*%^?FC9\4'H(_WS=)REP{M]L=_I#HS |>|\$A#H$R8 MS,,1HTL+233@Y/B0'HSYB]B(6I@C8,.!OQ7?HRLQLH"FQH!M$/'IH'_@]E-O M-\%^|*O],MD^XSL(]J-V47"_A/G6E@5G32RX:"FET;VO\UD\^W3*AU:8D:PX MNK2:O*I#\.FLWG;Y 517P5S&K,WZG"ORL,/6=3\TG]\Y?4[GE]2 MXIO?3_<6*>?W%/O#L1X/DR"(MARA/Q"W.S-9N45|W^HJ/BV0ED8EYM9@SS MMSZW$FCD7VA? Z_!C9+M8(LPSW<.0_C+WWZ<"B^M6AHZ6RN.MH&[$!#7|^M7M-MJRK^_>*V3&0;>?F^?$SC+3%|!\>"J15P^\6FX0A5@/!8<\(2^^.G/*!\<0LM' M QM4],##@!!.R8V8!LPI8,2O?BR#A1=U=H[1=1+E:6%_3_Q?JG,*%Y:XOT&A)? %:8]!AF8<"W9D#1 M?, _E./!8E9;/@^DM\ <'!(CHH$%,W\Y*!BDR+#P6]9UY#CK.@X9%!ZGWM!A M]1'CV/LA38I=R[5U)*MAI]?"C0/9C^6K'LO!M,+;&[V& /\Q=X&/Z]\22L$0 M>]T=OO[T6T/SZ0V I&QV!@5;.@1KC"2+>Y< MI"D9(EY*?&6/U3&6<-JUWIV3%*B I"^M%_#S-VRW_S'VPP2(^K5 !/C-WA MA^OJE74:W\YK80.Z&'VKl0I&;]!7&.A2]HM8,K<&LX.^KQVT? \F^9|,+GBP M$EAY;6[.?G=X,R9Y,FPNJ^^7JK3*(*[)'LYI&A4MN%=^G3A+Rf,$;$GF7IVF&C>V1XCXO\|MY? K>7V$2 MU"0X?@S&Q-L4'JKEY43B2BJ*H@)Z M)"MI/"RZLQD? TW]U04%!D>EY??AL"5Z90<&@C"K%"J"_I>G\EE,>OE=?4"Q'Y$'_M@#AH5'8X:A<3AP4?M,<'_B XIKUR<&(9:5> FB0)8LH=,<'_B2 1AWF35C_A2>9 X27O'2 M58%NXQO<)!J /O6P. [9D6XYE!47$0YI917!=?GIT"V2<^/^S]ZI-C2/+M>A? MJ8AI^Z)H$[.]-C'IO$GZM6C.&111V+/#GL^.'"'B*,%3!&@ E]J.^^-O96:] M (*26O40H3FQ8T^K179FK4*A'EF9:QE$SELH+8,(+=G&*OFXB]FF:,@0-W(R M>+BILOSBXO+RQ#_T]\PRM,O ,+NX8-+T6,"(_3CD_R[E_T[2!'X#8NIOL?8] MH[G:IRM41G/W2-H\ZN^61P%"F/;O[/,3#*]00'ICZP]Y3KZH/,T-A9#]JO M%X)M/IE9N&A2G8 .J4/09)'5]186HBOJT4X-(&I8V>IS,!*W!) N9.59]\9V MT9YG"PS4GWV7[/_MQJ2C+> !$VVRIC#/^.'?X6CT$F C+1!06G? *E[3(PS,Y' M!:I?+OKR$XN[Q/P[!S;>_%KNJE?9MP UR,H@(XOLV^WA-U_L:7F:924(A-ZP M2@_%GN);>0;AN4XWG2YDPS8"3FZG?%DL"J_E1EMG)HOVD^. *0_)4H+CH"U MJVEN@.5D;GR Q+[G-O#8XL[BCB"7NMZ9E?KBR&O-[50?U>KF2.[IS.71>'") M(4@W%|#*YX1/L/\YZ^-+3BK[U\CH|E9410N-6F0*RU!1.MT';K^.+[*BK&;2K M(3K!>EXLLU0[VAA7;&%//R@%8+N&*K;U!B/ M'[_H0*7Z5:U/3[Z8]H7:Y>3-U,U'G5#.FK8 1I-<-DCNKMNMWV+ (YK+&4P*JO!&2H?,|>@$VN,N]_&Q MBS?"3G/^BX^_-^;=? B#A6%B)V@=@^+#]4%FOL;4<5RNY*P/1HL%Q8> W!2R?/*$\7)UGS<%U7CT7,\^/MMP8X MA4WYVE2^+8^H8>X3O;C"R'CS(-\Z\L/NY-G#E,AEQLEXX0]+%#PP[8(=;QDX M@-',)W!25FW!CI@XM0ZW;4R$$ M2I-20CWH+\A-ZXKG$]JO:* CFWSRY(C=L2^9W';(B?DN] ^A1ZU*]1?I(#5^ M=&N8TQQFV\/F6\6+600JE+4YK2"!!A/!E4PBGF!D>MW@V(0G>93]JNVRX/&@ MF]&#*DY,=R:WDS4D:-7\ 0K;'SDIREQ6#7%ES;/OH8+CP)P#]1^.,T5,,7; MSFKA D9?K.-,"_9\ G\ 33!2"XFOV?=$=R&1NT+\4"^)TT@)YV|!XL'H))@ MMK-W>))>8$T"8!;,&[\4*X8=':"B#K!"8=D%) &@IK?;<90@!X#Y-6TH.J4!P MQ/LC>>,F='#S*9=".BW\TW#MN/4,@E#VZ M'GRO)W E/RI@+TY5HX,D>F@&9H04P92A_<2H<;U",$8A")X=:B \P M=D3/[IZ"!\O2L:R55+B*1V915>70(A"!OA_@]3ANH54UR3HP$ MTEQWO4!L8STUO[/QR]K=;=GXS^\IFUV M)DFU$:',E@S,,K(;EU6#(V> NE_P$[KBQ>IN(_^>0$?)K]6IYS$#"T,#RLXA MM[E/5:+;SI6]N$DE7VIY,)Y^TS 2? BW2N3[(!9"9P^M,VN>*?OL,NIQ+|(R M\2I0:5),P[/KC4-"N;$H'Q1*.DE'SS2Y73SP? ,3L>$'4H&C3L!(^4WD,P@V MR4V.,"$0MA-KT)Q_;X!%M?@S$!/4/NZ@#]T7:M3K-B!7E.T2'2SKQ: 6RLZ#4W$..VDS%]G]:R^ MA;T-"4*%D&%WBP(F;"V/WJCL-$)4H@.(4O^E;>0(1^QJG4HCT6Z3%)60G7R' MX2A9E)MJTURL(/<.=WSV1!$RT52KY\%6Q[IECM\$66]I.T+LZX/I;_H@=>]J MV,]8D;$8&A@+VRF%TRDV 3ZR[O0.1T^8B)1S\P2[*4ACU.F+**"HB(C2!;J" MH]5'X $RHOC1].!H^K61&I5_.8>0J3(>?6=\P[52P6R)U(#7)/#WY)(C*WRP M5)R0RN+!(WE!T0&/T5DM@",".D2;HGG "<25>OB;E263IYW->H==)GHYB|Q3 MSY^J,(5*TA;[?- M%MW&2COI"H=\VCU0%A2ULU^@B+N5JT>9)^# ^Y^C _C, MLJ,*,LEVU(K,W;0&NQ%8S9\EM#1W?<\|-=C@DI7%?$XG]&&F=R%KHLFKNT"?7:4;4\,KTV<;]M M&NRV/YQ^.ROE5%'C"(P[QUV;A12S"%6U;_J=AZ'>[ZD-R)-XK5=0MN9E2EK^M*%CUU.'LA08$ZU.;]D>:.$RIU0P+V">A\M>O?E\O>"[_D7^-RJX$--@=#Q;Q M'(SHQ2HO$ N<%\NHC!"?_V5LP,2SF P)+YA_3T:(-^/[,4:()>*,R@CQJ00:.MGI1+DUGSY&;63&OJ3:*,\Z G_^&A44T7M,>Q*@4F6^,T)? FY15_[7Q!U]C|C&ZVNMX\4KQZD2E\4Z4NIN_88&#STQHL]|4Z4 MG?(;%_F\^IK)N4IN!6\A%PEOCG6,.)^MD;L+*<6N*U$L?OS(X#P><'?45D?: MH=R8/? *F39(FE@"JL"CET8<9E-;9N4Z0TP>Y4QQRY#*ZA04+9%K@E+!ZY;T2,M_-^EP+7MQY$?0UC 1//8E)O:2L?R55+B*1V915>70(A"!OA_@]3ANH54UR3HP$ ODZ#BIV\^=.D96=(\+(Y79-FD2K&9+A:P76FT\N9E ME<$Y2JM>7H9@0M$^',W5!!PBL3""CRK,HL>4L/->?$?9W*1:[?^&P"RO5_|WP:FS$WT#PQ?ZED9:1,6%) 8PM*!\DO4U?.6EW)@ M'!="-+_|SW*LDLCDPQM,FDT|GXM! #]CO0:GF9_') IV;YAR)=<5C_(@+* MK19RX547!.%*XIRYJUIB5= <"IW8S(G>]#HM5,2TK6RK#A1//TH>HP0D+JX$W5XZ$M94R34'SCG%=1\(B#PP1O%;>"/#U>'8!E:\F>/K]UCBB$ o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{7JN.1Y(,K\MHH+#* M%B01'Y-Q(PJ2_EL&#YVLFM.W7'88=#7I$4P")MN7! M@79+%'8(D?4S'1TN,?CL!A]=U&U!%|@T? X0%UM2WGGK>$"&\]PL++R+ZM:65Y MQ%N72 #W/#IEVBE0/AT?MMZ>['?/+\&>BFH"RQQHOS:9"\T/U!9QsZYM)B@4 M=&+\LVQO>$B^_U9GSC[%OY?URN'E]HF:HKTC M,,@(:HG1%KKS)LQHF=0"<3 !6 F7>/|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{(..INNDDU-@_!5XCV]B?E_E?U>;%<7\ MZ/.\"RZ:Y!SK:.*$.94O365IO(T>OCOR-4B*;$(Q"D:&\M1U====9/:M1LB/_ M'53=Y8$-9YQX183K3 CD.HOO+K%-"\VO6D_A)SM #9*C1]VD!FNVO*IE MAJU8(\>0KIR=/35YOZAI^L(''WZPTBIYN%EKSWB2U6*.K"7GW00U77 5F7,B M6;?H >';1^C-S!:0Z=+OF9ER;Y(-^O#ZAV@-?P;!WT:GD\?>9V%H&,4!HFR M>/"- %)/M3B;1,RW;(B_$!L)$5O?L[#O0!? ZGA6DT@"'> O2&>[0BFVT01;Z=5$ 71[;+K(#O>LGVF$ER?0.VGB8&'-M%!\"PS#):=/C02$<-/8"0SXRDH5*$;(++#VHGQX">CK1]2%"=70, [4+N%)/I6 M+K/,.KQ6@?5UUG3";U(R#/|Y ?G610M!=/E7497W1+P(.E>,#:';59'B"=1MT M=N,3Y@Q_XY@,NBY!?$?9W+3W5K&]QN X->(0R["Q KCK998YAJ"_/8N=0AX8D MWA6-LRL"5;.WG<"[B<{3\YNS?__W*5N!0ED'W?[^E1RO4?5Y/ #L#A0;G$Z< MV*V8@[GE:R&[JJU*_I6W#U4>MLJ1)WH4\6'L5FWS$2JXPO1LXF"S7/Y2KDI![+S^16KO.;- U)4=/34K+G_ M]1?K!C5JC-RATRQG;#"W8?]XHIN&&P4W6UVUKIO!GH;TPP3S5:A)E^S_"1; MD\|U>;; @@K?BQX3K]?D5K*S5D7.%MF:+4A1>ZE<1,[3B0+7S/P:IK+.9J6< M27(F'6CA4>UBA"BF)08H#3Y2<|!|H*OX_TL0\?P!50)NB>8!?!N% U+'=?=-[M> "#@WN&!FOBLL^M>0F'YZC#=/Y4S1^]32,/E_ <1G3@H MH<)_ GYY__P!RS["JF\D5L9&IT2@]NV#D]40=X&FJ86*B+BWF #R5B-O M"3GH'K*%@QS%3:*'Z;M$9S<\YRND;Y6SXX*'H<_JES]8##A[P,5* PIE_'*HZ M:Y^A@P3\6A!'.%7CZ_]LLEIVO=C>|'55>^V/M4EF;#(R.@(K^7HWS]!6_^494TDC9;=F/"H$(D7P"3+.,5;5!|7U0('BV_;CK+) MT"C35L>"1-],0"8IG0]S!]S]7[-6 MY> [G$DO/A4T]8/'O'FXD(NF?4)U=[6'>$T\Q MQ^B.OGHZ=_OR(2(7!\V2VVII9MC:Q746VA M+7%2&#[3E#O)=WM,1TIX>ZH M4\PK4E*F1&2.8T4Q=\# .Y??]0PR_//'0*4>Ul.%51/D84$9$]?SA*:6\P1<M'+<<]:W\Z,.4D52T<7YM[KS^9"E%92+5,4'&A6%:6A2!3HN4F;%6L20&/NEJG*7E>.V$C]^#]P\Z;46+3;20!B8#H1EW) ; /)V/>(MK:GB,:V&QR$<"#/]>*;]QY.6XQ,;$Y*N-(FLE#\$T6\]<92"]?CLW%#%(;WE M4%$A5QLZ2SYE=0Y'|,4#QXUVB$0C='6$OLRUY/S-F'"8=P#1Q+@78W|G'\G M\ZR^YRW|QY_;QUU^(Q2"8!*9S'RNBQNE8^NND^U(2\3C: %3@.=_A-]P7< M,DHVK1T0F#:2*.KV]HG=V42@D0G.B(DV#$'6HS,YV':H6;/+$02FV4IN]1X. M%H%P^CS) (O2<'G=H;BR=G9>5)-#8_QWM@V#KP[[P$A9D77*HTS5O(:EQ8K=) M*^H@B#![J21*5ZD'OE_#/#V)UB5O&LZ[6RM##ZQBA-LXQ0WG&ZQRTZP9L^42 M;IAA9_P[? R@6\DMI%283=(5YX\$3Z^]#+3^TlO8. VO@@$R4@7;LY*J/FA MZ/=T71>"??YUPC[_/E7H@+,_"?$E,>+#EN_\\]D5I#H5=]-&]T^<1QXFC+" MY";;@>@GC]+D;5&RUU!"P+TQW7S!Z5$[&B=<&YC%RSJU>=++YS>$+;O92 ;5U M&M>9G%Z"%GX<5Z6*+*"M44 1.RC06,KW;-\-P9>Z;KQ$TUYB6D.'B;;QP7'V MHG]C:W_GSF9ON32:?]?@A(T{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lO8. VO@@$R4@7;LY*J/FA MZ/=T71>"??YUPC[_/E7H@+,_"?$E,>+#EN_\\]D5I#H5=]-&]T^<1QXFC+" MY";;@>@GC]+D;5&RUU!"P+TQW7S!Z5$[&B=<&YC%RSJU>=++YS>$+;O92 ;5U M&M>9G%Z"%GX<5Z6*+*"M44 1.RC06,KW;-\-P9>Z;KQ$TUYB6D.'B;;QP7'V MHG]C:W_GSF9ON32:?]?@A(T{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lO8. VO@@$R4@7;LY*J/FA MZ/=T71>"??YUPC[_/E7H@+,_"?$E,>+#EN_\\]D5I#H5=]-&]T^<1QXFC+" MY";;@>@GC]+D;5&RUU!"P+TQW7S!Z5$[&B=<&YC%RSJU>=++YS>$+;O92 ;5U M&M>9G%Z"%GX<5Z6*+*"M444

.N)QY@ON#T/RMW=H=UQH>JF/OU>";G\89Y7?*J+/F/7E=[2@N9F5SPL_J9'&" MW1% $4,H",0L+@CB8WLHZJK,CHM*'H/\7VIECDE[D'*XB'O8#!}XL=-N,'8B M+CS_YO'X,)4YZ4QRKK*A$Q\0U?@'YML2P6JBAF3ZT$7+%HJIEY M]4;^_[[B2<\YA),J7A6RR2:G^Q?43D+6&3F257@TLE)*TAXRMQA!>N8#=4SW MUNKP>P>*X*Z!LP4+S4+[!&%YW9L(UMI2MV@@+'T;!G@7%LX*?6;_]+!%,0] M_X0.'M*_$*02BAEY_KZ@['T&Y&KB'>.F$+E!T:=EKG^\D&M#]4CZ0&\D3P.Q3I/NN#:,FK">0] (@Z^1P8T'+7!M4BT*W!<_>T#RIHCN3T^6F7U MGOONN[^2#3\!}5#/&,.DR%P87$'-H6N7?>AR.Z2MG8L-+LLG++]#PT[KNJZ>+5W{CY! YM'8DKG!;-N8=.:%=&Z+(+A6"[&)?UJY1\@(6?(MHJO=,:[]L2=PR.[H_KM*GHT)"Y\->[> CM)9HAS=W@B=\E%SDFX=6[WT"%T MW\[MG;_L@X7K*;H.7&R<>A$#-YV[V(XCYGA*%0]]Y;7<)Q\70C2__-,_!IF. MR"1#FTP:C1R;"0! /Z1[#4^S"H0 T.7O[:)(N!-R)!]!!<3Z6Y_6D7^(2M(9 M =?0'E;>SUQ%BZ@'\ B07MBH[CRMZ+>*4-X(T^?7Y(%?%\3<\ 4O'E&_4XC] M"2($YU5-2H67GE0>4)'1/W*L1L^T=?R:T8@4TD$*SNGXl-7P?uX8^#)%}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}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|SfZK' >__F(:8DH]-F MWRV%Y? APJ;%K$LD(&[RQ:%Z+!DD'L;-#XF'L;38/!:N)53OU-XZ$>Y"XF1.\ M[E0FN5+QR2(NL0#O!NH_+M;>6.X2T-B*J<*ZBGZEZ,B_*M$I M=<(A44/25<;3@!)=\"4+VF>;MFGEQA2V IHC@(K3;WC.Y=`-^~SI6(=C;H>" M@-7*P:C1FF6R2U#@ K?<"ZKJ_^8C -]9.V4'V,F%5:]Y\I&)S]H2%/,N2CDB M>=,&V-])BT<+$,$KE$VM^#D",) 8 A!FTNRHPD#H4^MM^]HQ+[1+-M"\)Z3 MS.-,G5PP.6AZ7_ - Q428K81^F-*3'DY4)1?Q-5;TP@)!%]<=VK@ MG(#K0!2*\^TM^@-:-7..XLUU5N17_,'I[E!E3%NQ4C?*Y_*)? DJ"VQ,#4H399)&SKP,:N7%15 M#8ET?N-$+,"0ALB68'(,$/;LO=$>)A>. <0+^VA\&/A<(A/U2R.=A1J:1,%]\1@QG M5IYOVDW-Y>]CVS*O6TICWE7$D<]NB2Y8R54"_MA BB%\-Q8?6<>:EOAE*Q'P M]4DE7OL&@R';%A %A;1'[&KLB=K9>;&0]J6HU\-+-$R?R;)S=J34& M?U8+'AS!>5V6$'26+K>@(O HN,8LS8:Y1JGD4PY5Y0 Z/VCl,KNJH$E M\9T.@7M1|177+"W 7784_:,WR[#+SEI$25U M[_]$-U, RE43 #XZ/"B0%LFK#(TF[3=\6#14XD#EFH4)T&:,7%!?@73KDHY+E@:] MH-U1@!'OAX-2A NX<+D$MLD+N9*7]P6H7T%)*R1.06S/14"=+F7G V,$<$?X M4ZMN:,^;N22K* L&_B>,?U^(#6;UV9QB_ B/:O=5E3\50DR8R!9_8NJ?PI8I MH/>:S1TD!.J=Y! (Q.E$L.,9M8:P4Y.DY!$N =.N_@0T(&FRBB4|\N"LD+\" M=2YPL%#9I\ZG_X.=82MY0ZEAQ0H;EY7E!FB5\#&"""DOS>?ZE["5JOE:8I?> MB9!)V6_<$X'%OM8G BCL9Y\@8PM:E:W7=94M'GZ*&_--.%+42T$>C| ELSZI MP'O"M%OF^IVH\PBND6/EH_1))USVP&M..#___/F?XB\Z.5_N1=H<;[IF_UG5 M)T*^FQZI(>MESQ-O(F^'%%TBL* <=\Q= .5!A 4Q3-L>_PP>]%E$!U3$BE@?KNOTAS,?|OKET<+<+N$1Z\ G J M6H. (4?GX(W=>$1NA14Z9569@O(=]PJPJ#FH%%IV=0S'!$E?L77T Q/R0+,\N M-CE_JD*D@LU*)@_E>'IATW5=":/Y5^3F_,SF#W6UN:>[TXM2'!?5ES[CEWX= M:1^\.D@K/213,+C=W#5RH98-.7M4101^=X_&'D.#6%(0_7#[1$.5B:((C|<4- M,/?.EM\;.E7ZK [*+-WJ3!A:/JJ61]*VCAW0X7FZD-N\#MX3&HD>=8 M9FC9AH_!=K(%7'-ESY:&G&6 +M[_<6D_F%-D.6F<;A@S4M$#.>N -"3+3Q/" MO-X(V:"Z^ XWPT$BE,;@!/;7L55T? 1NOCZ^=1H^JYNS570=!|!B"$G@[KVJ7 M)7'.2X@IP.TC;)K>^C"T>ASOJ$?\|=/TEQ964HIQF"%Y_ZZQNMW"8] .GI9(8Z5WT63PDK#0LI; M6O80K,5&,U-=96CD>H#)1K%9;P4=V(>)REM7SO6$#3BJ(0"0;S>IYK! M6GL<,WHQ %P^8N,':(F)C146;)^\Q& /Z<;?!@=<+6)7&VO*L:OU%-AF#D MEF#JJ^A='*;*4|& TL(!=$!X&BPQ4& EG3&M C0-"IY7X/&.[!XCF!6_G" MP5?.5FM1,7DP/> N]_R+4K=PMXO?U.U(KA#\7OW5CW1T1 Q>TI#&&T?\)M?] MEEQI^KTZ;K_RQ:MZ[;D.2RD"(1>;38VEE+QMA8KY@F:67 "GD&X56!:DI /8 M0F3%:OQ0^Q,.HC2NF/4%02SEC5EWT3M@^Q;=6<4^;BA/?DC!C;$P 3&04 M3#)CDSEb+,E[PJPJ#FH%%IV=0S'!$E?L77T Q/R0+,\N M-M# 2+7Q1+.8=2".V=5<:]D|K?8@O@%-0X;9BH&HJ/VED]:DHM%5$K8>_:48K_MV!UA(H8$W X"7_1-C?-K'?%6R#!D"OE8Y'S_'C[K8ZEHU.(AJQ/3V-W9^ M.? O,+3N_F7UE%U>_G[W.+ZZ^L.G) ,+WB_G\V6UT&8GXD'6 C,?$, *)=L>,M M V>@Q.0UR|"\>TJ6OOQ?CRF6MX@SOF#Y M(%!;Y'* ((U;Q<,2!^OD=!FH0?"^,5^.#1)BP6O=[AFT0M*Z'YNIV5^6@ =Y-T&2UW#B5.0?8O1C, M8+.%-UF.|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|("8Q &=:IF5ZWSD-^ND4#)\'$^D4 M=*.EYS4J)BRVLR75DQ>+ %1)_;"HXJOB&/K,>;.HBW6:81@'ZY{(N'& (4'E M(C9-E,8ZDQO]>KI8U!N>.P46)R3#Z54U Y;'U7SAM)PIJV[Y"U-V$V1F|"IA M9&-*A8(R=ZR;W:7-5/4'IEPD6L;"0W7!9S6F=D:'1C1>V1N MF5;.@<4'!UK/9V4+.NAY+K_3J#\NBYV)_]BK*1J-,F9OH'Q@0#DD4@Z M4#Y3WFR$Q1<5P:3K^\0@UY,CR\ND;:#3;]V>U\=O*_?YM=GI[=N[X].ST[MOSBYB%X_%@NH>H;N1(]WTHX#1AY2Y2;W=B!:,^*B//N^D.,*|"06G-3#0VZX MEJ .;8BJ$7)%X.@+'"^FE-S@(;")?3D:$O6_O974R+H [*1&CE(9$/!TUXA=R M#E[QK*.%0&$&/E7-N]9!+|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|L,MPQ.]E\AKC1QEIAWD6@FTI@RZ>2>I MBF>V_%KEA=R8I4>5Z>V1(Z^(+(YYLVMEHQ\PT^N=V ^W&'\_$"],3"%J8Z8 M]3IB-M 1#)TG$>IYA[!I2[$[@X6;P;+J#9:V3XL:/_M:<;-?2P.MR\5^O'TK-ME70G'%V5]XI8<=[AZ!LA+C7:#7\^FNZRZ$/);T+&[+VEPDH_88&^.H@@>?+ ^51=O$"DG&O. [F$.SL^WV:\,LO0KKO737:2OR8RX!MY M-BLW 6)BRAY3!@^^ {6*PV6G>C1#M[RL&*!RUPK%"H\GNK#!C$LKA@EQ:(?T_ML@#%5R_R!=" O*+<4; 478)#GA%G98!75]EBT? 9Y05HLNHV5=M*)G?BT>I#* M!-I?E2D#T'O/MV^2N!@:,|E;<4-GW41R%[$#P2O#@%2'NEZK*GPKQPQD1_8M2 M,2=U_K-?^]W;.HL@^,WU6T&XNO.V^4ERB-_<9.? 5US8.M:TB33/5ED[VRD;. M[' I5[95O;VN1++'8!KDZD,89667&_+C0B/U &)E.%]@/#FYG*Z//($LM(>X MEU!G35NL,I0#7F>+HMV><|X@;<@M'-?>)N7>H3+4#ICVP. %,*+\&G? 7& 6: M>!:5YD51#J(RH\3#V!N4%NM"8UT"5D6OVBBL0+$:=ZS^.X*QNPES M6X^!Z^-=`A9=[GW321L^] M+P*V.\RUT Q>-5Q660G|&X;Z6@X=7CQ&R>0Q"C?6QR2%GF!"Z /OL$%-%TKH M%>,?EKC<.D[ZAJHBSNTI7U>-`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|W)U|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|<4!3Y(EOKG!?S,B4M7ZT5]YO%C|TC=53#5A7+XMU3*R?$TP &Z] MF8%P9TK$Q@#D7:=Y_ZDYV2Q:K=9R\;]-&<1*$S*IE^R2W!K{)P6C8(8+_^*&R MG2Q5.#"ZW;1A0LD-2HSO*1^1%X{@Z'}Z?T'F#D/,%E!B$.A9L^7OQ6\SNK% MP]:? CL6)$QBKB/1]^ONH08H=?*X7-H@[%4T+,;2,?NE?8F=K5QH!BLM%G=Z_& MJZ>B=M.1]V>ZQ?+\!W'/ZHZ+'*>'V^_-9!$0UA'##4"\?3=E M)0Q%;$X<,>T#3[09CP- 5W!LFU$VBGA$%-0-(8N"56B;?8 M 7-(!JX'0';"4]$^L*PID@_X-)75?W+(4UERD[E/A8_ZL!??+L64HUUM\1M7XC,#]+ MM#C,:;T A8;!WNJ) <2]]_ZK.TZU)FY>QEN[C3(&G7!SI'Z,YQJ83_AT%"+&__6FNDD(!Z6WH+"!|WH@O M9+\"/"M$ST?99&OCX*,9*R!O5D,]K.@5LY>#P,T7[<+*1;]"*U_1[(?]%16K1 M6 6G>*:#BKEC,W0V#?@Z8A LUA\|=++IHZ??0."O'OUFT]XO'4?4OHHH7N/HP7+G3W]<|V1EAT2O?.)9FC|NAU MAXG&7.W(9!>5L*FT.\@;GO,5GACI-_]_^XR'4NM@PJR+2>3H1TR(8A"=_TX'-M]Y,H?UHY:"-5'V+MMD+TB52_0^'0EV6[[4^SEPJ%8Z!6 .K0DLB/7V\(F7AV M)XI[(I[>| (OR%N;F[@'I*/VV#_\68-A>-^8&XZZ[@0L$)^_SSKW$C^>'AZ3VB MQF,M(X'GI3R=]!FXWLQ@0%86)&@_P+6= @DR$"%GB^Z[_JW;-#_A=2A'SI^B%V\$QJ4'] MVF5D6(N;I@HD&;(6';&[X7+ E,ULJ4N@E#"E[^@DWA9@I3&QP)IZGKK=:.MD[?(%VPLT'KRL20U'JQR 9P1HKA,>1DGUCYOU \\W:B YIO'K*E.KR_\5TDR MQ:2M0VZQZ#:67;.+-.N:9[M[,X3M[,CU)*1G5#QRS5,]*Z>/62&@_E.MT+>& M<=FW&L1H26;1#NUA;EN#T<%M6U3 ^EI-.,$$557M@:WZO=K?76U MEIX_1'>H$? Y,A:&JCJ?.0*?VXO7Z(_2F?TZTD0)F4MZXI2*O50-+8OC9#X MZC.#Y3E>A*> XFBWAF8D)R'>|1XU"NWLH5 $W95E5B0KT+GB8CXP@ 5#L.! MTK/X3&V%R.%68P4=R=/N7 IV M!N@DWE89UDY(:4\M,I>60.%M=U/ M$PC9WW#(%;PK[H5\SOO*7,8TU?77P?;_/Y3H79#3/YT#.W>217?Z??8G&18 M=@>U4I? RA"%WEE6!9&N$(1DQC2SME&;,$R0Q(MH4G'C!86U$^*S\-86'M3$ M1C\RJ/H(DT,KCU+(]"^/P3;C$L;$0\AP+U;R*[/EK?QMLZ0I%^DOX;,#?XG" MED!6O\GGM8UQ4F G3+>'48/@O.XV;<*P44GN8-ZW-FW4[SNFW M%;:|,"H(STS+_%2%4&]D^"]H'9'X"NKR0$1=.V0W$<+++$L"BAW76P3KM M8WT):(\1+U^BAW%7P3KM M8WT):(\1+U^4ERB-_<9.? 8URT5QV_+R/KVROLI7719XBA+ &&5@\=3B/1[_MY\KF=G.'$D5G8 (B7VO>,?*6HN[T^=5X*D?AHEC#B4OK)_D\<.M%4SZ$"A_=']Q<7MB3U%Q;7!D[?2(4\>4.3V"P>6E=! [W4)FJ2X9DE@;AQ@T" M7/$6#Y5$[5V;U=$WUVN1'&F'T!1'JW5 ZC=!Y#;AD??/Y]4 M33M;JAB*3[HA&(*9S=Q])LDF]&M^)W^ FE^3J8-NMW":/#,]'CUQTUQFO4B* MW^QCQ? V@>8L(RA%Z-MLO(_%.61P)O">6K@K!2;,.%Q*TS<(:\LS^/#9AX%LAG07S\2EG(^#;JR2QT#B7@%/SSB+,J*RSO?SA MP2P- 2LTM>#Y[Y/6\6/&OO'VH>K]+JE*OGS39D'*&Q^BYH1 4vX-Y/8U_R4Q/Z\RR!S:OACU("# M=<\G#ATU[!P9AWI W-0+FS!D?>@Y 3(_6&G2>0 ;K MEU)#,NIJ4M/,- FW39B54MQ]G3;'P&; [2356T5V)FSO>)@S]);1=B=H'XGGX MLR'XA'[4L+M9 3M)91YT4/8IYV6U@AO'JOY]\@'0/YM0IT!O8 -*\]#K33$+WC@;8T^UBQXM:'>7RST&))"^V,UG MN"Q*KCD8SL.%:E?X G;!OXD1TQYDP8P:[!}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|-"!9M|$ M &=_&-1'@.M

97O*6 (80+_7+)(/@(MY66CA:.&GB$K=1W :&3H@CE!ULN(<'$HOLA+[SDB7\7)/RZ$ZBF^BFI_7,@. M44S!5,/)71YHJ;SQY-G3!B)}[-<#;W6_:!+:C.8.O-UBH,F)<@B|VSY0.8E#M)?HJ.GW,"H&R %4-VD'=/ [[-Q\]@YTT&>/T:%G51^ V$7-!-+1NU*6$"V3< MUZ5+Q8X%3!^+M'D4-0<'SO-DO>=;'2LI3("F&X1R(.G(+R9J#3)M.55NC5(U M(/E7TD4)OC_7R@E*]]9X<0X@Y&=\2#N2HPIFMA?F^//")+K1GGF"2=>Z&+T#0 MJ%@6"QQ;LZ6Y<(52#8BUP@YP7H71$>N[@RCVRMSP8N&+]5)'9I#(XF)) ^L#<M4;T)>U3H%V6SD;_T2<U6H<-MK.BT,\W+Y=7@WINC,'4H'+/%[CX[1+R;0E7R-MRTY)?Z)MH1+,-T3QY$X&;,E<7E$HA?RRTQQ1?GV/5A*M(1028+I$Z/-(U#3 MO:,AAUS$HJ5D+=~\L=N!@A% (&AH;$-%_L8T,@[6,U1$)L,&)K&RK>GN3/7W- M9!<7f8 "!%#::7C]Z'?>DT;92EL='Q3S(BG##/ 8TQ@61C$ALA[}?A>2>$&X M6'8P7%:UV[=.$)T;,\2[WS,0[UP4[?\,#Q:Q"X.1Q7=A]['$1C@;6CXN6K[S> M(/%=A"RQ6Y(%A2>]"^8A|"@T.43BA M6E=!1$$#TTS;'A>R;G[XP),*OTUO-;4 ,:UN!\9H 1>36+&N,W52[Q7"0Q X: M;W("JANL]=AC$W+'/Z M?4GUGGD'D@. PAJ(<_,%:9 M=K>;W M)#*QAKIN=<^5#9@9K15(E0Y54%(4,T3!)+!PEC'&=Y/P.N'''/#A#"9>Y M9' 3,*.:#YCH81JBN4M7 -K.'SBI?\R62WGZ+ ^\#))^ V1^T?#/UJ1J(C$MXA_ M$1<,&- 8F#2HA5&TR40IP:&P]'.U.\^E4J;C'EE^!VZK!,]^R.2,>WEYXC^Z ME$5&)IFT.0(8KCM\G\G: <94&!B] ;7[*'+?PA)9Y VD"_I%;O7+98V6#K?- MHMO.18QT]=/|02-6+9M+E'6^@M$.0M<,)P\ZP/F-?;2DQ/E $ M[5#,!R G)]M]+OV1 !$& OL D69A#8=F1R5QZ,E$GT5O-W<-_Z|-A/8>?2,(MQA1#6TDJ';N19%7$KG6KY DK$U^KLGT06_A2)@3>S?B\01@\7RMF^=+(M7%P MQ5;D"^\-M+/QP]!S;;)R:QH&SIDRB.[^%"=|,+UD"89>|V(B%PN2]H-FE$U MC;A.7Q"" _=W_i=?2_G\KT!0QI:'G(*@,YX\A$%YOAGJ46QX&C*:^#O/Z32 M6!U)D.O64NW@.6)?I.D?^JJL]YATDI-"G=;B V4R 5(73[%#@OD3UGK=V\FX916* F2*UA M)58R4KG1]IC=<5CD?,RI\S/;G53OPK*+T==S2Q0U&[*GPPE>V'2>3X"<-'# M3(4FY$]7A?>]O-AN3=A'Z(F=1'K5(W#?E.L>4;*S.?2(K?$,&",QSVC2"59> MWV6+/QTN&5.-[76@02N3%,2=|?#H$RB\M,:R2[OC%,Y'.XODO/B/L[(%.85" M*.UDKUT!VF)@3)YQ#KGE(G6CAZ1%,8X]6WYK./* F9R&V=*0)E]71(MQ]KWE M90.[Q\NB\5-656-N0@'[HVI'Y] W]^* %$V;S%N29T%(WZV:P/U9Y3 ?4Z2- ML8HO[0C9=B^D^W1_X2; ^\+]#BH$N.?@IS_EW\4&Y, '/0B\>@^P/B^P.:EDO^ MYDTE922^)F^J_[M,"A6VENGF,MU>9AK,=(N)*Y#; _=@^ F[EUM?9G'TZ/3NY M.9O>GOW$+](H]_D#.YG>_C;|_[*S__/MXO?IY=G5_)9-KT[9S=GM_:,B9'YV MBI\G(A*%^LR3JL3CQM^^]N%D(]?H\]WR/-YH.E%4*]/V&3A@VD/"8T[_"|?\ M])80"Z[2=.R8MM>5/.Q?E/-B%8#?!(W)EYR!N7'!4 _&.U8* B %1@0$*.*.OR^>?/__R! -I] M@_2HB%[M3]UG $^XE+GN.SI *;1 _=+5@5^OGA]M0=5-;7M?RD 0\NT00E4,- MW1:>`^!%1*X.P;P+EQ(&S=@T$9*[%TDD\>5O/S+]6FQ7CG-F>F2W= IQD18D!-MRWIU-># *[5/4^=SCPKN'3>_[9\)X_7>FR(2RYY?6C_$L(BDY7;1=C)@W93]!7 M& 2-?O<4^J-4^D MYQP A!0QE(*CDW=_&]EKLF">*XW\NKBQ6OJE?^G/-?(/0@(4:M8Z">!PDR? M5)BBJ/KSH=$)\Q%CC7)M$US634F1.[+\P*L5"0KK]|&?917_'L[?^+BD6-^ MAE<46^X1__%#@7OS!E$>#!$W(^>4C1.?T@%O"D"%G>>R*0NN(Q-> 7 =E%N# M129G5[IG'0T8D1VD:U0RR-"BC;1$O4^[XBTD47#,B,'#"7P>["%9-HJG,_L M-6GOO A0!UKJST*)?7=ZYHCBE[A]UZ MD;!A&K%.PC>MZM>1-(P=)LXY.]Y(Y-DK6S8FV9(GX4@."$6_X2KILH,&S+*3 MN*FQ^[F,?(Y%5CIA@)NN270[*@#)3=B1AW!(6-,E62"$K0$=/A(US ,HI&*W_MO5LFH). ^[UY\0@;_04L#/=^-U=E";G_)FVYC]C.G@2<>F;| A"3-^" H8=N+IOC9)08Q0Z\V1YX M"=FX\)]M!;'I\ZH^KNJZ>N*YM\:'HOC3IC&'61M/J.X1 6 WI;F%O\(H?5] M+29P2XAW6Z(%E"<.R/!FM4T;S/D: [F?A/CHCK9"HIUF]2,Z6BCEA5E[Q5B6: M>1U$C&GQ

Z2MW$0OH9!{C>\3]I"|@\895A<`MDJ-`FP>I"<4]H`TGEB<$G7$3/C4YRM).I,;H=MK.2'<$X+8[%6%2:4,,.20`M_\"1\4KZ3XYZ]5_U6L,Q[=E?YI(!$^XVC?

-46D_K=6<$*^>:2%)]O"0H,XJY=U@*&]_L5'P1.%|UZPU52$GYN). M`,EF2YE^XR/6FPJ\I6N717;A26M*ZU"-"P.(F,1B_V\HZ$CIW23J7`M@%\D0,__@2K;6EO(B3FHZ5:SXN+3>C/-

->R?O!(+"@\F`5QS&59+P3G2SRP`M17.C'M.8_;'H;]$\U?2Q211<+0>TX<3";CX@"SP"N4W#C#R6#?;G[K6=$+9] M8IR]^F$$=DAR(\++4EQX.]VWO:830DH[D9E<;],T1X$:,]*

HZH08Q'#LC_GU.^D^3@(R&LF>@HD`;41]DF|&~M@"_B'D;I)3K*YYP8SFY0|6?2D0}4H#3' # ,;FC4OAXI#!|SN#A.("""\0B%(`M>BO\!<3:G4ROY-.+SBR'0$SZ-,#I2ZONDR"??

LPOT68F96GRQ6[5G%BPC\#K03J9`M%<>`(FY1,Y'H4=W^;#9?I7"W:):EJ,`3,U<&TOL1V)R?-PAE7Q*<[X#QLZ'8`M$Q67WKAWII#=8]NT/IH=? `HH!BMPBPM%/5'%/L1?

>N4>9@,9"9'-&=_^0H,<^O:U15T8D;[DWLU/)Q'-N7" M3,H[D#PU41S(&-EHKR1)ZE;-OGAE#AH*PR/G"G7GZ0WVU7+V\?A"2PCGHQ9'*

M07%07&9@0A#IO1=8[%KHWX1!L6LOH&I+B0\U?@#846=<+FEN*Q>VTGA#TPQ,,K6IA%"E#//329;4?ZE!/# MR"!PVNM6LC2tH-GE 5+ C>7*Y*W& LZ,>Z2NJ6C!H&*

&Q,E4,\FG!;Y=>!`MAPVU%&G5H?9:3@A7-=':>F9RFF]).B#%D\!S9A&36LCW$(6:0E9V4W6TU3HE) M/NS$$)=++F6Q02B6TP@EET5&-

B[ZT$\)HAUISG9K*.R%0ITP^G/M'EX2W;QM. M"&[T"JJ#;'I6=4+,.[IJND:V_=RM.""`]3ZS &WB?D1^2I6H-,=REQ_QD'+VHX M0IARVK0)U7ZWW^$O"3G#(8[\"C^!6^QE'

*3_8M2#;]BL.+*PR=*EP>O)!NG(__M,(>[G1P*R%3]HV':)P/I !]P8LAX<=ID'ZV8GN2#:5S2_D o/ M54$*;K9WY>E?8<#BXN;,3G.4XE1#S66RU%/5NR/PA-

QZ4ALM94V(GE^H1V M@LEJ1<$'1.W2Q5WJRMJ?$S"NDH-O\88-UE>Y@!-CKW&!/Y/G7!ST|)N7E9P0 MK;K34VC@?$5T/WH7%3'5$M[G$?,

<;X!,3<'[?!>JB58&;MK^HBTHY&@>(.(.% MH0$:!O!7IUI.K(%ZJ,%B;\JWK"]M?Z;T/JJ;<-7;KU74<6*6C&_2WH]8)T02 M)C()Z4H>:#<)+N-

*9Z,:AP=]+&ZM>"ZT/6PC:LPRC,U/6[.5NO$B>4Y4DL M_,*DK)+FR9T:C:W95L&>6P)?]`?)TJ.B&B=*%#@>@FPF|&8Y*IO'67VR6- M&TUV?

I+M(5.3*BN7]HP3,Z'C81/*9L##)1DO&7@&<)R% MKZCL-G1A2Y!I%'"TV?LSU MGB^D"6 "8V04RB4QT;?=&.C25Z5GV>K MA6Y_Z1!WJ(DMT7G!\A8VEZR.%@

M*R%::8GE:1R)AS3BQ#QKL2Q&?:B]EA/"U9@]P&RI52W4119T00TO86&>BKA&J M04ER,"D/LV/;M+]OG_TU.5M_1GZ4;9;DV'TD+_<8)>E-'@=%=E%R9S|>_WCW MJ--D^K?

AQ(04IDSH*P|_ZPM{0HY56A?K5?OR^C&/$!8-[?]G<1.Z2NEW54 MYX;ZBA.#)QQ."\S-I#HKC_(0!UK9_E[7$9DL\ 79!V'S/FZK8%_^BC#[\'~<0

M&D)\YT$10J>:@,I9V8REJ8L953KBN=9P03&*"EKVZ1I9A4PTGA)+(2&]CZ"11 MXE@,"U#*V8-%2C 9!Y=$W?/#F)-S,06^9-9O30(\QK><&,@#.(C?L&J4#FK(

MNLUK1J8U@*F]B?QUWN\-[6 M,5)@4X740ISG5V^C':Y5^X/30G7<$+NEO'V!)+_TX_A=8/+04&5GZU#^FA/B52U!9L>ZKJP3@LR"@%Y50-@9$B6*,W-(M*TQYT;76LK^GBG?

2JH[?7*U"5U)B7G37&'<[30D(/GPMIT8*#%*B0&B MLT:93IF(8Q72+'+;1RA0^2A0S0GQRL<5;'Q|T#+-.|O:7V9T?!O%_ O#] MD0<&(LYDU.L*\+[^M1S0,"-7

V45UM%^G!X*TXLUQH<4'\(*@M:AZ<_ 8"H M>?[5?K*_S%IL#S52D)]=^[6G%A>7U!,]@30H,V"+3SF,]@AKR874$L5)\0] M_3(%H[F&0D-=TA$A*EDZ=?S#BF+V]Q,CI@.:?

5XDAU%%8:XLZ,0L4T-@+E&*N MX810Y%SRU^L$K.EEF2MH6D^1],P3 A%-59;*D-CM'K.@NQ MNO.ZTO:WN;C5@%76?P>28(]P7F!X#W-,!0!$"%/C+$WQ.H0R$,>KRH$'E):2

MIKSFJVGT3]JQ1DHQ[U&R1@F74YMXT5C!"9&JZK$SAW4E!O#L"$G =#E2D@R MI8R*F)NMYYYKVA:27/BI82<6]XNNIPF6I/"EZUG=C@9+6YRO)_]}-

MC]Lj:`.,*MF%/1+T#T2[W_C]P(KBMDS:#MRY!2&H*LWU0I/@?+V!0:#\0*2WZ/9NR;IW^aO<$ $(4S(B8[NO\ MW,I"3BQ&&@+,;J!K1X,?[G/WM &,V0ELT(1[;2SNQ-

K0T&$0%W.'4C_I1 M9Q2UG!#.<)G>F;A!NM2SOQ0+RV\#JZ?XV8GY*/5NW<,#'E@^*7Y6+DOW2@S![ID_9)A'{G%JG:R5(Z@K61_YA9O>+'|>>K'P>*-=&L/H.)+')-W0 :* M

V5WA_\O]A-R8$=&@=CAI7*J;8O:7 M(WE/17MP(?-C$A)#&/ #YN).+ #J.<)FL[VDDNF-:,8*3HATX4=@VGC>0)3= MX26CX=2\IW5E!2^U.QRO8>G UN:

<6R$@178*2X^(N%AL$!2(4SET)>NV(1K> MH&+C+WYP8L'UY^:Y(65!/HX-+3DQ"\H(GI=&[3U1).=%IB8BVRV*T!V0N= M FZ[UW9$6#*849H)R=7ZC'/E\TE?V@EAJD S(7&

[6OI%M5^W9#&7A-:9&:L.NFHZN]MCA/S!\28!/B&DK:^H@C3!<8-2OK<.%>[*64V!03(L';ZEB?SEV M#N6X4X&&#FS"B=EDH/""0[+-

VH[H0X$'L(5D[R'SC:7\DQ84C%[" MA##L MG:'J,/O%B4Y6W^IZ7I%F,0>[+YU.M_$N[Q#B7Z_AA% 7388^Y<'5I;S]P_G> M3Z(73+'AU%*B 5*HBUD'$US+>5(OR3_GR0*_.:?

+:-HK9`-W%)DQP[%^$F)S] M.@Q+LXP3^X#*>_>$ G^C:,.%5_NSO$B>4Y4DL M_*DK)+FR9T:C:W95L&>6P)?]`?)TJ.B&B=*%#@>@FPF|&8Y*IO'67VR6- M&TUV?

MIE\1A$UD\5'V"3IM-PK@4O>]JL7\]@5KKO#B%_N=%-F&'_-HZV=)^"Y,UNDO MFW"YN4!K/V9_VJHN@GI5G=AS7?-4F:[WOFW8G^=%/EZB*,HO2'O_Q9E]Q6

M4.HBNFGWQON[(_X@%#(ZI#@J>274O)Y98>0Y3 M=NH"-"/3-#<@3VD;[/68)IT8%KC/B,9$UH]M_)C@-9BZ34!"?7G[R]1(17M/ M$X-3I.7!4MMX1S;DOU!D"CS5'H_)WH1<%

1"58;:\0#3NQ*MVZ!L4=B* M(!<)![BH-D/?-IP0O(!tE_>+<#>5-[^8K].LW!+3UM_YR_!D8!02E498T54>I73;>[^.23!OQ"EB$R'-X&L.?)6MFA2WGDTX(3;IX!*A@.(KX5(E

MNUMLB?GJ9Q0%"RS^MSIS\U$-.3$$&IV,7DX/Z(W^TB=#0;6B_1UZ53!/DLT`M#*ED%T8,T[#PWQ71T=UKV1>N4",D*YD41J*_T;I6=&*)2HA2CF$PJ5;ZTO;G MJVI-EQA]2|

*(:EV'.$"T5=@"^C9@7V2>);.6T*_IRE06L]]!4/9P%"$>HS5? MD7.!##=[@R#CP4]$3 Y"IWN?Z;`M_>54[D25.]VS3#]!>QIY@S*ZF2A&H1Q<;*|@721YW;0*RG*>?

$;!\,%TH2)1%G1#*S!2BB_MJK^6$# M< 6T@X,%-$@*4)*V0_TI571"1+V10:#\0*2WZ/9NR;IW^aO<$ $(4S(B8[NO\ MW,I"3BQ&&@+,;J!K1X,?[G/WM &,V0ELT(1[;2SNQ-

M&X"/^;KP)BE@+7HQ^]2WOTB+&"M];'BSB!/S)#"2-SB1W=0+%,,%*\)4E%=O MIYI.""FSIU=(:\GU!+-5-[^8]LBE,MX;IR 49EL&&IC9B;G4&'4[%G?OL B MDI&F &DZ!^5?

G5ANTLYXTN 8:T6_M*(OT5%1C2OF$-OTERF+VNR\?V29P-9DK*%*)/#+"N(=]V(DM(0M#UF">4%L\ MRK*(*V" E01F!GA?=\)_=6O%#>'S%Z(T?

\TX7]8P/NKL/J;R3(&A4I)#CV92E MN+DR6*O0I\,M/9Z>R5_3%8=DTF>KDDYV]+:=&"AXW89!Z"!=[!A'0S.F;=FUA MT1Y0!GX!,D6? T#%%SLR\D2.C?

BOT37@^\Y)RIZ;YA^4<=1P5I) MBWM6M2_F<[!;1<#-2YZ[Y-WXDE.'00NJK$LE)_9EW3*X\\.@@"EV,256*MB? M+;*]3\[^=H78?VIC->V6ZD'6HZX3<|<2E<;RF\,IF*:0M2-

8^,^&*[-/,_;G M^=Z/<[BQ*:B]\#ZP-.XH^=E/@C<_ 5#X,UYE\$_Q4U'VSG\I_JUA]-)BKR;[MMA/K3'+?,UPIC:]JL]V1 !T:<+ ^_])^K*\Q.02<$*I#.I37;Z.8SE7=*()9AJ>(+0C%Z\R/P

M+\"C?/.8;!O>2AHE#K_ZV5; O$@<25V'$!NA=2WG[M58I%GF$#C-!,"8 SN? M-SC)8%V5\[-E-1>]8QNP/#8]RD4(DP8)\ XRU"%I >]8T8ECYAO:.4<6 M7(<*3)HOP5:

(ZO/#LT&1@ZU2#)D6D7PM."%WL$DI42CZEM0"I"CHA N/6NR%/ M??!PZ5T3JG+V#X1Z,/@-3A8;1+0LZI3# DW8%UL.NIC%<4YC;QGB81Y3-:.Y M<;=6<6(YEGS

NJAO.=Z(CE6=$-.0+% 3-FBNX810,ETDG-R2$UUMKM(6=T*< MQIEMP+JIBSHA1BT4.J&8O.6>Z#_4G1(N%7[9OG6=$)2F7N"YE9I![" KQS#6<

M$*H^!2!=&3H=2:A:R7K,1&5'"\/W=$^_M1%L=8T(G9D18-O)EZI=YTK6M? MVZAS&',.X6U\ ,XDTP'X0Q4%EB+|AA|MU'-0M;H'3BQ&&@+8#4U F

M5P#_01C/8P36&NJT9=&?>@KK(=IU8H T+FH.H6J#]'2OI82P4D@+MZI"3 OC M7LL!6K'CA/]*8;O7=D+8ZBES"2F)B2X)(:@;>6#SQ_+W'<(\6OIP

M0N09F8H@C'*8I')/,H\@"CCMY2X7).#7?@*8&S!LTEAC_78?I&$GAD@<04]H M1]1S&E:82W=0%XQ]SR;LW]4U,*6"S"D.`D@;FM18 .H[,6]P4FJB\U?_H1D ;=QI?

^+LS\B&ZYEWLJB?$S*4BN$H+T>P\Z_@RO<@1QB*<16.05A>SVWUU]) 8CU_5!L@0 %XZTG?:A%9NM2?W:I9 MMT3PQ\,S?ON"*U#/QHI;+$.%YI:

(%3>5M[^T8#L\)F@;YENNOOP++GB--J2T M>'6OIL3\??.3$,S"\,;7G83U.DYTO&DU57IG&J7L+[)[XZ_)#C?2;8&"_.4 MXUH-Q=V8B\+]*D&&C,!34P7[_2 WK.OB+QK4O(@7

(FZ@J]H@A3G) @-M1, M5X^Z]@4MYX%9_>;K>QR4R;'C.D!"3P,W0'-,+&4MA<[%W@3RZ5#-"'?&TQL[R M84MG1OL]E39"5%5+*Q/SU_U!C]C!?M[M7;\Z\X?=3%'9]0DBY". N--

T5;'-M_KSPQ%(\7D?';Z(HY,2<"-VNH.\'X*8!%(?NC#FN!W#;S6#?B0)\ @-W-=)P3]&Q'G'P%D;*6$?QF_U%1-Y]=WY.EDD1C=]&GM5:PI%O^BCE9SA4]=M>L2"!B?

\V>K_5JQ#Z0-&)!Y<&> &4>3MF3PC-=4>]J:4%@)E2: MOM,81#7:QYP8RJ:30[_*Z<]=[-N3$< MG&G_"NUP]G;KU(HXT>TZTZ#I=:@K;_\|-<)%RY, K/WS6/C+I42.C7/WH%;L

M"\]S=T?!{3&60BWW_4]Z6.\1FU,$MVK.K%8.]T'#YC;XE P>_.3(%W@S(_D MW^>%.($?+WR'!B9A=^E*>[_1@LBD^,'\ER5&^A9]))-PM4VU?07]_]VSQA)7 M=

(^>5J5(+W=P4_;'P9BD6IXQO:%_0!O8'^.TL2N)$-]IBNH!,IS)0FMC2Y0^ZMPN1K3K5[5(-_M#(EL#C99\NNE[^_)*OD02,,) 5=<"N&BDI,CYJ:.U_BAB7*H8*_]A&S^'Z. M&0-

*B15KXI. MS%+|^Z4=G-\P.6,T6,Y>%9T049>*Y JERR3.X6ZLY(5Y1(Q/X,XE6)+W8 M2_^K@_^E6QM6!4^3K&1W>UZBV"<7?=T\I2UD_V !8V6<17NFK'##)B ?

(6RA[5K6.!A=U;F!8!@"[+I"MC M?_]*R.M\54N9)'LDJG/0V.(!M.'$ N5>"CG(G[FC1(8Y]4W;4LGZ=?*$=EQ9 M*RSS@G07KKLF2TJNB$[-7/C%PFM(8T!5.J%W:J*!WJ.:$> K=A*Z3

M3(PAS7);)?L'#O@\.<.)3'L,Q[A9EZ,HI 37:^_ MAI["]-<;LH3DD>[^EM+7=F$QQL+Q=44VR3+#NL2IVI+VA:C:6E*).(Y[>.E;

M'9970ZKN59U8F,*GML#\5*/D4!RR&;YRJC75HNQ6TPTAM.:!(!U9AVI.B$>O M7_+"LH]2S"*H.QJ0;I[NDWYQ'LV MX<1B);HOLVICT)F0B3_CI"""$E&

[!U5+>;BVK3]^[!#;CS@'7&W;*GZVOYP% M?WA\&W2A]3F["SJQ.!7\-F;0J;&*$RQ(GZ-ZZAV1,"<**V_O1NQOR#!IT(> M-*$?L;Q'VH A53'!W>>G%*)89$W?

%67L=QR2BX!"P;W0"\S($^#!4N+7&])T MJN7$?BI>7 6@V$ MHRUL?YZN_-O1MR8 MLJ #(]_*I%2U??+TQ0WJJJ,;LVY4O???(0M'Y(K/PW34O&*Z1.BME>SOM-

)I7>AIY$GKIQL8^U>BA1*M!; 8 MFK0OG>/[!UEC B7505?!J?J=V1%*M@A,B4:V.VDW]",;F)L)OMS'<-&6E]5C M52?$+%S7TGFC>)OH7<*M59T0L\Z>@5TK55UIJ6H$V(H:*

DQJ2 K+AP14/. MF0656U<#_HO)>37PI^R?[=6T/#KXJ+*4$VN@9=[<&NMZKE1 MCZC^7=U2Q8E9*XZR<%6GGX_A^1Z2Y8;0W:H7@TX(3+;Z"8^5+F $UWNGF)=

M)4_WVM8?1 *&>(.3M/15AA]!*2=FRABB]HI#>Z$!]HC-J-=T04DTH4$;17.S+ M(MPZ2H,[Z',YQE8=$T_)-#5D^_80CX.E80_DTI*14O?R8N/'/,SQ&PV;_4(: MRM);'2?

OM)W8GU6;4+DO(O#?Q)50D2EZQS!G2I:=XTQM]=-&*DTL_0&B<5 MRXNFB(,SH|#6L>,.'8.'T;!76G!",%X1#3 >@*_COFQ^[5@_\@KZ(0D[5"I M)>L*.C%O6N>XR6C26LG^[' :.I;0)::=@AQ.EWF:X2U*V-\C4AOS3#_P=.'H MD?; B\':=F(-U),0ZQ['ZI).":&+TV)7MEZD+O7L+^$)F". 4Z-68)YG#>YNQUK6E?

MR,7^U4_QU>.MCBRU^KO]#E\R#&/XB@0N9A{/?OTP D,]WRU]KHL#]EM_SW%+ MXPW1Y/T(3FY- E)=.2<."*W>:] 8^]9U8&&6!':DGQ7,>"-RO%,%)^;.B&[\

M&@<%HIJE!M5GD#RH(?NS6NH4\Q4]%#5%Y/#2<7<9TWEJZ6"?9%,7#^.J8]R M4=!B0I6$!=1EXLH(1 YW\CIV:\#ZBX*Y?Y[0.H1W=IRI

MF$-499Q8X#4E\CDG0TM&_9JLI0S!&EPQ_^,"4WH:)?BM;QOV%VFG30<9VI?A MCB5J8(!,G06^=T/VAZ 1&9?.R#;K'$B9TIQ]O^@J"?`M*)B1"]-?

E\NM."&5WMM^+3@A]&TLJ^HX7^"]_^!$\K/]*, .;(9 M^XM89D01Z27*4"YPYK%^<^<]>4R?LVX!]D8?$"]I"?#48.M3I(!NC->&WG=A; M$+8)R6?HA;7;-)4"3G2Y5 5;

<56!#C5@6/RR,;M/Z,V48K,$'6[$5FF"E8< M6HS*1\LPP*]!L]6'YQ8B7(#/ZM75O8"5&];F#!TUAWCK27=N1%=DWNN#49 MJ?)2LVL];]6(//=4Q:UOZ\-

B>+"]_[)Y40=)Q8:OV>4#R9FW@A1,"?:*N0Z MN$?9!@> I&\A23Z^5?NS7CQ.^$W#5#@%C8&NH!/S>T_ZM6<^BYL\#@Q&=']5) M^_/0G?!(WJ]4M6)N:H]#A]RF !^D.?

S/$N!R)DJ*>S5@:,B\[@% M_1.R4L#^8I0\%C1?9!-64BO@Q"@K]T&90.+-.*&HXH18.I\[>0Y*&JL$U>]3 MWPF!)9L|>3,+QSL/= U;6*LZ5W9"5,"0@%,%J(<=7[.<;

E)G4>H0W$GQ!%_M+)QUMP-[4+6D$T)H(4M$=UOET5VX4KY0.E1S0CP&037E6)(+.-%E:NY"00I& M1<"K4$U!)6T&S7R8*SEPS;[AQ0;G*5%7%F]DI>R!QU)R5(-

[6FP4';ZS=Q-. MS*B,CV;(:(8'O$ Q6H69Z+&"AOBP%IP0N@8$HC37Z1V8;`_0[T-#<2?$^1E% MP0(+4TP)N@53#?\KV*Q79"+F,5IL$IRO-5?DR0A6@91&KB?)'H+4M:##@3_A

MO+!!W\O(/I/BIBY!_]@:)(9;F3QLL):=F.F"24ABK-/@5$4"8%NMSNBD-+ B(3,SPZG?C1? M 0DD1;TPW$*-7U(.TX,0&E9DL+<7Y'LN6?>Y:7F9QD'W@$H,-17'+AM\R#$

MWT+R!HIJ^>Z,5ZVVJ'TQ+C$@QS%5285&H$6;ZXHZL90O%'E.28=OP(M)7DTL MH!>"*U4KM'-E^S/6BD-L3%QK#?M"P08GAP3-1:"S"C6*.+'L](&ZH)B:.]QW

MK>N&H$566GJ1@8W"H.WH2!M?;'?ADD.UTYB(+_E?\BI"7Z=:,H4C>C7-0NUUW)"N&8N!B,9O+.T&\(4+R(IP\"=*66ON8830C4YGDKN#^'O M,'+1!;AQ_]:IH7>)1KW-

MQ"==HG)?O(5-VMK#2=F\8ZHG!SNB;*,)50P^BRU MQ9T0!\87]$R]>3(R494N"6/)VS^SFPU2KC*$>TY,2#/&3GC]5%%;ZZIE"'C MTVG-

\+D[X%7CCXI]!\M?]****>8ONU[$5^\+7LA&J@>?FDDXL04UV*=-KI*6* M$V(()HC)UR[G"ZG=0.TL,*G2$ M^F9>_.6ODNNS\->H#02MM1R)*H4T#^SDD\50_>[$;,CA-

+6,B<5#;;XJP&Z/ MF+D/*5%/"G#ENS!MC=,YN&$GAHC,%H>Q-4_R$]C2M!(-F<" W&%V' ,)_XYR M"]B[?BV?9(PYCH@^R&&H=?,IT/;=&)@"A]35P^BMK@3XICN

M9J-7JKV>$P*68 >>[49_2FF*.B%&$29L1G\!BCG1?4I!SJ F*!"7FR&'LJF\ M$P+U:,MNXP?TGBW>4/2*J&E$G7;WF :=&!(Y_QNE)A?*B_+\T!6V_W!_@&Q2 M1'-

FD"")1]UXFFM+VA="\C^(\-IV3T6UI",/[.<-BB(C8Y- MH12R)?H1,"^9,A\;;S@A5!/3T WYX$3GJT9K85(KW\%$[2X9,U5R|6K D9VS M\-\%=R4#0)IL59K"3LP>?

S>90+]5$DYTN@=0ES1D*>>O'I?1J;(3C!+$P11 M7PDYL'!R@9,$OZ' #!;O4,W^J2H3Z"%QFMI5]ZA% ,2,E MPJ?$1;U/S,U.US):MSFR2M+.K%

*[S/Z;)^1'X,@2B=1TEU+W%IP06HORZ9B0 MN4]])P2&=UW&WW4+\B4=QX"JG!,"U+ ,QFM85];^H2$XA77IL"_.S'N"LNA M.7+74-[^^/,K$8(-(

T(W;$JCA%-.4=FLY74_F<'NHC]23U:L+^0!%=C9RW M>11@[7FTQ?V1+6%=TKO*0/I=)O=$/^.MTM!Q-<7LST$S67!C\)M%G-AW^L@RX\75H9K]6:&LZ?.84I?-$\ARI3D0=06=

ME"$-@Q=-7\&#TM^2P@66E>W4'9HRH#?-5&=5\"PP!+!0+))\S<# MT?3,UU%1U)SDOHIYU2AF?^9F6<+ZBX*Y?Y[0.H1W=IRI

<_1UECWZH9ACN6-<)04T0F.6298JG00]%(M$?72*-NQ?X"KCH+ M)+Y7]D_P[PB?I\+E<& 33LSYI1^%*YS$H7]#+X0PA>CY"TQN"/VUTEK)$=&. M &86$$S!J?4EP?E.Y#

(%=1$ZTL[(8R"$QG8]<4M;.TAK0EJ1.*-(T(M$WS3NBWH$G@V$N1?X]"1AEO^S8F%3/0YG+ (CCISU2SX1\[NMI:<9WW;<$)P M.3T9(%+-4O;W;:89Y-WR\0D$N,6;U

SW.:Y%)P;E M"\;!6Q@!DWG="-%!@>I>VPEAY\G:C[DMA4Q)2KH8L!L$%%J4@KF!(9X+>%H1 M#6)$!PS2L'6=X@XOR2-L@V--Z&_]=_M'T17:)6@9R@%GG*I]@06>ID*X8\[N

M?%QS3BOQ%?7>_E)]RW5+>J.*$6#.BLP<0)!,^2B?H]3O8?E# @F2WNUSLLG]0 MZ9V)M6^HMNUOA[H1HH4EUT$?0D%+RODNR[3O'C5)=T2HDM6 DU9)P31AP;4

MT3XJT;K7=D+8TCD/JU+;CI>HQAHL;L%0/9JP F1.Z8Y\;C;.TACC-$6=$(-;,R2WBOX)V;V&$T(!> \AF=S*G-S<5-X)@31N&H/1W5S#

M";&N(;,NWJ%@@9:;&$=XS=E?]8"3EBI.B'4,4PQ "B /1.H!O(/W6_UH[571 M$1'KC],K#+0_W1ZRK*P3@NC?<-1^&1P:6EZOJ82P3R@CXUZRLAA2U2M+.B%$

M)7RAU)/HG2!04;D&<-2UKA."UNUP%WX;+0LPSU4)N*.NJPXU"7+#$78:HUZ_.MZD[,(_?MM=R0[@$]?PPX$)0F(IYMD$)\UR^8CXQ4GDKN#^'O-Q M[8:PG,H@3F81AO,K!2V])!-

(8REG5ANS!R@>4&+T_PJ MIY&"BS>LMRAT;L+^%Z2/X1+/UI.ZCU^+QO\>UWK.#&?I4_C2%IXA^SB0WS!_M_FJ036"%LA7O(Q30VX,'-!#74V-I&W B74BQVY0L

@H:,IK15W2_KS=D_'. M$XIZ8%@]0Z":H:P3LW$)18!B@ZJ78?HKNRG@7VKWM+;X$^+TXQ7O3,T!0+-6 MARAK*I]#1^=&(F 0B:8[KM#;&1!4).=+T:9J@V_B M2,?

XCOUU5!YH\QT(GO)0$EGM<6=$*=F57S.2<<<0 "=HP6FZ0%5M$>=*CHA(O,_MXNTN01O(;?B*RLWY +G (89!F.3/&#AW=*TX{3 +&=|'2!X%B/[-!2=$

MZFJ@[Y0!Z,"VG!@(\2(L.=:,)&1UFE.>&&HX(13==\P*HHX*,!:T?[Z=0$\!XCNL';+=M3G@HS(7R-_MDZ/S*33;<$)P [M M[^)7@TX(3*9$!2N8[88R1%4I@@7,R-R7RA['9UK6P=2

M\40L1!/ &*K>K883,]B!WO()=+T.]"-#92=$;6*'FK9R@5PLE3^UC6RH-IT8 M&'*X^,MU@M8H?)04-FI4",EYIO%T1{-MGZ;LZV*%

<84%U3OF!:=LV.I)^.YG]\RQ/PN!:=&!0!W%4)) >FMD?2!$Y M#=Y!#5D'(3PO4>PG(?X:ISNT#%W?Q@(LO:K'%GHW!BDR6G.HY,1<2.\=;;*+ M>ADG.EZ/@>?

91B1V8D$^I3QD.M>VOP"Y8Q=P4YQKV)3]K5;.B;FB"6M?<$(C M>V9)0I0S)%B,P.:K^5FR+I@9D5?E'!BED5GR(7$UJ+F :XJ MYX0

918$YCP3X>1J*X*ZK/WEPR_.1WCRP#._^BK44QIUK&=?P.<-Z2(<1;-5S#OT8"JP9<W8 M*P!#,NJ49Z.^P7FBF=A>M>T+JP|!?(9 D*!GW&)9R8ESM+;<1)3B%1!@H*!3

M>HZ>33@AMHJ.CCOW&=<'#=IA5$H%KR1*5<.HB#$!*#_2(-MF;>#1H"D>);X"]6#,UCC3@Q5$SM/+]I>&/6/NRO!,"]6(?GE',WOP(E'17$E+

MQ5FQ5*$=7>53U75'T"8@44#&.R,8I0KV[]O"RBX}0){-5%PW-M2]0D_;PCETHPC[_Y"4UA#0_7#J$$^KKVCP5N$&,0PO\(XT#EV3>7M"^$%*O! MGV0K"9C5=.

<;BIL7!^,T:"!,I)^;L.QA7ZB2NHN.\MKM=N>'"7-D!=DLZPUP*4N%9T04?;1PE2H31[5 M.O9WSR\;4BKUQY20I4.VQ$L.8PV&-YKD&&]W&7F[*?-+'%+?OL!:9^,#@%/)

MXXXYXDJLF<&!.4B#3BS>K\^+A#F]Z\503^]E+VU_?E4O6D.*1'-Q^^(/Q(D M2G@E6XSYX.2%U%1 3*6=6&A5:[K4J8(3(O%4,O]

M7BG@1)>4>B:V*BX8^C%@[9AODTU>^6XEIP8A(XI>E?D;IK':+%)<-}>W)!E M!TI[F66RCWF@9[.+#)/L+.4*) U:ZY#W#NV-5)\2LA]:0AVA*-!'&"D[A#2P5 MIW(3=*SKA*!5^\

<3"M"6/MD84N,Y\Y.L'JC3LZH38H*W2T&,6(3/=R-@[-^* M?7VG##Z]8/ZQC#+DM \\8D!] MNAJK."%617OK\+HWE;>_'$M,O33V,,,;%VVC!.S4B>:(*=< 181U%!J#VY[M/?

NS5,,!3^]Q4,"#FU9,0V$GYJK6P?D+2[!Z&Y.1WT!(Z U:>B#ACVC,_LS. M5V1J@-+W&]J$RTB7\5-=S'[W:R16_DY,_-OB>Z^5MB],F?.G/1;)4-:^(4H

MVQ1DYBSCQ.%00!1OXUV>I7>_?0);X@P%"=*G.K\4\-W,L)-\2-H.TKW;M\/VMG!#\.7)T3)SQ#D^2^4@898)2$KK 3HM3RQ'1 *%9+,.B&$K'H"W?]N#3G16LG^

M64R/Q4GYN,B#R-0[_67-M3+6$$YV62:>N58"@_2KL%O-NI#_YX^E MC.30^U7ZA?ZP(U5!!:018N0/_,,-@;=^:!^;QL$2)!L_+/&6'/[CG[[_VT_?

M_S'SWW&,M_I_TB%X(O^G2"8N_@MG $49WL8KR*-3>?$!1]V__Z[>C]!59@/1-MM!(H^)UB|G!UXB+(3("++$=PD:,4$28DD=-I2M/S#&K_^,4 AE0+^\1G^\8?W M-/@?

*(F!Q&2PZ^9'.H0,,EG]7;6D1NA4D:&=M*CH4^7GB;HT(Q\,*/U8Y*\5 M?:K^/O$X,>/W=1S(5G/%@%7+3=S)DJ+^AOPE-72S7M)*1]E8=>NJ7':BSO)<*

*M>L_[!0N,%!VI_CY1|HC)!X36 "+RXPRBO!5!4Q:;M(N7")+M1K?DH'W_#[37 M]K%>;ML!LKN^/&-]>;2 .*MW_\,,+3,^@Z&VCR,1=$Y "S4M4665BZ2>;!%BK M7A%Y_DU[!BWI7%%5V6K8=9'QW/GS]\W(31@4"M8R^5MH11=QUU9Z'DP E M__Z[/_WM#]__SMLE(889^/??$?TG3TE'\(Z! >$WQ$"K=VP8M%VD_2/??\$I MHF5=`Y":-9&/R)^ `W9$R%(YD?'0&#++%N/QP[N/2L)V*D?GQMY%I&&O%V/QT MKF-3LPV+|?C3N8Z'VBPMAN7/YSTL#5.X&)=._ -QT5C?O?#\Y5R'1V_I%T/S MUW,=&J5G08S*P.KNJ8U*U9W!!^7?*

*SE,C53I1Q*BN RO\?&)DSE,]-3L6O?"SU8&;[EHQ)&>N)O=Q&*05E8/UC]CQ#K?STA0XICRIDT!04 M9;GX2XE1*6*|A0QW|43R')UB*#@(E:.03C^A5Q3G36*M6I<;Q:QUN!Y W-)Q M;7&K LQ70,$# _>)\D^DS+@\6A0B:"K:7#5_03 TC.@O8;:YS-.,;U%2IK-*.*M4\B3$RS\=_/*ZM72L&*G22:)3/Y7*2[Y'X*2>Y[PD9=)7+DLVF(Y.BHODFJ6 MTF90%66M+2F>U>+KBQD#CC=R<+6>LLG_Y]8'FMK]4RUKKZ M0!0)01/#)IT?Y2T+1+V>Q94N>#M8Q^J0A1+75/<\A7&3V[CK27*6.0J'3G. M8-*++<\ZXYG6E+7.:?TXK\ . :>++VQOU5+7-H5X']Y+-X.|(^5'@\|^3C-2^;? M!ED<[U;G:O:T"A21YM;F_5TK9/%>]XRD? -KKS9]#)WH/"=\|HV*-&^>G2*E+F2O5/YI;ZUD3Z=I/@"DV?40)Q0% IM"E1@QU66M=-MAX$KD\[,7OTP ML0.7&>_0B)XT4C2\?*UH2K4?HR],I\U@[K2]ED'^UH%G=LC?&C;V"\,;<6NT[QA#[^KNTRK9,UU*

*M'R7WFGI,1$%73V>=5EGG5#R+P=+YL17K@ ,3\D./7IM_$T:OQ;7XH<>GHV^R MPOA?\P-^Z/'IY'96Y+<61N(//3B|/9C5]$TZ'^%9C)G;FUX|CFI'UGD-C%%C MTJL.?)!^^-"#U%|S*GS9'WI\>A_76N_YAQZFHPlNOA[!04?R;VPD8[0&4*U+-M8ZD_T$TGVUDLIVY'NA(>)\U&&,^7C]HZ+76YUBKPX#.8H .?#<;.$B##MN1 M[\-184Z"NO8WQ:0K&FJ4$?L06_10Y-59C&B?O:[;PG.O0\]1GWV.1^HV** M5[U.%JZ-X4$[MPV2=A:KKZ-67_6\"0:@W^Y/+ WRN"=YL[3 M8 -<%,<."]&#EE=7Q.)9C&"W-=83!\E'[]\?>N2&>-Y7#K-AANO4G_5:0"Q$-6(OU?D2\;>2M$)F)(#[8HHO/&:"2M$[0V[98KQ;0ZZ6X3#5<,P& M[>RM1MP/RBOOK?GH;=<.R>-R5|8HZ+7E*2SPO)=?A8&T_7Z>!>[C%7OB1*

*M'R_1\P:A[,3T9X@KRE), _=]B>*G+VKOT_10P=?"?ZW_FX:L?P;MFEEWZ2;(G MA^LW/|(S@76[:YUB*T0=I\90P9H0L^42G-[HH|\'6ZPZ.W)+81=F)")P.:_*

*MP1$YZE)8+|F^^WR8[UODANPIDHM"/(IKA7;.M.%5)>WSG U%Q%6+%1!NS?[U!RSO^0: MJ7[T <===>VRJ:V^Q!$'(7IV;?D@>_Y?^+B2O26GKZ99,>T5[VB@_[=IO*E5)*

*MJZ32.6EV3S:?IK^5(@.6&,8BV%EZPN/WK&?IF%3>YIF<;_(#_\[=3"Z M8H7*S;)Z7=$\]@_1CYY6LW#TK6U1#\W\,$.:l0 A)\!\(56H5++9]KAXKVR"PQ M#M[""*-)TO?*

C9\C.]18,>9&-K(D 1)#-_B<(U-8T;;F9]X=%[9;Z9C>4=,NQU M-NA99:KTXS4\|-FZ(W=D$1G?LITZ51UXI5PFB#P6;OQEFU:I+F@_F\4=>$[*

*MWR/M]>PB:OC,MXJA+.N"C\|%%@]HN=,LZ/LP(L]%"'/14^;#KZ6&Y;O->*E9 M)'VG;SG4<_>UU1KZ<"NMK-2Z:K8(&4H/W"|NQA9P>_/RU!<>]2HP=TI;UH4C MJ/WLL6M?#YDUB)7@!=@C>*EOMNF&BZ,MM(K?* SV1&DD1=%4L$3=0-NG 5W-M8COZ0QXW';3BW(;J$R1#Q8"G&N:S&+QˆPZ7$59S).'6'9E1V9@WY<"9(7C7@*

*MHSDPYIGI.M^(;BC*6>"3>U^ .NC+N8U6[SNP%7-S%B/8=\SJP)XS&:3#;L'N MR_LAK']=JSCL,YH6'H\=]3 K[-@?^UV/?;"H9W,N'6^*'NBX\YB'/M=EUW*

*M=VT2!U:.L]X5+/@CVYGT&L& #UW ;N$-M8-YCM68QDO['K@N$]-MBV%KOQ%**.,9#4@70X_RG!^6@lLUAL,>]KX!+GT6=.4'[_IF1/=9C%V_LUR%*

M23]+W=A^=&=G>#0 %FO+&F?!]7Z,0MH!]7&8B^+S4! &B@:4 MQ+'$^*X=[@?K#VUAs6>13] KQNNWQ=1ZJK?&?YQ%EH6#MZ,I,N4L4@DON]T$3YBZ#XV7&

*<@W'TY7!-PQ9[HUP M0!'<(@>51K2.E1T1CF4XFN79AFQ&FO^U@U"-2DX)2]!> 6GA*CDG.HL MB5S+!2K3GENG2TT7Q.JX:4PUW!'#N%UTI=WI?OM&,59Q0^DZ-*

*%JFZT5U%K&2 MPPQBBNGGU99PDJ"_Y&?-JK MTS3*E/;HP=^2?TH))*_PU@lCG1#M%8?FW\L6&W3O)H]"G _9R63KWR-(N%WK M84MA^UF7V)Q#%!.,J.OE/6Q=W\HZUD2H|<.X4-1EK77|"KUDMS&Y:7(:"466 MKK'WVN(CDU[J5|:FI LV%66G]>4LLK[3Z!"B^V=[X^PK"@X\[_24BN.O"7^FE7%[1_F%6UC8Z9_+K4M2_;.PI ^K%;(7F?*

*SES0,0C_92Q>RZ4+1EG=B M-TI^1'QEW\QR-2C 8DV%EZPN/WK&?YDEFA3]0NZ@P_@D$101Z+IL.Z.SZTOL_MS48M/(SRG>-C<<*36T@O/X8W=B^1 M'@+XQ?*

8EB\Z$,1933$!E%;MQ_H]4*6%678/(9"++)1;LV28O?\O/JO0^/*)?Y;P EW(-K^(#_^@:0:(M<\^@Y8YU5>6L@M&(31?07]^0^)_U@:IXIBJ;!IFW\!*

*4NC6L+E'&EA@1'1!*DX4EC8P\PEK05;.,%FJ4RV7N_2-N;3(ZO>Q< M&+EL6$9G.IW% - M4LM0H4XH?$!A-[V>NFE2]\'&590WIXN?LC%#UD?/S0X#^4AJI@"({]Q&>!CE*

M7I[7I-9$/ZB#,*-64!B>`G( Y<3HPJ,V#H\BN$9 _26I2((<7#1NHOWY[_)`M>EKVO@>X?3< ^S*UPO-9EP!)>+OW$V!V"}-[1

*$2/A"T09P=VHYGN@8^C|7EY?'FK/X9 MA9X=CE\RO#=MZZ\K)TG)=_^VDH89\$&9%!))?GF*4%+L.+B#;7'B\++;?WANT M*#'XMS"*L,O\#"2#R?*

S;WN"C),.,,":6)S6MP4HC4TWV[Z]D2:]R@X2E5*K M=H[7F;WF,,4*<#&5V;ENW4/IK1\"8W5E]V:.815Q;Z9-$,M8Y@LKG, ;2G6K*

*M&TA6V3"LBUF###5,AS&$WV(ICXD),M,,VY)MB8U.B2PP@##WNVK7&[,*(-T-[?`M.1D)3W*3U.\HW*NIM_E2O+1 M4S&YZ^*+'8'H6^WPEGNK?*O\PR_[?|_TR#O!5PL4SY U\FQ6IN!5ADBWM+55A+ MN!7@L'TJ@SR\ M9W*^#CLM3C'W5.[P,K$!-W'/3APYUE*V#C&4NB_;C1.&2P^O)O$[*W@X7\C?R,CBC_6A'@*"X8 M9W@#[4622'8LW++ =4-*

*,K(DLMP%[% 50)7E=+:B\}\@F"-_MQ4E?I?*D6C)!JE MUD)EC4Z0L6*!&KRDZB&|QXLG2]E!;@.,I1'FZHQYJ*

*M'92H(''5R>Q==>5(0)D*T=CD/!N===SCP_$AXL92K'=HAE/)00'41;+R#?/W\+\M%$(=`?PW\-+/(+_QTO02OF_4MQA2AM8DJ3XNUT'WZ4Z\CD8L3_ M%H$SC4#3ZA9*YK4A*

*Y6ZS7*4P(04'BSQ Y]#-.#@1;151>8>L&U)S($AD M+P<3]NB:PS.E=3G T,;50[2,=T/WM0DYUYX546E;@2UPE5H1C;45[GQWLA7I*

*M>)7PE1[3MB(*0C4_F>)MMM%2'1^9(BW7]*EGFF@I=I.G7E M!.^05Y">$9&\P@1]TO_@VZK+]#.>#C6%%ZFU!HF*2.>6+|DAO;?LU$4%/#?U MA7A(`T&&3_!%;ZNYOF:(Q9!-(1,CNS~/2Y.D;5XF3=>ANI_HO]!-4 ^O*A\ M]M7J(C0|FZ^O'N(!E5$/_J-);-`TLF>"#)6*F1T5"!DW;/>"CQ,9!?6,,)-2%*[-.H=1*UV#++7#(=T]O$,1,:6 MB^[^CF!I,WA!*![W.QCYSLK?*

71YF)(2MORA^IC(K6 M0Z]=X;C6U7](IK)/#M_+EDFVJN&;]>$ER/H/#4[WHR7L'-M*95|\6VU:G9_%3YV?U6|C-E63S%SYZ+4L6F29=T#BG\F40_A=Y14%P'[$[

M(/_R\|J6XG|/6Z82#J6#[%SO]'0?E:6-6FRRU>BY# $BWEZ2YWF7Y>$9O3;K M*72DV1';ZF$$$M/9^S8@0878"I.:#,VYCS%) ;4"3+%T/E1-T0|\.'1E#L"L

*M,J]L97:81W#)Z;8"4)=="=?8%+&)7QM[#. . %1 *)(=!EZ/%2(?NY@BP&;T@$ MU DT+I/D.(//T+I@!7')%ND(-@\K7C]{2?2TRID*N%:Y&O[]* Yl-?!:Q*3" M9LKUP&&CLX++<9%\6-*

*%NA2^E+YG<,8Y;!]&EXK'M5RI&0S[WJMMS0!G,;EM PMI;"7+Y9M>91&C-L'5MF:=[S <*_=?X_^)?? MG\(D*/S\D+Z]*/T<6_EB,WD.BSY)HJ,(_4<;FRP$KVM,A|K/26J6W781F7M-MXI*>RWSE$,+'Q(M[Q#VYL$>KX.ZN?(`=I,H+E*V)DI%)86AL,Q|6N!BNI0;1 M50-*

*Z*8D%$LU|&'NQ#X68;M)\(@:;)BHRE;_B/D27$&.@9%90RDUI*#"'X|P2LN M@QI@"]\YJ#5^+=!%=0| E=PI;_G3|ZES?B-BRT0'4+R"]"V"P%".4Z?05ZD M,7;.TT;J.%$OK_)M4GS-CT4T930,QB0TAD9,%V77$62YO2Y]I6>6Z(0$9H;4 M8K2O@DMB&Y;^',A'1H,S5] :E6.@RC!6 $B1??!ZOJ"L806("R6Q$:<;<4.C M$11F2#.J7$&|GJIVAI843$/)!^'_ 51R/B _VALVT *R MUQ1N+*$1?>#%FUY^+Y3<"P(#2(;XJX;+<|G?0|'KD_<_27!39'ER!GCV(SS& M.F3R=/*@R/*%\|@(5WW!%1%%-N4P<1%(WR3/|$H< M(VMQ,T;4QNCK(",.\|>Q?9&A,%D!GO/Z20&I/NTM#;22:R#A4^_&3{'GX}I M:5DS.AZSL1A!7;ZWVPS('SMI$R;04\$EW'(BS3"FRE'&6B/<6*=UP"LL"U)-Z]KY|M-@B)8&GH!X@|&=A]^1_^#(O .QV/HM_!4!3M+GC4*CRMRD'9W5AR\),?\&U3IR=/EZ*6,2&Z2&-ZZE1FAC-]X@W#2 MCS"UBQX&%'ZU>610H>JE1EOG"'!M\Q1PI%O: 04NC\ (Z-AF*$<6Z|')^<@46B=F-(E1_DF0\,3YC-DC6&%@[3LL?;"DXJS*-J- MV[Q3V[=A6O&H?2;=4:VE#CA"*)N &7>5(@(&D5/+Y M)R\NCIX/Q0|(^?>>CR+Q*8^{Z!WTHZHUPJETNMRI:HT E{3;,*VI+R[2"+M=MNN%F`G",KR,ZKLE#[Z_H^'+!=NQUP2G/M/]E>,:839#YKH<6YGL;WA4K>']O0XG(@3*]#>>\;C@1N4P1.D|RAQ MI&?O3'H"AFVVI0,U\%ZD_LG+P-5;"DJ=8CPI8JE4_K[Z;9=[-J$1YP8/U'N2-MD9.!<734;U'.:.,,9L(+)+UC\#+XMOX?O9HEY;^U=^H3 M@#)@@*U@*#;.L@WA>X4EZPW31S;S&SYGL5\M*!I_S(TFMUDZ,!>"-)8'C<9JB3]C4|EUC5W0L(;.#OTC M^Z%E[*T]1^JVXLG$5C[B=9U-.M(A/8.3%"V\2=9"'>&B"M=TQ[G)Y ^P*_$;R$${RK+0&Y.H0E4:B4'C^$'",9KO+Y4U>$B M+\LH/G3:1$929;2B3[*9(=&C-'44#$SQERGO&>.8 "B, /D $N5;P"QQ3G<3) MV^4Y?#LQDFVQ>NE(HI.+CY\N'I6(]:M=2IA\^/[/R"4)F/X;/NVJ*V\@Z$ED_M#4,,!X78&+ST$1O(?"_Z,^"1SI6,D7<"RV=X;[^_]$'^>)3$^6G&J>09="=@ MH(U[_99(P: 9:T|+AU\F7:)S1|O1\N^30@Y#: ?;T^)A6WF+1X()3BA)G 7Z ML)^#0>Z=[R-4Q@B;NGBXG6QK-VE9>SL<40|#P0REKV\K$%.F|/')\;I.G'!, M=\-T*&.(7S0T2=[*/7;6M6P#1+]\/W-AGW_3#NQH?G!JAC746 MS3VW4C1[*_R9VR \-1)8X8/;!MS6Z&!%$JH-;,VL&5:DI=H.U4J?MB0=U8:@ ME@KZ=IFL=@3JO?';R+;?5D4;J1_8>+HBO/92R^'(*Y7%TOA8E6< M+,.5FBW2Q%/N(I2#/CEF7C.NKPM2/ 3@NYI+DH^BZ7 $^.FYB4>(9 :,|H_?(&4/\26 M2VJV@E1W'Z^A';++++G9AUN'B-X2[*L-2VV8'9VP80N0",42]6R1=6"]@^I5F M71'2?OU(N4$LV/J1>F3TA724%B"H':19XQ^|*=*T?'#N?47Y\$.0[=$)^.1=M$'=*JRK7Z449*[4@I8>ZM'SG]RBY@"85>F]3ZFTB+(;=3W;:SB++DS-($7FA MQ$XEC%&4?/-B*#+CGK$P>B@TCL-+|&1Y30|TG F-U3D0PQ3X.>1T$,0P?BLS M<=S6#.L%1(!3;U");8:D|?#WETX_)7)/Z#Y+XL/Q4PB/8H[$H#2E-/1[P1,2 M7U?),WX&>9'&I3*8?H#)+WR_RP@? $$*"@F;(:OCS+.'J2\#M+E0PRWONGO MXC*,3I(;^D07CHHC=DC[!L]Q/#" Z_>]_H.PZ'.UU$9I.6M6T/)S> 9G533 M$?,2':Q0N 7IC"2D6*%3"V(E(!-9\8Y! M[&ORBF56O%4008XM'EKQ$D'PK++$4"L>&HB0&:=0;,5+D%;8\G=V[T1V]F M,+A^-M9\,L-RNO_Z[F.845 ^*]_C M;^28,8KLNDD#V1#2_N4\U?MI+9611YFG&+(EA-H+%-=*Y">4KD^D,J#[%|)P M4>;_1[FB,_Q/U/APJ9_0R+I#C14G-E<9;3L&E?X.#-MZW8/3;=EOR35X\L*`MXPA-'\BN@W6"N X2,!"AGEFGUV*0-2[0-10NH4755>CA'!'6&$47>,:;H0OG M5I4D.GA{'RFY.Y'IH1>0GD=Q-OA],!6GE9@C1@ZPPA7"26ZS43\8]0D$P.KM3K+ M#H@A!7Y.\DF0&:Z%LFG6\0!/J-@AU4Z ::C%I*EZ/J:APA0:?0JEF?AP+;7 MNE>7]PCU'&";2K>[!#?>^_!+E+KLY-9*MB9TI[K0&AL2;40"%M3$-EDT97'A0!RAD1ICMHH@[=)/X ;8[>.#PF\1N2Y\H[ML+9VD:/F|%*'>ST;1.0DW/M-]%!E&,+5P*58%V2LL->09:(^+C@AQ IX*((. M"1^6X&*J89'ONA96IN2_AOE6PP+FG"1%1-:*MQ0B7&F@@MGV M6K[G"&AS8_3Y='NG072NXN#_@@O":I;W1R/U~=01&NO@$*#:K*?M M-#%93\Z@[BZ8X83@.0"59XQK_KWFFBRF>]V7V/#O,LB2{(((MVZA9791[*.N7AN@"?H:Z5D4;J1_8>+HBO/92R^'(*Y7%TOA8E6< M+,.5FBW2Q%/N(I2#/CEF7C.NKPM2/ 3@NYI+DH^BZ7 $^.FYB4>(9 :,|H_?(&4/\26 M2VJV@E1W'Z^A';++++G9AUN'B-X2[*L-2VV8'9VP80N0",42]6R1=6"]@^I5F M71'2?OU(N4$LV/J1>F3TA724%B"H':19XQ^|*=*T?'#N?47Y\$.0[=$)^.1=M$'=*JRK7Z449*[4@I8>ZM'SG]RBY@"85>F]3ZFTB+(;=3W;:SB++DS-($7FA MQ$XEC%&4?/-B*#+CGK$P>B@TCL-+|&1Y30|TG F-U3D0PQ3X.>1T$,0P?BLS M<=S6#.L%1(!3;U");8:D|?#WETX_)7)/Z#Y+XL/Q4PB/8H[$H#2E-/1[P1,2 M7U?),WX&>9'&I3*8?H#)+WR_RP@? $$*"@F;(:OCS+.'J2\#M+E0PRWONGO MXC*,3I(;^D07CHHC=DC[!L]Q/#" Z_>]_H.PZ'.UU$9I.6M6T/)S> 9G533 M$?,2':Q0N 7IC"2D6*%3"V(E(!-9\8Y! M[&ORBF56O%4008XM'EKQ$D'PK++$4"L>&HB0&:=0;,5+D%;8\G=V[T1V]F M,+A^-M9\,L-RNO_Z[F.845 ^*]_C M;^28,8KLNDD#V1#2_N4\U?MI+9611YFG&+(EA-H+%-=*Y">4KD^D,J#[%|)P M4>;_1[FB,_Q/U/APJ9_0R+I#C14G-E<9;3L&E?X.#-MZW8/3;=EOR35X\L*`MXPA-'\BN@W6"N X2,!"AGEFGUV*0-2[0-10NH4755>CA'!'6&$47>,:;H0OG M5I4D.GA{'RFY.Y'IH1>0GD=Q-OA],!6GE9@C1@ZPPA7"26ZS43\8]0D$P.KM3K+ M#H@A!7Y.\DF0&:Z%LFG6\0!/J-@AU4Z ::C%I*EZ/J:APA0:?0JEF?AP+;7 MNE>7]PCU'&";2K>[!#?>^_!+E+KLY-9*MB9TI[K0&AL2;40"%M3$-EDT97'A0!RAD1ICMHH@[=)/X ;8[>.#PF\1N2Y\H[ML+9VD:/F|%*'>ST;1.0DW/M-]%!E&,+5P*58%V2LL->09:(^+C@AQ IX*((. M"1^6X&*J89'ONA96IN2_AOE6PP+FG"1%1-:*MQ0B7&F@@MGV M6K[G"&AS8_3Y='NG072NXN#_@@O":I;W1R/U~=01&NO@$*#:K*?M M-#%93\Z@[BZ8X83@.0"59XQK_KWFFBRF>]V7V/#O,LB2{(((MVZA9791[*.N7AN@"?H:Z5D4;J1_8>+HBO/92R^'(*Y7%TOA8E6< M+,.5FBW2Q%/N(I2#/CEF7C.NKPM2/ 3@NYI+DH^BZ7 $^.FYB4>(9 :,|H_?(&4/\26 M2VJV@E1W'Z^A';++++G9AUN'B-X2[*L-2VV8'9VP80N0",42]6R1=6"]@^I5F M71'2?OU(N4$LV/J1>F3TA724%B"H':19XQ^|*=*T?'#N?47Y\$.0[=$)^.1=M$'=*JRK7Z449*[4@I8>ZM'SG]RBY@"85>F]3ZFTB+(;=3W;:SB++DS-($7FA MQ$XEC%&4?/-B*#+CGK$P>B@TCL-+|&1Y30|TG F-U3D0PQ3X.>1T$,0P?BLS M<=S6#.L%1(!3;U");8:D|?#WETX_)7)/Z#Y+XL/Q4PB/8H[$H#2E-/1[P1,2 M7U?),WX&>9'&I3*8?H#)+WR_RP@? $$*"@F;(:OCS+.'J2\#M+E0PRWONGO MXC*,3I(;^D07CHHC=DC[!L]Q/#" Z_>]_H.PZ'.UU$9I.6M6T/)S> 9G533 M$?,2':Q0N 7IC"2D6*%3"V(E(!-9\8Y! M[&ORBF56O%4008XM'EKQ$D'PK++$4"L>&HB0&:=0;,5+D%;8\G=V[T1V]F M,+A^-M9\,L-RNO_Z[F.845 ^*]_C M;^28,8KLNDD#V1#2_N4\U?MI+9611YFG&+(EA-H+%-=*Y">4KD^D,J#[%|)P M4>;_1[FB,_Q/U/APJ9_0R+I#C14G-E<9;3L&E?X.#-MZW8/3;=EOR35X\L*`MXPA-'\BN@W6"N X2,!"AGEFGUV*0-2[0-10NH4755>CA'!'6&$47>,:;H0OG M5I4D.GA{'RFY.Y'IH1>0GD=Q-OA],!6GE9@C1@ZPPA7"26ZS43\8]0D$P.KM3K+ M#H@A!7Y.\DF0&:Z%LFG6\0!/J-@AU4Z ::C%I*EZ/J:APA0:?0JEF?AP+;7 MNE>7]PCU'&";2K>[!#?>^_!+E+KLY-9*MB9TI[K0&AL2;40"%M3$-EDT97'A0!RAD1ICMHH@[=)/X ;8[>.#PF\1N2Y\H[ML+9VD:/F|%*'>ST;1.0DW/M-]%!E&,+5P*58%V2LL->09:(^+C@AQ IX*((. M"1^6X&*J89'ONA96IN2_AOE6PP+FG"1%1-:*MQ0B7&F@@MGV M6K[G"&AS8_3Y='NG072NXN#_@@O":I;W1R/U~=01&NO@$*#:K*?M M-#%93\Z@[BZ8X83@.0"59XQK_KWFFBR F

MR7T"^2D)A@W^1:3(&0.IRR$'ON9=%1THV'R - ^AIM1ZL5]3+RCSW%Y(ADVQ-M,70055L^P:$&M$W5$69U7NG2W:C1.D%7R J&?^ (')+!C|1TG1DA>T084RV0 MA);KS*>2_BC3J!O(?D37.4;*#%VX"4S:2)[#E|@!)_#@0Wl&,QU:\Q7OS.K. M:S:C8L3,&Q/?278:Q.,1^"A\\@&]M8?WQ3.:H/$-98<_P;WPLE/S"8K9EM!R MG?FPlF!Z6|F6A(J 2YYR,/(0/,.'LBNF;^EM-K^'|\QR5\GV%G=Q5_[< Y? MH|H 0KKVIPW5INYBI5EJ*LY2,AR96L6SV;.9V9%Z]09X$Q-9D7R2ELEHD!J5 MD#C(5'+CRB/6$M4HAY'1E,/*B|3P* (&41$;C1>I"XR M&AA6UH-'8J$U;.*B-;#2,.LR.X-9"Y-P1B6CR0W_3!J4-8Z1$QEAC!<%)61-"KM@4T 9#1%.0:1-!CX5[TWEX:TH-2$?H:Z!E0(161*)BB>=?PWC/PSU7..^2< G!WVM M7N*XZFG M4 /WLV-KI)!35L#J&@CNG_3&52\:CZ2S|8]3@8S2A:P"U/IB:LL28.=F7YO MN6HH*F>R#F"{),8]RJE)DL#EYV>[@E]"8!L-W)D:L-5VFFPDNH2V/>AI!<" M:@!5YEL6:C=CR)P-LG-0@Z\]D40>YJ3@V(=EK5!,Q%;5+/!C&IEHY] M(U:%FPO4LVHPM-/H03FZO+6UFH K.Y5Y#@\6N897 YW3N%3)K]LUF#HE D" M^=%KEC7PN9 C#'QC?]!?I2H5NSVHQ-IL#4Q.D1@R-9f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~YRO$U.,S;+/(PB;]_*=[?*6UGV1[BY2S,15L LSL3NI^^2UHVX!95H(BQ",,FZ3)^9L_Y'KG5Q M#*/G@ME%H68/HX=4OK@>!$. L2*R>5T051>%,AWN;6I#V8:BZA)1UN"]=]4H M"X%473#*&L@-3PBV$GP\0KD5L=7KXFIG%2D!VW-Q/GOH38|A3')#U7D<'. MY++P?D_-- PFF.*1LJF_2O7AJB-,>L.4_:.8)S\P*8"^NVL9%\MMHB^9QG@00Y# M]T[V%>R>Y|O1MI]OK?$R>Y|O1MI]OK?$R>QO#8|/] M'8_ S\,/3N9 SQLJF:V /*1F)DE.H@Z! 58>.`|_\0>ME,&^)6C*CAJ29JZE=1 P!ID1; M|EOHX3/AD>10Q+'VY8(Q]=T(]..+_/3#:,M!9&D6K4<"+^M;<>ZDW(.#.U"J2ULG M2BSS7B)4PX(PNTN*.CC]9""S-:+F'!T],ER MW#I3Q'9Q0),13V[\47S/P9P$'O_LH'1,*-]*B*X!6GX'7)&LH46TTJ936|$4)-#-*7V%RA?SH[MW211!"6AU(OND_0Z2=/D&PA>@(^2ZH> M!:>GKKL"^/=-ZFU3M.G>JW([94M-M ,%/-;&VN M. W/"D<(2U$Q3&.ZTLFZA;'KE0&;]^G6 M83/1 FGB@1UA7&3EGDP[EIXLK$0^2ZLW/5")ER41A?+ ")3%MG>8GH@#2\ -MB0@,EF%&-2%,;&%61./P4A5!85X#H[FT1$+ <1C@*1IZ%+]K\O24K3%[VX2.&B< 931(TNB,$#02O.DU@JG M7R>A@VIW513M"4J^_]5^\,.7H$-P$/4Y.2HZ1P!0"""O"M50H6F0 :H$G2#6W MD-RCI$R&7]/9B0/^GT4(E;*'&#)6E)&14C1TR8C]8$@N7D2(),6WD1PH-:+C M0US72H_?2(4VN+NI4\U`!(=[HY_O42.%]]H R?X- 3+5:R#T4Y_="/*961\RY5P761B73/\%@*.=N7;2]^@:/]40%;M9> 7^.?G M]E4NM6S1S,'4[I5;9]9$*/> |"V^:*=(4Q'[?|8-@\1N?N&7@1]]P(H$!U$E/ M^0FD1*V')$C1.ZG3^D#.% *':,2Q[W':]10R9DBR&<(,9(<8WB-PUXLP.Y6^-MF.,M^$HZUNQ^ZK)(>FD,IY,]@?3EY*7@VLM"G[,?%ME4T?=5'85Q]>&"$# M.^0X+UX$&O9"6 MG9V6+^PURS5,.[Z\/R% [>0!/W4N*>'8H\R[T8]3*T_1(. M0Q?AEW*.<"VU.3W853DQ'N0U%H_ZZ"H55"[,U)#.R%5L5-"' 6SW,ZCBW6(M=S%6.*E|_O^A#!@@^#__E]>E$;#^1ZB"@._Y753Z"Q_/0V7@K? \R;>Q/.QW2 M89S_)0C/K3O=B]KZ B.O.M'#.O"ACUR:%'_Y,"3^8X++8T8LZRN-:E Z!?[!M]E4NM6S1S,'4[I5;9]9$*/> |"V^:*=(4Q'[?|8-@\1N?N&7@1]]P(H$!U$E/ M^0FD1*V')$C1.ZG3^D#.% *':,2Q[W':]10R9DBR&<(,9(<8WB-PUXLP.Y6^-MF.,M^$HZUNQ^ZK)(>FD,IY,]@?3EY*7@VLM"G[,?%ME4T?=5'85Q]>&"$# M.^0X+UX$&O9"6 MG9V6+^PURS5,.[Z\/R% [>0!/W4N*>'8H\R[T8]3*T_1(. M0Q?AEW*.<"VU.3W853DQ'N0U%H_ZZ"H55"[,U)#.R%5L5-"' 6SW,ZCBW6(M=S%6.*E|_O^A#!@@^#__E]>E$;#^1ZB"@._Y753Z"Q_/0V7@K? \R;>Q/OW2 M89S_)0C/K3O=B]KZ B.O.M'#.O"ACUR:%'_Y,"3^8X++8T8LZRN->;

*7F3HB#,FV9/0H)B#C5NCPANO/?^EP1M'/BC@2!40!V,@=8V35X_`""6.^)L MMS?$'G:3^ .E.7$!/2;Q&Y%52GZ,!73!.R.;90_O]6[(0\C#.SW$.:N5HDC3 M#Z-BB ^0U3@%\XL&^#TQQ'&P^;(*#3%+.( .N++:+A"$>?#+Y S(>%$@")&T M0:GI?!D -/Q*UD1]J9)'*XZ9*04XX@+.9#A-LTA6?3A MJ*ENPKE+95[`\-TKD!/7G;,&#EH24Q9)-M85/J*MXP.PWH5!_\7G0CDFVWR M$FV3_&A)4I8RU"2,Z,@19) MVOGOOY!<)V<[9$X1/8BWO#^=: MO!09RSY?$J3XEW82IH!$ 0*-[?.YM,19YP"VA@-[%A34YOO#)4)@28)PY M%,S&)XB,]K%OPX4I3DPBT5D\0_%2O8#Z>.*F8R#'^P/=$EW!^)ST4[>N&[M%ZE))[0&3S!K&EL)27;QY*?2R#]Z:F3PL7,$Q@ STA2I+TN6P+..:8@WM!% M=X3?.AH=\GT-)RRZN\|>:0*,V!2$OLJ#AA-NE1G 2%>2CFK_DCLTT|IZ*,,_M*M&N,/[FH'?6"<6WL?&!=Z8,A]P*+Y9<.!$*3KAEC7H@^#:JL\(!NU" (FCG, M<43P%;?^)9AEDW(<1^+ 'I%Y"#+@6V#/%M@S77[@68AHBF#Q%D<@%V7Y30/=_MC22]+.JK*DY$1KQA4 =+\G0$ Z*+,0\%YW1!MA _D78ALW4ZC@%%D5IH*X6,_M M.^(\&4)7TCI1%L?3DD:?Z*TF.W M'V:MG%GK6O3*.Y9,$NR=W3@^.1*P!*FL&L!PD,&"6 M.=#*,IL:JK!L6+74X]+B[B]T'R40TP9@18NKN'!D)5#S,SS4<'W&2\#_-WCP"SW42^#@[Z!PL%B4O*8T"9H!IO(&< MJ><*F/W^.0-N*[YQS+%_6OIL?<,NKV^8^(]!?D^$Y*PZ&PB!6UM|92B|\]XMN]LKZ 5JCG_+ M3QPH-1=9Z&+@07(5AQX%E*;X@.C/7S23^"KX(),;JP\OC,B+R4@%5YVUZ#[O M:EMO&Z2ZBR-6%1Z=F4!(!U)-HEU.V?=ON*@$-?)U5;.-VT"%PE-I6A MK;L];JR_0.KDA/O,2'E-/1A/O(7TC!1

*7P55#Q@LJ':OCT_)F"#B)H<^CZ%GW+:5/Z67"H3_AU-M2;T(C[H*CEA{)AHZR7<>'NQ?SNE@6\GA/DFKMHE/6#OW3_53.TK4[^D;*

MAO^IP.S=RQ#!Q7.;V=T4=.Y[,)_/72"09N384;.+L5Z"YQ1A=BCl;_L>R_O[-M.8%-(.M">Z|^O# B#EI\.UZ\"#57H1/9_O.<@"^-K0IZI+Z@NF9EST4U;F9Q MT&6^:+\'-

M;2>%XO:J2U;4M)?;!Y_GB+!,PS!W.HCS/6DYC>MMMA6;KP3S8#\THM@AE"?=NV'.PU9QS$3JA/Y;0% M9P3A0#)^KH>?TEK$(X?ICG C5.S!E?HLP!HUG$ M+A352S

*,CG(9JY!4?&+6NN-(4JUN 8,-TYP/27&1 M9"[=>.^>3RO0J/.,R]MLZ T)M:&QXGGS%%X6!)BKK /6@^:"_4+\LXZ.E[MH)6;N?"'^\'1*T#RVS64NN(1)Y8<>O*'UDMGPAOL!N*

UCMFW-_PQ %=3D7 , M7.+4'0#\7^<,\!T!K _OS^<,[Y=P>+Q0HVI-/$8C:M:,MITC/0LW3\O&[(%K #{8CERENDЗU[M7W3DI7.CJEYJ^V5DHITMMI-

*6VVGM$"CLU5JWGI[{801K:VV MT].CU4Z.T"+5=MJ*MXH2 ?2N53=QM=W2[{?.9]EYZ_'9NVGK<:MI%/#*.M.G_7K#:=([L*!_H/ OZ!#Z$8+FTV[CF4B(-.*4T^(X6$;I*

*M"(U9X.TT)F 7SOT:!ZVEW\"98H@.I MA?V!J,O/ (4WFH+[:4[F>O1)K_>Q6X-I0B4"6$=Z,.?S\"RS:E'^K@&lI" MVZ_2,,.RS&V1D@B"LJU#]lG)18_6RB*4HFR44,B?*

*L65C*R8C+$UU;+5JA2_# M9.$*18FOO8B\32\'A)AM"U9G9E4I:!.;*JGYI*V.[4R?T?4_\WP])A/>;W?VK MH P O68H^)XA#%M0#O_%BZC*@0X2140)TGY2B!3D) Y,V1I9CC\KJBN*

,JG^D^XY-+0[]T M4V<'\+'(>CSV@C":M-/7A@\O#?>>>YA[$<5Z7:J+/(7KLD8Y"?'(E-^,,$F5 M@R8(X3DY>5'=NFQX3:&3M)3?-K+?_,(1%GCQ(8@8=T:62P<0(+JD_;;4=&*

*[[AO*VZ-N($?T%_G&J,:)G M$N(1H^#.2TDL2$8QIENT#WVJTXL#, MY3Z>*E2H80R1P $(]WE*T3L6;NO* M2%@PI%H9.@BO E/]/RHB&"$"R&=(C<&*

*I4[_U:F3&OU9W50(9@H!; /)(MLZ>4M0)426ZUD2*M0%,N1#C6'IV"D8>`Q[#.CQ+M^:DLB!Y"W5&ZJZ;L,KZV+.R=MV$5,B0 M&!#_T0&7IX@I?0XC+! E,:*

{&L<"$V@NG+R(,8IIJ'RUO;L DF7MLQMBKZ{5 MWH>UW<<#K6V:&2S$W#5KI/6"Z#)'"]<$.G<:(#D>P>Q3?&=9 RT%Z.K%FC$ MA$-MKCWVR DF8O-)IF"+O$<4+

<1A0H(I-H/ !X% ,;%H:#K.Z86XD#W?OO!D6 MP9"$ZG! $<^R)T PHW'8(@1KJ$TNQ NPX3$BSGB;O8EZ033,?0\&V<.W0E , M&_'RB8:SW-1C/'H;UIMK,?EEQW(

*(\'V[%'1=65IO*7/3[<\Y+;T?2<%#OM8J MAB\#/Y9B3/CX1$H!GOY'(?)3?B3#-'&C/RL%RX/[-\R1 MAI$H<+R/$YK'2!>.7WQO@NO&'PRMF)G\MDGG60-)YU84<>O*

B2;!?.R2L%2G6WX M6LC\L..[(9GA;"V&7DT=+SO<1\EW$#49B*D#[^,""OMQ;[R M_"#&UB I^W#O%=1QX'0 0+PP'W4MR-B4;S_#]3(JCK(0^RGA$?L&:.)G?-

*YW^SWRF1%B.EAW'Z_3:*F\]XUXO(OIGMA,*Z,SM9LXZ&B% M00$Z\P?H2"[QPM^]M+?4?Z$B1&5]N!&?" .-TRH9,C=|3U*3FC\N^NXJH0X*

M%3;4HHIO0#$;+9R\GS9M/N_T_4\2)\LW?NZ,.+J4;@^58S -R!ZI&.;_*.5, M:NPL_A3B(>|>1!S^?AJ=^JW?FPJ9N_AS&/C>2^]^8Q$+0H<+I=\XS<25:> M0WDU:6'IX-7[0?

HO<9BW M<6>[$D49*PL3)GG.?#1K3+XF5W[9[U'Z4+J*$!GZ:A7/!BVLW#>GH%9YQ/!4 M8I]&Y N[O2Q'SB'@)4?>^;O>FZ=[SRP[]%=':#W^^X/P09T5:%HQ$>1Z5Q@J1 M=.;2

*M&_3*QL@9BF%##4MC%8R<7*R_.*?)09!;?11;&*,NPU/D-(X%\Z]I+\WS +:6PQ MA)T\(S]YB_ HV#0*>-OCF)G(lU@E?"&]Q*ZB@L588L\)_@Q:3]8/2,L.;=8 M*AY2H#7#]?*

*DX5W/KCH]:1 YJE.SKSZ\"+"=VWX:YI5=2 ;#1 YJE.SKSZ\"+"=VWX:YI5=2=[BHBI M(BS+U.-7 1/'OP>WPH%R ?.PT \I>":@[O9XA3*FA\9)'3;7H<;!C//29[*&Q*

*M3<0;CI>H0J.'./C3?Y{W%.'/?[=O!9"R&Q"^,DWC'D4X?3*0XAA/U2 TB7.)/ MU!;SA^.[%Z.53)[>8%GLC?8A.%/I<2;-M';_TO,/;MGWIS^[>U<4Z6+LGQJG*

M0W7X^/D"\=%DT/1\;'^_0$34Z0]W==$)9MI"YROZSP0$4(F(;O8 (W^\0(P, M*AQTR#C(!Y>)BT&.=7-W.IV'T37IS^Z^Q9-1)8Q7[C#C0.G561%&([""#+?O M$8L#)3^-HJ2SJE?

*FU<;B3E'7Z'C;SQ9K=>C)D;&C2!5%/![962:-%<"00VP M6IAH_8=0H=C3=%A..E#*Y2[#[_V=&@75]!]EU8U@*X4]6,A9:/S\[8VM . M5A GH':PK 5L#7^PQ:(MO%A4YFES*

*MAX-X5E2#2:5OBN)"]LITR0-%F3#*YX'(G&>$?#+!$<^!PU(%@9MJ/)6_P%+2 M@SC"4B E""=:.Y*IP9+,XYFXV()'Q0YR5#HLYE33M8)40Q'',U:=:K%F*SNN MD$E*

*G,&&T2T.)ANC6#3<&EI5@_68:%;<;!$X0>@=!R+'^#"!E?%1BYYBP;2]C MMS(8.R*.#1EWO+TRJLHA;4R(E*?;$RFR>]UN_Q!@V.)/Z+6-21JS/);F;-D*JZM'TM.#.'P0*

M=8@9GISN0>:#U?1:88)'=<61E.M0^13S$^Z]*(XBFA7L[D)"S6(XZ-!=RK,F MO\.IZN]28=%&=08+A';9T43/A.]X:2\D"+$#Y04?5X2:4;=>CEH[&DO54UN4>._">!>C M?^+

*[0ZW',]:U".F8]X.0B.,&UBR]K*0J2U/0&+@9$Y39FF)+<[59/-4&B#" MJWV.4HS UT.:%&^'^_"CQ&4VID?HQ?$@'T,/FWS2U.}3.F,?H,#P)$D>[U.4"*

(47B49N!&OKJCZ#%+0NI? M@:FRE(UV)7H+Y0T?5,9Y3#!X# LK(Y- M@'W0$B ;8A["V1(G7WHUZ! .@EQ>0UQ0P44B \WW)X8^W(YY@M<*6Z'''9[$TR

*MR0ENU;&H<6(%)AWI+*B-IF)M[Z,?L[T79S@:_RE-L]R= 9\OZ4)>WJ]?#WC9 M#!-DBL\X3\-O!5G]'I61ZT]XW7=2D6=.>C_UK*G1'"=*&]M,*:X\XZK@>4"LV-*

/N(P.^IX4B)UZ173A1P+4\GQ&N"T=65\) ^C MLCGH-;?Y9B3/CC]:[LZY6OT4*6,&95/X4^ !4A.K'BC5)))N:HR'ZX^F89!.'R9<[MEDS%FY=5&QIBW(O?PC9^!H7PCO2TV[-^A<.XR8*

MMU"H=)GM[*%RJC5I.# N@"N:.!!8;N63H.(S)?B=$'D+023"0^$XIJ23EWX MJ2VC4INHJ.!E.%OW7/Q'8(ONH;4E>18DISAN$]05^[P% M8F#'!@#.>&L@*

*A03%#D\TR'OEGK'W63+#\/X4Q9/Q-M4F&G??RX0*EC=? M,L=>Q7YU88%)S.KSC1.UXC//HFZU]:.9(_<)%W%(WB2+?C;VP\QQK3$'VVV;*

MH//M622;M'YTAH_K}$V3[_CB=L;F2E;#;M\-@6/(&D))\V!;A9&2TP8=22? MH>P'Y))I0P87U?VS&=0C>=(DJH,SA<4ATE:@C95;U<'1 &7"(WA!|&^W= M"/9&Z2'V#W+,^'

*M.,O3@CB'V1F"O3>$NK<=C'0+T;81W3,Z>AB/*"7=A#(,&XB_XPKU^1]$'^IS$^<$[_!*BB"&WX?5[,B/T%."%J-3>NH=KV<*H=`0[ME,6S_)GC-Q0QY3?',5(W]51&1YE#/L;*

(7X#;.U70P&A6R9T"0C}?]H1+)?I) MRX) "&QU9=[#. ,?8&&N2@8KVJ9V/@68IBVR(\\9R.!!M$/G5CT.ADZN7,QX M"^S)3]

*!8,C!],>A;.M7!ZBKN&ICXI^Y3JS97+P/^8=QHONE%8UIW+@^JOE'] M:KN-MQ ^6[!!?S!A=;MYJXB%TH>#+Y ME&6L0E*QJKF E*M8@V/ =^< TU_*93VIB4:A87^(!TEZK)-*

;;:M&5$K4^'!8 MYG/F0%'Z#20IQ RT7Y+8'P8M0XSJ$$(Y3HECC(6U=7$(FW_*+$!H E'A9KE*

*M#DO4LAP1<"_&:G3W@U26<.2WQ<*X6)2/?I:.UB7@DR38WWKOG8ZCO48>!9U3F8@!AE,VKU0"R^Q:%;[W\ M^U(!H]&H^R+']/J,D7$LCLW-4;>D0^*3Z,G<|^ -]P-*

P_^(TN.7#^Q+NZX0!\K'\7U@1J2G8 MA_;_SA;:.P)'!B?SQ;8+V&,!&_[6R!?1U1=\A6G/X[K!8T'-MTCK"G M"]&DH 0.1+U%*$=SH,&$B7-*

*Z4#438,&$"VOZ4!$S0,'4B>2:4'43C-L&9!+ M4V!/3@'3.2GNDI2#U75*SUMDG+;\H,Y.:M,XN:<%#>9?4I'5V^3KAQ%J9YPW(M9C4H):@4_%F:Y4CP*^D67QOEGKTU,"Z,#"*

*M!6@!?4'82)!'Z<|>#CP")*G2FJNX ;XHPUA['2= 9L34 M3U[&=#;UM"=F;#B;MI"R?EC 2O[S#;|<_?/_(3A^&_O_3V,|PGYI_H?XCC) MRQ7*?R/_A*

(RW.I_A4%CYTN;'._=_@5A=954SHS+\F%U>;K8.V)>'K L\(K__3_^5U9\R_(P+QO^?Dj3XKT96HL+Y9\QTL(D>"T7

M"HJT=@_&8121NG'_YS_RE#R(EXH]7S\G.^]U'/?$[^YD4DR.[_{=/%/EOI.2F/C7_X&H=YU:/R/DGW"1(R!HLF5^?1FE6+F,,:!XQC<<9NGK# M[Q3YY19E?AJ^U^N6.!*

,Z4&4$R39AN@Y.7E1?B(^@S"NG"->CEI6P/E5AB/-M_V(;BE]+I0@%5Q_XK7!#;21OZP]I %(8V(.MWIQM^(@Y$Z5^Z$4OQ?M[=&JI MZS,Z'D-I YUTV) ;!PF!?

*V'HRK\+@.O7^+KWPO07+RJ=G67H.V8*GH^.^/D* M4*TI4#BS_#&_\]*(OFRD]CKFHIBAY)A8&^!EHX:'_%[]9IN&RX?@&E^S@%1S MQ3RR,M=\|\{@>TTQB@[H/L1]7H^B-*

2>!I. /6'@M/T85&9RE>?N0RD:!!.VZ MR(CDG.'#^593(Q:3B6D.C@(\-MR"M7+K^!80=IL=#7M\6_X&@=M;V_2 MX<)+ 0/086-1-

*$K>;6%LU4]"81U2H;XK;14')7^X^T%4MB+,,#F1@HZQAR34, M?.^]4G0PDZP=M(UB-&L1A[2F5HM\|\2+22J?R!%,2#MV:H1'IU$9#H18Y_'0G MS=V>O*9-M @^^DX_OD>*

(TH&49X A\.FU8>5T954(T\B,63^^&C/;5T\+==O/NOK\8$D]Q MWTB'=Q\791>KM*IO\8P'MSVP*HAU9@"5*(FZD\0#TP(FSK*:|Z;\4FZD?]f$ MQK'-T-D+2@W-6JQH#J<'?*

8&7FGLZI?6F6$;M6)\0\0U?VQ(J+O3!K^P/>Q M3ZZL7T 2(?^=-(19$]J=0=XL,JQ'.LB0IE,U?!N?' ,A'D$3XF&9.U&|&PXR 7\C_U3^:/W0P_?<)R#@9 P^%>0UW5<[HF@

MQ@H&N,-=[_9[Y)/KU71Y?;<%9P?@8JOTNHK|+$)ACET>,U+WUKL^_>,_SO(M&]Y(%#MIE]]7-OF_P_,#ME(_925]OF,\$DU?U@WK.6"4AX-YWZ2V/(S]-M+/L:8_TW(;D?*

*R110'@E_L>A$*\|Z,[W*4Q7MRBQHC!#EVB MI#6M*>Z0\NL!M>ZDQ\>;/O5R?@1)L'U!LBO013DJFJ>^#$*K?&<9%8XQ9P5W*

M2)^*%ZY@Z=Z!>|]XU/6RCL#7ZED%$C06C(CJ;D?88 (Y?G)$1%2[53" MH;+8L:J)T\&P+3D9_T+\WCYZ.GCIT1LO+MZO($!,& WWV4M_1SGF03X]QS76 MDB>,:5P.O$"\/>D21-*

S<6/4>-8U8@P">I'JG3Z3W/BX>J & MD8JB$4"!NO)|/*75"?K/%.=`D&_49R_#NRR911L&3-(X]LCFW],P&\4?JHX'M">Y3BAZ]O8/)"+2;I*8!&U35C[Q&# $(.4%5#1:I?J_)OCR-*

U> $;/& M'_5/_V\+,'7Q9)TIUCN5*E#/OZ0QP1U*'AH#[/T]8"H8,.N0N' X51E)DBY MIFG./=;GL.02IJ,$1/7Q/>4/0$HBE<;3# H:QI]*AH$\QEJQXUCS>+^"!$50 M*>Z5K$@S??

&X"4[|(/ OPXEHOL6WDF 7,R^4H?2#L(U:8NY\0Z,?W.&GC86$ MG WW#DD49%?X:[[Q"@9!)(F6P7\O\GX":2J?:!"S%Y1G[D89/LC]752F@?.MF_U)<8F&Y|\F@PB%&0N*

$0$5I(3OR>LA*3(LP+]^Q[^<2%6505(HVSPU929(M^]?MH=Q2(Y7^1V3 K"O-P32I:B\!U#8I>()(1NRO4SAN:+&KLXD9"?/5>HI M=LX; .,.*ZAYO3LY2DEB_PKRJC[$61&%

<1^"P3^"W#@W3^%+079-N$95^RCK M7';2' ?A7)H^0\R&WU!JFZ.T=U[5D 4%IF2XNTP.#<0&N_8I/0%P%Q7A7RR M0Y+F1**0I-+)Q]DC7-\D1!]-*

R%;XU6;X(T!>^88L:R?)+AZ+CT.KLW H& J6 M!X16I5)V.1K;E?K_#O+@%'J3-.F1TH'NW,#_J%VE'M_](+6=,M0O4C+R$KTF MUZB29KI'R\A24# GI?;'Q(NO4DS:;PRNQ?D1)-

V/F0[=OX$7.D>/@7)F"FFS M-F%_BCNGVPAPNWB@3@\E/,8 M,)=7'?;BA<=/Q&R4>Z<*H:?W5M>4]>,P$V;B=)#2 3L-D90=4,I7[T$">"P

*MG*FXV"EH4/@U3NAFIK)Z*/18=RXM'QZZV:X,=GJL.I#?>|G^TBB5:?3/((EV MG!T[^(>O9V"Q%]%]6#>W3DT_26,5.\S-=0=BM[E!Y1R+(+LWT#2-L:I/_"A*

*M1*DX^(KPG)__G!\3Y,/5!5H MJN+J6D.)ZG!W:)=33;JS!EV?NB&UF:`L^$>*0.:G+LC\V^W_=75]OX[@1_TA% M"*

[3W4A2PG4TNJ;,L9,%^L98=,PI630D.UGWTY=#41])D1+E>+/#OASVQ%B MBN3\G]_(D]X6FZ\L_A?TFAV)UYTK.Y=T+DO_]OXS-(>A#?7QQ!%FLZ)FQPE MW*

*+8%XUKR2DI"A.@9"*NC]CU-(?"T4CW0:MZRH1IL9K8&^4\1+DYWLL3:$S7 M<|T",Q*Z=198M9$\/>-5FTHR1)7.@>U]VVW>03!?(RJ1TU.Y^L,>#ClO>RB*

MG/^]>G<$Y6H75?N-XFRP3+>,)G+#)'DRZE&9FWAB*]>8E(<&>2M2!Y8[6YS M_M&Z"R^=G\X1<#KIY)R7)|)B6]Y.7F$> Q4E]X MD/M&3TOGBSR+%L\3F>38H.K*

MB491M43=#H.]Q|&BV=H(9W[Y\0EH3F:\]'C.J?50E.G"BY,+6I4FAG)5^:)) M]0 &.RCG /C;]3ZY_GLMIR:&2I5XT]#ILSW6LG2FIZ/>-4FGBZW,@E]LGZL:

MZ$P<@C9KT0N<=M%4-/=N6.Y1$%7YN49O4"J58D4K0.Y_D+!SMQCYIDL%PWN MSI?|(>=GZ@+ .T112@P_&$-3\G.B^4@8A_Z9#_!Z@BND>E4>HD=R\PWA'(1*

M7M!WKV,\)>[["0QJ7;.A^76L(7'T?#1X44.2%!O5)1-U3AU?]#>PNRC.3)##B.;8*0C3&T* @PX4\I27&SM_BW>)L!YQM G)_\G1 M3IV17L*

O(BC17F2!;!H+,>)ECFD9<<AA(D0+D@,'F$^*8QJ4TP$PHNG;I M-M&54%V9Q%*Y*5$B;K\L3Y@T&3 06'L7%2FVQNS*QTOL]LO MF(ET_\,H>U\ JO=3E2BIWH+2TX3P*

1]J=A(ZPIZ6]?,&HT(9Q74:8RB[XUKO M0QT8(=7.05=T0M=T73T1ZT?:5S4'HS)2&(TJX_HWWOGA#.-!RCY\]=RM>N<-M>HUZ&GIB#D'-M-*

K&KZ/808%GEX+63H:4.3LZ4U:9WVY8,(R8@E>O@O)5N6Z,$TD!ZLUI/QM&:-MNQV95?)5[2=GXMCP\i8=__LF=.X|<|%0_;,H.=1_*)S[;+DCY9X\.U968!#E M0BQ_5NMYMM7B8.

*<\KU?L6K<&O09UM^^D.=GH'A7J8$N7^/Q^VJ'CM 1B_T&@R M(N7Y^$^*TQ;*H$5-CX^)US<3X1RWU:,'Q:T%HIT?ZR$3^-*

V&DHS\,DE#'^PJH3R;6_UUEG#P7)5DQ">6N!*6^ MA6*3V2U>I^=E@G16V68HJ5NJNX^?!#,S^@=,A'+Y[M'$/O$" ME%S0 3"J3#U;'_->FG3B$474<2=1NV{J-B7Y@Y*

*+NUQV2"%Y+G4\OU84 M/=G<8"S8T+6JH[RK;D\BWQC*W6R1--I4FQH[4^CJ.HVRS]HD9A.Q$5/2D9*/ M0@37V>_ +QK.3+D"%4+P9,?+(ZS4*+P<Y:5H51G#T=7&%*

*(U'6*RG'*CE'P'1H?;]+2\O M-V-7.]JRM1XTE3^<#V!6VFNW/.@V-0V18%OQ!$,#2 %DP/J#YN]4:BZQ6(-] M:TCG.\GE/=&#]DJXH=6F9 ?3B.ZCN,#1}Y-Y5N*

*("U5&'6+!E'LZ>4?.2F=_M&VBRXH%!X,*6[UK=[2=*2-X+QT7U#:.8RD<'&EF'63N4-X%T+DF!ECF$(7.E] M:#*

*[BH+!H\DMT7!H8W"'3/^0?.U^QQB"J=*V+8\+*LOX*.EKWXS7(7/9.^E\IB MA2BZ@XYKLG89B'Z*^/EFB;_7[+=&4%J!9GJ8@JNOV@S5N(J-N'GN\C^?2'*-*

*M(H!NNRY'D^TA2.>@2CYS0W,F&, ^Y"XL7'+[^GEV%'[5FLV0L8!6#PT6Q%<@M M'C*W8^>AM:B[#A>M>8YTU S-0Z-N1"#J*^_QNB308^Z&G#L=![JVAZ_J2?PX[*

M\[.=#=.EPYQ:9)@#@33/X[F.YK1.YM"XN<8W6+;TFG_UU6P0XJ'7K\|WAQ! MJ16TC>)M9VBW79!N|M=CPT&'N.ZG?H.6%8?3^;K=0>-HT[F|;KK;8I=_ZJ-(M9YW2-

N;.MW(3/2:!4G';I\UK^__Q?,3$K\AI^^:3RF4L@\YAUNZ= Y&0!"O M!5&,P#;HTEES4TFOQP(*,BB=-9_8H6C ^D!O?3H!3Y M&N*J(Y<]75\(CB9&;CX.Y"BZ$0R0YRGT-,=M

*PEPT.5IUS,XKNB_8D9&\OHI5 M4RRUV"HX\.[1OG@ZTL/>&+ZZ E\7X/.R8QT'B*YK)U_+)2W>/X>:QWNQ <4; M<%F9FPLB!6"43&,CU.#U\E=@D5?#,1A=_MJ!-*

*_0.85E8C+K9#3$ZZ-$!%"B9 M=6LJ^CX&A@U'!,BKI=AB29)*6M+4Z3CG4[2O\"1B?23-'R+!2. -95TU(?JRB9:N(!%CISV@89FP^"XR1?.QOO(O8M$@ M!IG*

$YKIW=P/+WY";ZD?BG>E.PT!6VEJ'3M)Y[GPF-!%ZUTRQ[#'N'Q;T#K MV'4.]+41>B?$-Q08C)N)5+X_G<3%S?,GR$9\XB2[OY_/9TX[DCX2E'PVOM3D MB<+/SR7 M.ZX0R=RV?

O9CG/NGPJ4.6,BW^+?+5+$$%5^N^6+JHG;)O[\$>P.#?C;%X7S MTZ?T$>C'G)-B4I;0_Z%KYH7'41YBP.]<;+496F>,P4N%:ERG=C,)X&(:K5K8 M7#37W&L\92].+RA6 /+)C]?

Q>)E/ E04-FA M9G=+6H"RY?\R_3/2^0X.U%L&^_Q=V@ :$6%8]Z'R8DHI5,G54@R"'6H]%4*U ML&>G_2ZDRXF=\KH6$5'5W0#17S,\("GX%&S@UN=U-'%=7%2Z%%3PU*

MMU7NK}'=6ZIK S4^0:7OP#+G8C@)9.U\TQ"X^GL\8[H:3 R7ZB.41CU[Q> MU!.K_FQ=LLV'(XG3N0@-\FG6_H:3Y\.+[-\ M1MK^;'J8_RY.(_0M-UJ8=]J;S\FKV>I\>F(YQ%O-

*3+H>-]7/_LH#QYH &V4 M084>H&JEL0>(W?*00M:38!JR9OU(1\4?&: M7O|_S/3KQWJND2X >1JZ\5^HU?$ $5I3 I*%* YTB3\1B+R>($9$G*

,UPV\TWAVXF43!H\0RD74#LP&U+I+Q@>MY(I M$D1 7'_P\>%D/3$=#F-V;G'G;^%N,NW8+SVH__P+K+I;.LB>_.M_4$L#!!0 O M (-6 9UE:7L?0=U$$A(&\" 0 /

,6YK9"UE>#$P7S$N:'1M[5UK<|NX MU?[>7X%FIQU[1V8DV4YBR9NIXBAOU6QLUU:ZW>GT T2"%KHDP0@9>77O^> M-UU]D1U+H!"9V!:)RIF?YX =3S48?*

#^3^1XR@'O\FOYCI@[!O_VFO4G<;O MZ_0C-'B=M3@>"&],E!X'I)=7(957/&H1FFCQ9Q[&0FH;Z79,/8]'5RWR+KYI M!SQB>T/&KX:Z11KM5V86CU_G8WS?*

*XY";EI[^^Y01WG+NO.61^U8**ZYB%J2 M!53S:P;=CU]#9S-(G_ABTCO*?Z=M1KU6+=3JO:TB%OUMKGGTY 'XU:?ATR1*

*M4S8B%R*D4=YP(+068>L===-7L1N_1@%]%K8#+Y&J?# ?*)7!$(V?JL.OZU1T.N MV9Z*J M>U:I,;,:R>*_I KHAA<\ @-6>3!?TUV_OK33,/><-N7Z9U.?B>]|K5WB19$ M#@QFY3.*

(X&)/.E63,=!V,"84> Z9'C$?D*XVB+Q!BR8F0$.IQM-R^/QN.2PU ML\5#JC25Y'Q(90@L)YJ[-% U'THM-"SZUX@ =^,1#8 HCVKFD;\G\.=^ MHT:@Q8$9GRH"(KSF(E%PRW-*

*[0"N,U>+ 9-EZQU00L!93&S#)9Q(E4"F!6C*9#G#B>Z03'']JS!QXE-7)Y*9854:,W&8 25P8DQ$7H@GE$0%&>)B$Y"\X-2!<5L2I;.BVU9Q1 06A0VLW MD1(Z@-B-*

*J&V2'5)B<'ETA-Y,U-P+U(> #$YSR5_%IN5?/DN!GJD?2]K61]TCT]^ZV&I=5%^JZ;@UE0*Z$2*5|38.$ M#@+C"XI#CC+I.%CJ:!VPE1FI;TD3#*

*(2OFXA^*$SZ"4T1FF4.M M#RHXY%I4.*52.#?B"GW9-XZ<^F&-_X94.M3+HVY!GU^A_OH\HDRB18N LY M;I9H(6H($2 -$=C=*U@VEALR&F%,I\J5?(!#"@P?/)HVV6T)!?*

3>1:.&8!D658Q(YZ';$HD"Z%.03-C-S&7 M*49&J49"$Y,G-%3\8(V))#L'NV3,J%1.CHJW1-@J52Q=81.3+ Y@"I,%.01)

M:.0ETV.0+'!9/>F\VV:.O0@00P"B@CH!304KK+=&:/#'NOD;C'7HL"8,EHP M/_T8R]4C07:.N>&2100>&0)1;^F8D$KSN(*09R[&+*7U,60.$<'Of&^IAS6=

MYLO>F]LUML$=>1QIUC^.1%AR'5:|X)3%]?/)??9.JNNHH)/(T:Q4NA+$9I4 MC0I=O%R8AY6IA:HU^$3:%*=JF9K07BA8!M5A"F\ZQY$BBNN9>O'D'R-2M=Y3K@@$'L-RD:*

[!)K ML\R+/Z;_P'9_R(%VK9RQ5X.V6AC/1:$RN &_,)/[:G$?2L?%#7(\S2Q?<]YG_M4Q!>H.%(<$'9O_,.:3 !PHTR/OF]N85TT)+YD"6(0;.69DMJ,2D&-)R/1C

*MT9=AEA/2-5%@L%FZDS41URI!)_Y@**O\:<]4<[H7DL4WO&'K* Z%@# DSF] MXQ+!Z@IW]*BX^ B06%#=FU#@GQ3;ZUZ>R DE ;Y9V"0*!%P*

*MC_QT9/[=);^!)%9?V:0;;^KK-X]G90^W%:H!5>]75S&]8GN1\%C>!^A:O.O0 M#]C-G@?F8R!\"^PY":.VQQ68V+B%=^H6[J5L3]^ @=/+AJF!9/2/1,R6C080?S8YDV5*T>4EUX;*

*M%&L-MD*P%8*M$*!",#LIP6<06-\|P\U2W #1?#XP5_%:C;[*PX!/R3$V& , M."P?0[T@!?^CH+ ^4P0:H^8&5W"(NEM1OF<(6EW!%N+QO(;=PXD>6;QF%+[J"*

*MHV,CB0TNX&96X1]4QMW&W=-6<9DM..14;*Q:@.*T15]J2'8EX%3&$TQ; U MO:JG2.^UV($V:9ZWI*SB*

X9[1(XXE81J4IG^PHXFG+G///LC&KAALC#S)#)\9K)HJ39&ZM/,,ECF0#)11O6V: M[T&-+!(H@/D-\JKI+(UZW:G_)>^ !SAHK%A+,0AC8,:Y.,RIK'1L4[\" 45A M?,T5'_"

ZW$KI\U@E9>L;9@ICMT&H=',-T-R@-IRU@$@=^@VE9I2]HVG?J, MU7HV]WHH[$=@&NDZ1BM= MS< +"Q0\$^1#[GF!6;Y8Y)-YU_'NO?*

*BU$+QSG"7TE)5[JSN7BYW5GB48/_M;::KC#HM@3H]$W-M-51IT6N51+GQ:-;JA. M+1JUR.5R:CFU:/2)T>A;F^DJHTZ+7*JE3XM&JZ?31KW^EWN^-2_EI^>.!_@*

*M@7CN+3L6G9V*Mj#7 B3+Z59S:D'OG:#WG4VHE5&G!4C5TJ<=O=73:?/POIAW M&NOB-V+5)L0!57%N%:-&0YW6L:+<*|$^$>V>Q9&75:-%0M?5]6SV=6H2[*

M81AA>]"0Y;1ZG.;N#K_Q?:/F3_LU'_/L/?!K/NR[7NVI7A?T?-R[7FWE.5EY M-NL6U59&G;9]98^:>59/9W:RG/#L/OV5"F6T^!Q:A'NG0BW8;-G9=1IT5"U*

M|&D1;O5T:A'NAF&${4%#EMJ<6H1|IT(MVFS9V74:=%0M?11$6[U=&H1[H9A MA.U!0Y;3ZG%j$>Z=*"'??9L_*J-.BH6KITR+5?6WED_JT$VF9H6X7W.7RW'INN.'O/ M8\=-

*YX!LP5?SDJ61P)1A$>%:$6O2(=-C M,N)Z,:,P1M^(*$6Y8?C&"'*6%R$ $WE-(%J69O2(+*>+B\RNX%Q$W>$9R,F;P M*

U_&992(KYNID:\TBKYP^)@J&]>.Z9ATPAA2H8;VO!!I=I3"2UO-J"8!@UL$ M)B {C?HN\>A804>.#85IRY3F(=5@(%[^3;4>?'3(IVPP>BVX1R.7H<%Y(AGH

MVL24*2F10.OC\=3L,$%!<0)6%Q"5N$-(R>D;R;@"VW093.DYY ,#0XG !M%, M\>BQ83OG1[*0XG$-F=L\Y))PSO[G!72K<-#^83*XK,=[/I!!=@X.,PGY4H2& M(4,IRJ,
'FEO9TX$*AD $ &R@0.0&(B+!>"L4D2(N@!V3(@#!*A1YWC&A'1< M5X!XT 1==16-4#C6AYSA:1FX 0%AJ=CGL(TK]$N74YI_#=H%OT!3,!$L>.* M<'W^XI">#P(?
DQATB%%1^)/R!P/#,TH)VC:H+EID'JA2$%3>C(9&%6A[1MD M&4LXF0#00R.1,!&.I0X7T-R2L%8)!Q M%&(X
0&FD[.R:!2(NIH88'C()P3W@WPLN.KYDW[_30LK04XKD:@B5M#EJ M.#!I!I(FE4#0%4NQTV7,7.ZG"6\2)> T!2,4#1S?/*K+:R.>H0A##((-I#26 MPF5*(3UB@%)$@$!CN
SY:"&5F-1%HC,Y8$/N8:>2% -[=_AN"8Y@5,3#.T?3 M^&@D.29H(JGX">G]J_W2!$:2N8-TOC*.K'D5XS0MKA0!GW)^@%6P%F0F7 M.\XG ;%AKPDUI+!I5K="WE.U\ 7>S?
#GHG@;B M7F,38W"3I%&)N=^M9,&H\Y5#P;V(A/XBXA%S*;2S@;GXP?B]S>;")F:]2= MQAI3_O)5%]!9NNR2%KL?P1/,6[7W&_A:[>8^U(S0,/5871@B8@'SM@&,[NC)
M8'XT'AHVB^B)Y2_>]A/X"/$(DHPQ8M\'HG_EY:T? MNKKP":)J4+K4&E<4MB2T?\+U+8P@)7IA-\Q-RAIF09T"J=\$(Q\@*,!&0_D.[F&I1L1DH355.IDH&_X5 C3@'U9>*RR'=&Y?
%A@YV@]!.!6,2"@*LEM(M2K5Z2U9:DO >F)2JZDF;\!CU1_&VAJ=KED'+H&5P$QE\KKT:^W:OQGKS9L79 M>Z9'^:?DMU[_M'MY27[[W+WHGGVJ$4;=X>3JJ4%+Y7H8_"
(N391Y6KD(.P+X M&^0X/0=TC$OB)8#SH#(>"@DT>S"%SUTFU;9"L*=Z0>-!X];W,S[J;8R-?:=1 M7_'%B$WGH+EBUW<'SL'J+RFTYWM>PB[B'\]=!73W8TZW% >#]I<=#-
KD;==S MB_;+Q%HDL!,AXVQ!*%";CI->V1PL=/9XV7V>-G[#^/6"\HYCSFY4J&#*\L? MDBSC_K5Z#?6 !B _(N<^+IU*ZRT/-Z)3&C+K+Y51I_6(1XNPSW5@7:(Z^CSI
MGCTKQ+Z[E+$@=+NKP'+E\GQ(90B#)(9'52.]R'5L06@+PO7[XLOS/UL05BB; MKU80_ITJ$9'+(87606"=Q=:#6^(NRWBT#F'+0>L1DSR>2X:G#LN]TEO['ILM
MVAIU*.W1FW:[J!M/LER_'H@O/'[/QV_'NHP>/__4$L#!!0 (-6 9UG^ MA)1-/0< $8U / ;6YK9"UE>#$P7S(N:'1M[5MM;]LX$OZ^OV*N"QRZ MA9W8[6+12MX"KJ-P=/!X?
^(RTXW*P8 M+&2Z!FW6!?[ZJ&3JG(L 6&WD7WA92668,&'%TI2+\P">5ZNPX *[.?+SW 30 M#Q^Y4U)^T>SQH"02-T65;-! M)H7I:OX!@WZO,J'GJ6MD%?1"-Y>QDA?
K(.8E:IC@$F:R9*)9N)#&R#)X3J0& M5Z;+"GXN@@(S8X^S&S0');*0*OBQY[["9T$'?)(=XF7)4Y,'&3?=A%:BL"R,HED\'$]@-)TOH'QY'@Z M.QW&XZF;L
NB(QJ%^&0\AZ/IZ.TIK>S Z7#VFB9>O8=_/GGRY%\=.!G.X544 M36!Z.HYC.Q6-AF_G$8QC(,I7T_@$'H]_@LDT)N(XFMG3AI,C&J116A&?1!"_M/Z-O)T.[9#)Y/:;IT71V-IUYAN)9-
(SG0">=S<9_ITU@.MMC_V!P:"5!RJSN M0)7*:N-V==GO?Z$RHU7.%]R =ZX[%$)"YZ-Z(%(@(YT=P9!,],B:*<13F+\] M.WOS'H9_FT61';M3X=S$V6\HB9QK,#E7*;
214I_#3S^ZX^KI[U^$L9N8MA, M^.$T_F,)"*$>5U5Q1J&YPK142[6P$0*"S1+1 &G3(C7A*XPDHJPF5DPW>W> MS.ZVM;3#LLJ9-DS!6N#4]8H3LP%LG!CGR[<$O?
4F^Q@4KB*F4&4SA MMYK^^ZS? 5KQL]N?:2 !7G!9:YIREZ9UQ-BX56?G+/M XLR#G)R+#6[M *NJE:XI9;2(M1NPE^4=D%ADE^:VH,Y:86]';5GO,L]N<*9G6B:-
M3O9NN>7#;T&')+0G0H*4 MGW(!=!%>UB7\UQY-*29N86&S9=@VS3%!B,VU47Q1NR@A%6A6T":$ASL,W!.2 M76,_;J>;
<0>UM:8*8&^YSBDP$+!"P4MN@\/&&F)4BANIUJ%57KLD?YW+Y.P" M(47R&]K NHZS1;%.PT&LBH*,M=%.3B;A/O M^Y/N9/JN8RN5641E4M2Q,H!S*;V4+UA1LT5!
<""%YA1Q7/"Y#KTZ30+!K&_ M(>N,$A.YU&T!_?Z7YC=_:M _(I\0KFF@[R_N'P"\%82=VB>&2ZZM+V?.D;T? M=@ 9Q;H-
GB:LXH;T^<%B(GF\)O!TX=)6!AHN50$;''4(8:G3[96=X9;(A$5> MIA,"[1;%MC$OVYK2#)8?H'/S=.N,-R MX:DD]\MN&9TLDV%3<-['56VXI>9:>
MA]$J*6JKNI&L!:6SJ/W,BQLQ>\-RW&*R]AW8IC?1FN; _5GILP<)_<>V/_8= M[N_NGL=*EK[SF%%RY0 ;5YALRMSLRAR+"F)*L11FE*V)A(ZYG#[!8ZHH-H.7 M:%UWMD%
(M_F6JM-X_W;>IH,RNWJT9T9^LIH]42B:^$X591KRUQ8W^Y*C1"Q=DQJBV MGP]ZEE70LN I-)?[C"0^=_?>%R<7_5]Z]]\3_,:O]TW8\4-3HWUHD11,ZU\?
M5>P_P\@*7'53PFM7)06DF+H48?JKQ>TUHGZV; MG=V:+@'O)]YP[%YRY&K_/0DQXAZ-V/:;">S;DG!_@C;VP^Y*"X7L/UT7W0-6 M+-E:M^&1RG?6K51&'D M"E+
[(V#25BZ5ZW#)+.,)*OT]<#ZT>]YR27[5ZX.O1A9MT?G-[OEJ'3S$&OM0 M'\(I3W*&!8PL>IT+!O=7:?_[XZ^66,:$"L3@#TIHR>5C^V@V@%'.,:-:U34; M+A"F/O*U1
AMP<"OYYZW'-_\U+PJQ%+6]3_S8;ZWYB6 N;V_246Q4,)]"T+ M]?M*;G5-X'^3*%]2+3[:<[WWM*WW5L:'-K?@GKYP^#0_?[4_P!02P,$% M @ U8!G6;6:MPT[-P Y-@! \
!M;FMD+65X,3!?,RYH=&WM?>E3(\FU M[^=[_XI\]O4-< A&@EYA[@-K9[AF08>,.[KN.$/J:J4E-.E*KD60/[KWUDR
MLQ:5@.D&JM34A$V#5$MN9S_G=WZF]'26'HC!X1_H+;Z^ML_X]XX.?75[L+-_.->AO;*_^UZ' MAXLHT:F.PH-8!3+5UPIN__$'N)D>LK"/F$1ANI/H?ZN#07^1'O*H=M)H<=_
MI.\FQ7/#[;G@2XRCP#_/!O8<7W#D< M&,N-]M/9P42G.QYG'LXM/PZOC M,_H"+QA]@$_%U2_'E^+#V=&OG^#*GO@TO/@;?/'3/\3__OG/?_YG3_PRO!0_MC4:GXNS3\=45?
C4Z&OYZ.1+'5P+N_.GLZA>Q=;PM3L^NX.:KT06^;7CZ 3Z$ M3^&*JU]&XNH?Y_#CER%>-/YQ?'?X2'B M[*(T_-T??\"5@,U->/.Y.#O:^QKV(.!G(0F 5>OA/(992E\.1;Y1_R
M6P;]_F[_3_8&F$L@%XDZ2-1"QC)5S&C@=;%]U[5.8.T#G2X/[-7F(KC*MU>Y MA^.C;W'N. XS'5C<6V)!J<]/_R&-JZ^Y@0'MC&,EOQS0SQW\H'YU5]]^K>)4
M>S(P^S;7OA\0TZL['7N/=#KJ.%WM>-=M\7__@&:'TA'&_VWW;?_NGP\=A'M4%_2U+4CU9-L- MKF8Z<4RD^/K6[UOMJ)]GT;;2F1+__J-4N DD_4F&X=^ P8JC*
;C1J(MTMP2]H04'\ 0NI&Q M$EX^(K&U$2?1+F8+SF!/S.0UZ'6PH(M8AYY>R$ L G@?DOLX2\!F31(A4['? M?[_?%Q=9DJ@@$!.8"5 MRPBU%.\'^V_V8.O@%&W B?\UA!?YXFJFX
TJ V4TZ0[_(QS^FG7=*#H8]%_U MQ25>-!67*4CL%"A !V"OF$][XI.,EP$>\[W^^T%?;"D)M */<4P4OZM9!]S9 MC=C#7 M;34V6R8H/P/Q*=G@:>[EC'41@7J"_Q-
;>EMX*DZE#H&C1\"950IL6:3*FX4P MK.E23"(O2X %@^A$UK'(@GD4XC6^"L!,@%^ 9[MGS&0\AY%GY)5*6(W9TO 6 M=0OG5:L01 5^1G^F.E'B1J0YJI"JXC41)T#<8<*LX0B=
[6.KKN?.,5_B>=IDW\K) MT; %V@RP\#C)X&B"4BC@;:!U.\DPDXF8@HZ!*PW?UM&P9?7JU@M X8>]I(!9 M0GL7\#XF>+,A;=C=9*$\/='PI'I*1F;@E7:=A$+)$('%GF#@B,%9H9Y
.FX MS2VMJ,:L.D[46DYTGW4)QS;1L<+S1CR*.52*,86<%<$GJ&45.>"-#@*AKF60 4NC;R:P*B;8B (/-?P,,QC(U#Z/
MHS1*EPLE/MK/T8\A<:P3L+A],09"NP'KG%\WETMFLJ2O13AUH!E\J)AD,5J! M#Q"[&1S:F,<6R[FZB>(O0B48E=/)#%^YI"^!I164/+>X-$.9)#I):Q<9[]# M,W*JC^($V8
9&$X<'P_LPD.M'QG/[.ZI&X(AG5T MMEU=C.7GB]$(\T$ZOO:@]3J-;NAP*=B^!F,F/1:D80*,R0A2//U(2%YTK4*) MQE2BB":
6(AK,/7B91%QAFD4,6\D]H2I%Z4'LBH7*T_I!;..))M,M(>6';$N M9D%(F[@>P"6D]R6,;@+E@]9?5@0E\E,,F56&]!4D>?^2M3/99?#DB4TFW\7^ MO=L?
#&#CDBC0OK"S^YKAYSMBL"ND"GX;S2C2#D,HY09[WZO*S>1DZ0DF:9S&!7<^UM MKF2(NM 4[*P0U%-# :@]+0Z8/9NIZ :A^?_G#0D[53ACYREX/ M>U*?
R#L)U.V.#VJW1]F[,/1L'A[Z.ED$*E&"XH?S5K09S,,"_D6: 9HN$,2B/G$DD[2G;;X+W M)Q,!)IH U7,.:C-H@6&"5B#JHD!?P4X*[TKMH M5L=1-
IU1L!\C!#WFD#*A:\$PA"$I4#3>OCK,![Q4NK1"6YO,QRH1VC59VU(M"2J?=;1RZ)Q7_)MP;&/E:W(9X;D'42^YKJ)-(KL[_ON=O+F;\#ZP6PY]:"XR MW/2258@0?O%E*GL@.Y(L2!-
TAJ Q9]P6*\"PPECTMI7DKZ^1L\H6"T]CG?K M?V6*79/L"LF#X.A9I?09%%:HRB\D#@7=(SVF;'1X3%6(7A)T<_ANO> &T&/1
M_1*SUQ0]+:$8*QCZ!&6:)'_(TJKS7I3%":53@0E*XP\YNPJ__(Q>V/- HN2, M[1WL9BU>5KF3)&)^:\=ZVL1Z7G6LYU[6 WI=TXNT*O$Y(T4("-__HX"RZ7T-O"I::&
S\M\ZI)B8%)Z,8UV@SDY= M:P%G>+,9CI)C^ 4.G)=F<-+/XPB3;9?B@A*U&ACX?13*X-I%.MTA@]T/M&R/6RFA9%[WJ/!X0QS!0I6=&XRVYD@MZ/E M@5$6WZ?
GF"RES"I@)A&E=,L,;HJ3F5[0&J/Q+K:J=G8N 6+ M)6T2C"26/KJ/O5AY9%\G&LZ C$4@;Y)MG)@79 @P8VZ&08 ,H%PKNYXX@%A- MK3:.?V9AX0.W+_FSYC+YPI,I#"8IC29-
S(V4N0IGZ0:6G7*Z4LX;0P6_15X*,AQP(N& M,DM.)AC_)\$#JX$'N;C-=OIN>C6;TZ.=0>%'3H?:D\X#62P"N^F%!8W-)Y32 M"<<4#B/-'I8GZC3/JGQYVVF>]U2%
<=I>TZM4U3H+F-.%\580?W'14)NIL-.4V\3)WW7<=*[.>G9@HC@@Y(^ MIK@TO5IECDH&-6?'<]R4HJ9BJ60,R@4FWM E9;02CG\4\ZE:29+KZ6]3TUCW
MNC369T3G:_DRL)E?W__L81+O\V2Y;WS ;G*G%8S>M%B;^W'BKC--8^U-E=6K^ MV >]<1'=H&=A[5!L757^B)LH"[#]"L:6]#@U=:RDE9JG*Y]&JM%(KZN9-]KZ M5D'%-+HQ:
[L5W_/3;]O#CQ/LQ[6^CIH[20_T&CPS.WHZNGDX!WY!ZOV@W^GW M=].I8Y%-KQ/P?.3V";DJT04*WY*G$:&CPJUD6\PS#%0$2RX)JV12U)>A%[VI MB4U\JIH#L?#9;VJK=%7G
MP#!L9L>*AB#&B$U4JE-V.GC!06N%@$ M*DVII)=$"ZU>@U9/5P[R9.4@K63LCP28N8;**:[/(%"%X[F@4/47K^&%3QS ME?>&5!GN[6X"Q.1EFOE+<3:&E677>:
<+579Q(#X6\".&3G"U7$4?O-U]]>K% M[!'LTGF>E[TK&E1?;3V()KJF9IS66?U["*A).XAI9 I&'L*4]#B*-2>F.@ D8\P4LJ1 MWV+Z"-I-,DBLF<4.M)X9^R0CRY!<@IC(1O0^P2=7"
(MS3GCX8"AI=9WC#-Y= M3 ,7.1B3%"PI&$# &$6&\23T#28U&8929".<-NKRDAS%FAP8]"EB>'J1Q:#H MJP1VY\/]5FD='ZJ U#&$?*L6%UK.!0,Y+18\OK:?9W#8AJ/9-
&LEFF1:Z9T MLBCM"?-;"]^$$;QZO?[\0@D=DQ(N%/8O:Y3*/Y.+6>SWA0]&ISW8ALZ-'[LJ M?2N<(\=WB;@&U4?*ULR1O(U;FDR!S(+L*71J4 QFQ[P931%"FQ
M="IC]HSF[(=>!;R0DK0(L+"LN]!.UK&]RA*M"%[UKTPGV,XC^:*#P$'Q8!ZO M7J"#$%W)H<+$-$+3SN$BC6C.S96\>!>NRJ6S\R73N]"KBTI&T5UFW-$5_FXF
MY2ZLGTD1O/(A\[=+G&%6=;; Q!SRM;DI=D9(N_CFGOBD%#I*FS4/KSCULGB6 M$A?_!R-:I@;0RJF?0>3*!I2FK'9$E5=QPE57MJP63V_$Z>B!6LR0ZZ)#(L+
M50X)%>67J!"C,:B>)[-5LAD6CK/3K8/)#C%[4@AD13L%:ZKSQ@!SBW M.>;^VUG-V[%+R<);;]+0GN126A/,+E&8V)=*G=5GNV#KZZ$;)J&H82]-29'T(\5XY7#-M5HRP(
;KVL4443(6*[I45-T6=X%22+4?!SY M.B^E)3RTN:N6[F'KF0BH+W#O)QQU=8LP'*[)A1F2NH7U29)@Z5I9P0.'".D% MBO&KU>!XK
BT/9^CZ>2#H#T%/E@S/XL64AL'NW/"=IZD%MU@4)Q::B'>!(6. M[TAI1J\6&@%Q#CA9BNQ:" U-;3MHP;*4?YV @0#CJ,.)+#X!OEZ7EE-1P"X9 M:2-
8]JKFR%>=HCN7#$95YZM^T$F!H:X/J-^W_S5W.J%VSR8_UN;6#?ZK]IGN M80_=\LXX;)$1I.MAW$<\WX^I6F#QY M0^ ,^P^32&V:R7K.E4^J[IH[Y]<1;]PT/ZWN9WY\Y__W*
(\A7^V('V] MK=3Q@L+90!V-]H,YC5+TDV"2ABO5PS9_TX@0Y=!_P;%?YZ TEL8^Q:"+'O8% M>T3JDSM!_4QRZ$$0&CI%='G.0D44NB2U:K(50+72B82-DW%&S"2K6>=&*<1)
MU&EZ#G*SD)*,7!JRQ)0Z@>#L:SIK.ET8]NGN^<&_""3: N;@K):C'8%O6N; MT:NHYS#M0C[UXW. MM?103R[N4>T6\0I9\!JT@QXRXDXPKI#^7H.DOQE8KP\X6,WG^)D**?
G6%BA M9*#U$FY^,28'MO%6PR=3LSX&C8^KYFS=#MRMDSQPNRSD!#&FW"0+2JEXN;_' MH/(A>_@ZSM=*K6,]G]G4/*%779[0B\P3>L%"M,G^5E4=C'SRR?J"DS *=TC/
MPX*3GJG^6DCM[V2+GM!QK*XCKGX$[JU"Q.ET,)^N(HI>PLR7@(QA!B@)S!T(M $T"!#ES65-[@##MX0NP<+3'&>&8\]E#[M\3"?!X\RE"IO;@"1,&9A:)1&U>
MSZENAO"N$=U)CS.JQ\MU^EQTN!;VG!F+"?(:JT\IMZAP1Q%5=L-$2(?!M-&, MY17ZG^%8.LRT%O@61_>$!(L)!]4,NK@ IN[2A/*O2WE"/6!4Y1@6.7A-P!'X MG$E?
YQ1!DQ)!UW>90EVFT$9D"M'1W16BZ@$#(L&\H:D]U10JE=BL $C"$ /0 MDA6V)<*H-=SNHA9'R1D;@4BAW&(AE'-E^RW *GZQ;AV6DX(^ZM*(ZBV@34@C
M0MDB8V]6."@,6=W)XM1'.QGN)LC4+V617 M*:IHCL:45C2)HWE^6O-3:+5&+'JTDA+[3+$!:CM6D!L4 R)R'!DL8+)V\TIA M6PULX9#0U#W/_8\8LP@--8(%C$(\9= D//X)R%
NND:$H[)NK,3)T;"5!N6+ M9?1[AM@PB1HV.U&-;L\Q)GB2.A?!N>8!T;E9RR3J(Y]S6&4+7UJN@G=6F'L\ MP]&@HLE93@T6R4V\^OK1= M+<\AA]
[=*VX"LUA\#NS0;I._DLK*N\^5=-+ 9]T#SP3G] T?"QJ-;!KV,4-B((&Y* M6%';5LVNG'[[\1U4LQ[4&@14/?_$P53R,=&<'V/"1 %=DGQMC$ F25?"2B'L MZA#"0L314@;I3^X! YM-
>AFW03-M MV$#=V6XE8@^L+]A0.+X6,%H4JFL4R=SFJZYKH=$%-2]%MV.,8+5DZ>6;9$PS MW"O?+W[AU.$U-6-[NV_LT<5M[-G2$!0#!UU&7969-9I1-Z1<"6=EY*>[9Y+K
M@B"Z(?\B6RUE*7\:TPI07P5.G$DR;$JT7Y88\QT!V$5Q;!ICM)R77=X?MST M"JTVQEM5P$'28:_A"4$]@"2\5D7FB(;CBNMMN_7ZY4NBQ'%'B?=0XD>M@A88 MFE5:K#3J
C)S!ARJ,=SX=ZQ()-E0%HS+]. F"+-8R=1ZOL]=J[!?EI@CB+BK M=R0&KZ>-3]UEYS6?1_-,4N __J,3 V4QX'5BX!XQ\ EQY-,H;+*[B9,% M:'ALUJJ)NN:JNEY-8J)P(A:^9,'\/3<;!X+_
XO'PG MD,LH2^']M\H_Y+&\?[?;_Y.]GOQ&BT0=6*^0Y1;DM.5'4[(0O-]E(6&]%Q<- M'-C[S45PE>]$!+WM[9O=/7S;+:X9CLPL ["C6\HC2OTU=^[M[[Y[R)WP2UP=
MX0W,CO.>#CC["3^HW_5@5\K=$_+P##(N?;]@'*>ZN30WG-GB3]8WN[<(&]B2BY M]I[*EL';5Q2XFKN*6UID%J]V!V_W_U0:2+_*TQYCS[]-@RZ*@_LY^@AMB?M.
M_K=OWK=OQ(:OLY&<3TR':^GNCJUY(B(JK#.]_(&;^2V6YR.JXVMU[.'V5^H^ M=_/GNW]2EX@>:=W_;_"Z!S?A_SNBW'"B M_&E;T'\=G71TTM')>CHYZH171Y0=4;:+*#\8X?
7(I-F176-D!_^B_'[1T?H M2D#;5@)Z[_EH41>:EQ2:\[O0W#U!)DX05KX83@M^LL8#3)2J@7G0#TN6&NP. M:I*E>J8:F>I-AN?'7?)4BTA3=:1Y'VG2X6T771)X,?:C]
[O.QZL)VDWB'@YM MB]@"L"DE4.=(UEP+ISU;M70<:JP&0/PD[:E>\6\L9Z7T-NK+) EXF[\T2?TE M?IQG:V^OG!-":(%'858WMO?$#DZ+&!&XJZM,'-E9=TA7SWD3>*2'44Q-STB\
';1%I=^>/VKK6E"L\ M_>@?SN+G&78/Q&I:PFEL,&G]RC$V0[HEN=9L8]Y112!Z%0*#,5'I?+#N)!+ MRH5:9'&2(RJH8]P2;A.#^S>(I_9]$V/J2P?85GE3&VUG0J>%8>2T7
MMFRL5VH37^Y32.!Y5&Y(?3-7Q!1!]F$39S-<0E*@WM3 +!"]59K"-'P02"X9 M(O;":ALU7.6\4VB%+FP^N*\1)A#?#6+ 0OG9.CJ[DBAV"4^Z0V;S5L5W&&)O+)9:QSG5:;&8X(9#
[) HR&CQ"Q@L"[I*>H?= WBSAPLU! M:S@%[H$(IBP,IZ,TQPY'B\!*!$Z9.G''K_!).CJO86D&I,O,P),A%K 6)%+E[:9Z M?X+(05B_S^UG$85DF2.08[=;+*GG[M.5)Q0
*)QMQQ+R(1/%ZX:P$?^57&< M/= .(I=##B1KZH-M2UZD75Q. U2(&7QFW-0_9-2^G[GH5Z#6LX8\UF4A36/*ZL87D1JT=D,)G-0=V/%M!N M%*YKW4[#R9POTF#92O?
J>A5I4XOMWG3%=B\2"O\))M=L)6$=NV@;ZNKKC4!= M_>ALV;.\%VCSYZA#=G]2/!;JF.,;KX;S2Z#1<^W\&&/72+;2<-AJEJK0@Y3] M(M4VOQ8%>@U*:QTX]%V ? NYK.
%@I:W@XA6/6HC 1H5/)),[(DB]>^_!GV; M_E-2J<<96 @J29QN7=.=]UI+N >L=N8IV#X"T3F3-,ZLEFQ'LNMPZ+'7KVU" M7,"RY88_O:+SQFI=,N9.O#>A4?@8"FO!"*&$!AJ&)E9-
EE2QN^]*X-JA,>5; M\^0R?_, L=]L &/>%1<*FQC 7\9!.(2M_2QCI"FR-8^B:Q7*0FWO7>SLS>Z; M-X_&SAZ#@W=I;2U-:VOTU+2,"-_L#FQ+H!;A ZYP!EGB#,WV8\DE7&Q'R0.\
MX0$F#T5E>_UXZM=F:)S//^?FJ KHZBB*%Q$YCLZC&]2NX(P,3?>N%6P?0PX\XH#A65>F4:T.P:G2^RBF&Q;VV4VW2D@])@"<>D MG0?R)1)A^T3>-Q'>(P]G3_QD?-
'NO#?)%Z[*E*>Q@V&@IL9M3LRA0'3.CTX8 MQYHI585 I9XB,[4&7!G)E@+'"9FV:LX-DN.^.(U 7(:30'N-GGX*_[! (DEF
MY!'WIKS;+S%>FE054@W]2#$8OV=F98+$X3*/K?:,L\7VZB/999N2]> 3Q(]V MC?NH2Z?KQD!TR:^"2^#=[AO, Q@K,<;P,GJ-8G&MHT":KIP@PKGO_30+7+B8 M@H)1%L.
(IF!RQR&."%X^COQECR+2!4Q([#=DO6!@M(7>$J&,D0?\EL4Z\35[MG#>@43SW#>D M>>?K[!454!1A?D9^9*=T/C0=^L6=\C;'&1[]G.]9-\6RN1,.Y.4B"&M<%.L"
M%IS*8RC$M;; $@EL&$/O3V=QE$TIF<2F]M5(P[G4(78+PZ061;("9%1T$X* MF^E%#_^R_2ZL-#%41K47J0HP=23CF@K$#5Z:7KQYQ08F!^F8@R_4K!K6))M(
MN"NF/^(O*K4-JS'5A5I9\\]"UVIU2[]2$D@J:9;=,ZE=JW[G M?,%R9B9!TT65%YF:S9W'T1CUNL#/D%/E;Z=NB7ZA=JI-7.6[5T/?[H)H\=4\ MQ$(_^=#.NZT++#Z]RO;L4WZ>HU\
(W32=[K[6.C'G7MS4QB$N>W U(>3";!^8+FFF3ECF+X7H&$ MBI8*+\7TG2Q(I=5;T=$ O[9]UU"^FN3A-FP;U7[R\DET-;'["?^&W3R)DL36
MA^+G5S,=^V;WCEAMT*&7Q7&>+U\S32<)\3DDU",/;Z+R!/11P5;#1EH-!B/\ M0(/FK[*T[5E)N\3]Y\P/?F+N;C8"?Y5*:E.MR'4%[^$"32YWF8-2%(54L ??
MAFH*SZ;2C,H<"X\V3S$1I\(IY5-)8TRR,>X -BSDLTRJ!WKX."4*DX%Z-N^? MM+R4W85F&\PRN6K=!PW9+&-E40J[LV%JQJ9FG;_MLLZ[K//O0#]Z8LO@@#*U
M6UBJEUN0N[":>E*?Z,TQ.0S(<;-8JD"<[+@GMDD\=PFF;<--W%!V^7XCV.45 M$/NAP)\Z?+ GJ,V\\M%W<4"KTW R1HD3VX*2*4*^A'45+1+]XUG('@FSMV -
M83]YKFZIZ[3]'IN\\[/=/0([">1VMJ^[[]F4 MQ^428"K5UC4('I)*K5(TBJ6I&_WJ2S0XFS8##/D3)KU M7%?WUW8"?DEG$WC^3[:L\TC'7C;'9$&O83??L&1C_8Z#:4!!J'.TE2R%$$*.
M A/H?V7:-S[BL0R_Q-DB]<@OFU%4:'4[4+; 'HL0)4)-)K2!4FU8I/7E!G'*LWBT#K8"\?(J#1K#Y>!&.+P M/Y#35%/:.F@T2%V=E71E!HYCR:9SWCJKC"E6N
M\$I<9O&UOI9!H^+#'-9$[/?$FUWX\;8'%MD^_GC5$X,^N>L& P>UA4-6-8SC MSA/8#NC5MGEJ!OV-<-6L8YZ;3M'?#FGN%5<&:("!6%4JXV61L:G;44*[F!C3N#GHV;G
MY(J'MV5)"4"]D)()M2[WPP$+Q6D*B]6'N'R+ES>AT#:K$H^_A0/$ MP861-5V.7IO#[Z(XSD[LB="4151,S] D[^769BUBA*V:E31I;LR2PYQ9?#23
M"EF"W;;N5:YET'F]+N6PUKNVQ)8QR"K,05.=1NQ);3]_KD>;DVCA4^Q[<&7S:+BU,K>?%SAY][C4H M<.2JL,!TJ,')@#,>@\ D7*+W$U5(6">#"
(+W..0[ZQO@E7'%TY5UH4@^XP'* M8@YLJ7!MKN(I+K@=0Y)&WI?\3UAQ90Y77OAAHG3X7#A_+@]Z5XC3*,49VDIO
M&C6LM)I&M.AX.0U<.@KDI^0/*9P8&+]6QB+F&PJ)JYRQNM+# ;>U4LS^D(06 MXP%:P$0TREB[]Y?M(?WF>XT(^9&*A818[_/8Q&,MP70[# M3E5I49Q8N
B#RLYT6241(*=AN"Q2.=)SC3]W'1%=1_IA3;A>ENJR!U*)2P"Q MU+BZZ$WJ,HRYE>LQ%DD?Q7A=K!=/D:L;==N.F[I0M+.B4'-@RFL,6G]<7(*Q M2F^P(\5J]R"#4 ([F!
($%Y5ZNB+MWT @I0+C6OK)XP[#=G(LGJB67IM)3IZX#1E[Z:KS_]C'76V*\]WGMM(LQSZOG4QW9E?.[&MQB<:Z M04!HE%E^GH&^BF<"LQB:6(\8PW!,9(CL4WB;2:OEL(YR
MR;@Y5""?;DPJT!X! @;RQO!1/E)<=1%7!U$%(40GB,7LCZ,9V+(FVQ3A+*[MWL4MCMS3"S/*QTN\O%R<:;T']FTFS&S>I8NZA/F,6RFR\H7U)3B8E05E):U> MGR^N,;?
V(G@X[@VL)]69S$ (\7Z.%>LO6-'B1-]7!%DV-:#TO@LHO3C,P/QTDIR('"_K)23,GTPW$P41ZB89Y8 4'^F!B;K_&J1*VT8N] MT<%
[HA4ZU:#7F_%Z"G0H*J0'1D[N9H+%I)163(C0*M[.WTE\.S3]&S@9G-N[O](]$C[1R7!]H9Y4](M MRGY8Y(GL:#62 H?*O\0W[+H]RY$_V!IA+(!>).DA@ MXU'KM^M!VC8_FYRU,
#G!49-@!7+ WN_N0BN\AUSIM>]>K?[!M]VB\N!0S,S MA 6_)3]NZJ^Y\S587@^Y$WZ)JR,T_F,4EX:5%D<(V;!;.17F4-P'8W-GL]]_O]\5% MEB!4I+B0(;#4BTCZ/7&9P6/$?
G^PN9/[K)(T0/?IWS6P"Q2G1_JD!&AEN+] M8/_-WN;.[4H%:C&+0G4@MMX-WFV+-V\&.Z_A,9L[I8]6FSD0I3F]?[>YVN^:S(KSJ]9&^T[LH)K\ MAPV61779'-
^%=33HO^J+RP6!9EVFL4*(_4L=8!2"/T6D\W@9H/-MK_]^\'WP MDDY/;7[H#>FI==&.;S' =9!$H;C$?-Q0BY^CR(\Q>>F_Y7QQ"*-)@#]LZ-0&
M;_M]\3?'%4X_6X_)Z^=3DAY[MV0R YZ68I+9AR-@:/W^FR>]OB_=O]G7?O]OM?&4.BD?K*,S+M@$([F'6\=@0_CN._?N7+'J+#%B;U M_OTF3ZH@>?ZOQ
/S\ZXXPD2W+););JAY;]; #OQAS^/X#P5W2_N,E[3]/^X>O M9&F/$,4;VJH:$Z^NJ4RGI&7*I9G",@'Q8672S0PS.UW,64*8>?\\T.J]3$) MQR',-T=J^H E611=Q3,F4ZQ#G[AH0B@
H&GBGBGH_*1KWSUXO5H'8KJ^6;.\;?<]>6;R';QT]^>8M- MP!98KX =)8.L\39MQXBOX9LQ84.,-?5O10A/'>8*8<&H<]]IV['.5%X,"EV WG_% M:]AHN>&5-]-J8B&6,?=\,@%]-

,X{(;K@D#'Q#(B"ZYL<(Q ?=<^=D?=W/HC)ZS:RZ]:.OEX(U(5-,B<2]RL7 MW.9,DP) %69./>+2_979,"R"Z0!F]Q(KU]QVV@[*TH%F1#VG'-/X.*@0C4%
M0\O6=&)\0!85%C"B=$3lZ5,6CAY6P@[Z)8,EZ171,%<'/\^P0[MI"UF#],C ML96J*9J@M^%9+PP+UN02OZR\U%Y<8R ;P:RLB>4SJFV^#C>RN'14',C0)VJG ML'9?
Z.T]Y$'E2;IJPI5;>I8#E38F$M=P!$*"A$,%P^"L&4ZQ","0TJ')34-,_M9>(/X.]IO*>%997@"BA86$M.Y83%S<='UO4*1=9G&0R--@A%7Z0+W<1U.[U
M#,S;S=%,RHHM23,$=W@1@_M8]S\C0M =R@*X&[*Z>X<)+9KE?;8N#&E,%\N MY,=;@F MJZ0& ,.Y,ZD6233W!%I5D-'5@X%1(U95";ZUY'9:142;H%,]R?2]3VR.>FT1\DR,
M,8>E[*F94-GO;UG(}AL!;DVHW"HOB7=5N3)@S\YR&Y4%L-V\6{)1:T.;<[<& ML(*UNEZETP[#T4LO5U)((U,XQL2 N[":NZZ4;J9DS&7$OF(D"P,6#V/&;?Q'
M%\1E]P^{183Y5."BT>G*]M5"#=V1@?>UM/-]NZY]GC^;=MM.BQ$U;&: M HG::!QY?]$;Z(D<8< A MCF)Z9}]@1\7S7.X-C E!;$S,9>%50 _E)H/WFU
M;238TQ7(F!Q7A&VVDA],D^=(WR0Y(D(.Q!$[P3(0."3V]-M0$O(H3URSV5+!FO?@=-<[TR*Q']2KWO%$;C.O+,"$B%N?4<=*!0Q$"PJN,"M&D6C:L)5M1L0X=,D1"3JEC
W$O0[P8$WF!8$@NDSE^9"9<_L./L#8F7\F\;W M"A:K ZA\GM,=FDER7]C?HNCI#'W0*@#_.:N/#\$4QDIDH M,&@[:90N%S:0%KONWIA3'Z/=4706&F#+DT,Q"F"'K MXRC4'FH-
+EM27%),"1V\;>KP:M I'!;K"^B7$39P)>W(H1W?.3HVKFQFF'(K3=YZ3N+!* MD[KP8D*1Y0"A 1XQW:M*FY3?D]A- L*M358CU%DYM!|:!B>*4@3, A2>@7A1 ME-
V6CWFU!TRG.*W2U+XX0:>#2Y0YT6U &.X2G<=3XZ.AZ>],3QZ='Q![@5 M?S\Z.[T<_;]?\4'#$P'O/__U]/CJ^.\C\6'X.?CSZ!*NQHM.1T=7QV>GXC,, M
YY^>"F&/U^,1[@1KP+GW#R/#2R^A^&?%\<__W(E?LX8GEI!X& 8HU]/XPN M#[!HGMX<'@5DK_! V&@?\MQ-3BH>@"N?4'1$^NM)*I+ ?G1[?ATI%+B&] M5[6(FJ^.,)>?
ASU'V)E(O"QMQU76>4]KV"?&.DG%S'-.FX_F@04B<#B19^8 M'Y7C= 5"U_K[*BTDM_3$B<=M-LC(BD+7GYWL)(IF/=>.PF$P4OC===$?'YY$: MGZL 8
K8J'OY%H1"K;,O:NR4U8?WZ'GMZ7SSOT[W Y]=*MAV#/TG_VR/J?L= M0U4"Y7=!V"X(VP5AGV;N+6.UQZ'XK%.24Y\96;LY)MM;"<[E5B3(71\$K">I MX69%SAMPYX)GE7-
;JWCV-I'UR1E<6TF@+! SY>#B0WX3Z..CO#KX.]?'58/?M M5P)&[NWN?>6=P##VONI. ,:>[@P>]!"Z4RM>[!U[_/]#*PKK#7\"7N5_^L/\' M^]R%]#' Q_"@L,MO7^OPL+8PL?
ZT%X;&V\V7[L&R66OG>7RGX:GIW\[/OT MYO[%^=G%$.W]M? U;KGV7NIRH9\$/2^_C"Z&YZ-?KXZ/+N];N2<{O!N\ T^_MJ?14R_#L:FVW#-TR=,OPS\;!5_1VOK;?CNUBK'Y(?
Q"?M MS:0*Q)'$Y@"A?(f%$W^IH[R?B?EH;LD5/#N=#8.9)IV MTN')U_U4SM5CGM+O84V>4 *T9GDZ[MY1SA-03L?!GWW-KW0.W'$0.|_?$6& MN-(X<<:ADXYT?
\\O>IF+\CN:52R#5>2RR5^_&$<^/\S2>?#7 M_P!02P.$% @ U8!G6<$E&JCN" [#< \ !M;FMD+65X,S%?,2YH M=&WM6VU3XS@2_KZ_0L?&;$%5')(0WAR6*@["#G4[L
N9J_VJV.U$-[+EE>2\ M[*^_;LE. H29,#!'F&,]!K#=4K=;_:B?EN6CH4WE\4_L: @\QM_LR HKX;C[M9[#3K#>/MOTE"FR7$D=]%4^9L5,)OVRD7]$%C)>6/4/D>9*6Y[93L[C6&2#
MD!WDDXX4&01#$(.A#5FSL^&TQ&)4]5$*!U;E8:_^*[+.WX'(8IB$P4XG%5G5 MUC_+E1%6]"S4(+D5(^CTU20PXF_2UU=!=TMU/U%=:AK+&([#!-
A@P@E(2,E/]HK[C4Z1O4]OAH M.\?_Z#[GQN\Y1$U>OSO&2$FEPW<-JZ_$V(C'?L[Z3L:=.[9]BPNZDZ'H"\M\ M3'I'K(%9;&%25IR.KT?!XX)NU9$_:;"GW>O>Q?
G%Z4GOXNJ279VSTP\7W7/6 M_-.[^JEW\>\NWL*GW>NGS,W;5*PTT-_7=]\.KGLL=X5N_[T6Y6#C-=8!-J*9,KLD-MP?2*94F4DN3&_ M,*#"-)#"V DI$ -+&BK-
06_<3L@!.3=LUW=;/\^[L3"YY-,PD3'Y-WG_*0R- MN5+OA)'TB+8=-TT!J31AGQN@/'YO0N>#0&T[^^]?:H,;]?W=5G(_8*]]V-K9
M;^^W=M]WQL&@&KX&_GO)*C57+F#)$Y6N)\\@4?:!PWZ!5T+6K[/9:+R_MT^$+!30:\A$P#2.\8%QO@(5A?0OX-!RRF]:!E3&3M7.F7-1O '2Y1&,6!-
MS:0PBH2*&2#SBMD-Y#CO?=!LIU%CK4:KS53"/O(L^Q=2,W:]-')B8=UYN%* MI&1.3=[":]B7#MO4*PO:?.#LQA64Z99\S-980#Z#FHU?[F(T5]H0IRZ@5%QGC
MV905F=4%H*W@H>R$!I * M(I& PBJ%C84=X@!-#I$SD/HMT1>I$3:+67^ZZ(8WC*TEQG9>,_)2+#*"9 M+$0MQ15=X5.]\%ADF"U2M]KCWY$L*$,@,!8BM(:@$BZ+8%P3)
FJ4LXQ5X:[MN:,9#8U=.5\CB4*B)-8=@Z===Z>B)LA2Z0:FPJ%&@88Z9JC(DXW:TX.K:PM M@,E4QMRS]@U/:XFG]BO 4^]6]/W\;M)]- \!IL1,64'0(]^21."E"\P+QC4X M"&!
(B]X$1[\ Q)W"'\N2W,1C;&A@EIH>1E]9)V(;1!#. M7H[Y#!LBAQ M18[/GOQ}(<4TWTGFRYDIR0_O7OKF0G <)= M.+@2KKF9
VROM*O5/MIG9;DSM*D\ H%UAL!C_TZ5E@)Q[T_@]W&=K.SXR]1 M8*>4Z Q4/&'&3B3\M)%R?2.RD/"'JO^(-%?:\LRV$UG[fT!D;=R&P6X[%5G5UC_+E1%6]"S4
M(+D5(V@/U&U@Q-^D;Z'T##K .ZBFDU<:,$I59$H&P4<6MVQOM];7=LX2G0D[" M:Y&"8>[NQ0V^/.3H[_T7W.C=]R MB)]\?G^,D9)*A^_]fE_!\&/_9P-E(S:]VS[&A?
T;H=B("SS,>D=L0)FL;E) M67(ZOAP%3PNZ94?^O(&>]"ZO^V?]D^YU_-*<79RQDP_]WAD[ZY]WST_ZW5_Q M%C[M73YG,M93L=1 ?_]X>?6Q>WI-KB_8Y<=?>ZRQRX-&.Y-
OL8M+UMB+]XLS M=OVAQZYZ)OQO^[?]WA7K_7GRH?O^2UU3ZH<>-HMU5CW2O6_:UW?MH[_=X ML%)C)T.M#(Y(^)K]O.U^U_A$&%-
C$6@KD@FS0V[#U8EF2I>1Y,;\M($*TT"B M]0%(2($6-52;@]ZXFY0#XR,(!AHX)_"3P Y6B6GSA"9HR;.)Y_QP<9Q8[N:CCG;XG4VZO7W]SI\I.:F M0SX"IF$D8 PQ!K
P(\"!P!;3M@E$#=C*F-G2]>L40_^8(G2*,;LKZD41I%0 M,0-D7S&[@A5G?8 (V:W76+/>;#&5L-]XEOT7Z1D[41]fY,3%VK-P)6(RHR?K ML'W-
L&V^@:#]&6C5/9CA3UERC)QA7&>#9A169U M 6@KMRZ:*#0Y2_%"'RY9PB.\9E*D31.Y>4>"&00@3%<3T@DY9_P6':I%[M.]J##B7I1M0! I'049&B6(-
T1(L.1CZ)QHR4]"/6?LQ."@]H0&DPD@LHK!2 M86-AASA DT/D#*1^2_1%:H3-8C:8S+MAC;&5Q-CN6\88L$1D&,4$B+FHV;BZ M*TO4:/989)@M4K?:X]^1+'"A#(##F(K2&H!
(NBV!<$R0)JE+.,%>&N[FG&0V- M74E?(XE"H@ "36'8.G7>GHB;(4ND&IL*A1IN,-(U1T6<;M:<'%I9FP.3]8QY M8.T;3RN)H8;P-
/UG>C[\=UML]XX:IL2,V4%08N\2A*!ERXP^XQKW0#K8E:Y+'1*N.IP;Q.V7%-7'M*5OT1=H#./0>]?4>J9@Z:'"MFR MM*+DCJ{$%54T%P:/#QO[^;G,_>=AJ-.O[
M+P3!3;ZU^A@\!8/^QF!TE.O+2*D!&XQX899O0K1L !CUI29/!%2AL0,.OY$P M+F>A%&2N'|HSF&6[^8S!JZH1B73FI&A5F93>B@P\Z$M1DD1<^L,'1@1"ZX%
M#4!X/NI2>$8!%88XHEMUC".4+L,I XQV.ZQKE,...V.(S MUWG"C7\.@ 1QPK)Q"^?*!;JCH"*=Q!1.$K^ #(86=$/M:C(5)$*:8A>Z) ME[9'&(1NTY7V8I-
B:MF6MVO(S90*4_YRL(;8)7;GDC+I3I@4GT"6.[#WY&O/ M]]*WP?)ZJ^<%T+SW_6[UN%=Q<;40U&:9AA+?/!1G28>P] 1^_*"0G-G&L9JT M2IL!)W4WL,\T%=8":"ZQ#Q327A*
(!5KN>ME$Q"(.#.5I_$U%;;70P%^%P &X M-:7((K=;N[7>TUG%$/D6]G2Z$LLD]+A *-$N(>TW1@(P]DL^.=U;&:,.WB"#Z MLLE11%?PN5=^U8N#)R&]W ;>]0+'>0)<{JGF6
M)K*1DB,@J;QF_)%NBZS&Z2Y5!/ I^.A\BF-W\$GXNEEJ.SV8Y^W9[@=0>M MW9J3 IC28>IV>929;*&3S6@ZB0<86E@]8_>W$+?+4&]M8]R5\AA@DN<&0N/W MH<"?
MT9MNE)%>Y!^D0HKZ5((I>(%(3UWP+H<4G7">L?&OO<=]^_^KF8.,^QG0 MC<4A_U#[B)@55AWE7*4BCB6LS)GN)QS4_HR#RF/MSOR7=!;ZH#T]",]'N;V7
MXXCHO<(W&$#FSY_E7_.ISMFY[3FJO@Z%<{R6\0*'>1W_\!4$L#!!0 (-6 9UF;T9TLP 8 M "XF / ;6YK9"UE>#,R7$S\N:'1M!5K;.-G(]T4U>(1(4T9 @
X"6E*_O+DC*M"V[CGR)G=]3Q"%QV=VSP"[V M$+U(_'!"]*+& W@-^EIKF-VX'ZVNMO-3]]5/$*'5MFC-TV#)5%Z&;/?7B94 MSKBP"+VV)TR1$9N3<9I0476=W;;3:^'8@UXK@f\
GX'Q/DV4B/I%&_TT3J7]]FU^G*LM MGA<^FZ9QX%S0;1,(W7IUR38DT60#P"M4C-*3=TQW^O@JL]XH-4)C=UR>U, M';AC;W@X'/2]X?&('|_>Q@L/#OK&>_^"'(GXT=
^)^ID=G'C#OUW`\;WQ_MWJ>='T_&DV/^R"/>\3/8!VWG^.1/EW2ZU.]W9J^(<=CTMD)JH=#XAVY9 (I M8#STANX$=L/@I#_ZW27]@8?-G7?=MPW2GV#^.M?
TWGT/_Q^]QP$F2G6Z.^VG M%JJ>;'XXZG_TW#'9[1JW#3UTZWIEPI/1T'/!,5[? R\.CM^[9 M:3YJ3YJ!) M\('SYQAWO;FK{'[*I.8^C4MH5)X!,F=V[C:W-C3T?WS^6'?H?9C5-
10$'@3S M\>A/YEQ'1$>,A!R*BQE)0_/T-.;<2UG^\)))A)8+O/U-A_H:J@@Q2"> ^H&,^% MO5^_6FRW.[XS2),,BF7Q&#AO""0X3&5".FWK+Q*F\L+K2!35+ M5U;V?>,)
(E2#BC0IL#NG7;WW2L>&47)2>MU$J2'(< M-4C;:TUC NGR\IGH)&.J&Y4>$^9,MB@6[^(= ZK9L;L)Y&O=!B,.DTB0?P
M%UN"A'D, ^]H'W\7HH=6VK>T&A5XZ6XA;U.R!U8N=K6"U!>HKV2S@9W?>MYW; MA3NY@'B5%-L2&RD7$ D@>NF:KRDW05PRA6YM8#.-8P+#(*[3&)RN,G KM!0)
M1E#AXWN8,##$DXE)T"N/BU610D(P,E6U LHHT'Q2CG^RYX)/7 NF%/FTRL;@ M@APRC%2@&RR_"'(,)C,,LA$Z#SM" *8KA^W!A@_H$A]'Z;G)YT4R?UHN?% R
M22Q$71R.F"IMAJQ70)AR.8;<$"IYAYI|U!_^J4_<$M M,PG;:9>4%XKFYMY,!3&G, U*%@=M'PZN@;;G6NI/JSXKU_0'Y#.(= M@'A%>?0=D/ ;_ C!9+';;\T?E^A*6U
I&S^@.C?/?)"=KDU!Y=3F$UXQ]^V2 M87-__R;9\/+(=_O-SO:FB?2GW68XO?6VN;O_KOZS.:!FA<#/;D%$PZ5].KW(]*/3:MTKYK@3(]-GM, MJ0IOZ/@Q50IOZ,R8)=*.56-
K]H%GMIUG3!F"RO@LEB7F%CR1#@!5QDD,1M; MJ[M!9RD;._5+!&EVJDWC.5TJDT9[+,SM=?"BUS+WQ/X%4$L# M!!0 (-6 9UF"|/ 7P08 #HF / ;6YK9"UE>#,R75(N:'1M[519
M<]LV$'[OKT"3:<:9$77&1T@U,ZI,UYHFSQ+7:!C^A':HG?_4+Z$;,|_"9]S77,WKF?K5ZWV>VWBD?H MT"I[]&=IL")*KV+V^XN$RCD7-J&Y3G_E299*385V,AH$7,QMLI+)4!DQ:|
3'!K)(0ID)C%Y9WVIEV"J4+>8YI"VG"XY7M M\80I,F8+,DD3'JJ.LU3K-(&^FBVU16,^%W;.0HTR<'@E9A%QS2R549_9F636 M0M+,]\F M2O3Z>1O]-$ZE_;)M?
IRK+5X4F,W2,'#.Z;.)"]QEQ&=*.#T7#@C8[&Y.C@-B@\N-,W7@_.U.'(_> M'(S&@_%P-'@//@?WNY-GQ]^WG1^/)\/CP=@CWM&SL^_;SLGQ>Y=T>M3JO-F: MO29'$|+9#JJ'
^(=NF3J#I\G(V_D3HG[>7@X&/_IDL'0P^;.V]Z;!AE,R>"# M.]YW]^'_XWT<8+)4I[?=?FJIZLG6A\//1\^=D)V>@6WD(;O[%83'XY'G C#> MP ,4AT?
[+MF"UN/FM#EL$MS@[#H&KM=W5=U/F-3;NQL: MVOG_[C\NV_0^3'2-!($'P7S<^I,%UQ'1$2,AA\/%G*2A>?]:4PGQ'Z^(9'@2 MP?>2)0SQ91]M!Q.X
MO.\9K4L#:H6.];INH2@9NG:RH%OD"A2-;A(D\)W9[2K\U/KV#!*3DO433:' MB888!:=+S#3PY.'Y%#--J<&Q@ B$01H3 M?)1@-L"!#9R%Y(+*GQ.8W(4@KNATT;QU#
PSE85;]"5CJAN5#Z',67]@=]^ M$>D"(F?,[''=5LW:>8DKI-(D'[B ^6!0GS&-:V#]C%B-!ZZ=96A$*43H-QBY!U ML'ZQO16LET$]FDT0/\-YWW9\"SBY(@)R5%,L2&RD7D
T@@^D:U12,1'Z90E@:, MV$SCF. PR.VPW]$A UBAI2@R51Z "0-#/IF\|+WRN(B*%(["D;F[""BS0/-) M ?]DJP:?N!9,*?)!73&!@ARJC%2@&P1 |'4""OHFV0C!PXZ0@.D.I%U8\ %=
MX>,X/3$UO2CH3PO"!R4T-[7K]%I>&2BZ)7!2-O"YHBJU63%>P08+9 MEBQPBIFWV\WV;T[9'V")...8K5A&846R@FV&R64U\PE7L$&*N5[95>^R$_0*
MUI:,N3MM,_6:7BXMJ/CEE@Z*V5M:GA>S (6LF63TBVW^M?#%Y8%R4?]YLTO" M@R!FCX;1_@Z;^AH'E;2^4?\NG04^N!=/K3\M%,_-W>T,W)3&/"!5&KA]-K5*
MM2W5NF]W^K/Z^_Z<^>S(.W/DI<>DZQP)OS&$\WT\UN_T2_7$%KI0%E;+Q8ZIS M\PH(5>K;$EA,;3G%7/?KB@\V9N4A4OCGRIU^QT-RVH/_6RP^FM-\V=O;?U-MGVTTI?
J(+&C,B]_$[Y]\O,D.]5+D'Z.WO\M"!U+*;<:0=PQS^,A"Y@VR#(,C M9XH?+\X^A5DW45.LLXNUOFW4Y*J3G@5%!A,)%)- L82$%.PB\A,PGC GIUE M)O8N8R%
(R6/6"+I37]Y7Y^7,2.3"+WDND#A#(T(X. D?#]HH+)AYEH,MS[T- MLHB8Q@],T Y+M"6&&88S1.KN L,IV9Q*V.0]8PI..V<"SM1Q30,T+@9[<@HF MG3G;]]R/2CTV/:U]5X
_2#5[3*4*:^OX,54*;^O,F272@%5C0*_;99[:U9TP M9DLKX+*(2RPL>2*<@*L,BIB-K=4]H=.2C3=\+ESY^2=7L/6E4 SU()8O>,@O2[_\/
]X%.;P5%\MRV@@MS"4MI2$;%%%I:L SBS>&W0+6JJ6:DVC1=T MI4P9[,?PYM>[7_HM#$P7S(N:'1M4$L! A0# M% @ U8!G6;6:MPTI-P Y-@! \ (:6[4& &UN:V0M
M97@O,%\S+FAT;5!+ 0(4 Q0 (-6 9UG!)1JH[@@ .PW / M " D(#K-P #P @ ~'>]08 ,6YK9"UE>#,Q7S(N:'1M4$L! M A0#% @ U8!G69K1G2S !@ +B8 \ (:]/X& &UN
M:V0M97@S,E\Q+FAT;5!+ 0(4 Q0 (-6 9UF"]/ 7P08 #HF / M " >$%!P!M;FMD+65X,S)?,BYH=&U02P4& D "0 I @ &SPP' end XML 117 mnkd-20240930_htm.xml IDEA: XBRL
DOCUMENT 0000899460 us-gaap:ServiceMember 2024-01-012024-09-30 0000899460 us-gaap:InProcessResearchAndDevelopmentMember 2024-09-30 0000899460 us-
gaap:LicenseAndServiceMember 2024-09-30 0000899460 mnkd:RemainderOfYearMembermnkd:SagardHealthcarePartnersFundingBorrower5PE2LPMember 2023-12-
012023-12-31 0000899460 us-gaap:ProductMember 2024-09-30 0000899460 mnkd:StevenBBinderMember 2024-09-30 0000899460 us-gaap:CommonStockMember 2023-
07-012023-09-30 0000899460 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Membermnkd:EstimatedFairValueMember 2023-12-31 0000899460 us-
gaap:LicenseAndServiceMembermnkd:UnitedTherapeuticsCorporationMembermnkd:CommercialSupplyAgreementMember 2024-07-012024-09-30 0000899460
mnkd:MidCapCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-09-30 0000899460 mnkd:InsulinMember 2023-
12-31 0000899460 us-gaap:RetainedEarningsMember 2023-03-31 0000899460 2024-04-012024-06-30 0000899460
mnkd:CommonStockOptionsAndPerformanceBasedStockOptionAwardsMember 2024-01-012024-09-30 0000899460
mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMemberus-gaap:CommonStockMember 2023-07-012023-09-30 0000899460
mnkd:ConvertibleNotePrincipalAndInterestMembermnkd:TheMannGroupLLCMember 2024-04-012024-06-30 0000899460 mnkd:MilestoneRightsLiabilityMemberus-
gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000899460 us-
gaap:LicenseAndServiceMembermnkd:UnitedTherapeuticsCorporationMembermnkd:LicenseAgreementMember 2023-01-012023-09-30 0000899460 2023-01-012023-03-
31 0000899460 mnkd:UnitedTherapeuticsCorporationMembermnkd:RoyaltiesArrangementMember 2024-07-012024-09-30 0000899460 2023-03-31 0000899460 2023-01-
012023-09-30 0000899460 mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMemberus-gaap:CommonStockMember 2023-04-012023-06-30 0000899460
mnkd:EmployeeStockPurchasePlanMember 2024-01-012024-09-30 0000899460 us-gaap:ProductMember 2024-01-012024-09-30 0000899460 us-
gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-01-012024-03-31 0000899460
mnkd:UnitedTherapeuticsCorporationMembermnkd:CollaborationAndLicenseAgreementMember 2023-12-012023-12-31 0000899460 mnkd:PulmatrixIncMember 2024-
07-31 0000899460 us-gaap:RetainedEarningsMember 2023-09-30 0000899460 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000899460
mnkd:MilestoneRightsLiabilityMemberus-gaap:MeasurementInputExpectedTermMember 2024-09-30 0000899460 us-
gaap:BuildingMembermnkd:MarlboroughLeaseMember 2022-06-012022-06-30 0000899460 mnkd:CiplaLtdMembermnkd:LicenseAndDistributionAgreementMember
2024-09-30 0000899460 mnkd:ProductRevenueMember 2024-07-012024-09-30 0000899460 mnkd:ConvertiblePromissoryNoteMembermnkd:TheMannGroupLLCMember
2024-01-012024-09-30 0000899460 mnkd:EmployeeMembermnkd:MarketRestrictedStockUnitsMember 2024-04-012024-06-30 0000899460 mnkd:StevenBBinderMember
2024-07-012024-09-30 0000899460 us-gaap:CommonStockMember 2024-01-012024-03-31 0000899460 mnkd:RestrictedStockUnitsAndOptionsMember 2023-07-012023-
09-30 0000899460 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0000899460 us-gaap:EquipmentMember 2024-01-012024-09-30 0000899460
mnkd:ContingentMilestoneLiabilityMembers-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0000899460 us-gaap:BuildingMember 2023-12-31
0000899460 mnkd:MannGroupConvertibleNoteMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0000899460
mnkd:ConvertiblePromissoryNoteMembermnkd:ThironaBioIncMember 2023-01-012023-09-30 0000899460
mnkd:ManufacturingServicesAndProductSalesMembermnkd:UnitedTherapeuticsCorporationMembermnkd:CollaborationAndLicenseAgreementMember 2022-12-012022-
12-31 0000899460 us-gaap:CommonStockMember 2024-03-31 0000899460 us-gaap:SeniorNotesMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-09-30
0000899460 us-gaap:SeniorNotesMember 2023-12-31 0000899460 2022-12-31 0000899460 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0000899460 us-
gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-07-012024-09-30 0000899460 us-
gaap:ProductMembersrt:MinimumMember 2024-01-012024-09-30 0000899460
mnkd:UnitedTherapeuticsCorporationMembermnkd:CollaborationAndLicenseAgreementMember 2022-12-31 0000899460 us-gaap:CommonStockMember 2024-04-
012024-06-30 0000899460 mnkd:MilestoneRightsLiabilityMembermnkd:DeerfieldManagementCompanyLpMember 2024-09-30 0000899460 mnkd:BiommSAMemberus-
gaap:ProductMembermnkd:SupplyAndDistributionAgreementMember 2023-01-012023-12-31 0000899460 us-gaap:SeniorNotesMemberus-
gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0000899460 mnkd:SenateBills167CaliforniaFranchiseTaxBoardMember 2024-06-
30 0000899460 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0000899460 2024-07-082024-07-08 0000899460 us-gaap:RetainedEarningsMember

2024-03-31 0000899460 mnkd:ConvertiblePromissoryNoteMembermnkd:ThironaBioIncMember 2021-06-30 0000899460 us-gaap:CommonStockMember 2024-09-30 0000899460 mnkd:UnitedTherapeuticsCorporationMembermnkd:CommercialSupplyMember 2024-07-012024-09-30 0000899460 mnkd:ManufacturingServicesAndProductSalesMembermnkd:UnitedTherapeuticsCorporationMemberus-gaap:TransferredAtPointInTimeMembermnkd:CollaborationAndLicenseAgreementMember 2022-12-012022-12-31 0000899460 us-gaap:EmployeeStockMember 2024-09-30 0000899460 us-gaap:RestrictedStockUnitsRSUMember 2024-07-012024-09-30 0000899460 mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMemberus-gaap:CommonStockMember 2023-01-012023-03-31 0000899460 us-gaap:CommonStockMember 2023-01-012023-03-31 0000899460 mnkd:PreLaunchInventoryMember 2024-09-30 0000899460 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000899460 srt:MaximumMembermnkd:MidCapCreditFacilityMember 2023-12-31 0000899460 mnkd:MilestoneRightsLiabilityMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0000899460 mnkd:TrancheOneMember 2019-08-012019-08-31 0000899460 mnkd:BiommSAMemberus-gaap:ProductMembermnkd:SupplyAndDistributionAgreementMember 2024-01-012024-03-31 0000899460 srt:MaximumMembermnkd:MilestoneRightsLiabilityMembermnkd:DeerfieldManagementCompanyLpMember 2013-07-01 0000899460 mnkd:EmployeeMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-01-012024-03-31 0000899460 2019-08-012019-08-31 0000899460 us-gaap:ConstructionInProgressMember 2024-09-30 0000899460 mnkd:FinancingLiabilityMember 2024-01-012024-09-30 0000899460 mnkd:RestrictedStockUnitsAndOptionsMember 2024-07-012024-09-30 0000899460 mnkd:ConvertiblePromissoryNoteMembermnkd:TheMannGroupLLCMember 2024-09-30 0000899460 mnkd:TrancheTwoMember 2020-12-012020-12-31 0000899460 us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Membermnkd:GrossUnrealizedHoldingGainsMember 2024-09-30 0000899460 mnkd:ContingentMilestoneLiabilityMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0000899460 mnkd:EmployeeMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-07-012024-09-30 0000899460 mnkd:MidCapCreditFacilityMembermnkd:TrancheTwoMember 2020-01-012020-12-31 0000899460 mnkd:ConvertiblePromissoryNoteMembermnkd:ThironaBioIncMember 2023-12-31 0000899460 us-gaap:ProductMember 2024-07-012024-09-30 0000899460 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Membermnkd:GrossUnrealizedHoldingGainsMember 2023-12-31 0000899460 mnkd:ComputerEquipmentAndSoftwareMember 2023-12-31 0000899460 mnkd:TrancheTwoMember 2020-12-31 0000899460 mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMember 2024-01-012024-03-31 0000899460 mnkd:UnitedTherapeuticsCorporationMembermnkd:CollaborationAndLicenseAgreementMember 2024-01-012024-09-30 0000899460 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Membermnkd:AmortizedCostMember 2023-12-31 0000899460 mnkd:VGoMemberus-gaap:EquipmentMember 2022-06-012022-06-30 0000899460 2023-12-31 0000899460 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0000899460 mnkd:GrossUnrealizedHoldingGainsMember 2024-09-30 0000899460 us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Membermnkd:GrossUnrealizedHoldingLossesMember 2024-09-30 0000899460 mnkd:EmployeeMemberus-gaap:EmployeeStockMember 2024-01-012024-09-30 0000899460 mnkd:ManufacturingServicesAndProductSalesMembermnkd:UnitedTherapeuticsCorporationMemberus-gaap:TransferredAtPointInTimeMembermnkd:CollaborationAndLicenseAgreementMember 2022-12-31 0000899460 mnkd:NextGenResearchAndDevelopmentServicesMembermnkd:TransactionPriceForThePerformanceObligationsMembermnkd:UnitedTherapeuticsCorporationMembermnkd 2022-12-31 0000899460 mnkd:SeniorConvertibleNotesMember 2024-01-012024-09-30 0000899460 mnkd:AmortizedCostMember 2024-09-30 0000899460 us-gaap:ServiceMember 2024-07-012024-09-30 0000899460 mnkd:ProductRevenueMember 2023-07-012023-09-30 0000899460 mnkd:ContingentMilestoneLiabilityMemberus-gaap:MeasurementInputExpectedTermMember 2024-09-30 0000899460 mnkd:ConvertiblePromissoryNoteMembermnkd:LoanArrangementMembermnkd:TheMannGroupLLCMembermnkd:PrivatelyNegotiatedExchangeAgreementMember 2019-08-31 0000899460 2024-07-012024-09-30 0000899460 mnkd:UnitedTherapeuticsCorporationMembermnkd:LicenseAgreementMember 2023-07-012023-09-30 0000899460 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0000899460 us-gaap:CommonStockMember 2023-09-30 0000899460 mnkd:EmployeeMemberus-gaap:RestrictedStockUnitsRSUMember 2024-07-012024-09-30 0000899460 mnkd:ConvertiblePromissoryNoteMembermnkd:TheMannGroupLLCMember 2023-01-012023-09-30 0000899460 mnkd:RestrictedStockUnitsAndOptionsMember 2024-01-012024-09-30 0000899460 mnkd:RoyaltyLiabilityMember 2023-12-31 0000899460 mnkd:SenateBills167Memberus-gaap:CaliforniaFranchiseTaxBoardMember 2024-06-012024-06-30 0000899460 mnkd:MidCapCreditFacilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000899460 mnkd:ProductRevenueMember 2023-01-012023-09-30 0000899460 2023-04-012023-06-30 0000899460 srt:MaximumMember 2024-01-012024-09-30 0000899460 mnkd:FinancingLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000899460 mnkd:ContingentMilestoneLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000899460 mnkd:EmployeeStockPurchasePlanMember 2024-07-012024-09-30 0000899460 us-gaap:RoyaltyMember 2024-07-012024-09-30 0000899460 mnkd:AudioVisualEquipmentMember 2024-01-012024-09-30 0000899460 srt:MinimumMembermnkd:LiabilityForSaleOfFutureRoyaltiesMember 2024-09-30 0000899460 us-gaap:SeniorNotesMember 2024-09-30 0000899460 mnkd:TyvasoDPIMember 2023-12-012023-12-31 0000899460 mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMember 2023-01-012023-03-31 0000899460 mnkd:MidCapCreditFacilityMember 2024-04-012024-04-01 0000899460 mnkd:MilestoneRightsLiabilityMemberus-gaap:MeasurementInputEntityCreditRiskMember 2024-09-30 0000899460 mnkd:RestrictedStockUnitsAndMarketRestrictedStockUnitsMember 2024-01-012024-09-30 0000899460 mnkd:TrancheTwoMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2020-12-012020-12-31 0000899460 mnkd:FinancingLiabilityMember 2023-12-31 0000899460 mnkd:MilestoneRightsLiabilityMembermnkd:DeerfieldManagementCompanyLpMember 2023-01-012023-09-30 0000899460 srt:MinimumMemberus-gaap:SeniorNotesMember 2024-09-30 0000899460 mnkd:ConvertiblePromissoryNoteMembermnkd:ThironaBioIncMember 2021-06-012021-06-30 0000899460 2024-03-31 0000899460 mnkd:ComputerEquipmentAndSoftwareMember 2024-09-30 0000899460 mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMemberus-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0000899460 us-gaap:RestrictedStockUnitsRSUMember 2021-01-012021-12-31 0000899460 mnkd:ConvertiblePromissoryNoteMembermnkd:ThironaBioIncMember 2024-09-30 0000899460 us-gaap:SeniorNotesMember 2021-03-04 0000899460 mnkd:MilestoneRightsLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000899460 mnkd:UtManufacturingFacilityMember 2024-09-30 0000899460 mnkd:InsulinMember 2024-09-30 0000899460 mnkd:ConvertibleNotePrincipalAndInterestMembermnkd:TheMannGroupLLCMemberus-gaap:CommonStockMember 2024-04-012024-06-30 0000899460 mnkd:SagardHealthcarePartnersFundingBorrowerSPE2LPMember 2023-01-012023-12-31 0000899460 srt:MaximumMemberus-gaap:BuildingMember 2024-09-30 0000899460 mnkd:RoyaltyLiabilityMember 2024-01-012024-09-30 0000899460 mnkd:PulmatrixIncMember 2024-07-08 0000899460 mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMemberus-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0000899460 mnkd:CantorFitzgeraldMemberus-gaap:CommonStockMembermnkd:AtMarketIssuanceSalesAgreementMember 2024-01-012024-09-30 0000899460 mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMemberus-gaap:CommonStockMember 2024-01-012024-03-31 0000899460 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0000899460 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2024-09-30 0000899460 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000899460 mnkd:CiplaLtdMembermnkd:LicenseAndDistributionAgreementMember 2018-05-012018-05-31 0000899460 mnkd:EmployeeMembermnkd:MarketRestrictedStockUnitsMember 2024-01-012024-09-30 0000899460 us-gaap:LicenseAndServiceMembermnkd:UnitedTherapeuticsCorporationMembermnkd:CommercialSupplyAgreementMember 2023-01-012023-09-30 0000899460 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-04-012024-06-30 0000899460 us-gaap:LandMember 2024-09-30 0000899460 mnkd:MilestoneRightsLiabilityMembermnkd:DeerfieldManagementCompanyLpMember 2013-07-01 0000899460 mnkd:CiplaLtdMemberus-gaap:LicenseAndServiceMembermnkd:LicenseAndDistributionAgreementMember 2023-01-012023-09-30 0000899460 2023-09-30 0000899460 us-gaap:RetainedEarningsMember 2024-09-30 0000899460 mnkd:ManufacturingServicesAndProductSalesMembermnkd:TransactionPriceForTheContractualObligationsMembermnkd:UnitedTherapeuticsCorporationMembermnkd:Co 2022-12-31 0000899460 mnkd:OfficeMembermnkd:RussellRanchRoadHLLCMember 2023-02-012023-02-28 0000899460 mnkd:RoyaltyLiabilityMember 2024-09-30 0000899460 mnkd:SagardHealthcarePartnersFundingBorrowerSPE2LPMember 2024-01-012024-09-30 0000899460 us-gaap:SeniorNotesMember 2024-01-012024-09-30 0000899460 mnkd:EmployeeMembermnkd:MarketRestrictedStockUnitsMembermnkd:ShareBasedCompensationAwardsTrancheFiveMember 2024-04-012024-06-30 0000899460 mnkd:RestrictedStockUnitsAndOptionsMember 2023-01-012023-09-30 0000899460 2024-01-012024-03-31 0000899460 mnkd:UnitedTherapeuticsCorporationMember 2024-07-012024-09-30 0000899460 us-gaap:SeniorNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-09-30 0000899460 us-gaap:SeniorNotesMember 2024-09-30 0000899460 mnkd:LiabilityForSaleOfFutureRoyaltiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000899460 mnkd:AccruedInterestMembermnkd:ConvertiblePromissoryNoteMembermnkd:TheMannGroupLLCMember 2023-01-012023-09-30 0000899460 mnkd:UnitedTherapeuticsCorporationMember 2023-07-012023-09-30 0000899460 mnkd:MannGroupConvertibleNoteMember 2023-01-012023-09-30 0000899460 us-gaap:DevelopedTechnologyRightsMember 2024-09-30 0000899460 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Membermnkd:AmortizedCostMember 2024-09-30 0000899460 us-gaap:RetainedEarningsMember 2023-12-31 0000899460 srt:MaximumMemberus-gaap:SeniorNotesMember 2023-12-31 0000899460 mnkd:TheMannGroupLLCMember 2023-01-012023-09-30 0000899460 mnkd:BiommSAMemberus-gaap:ProductMembermnkd:SupplyAndDistributionAgreementMember 2024-07-012024-09-30 0000899460 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000899460 srt:MaximumMembermnkd:OfficeMembermnkd:RussellRanchRoadHLLCMember 2023-02-012023-02-28 0000899460 mnkd:ConvertiblePromissoryNoteMembermnkd:NewLoanArrangementMembermnkd:TheMannGroupLLCMember 2019-08-012019-08-31 0000899460 mnkd:ContingentMilestoneLiabilityMemberus-gaap:MeasurementInputEntityCreditRiskMember 2024-09-30 0000899460 mnkd:DueInOneYearOrLessMember 2023-12-31 0000899460 mnkd:EstimatedFairValueMember 2024-09-30 0000899460 mnkd:EmployeeMembermnkd:MarketRestrictedStockUnitsMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-04-012024-06-30 0000899460 mnkd:NetSalesThresholdsAAndBMembermnkd:TyvasoDPIMembermnkd:SagardHealthcarePartnersFundingBorrowerSPE2LPMember 2023-12-012023-12-31 0000899460 mnkd:ContingentMilestoneLiabilityMemberus-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0000899460 srt:MaximumMembermnkd:CantorFitzgeraldMemberus-gaap:CommonStockMembermnkd:ContolledEquityOfferingSalesAgreementMember 2018-02-012018-02-28 0000899460 mnkd:FurnitureFixturesAndOfficeEquipmentMember 2023-12-31 0000899460 mnkd:MilestoneRightsLiabilityMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0000899460 mnkd:ConvertiblePromissoryNoteMembermnkd:ThironaBioIncMember 2024-01-012024-09-30 0000899460 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000899460 srt:MinimumMembermnkd:MidCapCreditFacilityMember 2023-12-31 0000899460 mnkd:ContingentMilestoneLiabilityMemberus-gaap:MeasurementInputEntityCreditRiskMember 2023-12-31 0000899460 mnkd:EmployeeMember 2024-01-012024-09-30 0000899460 mnkd:MidCapCreditFacilityMember 2021-04-012021-04-30 0000899460 mnkd:MidCapCreditFacilityMember 2024-01-012024-09-30 0000899460 mnkd:MarketRestrictedStockUnitsMember 2024-04-012024-06-30 0000899460 mnkd:EmployeeMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-04-012024-06-30 0000899460 mnkd:TrancheOneMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2019-08-012019-08-31 0000899460 srt:MaximumMemberus-gaap:SeniorNotesMember 2024-09-30 0000899460 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0000899460 mnkd:MidCapCreditFacilityMember 2023-12-31 0000899460 mnkd:UnitedTherapeuticsCorporationMembermnkd:LicenseAgreementMember 2023-01-012023-09-30 0000899460 mnkd:EmployeeMembermnkd:MarketRestrictedStockUnitsMembermnkd:ShareBasedCompensationAwardsTrancheFourMember 2024-04-012024-06-30 0000899460 srt:MaximumMembermnkd:FurnitureFixturesAndOfficeEquipmentMember 2024-09-30 0000899460 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-07-012024-09-30 0000899460 us-gaap:SeniorNotesMember 2023-01-012023-12-31 0000899460 mnkd:NetSalesThresholdAMembermnkd:TyvasoDPIMembermnkd:SagardHealthcarePartnersFundingBorrowerSPE2LPMember 2023-12-012023-12-31 0000899460 mnkd:ContingentMilestoneLiabilityMemberus-gaap:MeasurementInputExpectedDividendRateMember 2024-09-30 0000899460 us-gaap:CommonStockMember 2023-06-30 0000899460 us-gaap:ProductMembersrt:MaximumMember 2024-01-012024-09-30 0000899460 mnkd:PreLaunchInventoryMember 2023-12-31 0000899460 mnkd:DueInOneYearOrLessMember 2024-09-30 0000899460 mnkd:ConvertiblePromissoryNoteMembermnkd:ThironaBioIncMember 2023-07-012023-09-30 0000899460 mnkd:CommonStockOptionsAndPerformanceBasedStockOptionAwardsMember 2023-07-012023-09-30 0000899460 us-gaap:LicenseAndServiceMembermnkd:UnitedTherapeuticsCorporationMembermnkd:LicenseAgreementMember 2023-07-012023-09-30 0000899460 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Membermnkd:EstimatedFairValueMember 2024-09-30 0000899460 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000899460 us-gaap:BuildingImprovementsMember 2023-12-31 0000899460 srt:MinimumMemberus-

gaap:BuildingImprovementsMember 2024-09-30 0000899460 2024-01-012024-09-30 0000899460 mnkd:ConvertiblePromissoryNoteMembermnkd:TheMannGroupLLCMember 2023-12-31 0000899460 mnkd:MidCapCreditFacilityMember 2024-01-012024-03-31 0000899460 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000899460 mnkd:UnitedTherapeuticsCorporationMember 2023-01-012023-09-30 0000899460 mnkd:EmployeeMemberus-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-03-31 0000899460 mnkd:ContingentMilestoneLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000899460 us-gaap:LicenseAndServiceMembermnkd:UnitedTherapeuticsCorporationMembermnkd:CommercialSupplyAgreementMember 2023-07-012023-09-30 0000899460 mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMember 2023-04-012023-06-30 0000899460 mnkd:EmployeeStockPurchasePlanMember 2023-07-012023-09-30 0000899460 mnkd:MilestoneRightsLiabilityMembermnkd:DeerfieldManagementCompanyLpMember 2024-01-012024-09-30 0000899460 mnkd:NetSalesThresholdBMembermnkd:TyvasoDPIMembermnkd:SagardHealthcarePartnersFundingBorrowerSPE2LPMember 2023-12-012023-12-31 0000899460 mnkd:CasperLLCMembersrt:MinimumMember 2021-11-30 0000899460 us-gaap:RoyaltyMember 2023-01-012023-09-30 0000899460 us-gaap:SeniorNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000899460 mnkd:LoanArrangementMembermnkd:TheMannGroupLLCMembermnkd:PrivatelyNegotiatedExchangeAgreementMember 2019-08-31 0000899460 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30 0000899460 mnkd:MidCapCreditFacilityMember 2023-01-012023-12-31 0000899460 mnkd:MilestoneRightsLiabilityMembermnkd:DeerfieldManagementCompanyLpMember 2024-06-30 0000899460 us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Membermnkd:GrossUnrealizedHoldingLossesMember 2023-12-31 0000899460 mnkd:EmployeeMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-04-012024-06-30 0000899460 mnkd:FinancingLiabilityMember 2024-09-30 0000899460 mnkd:NonEmployeeDirectorMemberus-gaap:RestrictedStockUnitsRSUMember 2024-04-012024-06-30 0000899460 mnkd:ConvertibleNotePrincipalAndInterestMembermnkd:TheMannGroupLLCMemberus-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0000899460 mnkd:TheMannGroupLLCMember 2024-04-022024-04-02 0000899460 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000899460 mnkd:CasperLLCMember 2021-11-012021-11-30 0000899460 mnkd:MannGroupConvertibleNoteMemberus-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0000899460 mnkd:TrancheOneMember 2019-08-31 0000899460 mnkd:TheMannGroupLLCMember 2024-04-02 0000899460 mnkd:EmployeeMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-01-012024-03-31 0000899460 mnkd:RoyaltyLiabilityMembermnkd:SagardHealthcarePartnersFundingBorrowerSPE2LPMember 2023-12-012023-12-31 0000899460 mnkd:UnitedTherapeuticsCorporationMembermnkd:RoyaltiesArrangementMember 2023-07-012023-09-30 0000899460 us-gaap:RoyaltyMember 2023-07-012023-09-30 0000899460 us-gaap:ProductMember 2023-12-31 0000899460 us-gaap:ServiceMember 2023-07-012023-09-30 0000899460 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Membermnkd:GrossUnrealizedHoldingGainsMember 2024-09-30 0000899460 2023-01-012023-12-31 0000899460 us-gaap:SeniorNotesMemberus-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0000899460 mnkd:NextGenResearchAndDevelopmentServicesMembermnkd:UnitedTherapeuticsCorporationMemberus-gaap:TransferredOverTimeMembermnkd:CollaborationAndLicenseAgreementMember 2022-12-31 0000899460 mnkd:CommercializationAndContinuousImprovementActivitiesMembermnkd:UnitedTherapeuticsCorporationMember 2022-12-012022-12-31 0000899460 mnkd:GrossUnrealizedHoldingLossesMember 2023-12-31 0000899460 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-07-012024-09-30 0000899460 2024-09-30 0000899460 mnkd:ConvertiblePromissoryNoteMembermnkd:ThironaBioIncMember 2024-07-012024-09-30 0000899460 mnkd:AccruedInterestMembermnkd:ConvertiblePromissoryNoteMembermnkd:TheMannGroupLLCMember 2024-01-012024-09-30 0000899460 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-03-31 0000899460 us-gaap:CommonStockMember 2024-06-30 0000899460 us-gaap:LicenseAndServiceMembermnkd:UnitedTherapeuticsCorporationMembermnkd:LicenseAgreementMember 2024-01-012024-09-30 0000899460 mnkd:UnitedTherapeuticsCorporationMembermnkd:CommercialSupplyMember 2023-07-012023-09-30 0000899460 mnkd:GrossUnrealizedHoldingLossesMember 2024-09-30 0000899460 mnkd:TyvasoDPIMembermnkd:SagardHealthcarePartnersFundingBorrowerSPE2LPMember 2023-12-012023-12-31 0000899460 mnkd:UnitedTherapeuticsCorporationMember 2024-01-012024-09-30 0000899460 mnkd:MidCapCreditFacilityMembermnkd:TrancheOneMember 2024-04-012024-04-01 0000899460 mnkd:MannGroupConvertibleNoteMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000899460 mnkd:MilestoneRightsLiabilityMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0000899460 mnkd:FinancingLiabilityMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0000899460 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Membermnkd:AmortizedCostMember 2024-09-30 0000899460 mnkd:RestrictedStockUnitsAndMarketRestrictedStockUnitsMember 2024-07-012024-09-30 0000899460 us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Membermnkd:GrossUnrealizedHoldingGainsMember 2023-12-31 0000899460 us-gaap:SeniorNotesMember 2024-01-012024-09-30 0000899460 srt:MinimumMembermnkd:MannGroupConvertibleNoteMember 2023-12-31 0000899460 us-gaap:CommonStockMember 2023-03-31 0000899460 us-gaap:ConstructionInProgressMember 2023-12-31 0000899460 mnkd:MilestoneRightsLiabilityMemberus-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0000899460 mnkd:ContingentMilestoneLiabilityMemberus-gaap:MeasurementInputExpectedTermMember 2023-12-31 0000899460 mnkd:EmployeeMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-07-012024-09-30 0000899460 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-04-012024-06-30 0000899460 mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMemberus-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0000899460 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Membermnkd:GrossUnrealizedHoldingLossesMember 2024-09-30 0000899460 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000899460 mnkd:ThironaBioIncMember 2024-01-012024-09-30 0000899460 mnkd:ManufacturingServicesMembermnkd:UnitedTherapeuticsCorporationMember 2022-12-012022-12-31 0000899460 mnkd:CasperLLCMember 2021-11-30 0000899460 mnkd:ManufacturingServicesMembermnkd:UnitedTherapeuticsCorporationMembermnkd:CollaborationAndLicenseAgreementMember 2022-12-31 0000899460 mnkd:MidCapCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-01-012024-09-30 0000899460 mnkd:ProductRevenueMember 2024-01-012024-09-30 0000899460 us-gaap:SeniorNotesMember 2021-03-042021-03-04 0000899460 mnkd:MarketRestrictedStockUnitsMember 2024-09-30 0000899460 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000899460 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0000899460 mnkd:FinancingLiabilityMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-09-30 0000899460 mnkd:UnitedTherapeuticsCorporationMember 2023-01-012023-12-31 0000899460 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Membermnkd:EstimatedFairValueMember 2024-09-30 0000899460 us-gaap:CommonStockMember 2024-07-012024-09-30 0000899460 mnkd:FurnitureFixturesAndOfficeEquipmentMember 2024-09-30 0000899460 mnkd:UnitedTherapeuticsCorporationMembermnkd:CommercialSupplyMember 2023-01-012023-09-30 0000899460 us-gaap:SeniorNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000899460 srt:MaximumMembermnkd:MannGroupConvertibleNoteMember 2023-12-31 0000899460 mnkd:ContingentMilestoneLiabilityMemberus-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0000899460 srt:MinimumMemberus-gaap:MachineryAndEquipmentMember 2024-09-30 0000899460 us-gaap:LicenseAndServiceMember 2023-01-012023-09-30 0000899460 mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMemberus-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0000899460 mnkd:RestrictedStockUnitsAndMarketRestrictedStockUnitsMember 2023-01-012023-09-30 0000899460 us-gaap:LicenseAndServiceMember 2024-04-01 2024-09-30 0000899460 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Membermnkd:AmortizedCostMember 2023-12-31 0000899460 mnkd:PulmatrixIncMember 2024-07-012024-07-31 0000899460 mnkd:OfficeMembermnkd:RussellRanchRoadHLLCMember 2024-01-012024-09-30 0000899460 us-gaap:LicenseAndServiceMember 2024-01-012024-09-30 0000899460 us-gaap:RestrictedStockUnitsRSUMembermnkd:ShareBasedCompensationAwardsTrancheFourMember 2024-04-012024-06-30 0000899460 mnkd:EmployeeMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-04-012024-06-30 0000899460 mnkd:TheMannGroupLLCMember 2024-01-012024-09-30 0000899460 mnkd:MidCapCreditFacilityMember 2024-04-01 0000899460 srt:MaximumMembermnkd:LiabilityForSaleOfFutureRoyaltiesMember 2024-09-30 0000899460 mnkd:NonEmployeeDirectorMemberus-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0000899460 us-gaap:RetainedEarningsMember 2023-06-30 0000899460 us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Membermnkd:EstimatedFairValueMember 2024-09-30 0000899460 mnkd:SagardHealthcarePartnersFundingBorrowerSPE2LPMember 2023-12-012023-12-31 0000899460 mnkd:OfficeAndVehicleMember 2024-09-30 0000899460 mnkd:ConvertibleNoteInterestMembermnkd:TheMannGroupLLCMember 2023-07-012023-09-30 0000899460 mnkd:ConvertiblePromissoryNoteMembermnkd:ThironaBioIncMember 2024-06-272024-06-27 0000899460 mnkd:MilestoneRightsLiabilityMemberus-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0000899460 srt:MaximumMemberus-gaap:BuildingImprovementsMember 2024-09-30 0000899460 mnkd:EmployeeStockPurchasePlanMember 2023-01-012023-09-30 0000899460 mnkd:MidCapCreditFacilityMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0000899460 2024-07-08 0000899460 us-gaap:LicenseAndServiceMember 2023-07-012023-09-30 0000899460 mnkd:CiplaLtdMember 2018-06-01mnkd:LicenseAndDistributionAgreementMember 2018-05-31 0000899460 mnkd:ZealandPharmaUsMember 2023-12-31 0000899460 us-gaap:RestrictedStockUnitsRSUMember 2024-04-012024-06-30 0000899460 mnkd:UnitedTherapeuticsCorporationMembermnkd:RoyaltiesArrangementMember 2023-01-012023-09-30 0000899460 mnkd:SeniorConvertibleNotesMember 2023-01-012023-09-30 0000899460 mnkd:UnitedTherapeuticsCorporationMembermnkd:LicenseAgreementMember 2024-01-012024-09-30 0000899460 us-gaap:BuildingImprovementsMember 2024-09-30 0000899460 mnkd:CiplaLtdMembermnkd:LicenseAndDistributionAgreementMember 2023-12-31 0000899460 srt:MinimumMembermnkd:FurnitureFixturesAndOfficeEquipmentMember 2024-09-30 0000899460 us-gaap:CommonStockMember 2022-12-31 0000899460 srt:WeightedAverageMembermnkd:CantorFitzgeraldMemberus-gaap:CommonStockMembermnkd:AtMarketIssuanceSalesAgreementMember 2024-09-30 0000899460 us-gaap:ServiceMember 2023-01-012023-09-30 0000899460 2023-07-012023-09-30 0000899460 mnkd:ResearchAndDevelopmentServicesAndLicenseMembermnkd:UnitedTherapeuticsCorporationMemberus-gaap:TransferredOverTimeMembermnkd:CollaborationAndLicenseAgreementMember 2022-12-012022-12-31 0000899460 mnkd:UnitedTherapeuticsCorporationMembermnkd:RoyaltiesArrangementMember 2024-01-012024-09-30 0000899460 srt:MaximumMembermnkd:FinancingLiabilityMember 2024-09-30 0000899460 mnkd:MannGroupConvertibleNoteMember 2023-12-31 0000899460 mnkd:UnitedTherapeuticsCorporationMembermnkd:CollaborationAndLicenseAgreementMember 2018-10-312018-10-31 0000899460 mnkd:CiplaLtdMemberus-gaap:LicenseAndServiceMembermnkd:LicenseAndDistributionAgreementMember 2024-07-012024-09-30 0000899460 mnkd:CommonStockOptionsAndPerformanceBasedStockOptionAwardsMember 2023-01-012023-09-30 0000899460 mnkd:EstimatedFairValueMember 2023-12-31 0000899460 mnkd:PromissoryNotesMembermnkd:NewLoanArrangementMembermnkd:TheMannGroupLLCMember 2019-08-012019-08-31 0000899460 mnkd:AtTheMarketIssuanceMember 2023-01-012023-09-30 0000899460 us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Membermnkd:EstimatedFairValueMember 2023-12-31 0000899460 mnkd:EmployeeMembermnkd:MarketRestrictedStockUnitsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-04-012024-06-30 0000899460 mnkd:GrossUnrealizedHoldingGainsMember 2023-12-31 0000899460 mnkd:EmployeeMemberus-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0000899460 mnkd:ThironaBioIncMember 2023-02-28 0000899460 mnkd:UnitedTherapeuticsCorporationMembermnkd:CollaborationAndLicenseAgreementMember 2023-12-31 0000899460 us-gaap:LicenseAndServiceMember 2023-12-31 0000899460 mnkd:FinancingLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000899460 mnkd:AudioVisualEquipmentMember 2024-09-30 0000899460 us-gaap:VehiclesMembermnkd:MasterLeaseAgreementWithEnterpriseMember 2024-01-012024-09-30 0000899460 us-gaap:EquipmentMember 2024-07-012024-09-30 0000899460 us-gaap:ProductMember 2023-07-012023-09-30 0000899460 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-01-012024-03-31 0000899460 us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Membermnkd:AmortizedCostMember 2024-09-30 0000899460 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0000899460 srt:MinimumMemberus-gaap:SeniorNotesMember 2023-12-31 0000899460 2024-10-25 0000899460 srt:MinimumMemberus-gaap:SeniorNotesMember 2021-03-04 0000899460 mnkd:MilestoneRightsLiabilityMemberus-gaap:MeasurementInputExpectedTermMember 2023-12-31 0000899460 mnkd:MidCapCreditFacilityMembermnkd:TrancheOneMember 2019-08-012019-08-31 0000899460 mnkd:CiplaLtdMemberus-gaap:LicenseAndServiceMembermnkd:LicenseAndDistributionAgreementMember 2023-07-012023-09-30 0000899460 mnkd:ConvertiblePromissoryNoteMembermnkd:ThironaBioIncMember 2022-01-012022-01-31 0000899460 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0000899460 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2023-12-31 0000899460 srt:MaximumMemberus-gaap:MachineryAndEquipmentMember 2024-

09-30 0000899460 mnkd:UnitedTherapeuticsCorporationMembermnkd:CommercialSupplyMember 2024-01-012024-09-30 0000899460 mnkd:PulmatrixIncMember 2024-07-08 0000899460 us-gaap:BuildingMember 2024-09-30 0000899460 mnkd:MilestoneRightsLiabilityMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0000899460 us-gaap:LandMember 2023-12-31 0000899460 mnkd:MilestoneRightsLiabilityMemberus-gaap:MeasurementInputExpectedDividendRateMember 2024-09-30 0000899460 us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Membermnkd:AmortizedCostMember 2023-12-31 0000899460 mnkd:SenateBills175Memberus-gaap:CaliforniaFranchiseTaxBoardMember 2024-06-012024-06-30 0000899460 mnkd:MarketRestrictedStockUnitsMember 2024-01-012024-09-30 0000899460 mnkd:EmployeeMembermnkd:MarketRestrictedStockUnitsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-04-012024-06-30 0000899460 mnkd:PulmatrixIncMember 2024-07-082024-07-08 0000899460 mnkd:LiabilityForSaleOfFutureRoyaltiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-09-30 0000899460 us-gaap:RetainedEarningsMember 2022-12-31 0000899460 us-gaap:CommonStockMember 2023-12-31 0000899460 us-gaap:ProductMember 2023-01-012023-09-30 0000899460 us-gaap:RetainedEarningsMember 2024-06-30 0000899460 us-gaap:LicenseAndServiceMembermnkd:UnitedTherapeuticsCorporationMembermnkd:CommercialSupplyAgreementMember 2024-01-012024-09-30 0000899460 mnkd:UnitedTherapeuticsCorporationMembermnkd:CollaborationAndLicenseAgreementMember 2024-09-30 0000899460 mnkd:ContingentMilestoneLiabilityMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0000899460 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0000899460 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0000899460 us-gaap:LicenseAndServiceMember 2023-04-01 2024-09-30 0000899460 2024-06-012024-06-30 0000899460 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-012024-03-31 0000899460 mnkd:LiabilityForSaleOfFutureRoyaltiesMember 2024-09-30 0000899460 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0000899460 2023-06-30 0000899460 mnkd:SeniorConvertibleNotesMember 2024-07-012024-09-30 0000899460 mnkd:CiplaLtdMemberus-gaap:LicenseAndServiceMembermnkd:LicenseAndDistributionAgreementMember 2024-01-012024-09-30 0000899460 us-gaap:RestrictedStockUnitsRSUMember 2022-01-012022-12-31 0000899460 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Membermnkd:EstimatedFairValueMember 2023-12-31 0000899460 srt:MinimumMemberus-gaap:BuildingMember 2024-09-30 0000899460 mnkd:EmployeeMemberus-gaap:RestrictedStockUnitsRSUMember 2024-04-012024-06-30 0000899460 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0000899460 us-gaap:LicenseAndServiceMember 2024-07-012024-09-30 0000899460 mnkd:CommonStockOptionsAndPerformanceBasedStockOptionAwardsMember 2024-07-012024-09-30 0000899460 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-04-012024-06-30 0000899460 mnkd:ContingentMilestoneLiabilityMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-09-30 0000899460 mnkd:LiabilityForSaleOfFutureRoyaltiesMember 2024-01-012024-09-30 0000899460 mnkd:MilestoneRightsLiabilityMemberus-gaap:MeasurementInputEntityCreditRiskMember 2023-12-31 0000899460 mnkd:PromissoryNotesMembermnkd:NewLoanArrangementMembermnkd:TheMannGroupLLCMember 2019-08-31 0000899460 mnkd:DavidThomsonMember 2024-07-012024-09-30 0000899460 srt:MinimumMembermnkd:FinancingLiabilityMember 2024-09-30 0000899460 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000899460 us-gaap:RelatedPartyMember 2023-12-31 0000899460 us-gaap:SeniorNotesMemberus-gaap:PrivatePlacementMember 2021-03-31 0000899460 mnkd:MannGroupConvertibleNoteMember 2023-01-012023-12-31 0000899460 srt:MinimumMember 2024-01-012024-09-30 0000899460 mnkd:ConvertiblePromissoryNoteMembermnkd:ThironaBioIncMember 2024-06-30 0000899460 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-12-31 0000899460 mnkd:DavidThomsonMember 2024-09-30 0000899460 us-gaap:SeniorNotesMember 2023-12-31 0000899460 us-gaap:MachineryAndEquipmentMember 2023-12-31 0000899460 mnkd:MilestoneRightsLiabilityMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-09-30 0000899460 us-gaap:MachineryAndEquipmentMember 2024-09-30 0000899460 mnkd:TyvasoDPIMember 2024-01-012024-09-30 0000899460 mnkd:PulmatrixIncMember 2024-05-282024-05-28 0000899460 mnkd:EmployeeMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-07-012024-09-30 0000899460 2024-06-30 0000899460 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0000899460 mnkd:RestrictedStockUnitsAndMarketRestrictedStockUnitsMember 2023-07-012023-09-30 0000899460 mnkd:ConvertiblePromissoryNoteMembermnkd:NewLoanArrangementMembermnkd:TheMannGroupLLCMember 2019-08-31 0000899460 mnkd:MilestoneRightsLiabilityMembermnkd:DeerfieldManagementCompanyLpMember 2023-12-31 0000899460 us-gaap:RoyaltyMember 2024-01-012024-09-30 0000899460 mnkd:EmployeeMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-012024-03-31 0000899460 us-gaap:CommonStockMember 2023-04-012023-06-30 0000899460 mnkd:ContingentMilestoneLiabilityMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0000899460 mnkd:AmortizedCostMember 2023-12-31 0000899460 mnkd:NextGenResearchAndDevelopmentServicesMembermnkd:UnitedTherapeuticsCorporationMemberus-gaap:TransferredOverTimeMembermnkd:CollaborationAndLicenseAgreementMember 2022-12-012022-12-31 0000899460 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 iso4217:EUR pure mnkd:Employees shares mnkd:Distributor utr:D mnkd:ConsecutiveMonth mnkd:Note mnkd:Segment iso4217:USD iso4217:USD shares mnkd:Installment--12-31Q3false0000899460 P2YP3YP4YP2YP3YP4YP2YP3YP4Yhttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#FinanceLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent2024 2025 20262025 2026P379DP366D10-Qtrue2024-09-302024false000-50865MannKind CorporationDE13-36077361 Casper StreetDanburyCT06810818661-5000Common Stock, par value $0.01 per shareMNKDNASDAQYesYesLarge Accelerated Filerfalsefalsefalse2757776931972800017927000592720005383400023268000131080007413000035705000270830002021800075326000509510007007900051253000206245400020650005260008600005731900041560001626360001396700001276000050970004609200082000031790001580000979000044290004089000127200002470000245900073610007050000-1550000932000110000-3376000-24019000-14159000128700001721000220730001333900013200001907000115500001721000201660001333900000.040.010.07-0.052749980002687320002728110002661260000.040.010.07-0.052846930003237700002814070002661260001155000017210002016600013339000588000588000443000121380001721000207540001289600062373000238480000189215000566190001818400014901000266630002854500031229000348480003276400037339300073500016796000715500085339000843209241000-3229407000-2099260000-2461680004642000004751980026379300026380002964293000-3217469000-2505380002690003000119600011990002400024000206000200050000520001100055000550003655000365500097950000-979500026427900026430002969225000-3227264000-2553960003620004000157900015830001700017000130005400054000327900032000-8576000-8544000266000300092000092300055800005580000360001520001520004430004430005265000-52650002682350002682000296891700044300032332529000-2604870004700080004097000410500067000670001300010005500056000448000400017120000-1708000460100046010001721000172100026954300026950002975891000443000-3230808000-2517790002700340002700000298053900032294070002461680004160001361000136100033700030000263000266000150005600056000388500038850001063000010630000270802000270300029861040003218777000-2299700001855000190004952000-4933000150000015000373500037500003100003000956000959000642800064280000-2014000-2014000274467000274000029922710003220791000-2257800001308000130001524000-1511000522700052270005588000558800011550000115500002757750002753000299597400058800032092410002099260002016600013339000154400013836000127200007050000521100033100019090003659000155000093200144400013330001570000114000097800052600008600005600016500049000-1300075330005259000376500042000037280005021000270009004000644200085160002821000350003136000570200048090003824000-7211000337220002689000-6810000-1407000-1778000198670001241600027378900050516000135317000926080006797000365670003960003820001448730005907000366170001667000885400061780001020000032000010750007520009240002820001377000300068870001080005036600005074000175372000132490002384800006976700063108000830160001361600079780001961000100570004300000380600016500029120001486000249000095900022600007280000style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">1. Description of Business and Significant Accounting Policies The unaudited condensed consolidated financial statements of MannKind Corporation and its subsidiaries (“MannKind,” the “Company,” “we” or “us”), have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 27, 2024 (the “Annual Report”). In the opinion of management, all adjustments, consisting only of normal, recurring adjustments, considered necessary for a fair presentation of the results of these interim periods have been included. The results of operations for the three and nine months ended September 30, 2024 may not be indicative of the results that may be expected for the full year. Financial Statement Estimates — The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and notes. Actual results could differ from those estimates or assumptions. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. These effects could have a material impact on the estimates and assumptions used in the preparation of the condensed consolidated financial statements. The more significant estimates include revenue recognition, including gross-to-net adjustments, stand-alone selling price considerations for recognition of collaboration revenue, assessing long-lived assets for impairment, clinical trial expenses, inventory costing, stock-based compensation, the determination of the provision for income taxes and corresponding deferred tax assets and liabilities, the valuation allowance recorded against net deferred tax assets, and expected cash flows from royalties received in connection with United Therapeutics‘ (“UT’s”) net revenue for the sale of Tyvaso DPI. Business — MannKind is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The Company’s signature technologies—Technosphere dry-powder formulations and Dreamboat inhalation devices—offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. The Company is currently commercializing Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. The first product to come out of the orphan lung disease pipeline, Tyvaso DPI (treprostinil) inhalation powder, received approval from the U.S. Food and Drug Administration (“FDA”) in May 2022 for the treatment of pulmonary arterial hypertension (“PAH”) and for the treatment of pulmonary hypertension associated with interstitial lung disease (“PH-ILD”). The Company’s development and marketing partner, UT, began commercializing Tyvaso DPI in June 2022 and is obligated to pay a 10% royalty on net sales of the product, of which 9% is allocated to the Company and 1% to another party as detailed in Note 15 – <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-

width:fit-content;">Commitments and Contingencies. The Company also receives a margin on supplies of Tyvaso DPI that it manufactures for UT. Basis of Presentation — The condensed consolidated financial statements have been prepared in accordance with GAAP. Principles of Consolidation — The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated. Reclassifications — Certain amounts reported in the prior period have been reclassified to conform with current period presentation. The Company has separated non-cash accretion income on investments from other, net, and presented it as net accretion of investments in the condensed consolidated statements of cash flows. The Company has also presented non-cash interest accretion on financing liability in other, net. Additionally, the Company has combined accruals for the Danbury facility buildout with other in Note 8 - Accrued Expenses and Other Current Liabilities. Segment Information — Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and manages its business as one segment operating in the United States of America ("U.S."). Revenue Recognition — The Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC 606, including when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company has two types of contracts with customers: (i) contracts for commercial product sales with wholesale distributors, specialty and retail pharmacies, and durable medical equipment suppliers ("DMEs") and (ii) collaboration arrangements. Revenue Recognition — Net Revenue — Commercial Product Sales — The Company sells its products to a limited number of wholesale distributors, specialty and retail pharmacies, and DMEs in the U.S. (collectively, its "Customers"). Wholesale distributors subsequently resell the Company's products to retail pharmacies and certain medical centers or hospitals. Specialty and retail pharmacies sell directly to patients. In addition to distribution agreements with Customers, the Company enters into arrangements with payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company's products. The Company transfers control and recognizes revenue upon delivery of product to wholesale distributors and specialty pharmacies. The Company transfers control and recognizes revenue on product sales to a retail pharmacy as the product is dispensed to patients. Product revenues are recorded net of applicable reserves, including discounts, allowances, rebates, returns and other incentives. See Reserves for Variable Consideration below. Reserves for Variable Consideration — Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its Customers, payers, and other indirect customers relating to the Company's sale of its products. These reserves, as further detailed below, are based on the amounts earned, or to be claimed on the related sales, and result in a reduction of accounts receivable or establishment of a current liability. Significant judgment is required in estimating gross-to-net adjustments, including historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, claim submission time lags and inventory levels in the distribution channel. Where appropriate, these estimates take into consideration a range of possible outcomes, which are probability-weighted in accordance with the expected value method in ASC 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reduce recognized revenue to the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company's analysis also contemplates application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the current period estimates of gross-to-net adjustments and, therefore, the transaction price was not reduced further during the current period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from the Company's estimates, the Company will adjust these estimates, which would affect net revenue from commercial product sales and earnings in the period such variances become known. Trade Discounts and Allowances — The Company generally provides Customers with discounts which include incentives, such as prompt pay discounts, that are explicitly stated in the Company's contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its Customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company's sale of products to the Customer and, therefore, these payments have been recorded as a reduction of revenue and as a reduction to accounts receivable, net. Product Returns — Consistent with industry practice, the Company generally offers Customers a right of return for unopened product that has been purchased from the Company for a period beginning six months prior to and ending 12 months after its expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as reductions to accounts receivable, net. The Company currently estimates product returns using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company's current return reserve percentage is estimated to be in the single digits. Adjustments to the returns reserve are made when changes in the Company's assumptions result in revised estimates. Provider Chargebacks and Discounts — Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase products from the Company. Customers charge the Company for the difference between what they pay for products and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is recorded in accrued expenses and other current liabilities. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by Customers, and the Company generally issues credits for such amounts within a few weeks of the Customer's notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold to qualified healthcare providers, and chargebacks that Customers have claimed, but for which the Company has not yet issued a credit. Government Rebates — The Company is subject to discount obligations under Medicare and state Medicaid programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses and other current liabilities.

Estimates around Medicaid have historically required significant judgment due to timing lags in receiving invoices for claims from states. For Afrezza, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company's liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for products that have been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. The Company's estimates include consideration of historical claims experience, payer channel mix, current contract prices, unbilled claims, claim submission time lags and inventory in the distribution channel. Payer Rebates — The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates, including estimates for product that has been recognized as revenue, but which remains in the distribution channel, and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities. The Company's estimates include consideration of historical claims experience, payer channel mix, current contract prices, unbilled claims, claim submission time lags and inventory in the distribution channel. Other Incentives — Other incentives which the Company offers include voluntary patient support programs, such as the Company's co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with co-payments required by payers. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with the products that have been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses and other current liabilities. Revenue Recognition — Revenue — Collaborations and Services — The Company enters into licensing, research or other agreements under which the Company licenses certain rights to its product candidates to third parties, conducts research or provides other services to third parties. The terms of these arrangements may include but are not limited to payment to the Company of one or more of the following: up-front license fees; development, regulatory, and commercial milestone payments; payments for commercial manufacturing and clinical supply services the Company provides; and royalties on net sales of licensed products and sublicenses of the rights. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment such as determining the performance obligation in the contract and determining the stand-alone selling price for each performance obligation identified in the contract. With respect to the Company's significant collaboration and service agreement with UT that includes a long-term commercial supply agreement (as amended, the "CSA"), the Company has identified three distinct performance obligations: (1) the license, supply of product to be used in clinical development, and continued development and approval support for Tyvaso DPI ("R&D Services and License"); (2) development activities for the next generation of the product ("Next-Gen R&D Services"); and (3) a material right associated with current and future manufacturing and supply of product ("Manufacturing Services and Product Sales"). Pre-production activities under the CSA, such as facility expansion services and other administrative services, were considered bundled services under the Manufacturing Services and Product Sales performance obligation as required by ASC 606. Following the FDA's approval of Tyvaso DPI, UT began issuing purchase orders for the supply of product, which represents distinct contracts and performance obligations under ASC 606. Revenue is recognized for the supply of product at a point in time, once control is transferred to UT. See Note 10 – Collaboration, Licensing and Other Arrangements. If an arrangement has multiple performance obligations, the allocation of the transaction price is determined from observable market inputs, and the Company uses key assumptions to determine the stand-alone selling price, which may include development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success. Revenue is recognized based on the measurement of progress as the performance obligation is satisfied and consideration received that does not meet the requirements to satisfy the revenue recognition criteria is recorded as deferred revenue. Current deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. For further information, see Note 10 – Collaboration, Licensing and Other Arrangements. The Company recognizes upfront license payments as revenue upon delivery of the license only if the license is determined to be a separate unit of accounting from the other undelivered performance obligations. The undelivered performance obligations typically include manufacturing or development services or research and/or steering committee services. If the license is not considered as a distinct performance obligation, then the license and other undelivered performance obligations would be evaluated to determine if such should be accounted for as a single unit of accounting. If concluded to be a single performance obligation, the transaction price for the single performance obligation is recognized as revenue over the estimated period of when the performance obligation is satisfied. If the license is considered to be a distinct performance obligation, then the estimated revenue is included in the transaction price for the contract, which is then allocated to each performance obligation based on the respective standalone selling prices. Whenever the Company determines that an arrangement should be accounted for over time, the Company determines the period over which the performance obligations will be performed, and revenue will be recognized over the period the Company is expected to complete its performance obligations. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. The Company's collaboration agreements typically entitle the Company to additional payments upon the achievement of development, regulatory and sales milestones. If the achievement of a milestone is considered probable at the inception of the collaboration, the related milestone payment is included with other collaboration consideration, such as upfront fees and research funding, in the Company's revenue calculation. If these milestones are not considered probable at the inception of the collaboration, the milestones will typically be recognized in one of two ways depending on the timing of when the milestone is achieved. If the milestone is improbable at inception and subsequently deemed probable of achievement, such will be added to the transaction price, resulting in a cumulative adjustment to revenue. If the milestone is achieved after the performance period has been completed and all performance obligations have been delivered, the Company will recognize the milestone payment as revenue in its entirety in the period the milestone was achieved. The Company's collaboration agreements, for accounting purposes, represent contracts with customers and therefore are not subject to accounting literature on collaboration agreements. The Company grants licenses to its intellectual property, supplies raw materials, semi-finished goods or finished goods, provides research and development services and offers sales support for the co-promotion of products, all of which are outputs of the Company's ongoing activities, in exchange for consideration. Accordingly, the Company concluded that its collaboration agreements must generally be accounted for pursuant to ASC 606. For collaboration agreements that allow collaboration partners to select additional optioned products or services, the Company evaluates whether such options contain material rights (i.e., have exercise prices that are discounted compared to what the Company would charge for a similar product or service to a new collaboration partner). The exercise price of these options includes a combination of licensing fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, the Company concludes the option does not contain a material right, and therefore is not included in the transaction price at contract inception. The Company assessed the long-term commercial supply agreement with UT (as amended, the "CSA") and determined that a material right existed for the manufacturing services performance obligation. The transaction price is allocated to the material right as well as the remaining performance obligations in accordance with ASC 606. The Company also evaluates grants of additional licensing rights upon option exercises to determine whether such should be accounted for as separate contracts. Revenue Recognition — Royalties — The Company recognizes royalty revenue for a sales-based or usage-based royalty if it is promised in exchange for an intellectual property license. The royalty revenue is recognized as the latter of the subsequent sale of the product occurs or if the performance obligation to which the royalty has been allocated has been satisfied or partially satisfied. The Company's UT License Agreement (as defined in Note 10 – Collaboration, Licensing and Other Arrangements) entitles it to receive a 10% royalty on net sales of Tyvaso DPI for the license of the Company's IP that was considered to be interdependent with the development activities that supported the approval of Tyvaso DPI. Although the Company recognizes a 10% royalty on net revenue from the sale of Tyvaso DPI as revenue, it only collects 9% due to its sale in December 2023 of 1% of future royalties as detailed in Note 15 – Commitments and Contingencies. The Company's net revenue and cost of revenue and goods sold as shown on the condensed consolidated statement of operations is comprised of revenue generated from product sales, services and royalties as shown below (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.07%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td

style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Net revenue: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Product revenue (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">42,959</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 30,727 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">132,945</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 88,731 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Services (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 308 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 457 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 808 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-

left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Royalties (3) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,083 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 20,218 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 75,326 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,951 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total net revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">70,079</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 51,253 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">208,728</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 140,490 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> _____ (1) Amounts represent the revenue from Afrezza and V-Go sales to wholesalers and specialty pharmacies and Tyvaso DPI to UT. (2) Amounts represent revenue generated from the Company's collaboration arrangements, including Next-Gen R&D Services (as defined in Note 10) for UT as well as arrangements with other collaboration partners. See Note 10 - Collaboration, Licensing and Other Arrangements. (3) Amounts represent royalties on UT's net revenue from Tyvaso DPI sales. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cost of goods sold and cost of revenue: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Product revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,023</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,983 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">56,651</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content,">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44,006 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 271 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 347 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 698 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total cost of goods sold and cost of revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,023</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,254 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">56,998</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content,">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 44,704 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The Company follows accounting guidance in measuring revenue and certain judgments affect the application of its revenue policy. For example, in connection with its existing collaboration agreements, the Company has recorded short-term and long-term deferred revenue on its condensed consolidated balance sheets based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. However, this estimate is based on the Company's current project development plan and, if the development plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period. <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-

family:Times New Roman;font-style:italic;min-width:fit-content;">Milestone Payments — At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the customer, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as, or when, the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration, other revenue, and earnings in the period of adjustment. Cost of Goods Sold — Cost of goods sold includes material, labor costs and manufacturing overhead. Cost of goods sold also includes a component of current period manufacturing costs in excess of costs capitalized into inventory (“excess capacity costs”). These costs, in addition to the impact of the revaluation of inventory for standard costing, and write-offs of inventory are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. Cost of goods sold excludes the cost of insulin purchased under the Company’s Insulin Supply Agreement (the “Insulin Supply Agreement”) with Amphastar Pharmaceuticals, Inc. (“Amphastar”). All insulin inventory on hand was written off and the full purchase commitment contract to purchase future insulin was accrued as a recognized loss on purchase commitments as of the end of 2016. Cost of Revenues — Collaborations and Services — Cost of revenues for collaborations and services includes material, labor costs, manufacturing overhead, and excess capacity costs. These costs, in addition to the write-offs of inventory are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. Cost of revenues for collaborations and services also includes the cost of product development. Research and Development (“R&D”) — Clinical trial expenses result from obligations under contracts with vendors, consultants and clinical site agreements in addition to internal costs associated with conducting clinical trials. R&D costs are expensed as incurred. Clinical study and certain research costs are recognized over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Nonrefundable advance payments for services to be received in the future for use in R&D activities are recorded as prepaid assets and expensed in the period when the services are performed. Cash, Cash Equivalents and Restricted Cash — The Company considers all highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase that are readily convertible into cash to be cash equivalents. As of September 30, 2024 and December 31, 2023, cash equivalents were comprised of money market funds, U.S. Treasury securities, corporate bonds and commercial paper with original maturities less than 90 days from the date of purchase. The Company records restricted cash when cash and cash equivalents are restricted as to withdrawal or usage. Restricted cash under a letter of credit issued in connection with a facility lease assumed by the Company that will not be available for use in the Company’s operations within 12 months of the reporting date is presented in non-current assets. See Note 2 - Pulmatrix Transaction. Held-to-Maturity Investments — The Company’s investments generally consist of commercial paper, corporate notes or bonds and U.S. Treasury securities. As of September 30, 2024 and December 31, 2023, the Company held short-term and long-term investments of debt securities, including commercial paper and bonds. The Company intends to hold its investments until maturity; therefore, these investments are stated at amortized cost. The investments with maturities less than 12 months are included in short-term investments and investments with maturities in excess of twelve months are included in long-term investments in the condensed consolidated balance sheets. The amortization or accretion of the Company’s investments is recognized as interest income in the condensed consolidated statements of operations. Available-for-Sale Investment— In June 2021, the Company purchased a $3.0 million convertible promissory note issued by Thirona Bio, Inc. (“Thirona”). In January 2022, the Company purchased an additional $5.0 million convertible promissory note issued by Thirona (the “Thirona convertible notes”). The Thirona convertible notes are general unsecured obligations of Thirona and initially accrued interest at a rate of 6% per annum. Unless earlier converted into conversion shares pursuant to the note purchase agreement, the aggregate principal of $8.0 million and accrued interest shall be due and payable by Thirona on demand by the Company at any time after the maturity date. The Thirona convertible notes were amended in February 2023 to extend the maturity date from December 31, 2022 to June 30, 2024, and again on June 27, 2024 to extend the maturity date to June 30, 2026 and increase the interest rate to 10% per annum. The Thirona convertible notes are classified as available-for-sale securities and included in other assets as of September 30, 2024 and prepaid expense and other current assets as of December 31, 2023 in the condensed consolidated balance sheets. The Company periodically assesses whether it has any intention to sell the investment, determines the fair value of its available-for-sale investment using level 3 inputs and assesses whether there were other-than-temporary impairments associated with the investment. Unrealized holding gains and losses are excluded from earnings and reported in other comprehensive income until realized, while unrealized losses related to credit risk are reported through earnings in the period incurred. Concentration of Credit Risk — Financial instruments that potentially subject the Company to concentration of credit risk consisted of cash and cash equivalents and investments. Cash and cash equivalents are held in high credit quality institutions. Cash equivalents consisted of interest-bearing money market funds and U.S. Treasury securities with original or remaining maturities of 90 days or less at the time of purchase. Investments generally consisted of commercial paper, corporate notes or bonds and U.S. Treasury securities. The cash equivalents and investments are regularly monitored by management. Accounts Receivable and Allowance for Credit Losses — Accounts receivable are recorded at the invoiced amount and are not interest bearing. Accounts receivable are presented net of an allowance for credit losses if there are estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for credit losses. The allowance for expected credit losses is based primarily on past collections experience relative to the length of time receivables are past due. However, when available evidence reasonably supports an assumption that future economic conditions will differ from current and historical payment collections, an adjustment is reflected in the allowance for expected credit losses. Accounts receivable are also presented net of an allowance for product returns and trade discounts and allowances because the Company’s customers have the right of setoff for these amounts against the related accounts receivable. Pre-Launch Inventory — An improvement to the manufacturing process for the Company’s primary excipient, fumaryl diketopiperazine (“FDKP”) was demonstrated to be viable and management expects to realize an economic benefit in the future as a result of such process improvement. Accordingly, the Company is required to assess whether to capitalize inventory costs related to such excipient prior to validation of the improved manufacturing process and adoption of the new supplier. In doing so, management must consider a number of factors in order to determine the amount of inventory to be capitalized, including the historical experience of modifying the Company’s manufacturing processes, feedback from technical experts and regulatory agencies on the changes being effected and the amount of inventory that is likely to be used in commercial production. The shelf life of the excipient will be determined as part of the validation process; in the interim, the Company must assess the available stability data to determine whether there is likely to be adequate shelf life to support anticipated future sales occurring beyond the expected adoption date of the new raw material. If management is aware of any specific material risks or contingencies other than the normal regulatory reporting process, or if the criteria for capitalizing inventory produced prior to regulatory approval are otherwise not met, the Company would not capitalize such inventory costs, choosing instead to recognize such costs as R&D expense in the period incurred. See Note 5 - Inventories. <div style="font-size:10pt;font-family:Times New

Roman;"> Inventories — Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. The Company capitalizes inventory costs associated with the Company's products based on management's judgment that future economic benefits are expected to be realized; otherwise, such costs are expensed as incurred as cost of goods sold. The Company uses a contract manufacturing organization outside of the U.S. for certain stages of V-Go inventory. The Company periodically analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value and writes down such inventories, as appropriate. In addition, the Company's products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or may become obsolete or are forecasted to become obsolete due to expiration, the Company will record a charge to write down such unmarketable inventory to its estimated net realizable value. The Company analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company performs an assessment of projected sales and evaluates the lower of cost or net realizable value and the potential excess inventory on hand at the end of each reporting period. Property and Equipment — Property and equipment is recorded at historical cost, net of accumulated depreciation. Depreciation expense is recorded over the assets' useful lives on a straight-line basis and included in cost of goods sold, research and development, and general and administrative expense in the condensed consolidated statements of operations. See Note 6 - Property and Equipment. Impairment of Long-Lived Assets — Long-lived assets include property and equipment, operating lease right-of-use assets and other intangible assets. The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Assets are considered to be impaired if the carrying value is considered to be unrecoverable. If the Company believes an asset to be impaired, the impairment recognized is the amount by which the carrying value of the asset exceeds the fair value of the asset. Fair value is determined using the market, income or cost approaches as appropriate for the asset. Any write-downs are treated as permanent reductions in the carrying amount of the asset and recognized as an operating loss. Acquisitions — The Company first determines whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, the Company accounts for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process R&D ("IPR&D"), and liabilities assumed are recorded at their respective fair values as of the acquisition date in the Company's condensed consolidated financial statements. Leases are recorded at the net present value of the remaining lease payments. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. A gain on bargain purchase is recorded if the fair value of the net assets acquired exceeds the fair value of the consideration transferred. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree's liability arising from an acquisition it consummated prior to the Company's acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&D projects with no alternative future use are recorded in R&D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. Goodwill and Other Intangible Assets — The fair value of acquired intangible assets is determined using either a cost approach or an income approach. The cost approach establishes fair value based on the cost of reproducing or replacing the asset, less depreciation for functional or economic obsolescence. The income approach, referred to as the excess earnings method, utilizes Level 3 fair value inputs to determine the present value of future economic benefits to be derived from ownership of the intangible asset. Market participant valuations assume a global view considering all potential jurisdictions and indications based on discounted after-tax cash flow projections, risk adjusted for estimated probability of technical and regulatory success. The Company tests for impairment annually on a reporting unit basis, at the beginning of the Company's fourth fiscal quarter and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying amount. To the extent the carrying amount of a reporting unit is less than its estimated fair value, an impairment charge will be recorded. Finite-lived intangible assets are amortized on a straight-line basis over the estimated useful life. Estimated useful lives are determined considering the period assets are expected to contribute to future cash flows. Finite-lived intangible assets are tested for impairment when facts or circumstances suggest that the carrying value of the asset may not be recoverable. If the carrying value exceeds the projected undiscounted pretax cash flows of the intangible asset, an impairment loss equal to the excess of the carrying value over the estimated fair value (discounted after-tax cash flows) is recognized. IPR&D acquired in a business combination is considered an indefinite-lived intangible asset until the completion or abandonment of the associated R&D efforts. During the R&D period, the asset is not amortized but rather is tested for impairment when facts or circumstances suggest that the carrying value of the asset may not be recoverable. Once the R&D efforts are completed, the Company accounts for the resulting asset as a finite-lived intangible asset. If the R&D efforts are abandoned, the asset balance is written off to R&D expense. Recognized Loss on Purchase Commitments — The Company reviews the terms of the long-term supply agreements and assesses the need for any accrual for estimated losses, such as lower of cost or net realizable value, that will not be recovered by future product sales. The recognized loss on purchase commitments is reduced as inventory items are received or as the liability is extinguished. See Note 15 - Commitments and Contingencies. Milestone Rights Liability — In July 2013, in conjunction with the execution of a (now repaid) loan agreement with Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively, "Deerfield"), the Company entered into a Milestone Rights Purchase Agreement (the "Milestone Rights Agreement") pursuant to which the Company issued certain milestone rights to Deerfield Private Design Fund II, L.P. and Horizon Santé FLML SARL (the "Original Milestone Purchasers"). The foregoing milestone rights provided the Original Milestone Purchasers certain rights to receive payments of up to $90.0 million upon the occurrence of specified strategic and Afrezza sales milestones, <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$50.0 million of which remains payable as of September 30, 2024 upon achievement of such milestones (collectively, the "Milestone Rights"). In December 2021, the Milestone Rights were purchased by Barings Global Special Situations Credit Fund 4 (Delaware), L.P. and Barings Global Special Situations Credit 4 (LUX) S.ar.l. (together, the "Milestone Purchasers"). As a result, the Milestone Purchasers have assumed the obligations of the Original Milestone Purchasers and are now entitled to all rights under the Milestone Rights Agreement. The Milestone Rights liability is reported at fair value at the date of the agreement which is periodically offset against payments. See Note 11 - Fair Value of Financial Instruments. The initial fair value estimate of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones and discounted to present value using a selected market discount rate. The expected timing and probability of achieving the milestones was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. The Milestone Rights liability is remeasured as the specified milestone events are achieved. Specifically, as each milestone event is achieved, the portion of the initially recorded Milestone Rights liability that pertains to the milestone event being achieved, is remeasured to the amount of the specified related milestone payment. The resulting change in the balance of the Milestone Rights liability due to remeasurement is recorded in the Company's condensed consolidated statements of operations as interest expense. Furthermore, the Milestone Rights liability is reduced upon the settlement of each milestone payment. As a result, each milestone payment is effectively allocated between a reduction of the recorded Milestone Rights liability and an expense representing a return on a portion of the Milestone Rights liability paid to the investor for the achievement of the related milestone event. See Note 8 - Accrued Expenses and Other Current Liabilities and Note 15 - Commitments and Contingencies. <div

style="font-size:10pt;font-family:Times New Roman;"> Fair Value of Financial Instruments — The Company applies various valuation approaches in determining the fair value of its financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 — Quoted prices for identical instruments in active markets. Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 — Significant inputs to the valuation model are unobservable. Income Taxes — The provisions for federal, foreign, state and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized. For uncertain tax positions, the Company determines whether it is "more likely than not" that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit can be recorded in the financial statements. For those tax positions where it is "not more likely than not" that a tax benefit will be sustained, no tax benefit is recognized. Penalties, if probable and reasonably estimable, are recognized as a component of income tax expense. The Company has reduced its deferred tax assets for uncertain tax positions but has not recorded liabilities for income tax expense, penalties, or interest. Contingencies — The Company records a loss contingency for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These accruals represent management's best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may revise its estimates. Stock-Based Compensation — Share-based payments to employees, including grants of restricted stock units ("RSUs"), performance-based non-qualified stock options awards ("PNQs"), restricted stock units with market conditions ("Market RSUs"), options and the compensatory elements of employee stock purchase plans, are recognized in the condensed consolidated statements of operations based upon the fair value of the awards at the grant date. RSUs are valued based on the market price on the grant date. Market RSUs are valued using a Monte Carlo valuation model and RSUs with performance conditions are evaluated for the probability that the performance conditions will be met and estimates the date at which the performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period. The Company uses the Black-Scholes option valuation model to estimate the grant date fair value of employee stock options and the compensatory elements of employee stock purchase plans. Net Income (Loss) Per Share of Common Stock — Basic net income or loss per share ("EPS") is calculated by dividing net income by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the effect of potential common stock issuances resulting from assumed stock option exercises and vesting of restricted stock units, unless the effect is anti-dilutive, when applying the treasury stock method, as well as potential dilution under the if-converted method for convertible debt securities. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted EPS as they would be anti-dilutive. Recently Issued Accounting Standards — In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). This ASU requires disaggregated information about a public entity's effective tax rate reconciliation as well as additional information on income taxes paid. This ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact of the guidance on its condensed consolidated financial statement disclosures. From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company's condensed consolidated financial position or results of operations upon adoption. Business — MannKind is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The Company's signature technologies—Technosphere dry-powder formulations and Dreamboat inhalation devices—offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. The Company is currently commercializing Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. The first product to come out of the orphan lung disease pipeline, Tyvaso DPI (treprostinil) inhalation powder, received approval from the U.S. Food and Drug Administration ("FDA") in May 2022 for the treatment of pulmonary arterial hypertension ("PAH") and for the treatment of pulmonary hypertension associated with interstitial lung disease ("PH-ILD"). The Company's development and marketing partner, UT, began commercializing Tyvaso DPI in June 2022 and is obligated to pay a 10% royalty on net sales of the product, of which 9% is allocated to the Company and 1% to another party as detailed in Note 15 - Commitments and Contingencies. The Company also receives a margin on supplies of Tyvaso DPI that it manufactures for UT. 0.100.090.01 Basis of Presentation — The condensed consolidated financial statements have been prepared in accordance with GAAP. Principles of Consolidation — The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated. Reclassifications — Certain amounts reported in the prior period have been reclassified to conform with current period presentation. The Company has separated non-cash accretion income on investments from other, net, and presented it as net accretion of investments in the condensed consolidated statements of cash flows. The Company has also presented non-cash interest accretion on financing liability in other, net. Additionally, the Company has combined accruals for the Danbury facility buildout with other in Note 8 - Accrued Expenses and Other Current Liabilities. Segment Information — Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and manages its business as one segment operating in the United States of America ("U.S."). 1 Revenue Recognition — The Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts

with Customers (“ASC 606”), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC 606, including when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company has two types of contracts with customers: (i) contracts for commercial product sales with wholesale distributors, specialty and retail pharmacies, and durable medical equipment suppliers ("DMEs") and (ii) collaboration arrangements. Revenue Recognition — Net Revenue — Commercial Product Sales — The Company sells its products to a limited number of wholesale distributors, specialty and retail pharmacies, and DMEs in the U.S. (collectively, its “Customers”). Wholesale distributors subsequently resell the Company’s products to retail pharmacies and certain medical centers or hospitals. Specialty and retail pharmacies sell directly to patients. In addition to distribution agreements with Customers, the Company enters into arrangements with payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company transfers control and recognizes revenue upon delivery of product to wholesale distributors and specialty pharmacies. The Company transfers control and recognizes revenue on product sales to a retail pharmacy as the product is dispensed to patients. Product revenues are recorded net of applicable reserves, including discounts, allowances, rebates, returns and other incentives. See Reserves for Variable Consideration below. Reserves for Variable Consideration — Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its Customers, payers, and other indirect customers relating to the Company’s sale of its products. These reserves, as further detailed below, are based on the amounts earned, or to be claimed on the related sales, and result in a reduction of accounts receivable or establishment of a current liability. Significant judgment is required in estimating gross-to-net adjustments, including historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, claim submission time lags and inventory levels in the distribution channel. Where appropriate, these estimates take into consideration a range of possible outcomes, which are probability-weighted in accordance with the expected value method in ASC 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reduce recognized revenue to the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analysis also contemplates application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the current period estimates of gross-to-net adjustments and, therefore, the transaction price was not reduced further during the current period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net revenue from commercial product sales and earnings in the period such variances become known. Trade Discounts and Allowances — The Company generally provides Customers with discounts which include incentives, such as prompt pay discounts, that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its Customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company’s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of revenue and as a reduction to accounts receivable, net. Product Returns — Consistent with industry practice, the Company generally offers Customers a right of return for unopened product that has been purchased from the Company for a period beginning six months prior to and ending 12 months after its expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as reductions to accounts receivable, net. The Company currently estimates product returns using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company’s current return reserve percentage is estimated to be in the single digits. Adjustments to the returns reserve are made when changes in the Company’s assumptions result in revised estimates. Provider Chargebacks and Discounts — Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase products from the Company. Customers charge the Company for the difference between what they pay for products and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is recorded in accrued expenses and other current liabilities. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by Customers, and the Company generally issues credits for such amounts within a few weeks of the Customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold to qualified healthcare providers, and chargebacks that Customers have claimed, but for which the Company has not yet issued a credit. Government Rebates — The Company is subject to discount obligations under Medicare and state Medicaid programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses and other current liabilities. Estimates around Medicaid have historically required significant judgment due to timing lags in receiving invoices for claims from states. For Afrezza, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for products that have been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. The Company’s estimates include consideration of historical claims experience, payer channel mix, current contract prices, unbilled claims, claim submission time lags and inventory in the distribution channel. Payer Rebates — The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates, including estimates for product that has been recognized as revenue, but which remains in the distribution channel, and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities. The Company’s estimates include consideration of historical claims experience, payer channel mix, current contract prices, unbilled claims, claim submission time lags and inventory in the distribution channel. Other Incentives — Other incentives which the Company offers include voluntary patient support programs, such as the Company’s co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with co-payments required by payers. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with the products that have been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses and other current liabilities. P6MP12M Revenue Recognition — Revenue — Collaborations and Services — The Company enters into licensing, research or other agreements under which the Company licenses certain rights to its product candidates to third parties, conducts research or provides other services to third parties. The terms of these arrangements may include but are not limited to payment to the Company of one or more of the following: up-front license fees; development, regulatory, and commercial milestone payments; payments for commercial manufacturing and clinical supply services the Company provides; and royalties on net sales of licensed products and sublicenses of the rights. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment such as determining the performance obligation in the contract and determining the stand-alone selling price for each performance obligation identified in the contract. With respect to the Company’s significant collaboration and service agreement with UT that includes a long-term commercial supply agreement (as amended, the “CSA”), the Company has identified three distinct performance obligations: (1) the license, supply of product to be used in clinical development, and continued development and approval support for Tyvaso DPI (“R&D Services and License”); (2) development activities for the next generation of the product (“Next-Gen R&D Services”); and (3) a material right associated with current and future manufacturing and supply of product (“Manufacturing Services and Product Sales”). Pre-production activities under the CSA, such as facility expansion services and other administrative services, were considered bundled services under the Manufacturing Services and Product Sales performance obligation as required by ASC 606. Following the FDA’s

*approval of Tyvaso DPI, UT began issuing purchase orders for the supply of product, which represents distinct contracts and performance obligations under ASC 606. Revenue is recognized for the supply of product at a point in time, once control is transferred to UT. See Note 10 – Collaboration, Licensing and Other Arrangements. If an arrangement has multiple performance obligations, the allocation of the transaction price is determined from observable market inputs, and the Company uses key assumptions to determine the stand-alone selling price, which may include development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success. Revenue is recognized based on the measurement of progress as the performance obligation is satisfied and consideration received that does not meet the requirements to satisfy the revenue recognition criteria is recorded as deferred revenue. Current deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. For further information, see Note 10 – Collaboration, Licensing and Other Arrangements. The Company recognizes upfront license payments as revenue upon delivery of the license only if the license is determined to be a separate unit of accounting from the other undelivered performance obligations. The undelivered performance obligations typically include manufacturing or development services or research and/or steering committee services. If the license is not considered as a distinct performance obligation, then the license and other undelivered performance obligations would be evaluated to determine if such should be accounted for as a single unit of accounting. If concluded to be a single performance obligation, the transaction price for the single performance obligation is recognized as revenue over the estimated period of when the performance obligation is satisfied. If the license is considered to be a distinct performance obligation, then the estimated revenue is included in the transaction price for the contract, which is then allocated to each performance obligation based on the respective standalone selling prices. Whenever the Company determines that an arrangement should be accounted for over time, the Company determines the period over which the performance obligations will be performed, and revenue will be recognized over the period the Company is expected to complete its performance obligations. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. The Company's collaboration agreements typically entitle the Company to additional payments upon the achievement of development, regulatory and sales milestones. If the achievement of a milestone is considered probable at the inception of the collaboration, the related milestone payment is included with other collaboration consideration, such as upfront fees and research funding, in the Company's revenue calculation. If these milestones are not considered probable at the inception of the collaboration, the milestones will typically be recognized in one of two ways depending on the timing of when the milestone is achieved. If the milestone is improbable at inception and subsequently deemed probable of achievement, such will be added to the transaction price, resulting in a cumulative adjustment to revenue. If the milestone is achieved after the performance period has been completed and all performance obligations have been delivered, the Company will recognize the milestone payment as revenue in its entirety in the period the milestone was achieved. The Company's collaboration agreements, for accounting purposes, represent contracts with customers and therefore are not subject to accounting literature on collaboration agreements. The Company grants licenses to its intellectual property, supplies raw materials, semi-finished goods or finished goods, provides research and development services and offers sales support for the co-promotion of products, all of which are outputs of the Company's ongoing activities, in exchange for consideration. Accordingly, the Company concluded that its collaboration agreements must generally be accounted for pursuant to ASC 606. For collaboration agreements that allow collaboration partners to select additional optioned products or services, the Company evaluates whether such options contain material rights (i.e., have exercise prices that are discounted compared to what the Company would charge for a similar product or service to a new collaboration partner). The exercise price of these options includes a combination of licensing fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, the Company concludes the option does not contain a material right, and therefore is not included in the transaction price at contract inception. The Company assessed the long-term commercial supply agreement with UT (as amended, the "CSA") and determined that a material right existed for the manufacturing services performance obligation. The transaction price is allocated to the material right as well as the remaining performance obligations in accordance with ASC 606. The Company also evaluates grants of additional licensing rights upon option exercises to determine whether such should be accounted for as separate contracts. Revenue Recognition — Royalties — The Company recognizes royalty revenue for a sales-based or usage-based royalty if it is promised in exchange for an intellectual property license. The royalty revenue is recognized as the latter of the subsequent sale of the product occurs or if the performance obligation to which the royalty has been allocated has been satisfied or partially satisfied. The Company's UT License Agreement (as defined in Note 10 – Collaboration, Licensing and Other Arrangements) entitles it to receive a 10% royalty on net sales of Tyvaso DPI for the license of the Company's IP that was considered to be interdependent with the development activities that supported the approval of Tyvaso DPI. Although the Company recognizes a 10% royalty on net revenue from the sale of Tyvaso DPI as revenue, it only collects 9% due to its sale in December 2023 of 1% of future royalties as detailed in Note 15 – Commitments and Contingencies. The Company's net revenue and cost of revenue and goods sold as shown on the condensed consolidated statement of operations is comprised of revenue generated from product sales, services and royalties as shown below (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.07%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months
Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months
Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"><p style="font-

size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Net revenue; </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Product revenue (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">42,959</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 30,727 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">132,945</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 88,731 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Services (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 308 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 457 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 808 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Royalties (3) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,083 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 20,218 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 75,326 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,951 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total net revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-

wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 70,079 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">51,253</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 208,728 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">140,490</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">_____</p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;">(1)<div style="width:100%;display:inline;">Amounts represent the revenue from Afrezza and V-Go sales to wholesalers and specialty pharmacies and Tyvaso DPI to UT.</div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;">(2)<div style="width:100%;display:inline;">Amounts represent revenue generated from the Company's collaboration arrangements, including Next-Gen R&D Services (as defined in Note 10) for UT as well as arrangements with other collaboration partners. See Note 10 - Collaboration, Licensing and Other Arrangements. </div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;">(3)<div style="width:100%;display:inline;">Amounts represent royalties on UT's net revenue from Tyvaso DPI sales.</div></div><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.07%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months
Ended September 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months
Ended September 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cost of goods sold and cost of revenue:</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Product revenue</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,023 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,983 </td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">56,651</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44,006 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 271 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 347 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 698 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total cost of goods sold and cost of revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,023</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,254 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">56,998</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 44,704 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The Company follows accounting guidance in measuring revenue and certain judgments affect the application of its revenue policy. For example, in connection with its existing collaboration agreements, the Company has recorded short-term and long-term deferred revenue on its condensed consolidated balance sheets based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. However, this estimate is based on the Company's current project development plan and, if the development plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period. P12M0.100.100.090.01 The Company's net revenue and cost of revenue and goods sold as shown on the condensed consolidated statement of operations is comprised of revenue generated from product sales, services and royalties as shown below (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> <span style="white-space:pre-

wrap;min-width:fit-content;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Net revenue: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Product revenue (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">42,959</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 30,727 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">132,945</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 88,731 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Services (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 308 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 457 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 808 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Royalties (3) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,083 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 20,218 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 75,326 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,951 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;">

Total net revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">70,079</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 51,253 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">208,728</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 140,490 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> _____ (1) Amounts represent the revenue from Afrezza and V-Go sales to wholesalers and specialty pharmacies and Tyvaso DPI to UT. (2) Amounts represent revenue generated from the Company's collaboration arrangements, including Next-Gen R&D Services (as defined in Note 10) for UT as well as arrangements with other collaboration partners. See Note 10 - Collaboration, Licensing and Other Arrangements. (3) Amounts represent royalties on UT's net revenue from Tyvaso DPI sales. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.07%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months
Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months
Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> Cost of goods sold and cost of revenue: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Product revenue </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,023 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td>

<td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13,983</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 56,651 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">44,006</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Services</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">271</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">347</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">698</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total cost of goods sold and cost of revenue</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 18,023 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,254</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 56,998 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 44,704 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>42959000307270001329450008873100037000308000457000080800027083000202180007532600050951000700790005125300020872800014049000018023000131

Milestone Payments — At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the customer, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as, or when, the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration, other revenue, and earnings in the period of adjustment.

Cost of Goods Sold — Cost of goods sold includes material, labor costs and manufacturing overhead. Cost of goods sold also includes a component of current period manufacturing costs in excess of costs capitalized into inventory (“excess capacity costs”). These costs, in addition to the impact of the revaluation of inventory for standard costing, and write-offs of inventory are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. Cost of goods sold excludes the cost of insulin purchased under the Company’s Insulin Supply Agreement (the “Insulin Supply Agreement”) with Amphastar Pharmaceuticals, Inc. (“Amphastar”). All insulin inventory on hand was written off and the full purchase commitment contract to purchase future insulin was accrued as a recognized loss on purchase commitments as of the end of 2016.

Cost of Revenues — — Cost of revenues for collaborations and services includes material, labor costs, manufacturing overhead, and excess capacity costs. These costs, in addition to the write-offs of inventory are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. Cost of revenues for collaborations and services also includes the cost of product development.

Research and Development ("R&D") — Clinical trial expenses result from obligations under contracts with vendors, consultants and clinical site agreements in addition to internal costs associated with conducting clinical trials. R&D costs are expensed as incurred. Clinical study and certain research costs are recognized over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Nonrefundable advance payments for services to be received in the future for use in R&D activities are recorded as prepaid assets and expensed in the period when the services are performed.

Cash, Cash Equivalents and Restricted Cash — The Company considers all highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase that are readily convertible into cash to be cash equivalents. As of

September 30, 2024 and December 31, 2023, cash equivalents were comprised of money market funds, U.S. Treasury securities, corporate bonds and commercial paper with original maturities less than 90 days from the date of purchase. The Company records restricted cash when cash and cash equivalents are restricted as to withdrawal or usage. Restricted cash under a letter of credit issued in connection with a facility lease assumed by the Company that will not be available for use in the Company's operations within 12 months of the reporting date is presented in non-current assets. See Note 2 - Pulmatrix Transaction. Held-to-Maturity Investments — The Company's investments generally consist of commercial paper, corporate notes or bonds and U.S. Treasury securities. As of September 30, 2024 and December 31, 2023, the Company held short-term and long-term investments of debt securities, including commercial paper and bonds. The Company intends to hold its investments until maturity; therefore, these investments are stated at amortized cost. The investments with maturities less than 12 months are included in short-term investments and investments with maturities in excess of twelve months are included in long-term investments in the condensed consolidated balance sheets. The amortization or accretion of the Company's investments is recognized as interest income in the condensed consolidated statements of operations. Available-for-Sale Investment — In June 2021, the Company purchased a $3.0 million convertible promissory note issued by Thirona Bio, Inc. ("Thirona"). In January 2022, the Company purchased an additional $5.0 million convertible promissory note issued by Thirona (the "Thirona convertible notes"). The Thirona convertible notes are general unsecured obligations of Thirona and initially accrued interest at a rate of 6% per annum. Unless earlier converted into conversion shares pursuant to the note purchase agreement, the aggregate principal of $8.0 million and accrued interest shall be due and payable by Thirona on demand by the Company at any time after the maturity date. The Thirona convertible notes were amended in February 2023 to extend the maturity date from December 31, 2022 to June 30, 2024, and again on June 27, 2024 to extend the maturity date to June 30, 2026 and increase the interest rate to 10% per annum. The Thirona convertible notes are classified as available-for-sale securities and included in other assets as of September 30, 2024 and prepaid expense and other current assets as of December 31, 2023 in the condensed consolidated balance sheets. The Company periodically assesses whether it has any intention to sell the investment, determines the fair value of its available-for-sale investment using level 3 inputs and assesses whether there were other-than-temporary impairments associated with the investment. Unrealized holding gains and losses are excluded from earnings and reported in other comprehensive income until realized, while unrealized losses related to credit risk are reported through earnings in the period incurred. 30000005000000.00.0680000000.10 Concentration of Credit Risk — Financial instruments that potentially subject the Company to concentration of credit risk consisted of cash and cash equivalents and investments. Cash and cash equivalents are held in high credit quality institutions. Cash equivalents consisted of interest-bearing money market funds and U.S. Treasury securities with original or remaining maturities of 90 days or less at the time of purchase. Investments generally consisted of commercial paper, corporate notes or bonds and U.S. Treasury securities. The cash equivalents and investments are regularly monitored by management. Accounts Receivable and Allowance for Credit Losses — Accounts receivable are recorded at the invoiced amount and are not interest bearing. Accounts receivable are presented net of an allowance for credit losses if there are estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for credit losses. The allowance for expected credit losses is based primarily on past collections experience relative to the length of time receivables are past due. However, when available evidence reasonably supports an assumption that future economic conditions will differ from current and historical payment collections, an adjustment is reflected in the allowance for expected credit losses. Accounts receivable are also presented net of an allowance for product returns and trade discounts and allowances because the Company's customers have the right of setoff for these amounts against the related accounts receivable. Pre-Launch Inventory — An improvement to the manufacturing process for the Company's primary excipient, fumaryl diketopiperazine ("FDKP") was demonstrated to be viable and management expects to realize an economic benefit in the future as a result of such process improvement. Accordingly, the Company is required to assess whether to capitalize inventory costs related to such excipient prior to validation of the improved manufacturing process and adoption of the new supplier. In doing so, management must consider a number of factors in order to determine the amount of inventory to be capitalized, including the historical experience of modifying the Company's manufacturing processes, feedback from technical experts and regulatory agencies on the changes being effected and the amount of inventory that is likely to be used in commercial production. The shelf life of the excipient will be determined as part of the validation process; in the interim, the Company must assess the available stability data to determine whether there is likely to be adequate shelf life to support anticipated future sales occurring beyond the expected adoption date of the new raw material. If management is aware of any specific material risks or contingencies other than the normal regulatory reporting process, or if the criteria for capitalizing inventory produced prior to regulatory approval are otherwise not met, the Company would not capitalize such inventory costs, choosing instead to recognize such costs as R&D expense in the period incurred. See Note 5 - Inventories. Inventories — Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. The Company capitalizes inventory costs associated with the Company's products based on management's judgment that future economic benefits are expected to be realized; otherwise, such costs are expensed as incurred as cost of goods sold. The Company uses a contract manufacturing organization outside of the U.S. for certain stages of V-Go inventory. The Company periodically analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value and writes down such inventories, as appropriate. In addition, the Company's products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or may become obsolete or are forecasted to become obsolete due to expiration, the Company will record a charge to write down such unmarketable inventory to its estimated net realizable value. The Company analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company performs an assessment of projected sales and evaluates the lower of cost or net realizable value and the potential excess inventory on hand at the end of each reporting period. Property and Equipment — Property and equipment is recorded at historical cost, net of accumulated depreciation. Depreciation expense is recorded over the assets' useful lives on a straight-line basis and included in cost of goods sold, research and development, and general and administrative expense in the condensed consolidated statements of operations. See Note 6 - Property and Equipment. Impairment of Long-Lived Assets — Long-lived assets include property and equipment, operating lease right-of-use assets and other intangible assets. The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Assets are considered to be impaired if the carrying value is considered to be unrecoverable. If the Company believes an asset to be impaired, the impairment recognized is the amount by which the carrying value of the asset exceeds the fair value of the asset. Fair value is determined using the market, income or cost approaches as appropriate for the asset. Any write-downs are treated as permanent reductions in the carrying amount of the asset and recognized as an operating loss. Acquisitions — The Company first determines whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, the Company accounts for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process R&D ("IPR&D"), and liabilities assumed are recorded at their respective fair values as of the acquisition date in the Company's condensed consolidated financial statements. Leases are recorded at the net present value of the remaining lease payments. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. A gain on bargain purchase is recorded if the fair value of the net assets acquired exceeds the fair value of the consideration transferred. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree's liability arising from an acquisition it consummated prior to the Company's acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. <p style="font-size:10pt;margin-

top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&D projects with no alternative future use are recorded in R&D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. Goodwill and Other Intangible Assets — The fair value of acquired intangible assets is determined using either a cost approach or an income approach. The cost approach establishes fair value based on the cost of reproducing or replacing the asset, less depreciation for functional or economic obsolescence. The income approach, referred to as the excess earnings method, utilizes Level 3 fair value inputs to determine the present value of future economic benefits to be derived from ownership of the intangible asset. Market participant valuations assume a global view considering all potential jurisdictions and indications based on discounted after-tax cash flow projections, risk adjusted for estimated probability of technical and regulatory success. The Company tests for impairment annually on a reporting unit basis, at the beginning of the Company's fourth fiscal quarter and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying amount. To the extent the carrying amount of a reporting unit is less than its estimated fair value, an impairment charge will be recorded. Finite-lived intangible assets are amortized on a straight-line basis over the estimated useful life. Estimated useful lives are determined considering the period assets are expected to contribute to future cash flows. Finite-lived intangible assets are tested for impairment when facts or circumstances suggest that the carrying value of the asset may not be recoverable. If the carrying value exceeds the projected undiscounted pretax cash flows of the intangible asset, an impairment loss equal to the excess of the carrying value over the estimated fair value (discounted after-tax cash flows) is recognized. IPR&D acquired in a business combination is considered an indefinite-lived intangible asset until the completion or abandonment of the associated R&D efforts. During the R&D period, the asset is not amortized but rather is tested for impairment when facts or circumstances suggest that the carrying value of the asset may not be recoverable. Once the R&D efforts are completed, the Company accounts for the resulting asset as a finite-lived intangible asset. If the R&D efforts are abandoned, the asset balance is written off to R&D expense. Recognized Loss on Purchase Commitments — The Company reviews the terms of the long-term supply agreements and assesses the need for any accrual for estimated losses, such as lower of cost or net realizable value, that will not be recovered by future product sales. The recognized loss on purchase commitments is reduced as inventory items are received or as the liability is extinguished. See Note 15 - Commitments and Contingencies. Milestone Rights Liability — In July 2013, in conjunction with the execution of a (now repaid) loan agreement with Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively, "Deerfield"), the Company entered into a Milestone Rights Purchase Agreement (the "Milestone Rights Agreement") pursuant to which the Company issued certain milestone rights to Deerfield Private Design Fund II, L.P. and Horizon Santé FLML SÀRL (the "Original Milestone Purchasers"). The foregoing milestone rights provided the Original Milestone Purchasers certain rights to receive payments of up to $90.0 million upon the occurrence of specified strategic and Afrezza sales milestones. <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$50.0 million of which remains payable as of September 30, 2024 upon achievement of such milestones (collectively, the "Milestone Rights"). In December 2021, the Milestone Rights were purchased by Barings Global Special Situations Credit Fund 4 (Delaware), L.P. and Barings Global Special Situations Credit 4 (LUX) S.ar.l. (together, the "Milestone Purchasers"). As a result, the Milestone Purchasers have assumed the obligations of the Original Milestone Purchasers and are now entitled to all rights under the Milestone Rights Agreement. The Milestone Rights liability is reported at fair value at the date of the agreement which is periodically offset against payments. See Note 11 - Fair Value of Financial Instruments. The initial fair value estimate of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones and discounted to present value using a selected market discount rate. The expected timing and probability of achieving the milestones was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. The Milestone Rights liability is remeasured as the specified milestone events are achieved. Specifically, as each milestone event is achieved, the portion of the initially recorded Milestone Rights liability that pertains to the milestone event being achieved, is remeasured to the amount of the specified related milestone payment. The resulting change in the balance of the Milestone Rights liability due to remeasurement is recorded in the Company's condensed consolidated statements of operations as interest expense. Furthermore, the Milestone Rights liability is reduced upon the settlement of each milestone payment. As a result, each milestone payment is effectively allocated between a reduction of the recorded Milestone Rights liability and an expense representing a return on a portion of the Milestone Rights liability paid to the investor for the achievement of the related milestone event. See Note 8 - Accrued Expenses and Other Current Liabilities and Note 15 - Commitments and Contingencies. 9000000050000000 Fair Value of Financial Instruments — The Company applies various valuation approaches in determining the fair value of its financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 — Quoted prices for identical instruments in active markets. Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 — Significant inputs to the valuation model are unobservable. Income Taxes — The provisions for federal, foreign, state and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized. For uncertain tax positions, the Company determines whether it is "more likely than not" that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit can be recorded in the financial statements. For those tax positions where it is "not more likely than not" that a tax benefit will be sustained, no tax benefit is recognized. Penalties, if probable and reasonably estimable, are recognized as a component of income tax expense. The Company has reduced its deferred tax assets for uncertain tax positions but has not recorded liabilities for income tax expense, penalties, or interest. Contingencies — The Company records a loss contingency for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These accruals represent management's best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may revise its estimates. Stock-Based Compensation — Share-based payments to employees, including grants of restricted stock units ("RSUs"), performance-based non-qualified stock options awards ("PNQs"), restricted stock units with market conditions ("Market RSUs"), options and the compensatory elements of employee stock purchase plans, are recognized in the condensed consolidated statements of operations based upon the fair value of the awards at the grant date. RSUs are valued based on the market price on the grant date. Market RSUs are valued using a Monte Carlo valuation model and RSUs with performance conditions are evaluated for the probability that the performance conditions will be met and estimates the date at which the performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period. The Company uses the Black-Scholes option valuation model to estimate the grant date fair value of employee stock options and the compensatory elements of employee stock purchase plans. <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New

Roman;font-style:italic;min-width:fit-content;">Net Income (Loss) Per Share of Common Stock — Basic net income or loss per share ("EPS") is calculated by dividing net income by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the effect of potential common stock issuances resulting from assumed stock option exercises and vesting of restricted stock units, unless the effect is anti-dilutive, when applying the treasury stock method, as well as potential dilution under the if-converted method for convertible debt securities. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted EPS as they would be anti-dilutive. Recently Issued Accounting Standards — In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). This ASU requires disaggregated information about a public entity's effective tax rate reconciliation as well as additional information on income taxes paid. This ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact of the guidance on its condensed consolidated financial statement disclosures. From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company's condensed consolidated financial position or results of operations upon adoption. 2. Pulmatrix Transaction On May 28, 2024, the Company executed a bill of sale and assignment agreement with Pulmatrix, Inc. ("Pulmatrix") whereby the Company acquired from Pulmatrix certain lab assets and assumed certain liabilities, including the lease for an R&D facility in Bedford, Massachusetts. Concurrently, the Company and Pulmatrix entered into an intellectual property cross-license agreement (the "Cross License Agreement") for the Company's out-licensing of its Cricket® Device to Pulmatrix and in-licensing of Pulmatrix's iSPERSE™ technology, and a master service agreement. The parties and landlord also entered into an amendment to lease and consent to assignment of the lease. Each of these agreements became effective upon the closing of the collective transaction (the "Pulmatrix Transaction") on July 8, 2024 (the "Effective Date"). The Company also entered into employment agreements with 13 Pulmatrix R&D employees who began employment with the Company on the Effective Date. Pursuant to the Cross License Agreement, the Company granted to Pulmatrix certain exclusive and non-exclusive rights to develop, use, manufacture, market, offer and sell its single-use disposable dry powder inhaler (the "Cricket Device") for the inhaled delivery of dihydroergotamine in any formulation whatsoever (including Pulmatrix's's PUR3100 treatment of acute migraine), and the inhaled delivery of one or more active pharmaceutical ingredients formulated with iSPERSE for the treatment of neurological disease in humans (collectively, the "Cricket License"). In return, Pulmatrix granted to the Company certain exclusive and non-exclusive rights to develop, use, manufacture, market, offer and sell iSPERSE formulations of clofazimine and insulin, and formulations of iSPERSE with one or more active pharmaceutical ingredients for the treatment of nontuberculous mycobacteria lung disease in humans, endocrine disease in humans, and interstitial lung diseases in humans (collectively, the "iSPERSE License"). The Company may also provide certain development services to Pulmatrix under the Master Services Agreement, including but not limited to, activities to develop a dry powder formulation of the active pharmaceutical ingredient that Pulmatrix provides to the Company for oral inhalation using iSPERSE. Accounting Treatment The Pulmatrix Transaction was accounted for as a business combination using the acquisition method of accounting, which requires, among other things, the assets acquired and liabilities assumed to be recognized at their respective fair values as of the Effective Date. The excess of the fair value of the net assets acquired over the purchase price in this non-cash transaction was recorded as a gain on bargain purchase. The fair values of identifiable assets acquired and liabilities assumed by the Company from Pulmatrix as of the Effective Date are reflected below (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:82.22%;box-sizing:content-box;"></td><td style="width:2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.780000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amount </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> Assets: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> iSPERSE License – IPR&D </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,300 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Right-of-use asset – Bedford R&D facility </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,057 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 959 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total assets </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,316 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> Liabilities: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Operating lease liability – Bedford R&D facility </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 10,057 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 10,057 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net assets acquired – Gain on bargain purchase </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,259 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The fair value of the Cricket License transferred to Pulmatrix was determined to be immaterial based on the current market availability of numerous third party single-dose dry powder inhalers and the significant time, cost, and risk required to potentially commercialize the Cricket Device. The transfer of the Cricket License was within the scope of ASC 606 as a sale of functional intellectual property, however, since no value was attributed to the Cricket License, no revenue was recognized by the Company. The fair value of the iSPERSE License was determined by applying a cost approach, which assesses current replacement cost to acquire or construct a substitute asset of comparable utility as of the Effective Date. The iSPERSE License was deemed to have a fair value of $4.3 million based on the estimate of internal and external costs to recreate the underlying technology, which are inputs not observable in the market and therefore considered Level 3 measurements. The iSPERSE technology will be utilized in the Company's continuing R&D efforts and accounted for as IPR&D. The fair values of the right-of-use asset and lease liability for the assumed R&D facility operating lease were assessed in accordance with ASC 842, Leases, based on discounted cash flows from future lease payments, utilizing the Company's incremental borrowing rate of 7.25%. In June 2024, in anticipation of the facility lease assumption on the Effective Date, the Company transferred $0.7 million to a depository account at a financial institution to collateralize a conditional stand-by letter of credit as required under the lease. This amount is reflected as long-term restricted cash as of September 30, 2024. The lease term extends from the Effective Date through November 30, 2033 with monthly payments of $0.1 million increasing 3% annually starting on December 1, 2024. See Note 15 – Commitments and Contingencies. Property and equipment were assessed for monetary benefit, remaining economic life, and relative risk based on the Company's industry knowledge and analysis of sales of comparable equipment to arrive at fair value. Transaction costs totaling $0.1 million were expensed as incurred and reflected in the condensed consolidated statements of operations for the three and nine months ended September 30, 2024.</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">Pro forma results of operation for the Transaction have not been presented, as the effects of the Transaction were not material to the condensed consolidated financial statements.</p>2024-05-282024-07-0813<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">The fair values of identifiable assets acquired and liabilities assumed by the Company from Pulmatrix as of the Effective Date are reflected below (in thousands):</p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:82.22%;box-sizing:content-box;"></td> <td style="width:2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.780000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amount</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Assets:</p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">iSPERSE License – IPR&D</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,300 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Right-of-use asset – Bedford R&D facility </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,057 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid

#000000;text-align:center;"> 959 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,316 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Liabilities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Operating lease liability - Bedford R&D facility </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 10,057 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 10,057 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net assets acquired - Gain on bargain purchase </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,259 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>430000010057000959000153160001005700010057000525900043000000.0725700000Effective Date through November 30, 20331000000.03100000 3. Investments Cash Equivalents — Cash equivalents consist of highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase that are readily convertible into cash. Available-for-Sale Investment — The Company's investment in Thirona is comprised of two notes with aggregate face value of $8.0 million and stated interest rate of 10%. The Thirona convertible notes are classified as available-for-sale securities and are included in other assets as of September 30, 2024 and prepaid expenses and other current assets as of December 31, 2023 in the condensed consolidated balance sheets. Available-for-sale investments are measured at fair value with realized gains and losses reported in other income (expense) in the condensed consolidated statements of operations. Unrealized holding gains and losses are excluded from earnings and reported in other comprehensive income (loss) until realized. The Company determines the fair value of its available-for-sale investments using level 3 inputs and evaluates the fair value of its investment in Thirona by applying a scenario based method with a hypothetical yield of 28.0% and 35.0%, and volatility of 70.0% and 90.0% at September 30, 2024 and December 31, 2023, respectively. As of September 30, 2024 and December 31, 2023, the fair value of the Company's investment in Thirona was $5.9 million and $6.9 million, respectively. For the three and nine months ended September 30, 2024, the Company recorded an unrealized holding gain of $0.6 million. Additionally, for the nine months ended September 30, 2024, the Company recognized a loss of $1.6 million on its investment in Thirona as a result of modification of the Thirona convertible notes. For the three and nine months ended September 30, 2023, the Company recognized a gain of $0.9 million on its investment in Thirona as a result of the recovery of a temporary impairment and an unrealized holding gain of $0.4 million. For the three and nine months ended September 30, 2024, the Company recognized no interest income on investment and $0.1 million and $0.4 million for the three and nine months ended September 30, 2023, respectively. Held-to-Maturity Investments — Investments consist of highly liquid investments that are intended to facilitate liquidity and capital preservation. The amortization or accretion of the Company's investments is recognized in the condensed consolidated statements of operations as interest income. For the three and nine months ended September 30, 2024, the Company recognized $3.2 million and $9.8 million, respectively, of interest income on investments, of which $2.1 million and $6.0 million, respectively, was

net accretion on certain investments. For the three and nine months ended September 30, 2023, the Company recognized $1.5 million and $4.0 million, respectively, of interest income on investments, of which $0.5 million and $0.9 million, respectively, was net accretion on certain investments. No allowance for credit losses on held-to-maturity securities was required as of September 30, 2024 or December 31, 2023.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">The contractual maturities of the Company’s held-to-maturity investments are summarized below (in thousands): </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:40.492%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.878%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.878%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.46%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.418000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.46%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.418000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amortized
Cost Basis</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Aggregate
Fair Value</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amortized
Cost Basis</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Aggregate
Fair Value</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Due in one year or less(1)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 230,797 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">231,555</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 115,263 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 115,374 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Due after one year through five years </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 16,796 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 16,992 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,155 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,197 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times

*New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">247,593</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">248,547</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">122,418</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">122,571</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">_____</p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;">(1)<div style="width:100%;display:inline;">The investments due in one year or less include cash equivalents of $41.6 million as of September 30, 2024 and $58.6 million as of December 31, 2023. </div></div></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">The fair value of the cash equivalents, long-term and short-term investments are disclosed below (dollars in thousands).</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:44.247%;box-sizing:content-box;"></td><td style="width:1.141%;box-sizing:content-box;"></td><td style="width:9.886%;box-sizing:content-box;"></td><td style="width:1.141%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.887000000000005%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.141%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.141%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.887000000000005%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.141%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.887000000000005%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Investment Level</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amortized Cost
(Carrying Value)</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Gross Unrealized Holding
Gains</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Gross Unrealized
Holding
Losses</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Estimated
Fair Value</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Money market funds and other</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Level 1</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">31,298</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">31,298</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-*

bottom:0;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Commercial bonds and paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 57,477 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 268 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (12 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 57,733 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> U.S. Treasury Securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 158,818 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 700 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 159,516 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents and investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 247,593 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 968 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (14 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 248,547 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Less: cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (41,582 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid

*#000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (41,582 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"> Total Investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">206,011</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 968 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(14</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 206,965 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.247%;box-sizing:content-box;"></td> <td style="width:1.141%;box-sizing:content-box;"></td> <td style="width:9.886%;box-sizing:content-box;"></td> <td style="width:1.141%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.8870000000000005%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.141%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.507%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.141%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.8870000000000005%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.141%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.8870000000000005%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Investment Level </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost
(Carrying Value) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross Unrealized Holding
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross Unrealized
Holding
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated
Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> Level 1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">69,611</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 69,611 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-*

bottom:0;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Commercial bonds and paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43,251 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 135 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (38 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43,348 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> U.S. Treasury Securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9,556 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 56 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9,612 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents and investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 122,418 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 191 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (38 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 122,571 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Less: cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (58,644 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (58,644 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"> Total Investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">63,774</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 191 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(38</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 63,927 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> As of September 30, 2024 and December 31, 2023, there was $1.1 million and $0.5 million, respectively, of accrued interest receivable on investments which is included in prepaid expense and other current assets in our condensed consolidated balance sheets.
280000000.10283570905900000690000060000016000009000009000004000004000000010000040000032000009800000210000006000000150000040000005000009000
style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">The contractual maturities of the Company's held-to-maturity investments are summarized below (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.492%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.878%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.878%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.46%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.418000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.46%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.418000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost Basis </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate
Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost Basis </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate
Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Due in one year or less(1)
</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">230,797</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 231,555 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;">115,263</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">115,374</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Due after one year through five years</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,796</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,992</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,155</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,197</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">247,593</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">248,547</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">122,418</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">122,571</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">_____</p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;">(1)<div style="width:100%;display:inline;">The investments due in one year or less include cash equivalents of $41.6 million as of September 30, 2024 and $58.6 million as of December 31, 2023. </div></div>230797000231555000115263000115374000167960001699200071550007197000247593000248547000122418000122571000416000005860000<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">The fair value of the cash equivalents, long-term and short-term investments are disclosed below (dollars in thousands).</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.247%;box-sizing:content-box;"></td> <td style="width:1.141%;box-sizing:content-box;"></td> <td style="width:9.886%;box-sizing:content-box;"></td> <td style="width:1.141%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.887000000000005%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.141%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.507%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.141%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.887000000000005%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.141%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.887000000000005%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Investment Level</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amortized Cost
(Carrying Value)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Gross Unrealized Holding
Gains</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-

*align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross Unrealized
Holding
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated
Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Money market funds and other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> Level 1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">31,298</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 31,298 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Commercial bonds and paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 57,477 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 268 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (12 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 57,733 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> U.S. Treasury Securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 158,818 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 700 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 159,516 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents and investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 247,593 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> *

</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 968 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (14 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 248,547 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Less: cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (41,582 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"> Total Investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">206,011</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 968 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(14</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 206,965 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.247%;box-sizing:content-box;"></td> <td style="width:1.141%;box-sizing:content-box;"></td> <td style="width:9.886%;box-sizing:content-box;"></td> <td style="width:1.141%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.887000000000005%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.141%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.507%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.141%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.887000000000005%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.141%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.887000000000005%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Investment Level </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost
(Carrying Value) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross Unrealized Holding
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross Unrealized
Holding
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated
Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> Level 1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">69,611</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 69,611 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Commercial bonds and paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43,251 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 135 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (38 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43,348 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> U.S. Treasury Securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9,556 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 56 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9,612 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents and investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 122,418 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-

align:bottom;text-align:center;"> 191 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (38 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 122,571 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Less: cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (58,644 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (58,644 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"> Total Investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">63,774</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 191 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(38</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 63,927 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>-31298000-31298000-57477000-26800012000-57733000-158818000-7000002000-159516000-247593000-96800014000-248547000415820004158200041582000-206011000-96800014000-206965000-69611000-69611000-43251000-13500038000-43348000-9556000-56000-9612000-122418000-19100038000-122571000586440005864400063774000-19100038000-639270001100000500000 4. Accounts Receivable Accounts receivable, net consists of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.92%;box-sizing:content-box;"></td><td style="width:1.58%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.96%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.58%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.96%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> Accounts receivable – commercial </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td>

<td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Accounts receivable, gross </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,359</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,199 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Wholesaler distribution fees and prompt pay discounts </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (2,363 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (2,469 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Reserve for returns </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (7,817 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (6,215 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Allowance for credit losses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (157 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total accounts receivable – commercial, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,179 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,358 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accounts receivable – collaborations and services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,005 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,543 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"> Total accounts receivable, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,184</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,901 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> As of December 31, 2023, the allowance for credit losses and doubtful accounts for commercial accounts receivable of $0.2 million was related to accounts receivable for Zealand Pharma US, Inc. As of September 30, 2024<span

style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had three wholesale distributors representing approximately 87% of commercial accounts receivable and 77% and 73% of gross sales during the three and nine months ended September 30, 2024, respectively. As of September 30, 2024 and December 31, 2023, there was no allowance for credit losses for accounts receivable for collaborations and services. The Company had one collaboration partner, UT, that comprised 100% of the collaboration and services net accounts receivable as of September 30, 2024 and December 31, 2023 and approximately 100% of gross revenue from collaborations and services for the three and nine months ended September 30, 2024. Accounts receivable, net consists of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.92%;box-sizing:content-box;"></td><td style="width:1.58%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.96%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.58%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.96%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> Accounts receivable - commercial </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Accounts receivable, gross </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,359</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content,">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,199 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word,"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top,"> Wholesaler distribution fees and prompt pay discounts </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom,"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> (2,363 </td><td style="white-space:nowrap;vertical-align:bottom,">) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom,"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> (2,469 </td><td style="white-space:nowrap;vertical-align:bottom,">) </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Reserve for returns </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (7,817 </td><td style="white-space:nowrap;vertical-align:bottom,">) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (6,215 </td><td style="white-space:nowrap;vertical-align:bottom,">) </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Allowance for credit losses </td><td style="white-space:pre-wrap;vertical-align:bottom,"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (157 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-

left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total accounts receivable – commercial, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,179 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,358 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accounts receivable – collaborations and services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,005 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,543 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"> Total accounts receivable, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,184</p></td> <td style="border-top:0.5pt solid #fffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,901 </td> <td style="border-top:0.5pt solid #fffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table>1835900020199000236300024690007817000621500001570000817900011358000100050003543000181840001490100020000033O.870.770.73001111 5. Inventories Inventories consist of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.72%;box-sizing:content-box;"></td><td style="width:1.72%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.92%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.72%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.92%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Raw materials </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,437</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,262 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Work-in-process </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,074 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,646 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Finished goods </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11,152 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8,637 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total inventory </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td><td style="white-space:pre-wrap;vertical-

align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 26,663 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 28,545 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table> Work-in-process and finished goods as of September 30, 2024 and December 31, 2023 include conversion costs and exclude the cost of insulin. All insulin inventory on hand was written off and the projected loss on the purchase commitment contract to purchase future insulin was accrued as of the end of 2016. Raw materials inventory included $0.8 million of pre-launch inventory as of September 30, 2024 and December 31, 2023. The Company analyzed its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company also performed an assessment of projected sales and evaluated the lower of cost or net realizable value and the potential excess inventory on hand as of September 30, 2024 and December 31, 2023. Inventory that did not meet acceptable standards or was forecasted to become obsolete due to expiration is reserved for inventory obsolescence in the condensed consolidated balance sheets and recorded in costs of goods sold in the condensed consolidated statements of operations. As a result of these assessments there were inventory write-offs of $0.3 million and $1.9 million for the three and nine months ended September 30, 2024, respectively, and $0.3 million and $3.7 million for the three and nine months ended September 30, 2023, respectively. </p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">Inventories consist of the following (in thousands): </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.72%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Raw materials</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,437 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,262</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Work-in-process</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,074</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13,646</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Finished goods</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,152</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,637</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total inventory</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 26,663 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 28,545 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table>643700062620009074000136460001115200086370002666300028545000800000800000300000190000030000037000000<p style="font-size:10pt;margin-

top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">6. Property and Equipment Property and equipment consisted of the following (dollars in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:45.08%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.48%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.48%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Estimated Useful </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Life (Years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Land </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">875</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 875 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Buildings </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 39-40 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,389 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,389 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Building improvements(1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5-40 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 90,573 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 46,357 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Machinery and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3-15 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,733 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 60,410 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Furniture, fixtures and office equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5-10 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,350 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,070 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Computer equipment and software </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,658 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Construction in progress(1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,242 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 48,997 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 191,973 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 185,756 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Less accumulated depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (106,634 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (101,536 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">85,339</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 84,220 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> _____ (1) During the nine months ended September 30, 2024, the Company transferred $43.5 million from construction in progress to building improvements for assets placed in service related to the expansion of the Company's manufacturing facility.</div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">Depreciation expense related to property and equipment was as follows (in thousands): </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months
Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months
Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Depreciation Expense</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:center;"> 2,099 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,117</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,151 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,250 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> During each of the three and nine months ended September 30, 2024, the Company retired $0.1 million of manufacturing equipment as it was no longer in service. The net book value for the disposed assets was de minimis. There were no asset retirements during the three and nine months ended September 30, 2023. Property and equipment consisted of the following (dollars in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:45.08%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.48%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.48%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Estimated Useful </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Life (Years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Land </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Buildings </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 39-40 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,389 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,389 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Building improvements(1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5-40 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 90,573 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 46,357 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Machinery and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3-15 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,733 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 60,410 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Furniture, fixtures and office equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5-10 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="white-space:pre-

wrap;min-width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,350 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,070 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Computer equipment and software </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,658 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Construction in progress(1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,242 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 48,997 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 191,973 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 185,756 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less accumulated depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (106,634 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (101,536 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">85,339</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 84,220 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> </tr> </table> _____ (1) During the nine months ended September 30, 2024, the Company transferred $43.5 million from construction in progress to building improvements for assets placed in service related to the expansion of the Company's manufacturing facility.
875000875000P39YP40Y173890001738900017389000P5YP40Y90573000463570000P3YP15Y6573300006041000P5YP10Y335000030700000P3Y8811000865800052420004899760
style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">Depreciation expense related to property and equipment was as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Depreciation Expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,099</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,117 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,151</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,250 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr>
</table>2099000111700051510003250000100000010000000
7. Goodwill and Other Intangible Assets Goodwill — Goodwill represents the excess of the purchase price over the identifiable tangible and intangible assets acquired plus liabilities assumed arising from business combinations. The balance of goodwill was $1.9 million as of September 30, 2024 and December 31, 2023 as a result of the Company's acquisition of V-Go in May 2022. Goodwill is tested at least annually for impairment by assessing qualitative factors in determining whether it is more likely than not that the fair value of net assets is below their carrying amounts. See Note 1 - Description of Business and Significant Accounting Policies.
Other Intangible Assets
— Other intangible assets consisted of the following (dollars in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:21.9%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Estimated </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"><p style="font-

size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Useful
Life (Years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Accumulated
Amortization </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Net Book Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Accumulated
Amortization </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Net Book Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Developed technology </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,200</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (187 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,013</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (127 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,073 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> iSPERSE License - IPR&D </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,300 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:

space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,300 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,500</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (187 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,313</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,200 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(127</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,073 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> Amortization expense related to the developed technology was de minimis for the three and nine months ended September 30, 2024 and 2023. The estimated annual amortization expense for the developed technology for the years ended December 31, 2024 through 2028 is approximately $0.1 million per year and <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$0.6 million, thereafter. The iSPERSE License — IPR&D is an indefinite-lived intangible asset, and as such is not amortized but rather is tested for impairment when facts or circumstances indicate the carrying value of the asset may not be recoverable. Upon completion of the underlying R&D efforts, the intangible asset will be accounted for as a finite-lived intangible asset. If the R&D efforts are abandoned, the IPR&D asset balance will be written off to R&D expense. The Company evaluates its other intangible assets for potential impairment annually and when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. See Note 1 - Description of Business and Significant Accounting Policies. 1900000190000000 Other Intangible Assets — Other intangible assets consisted of the following (dollars in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:21.9%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Estimated </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"><p style="font-

size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Useful
Life (Years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Accumulated
Amortization </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Net Book Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Accumulated
Amortization </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Net Book Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Developed technology </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,200</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (187 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,013</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(127</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,073 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> iSPERSE License - IPR&D </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,300 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:

space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,300 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,500</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (187 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,313</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,200 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(127</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,073 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>P15Y120000018700010130001200000127000107300043000004300000550000018700053130001200000127000107300010000010000010000010000010000060000
style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">8. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities were comprised of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.72%;box-sizing:content-box;"></td><td style="width:1.72%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.92%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.92%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Salary and related expenses </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,239</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 19,506 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Discounts and allowances for commercial product sales </td><td style="white-

space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,869 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,541 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued interest </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 479 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,153 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Deferred lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,483 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,423 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Current portion of milestone rights liability(1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 639 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 752 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Returns reserve for acquired product(2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,468 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 601 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Professional fees </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 563 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 979 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> State income tax liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,507 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,561 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,139 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,520 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-

left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accrued expenses and other current liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">37,386</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 42,036 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> _____ (1) See Note 15 - Commitments and Contingencies under Contingencies — Milestone Rights. (2) See Note 15 - Commitments and Contingencies under Loss Contingencies — Returns Reserve for Acquired Product. Accrued expenses and other current liabilities were comprised of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.72%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td></tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Salary and related expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,239</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 19,506 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Discounts and allowances for commercial product sales </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,869 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,541 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued interest </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 479 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,153 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Deferred lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,483 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,423 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Current portion of milestone rights liability(1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span

style="color:#000000;white-space:pre-wrap;min-width:fit-content;">639 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 752 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Returns reserve for acquired product(2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,468 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 601 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Professional fees </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 563 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 979 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> State income tax liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,507 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,561 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,139 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,520 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Accrued expenses and other current liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">37,386</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 42,036 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> _____ (1) See Note 15 - Commitments and Contingencies under Contingencies — Milestone Rights. (2) See Note 15 - Commitments and Contingencies under Loss Contingencies — Returns Reserve for Acquired Product. 1623900019506000986900095410004790002153000248300014230006390007520001468000601000563000979000150700015610004139000552000037386000420
style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">9. Borrowings Carrying amount of the Company's borrowings consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.72%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td>

<td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Senior convertible notes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">227,941</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 226,851 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> MidCap credit facility </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,019 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Mann Group convertible note </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8,829 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total debt – net carrying amount </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">227,941</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 268,699 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table>
The following table provides a summary of the Company's principal balance of debt and key terms: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.008%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.002%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.842%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.382%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amount Due </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Terms </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Annual Interest
Rate </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Maturity Date </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Conversion Price </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Senior convertible notes </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;text-align:left;"> $230.0 million </td> <td style="vertical-align:top;text-align:left;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$230.0 million</p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2.50%</p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">March 2026</p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$5.21
per share</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">MidCap credit facility(1)</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$33.3 million</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">one-month
SOFR
(1% floor)
plus 6.25%,
cap of 8.25%</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">August 2025</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">N/A</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Mann Group convertible note(2)</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$8.8 million</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2.50%</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 2025</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$2.50
per share</p></td> </tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">_____</p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;">(1)<div style="width:100%;display:inline;">Repaid on April 1, 2024.</div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;">(2)<div style="width:100%;display:inline;">Repaid on April 2, 2024.</div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">The maturities of the Company’s borrowings as of September 30, 2024 are as follows (in thousands):</p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.04%;box-sizing:content-box;"></td> <td style="width:2.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amounts</p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Remainder of 2024</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">230,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total principal payments</p></td> <td style="text-indent:10pt;white-space:pre-

wrap;vertical-align:top;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 230,000 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Debt issuance costs </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,059 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total debt </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 227,941 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> Senior convertible notes - In March 2021, the Company issued $230.0 million aggregate principal amount of Senior convertible notes in a private offering. The Senior convertible notes were issued pursuant to an indenture, dated March 4, 2021 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. The Senior convertible notes are general unsecured obligations of the Company and will mature on March 1, 2026, unless earlier converted, redeemed or repurchased by the Company. The Senior convertible notes will bear cash interest from March 4, 2021 at an annual rate of 2.50% payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2021. The Senior convertible notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding December 1, 2025, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock, par value $0.01 per share, for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the Senior convertible notes on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Senior convertible notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on each such trading day; (3) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Senior convertible notes called (or deemed called) for redemption; or (4) upon the occurrence of specified corporate events as set forth in the Indenture. On or after December 1, 2025 until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. The initial conversion rate is 191.8281 shares of common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.21 per share of common stock). The initial conversion price of the Senior convertible notes represents a premium of approximately 30% to the last reported sale price of the common stock on the Nasdaq Global Market on March 1, 2021. The conversion rate for the Senior convertible notes is subject to adjustment under certain circumstances in accordance with the terms of the Indenture, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date of the Senior convertible notes or if the Company delivers a notice of redemption in respect of the Senior convertible notes, the Company will, in certain circumstances, increase the conversion rate of the Senior convertible notes for a holder who elects to convert its Senior convertible notes in connection with such a corporate event or convert its Notes called for redemption during the related redemption period (as defined in the Indenture), as the case may be. The Company may redeem for cash all or any portion of the Senior convertible notes, at its option, on or after March 6, 2024 and prior to the 36th scheduled trading day immediately preceding the maturity date, if the last reported sale price of common stock has been at least 130% of the conversion price for the Senior convertible notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Senior convertible notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company elects to redeem less than all of the outstanding Senior convertible notes, at least $75.0 million aggregate principal amount of Senior convertible notes must be outstanding and not subject to redemption as of the relevant redemption notice date. No sinking fund is provided for the Senior convertible notes. If the Company undergoes a fundamental change (as defined in the Indenture), then, subject to certain conditions and except as described in the Indenture, holders may require the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Senior convertible notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture includes customary covenants and sets forth certain events of default after which the Senior convertible notes may be declared immediately due and payable. If certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries) occur, 100% of the principal of and accrued and unpaid interest on the Senior convertible notes will automatically become due and payable. If an event of default with respect to the Senior convertible notes, other than certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries), occurs and is continuing, the trustee, by notice to the Company, or the holders of at least 25% in principal amount of the outstanding Senior convertible notes by notice to the Company and the trustee, may, and the trustee at the request of such holders shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the Senior

convertible notes to be due and payable. Notwithstanding the foregoing, the Indenture provides that, to the extent the Company so elects, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture will, for the first 365 days after the occurrence of such an event of default consist exclusively of the right to receive additional interest on the Senior convertible notes as set forth in the Indenture. The Indenture provides that the Company shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of the consolidated properties and assets of the Company and its subsidiaries, taken as a whole, to, another person (other than any such sale, conveyance, transfer or lease to one or more of the Company's direct or indirect wholly owned subsidiaries), unless: (i) the resulting, surviving or transferee person (if not the Company) is a corporation organized and existing under the laws of the United States of America, any State thereof or the District of Columbia, and such corporation (if not the Company) expressly assumes by supplemental indenture all of the Company's obligations under the Senior convertible notes and the Indenture; and (ii) immediately after giving effect to such transaction, no default or event of default has occurred and is continuing under the Indenture. The Company's net proceeds from the March 2021 offering were approximately $222.7 million, after deducting the initial purchasers' discounts and commissions and the estimated offering expenses payable by the Company. As of September 30, 2024 and December 31, 2023, the unamortized debt issuance cost was $2.1 million and $3.1 million, respectively. MidCap credit facility — In August 2019, the Company entered into the MidCap credit facility and borrowed the first advance of $40.0 million ("Tranche 1") in August 2019 and the second advance of $10.0 million ("Tranche 2") in December 2020. In April 2021, $10.0 million was prepaid. Tranche 1 and Tranche 2 accrued interest at an annual rate equal to the lesser of (i) 8.25% and (ii) the one-month Secured Overnight Financing Rate ("SOFR") (subject to a one-month SOFR floor of 1.00%) plus 6.25%. Interest on each term loan advance was due and payable monthly in arrears. Principal on each term loan advance under Tranche 1 and Tranche 2 was payable in 24 equal monthly installments that began September 1, 2023. During the three months ended March 31, 2024, the Company made $5.0 million in principal payments on the MidCap credit facility. On April 1, 2024, the Company exercised its option to prepay in full all outstanding indebtedness, consisting of $28.3 million in principal and $0.2 million in accrued interest, and terminated all commitments and obligations under the MidCap credit facility that would have matured on August 1, 2025 in exchange for a payment of $31.6 million, including an exit fee of $2.8 million which is 7.00% of the initial Tranche 1 balance of $40.0 million, and a prepayment fee of $0.3 million which is 1.00% of principal prepaid. Additionally, unamortized debt discount and capitalized prepayment fees totaling $0.2 million were written off, resulting in a loss on extinguishment of debt of $3.3 million recognized in the condensed consolidated statements of operations. In connection with the repayment of outstanding indebtedness by the Company, all liens, mortgages and security interests in any assets or property securing the obligations under the MidCap credit facility were automatically terminated and released and the Company was automatically released from all guarantees. Mann Group convertible note — In August 2019, the Company issued a $35.0 million note that was convertible into shares of the Company's common stock at $2.50 per share (the "Mann Group convertible note") as part of a restructuring of its then existing indebtedness to Mann Group. The Mann Group convertible note accrued interest at the rate of 2.5% per year on the principal amount, payable quarterly in arrears on the first day of each calendar quarter, with a maturity date of December 31, 2025. The principal and any accrued and unpaid interest under the Mann Group convertible note was convertible, at the option of Mann Group, at any time on or prior to the close of business on the business day immediately preceding the stated maturity date, into shares of the Company's common stock at a conversion rate of 400 shares per $1,000 of principal and/or accrued and unpaid interest, which is equal to a conversion price of $2.50 per share. Interest on the convertible note was payable in kind by adding the amount thereof to the principal amount; provided that with respect to interest accruing from and after January 1, 2021, the Company had the option to pay any such interest on any interest payment date, if certain conditions were met, in shares of the Company's common stock at a price per share equal to the last reported sale price on the trading day immediately prior to the payment date. During the nine months ended September 30, 2024, Mann Group converted $0.1 million of interest into 15,285 shares of common stock. During the nine months ended September 30, 2023, Mann Group converted $0.2 million of interest into 37,122 shares of common stock. On April 2, 2024,

the Company and Mann Group agreed to discharge and terminate the Mann Group convertible note. As of April 2, 2024, the outstanding principal balance of the Mann Group convertible note plus accrued interest was $8.9 million and was convertible at Mann Group's option into 3,554,198 shares of common stock of the Company. The Company and Mann Group agreed to terminate all outstanding indebtedness, rights and obligations under the Mann Group convertible note in exchange for (i) the Company's issuance to Mann Group of 1,500,000 shares of the Company's common stock converted at the contractual rate of $2.50 per share and (ii) the Company's payment to Mann Group of $8.9 million, which represented the market value of 2,054,198 shares of common stock of the Company on April 2, 2024 to settle the remaining principal and interest of $5.1 million, after the conversion noted in (i) above. Termination of the Mann Group convertible note resulted in a loss on extinguishment of debt of $3.7 million recognized in the condensed consolidated statements of operations.
Amortization of the premium and accretion of debt issuance costs related to all borrowings were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Amortization of debt discount and prepayment fee </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 109 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">85</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 323 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Amortization of debt issuance cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 363 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 363 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,175 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span

style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,090 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> Carrying amount of the Company's borrowings consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.72%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Senior convertible notes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">227,941</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 226,851 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> MidCap credit facility </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,019 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Mann Group convertible note </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8,829 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total debt – net carrying amount </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">227,941</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 268,699 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>227941000226851000330190000882900022794100026869900 0 The following table provides a summary of the Company's principal balance of debt and key terms: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.008%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.002%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.842%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.382%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amount Due </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Terms </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Annual Interest
Rate </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:center;">Maturity Date</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Conversion Price</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Senior convertible notes</p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$230.0 million</p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$230.0 million</p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2.50%</p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">March 2026</p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$5.21
per share</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">MidCap credit facility(1)</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$33.3 million</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">one-month
SOFR
(1% floor)
plus 6.25%
cap of 8.25%</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">August 2025</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">N/A</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Mann Group convertible note(2)</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$8.8 million</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2.50%</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 2025</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$2.50
per share</p></td> </tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">_____</p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;">(1)<div style="width:100%;display:inline;">Repaid on April 1, 2024.</div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;">(2)<div style="width:100%;display:inline;">Repaid on April 2, 2024.</div></div>2300000002300000000.0252026-035.21333000000.010.06250.08252025-08880000000.0252025-122.5<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">The maturities of the Company's borrowings as of September 30, 2024 are as follows (in thousands):</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.04%;box-sizing:content-box;"></td> <td style="width:2.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amounts</p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Remainder of 2024</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span

style="color:#000000;white-space:pre-wrap;min-width:fit-content;">— </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 230,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total principal payments </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 230,000 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Debt issuance costs </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,059 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total debt </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 227,941 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>0023000000023000000020590002279410002300000000.02026-03-010.0250.0120301.3010000.98191.828110005.210.30The Company may redeem for cash all or any portion of the Senior convertible notes, at its option, on or after March 6, 2024 and prior to the 36th scheduled trading day immediately preceding the maturity date, if the last reported sale price of common stock has been at least 130% of the conversion price for the Senior convertible notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Senior convertible notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company elects to redeem less than all of the outstanding Senior convertible notes, at least $75.0 million aggregate principal amount of Senior convertible notes must be outstanding and not subject to redemption as of the relevant redemption notice date. No sinking fund is provided for the Senior convertible notes.2024-03-061.3020301750000000.001If certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries) occur, 100% of the principal of and accrued and unpaid interest on the Senior convertible notes will automatically become due and payable. If an event of default with respect to the Senior convertible notes, other than certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries), occurs and is continuing, the trustee, by notice to the Company, or the holders of at least 25% in principal amount of the outstanding Senior convertible notes by notice to the Company and the trustee, may, and the trustee at the request of such holders shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the Senior convertible notes to be due and payable. Notwithstanding the foregoing, the Indenture provides that, to the extent the Company so elects, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture will, for the first 365 days after the occurrence of such an event of default consist exclusively of the right to receive additional interest on the Senior convertible notes as set forth in the Indenture112227000002100000310000040000000.010000000.010000000.00.08250.08250.01000.01000.06250.0625Principal on each term loan advance under Tranche 1 and Tranche 2 was payable in 24 equal monthly installments that began September 1, 2023.24242023-09-012023-09-015000000283000002000003160000028000000.074000000003000000.012000003300000350000000.02.500.025quarterly2025-12-3140010002.501000001528520000037122890000035541981500000 2.589000002054198510000037000000<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">Amortization of the premium and accretion of debt issuance costs related to all borrowings were as follows (in thousands):</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months
Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months
Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Amortization of debt discount and prepayment fee</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 109 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td

style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">85</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 323 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Amortization of debt issuance cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 363 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,175 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,090 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table>10900085000323000363000363000117500010900000 10. Collaboration, Licensing and Other Arrangements Revenue from collaborations and services were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.07%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months
Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months
Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> UT CSA(1) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,231</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,800 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">73,673</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34,897 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> UT License Agreement(2) </td><td

style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 271 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 347 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 698 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cipla License and Distribution Agreement </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 110 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 110 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total revenue from collaborations and services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,268</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13,108 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">74,130</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 35,705 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> _____ (1) Amounts consist of revenue recognized for Manufacturing Services and Product Sales to UT for the periods presented. (2) Amounts consist of revenue recognized for Next-Gen R&D Services and R&D Services and License for the periods presented. United Therapeutics License Agreement — In September 2018, the Company and UT entered into an exclusive global license and collaboration agreement (the “UT License Agreement”), pursuant to which UT is responsible for global development, regulatory and commercial activities with respect to Tyvaso DPI. Pursuant to the UT License Agreement, the Company receives a 10% royalty on net sales of Tyvaso DPI. In December 2023, the Company sold a 1% royalty on future net sales of Tyvaso DPI to a royalty purchaser, with the Company retaining a 9% royalty. In August 2021, the Company and UT entered into the CSA, pursuant to which the Company is responsible for manufacturing and supplying to UT, and UT is responsible for purchasing from the Company on a cost-plus basis. In addition, UT is responsible for supplying treprostinil at its expense in quantities necessary to enable the Company to manufacture Tyvaso DPI as required by the CSA. Total revenue from UT was as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> UT Revenue </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> UT CSA </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,231</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,800 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">73,673</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34,897 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> UT License Agreement </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 271 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 347 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 698 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Royalties - Collaboration (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,083 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 20,218 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 75,326 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,951 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total revenue from UT </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,314</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 33,289 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">149,346</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 86,546 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> _____ (1) Amounts consist of royalties associated with the UT License Agreement. The contract assets related to the royalties is included in prepaid expense and other current assets in the condensed consolidated balance sheets. The activities and deliverables under the CSA and UT License Agreement resulted in distinct performance obligations which include the: (1) R&D Services and License, (2) Next-Gen R&D Services, and (3) Manufacturing Services and Product Sales. There have been various amendments to the UT License Agreement and the CSA since inception. As amended, the term of the CSA continues until December 31, 2031 (unless earlier terminated) and is thereafter renewed automatically for additional, successive two-year terms unless (i) UT provides notice to the Company at least 24 months in advance of such renewal that UT does not wish to renew the CSA or (ii) the Company provides notice to UT at least 48 months in advance of such renewal that the Company does not wish to renew the CSA. The Company and UT each have normal and customary termination rights, including termination for material breach that is not cured within a specific timeframe or in the event of liquidation, bankruptcy or insolvency of the other party. The Company accounted for the contract modification as if it were part of the existing contract since the amendment modified the scope and price of the CSA by extending the term and increasing the occupancy rate. The effect of the modification on the transaction price and on the measure of progress is recognized as an adjustment to revenue as of the date of modification. The modification did not result in a change in the activities and deliverables under the CSA. In December 2022, the Company and UT agreed to fund an additional $39.5 million to support capital and continuous improvement activities and $2.3 million in the development of alternative manufacturing processes. The Company determined that the capital and continuous improvements should be combined with the manufacturing services performance obligation and the alternative manufacturing processes should be combined with the Next-Gen R&D Services. The total revised anticipated cash flows of $722.3 million from the transaction was allocated to the three distinct performance obligations as follows (dollars in millions): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:40.86%;box-sizing:content-box;"></td><td style="width:1.16%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.140000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.24%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.140000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.54%;box-sizing:content-box;"></td><td style="width:9.14%;box-sizing:content-box;"></td><td style="width:1.06%;box-sizing:content-box;"></td><td style="width:9.14%;box-sizing:content-box;"></td><td style="width:1.06%;box-sizing:content-box;"></td><td style="width:13.74%;box-sizing:content-box;"></td><td style="width:2.78%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Anticipated </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Cash Flow </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Revenue Allocation

</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Recognition Method </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Progress Measure </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Revenue
Recognition </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total anticipated cash flow(1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 722.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td>

bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">712.3</p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Point in time</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Transfer of control</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">_____</p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;">(1)<div style="width:100%;display:inline;">The total anticipated cash flow includes a transaction price of $120.0 million for the contractual obligations under the CSA for the Manufacturing Services and Product Sales and the Next-Gen R&D Services performance obligations and $602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA.</div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;">(2)<div style="width:100%;display:inline;">The Manufacturing Services and Product Sales performance obligation will be recognized as control of manufactured products is transferred to UT. The modification did not result in a cumulative catch-up adjustment as a result of the revenue being deferred for the performance obligations that were affected by the modification. The allocation of the transaction price for the Manufacturing Services and Product Sales includes a material right related to the Company's estimated production of product in the amount of $220.8 million. The Company will sell product to UT under individual purchase orders, which represent distinct performance obligations. The ultimate cash flows may vary as manufacturing purchase orders are received.</div></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">In February 2024, the Company entered into an additional agreement for a separate performance obligation which was accounted for separately as it was distinct from Manufacturing Services and Product Sales and offered at a standalone selling price. Revenue is recognized at a point in time as services are rendered.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024, deferred revenue from UT consisted of $70.5 million, of which $6.4 million was classified as current and $64.1 million was classified as long-term on the condensed consolidated balance sheet. As of December 31, 2023, deferred revenue consisted of $77.5 million, of which $8.9 million was classified as current and $68.6 million was classified as long-term on the condensed consolidated balance sheet. The Company determined that the revenue recognition associated with the capital improvements should be combined with the Manufacturing Services and Product Sales performance obligation.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Thirona Collaboration Agreement — In June 2021, the Company and Thirona entered into a collaboration agreement to evaluate the therapeutic potential of Thirona's compound for the treatment of fibrotic pulmonary diseases. If initial studies are promising, the Company can exercise certain rights to seek a full license to the compound for clinical development and commercialization. The parties will perform their respective obligations and provide reasonable support for research, clinical development and regulatory strategy. The collaboration agreement was accounted for under ASC 808, Collaborative Agreements; however, no consideration was exchanged between the parties. The costs incurred by the Company were expensed as R&D in the condensed consolidated statements of operations. On February 28, 2023, the collaboration agreement was amended to extend the term through June 2024. In accordance </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">with the amendment, the Company agreed to fund a minimum of $1.1 million to be expended on a revised development plan prepared by Thirona, of which $1.1 million has been funded through September 30, 2024. </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Biomm Supply and Distribution Agreement — In May 2017, the Company and Biomm S.A. ("Biomm") entered into a supply and distribution agreement for the commercialization of Afrezza in Brazil. Under this agreement, Biomm was responsible for pursuing regulatory approvals of Afrezza in Brazil, including from the Agência Nacional de Vigilância Sanitária ("ANVISA") and, with respect to pricing matters, from the Camara de Regulação de Mercado de Medicamentos ("CMED"), both of which were received. Biomm commenced product sales in January 2020. No shipments of product were made to Biomm in 2023 or the first three quarters of 2024.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cipla License and Distribution Agreement — In May 2018, the Company and Cipla Ltd. ("Cipla") entered into an exclusive agreement for the marketing and distribution of Afrezza in India and the Company received a $2.2 million nonrefundable license fee. Under the terms of the agreement, Cipla is responsible for obtaining regulatory approvals to distribute Afrezza in India and for all marketing and sales activities of Afrezza in India. The Company is responsible for supplying Afrezza to Cipla. The Company has the potential to receive an additional regulatory milestone payment, minimum purchase commitment revenue and royalties on Afrezza sales in India once cumulative gross sales have reached a specified threshold. Cipla is currently seeking regulatory approval with the India authorities.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The nonrefundable licensing fee was recorded in deferred revenue and is being recognized in net revenue – collaborations over 15 years, representing the estimated period to satisfy the performance obligation. The additional milestone payment represents variable consideration for which the Company has not recognized any revenue because Cipla has not yet obtained all of the required marketing approvals.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024, the deferred revenue balance for Cipla was $1.2 million, of which $0.1 million was classified as current and $1.1<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-

*content;"> million was classified as long term in the condensed consolidated balance sheets. As of December 31, 2023, the deferred revenue balance was $1.4 million, of which $0.2 million was classified as current and $1.2 million was classified as long term in the condensed consolidated balance sheets.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">Revenue from collaborations and services were as follows (in thousands):</p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.07%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months
Ended September 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months
Ended September 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">UT CSA(1)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,231 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,800</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 73,673 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34,897 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> UT License Agreement(2) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 271 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 347 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 698 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Cipla License and Distribution Agreement </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td*

style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 110 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 110 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total revenue from collaborations and services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,268</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13,108 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">74,130</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 35,705 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> _____ (1) Amounts consist of revenue recognized for Manufacturing Services and Product Sales to UT for the periods presented. (2) Amounts consist of revenue recognized for Next-Gen R&D Services and R&D Services and License for the periods presented.
2323100012800000736730003489700027100034700069800037000370001100001100002326800013108000074130000357050000.100.010.09 Total revenue from UT was as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> UT Revenue </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:right;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> UT CSA </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,231</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,800 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">73,673</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34,897 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> UT License Agreement </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 271 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 347 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 698 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Royalties – Collaboration (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,083 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 20,218 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 75,326 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,951 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total revenue from UT </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,314</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 33,289 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 149,346 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-

space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 86,546 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> _____ (1) Amounts consist of royalties associated with the UT License Agreement. The contract assets related to the royalties is included in prepaid expense and other current assets in the condensed consolidated balance sheets.
2323100012800000736730003489700027100034700069800027083000202180007532600050951000503140003328900014934600086546000There have been various amendments to the UT License Agreement and the CSA since inception. As amended, the term of the CSA continues until December 31, 2031 (unless earlier terminated) and is thereafter renewed automatically for additional, successive two-year terms unless (i) UT provides notice to the Company at least 24 months in advance of such renewal that UT does not wish to renew the CSA or (ii) the Company provides notice to UT at least 48 months in advance of such renewal that the Company does not wish to renew the CSA39500000230000The Company determined that the capital and continuous improvements should be combined with the manufacturing services performance obligation and the alternative manufacturing processes should be combined with the Next-Gen R&D Services. The total revised anticipated cash flows of $722.3 million from the transaction was allocated to the three distinct performance obligations as follows (dollars in millions): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.86%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.140000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.140000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.54%;box-sizing:content-box;"></td> <td style="width:9.14%;box-sizing:content-box;"></td> <td style="width:1.06%;box-sizing:content-box;"></td> <td style="width:9.14%;box-sizing:content-box;"></td> <td style="width:1.06%;box-sizing:content-box;"></td> <td style="width:13.74%;box-sizing:content-box;"></td> <td style="width:2.78%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Anticipated </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left

content;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> R&D Services and License </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:top;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Over time</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Ratably</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Aug 2021 - Oct 2021</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Next-Gen R&D Services</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"> 10.0 </td> <td style="white-space:nowrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Over time </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Input </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> % of completion of costs </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Manufacturing Services and
  Product Sales(2) </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:top;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:top;"> $ </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"> 712.3 </td> <td style="white-space:nowrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Point in time </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Transfer of control </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> </tr> </table> _____ (1) The total anticipated cash flow includes a transaction price of $120.0 million for the contractual obligations under the CSA for the Manufacturing Services and Product Sales and the Next-Gen R&D Services performance obligations and $602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA. (2) The Manufacturing Services and Product Sales performance obligation will be recognized as control of manufactured products is transferred to UT. The modification did not result in a cumulative catch-up adjustment as a result of the revenue being deferred for the performance obligations that were affected by the modification. The allocation of the transaction price for the Manufacturing Services and Product Sales includes a material right related to the Company's estimated production of product in the amount of $220.8 million. The Company will sell product to UT under individual purchase orders, which represent distinct performance obligations. The ultimate cash flows may vary as manufacturing purchase orders are received. 722300000722300000RatablyAug 2021 - Oct 2021100000000Input% of completion of costs712300000Transfer of control120000000602300000220800000705000006400000641000007750000089000006860000011000001100000000020180522000000P15Y120000010000011000001400000200000120000 11. Fair Value of Financial Instruments The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement. The Company uses the exit price method for estimating the fair value of loans for disclosure purposes. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy, as follows: Level 1 — Quoted prices for identical instruments in active markets. Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 — Significant inputs to the valuation model are unobservable. The carrying amounts reported in the condensed consolidated financial statements for cash, accounts receivable, accounts payable, and accrued expenses and other current liabilities (excluding the Milestone Rights liability) approximate their fair value due to their relatively short

*maturities. The fair value of the Senior convertible notes, MidCap credit facility, Mann Group convertible note, Milestone Rights liability, Contingent milestone liability, Financing liability and Liability for sale of future royalties are disclosed below. Financial Liabilities — The following tables set forth the fair value of the Company's financial instruments (Level 3 in the fair value hierarchy) (in millions):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.72%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Carrying Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Significant
Unobservable
Inputs (Level 3) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Financial liabilities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Senior convertible notes(1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">227.9</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 284.7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Milestone rights(2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.2 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Contingent milestone liability(3) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Financing liability(4) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 104.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 106.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-*

left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liability for sale of future royalties(5) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 147.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 137.4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table> _____ (1) Fair value was determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 11.0%, volatility of 52.0% and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or - 2% would result in a fair value of $279.6 million and $290.0 million, respectively. (2) Fair value was determined by applying a Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.7%, dividend yield of 0.0%, volatility of 50.0%, period of 7.3 years and credit risk of 15.0%. (3) Fair value was determined by using the Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.9%, dividend yield of 0.0%, volatility of 43.0%, period of 13.3 years and credit risk of 15.0%. (4) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 9.5%.A change in yield of + or - 2% would result in a fair value of $94.1 million and $121.8 million, respectively. (5) At September 30, 2024, fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 11.0%. A change in yield of + or - 2% would result in a fair value of $121.9 million and $156.4 million, respectively. At December 31, 2023, the carrying value approximated the fair value. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.72%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Carrying Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Significant
Unobservable
Inputs (Level 3) </td> <td style="vertical-align:bottom;border-

bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Financial liabilities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Senior convertible notes(1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">226.9</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 231.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> MidCap credit facility(2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Mann Group convertible note(3) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14.4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Milestone rights(4) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11.9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Contingent milestone liability(5) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Financing liability(6) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 104.1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 106.8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> _____ (1) Fair value was determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 11.0%, volatility of 62.7% and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or - 2<span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-

content;">% would result in a fair value of $224.1 million and $238.9 million, respectively. (2) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 12.0%. A change in yield of + or – 2% would result in a fair value of $35.0 million and $36.0 million, respectively. (3) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 13.0% and volatility of 62.7% to the straight note and a binomial option pricing model for the value of the conversion feature. A change in yield of + or – 2% would result in a fair value of $14.2 million and $14.7 million, respectively. (4) Fair value was determined by applying a Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.9%, dividend yield of 0.0%, volatility of 50.0%, period of 8 years and credit risk of 17.0%. (5) Fair value was determined by using the Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market-based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 4.0%, dividend yield of 0.0%, volatility of 43.0%, period of 15 years and credit risk of 17.0%. (6) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 9.5%. Milestone Rights Liability — The fair value measurement of the Milestone Rights liability is sensitive to the discount rate and the timing of achievement of milestones. The Company utilized a Monte-Carlo Simulation Method to simulate the Afrezza net sales under a neutral framework to estimate the potential payments and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. The Company then discounted the future expected payments at cost of debt with a term equal to the simulated time to payout based on cumulative sales. See Note 15 - Commitments and Contingencies. Contingent Milestone Liability — The acquisition of V-Go in May 2022 resulted in a contingent milestone liability which could result in obligations to the seller if certain revenue thresholds are met. The initial fair value of the contingent milestone liability was recorded as an adjustment to the purchase price. Subsequent changes in the fair value are reported in general and administrative expenses. Financing Liability — The Sale-Leaseback Transaction in November 2021 resulted in a financing liability. See Note 15 - Commitments and Contingencies. Liability for Sale of Future Royalties — The sale of a portion of our royalty rights in December 2023 resulted in a liability for sale of future royalties. See Note 15 - Commitments and Contingencies. The following tables set forth the fair value of the Company's financial instruments (Level 3 in the fair value hierarchy) (in millions): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.72%;box-sizing:content-box;"></td><td style="width:1.72%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.92%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.72%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.92%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> <span style="white-space:pre-

wrap;min-width:fit-content;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Carrying Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Significant
Unobservable
Inputs (Level 3) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Financial liabilities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Senior convertible notes(1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">227.9</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 284.7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Milestone rights(2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.2 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Contingent milestone liability(3) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Financing liability(4) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 104.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 106.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Liability for sale of future royalties(5) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 147.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 137.4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table> _____ (1) Fair value was determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 11.0%, volatility of 52.0% and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or - 2% would result in a fair value of $279.6 million and $290.0 million, respectively. (2) Fair value was

*determined by applying a Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.7%, dividend yield of 0.0%, volatility of 50.0%, period of 7.3 years and credit risk of 15.0%. (3) Fair value was determined by using the Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.9%, dividend yield of 0.0%, volatility of 43.0%, period of 13.3 years and credit risk of 15.0%. (4) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 9.5%. A change in yield of + or - 2% would result in a fair value of $94.1 million and $121.8 million, respectively. (5) At September 30, 2024, fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 11.0%. A change in yield of + or - 2% would result in a fair value of $121.9 million and $156.4 million, respectively. At December 31, 2023, the carrying value approximated the fair value.</div></div><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.72%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Fair Value</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Carrying Value</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Significant
Unobservable
Inputs (Level 3)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Financial liabilities:</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Senior convertible notes(1)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 226.9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 231.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> MidCap credit facility(2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-*

space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Mann Group convertible note(3) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14.4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Milestone rights(4) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11.9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Contingent milestone liability(5) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Financing liability(6) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 104.1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 106.8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table> _____ (1) Fair value was determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 11.0%, volatility of 62.7% and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or - 2% would result in a fair value of $224.1 million and $238.9 million, respectively. (2) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 12.0%, A change in yield of + or - 2% would result in a fair value of $35.0 million and $36.0 million, respectively. (3) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 13.0% and volatility of 62.7% to the straight note and a binomial option pricing model for the value of the conversion feature. A change in yield of + or - 2% would result in a fair value of $14.2 million and $14.7 million, respectively. (4) Fair value was determined by applying a Monte Carlo simulation method for the calculation of the potential payment and the Geometric

*Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.9%, dividend yield of 0.0%, volatility of 50.0%, period of 8 years and credit risk of 17.0%. (5) Fair value was determined by using the Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market-based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 4.0%, dividend yield of 0.0%, volatility of 43.0%, period of 15 years and credit risk of 17.0%. (6) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 9.5%.
2279000002847000003200000113000003000003000001040000001065000001475000001374000001152O.022796000002900000003.70507.3153.904313.3159.50.02
style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">12. Common and Preferred Stock</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company is authorized to issue 800,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of undesignated preferred stock, par value $0.01 per share, issuable in one or more series as designated by the Company's board of directors. No other class of capital stock is authorized. As of September 30, 2024 and December 31, 2023, 275,775,038 and 270,034,495 shares of common stock, respectively, were issued and outstanding and no shares of preferred stock were outstanding. </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In February 2018, the Company entered into a controlled equity offering sales agreement (the "CF Sales Agreement") with Cantor Fitzgerald & Co. ("Cantor Fitzgerald"), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor Fitzgerald, shares of the Company's common stock having an aggregate offering price of up to $50.0 million or such other amount as may be permitted by the Sales Agreement. Under the Sales Agreement, Cantor Fitzgerald may sell shares by any method deemed to be an "at-the-market offering" as defined in Rule 415 under the Securities Act of 1933, as amended. There were no sales under the CF Sales Agreement during the nine months ended September 30, 2024. During the nine months ended September 30, 2023, the Company sold 1,478,090 shares of common stock at a weighted average purchase price of $4.66 per share for gross proceeds of approximately $6.9 million pursuant to the CF Sales Agreement. </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">During the nine months ended September 30, 2024, the Company received $1.4 million from the market price stock purchase plan ("MPSPP") for 416,099 shares of common stock. During the nine months ended September 30, 2023, the Company received $0.2 million from the MPSPP for 36,004 shares.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">For shares of common stock issued pursuant to the Company's 2004 employee stock purchase plan ("ESPP"), see Note 14 – Stock-Based Compensation Expense.
8000000000.01100000000.012757750382757750382700344952700344950050000000014780904.666900000140000041609920000036004 13. Earnings per Common Share The following tables summarize the components of the basic and diluted EPS computations (in thousands, except per share amounts): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.07%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.182%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months
Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months
Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-

bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> EPS — basic: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Net income (loss) (numerator) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,550</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,721 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">20,166</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (13,339 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Weighted average common shares (denominator) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 274,998 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 268,732 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 272,811 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 266,126 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Net income (loss) per share </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.04</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 0.01 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 0.07 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.05</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">EPS — diluted</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Adjusted net income (loss) (numerator)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 11,550 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,578</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (13,339 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Weighted average common shares </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 274,998 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 268,732 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 272,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 266,126 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Effect of dilutive securities — common shares issuable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9,695 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 55,038 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8,596 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Adjusted weighted average common shares

(denominator) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 284,693 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 323,770 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 281,407 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 266,126 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Net income (loss) per share </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.04</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 0.01 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.07</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (0.05 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr></table> For the three months ended September 30, 2024, diluted net income per share excluded the weighted average effect of 10.4 million shares of RSUs and Market RSUs, 0.4 million options and PNQs and 44.1 million common shares issuable upon conversion of our Senior convertible notes, as they were antidilutive. For the nine months ended September 30, 2024, diluted net income per share excluded the weighted average effect of 9.1 million RSUs and Market RSUs, 0.7 million options and PNQs and 44.1 million common shares issuable upon conversion of our Senior convertible notes, as they were antidilutive. For the three months ended September 30, 2023, diluted net income per share excluded the weighted average effect of 9.4 million shares of RSUs and Market RSUs and 2.0 million options and PNQs as they were antidilutive. Common shares issuable represents incremental shares of common stock which consist of RSUs, stock options, warrants, and shares that could be issued upon conversion of the Senior convertible notes and the Mann Group convertible notes. Potentially dilutive securities outstanding which were considered antidilutive due to the net losses incurred for the nine months ended September 30, 2023 are summarized as follows (in shares): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:81.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Senior convertible notes </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44,120,463 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> RSUs and Market RSUs(1) </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,151,454 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock options and PNQs </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,447,339 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Mann Group convertible notes </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,370,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total shares </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 77,089,256 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> _____ (1) Market RSUs issued in 2021, 2022 and 2023 are included at the share delivery of 0%, 205% and 219%, respectively, in accordance with a valuation assessment obtained as of September 30, 2023. The following tables summarize the components of the basic and diluted EPS computations (in thousands, except per share amounts): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> EPS — basic: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Net income (loss) (numerator) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,550</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">1,721 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">20,166</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (13,339 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Weighted average common shares (denominator) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 274,998 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 268,732 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 272,811 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 266,126 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Net income (loss) per share </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.04</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 0.01 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.07</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (0.05 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> EPS — diluted: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Adjusted net income (loss) (numerator) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,550</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,578 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 20,166 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(13,339</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Weighted average common shares</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">274,998</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">268,732</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">272,811</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">266,126</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Effect of dilutive securities — common shares issuable</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,695</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">55,038</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,596</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Adjusted weighted average common shares (denominator)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">284,693</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">323,770</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">281,407</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;font-family:Times New Roman;margin-bottom:0;text-align:right;">266,126</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net income (loss) per share</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 0.04 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.01</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 0.07 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (0.05 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr></table> For the three months ended September 30, 2024, diluted net income per share excluded the weighted average effect of 10.4 million shares of RSUs and Market RSUs, 0.4 million options and PNQs and 44.1 million common shares issuable upon conversion of our Senior convertible notes, as they were antidilutive. For the nine months ended September 30, 2024, diluted net income per share excluded the weighted average effect of 9.1 million RSUs and Market RSUs, 0.7 million options and PNQs and 44.1 million common shares issuable upon conversion of our Senior convertible notes, as they were antidilutive. For the three months ended September 30, 2023, diluted net income per share excluded the weighted average effect of 9.4 million shares of RSUs and Market RSUs and 2.0 million options and PNQs as they were antidilutive. 1155000017210002016600 0-133390002749980002687320002728110002661260000.040.010.07-0.05115500003578000201660000-133390002749980002687320002728110002661260009695000550380008596000284693000323770000281407000266126000 0.040.010.07-0.05104000004000004410000091000007000004410000094000002000000Potentially dilutive securities outstanding which were considered antidilutive due to the net losses incurred for the nine months ended September 30, 2023 are summarized as follows (in shares): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:81.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Senior convertible notes </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44,120,463 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> RSUs and Market RSUs(1) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,151,454 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock options and PNQs </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,447,339 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Mann Group convertible notes </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,370,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total shares </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 77,089,256 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> _____ (1) Market RSUs issued in 2021, 2022 and 2023 are included at the share delivery of 0%, 205% and 219%, respectively, in accordance with a valuation assessment obtained as of September 30, 2023. 4412046321151454844733933700007708925602.052.19 14. Stock-Based Compensation Expense The Company granted the following awards (in shares): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:45.848%;box-sizing:content-box;"></td> <td style="width:1.001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.508%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.041%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.508%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.041%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.508%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.041%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.508%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-

size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
March 31, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Employee awards: </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> RSUs </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 267,990 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> (1) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,205,910 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> (2) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 241,253 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> (5) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,715,153 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Market RSUs </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,144,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> (3) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td

style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,144,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Non-employee director RSUs </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 280,376 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> (4) </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 280,376 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"> Total awards issued </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 267,990 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,630,286 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 241,253 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,139,529 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> _____ (1) RSUs had a weighted average grant date fair value of $3.28 per share, of which 211,895 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, 53,720 RSUs had a cliff vesting period of three years, and 2,375 RSUs had a vesting period of 25% annually over four years, (2) RSUs had a weighted average grant date fair value of $4.45 per share, of which 3,033,680 RSUs had a vesting period of 25% annually over four years, 145,980 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, and 26,250 RSUs had a cliff vesting period of <span

style="font-size:9pt;font-family:Times New Roman;">two years, (3) Market RSUs had a grant date fair value of $10.30 per share and will vest on July 15, 2027. The number of shares delivered on the vesting date is determined by the percentile ranking of MannKind total shareholder return ("TSR") over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. (4) RSUs had a weighted average grant date fair value of $4.45 per share and vested immediately upon the grant date; however, the underlying shares of common stock will not be delivered until there is a separation of service such as resignation, retirement or death. (5) RSUs had a weighted average grant date fair value of $5.34 per share, of which 219,285 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, and 21,968 RSUs had a vesting period of 40% on the first anniversary and 60% on the second anniversary of the vesting determination date. As of September 30, 2024, there was $26.2 million and $27.4 million of unrecognized stock-based compensation expense related to RSUs and Market RSUs, respectively, which is expected to be recognized over a weighted average period of approximately 2.84 and 1.98 years, respectively. </p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">Total stock-based compensation expense recognized in the condensed consolidated statements of operations as cost of goods sold, cost of revenue - collaborations and services, R&D and selling, general and administrative expense was as follows (in thousands):</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:53.831%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.342%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.342%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.342%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months
Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months
Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">RSUs and options</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:right;">5,047 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,442</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,994 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13,324</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Employee stock purchase plan</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">180</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">159</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">546</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">512</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,227 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,601</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,540 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13,836 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> Employee Stock Purchase Plan The Company provides all employees, including executive officers, the ability to purchase common stock at a discount under the ESPP. The ESPP is designed to comply with Section 423 of the Internal Revenue Code and provides all employees with the opportunity to purchase up to $25,000 worth of common stock (based on the undiscounted fair market value at the commencement of the offering period) each year at a purchase price that is the lower of 85% of the fair market value of the common stock on either the date of purchase or the commencement of the offering period. An employee may not purchase more than 5,000 shares of common stock on any purchase date. The executives' rights under the ESPP are the same as those of all other employees. There were approximately 2.6 million shares of common stock available for issuance under the ESPP as of September 30, 2024. The Company granted the following awards (in shares): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:45.848%;box-sizing:content-box;"></td><td style="width:1.001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.508%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.041%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.508%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.041%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.508%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.041%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.508%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
March 31, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> <span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-

content;">Three Months Ended
June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
 September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:top;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Employee awards: </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> RSUs </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 267,990 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> (1) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,205,910 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> (2) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 241,253 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> (5) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,715,153 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Market RSUs </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,144,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> (3) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,144,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Non-employee director RSUs </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 280,376 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> (4) </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 280,376 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"> Total awards issued </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 267,990 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,630,286 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 241,253 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,139,529 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> _____ (1) RSUs had a weighted average grant date fair value of $3.28 per share, of which 211,895 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, 53,720 RSUs had a cliff vesting period of three years, and 2,375 RSUs had a vesting period of 25% annually over four years, (2) RSUs had a weighted average grant date fair value of $4.45 per share, of which 3,033,680 RSUs had a vesting period of 25% annually over four years, 145,980 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, and 26,250 RSUs had a cliff vesting period of two years. (3) Market RSUs had a grant date fair value of $10.30 per share and will vest on July 15, 2027, The number of shares delivered on the vesting date is determined by the percentile ranking of MannKind

total shareholder return ("TSR") over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. (4) RSUs had a weighted average grant date fair value of $4.45 per share and vested immediately upon the grant date; however, the underlying shares of common stock will not be delivered until there is a separation of service such as resignation, retirement or death. (5) RSUs had a weighted average grant date fair value of $5.34 per share, of which 219,285 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, and 21,968 RSUs had a vesting period of 40% on the first anniversary and 60% on the second anniversary of the vesting determination date.
2679903205910241253371515321440002144000280376280376267990563028624125361395293.282118950.3330.3330.33353720P3Y23750.25P4Y4.4530336800.2507-1500.501234.455.32192850.3330.3330.333219680.400.6026200000274000000P2Y10M2DP1Y11M23D Total stock-based compensation expense recognized in the condensed consolidated statements of operations as cost of goods sold, cost of revenue - collaborations and services, R&D and selling, general and administrative expense was as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:53.831%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.342%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.342%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.342%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> RSUs and options </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,047</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,442 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,994</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,324 </td> <td style="white-space:nowrap;vertical-align:bottom;">

</td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Employee stock purchase plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 180 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 159 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 546 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 512 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,227</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,601 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">15,540</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13,836 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table>504700044420001499400013324000180000159000546000512000522700046010001554000013836000250000.8550002600000 15. Commitments and Contingencies Guarantees and Indemnifications — In the ordinary course of its business, the Company makes certain indemnities, commitments and guarantees under which it may be required to make payments in relation to certain transactions. The Company, as permitted under Delaware law and in accordance with its Bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company's request in such capacity. The term of the indemnification period is for the officer's or director's lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal and therefore has not recorded any liability for these indemnities in the condensed consolidated balance sheets. The Company accrues for losses for any known contingent liability, including those that may arise from indemnification provisions, when future payment is probable and the amount can be reasonably estimated. No such losses have been recorded to date. Litigation — The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. The Company does not anticipate the final disposition of any matters will have a material adverse effect on the results of operations, financial position, or cash flows of the Company. The Company maintains liability insurance coverage to protect the Company's assets from losses arising out of or involving activities associated with ongoing and normal business operations. The Company records a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company's policy is to accrue for legal expenses in connection with legal proceedings and claims as they are incurred. Contingencies — Milestone Rights — In July 2013, the Company entered into the Milestone Rights Agreement with the Original Milestone Purchasers, pursuant to which the Company granted the Milestone Rights to receive payments up to $90.0 million upon the occurrence of specified strategic and sales milestones, $50.0 million of which remains payable to the Milestone Purchasers as of September 30, 2024. The Milestone Rights Agreement includes customary representations and warranties and covenants by the Company, including restrictions on transfers of intellectual property related to Afrezza. The Milestone Rights are subject to acceleration in the event the Company transfers its intellectual property related to Afrezza in violation of the terms of such agreement. During each of the nine months ended September 30, 2024 and 2023, the Company made milestone payments of $5.0 million to the Milestone Purchasers. As of September 30, 2024 and December 31, 2023, the remaining Milestone Rights liability balance was $3.2 million and $3.9 million, respectively, and consisted of $0.7 million and $0.8 million, respectively, of current liability, which was presented as accrued expenses and other current liabilities, and <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$2.5 million and $3.1 million, respectively, of long-term liability, which was presented as milestone liabilities in the condensed consolidated balance sheets. The value of the Milestone Rights liability was based on initial fair value estimates calculated using the income

approach and is reduced by milestone achievement payments made. Loss Contingencies — Returns Reserve for Acquired Product — During the nine months ended September 30, 2024, the Company reassessed its previously-determined estimate for product returns associated with sales of Y-Go that pre-date the Company's acquisition of the product and recorded an additional $1.4 million, which is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets as of September 30, 2024 and being reduced as product returns are received. Losses on estimated returns of acquired product were recorded in general and administrative expenses in the condensed consolidated statements of operations. Liability for Sale of Future Royalties— In December 2023, the Company executed a Purchase and Sale Agreement (the "PSA") with Sagard Healthcare Partners Funding Borrower SPE 2, LP ("Sagard"). Pursuant to the PSA, Sagard paid the Company $150.0 million (the "Upfront Proceeds"), net of $0.4 million in reimbursements of Sagard's fees and expenses (the "Reimbursements"), for the purchase of a 1% royalty on future net sales of Tyvaso DPI by UT under the terms of the UT License Agreement (the "Sagard Royalty"). Sagard will also pay the Company a milestone of $50.0 million if net sales of Tyvaso DPI meet or exceed $1.9 billion for any twelve consecutive months on or prior to December 31, 2026 ("Net Sales Threshold A"), or a milestone of $45.0 million if net Sales Threshold A is not met and net sales of Tyvaso DPI meet or exceed $2.3 billion for any twelve consecutive months on or prior to September 30, 2027 ("Net Sales Threshold B"), resulting in a purchase price not to exceed $200.0 million (the "Purchase Price"). If Net Sales Thresholds A and B are not met and net sales of Tyvaso DPI meet or exceed $3.5 billion for any calendar year after September 30, 2027, no royalties will be payable to Sagard for the remainder of that year. The PSA applies to net sales of Tyvaso DPI generated during October 1, 2023 through December 31, 2042 (the "Termination Date") and will automatically terminate upon payment of the final royalty owed to Sagard thereafter. Upon the Termination Date, ownership of the Sagard Royalty will revert to the Company. Given the Company's continuing involvement with the generation of Tyvaso DPI revenue under the UT License Agreement and CSA, which includes the Company's supply and manufacture of Tyvaso DPI, and the Company's retention and associated defense and maintenance obligations of the intellectual property required in the manufacture of Tyvaso DPI, the Upfront Proceeds were recorded as a liability for sale of future royalties (the "Royalty Liability") on the condensed consolidated balance sheets, and any proceeds from future milestones will be added to the Royalty Liability balance upon receipt. Although the Company is not obligated to repay any portion of the Purchase Price to Sagard, the Royalty Liability under the PSA is secured by a security interest granted to Sagard in the underlying 1% royalty rights and any proceeds therefrom. As a result of the PSA, transaction costs totaling $4.4 million (including the Reimbursements) are reported net of the Royalty Liability balance and amortized to interest expense in the condensed consolidated statements of operations over the life of the PSA using the effective interest method. Unamortized transaction costs totaled $4.2 million and $4.4 million at September 30, 2024 and December 31, 2023, respectively.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company will continue to recognize the full 10% of future royalty revenues in its condensed consolidated statements of operations, with the Sagard Royalty being non-cash revenue for the Company. As royalty payments are earned by and remitted to Sagard, the balance of the Royalty Liability will be effectively repaid as it is amortized over the life of the PSA. To amortize the Royalty Liability, the Company estimated the total amount of future royalty payments to be made to Sagard over the life of the PSA. The excess of those future estimated royalty payments over the Purchase Price proceeds received is recognized in the condensed consolidated statements of operations as non-cash interest expense over the life of the PSA utilizing an imputed effective interest rate. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate may vary during the term of the agreement depending on a number of factors, including the amount and timing of forecasted royalty payments which affects the timing and ultimate amount of reductions to the liability. The Company will evaluate the effective interest rate periodically based on its forecasted royalty payments utilizing the prospective method.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company periodically assesses the forecasted royalty payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments, or the timing of such payments, are materially different than original estimates, the Company will prospectively adjust the effective interest rate and amortization of the Royalty Liability. </p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">The following table shows the activity within the Royalty Liability account during the nine months ended September 30, 2024 as well as the effective interest rate (dollars in thousands):</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.7%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance, January 1, 2024</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 145,810 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Amortization of deferred transaction costs </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 172 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Non-cash interest expense on liability for sale of future royalties </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,548 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Royalty revenue earned by or payable to Sagard </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (9,635 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Balance, September 30,

2024 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 148,895 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Effective interest rate </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 8.8% - 11.5% </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> </table> Sale-Leaseback Transaction— In November 2021, the Company sold certain land, building and improvements located in Danbury, CT (the "Property") to an affiliate of Creative Manufacturing Properties (the "Purchaser") for a sales price of $102.3 million, subject to terms and the conditions contained in a purchase and sale agreement. Effective with the closing of the Sale-Leaseback Transaction, the Company and the Purchaser entered into a lease agreement (the "Lease"), pursuant to which the Company leased the Property from the Purchaser for an initial term of 20 years, with four renewal options of five years each. The total annual rent under the Lease starts at approximately $9.5 million per year, subject to a 50% rent abatement during the first year of the Lease, and will increase annually by (i) 2.5% in the second through fifth year of the Lease and (ii) 3% in the sixth and each subsequent year of the Lease, including any renewal term, utilizing a weighted average discount rate of 9.0%. The Company is responsible for payment of operating expenses, property taxes and insurance for the Property. The Purchaser will hold a security deposit of $2.0 million during the Lease term. Pursuant to the terms of the Lease, the Company has four options to repurchase the Property, in 2026, 2031, 2036 and 2041, for the greater of (i) $102.3 million and (ii) the fair market value of the Property. </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Effective with the closing of the Sale-Leaseback Transaction, the Company and the Purchaser also entered into a right of first refusal agreement (the "ROFR"), pursuant to which the Company has a right to re-purchase the Property from the Purchaser in accordance with terms and conditions set forth in the ROFR. Specifically, if the Purchaser receives, and is willing to accept, a bona fide purchase offer for the Property from a third-party purchaser, the Company has certain rights of first refusal to purchase the Property on the same material terms as proposed in such bona fide purchase offer.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024, the related financing liability was $104.0 million, which was recognized in the condensed consolidated balance sheet and of which $94.0 million was long-term and $10.0 million was current. As of December 31, 2023, the related financing liability was $104.1 million, of which <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$94.3 million was long-term and $9.8 million was current. Financing liability information was as follows (dollars in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.313%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.283%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.283%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted average remaining lease term (in years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17.1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17.8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.73%;box-sizing:content-box;"></td> <td style="width:1.641%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.107%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.401%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.107%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.401%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.107%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.401%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.107%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Interest expense on financing liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,470</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,459 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,361</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>
The Company's remaining financing liability payments were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.596%;box-sizing:content-box;"></td> <td style="width:2.621%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.783000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Remainder of 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,532 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,269 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,533 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2027 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,849 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2028 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,174 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">Thereafter </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 177,278 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 222,635 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Interest payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (116,113 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Debt issuance costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,519 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total financing liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">104,003</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Financing Lease — In May 2024, the Company acquired audio-visual equipment via a financing lease with de minimis monthly principal and interest payments and a termination date in May 2029. </p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">Financing lease information was as follows (dollars in thousands): </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:79.596%;box-sizing:content-box;"></td><td style="width:2.621%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.783%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Financing lease right-of-use asset(1)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 219 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td></tr><tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Financing lease liability-current(2) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">52</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Financing lease liability-long-term</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">171</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 223 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td></tr><tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;">

Weighted average remaining lease term (in years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted average discount rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> _____ (1) Financing right-of-use asset is included in other assets in the condensed consolidated balance sheets. (2) Financing lease liability - current is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. The Company's remaining financing lease payments were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.596%;box-sizing:content-box;"></td> <td style="width:2.621%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.783000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Remainder of 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">54</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">54</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">54</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2028</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">54</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Thereafter</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">266</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Interest payments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(43</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total financing liability</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 223 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <span style="color:#000000;white-space:pre-wrap;font-

size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commitments — In July 2014, the Company entered into the Insulin Supply Agreement pursuant to which Amphastar manufactures for and supplies to the Company certain quantities of recombinant human insulin for use in Afrezza. Under the terms of the Insulin Supply Agreement, Amphastar is responsible for manufacturing the insulin in accordance with the Company's specifications and agreed-upon quality standards. In December 2023, the Company and Amphastar amended the Insulin Supply Agreement to extend the term, restructure the annual purchase commitments and include a capacity fee for certain future periods. The Company's remaining purchase commitments and estimated capacity fee liability as of September 30, 2024 were as follows (€ in millions): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:61.308%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:16.757%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.34%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:16.597%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Remaining Purchase Commitments </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated Capacity Fees </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.5 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> 2026(1) </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.2 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.0 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> 2027 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.0 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.0 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> 2028 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.0 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.0 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> 2029 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.0 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.0 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> 2030 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.0 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.0 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> 2031 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.0 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> <span

style="min-width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2032 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2033 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2034 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4.4 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 0.5 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 56.6 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9.5 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> _____ (1) If there is a delay in the availability of insulin with FDA approved inclusion bodies and supply does not begin in 2026 as currently expected, the Company will incur a capacity fee of €750,000 per quarter that the product is not available for purchase. Pursuant to the amendment, the term of the Insulin Supply Agreement expires on the later of December 31, 2034 or until the completion of the total remaining purchase commitment quantities, unless terminated earlier, and can be renewed for additional, successive two-year terms upon 12 months' written notice given prior to the end of the initial term or any additional two-year term. The Company and Amphastar each have normal and customary termination rights, including termination for a material breach that is not cured within a specific time frame or in the event of liquidation, bankruptcy or insolvency of the other party. In addition, the Company may terminate the Insulin Supply Agreement upon two years' prior written notice to Amphastar without cause or upon 30 days' prior written notice to Amphastar if a controlling regulatory authority withdraws approval for Afrezza, provided, however, in the event of a termination pursuant to either of the latter two scenarios, the provisions of the Insulin Supply Agreement require the Company to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination. The Company periodically reviews the terms of the long-term Insulin Supply Agreement and assesses the need for any accrual for estimated losses, such as lower-of-cost or net-realizable-value that will not be recovered by future product sales. The recognized loss on purchase commitments of $62.6 million and <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$64.8 million is included in our condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023, respectively, and is reduced as inventory items are received or such liability is extinguished. As a result of the increase in future cash flows for the excess capacity fees and extended term included in the amendment of the Insulin Supply Agreement, the Company analyzed the need for additional estimated losses and concluded that an increase in the recognized loss on purchase commitments was not required as the net realizable value of inventory resulting from the purchase commitment was in excess of the carrying value. Increases in costs associated with the amendment will be recognized through inventory as incurred. Vehicle Leases — During the second quarter of 2018, the Company entered into a master lease agreement with Enterprise Fleet Management Inc. The monthly payment inclusive of maintenance fees, insurance and taxes is approximately $0.1 million. The lease expense is included in selling expenses in the condensed consolidated statements of operations. Office Leases — In May 2017, the Company executed an office lease with Russell Ranch Road II LLC for the Company's corporate offices in Westlake Village, California, which was renewed in April 2022. Pursuant to the renewal, the monthly lease payments of $79,543 began in February 2023 and are subject to 3% annual increases, plus the estimated cost of maintaining the property and common areas by the landlord, and are further subject to a six-month base rent concession beginning February 2023. The Company is also entitled to a one-time allowance up to $0.9 million as reimbursement for tenant improvements or the purchase of furniture,<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-

content;"> fixtures or equipment. Of the $0.9 million allowance, an amount up to $0.7 million may be applied as an additional base rent concession. The Company has no further right to extend the lease term beyond July 31, 2028. In May 2022, the Company assumed certain leased real property (the "Marlborough Lease") in connection with the V-Go acquisition. The Marlborough Lease pertains to certain premises in a building located in Marlborough, Massachusetts. The monthly payments of $28,895 began in June 2022, subject to approximately 3% annual increases through February 28, 2026. The Company also acquired rights to a manufacturing service agreement where V-Go is manufactured using Company-owned equipment located at the manufacturing facility. The Company determined that this arrangement results in an embedded lease which granted the Company exclusive use of space within the manufacturing facility. The Company assessed the embedded lease cost to be $14,370 per month through February 28, 2026. In July 2024, the Company assumed certain leased real property (the "Bedford Lease") in connection with the Pulmatrix Transaction. The Bedford Lease pertains to certain premises in a building located in Bedford, Massachusetts. The monthly base rent payments of $101,282 are subject to 3% annual increases, plus the estimated cost of maintaining the property and common areas by the landlord. The Company also assumed from Pulmatrix a $0.7 million obligation to repay landlord-funded tenant improvements at a rate of $6,000 per month through the end of the lease term in November 2033. The Company has the right to extend the lease term for an additional five-year term.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">Lease information was as follows (dollars in thousands):</p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.747%;box-sizing:content-box;"></td><td style="width:1.721%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.906%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.721%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.906%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease right-of-use assets(1)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13,637 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,685</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease liability-current(2)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,431 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,423 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Operating lease liability-long-term </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12,167 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,925 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-

indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,598</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,348 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted average remaining lease term (in years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted average discount rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> _____ (1) Operating right-of-use assets related to vehicles, offices and the manufacturing facility for V-Go are included in other assets in the condensed consolidated balance sheets. (2) Operating lease liability – current is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> Three Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating lease costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 719 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">422</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,417 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,253 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Variable lease costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 104 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 48 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 122 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 97 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash paid </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 860 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 268 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,407 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 825 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>
The Company's future minimum office and vehicle lease payments were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.04%;box-sizing:content-box;"></td> <td style="width:2.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Remainder of 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 784 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,157 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,579 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> 2027 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,540 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr

*style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2028 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,087 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Thereafter </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,721 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,868 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Interest expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4,270 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total operating lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,598 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>
900000005000000050000005000000320000039000007000008000002500000031000001400000015000000040000000.015000000019000000004500000023000000012,10-012042-12-310.01440000042000004400000.10 The following table shows the activity within the Royalty Liability account during the nine months ended September 30, 2024 as well as the effective interest rate (dollars in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.7%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Balance, January 1, 2024 </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">145,810</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Amortization of deferred transaction costs</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">172</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Non-cash interest expense on liability for sale of future royalties</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,548</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Royalty revenue earned by or payable to Sagard</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(9,635</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance, September 30, 2024</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 148,895 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Effective interest rate </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 8.8% – 11.5% </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> </table>1458100001720001254800096350001488950000.0880.115102300000P20Ytruerenewal options of five yearsThe total annual rent under the Lease starts at approximately $9.5 million per year, subject to a 50% rent abatement during the first year of the Lease, and will increase annually by (i) 2.5% in the second through fifth year of the Lease and (ii) 3% in the sixth and each subsequent year of the Lease, including any renewal term, utilizing a weighted average discount rate of 9.0%.95000000.092000000.0the Company has four options to repurchase the Property, in 2026, 2031, 2036 and 2041, for the greater of (i) $102.3 million and (ii) the fair market value of the Property.10230000010400000094000000100000001041000009430000098000000 Financing liability information was as follows (dollars in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.313%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.283%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.283%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> <span style="color:#000000;white-space:pre-*

wrap;font-weight:bold;min-width:fit-content;">September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted average remaining lease term (in years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17.1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17.8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> Lease information was as follows (dollars in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.747%;box-sizing:content-box;"></td> <td style="width:1.721%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.906%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.721%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.906%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Operating lease right-of-use assets(1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13,637</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,685 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Operating lease liability-current(2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,431</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,423 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Operating lease liability-long-term </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12,167 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,925 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,598</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,348 </td> <td style="white-

space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted average remaining lease term (in years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted average discount rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> _____ (1) Operating right-of-use assets related to vehicles, offices and the manufacturing facility for V-Go are included in other assets in the condensed consolidated balance sheets. (2) Operating lease liability – current is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. P17Y1M6DP17Y9M18D <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.73%;box-sizing:content-box;"></td> <td style="width:1.641%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.107%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.401%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.401%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.107%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.401%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.107%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months
Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Interest expense on financing liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,470</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,459 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,361 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-

*space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,332</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months
Ended September 30, </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months
Ended September 30, </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease costs</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 719 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">422</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,417 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,253 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Variable lease costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 104 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 48 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 122 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 97 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash paid </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 860 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 268 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-*

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,407 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 825 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table>2470000245900073610007332000 The Company's remaining financing liability payments were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.596%;box-sizing:content-box;"></td> <td style="width:2.621%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.783000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Remainder of 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,532</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,269</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,533</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,849</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2028</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,174</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Thereafter</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">177,278</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">222,635</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Interest payments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(116,113</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Debt issuance costs</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(2,519</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total financing liability</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 104,003 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table>25320001026900010533000108490000111740001772780002226350001161130002519000104003000 Financing lease information was as follows (dollars in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.596%;box-sizing:content-box;"></td> <td style="width:2.621%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.783%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-

align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Financing lease right-of-use asset(1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Financing lease liability-current(2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">52</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Financing lease liability-long-term</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">171</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 223 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Weighted average remaining lease term (in years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted average discount rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> _____ (1) Financing right-of-use asset is included in other assets in the condensed consolidated balance sheets. (2) Financing lease liability – current is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. 2190005200017100022300OP4Y8M12D0.0725 The Company's remaining financing lease payments were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.596%;box-sizing:content-box;"></td> <td style="width:2.621%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.783000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Remainder of 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 27 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

*style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2027 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2028 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Thereafter </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 23 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 266 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Interest payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (43 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total financing liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 223 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>
270005400054000540005400023000266000430002230000The Company's remaining purchase commitments and estimated capacity fee liability as of September 30, 2024 were as follows (€ in millions): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.308%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.757%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.597%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;">   </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Remaining Purchase Commitments </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated Capacity Fees </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2026(1)
</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.2 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2027 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-*

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2028 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2029 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2030 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2031 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2032 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2033 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2034 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4.4 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 0.5 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 56.6 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9.5 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> _____ If there is a delay in the availability of insulin with FDA approved inclusion bodies and supply does not begin in 2026 as currently expected, the Company will incur a capacity fee of €750,000 per quarter that the product is not available for purchase.
150000042000002000000600000010000006000000100000060000001000000600000010000006000000100000008000000500000080000005000008000000500000440000050000056600
12-31P2Y626000006480000010000079543O.0390000090000700000 The Company has no further right to extend the lease term beyond July 31,
2028.288950.03143701012820.037000006000000000P5Y1363700046850002431000142300012167000392500014598000053480000P7Y3M18DP3Y8M12D0.07250.0725719000

style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">The Company's future minimum office and vehicle lease payments were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.04%;box-sizing:content-box;"></td> <td style="width:2.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Remainder of 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">784</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,157</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,579</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,540</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2028</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,087</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Thereafter</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,721</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,868</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Interest expense</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(4,270</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total operating lease liability</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,598 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>7840003157000257900025400002087000772100018868000427000014598000 16. Income Taxes During the three and nine months ended September 30, 2024, the Company recorded income tax expense of $1.3 million and <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$1.9 million, respectively, related to state taxes, which was calculated using the discrete year-to-date method. The income tax provision for the three and nine months ended September 30, 2023 resulted in no tax expense. The effective tax rate differs from the statutory tax rate of 21% primarily due to the existence of valuation allowances against net deferred tax assets and current liabilities resulting from the estimated state income tax liabilities. Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and concluded, in accordance with the applicable accounting standards, that net deferred tax assets should be fully reserved. The Company has assessed its position with regards to uncertainty in tax positions and has not recognized a liability for unrecognized tax benefits. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. The Company recognizes interest and penalties accrued related to unrecognized tax benefits in income tax expense. During the nine months ended September 30, 2024, the Company did not recognize any interest or penalties. The Company's tax years since 2019 remain subject to examination by tax authorities. In June 2024, California enacted Senate Bills 167 and 175 ("SB 167" and "SB 175"). SB 167 suspends the use of net operating losses ("NOLs") and limits the use of business credits to

*$5.0 million for the 2024-2026 tax years. Under SB 175, the NOL suspension and credit limitations will not apply for the 2025 and 2026 tax years if certain budget goals are met. Although the Company does not expect this legislation to have a material effect on its results of operations or cash flows, management continues to evaluate any potential impact. 1300000019000000.2105000000 During the three months ended September 30, 2024, two of our officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted written trading plans for the orderly disposition of the Company's securities as set forth in the table below: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:20.392%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:12.195%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:12.195%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:11.795%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.256%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.656%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:12.195%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="4" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Type of Trading Arrangement </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Name and Position </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Action </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Adoption
Date </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Rule 10b5-1(1) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Non-Rule 10b5-1(2) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Total Shares of Common Stock to be Sold(3) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Expiration Date </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Steven B. Binder
Director </td><td style="white-space:pre-wrap;vertical-align:top;"> </td><td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Adoption </td><td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> </td><td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> August 16, 2024 </td><td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> </td><td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> X </td><td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> </td><td style="white-space:nowrap;vertical-align:top;"> </td><td style="white-space:pre-wrap;vertical-align:top;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:top;"> </td><td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> </td><td style="white-space:nowrap;vertical-align:top;"> </td><td style="white-space:pre-wrap;vertical-align:top;text-align:center;"> 297,075 </td><td style="white-space:nowrap;vertical-align:top;"> </td><td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> </td><td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> August 29, 2025 </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> David Thomson
EVP, General Counsel </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Adoption </td><td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> </td><td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> August 19, 2024 </td><td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> </td><td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> X </td><td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> </td><td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-*

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"> 188,780 </td> <td style="white-space:nowrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> August 19, 2025 </td> </tr></table> _____ (1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. (2) "Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act. (3) These trading plans include the potential exercise and sale by Steven Binder and David Thomson of short-dated options exercisable for up to 135,075 and 147,780 shares of common stock, respectively. The remainder of each plan is designed to sell a specified percentage of the net shares delivered after tax withholding upon the vesting of restricted stock unit awards held by each individual. The actual number of shares to be sold will depend on state and federal tax rates applicable on the relevant vesting dates (currently assumed to be a combined 34%) as well as the payout, if any, of market RSU awards that will deliver a number of shares determined by the percentile ranking of MannKind total shareholder return ("TSR") over a three-year measurement period relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period (currently assumed to be 100% of target). Based on these assumptions, the number of shares of common stock to be sold by Steven Binder and David Thomson after tax withholdings approximate 162,000 and 41,000, respectively, for total estimated shares of common stock to be sold of up to 297,075 and 188,780, respectively. Steven B. BinderDirectorAugust 16, 2024truefalse297075August 29, 2025David ThomsonEVP, General CounselAugust 19, 2024truefalse188780August 19, 2025297075188780 The investments due in one year or less include cash equivalents of $41.6 million as of September 30, 2024 and $58.6 million as of December 31, 2023. See Note 15 – Commitments and Contingencies under Loss Contingencies — Returns Reserve for Acquired Product. The total anticipated cash flow includes a transaction price of $120.0 million for the contractual obligations under the CSA for the Manufacturing Services and Product Sales and the Next-Gen R&D Services performance obligations and $602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA. The Manufacturing Services and Product Sales performance obligation will be recognized as control of manufactured products is transferred to UT. The modification did not result in a cumulative catch-up adjustment as a result of the revenue being deferred for the performance obligations that were affected by the modification. The allocation of the transaction price for the Manufacturing Services and Product Sales includes a material right related to the Company's estimated production of product in the amount of $220.8 million. The Company will sell product to UT under individual purchase orders, which represent distinct performance obligations. The ultimate cash flows may vary as manufacturing purchase orders are received.